node_type,node_id,trial_id,label,phase,search_condition,conditions,sponsor_class,enrollment_count,start_date,completion_date,num_countries,total_sites,arm_id,description,period_order,outcome_type,timeframe
trial,NCT03242252,NCT03242252,"Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control",PHASE3,diabetes type 2,Type 2 Diabetes Mellitus; Chronic Kidney Disease Stage 3,INDUSTRY,787.0,2017-08-16,2019-10-25,16.0,170.0,,,,,
arm,NCT03242252::arm::FG000,NCT03242252,Placebo,,,,,,,,,,FG000,"Following a 2-week run-in period, participants received two placebo tablets (identical to sotagliflozin 200 mg in appearance), orally once daily, before the first meal of the day for up to 54 weeks.",,,
arm,NCT03242252::arm::FG001,NCT03242252,Sotagliflozin 200 mg,,,,,,,,,,FG001,"Following a 2-week run-in period, participants received two tablets, 1 sotagliflozin 200 mg tablet and 1 placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily, before the",,,
arm,NCT03242252::arm::FG002,NCT03242252,Sotagliflozin 400 mg,,,,,,,,,,FG002,"Following a 2-week run-in period, participants received sotagliflozin 400 mg, administered as two 200 mg sotagliflozin tablets, orally once daily, before the first meal of the day for up to 60 weeks.",,,
period,NCT03242252::period::1,NCT03242252,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03242252::outcome::primary::1,NCT03242252,Change From Baseline in HbA1c at Week 26,,,,,,,,,,,,,PRIMARY,Baseline to Week 26
country,NCT03242252::country::United States,NCT03242252,United States,,,,,,,,,,,,,,
country,NCT03242252::country::Israel,NCT03242252,Israel,,,,,,,,,,,,,,
country,NCT03242252::country::Poland,NCT03242252,Poland,,,,,,,,,,,,,,
country,NCT03242252::country::Canada,NCT03242252,Canada,,,,,,,,,,,,,,
country,NCT03242252::country::Hungary,NCT03242252,Hungary,,,,,,,,,,,,,,
country,NCT03242252::country::Ukraine,NCT03242252,Ukraine,,,,,,,,,,,,,,
country,NCT03242252::country::Colombia,NCT03242252,Colombia,,,,,,,,,,,,,,
country,NCT03242252::country::Romania,NCT03242252,Romania,,,,,,,,,,,,,,
country,NCT03242252::country::Argentina,NCT03242252,Argentina,,,,,,,,,,,,,,
country,NCT03242252::country::Brazil,NCT03242252,Brazil,,,,,,,,,,,,,,
country,NCT03242252::country::Italy,NCT03242252,Italy,,,,,,,,,,,,,,
country,NCT03242252::country::Mexico,NCT03242252,Mexico,,,,,,,,,,,,,,
country,NCT03242252::country::Spain,NCT03242252,Spain,,,,,,,,,,,,,,
country,NCT03242252::country::Russia,NCT03242252,Russia,,,,,,,,,,,,,,
country,NCT03242252::country::South Africa,NCT03242252,South Africa,,,,,,,,,,,,,,
country,NCT03242252::country::Germany,NCT03242252,Germany,,,,,,,,,,,,,,
trial,NCT01798706,NCT01798706,Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,350.0,2013-06,2015-02,13.0,83.0,,,,,
arm,NCT01798706::arm::FG000,NCT01798706,Lixisenatide,,,,,,,,,,FG000,"Lixisenatide 10 mcg subcutaneously once daily (QD) for 2 weeks post-randomization, then at a maintenance dose of 20 mcg QD up to Week 24. If the maintenance dose of 20 mcg was not tolerated, dose coul",,,
arm,NCT01798706::arm::FG001,NCT01798706,Placebo,,,,,,,,,,FG001,Placebo (matched to lixisenatide) subcutaneously QD for 24 Weeks.,,,
period,NCT01798706::period::1,NCT01798706,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01798706::outcome::primary::1,NCT01798706,Absolute Change in HbA1c From Baseline to Week 24,,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
country,NCT01798706::country::United States,NCT01798706,United States,,,,,,,,,,,,,,
country,NCT01798706::country::Canada,NCT01798706,Canada,,,,,,,,,,,,,,
country,NCT01798706::country::Germany,NCT01798706,Germany,,,,,,,,,,,,,,
country,NCT01798706::country::Peru,NCT01798706,Peru,,,,,,,,,,,,,,
country,NCT01798706::country::Australia,NCT01798706,Australia,,,,,,,,,,,,,,
country,NCT01798706::country::Spain,NCT01798706,Spain,,,,,,,,,,,,,,
country,NCT01798706::country::Sweden,NCT01798706,Sweden,,,,,,,,,,,,,,
country,NCT01798706::country::Bulgaria,NCT01798706,Bulgaria,,,,,,,,,,,,,,
country,NCT01798706::country::Denmark,NCT01798706,Denmark,,,,,,,,,,,,,,
country,NCT01798706::country::Norway,NCT01798706,Norway,,,,,,,,,,,,,,
country,NCT01798706::country::Poland,NCT01798706,Poland,,,,,,,,,,,,,,
country,NCT01798706::country::United Kingdom,NCT01798706,United Kingdom,,,,,,,,,,,,,,
country,NCT01798706::country::South Africa,NCT01798706,South Africa,,,,,,,,,,,,,,
trial,NCT01621178,NCT01621178,A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD),PHASE3,diabetes type 2,Type 2 Diabetes; Chronic Kidney Disease,INDUSTRY,577.0,2012-07,2016-12,9.0,89.0,,,,,
arm,NCT01621178::arm::FG000,NCT01621178,Insulin Glargine,,,,,,,,,,FG000,Insulin glargine was administered subcutaneously (SC) at bedtime per a modified forced-titration treat-to-target algorithm. Participants were instructed to administer their titrated prandial insulin l,,,
arm,NCT01621178::arm::FG001,NCT01621178,0.75 mg Dulaglutide,,,,,,,,,,FG001,0.75 milligram (mg) of dulaglutide was administered once weekly as a SC injection. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most signifi,,,
arm,NCT01621178::arm::FG002,NCT01621178,1.5 mg Dulaglutide,,,,,,,,,,FG002,1.5 mg of dulaglutide was administered once weekly as a SC injection. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of,,,
period,NCT01621178::period::1,NCT01621178,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01621178::outcome::primary::1,NCT01621178,Change From Baseline in Hemoglobin A1c (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline, 26 Weeks"
country,NCT01621178::country::United States,NCT01621178,United States,,,,,,,,,,,,,,
country,NCT01621178::country::Hungary,NCT01621178,Hungary,,,,,,,,,,,,,,
country,NCT01621178::country::Brazil,NCT01621178,Brazil,,,,,,,,,,,,,,
country,NCT01621178::country::Romania,NCT01621178,Romania,,,,,,,,,,,,,,
country,NCT01621178::country::Mexico,NCT01621178,Mexico,,,,,,,,,,,,,,
country,NCT01621178::country::South Africa,NCT01621178,South Africa,,,,,,,,,,,,,,
country,NCT01621178::country::Ukraine,NCT01621178,Ukraine,,,,,,,,,,,,,,
country,NCT01621178::country::Poland,NCT01621178,Poland,,,,,,,,,,,,,,
country,NCT01621178::country::Spain,NCT01621178,Spain,,,,,,,,,,,,,,
trial,NCT00683878,NCT00683878,Add-on to Thiazolidinedione (TZD) Failures,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,972.0,2008-07,2010-06,9.0,89.0,,,,,
arm,NCT00683878::arm::FG000,NCT00683878,PLACEBO + Pioglitazone,,,,,,,,,,FG000,"Placebo tablets, oral, once daily, up to 48 weeks plus pioglitazone tablets, ≥ 30 mg, once daily up to 48 weeks",,,
arm,NCT00683878::arm::FG001,NCT00683878,Dapagliflozin 5MG + Pioglitazone,,,,,,,,,,FG001,"Dapagliflozin tablets, oral, once daily, up to 48 weeks plus pioglitazone tablets, ≥ 30 mg, once daily up to 48 weeks",,,
arm,NCT00683878::arm::FG002,NCT00683878,Dapagliflozin 10MG + Pioglitazone,,,,,,,,,,FG002,"Dapagliflozin tablets, oral, once daily, up to 48 weeks plus pioglitazone tablets, ≥ 30 mg, once daily up to 48 weeks",,,
period,NCT00683878::period::1,NCT00683878,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00683878::outcome::primary::1,NCT00683878,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]),,,,,,,,,,,,,PRIMARY,From Baseline to Week 24
country,NCT00683878::country::United States,NCT00683878,United States,,,,,,,,,,,,,,
country,NCT00683878::country::Mexico,NCT00683878,Mexico,,,,,,,,,,,,,,
country,NCT00683878::country::Canada,NCT00683878,Canada,,,,,,,,,,,,,,
country,NCT00683878::country::Argentina,NCT00683878,Argentina,,,,,,,,,,,,,,
country,NCT00683878::country::India,NCT00683878,India,,,,,,,,,,,,,,
country,NCT00683878::country::Peru,NCT00683878,Peru,,,,,,,,,,,,,,
country,NCT00683878::country::Philippines,NCT00683878,Philippines,,,,,,,,,,,,,,
country,NCT00683878::country::Taiwan,NCT00683878,Taiwan,,,,,,,,,,,,,,
country,NCT00683878::country::Puerto Rico,NCT00683878,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01215097,NCT01215097,Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,306.0,2010-10,2012-04,3.0,19.0,,,,,
arm,NCT01215097::arm::FG000,NCT01215097,Placebo,,,,,,,,,,FG000,Placebo,,,
arm,NCT01215097::arm::FG001,NCT01215097,Linagliptin 5mg,,,,,,,,,,FG001,"Linagliptin 5mg, once daily tablets, oral",,,
period,NCT01215097::period::1,NCT01215097,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01215097::outcome::primary::1,NCT01215097,HbA1c Change From Baseline at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and at week 24
country,NCT01215097::country::China,NCT01215097,China,,,,,,,,,,,,,,
country,NCT01215097::country::Malaysia,NCT01215097,Malaysia,,,,,,,,,,,,,,
country,NCT01215097::country::Philippines,NCT01215097,Philippines,,,,,,,,,,,,,,
trial,NCT00494013,NCT00494013,Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY),PHASE3,diabetes type 2,Diabetes Mellitus Type 2,INDUSTRY,442.0,2007-08,2008-09,9.0,56.0,,,,,
arm,NCT00494013::arm::FG000,NCT00494013,Insulin Lispro Protamine Suspension,,,,,,,,,,FG000,Insulin Lispro Protamine Suspension: Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks.,,,
arm,NCT00494013::arm::FG001,NCT00494013,Detemir,,,,,,,,,,FG001,Detemir: Patient specific dose administered subcutaneously once daily x 24 weeks.,,,
period,NCT00494013::period::1,NCT00494013,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00494013::outcome::primary::1,NCT00494013,Change From Baseline to 24 Week Endpoint in Hemoglobin A1c (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline, 24 Weeks"
country,NCT00494013::country::United States,NCT00494013,United States,,,,,,,,,,,,,,
country,NCT00494013::country::Hungary,NCT00494013,Hungary,,,,,,,,,,,,,,
country,NCT00494013::country::India,NCT00494013,India,,,,,,,,,,,,,,
country,NCT00494013::country::Taiwan,NCT00494013,Taiwan,,,,,,,,,,,,,,
country,NCT00494013::country::Spain,NCT00494013,Spain,,,,,,,,,,,,,,
country,NCT00494013::country::Poland,NCT00494013,Poland,,,,,,,,,,,,,,
country,NCT00494013::country::Argentina,NCT00494013,Argentina,,,,,,,,,,,,,,
country,NCT00494013::country::Mexico,NCT00494013,Mexico,,,,,,,,,,,,,,
country,NCT00494013::country::South Korea,NCT00494013,South Korea,,,,,,,,,,,,,,
trial,NCT00359762,NCT00359762,Exenatide Versus Glimepiride in Patients With Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,1029.0,2006-09,2011-03,14.0,114.0,,,,,
arm,NCT00359762::arm::FG000,NCT00359762,"Period II, Glim + Met",,,,,,,,,,FG000,Glimepiride one 1 mg tablet daily with subsequent titration every 4 weeks to maximally-tolerated dose for the remainder of Period II and daily oral Metformin,,,
arm,NCT00359762::arm::FG001,NCT00359762,"Period III, Exen + Met + Glim - Randomized",,,,,,,,,,FG001,"Glimepiride once daily, started at 1 mg dose and titrated up to maintenance doses, was added to Exenatide 10 mcg twice daily subcutaneously injected and daily oral Metformin in Period III",,,
arm,NCT00359762::arm::FG002,NCT00359762,"Period III, Exen + Met + Pio or Rosi - Randomized",,,,,,,,,,FG002,"Oral Rosiglitazone or Pioglitazone once or twice daily, started 15 mg per day, was added to Exenatide 10 mcg twice daily subcutaneously injected and daily oral Metformin in Period III",,,
arm,NCT00359762::arm::FG003,NCT00359762,"Period III, Glim + Met + Exen - Not Randomized",,,,,,,,,,FG003,Exenatide 10 mcg twice daily subcutaneously injected (5 mcg exenatide per dose for the first 4 weeks followed by 10 mcg exenatide per dose for the remainder of period III) was added to oral Glimepirid,,,
arm,NCT00359762::arm::FG004,NCT00359762,"Period II, Exen + Met",,,,,,,,,,FG004,Exenatide 10 mcg twice daily subcutaneously injected (5 mcg exenatide per dose for first 4 weeks followed by 10 mcg exenatide per dose for the remainder of period II) and daily oral Metformin,,,
period,NCT00359762::period::1,NCT00359762,Period II,,,,,,,,,,,,1.0,,
period,NCT00359762::period::2,NCT00359762,Period III,,,,,,,,,,,,2.0,,
period,NCT00359762::period::3,NCT00359762,Period I,,,,,,,,,,,,3.0,,
outcome,NCT00359762::outcome::primary::1,NCT00359762,Number of Patients With Treatment Failure,,,,,,,,,,,,,PRIMARY,Baseline to end of Period II (up to 4.5 years)
outcome,NCT00359762::outcome::primary::2,NCT00359762,Time to Treatment Failure,,,,,,,,,,,,,PRIMARY,Baseline to end of Period II (up to 4.5 years)
country,NCT00359762::country::Italy,NCT00359762,Italy,,,,,,,,,,,,,,
country,NCT00359762::country::Germany,NCT00359762,Germany,,,,,,,,,,,,,,
country,NCT00359762::country::France,NCT00359762,France,,,,,,,,,,,,,,
country,NCT00359762::country::United Kingdom,NCT00359762,United Kingdom,,,,,,,,,,,,,,
country,NCT00359762::country::Czechia,NCT00359762,Czechia,,,,,,,,,,,,,,
country,NCT00359762::country::Poland,NCT00359762,Poland,,,,,,,,,,,,,,
country,NCT00359762::country::Hungary,NCT00359762,Hungary,,,,,,,,,,,,,,
country,NCT00359762::country::Austria,NCT00359762,Austria,,,,,,,,,,,,,,
country,NCT00359762::country::Finland,NCT00359762,Finland,,,,,,,,,,,,,,
country,NCT00359762::country::Israel,NCT00359762,Israel,,,,,,,,,,,,,,
country,NCT00359762::country::Mexico,NCT00359762,Mexico,,,,,,,,,,,,,,
country,NCT00359762::country::Switzerland,NCT00359762,Switzerland,,,,,,,,,,,,,,
country,NCT00359762::country::Ireland,NCT00359762,Ireland,,,,,,,,,,,,,,
country,NCT00359762::country::Spain,NCT00359762,Spain,,,,,,,,,,,,,,
trial,NCT03689374,NCT03689374,"A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes",PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,2274.0,2018-10-01,2021-02-22,21.0,210.0,,,,,
arm,NCT03689374::arm::FG000,NCT03689374,All Participants,,,,,,,,,,FG000,During run-in period insulin glargine in combination with metformin was to be optimized. All enrolled participants received metformin orally and IGlar U100 s.c. injection in run-in period. Metformin w,,,
arm,NCT03689374::arm::FG001,NCT03689374,Semaglutide,,,,,,,,,,FG001,"Participants received metformin, IGlar U100 and semaglutide for 52 weeks in treatment period. Metformin dose was maintained at same level and frequency as optimized in run-in period unless safety conc",,,
arm,NCT03689374::arm::FG002,NCT03689374,Insulin Aspart,,,,,,,,,,FG002,"Participants received metformin, IGlar U100 and insulin aspart for 52 weeks in treatment period. Metformin dose was maintained at same level and frequency as optimized in run-in period unless safety c",,,
period,NCT03689374::period::1,NCT03689374,Run-in Period (12 Weeks),,,,,,,,,,,,1.0,,
period,NCT03689374::period::2,NCT03689374,Treatment Period (Week 0 to 52),,,,,,,,,,,,2.0,,
outcome,NCT03689374::outcome::primary::1,NCT03689374,Change From Baseline in Glycated Haemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline (week 0), week 52"
country,NCT03689374::country::Germany,NCT03689374,Germany,,,,,,,,,,,,,,
country,NCT03689374::country::India,NCT03689374,India,,,,,,,,,,,,,,
country,NCT03689374::country::Poland,NCT03689374,Poland,,,,,,,,,,,,,,
country,NCT03689374::country::Greece,NCT03689374,Greece,,,,,,,,,,,,,,
country,NCT03689374::country::Turkey (Türkiye),NCT03689374,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT03689374::country::Slovakia,NCT03689374,Slovakia,,,,,,,,,,,,,,
country,NCT03689374::country::South Africa,NCT03689374,South Africa,,,,,,,,,,,,,,
country,NCT03689374::country::Bulgaria,NCT03689374,Bulgaria,,,,,,,,,,,,,,
country,NCT03689374::country::Hungary,NCT03689374,Hungary,,,,,,,,,,,,,,
country,NCT03689374::country::Spain,NCT03689374,Spain,,,,,,,,,,,,,,
country,NCT03689374::country::Czechia,NCT03689374,Czechia,,,,,,,,,,,,,,
country,NCT03689374::country::Portugal,NCT03689374,Portugal,,,,,,,,,,,,,,
country,NCT03689374::country::Romania,NCT03689374,Romania,,,,,,,,,,,,,,
country,NCT03689374::country::Croatia,NCT03689374,Croatia,,,,,,,,,,,,,,
country,NCT03689374::country::Latvia,NCT03689374,Latvia,,,,,,,,,,,,,,
country,NCT03689374::country::Lithuania,NCT03689374,Lithuania,,,,,,,,,,,,,,
country,NCT03689374::country::Serbia,NCT03689374,Serbia,,,,,,,,,,,,,,
country,NCT03689374::country::Slovenia,NCT03689374,Slovenia,,,,,,,,,,,,,,
country,NCT03689374::country::Estonia,NCT03689374,Estonia,,,,,,,,,,,,,,
country,NCT03689374::country::Bosnia and Herzegovina,NCT03689374,Bosnia and Herzegovina,,,,,,,,,,,,,,
country,NCT03689374::country::North Macedonia,NCT03689374,North Macedonia,,,,,,,,,,,,,,
trial,NCT01850615,NCT01850615,"Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes",PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,323.0,2013-09-23,2014-11-17,6.0,58.0,,,,,
arm,NCT01850615::arm::FG000,NCT01850615,Faster Aspart + Basal,,,,,,,,,,FG000,"During the 18-week treatment period, subjects received subcutaneous (s.c., under the skin) injection of faster aspart (bolus insulin) along with s.c. basal insulin (insulin detemir or insulin glargine",,,
arm,NCT01850615::arm::FG001,NCT01850615,Basal,,,,,,,,,,FG001,"During the 18-week treatment period, subjects received s.c. injection of basal insulin (insulin detemir or insulin glargine or NPH insulin) and metformin. Treatment recommendations were developed for ",,,
period,NCT01850615::period::1,NCT01850615,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01850615::outcome::primary::1,NCT01850615,Change From Baseline in HbA1c,,,,,,,,,,,,,PRIMARY,"Week 0, week 18"
country,NCT01850615::country::United States,NCT01850615,United States,,,,,,,,,,,,,,
country,NCT01850615::country::India,NCT01850615,India,,,,,,,,,,,,,,
country,NCT01850615::country::Argentina,NCT01850615,Argentina,,,,,,,,,,,,,,
country,NCT01850615::country::Romania,NCT01850615,Romania,,,,,,,,,,,,,,
country,NCT01850615::country::Slovenia,NCT01850615,Slovenia,,,,,,,,,,,,,,
country,NCT01850615::country::Mexico,NCT01850615,Mexico,,,,,,,,,,,,,,
trial,NCT02547935,NCT02547935,"A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD",PHASE3,diabetes type 2,"Type 2 Diabetes Mellitus, CKD and Albuminuria",INDUSTRY,459.0,2015-09-21,2018-05-18,9.0,112.0,,,,,
arm,NCT02547935::arm::FG000,NCT02547935,Dapagliflozin 10 mg + Saxagliptin 2.5 mg,,,,,,,,,,FG000,"Dapagliflozin 10 milligram (mg) and saxagliptin 2.5 mg tablets were taken orally, once daily (in the morning) for 24 weeks.",,,
arm,NCT02547935::arm::FG001,NCT02547935,Dapagliflozin 10 mg,,,,,,,,,,FG001,"Dapagliflozin 10 mg tablets were taken orally, once daily (in the morning) for 24 weeks. Patients also took placebo tablets to match saxagliptin.",,,
arm,NCT02547935::arm::FG002,NCT02547935,Placebo,,,,,,,,,,FG002,"Placebo tablets to match both active products (dapagliflozin and saxagliptin) were taken orally, once daily (in the morning) for 24 weeks.",,,
period,NCT02547935::period::1,NCT02547935,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02547935::outcome::primary::1,NCT02547935,Adjusted Mean Change From Baseline in Glycosylated Haemoglobin (HbA1c): Comparison of Dapagliflozin 10 mg Plus Saxagliptin 2.5 mg and Placebo at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and Week 24
outcome,NCT02547935::outcome::primary::2,NCT02547935,Adjusted Mean Percent Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and Week 24
country,NCT02547935::country::United States,NCT02547935,United States,,,,,,,,,,,,,,
country,NCT02547935::country::Japan,NCT02547935,Japan,,,,,,,,,,,,,,
country,NCT02547935::country::Mexico,NCT02547935,Mexico,,,,,,,,,,,,,,
country,NCT02547935::country::Canada,NCT02547935,Canada,,,,,,,,,,,,,,
country,NCT02547935::country::South Korea,NCT02547935,South Korea,,,,,,,,,,,,,,
country,NCT02547935::country::South Africa,NCT02547935,South Africa,,,,,,,,,,,,,,
country,NCT02547935::country::Taiwan,NCT02547935,Taiwan,,,,,,,,,,,,,,
country,NCT02547935::country::Spain,NCT02547935,Spain,,,,,,,,,,,,,,
country,NCT02547935::country::Australia,NCT02547935,Australia,,,,,,,,,,,,,,
trial,NCT01087502,NCT01087502,Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,241.0,2010-03,,9.0,52.0,,,,,
arm,NCT01087502::arm::FG000,NCT01087502,Placebo/Glimepiride,,,,,,,,,,FG000,Patients randomized to receive treatment with matching placebo for 12 weeks and then switch to glimepiride for further 40 weeks.,,,
arm,NCT01087502::arm::FG001,NCT01087502,Linagliptin 5 mg,,,,,,,,,,FG001,Patients randomized to receive treatment with Linagliptin 5mg,,,
period,NCT01087502::period::1,NCT01087502,Up to Interim Analysis (Week 12),,,,,,,,,,,,1.0,,
period,NCT01087502::period::2,NCT01087502,Up to Final Analysis (Week 52),,,,,,,,,,,,2.0,,
outcome,NCT01087502::outcome::primary::1,NCT01087502,HbA1c Change From Baseline to Week 12,,,,,,,,,,,,,PRIMARY,Baseline and week 12
country,NCT01087502::country::United States,NCT01087502,United States,,,,,,,,,,,,,,
country,NCT01087502::country::Japan,NCT01087502,Japan,,,,,,,,,,,,,,
country,NCT01087502::country::Canada,NCT01087502,Canada,,,,,,,,,,,,,,
country,NCT01087502::country::Israel,NCT01087502,Israel,,,,,,,,,,,,,,
country,NCT01087502::country::Australia,NCT01087502,Australia,,,,,,,,,,,,,,
country,NCT01087502::country::Slovakia,NCT01087502,Slovakia,,,,,,,,,,,,,,
country,NCT01087502::country::Finland,NCT01087502,Finland,,,,,,,,,,,,,,
country,NCT01087502::country::Sweden,NCT01087502,Sweden,,,,,,,,,,,,,,
country,NCT01087502::country::New Zealand,NCT01087502,New Zealand,,,,,,,,,,,,,,
trial,NCT05362058,NCT05362058,A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time,PHASE3,diabetes type 2,Diabetes; Type 2 Diabetes,INDUSTRY,928.0,2022-06-03,2024-04-10,11.0,113.0,,,,,
arm,NCT05362058::arm::FG000,NCT05362058,500 U/mL - Insulin Efsitora Alfa,,,,,,,,,,FG000,"\- Participants received 500 units per milliliter (U/mL) of insulin efsitora alfa administered subcutaneously (SC) once weekly (QW) over a 52-week treatment period, followed by a 5-week safety follow-",,,
arm,NCT05362058::arm::FG001,NCT05362058,100 U/mL - Insulin Degludec,,,,,,,,,,FG001,"\- Participants received 100 U/mL insulin degludec administered SC once daily (QD) over a 52-week treatment period, followed by a 5-week safety follow-up period.",,,
period,NCT05362058::period::1,NCT05362058,Treatment Period,,,,,,,,,,,,1.0,,
period,NCT05362058::period::2,NCT05362058,Follow-Up Period,,,,,,,,,,,,2.0,,
outcome,NCT05362058::outcome::primary::1,NCT05362058,Change From Baseline in HbA1c at Week 52 [Noninferiority Analysis],,,,,,,,,,,,,PRIMARY,"Baseline, Week 52"
country,NCT05362058::country::United States,NCT05362058,United States,,,,,,,,,,,,,,
country,NCT05362058::country::China,NCT05362058,China,,,,,,,,,,,,,,
country,NCT05362058::country::Japan,NCT05362058,Japan,,,,,,,,,,,,,,
country,NCT05362058::country::Germany,NCT05362058,Germany,,,,,,,,,,,,,,
country,NCT05362058::country::Brazil,NCT05362058,Brazil,,,,,,,,,,,,,,
country,NCT05362058::country::Canada,NCT05362058,Canada,,,,,,,,,,,,,,
country,NCT05362058::country::Czechia,NCT05362058,Czechia,,,,,,,,,,,,,,
country,NCT05362058::country::Greece,NCT05362058,Greece,,,,,,,,,,,,,,
country,NCT05362058::country::South Korea,NCT05362058,South Korea,,,,,,,,,,,,,,
country,NCT05362058::country::Puerto Rico,NCT05362058,Puerto Rico,,,,,,,,,,,,,,
country,NCT05362058::country::Mexico,NCT05362058,Mexico,,,,,,,,,,,,,,
trial,NCT00449930,NCT00449930,Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,1050.0,2007-03-01,2008-07-25,0.0,0.0,,,,,
arm,NCT00449930::arm::FG000,NCT00449930,Sitagliptin 100 mg,,,,,,,,,,FG000,The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablet of sitagliptin once daily.,,,
arm,NCT00449930::arm::FG001,NCT00449930,Metformin,,,,,,,,,,FG001,The Metformin group includes data from patients randomized to receive treatment with metformin initiated at a dose of 1 tablet (500 mg) per day. Patients were then to be up-titrated over a maximum of ,,,
period,NCT00449930::period::1,NCT00449930,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00449930::outcome::primary::1,NCT00449930,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and 24 weeks
trial,NCT03952143,NCT03952143,A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,628.0,2019-05-27,2021-01-20,3.0,41.0,,,,,
arm,NCT03952143::arm::FG000,NCT03952143,Insulin Lispro (Humalog) Lead-in,,,,,,,,,,FG000,Participants received 100 units per milliliter (U/mL) insulin lispro (Humalog) subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine or insulin degludec given SC once dai,,,
arm,NCT03952143::arm::FG001,NCT03952143,Insulin Lispro (Humalog),,,,,,,,,,FG001,Participants received 100 units per milliliter (U/mL) insulin lispro (Humalog) subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine or insulin degludec given SC once dai,,,
arm,NCT03952143::arm::FG002,NCT03952143,LY900014,,,,,,,,,,FG002,Participants received 100 U/mL LY900014 by SC 0-2 minutes before each meal with either basal insulin glargine or insulin degludec given SC once daily.,,,
period,NCT03952143::period::1,NCT03952143,Lead-In Period,,,,,,,,,,,,1.0,,
period,NCT03952143::period::2,NCT03952143,Treatment Period,,,,,,,,,,,,2.0,,
outcome,NCT03952143::outcome::primary::1,NCT03952143,Change From Baseline in Hemoglobin A1c (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline, Week 26"
country,NCT03952143::country::China,NCT03952143,China,,,,,,,,,,,,,,
country,NCT03952143::country::Mexico,NCT03952143,Mexico,,,,,,,,,,,,,,
country,NCT03952143::country::Argentina,NCT03952143,Argentina,,,,,,,,,,,,,,
trial,NCT03242018,NCT03242018,"A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control",PHASE3,diabetes type 2,Type 2 Diabetes Mellitus; Chronic Kidney Disease Stage 4,INDUSTRY,277.0,2017-08-16,2019-12-11,15.0,106.0,,,,,
arm,NCT03242018::arm::FG000,NCT03242018,Placebo,,,,,,,,,,FG000,"Following a 2-week run-in phase, participants received two placebo tablets (identical to sotagliflozin 200 mg in appearance) orally once daily for up to 56.3 weeks.",,,
arm,NCT03242018::arm::FG001,NCT03242018,Sotagliflozin 200 mg,,,,,,,,,,FG001,"Following a 2-week run-in phase, participants received two tablets, one sotagliflozin 200 mg tablet and one placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily for up t",,,
arm,NCT03242018::arm::FG002,NCT03242018,Sotagliflozin 400 mg,,,,,,,,,,FG002,"Following a 2-week run-in phase, participants received sotagliflozin 400 mg, administered as 2 sotagliflozin 200 mg tablets, orally once daily for up to 56.1 weeks.",,,
period,NCT03242018::period::1,NCT03242018,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03242018::outcome::primary::1,NCT03242018,Change From Baseline in HbA1c at Week 26 Comparing Sotagliflozin 400 mg Versus Placebo,,,,,,,,,,,,,PRIMARY,Baseline to Week 26
country,NCT03242018::country::United States,NCT03242018,United States,,,,,,,,,,,,,,
country,NCT03242018::country::Mexico,NCT03242018,Mexico,,,,,,,,,,,,,,
country,NCT03242018::country::Spain,NCT03242018,Spain,,,,,,,,,,,,,,
country,NCT03242018::country::Israel,NCT03242018,Israel,,,,,,,,,,,,,,
country,NCT03242018::country::Italy,NCT03242018,Italy,,,,,,,,,,,,,,
country,NCT03242018::country::Romania,NCT03242018,Romania,,,,,,,,,,,,,,
country,NCT03242018::country::Ukraine,NCT03242018,Ukraine,,,,,,,,,,,,,,
country,NCT03242018::country::Poland,NCT03242018,Poland,,,,,,,,,,,,,,
country,NCT03242018::country::Russia,NCT03242018,Russia,,,,,,,,,,,,,,
country,NCT03242018::country::Brazil,NCT03242018,Brazil,,,,,,,,,,,,,,
country,NCT03242018::country::Colombia,NCT03242018,Colombia,,,,,,,,,,,,,,
country,NCT03242018::country::South Africa,NCT03242018,South Africa,,,,,,,,,,,,,,
country,NCT03242018::country::Argentina,NCT03242018,Argentina,,,,,,,,,,,,,,
country,NCT03242018::country::Germany,NCT03242018,Germany,,,,,,,,,,,,,,
country,NCT03242018::country::Hungary,NCT03242018,Hungary,,,,,,,,,,,,,,
trial,NCT01137474,NCT01137474,A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,2996.0,2010-07,2013-02,16.0,329.0,,,,,
arm,NCT01137474::arm::FG000,NCT01137474,Placebo,,,,,,,,,,FG000,Participants with type 2 diabetes and inadequate glycemic and hypertension control while taking an oral antidiabetic drug (OAD) with or without insulin and an angiotensin-converting enzyme (ACE) inhib,,,
arm,NCT01137474::arm::FG001,NCT01137474,"Dapagliflozin, 2.5 mg (Randomized Before Protocol Amendment 8)",,,,,,,,,,FG001,"Participants with type 2 diabetes and inadequate glycemic and hypertension control while taking an OAD with or without insulin and an ACE inhibitor or ARB, received dapagliflozin, 2.5 mg, daily with a",,,
arm,NCT01137474::arm::FG002,NCT01137474,"Dapagliflozin, 5 mg (Randomized Before Protocol Amendment 8)",,,,,,,,,,FG002,"Participants with type 2 diabetes and inadequate glycemic and hypertension control while taking an OAD with or without insulin and an ACE inhibitor or ARB, received dapagliflozin, 5 mg, daily with a m",,,
arm,NCT01137474::arm::FG003,NCT01137474,Dapagliflozin 10 mg,,,,,,,,,,FG003,"Participants with type 2 diabetes and inadequate glycemic and hypertension control while taking an OAD with or without insulin and an ACE inhibitor or ARB, received dapagliflozin, 10 mg, daily with a ",,,
period,NCT01137474::period::1,NCT01137474,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01137474::outcome::primary::1,NCT01137474,Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (BP) at Week 12,,,,,,,,,,,,,PRIMARY,From Baseline to Week 12
outcome,NCT01137474::outcome::primary::2,NCT01137474,Adjusted Mean Change From Baseline in Hemoglobin (HbA1c) at Week 12,,,,,,,,,,,,,PRIMARY,From Baseline to Week 12
country,NCT01137474::country::United States,NCT01137474,United States,,,,,,,,,,,,,,
country,NCT01137474::country::Poland,NCT01137474,Poland,,,,,,,,,,,,,,
country,NCT01137474::country::India,NCT01137474,India,,,,,,,,,,,,,,
country,NCT01137474::country::Mexico,NCT01137474,Mexico,,,,,,,,,,,,,,
country,NCT01137474::country::Germany,NCT01137474,Germany,,,,,,,,,,,,,,
country,NCT01137474::country::Romania,NCT01137474,Romania,,,,,,,,,,,,,,
country,NCT01137474::country::Russia,NCT01137474,Russia,,,,,,,,,,,,,,
country,NCT01137474::country::Peru,NCT01137474,Peru,,,,,,,,,,,,,,
country,NCT01137474::country::Hungary,NCT01137474,Hungary,,,,,,,,,,,,,,
country,NCT01137474::country::Colombia,NCT01137474,Colombia,,,,,,,,,,,,,,
country,NCT01137474::country::Czechia,NCT01137474,Czechia,,,,,,,,,,,,,,
country,NCT01137474::country::Canada,NCT01137474,Canada,,,,,,,,,,,,,,
country,NCT01137474::country::Denmark,NCT01137474,Denmark,,,,,,,,,,,,,,
country,NCT01137474::country::Puerto Rico,NCT01137474,Puerto Rico,,,,,,,,,,,,,,
country,NCT01137474::country::Spain,NCT01137474,Spain,,,,,,,,,,,,,,
country,NCT01137474::country::Finland,NCT01137474,Finland,,,,,,,,,,,,,,
trial,NCT00734474,NCT00734474,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,1202.0,2008-08,2012-07,13.0,99.0,,,,,
arm,NCT00734474::arm::FG000,NCT00734474,3.0 mg LY2189265,,,,,,,,,,FG000,"LY2189265 (Dulaglutide): 3.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.1 weeks)

Placebo: tablet, administered orally, once daily ",,,
arm,NCT00734474::arm::FG001,NCT00734474,2.0 mg LY2189265,,,,,,,,,,FG001,"LY2189265 (Dulaglutide): 2.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 20.4 weeks)

Placebo: tablet, administered orally, once daily ",,,
arm,NCT00734474::arm::FG002,NCT00734474,1.5 mg LY2189265,,,,,,,,,,FG002,"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks

Placebo: tablet, administered orally, once daily for 104 weeks

Metformin: at least 1500 milligram",,,
arm,NCT00734474::arm::FG003,NCT00734474,1.0 mg LY2189265,,,,,,,,,,FG003,"LY2189265 (Dulaglutide): 1.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.4 weeks)

Placebo: tablet, administered orally, once daily ",,,
arm,NCT00734474::arm::FG004,NCT00734474,0.75 mg LY2189265,,,,,,,,,,FG004,"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks

Placebo: tablet, administered orally, once daily for 104 weeks

Metformin: at least 1500 milligra",,,
arm,NCT00734474::arm::FG005,NCT00734474,0.5 mg LY2189265,,,,,,,,,,FG005,"LY2189265 (Dulaglutide): 0.5 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 27.4 weeks)

Placebo: tablet, administered orally, once daily ",,,
arm,NCT00734474::arm::FG006,NCT00734474,0.25 mg LY2189265,,,,,,,,,,FG006,"LY2189265 (Dulaglutide): 0.25 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.4 weeks)

Placebo: tablet, administered orally, once daily",,,
arm,NCT00734474::arm::FG007,NCT00734474,Sitagliptin,,,,,,,,,,FG007,"Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks

Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks

Metformin: at least 1500 milligrams p",,,
arm,NCT00734474::arm::FG008,NCT00734474,Placebo/Sitagliptin,,,,,,,,,,FG008,"Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks

Placebo: tablet, administered orally, once daily for 26 weeks

Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, admin",,,
period,NCT00734474::period::1,NCT00734474,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00734474::outcome::primary::1,NCT00734474,Glycosylated Hemoglobin (HbA1c) Change From Baseline,,,,,,,,,,,,,PRIMARY,"Baseline, 52 weeks"
country,NCT00734474::country::United States,NCT00734474,United States,,,,,,,,,,,,,,
country,NCT00734474::country::Germany,NCT00734474,Germany,,,,,,,,,,,,,,
country,NCT00734474::country::France,NCT00734474,France,,,,,,,,,,,,,,
country,NCT00734474::country::Taiwan,NCT00734474,Taiwan,,,,,,,,,,,,,,
country,NCT00734474::country::India,NCT00734474,India,,,,,,,,,,,,,,
country,NCT00734474::country::Poland,NCT00734474,Poland,,,,,,,,,,,,,,
country,NCT00734474::country::South Korea,NCT00734474,South Korea,,,,,,,,,,,,,,
country,NCT00734474::country::Spain,NCT00734474,Spain,,,,,,,,,,,,,,
country,NCT00734474::country::Canada,NCT00734474,Canada,,,,,,,,,,,,,,
country,NCT00734474::country::Mexico,NCT00734474,Mexico,,,,,,,,,,,,,,
country,NCT00734474::country::Romania,NCT00734474,Romania,,,,,,,,,,,,,,
country,NCT00734474::country::Russia,NCT00734474,Russia,,,,,,,,,,,,,,
country,NCT00734474::country::Puerto Rico,NCT00734474,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00509262,NCT00509262,Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1),PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2; Renal Insufficiency, Chronic",INDUSTRY,426.0,2007-10-09,2011-03-16,0.0,0.0,,,,,
arm,NCT00509262::arm::FG000,NCT00509262,Sitagliptin,,,,,,,,,,FG000,Participants randomized to 25 or 50 mg of sitagliptin orally daily + placebo for glipizide,,,
arm,NCT00509262::arm::FG001,NCT00509262,Glipizide,,,,,,,,,,FG001,Participants randomized to glipizide 2.5 to 20 mg orally daily + placebo for sitagliptin,,,
period,NCT00509262::period::1,NCT00509262,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00509262::outcome::primary::1,NCT00509262,Change From Baseline in Hemoglobin A1c (A1C) Levels at Week 54,,,,,,,,,,,,,PRIMARY,Baseline to Week 54
outcome,NCT00509262::outcome::primary::2,NCT00509262,Percentage of Participants With Hypoglycemic Events,,,,,,,,,,,,,PRIMARY,Baseline up to 28 days following the last dose of study therapy
trial,NCT03136484,NCT03136484,Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,788.0,2017-03-15,2018-11-16,12.0,119.0,,,,,
arm,NCT03136484::arm::FG000,NCT03136484,Semaglutide + Canagliflozin Placebo,,,,,,,,,,FG000,Participants received subcutaneous (s.c.) injection of semaglutide once-weekly for 52 weeks: 0.25 milligrams (mg) during 0-4 weeks followed by 0.5 mg during 5-8 weeks and then 1.0 mg during 9-52 weeks,,,
arm,NCT03136484::arm::FG001,NCT03136484,Canagliflozin + Semaglutide Placebo,,,,,,,,,,FG001,Participants received canagliflozin tablet once-daily orally for 52 weeks: 100 mg tablet during 0-8 weeks followed by 300 mg tablet during 9-52 weeks. Participants also received placebo matched to sem,,,
period,NCT03136484::period::1,NCT03136484,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03136484::outcome::primary::1,NCT03136484,Change in HbA1c,,,,,,,,,,,,,PRIMARY,"Week 0, week 52"
country,NCT03136484::country::United States,NCT03136484,United States,,,,,,,,,,,,,,
country,NCT03136484::country::India,NCT03136484,India,,,,,,,,,,,,,,
country,NCT03136484::country::United Kingdom,NCT03136484,United Kingdom,,,,,,,,,,,,,,
country,NCT03136484::country::Canada,NCT03136484,Canada,,,,,,,,,,,,,,
country,NCT03136484::country::Malaysia,NCT03136484,Malaysia,,,,,,,,,,,,,,
country,NCT03136484::country::Argentina,NCT03136484,Argentina,,,,,,,,,,,,,,
country,NCT03136484::country::Ireland,NCT03136484,Ireland,,,,,,,,,,,,,,
country,NCT03136484::country::Lebanon,NCT03136484,Lebanon,,,,,,,,,,,,,,
country,NCT03136484::country::Sweden,NCT03136484,Sweden,,,,,,,,,,,,,,
country,NCT03136484::country::Mexico,NCT03136484,Mexico,,,,,,,,,,,,,,
country,NCT03136484::country::Brazil,NCT03136484,Brazil,,,,,,,,,,,,,,
country,NCT03136484::country::Italy,NCT03136484,Italy,,,,,,,,,,,,,,
trial,NCT00799643,NCT00799643,Targeting Inflammation Using Salsalate for Type 2 Diabetes-Stage II,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,OTHER,638.0,2008-11,,1.0,21.0,,,,,
arm,NCT00799643::arm::FG000,NCT00799643,Placebo,,,,,,,,,,FG000,"Placebo for salsalate, orally, divided dosing",,,
arm,NCT00799643::arm::FG001,NCT00799643,Salsalate,,,,,,,,,,FG001,"Salsalate, 3.5 g/d orally,divided dosing",,,
period,NCT00799643::period::1,NCT00799643,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00799643::outcome::primary::1,NCT00799643,"The Primary Outcome for the TINSAL-T2D Study is Change in HbA1c Level From Baseline to Week 48 From Baseline, Compared Between Treatment Groups.",,,,,,,,,,,,,PRIMARY,48 weeks from baseline
country,NCT00799643::country::United States,NCT00799643,United States,,,,,,,,,,,,,,
trial,NCT00286455,NCT00286455,Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,Diabetes Mellitus,INDUSTRY,329.0,2006-02,2007-07,18.0,67.0,,,,,
arm,NCT00286455::arm::FG000,NCT00286455,Placebo QD,,,,,,,,,,FG000,"Alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.",,,
arm,NCT00286455::arm::FG001,NCT00286455,Alogliptin 12.5 mg QD,,,,,,,,,,FG001,"Alogliptin 12.5 mg, tablets, orally, once daily for up to 26 weeks.",,,
arm,NCT00286455::arm::FG002,NCT00286455,Alogliptin 25 mg QD,,,,,,,,,,FG002,"Alogliptin 25 mg, tablets, orally, once daily for up to 26 weeks.",,,
period,NCT00286455::period::1,NCT00286455,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00286455::outcome::primary::1,NCT00286455,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.,,,,,,,,,,,,,PRIMARY,Baseline and Week 26.
country,NCT00286455::country::United States,NCT00286455,United States,,,,,,,,,,,,,,
country,NCT00286455::country::Argentina,NCT00286455,Argentina,,,,,,,,,,,,,,
country,NCT00286455::country::Australia,NCT00286455,Australia,,,,,,,,,,,,,,
country,NCT00286455::country::Brazil,NCT00286455,Brazil,,,,,,,,,,,,,,
country,NCT00286455::country::Chile,NCT00286455,Chile,,,,,,,,,,,,,,
country,NCT00286455::country::Czechia,NCT00286455,Czechia,,,,,,,,,,,,,,
country,NCT00286455::country::Dominican Republic,NCT00286455,Dominican Republic,,,,,,,,,,,,,,
country,NCT00286455::country::Germany,NCT00286455,Germany,,,,,,,,,,,,,,
country,NCT00286455::country::Guatemala,NCT00286455,Guatemala,,,,,,,,,,,,,,
country,NCT00286455::country::Hungary,NCT00286455,Hungary,,,,,,,,,,,,,,
country,NCT00286455::country::India,NCT00286455,India,,,,,,,,,,,,,,
country,NCT00286455::country::Mexico,NCT00286455,Mexico,,,,,,,,,,,,,,
country,NCT00286455::country::Netherlands,NCT00286455,Netherlands,,,,,,,,,,,,,,
country,NCT00286455::country::New Zealand,NCT00286455,New Zealand,,,,,,,,,,,,,,
country,NCT00286455::country::Peru,NCT00286455,Peru,,,,,,,,,,,,,,
country,NCT00286455::country::Poland,NCT00286455,Poland,,,,,,,,,,,,,,
country,NCT00286455::country::South Africa,NCT00286455,South Africa,,,,,,,,,,,,,,
country,NCT00286455::country::United Kingdom,NCT00286455,United Kingdom,,,,,,,,,,,,,,
trial,NCT01819129,NCT01819129,Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,881.0,2013-09-09,2015-01-22,10.0,144.0,,,,,
arm,NCT01819129::arm::FG000,NCT01819129,Faster Aspart,,,,,,,,,,FG000,"At randomization, all subjects started on 4 units of mealtime faster aspart (bolus insulin) in combination with once-daily subcutaneous (sc) injection of insulin glargine (basal insulin) and metformin",,,
arm,NCT01819129::arm::FG001,NCT01819129,NovoRapid,,,,,,,,,,FG001,"At randomization, all subjects started on 4 units of mealtime NovoRapid®/NovoLog® (insulin aspart; bolus insulin) in combination with once-daily sc injection of insulin glargine (basal insulin) and me",,,
period,NCT01819129::period::1,NCT01819129,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01819129::outcome::primary::1,NCT01819129,Change From Baseline in HbA1c,,,,,,,,,,,,,PRIMARY,"Week 0, Week 26"
country,NCT01819129::country::United States,NCT01819129,United States,,,,,,,,,,,,,,
country,NCT01819129::country::Canada,NCT01819129,Canada,,,,,,,,,,,,,,
country,NCT01819129::country::Russia,NCT01819129,Russia,,,,,,,,,,,,,,
country,NCT01819129::country::India,NCT01819129,India,,,,,,,,,,,,,,
country,NCT01819129::country::United Kingdom,NCT01819129,United Kingdom,,,,,,,,,,,,,,
country,NCT01819129::country::Croatia,NCT01819129,Croatia,,,,,,,,,,,,,,
country,NCT01819129::country::Israel,NCT01819129,Israel,,,,,,,,,,,,,,
country,NCT01819129::country::Slovakia,NCT01819129,Slovakia,,,,,,,,,,,,,,
country,NCT01819129::country::Serbia,NCT01819129,Serbia,,,,,,,,,,,,,,
country,NCT01819129::country::Puerto Rico,NCT01819129,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01128153,NCT01128153,Saxagliptin Triple Oral Therapy,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,257.0,2010-06,2011-06,6.0,33.0,,,,,
arm,NCT01128153::arm::FG000,NCT01128153,SAXAGLIPTIN,,,,,,,,,,FG000,Saxagliptin 5 mg tablet once daily for 24 weeks to be taken orally,,,
arm,NCT01128153::arm::FG001,NCT01128153,PLACEBO,,,,,,,,,,FG001,Placebo tablet once daily for 24 weeks to be taken orally,,,
period,NCT01128153::period::1,NCT01128153,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01128153::outcome::primary::1,NCT01128153,"Change in HbA1c From Baseline to Week 24, Last Observation Carried Forward (LOCF)",,,,,,,,,,,,,PRIMARY,From Baseline to Week 24 weeks
country,NCT01128153::country::United Kingdom,NCT01128153,United Kingdom,,,,,,,,,,,,,,
country,NCT01128153::country::Australia,NCT01128153,Australia,,,,,,,,,,,,,,
country,NCT01128153::country::India,NCT01128153,India,,,,,,,,,,,,,,
country,NCT01128153::country::Canada,NCT01128153,Canada,,,,,,,,,,,,,,
country,NCT01128153::country::South Korea,NCT01128153,South Korea,,,,,,,,,,,,,,
country,NCT01128153::country::Thailand,NCT01128153,Thailand,,,,,,,,,,,,,,
trial,NCT00984867,NCT00984867,Dapagliflozin DPPIV Inhibitor add-on Study,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,833.0,2009-10,2011-09,6.0,88.0,,,,,
arm,NCT00984867::arm::FG000,NCT00984867,Placebo,,,,,,,,,,FG000,Placebo plus sitagliptin alone or in combination with metformin,,,
arm,NCT00984867::arm::FG001,NCT00984867,Dapagliflozin,,,,,,,,,,FG001,Dapagliflozin 10 mg plus sitagliptin alone or in combination with metformin,,,
period,NCT00984867::period::1,NCT00984867,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00984867::outcome::primary::1,NCT00984867,Adjusted Mean Change in HbA1c Levels,,,,,,,,,,,,,PRIMARY,Baseline to Week 24
country,NCT00984867::country::United States,NCT00984867,United States,,,,,,,,,,,,,,
country,NCT00984867::country::Poland,NCT00984867,Poland,,,,,,,,,,,,,,
country,NCT00984867::country::United Kingdom,NCT00984867,United Kingdom,,,,,,,,,,,,,,
country,NCT00984867::country::Argentina,NCT00984867,Argentina,,,,,,,,,,,,,,
country,NCT00984867::country::Germany,NCT00984867,Germany,,,,,,,,,,,,,,
country,NCT00984867::country::Mexico,NCT00984867,Mexico,,,,,,,,,,,,,,
trial,NCT01183013,NCT01183013,"30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks",PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,936.0,2010-08,2013-02,6.0,132.0,,,,,
arm,NCT01183013::arm::FG000,NCT01183013,Pio15/Pio30,,,,,,,,,,FG000,Participants treated with pioglitazone 15mg for 30 weeks followed by pioglitazone 30mg for up to 54 weeks.,,,
arm,NCT01183013::arm::FG001,NCT01183013,Pio30/Pio30,,,,,,,,,,FG001,Participants treated with pioglitazone 30mg for 30 weeks followed by pioglitazone 30mg for up to 54 weeks.,,,
arm,NCT01183013::arm::FG002,NCT01183013,Pio45/Pio45,,,,,,,,,,FG002,Participants treated with pioglitazone 30 mg for 6 weeks and then were titrated up to pioglitazone 45mg for 24 weeks followed by pioglitazone 45mg for up to 54 weeks.,,,
arm,NCT01183013::arm::FG003,NCT01183013,Lina5/Lina5,,,,,,,,,,FG003,Participants treated with linagliptin 5mg once daily for 30 weeks followed by linagliptin 5mg once daily for up to 54 weeks.,,,
arm,NCT01183013::arm::FG004,NCT01183013,Lina5Pio15/Lina5Pio30,,,,,,,,,,FG004,Participants treated with linagliptin 5mg + pioglitazone 15mg fixed dose combination (FDC) for 30 weeks followed by linagliptin 5mg + pioglitazone 30mg FDC for up to 54 weeks.,,,
arm,NCT01183013::arm::FG005,NCT01183013,Lina5Pio30/Lina5Pio30,,,,,,,,,,FG005,Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for 30 weeks followed by linagliptin 5mg + pioglitazone 30mg FDC for up to 54 weeks.,,,
arm,NCT01183013::arm::FG006,NCT01183013,Lina5Pio45/Lina5Pio45,,,,,,,,,,FG006,Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for 6 weeks and linagliptin 5mg + pioglitazone 45mg FDC for 24 weeks followed by linagliptin 5mg + pioglitazo,,,
period,NCT01183013::period::1,NCT01183013,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01183013::outcome::primary::1,NCT01183013,Change From Baseline in HbA1c After 30 Weeks of Treatment.,,,,,,,,,,,,,PRIMARY,Baseline and 30 weeks
country,NCT01183013::country::United States,NCT01183013,United States,,,,,,,,,,,,,,
country,NCT01183013::country::Latvia,NCT01183013,Latvia,,,,,,,,,,,,,,
country,NCT01183013::country::United Kingdom,NCT01183013,United Kingdom,,,,,,,,,,,,,,
country,NCT01183013::country::Spain,NCT01183013,Spain,,,,,,,,,,,,,,
country,NCT01183013::country::Estonia,NCT01183013,Estonia,,,,,,,,,,,,,,
country,NCT01183013::country::Germany,NCT01183013,Germany,,,,,,,,,,,,,,
trial,NCT00789750,NCT00789750,Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,562.0,2009-04,2012-07,1.0,141.0,,,,,
arm,NCT00789750::arm::FG000,NCT00789750,Colesevelam,,,,,,,,,,FG000,Colesevelam tablets with pioglitazone therapy,,,
arm,NCT00789750::arm::FG001,NCT00789750,Placebo,,,,,,,,,,FG001,Placebo tablets with pioglitazone therapy,,,
period,NCT00789750::period::1,NCT00789750,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00789750::outcome::primary::1,NCT00789750,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24,,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
country,NCT00789750::country::United States,NCT00789750,United States,,,,,,,,,,,,,,
trial,NCT03371108,NCT03371108,Gan & Lee Insulin Glargine Target Type (2) Evaluating Research,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,567.0,2017-10-31,2019-04-17,1.0,57.0,,,,,
arm,NCT03371108::arm::FG000,NCT03371108,Gan & Lee Insulin Glargine Injection,,,,,,,,,,FG000,"Gan \& Lee Insulin Glargine Injection solution for subcutaneous injection, 100 U/mL, in the integrated, disposable 3.0 mL prefilled Gan \& Lee injector pen. Subjects randomized to the Gan \& Lee Insul",,,
arm,NCT03371108::arm::FG001,NCT03371108,Lantus®,,,,,,,,,,FG001,"Lantus® solution for subcutaneous injection, 100 U/mL, in the SoloStar® 3.0 mL prefilled insulin pen. Subjects randomized to the Lantus® group will participate for 26 weeks.

Lantus®: Route of adminis",,,
period,NCT03371108::period::1,NCT03371108,Safety Analysis Set,,,,,,,,,,,,1.0,,
period,NCT03371108::period::2,NCT03371108,Completers,,,,,,,,,,,,2.0,,
outcome,NCT03371108::outcome::primary::1,NCT03371108,Treatment-induced Anti-Insulin Antibody (TI-AIA) is the Primary Endpoint,,,,,,,,,,,,,PRIMARY,Baseline to Week 26
country,NCT03371108::country::United States,NCT03371108,United States,,,,,,,,,,,,,,
trial,NCT04848480,NCT04848480,"A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)",PHASE3,diabetes type 2,"Diabetes Mellitus, Type 1",INDUSTRY,582.0,2021-04-30,2022-12-02,12.0,130.0,,,,,
arm,NCT04848480::arm::FG000,NCT04848480,Insulin Icodec + Insulin Aspart,,,,,,,,,,FG000,Participants received Insulin icodec along with Insulin aspart for 52 weeks subcutaneously. Participants received once weekly subcutaneous (s.c.) injection of Insulin icodec using PDS290 prefilled pen,,,
arm,NCT04848480::arm::FG001,NCT04848480,Insulin Degludec + Insulin Aspart,,,,,,,,,,FG001,Participants received Insulin degludec along with Insulin aspart for 52 weeks subcutaneously. Participants received once daily s.c. injection of Insulin degludec using PDS290 prefilled pen-injector at,,,
period,NCT04848480::period::1,NCT04848480,Main Phase (26 Weeks),,,,,,,,,,,,1.0,,
period,NCT04848480::period::2,NCT04848480,Extension Phase (26 Weeks),,,,,,,,,,,,2.0,,
outcome,NCT04848480::outcome::primary::1,NCT04848480,Change in Glycosylated Haemoglobin (HbA1c) at Week 26,,,,,,,,,,,,,PRIMARY,"Baseline (week 0), week 26"
country,NCT04848480::country::United States,NCT04848480,United States,,,,,,,,,,,,,,
country,NCT04848480::country::Russia,NCT04848480,Russia,,,,,,,,,,,,,,
country,NCT04848480::country::Canada,NCT04848480,Canada,,,,,,,,,,,,,,
country,NCT04848480::country::Germany,NCT04848480,Germany,,,,,,,,,,,,,,
country,NCT04848480::country::India,NCT04848480,India,,,,,,,,,,,,,,
country,NCT04848480::country::United Kingdom,NCT04848480,United Kingdom,,,,,,,,,,,,,,
country,NCT04848480::country::Italy,NCT04848480,Italy,,,,,,,,,,,,,,
country,NCT04848480::country::Japan,NCT04848480,Japan,,,,,,,,,,,,,,
country,NCT04848480::country::Netherlands,NCT04848480,Netherlands,,,,,,,,,,,,,,
country,NCT04848480::country::Turkey (Türkiye),NCT04848480,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT04848480::country::Austria,NCT04848480,Austria,,,,,,,,,,,,,,
country,NCT04848480::country::Spain,NCT04848480,Spain,,,,,,,,,,,,,,
trial,NCT01147250,NCT01147250,Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide),PHASE3,diabetes type 2,Acute Coronary Syndrome,INDUSTRY,6068.0,2010-06,2015-02,49.0,829.0,,,,,
arm,NCT01147250::arm::FG000,NCT01147250,Placebo,,,,,,,,,,FG000,Placebo matched to lixisenatide once daily (QD) subcutaneously (SC) up to end of treatment (median exposure: 23 months).,,,
arm,NCT01147250::arm::FG001,NCT01147250,Lixisenatide,,,,,,,,,,FG001,"Lixisenatide 10 mcg QD SC for 2 weeks post-randomization, then at a maintenance dose of 20 mcg QD up to end of treatment (median exposure: 22 months).",,,
period,NCT01147250::period::1,NCT01147250,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01147250::outcome::primary::1,NCT01147250,"Time to First Occurence of Primary CV Event: CV Death, Non-Fatal MI, Non-Fatal Stroke or Hospitalization for Unstable Angina",,,,,,,,,,,,,PRIMARY,From randomization up to the end of study (median follow-up of 25 months)
country,NCT01147250::country::United States,NCT01147250,United States,,,,,,,,,,,,,,
country,NCT01147250::country::Russia,NCT01147250,Russia,,,,,,,,,,,,,,
country,NCT01147250::country::Argentina,NCT01147250,Argentina,,,,,,,,,,,,,,
country,NCT01147250::country::United Kingdom,NCT01147250,United Kingdom,,,,,,,,,,,,,,
country,NCT01147250::country::Chile,NCT01147250,Chile,,,,,,,,,,,,,,
country,NCT01147250::country::Mexico,NCT01147250,Mexico,,,,,,,,,,,,,,
country,NCT01147250::country::India,NCT01147250,India,,,,,,,,,,,,,,
country,NCT01147250::country::Japan,NCT01147250,Japan,,,,,,,,,,,,,,
country,NCT01147250::country::Brazil,NCT01147250,Brazil,,,,,,,,,,,,,,
country,NCT01147250::country::Romania,NCT01147250,Romania,,,,,,,,,,,,,,
country,NCT01147250::country::Poland,NCT01147250,Poland,,,,,,,,,,,,,,
country,NCT01147250::country::China,NCT01147250,China,,,,,,,,,,,,,,
country,NCT01147250::country::Colombia,NCT01147250,Colombia,,,,,,,,,,,,,,
country,NCT01147250::country::Germany,NCT01147250,Germany,,,,,,,,,,,,,,
country,NCT01147250::country::Italy,NCT01147250,Italy,,,,,,,,,,,,,,
country,NCT01147250::country::South Africa,NCT01147250,South Africa,,,,,,,,,,,,,,
country,NCT01147250::country::Peru,NCT01147250,Peru,,,,,,,,,,,,,,
country,NCT01147250::country::Spain,NCT01147250,Spain,,,,,,,,,,,,,,
country,NCT01147250::country::Canada,NCT01147250,Canada,,,,,,,,,,,,,,
country,NCT01147250::country::South Korea,NCT01147250,South Korea,,,,,,,,,,,,,,
country,NCT01147250::country::Ukraine,NCT01147250,Ukraine,,,,,,,,,,,,,,
country,NCT01147250::country::Bulgaria,NCT01147250,Bulgaria,,,,,,,,,,,,,,
country,NCT01147250::country::Denmark,NCT01147250,Denmark,,,,,,,,,,,,,,
country,NCT01147250::country::Israel,NCT01147250,Israel,,,,,,,,,,,,,,
country,NCT01147250::country::Turkey (Türkiye),NCT01147250,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01147250::country::Guatemala,NCT01147250,Guatemala,,,,,,,,,,,,,,
country,NCT01147250::country::Serbia,NCT01147250,Serbia,,,,,,,,,,,,,,
country,NCT01147250::country::France,NCT01147250,France,,,,,,,,,,,,,,
country,NCT01147250::country::Philippines,NCT01147250,Philippines,,,,,,,,,,,,,,
country,NCT01147250::country::Taiwan,NCT01147250,Taiwan,,,,,,,,,,,,,,
country,NCT01147250::country::Latvia,NCT01147250,Latvia,,,,,,,,,,,,,,
country,NCT01147250::country::Netherlands,NCT01147250,Netherlands,,,,,,,,,,,,,,
country,NCT01147250::country::Sweden,NCT01147250,Sweden,,,,,,,,,,,,,,
country,NCT01147250::country::Australia,NCT01147250,Australia,,,,,,,,,,,,,,
country,NCT01147250::country::Estonia,NCT01147250,Estonia,,,,,,,,,,,,,,
country,NCT01147250::country::Finland,NCT01147250,Finland,,,,,,,,,,,,,,
country,NCT01147250::country::Lithuania,NCT01147250,Lithuania,,,,,,,,,,,,,,
country,NCT01147250::country::Portugal,NCT01147250,Portugal,,,,,,,,,,,,,,
country,NCT01147250::country::Tunisia,NCT01147250,Tunisia,,,,,,,,,,,,,,
country,NCT01147250::country::Georgia,NCT01147250,Georgia,,,,,,,,,,,,,,
country,NCT01147250::country::Panama,NCT01147250,Panama,,,,,,,,,,,,,,
country,NCT01147250::country::Belarus,NCT01147250,Belarus,,,,,,,,,,,,,,
country,NCT01147250::country::Ecuador,NCT01147250,Ecuador,,,,,,,,,,,,,,
country,NCT01147250::country::Norway,NCT01147250,Norway,,,,,,,,,,,,,,
country,NCT01147250::country::Austria,NCT01147250,Austria,,,,,,,,,,,,,,
country,NCT01147250::country::Belgium,NCT01147250,Belgium,,,,,,,,,,,,,,
country,NCT01147250::country::Egypt,NCT01147250,Egypt,,,,,,,,,,,,,,
country,NCT01147250::country::United Arab Emirates,NCT01147250,United Arab Emirates,,,,,,,,,,,,,,
country,NCT01147250::country::Switzerland,NCT01147250,Switzerland,,,,,,,,,,,,,,
trial,NCT02099110,NCT02099110,"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)",PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,1233.0,2014-04-22,2016-05-26,0.0,0.0,,,,,
arm,NCT02099110::arm::FG000,NCT02099110,Ertugliflozin 5 mg,,,,,,,,,,FG000,"Ertugliflozin 5 mg, oral, once daily for 52 weeks",,,
arm,NCT02099110::arm::FG001,NCT02099110,Ertugliflozin 15 mg,,,,,,,,,,FG001,"Ertugliflozin, oral, once daily for 52 weeks",,,
arm,NCT02099110::arm::FG002,NCT02099110,Sitagliptin 100 mg,,,,,,,,,,FG002,"Sitagliptin 100 mg, oral, once daily for 52 weeks",,,
arm,NCT02099110::arm::FG003,NCT02099110,Ertugliflozin 5 mg + Sitagliptin 100 mg,,,,,,,,,,FG003,"Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks",,,
arm,NCT02099110::arm::FG004,NCT02099110,Ertugliflozin 15 mg + Sitagliptin 100 mg,,,,,,,,,,FG004,"Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks",,,
period,NCT02099110::period::1,NCT02099110,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02099110::outcome::primary::1,NCT02099110,Change From Baseline in A1C at Week 26: Excluding Rescue Approach,,,,,,,,,,,,,PRIMARY,Baseline and Week 26
outcome,NCT02099110::outcome::primary::2,NCT02099110,Percentage of Participants Who Experienced an Adverse Event (AE): Including Rescue Approach,,,,,,,,,,,,,PRIMARY,Up to 54 weeks
outcome,NCT02099110::outcome::primary::3,NCT02099110,Percentage of Participants Who Discontinued Study Treatment Due to an AE: Including Rescue Approach,,,,,,,,,,,,,PRIMARY,Up to 52 weeks
trial,NCT02906917,NCT02906917,A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,532.0,2016-09-20,2017-12-24,7.0,71.0,,,,,
arm,NCT02906917::arm::FG000,NCT02906917,Insulin Degludec/Insulin Aspart,,,,,,,,,,FG000,"Subjects received treatment for 38 weeks as per the following sequence: 1) Initiation period (period-1, week 0-26): Insulin degludec/insulin aspart (IDegAsp) once daily (OD) administered at the larges",,,
arm,NCT02906917::arm::FG001,NCT02906917,Insulin Glargine + Insulin Aspart,,,,,,,,,,FG001,"Subjects received treatment for 38 weeks as per the following sequence: 1) Initiation period (period-1, week 0-26): Insulin glargine (IGlar) OD administered in accordance with local labelling and insu",,,
period,NCT02906917::period::1,NCT02906917,Initiation Period (Week 0-26),,,,,,,,,,,,1.0,,
period,NCT02906917::period::2,NCT02906917,Intensification Period (Week 26-38),,,,,,,,,,,,2.0,,
outcome,NCT02906917::outcome::primary::1,NCT02906917,Change in HbA1c (%) - Week 26,,,,,,,,,,,,,PRIMARY,"Week 0, week 26"
country,NCT02906917::country::United States,NCT02906917,United States,,,,,,,,,,,,,,
country,NCT02906917::country::Russia,NCT02906917,Russia,,,,,,,,,,,,,,
country,NCT02906917::country::India,NCT02906917,India,,,,,,,,,,,,,,
country,NCT02906917::country::Turkey (Türkiye),NCT02906917,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02906917::country::Czechia,NCT02906917,Czechia,,,,,,,,,,,,,,
country,NCT02906917::country::Algeria,NCT02906917,Algeria,,,,,,,,,,,,,,
country,NCT02906917::country::Serbia,NCT02906917,Serbia,,,,,,,,,,,,,,
trial,NCT02207374,NCT02207374,A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,601.0,2014-08-04,2016-02-27,1.0,43.0,,,,,
arm,NCT02207374::arm::FG000,NCT02207374,Semaglutide 0.5 mg,,,,,,,,,,FG000,"Subjects were randomized to receive semaglutide 0.5 mg once weekly subcutaneously (s.c.; under the skin) in the thigh, abdomen, or upper arm for a period up to 56 weeks. The treatment period was divid",,,
arm,NCT02207374::arm::FG001,NCT02207374,Semaglutide 1.0 mg,,,,,,,,,,FG001,"Subjects were randomized to receive semaglutide 1.0 mg once weekly subcutaneously (s.c.; under the skin) in the thigh, abdomen, or upper arm for a period up to 56 weeks. The treatment period was divid",,,
arm,NCT02207374::arm::FG002,NCT02207374,Additional OAD,,,,,,,,,,FG002,Subjects were randomised to receive one additional OAD in addition to the pre-trial treatment for a duration of 56 weeks. The type and dosage of the additional OAD was selected by the investigator acc,,,
period,NCT02207374::period::1,NCT02207374,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02207374::outcome::primary::1,NCT02207374,Number of Treatment Emergent Adverse Events (TEAEs),,,,,,,,,,,,,PRIMARY,Weeks 0-56
country,NCT02207374::country::Japan,NCT02207374,Japan,,,,,,,,,,,,,,
trial,NCT02585778,NCT02585778,Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin),PHASE3,diabetes type 2,Hypercholesterolaemia,INDUSTRY,517.0,2015-10-23,2017-04-03,10.0,110.0,,,,,
arm,NCT02585778::arm::FG000,NCT02585778,Alirocumab 75 mg Q2W/Up to 150 mg Q2W,,,,,,,,,,FG000,"Alirocumab 75 mg subcutaneous (SC) injection every 2 weeks (Q2W) added to stable, maximally tolerated dose of statin therapy with or without other lipid-modifying therapy (LMT), insulin alone or with ",,,
arm,NCT02585778::arm::FG001,NCT02585778,Placebo Q2W,,,,,,,,,,FG001,"Placebo (for alirocumab) SC injection Q2W added to stable, maximally tolerated dose of statin therapy with or without other LMT, insulin alone or with other antihyperglycemic drugs for 24 weeks.",,,
period,NCT02585778::period::1,NCT02585778,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02585778::outcome::primary::1,NCT02585778,Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis,,,,,,,,,,,,,PRIMARY,From Baseline to Week 24
outcome,NCT02585778::outcome::primary::2,NCT02585778,Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs),,,,,,,,,,,,,PRIMARY,From Baseline up to 10 weeks after last study drug administration (maximum of 32 weeks)
country,NCT02585778::country::United States,NCT02585778,United States,,,,,,,,,,,,,,
country,NCT02585778::country::Germany,NCT02585778,Germany,,,,,,,,,,,,,,
country,NCT02585778::country::Spain,NCT02585778,Spain,,,,,,,,,,,,,,
country,NCT02585778::country::United Kingdom,NCT02585778,United Kingdom,,,,,,,,,,,,,,
country,NCT02585778::country::Italy,NCT02585778,Italy,,,,,,,,,,,,,,
country,NCT02585778::country::France,NCT02585778,France,,,,,,,,,,,,,,
country,NCT02585778::country::Austria,NCT02585778,Austria,,,,,,,,,,,,,,
country,NCT02585778::country::Netherlands,NCT02585778,Netherlands,,,,,,,,,,,,,,
country,NCT02585778::country::Belgium,NCT02585778,Belgium,,,,,,,,,,,,,,
country,NCT02585778::country::Switzerland,NCT02585778,Switzerland,,,,,,,,,,,,,,
trial,NCT00968708,NCT00968708,Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2; Acute Coronary Syndrome",INDUSTRY,5380.0,2009-09,2013-06,50.0,908.0,,,,,
arm,NCT00968708::arm::FG000,NCT00968708,Placebo,,,,,,,,,,FG000,"Alogliptin placebo matching tablets, orally, once daily. Participants continued to receive standard of care for cardiovascular disease and diabetes according to regional guidelines.",,,
arm,NCT00968708::arm::FG001,NCT00968708,Alogliptin,,,,,,,,,,FG001,"Alogliptin 25 mg, tablets, orally, once daily for participants with normal or mildly impaired renal function as defined by estimated glomerular filtration rate (eGFR) ≥ 60 mL/min). Alogliptin 12.5 mg,",,,
period,NCT00968708::period::1,NCT00968708,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00968708::outcome::primary::1,NCT00968708,Percentage of Participants With Primary Major Adverse Cardiac Events (MACE),,,,,,,,,,,,,PRIMARY,From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).
country,NCT00968708::country::United States,NCT00968708,United States,,,,,,,,,,,,,,
country,NCT00968708::country::Brazil,NCT00968708,Brazil,,,,,,,,,,,,,,
country,NCT00968708::country::Japan,NCT00968708,Japan,,,,,,,,,,,,,,
country,NCT00968708::country::Argentina,NCT00968708,Argentina,,,,,,,,,,,,,,
country,NCT00968708::country::Mexico,NCT00968708,Mexico,,,,,,,,,,,,,,
country,NCT00968708::country::India,NCT00968708,India,,,,,,,,,,,,,,
country,NCT00968708::country::Canada,NCT00968708,Canada,,,,,,,,,,,,,,
country,NCT00968708::country::Poland,NCT00968708,Poland,,,,,,,,,,,,,,
country,NCT00968708::country::United Kingdom,NCT00968708,United Kingdom,,,,,,,,,,,,,,
country,NCT00968708::country::Germany,NCT00968708,Germany,,,,,,,,,,,,,,
country,NCT00968708::country::Russia,NCT00968708,Russia,,,,,,,,,,,,,,
country,NCT00968708::country::Peru,NCT00968708,Peru,,,,,,,,,,,,,,
country,NCT00968708::country::Hungary,NCT00968708,Hungary,,,,,,,,,,,,,,
country,NCT00968708::country::Slovakia,NCT00968708,Slovakia,,,,,,,,,,,,,,
country,NCT00968708::country::Israel,NCT00968708,Israel,,,,,,,,,,,,,,
country,NCT00968708::country::France,NCT00968708,France,,,,,,,,,,,,,,
country,NCT00968708::country::Romania,NCT00968708,Romania,,,,,,,,,,,,,,
country,NCT00968708::country::South Korea,NCT00968708,South Korea,,,,,,,,,,,,,,
country,NCT00968708::country::Australia,NCT00968708,Australia,,,,,,,,,,,,,,
country,NCT00968708::country::Bulgaria,NCT00968708,Bulgaria,,,,,,,,,,,,,,
country,NCT00968708::country::Puerto Rico,NCT00968708,Puerto Rico,,,,,,,,,,,,,,
country,NCT00968708::country::South Africa,NCT00968708,South Africa,,,,,,,,,,,,,,
country,NCT00968708::country::Spain,NCT00968708,Spain,,,,,,,,,,,,,,
country,NCT00968708::country::Thailand,NCT00968708,Thailand,,,,,,,,,,,,,,
country,NCT00968708::country::Chile,NCT00968708,Chile,,,,,,,,,,,,,,
country,NCT00968708::country::Philippines,NCT00968708,Philippines,,,,,,,,,,,,,,
country,NCT00968708::country::Ukraine,NCT00968708,Ukraine,,,,,,,,,,,,,,
country,NCT00968708::country::Croatia,NCT00968708,Croatia,,,,,,,,,,,,,,
country,NCT00968708::country::Italy,NCT00968708,Italy,,,,,,,,,,,,,,
country,NCT00968708::country::Malaysia,NCT00968708,Malaysia,,,,,,,,,,,,,,
country,NCT00968708::country::Sweden,NCT00968708,Sweden,,,,,,,,,,,,,,
country,NCT00968708::country::Belgium,NCT00968708,Belgium,,,,,,,,,,,,,,
country,NCT00968708::country::Czechia,NCT00968708,Czechia,,,,,,,,,,,,,,
country,NCT00968708::country::Finland,NCT00968708,Finland,,,,,,,,,,,,,,
country,NCT00968708::country::Lithuania,NCT00968708,Lithuania,,,,,,,,,,,,,,
country,NCT00968708::country::New Zealand,NCT00968708,New Zealand,,,,,,,,,,,,,,
country,NCT00968708::country::Latvia,NCT00968708,Latvia,,,,,,,,,,,,,,
country,NCT00968708::country::Turkey (Türkiye),NCT00968708,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00968708::country::Austria,NCT00968708,Austria,,,,,,,,,,,,,,
country,NCT00968708::country::Colombia,NCT00968708,Colombia,,,,,,,,,,,,,,
country,NCT00968708::country::Hong Kong,NCT00968708,Hong Kong,,,,,,,,,,,,,,
country,NCT00968708::country::Portugal,NCT00968708,Portugal,,,,,,,,,,,,,,
country,NCT00968708::country::Denmark,NCT00968708,Denmark,,,,,,,,,,,,,,
country,NCT00968708::country::Egypt,NCT00968708,Egypt,,,,,,,,,,,,,,
country,NCT00968708::country::Taiwan,NCT00968708,Taiwan,,,,,,,,,,,,,,
country,NCT00968708::country::Guatemala,NCT00968708,Guatemala,,,,,,,,,,,,,,
country,NCT00968708::country::Serbia,NCT00968708,Serbia,,,,,,,,,,,,,,
country,NCT00968708::country::Greece,NCT00968708,Greece,,,,,,,,,,,,,,
country,NCT00968708::country::Kuwait,NCT00968708,Kuwait,,,,,,,,,,,,,,
country,NCT00968708::country::United Arab Emirates,NCT00968708,United Arab Emirates,,,,,,,,,,,,,,
trial,NCT01894568,NCT01894568,A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,388.0,2013-07,2015-04,3.0,31.0,,,,,
arm,NCT01894568::arm::FG000,NCT01894568,Insulin Peglispro,,,,,,,,,,FG000,Insulin Peglispro administered subcutaneously (SC) once daily for 26 weeks.,,,
arm,NCT01894568::arm::FG001,NCT01894568,Insulin Glargine,,,,,,,,,,FG001,Insulin Glargine administered SC once daily for 26 weeks.,,,
period,NCT01894568::period::1,NCT01894568,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01894568::outcome::primary::1,NCT01894568,Change From Baseline to Week 26 in Hemoglobin A1c (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline, Week 26"
country,NCT01894568::country::Japan,NCT01894568,Japan,,,,,,,,,,,,,,
country,NCT01894568::country::Taiwan,NCT01894568,Taiwan,,,,,,,,,,,,,,
country,NCT01894568::country::South Korea,NCT01894568,South Korea,,,,,,,,,,,,,,
trial,NCT00553787,NCT00553787,Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions,PHASE3,diabetes type 2,Obesity; Type 2 Diabetes,INDUSTRY,2487.0,2007-11,2009-06,1.0,6.0,,,,,
arm,NCT00553787::arm::FG000,NCT00553787,Placebo,,,,,,,,,,FG000,,,,
arm,NCT00553787::arm::FG001,NCT00553787,VI-0521 Mid,,,,,,,,,,FG001,7.5 mg/46 mg phentermine/topiramate,,,
arm,NCT00553787::arm::FG002,NCT00553787,VI-0521 Top,,,,,,,,,,FG002,15 mg/92 mg phentermine/topiramate,,,
period,NCT00553787::period::1,NCT00553787,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00553787::outcome::primary::1,NCT00553787,Percent Weight Loss From Baseline to Week 56,,,,,,,,,,,,,PRIMARY,Baseline to 56 weeks
outcome,NCT00553787::outcome::primary::2,NCT00553787,Percentage of Subjects With a Weight Loss of at Least 5% at Week 56 With LOCF,,,,,,,,,,,,,PRIMARY,Baseline to 56 weeks
country,NCT00553787::country::United States,NCT00553787,United States,,,,,,,,,,,,,,
trial,NCT01326026,NCT01326026,Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,222.0,2011-03,2011-12,4.0,45.0,,,,,
arm,NCT01326026::arm::FG000,NCT01326026,IDeg Simple,,,,,,,,,,FG000,Insulin degludec (IDeg) was given once daily (OD) subcutaneously (approximately 8-40 hours intervals between doses) with pre-trial metformin according to simple titration algorithm: self-titration was,,,
arm,NCT01326026::arm::FG001,NCT01326026,IDeg Step Wise,,,,,,,,,,FG001,Insulin degludec (IDeg) was given once daily (OD) subcutaneously (approximately 8-40 hours intervals between doses) with pre-trial metformin according to step wise titration algorithm: self-titration ,,,
period,NCT01326026::period::1,NCT01326026,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01326026::outcome::primary::1,NCT01326026,Change in Glycosylated Haemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Week 0, Week 26"
country,NCT01326026::country::United States,NCT01326026,United States,,,,,,,,,,,,,,
country,NCT01326026::country::Spain,NCT01326026,Spain,,,,,,,,,,,,,,
country,NCT01326026::country::Germany,NCT01326026,Germany,,,,,,,,,,,,,,
country,NCT01326026::country::Finland,NCT01326026,Finland,,,,,,,,,,,,,,
trial,NCT04537923,NCT04537923,A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,1428.0,2020-10-19,2022-11-01,16.0,135.0,,,,,
arm,NCT04537923::arm::FG000,NCT04537923,5 mg Tirzepatide,,,,,,,,,,FG000,Participants received 5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.,,,
arm,NCT04537923::arm::FG001,NCT04537923,10 mg Tirzepatide,,,,,,,,,,FG001,Participants received 10 mg tirzepatide administered SC once a week .,,,
arm,NCT04537923::arm::FG002,NCT04537923,15 mg Tirzepatide,,,,,,,,,,FG002,Participants received 15 mg tirzepatide administered SC once a week.,,,
arm,NCT04537923::arm::FG003,NCT04537923,Insulin Lispro,,,,,,,,,,FG003,Participants received Insulin lispro 100 units per milliliter (U100) administered SC three times a day.,,,
period,NCT04537923::period::1,NCT04537923,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04537923::outcome::primary::1,NCT04537923,"Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg)",,,,,,,,,,,,,PRIMARY,"Baseline, Week 52"
country,NCT04537923::country::United States,NCT04537923,United States,,,,,,,,,,,,,,
country,NCT04537923::country::Brazil,NCT04537923,Brazil,,,,,,,,,,,,,,
country,NCT04537923::country::Argentina,NCT04537923,Argentina,,,,,,,,,,,,,,
country,NCT04537923::country::Romania,NCT04537923,Romania,,,,,,,,,,,,,,
country,NCT04537923::country::Germany,NCT04537923,Germany,,,,,,,,,,,,,,
country,NCT04537923::country::Russia,NCT04537923,Russia,,,,,,,,,,,,,,
country,NCT04537923::country::Mexico,NCT04537923,Mexico,,,,,,,,,,,,,,
country,NCT04537923::country::Slovakia,NCT04537923,Slovakia,,,,,,,,,,,,,,
country,NCT04537923::country::Spain,NCT04537923,Spain,,,,,,,,,,,,,,
country,NCT04537923::country::Turkey (Türkiye),NCT04537923,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT04537923::country::Czechia,NCT04537923,Czechia,,,,,,,,,,,,,,
country,NCT04537923::country::Greece,NCT04537923,Greece,,,,,,,,,,,,,,
country,NCT04537923::country::Hungary,NCT04537923,Hungary,,,,,,,,,,,,,,
country,NCT04537923::country::Italy,NCT04537923,Italy,,,,,,,,,,,,,,
country,NCT04537923::country::Puerto Rico,NCT04537923,Puerto Rico,,,,,,,,,,,,,,
country,NCT04537923::country::Belgium,NCT04537923,Belgium,,,,,,,,,,,,,,
trial,NCT01340768,NCT01340768,Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,870.0,2010-06-22,2011-09-21,0.0,0.0,,,,,
arm,NCT01340768::arm::FG000,NCT01340768,Sitagliptin,,,,,,,,,,FG000,"Sitagliptin 100mg taken orally once daily, with or without metformin",,,
arm,NCT01340768::arm::FG001,NCT01340768,Sulfonylurea Therapy,,,,,,,,,,FG001,"Usual sulfonylurea therapy and dose for each participant, with or without metformin",,,
period,NCT01340768::period::1,NCT01340768,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01340768::outcome::primary::1,NCT01340768,Percentage of Participants With at Least One Symptomatic Hypoglycemic Event,,,,,,,,,,,,,PRIMARY,Up to 30 days (Day 1 through last day of Ramadan)
trial,NCT01029886,NCT01029886,Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,912.0,2010-01,2011-04,21.0,108.0,,,,,
arm,NCT01029886::arm::FG000,NCT01029886,Exenatide Once Weekly,,,,,,,,,,FG000,"Subcutaneous injection, 2mg, once weekly",,,
arm,NCT01029886::arm::FG001,NCT01029886,Liraglutide Once Daily,,,,,,,,,,FG001,"Subcutaneous injection, forced titration to 1.8mg, once daily",,,
period,NCT01029886::period::1,NCT01029886,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01029886::outcome::primary::1,NCT01029886,Change in HbA1c From Baseline to Week 26,,,,,,,,,,,,,PRIMARY,"Baseline, Week 26"
country,NCT01029886::country::Germany,NCT01029886,Germany,,,,,,,,,,,,,,
country,NCT01029886::country::India,NCT01029886,India,,,,,,,,,,,,,,
country,NCT01029886::country::Canada,NCT01029886,Canada,,,,,,,,,,,,,,
country,NCT01029886::country::France,NCT01029886,France,,,,,,,,,,,,,,
country,NCT01029886::country::Italy,NCT01029886,Italy,,,,,,,,,,,,,,
country,NCT01029886::country::Hungary,NCT01029886,Hungary,,,,,,,,,,,,,,
country,NCT01029886::country::Poland,NCT01029886,Poland,,,,,,,,,,,,,,
country,NCT01029886::country::Spain,NCT01029886,Spain,,,,,,,,,,,,,,
country,NCT01029886::country::Belgium,NCT01029886,Belgium,,,,,,,,,,,,,,
country,NCT01029886::country::South Africa,NCT01029886,South Africa,,,,,,,,,,,,,,
country,NCT01029886::country::Taiwan,NCT01029886,Taiwan,,,,,,,,,,,,,,
country,NCT01029886::country::Israel,NCT01029886,Israel,,,,,,,,,,,,,,
country,NCT01029886::country::Romania,NCT01029886,Romania,,,,,,,,,,,,,,
country,NCT01029886::country::Slovakia,NCT01029886,Slovakia,,,,,,,,,,,,,,
country,NCT01029886::country::Argentina,NCT01029886,Argentina,,,,,,,,,,,,,,
country,NCT01029886::country::Australia,NCT01029886,Australia,,,,,,,,,,,,,,
country,NCT01029886::country::Czechia,NCT01029886,Czechia,,,,,,,,,,,,,,
country,NCT01029886::country::Greece,NCT01029886,Greece,,,,,,,,,,,,,,
country,NCT01029886::country::Mexico,NCT01029886,Mexico,,,,,,,,,,,,,,
country,NCT01029886::country::South Korea,NCT01029886,South Korea,,,,,,,,,,,,,,
country,NCT01029886::country::Austria,NCT01029886,Austria,,,,,,,,,,,,,,
trial,NCT02836873,NCT02836873,Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,312.0,2016-09-23,2018-01-11,4.0,56.0,,,,,
arm,NCT02836873::arm::FG000,NCT02836873,Bexagliflozin 20 mg,,,,,,,,,,FG000,"Each subject will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study.",,,
arm,NCT02836873::arm::FG001,NCT02836873,Placebo,,,,,,,,,,FG001,Each subject will receive a placebo (inactive) tablet once daily for the duration of the study.,,,
period,NCT02836873::period::1,NCT02836873,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02836873::outcome::primary::1,NCT02836873,Change From Baseline in HbA1c at 24 Weeks,,,,,,,,,,,,,PRIMARY,24 weeks
country,NCT02836873::country::United States,NCT02836873,United States,,,,,,,,,,,,,,
country,NCT02836873::country::Japan,NCT02836873,Japan,,,,,,,,,,,,,,
country,NCT02836873::country::Spain,NCT02836873,Spain,,,,,,,,,,,,,,
country,NCT02836873::country::France,NCT02836873,France,,,,,,,,,,,,,,
trial,NCT02863328,NCT02863328,Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,822.0,2016-08-10,2018-03-08,12.0,106.0,,,,,
arm,NCT02863328::arm::FG000,NCT02863328,Oral Semaglutide 14 mg,,,,,,,,,,FG000,Participants received once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until the final maintenance dose of 1,,,
arm,NCT02863328::arm::FG001,NCT02863328,Empagliflozin 25 mg,,,,,,,,,,FG001,Participants received once-daily empagliflozin tablets for 52 weeks. Participants started empagliflozin at 10 mg for 8 weeks. Participants were treated with empagliflozin 25 mg if their eGFR was great,,,
period,NCT02863328::period::1,NCT02863328,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02863328::outcome::primary::1,NCT02863328,Change in HbA1c,,,,,,,,,,,,,PRIMARY,"Week 0, week 26"
country,NCT02863328::country::United States,NCT02863328,United States,,,,,,,,,,,,,,
country,NCT02863328::country::Spain,NCT02863328,Spain,,,,,,,,,,,,,,
country,NCT02863328::country::Greece,NCT02863328,Greece,,,,,,,,,,,,,,
country,NCT02863328::country::Croatia,NCT02863328,Croatia,,,,,,,,,,,,,,
country,NCT02863328::country::Hungary,NCT02863328,Hungary,,,,,,,,,,,,,,
country,NCT02863328::country::Italy,NCT02863328,Italy,,,,,,,,,,,,,,
country,NCT02863328::country::Poland,NCT02863328,Poland,,,,,,,,,,,,,,
country,NCT02863328::country::Russia,NCT02863328,Russia,,,,,,,,,,,,,,
country,NCT02863328::country::Argentina,NCT02863328,Argentina,,,,,,,,,,,,,,
country,NCT02863328::country::Brazil,NCT02863328,Brazil,,,,,,,,,,,,,,
country,NCT02863328::country::Serbia,NCT02863328,Serbia,,,,,,,,,,,,,,
country,NCT02863328::country::Thailand,NCT02863328,Thailand,,,,,,,,,,,,,,
trial,NCT02906930,NCT02906930,Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,703.0,2016-09-20,2017-12-08,11.0,105.0,,,,,
arm,NCT02906930::arm::FG000,NCT02906930,Oral Semaglutide 3 mg,,,,,,,,,,FG000,Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 26.,,,
arm,NCT02906930::arm::FG001,NCT02906930,Oral Semaglutide 7 mg,,,,,,,,,,FG001,Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 26: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 26.,,,
arm,NCT02906930::arm::FG002,NCT02906930,Oral Semaglutide 14 mg,,,,,,,,,,FG002,"Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 26: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 2",,,
arm,NCT02906930::arm::FG003,NCT02906930,Placebo,,,,,,,,,,FG003,Participants were to take placebo tablets once daily for a period of 26 weeks.,,,
period,NCT02906930::period::1,NCT02906930,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02906930::outcome::primary::1,NCT02906930,Change in HbA1c,,,,,,,,,,,,,PRIMARY,"Week 0, week 26"
country,NCT02906930::country::United States,NCT02906930,United States,,,,,,,,,,,,,,
country,NCT02906930::country::Turkey (Türkiye),NCT02906930,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02906930::country::Russia,NCT02906930,Russia,,,,,,,,,,,,,,
country,NCT02906930::country::Japan,NCT02906930,Japan,,,,,,,,,,,,,,
country,NCT02906930::country::Czechia,NCT02906930,Czechia,,,,,,,,,,,,,,
country,NCT02906930::country::Italy,NCT02906930,Italy,,,,,,,,,,,,,,
country,NCT02906930::country::Romania,NCT02906930,Romania,,,,,,,,,,,,,,
country,NCT02906930::country::Algeria,NCT02906930,Algeria,,,,,,,,,,,,,,
country,NCT02906930::country::Bulgaria,NCT02906930,Bulgaria,,,,,,,,,,,,,,
country,NCT02906930::country::Mexico,NCT02906930,Mexico,,,,,,,,,,,,,,
country,NCT02906930::country::Serbia,NCT02906930,Serbia,,,,,,,,,,,,,,
trial,NCT01872611,NCT01872611,Nepafenac Once Daily for Macular Edema - Study 2,PHASE3,diabetes type 2,Non-Proliferative Diabetic Retinopathy; Cataract,INDUSTRY,819.0,2013-06,2015-05,0.0,0.0,,,,,
arm,NCT01872611::arm::FG000,NCT01872611,Nepafenac,,,,,,,,,,FG000,"Nepafenac Ophthalmic Suspension, 0.3%",,,
arm,NCT01872611::arm::FG001,NCT01872611,Vehicle,,,,,,,,,,FG001,Nepafenac Ophthalmic Suspension Vehicle,,,
period,NCT01872611::period::1,NCT01872611,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01872611::outcome::primary::1,NCT01872611,Percentage of Participants With Best-corrected Visual Acuity (BCVA) Improvement of ≥ 15 Letters From Preoperative Baseline to Day 14 and Maintained Through Day 90,,,,,,,,,,,,,PRIMARY,"Baseline to Day 14, and maintained through Day 90"
outcome,NCT01872611::outcome::primary::2,NCT01872611,Percentage of Participants Who Develop Macular Edema Within 90 Days Following Cataract Surgery (Day 0),,,,,,,,,,,,,PRIMARY,Day 0 to Day 90
trial,NCT01760447,NCT01760447,A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,223.0,2011-12-07,2019-09-17,0.0,0.0,,,,,
arm,NCT01760447::arm::FG000,NCT01760447,Sitagliptin/Metformin,,,,,,,,,,FG000,"Participants received one tablet of sitagliptin/metformin and one tablet of metformin-placebo, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alo",,,
arm,NCT01760447::arm::FG001,NCT01760447,Metformin,,,,,,,,,,FG001,"Participants received one tablet of metformin and one tablet of placebo to sitagliptin/metformin, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study ",,,
arm,NCT01760447::arm::FG002,NCT01760447,Sitagliptin/Metformin XR,,,,,,,,,,FG002,"Participants received two tablets of sitagliptin/metformin XR and two tablets of metformin XR placebo, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled i",,,
arm,NCT01760447::arm::FG003,NCT01760447,Metformin XR,,,,,,,,,,FG003,"Participants received two tablets of metformin XR and two tablets of placebo to sitagliptin/metformin XR, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolle",,,
period,NCT01760447::period::1,NCT01760447,Weeks 0-20,,,,,,,,,,,,1.0,,
period,NCT01760447::period::2,NCT01760447,Weeks 20-54,,,,,,,,,,,,2.0,,
outcome,NCT01760447::outcome::primary::1,NCT01760447,Change From Baseline in A1C at Week 20,,,,,,,,,,,,,PRIMARY,Baseline and Week 20
outcome,NCT01760447::outcome::primary::2,NCT01760447,Number of Participants Who Experienced ≥1 Adverse Event During Weeks 0-20,,,,,,,,,,,,,PRIMARY,Up to Week 20
outcome,NCT01760447::outcome::primary::3,NCT01760447,Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event During Weeks 0-20,,,,,,,,,,,,,PRIMARY,Up to Week 20
outcome,NCT01760447::outcome::primary::4,NCT01760447,Number of Participants Who Experienced ≥1 Adverse Event During Weeks 0-56,,,,,,,,,,,,,PRIMARY,Up to approximately Week 56
outcome,NCT01760447::outcome::primary::5,NCT01760447,Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event During Weeks 0-54,,,,,,,,,,,,,PRIMARY,Up to Week 54
trial,NCT00130208,NCT00130208,Effect of Sulodexide in Early Diabetic Nephropathy,PHASE3,diabetes type 2,Diabetic Nephropathy,INDUSTRY,1056.0,2005-08,2008-02,3.0,3.0,,,,,
arm,NCT00130208::arm::FG000,NCT00130208,Sulodexide,,,,,,,,,,FG000,"Also known as KRX-101. All patients will be on standard of care ACE or ARBs.

Sulodexide: 100 mg sulodexide gelcaps",,,
arm,NCT00130208::arm::FG001,NCT00130208,Placebo,,,,,,,,,,FG001,"All patients will be on standard of care ACE or ARBs.

Placebo: 0 mg gelcap",,,
period,NCT00130208::period::1,NCT00130208,Maintenance Period (26 Weeks),,,,,,,,,,,,1.0,,
period,NCT00130208::period::2,NCT00130208,Washout Period (8 Weeks),,,,,,,,,,,,2.0,,
outcome,NCT00130208::outcome::primary::1,NCT00130208,Number of Subjects With Conversion From Microalbuminuria to Normoalbuminuria,,,,,,,,,,,,,PRIMARY,26 Weeks
outcome,NCT00130208::outcome::primary::2,NCT00130208,Number of Subjects With Greater Than 50% Reduction in Microalbuminuria,,,,,,,,,,,,,PRIMARY,26 Weeks
country,NCT00130208::country::United States,NCT00130208,United States,,,,,,,,,,,,,,
country,NCT00130208::country::Australia,NCT00130208,Australia,,,,,,,,,,,,,,
country,NCT00130208::country::Netherlands,NCT00130208,Netherlands,,,,,,,,,,,,,,
trial,NCT00432276,NCT00432276,Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Diabetes Mellitus,INDUSTRY,803.0,2007-01,2009-06,1.0,86.0,,,,,
arm,NCT00432276::arm::FG000,NCT00432276,Alogliptin 25 mg + Pioglitazone 30 mg + Metformin,,,,,,,,,,FG000,"Alogliptin 25 mg, tablets, orally, once daily; pioglitazone 30 mg, tablets, orally, once daily; and the maximum tolerated dose of metformin, tablets, orally, for up to 52 weeks.",,,
arm,NCT00432276::arm::FG001,NCT00432276,Pioglitazone 45 mg + Metformin,,,,,,,,,,FG001,"Alogliptin placebo-matching tablets, orally, once daily; pioglitazone 45 mg, tablets, orally, once daily; and the maximum tolerated dose of metformin, tablets, orally, for up to 52 weeks.",,,
period,NCT00432276::period::1,NCT00432276,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00432276::outcome::primary::1,NCT00432276,Change From Baseline in Glycosylated Hemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,Baseline and Weeks 26 and 52.
country,NCT00432276::country::United States,NCT00432276,United States,,,,,,,,,,,,,,
trial,NCT01318135,NCT01318135,Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,576.0,2009-01,2010-04,0.0,0.0,,,,,
arm,NCT01318135::arm::FG000,NCT01318135,CCT/005 - 12.5 mg Dose Group* → 12.5 mg Combination Group,,,,,,,,,,FG000,"Alogliptin 12.5 mg, tablets, orally, once daily and glimepiride 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.

\*for participants from the 12.5 mg combination dosing ",,,
arm,NCT01318135::arm::FG001,NCT01318135,CCT/005 - 25 mg Dose Group* → 25 mg Combination Dose Group,,,,,,,,,,FG001,"Alogliptin 25 mg, tablets, orally, once daily and glimepiride 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.

\*for participants from the 25 mg combination dosing ARM ",,,
arm,NCT01318135::arm::FG002,NCT01318135,Glimepiride Monotherapy Group* → 12.5 mg Combination Group,,,,,,,,,,FG002,"Alogliptin 12.5 mg, tablets, orally, once daily and glimepiride 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.

\*for participants from the glimepiride 1, 2, 3 or 4 mg",,,
arm,NCT01318135::arm::FG003,NCT01318135,Glimepiride Monotherapy Group* → 25 mg Combination Group,,,,,,,,,,FG003,"Alogliptin 25 mg, tablets, orally, once daily and glimepiride 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.

\*for participants from the glimepiride 1, 2, 3 or 4 mg d",,,
arm,NCT01318135::arm::FG004,NCT01318135,CCT/006 - 12.5 mg Dose Group* → 12.5 mg Combination Group,,,,,,,,,,FG004,"Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.

\*for participants from ",,,
arm,NCT01318135::arm::FG005,NCT01318135,CCT/006 - 25 mg Dose Group* → 25 mg Combination Group,,,,,,,,,,FG005,"Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.

\*for participants from th",,,
arm,NCT01318135::arm::FG006,NCT01318135,Metformin Monotherapy Group* → 12.5 mg Combination Group,,,,,,,,,,FG006,"Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.

\*for participants from ",,,
arm,NCT01318135::arm::FG007,NCT01318135,Metformin Monotherapy Group* → 25 mg Combination Group,,,,,,,,,,FG007,"Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.

\*for participants from th",,,
period,NCT01318135::period::1,NCT01318135,Enrolled - Long-Term Extension Study,,,,,,,,,,,,1.0,,
period,NCT01318135::period::2,NCT01318135,Entered - Long-Term Extension Study,,,,,,,,,,,,2.0,,
outcome,NCT01318135::outcome::primary::1,NCT01318135,Number of Participants With Adverse Events.,,,,,,,,,,,,,PRIMARY,52 Weeks.
trial,NCT02065791,NCT02065791,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2; Diabetic Nephropathy",INDUSTRY,4401.0,2014-02-17,2018-10-30,34.0,575.0,,,,,
arm,NCT02065791::arm::FG000,NCT02065791,Placebo,,,,,,,,,,FG000,Participants received matching placebo orally once daily.,,,
arm,NCT02065791::arm::FG001,NCT02065791,Canagliflozin 100 mg,,,,,,,,,,FG001,Participants received canagliflozin 100 milligram (mg) orally once daily.,,,
period,NCT02065791::period::1,NCT02065791,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02065791::outcome::primary::1,NCT02065791,"Primary Composite Endpoint of Doubling of Serum Creatinine (DoSC), End-stage Kidney Disease (ESKD), and Renal or Cardiovascular (CV) Death",,,,,,,,,,,,,PRIMARY,Up to 4.6 years
country,NCT02065791::country::United States,NCT02065791,United States,,,,,,,,,,,,,,
country,NCT02065791::country::United Kingdom,NCT02065791,United Kingdom,,,,,,,,,,,,,,
country,NCT02065791::country::Argentina,NCT02065791,Argentina,,,,,,,,,,,,,,
country,NCT02065791::country::Japan,NCT02065791,Japan,,,,,,,,,,,,,,
country,NCT02065791::country::Brazil,NCT02065791,Brazil,,,,,,,,,,,,,,
country,NCT02065791::country::Mexico,NCT02065791,Mexico,,,,,,,,,,,,,,
country,NCT02065791::country::Spain,NCT02065791,Spain,,,,,,,,,,,,,,
country,NCT02065791::country::Canada,NCT02065791,Canada,,,,,,,,,,,,,,
country,NCT02065791::country::Hungary,NCT02065791,Hungary,,,,,,,,,,,,,,
country,NCT02065791::country::China,NCT02065791,China,,,,,,,,,,,,,,
country,NCT02065791::country::Australia,NCT02065791,Australia,,,,,,,,,,,,,,
country,NCT02065791::country::France,NCT02065791,France,,,,,,,,,,,,,,
country,NCT02065791::country::Russia,NCT02065791,Russia,,,,,,,,,,,,,,
country,NCT02065791::country::Poland,NCT02065791,Poland,,,,,,,,,,,,,,
country,NCT02065791::country::India,NCT02065791,India,,,,,,,,,,,,,,
country,NCT02065791::country::Czechia,NCT02065791,Czechia,,,,,,,,,,,,,,
country,NCT02065791::country::Malaysia,NCT02065791,Malaysia,,,,,,,,,,,,,,
country,NCT02065791::country::Philippines,NCT02065791,Philippines,,,,,,,,,,,,,,
country,NCT02065791::country::Slovakia,NCT02065791,Slovakia,,,,,,,,,,,,,,
country,NCT02065791::country::Ukraine,NCT02065791,Ukraine,,,,,,,,,,,,,,
country,NCT02065791::country::Colombia,NCT02065791,Colombia,,,,,,,,,,,,,,
country,NCT02065791::country::Romania,NCT02065791,Romania,,,,,,,,,,,,,,
country,NCT02065791::country::South Africa,NCT02065791,South Africa,,,,,,,,,,,,,,
country,NCT02065791::country::Bulgaria,NCT02065791,Bulgaria,,,,,,,,,,,,,,
country,NCT02065791::country::Germany,NCT02065791,Germany,,,,,,,,,,,,,,
country,NCT02065791::country::New Zealand,NCT02065791,New Zealand,,,,,,,,,,,,,,
country,NCT02065791::country::South Korea,NCT02065791,South Korea,,,,,,,,,,,,,,
country,NCT02065791::country::Taiwan,NCT02065791,Taiwan,,,,,,,,,,,,,,
country,NCT02065791::country::Chile,NCT02065791,Chile,,,,,,,,,,,,,,
country,NCT02065791::country::Lithuania,NCT02065791,Lithuania,,,,,,,,,,,,,,
country,NCT02065791::country::Puerto Rico,NCT02065791,Puerto Rico,,,,,,,,,,,,,,
country,NCT02065791::country::Serbia,NCT02065791,Serbia,,,,,,,,,,,,,,
country,NCT02065791::country::United Arab Emirates,NCT02065791,United Arab Emirates,,,,,,,,,,,,,,
country,NCT02065791::country::Guatemala,NCT02065791,Guatemala,,,,,,,,,,,,,,
trial,NCT02058160,NCT02058160,Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,736.0,2014-01,2015-07,18.0,236.0,,,,,
arm,NCT02058160::arm::FG000,NCT02058160,Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC),,,,,,,,,,FG000,FRC injected subcutaneously once daily (QD) for 30 weeks. Dose individually adjusted.,,,
arm,NCT02058160::arm::FG001,NCT02058160,Insulin Glargine,,,,,,,,,,FG001,Insulin glargine 100 U/mL injected subcutaneously QD for 30 weeks. Dose individually adjusted.,,,
period,NCT02058160::period::1,NCT02058160,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02058160::outcome::primary::1,NCT02058160,Change in Glycated Hemoglobin (HbA1c) From Baseline to Week 30,,,,,,,,,,,,,PRIMARY,"Baseline, Week 30"
country,NCT02058160::country::United States,NCT02058160,United States,,,,,,,,,,,,,,
country,NCT02058160::country::Russia,NCT02058160,Russia,,,,,,,,,,,,,,
country,NCT02058160::country::Canada,NCT02058160,Canada,,,,,,,,,,,,,,
country,NCT02058160::country::Czechia,NCT02058160,Czechia,,,,,,,,,,,,,,
country,NCT02058160::country::Romania,NCT02058160,Romania,,,,,,,,,,,,,,
country,NCT02058160::country::Slovakia,NCT02058160,Slovakia,,,,,,,,,,,,,,
country,NCT02058160::country::Spain,NCT02058160,Spain,,,,,,,,,,,,,,
country,NCT02058160::country::Chile,NCT02058160,Chile,,,,,,,,,,,,,,
country,NCT02058160::country::Mexico,NCT02058160,Mexico,,,,,,,,,,,,,,
country,NCT02058160::country::Poland,NCT02058160,Poland,,,,,,,,,,,,,,
country,NCT02058160::country::Ukraine,NCT02058160,Ukraine,,,,,,,,,,,,,,
country,NCT02058160::country::Denmark,NCT02058160,Denmark,,,,,,,,,,,,,,
country,NCT02058160::country::Hungary,NCT02058160,Hungary,,,,,,,,,,,,,,
country,NCT02058160::country::Sweden,NCT02058160,Sweden,,,,,,,,,,,,,,
country,NCT02058160::country::Lithuania,NCT02058160,Lithuania,,,,,,,,,,,,,,
country,NCT02058160::country::Australia,NCT02058160,Australia,,,,,,,,,,,,,,
country,NCT02058160::country::Estonia,NCT02058160,Estonia,,,,,,,,,,,,,,
country,NCT02058160::country::Netherlands,NCT02058160,Netherlands,,,,,,,,,,,,,,
trial,NCT01680341,NCT01680341,Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,272.0,2012-08-31,2013-08-22,5.0,45.0,,,,,
arm,NCT01680341::arm::FG000,NCT01680341,IDegAsp Simple,,,,,,,,,,FG000,"Insulin degludec/insulin aspart (IDegAsp) was injected subcutaneously (s.c.) in either abdomen, upper arm (deltoid area) or thigh. A pre-filled pen injector (PDS290) was used to administer IDegAsp. Du",,,
arm,NCT01680341::arm::FG001,NCT01680341,IDegAsp Step Wise,,,,,,,,,,FG001,"IDegAsp was injected subcutaneously (s.c.) in either abdomen, upper arm (deltoid area) or thigh. A pre-filled pen injector (PDS290) was used to administer IDegAsp. During treatment period subjects wer",,,
period,NCT01680341::period::1,NCT01680341,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01680341::outcome::primary::1,NCT01680341,Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%),,,,,,,,,,,,,PRIMARY,"Week 0, Week 26"
country,NCT01680341::country::United States,NCT01680341,United States,,,,,,,,,,,,,,
country,NCT01680341::country::Germany,NCT01680341,Germany,,,,,,,,,,,,,,
country,NCT01680341::country::Turkey (Türkiye),NCT01680341,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01680341::country::Algeria,NCT01680341,Algeria,,,,,,,,,,,,,,
country,NCT01680341::country::Malaysia,NCT01680341,Malaysia,,,,,,,,,,,,,,
trial,NCT00139659,NCT00139659,A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma,PHASE3,diabetes type 2,Asthma; Diabetes Mellitus,INDUSTRY,288.0,2003-01,2008-10,5.0,102.0,,,,,
arm,NCT00139659::arm::FG000,NCT00139659,Inhaled Insulin,,,,,,,,,,FG000,Inhaled insulin (Exubera®) with dose adjusted according to premeal blood glucose plus basal insulin.,,,
arm,NCT00139659::arm::FG001,NCT00139659,Subcutaneous Insulin,,,,,,,,,,FG001,Subcutaneous insulin with dose adjusted according to premeal blood glucose plus basal insulin.,,,
period,NCT00139659::period::1,NCT00139659,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00139659::outcome::primary::1,NCT00139659,Annualized Rate of Change for Forced Expiratory Volume in 1 Second (FEV1),,,,,,,,,,,,,PRIMARY,"Weeks -3, -2, -1, 1, 2, 3, 4, 6, 12, 18, 26, 39, and 52"
outcome,NCT00139659::outcome::primary::2,NCT00139659,Annualized Rate of Change for Hemoglobin-adjusted Carbon Monoxide Diffusion Capacity (DLco),,,,,,,,,,,,,PRIMARY,"Weeks -3, -2, -1, 1, 2, 3, 4, 6, 12, 18, 26, 39, and 52"
outcome,NCT00139659::outcome::primary::3,NCT00139659,Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in One Second (FEV1),,,,,,,,,,,,,PRIMARY,Baseline through Week 52 Last Observation Carried Forward (LOCF)
outcome,NCT00139659::outcome::primary::4,NCT00139659,Change From Baseline in Post-Bronchodilator Carbon Monoxide Diffusing Capacity (DLco),,,,,,,,,,,,,PRIMARY,"Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 12, Week 18, Week 26, Week 39, Week 52, Week 52 Last Observation Carried Forward (LOCF)"
country,NCT00139659::country::United States,NCT00139659,United States,,,,,,,,,,,,,,
country,NCT00139659::country::Canada,NCT00139659,Canada,,,,,,,,,,,,,,
country,NCT00139659::country::Brazil,NCT00139659,Brazil,,,,,,,,,,,,,,
country,NCT00139659::country::Costa Rica,NCT00139659,Costa Rica,,,,,,,,,,,,,,
country,NCT00139659::country::Germany,NCT00139659,Germany,,,,,,,,,,,,,,
trial,NCT00773279,NCT00773279,"Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics",PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Delivery Systems",INDUSTRY,242.0,2008-09,2009-06,1.0,65.0,,,,,
arm,NCT00773279::arm::FG000,NCT00773279,PDS290 -> FlexPen®,,,,,,,,,,FG000,,,,
arm,NCT00773279::arm::FG001,NCT00773279,FlexPen® -> PDS290,,,,,,,,,,FG001,,,,
period,NCT00773279::period::1,NCT00773279,Period 1,,,,,,,,,,,,1.0,,
period,NCT00773279::period::2,NCT00773279,Period 2,,,,,,,,,,,,2.0,,
outcome,NCT00773279::outcome::primary::1,NCT00773279,HbA1c (Glycosylated Haemoglobin) for Participants Treated With PDS290 and FlexPen®,,,,,,,,,,,,,PRIMARY,Week 12 of each treatment sequence
country,NCT00773279::country::United States,NCT00773279,United States,,,,,,,,,,,,,,
trial,NCT00643851,NCT00643851,An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,994.0,2008-06,2009-08,7.0,99.0,,,,,
arm,NCT00643851::arm::FG000,NCT00643851,Dapagliflozin 5 mg + Metformin XR,,,,,,,,,,FG000,"Dapagliflozin tablets, oral, once daily for 24 weeks plus metfomin XR tablets (up to 2000mg), oral, once daily for 24 weeks",,,
arm,NCT00643851::arm::FG001,NCT00643851,Dapagliflozin 5 mg,,,,,,,,,,FG001,"Dapagliflozin tablets, oral, once daily for 24 weeks",,,
arm,NCT00643851::arm::FG002,NCT00643851,Metformin XR,,,,,,,,,,FG002,"Metfomin XR tablets (500mg up to 2000mg), oral, once daily for 24 weeks",,,
period,NCT00643851::period::1,NCT00643851,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00643851::outcome::primary::1,NCT00643851,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]),,,,,,,,,,,,,PRIMARY,From Baseline to Week 24
country,NCT00643851::country::United States,NCT00643851,United States,,,,,,,,,,,,,,
country,NCT00643851::country::Russia,NCT00643851,Russia,,,,,,,,,,,,,,
country,NCT00643851::country::Mexico,NCT00643851,Mexico,,,,,,,,,,,,,,
country,NCT00643851::country::Ukraine,NCT00643851,Ukraine,,,,,,,,,,,,,,
country,NCT00643851::country::South Korea,NCT00643851,South Korea,,,,,,,,,,,,,,
country,NCT00643851::country::Philippines,NCT00643851,Philippines,,,,,,,,,,,,,,
country,NCT00643851::country::Puerto Rico,NCT00643851,Puerto Rico,,,,,,,,,,,,,,
trial,NCT02681094,NCT02681094,"A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes",PHASE3,diabetes type 2,Type 2 Diabetes Mellitus; Inadequate Glycaemic Control,INDUSTRY,905.0,2016-02-26,2017-07-15,6.0,110.0,,,,,
arm,NCT02681094::arm::FG000,NCT02681094,Dapagliflozin + Saxagliptin + Metformin,,,,,,,,,,FG000,Randomized participants received orally once daily (QD) dapagliflozin 5 mg and saxagliptin 5 mg film coated tablets as an add-on to metformin (≥1500 mg/day orally),,,
arm,NCT02681094::arm::FG001,NCT02681094,Dapagliflozin + Metformin,,,,,,,,,,FG001,Randomized participants received orally QD dapagliflozin 5 mg film coated tablet and placebo for saxagliptin as an add-on to metformin (≥1500 mg/day orally),,,
arm,NCT02681094::arm::FG002,NCT02681094,Saxagliptin + Metformin,,,,,,,,,,FG002,Randomized participants received orally QD saxagliptin 5 mg film coated tablet and placebo for dapagliflozin as an add-on to metformin (≥1500 mg/day orally),,,
period,NCT02681094::period::1,NCT02681094,1 -Modified Enrolled Participants Set,,,,,,,,,,,,1.0,,
period,NCT02681094::period::2,NCT02681094,2 - Enrolled Participants Set,,,,,,,,,,,,2.0,,
outcome,NCT02681094::outcome::primary::1,NCT02681094,Change From Baseline in HbA1c at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and week 24
country,NCT02681094::country::United States,NCT02681094,United States,,,,,,,,,,,,,,
country,NCT02681094::country::Russia,NCT02681094,Russia,,,,,,,,,,,,,,
country,NCT02681094::country::Germany,NCT02681094,Germany,,,,,,,,,,,,,,
country,NCT02681094::country::Canada,NCT02681094,Canada,,,,,,,,,,,,,,
country,NCT02681094::country::Czechia,NCT02681094,Czechia,,,,,,,,,,,,,,
country,NCT02681094::country::Mexico,NCT02681094,Mexico,,,,,,,,,,,,,,
trial,NCT01031680,NCT01031680,"Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension",PHASE3,diabetes type 2,Type 2 Diabetes Mellitus; Cardiovascular Disease; Hypertension; Inadequate Glycaemic Control,INDUSTRY,922.0,2010-02,2012-12,9.0,140.0,,,,,
arm,NCT01031680::arm::FG000,NCT01031680,Experimental,,,,,,,,,,FG000,"Dapagliflozin, 10 mg tablet, oral, once daily",,,
arm,NCT01031680::arm::FG001,NCT01031680,Placebo Comparator,,,,,,,,,,FG001,"Placebo, Matching placebo tablet, oral, once daily",,,
period,NCT01031680::period::1,NCT01031680,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01031680::outcome::primary::1,NCT01031680,Adjusted Mean Change in HbA1c Levels,,,,,,,,,,,,,PRIMARY,Baseline to Week 24
outcome,NCT01031680::outcome::primary::2,NCT01031680,Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit,,,,,,,,,,,,,PRIMARY,Baseline to week 24
country,NCT01031680::country::United States,NCT01031680,United States,,,,,,,,,,,,,,
country,NCT01031680::country::Canada,NCT01031680,Canada,,,,,,,,,,,,,,
country,NCT01031680::country::Slovakia,NCT01031680,Slovakia,,,,,,,,,,,,,,
country,NCT01031680::country::Germany,NCT01031680,Germany,,,,,,,,,,,,,,
country,NCT01031680::country::Spain,NCT01031680,Spain,,,,,,,,,,,,,,
country,NCT01031680::country::Argentina,NCT01031680,Argentina,,,,,,,,,,,,,,
country,NCT01031680::country::Romania,NCT01031680,Romania,,,,,,,,,,,,,,
country,NCT01031680::country::Taiwan,NCT01031680,Taiwan,,,,,,,,,,,,,,
country,NCT01031680::country::Vietnam,NCT01031680,Vietnam,,,,,,,,,,,,,,
trial,NCT03861039,NCT03861039,A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,443.0,2019-03-30,2021-02-16,1.0,34.0,,,,,
arm,NCT03861039::arm::FG000,NCT03861039,5 mg Tirzepatide,,,,,,,,,,FG000,"5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week. Participant received the following pre-treatment oral antihyperglycemic medication (OAM): Sulfonylurea, biguanide, alpha-glu",,,
arm,NCT03861039::arm::FG001,NCT03861039,10 mg Tirzepatide,,,,,,,,,,FG001,"10 mg tirzepatide administered SC once a week. Participant received the following pre-treatment oral antihyperglycemic medication (OAM): Sulfonylurea, biguanide, alpha-glucosidase inhibitor, thiazolid",,,
arm,NCT03861039::arm::FG002,NCT03861039,15 mg Tirzepatide,,,,,,,,,,FG002,"15 mg tirzepatide administered SC once a week. Participant received the following pre-treatment oral antihyperglycemic medication (OAM): Sulfonylurea, biguanide, alpha-glucosidase inhibitor, thiazolid",,,
period,NCT03861039::period::1,NCT03861039,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03861039::outcome::primary::1,NCT03861039,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,,,,,,,,,,,,,PRIMARY,Baseline through Week 52
country,NCT03861039::country::Japan,NCT03861039,Japan,,,,,,,,,,,,,,
trial,NCT02597049,NCT02597049,A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,424.0,2015-11,2017-02,9.0,41.0,,,,,
arm,NCT02597049::arm::FG000,NCT02597049,1.5 mg Dulaglutide,,,,,,,,,,FG000,Dulaglutide 1.5 milligrams (mg) given SC QW for 24 weeks.,,,
arm,NCT02597049::arm::FG001,NCT02597049,0.75 mg Dulaglutide,,,,,,,,,,FG001,Dulaglutide 0.75 mg given subcutaneously (SC) once a week (QW) for 24 weeks.,,,
arm,NCT02597049::arm::FG002,NCT02597049,Placebo,,,,,,,,,,FG002,Placebo given SC QW for 24 weeks.,,,
period,NCT02597049::period::1,NCT02597049,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02597049::outcome::primary::1,NCT02597049,Change From Baseline in Hemoglobin A1c (HbA1c) at 24 Weeks (Treatment-regimen Estimand),,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
outcome,NCT02597049::outcome::primary::2,NCT02597049,Change From Baseline in the HbA1c at 24 Weeks (Efficacy Estimand),,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
country,NCT02597049::country::United States,NCT02597049,United States,,,,,,,,,,,,,,
country,NCT02597049::country::Czechia,NCT02597049,Czechia,,,,,,,,,,,,,,
country,NCT02597049::country::Hungary,NCT02597049,Hungary,,,,,,,,,,,,,,
country,NCT02597049::country::Spain,NCT02597049,Spain,,,,,,,,,,,,,,
country,NCT02597049::country::Austria,NCT02597049,Austria,,,,,,,,,,,,,,
country,NCT02597049::country::Israel,NCT02597049,Israel,,,,,,,,,,,,,,
country,NCT02597049::country::Mexico,NCT02597049,Mexico,,,,,,,,,,,,,,
country,NCT02597049::country::Puerto Rico,NCT02597049,Puerto Rico,,,,,,,,,,,,,,
country,NCT02597049::country::Germany,NCT02597049,Germany,,,,,,,,,,,,,,
trial,NCT03061214,NCT03061214,Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT),PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,868.0,2017-08-28,2019-04-15,7.0,67.0,,,,,
arm,NCT03061214::arm::FG000,NCT03061214,Semaglutide 0.5 mg,,,,,,,,,,FG000,"Participants took subcutaneous (s.c., under the skin) injection of semaglutide, once weekly for 30 weeks: 0.25 mg for 0-4 weeks followed by 0.5 mg for 5-30 weeks. Participants also took sitagliptin pl",,,
arm,NCT03061214::arm::FG001,NCT03061214,Semaglutide 1.0 mg,,,,,,,,,,FG001,"Participants took subcutaneous (s.c., under the skin) injection of semaglutide, once weekly for 30 weeks: 0.25 mg for 0-4 weeks followed by 0.5 mg for 5-8 weeks and then 1.0 mg for 9-30 weeks. Partici",,,
arm,NCT03061214::arm::FG002,NCT03061214,Sitagliptin,,,,,,,,,,FG002,Participants were randomised to 2 different groups (Group 1: sitagliptin + semaglutide placebo 0.5 mg and Group 2: sitagliptin + semaglutide placebo 1.0 mg). Both groups were pooled together for data ,,,
period,NCT03061214::period::1,NCT03061214,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03061214::outcome::primary::1,NCT03061214,Change in HbA1c,,,,,,,,,,,,,PRIMARY,"Week 0, week 30"
country,NCT03061214::country::China,NCT03061214,China,,,,,,,,,,,,,,
country,NCT03061214::country::South Korea,NCT03061214,South Korea,,,,,,,,,,,,,,
country,NCT03061214::country::South Africa,NCT03061214,South Africa,,,,,,,,,,,,,,
country,NCT03061214::country::Brazil,NCT03061214,Brazil,,,,,,,,,,,,,,
country,NCT03061214::country::Taiwan,NCT03061214,Taiwan,,,,,,,,,,,,,,
country,NCT03061214::country::Ukraine,NCT03061214,Ukraine,,,,,,,,,,,,,,
country,NCT03061214::country::Hong Kong,NCT03061214,Hong Kong,,,,,,,,,,,,,,
trial,NCT01703221,NCT01703221,Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,414.0,2012-10-24,2014-04-25,0.0,0.0,,,,,
arm,NCT01703221::arm::FG000,NCT01703221,Omarigliptin (Phase A+B),,,,,,,,,,FG000,Omarigliptin 25 mg once weekly for 52 weeks (Phase A + B),,,
arm,NCT01703221::arm::FG001,NCT01703221,Sitagliptin (Phase A) Switching to Omarigliptin (Phase B),,,,,,,,,,FG001,Sitagliptin 50 mg once daily for 24 weeks (Phase A) switching to omarigliptin 25 mg once weekly for 28 weeks (Phase B),,,
arm,NCT01703221::arm::FG002,NCT01703221,Placebo (Phase A) Switching to Omarigliptin (Phase B),,,,,,,,,,FG002,Placebo for 24 weeks (Phase A) switching to omarigliptin 25 mg once weekly for 28 weeks (Phase B),,,
period,NCT01703221::period::1,NCT01703221,Phase A (Up to 24 Weeks),,,,,,,,,,,,1.0,,
period,NCT01703221::period::2,NCT01703221,Phase B - (Week 25 to 52),,,,,,,,,,,,2.0,,
outcome,NCT01703221::outcome::primary::1,NCT01703221,Change From Baseline for Hemoglobin A1c (HbA1c) at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and Week 24
outcome,NCT01703221::outcome::primary::2,NCT01703221,Percentage of Participants Who Experienced at Least One Adverse Event During Phase A,,,,,,,,,,,,,PRIMARY,Up to 24 weeks
outcome,NCT01703221::outcome::primary::3,NCT01703221,Percentage of Participants Who Experienced at Least One Adverse Event During the Overall Study,,,,,,,,,,,,,PRIMARY,Up to 52 weeks
outcome,NCT01703221::outcome::primary::4,NCT01703221,Percentage of Participants Who Discontinued From the Study Due to an Adverse Event During Phase A,,,,,,,,,,,,,PRIMARY,Up to 24 weeks
outcome,NCT01703221::outcome::primary::5,NCT01703221,Percentage of Participants Who Discontinued From the Study Due to an Adverse Event During the Overall Study,,,,,,,,,,,,,PRIMARY,Up to 52 weeks
trial,NCT02735044,NCT02735044,Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus,PHASE3,diabetes type 2,Type 1 Diabetes Mellitus,INDUSTRY,463.0,2016-04-14,2018-12-20,24.0,107.0,,,,,
arm,NCT02735044::arm::FG000,NCT02735044,HOE901-U300,,,,,,,,,,FG000,Insulin glargine 300 Units/milliliter (U/mL) subcutaneous (SC) injection once daily in the morning or evening for 12 months.,,,
arm,NCT02735044::arm::FG001,NCT02735044,Lantus,,,,,,,,,,FG001,Insulin glargine 100 U/mL SC injection once daily in the morning or evening for 12 months.,,,
period,NCT02735044::period::1,NCT02735044,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02735044::outcome::primary::1,NCT02735044,Change From Baseline in HbA1c to Month 6,,,,,,,,,,,,,PRIMARY,Baseline to Month 6
country,NCT02735044::country::United States,NCT02735044,United States,,,,,,,,,,,,,,
country,NCT02735044::country::Argentina,NCT02735044,Argentina,,,,,,,,,,,,,,
country,NCT02735044::country::Hungary,NCT02735044,Hungary,,,,,,,,,,,,,,
country,NCT02735044::country::Brazil,NCT02735044,Brazil,,,,,,,,,,,,,,
country,NCT02735044::country::Japan,NCT02735044,Japan,,,,,,,,,,,,,,
country,NCT02735044::country::Poland,NCT02735044,Poland,,,,,,,,,,,,,,
country,NCT02735044::country::Spain,NCT02735044,Spain,,,,,,,,,,,,,,
country,NCT02735044::country::Chile,NCT02735044,Chile,,,,,,,,,,,,,,
country,NCT02735044::country::Italy,NCT02735044,Italy,,,,,,,,,,,,,,
country,NCT02735044::country::Mexico,NCT02735044,Mexico,,,,,,,,,,,,,,
country,NCT02735044::country::Romania,NCT02735044,Romania,,,,,,,,,,,,,,
country,NCT02735044::country::Canada,NCT02735044,Canada,,,,,,,,,,,,,,
country,NCT02735044::country::Germany,NCT02735044,Germany,,,,,,,,,,,,,,
country,NCT02735044::country::Israel,NCT02735044,Israel,,,,,,,,,,,,,,
country,NCT02735044::country::Russia,NCT02735044,Russia,,,,,,,,,,,,,,
country,NCT02735044::country::United Kingdom,NCT02735044,United Kingdom,,,,,,,,,,,,,,
country,NCT02735044::country::Bulgaria,NCT02735044,Bulgaria,,,,,,,,,,,,,,
country,NCT02735044::country::Czechia,NCT02735044,Czechia,,,,,,,,,,,,,,
country,NCT02735044::country::Serbia,NCT02735044,Serbia,,,,,,,,,,,,,,
country,NCT02735044::country::France,NCT02735044,France,,,,,,,,,,,,,,
country,NCT02735044::country::Latvia,NCT02735044,Latvia,,,,,,,,,,,,,,
country,NCT02735044::country::Denmark,NCT02735044,Denmark,,,,,,,,,,,,,,
country,NCT02735044::country::North Macedonia,NCT02735044,North Macedonia,,,,,,,,,,,,,,
country,NCT02735044::country::Sweden,NCT02735044,Sweden,,,,,,,,,,,,,,
trial,NCT00856986,NCT00856986,The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,987.0,2009-03,2010-11,10.0,233.0,,,,,
arm,NCT00856986::arm::FG000,NCT00856986,Lira 1.8,,,,,,,,,,FG000,Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily),,,
arm,NCT00856986::arm::FG001,NCT00856986,Insulin Detemir + Lira 1.8,,,,,,,,,,FG001,Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily),,,
arm,NCT00856986::arm::FG002,NCT00856986,Non-Randomised Lira 1.8,,,,,,,,,,FG002,Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily),,,
arm,NCT00856986::arm::FG003,NCT00856986,Early Withdrawals Lira 1.8,,,,,,,,,,FG003,Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily),,,
arm,NCT00856986::arm::FG004,NCT00856986,Intensified Group,,,,,,,,,,FG004,Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c ≥ 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group.,,,
period,NCT00856986::period::1,NCT00856986,"Run-in Period, Weeks -12-0",,,,,,,,,,,,1.0,,
period,NCT00856986::period::2,NCT00856986,"Main Period, Weeks 0-26",,,,,,,,,,,,2.0,,
period,NCT00856986::period::3,NCT00856986,"Extension Period, Weeks 26-52",,,,,,,,,,,,3.0,,
outcome,NCT00856986::outcome::primary::1,NCT00856986,Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26.,,,,,,,,,,,,,PRIMARY,"Week 0 (Randomisation), week 26"
country,NCT00856986::country::United States,NCT00856986,United States,,,,,,,,,,,,,,
country,NCT00856986::country::Germany,NCT00856986,Germany,,,,,,,,,,,,,,
country,NCT00856986::country::United Kingdom,NCT00856986,United Kingdom,,,,,,,,,,,,,,
country,NCT00856986::country::Spain,NCT00856986,Spain,,,,,,,,,,,,,,
country,NCT00856986::country::France,NCT00856986,France,,,,,,,,,,,,,,
country,NCT00856986::country::Italy,NCT00856986,Italy,,,,,,,,,,,,,,
country,NCT00856986::country::Netherlands,NCT00856986,Netherlands,,,,,,,,,,,,,,
country,NCT00856986::country::Canada,NCT00856986,Canada,,,,,,,,,,,,,,
country,NCT00856986::country::Puerto Rico,NCT00856986,Puerto Rico,,,,,,,,,,,,,,
country,NCT00856986::country::Belgium,NCT00856986,Belgium,,,,,,,,,,,,,,
trial,NCT04251156,NCT04251156,Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.,PHASE3,diabetes type 2,"Overweight; Obesity; Diabetes Mellitus, Type 2",INDUSTRY,375.0,2020-12-08,2022-08-23,4.0,33.0,,,,,
arm,NCT04251156::arm::FG000,NCT04251156,Semaglutide 2.4 mg,,,,,,,,,,FG000,"Participants initiated at a once weekly dose of 0.25 mg semaglutide s.c. followed a fixed-dose escalation regimen, with dose increasing every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), to re",,,
arm,NCT04251156::arm::FG001,NCT04251156,Placebo,,,,,,,,,,FG001,Participants received placebo matched to semaglutide s.c. once weekly for 44 weeks,,,
period,NCT04251156::period::1,NCT04251156,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04251156::outcome::primary::1,NCT04251156,Change From Baseline in Body Weight (Percentage [%]),,,,,,,,,,,,,PRIMARY,"Baseline (week 0), week 44"
outcome,NCT04251156::outcome::primary::2,NCT04251156,Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 5% (Yes/No),,,,,,,,,,,,,PRIMARY,At week 44
country,NCT04251156::country::China,NCT04251156,China,,,,,,,,,,,,,,
country,NCT04251156::country::Brazil,NCT04251156,Brazil,,,,,,,,,,,,,,
country,NCT04251156::country::South Korea,NCT04251156,South Korea,,,,,,,,,,,,,,
country,NCT04251156::country::Hong Kong,NCT04251156,Hong Kong,,,,,,,,,,,,,,
trial,NCT00541775,NCT00541775,Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,273.0,2006-06,2007-03,0.0,0.0,,,,,
arm,NCT00541775::arm::FG000,NCT00541775,Sitagliptin,,,,,,,,,,FG000,The Sitagliptin group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg and placebo matching rosiglitazone q.d. (once-daily) with metformin (≥1500 mg/,,,
arm,NCT00541775::arm::FG001,NCT00541775,Rosiglitazone,,,,,,,,,,FG001,The Rosiglitazone group includes data from patients randomized to receive treatment with oral tablets of rosiglitazone 8 mg and placebo matching sitagliptin q.d. in combination with metformin (≥1500 m,,,
arm,NCT00541775::arm::FG002,NCT00541775,Placebo,,,,,,,,,,FG002,The Placebo group includes data from patients randomized to receive treatment with oral tablets of placebo matching sitagliptin and placebo matching rosiglitazone q.d. with metformin (≥1500 mg/day).,,,
period,NCT00541775::period::1,NCT00541775,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00541775::outcome::primary::1,NCT00541775,Hemoglobin A1C (A1C) at Week 18,,,,,,,,,,,,,PRIMARY,Baseline and 18 Weeks
trial,NCT00225277,NCT00225277,Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Diabetes Mellitus,INDUSTRY,547.0,2003-07,2007-10,4.0,79.0,,,,,
arm,NCT00225277::arm::FG000,NCT00225277,Pioglitazone QD,,,,,,,,,,FG000,Subjects received up to 45 mg Pioglitazone (dose optimized for glucose control) for up to 72 weeks.,,,
arm,NCT00225277::arm::FG001,NCT00225277,Glimepiride QD,,,,,,,,,,FG001,Subjects received up to 4 mg Glimepiride (dose optimized for glucose control) for up to 72 weeks.,,,
period,NCT00225277::period::1,NCT00225277,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00225277::outcome::primary::1,NCT00225277,Nominal Change From Baseline in Percent Atheroma Volume,,,,,,,,,,,,,PRIMARY,Baseline and Final Visit (up to 72 weeks)
country,NCT00225277::country::United States,NCT00225277,United States,,,,,,,,,,,,,,
country,NCT00225277::country::Canada,NCT00225277,Canada,,,,,,,,,,,,,,
country,NCT00225277::country::Argentina,NCT00225277,Argentina,,,,,,,,,,,,,,
country,NCT00225277::country::Chile,NCT00225277,Chile,,,,,,,,,,,,,,
trial,NCT00116831,NCT00116831,Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes,PHASE3,diabetes type 2,Atherosclerosis,INDUSTRY,672.0,2005-01,2008-08,20.0,156.0,,,,,
arm,NCT00116831::arm::FG000,NCT00116831,Glipizide (GLP) 5 mg,,,,,,,,,,FG000,Glipizide (GLP) 5 mg once daily for 18 months,,,
arm,NCT00116831::arm::FG001,NCT00116831,Rosiglitazone (RSG) 4 mg,,,,,,,,,,FG001,Rosiglitazone (RSG) 4 mg once daily for 18 months,,,
period,NCT00116831::period::1,NCT00116831,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00116831::outcome::primary::1,NCT00116831,Change From Baseline in Percent Atheroma Volume (PAV) to Month 18,,,,,,,,,,,,,PRIMARY,Baseline to Month 18
outcome,NCT00116831::outcome::primary::2,NCT00116831,Model Adjusted Change From Baseline in Percent Atheroma Volume (PAV) to Month 18,,,,,,,,,,,,,PRIMARY,Baseline to Month 18
country,NCT00116831::country::United States,NCT00116831,United States,,,,,,,,,,,,,,
country,NCT00116831::country::Germany,NCT00116831,Germany,,,,,,,,,,,,,,
country,NCT00116831::country::Argentina,NCT00116831,Argentina,,,,,,,,,,,,,,
country,NCT00116831::country::Spain,NCT00116831,Spain,,,,,,,,,,,,,,
country,NCT00116831::country::Netherlands,NCT00116831,Netherlands,,,,,,,,,,,,,,
country,NCT00116831::country::Canada,NCT00116831,Canada,,,,,,,,,,,,,,
country,NCT00116831::country::Hong Kong,NCT00116831,Hong Kong,,,,,,,,,,,,,,
country,NCT00116831::country::Poland,NCT00116831,Poland,,,,,,,,,,,,,,
country,NCT00116831::country::Brazil,NCT00116831,Brazil,,,,,,,,,,,,,,
country,NCT00116831::country::France,NCT00116831,France,,,,,,,,,,,,,,
country,NCT00116831::country::Greece,NCT00116831,Greece,,,,,,,,,,,,,,
country,NCT00116831::country::South Korea,NCT00116831,South Korea,,,,,,,,,,,,,,
country,NCT00116831::country::Russia,NCT00116831,Russia,,,,,,,,,,,,,,
country,NCT00116831::country::India,NCT00116831,India,,,,,,,,,,,,,,
country,NCT00116831::country::Italy,NCT00116831,Italy,,,,,,,,,,,,,,
country,NCT00116831::country::Mexico,NCT00116831,Mexico,,,,,,,,,,,,,,
country,NCT00116831::country::Sweden,NCT00116831,Sweden,,,,,,,,,,,,,,
country,NCT00116831::country::Thailand,NCT00116831,Thailand,,,,,,,,,,,,,,
country,NCT00116831::country::Czechia,NCT00116831,Czechia,,,,,,,,,,,,,,
country,NCT00116831::country::Latvia,NCT00116831,Latvia,,,,,,,,,,,,,,
trial,NCT05259033,NCT05259033,"A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)",PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,683.0,2022-04-11,2024-01-16,14.0,136.0,,,,,
arm,NCT05259033::arm::FG000,NCT05259033,IcoSema,,,,,,,,,,FG000,Participants received once weekly 700 units per millilitre (U/mL) of insulin icodec and 2 milligram per millilitre (mg/mL) of semaglutide subcutaneously for 52 weeks. Participants were to perform once,,,
arm,NCT05259033::arm::FG001,NCT05259033,Semaglutide,,,,,,,,,,FG001,"Participants received once weekly semaglutide subcutaneously in a dose escalation manner, with dose increases every 4 weeks for up to week 8 (0.25 milligrams \[mg\], 0.5 mg) followed by dose of 1.0 mg",,,
period,NCT05259033::period::1,NCT05259033,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT05259033::outcome::primary::1,NCT05259033,Change From Baseline in Glycosylated Haemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline (week 0), (week 52)"
country,NCT05259033::country::United States,NCT05259033,United States,,,,,,,,,,,,,,
country,NCT05259033::country::China,NCT05259033,China,,,,,,,,,,,,,,
country,NCT05259033::country::Canada,NCT05259033,Canada,,,,,,,,,,,,,,
country,NCT05259033::country::Japan,NCT05259033,Japan,,,,,,,,,,,,,,
country,NCT05259033::country::Greece,NCT05259033,Greece,,,,,,,,,,,,,,
country,NCT05259033::country::Russia,NCT05259033,Russia,,,,,,,,,,,,,,
country,NCT05259033::country::Brazil,NCT05259033,Brazil,,,,,,,,,,,,,,
country,NCT05259033::country::France,NCT05259033,France,,,,,,,,,,,,,,
country,NCT05259033::country::Israel,NCT05259033,Israel,,,,,,,,,,,,,,
country,NCT05259033::country::Slovakia,NCT05259033,Slovakia,,,,,,,,,,,,,,
country,NCT05259033::country::Taiwan,NCT05259033,Taiwan,,,,,,,,,,,,,,
country,NCT05259033::country::Hungary,NCT05259033,Hungary,,,,,,,,,,,,,,
country,NCT05259033::country::Sweden,NCT05259033,Sweden,,,,,,,,,,,,,,
country,NCT05259033::country::Switzerland,NCT05259033,Switzerland,,,,,,,,,,,,,,
trial,NCT02692716,NCT02692716,A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,3183.0,2017-01-17,2018-09-25,21.0,228.0,,,,,
arm,NCT02692716::arm::FG000,NCT02692716,Oral Semaglutide,,,,,,,,,,FG000,"Participants were to take once-daily semaglutide tablets in a dose escalation manner for upto 82 weeks: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 9 to upto week 82.",,,
arm,NCT02692716::arm::FG001,NCT02692716,Placebo,,,,,,,,,,FG001,Participants were to take oral semaglutide placebo tablets once-daily for a period of upto 82 weeks.,,,
period,NCT02692716::period::1,NCT02692716,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02692716::outcome::primary::1,NCT02692716,"Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE) Composite Endpoint Consisting of: Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke",,,,,,,,,,,,,PRIMARY,Maximum treatment duration is dependent on event rates and is estimated to be no longer than 19 months + 5 weeks of follow-up period.
country,NCT02692716::country::United States,NCT02692716,United States,,,,,,,,,,,,,,
country,NCT02692716::country::India,NCT02692716,India,,,,,,,,,,,,,,
country,NCT02692716::country::Germany,NCT02692716,Germany,,,,,,,,,,,,,,
country,NCT02692716::country::Spain,NCT02692716,Spain,,,,,,,,,,,,,,
country,NCT02692716::country::Turkey (Türkiye),NCT02692716,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02692716::country::Malaysia,NCT02692716,Malaysia,,,,,,,,,,,,,,
country,NCT02692716::country::South Africa,NCT02692716,South Africa,,,,,,,,,,,,,,
country,NCT02692716::country::United Kingdom,NCT02692716,United Kingdom,,,,,,,,,,,,,,
country,NCT02692716::country::Israel,NCT02692716,Israel,,,,,,,,,,,,,,
country,NCT02692716::country::Romania,NCT02692716,Romania,,,,,,,,,,,,,,
country,NCT02692716::country::Argentina,NCT02692716,Argentina,,,,,,,,,,,,,,
country,NCT02692716::country::Canada,NCT02692716,Canada,,,,,,,,,,,,,,
country,NCT02692716::country::Italy,NCT02692716,Italy,,,,,,,,,,,,,,
country,NCT02692716::country::Mexico,NCT02692716,Mexico,,,,,,,,,,,,,,
country,NCT02692716::country::Thailand,NCT02692716,Thailand,,,,,,,,,,,,,,
country,NCT02692716::country::Denmark,NCT02692716,Denmark,,,,,,,,,,,,,,
country,NCT02692716::country::Netherlands,NCT02692716,Netherlands,,,,,,,,,,,,,,
country,NCT02692716::country::Poland,NCT02692716,Poland,,,,,,,,,,,,,,
country,NCT02692716::country::Algeria,NCT02692716,Algeria,,,,,,,,,,,,,,
country,NCT02692716::country::Brazil,NCT02692716,Brazil,,,,,,,,,,,,,,
country,NCT02692716::country::Taiwan,NCT02692716,Taiwan,,,,,,,,,,,,,,
trial,NCT02532855,NCT02532855,A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,614.0,2015-10-20,2017-10-10,0.0,0.0,,,,,
arm,NCT02532855::arm::FG000,NCT02532855,Sitagliptin,,,,,,,,,,FG000,Participants receive sitagliptin 100 mg once daily plus matching placebo for dapagliflozin 5 mg once daily for 4 weeks followed by sitagliptin 100 mg once daily plus matching placebo for dapagliflozin,,,
arm,NCT02532855::arm::FG001,NCT02532855,Dapagliflozin,,,,,,,,,,FG001,Participants receive dapagliflozin 5 mg once daily plus matching placebo for sitagliptin 100 mg once daily for 4 weeks followed by dapagliflozin 10 mg once daily plus matching placebo for sitagliptin ,,,
period,NCT02532855::period::1,NCT02532855,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02532855::outcome::primary::1,NCT02532855,Change From Baseline in A1C at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and Week 24
outcome,NCT02532855::outcome::primary::2,NCT02532855,Percentage of Participants Who Experienced One or More Adverse Events,,,,,,,,,,,,,PRIMARY,Up to 26 weeks
outcome,NCT02532855::outcome::primary::3,NCT02532855,Percentage of Participants Who Discontinued Study Drug Due to an AE,,,,,,,,,,,,,PRIMARY,Up to 24 weeks
trial,NCT00918879,NCT00918879,Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,213.0,2009-05,2010-07,1.0,9.0,,,,,
arm,NCT00918879::arm::FG000,NCT00918879,Saxagliptin 5 mg,,,,,,,,,,FG000,"Saxagliptin 5 mg tablet, once daily( OD) for 24 weeks",,,
arm,NCT00918879::arm::FG001,NCT00918879,Placebo,,,,,,,,,,FG001,"Placebo tablet, once daily( OD) for 24 weeks",,,
period,NCT00918879::period::1,NCT00918879,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00918879::outcome::primary::1,NCT00918879,Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline , Week 24"
country,NCT00918879::country::India,NCT00918879,India,,,,,,,,,,,,,,
trial,NCT00660907,NCT00660907,Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,1217.0,2008-03,2013-01,10.0,76.0,,,,,
arm,NCT00660907::arm::FG000,NCT00660907,Dapagliflozin Plus Metformin,,,,,,,,,,FG000,Experimental dapagliflozin plus metformin,,,
arm,NCT00660907::arm::FG001,NCT00660907,Glipizide Plus Metformin,,,,,,,,,,FG001,Active Comparator glipizide plus metformin,,,
period,NCT00660907::period::1,NCT00660907,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00660907::outcome::primary::1,NCT00660907,Adjusted Mean Change in HbA1c Levels,,,,,,,,,,,,,PRIMARY,Baseline to Week 52
country,NCT00660907::country::Germany,NCT00660907,Germany,,,,,,,,,,,,,,
country,NCT00660907::country::United Kingdom,NCT00660907,United Kingdom,,,,,,,,,,,,,,
country,NCT00660907::country::Netherlands,NCT00660907,Netherlands,,,,,,,,,,,,,,
country,NCT00660907::country::Argentina,NCT00660907,Argentina,,,,,,,,,,,,,,
country,NCT00660907::country::Sweden,NCT00660907,Sweden,,,,,,,,,,,,,,
country,NCT00660907::country::South Africa,NCT00660907,South Africa,,,,,,,,,,,,,,
country,NCT00660907::country::France,NCT00660907,France,,,,,,,,,,,,,,
country,NCT00660907::country::Spain,NCT00660907,Spain,,,,,,,,,,,,,,
country,NCT00660907::country::Mexico,NCT00660907,Mexico,,,,,,,,,,,,,,
country,NCT00660907::country::Italy,NCT00660907,Italy,,,,,,,,,,,,,,
trial,NCT00482729,NCT00482729,MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,1246.0,2007-06-19,2009-04-27,0.0,0.0,,,,,
arm,NCT00482729::arm::FG000,NCT00482729,Sita/Met FDC,,,,,,,,,,FG000,The Sitagliptin/Metformin Fixed Dose Combination (Sita/Met FDC) group includes data from patients randomized to receive treatment with oral tablets of Sita/Met initiated at a dose of 50/500 mg twice a,,,
arm,NCT00482729::arm::FG001,NCT00482729,Metformin,,,,,,,,,,FG001,The Metformin group includes data from patients randomized to receive treatment with oral tablets of metformin initiated at a dose of 500 mg twice a day (b.i.d.) The dose was to have been up-titrated ,,,
period,NCT00482729::period::1,NCT00482729,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00482729::outcome::primary::1,NCT00482729,Change From Baseline in Hemoglobin A1c (A1C) at Week 18,,,,,,,,,,,,,PRIMARY,Baseline and Week 18
trial,NCT00877929,NCT00877929,Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Hypertension,INDUSTRY,706.0,2009-02,,9.0,65.0,,,,,
arm,NCT00877929::arm::FG000,NCT00877929,Telmisartan 80 mg + Amlodipine 10 mg,,,,,,,,,,FG000,Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.,,,
arm,NCT00877929::arm::FG001,NCT00877929,Amlodipine 10 mg,,,,,,,,,,FG001,Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.,,,
period,NCT00877929::period::1,NCT00877929,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00877929::outcome::primary::1,NCT00877929,Change From Baseline in Trough Seated Systolic Blood Pressure to Week 8,,,,,,,,,,,,,PRIMARY,"Baseline, week 8"
country,NCT00877929::country::United States,NCT00877929,United States,,,,,,,,,,,,,,
country,NCT00877929::country::Netherlands,NCT00877929,Netherlands,,,,,,,,,,,,,,
country,NCT00877929::country::Slovakia,NCT00877929,Slovakia,,,,,,,,,,,,,,
country,NCT00877929::country::South Africa,NCT00877929,South Africa,,,,,,,,,,,,,,
country,NCT00877929::country::Mexico,NCT00877929,Mexico,,,,,,,,,,,,,,
country,NCT00877929::country::Argentina,NCT00877929,Argentina,,,,,,,,,,,,,,
country,NCT00877929::country::South Korea,NCT00877929,South Korea,,,,,,,,,,,,,,
country,NCT00877929::country::Spain,NCT00877929,Spain,,,,,,,,,,,,,,
country,NCT00877929::country::Sweden,NCT00877929,Sweden,,,,,,,,,,,,,,
trial,NCT02607865,NCT02607865,Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,1864.0,2016-02-15,2018-03-28,15.0,242.0,,,,,
arm,NCT02607865::arm::FG000,NCT02607865,Oral Semaglutide 3 mg,,,,,,,,,,FG000,"Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.",,,
arm,NCT02607865::arm::FG001,NCT02607865,Oral Semaglutide 7 mg,,,,,,,,,,FG001,"Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants ",,,
arm,NCT02607865::arm::FG002,NCT02607865,Oral Semaglutide 14 mg,,,,,,,,,,FG002,"Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 7",,,
arm,NCT02607865::arm::FG003,NCT02607865,Sitagliptin 100 mg,,,,,,,,,,FG003,"Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.",,,
period,NCT02607865::period::1,NCT02607865,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02607865::outcome::primary::1,NCT02607865,Change in HbA1c: Week 26,,,,,,,,,,,,,PRIMARY,"Week 0, week 26"
country,NCT02607865::country::United States,NCT02607865,United States,,,,,,,,,,,,,,
country,NCT02607865::country::India,NCT02607865,India,,,,,,,,,,,,,,
country,NCT02607865::country::France,NCT02607865,France,,,,,,,,,,,,,,
country,NCT02607865::country::Japan,NCT02607865,Japan,,,,,,,,,,,,,,
country,NCT02607865::country::United Kingdom,NCT02607865,United Kingdom,,,,,,,,,,,,,,
country,NCT02607865::country::Romania,NCT02607865,Romania,,,,,,,,,,,,,,
country,NCT02607865::country::Germany,NCT02607865,Germany,,,,,,,,,,,,,,
country,NCT02607865::country::South Africa,NCT02607865,South Africa,,,,,,,,,,,,,,
country,NCT02607865::country::Turkey (Türkiye),NCT02607865,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02607865::country::Russia,NCT02607865,Russia,,,,,,,,,,,,,,
country,NCT02607865::country::Israel,NCT02607865,Israel,,,,,,,,,,,,,,
country,NCT02607865::country::Ukraine,NCT02607865,Ukraine,,,,,,,,,,,,,,
country,NCT02607865::country::Argentina,NCT02607865,Argentina,,,,,,,,,,,,,,
country,NCT02607865::country::Mexico,NCT02607865,Mexico,,,,,,,,,,,,,,
country,NCT02607865::country::Brazil,NCT02607865,Brazil,,,,,,,,,,,,,,
trial,NCT02229227,NCT02229227,Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,814.0,2014-11-21,2017-07-24,14.0,157.0,,,,,
arm,NCT02229227::arm::FG000,NCT02229227,Albiglutide + Insulin Glargine,,,,,,,,,,FG000,"During standardization period, participants transitioned from basal bolus regimen received during screening period to insulin glargine plus insulin lispro. Eligible participants received Albiglutide 3",,,
arm,NCT02229227::arm::FG001,NCT02229227,Insulin Lispro + Insulin Glargine,,,,,,,,,,FG001,"During standardization period, participants transitioned from basal bolus regimen received during screening period to insulin glargine plus insulin lispro. Eligible participants continued with the sam",,,
period,NCT02229227::period::1,NCT02229227,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02229227::outcome::primary::1,NCT02229227,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26,,,,,,,,,,,,,PRIMARY,Baseline (Day -1) and Week 26
country,NCT02229227::country::United States,NCT02229227,United States,,,,,,,,,,,,,,
country,NCT02229227::country::Spain,NCT02229227,Spain,,,,,,,,,,,,,,
country,NCT02229227::country::Mexico,NCT02229227,Mexico,,,,,,,,,,,,,,
country,NCT02229227::country::Germany,NCT02229227,Germany,,,,,,,,,,,,,,
country,NCT02229227::country::Brazil,NCT02229227,Brazil,,,,,,,,,,,,,,
country,NCT02229227::country::Hungary,NCT02229227,Hungary,,,,,,,,,,,,,,
country,NCT02229227::country::Poland,NCT02229227,Poland,,,,,,,,,,,,,,
country,NCT02229227::country::South Africa,NCT02229227,South Africa,,,,,,,,,,,,,,
country,NCT02229227::country::Canada,NCT02229227,Canada,,,,,,,,,,,,,,
country,NCT02229227::country::Italy,NCT02229227,Italy,,,,,,,,,,,,,,
country,NCT02229227::country::France,NCT02229227,France,,,,,,,,,,,,,,
country,NCT02229227::country::United Kingdom,NCT02229227,United Kingdom,,,,,,,,,,,,,,
country,NCT02229227::country::Philippines,NCT02229227,Philippines,,,,,,,,,,,,,,
country,NCT02229227::country::South Korea,NCT02229227,South Korea,,,,,,,,,,,,,,
trial,NCT00849017,NCT00849017,Safety and Efficacy Study of Albiglutide in Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,309.0,2009-01,2013-02,3.0,262.0,,,,,
arm,NCT00849017::arm::FG000,NCT00849017,Placebo,,,,,,,,,,FG000,Participants received matching placebo as a subcutaneous injection weekly via a fully disposable pen injector system. Participants did not receive investigational product during the Follow-up Period.,,,
arm,NCT00849017::arm::FG001,NCT00849017,Albiglutide 30 mg,,,,,,,,,,FG001,Participants received albiglutide 30 milligrams (mg) as a subcutaneous injection weekly via a fully disposable pen injector system. Participants did not receive investigational product during the Foll,,,
arm,NCT00849017::arm::FG002,NCT00849017,Albiglutide 50 mg,,,,,,,,,,FG002,Participants received albiglutide 30 mg from Baseline to Week 12 with a forced blinded uptitration to 50 mg at Week 12 as a subcutaneous injection weekly via a fully disposable pen injector system. Pa,,,
period,NCT00849017::period::1,NCT00849017,Treatment Period (156 Weeks),,,,,,,,,,,,1.0,,
period,NCT00849017::period::2,NCT00849017,Follow-up Period (8 Weeks),,,,,,,,,,,,2.0,,
outcome,NCT00849017::outcome::primary::1,NCT00849017,Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52,,,,,,,,,,,,,PRIMARY,Baseline and Week 52
country,NCT00849017::country::United States,NCT00849017,United States,,,,,,,,,,,,,,
country,NCT00849017::country::Mexico,NCT00849017,Mexico,,,,,,,,,,,,,,
country,NCT00849017::country::South Africa,NCT00849017,South Africa,,,,,,,,,,,,,,
trial,NCT01370005,NCT01370005,12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2; Hypertension",INDUSTRY,825.0,2011-06,2012-07,12.0,120.0,,,,,
arm,NCT01370005::arm::FG000,NCT01370005,Placebo,,,,,,,,,,FG000,"A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 12 weeks.",,,
arm,NCT01370005::arm::FG001,NCT01370005,Empa 10mg,,,,,,,,,,FG001,Single oral dose of empagliflozin (empa) 10mg taken once daily for 12 weeks.,,,
arm,NCT01370005::arm::FG002,NCT01370005,Empa 25mg,,,,,,,,,,FG002,Single oral dose of empagliflozin (empa) 25mg taken once daily for 12 weeks.,,,
period,NCT01370005::period::1,NCT01370005,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01370005::outcome::primary::1,NCT01370005,HbA1c Change From Baseline,,,,,,,,,,,,,PRIMARY,Baseline and 12 weeks
outcome,NCT01370005::outcome::primary::2,NCT01370005,Mean 24-hour Systolic Blood Pressure Change From Baseline,,,,,,,,,,,,,PRIMARY,Baseline and 12 weeks
country,NCT01370005::country::United States,NCT01370005,United States,,,,,,,,,,,,,,
country,NCT01370005::country::Netherlands,NCT01370005,Netherlands,,,,,,,,,,,,,,
country,NCT01370005::country::Denmark,NCT01370005,Denmark,,,,,,,,,,,,,,
country,NCT01370005::country::Germany,NCT01370005,Germany,,,,,,,,,,,,,,
country,NCT01370005::country::Norway,NCT01370005,Norway,,,,,,,,,,,,,,
country,NCT01370005::country::Czechia,NCT01370005,Czechia,,,,,,,,,,,,,,
country,NCT01370005::country::Canada,NCT01370005,Canada,,,,,,,,,,,,,,
country,NCT01370005::country::Finland,NCT01370005,Finland,,,,,,,,,,,,,,
country,NCT01370005::country::France,NCT01370005,France,,,,,,,,,,,,,,
country,NCT01370005::country::Sweden,NCT01370005,Sweden,,,,,,,,,,,,,,
country,NCT01370005::country::Estonia,NCT01370005,Estonia,,,,,,,,,,,,,,
country,NCT01370005::country::Lebanon,NCT01370005,Lebanon,,,,,,,,,,,,,,
trial,NCT05462756,NCT05462756,A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections,PHASE3,diabetes type 2,Type 2 Diabetes; Type 2 Diabetes Treated With Insulin,INDUSTRY,730.0,2022-08-11,2024-02-27,8.0,81.0,,,,,
arm,NCT05462756::arm::FG000,NCT05462756,500 U/mL - Insulin Efsitora,,,,,,,,,,FG000,Participants received 500 units per milliliter (U/mL) Insulin Efsitora Alfa (insulin efsitora) administered subcutaneously (SC) once weekly (QW) along with 100 U/mL insulin lispro given SC.,,,
arm,NCT05462756::arm::FG001,NCT05462756,100 U/mL - Insulin Glargine,,,,,,,,,,FG001,Participants received 100 U/mL insulin glargine administered SC once daily (QD) along with 100 U/mL insulin lispro given SC.,,,
period,NCT05462756::period::1,NCT05462756,Treatment Period,,,,,,,,,,,,1.0,,
period,NCT05462756::period::2,NCT05462756,Follow-Up Period,,,,,,,,,,,,2.0,,
outcome,NCT05462756::outcome::primary::1,NCT05462756,Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority],,,,,,,,,,,,,PRIMARY,"Baseline, Week 26"
country,NCT05462756::country::United States,NCT05462756,United States,,,,,,,,,,,,,,
country,NCT05462756::country::Argentina,NCT05462756,Argentina,,,,,,,,,,,,,,
country,NCT05462756::country::Spain,NCT05462756,Spain,,,,,,,,,,,,,,
country,NCT05462756::country::Italy,NCT05462756,Italy,,,,,,,,,,,,,,
country,NCT05462756::country::Germany,NCT05462756,Germany,,,,,,,,,,,,,,
country,NCT05462756::country::India,NCT05462756,India,,,,,,,,,,,,,,
country,NCT05462756::country::Mexico,NCT05462756,Mexico,,,,,,,,,,,,,,
country,NCT05462756::country::Puerto Rico,NCT05462756,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00097786,NCT00097786,Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,9306.0,2002-01,2009-10,38.0,38.0,,,,,
arm,NCT00097786::arm::FG000,NCT00097786,Valsartan 160 mg od + Nateglinide 60 mg ac,,,,,,,,,,FG000,"For the first 2 weeks of treatment, patients took the combination of nateglinide 30 mg (3 times daily ante cibum \[ac, before meals\]) and valsartan 80 mg (once daily \[od\] in the morning). After 2 w",,,
arm,NCT00097786::arm::FG001,NCT00097786,Valsartan 160 mg od + Placebo Nateglinide,,,,,,,,,,FG001,"For the first 2 weeks of treatment, patients took valsartan 80 mg once daily (od) once in the morning. After 2 weeks, patients were uptitrated to 160 mg valsartan od. Patient also received placebo mat",,,
arm,NCT00097786::arm::FG002,NCT00097786,Nateglinide 60 mg ac + Placebo Valsartan,,,,,,,,,,FG002,"For the first 2 weeks of treatment, patients took one 30 mg tablet of nateglinide with a glass of water 1-30 minutes before each main meal of the day, ie, 3 times daily ante cibum (ac, before meals). ",,,
arm,NCT00097786::arm::FG003,NCT00097786,Placebo,,,,,,,,,,FG003,Patients took 3 placebo tablets identical to nateglinide tablets 3 times daily ac and 1 placebo capsule identical to valsartan capsule once daily in the morning.,,,
period,NCT00097786::period::1,NCT00097786,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00097786::outcome::primary::1,NCT00097786,Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Valsartan Versus Non-valsartan,,,,,,,,,,,,,PRIMARY,Mean patient duration of 4.2 years
outcome,NCT00097786::outcome::primary::2,NCT00097786,Percentage of Patients Reaching the Endpoint: Extended Morbidity and Mortality Event - Valsartan Versus Non-valsartan,,,,,,,,,,,,,PRIMARY,Mean patient duration of 5.6 years
outcome,NCT00097786::outcome::primary::3,NCT00097786,Percentage of Patients Reaching the Endpoint: Core Cardiovascular Morbidity and Mortality Event - Valsartan Versus Non-valsartan,,,,,,,,,,,,,PRIMARY,Mean patient duration of 5.8 years
outcome,NCT00097786::outcome::primary::4,NCT00097786,Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Nateglinide Versus Non-nateglinide,,,,,,,,,,,,,PRIMARY,Mean patient duration of 4.2 years
outcome,NCT00097786::outcome::primary::5,NCT00097786,Percentage of Patients Reaching the Endpoint: Extended Morbidity and Mortality Event - Nateglinide Versus Non-nateglinide,,,,,,,,,,,,,PRIMARY,Mean patient duration of 5.6 years
outcome,NCT00097786::outcome::primary::6,NCT00097786,Percentage of Patients Reaching the Endpoint: Core Cardiovascular Morbidity and Mortality Event - Nateglinide Versus Non-nateglinide,,,,,,,,,,,,,PRIMARY,Mean patient duration of 5.8 years
country,NCT00097786::country::United States,NCT00097786,United States,,,,,,,,,,,,,,
country,NCT00097786::country::Argentina,NCT00097786,Argentina,,,,,,,,,,,,,,
country,NCT00097786::country::Australia,NCT00097786,Australia,,,,,,,,,,,,,,
country,NCT00097786::country::Austria,NCT00097786,Austria,,,,,,,,,,,,,,
country,NCT00097786::country::Belgium,NCT00097786,Belgium,,,,,,,,,,,,,,
country,NCT00097786::country::Brazil,NCT00097786,Brazil,,,,,,,,,,,,,,
country,NCT00097786::country::Canada,NCT00097786,Canada,,,,,,,,,,,,,,
country,NCT00097786::country::Chile,NCT00097786,Chile,,,,,,,,,,,,,,
country,NCT00097786::country::China,NCT00097786,China,,,,,,,,,,,,,,
country,NCT00097786::country::Colombia,NCT00097786,Colombia,,,,,,,,,,,,,,
country,NCT00097786::country::Czechia,NCT00097786,Czechia,,,,,,,,,,,,,,
country,NCT00097786::country::Denmark,NCT00097786,Denmark,,,,,,,,,,,,,,
country,NCT00097786::country::Ecuador,NCT00097786,Ecuador,,,,,,,,,,,,,,
country,NCT00097786::country::Finland,NCT00097786,Finland,,,,,,,,,,,,,,
country,NCT00097786::country::France,NCT00097786,France,,,,,,,,,,,,,,
country,NCT00097786::country::Germany,NCT00097786,Germany,,,,,,,,,,,,,,
country,NCT00097786::country::Greece,NCT00097786,Greece,,,,,,,,,,,,,,
country,NCT00097786::country::Guatemala,NCT00097786,Guatemala,,,,,,,,,,,,,,
country,NCT00097786::country::Hong Kong,NCT00097786,Hong Kong,,,,,,,,,,,,,,
country,NCT00097786::country::Hungary,NCT00097786,Hungary,,,,,,,,,,,,,,
country,NCT00097786::country::Italy,NCT00097786,Italy,,,,,,,,,,,,,,
country,NCT00097786::country::Malaysia,NCT00097786,Malaysia,,,,,,,,,,,,,,
country,NCT00097786::country::Mexico,NCT00097786,Mexico,,,,,,,,,,,,,,
country,NCT00097786::country::Netherlands,NCT00097786,Netherlands,,,,,,,,,,,,,,
country,NCT00097786::country::Norway,NCT00097786,Norway,,,,,,,,,,,,,,
country,NCT00097786::country::Peru,NCT00097786,Peru,,,,,,,,,,,,,,
country,NCT00097786::country::Poland,NCT00097786,Poland,,,,,,,,,,,,,,
country,NCT00097786::country::Russia,NCT00097786,Russia,,,,,,,,,,,,,,
country,NCT00097786::country::Singapore,NCT00097786,Singapore,,,,,,,,,,,,,,
country,NCT00097786::country::Slovakia,NCT00097786,Slovakia,,,,,,,,,,,,,,
country,NCT00097786::country::South Africa,NCT00097786,South Africa,,,,,,,,,,,,,,
country,NCT00097786::country::Spain,NCT00097786,Spain,,,,,,,,,,,,,,
country,NCT00097786::country::Sweden,NCT00097786,Sweden,,,,,,,,,,,,,,
country,NCT00097786::country::Switzerland,NCT00097786,Switzerland,,,,,,,,,,,,,,
country,NCT00097786::country::Taiwan,NCT00097786,Taiwan,,,,,,,,,,,,,,
country,NCT00097786::country::Turkey (Türkiye),NCT00097786,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00097786::country::United Kingdom,NCT00097786,United Kingdom,,,,,,,,,,,,,,
country,NCT00097786::country::Uruguay,NCT00097786,Uruguay,,,,,,,,,,,,,,
trial,NCT00379769,NCT00379769,RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,4447.0,2001-04,2008-12,25.0,446.0,,,,,
arm,NCT00379769::arm::FG000,NCT00379769,RSG in Addition to Background MET,,,,,,,,,,FG000,"Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to ",,,
arm,NCT00379769::arm::FG001,NCT00379769,SU in Addition to Background MET,,,,,,,,,,FG001,"Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased t",,,
arm,NCT00379769::arm::FG002,NCT00379769,RSG in Addition to Background SU,,,,,,,,,,FG002,"Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per da",,,
arm,NCT00379769::arm::FG003,NCT00379769,MET in Addition to Background SU,,,,,,,,,,FG003,"Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to ac",,,
arm,NCT00379769::arm::FG004,NCT00379769,Combined RSG: Observational Follow-up,,,,,,,,,,FG004,"Participants randomized to receive RSG (MET+RSG and SU+RSG) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatm",,,
arm,NCT00379769::arm::FG005,NCT00379769,Combined MET/SU: Observational Follow-up,,,,,,,,,,FG005,"Participants randomized to the active control groups (MET+SU and SU+MET) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-di",,,
period,NCT00379769::period::1,NCT00379769,Main Study,,,,,,,,,,,,1.0,,
period,NCT00379769::period::2,NCT00379769,Observational Follow-up,,,,,,,,,,,,2.0,,
outcome,NCT00379769::outcome::primary::1,NCT00379769,Number of Participants With Cardiovascular Death/Cardiovascular Hospitalisation Events,,,,,,,,,,,,,PRIMARY,Baseline through End of Study (up to 7.5 years)
outcome,NCT00379769::outcome::primary::2,NCT00379769,Independent Re-adjudication Outcome: Number of Participants Who Died Due to Any Cause,,,,,,,,,,,,,PRIMARY,Baseline through End of Study (up to 7.5 years)
outcome,NCT00379769::outcome::primary::3,NCT00379769,"Independent Re-adjudication (IR) Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Original RECORD Endpoint Definitions",,,,,,,,,,,,,PRIMARY,Baseline through End of Study (up to 7.5 years)
outcome,NCT00379769::outcome::primary::4,NCT00379769,"Independent Re-adjudication Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Contemporary Endpoint Definitions",,,,,,,,,,,,,PRIMARY,Baseline through End of Study (up to 7.5 years)
outcome,NCT00379769::outcome::primary::5,NCT00379769,"Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Original RECORD Endpoint Definitions",,,,,,,,,,,,,PRIMARY,Baseline through End of Study (up to 7.5 years)
outcome,NCT00379769::outcome::primary::6,NCT00379769,"Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Contemporary Endpoint Definitions",,,,,,,,,,,,,PRIMARY,Baseline through End of Study (up to 7.5 years)
outcome,NCT00379769::outcome::primary::7,NCT00379769,"Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions",,,,,,,,,,,,,PRIMARY,Baseline through End of Study (up to 7.5 years)
outcome,NCT00379769::outcome::primary::8,NCT00379769,"Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions",,,,,,,,,,,,,PRIMARY,Baseline through End of Study (up to 7.5 years)
outcome,NCT00379769::outcome::primary::9,NCT00379769,"Independent Re-adjudication Outcome: Number of Participants (Par.) With an Event of Stroke (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions",,,,,,,,,,,,,PRIMARY,Baseline through End of Study (up to 7.5 years)
outcome,NCT00379769::outcome::primary::10,NCT00379769,"Independent Re-adjudication Outcome: Number of Participants With an Event of Stroke (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions",,,,,,,,,,,,,PRIMARY,Baseline through End of Study (up to 7.5 years)
country,NCT00379769::country::France,NCT00379769,France,,,,,,,,,,,,,,
country,NCT00379769::country::United Kingdom,NCT00379769,United Kingdom,,,,,,,,,,,,,,
country,NCT00379769::country::Germany,NCT00379769,Germany,,,,,,,,,,,,,,
country,NCT00379769::country::Italy,NCT00379769,Italy,,,,,,,,,,,,,,
country,NCT00379769::country::Sweden,NCT00379769,Sweden,,,,,,,,,,,,,,
country,NCT00379769::country::Finland,NCT00379769,Finland,,,,,,,,,,,,,,
country,NCT00379769::country::Hungary,NCT00379769,Hungary,,,,,,,,,,,,,,
country,NCT00379769::country::Netherlands,NCT00379769,Netherlands,,,,,,,,,,,,,,
country,NCT00379769::country::Poland,NCT00379769,Poland,,,,,,,,,,,,,,
country,NCT00379769::country::Slovakia,NCT00379769,Slovakia,,,,,,,,,,,,,,
country,NCT00379769::country::Spain,NCT00379769,Spain,,,,,,,,,,,,,,
country,NCT00379769::country::Belgium,NCT00379769,Belgium,,,,,,,,,,,,,,
country,NCT00379769::country::Greece,NCT00379769,Greece,,,,,,,,,,,,,,
country,NCT00379769::country::Czechia,NCT00379769,Czechia,,,,,,,,,,,,,,
country,NCT00379769::country::Denmark,NCT00379769,Denmark,,,,,,,,,,,,,,
country,NCT00379769::country::Australia,NCT00379769,Australia,,,,,,,,,,,,,,
country,NCT00379769::country::Estonia,NCT00379769,Estonia,,,,,,,,,,,,,,
country,NCT00379769::country::Latvia,NCT00379769,Latvia,,,,,,,,,,,,,,
country,NCT00379769::country::Bulgaria,NCT00379769,Bulgaria,,,,,,,,,,,,,,
country,NCT00379769::country::Lithuania,NCT00379769,Lithuania,,,,,,,,,,,,,,
country,NCT00379769::country::New Zealand,NCT00379769,New Zealand,,,,,,,,,,,,,,
country,NCT00379769::country::Romania,NCT00379769,Romania,,,,,,,,,,,,,,
country,NCT00379769::country::Ukraine,NCT00379769,Ukraine,,,,,,,,,,,,,,
country,NCT00379769::country::Russia,NCT00379769,Russia,,,,,,,,,,,,,,
country,NCT00379769::country::Croatia,NCT00379769,Croatia,,,,,,,,,,,,,,
trial,NCT00570739,NCT00570739,"Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.",PHASE3,diabetes type 2,Type 2 Diabetes Mellitus; Hypercholesterolemia; Pre-diabetes,INDUSTRY,502.0,2007-11,2009-05,4.0,31.0,,,,,
arm,NCT00570739::arm::FG000,NCT00570739,Type 2 Diabetes Group: Placebo + Metformin,,,,,,,,,,FG000,This group received 6 matching colesevalm placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. This treatment duration was 16 weeks.,,,
arm,NCT00570739::arm::FG001,NCT00570739,Type 2 Diabetes Group: Colesevelam + Metformin,,,,,,,,,,FG001,This group received 6 colevevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. This treatment duration was 1,,,
arm,NCT00570739::arm::FG002,NCT00570739,Pre-diabetic Group: Placebo,,,,,,,,,,FG002,This group was given 6 placebo tablets once a day. They matched the colesevelam tablets. This treatment duration was 16 weeks.,,,
arm,NCT00570739::arm::FG003,NCT00570739,Pre-diabetic Group: Colesevelam,,,,,,,,,,FG003,"This group was given 6 colesevelam tablets, 625mg, once a day. This treatment duration was 16 weeks.",,,
period,NCT00570739::period::1,NCT00570739,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00570739::outcome::primary::1,NCT00570739,"Percent Change of Hemoglobin A1C (HbA1C) From Baseline to 16 Weeks When Given as Initial Therapy to Drug-naïve, Diabetic Subjects.",,,,,,,,,,,,,PRIMARY,Baseline to 16 weeks
outcome,NCT00570739::outcome::primary::2,NCT00570739,Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) in Pre-Diabetic Subjects From Baseline to 16 Weeks,,,,,,,,,,,,,PRIMARY,Baseline to 16 Weeks
country,NCT00570739::country::United States,NCT00570739,United States,,,,,,,,,,,,,,
country,NCT00570739::country::Mexico,NCT00570739,Mexico,,,,,,,,,,,,,,
country,NCT00570739::country::India,NCT00570739,India,,,,,,,,,,,,,,
country,NCT00570739::country::Colombia,NCT00570739,Colombia,,,,,,,,,,,,,,
trial,NCT00103857,NCT00103857,MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,1208.0,2005-03-17,2008-02-21,0.0,0.0,,,,,
arm,NCT00103857::arm::FG000,NCT00103857,Sitagliptin 100 mg q.d.,,,,,,,,,,FG000,The Sitagliptin 100 mg q.d. (q.d. = once daily) group includes data from patients randomized to receive treatment with two 50 mg oral tablets of sitagliptin once daily for up to 104 weeks (including t,,,
arm,NCT00103857::arm::FG001,NCT00103857,Metformin 500 mg b.i.d.,,,,,,,,,,FG001,The Metformin 500 mg b.i.d. (b.i.d. = twice daily) group includes data from patients randomized to receive treatment with oral tablets of metformin 500 mg b.i.d. Treatment was administered as 500 mg q,,,
arm,NCT00103857::arm::FG002,NCT00103857,Metformin 1000 mg b.i.d.,,,,,,,,,,FG002,The Metformin 1000 mg b.i.d. (b.i.d. = twice daily) group includes data from patients randomized to receive treatment with oral tablets of metformin 1000 mg b.i.d. Treatment was administered as 500 mg,,,
arm,NCT00103857::arm::FG003,NCT00103857,Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d.,,,,,,,,,,FG003,The Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. (b.i.d. = twice daily) group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 50 mg b.i.d + metformin,,,
arm,NCT00103857::arm::FG004,NCT00103857,Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d.,,,,,,,,,,FG004,The Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. (b.i.d. = twice daily) group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 50 mg b.i.d + metformin,,,
arm,NCT00103857::arm::FG005,NCT00103857,Placebo/Metformin 1000 mg b.i.d.,,,,,,,,,,FG005,The Placebo/Metformin 1000 mg b.i.d. group (b.i.d. = twice daily) includes data from patients randomized to receive the sequence of treatment with oral tablets of placebo (randomization/Day 1 through ,,,
arm,NCT00103857::arm::FG006,NCT00103857,Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. OLC,,,,,,,,,,FG006,"The Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. (b.i.d. = twice daily) OLC (Open-label Cohort) includes data from non-randomized patients assigned to receive treatment with open-label, oral tab",,,
period,NCT00103857::period::1,NCT00103857,54-Week Base Study,,,,,,,,,,,,1.0,,
period,NCT00103857::period::2,NCT00103857,50-Week Extension Study,,,,,,,,,,,,2.0,,
outcome,NCT00103857::outcome::primary::1,NCT00103857,Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24,,,,,,,,,,,,,PRIMARY,Week 24
trial,NCT02096705,NCT02096705,Phase III Insulin Add-On Asia Regional Program - ST,PHASE3,diabetes type 2,Diabetes,INDUSTRY,477.0,2014-03-31,2016-01-28,3.0,29.0,,,,,
arm,NCT02096705::arm::FG000,NCT02096705,Placebo,,,,,,,,,,FG000,Dapagliflozin Placebo 0 mg oral Tablet once daily for 24 weeks + Background Insulin,,,
arm,NCT02096705::arm::FG001,NCT02096705,Dapagliflozin,,,,,,,,,,FG001,Dapagliflozin 10 mg oral Tablet once daily for 24 weeks + Background Insulin,,,
period,NCT02096705::period::1,NCT02096705,Treatment,,,,,,,,,,,,1.0,,
period,NCT02096705::period::2,NCT02096705,Follow-up,,,,,,,,,,,,2.0,,
outcome,NCT02096705::outcome::primary::1,NCT02096705,Adjusted Mean Change in HbA1c From Baseline to Week 24,,,,,,,,,,,,,PRIMARY,Baseline (Day 1) and 24 weeks
country,NCT02096705::country::China,NCT02096705,China,,,,,,,,,,,,,,
country,NCT02096705::country::South Korea,NCT02096705,South Korea,,,,,,,,,,,,,,
country,NCT02096705::country::Singapore,NCT02096705,Singapore,,,,,,,,,,,,,,
trial,NCT02227875,NCT02227875,Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2),PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,560.0,2014-08,2015-12,6.0,120.0,,,,,
arm,NCT02227875::arm::FG000,NCT02227875,Mylan's Insulin Glargine,,,,,,,,,,FG000,"receive Mylan's insulin Glargine

Mylan's insulin glargine: Patients who are randomized to receive Mylan's insulin glargine during the comparative phase will receive the same dose as the dose of Lantu",,,
arm,NCT02227875::arm::FG001,NCT02227875,Lantus®,,,,,,,,,,FG001,"receive Lantus®

Lantus®: For patients who are randomized to receive Lantus® during the comparative phase the dose of Lantus® will be equal to the dose received during the screening period.",,,
period,NCT02227875::period::1,NCT02227875,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02227875::outcome::primary::1,NCT02227875,Change in HbA1c From Baseline to 24 Weeks,,,,,,,,,,,,,PRIMARY,24 weeks
country,NCT02227875::country::United States,NCT02227875,United States,,,,,,,,,,,,,,
country,NCT02227875::country::Slovakia,NCT02227875,Slovakia,,,,,,,,,,,,,,
country,NCT02227875::country::South Africa,NCT02227875,South Africa,,,,,,,,,,,,,,
country,NCT02227875::country::South Korea,NCT02227875,South Korea,,,,,,,,,,,,,,
country,NCT02227875::country::Jordan,NCT02227875,Jordan,,,,,,,,,,,,,,
country,NCT02227875::country::Taiwan,NCT02227875,Taiwan,,,,,,,,,,,,,,
trial,NCT05691712,NCT05691712,A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes,PHASE3,diabetes type 2,Diabetes Type 2; Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Disease; Endocrine System Diseases,INDUSTRY,257.0,2023-02-05,2024-07-01,1.0,25.0,,,,,
arm,NCT05691712::arm::FG000,NCT05691712,5 Milligram (mg) Tirzepatide,,,,,,,,,,FG000,"Participants received 5 mg of tirzepatide administered as subcutaneous (SC) injection via a single-dose pen (SDP) once weekly (QW) for 40 weeks.

The starting dose of tirzepatide was 2.5 mg QW, which ",,,
arm,NCT05691712::arm::FG001,NCT05691712,10 mg Tirzepatide,,,,,,,,,,FG001,"Participants received 10 mg of tirzepatide administered as SC injection via a SDP QW for 40 weeks.

The starting dose of tirzepatide was 2.5 mg QW, which increased by 2.5 mg every 4 weeks (2.5 mg to 5",,,
arm,NCT05691712::arm::FG002,NCT05691712,15 mg Tirzepatide,,,,,,,,,,FG002,"Participants received 15 mg of tirzepatide administered as SC injection via a SDP QW for 40 weeks.

The starting dose of tirzepatide was 2.5 mg QW, which increased by 2.5 mg every 4 weeks (2.5 mg to 5",,,
arm,NCT05691712::arm::FG003,NCT05691712,Placebo,,,,,,,,,,FG003,Participants received tirzepatide matched placebo administered as SC injection via a SDP QW for 40 weeks.,,,
period,NCT05691712::period::1,NCT05691712,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT05691712::outcome::primary::1,NCT05691712,Mean Change From Baseline in HbA1c (Tirzepatide 10 or 15 Milligram [mg]),,,,,,,,,,,,,PRIMARY,"Baseline, Week 40"
country,NCT05691712::country::China,NCT05691712,China,,,,,,,,,,,,,,
trial,NCT02963922,NCT02963922,Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin,PHASE3,diabetes type 2,Metabolism and Nutrition Disorder; Obesity,INDUSTRY,396.0,2017-02-06,2018-09-25,7.0,54.0,,,,,
arm,NCT02963922::arm::FG000,NCT02963922,Liraglutide 3.0 mg,,,,,,,,,,FG000,Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was es,,,
arm,NCT02963922::arm::FG001,NCT02963922,Placebo,,,,,,,,,,FG001,Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 we,,,
period,NCT02963922::period::1,NCT02963922,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02963922::outcome::primary::1,NCT02963922,Change in Body Weight (%),,,,,,,,,,,,,PRIMARY,"Week 0, week 56"
outcome,NCT02963922::outcome::primary::2,NCT02963922,Participants Losing at Least 5% of Baseline Body Weight,,,,,,,,,,,,,PRIMARY,Week 56
country,NCT02963922::country::United States,NCT02963922,United States,,,,,,,,,,,,,,
country,NCT02963922::country::Canada,NCT02963922,Canada,,,,,,,,,,,,,,
country,NCT02963922::country::Germany,NCT02963922,Germany,,,,,,,,,,,,,,
country,NCT02963922::country::Turkey (Türkiye),NCT02963922,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02963922::country::Israel,NCT02963922,Israel,,,,,,,,,,,,,,
country,NCT02963922::country::Italy,NCT02963922,Italy,,,,,,,,,,,,,,
country,NCT02963922::country::Mexico,NCT02963922,Mexico,,,,,,,,,,,,,,
trial,NCT00510952,NCT00510952,Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE),PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,471.0,2007-08,2008-10,4.0,17.0,,,,,
arm,NCT00510952::arm::FG000,NCT00510952,Lispro,,,,,,,,,,FG000,"Insulin Lispro protamine suspension: Patient adjusted dose, once daily (QD) or twice daily (BID), injected subcutaneous (SC) x 24 weeks",,,
arm,NCT00510952::arm::FG001,NCT00510952,Glargine,,,,,,,,,,FG001,"Insulin glargine: Patient adjusted dose, once daily (QD), injected subcutaneous (SC) x 24 weeks",,,
period,NCT00510952::period::1,NCT00510952,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00510952::outcome::primary::1,NCT00510952,Change From Baseline to 24 Week Endpoint in Hemoglobin A1c (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline, 24 Weeks"
country,NCT00510952::country::United States,NCT00510952,United States,,,,,,,,,,,,,,
country,NCT00510952::country::Brazil,NCT00510952,Brazil,,,,,,,,,,,,,,
country,NCT00510952::country::Canada,NCT00510952,Canada,,,,,,,,,,,,,,
country,NCT00510952::country::Puerto Rico,NCT00510952,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01394952,NCT01394952,Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND),PHASE3,diabetes type 2,"Cardiovascular Disease; Diabetes Mellitus, Type 2",INDUSTRY,9901.0,2011-07-22,2018-08-21,25.0,300.0,,,,,
arm,NCT01394952::arm::FG000,NCT01394952,Placebo,,,,,,,,,,FG000,"Placebo was administered once weekly, subcutaneously",,,
arm,NCT01394952::arm::FG001,NCT01394952,Dulaglutide,,,,,,,,,,FG001,"1.5 mg Dulaglutide was administered once weekly, subcutaneously",,,
period,NCT01394952::period::1,NCT01394952,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01394952::outcome::primary::1,NCT01394952,"Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)",,,,,,,,,,,,,PRIMARY,From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)
country,NCT01394952::country::United States,NCT01394952,United States,,,,,,,,,,,,,,
country,NCT01394952::country::Canada,NCT01394952,Canada,,,,,,,,,,,,,,
country,NCT01394952::country::Argentina,NCT01394952,Argentina,,,,,,,,,,,,,,
country,NCT01394952::country::Germany,NCT01394952,Germany,,,,,,,,,,,,,,
country,NCT01394952::country::Romania,NCT01394952,Romania,,,,,,,,,,,,,,
country,NCT01394952::country::South Africa,NCT01394952,South Africa,,,,,,,,,,,,,,
country,NCT01394952::country::United Kingdom,NCT01394952,United Kingdom,,,,,,,,,,,,,,
country,NCT01394952::country::New Zealand,NCT01394952,New Zealand,,,,,,,,,,,,,,
country,NCT01394952::country::Brazil,NCT01394952,Brazil,,,,,,,,,,,,,,
country,NCT01394952::country::Mexico,NCT01394952,Mexico,,,,,,,,,,,,,,
country,NCT01394952::country::Spain,NCT01394952,Spain,,,,,,,,,,,,,,
country,NCT01394952::country::Colombia,NCT01394952,Colombia,,,,,,,,,,,,,,
country,NCT01394952::country::Sweden,NCT01394952,Sweden,,,,,,,,,,,,,,
country,NCT01394952::country::Czechia,NCT01394952,Czechia,,,,,,,,,,,,,,
country,NCT01394952::country::Hungary,NCT01394952,Hungary,,,,,,,,,,,,,,
country,NCT01394952::country::Australia,NCT01394952,Australia,,,,,,,,,,,,,,
country,NCT01394952::country::Latvia,NCT01394952,Latvia,,,,,,,,,,,,,,
country,NCT01394952::country::Poland,NCT01394952,Poland,,,,,,,,,,,,,,
country,NCT01394952::country::Russia,NCT01394952,Russia,,,,,,,,,,,,,,
country,NCT01394952::country::South Korea,NCT01394952,South Korea,,,,,,,,,,,,,,
country,NCT01394952::country::Chile,NCT01394952,Chile,,,,,,,,,,,,,,
country,NCT01394952::country::Bulgaria,NCT01394952,Bulgaria,,,,,,,,,,,,,,
country,NCT01394952::country::Lithuania,NCT01394952,Lithuania,,,,,,,,,,,,,,
country,NCT01394952::country::Puerto Rico,NCT01394952,Puerto Rico,,,,,,,,,,,,,,
country,NCT01394952::country::Taiwan,NCT01394952,Taiwan,,,,,,,,,,,,,,
trial,NCT01068678,NCT01068678,Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,460.0,2010-02,2010-11,8.0,99.0,,,,,
arm,NCT01068678::arm::FG000,NCT01068678,IDeg 3TW,,,,,,,,,,FG000,"Insulin degludec (IDeg) 200U/mL given 3 times weekly (Mondays, Wednesdays, Fridays) in the morning with metformin with or without dipeptidyl peptidase-4 (DPP-4) inhibitor treatment for 26 weeks.",,,
arm,NCT01068678::arm::FG001,NCT01068678,IGlar OD,,,,,,,,,,FG001,"Insulin glargine (IGlar) 100U/mL given once a day (OD), according to the labelling instructions with metformin with or without dipeptidyl peptidase-4 (DPP-4) inhibitor treatment for 26 weeks.",,,
period,NCT01068678::period::1,NCT01068678,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01068678::outcome::primary::1,NCT01068678,Change in Glycosylated Haemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,Week 26
country,NCT01068678::country::United States,NCT01068678,United States,,,,,,,,,,,,,,
country,NCT01068678::country::Canada,NCT01068678,Canada,,,,,,,,,,,,,,
country,NCT01068678::country::United Kingdom,NCT01068678,United Kingdom,,,,,,,,,,,,,,
country,NCT01068678::country::Czechia,NCT01068678,Czechia,,,,,,,,,,,,,,
country,NCT01068678::country::Israel,NCT01068678,Israel,,,,,,,,,,,,,,
country,NCT01068678::country::Slovakia,NCT01068678,Slovakia,,,,,,,,,,,,,,
country,NCT01068678::country::South Africa,NCT01068678,South Africa,,,,,,,,,,,,,,
country,NCT01068678::country::Puerto Rico,NCT01068678,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01730534,NCT01730534,Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events,PHASE3,diabetes type 2,"Diabetes Mellitus, Non-Insulin-Dependent; High Risk for Cardiovascular Event",INDUSTRY,17190.0,2013-04-25,2018-09-11,34.0,805.0,,,,,
arm,NCT01730534::arm::FG000,NCT01730534,Dapa 10 mg,,,,,,,,,,FG000,Dapagliflozin 10 mg tablets administered orally once daily,,,
arm,NCT01730534::arm::FG001,NCT01730534,Placebo,,,,,,,,,,FG001,Matching placebo for dapagliflozin 10 mg administered orally once daily,,,
period,NCT01730534::period::1,NCT01730534,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01730534::outcome::primary::1,NCT01730534,"Subjects Included in the Composite Endpoint of CV Death, MI or Ischemic Stroke",,,,,,,,,,,,,PRIMARY,up to 5.2 years
outcome,NCT01730534::outcome::primary::2,NCT01730534,Subjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure.,,,,,,,,,,,,,PRIMARY,up to 5.2 years
country,NCT01730534::country::United States,NCT01730534,United States,,,,,,,,,,,,,,
country,NCT01730534::country::Canada,NCT01730534,Canada,,,,,,,,,,,,,,
country,NCT01730534::country::Poland,NCT01730534,Poland,,,,,,,,,,,,,,
country,NCT01730534::country::Russia,NCT01730534,Russia,,,,,,,,,,,,,,
country,NCT01730534::country::Hungary,NCT01730534,Hungary,,,,,,,,,,,,,,
country,NCT01730534::country::Czechia,NCT01730534,Czechia,,,,,,,,,,,,,,
country,NCT01730534::country::Bulgaria,NCT01730534,Bulgaria,,,,,,,,,,,,,,
country,NCT01730534::country::Mexico,NCT01730534,Mexico,,,,,,,,,,,,,,
country,NCT01730534::country::Netherlands,NCT01730534,Netherlands,,,,,,,,,,,,,,
country,NCT01730534::country::Romania,NCT01730534,Romania,,,,,,,,,,,,,,
country,NCT01730534::country::Slovakia,NCT01730534,Slovakia,,,,,,,,,,,,,,
country,NCT01730534::country::South Korea,NCT01730534,South Korea,,,,,,,,,,,,,,
country,NCT01730534::country::Argentina,NCT01730534,Argentina,,,,,,,,,,,,,,
country,NCT01730534::country::Philippines,NCT01730534,Philippines,,,,,,,,,,,,,,
country,NCT01730534::country::South Africa,NCT01730534,South Africa,,,,,,,,,,,,,,
country,NCT01730534::country::Australia,NCT01730534,Australia,,,,,,,,,,,,,,
country,NCT01730534::country::Sweden,NCT01730534,Sweden,,,,,,,,,,,,,,
country,NCT01730534::country::United Kingdom,NCT01730534,United Kingdom,,,,,,,,,,,,,,
country,NCT01730534::country::Belgium,NCT01730534,Belgium,,,,,,,,,,,,,,
country,NCT01730534::country::Germany,NCT01730534,Germany,,,,,,,,,,,,,,
country,NCT01730534::country::Italy,NCT01730534,Italy,,,,,,,,,,,,,,
country,NCT01730534::country::Israel,NCT01730534,Israel,,,,,,,,,,,,,,
country,NCT01730534::country::Ukraine,NCT01730534,Ukraine,,,,,,,,,,,,,,
country,NCT01730534::country::Brazil,NCT01730534,Brazil,,,,,,,,,,,,,,
country,NCT01730534::country::China,NCT01730534,China,,,,,,,,,,,,,,
country,NCT01730534::country::Japan,NCT01730534,Japan,,,,,,,,,,,,,,
country,NCT01730534::country::Thailand,NCT01730534,Thailand,,,,,,,,,,,,,,
country,NCT01730534::country::France,NCT01730534,France,,,,,,,,,,,,,,
country,NCT01730534::country::Spain,NCT01730534,Spain,,,,,,,,,,,,,,
country,NCT01730534::country::Turkey (Türkiye),NCT01730534,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01730534::country::Taiwan,NCT01730534,Taiwan,,,,,,,,,,,,,,
country,NCT01730534::country::India,NCT01730534,India,,,,,,,,,,,,,,
country,NCT01730534::country::Vietnam,NCT01730534,Vietnam,,,,,,,,,,,,,,
country,NCT01730534::country::Hong Kong,NCT01730534,Hong Kong,,,,,,,,,,,,,,
trial,NCT04109547,NCT04109547,A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,521.0,2019-10-01,2021-10-27,6.0,66.0,,,,,
arm,NCT04109547::arm::FG000,NCT04109547,Oral Semaglutide 3 mg,,,,,,,,,,FG000,Participants received oral semaglutide 3 mg tablets once daily from week 0 to week 26.,,,
arm,NCT04109547::arm::FG001,NCT04109547,Oral Semaglutide 7 mg,,,,,,,,,,FG001,Participants received oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 26: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 26.,,,
arm,NCT04109547::arm::FG002,NCT04109547,Oral Semaglutide 14 mg,,,,,,,,,,FG002,"Participants received oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 26: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 26.",,,
arm,NCT04109547::arm::FG003,NCT04109547,Placebo,,,,,,,,,,FG003,Participants received oral semaglutide matching placebo tablets once daily from week 0 to week 26.,,,
period,NCT04109547::period::1,NCT04109547,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04109547::outcome::primary::1,NCT04109547,Change From Baseline in Glycosylated Haemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline (Week 0), Week 26"
country,NCT04109547::country::China,NCT04109547,China,,,,,,,,,,,,,,
country,NCT04109547::country::Ukraine,NCT04109547,Ukraine,,,,,,,,,,,,,,
country,NCT04109547::country::Hungary,NCT04109547,Hungary,,,,,,,,,,,,,,
country,NCT04109547::country::Taiwan,NCT04109547,Taiwan,,,,,,,,,,,,,,
country,NCT04109547::country::Algeria,NCT04109547,Algeria,,,,,,,,,,,,,,
country,NCT04109547::country::Serbia,NCT04109547,Serbia,,,,,,,,,,,,,,
trial,NCT01584232,NCT01584232,A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,361.0,2012-04,2013-07,1.0,15.0,,,,,
arm,NCT01584232::arm::FG000,NCT01584232,LY2189265 + OAM,,,,,,,,,,FG000,"LY2189265: 0.75 milligrams (mg), administered subcutaneously (SC), once weekly for 26 weeks

Participants were to continue on their stable, pre-study, physician-prescribed dose of oral antihyperglycem",,,
arm,NCT01584232::arm::FG001,NCT01584232,Insulin Glargine + OAM,,,,,,,,,,FG001,"Insulin glargine: dose based on targeting fasting blood glucose ≤110 milligrams per deciliter (mg/dL), administered subcutaneously (SC), once daily for 26 weeks

Participants were to continue on their",,,
period,NCT01584232::period::1,NCT01584232,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01584232::outcome::primary::1,NCT01584232,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks,,,,,,,,,,,,,PRIMARY,"Baseline, 26 weeks"
country,NCT01584232::country::Japan,NCT01584232,Japan,,,,,,,,,,,,,,
trial,NCT01644500,NCT01644500,A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,737.0,2012-07,2014-08,3.0,30.0,,,,,
arm,NCT01644500::arm::FG000,NCT01644500,1.5 mg Dulaglutide,,,,,,,,,,FG000,1.5 milligrams (mg) dulaglutide administered as one subcutaneous (SC) injection once-weekly plus one to three capsules of placebo each day for blinding purposes for up to 26 weeks.,,,
arm,NCT01644500::arm::FG001,NCT01644500,0.75 mg Dulaglutide,,,,,,,,,,FG001,0.75 mg dulaglutide administered as one SC injection once-weekly plus one to three capsules of placebo each day for blinding purposes for up to 26 weeks.,,,
arm,NCT01644500::arm::FG002,NCT01644500,Glimepiride,,,,,,,,,,FG002,1 to 3 mg/day glimepiride administered orally as one to three capsules per day plus one SC injection of placebo once-weekly for blinding purposes for up to 26 weeks.,,,
period,NCT01644500::period::1,NCT01644500,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01644500::outcome::primary::1,NCT01644500,Change From Baseline in HbA1c at 26 Weeks,,,,,,,,,,,,,PRIMARY,"Baseline, 26 Weeks"
country,NCT01644500::country::China,NCT01644500,China,,,,,,,,,,,,,,
country,NCT01644500::country::Taiwan,NCT01644500,Taiwan,,,,,,,,,,,,,,
country,NCT01644500::country::South Korea,NCT01644500,South Korea,,,,,,,,,,,,,,
trial,NCT02324569,NCT02324569,"A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes",PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,240.0,2014-12-27,2016-12-28,1.0,65.0,,,,,
arm,NCT02324569::arm::FG000,NCT02324569,Treatment Group I,,,,,,,,,,FG000,"SYR-472 100 mg, one tablet, orally before breakfast, weekly for up to Week 12 as Period I, followed by SYR-472 100 mg, one tablet, orally before breakfast, weekly for up to Week 52 as Period II of thi",,,
arm,NCT02324569::arm::FG001,NCT02324569,Treatment Group II,,,,,,,,,,FG001,"SYR-472 placebo, one tablet, orally before breakfast, weekly for up to Week 12 as Period I, followed by SYR-472 100 mg, one tablet, orally before breakfast, weekly for up to Week 52 as Period II of th",,,
period,NCT02324569::period::1,NCT02324569,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02324569::outcome::primary::1,NCT02324569,Change in HbA1c From Baseline at the End of Treatment Period I (End of Treatment Period I - End of the Screening Period),,,,,,,,,,,,,PRIMARY,End of the screening period (Week 0) and End of Treatment Period I (Up to Week 12)
outcome,NCT02324569::outcome::primary::2,NCT02324569,Number of Participants Reporting One or More Treatment-Emergent Adverse Events (TEAEs) That Occurred Before Start of Treatment Period II,,,,,,,,,,,,,PRIMARY,Up to Week 12
country,NCT02324569::country::Japan,NCT02324569,Japan,,,,,,,,,,,,,,
trial,NCT05352815,NCT05352815,"A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec",PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,1291.0,2022-06-01,2024-04-23,22.0,281.0,,,,,
arm,NCT05352815::arm::FG000,NCT05352815,IcoSema,,,,,,,,,,FG000,Participants received once-weekly subcutaneous injections of 700 units per milliliter (U/mL) of insulin icodec and 2 milligrams per milliliter (mg/mL) of semaglutide for 52 weeks.,,,
arm,NCT05352815::arm::FG001,NCT05352815,Insulin Icodec,,,,,,,,,,FG001,Participants received once-weekly subcutaneous injections of 700 U/mL of insulin icodec for 52 weeks.,,,
period,NCT05352815::period::1,NCT05352815,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT05352815::outcome::primary::1,NCT05352815,Change in Glycated Haemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline (Week 0), Week 52"
country,NCT05352815::country::United States,NCT05352815,United States,,,,,,,,,,,,,,
country,NCT05352815::country::India,NCT05352815,India,,,,,,,,,,,,,,
country,NCT05352815::country::Japan,NCT05352815,Japan,,,,,,,,,,,,,,
country,NCT05352815::country::China,NCT05352815,China,,,,,,,,,,,,,,
country,NCT05352815::country::South Korea,NCT05352815,South Korea,,,,,,,,,,,,,,
country,NCT05352815::country::Portugal,NCT05352815,Portugal,,,,,,,,,,,,,,
country,NCT05352815::country::Australia,NCT05352815,Australia,,,,,,,,,,,,,,
country,NCT05352815::country::Belgium,NCT05352815,Belgium,,,,,,,,,,,,,,
country,NCT05352815::country::Norway,NCT05352815,Norway,,,,,,,,,,,,,,
country,NCT05352815::country::Russia,NCT05352815,Russia,,,,,,,,,,,,,,
country,NCT05352815::country::South Africa,NCT05352815,South Africa,,,,,,,,,,,,,,
country,NCT05352815::country::Turkey (Türkiye),NCT05352815,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT05352815::country::Finland,NCT05352815,Finland,,,,,,,,,,,,,,
country,NCT05352815::country::Italy,NCT05352815,Italy,,,,,,,,,,,,,,
country,NCT05352815::country::Romania,NCT05352815,Romania,,,,,,,,,,,,,,
country,NCT05352815::country::Bulgaria,NCT05352815,Bulgaria,,,,,,,,,,,,,,
country,NCT05352815::country::Croatia,NCT05352815,Croatia,,,,,,,,,,,,,,
country,NCT05352815::country::Taiwan,NCT05352815,Taiwan,,,,,,,,,,,,,,
country,NCT05352815::country::Poland,NCT05352815,Poland,,,,,,,,,,,,,,
country,NCT05352815::country::Mexico,NCT05352815,Mexico,,,,,,,,,,,,,,
country,NCT05352815::country::Puerto Rico,NCT05352815,Puerto Rico,,,,,,,,,,,,,,
country,NCT05352815::country::Serbia,NCT05352815,Serbia,,,,,,,,,,,,,,
trial,NCT00532935,NCT00532935,MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,517.0,2008-01-26,2009-10-23,0.0,0.0,,,,,
arm,NCT00532935::arm::FG000,NCT00532935,Sitagliptin/Metformin Fixed-Dose Combination,,,,,,,,,,FG000,The Sitagliptin/Metformin Fixed-Dose Combination (Sita/Met FDC) group includes data from patients randomized to receive treatment with oral tablets of Sita/Met FDC initiated at a dose of 50/500 mg twi,,,
arm,NCT00532935::arm::FG001,NCT00532935,Pioglitazone,,,,,,,,,,FG001,The Pioglitazone group includes data from patients randomized to receive treatment with oral tablets of pioglitazone initiated at a dose of 30 mg once daily (q.d.). The dose was to have been up-titrat,,,
period,NCT00532935::period::1,NCT00532935,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00532935::outcome::primary::1,NCT00532935,Change From Baseline in A1C at Week 32,,,,,,,,,,,,,PRIMARY,Baseline and Week 32
trial,NCT01046110,NCT01046110,Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,458.0,2010-01,2010-11,7.0,93.0,,,,,
arm,NCT01046110::arm::FG000,NCT01046110,IDeg OD,,,,,,,,,,FG000,"Insulin degludec (IDeg) was given once daily subcutaneously (s.c.) for 26 weeks with pre-trial treatment being 1 or 2 oral anti-diabetic drugs (metformin, sulfonylureas, glinides, pioglitazone) in any",,,
arm,NCT01046110::arm::FG001,NCT01046110,DPP-IV Inhibitor,,,,,,,,,,FG001,"Sitagliptin was given once daily dose of 100 mg for 26 weeks with pre-trial treatment being 1 or 2 oral anti-diabetic drugs (metformin, sulfonylureas, glinides, pioglitazone) in any combination.",,,
period,NCT01046110::period::1,NCT01046110,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01046110::outcome::primary::1,NCT01046110,Change in Glycosylated Haemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Week 0, Week 26"
country,NCT01046110::country::United States,NCT01046110,United States,,,,,,,,,,,,,,
country,NCT01046110::country::Canada,NCT01046110,Canada,,,,,,,,,,,,,,
country,NCT01046110::country::India,NCT01046110,India,,,,,,,,,,,,,,
country,NCT01046110::country::Argentina,NCT01046110,Argentina,,,,,,,,,,,,,,
country,NCT01046110::country::Turkey (Türkiye),NCT01046110,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01046110::country::South Africa,NCT01046110,South Africa,,,,,,,,,,,,,,
country,NCT01046110::country::Mexico,NCT01046110,Mexico,,,,,,,,,,,,,,
trial,NCT01301833,NCT01301833,Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,462.0,2011-02,2012-09,1.0,1.0,,,,,
arm,NCT01301833::arm::FG000,NCT01301833,Teneligliptin,,,,,,,,,,FG000,"teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained )",,,
arm,NCT01301833::arm::FG001,NCT01301833,Teneligliptin and Glinide,,,,,,,,,,FG001,"teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus glinide",,,
arm,NCT01301833::arm::FG002,NCT01301833,Teneligliptin and Biguanide,,,,,,,,,,FG002,"teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus biguanide",,,
arm,NCT01301833::arm::FG003,NCT01301833,Teneligliptin and Alpha-glucosidase Inhibitor,,,,,,,,,,FG003,"teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus alpha-glucosidase inhibitor",,,
period,NCT01301833::period::1,NCT01301833,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01301833::outcome::primary::1,NCT01301833,Number of Participants With Adverse Events,,,,,,,,,,,,,PRIMARY,52 Weeks
country,NCT01301833::country::Japan,NCT01301833,Japan,,,,,,,,,,,,,,
trial,NCT01144338,NCT01144338,Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,14752.0,2010-06-18,2017-04-24,35.0,629.0,,,,,
arm,NCT01144338::arm::FG000,NCT01144338,Placebo,,,,,,,,,,FG000,Matching placebo subcutaneous injections,,,
arm,NCT01144338::arm::FG001,NCT01144338,Exenatide Once Weekly,,,,,,,,,,FG001,Exenatide 2mg once weekly subcutaneous injections,,,
period,NCT01144338::period::1,NCT01144338,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01144338::outcome::primary::1,NCT01144338,Primary Efficacy Outcome MACE Events,,,,,,,,,,,,,PRIMARY,Time to first event. Information collected during study period (anticipated to be up to 7.5 years).
outcome,NCT01144338::outcome::primary::2,NCT01144338,Primary Safety Outcome MACE Events,,,,,,,,,,,,,PRIMARY,Time to first event. Information collected during study period (anticipated to be up to 7.5 years).
country,NCT01144338::country::United States,NCT01144338,United States,,,,,,,,,,,,,,
country,NCT01144338::country::Germany,NCT01144338,Germany,,,,,,,,,,,,,,
country,NCT01144338::country::Hungary,NCT01144338,Hungary,,,,,,,,,,,,,,
country,NCT01144338::country::United Kingdom,NCT01144338,United Kingdom,,,,,,,,,,,,,,
country,NCT01144338::country::Canada,NCT01144338,Canada,,,,,,,,,,,,,,
country,NCT01144338::country::Ukraine,NCT01144338,Ukraine,,,,,,,,,,,,,,
country,NCT01144338::country::China,NCT01144338,China,,,,,,,,,,,,,,
country,NCT01144338::country::South Africa,NCT01144338,South Africa,,,,,,,,,,,,,,
country,NCT01144338::country::Spain,NCT01144338,Spain,,,,,,,,,,,,,,
country,NCT01144338::country::Argentina,NCT01144338,Argentina,,,,,,,,,,,,,,
country,NCT01144338::country::Romania,NCT01144338,Romania,,,,,,,,,,,,,,
country,NCT01144338::country::Poland,NCT01144338,Poland,,,,,,,,,,,,,,
country,NCT01144338::country::South Korea,NCT01144338,South Korea,,,,,,,,,,,,,,
country,NCT01144338::country::Brazil,NCT01144338,Brazil,,,,,,,,,,,,,,
country,NCT01144338::country::Israel,NCT01144338,Israel,,,,,,,,,,,,,,
country,NCT01144338::country::Lithuania,NCT01144338,Lithuania,,,,,,,,,,,,,,
country,NCT01144338::country::Russia,NCT01144338,Russia,,,,,,,,,,,,,,
country,NCT01144338::country::Australia,NCT01144338,Australia,,,,,,,,,,,,,,
country,NCT01144338::country::Bulgaria,NCT01144338,Bulgaria,,,,,,,,,,,,,,
country,NCT01144338::country::Mexico,NCT01144338,Mexico,,,,,,,,,,,,,,
country,NCT01144338::country::Latvia,NCT01144338,Latvia,,,,,,,,,,,,,,
country,NCT01144338::country::New Zealand,NCT01144338,New Zealand,,,,,,,,,,,,,,
country,NCT01144338::country::Slovakia,NCT01144338,Slovakia,,,,,,,,,,,,,,
country,NCT01144338::country::Netherlands,NCT01144338,Netherlands,,,,,,,,,,,,,,
country,NCT01144338::country::Philippines,NCT01144338,Philippines,,,,,,,,,,,,,,
country,NCT01144338::country::Taiwan,NCT01144338,Taiwan,,,,,,,,,,,,,,
country,NCT01144338::country::Austria,NCT01144338,Austria,,,,,,,,,,,,,,
country,NCT01144338::country::Colombia,NCT01144338,Colombia,,,,,,,,,,,,,,
country,NCT01144338::country::Italy,NCT01144338,Italy,,,,,,,,,,,,,,
country,NCT01144338::country::Malaysia,NCT01144338,Malaysia,,,,,,,,,,,,,,
country,NCT01144338::country::Chile,NCT01144338,Chile,,,,,,,,,,,,,,
country,NCT01144338::country::Czechia,NCT01144338,Czechia,,,,,,,,,,,,,,
country,NCT01144338::country::Belgium,NCT01144338,Belgium,,,,,,,,,,,,,,
country,NCT01144338::country::Hong Kong,NCT01144338,Hong Kong,,,,,,,,,,,,,,
country,NCT01144338::country::Thailand,NCT01144338,Thailand,,,,,,,,,,,,,,
trial,NCT01769378,NCT01769378,Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,300.0,2013-01,2014-12,8.0,31.0,,,,,
arm,NCT01769378::arm::FG000,NCT01769378,Dulaglutide,,,,,,,,,,FG000,Dulaglutide 1.5 milligram (mg) administered subcutaneously (SQ) once weekly for 24 weeks added to the participant's prescribed glimepiride dose.,,,
arm,NCT01769378::arm::FG001,NCT01769378,Placebo,,,,,,,,,,FG001,Placebo administered SQ once weekly for 24 weeks added to the participant's prescribed glimepiride dose.,,,
period,NCT01769378::period::1,NCT01769378,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01769378::outcome::primary::1,NCT01769378,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 24 Weeks,,,,,,,,,,,,,PRIMARY,"Baseline, 24 Weeks"
country,NCT01769378::country::United States,NCT01769378,United States,,,,,,,,,,,,,,
country,NCT01769378::country::Croatia,NCT01769378,Croatia,,,,,,,,,,,,,,
country,NCT01769378::country::Romania,NCT01769378,Romania,,,,,,,,,,,,,,
country,NCT01769378::country::Argentina,NCT01769378,Argentina,,,,,,,,,,,,,,
country,NCT01769378::country::South Africa,NCT01769378,South Africa,,,,,,,,,,,,,,
country,NCT01769378::country::Austria,NCT01769378,Austria,,,,,,,,,,,,,,
country,NCT01769378::country::Mexico,NCT01769378,Mexico,,,,,,,,,,,,,,
country,NCT01769378::country::Slovenia,NCT01769378,Slovenia,,,,,,,,,,,,,,
trial,NCT01435616,NCT01435616,A Study in Patients With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,1538.0,2011-11,2014-01,23.0,167.0,,,,,
arm,NCT01435616::arm::FG000,NCT01435616,LY2605541,,,,,,,,,,FG000,"LY2605541 titrated based on blood glucose readings, administered subcutaneously (SC), once daily in combination with at least 2 pre-study oral antihyperglycemic medications (OAMs) prescribed by the pe",,,
arm,NCT01435616::arm::FG001,NCT01435616,Glargine,,,,,,,,,,FG001,"Glargine titrated based on blood glucose readings, administered SC, once daily in combination with at least 2 pre-study OAMs prescribed by the personal physician, for 52 or 78 weeks",,,
period,NCT01435616::period::1,NCT01435616,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01435616::outcome::primary::1,NCT01435616,Change From Baseline to 52 Week Endpoint in Hemoglobin A1c (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline, 52 weeks"
country,NCT01435616::country::United States,NCT01435616,United States,,,,,,,,,,,,,,
country,NCT01435616::country::Germany,NCT01435616,Germany,,,,,,,,,,,,,,
country,NCT01435616::country::Canada,NCT01435616,Canada,,,,,,,,,,,,,,
country,NCT01435616::country::Poland,NCT01435616,Poland,,,,,,,,,,,,,,
country,NCT01435616::country::Romania,NCT01435616,Romania,,,,,,,,,,,,,,
country,NCT01435616::country::Italy,NCT01435616,Italy,,,,,,,,,,,,,,
country,NCT01435616::country::Spain,NCT01435616,Spain,,,,,,,,,,,,,,
country,NCT01435616::country::Hungary,NCT01435616,Hungary,,,,,,,,,,,,,,
country,NCT01435616::country::Russia,NCT01435616,Russia,,,,,,,,,,,,,,
country,NCT01435616::country::Argentina,NCT01435616,Argentina,,,,,,,,,,,,,,
country,NCT01435616::country::Australia,NCT01435616,Australia,,,,,,,,,,,,,,
country,NCT01435616::country::Brazil,NCT01435616,Brazil,,,,,,,,,,,,,,
country,NCT01435616::country::Turkey (Türkiye),NCT01435616,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01435616::country::United Kingdom,NCT01435616,United Kingdom,,,,,,,,,,,,,,
country,NCT01435616::country::Greece,NCT01435616,Greece,,,,,,,,,,,,,,
country,NCT01435616::country::Israel,NCT01435616,Israel,,,,,,,,,,,,,,
country,NCT01435616::country::Mexico,NCT01435616,Mexico,,,,,,,,,,,,,,
country,NCT01435616::country::Puerto Rico,NCT01435616,Puerto Rico,,,,,,,,,,,,,,
country,NCT01435616::country::Slovakia,NCT01435616,Slovakia,,,,,,,,,,,,,,
country,NCT01435616::country::South Africa,NCT01435616,South Africa,,,,,,,,,,,,,,
country,NCT01435616::country::Finland,NCT01435616,Finland,,,,,,,,,,,,,,
country,NCT01435616::country::Lithuania,NCT01435616,Lithuania,,,,,,,,,,,,,,
country,NCT01435616::country::New Zealand,NCT01435616,New Zealand,,,,,,,,,,,,,,
trial,NCT02489968,NCT02489968,Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,880.0,2015-05-12,2017-06-16,1.0,83.0,,,,,
arm,NCT02489968::arm::FG000,NCT02489968,Empagliflozin 10 mg OL,,,,,,,,,,FG000,"Patients were administered empagliflozin 10 milligram (mg) tablets, orally with water, once daily for 16-weeks of open-label stabilisation period.",,,
arm,NCT02489968::arm::FG001,NCT02489968,Empagliflozin 25 mg OL,,,,,,,,,,FG001,"Patients were administered empagliflozin 25 mg tablets, orally with water, once daily for 16-weeks of open-label stabilisation period.",,,
arm,NCT02489968::arm::FG002,NCT02489968,Empagliflozin 10 mg + Linagliptin 5 mg,,,,,,,,,,FG002,Patients who received empagliflozin 10 mg during open-label stabilisation period were randomized to receive a fixed dose combination (FDC) tablet of empagliflozin 10 mg and linagliptin 5 mg along with,,,
arm,NCT02489968::arm::FG003,NCT02489968,Empagliflozin 10 mg + Placebo,,,,,,,,,,FG003,Patients who received empagliflozin 10 mg during open-label stabilisation period were randomized to receive empagliflozin 10 mg along with a matching placebo of the FDC tablet of empagliflozin 10 mg a,,,
arm,NCT02489968::arm::FG004,NCT02489968,Empagliflozin 25 mg + Linagliptin 5 mg,,,,,,,,,,FG004,Patients who received empagliflozin 25 mg during open-label stabilisation period were randomized to receive a FDC tablet of empagliflozin 25 mg and linagliptin 5 mg along with a matching placebo of em,,,
arm,NCT02489968::arm::FG005,NCT02489968,Empagliflozin 25 mg + Placebo,,,,,,,,,,FG005,Patients who received empagliflozin 25 mg during open-label stabilisation period were randomized to receive empagliflozin 25 mg along with a matching placebo of the FDC tablet of empagliflozin 25 mg a,,,
period,NCT02489968::period::1,NCT02489968,Open-label Treatment Period,,,,,,,,,,,,1.0,,
period,NCT02489968::period::2,NCT02489968,Double-blind Treatment Period,,,,,,,,,,,,2.0,,
outcome,NCT02489968::outcome::primary::1,NCT02489968,Change in Glycated Haemoglobin A1c (HbA1c) (%) From Baseline After 24 Weeks of Treatment,,,,,,,,,,,,,PRIMARY,Baseline and 24 week
country,NCT02489968::country::Japan,NCT02489968,Japan,,,,,,,,,,,,,,
trial,NCT00798161,NCT00798161,"Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design",PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,857.0,2008-12,,14.0,138.0,,,,,
arm,NCT00798161::arm::FG000,NCT00798161,Placebo,,,,,,,,,,FG000,Patients treated with matching placebo,,,
arm,NCT00798161::arm::FG001,NCT00798161,M500 Twice Daily (BID),,,,,,,,,,FG001,Patients treated with Metformin 500 mg BID,,,
arm,NCT00798161::arm::FG002,NCT00798161,M1000 BID,,,,,,,,,,FG002,Patients treated with Metformin 1000 mg BID,,,
arm,NCT00798161::arm::FG003,NCT00798161,Lina 5,,,,,,,,,,FG003,Patients treated with Linagliptin 5 mg once daily (OD),,,
arm,NCT00798161::arm::FG004,NCT00798161,L2.5+M500 BID,,,,,,,,,,FG004,Patients treated with Linagliptin 2.5 mg + Metformin 500 mg BID,,,
arm,NCT00798161::arm::FG005,NCT00798161,L2.5 + M1000 BID,,,,,,,,,,FG005,Patients treated with Linagliptin 2.5 mg + Metformin 1000 mg BID,,,
arm,NCT00798161::arm::FG006,NCT00798161,OL: L2.5+M1000 BID,,,,,,,,,,FG006,Open label set: Linagliptin 2.5 mg + Metformin 1000 mg BID,,,
period,NCT00798161::period::1,NCT00798161,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00798161::outcome::primary::1,NCT00798161,HbA1c Change From Baseline at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and week 24
country,NCT00798161::country::France,NCT00798161,France,,,,,,,,,,,,,,
country,NCT00798161::country::India,NCT00798161,India,,,,,,,,,,,,,,
country,NCT00798161::country::Netherlands,NCT00798161,Netherlands,,,,,,,,,,,,,,
country,NCT00798161::country::Canada,NCT00798161,Canada,,,,,,,,,,,,,,
country,NCT00798161::country::Mexico,NCT00798161,Mexico,,,,,,,,,,,,,,
country,NCT00798161::country::Russia,NCT00798161,Russia,,,,,,,,,,,,,,
country,NCT00798161::country::Croatia,NCT00798161,Croatia,,,,,,,,,,,,,,
country,NCT00798161::country::Germany,NCT00798161,Germany,,,,,,,,,,,,,,
country,NCT00798161::country::Ukraine,NCT00798161,Ukraine,,,,,,,,,,,,,,
country,NCT00798161::country::Romania,NCT00798161,Romania,,,,,,,,,,,,,,
country,NCT00798161::country::Sweden,NCT00798161,Sweden,,,,,,,,,,,,,,
country,NCT00798161::country::Tunisia,NCT00798161,Tunisia,,,,,,,,,,,,,,
country,NCT00798161::country::Estonia,NCT00798161,Estonia,,,,,,,,,,,,,,
country,NCT00798161::country::Lithuania,NCT00798161,Lithuania,,,,,,,,,,,,,,
trial,NCT01189890,NCT01189890,Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,480.0,2010-08-16,2012-10-31,0.0,0.0,,,,,
arm,NCT01189890::arm::FG000,NCT01189890,Sitagliptin,,,,,,,,,,FG000,Sitagliptin phosphate 100 mg once daily (QD) or 50 mg QD,,,
arm,NCT01189890::arm::FG001,NCT01189890,Glimepiride,,,,,,,,,,FG001,Glimepiride 1-6 mg QD,,,
period,NCT01189890::period::1,NCT01189890,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01189890::outcome::primary::1,NCT01189890,Least Squares (LS) Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 30,,,,,,,,,,,,,PRIMARY,Baseline and Week 30
outcome,NCT01189890::outcome::primary::2,NCT01189890,Number of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 30,,,,,,,,,,,,,PRIMARY,Up to Week 30
outcome,NCT01189890::outcome::primary::3,NCT01189890,Number of Participants Experiencing An Adverse Event (AE),,,,,,,,,,,,,PRIMARY,Up to Week 30
outcome,NCT01189890::outcome::primary::4,NCT01189890,Number of Participants Discontinuing Study Treatment Due to An AE,,,,,,,,,,,,,PRIMARY,Up to Week 30
trial,NCT01708902,NCT01708902,Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,876.0,2012-10,2014-04,4.0,56.0,,,,,
arm,NCT01708902::arm::FG000,NCT01708902,Main: Linagliptin 5mg QD,,,,,,,,,,FG000,"Main Group: Patients received linagliptin 5mg once daily (QD), administered oral as tablet.",,,
arm,NCT01708902::arm::FG001,NCT01708902,Main: Metformin 500mg BID,,,,,,,,,,FG001,"Main Group: Patients received metformin 500mg twice daily (BID), administered oral as tablet.",,,
arm,NCT01708902::arm::FG002,NCT01708902,Main: Metformin 1000mg BID,,,,,,,,,,FG002,"Main Group: Patients received metformin 1000mg twice daily (BID), administered oral as tablet.",,,
arm,NCT01708902::arm::FG003,NCT01708902,Main: Linagliptin 2.5mg / Metformin 500mg BID,,,,,,,,,,FG003,"Main Group: Patients received linagliptin 2.5mg and metformin 500mg twice daily (BID), administered oral as fixed dose combination (FDC) tablet.",,,
arm,NCT01708902::arm::FG004,NCT01708902,Main: Linagliptin 2.5mg / Metformin 1000mg BID,,,,,,,,,,FG004,"Main Group: Patients received linagliptin 2.5mg and metformin 1000mg twice daily (BID), administered oral as fixed dose combination (FDC) tablet.",,,
arm,NCT01708902::arm::FG005,NCT01708902,APG: Linagliptin 5mg QD,,,,,,,,,,FG005,"Additional parallel group (APG): Patients received linagliptin 5mg once daily (QD), administered oral as tablet.

(Data up to week 12)",,,
arm,NCT01708902::arm::FG006,NCT01708902,APG: Linagliptin 2.5mg / Metformin 1000mg BID,,,,,,,,,,FG006,"Additional parallel group (APG): Patients received linagliptin 2.5mg and metformin 1000mg twice daily (BID), administered oral as fixed dose combination (FDC) tablet.

(Data up to week 12)",,,
period,NCT01708902::period::1,NCT01708902,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01708902::outcome::primary::1,NCT01708902,The Change From Baseline in HbA1c After 24 Weeks of Treatment in Main Group,,,,,,,,,,,,,PRIMARY,Baseline and week 24
outcome,NCT01708902::outcome::primary::2,NCT01708902,The Change From Baseline in HbA1c After 24 Weeks of Treatment in Main Group - FAS (OC),,,,,,,,,,,,,PRIMARY,Baseline and week 24
outcome,NCT01708902::outcome::primary::3,NCT01708902,The Change From Baseline in HbA1c After 12 Weeks of Treatment in APG,,,,,,,,,,,,,PRIMARY,Baseline and week 12
country,NCT01708902::country::China,NCT01708902,China,,,,,,,,,,,,,,
country,NCT01708902::country::Malaysia,NCT01708902,Malaysia,,,,,,,,,,,,,,
country,NCT01708902::country::Philippines,NCT01708902,Philippines,,,,,,,,,,,,,,
country,NCT01708902::country::Vietnam,NCT01708902,Vietnam,,,,,,,,,,,,,,
trial,NCT00106704,NCT00106704,Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035),PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,441.0,2005-03,2007-01,0.0,0.0,,,,,
arm,NCT00106704::arm::FG000,NCT00106704,Sitagliptin,,,,,,,,,,FG000,The Sitagliptin group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg q.d. (once daily) with glimepiride (≥4 mg/day) alone or in combination with me,,,
arm,NCT00106704::arm::FG001,NCT00106704,Placebo/ Pioglitazone,,,,,,,,,,FG001,The Placebo group includes data from patients randomized to receive treatment with placebo to sitagliptin oral tablets q.d. with glimepiride (≥4 mg/day) alone or in combination with metformin (≥1500 m,,,
period,NCT00106704::period::1,NCT00106704,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00106704::outcome::primary::1,NCT00106704,Change From Baseline in A1C at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and 24 Weeks
trial,NCT01368081,NCT01368081,Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,1162.0,2011-05,2013-04,1.0,87.0,,,,,
arm,NCT01368081::arm::FG000,NCT01368081,Sulfonylurea: Empa 10mg,,,,,,,,,,FG000,One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Sulfonylurea,,,
arm,NCT01368081::arm::FG001,NCT01368081,Sulfonylurea: Empa 25mg,,,,,,,,,,FG001,One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Sulfonylurea,,,
arm,NCT01368081::arm::FG002,NCT01368081,Sulfonylurea: Metformin,,,,,,,,,,FG002,"250mg tablet of metformin twice daily for 52 weeks, as an open-label treatment, for patients with background treatment of Sulfonylurea",,,
arm,NCT01368081::arm::FG003,NCT01368081,Biguanide: Empa 10mg,,,,,,,,,,FG003,One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Biguanide,,,
arm,NCT01368081::arm::FG004,NCT01368081,Biguanide: Empa 25mg,,,,,,,,,,FG004,One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Biguanide,,,
arm,NCT01368081::arm::FG005,NCT01368081,Thiazolidinedione: Empa 10mg,,,,,,,,,,FG005,One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Thiazolidinedione,,,
arm,NCT01368081::arm::FG006,NCT01368081,Thiazolidinedione: Empa 25mg,,,,,,,,,,FG006,One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Thiazolidinedione,,,
arm,NCT01368081::arm::FG007,NCT01368081,Alpha Glucosidase Inhibitor: Empa 10mg,,,,,,,,,,FG007,One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Alpha glucosidase inhibitor,,,
arm,NCT01368081::arm::FG008,NCT01368081,Alpha Glucosidase Inhibitor: Empa 25mg,,,,,,,,,,FG008,One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Alpha glucosidase inhibitor,,,
arm,NCT01368081::arm::FG009,NCT01368081,DPP-IV Inhibitor: Empa 10mg,,,,,,,,,,FG009,One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of dipeptidyl peptidase IV (DPP-IV) inhibitor,,,
arm,NCT01368081::arm::FG010,NCT01368081,DPP-IV Inhibitor: Empa 25mg,,,,,,,,,,FG010,One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of dipeptidyl peptidase IV (DPP-IV) inhibitor,,,
arm,NCT01368081::arm::FG011,NCT01368081,Glinide: Empa 10mg,,,,,,,,,,FG011,One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Glinide,,,
arm,NCT01368081::arm::FG012,NCT01368081,Glinide: Empa 25mg,,,,,,,,,,FG012,One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Glinide,,,
period,NCT01368081::period::1,NCT01368081,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01368081::outcome::primary::1,NCT01368081,Number of Patients With Drug Related Adverse Events,,,,,,,,,,,,,PRIMARY,"After the first drug intake until 7 days after the last treatment administration, up to 383 days"
country,NCT01368081::country::Japan,NCT01368081,Japan,,,,,,,,,,,,,,
trial,NCT02413398,NCT02413398,A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,321.0,2015-06-15,2017-11-07,8.0,87.0,,,,,
arm,NCT02413398::arm::FG000,NCT02413398,Dapagliflozin 10mg QD,,,,,,,,,,FG000,"10 mg Tablets, Oral, Once daily, 24 weeks",,,
arm,NCT02413398::arm::FG001,NCT02413398,Placebo QD,,,,,,,,,,FG001,"Matching Placebo, 10 mg Tablets, Oral, Once daily, 24 weeks",,,
period,NCT02413398::period::1,NCT02413398,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02413398::outcome::primary::1,NCT02413398,Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24,,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
country,NCT02413398::country::United States,NCT02413398,United States,,,,,,,,,,,,,,
country,NCT02413398::country::Canada,NCT02413398,Canada,,,,,,,,,,,,,,
country,NCT02413398::country::Spain,NCT02413398,Spain,,,,,,,,,,,,,,
country,NCT02413398::country::Bulgaria,NCT02413398,Bulgaria,,,,,,,,,,,,,,
country,NCT02413398::country::Italy,NCT02413398,Italy,,,,,,,,,,,,,,
country,NCT02413398::country::Czechia,NCT02413398,Czechia,,,,,,,,,,,,,,
country,NCT02413398::country::Poland,NCT02413398,Poland,,,,,,,,,,,,,,
country,NCT02413398::country::Sweden,NCT02413398,Sweden,,,,,,,,,,,,,,
trial,NCT00614939,NCT00614939,Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,572.0,2008-01,2010-03,14.0,74.0,,,,,
arm,NCT00614939::arm::FG000,NCT00614939,Placebo,,,,,,,,,,FG000,Placebo,,,
arm,NCT00614939::arm::FG001,NCT00614939,Saxa,,,,,,,,,,FG001,Saxagliptin 2.5 mg once daily oral dose,,,
period,NCT00614939::period::1,NCT00614939,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00614939::outcome::primary::1,NCT00614939,Absolute Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) Level to Week 12 Last Observation Carried Forward (LOCF),,,,,,,,,,,,,PRIMARY,"Baseline , Week 12 (LOCF)"
country,NCT00614939::country::Poland,NCT00614939,Poland,,,,,,,,,,,,,,
country,NCT00614939::country::United States,NCT00614939,United States,,,,,,,,,,,,,,
country,NCT00614939::country::Ukraine,NCT00614939,Ukraine,,,,,,,,,,,,,,
country,NCT00614939::country::Croatia,NCT00614939,Croatia,,,,,,,,,,,,,,
country,NCT00614939::country::Czechia,NCT00614939,Czechia,,,,,,,,,,,,,,
country,NCT00614939::country::Germany,NCT00614939,Germany,,,,,,,,,,,,,,
country,NCT00614939::country::Hungary,NCT00614939,Hungary,,,,,,,,,,,,,,
country,NCT00614939::country::Romania,NCT00614939,Romania,,,,,,,,,,,,,,
country,NCT00614939::country::Russia,NCT00614939,Russia,,,,,,,,,,,,,,
country,NCT00614939::country::Lithuania,NCT00614939,Lithuania,,,,,,,,,,,,,,
country,NCT00614939::country::Belarus,NCT00614939,Belarus,,,,,,,,,,,,,,
country,NCT00614939::country::Bulgaria,NCT00614939,Bulgaria,,,,,,,,,,,,,,
country,NCT00614939::country::Estonia,NCT00614939,Estonia,,,,,,,,,,,,,,
country,NCT00614939::country::Latvia,NCT00614939,Latvia,,,,,,,,,,,,,,
trial,NCT01959529,NCT01959529,A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,7637.0,2013-10-29,2016-10-16,20.0,446.0,,,,,
arm,NCT01959529::arm::FG000,NCT01959529,Insulin Degludec,,,,,,,,,,FG000,"Subjects received insulin degludec (IDeg) 100 units/mL once daily (OD) subcutaneously (S.C.; under the skin) in the thigh, upper arm, or the abdominal wall between dinner and bedtime. Subjects continu",,,
arm,NCT01959529::arm::FG001,NCT01959529,Insulin Glargine,,,,,,,,,,FG001,"Subjects received insulin glargine (IGlar) 100 units/mL OD subcutaneously (S.C.; under the skin) in the thigh, upper arm, or the abdominal wall between dinner and bedtime. Subjects continued their pre",,,
period,NCT01959529::period::1,NCT01959529,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01959529::outcome::primary::1,NCT01959529,"Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE): Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke",,,,,,,,,,,,,PRIMARY,From randomisation to individual end of trial date (maximum patient year observation: 2.75 years)
country,NCT01959529::country::United States,NCT01959529,United States,,,,,,,,,,,,,,
country,NCT01959529::country::India,NCT01959529,India,,,,,,,,,,,,,,
country,NCT01959529::country::Russia,NCT01959529,Russia,,,,,,,,,,,,,,
country,NCT01959529::country::South Africa,NCT01959529,South Africa,,,,,,,,,,,,,,
country,NCT01959529::country::Italy,NCT01959529,Italy,,,,,,,,,,,,,,
country,NCT01959529::country::Brazil,NCT01959529,Brazil,,,,,,,,,,,,,,
country,NCT01959529::country::Mexico,NCT01959529,Mexico,,,,,,,,,,,,,,
country,NCT01959529::country::Japan,NCT01959529,Japan,,,,,,,,,,,,,,
country,NCT01959529::country::Poland,NCT01959529,Poland,,,,,,,,,,,,,,
country,NCT01959529::country::United Kingdom,NCT01959529,United Kingdom,,,,,,,,,,,,,,
country,NCT01959529::country::Malaysia,NCT01959529,Malaysia,,,,,,,,,,,,,,
country,NCT01959529::country::Spain,NCT01959529,Spain,,,,,,,,,,,,,,
country,NCT01959529::country::Canada,NCT01959529,Canada,,,,,,,,,,,,,,
country,NCT01959529::country::Greece,NCT01959529,Greece,,,,,,,,,,,,,,
country,NCT01959529::country::Argentina,NCT01959529,Argentina,,,,,,,,,,,,,,
country,NCT01959529::country::Croatia,NCT01959529,Croatia,,,,,,,,,,,,,,
country,NCT01959529::country::Thailand,NCT01959529,Thailand,,,,,,,,,,,,,,
country,NCT01959529::country::Algeria,NCT01959529,Algeria,,,,,,,,,,,,,,
country,NCT01959529::country::Romania,NCT01959529,Romania,,,,,,,,,,,,,,
country,NCT01959529::country::South Korea,NCT01959529,South Korea,,,,,,,,,,,,,,
trial,NCT00915772,NCT00915772,Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,567.0,2009-06,,14.0,112.0,,,,,
arm,NCT00915772::arm::FG000,NCT00915772,M1000,,,,,,,,,,FG000,Metformin 1000mg monotherapy twice daily,,,
arm,NCT00915772::arm::FG001,NCT00915772,L2.5+M500,,,,,,,,,,FG001,Linagliptin 2.5mg and metformin 500mg twice daily,,,
arm,NCT00915772::arm::FG002,NCT00915772,L2.5+M1000,,,,,,,,,,FG002,Linagliptin 2.5mg and metformin 1000mg twice daily,,,
period,NCT00915772::period::1,NCT00915772,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00915772::outcome::primary::1,NCT00915772,Frequency of Patients With Adverse Events (AEs),,,,,,,,,,,,,PRIMARY,54 weeks
outcome,NCT00915772::outcome::primary::2,NCT00915772,Change From Baseline at Week 54 in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP),,,,,,,,,,,,,PRIMARY,54 weeks
outcome,NCT00915772::outcome::primary::3,NCT00915772,Change From Baseline at Week 54 in Pulse Rate,,,,,,,,,,,,,PRIMARY,54 weeks
outcome,NCT00915772::outcome::primary::4,NCT00915772,Frequency of Patients With Possibly Clinically Significant Abnormal Laboratory Parameters: Haematology,,,,,,,,,,,,,PRIMARY,54 weeks
outcome,NCT00915772::outcome::primary::5,NCT00915772,Possibly Clinically Significant Abnormal Laboratory Parameters: Clinical Chemistry,,,,,,,,,,,,,PRIMARY,54 weeks
outcome,NCT00915772::outcome::primary::6,NCT00915772,Clinical Relevant Drug-related Abnormal Findings in Physical Examination and ECG as Reported as AE,,,,,,,,,,,,,PRIMARY,Baseline and drug stop (up to 54 weeks) + 7 days
country,NCT00915772::country::France,NCT00915772,France,,,,,,,,,,,,,,
country,NCT00915772::country::India,NCT00915772,India,,,,,,,,,,,,,,
country,NCT00915772::country::Tunisia,NCT00915772,Tunisia,,,,,,,,,,,,,,
country,NCT00915772::country::Canada,NCT00915772,Canada,,,,,,,,,,,,,,
country,NCT00915772::country::Netherlands,NCT00915772,Netherlands,,,,,,,,,,,,,,
country,NCT00915772::country::Mexico,NCT00915772,Mexico,,,,,,,,,,,,,,
country,NCT00915772::country::Russia,NCT00915772,Russia,,,,,,,,,,,,,,
country,NCT00915772::country::Ukraine,NCT00915772,Ukraine,,,,,,,,,,,,,,
country,NCT00915772::country::Croatia,NCT00915772,Croatia,,,,,,,,,,,,,,
country,NCT00915772::country::Romania,NCT00915772,Romania,,,,,,,,,,,,,,
country,NCT00915772::country::Germany,NCT00915772,Germany,,,,,,,,,,,,,,
country,NCT00915772::country::Sweden,NCT00915772,Sweden,,,,,,,,,,,,,,
country,NCT00915772::country::Estonia,NCT00915772,Estonia,,,,,,,,,,,,,,
country,NCT00915772::country::Lithuania,NCT00915772,Lithuania,,,,,,,,,,,,,,
trial,NCT04707469,NCT04707469,Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,1606.0,2021-01-15,2023-03-08,15.0,228.0,,,,,
arm,NCT04707469::arm::FG000,NCT04707469,Oral Semaglutide 14 mg,,,,,,,,,,FG000,"Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 6",,,
arm,NCT04707469::arm::FG001,NCT04707469,Oral Semaglutide 25 mg,,,,,,,,,,FG001,"Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25",,,
arm,NCT04707469::arm::FG002,NCT04707469,Oral Semaglutide 50 mg,,,,,,,,,,FG002,"Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg",,,
period,NCT04707469::period::1,NCT04707469,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04707469::outcome::primary::1,NCT04707469,Change From Baseline in Glycated Haemoglobin (HbA1c) (Week 52),,,,,,,,,,,,,PRIMARY,"Baseline (week 0), week 52"
country,NCT04707469::country::United States,NCT04707469,United States,,,,,,,,,,,,,,
country,NCT04707469::country::India,NCT04707469,India,,,,,,,,,,,,,,
country,NCT04707469::country::Poland,NCT04707469,Poland,,,,,,,,,,,,,,
country,NCT04707469::country::Bulgaria,NCT04707469,Bulgaria,,,,,,,,,,,,,,
country,NCT04707469::country::Canada,NCT04707469,Canada,,,,,,,,,,,,,,
country,NCT04707469::country::Hungary,NCT04707469,Hungary,,,,,,,,,,,,,,
country,NCT04707469::country::Slovakia,NCT04707469,Slovakia,,,,,,,,,,,,,,
country,NCT04707469::country::Czechia,NCT04707469,Czechia,,,,,,,,,,,,,,
country,NCT04707469::country::Germany,NCT04707469,Germany,,,,,,,,,,,,,,
country,NCT04707469::country::Australia,NCT04707469,Australia,,,,,,,,,,,,,,
country,NCT04707469::country::Croatia,NCT04707469,Croatia,,,,,,,,,,,,,,
country,NCT04707469::country::Estonia,NCT04707469,Estonia,,,,,,,,,,,,,,
country,NCT04707469::country::Slovenia,NCT04707469,Slovenia,,,,,,,,,,,,,,
country,NCT04707469::country::Taiwan,NCT04707469,Taiwan,,,,,,,,,,,,,,
country,NCT04707469::country::Puerto Rico,NCT04707469,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00740051,NCT00740051,"A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate",PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,227.0,2008-08,,7.0,53.0,,,,,
arm,NCT00740051::arm::FG000,NCT00740051,Placebo/Glimepiride,,,,,,,,,,FG000,Patients treated with matching placebo (up to 18 weeks) followed by Glimepiride (after 18 weeks to 52 weeks),,,
arm,NCT00740051::arm::FG001,NCT00740051,Linagliptin,,,,,,,,,,FG001,Patients treated with Linagliptin 5mg once daily (up to 52 weeks),,,
period,NCT00740051::period::1,NCT00740051,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00740051::outcome::primary::1,NCT00740051,HbA1c Change From Baseline at Week 18 (Interim Analysis),,,,,,,,,,,,,PRIMARY,Baseline and week 18
outcome,NCT00740051::outcome::primary::2,NCT00740051,HbA1c Change From Baseline at Week 18 (Final Analysis),,,,,,,,,,,,,PRIMARY,Baseline and week 18
country,NCT00740051::country::United States,NCT00740051,United States,,,,,,,,,,,,,,
country,NCT00740051::country::Mexico,NCT00740051,Mexico,,,,,,,,,,,,,,
country,NCT00740051::country::Philippines,NCT00740051,Philippines,,,,,,,,,,,,,,
country,NCT00740051::country::Canada,NCT00740051,Canada,,,,,,,,,,,,,,
country,NCT00740051::country::Romania,NCT00740051,Romania,,,,,,,,,,,,,,
country,NCT00740051::country::Russia,NCT00740051,Russia,,,,,,,,,,,,,,
country,NCT00740051::country::Ukraine,NCT00740051,Ukraine,,,,,,,,,,,,,,
trial,NCT03285594,NCT03285594,Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,571.0,2017-09-15,2019-09-27,8.0,106.0,,,,,
arm,NCT03285594::arm::FG000,NCT03285594,Placebo,,,,,,,,,,FG000,"Following a 4-week run-in period, participants were randomized to receive matching placebo to sotagliflozin 200 mg administered as 2 tablets, once daily, before the first meal of the day in the double",,,
arm,NCT03285594::arm::FG001,NCT03285594,Sotagliflozin 200 mg,,,,,,,,,,FG001,"Following a 4-week run-in period, participants were randomized to sotagliflozin 200 mg administered as 1 tablet and matching placebo as 1 tablet, once daily, before the first meal of the day in the do",,,
arm,NCT03285594::arm::FG002,NCT03285594,Sotagliflozin 400 mg,,,,,,,,,,FG002,"Following a 4-week run-in period, participants were randomized to sotagliflozin 400 mg administered as 2 tablets, once daily, before the first meal of the day in the double-blind treatment period for ",,,
period,NCT03285594::period::1,NCT03285594,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03285594::outcome::primary::1,NCT03285594,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 18,,,,,,,,,,,,,PRIMARY,Baseline and Week 18
country,NCT03285594::country::United States,NCT03285594,United States,,,,,,,,,,,,,,
country,NCT03285594::country::France,NCT03285594,France,,,,,,,,,,,,,,
country,NCT03285594::country::Slovakia,NCT03285594,Slovakia,,,,,,,,,,,,,,
country,NCT03285594::country::Bulgaria,NCT03285594,Bulgaria,,,,,,,,,,,,,,
country,NCT03285594::country::Hungary,NCT03285594,Hungary,,,,,,,,,,,,,,
country,NCT03285594::country::Czechia,NCT03285594,Czechia,,,,,,,,,,,,,,
country,NCT03285594::country::United Kingdom,NCT03285594,United Kingdom,,,,,,,,,,,,,,
country,NCT03285594::country::Canada,NCT03285594,Canada,,,,,,,,,,,,,,
trial,NCT00641056,NCT00641056,Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,467.0,2008-04,2009-11,16.0,75.0,,,,,
arm,NCT00641056::arm::FG000,NCT00641056,Exenatide Once Weekly,,,,,,,,,,FG000,Patients assigned to the Exenatide Once Weekly group received a 2 mg dose of exenatide injected once a week.,,,
arm,NCT00641056::arm::FG001,NCT00641056,Insulin Glargine,,,,,,,,,,FG001,"Patients assigned to the Insulin Glargine group started insulin glargine treatment with 10 units per day, utilizing the INITIATE (Initiate Insulin by Aggressive Titration and Education) dosing and wer",,,
period,NCT00641056::period::1,NCT00641056,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00641056::outcome::primary::1,NCT00641056,Change in HbA1c From Baseline to Week 26,,,,,,,,,,,,,PRIMARY,"Baseline, Week 26"
country,NCT00641056::country::United States,NCT00641056,United States,,,,,,,,,,,,,,
country,NCT00641056::country::Germany,NCT00641056,Germany,,,,,,,,,,,,,,
country,NCT00641056::country::Spain,NCT00641056,Spain,,,,,,,,,,,,,,
country,NCT00641056::country::Australia,NCT00641056,Australia,,,,,,,,,,,,,,
country,NCT00641056::country::Netherlands,NCT00641056,Netherlands,,,,,,,,,,,,,,
country,NCT00641056::country::France,NCT00641056,France,,,,,,,,,,,,,,
country,NCT00641056::country::Denmark,NCT00641056,Denmark,,,,,,,,,,,,,,
country,NCT00641056::country::Hungary,NCT00641056,Hungary,,,,,,,,,,,,,,
country,NCT00641056::country::Mexico,NCT00641056,Mexico,,,,,,,,,,,,,,
country,NCT00641056::country::Taiwan,NCT00641056,Taiwan,,,,,,,,,,,,,,
country,NCT00641056::country::Czechia,NCT00641056,Czechia,,,,,,,,,,,,,,
country,NCT00641056::country::Russia,NCT00641056,Russia,,,,,,,,,,,,,,
country,NCT00641056::country::Belgium,NCT00641056,Belgium,,,,,,,,,,,,,,
country,NCT00641056::country::Greece,NCT00641056,Greece,,,,,,,,,,,,,,
country,NCT00641056::country::Puerto Rico,NCT00641056,Puerto Rico,,,,,,,,,,,,,,
country,NCT00641056::country::South Korea,NCT00641056,South Korea,,,,,,,,,,,,,,
trial,NCT03730662,NCT03730662,A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,2002.0,2018-11-20,2021-04-22,15.0,216.0,,,,,
arm,NCT03730662::arm::FG000,NCT03730662,5 mg Tirzepatide,,,,,,,,,,FG000,5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.,,,
arm,NCT03730662::arm::FG001,NCT03730662,10 mg Tirzepatide,,,,,,,,,,FG001,10 mg tirzepatide administered SC once a week.,,,
arm,NCT03730662::arm::FG002,NCT03730662,15 mg Tirzepatide,,,,,,,,,,FG002,15 mg tirzepatide administered SC once a week.,,,
arm,NCT03730662::arm::FG003,NCT03730662,Insulin Glargine,,,,,,,,,,FG003,"Insulin glargine administered SC once a day. Doses were individualized and titrated according to protocol-defined targets.

The starting dose of insulin glargine was 10 IU/day at bedtime, titrated to ",,,
period,NCT03730662::period::1,NCT03730662,Treatment Period (52 Weeks),,,,,,,,,,,,1.0,,
period,NCT03730662::period::2,NCT03730662,Variable Treatment Period,,,,,,,,,,,,2.0,,
outcome,NCT03730662::outcome::primary::1,NCT03730662,Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg),,,,,,,,,,,,,PRIMARY,"Baseline, Week 52"
country,NCT03730662::country::United States,NCT03730662,United States,,,,,,,,,,,,,,
country,NCT03730662::country::Canada,NCT03730662,Canada,,,,,,,,,,,,,,
country,NCT03730662::country::Argentina,NCT03730662,Argentina,,,,,,,,,,,,,,
country,NCT03730662::country::Australia,NCT03730662,Australia,,,,,,,,,,,,,,
country,NCT03730662::country::Spain,NCT03730662,Spain,,,,,,,,,,,,,,
country,NCT03730662::country::Poland,NCT03730662,Poland,,,,,,,,,,,,,,
country,NCT03730662::country::Russia,NCT03730662,Russia,,,,,,,,,,,,,,
country,NCT03730662::country::Brazil,NCT03730662,Brazil,,,,,,,,,,,,,,
country,NCT03730662::country::Israel,NCT03730662,Israel,,,,,,,,,,,,,,
country,NCT03730662::country::Romania,NCT03730662,Romania,,,,,,,,,,,,,,
country,NCT03730662::country::Taiwan,NCT03730662,Taiwan,,,,,,,,,,,,,,
country,NCT03730662::country::Puerto Rico,NCT03730662,Puerto Rico,,,,,,,,,,,,,,
country,NCT03730662::country::Mexico,NCT03730662,Mexico,,,,,,,,,,,,,,
country,NCT03730662::country::Slovakia,NCT03730662,Slovakia,,,,,,,,,,,,,,
country,NCT03730662::country::Greece,NCT03730662,Greece,,,,,,,,,,,,,,
trial,NCT03259789,NCT03259789,Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects,PHASE3,diabetes type 2,Type2 Diabetes Mellitus,INDUSTRY,351.0,2017-11-28,2019-01-23,2.0,43.0,,,,,
arm,NCT03259789::arm::FG000,NCT03259789,Double-blind Group: Bexagliflozin 20 mg,,,,,,,,,,FG000,"Each subject will receive bexagliflozin, 20 mg, once daily and open-labeled metformin background medication during the entire study at a stable dose and frequency.",,,
arm,NCT03259789::arm::FG001,NCT03259789,Double-blind Group: Placebo,,,,,,,,,,FG001,Each subject will receive placebo (inactive tablet) once daily and open-labeled metformin background medication during the entire study at a stable dose and frequency.,,,
arm,NCT03259789::arm::FG002,NCT03259789,High Glycemic Group,,,,,,,,,,FG002,"Each subject will receive Bexagliflozin tablet, 20 mg, once daily and open-labeled metformin background medication during the entire study at a stable dose and frequency.",,,
period,NCT03259789::period::1,NCT03259789,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03259789::outcome::primary::1,NCT03259789,Change From Baseline in HbA1c at Week 24 for Double-blind Group,,,,,,,,,,,,,PRIMARY,Baseline to week 24
outcome,NCT03259789::outcome::primary::2,NCT03259789,Change From Baseline in HbA1c at Week 24 for High Glycemic Group,,,,,,,,,,,,,PRIMARY,Baseline to week 24
country,NCT03259789::country::United States,NCT03259789,United States,,,,,,,,,,,,,,
country,NCT03259789::country::Japan,NCT03259789,Japan,,,,,,,,,,,,,,
trial,NCT02926950,NCT02926950,Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,518.0,2016-11,2019-03-22,4.0,93.0,,,,,
arm,NCT02926950::arm::FG000,NCT02926950,Placebo + Metformin,,,,,,,,,,FG000,"Following a 2-week run-in period, matching placebo was administered as 2 tablets, QD, before the first meal of the day plus Metformin as prescribed by the Principal Investigator for up to 26 weeks in ",,,
arm,NCT02926950::arm::FG001,NCT02926950,Sotagliflozin 400 mg + Metformin,,,,,,,,,,FG001,"Following a 2-week run-in period, Sotagliflozin 400 mg was administered as 2 tablets, QD, before the first meal of the day plus Metformin as prescribed by the Principal Investigator for up to 26 weeks",,,
period,NCT02926950::period::1,NCT02926950,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02926950::outcome::primary::1,NCT02926950,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26,,,,,,,,,,,,,PRIMARY,Baseline and Week 26
country,NCT02926950::country::United States,NCT02926950,United States,,,,,,,,,,,,,,
country,NCT02926950::country::Canada,NCT02926950,Canada,,,,,,,,,,,,,,
country,NCT02926950::country::Hungary,NCT02926950,Hungary,,,,,,,,,,,,,,
country,NCT02926950::country::Slovakia,NCT02926950,Slovakia,,,,,,,,,,,,,,
trial,NCT03861052,NCT03861052,A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,636.0,2019-05-07,2021-03-31,1.0,46.0,,,,,
arm,NCT03861052::arm::FG000,NCT03861052,5 mg Tirzepatide,,,,,,,,,,FG000,Participants received 5 mg tirzepatide administered SC once weekly for 52 weeks.,,,
arm,NCT03861052::arm::FG001,NCT03861052,10 mg Tirzepatide,,,,,,,,,,FG001,Participants received 10 mg tirzepatide administered SC once weekly for 52 weeks.,,,
arm,NCT03861052::arm::FG002,NCT03861052,15 mg Tirzepatide,,,,,,,,,,FG002,Participants received 15 mg tirzepatide administered SC once weekly for 52 weeks.,,,
arm,NCT03861052::arm::FG003,NCT03861052,0.75 mg Dulaglutide,,,,,,,,,,FG003,Participants received 0.75 mg dulaglutide administered SC once weekly for 52 weeks,,,
period,NCT03861052::period::1,NCT03861052,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03861052::outcome::primary::1,NCT03861052,Change From Baseline in Hemoglobin A1c (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline, Week 52"
country,NCT03861052::country::Japan,NCT03861052,Japan,,,,,,,,,,,,,,
trial,NCT00955747,NCT00955747,Naturlose (D-Tagatose) Efficacy Evaluation Trial,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,494.0,2007-04,2010-10,2.0,46.0,,,,,
arm,NCT00955747::arm::FG000,NCT00955747,Sugar Substitute Splenda,,,,,,,,,,FG000,"1.5 g Sugar Substitute Splenda, dissolved in 125 ml of water three times per day. If intestinal problems occur, the dose should be reduced to 1 g dissolved in water tid or additionally reduced to 0.5 ",,,
arm,NCT00955747::arm::FG001,NCT00955747,Tagatose,,,,,,,,,,FG001,15 g Tagatose dissolved in 125 ml of water three times a day. The Tagatose dosage will be decreased to 10 g dissolved in 125 ml of water tid or decreased additionally to 5 g Tagatose dissolved in 125 ,,,
period,NCT00955747::period::1,NCT00955747,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00955747::outcome::primary::1,NCT00955747,Change in Hemoglobin A1C Level From Baseline,,,,,,,,,,,,,PRIMARY,1 year from baseline
country,NCT00955747::country::India,NCT00955747,India,,,,,,,,,,,,,,
country,NCT00955747::country::United States,NCT00955747,United States,,,,,,,,,,,,,,
trial,NCT00838916,NCT00838916,A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,779.0,2009-02,2013-05,4.0,337.0,,,,,
arm,NCT00838916::arm::FG000,NCT00838916,Albiglutide 30 mg + Metformin +/- Sulfonylurea,,,,,,,,,,FG000,Participants received albiglutide 30 milligrams (mg) weekly (with up-titration to 50 mg weekly if required) as a subcutaneous injection via a fully disposable pen injector system plus metformin \>=150,,,
arm,NCT00838916::arm::FG001,NCT00838916,Insulin Glargine 10 Units + Metformin +/- Sulfonylurea,,,,,,,,,,FG001,Participants received 10 units of insulin glargine daily (with dose adjusted weekly depending on the need for additional glycemic control) as a subcutaneous injection via a fully disposable pen inject,,,
period,NCT00838916::period::1,NCT00838916,Treatment Period (156 Weeks),,,,,,,,,,,,1.0,,
period,NCT00838916::period::2,NCT00838916,Follow-up Period (8 Weeks),,,,,,,,,,,,2.0,,
outcome,NCT00838916::outcome::primary::1,NCT00838916,Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52,,,,,,,,,,,,,PRIMARY,Baseline and Week 52
country,NCT00838916::country::United States,NCT00838916,United States,,,,,,,,,,,,,,
country,NCT00838916::country::South Africa,NCT00838916,South Africa,,,,,,,,,,,,,,
country,NCT00838916::country::Russia,NCT00838916,Russia,,,,,,,,,,,,,,
country,NCT00838916::country::United Kingdom,NCT00838916,United Kingdom,,,,,,,,,,,,,,
trial,NCT01572740,NCT01572740,Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,257.0,2012-04-05,2013-03-27,1.0,23.0,,,,,
arm,NCT01572740::arm::FG000,NCT01572740,Lira + Insulin,,,,,,,,,,FG000,"Liraglutide was administered subcutaneously (s.c., under the skin) once daily (OD) for 36 weeks combined with insulin therapy. The starting dose of the liraglutide was 0.3 mg (50 μL)/day; dose was esc",,,
arm,NCT01572740::arm::FG001,NCT01572740,Placebo + Insulin,,,,,,,,,,FG001,"Liraglutide placebo was administered subcutaneously (s.c., under the skin) OD for 36 weeks combined with insulin therapy. The starting dose of the placebo was 50 μL/day; dose was escalated to100 μL/da",,,
period,NCT01572740::period::1,NCT01572740,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01572740::outcome::primary::1,NCT01572740,Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 16,,,,,,,,,,,,,PRIMARY,"Week 0, Week 16"
country,NCT01572740::country::Japan,NCT01572740,Japan,,,,,,,,,,,,,,
trial,NCT01306214,NCT01306214,Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2; Obesity",INDUSTRY,566.0,2011-02,2013-04,14.0,103.0,,,,,
arm,NCT01306214::arm::FG000,NCT01306214,Placebo,,,,,,,,,,FG000,Placebo matching empagliflozin 10 mg tablet plus placebo matching empagliflozin 25 mg tablet once daily,,,
arm,NCT01306214::arm::FG001,NCT01306214,Empagliflozin 10 mg,,,,,,,,,,FG001,Empagliflozin film-coated 10 mg tablet plus one placebo matching empagliflozin 25 mg tablet once daily,,,
arm,NCT01306214::arm::FG002,NCT01306214,Empagliflozin 25 mg,,,,,,,,,,FG002,Empagliflozin film-coated 25 mg tablet plus one placebo matching empagliflozin 10 mg tablet once daily,,,
period,NCT01306214::period::1,NCT01306214,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01306214::outcome::primary::1,NCT01306214,Change From Baseline in HbA1c After 18 Weeks of Treatment,,,,,,,,,,,,,PRIMARY,Baseline and 18 weeks
country,NCT01306214::country::United States,NCT01306214,United States,,,,,,,,,,,,,,
country,NCT01306214::country::Mexico,NCT01306214,Mexico,,,,,,,,,,,,,,
country,NCT01306214::country::France,NCT01306214,France,,,,,,,,,,,,,,
country,NCT01306214::country::Spain,NCT01306214,Spain,,,,,,,,,,,,,,
country,NCT01306214::country::Belgium,NCT01306214,Belgium,,,,,,,,,,,,,,
country,NCT01306214::country::Czechia,NCT01306214,Czechia,,,,,,,,,,,,,,
country,NCT01306214::country::Germany,NCT01306214,Germany,,,,,,,,,,,,,,
country,NCT01306214::country::Peru,NCT01306214,Peru,,,,,,,,,,,,,,
country,NCT01306214::country::Colombia,NCT01306214,Colombia,,,,,,,,,,,,,,
country,NCT01306214::country::Guatemala,NCT01306214,Guatemala,,,,,,,,,,,,,,
country,NCT01306214::country::Ukraine,NCT01306214,Ukraine,,,,,,,,,,,,,,
country,NCT01306214::country::Russia,NCT01306214,Russia,,,,,,,,,,,,,,
country,NCT01306214::country::Bulgaria,NCT01306214,Bulgaria,,,,,,,,,,,,,,
country,NCT01306214::country::Finland,NCT01306214,Finland,,,,,,,,,,,,,,
trial,NCT01388361,NCT01388361,Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,413.0,2011-09,2012-07,12.0,124.0,,,,,
arm,NCT01388361::arm::FG000,NCT01388361,IDeg,,,,,,,,,,FG000,This non-randomised arm consisted of subjects treated with IDeg + metformin who achieved the target glycosylated haemoglobin (HbA1c) \< 7.0 % at the end of treatment in NN1250-3643. Subjects were trea,,,
arm,NCT01388361::arm::FG001,NCT01388361,IDeg + Liraglutide,,,,,,,,,,FG001,All subjects in this arm were randomised to once-daily subcutaneous administration of IDeg 100 U/mL in a prefilled pen along with once-daily subcutaneous administration of liraglutide (6 mg/mL) in a p,,,
arm,NCT01388361::arm::FG002,NCT01388361,IDeg + IAsp OD,,,,,,,,,,FG002,Subjects in this arm were randomised to once-daily subcutaneous administration of IDeg 100 U/mL in prefilled pen along with once-daily subcutaneous administration of insulin aspart (IAsp)100 U/mL in a,,,
period,NCT01388361::period::1,NCT01388361,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01388361::outcome::primary::1,NCT01388361,Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin),,,,,,,,,,,,,PRIMARY,"week 0, week 26"
country,NCT01388361::country::United States,NCT01388361,United States,,,,,,,,,,,,,,
country,NCT01388361::country::Canada,NCT01388361,Canada,,,,,,,,,,,,,,
country,NCT01388361::country::Germany,NCT01388361,Germany,,,,,,,,,,,,,,
country,NCT01388361::country::Norway,NCT01388361,Norway,,,,,,,,,,,,,,
country,NCT01388361::country::Spain,NCT01388361,Spain,,,,,,,,,,,,,,
country,NCT01388361::country::Denmark,NCT01388361,Denmark,,,,,,,,,,,,,,
country,NCT01388361::country::Finland,NCT01388361,Finland,,,,,,,,,,,,,,
country,NCT01388361::country::Austria,NCT01388361,Austria,,,,,,,,,,,,,,
country,NCT01388361::country::Belgium,NCT01388361,Belgium,,,,,,,,,,,,,,
country,NCT01388361::country::Czechia,NCT01388361,Czechia,,,,,,,,,,,,,,
country,NCT01388361::country::France,NCT01388361,France,,,,,,,,,,,,,,
country,NCT01388361::country::Serbia,NCT01388361,Serbia,,,,,,,,,,,,,,
trial,NCT02926937,NCT02926937,Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,399.0,2016-11-11,2019-05-17,3.0,70.0,,,,,
arm,NCT02926937::arm::FG000,NCT02926937,Placebo,,,,,,,,,,FG000,"Following a 2-week run-in period, participants were randomized to matching placebo to sotagliflozin administered as 2 tablets, once daily (QD), before the first meal of the day in the double-blind tre",,,
arm,NCT02926937::arm::FG001,NCT02926937,Sotagliflozin 400 mg,,,,,,,,,,FG001,"Following a 2-week run-in period, participants were randomized to Sotagliflozin 400 mg administered as two 200 mg tablets, QD, before the first meal of the day in the double-blind treatment period for",,,
arm,NCT02926937::arm::FG002,NCT02926937,Sotagliflozin 200 mg,,,,,,,,,,FG002,"Following a 2-week run-in period, participants were randomized to Sotagliflozin 200 mg administered as 1 sotagliflozin tablet and 1 matching placebo tablet, QD, before the first meal of the day in the",,,
period,NCT02926937::period::1,NCT02926937,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02926937::outcome::primary::1,NCT02926937,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 (Sotagliflozin 400 mg Versus Placebo),,,,,,,,,,,,,PRIMARY,Baseline to Week 26
country,NCT02926937::country::United States,NCT02926937,United States,,,,,,,,,,,,,,
country,NCT02926937::country::Mexico,NCT02926937,Mexico,,,,,,,,,,,,,,
country,NCT02926937::country::Canada,NCT02926937,Canada,,,,,,,,,,,,,,
trial,NCT01841697,NCT01841697,Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026),PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,642.0,2013-06-13,2014-11-17,0.0,0.0,,,,,
arm,NCT01841697::arm::FG000,NCT01841697,Omarigliptin 25 mg Once Weekly,,,,,,,,,,FG000,Participants received omarigliptin 25 mg once a week plus placebo to sitagliptin once daily for 24 weeks. Participants continued pre-study stable dose of metformin (total daily dose ≥1500 mg) througho,,,
arm,NCT01841697::arm::FG001,NCT01841697,Sitagliptin 100 mg Once Daily,,,,,,,,,,FG001,Participants received sitagliptin 100 mg once daily plus placebo to omarigliptin once a week for 24 weeks. Participants continued pre-study stable dose of metformin (total daily dose ≥1500 mg) through,,,
period,NCT01841697::period::1,NCT01841697,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01841697::outcome::primary::1,NCT01841697,Change From Baseline in A1C at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and Week 24
outcome,NCT01841697::outcome::primary::2,NCT01841697,Percentage of Participants Who Experienced at Least One Adverse Event,,,,,,,,,,,,,PRIMARY,Up to 27 weeks (including 3-week follow-up)
outcome,NCT01841697::outcome::primary::3,NCT01841697,Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event,,,,,,,,,,,,,PRIMARY,Up to 24 weeks
trial,NCT00332488,NCT00332488,Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,547.0,2004-12,,11.0,120.0,,,,,
arm,NCT00332488::arm::FG000,NCT00332488,TI Inhalation Powder Alone,,,,,,,,,,FG000,Technosphere® Insulin Inhalation Powder administered prior to each meal without any other anti-diabetic treatment; dose individualized for each subject,,,
arm,NCT00332488::arm::FG001,NCT00332488,Metformin & Secretagogues,,,,,,,,,,FG001,"Metformin (\>= 1,000 mg/day or maximum tolerate dose) \& Secretagogue (Sulfonylurea or meglitinide at \>= half maximum manufacturer recommended dose or maximum tolerated dose)",,,
arm,NCT00332488::arm::FG002,NCT00332488,TI Inhalation Powder + Metformin,,,,,,,,,,FG002,"Technosphere® Insulin Inhalation Powder administered prior to each meal (dose individualized for each subject) \& Metformin (\>= 1,000 mg/day or maximum tolerate dose)",,,
period,NCT00332488::period::1,NCT00332488,Initial Treatment Phase (Weeks 0 - 12),,,,,,,,,,,,1.0,,
period,NCT00332488::period::2,NCT00332488,Transfer Treatment Phase (Weeks 12 - 24),,,,,,,,,,,,2.0,,
outcome,NCT00332488::outcome::primary::1,NCT00332488,Difference in Change From Baseline for HbA1c Between TI+ Metformin and Metformin+Secretagogue,,,,,,,,,,,,,PRIMARY,Baseline to Week 12
country,NCT00332488::country::United States,NCT00332488,United States,,,,,,,,,,,,,,
country,NCT00332488::country::Ukraine,NCT00332488,Ukraine,,,,,,,,,,,,,,
country,NCT00332488::country::Russia,NCT00332488,Russia,,,,,,,,,,,,,,
country,NCT00332488::country::Brazil,NCT00332488,Brazil,,,,,,,,,,,,,,
country,NCT00332488::country::Czechia,NCT00332488,Czechia,,,,,,,,,,,,,,
country,NCT00332488::country::Poland,NCT00332488,Poland,,,,,,,,,,,,,,
country,NCT00332488::country::Canada,NCT00332488,Canada,,,,,,,,,,,,,,
country,NCT00332488::country::Mexico,NCT00332488,Mexico,,,,,,,,,,,,,,
country,NCT00332488::country::Argentina,NCT00332488,Argentina,,,,,,,,,,,,,,
country,NCT00332488::country::Spain,NCT00332488,Spain,,,,,,,,,,,,,,
country,NCT00332488::country::Chile,NCT00332488,Chile,,,,,,,,,,,,,,
trial,NCT00673231,NCT00673231,"Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin",PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,1240.0,2008-04,2011-01,13.0,92.0,,,,,
arm,NCT00673231::arm::FG000,NCT00673231,Placebo,,,,,,,,,,FG000,Placebo,,,
arm,NCT00673231::arm::FG001,NCT00673231,Dapagliflozin 2.5mg,,,,,,,,,,FG001,Dapagliflozin tablet oral 2.5 mg total daily dose once daily 24 weeks,,,
arm,NCT00673231::arm::FG002,NCT00673231,Dapagliflozin 5mg,,,,,,,,,,FG002,Dapagliflozin tablet oral 5 mg total daily dose once daily 24 weeks,,,
arm,NCT00673231::arm::FG003,NCT00673231,Dapagliflozin 10mg,,,,,,,,,,FG003,Dapagliflozin tablet oral 10 mg total daily dose once daily 24 weeks,,,
period,NCT00673231::period::1,NCT00673231,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00673231::outcome::primary::1,NCT00673231,Adjusted Mean Change in HbA1c Levels,,,,,,,,,,,,,PRIMARY,Baseline to Week 24
country,NCT00673231::country::Canada,NCT00673231,Canada,,,,,,,,,,,,,,
country,NCT00673231::country::United States,NCT00673231,United States,,,,,,,,,,,,,,
country,NCT00673231::country::Germany,NCT00673231,Germany,,,,,,,,,,,,,,
country,NCT00673231::country::Hungary,NCT00673231,Hungary,,,,,,,,,,,,,,
country,NCT00673231::country::Finland,NCT00673231,Finland,,,,,,,,,,,,,,
country,NCT00673231::country::United Kingdom,NCT00673231,United Kingdom,,,,,,,,,,,,,,
country,NCT00673231::country::Slovakia,NCT00673231,Slovakia,,,,,,,,,,,,,,
country,NCT00673231::country::Bulgaria,NCT00673231,Bulgaria,,,,,,,,,,,,,,
country,NCT00673231::country::Netherlands,NCT00673231,Netherlands,,,,,,,,,,,,,,
country,NCT00673231::country::Spain,NCT00673231,Spain,,,,,,,,,,,,,,
country,NCT00673231::country::Romania,NCT00673231,Romania,,,,,,,,,,,,,,
country,NCT00673231::country::Russia,NCT00673231,Russia,,,,,,,,,,,,,,
country,NCT00673231::country::Austria,NCT00673231,Austria,,,,,,,,,,,,,,
trial,NCT01106651,NCT01106651,A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,716.0,2010-06,2013-05,17.0,86.0,,,,,
arm,NCT01106651::arm::FG000,NCT01106651,Placebo,,,,,,,,,,FG000,Each patient received matching placebo once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.,,,
arm,NCT01106651::arm::FG001,NCT01106651,Canagliflozin 100 mg,,,,,,,,,,FG001,Each patient received 100 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.,,,
arm,NCT01106651::arm::FG002,NCT01106651,Canagliflozin 300 mg,,,,,,,,,,FG002,Each patient received 300 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.,,,
period,NCT01106651::period::1,NCT01106651,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01106651::outcome::primary::1,NCT01106651,Change in HbA1c From Baseline to Week 26,,,,,,,,,,,,,PRIMARY,Day 1 (Baseline) and Week 26
country,NCT01106651::country::United States,NCT01106651,United States,,,,,,,,,,,,,,
country,NCT01106651::country::Canada,NCT01106651,Canada,,,,,,,,,,,,,,
country,NCT01106651::country::United Kingdom,NCT01106651,United Kingdom,,,,,,,,,,,,,,
country,NCT01106651::country::Poland,NCT01106651,Poland,,,,,,,,,,,,,,
country,NCT01106651::country::Australia,NCT01106651,Australia,,,,,,,,,,,,,,
country,NCT01106651::country::New Zealand,NCT01106651,New Zealand,,,,,,,,,,,,,,
country,NCT01106651::country::Spain,NCT01106651,Spain,,,,,,,,,,,,,,
country,NCT01106651::country::France,NCT01106651,France,,,,,,,,,,,,,,
country,NCT01106651::country::India,NCT01106651,India,,,,,,,,,,,,,,
country,NCT01106651::country::Colombia,NCT01106651,Colombia,,,,,,,,,,,,,,
country,NCT01106651::country::Greece,NCT01106651,Greece,,,,,,,,,,,,,,
country,NCT01106651::country::Romania,NCT01106651,Romania,,,,,,,,,,,,,,
country,NCT01106651::country::Sweden,NCT01106651,Sweden,,,,,,,,,,,,,,
country,NCT01106651::country::Switzerland,NCT01106651,Switzerland,,,,,,,,,,,,,,
country,NCT01106651::country::Ukraine,NCT01106651,Ukraine,,,,,,,,,,,,,,
country,NCT01106651::country::Hong Kong,NCT01106651,Hong Kong,,,,,,,,,,,,,,
country,NCT01106651::country::South Africa,NCT01106651,South Africa,,,,,,,,,,,,,,
trial,NCT00789737,NCT00789737,Welchol as Monotherapy for Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,357.0,2009-01,2011-12,1.0,107.0,,,,,
arm,NCT00789737::arm::FG000,NCT00789737,Welchol,,,,,,,,,,FG000,"Welchol 625mg tablets

Welchol : Welchol 625mg tablets",,,
arm,NCT00789737::arm::FG001,NCT00789737,Placebo,,,,,,,,,,FG001,"placebo

Placebo : placebo",,,
period,NCT00789737::period::1,NCT00789737,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00789737::outcome::primary::1,NCT00789737,Percent Change in Hemoglobin A1c,,,,,,,,,,,,,PRIMARY,24 week
country,NCT00789737::country::United States,NCT00789737,United States,,,,,,,,,,,,,,
trial,NCT04588259,NCT04588259,"Research Study to Compare a New Medicine ""Fast-acting Insulin Aspart"" to Another Medicine ""Insulin Aspart"" in Chinese People With Diabetes",PHASE3,diabetes type 2,"Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2",INDUSTRY,331.0,2020-10-09,2022-08-05,2.0,40.0,,,,,
arm,NCT04588259::arm::FG000,NCT04588259,Faster aspart,,,,,,,,,,FG000,"Participants received subcutaneous injections of NovoRapid + insulin degludec with or without metformin for 8 weeks in the run-in period, followed by Faster aspart + insulin degludec with or without m",,,
arm,NCT04588259::arm::FG001,NCT04588259,NovoRapid,,,,,,,,,,FG001,Participants received subcutaneous injections of NovoRapid thrice daily + insulin degludec once daily with or without metformin for 24 weeks (8 weeks run-in period + 16 weeks treatment period). During,,,
period,NCT04588259::period::1,NCT04588259,Run-in period,,,,,,,,,,,,1.0,,
period,NCT04588259::period::2,NCT04588259,Treatment period,,,,,,,,,,,,2.0,,
outcome,NCT04588259::outcome::primary::1,NCT04588259,Change From Baseline in Glycosylated Haemoglobin (HbA1c) (Percentage [%]),,,,,,,,,,,,,PRIMARY,"Baseline (week 0), week 16"
outcome,NCT04588259::outcome::primary::2,NCT04588259,Change From Baseline in HbA1c (Millimoles Per Mole [mmol/Mol]),,,,,,,,,,,,,PRIMARY,"Baseline (week 0), week 16"
country,NCT04588259::country::China,NCT04588259,China,,,,,,,,,,,,,,
country,NCT04588259::country::Hong Kong,NCT04588259,Hong Kong,,,,,,,,,,,,,,
trial,NCT01682759,NCT01682759,A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,751.0,2012-09-10,2015-01-26,0.0,0.0,,,,,
arm,NCT01682759::arm::FG000,NCT01682759,Omarigliptin,,,,,,,,,,FG000,"Participants will receive omarigliptin, 25 mg once weekly and placebo matching glimepiride once daily for up to 54 weeks.",,,
arm,NCT01682759::arm::FG001,NCT01682759,Glimepiride,,,,,,,,,,FG001,"Participants will receive glimepiride titrated to a maximum of 6 mg, once daily, and placebo to omarigliptin, once weekly for up to 54 weeks.",,,
period,NCT01682759::period::1,NCT01682759,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01682759::outcome::primary::1,NCT01682759,Change From Baseline in Hemoglobin A1C at Week 54,,,,,,,,,,,,,PRIMARY,Baseline and Week 54
outcome,NCT01682759::outcome::primary::2,NCT01682759,Percentage of Participants Who Experienced at Least One Adverse Event Excluding Data After Glycemic Rescue,,,,,,,,,,,,,PRIMARY,Up to Week 57
outcome,NCT01682759::outcome::primary::3,NCT01682759,Percentage of Participants Who Discontinued From the Study Due to an Adverse Event Excluding Data After Glycemic Rescue,,,,,,,,,,,,,PRIMARY,Up to Week 54
trial,NCT03086330,NCT03086330,Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,302.0,2017-03-15,2018-08-06,7.0,72.0,,,,,
arm,NCT03086330::arm::FG000,NCT03086330,Semaglutide 1.0 mg,,,,,,,,,,FG000,"Participants received semaglutide in a dose escalation manner for 30 weeks: 0.25 mg (weeks 1 to 4), 0.50 mg (weeks 5 to 8) and 1.0 mg (weeks 9 to 30). Semaglutide was taken once weekly as subcutaneous",,,
arm,NCT03086330::arm::FG001,NCT03086330,Placebo,,,,,,,,,,FG001,Participants received matching placebo (for semaglutide) in a dose escalation manner for 30 weeks. Placebo was taken once weekly as s.c. injections. Dose escalation for placebo matched that for semagl,,,
period,NCT03086330::period::1,NCT03086330,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03086330::outcome::primary::1,NCT03086330,Change in HbA1c,,,,,,,,,,,,,PRIMARY,"Week 0, week 30"
country,NCT03086330::country::United States,NCT03086330,United States,,,,,,,,,,,,,,
country,NCT03086330::country::Canada,NCT03086330,Canada,,,,,,,,,,,,,,
country,NCT03086330::country::Norway,NCT03086330,Norway,,,,,,,,,,,,,,
country,NCT03086330::country::Russia,NCT03086330,Russia,,,,,,,,,,,,,,
country,NCT03086330::country::Austria,NCT03086330,Austria,,,,,,,,,,,,,,
country,NCT03086330::country::Japan,NCT03086330,Japan,,,,,,,,,,,,,,
country,NCT03086330::country::Puerto Rico,NCT03086330,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01606007,NCT01606007,Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,1282.0,2012-07,2014-01,8.0,139.0,,,,,
arm,NCT01606007::arm::FG000,NCT01606007,Arm 1: Saxagliptin+Metformin XR+Placebo,,,,,,,,,,FG000,"Drug: Saxagliptin Tablets, Oral, 5mg , Once daily, 24 weeks Other Names: Onglyza Drug: Metformin XR Tablets, Oral, ≥ 1500mg/≤ 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Placebo matc",,,
arm,NCT01606007::arm::FG001,NCT01606007,Arm 2: Dapagliflozin+Metformin XR+Placebo,,,,,,,,,,FG001,"Drug: Metformin XR Tablets, Oral, ≥ 1500mg/≤ 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Dapagliflozin Tablets, Oral, 10mg , Once daily, 24 weeks Other Names: BMS512148 Drug: Placebo",,,
arm,NCT01606007::arm::FG002,NCT01606007,Arm 3: Saxagliptin+Dapagliflozin+Metformin XR,,,,,,,,,,FG002,"Drug: Saxagliptin Tablets, Oral, 5mg , Once daily, 24 weeks Other Names: Onglyza Drug: Metformin XR Tablets, Oral, ≥ 1500mg/≤ 2000mg, Once daily, 24 weeks Other Names: Glucophage XR Drug: Dapagliflozi",,,
period,NCT01606007::period::1,NCT01606007,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01606007::outcome::primary::1,NCT01606007,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24,,,,,,,,,,,,,PRIMARY,Baseline (Week 0) and at Week 24
country,NCT01606007::country::United States,NCT01606007,United States,,,,,,,,,,,,,,
country,NCT01606007::country::Romania,NCT01606007,Romania,,,,,,,,,,,,,,
country,NCT01606007::country::South Africa,NCT01606007,South Africa,,,,,,,,,,,,,,
country,NCT01606007::country::Poland,NCT01606007,Poland,,,,,,,,,,,,,,
country,NCT01606007::country::Canada,NCT01606007,Canada,,,,,,,,,,,,,,
country,NCT01606007::country::Mexico,NCT01606007,Mexico,,,,,,,,,,,,,,
country,NCT01606007::country::Puerto Rico,NCT01606007,Puerto Rico,,,,,,,,,,,,,,
country,NCT01606007::country::South Korea,NCT01606007,South Korea,,,,,,,,,,,,,,
trial,NCT00121667,NCT00121667,Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,1462.0,2005-08,2010-02,9.0,152.0,,,,,
arm,NCT00121667::arm::FG000,NCT00121667,Saxagliptin 2.5 mg + Metformin,,,,,,,,,,FG000,"Tablets, Oral, 2.5 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT); Pioglitazone 15-45 mg (as needed for rescue).",,,
arm,NCT00121667::arm::FG001,NCT00121667,Saxagliptin 5 mg + Metformin,,,,,,,,,,FG001,"Tablets, Oral, 5 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT); Pioglitazone 15-45 mg (as needed for rescue).",,,
arm,NCT00121667::arm::FG002,NCT00121667,Saxagliptin 10 mg + Metformin,,,,,,,,,,FG002,"Tablets, Oral, 10 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT); Pioglitazone 15-45 mg (as needed for rescue).",,,
arm,NCT00121667::arm::FG003,NCT00121667,Placebo+ Metformin,,,,,,,,,,FG003,"Tablets, Oral, 0 mg, Once daily (24 weeks ST, 42 months LT); Pioglitazone 15-45 mg (as needed for rescue).",,,
period,NCT00121667::period::1,NCT00121667,Short Term (ST) Period,,,,,,,,,,,,1.0,,
period,NCT00121667::period::2,NCT00121667,Short Term (ST) + Long Term (LT) Period,,,,,,,,,,,,2.0,,
outcome,NCT00121667::outcome::primary::1,NCT00121667,Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24,,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
country,NCT00121667::country::United States,NCT00121667,United States,,,,,,,,,,,,,,
country,NCT00121667::country::Canada,NCT00121667,Canada,,,,,,,,,,,,,,
country,NCT00121667::country::Australia,NCT00121667,Australia,,,,,,,,,,,,,,
country,NCT00121667::country::Mexico,NCT00121667,Mexico,,,,,,,,,,,,,,
country,NCT00121667::country::Brazil,NCT00121667,Brazil,,,,,,,,,,,,,,
country,NCT00121667::country::Argentina,NCT00121667,Argentina,,,,,,,,,,,,,,
country,NCT00121667::country::Puerto Rico,NCT00121667,Puerto Rico,,,,,,,,,,,,,,
country,NCT00121667::country::Taiwan,NCT00121667,Taiwan,,,,,,,,,,,,,,
country,NCT00121667::country::Chile,NCT00121667,Chile,,,,,,,,,,,,,,
trial,NCT01517412,NCT01517412,Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,451.0,2012-02,2013-05,10.0,82.0,,,,,
arm,NCT01517412::arm::FG000,NCT01517412,Lixisenatide Main Meal,,,,,,,,,,FG000,"Lixisenatide 10 mcg subcutaneous (SC) injection once daily (QD) within 1 hour before ""main meal of the day"" for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24 on top of metformin.",,,
arm,NCT01517412::arm::FG001,NCT01517412,Lixisenatide Breakfast,,,,,,,,,,FG001,"Lixisenatide 10 mcg SC injection QD within 1 hour before ""breakfast"" for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24 on top of metformin.",,,
period,NCT01517412::period::1,NCT01517412,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01517412::outcome::primary::1,NCT01517412,Change in HbA1c From Baseline to Week 24,,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
country,NCT01517412::country::United States,NCT01517412,United States,,,,,,,,,,,,,,
country,NCT01517412::country::Canada,NCT01517412,Canada,,,,,,,,,,,,,,
country,NCT01517412::country::Russia,NCT01517412,Russia,,,,,,,,,,,,,,
country,NCT01517412::country::Poland,NCT01517412,Poland,,,,,,,,,,,,,,
country,NCT01517412::country::Spain,NCT01517412,Spain,,,,,,,,,,,,,,
country,NCT01517412::country::Germany,NCT01517412,Germany,,,,,,,,,,,,,,
country,NCT01517412::country::Ukraine,NCT01517412,Ukraine,,,,,,,,,,,,,,
country,NCT01517412::country::Czechia,NCT01517412,Czechia,,,,,,,,,,,,,,
country,NCT01517412::country::Romania,NCT01517412,Romania,,,,,,,,,,,,,,
country,NCT01517412::country::France,NCT01517412,France,,,,,,,,,,,,,,
trial,NCT01618162,NCT01618162,The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,435.0,2012-08-29,2013-10-23,8.0,87.0,,,,,
arm,NCT01618162::arm::FG000,NCT01618162,IDegLira,,,,,,,,,,FG000,"In this arm, subjects suboptimally controlled on sulfonyl urea (SU) +/- metformin, were given subcutenaous (s.c.) injection of insulin degludec/liraglutide (IDegLira). SU and metformin were maintained",,,
arm,NCT01618162::arm::FG001,NCT01618162,Placebo,,,,,,,,,,FG001,"In this arm, subjects suboptimally controlled on SU +/- metformin, were given s.c. injection of placebo solution (matched to IDegLira) and was initiated and titrated as described for IDegLira. SU and ",,,
period,NCT01618162::period::1,NCT01618162,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01618162::outcome::primary::1,NCT01618162,Change in Glycosylated Haemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Week 0, Week 26"
country,NCT01618162::country::United States,NCT01618162,United States,,,,,,,,,,,,,,
country,NCT01618162::country::Canada,NCT01618162,Canada,,,,,,,,,,,,,,
country,NCT01618162::country::India,NCT01618162,India,,,,,,,,,,,,,,
country,NCT01618162::country::Germany,NCT01618162,Germany,,,,,,,,,,,,,,
country,NCT01618162::country::Israel,NCT01618162,Israel,,,,,,,,,,,,,,
country,NCT01618162::country::Bulgaria,NCT01618162,Bulgaria,,,,,,,,,,,,,,
country,NCT01618162::country::Turkey (Türkiye),NCT01618162,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01618162::country::Puerto Rico,NCT01618162,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00859898,NCT00859898,Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,1093.0,2009-04,2010-05,6.0,123.0,,,,,
arm,NCT00859898::arm::FG000,NCT00859898,Dapagliflozin + Metformin XR,,,,,,,,,,FG000,"Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks

Metformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks",,,
arm,NCT00859898::arm::FG001,NCT00859898,Dapagliflozin,,,,,,,,,,FG001,"Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks.

Placebo: Metformin hydrochloride (HCl) Modified Release matching placebo tablets, once daily, 24 weeks.",,,
arm,NCT00859898::arm::FG002,NCT00859898,Metformin XR,,,,,,,,,,FG002,"Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks

Placebo: Dapagliflozin matching placebo tablets once daily, 24 weeks",,,
period,NCT00859898::period::1,NCT00859898,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00859898::outcome::primary::1,NCT00859898,Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 (Last Observation Carried Forward) - Randomized Treated Participants,,,,,,,,,,,,,PRIMARY,Week 24
country,NCT00859898::country::United States,NCT00859898,United States,,,,,,,,,,,,,,
country,NCT00859898::country::Russia,NCT00859898,Russia,,,,,,,,,,,,,,
country,NCT00859898::country::Mexico,NCT00859898,Mexico,,,,,,,,,,,,,,
country,NCT00859898::country::India,NCT00859898,India,,,,,,,,,,,,,,
country,NCT00859898::country::South Korea,NCT00859898,South Korea,,,,,,,,,,,,,,
country,NCT00859898::country::Puerto Rico,NCT00859898,Puerto Rico,,,,,,,,,,,,,,
trial,NCT02683746,NCT02683746,Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,308.0,2016-03-16,2017-05-15,1.0,70.0,,,,,
arm,NCT02683746::arm::FG000,NCT02683746,Albiglutide Liquid,,,,,,,,,,FG000,Eligible participants received 30 milligrams (mg) of albiglutide active liquid auto-injector along with placebo lyophilized dual chamber cartridge (DCC) pen injector once weekly for 4 weeks by subcuta,,,
arm,NCT02683746::arm::FG001,NCT02683746,Albiglutide Lyophilized,,,,,,,,,,FG001,"Eligible participants received 30 mg of albiglutide active lyophilized DCC pen injector along with placebo liquid auto-injector once weekly for 4 weeks by SC injection in the abdomen, thigh, or upper ",,,
period,NCT02683746::period::1,NCT02683746,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02683746::outcome::primary::1,NCT02683746,Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26,,,,,,,,,,,,,PRIMARY,Baseline and Week 26
country,NCT02683746::country::United States,NCT02683746,United States,,,,,,,,,,,,,,
trial,NCT00528879,NCT00528879,A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,915.0,2007-09,2010-05,5.0,75.0,,,,,
arm,NCT00528879::arm::FG000,NCT00528879,Placebo + Metformin,,,,,,,,,,FG000,Participants received dapagliflozin-matching placebo once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks,,,
arm,NCT00528879::arm::FG001,NCT00528879,"Dapagliflozin, 2.5 mg + Metformin",,,,,,,,,,FG001,"Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks",,,
arm,NCT00528879::arm::FG002,NCT00528879,"Dapagliflozin, 5 mg + Metformin",,,,,,,,,,FG002,"Participants received dapagliflozin, 5 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks",,,
arm,NCT00528879::arm::FG003,NCT00528879,"Dapagliflozin, 10 mg + Metformin",,,,,,,,,,FG003,"Participants received dapagliflozin, 10 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks",,,
period,NCT00528879::period::1,NCT00528879,Short-term Period (Day 1 to Week 24),,,,,,,,,,,,1.0,,
period,NCT00528879::period::2,NCT00528879,Long-term Period (Weeks 24 to 102),,,,,,,,,,,,2.0,,
outcome,NCT00528879::outcome::primary::1,NCT00528879,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]),,,,,,,,,,,,,PRIMARY,From Baseline to Week 24
country,NCT00528879::country::United States,NCT00528879,United States,,,,,,,,,,,,,,
country,NCT00528879::country::Canada,NCT00528879,Canada,,,,,,,,,,,,,,
country,NCT00528879::country::Argentina,NCT00528879,Argentina,,,,,,,,,,,,,,
country,NCT00528879::country::Mexico,NCT00528879,Mexico,,,,,,,,,,,,,,
country,NCT00528879::country::Brazil,NCT00528879,Brazil,,,,,,,,,,,,,,
trial,NCT01590771,NCT01590771,A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,498.0,2012-07-09,2014-06-24,0.0,0.0,,,,,
arm,NCT01590771::arm::FG000,NCT01590771,Sitagliptin,,,,,,,,,,FG000,Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.,,,
arm,NCT01590771::arm::FG001,NCT01590771,Placebo,,,,,,,,,,FG001,Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.,,,
period,NCT01590771::period::1,NCT01590771,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01590771::outcome::primary::1,NCT01590771,Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin,,,,,,,,,,,,,PRIMARY,Baseline and Week 24
outcome,NCT01590771::outcome::primary::2,NCT01590771,Number of Participants Who Experienced an Adverse Event,,,,,,,,,,,,,PRIMARY,Up to 26 weeks
outcome,NCT01590771::outcome::primary::3,NCT01590771,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,,,,,,,,,,,,,PRIMARY,Up to 24 weeks
trial,NCT04560998,NCT04560998,A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2; Peripheral Arterial Disease",INDUSTRY,792.0,2020-10-01,2024-07-12,21.0,194.0,,,,,
arm,NCT04560998::arm::FG000,NCT04560998,Semaglutide,,,,,,,,,,FG000,"Participants received once-weekly (OW) subcutaneous injection (s. c.) of semaglutide for 52 weeks. Participants received a dose of 0.25 milligrams (mg) from week 0 to week 4, then the dose was increas",,,
arm,NCT04560998::arm::FG001,NCT04560998,Placebo,,,,,,,,,,FG001,Participants received once-weekly (OW) subcutaneous injection (s. c.) of placebo matched for semaglutide for 52 weeks.,,,
period,NCT04560998::period::1,NCT04560998,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04560998::outcome::primary::1,NCT04560998,Change in Maximum Walking Distance on a Constant Load Treadmill Test,,,,,,,,,,,,,PRIMARY,"Baseline (week 0), end of treatment (week 52)"
country,NCT04560998::country::United States,NCT04560998,United States,,,,,,,,,,,,,,
country,NCT04560998::country::Russia,NCT04560998,Russia,,,,,,,,,,,,,,
country,NCT04560998::country::Japan,NCT04560998,Japan,,,,,,,,,,,,,,
country,NCT04560998::country::India,NCT04560998,India,,,,,,,,,,,,,,
country,NCT04560998::country::Canada,NCT04560998,Canada,,,,,,,,,,,,,,
country,NCT04560998::country::Germany,NCT04560998,Germany,,,,,,,,,,,,,,
country,NCT04560998::country::Thailand,NCT04560998,Thailand,,,,,,,,,,,,,,
country,NCT04560998::country::Greece,NCT04560998,Greece,,,,,,,,,,,,,,
country,NCT04560998::country::Poland,NCT04560998,Poland,,,,,,,,,,,,,,
country,NCT04560998::country::China,NCT04560998,China,,,,,,,,,,,,,,
country,NCT04560998::country::Malaysia,NCT04560998,Malaysia,,,,,,,,,,,,,,
country,NCT04560998::country::Spain,NCT04560998,Spain,,,,,,,,,,,,,,
country,NCT04560998::country::Taiwan,NCT04560998,Taiwan,,,,,,,,,,,,,,
country,NCT04560998::country::Belgium,NCT04560998,Belgium,,,,,,,,,,,,,,
country,NCT04560998::country::Hungary,NCT04560998,Hungary,,,,,,,,,,,,,,
country,NCT04560998::country::Czechia,NCT04560998,Czechia,,,,,,,,,,,,,,
country,NCT04560998::country::Austria,NCT04560998,Austria,,,,,,,,,,,,,,
country,NCT04560998::country::Denmark,NCT04560998,Denmark,,,,,,,,,,,,,,
country,NCT04560998::country::Norway,NCT04560998,Norway,,,,,,,,,,,,,,
country,NCT04560998::country::Sweden,NCT04560998,Sweden,,,,,,,,,,,,,,
country,NCT04560998::country::Latvia,NCT04560998,Latvia,,,,,,,,,,,,,,
trial,NCT00713830,NCT00713830,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea",PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,859.0,2008-07,2011-01,16.0,16.0,,,,,
arm,NCT00713830::arm::FG000,NCT00713830,Placebo,,,,,,,,,,FG000,"2-step initiation regimen of volume matching placebo: 10 microgram (mcg) once daily (QD) subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.",,,
arm,NCT00713830::arm::FG001,NCT00713830,Lixisenatide,,,,,,,,,,FG001,"2-step initiation regimen of lixisenatide: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.",,,
period,NCT00713830::period::1,NCT00713830,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00713830::outcome::primary::1,NCT00713830,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
country,NCT00713830::country::United States,NCT00713830,United States,,,,,,,,,,,,,,
country,NCT00713830::country::Bulgaria,NCT00713830,Bulgaria,,,,,,,,,,,,,,
country,NCT00713830::country::Czechia,NCT00713830,Czechia,,,,,,,,,,,,,,
country,NCT00713830::country::Egypt,NCT00713830,Egypt,,,,,,,,,,,,,,
country,NCT00713830::country::Germany,NCT00713830,Germany,,,,,,,,,,,,,,
country,NCT00713830::country::India,NCT00713830,India,,,,,,,,,,,,,,
country,NCT00713830::country::Israel,NCT00713830,Israel,,,,,,,,,,,,,,
country,NCT00713830::country::Japan,NCT00713830,Japan,,,,,,,,,,,,,,
country,NCT00713830::country::Netherlands,NCT00713830,Netherlands,,,,,,,,,,,,,,
country,NCT00713830::country::Romania,NCT00713830,Romania,,,,,,,,,,,,,,
country,NCT00713830::country::Russia,NCT00713830,Russia,,,,,,,,,,,,,,
country,NCT00713830::country::South Korea,NCT00713830,South Korea,,,,,,,,,,,,,,
country,NCT00713830::country::Taiwan,NCT00713830,Taiwan,,,,,,,,,,,,,,
country,NCT00713830::country::Thailand,NCT00713830,Thailand,,,,,,,,,,,,,,
country,NCT00713830::country::Tunisia,NCT00713830,Tunisia,,,,,,,,,,,,,,
country,NCT00713830::country::Turkey (Türkiye),NCT00713830,Turkey (Türkiye),,,,,,,,,,,,,,
trial,NCT00395512,NCT00395512,Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Diabetes Mellitus,INDUSTRY,655.0,2006-11,2008-02,23.0,161.0,,,,,
arm,NCT00395512::arm::FG000,NCT00395512,Alogliptin 25 mg,,,,,,,,,,FG000,"Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.",,,
arm,NCT00395512::arm::FG001,NCT00395512,Pioglitazone 30 mg,,,,,,,,,,FG001,"Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.",,,
arm,NCT00395512::arm::FG002,NCT00395512,Alogliptin 25 mg + Pioglitazone 30 mg,,,,,,,,,,FG002,"Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.",,,
arm,NCT00395512::arm::FG003,NCT00395512,Alogliptin 12.5 mg + Pioglitazone 30 mg,,,,,,,,,,FG003,"Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.",,,
period,NCT00395512::period::1,NCT00395512,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00395512::outcome::primary::1,NCT00395512,Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,Baseline and Week 26
country,NCT00395512::country::United States,NCT00395512,United States,,,,,,,,,,,,,,
country,NCT00395512::country::Brazil,NCT00395512,Brazil,,,,,,,,,,,,,,
country,NCT00395512::country::Poland,NCT00395512,Poland,,,,,,,,,,,,,,
country,NCT00395512::country::Argentina,NCT00395512,Argentina,,,,,,,,,,,,,,
country,NCT00395512::country::Hungary,NCT00395512,Hungary,,,,,,,,,,,,,,
country,NCT00395512::country::India,NCT00395512,India,,,,,,,,,,,,,,
country,NCT00395512::country::Israel,NCT00395512,Israel,,,,,,,,,,,,,,
country,NCT00395512::country::South Africa,NCT00395512,South Africa,,,,,,,,,,,,,,
country,NCT00395512::country::Slovakia,NCT00395512,Slovakia,,,,,,,,,,,,,,
country,NCT00395512::country::Ukraine,NCT00395512,Ukraine,,,,,,,,,,,,,,
country,NCT00395512::country::Australia,NCT00395512,Australia,,,,,,,,,,,,,,
country,NCT00395512::country::Mexico,NCT00395512,Mexico,,,,,,,,,,,,,,
country,NCT00395512::country::Romania,NCT00395512,Romania,,,,,,,,,,,,,,
country,NCT00395512::country::Russia,NCT00395512,Russia,,,,,,,,,,,,,,
country,NCT00395512::country::Serbia,NCT00395512,Serbia,,,,,,,,,,,,,,
country,NCT00395512::country::Lithuania,NCT00395512,Lithuania,,,,,,,,,,,,,,
country,NCT00395512::country::New Zealand,NCT00395512,New Zealand,,,,,,,,,,,,,,
country,NCT00395512::country::Bulgaria,NCT00395512,Bulgaria,,,,,,,,,,,,,,
country,NCT00395512::country::Chile,NCT00395512,Chile,,,,,,,,,,,,,,
country,NCT00395512::country::Croatia,NCT00395512,Croatia,,,,,,,,,,,,,,
country,NCT00395512::country::Estonia,NCT00395512,Estonia,,,,,,,,,,,,,,
country,NCT00395512::country::Guatemala,NCT00395512,Guatemala,,,,,,,,,,,,,,
country,NCT00395512::country::Latvia,NCT00395512,Latvia,,,,,,,,,,,,,,
trial,NCT01294423,NCT01294423,Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Type 2 Diabetes; High Blood Sugar,INDUSTRY,261.0,2011-02,2012-03,1.0,26.0,,,,,
arm,NCT01294423::arm::FG000,NCT01294423,Dapagliflozin 5 mg,,,,,,,,,,FG000,Dapagliflozin : Dapagliflozin 5mg/matching placebo for Dapagliflozin 10mg oral dose,,,
arm,NCT01294423::arm::FG001,NCT01294423,Dapagliflozin 10 mg,,,,,,,,,,FG001,Dapagliflozin : Dapagliflozin 10mg/matching placebo for Dapagliflozin 5mg oral dose,,,
arm,NCT01294423::arm::FG002,NCT01294423,Placebo,,,,,,,,,,FG002,Placebo : Matching placebo for Dapagliflozin 5mg/10mg oral dose,,,
period,NCT01294423::period::1,NCT01294423,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01294423::outcome::primary::1,NCT01294423,Adjusted Mean Change in HbA1c Levels,,,,,,,,,,,,,PRIMARY,From Baseline to Week 24
country,NCT01294423::country::Japan,NCT01294423,Japan,,,,,,,,,,,,,,
trial,NCT01387737,NCT01387737,Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,1299.0,2011-05,2012-12,1.0,7.0,,,,,
arm,NCT01387737::arm::FG000,NCT01387737,TA-7284-Low,,,,,,,,,,FG000,"TA-7284 low dose, once daily for 52 weeks",,,
arm,NCT01387737::arm::FG001,NCT01387737,TA-7284-High,,,,,,,,,,FG001,"TA-7284 high dose, once daily for 52 weeks",,,
period,NCT01387737::period::1,NCT01387737,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01387737::outcome::primary::1,NCT01387737,"Safety and Tolerability Assessed by Adverse Events, Hypoglycemic Events",,,,,,,,,,,,,PRIMARY,54 weeks
country,NCT01387737::country::Japan,NCT01387737,Japan,,,,,,,,,,,,,,
trial,NCT02558296,NCT02558296,Bexagliflozin Efficacy and Safety Trial,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,1700.0,2015-10,2019-10-23,10.0,157.0,,,,,
arm,NCT02558296::arm::FG000,NCT02558296,"Bexagliflozin Tablets, 20 mg",,,,,,,,,,FG000,"Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.

Bexagliflozin: 20 mg, tablet",,,
arm,NCT02558296::arm::FG001,NCT02558296,Placebo Tablets,,,,,,,,,,FG001,"Each subject will receive placebo (inactive tablet) once daily for the duration of the study.

Placebo: 20 mg tablet to match active comparator",,,
period,NCT02558296::period::1,NCT02558296,Completed the Study Through Week 24,,,,,,,,,,,,1.0,,
period,NCT02558296::period::2,NCT02558296,Completed the Study,,,,,,,,,,,,2.0,,
outcome,NCT02558296::outcome::primary::1,NCT02558296,Change in HbA1c From Baseline to Week 24,,,,,,,,,,,,,PRIMARY,24 weeks
country,NCT02558296::country::United States,NCT02558296,United States,,,,,,,,,,,,,,
country,NCT02558296::country::Poland,NCT02558296,Poland,,,,,,,,,,,,,,
country,NCT02558296::country::Czechia,NCT02558296,Czechia,,,,,,,,,,,,,,
country,NCT02558296::country::Canada,NCT02558296,Canada,,,,,,,,,,,,,,
country,NCT02558296::country::Russia,NCT02558296,Russia,,,,,,,,,,,,,,
country,NCT02558296::country::Mexico,NCT02558296,Mexico,,,,,,,,,,,,,,
country,NCT02558296::country::Netherlands,NCT02558296,Netherlands,,,,,,,,,,,,,,
country,NCT02558296::country::South Korea,NCT02558296,South Korea,,,,,,,,,,,,,,
country,NCT02558296::country::Taiwan,NCT02558296,Taiwan,,,,,,,,,,,,,,
country,NCT02558296::country::Denmark,NCT02558296,Denmark,,,,,,,,,,,,,,
trial,NCT01095666,NCT01095666,A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,1484.0,2010-06,2013-03,3.0,33.0,,,,,
arm,NCT01095666::arm::FG000,NCT01095666,Placebo + Metformin,,,,,,,,,,FG000,,,,
arm,NCT01095666::arm::FG001,NCT01095666,Dapagliflozin 5 mg + Metformin,,,,,,,,,,FG001,,,,
arm,NCT01095666::arm::FG002,NCT01095666,Dapagliflozin 10 mg + Metformin,,,,,,,,,,FG002,,,,
period,NCT01095666::period::1,NCT01095666,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01095666::outcome::primary::1,NCT01095666,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]),,,,,,,,,,,,,PRIMARY,From Baseline to Week 24
country,NCT01095666::country::China,NCT01095666,China,,,,,,,,,,,,,,
country,NCT01095666::country::India,NCT01095666,India,,,,,,,,,,,,,,
country,NCT01095666::country::South Korea,NCT01095666,South Korea,,,,,,,,,,,,,,
trial,NCT01594333,NCT01594333,Cardiovascular Inflammation Reduction Trial,PHASE3,diabetes type 2,Cardiovascular Disease,OTHER,4786.0,2013-04,2019-10-30,3.0,470.0,,,,,
arm,NCT01594333::arm::FG000,NCT01594333,Methotrexate,,,,,,,,,,FG000,"Methotrexate: Tablet, Oral, Target dose 15-20 mg weekly plus 1.0 mg folic acid 6 days/week",,,
arm,NCT01594333::arm::FG001,NCT01594333,Placebo,,,,,,,,,,FG001,"Placebo: Tablet, Oral, weekly plus 1.0 mg folic acid 6 days/week",,,
period,NCT01594333::period::1,NCT01594333,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01594333::outcome::primary::1,NCT01594333,Number of Subjects With Major Adverse Cardiovascular Events,,,,,,,,,,,,,PRIMARY,"From randomization to trial end (April 2, 2018) up to a maximum of 5 years"
outcome,NCT01594333::outcome::primary::2,NCT01594333,Number of Subjects With Major Adverse Cardiovascular Event or Hospitalization for Unstable Angina That Led to Urgent Coronary Revascularization,,,,,,,,,,,,,PRIMARY,"From randomization to trial end (April 2, 2018) - up to a maximum of 5 years"
country,NCT01594333::country::United States,NCT01594333,United States,,,,,,,,,,,,,,
country,NCT01594333::country::Canada,NCT01594333,Canada,,,,,,,,,,,,,,
country,NCT01594333::country::Puerto Rico,NCT01594333,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01778049,NCT01778049,Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,708.0,2013-01,2015-03,11.0,114.0,,,,,
arm,NCT01778049::arm::FG000,NCT01778049,Empa 10 mg OL,,,,,,,,,,FG000,"Subjects were orally administered once daily empa 10 mg film-coated tablet for 16 wk during OL treatment period, thereafter patients received once daily fixed dose combination (FDC) placebo tablet mat",,,
arm,NCT01778049::arm::FG001,NCT01778049,Empa 25 mg OL,,,,,,,,,,FG001,"Subjects were orally administered once daily empa 25 mg film-coated tablet for 16 week during OL treatment period, thereafter patients received once daily FDC Plc tablet matching to FDC empa 25 mg/lin",,,
arm,NCT01778049::arm::FG002,NCT01778049,Lina5 (E10),,,,,,,,,,FG002,Subjects were orally administered FDC empa 10 mg/lina 5 mg and placebo matching to empa 10 mg for 24 wk during the double-blind treatment period.,,,
arm,NCT01778049::arm::FG003,NCT01778049,Plc (E10),,,,,,,,,,FG003,Subjects were orally administered empa 10 mg and matching placebo to FDC empa 10 mg/lina 5 mg for 24 wk during the double-blind treatment period.,,,
arm,NCT01778049::arm::FG004,NCT01778049,Lina5 (E25),,,,,,,,,,FG004,Subjects were orally administered FDC empa 25 mg/lina 5 mg and placebo matching to empa 25 mg for 24 wk during the double-blind treatment period.,,,
arm,NCT01778049::arm::FG005,NCT01778049,Plc (E25),,,,,,,,,,FG005,Subjects were orally administered empa 25 mg and matching placebo to FDC empa 25 mg/lina 5 mg for 24 wk during the double-blind treatment period.,,,
period,NCT01778049::period::1,NCT01778049,Open Label Treatment Period,,,,,,,,,,,,1.0,,
period,NCT01778049::period::2,NCT01778049,Double Blind Treatment Period,,,,,,,,,,,,2.0,,
outcome,NCT01778049::outcome::primary::1,NCT01778049,Change From Baseline of HbA1c After 24 Weeks of Treatment.,,,,,,,,,,,,,PRIMARY,Baseline and 24 weeks
country,NCT01778049::country::United States,NCT01778049,United States,,,,,,,,,,,,,,
country,NCT01778049::country::Italy,NCT01778049,Italy,,,,,,,,,,,,,,
country,NCT01778049::country::Argentina,NCT01778049,Argentina,,,,,,,,,,,,,,
country,NCT01778049::country::Canada,NCT01778049,Canada,,,,,,,,,,,,,,
country,NCT01778049::country::Germany,NCT01778049,Germany,,,,,,,,,,,,,,
country,NCT01778049::country::Spain,NCT01778049,Spain,,,,,,,,,,,,,,
country,NCT01778049::country::Ukraine,NCT01778049,Ukraine,,,,,,,,,,,,,,
country,NCT01778049::country::Portugal,NCT01778049,Portugal,,,,,,,,,,,,,,
country,NCT01778049::country::Russia,NCT01778049,Russia,,,,,,,,,,,,,,
country,NCT01778049::country::Australia,NCT01778049,Australia,,,,,,,,,,,,,,
country,NCT01778049::country::El Salvador,NCT01778049,El Salvador,,,,,,,,,,,,,,
trial,NCT01263483,NCT01263483,Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,230.0,2007-01,2008-04,0.0,0.0,,,,,
arm,NCT01263483::arm::FG000,NCT01263483,Voglibose 0.2 mg TID,,,,,,,,,,FG000,"Alogliptin placebo-matching tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.",,,
arm,NCT01263483::arm::FG001,NCT01263483,Alogliptin 12.5 mg QD,,,,,,,,,,FG001,Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID,,,
arm,NCT01263483::arm::FG002,NCT01263483,Alogliptin 25 mg QD and Voglibose 0.2 mg TID,,,,,,,,,,FG002,"Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.",,,
period,NCT01263483::period::1,NCT01263483,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01263483::outcome::primary::1,NCT01263483,Change From Baseline in Glycosylated Hemoglobin (Week 12).,,,,,,,,,,,,,PRIMARY,Baseline and Week 12.
trial,NCT00350779,NCT00350779,Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,262.0,2006-06-12,2008-06-11,0.0,0.0,,,,,
arm,NCT00350779::arm::FG000,NCT00350779,Sitagliptin 100 mg,,,,,,,,,,FG000,The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing treatment with open-label r,,,
arm,NCT00350779::arm::FG001,NCT00350779,Placebo,,,,,,,,,,FG001,The Placebo group includes data from patients randomized to receive treatment with placebo to sitagliptin 100 mg tablet once daily (blinded) in addition to ongoing treatment with open-label rosiglitaz,,,
period,NCT00350779::period::1,NCT00350779,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00350779::outcome::primary::1,NCT00350779,Change From Baseline in HbA1c (Hemoglobin A1C) at Week 18,,,,,,,,,,,,,PRIMARY,Baseline and 18 Weeks
trial,NCT01032629,NCT01032629,CANVAS - CANagliflozin cardioVascular Assessment Study,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2; Cardiovascular Diseases; Risk Factors",INDUSTRY,4330.0,2009-12-09,2017-02-22,25.0,305.0,,,,,
arm,NCT01032629::arm::FG000,NCT01032629,Placebo,,,,,,,,,,FG000,Participants received one placebo capsule orally once daily for the duration of the study or until early discontinuation from treatment.,,,
arm,NCT01032629::arm::FG001,NCT01032629,Canagliflozin 100 mg,,,,,,,,,,FG001,Participants received one canagliflozin 100 milligram (mg) capsule once daily for the duration of the study or until early discontinuation from treatment.,,,
arm,NCT01032629::arm::FG002,NCT01032629,Canagliflozin 300 mg,,,,,,,,,,FG002,Participants received one canagliflozin 300 mg capsule once daily for the duration of the study or until early discontinuation from treatment.,,,
period,NCT01032629::period::1,NCT01032629,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01032629::outcome::primary::1,NCT01032629,"Major Adverse Cardiovascular Events (MACE) Composite of Cardiovascular (CV) Death, Non-Fatal Myocardial Infarction (MI), and Non-Fatal Stroke",,,,,,,,,,,,,PRIMARY,Up to approximately 8 years
country,NCT01032629::country::United States,NCT01032629,United States,,,,,,,,,,,,,,
country,NCT01032629::country::India,NCT01032629,India,,,,,,,,,,,,,,
country,NCT01032629::country::Australia,NCT01032629,Australia,,,,,,,,,,,,,,
country,NCT01032629::country::Russia,NCT01032629,Russia,,,,,,,,,,,,,,
country,NCT01032629::country::Canada,NCT01032629,Canada,,,,,,,,,,,,,,
country,NCT01032629::country::Netherlands,NCT01032629,Netherlands,,,,,,,,,,,,,,
country,NCT01032629::country::United Kingdom,NCT01032629,United Kingdom,,,,,,,,,,,,,,
country,NCT01032629::country::Poland,NCT01032629,Poland,,,,,,,,,,,,,,
country,NCT01032629::country::Spain,NCT01032629,Spain,,,,,,,,,,,,,,
country,NCT01032629::country::Germany,NCT01032629,Germany,,,,,,,,,,,,,,
country,NCT01032629::country::Ukraine,NCT01032629,Ukraine,,,,,,,,,,,,,,
country,NCT01032629::country::Argentina,NCT01032629,Argentina,,,,,,,,,,,,,,
country,NCT01032629::country::Norway,NCT01032629,Norway,,,,,,,,,,,,,,
country,NCT01032629::country::Sweden,NCT01032629,Sweden,,,,,,,,,,,,,,
country,NCT01032629::country::Czechia,NCT01032629,Czechia,,,,,,,,,,,,,,
country,NCT01032629::country::Malaysia,NCT01032629,Malaysia,,,,,,,,,,,,,,
country,NCT01032629::country::Belgium,NCT01032629,Belgium,,,,,,,,,,,,,,
country,NCT01032629::country::Mexico,NCT01032629,Mexico,,,,,,,,,,,,,,
country,NCT01032629::country::New Zealand,NCT01032629,New Zealand,,,,,,,,,,,,,,
country,NCT01032629::country::Estonia,NCT01032629,Estonia,,,,,,,,,,,,,,
country,NCT01032629::country::Hungary,NCT01032629,Hungary,,,,,,,,,,,,,,
country,NCT01032629::country::Israel,NCT01032629,Israel,,,,,,,,,,,,,,
country,NCT01032629::country::France,NCT01032629,France,,,,,,,,,,,,,,
country,NCT01032629::country::Colombia,NCT01032629,Colombia,,,,,,,,,,,,,,
country,NCT01032629::country::Luxembourg,NCT01032629,Luxembourg,,,,,,,,,,,,,,
trial,NCT00621140,NCT00621140,Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,503.0,2008-02,,11.0,69.0,,,,,
arm,NCT00621140::arm::FG000,NCT00621140,Placebo,,,,,,,,,,FG000,Patients randomized to receive treatment with matching placebo,,,
arm,NCT00621140::arm::FG001,NCT00621140,Linagliptin,,,,,,,,,,FG001,Patients randomized to receive treatment with Linagliptin 5mg,,,
period,NCT00621140::period::1,NCT00621140,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00621140::outcome::primary::1,NCT00621140,HbA1c Change From Baseline at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and week 24
country,NCT00621140::country::India,NCT00621140,India,,,,,,,,,,,,,,
country,NCT00621140::country::Ukraine,NCT00621140,Ukraine,,,,,,,,,,,,,,
country,NCT00621140::country::Netherlands,NCT00621140,Netherlands,,,,,,,,,,,,,,
country,NCT00621140::country::Malaysia,NCT00621140,Malaysia,,,,,,,,,,,,,,
country,NCT00621140::country::Israel,NCT00621140,Israel,,,,,,,,,,,,,,
country,NCT00621140::country::Slovakia,NCT00621140,Slovakia,,,,,,,,,,,,,,
country,NCT00621140::country::Italy,NCT00621140,Italy,,,,,,,,,,,,,,
country,NCT00621140::country::Poland,NCT00621140,Poland,,,,,,,,,,,,,,
country,NCT00621140::country::Croatia,NCT00621140,Croatia,,,,,,,,,,,,,,
country,NCT00621140::country::Romania,NCT00621140,Romania,,,,,,,,,,,,,,
country,NCT00621140::country::Thailand,NCT00621140,Thailand,,,,,,,,,,,,,,
trial,NCT01545388,NCT01545388,Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,337.0,2012-02-23,2013-03-12,0.0,0.0,,,,,
arm,NCT01545388::arm::FG000,NCT01545388,Metformin 500 mg q.d.,,,,,,,,,,FG000,"Participants received sitagliptin daily at pre-study dose, 2 metformin 250 mg tablets in the morning and 1 matching placebo tablet in the evening.",,,
arm,NCT01545388::arm::FG001,NCT01545388,Metformin 250 mg b.i.d.,,,,,,,,,,FG001,"Participants received sitagliptin daily at pre-study dose, 1 metformin 250 mg tablet and 1 matching placebo tablet in the morning and 1 metformin 250 mg tablet in the evening.",,,
arm,NCT01545388::arm::FG002,NCT01545388,Placebo,,,,,,,,,,FG002,"Participants received sitagliptin daily at pre-study dose, 2 matching placebo tablets in the morning and 1 matching placebo tablet in the evening.",,,
period,NCT01545388::period::1,NCT01545388,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01545388::outcome::primary::1,NCT01545388,Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c),,,,,,,,,,,,,PRIMARY,Baseline and Week 24
outcome,NCT01545388::outcome::primary::2,NCT01545388,Percentage of Participants Who Experienced at Least One Adverse Event,,,,,,,,,,,,,PRIMARY,Up to 26 weeks
outcome,NCT01545388::outcome::primary::3,NCT01545388,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,,,,,,,,,,,,,PRIMARY,Up to 24 weeks
trial,NCT00286468,NCT00286468,Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.,PHASE3,diabetes type 2,Diabetes Mellitus,INDUSTRY,500.0,2006-04,2007-06,15.0,68.0,,,,,
arm,NCT00286468::arm::FG000,NCT00286468,Placebo,,,,,,,,,,FG000,"Alogliptin placebo-matching tablets, orally, once daily and glyburide for up to 26 weeks.",,,
arm,NCT00286468::arm::FG001,NCT00286468,Alogliptin 12.5 mg QD,,,,,,,,,,FG001,"Alogliptin 12.5 mg, tablets, orally, once daily and glyburide for up to 26 weeks.",,,
arm,NCT00286468::arm::FG002,NCT00286468,Alogliptin 25 mg QD,,,,,,,,,,FG002,"Alogliptin 25 mg, tablets, orally, once daily and glyburide for up to 26 weeks.",,,
period,NCT00286468::period::1,NCT00286468,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00286468::outcome::primary::1,NCT00286468,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.,,,,,,,,,,,,,PRIMARY,Baseline and Week 26.
country,NCT00286468::country::United States,NCT00286468,United States,,,,,,,,,,,,,,
country,NCT00286468::country::Argentina,NCT00286468,Argentina,,,,,,,,,,,,,,
country,NCT00286468::country::Australia,NCT00286468,Australia,,,,,,,,,,,,,,
country,NCT00286468::country::Brazil,NCT00286468,Brazil,,,,,,,,,,,,,,
country,NCT00286468::country::Chile,NCT00286468,Chile,,,,,,,,,,,,,,
country,NCT00286468::country::Dominican Republic,NCT00286468,Dominican Republic,,,,,,,,,,,,,,
country,NCT00286468::country::Guatemala,NCT00286468,Guatemala,,,,,,,,,,,,,,
country,NCT00286468::country::India,NCT00286468,India,,,,,,,,,,,,,,
country,NCT00286468::country::Mexico,NCT00286468,Mexico,,,,,,,,,,,,,,
country,NCT00286468::country::Netherlands,NCT00286468,Netherlands,,,,,,,,,,,,,,
country,NCT00286468::country::New Zealand,NCT00286468,New Zealand,,,,,,,,,,,,,,
country,NCT00286468::country::Peru,NCT00286468,Peru,,,,,,,,,,,,,,
country,NCT00286468::country::Poland,NCT00286468,Poland,,,,,,,,,,,,,,
country,NCT00286468::country::South Africa,NCT00286468,South Africa,,,,,,,,,,,,,,
country,NCT00286468::country::United Kingdom,NCT00286468,United Kingdom,,,,,,,,,,,,,,
trial,NCT00722371,NCT00722371,MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,1615.0,2008-09-05,2011-03-25,0.0,0.0,,,,,
arm,NCT00722371::arm::FG000,NCT00722371,Sitagliptin 100 mg,,,,,,,,,,FG000,Sitagliptin 100 mg and matching placebo to pioglitazone once daily for 54 weeks.,,,
arm,NCT00722371::arm::FG001,NCT00722371,Pioglitazone 15 mg,,,,,,,,,,FG001,Pioglitazone 15 mg and matching placebo to sitagliptin once daily for 54 weeks.,,,
arm,NCT00722371::arm::FG002,NCT00722371,Pioglitazone 30 mg,,,,,,,,,,FG002,Pioglitazone 30 mg and matching placebo to sitagliptin once daily for 54 weeks.,,,
arm,NCT00722371::arm::FG003,NCT00722371,Pioglitazone 45 mg,,,,,,,,,,FG003,Pioglitazone 45 mg and matching placebo to sitagliptin once daily for 54 weeks.,,,
arm,NCT00722371::arm::FG004,NCT00722371,Sitagliptin 100 mg/ Pioglitazone 15 mg,,,,,,,,,,FG004,Sitagliptin 100 mg and pioglitazone 15 mg once daily for 54 weeks.,,,
arm,NCT00722371::arm::FG005,NCT00722371,Sitagliptin 100 mg/ Pioglitazone 30 mg,,,,,,,,,,FG005,Sitagliptin 100 mg and pioglitazone 30 mg once daily for 54 weeks.,,,
arm,NCT00722371::arm::FG006,NCT00722371,Sitagliptin 100 mg/ Pioglitazone 45 mg,,,,,,,,,,FG006,Sitagliptin 100 mg and pioglitazone 45 mg once daily for 54 weeks.,,,
period,NCT00722371::period::1,NCT00722371,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00722371::outcome::primary::1,NCT00722371,Change From Baseline in Hemoglobin A1C (A1C) at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and Week 24
outcome,NCT00722371::outcome::primary::2,NCT00722371,Change From Baseline in A1C at Week 54,,,,,,,,,,,,,PRIMARY,Baseline and Week 54
trial,NCT04233801,NCT04233801,A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,219.0,2020-04-15,2022-03-10,1.0,24.0,,,,,
arm,NCT04233801::arm::FG000,NCT04233801,Placebo,,,,,,,,,,FG000,"Matching placebo was administered orally once daily for a treatment period of 24 weeks.

Before the first dose of randomised drug, all participants went through a 2-week open label placebo run-in peri",,,
arm,NCT04233801::arm::FG001,NCT04233801,Empagliflozin 10 mg,,,,,,,,,,FG001,"1 table of 10 milligrams (mg) of Empagliflozin was administered orally once daily for a treatment period of 24 weeks.

Before the first dose of randomised drug, all participants went through a 2-week ",,,
arm,NCT04233801::arm::FG002,NCT04233801,Empagliflozin 25 mg,,,,,,,,,,FG002,"1 table of 25 milligrams (mg) of Empagliflozin was administered orally once daily for a treatment period of 24 weeks.

Before the first dose of randomised drug, all participants went through a 2-week ",,,
period,NCT04233801::period::1,NCT04233801,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04233801::outcome::primary::1,NCT04233801,Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 24,,,,,,,,,,,,,PRIMARY,At baseline (Week 0) and at Week 24
country,NCT04233801::country::China,NCT04233801,China,,,,,,,,,,,,,,
trial,NCT00081328,NCT00081328,Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY),PHASE3,diabetes type 2,"Diabetes Mellitus, Type II",NIH,699.0,2004-05,2014-02,1.0,16.0,,,,,
arm,NCT00081328::arm::FG000,NCT00081328,1 Metformin Alone,,,,,,,,,,FG000,"Metformin alone

Metformin: capsule, 1000 mg bid, provided encapsulated in weekly packets",,,
arm,NCT00081328::arm::FG001,NCT00081328,2 Metformin + Rosliglitazone,,,,,,,,,,FG001,"Metformin + Rosiglitazone

Metformin: capsule, 1000 mg bid

Rosiglitazone: capsule, 4 mg bid, provided encapsulated in weekly packets",,,
arm,NCT00081328::arm::FG002,NCT00081328,3 Metformin + Lifestyle Program,,,,,,,,,,FG002,"Metformin + Lifestyle Program

Metformin: capsule, 1000 mg bid, encapsulated, provided in weekly packets

Lifestyle Program: a lifestyle change (LC) phase of weekly sessions for months 1-6, followed b",,,
period,NCT00081328::period::1,NCT00081328,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00081328::outcome::primary::1,NCT00081328,Treatment Failure (Loss of Glycemic Control),,,,,,,,,,,,,PRIMARY,Study duration - 2 years to 6.5 years of follow up from randomization
country,NCT00081328::country::United States,NCT00081328,United States,,,,,,,,,,,,,,
trial,NCT01272232,NCT01272232,Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes,PHASE3,diabetes type 2,Metabolism and Nutrition Disorder; Obesity,INDUSTRY,846.0,2011-06-01,2013-01-25,13.0,161.0,,,,,
arm,NCT01272232::arm::FG000,NCT01272232,Liraglutide 3.0 mg,,,,,,,,,,FG000,"Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 3.0 mg. I",,,
arm,NCT01272232::arm::FG001,NCT01272232,Liraglutide 1.8 mg,,,,,,,,,,FG001,"Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 1.8 mg. I",,,
arm,NCT01272232::arm::FG002,NCT01272232,Liraglutide Placebo,,,,,,,,,,FG002,"Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide placebo. In the 12-week follow-up period, treatment was discontinued. In addition to placebo treatment,",,,
period,NCT01272232::period::1,NCT01272232,Weeks 0-56,,,,,,,,,,,,1.0,,
period,NCT01272232::period::2,NCT01272232,Off Drug Follow-up Period (Weeks 56-68),,,,,,,,,,,,2.0,,
outcome,NCT01272232::outcome::primary::1,NCT01272232,Change (%) From Baseline in Body Weight (Fasting),,,,,,,,,,,,,PRIMARY,"Week 0, week 56"
outcome,NCT01272232::outcome::primary::2,NCT01272232,Proportion of Subjects Losing at Least 5% of Baseline Body Weight,,,,,,,,,,,,,PRIMARY,at 56 weeks
outcome,NCT01272232::outcome::primary::3,NCT01272232,Proportion of Subjects Losing More Than 10% of Baseline Body Weight,,,,,,,,,,,,,PRIMARY,at 56 weeks
country,NCT01272232::country::United States,NCT01272232,United States,,,,,,,,,,,,,,
country,NCT01272232::country::United Kingdom,NCT01272232,United Kingdom,,,,,,,,,,,,,,
country,NCT01272232::country::Germany,NCT01272232,Germany,,,,,,,,,,,,,,
country,NCT01272232::country::Italy,NCT01272232,Italy,,,,,,,,,,,,,,
country,NCT01272232::country::South Africa,NCT01272232,South Africa,,,,,,,,,,,,,,
country,NCT01272232::country::Sweden,NCT01272232,Sweden,,,,,,,,,,,,,,
country,NCT01272232::country::France,NCT01272232,France,,,,,,,,,,,,,,
country,NCT01272232::country::Spain,NCT01272232,Spain,,,,,,,,,,,,,,
country,NCT01272232::country::Israel,NCT01272232,Israel,,,,,,,,,,,,,,
country,NCT01272232::country::Turkey (Türkiye),NCT01272232,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01272232::country::India,NCT01272232,India,,,,,,,,,,,,,,
country,NCT01272232::country::Taiwan,NCT01272232,Taiwan,,,,,,,,,,,,,,
country,NCT01272232::country::Puerto Rico,NCT01272232,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01026194,NCT01026194,Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,204.0,2009-12,2011-06,1.0,1.0,,,,,
arm,NCT01026194::arm::FG000,NCT01026194,Placebo/Teneli + Pio,,,,,,,,,,FG000,Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.,,,
arm,NCT01026194::arm::FG001,NCT01026194,Teneli/Teneli + Pio,,,,,,,,,,FG001,Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.,,,
period,NCT01026194::period::1,NCT01026194,Period 1：Double Blind Period,,,,,,,,,,,,1.0,,
period,NCT01026194::period::2,NCT01026194,Period 2：Open-label Period,,,,,,,,,,,,2.0,,
outcome,NCT01026194::outcome::primary::1,NCT01026194,Change From Baseline in HbA1c at Week 12,,,,,,,,,,,,,PRIMARY,at Week 0 and Week 12
country,NCT01026194::country::Japan,NCT01026194,Japan,,,,,,,,,,,,,,
trial,NCT05413369,NCT05413369,iGlarLixi vs IDegAsp in Chinese Participants After OAD(s),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,582.0,2022-07-07,2023-10-20,1.0,60.0,,,,,
arm,NCT05413369::arm::FG000,NCT05413369,iGlarLixi,,,,,,,,,,FG000,Participants self-administered iGlarLixi (100 units per milliliter \[U/mL\] insulin glargine + 100 or 50 microgram \[mcg\]/mL lixisenatide respectively) subcutaneous (SC) injection once daily on top o,,,
arm,NCT05413369::arm::FG001,NCT05413369,IDegAsp,,,,,,,,,,FG001,Participants self-administered IDegAsp (100 U/mL of insulin degludec + insulin aspart with a ratio of 70:30) SC injection once daily on top of metformin +/- SGLT-2i for 24 weeks. Dose was individually,,,
period,NCT05413369::period::1,NCT05413369,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT05413369::outcome::primary::1,NCT05413369,Change in HbA1c From Baseline to Week 24: Non-Inferiority Analysis,,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
country,NCT05413369::country::China,NCT05413369,China,,,,,,,,,,,,,,
trial,NCT01106690,NCT01106690,The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone),PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,344.0,2010-06,2012-07,11.0,83.0,,,,,
arm,NCT01106690::arm::FG000,NCT01106690,Placebo/Sitagliptin,,,,,,,,,,FG000,"Each patient received matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients were switched from placebo to 100 mg of sitagliptin once daily with",,,
arm,NCT01106690::arm::FG001,NCT01106690,Canagliflozin 100 mg,,,,,,,,,,FG001,Each patient received 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.,,,
arm,NCT01106690::arm::FG002,NCT01106690,Canagliflozin 300 mg,,,,,,,,,,FG002,Each patient received 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.,,,
period,NCT01106690::period::1,NCT01106690,Core Period: Baseline to Week 26,,,,,,,,,,,,1.0,,
period,NCT01106690::period::2,NCT01106690,Extension Period: Week 26 to Week 52,,,,,,,,,,,,2.0,,
outcome,NCT01106690::outcome::primary::1,NCT01106690,Change in HbA1c From Baseline to Week 26,,,,,,,,,,,,,PRIMARY,Day 1 (Baseline) and Week 26
country,NCT01106690::country::United States,NCT01106690,United States,,,,,,,,,,,,,,
country,NCT01106690::country::Canada,NCT01106690,Canada,,,,,,,,,,,,,,
country,NCT01106690::country::India,NCT01106690,India,,,,,,,,,,,,,,
country,NCT01106690::country::Germany,NCT01106690,Germany,,,,,,,,,,,,,,
country,NCT01106690::country::Mexico,NCT01106690,Mexico,,,,,,,,,,,,,,
country,NCT01106690::country::Finland,NCT01106690,Finland,,,,,,,,,,,,,,
country,NCT01106690::country::France,NCT01106690,France,,,,,,,,,,,,,,
country,NCT01106690::country::Greece,NCT01106690,Greece,,,,,,,,,,,,,,
country,NCT01106690::country::Spain,NCT01106690,Spain,,,,,,,,,,,,,,
country,NCT01106690::country::Thailand,NCT01106690,Thailand,,,,,,,,,,,,,,
country,NCT01106690::country::United Kingdom,NCT01106690,United Kingdom,,,,,,,,,,,,,,
trial,NCT01717313,NCT01717313,A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,329.0,2012-12-05,2015-06-19,0.0,0.0,,,,,
arm,NCT01717313::arm::FG000,NCT01717313,Omarigliptin,,,,,,,,,,FG000,Omarigliptin 25 mg capsule administered orally once a week for 24 weeks (Phase A) followed by omarigliptin 25 mg administered orally once a week plus placebo to metformin daily (Phase B). Open-label m,,,
arm,NCT01717313::arm::FG001,NCT01717313,Placebo to Omarigliptin,,,,,,,,,,FG001,Placebo to omarigliptin administered orally once a week for 24 weeks (Phase A) followed by placebo to omarigliptin administered orally once a week plus metformin daily for an additional 30 weeks (Phas,,,
period,NCT01717313::period::1,NCT01717313,Phase A (Weeks 0 to 24),,,,,,,,,,,,1.0,,
period,NCT01717313::period::2,NCT01717313,Interphase,,,,,,,,,,,,2.0,,
period,NCT01717313::period::3,NCT01717313,Phase B (Weeks 24 to 54),,,,,,,,,,,,3.0,,
outcome,NCT01717313::outcome::primary::1,NCT01717313,"Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Phase A, FAS Population)",,,,,,,,,,,,,PRIMARY,Baseline and Week 24
outcome,NCT01717313::outcome::primary::2,NCT01717313,"Percentage of Participants Who Experienced at Least One Adverse Event in Phase A (Excluding Data After Glycemic Rescue, Safety Population)",,,,,,,,,,,,,PRIMARY,Up to 27 weeks
outcome,NCT01717313::outcome::primary::3,NCT01717313,"Percentage of Participants Who Discontinued From the Study Drug Due to an Adverse Event in Phase A (Excluding Data After Glycemic Rescue, Safety Population)",,,,,,,,,,,,,PRIMARY,Up to 24 weeks
outcome,NCT01717313::outcome::primary::4,NCT01717313,"Percentage of Participants Who Experienced at Least One Adverse Event (Phase A + Phase B, Excluding Data After Glycemic Rescue, Safety Population)",,,,,,,,,,,,,PRIMARY,Up to 57 weeks
outcome,NCT01717313::outcome::primary::5,NCT01717313,"Percentage of Participants Who Discontinued From the Study Drug Due to an Adverse Event (Phase A + Phase B, Excluding Data After Glycemic Rescue, Safety Population)",,,,,,,,,,,,,PRIMARY,Up to 57 weeks
trial,NCT00603291,NCT00603291,BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus,PHASE3,diabetes type 2,Obesity,INDUSTRY,604.0,2007-12,2010-10,1.0,1.0,,,,,
arm,NCT00603291::arm::FG000,NCT00603291,Lorcaserin 10 mg Once Daily (QD),,,,,,,,,,FG000,lorcaserin 10 mg QD tablets,,,
arm,NCT00603291::arm::FG001,NCT00603291,Lorcaserin 10 mg Twice a Day (BID),,,,,,,,,,FG001,lorcaserin 10 mg BID tablets,,,
arm,NCT00603291::arm::FG002,NCT00603291,Matching Placebo,,,,,,,,,,FG002,matching placebo tablets,,,
period,NCT00603291::period::1,NCT00603291,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00603291::outcome::primary::1,NCT00603291,Co-primary Endpoint- Percentage of Participants Achieving Greater Than or Equal to 5% Weight Loss From Baseline to Week 52,,,,,,,,,,,,,PRIMARY,Baseline and Week 52
country,NCT00603291::country::United States,NCT00603291,United States,,,,,,,,,,,,,,
trial,NCT00308139,NCT00308139,Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,303.0,2006-04,2014-08,2.0,25.0,,,,,
arm,NCT00308139::arm::FG000,NCT00308139,Exenatide Once Weekly -> Exenatide Once Weekly,,,,,,,,,,FG000,"Subcutaneous injection of 2 mg exenatide, once a week.",,,
arm,NCT00308139::arm::FG001,NCT00308139,Exenatide Twice Daily -> Exenatide Once Weekly,,,,,,,,,,FG001,"Subcutaneous injection of exenatide, twice a day (5 mcg exenatide per dose for first 4 weeks, then 10 mcg exenatide per dose for 26 weeks) followed by 2 mg exenatide, once a week.",,,
period,NCT00308139::period::1,NCT00308139,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00308139::outcome::primary::1,NCT00308139,Change in HbA1c From Baseline to Week 30,,,,,,,,,,,,,PRIMARY,"Day -3, Week 30"
outcome,NCT00308139::outcome::primary::2,NCT00308139,Sub-study Relative Bioavailability of Exenatide When Administered Using the Exenatide Once Weekly Dual Chambered Pen and the Exenatide Once Weekly Single Dose Tray (Single Dose Tray-11 Weekly Doses Switch to Dual Chamber Pen-11 Weekly Dose),,,,,,,,,,,,,PRIMARY,Week 22
country,NCT00308139::country::United States,NCT00308139,United States,,,,,,,,,,,,,,
country,NCT00308139::country::Canada,NCT00308139,Canada,,,,,,,,,,,,,,
trial,NCT01296412,NCT01296412,Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403),PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,653.0,2011-03-11,2012-02-29,0.0,0.0,,,,,
arm,NCT01296412::arm::FG000,NCT01296412,Sitagliptin +/- Glimepiride,,,,,,,,,,FG000,Sitagliptin 100 mg tablet once daily for 26 weeks. Participants continued their stable dose of metformin \>=1500 mg orally daily. Participants may have received glimepiride for glycemic control.,,,
arm,NCT01296412::arm::FG001,NCT01296412,Liraglutide,,,,,,,,,,FG001,Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin \>=1500 mg orally da,,,
period,NCT01296412::period::1,NCT01296412,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01296412::outcome::primary::1,NCT01296412,Change From Baseline in Hemoglobin A1c (A1C),,,,,,,,,,,,,PRIMARY,Baseline and Week 26
trial,NCT01042977,NCT01042977,Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus; Cardiovascular Disease; Inadequate Glycaemic Control,INDUSTRY,964.0,2010-03,2012-12,10.0,135.0,,,,,
arm,NCT01042977::arm::FG000,NCT01042977,Dapagliflozin,,,,,,,,,,FG000,Dapagliflozin 10 mg plus usual care,,,
arm,NCT01042977::arm::FG001,NCT01042977,Placebo,,,,,,,,,,FG001,Placebo plus usual care,,,
period,NCT01042977::period::1,NCT01042977,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01042977::outcome::primary::1,NCT01042977,Adjusted Mean Change in HbA1c Levels,,,,,,,,,,,,,PRIMARY,Baseline to Week 24
outcome,NCT01042977::outcome::primary::2,NCT01042977,Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit,,,,,,,,,,,,,PRIMARY,Baseline to Week 24
country,NCT01042977::country::United States,NCT01042977,United States,,,,,,,,,,,,,,
country,NCT01042977::country::Poland,NCT01042977,Poland,,,,,,,,,,,,,,
country,NCT01042977::country::Australia,NCT01042977,Australia,,,,,,,,,,,,,,
country,NCT01042977::country::Canada,NCT01042977,Canada,,,,,,,,,,,,,,
country,NCT01042977::country::Hungary,NCT01042977,Hungary,,,,,,,,,,,,,,
country,NCT01042977::country::Bulgaria,NCT01042977,Bulgaria,,,,,,,,,,,,,,
country,NCT01042977::country::Argentina,NCT01042977,Argentina,,,,,,,,,,,,,,
country,NCT01042977::country::Germany,NCT01042977,Germany,,,,,,,,,,,,,,
country,NCT01042977::country::Austria,NCT01042977,Austria,,,,,,,,,,,,,,
country,NCT01042977::country::Chile,NCT01042977,Chile,,,,,,,,,,,,,,
trial,NCT02320721,NCT02320721,Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,1014.0,2015-01,2016-05,18.0,162.0,,,,,
arm,NCT02320721::arm::FG000,NCT02320721,HOE901-U300,,,,,,,,,,FG000,"HOE901-U300 (Insulin glargine, 300 U/mL) subcutaneous (SC) injection once daily up to Week 26 on top of stable non-insulin antihyperglycemic therapy.",,,
arm,NCT02320721::arm::FG001,NCT02320721,Lantus,,,,,,,,,,FG001,"Lantus (Insulin glargine, 100 U/mL) SC injection once daily up to Week 26 on top of stable non-insulin antihyperglycemic therapy.",,,
period,NCT02320721::period::1,NCT02320721,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02320721::outcome::primary::1,NCT02320721,Change in HbA1c From Baseline to Week 26,,,,,,,,,,,,,PRIMARY,"Baseline, Week 26"
country,NCT02320721::country::United States,NCT02320721,United States,,,,,,,,,,,,,,
country,NCT02320721::country::Canada,NCT02320721,Canada,,,,,,,,,,,,,,
country,NCT02320721::country::Hungary,NCT02320721,Hungary,,,,,,,,,,,,,,
country,NCT02320721::country::Spain,NCT02320721,Spain,,,,,,,,,,,,,,
country,NCT02320721::country::Japan,NCT02320721,Japan,,,,,,,,,,,,,,
country,NCT02320721::country::Peru,NCT02320721,Peru,,,,,,,,,,,,,,
country,NCT02320721::country::Romania,NCT02320721,Romania,,,,,,,,,,,,,,
country,NCT02320721::country::United Kingdom,NCT02320721,United Kingdom,,,,,,,,,,,,,,
country,NCT02320721::country::Argentina,NCT02320721,Argentina,,,,,,,,,,,,,,
country,NCT02320721::country::Colombia,NCT02320721,Colombia,,,,,,,,,,,,,,
country,NCT02320721::country::Germany,NCT02320721,Germany,,,,,,,,,,,,,,
country,NCT02320721::country::Italy,NCT02320721,Italy,,,,,,,,,,,,,,
country,NCT02320721::country::Poland,NCT02320721,Poland,,,,,,,,,,,,,,
country,NCT02320721::country::South Korea,NCT02320721,South Korea,,,,,,,,,,,,,,
country,NCT02320721::country::Australia,NCT02320721,Australia,,,,,,,,,,,,,,
country,NCT02320721::country::Mexico,NCT02320721,Mexico,,,,,,,,,,,,,,
country,NCT02320721::country::Sweden,NCT02320721,Sweden,,,,,,,,,,,,,,
country,NCT02320721::country::France,NCT02320721,France,,,,,,,,,,,,,,
trial,NCT01003184,NCT01003184,Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,222.0,2009-10,2011-12,2.0,34.0,,,,,
arm,NCT01003184::arm::FG000,NCT01003184,Exenatide Once Weekly,,,,,,,,,,FG000,"Exenatide once weekly : subcutaneous injection, 2mg, once a week",,,
arm,NCT01003184::arm::FG001,NCT01003184,Insulin Detemir,,,,,,,,,,FG001,"Insulin detemir : subcutaneous injection, with dosage titrated according to the detemir label and published titration schedule, once or twice a day",,,
period,NCT01003184::period::1,NCT01003184,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01003184::outcome::primary::1,NCT01003184,Percentage of Patients Achieving Glycosylated Hemoglobin (HbA1c) Concentration ≤7.0% With Weight Loss (≥1.0 kg) at Endpoint (Week 26),,,,,,,,,,,,,PRIMARY,"Baseline, Week 26"
country,NCT01003184::country::United Kingdom,NCT01003184,United Kingdom,,,,,,,,,,,,,,
country,NCT01003184::country::Ireland,NCT01003184,Ireland,,,,,,,,,,,,,,
trial,NCT00676338,NCT00676338,"Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)",PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,820.0,2008-11,2011-01,22.0,106.0,,,,,
arm,NCT00676338::arm::FG000,NCT00676338,Exenatide Once Weekly,,,,,,,,,,FG000,"Exenatide once weekly (subcutaneous injection of 2 mg exenatide, once a week) + daily oral placebo",,,
arm,NCT00676338::arm::FG001,NCT00676338,Metformin,,,,,,,,,,FG001,"Metformin (1000 mg/day for 2 weeks, then 1500 mg/day for 2 weeks, then 2000 mg/day for 22 weeks) + weekly subcutaneous placebo injection",,,
arm,NCT00676338::arm::FG002,NCT00676338,Pioglitazone,,,,,,,,,,FG002,"Pioglitazone (30 mg/day for 4 weeks, then 45 mg/day for 22 weeks) + weekly subcutaneous placebo injection",,,
arm,NCT00676338::arm::FG003,NCT00676338,Sitagliptin,,,,,,,,,,FG003,Sitagliptin (100 mg/day for 26 weeks) + weekly subcutaneous placebo injection,,,
period,NCT00676338::period::1,NCT00676338,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00676338::outcome::primary::1,NCT00676338,Change in HbA1c From Baseline to Week 26,,,,,,,,,,,,,PRIMARY,"Baseline, Week 26"
outcome,NCT00676338::outcome::primary::2,NCT00676338,Percentage of Patients Achieving HbA1c <=7% at Week 26,,,,,,,,,,,,,PRIMARY,"Baseline, Week 26"
country,NCT00676338::country::United States,NCT00676338,United States,,,,,,,,,,,,,,
country,NCT00676338::country::Canada,NCT00676338,Canada,,,,,,,,,,,,,,
country,NCT00676338::country::Brazil,NCT00676338,Brazil,,,,,,,,,,,,,,
country,NCT00676338::country::United Kingdom,NCT00676338,United Kingdom,,,,,,,,,,,,,,
country,NCT00676338::country::India,NCT00676338,India,,,,,,,,,,,,,,
country,NCT00676338::country::Russia,NCT00676338,Russia,,,,,,,,,,,,,,
country,NCT00676338::country::South Korea,NCT00676338,South Korea,,,,,,,,,,,,,,
country,NCT00676338::country::France,NCT00676338,France,,,,,,,,,,,,,,
country,NCT00676338::country::Germany,NCT00676338,Germany,,,,,,,,,,,,,,
country,NCT00676338::country::Hungary,NCT00676338,Hungary,,,,,,,,,,,,,,
country,NCT00676338::country::South Africa,NCT00676338,South Africa,,,,,,,,,,,,,,
country,NCT00676338::country::Spain,NCT00676338,Spain,,,,,,,,,,,,,,
country,NCT00676338::country::Belgium,NCT00676338,Belgium,,,,,,,,,,,,,,
country,NCT00676338::country::Italy,NCT00676338,Italy,,,,,,,,,,,,,,
country,NCT00676338::country::Mexico,NCT00676338,Mexico,,,,,,,,,,,,,,
country,NCT00676338::country::Poland,NCT00676338,Poland,,,,,,,,,,,,,,
country,NCT00676338::country::Romania,NCT00676338,Romania,,,,,,,,,,,,,,
country,NCT00676338::country::Turkey (Türkiye),NCT00676338,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00676338::country::Argentina,NCT00676338,Argentina,,,,,,,,,,,,,,
country,NCT00676338::country::Israel,NCT00676338,Israel,,,,,,,,,,,,,,
country,NCT00676338::country::Puerto Rico,NCT00676338,Puerto Rico,,,,,,,,,,,,,,
country,NCT00676338::country::Slovakia,NCT00676338,Slovakia,,,,,,,,,,,,,,
trial,NCT04660643,NCT04660643,A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss,PHASE3,diabetes type 2,Obesity; Overweight,INDUSTRY,783.0,2021-03-29,2023-05-18,5.0,70.0,,,,,
arm,NCT04660643::arm::FG000,NCT04660643,Tirzepatide (lead-in),,,,,,,,,,FG000,"Participants received weekly doses of tirzepatide subcutaneously (SC) for 36 weeks, starting at 2.5 milligrams (mg) and increasing by 2.5 mg every 4 weeks, as tolerated, up to the maximum tolerated do",,,
arm,NCT04660643::arm::FG001,NCT04660643,Placebo,,,,,,,,,,FG001,Participants received weekly doses of placebo SC for 52 weeks.,,,
arm,NCT04660643::arm::FG002,NCT04660643,Tirzepatide MTD,,,,,,,,,,FG002,Participants continued tirzepatide MTD (either 10 mg or 15 mg) for an additional 52 weeks.,,,
period,NCT04660643::period::1,NCT04660643,Open-label Lead-in Period (Week 0 - 36),,,,,,,,,,,,1.0,,
period,NCT04660643::period::2,NCT04660643,Double-blind Study Period (Week 36 - 92),,,,,,,,,,,,2.0,,
outcome,NCT04660643::outcome::primary::1,NCT04660643,Percent Change From Randomization in Body Weight at Week 88,,,,,,,,,,,,,PRIMARY,"Randomization (Week 36), Week 88"
country,NCT04660643::country::United States,NCT04660643,United States,,,,,,,,,,,,,,
country,NCT04660643::country::Brazil,NCT04660643,Brazil,,,,,,,,,,,,,,
country,NCT04660643::country::Argentina,NCT04660643,Argentina,,,,,,,,,,,,,,
country,NCT04660643::country::Taiwan,NCT04660643,Taiwan,,,,,,,,,,,,,,
country,NCT04660643::country::Puerto Rico,NCT04660643,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00141453,NCT00141453,ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial,PHASE3,diabetes type 2,Diabetic Nephropathy; Type 2 Diabetes Mellitus; Proteinuria,INDUSTRY,577.0,2003-04,2009-01,2.0,2.0,,,,,
arm,NCT00141453::arm::FG000,NCT00141453,Olmesartan Medoxomil,,,,,,,,,,FG000,Experimental: Olmesartan medoxomil tablets 10mg to 40 mg,,,
arm,NCT00141453::arm::FG001,NCT00141453,Placebo Comparator,,,,,,,,,,FG001,Matching placebo tablets,,,
period,NCT00141453::period::1,NCT00141453,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00141453::outcome::primary::1,NCT00141453,Renal Composite Outcomes,,,,,,,,,,,,,PRIMARY,Randomization to 5 years
country,NCT00141453::country::China,NCT00141453,China,,,,,,,,,,,,,,
country,NCT00141453::country::Japan,NCT00141453,Japan,,,,,,,,,,,,,,
trial,NCT00688701,NCT00688701,GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,361.0,2008-05,2009-12,12.0,12.0,,,,,
arm,NCT00688701::arm::FG000,NCT00688701,Placebo (Two-Step Titration),,,,,,,,,,FG000,"2-step initiation regimen of volume matching placebo: 10 microgram (mcg) once daily (QD) subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 12.",,,
arm,NCT00688701::arm::FG001,NCT00688701,Placebo (One-Step Titration),,,,,,,,,,FG001,"1-step initiation regimen of volume matching placebo: 10 mcg QD subcutaneously for 2 weeks, then 20 mcg QD up to Week 12.",,,
arm,NCT00688701::arm::FG002,NCT00688701,Lixisenatide (Two-Step Titration),,,,,,,,,,FG002,"2-step initiation regimen of lixisenatide: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 12.",,,
arm,NCT00688701::arm::FG003,NCT00688701,Lixisenatide (One-Step Titration),,,,,,,,,,FG003,"1-step initiation regimen of lixisenatide: 10 mcg QD subcutaneously for 2 weeks, then 20 mcg QD up to Week 12.",,,
period,NCT00688701::period::1,NCT00688701,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00688701::outcome::primary::1,NCT00688701,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12,,,,,,,,,,,,,PRIMARY,"Baseline, Week 12"
country,NCT00688701::country::United States,NCT00688701,United States,,,,,,,,,,,,,,
country,NCT00688701::country::Belgium,NCT00688701,Belgium,,,,,,,,,,,,,,
country,NCT00688701::country::India,NCT00688701,India,,,,,,,,,,,,,,
country,NCT00688701::country::Israel,NCT00688701,Israel,,,,,,,,,,,,,,
country,NCT00688701::country::Japan,NCT00688701,Japan,,,,,,,,,,,,,,
country,NCT00688701::country::Mexico,NCT00688701,Mexico,,,,,,,,,,,,,,
country,NCT00688701::country::Poland,NCT00688701,Poland,,,,,,,,,,,,,,
country,NCT00688701::country::Romania,NCT00688701,Romania,,,,,,,,,,,,,,
country,NCT00688701::country::Russia,NCT00688701,Russia,,,,,,,,,,,,,,
country,NCT00688701::country::South Korea,NCT00688701,South Korea,,,,,,,,,,,,,,
country,NCT00688701::country::Tunisia,NCT00688701,Tunisia,,,,,,,,,,,,,,
country,NCT00688701::country::Ukraine,NCT00688701,Ukraine,,,,,,,,,,,,,,
trial,NCT00086502,NCT00086502,Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,353.0,2004-06,2005-11,0.0,0.0,,,,,
arm,NCT00086502::arm::FG000,NCT00086502,Sitagliptin 100 mg,,,,,,,,,,FG000,The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing treatment with open-label p,,,
arm,NCT00086502::arm::FG001,NCT00086502,Placebo,,,,,,,,,,FG001,The Placebo group includes data from patients randomized to receive treatment with placebo matching sitagliptin 100 mg tablet once daily (blinded) in addition to ongoing treatment with open-label piog,,,
period,NCT00086502::period::1,NCT00086502,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00086502::outcome::primary::1,NCT00086502,Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and week 24
trial,NCT00286429,NCT00286429,Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.,PHASE3,diabetes type 2,Diabetes Mellitus,INDUSTRY,390.0,2006-02,2007-05,16.0,60.0,,,,,
arm,NCT00286429::arm::FG000,NCT00286429,Placebo,,,,,,,,,,FG000,"Alogliptin placebo-matching tablets, orally, once daily and insulin for up to 26 weeks.",,,
arm,NCT00286429::arm::FG001,NCT00286429,Alogliptin 12.5 mg QD,,,,,,,,,,FG001,"Alogliptin 12.5 mg, tablets, orally, once daily and insulin for up to 26 weeks.",,,
arm,NCT00286429::arm::FG002,NCT00286429,Alogliptin 25 mg QD,,,,,,,,,,FG002,"Alogliptin 25 mg, tablets, orally, once daily and insulin for up to 26 weeks.",,,
period,NCT00286429::period::1,NCT00286429,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00286429::outcome::primary::1,NCT00286429,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.,,,,,,,,,,,,,PRIMARY,Baseline and Week 26.
country,NCT00286429::country::United States,NCT00286429,United States,,,,,,,,,,,,,,
country,NCT00286429::country::Argentina,NCT00286429,Argentina,,,,,,,,,,,,,,
country,NCT00286429::country::Australia,NCT00286429,Australia,,,,,,,,,,,,,,
country,NCT00286429::country::Brazil,NCT00286429,Brazil,,,,,,,,,,,,,,
country,NCT00286429::country::Chile,NCT00286429,Chile,,,,,,,,,,,,,,
country,NCT00286429::country::Czechia,NCT00286429,Czechia,,,,,,,,,,,,,,
country,NCT00286429::country::Germany,NCT00286429,Germany,,,,,,,,,,,,,,
country,NCT00286429::country::Guatemala,NCT00286429,Guatemala,,,,,,,,,,,,,,
country,NCT00286429::country::Hungary,NCT00286429,Hungary,,,,,,,,,,,,,,
country,NCT00286429::country::India,NCT00286429,India,,,,,,,,,,,,,,
country,NCT00286429::country::Mexico,NCT00286429,Mexico,,,,,,,,,,,,,,
country,NCT00286429::country::Netherlands,NCT00286429,Netherlands,,,,,,,,,,,,,,
country,NCT00286429::country::New Zealand,NCT00286429,New Zealand,,,,,,,,,,,,,,
country,NCT00286429::country::Peru,NCT00286429,Peru,,,,,,,,,,,,,,
country,NCT00286429::country::Poland,NCT00286429,Poland,,,,,,,,,,,,,,
country,NCT00286429::country::South Africa,NCT00286429,South Africa,,,,,,,,,,,,,,
trial,NCT02863419,NCT02863419,Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,711.0,2016-08-10,2018-03-30,13.0,108.0,,,,,
arm,NCT02863419::arm::FG000,NCT02863419,Oral Semaglutide 14 mg,,,,,,,,,,FG000,Participants were to take once-daily oral semaglutide tablets for 52 weeks. Participants started oral semaglutide at 3 mg and were dose-escalated in 4-week increments until the final maintenance dose ,,,
arm,NCT02863419::arm::FG001,NCT02863419,Liraglutide 1.8 mg,,,,,,,,,,FG001,Participants were to take once-daily liraglutide subcutaneous injection (under the skin) for 52 weeks. Participants started liraglutide at 0.6 mg and were dose-escalated in one-week increments until t,,,
arm,NCT02863419::arm::FG002,NCT02863419,Placebo,,,,,,,,,,FG002,Participants were to take both oral semaglutide placebo tablets and liraglutide placebo once-daily as a subcutaneous injection (under the skin) from week 0 to week 52. Participants were to continue th,,,
period,NCT02863419::period::1,NCT02863419,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02863419::outcome::primary::1,NCT02863419,Change in HbA1c (Week 26),,,,,,,,,,,,,PRIMARY,"Week 0, week 26"
country,NCT02863419::country::United States,NCT02863419,United States,,,,,,,,,,,,,,
country,NCT02863419::country::Hungary,NCT02863419,Hungary,,,,,,,,,,,,,,
country,NCT02863419::country::Japan,NCT02863419,Japan,,,,,,,,,,,,,,
country,NCT02863419::country::Poland,NCT02863419,Poland,,,,,,,,,,,,,,
country,NCT02863419::country::Germany,NCT02863419,Germany,,,,,,,,,,,,,,
country,NCT02863419::country::Slovakia,NCT02863419,Slovakia,,,,,,,,,,,,,,
country,NCT02863419::country::Croatia,NCT02863419,Croatia,,,,,,,,,,,,,,
country,NCT02863419::country::South Africa,NCT02863419,South Africa,,,,,,,,,,,,,,
country,NCT02863419::country::United Arab Emirates,NCT02863419,United Arab Emirates,,,,,,,,,,,,,,
country,NCT02863419::country::Latvia,NCT02863419,Latvia,,,,,,,,,,,,,,
country,NCT02863419::country::Czechia,NCT02863419,Czechia,,,,,,,,,,,,,,
country,NCT02863419::country::Ukraine,NCT02863419,Ukraine,,,,,,,,,,,,,,
country,NCT02863419::country::Puerto Rico,NCT02863419,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01777282,NCT01777282,A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Diabetes Mellitus,INDUSTRY,374.0,2013-02-23,2015-01-27,1.0,49.0,,,,,
arm,NCT01777282::arm::FG000,NCT01777282,Albiglutide Plus (+) Background OAD (Sulfonylurea),,,,,,,,,,FG000,Participants received current regimen of 30 milligrams (mg) albiglutide + sulfonylurea (with titration to 50 mg at Week 4 or later based on specific guidelines on glycemic control) through Week 52.,,,
arm,NCT01777282::arm::FG001,NCT01777282,Albiglutide Plus (+) Background OAD (Biguanide),,,,,,,,,,FG001,Participants received current regimen of 30 mg albiglutide + biguanide (with titration to 50 mg at Week 4 or later based on specific guidelines on glycemic control) through Week 52.,,,
arm,NCT01777282::arm::FG002,NCT01777282,Albiglutide Plus (+) Background OAD (Glinide),,,,,,,,,,FG002,Participants received current regimen of 30 mg albiglutide + glinide as a subcutaneous injection weekly (with titration to 50 mg at Week 4 or later based on specific guidelines on glycemic control) th,,,
arm,NCT01777282::arm::FG003,NCT01777282,Albiglutide Plus (+) Background OAD (Thiazolidinedione),,,,,,,,,,FG003,Participants received current regimen of 30 mg albiglutide + thiazolidinedione as a subcutaneous injection weekly (with titration to 50 mg at Week 4 or later based on specific guidelines on glycemic c,,,
arm,NCT01777282::arm::FG004,NCT01777282,Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor),,,,,,,,,,FG004,Participants received current regimen of 30 mg albiglutide + α-glucosidase inhibitor as a subcutaneous injection weekly (with titration to 50 mg at Week 4 or later based on specific guidelines on glyc,,,
period,NCT01777282::period::1,NCT01777282,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01777282::outcome::primary::1,NCT01777282,Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE),,,,,,,,,,,,,PRIMARY,From Baseline through Week 52
outcome,NCT01777282::outcome::primary::2,NCT01777282,Number of Participants With Any Hypoglycemic Event,,,,,,,,,,,,,PRIMARY,From Baseline through Week 52
country,NCT01777282::country::Japan,NCT01777282,Japan,,,,,,,,,,,,,,
trial,NCT01210001,NCT01210001,Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,499.0,2010-09,,7.0,68.0,,,,,
arm,NCT01210001::arm::FG000,NCT01210001,Placebo,,,,,,,,,,FG000,"A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 24 weeks",,,
arm,NCT01210001::arm::FG001,NCT01210001,Empa 10mg,,,,,,,,,,FG001,Single oral dose of empagliflozin (empa) 10mg taken once daily for 24 weeks,,,
arm,NCT01210001::arm::FG002,NCT01210001,Empa 25mg,,,,,,,,,,FG002,Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks,,,
period,NCT01210001::period::1,NCT01210001,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01210001::outcome::primary::1,NCT01210001,HbA1c Change From Baseline,,,,,,,,,,,,,PRIMARY,Baseline and 24 weeks
outcome,NCT01210001::outcome::primary::2,NCT01210001,HbA1c Change From Baseline for Pio and Met Background Medication Patients,,,,,,,,,,,,,PRIMARY,Baseline and 24 weeks
country,NCT01210001::country::United States,NCT01210001,United States,,,,,,,,,,,,,,
country,NCT01210001::country::India,NCT01210001,India,,,,,,,,,,,,,,
country,NCT01210001::country::Canada,NCT01210001,Canada,,,,,,,,,,,,,,
country,NCT01210001::country::Ukraine,NCT01210001,Ukraine,,,,,,,,,,,,,,
country,NCT01210001::country::Philippines,NCT01210001,Philippines,,,,,,,,,,,,,,
country,NCT01210001::country::Greece,NCT01210001,Greece,,,,,,,,,,,,,,
country,NCT01210001::country::Thailand,NCT01210001,Thailand,,,,,,,,,,,,,,
trial,NCT02586155,NCT02586155,Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2; Coronary Artery Disease",INDUSTRY,2425.0,2015-11,2021-06-21,15.0,214.0,,,,,
arm,NCT02586155::arm::FG000,NCT02586155,High-Intensity Statin Therapy+RVX000222,,,,,,,,,,FG000,"Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)

Apabetalone: 100 mg capsule

Atorvastatin: High-Intensity Statin

Rosuvastatin: High-Intensity Stati",,,
arm,NCT02586155::arm::FG001,NCT02586155,High-Intensity Statin Therapy+Placebo,,,,,,,,,,FG001,"Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)

Placebo: Capsule manufactured to mimic RVX000222 100 mg capsule

Atorvastatin: High-Int",,,
period,NCT02586155::period::1,NCT02586155,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02586155::outcome::primary::1,NCT02586155,Incidence of First Occurrence of Adjudication-confirmed Narrowly Defined MACE,,,,,,,,,,,,,PRIMARY,120 weeks
country,NCT02586155::country::Argentina,NCT02586155,Argentina,,,,,,,,,,,,,,
country,NCT02586155::country::Mexico,NCT02586155,Mexico,,,,,,,,,,,,,,
country,NCT02586155::country::Poland,NCT02586155,Poland,,,,,,,,,,,,,,
country,NCT02586155::country::Israel,NCT02586155,Israel,,,,,,,,,,,,,,
country,NCT02586155::country::Russia,NCT02586155,Russia,,,,,,,,,,,,,,
country,NCT02586155::country::Hungary,NCT02586155,Hungary,,,,,,,,,,,,,,
country,NCT02586155::country::Serbia,NCT02586155,Serbia,,,,,,,,,,,,,,
country,NCT02586155::country::Bulgaria,NCT02586155,Bulgaria,,,,,,,,,,,,,,
country,NCT02586155::country::Taiwan,NCT02586155,Taiwan,,,,,,,,,,,,,,
country,NCT02586155::country::Slovakia,NCT02586155,Slovakia,,,,,,,,,,,,,,
country,NCT02586155::country::Germany,NCT02586155,Germany,,,,,,,,,,,,,,
country,NCT02586155::country::Croatia,NCT02586155,Croatia,,,,,,,,,,,,,,
country,NCT02586155::country::Belgium,NCT02586155,Belgium,,,,,,,,,,,,,,
country,NCT02586155::country::Netherlands,NCT02586155,Netherlands,,,,,,,,,,,,,,
country,NCT02586155::country::Australia,NCT02586155,Australia,,,,,,,,,,,,,,
trial,NCT01704261,NCT01704261,Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,307.0,2012-10-18,2014-12-23,0.0,0.0,,,,,
arm,NCT01704261::arm::FG000,NCT01704261,Omarigliptin,,,,,,,,,,FG000,Omarigliptin 25 mg capsule administered orally once a week for 24 weeks. Participants continue pre-study concomitant therapy of open-label glimepiride tablet(s) orally once daily (total daily dose \>=,,,
arm,NCT01704261::arm::FG001,NCT01704261,Placebo,,,,,,,,,,FG001,Matching placebo to omarigliptin capsule administered orally once a week for 24 weeks. Participants continue pre-study concomitant therapy of open-label glimepiride tablet(s) orally once daily (total ,,,
period,NCT01704261::period::1,NCT01704261,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01704261::outcome::primary::1,NCT01704261,Change From Baseline in Hemoglobin A1c (A1C) at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and Week 24
outcome,NCT01704261::outcome::primary::2,NCT01704261,Percentage of Participants Who Experienced at Least One Adverse Event (AE),,,,,,,,,,,,,PRIMARY,Up to Week 27
outcome,NCT01704261::outcome::primary::3,NCT01704261,Percentage of Participants Who Discontinued From the Study Due to an AE,,,,,,,,,,,,,PRIMARY,Up to Week 24
trial,NCT01768559,NCT01768559,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,894.0,2013-01,2014-12,18.0,199.0,,,,,
arm,NCT01768559::arm::FG000,NCT01768559,Lixisenatide,,,,,,,,,,FG000,"Lixisenatide 10 mcg once daily (QD) subcutaneously (SC) for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 26 on top of insulin glargine with or without metformin.",,,
arm,NCT01768559::arm::FG001,NCT01768559,Insulin Glulisine QD,,,,,,,,,,FG001,Insulin glulisine QD SC up to Week 26 on top of insulin glargine with or without metformin.,,,
arm,NCT01768559::arm::FG002,NCT01768559,Insulin Glulisine TID,,,,,,,,,,FG002,Insulin glulisine thrice daily (TID) SC up to Week 26 on top of insulin glargine with or without metformin.,,,
period,NCT01768559::period::1,NCT01768559,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01768559::outcome::primary::1,NCT01768559,Change in HbA1c From Baseline to Week 26,,,,,,,,,,,,,PRIMARY,"Baseline, Week 26"
outcome,NCT01768559::outcome::primary::2,NCT01768559,Change in Body Weight From Baseline to Week 26,,,,,,,,,,,,,PRIMARY,"Baseline, Week 26"
country,NCT01768559::country::United States,NCT01768559,United States,,,,,,,,,,,,,,
country,NCT01768559::country::Canada,NCT01768559,Canada,,,,,,,,,,,,,,
country,NCT01768559::country::Romania,NCT01768559,Romania,,,,,,,,,,,,,,
country,NCT01768559::country::Germany,NCT01768559,Germany,,,,,,,,,,,,,,
country,NCT01768559::country::United Kingdom,NCT01768559,United Kingdom,,,,,,,,,,,,,,
country,NCT01768559::country::Mexico,NCT01768559,Mexico,,,,,,,,,,,,,,
country,NCT01768559::country::Russia,NCT01768559,Russia,,,,,,,,,,,,,,
country,NCT01768559::country::France,NCT01768559,France,,,,,,,,,,,,,,
country,NCT01768559::country::Chile,NCT01768559,Chile,,,,,,,,,,,,,,
country,NCT01768559::country::Czechia,NCT01768559,Czechia,,,,,,,,,,,,,,
country,NCT01768559::country::Hungary,NCT01768559,Hungary,,,,,,,,,,,,,,
country,NCT01768559::country::Ukraine,NCT01768559,Ukraine,,,,,,,,,,,,,,
country,NCT01768559::country::Poland,NCT01768559,Poland,,,,,,,,,,,,,,
country,NCT01768559::country::Italy,NCT01768559,Italy,,,,,,,,,,,,,,
country,NCT01768559::country::Latvia,NCT01768559,Latvia,,,,,,,,,,,,,,
country,NCT01768559::country::Lithuania,NCT01768559,Lithuania,,,,,,,,,,,,,,
country,NCT01768559::country::Estonia,NCT01768559,Estonia,,,,,,,,,,,,,,
country,NCT01768559::country::Spain,NCT01768559,Spain,,,,,,,,,,,,,,
trial,NCT01779362,NCT01779362,RISE Adult Medication Study,PHASE3,diabetes type 2,Prediabetes; Type 2 Diabetes,NETWORK,267.0,2013-04,2019-08,1.0,4.0,,,,,
arm,NCT01779362::arm::FG000,NCT01779362,Metformin Alone,,,,,,,,,,FG000,"Metformin will be titrated to the maximum dose tolerated (up to 2000 mg/day). Participants randomized to the metformin-alone arm will be blinded to treatment.

Metformin: Titrated to 1000 mg BID",,,
arm,NCT01779362::arm::FG001,NCT01779362,Glargine Followed by Metformin,,,,,,,,,,FG001,"Basal insulin glargine for 3 months titrated to achieve a morning fasting blood glucose of 80-90 mg/dl, followed by open-label metformin (titrated up to 2000 mg/day) for 9 months.

Metformin: Titrated",,,
arm,NCT01779362::arm::FG002,NCT01779362,Placebo,,,,,,,,,,FG002,"Placebo - masked to metformin-alone. Placebo will be titrated to the maximum number of tablets equivalent to maximum dose of metformin.

Placebo: Matching to metformin 1000 mg BI",,,
arm,NCT01779362::arm::FG003,NCT01779362,Liraglutide + Metformin,,,,,,,,,,FG003,Liraglutide + open-label Metformin. Liraglutide will be titrated to the maximum dose tolerated (up to 1.8 mg/day) after which metformin will be titrated to the maximum dose tolerated (up to 2000 mg/da,,,
period,NCT01779362::period::1,NCT01779362,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01779362::outcome::primary::1,NCT01779362,ß-cell Response Measured by Hyperglycemic Clamp,,,,,,,,,,,,,PRIMARY,3-months after medication washout (Month 15)
outcome,NCT01779362::outcome::primary::2,NCT01779362,"Insulin Sensitivity, M/I",,,,,,,,,,,,,PRIMARY,3-months after a medication washout
country,NCT01779362::country::United States,NCT01779362,United States,,,,,,,,,,,,,,
trial,NCT00395746,NCT00395746,Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,264.0,2006-10,2008-05,1.0,1.0,,,,,
arm,NCT00395746::arm::FG000,NCT00395746,0.6 mg + SU,,,,,,,,,,FG000,"Liraglutide 0.6 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment",,,
arm,NCT00395746::arm::FG001,NCT00395746,0.9 mg + SU,,,,,,,,,,FG001,"Liraglutide 0.9 mg/day in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment",,,
arm,NCT00395746::arm::FG002,NCT00395746,SU Mono,,,,,,,,,,FG002,"Liraglutide placebo (0.6 mg/day or 0.9 mg/day) in addition to subject's own sulphonylurea (glibenclamide, gliclazide or glimepiride) treatment",,,
period,NCT00395746::period::1,NCT00395746,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00395746::outcome::primary::1,NCT00395746,Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment,,,,,,,,,,,,,PRIMARY,after 24 weeks of treatment
country,NCT00395746::country::Japan,NCT00395746,Japan,,,,,,,,,,,,,,
trial,NCT00344370,NCT00344370,Follow-On Study of Pitavastatin Versus Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia,PHASE3,diabetes type 2,Type II Diabetes Mellitus; Dyslipidemia,INDUSTRY,214.0,2006-08,2008-04,6.0,35.0,,,,,
arm,NCT00344370::arm::FG000,NCT00344370,Pitavastatin 4 mg,,,,,,,,,,FG000,Pitavastatin 4 mg once daily,,,
arm,NCT00344370::arm::FG001,NCT00344370,Atorvastatin 40 mg,,,,,,,,,,FG001,Atorvastatin 40 mg once daily,,,
period,NCT00344370::period::1,NCT00344370,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00344370::outcome::primary::1,NCT00344370,NCEP LDL-C Target Attainment,,,,,,,,,,,,,PRIMARY,44 weeks
country,NCT00344370::country::Poland,NCT00344370,Poland,,,,,,,,,,,,,,
country,NCT00344370::country::Netherlands,NCT00344370,Netherlands,,,,,,,,,,,,,,
country,NCT00344370::country::Germany,NCT00344370,Germany,,,,,,,,,,,,,,
country,NCT00344370::country::India,NCT00344370,India,,,,,,,,,,,,,,
country,NCT00344370::country::United Kingdom,NCT00344370,United Kingdom,,,,,,,,,,,,,,
country,NCT00344370::country::Denmark,NCT00344370,Denmark,,,,,,,,,,,,,,
trial,NCT01991795,NCT01991795,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,19271.0,2014-02-10,2019-01-25,43.0,1237.0,,,,,
arm,NCT01991795::arm::FG000,NCT01991795,Ticagrelor 60 mg,,,,,,,,,,FG000,"Initially ticagrelor 90 mg or corresponding placebo was the selected dose, but reduced to ticagrelor 60 mg or corresponding placebo in Clinical Study Protocol Amendment No 1.",,,
arm,NCT01991795::arm::FG001,NCT01991795,Ticagrelor Placebo,,,,,,,,,,FG001,"Initially ticagrelor 90 mg or corresponding placebo was the selected dose, but reduced to ticagrelor 60 mg or corresponding placebo in Clinical Study Protocol Amendment No 1.",,,
period,NCT01991795::period::1,NCT01991795,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01991795::outcome::primary::1,NCT01991795,"Composite of Cardiovascular (CV) Death, MI or Stroke",,,,,,,,,,,,,PRIMARY,From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.
country,NCT01991795::country::United States,NCT01991795,United States,,,,,,,,,,,,,,
country,NCT01991795::country::Poland,NCT01991795,Poland,,,,,,,,,,,,,,
country,NCT01991795::country::Russia,NCT01991795,Russia,,,,,,,,,,,,,,
country,NCT01991795::country::Canada,NCT01991795,Canada,,,,,,,,,,,,,,
country,NCT01991795::country::Japan,NCT01991795,Japan,,,,,,,,,,,,,,
country,NCT01991795::country::Brazil,NCT01991795,Brazil,,,,,,,,,,,,,,
country,NCT01991795::country::Ukraine,NCT01991795,Ukraine,,,,,,,,,,,,,,
country,NCT01991795::country::Spain,NCT01991795,Spain,,,,,,,,,,,,,,
country,NCT01991795::country::Bulgaria,NCT01991795,Bulgaria,,,,,,,,,,,,,,
country,NCT01991795::country::Czechia,NCT01991795,Czechia,,,,,,,,,,,,,,
country,NCT01991795::country::Germany,NCT01991795,Germany,,,,,,,,,,,,,,
country,NCT01991795::country::Hungary,NCT01991795,Hungary,,,,,,,,,,,,,,
country,NCT01991795::country::United Kingdom,NCT01991795,United Kingdom,,,,,,,,,,,,,,
country,NCT01991795::country::South Korea,NCT01991795,South Korea,,,,,,,,,,,,,,
country,NCT01991795::country::Netherlands,NCT01991795,Netherlands,,,,,,,,,,,,,,
country,NCT01991795::country::China,NCT01991795,China,,,,,,,,,,,,,,
country,NCT01991795::country::Argentina,NCT01991795,Argentina,,,,,,,,,,,,,,
country,NCT01991795::country::South Africa,NCT01991795,South Africa,,,,,,,,,,,,,,
country,NCT01991795::country::Taiwan,NCT01991795,Taiwan,,,,,,,,,,,,,,
country,NCT01991795::country::Mexico,NCT01991795,Mexico,,,,,,,,,,,,,,
country,NCT01991795::country::Belgium,NCT01991795,Belgium,,,,,,,,,,,,,,
country,NCT01991795::country::France,NCT01991795,France,,,,,,,,,,,,,,
country,NCT01991795::country::Italy,NCT01991795,Italy,,,,,,,,,,,,,,
country,NCT01991795::country::Chile,NCT01991795,Chile,,,,,,,,,,,,,,
country,NCT01991795::country::Norway,NCT01991795,Norway,,,,,,,,,,,,,,
country,NCT01991795::country::Slovakia,NCT01991795,Slovakia,,,,,,,,,,,,,,
country,NCT01991795::country::Australia,NCT01991795,Australia,,,,,,,,,,,,,,
country,NCT01991795::country::Peru,NCT01991795,Peru,,,,,,,,,,,,,,
country,NCT01991795::country::Sweden,NCT01991795,Sweden,,,,,,,,,,,,,,
country,NCT01991795::country::Colombia,NCT01991795,Colombia,,,,,,,,,,,,,,
country,NCT01991795::country::Denmark,NCT01991795,Denmark,,,,,,,,,,,,,,
country,NCT01991795::country::Turkey (Türkiye),NCT01991795,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01991795::country::Austria,NCT01991795,Austria,,,,,,,,,,,,,,
country,NCT01991795::country::India,NCT01991795,India,,,,,,,,,,,,,,
country,NCT01991795::country::Finland,NCT01991795,Finland,,,,,,,,,,,,,,
country,NCT01991795::country::Romania,NCT01991795,Romania,,,,,,,,,,,,,,
country,NCT01991795::country::Israel,NCT01991795,Israel,,,,,,,,,,,,,,
country,NCT01991795::country::Saudi Arabia,NCT01991795,Saudi Arabia,,,,,,,,,,,,,,
country,NCT01991795::country::Philippines,NCT01991795,Philippines,,,,,,,,,,,,,,
country,NCT01991795::country::Thailand,NCT01991795,Thailand,,,,,,,,,,,,,,
country,NCT01991795::country::Vietnam,NCT01991795,Vietnam,,,,,,,,,,,,,,
country,NCT01991795::country::Puerto Rico,NCT01991795,Puerto Rico,,,,,,,,,,,,,,
country,NCT01991795::country::Hong Kong,NCT01991795,Hong Kong,,,,,,,,,,,,,,
trial,NCT03066830,NCT03066830,Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,507.0,2017-02-24,2019-04-30,10.0,76.0,,,,,
arm,NCT03066830::arm::FG000,NCT03066830,Placebo,,,,,,,,,,FG000,"Following a 2-week run-in period, participants were randomized to matching placebo administered as 2 tablets, once daily, before the first meal of the day plus Metformin and Sulfonylurea as prescribed",,,
arm,NCT03066830::arm::FG001,NCT03066830,Sotagliflozin 400 mg,,,,,,,,,,FG001,"Following a 2-week run-in phase, participants received two Sotagliflozin tablets of 200 mg, orally once daily, before the first meal of the day plus Metformin and Sulfonylurea as prescribed for up to ",,,
period,NCT03066830::period::1,NCT03066830,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03066830::outcome::primary::1,NCT03066830,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26,,,,,,,,,,,,,PRIMARY,Baseline to Week 26
country,NCT03066830::country::United States,NCT03066830,United States,,,,,,,,,,,,,,
country,NCT03066830::country::Hungary,NCT03066830,Hungary,,,,,,,,,,,,,,
country,NCT03066830::country::South Korea,NCT03066830,South Korea,,,,,,,,,,,,,,
country,NCT03066830::country::United Kingdom,NCT03066830,United Kingdom,,,,,,,,,,,,,,
country,NCT03066830::country::Poland,NCT03066830,Poland,,,,,,,,,,,,,,
country,NCT03066830::country::Slovakia,NCT03066830,Slovakia,,,,,,,,,,,,,,
country,NCT03066830::country::Bulgaria,NCT03066830,Bulgaria,,,,,,,,,,,,,,
country,NCT03066830::country::Ukraine,NCT03066830,Ukraine,,,,,,,,,,,,,,
country,NCT03066830::country::Romania,NCT03066830,Romania,,,,,,,,,,,,,,
country,NCT03066830::country::Estonia,NCT03066830,Estonia,,,,,,,,,,,,,,
trial,NCT00698932,NCT00698932,Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,568.0,2008-06,2009-10,4.0,30.0,,,,,
arm,NCT00698932::arm::FG000,NCT00698932,Saxagliptin 5 mg,,,,,,,,,,FG000,"Saxagliptin 5 mg tablet, once daily (OD) for 24 weeks",,,
arm,NCT00698932::arm::FG001,NCT00698932,Placebo,,,,,,,,,,FG001,"Placebo tablet, once daily( OD) for 24 weeks",,,
period,NCT00698932::period::1,NCT00698932,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00698932::outcome::primary::1,NCT00698932,Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline , Week 24"
country,NCT00698932::country::China,NCT00698932,China,,,,,,,,,,,,,,
country,NCT00698932::country::India,NCT00698932,India,,,,,,,,,,,,,,
country,NCT00698932::country::Philippines,NCT00698932,Philippines,,,,,,,,,,,,,,
country,NCT00698932::country::South Korea,NCT00698932,South Korea,,,,,,,,,,,,,,
trial,NCT00736879,NCT00736879,Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,497.0,2008-09-22,2009-12-29,7.0,62.0,,,,,
arm,NCT00736879::arm::FG000,NCT00736879,Placebo,,,,,,,,,,FG000,"Placebo tablets matching either 1 mg, 2.5 mg, or 5 mg dapagliflozin tablets were taken orally once daily (with morning meal) for 24 weeks during the Double Blind Treatment Period.",,,
arm,NCT00736879::arm::FG001,NCT00736879,Dapagliflozin 1mg,,,,,,,,,,FG001,1 mg dapagliflozin tablets were taken orally once daily (with morning meal) for 24 weeks during the Double Blind Treatment Period.,,,
arm,NCT00736879::arm::FG002,NCT00736879,Dapagliflozin 2.5 mg,,,,,,,,,,FG002,2.5 mg dapagliflozin tablets were taken orally once daily (with morning meal) for 24 weeks during the Double Blind Treatment Period.,,,
arm,NCT00736879::arm::FG003,NCT00736879,Dapagliflozin 5 mg,,,,,,,,,,FG003,5 mg dapagliflozin tablets were taken orally once daily (with morning meal) for 24 weeks during the Double Blind Treatment Period.,,,
period,NCT00736879::period::1,NCT00736879,Double Blind Treatment Period,,,,,,,,,,,,1.0,,
period,NCT00736879::period::2,NCT00736879,Follow up Period - No Drug Treatment,,,,,,,,,,,,2.0,,
outcome,NCT00736879::outcome::primary::1,NCT00736879,Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 Last Observation Carried Forward (LOCF) - All Randomized Participants,,,,,,,,,,,,,PRIMARY,"Baseline (Day 1), Week 24"
country,NCT00736879::country::United States,NCT00736879,United States,,,,,,,,,,,,,,
country,NCT00736879::country::Canada,NCT00736879,Canada,,,,,,,,,,,,,,
country,NCT00736879::country::Russia,NCT00736879,Russia,,,,,,,,,,,,,,
country,NCT00736879::country::Mexico,NCT00736879,Mexico,,,,,,,,,,,,,,
country,NCT00736879::country::India,NCT00736879,India,,,,,,,,,,,,,,
country,NCT00736879::country::South Africa,NCT00736879,South Africa,,,,,,,,,,,,,,
country,NCT00736879::country::Puerto Rico,NCT00736879,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01849289,NCT01849289,A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,833.0,2013-06-02,2014-05-15,7.0,81.0,,,,,
arm,NCT01849289::arm::FG000,NCT01849289,IDeg OD,,,,,,,,,,FG000,"Insulin degludec (IDeg) 10U was injected subcutaneously (under the skin) once daily (OD) in the evening (start of main evening meal to bedtime) either in the thigh, upper arm (deltoid area) or abdomen",,,
arm,NCT01849289::arm::FG001,NCT01849289,IGlar OD,,,,,,,,,,FG001,"Insulin glargine (IGlar) 10U was injected subcutaneously (under the skin) once daily (OD) in the evening (start of main evening meal to bedtime) either in the thigh, upper arm (deltoid area) or abdome",,,
period,NCT01849289::period::1,NCT01849289,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01849289::outcome::primary::1,NCT01849289,Change From Baseline in HbA1c (%) (Analysed by Central Laboratory),,,,,,,,,,,,,PRIMARY,"Week 0, week 26"
country,NCT01849289::country::China,NCT01849289,China,,,,,,,,,,,,,,
country,NCT01849289::country::United States,NCT01849289,United States,,,,,,,,,,,,,,
country,NCT01849289::country::Canada,NCT01849289,Canada,,,,,,,,,,,,,,
country,NCT01849289::country::Romania,NCT01849289,Romania,,,,,,,,,,,,,,
country,NCT01849289::country::South Africa,NCT01849289,South Africa,,,,,,,,,,,,,,
country,NCT01849289::country::Ukraine,NCT01849289,Ukraine,,,,,,,,,,,,,,
country,NCT01849289::country::Brazil,NCT01849289,Brazil,,,,,,,,,,,,,,
trial,NCT04591626,NCT04591626,A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,291.0,2020-12-07,2022-04-28,1.0,27.0,,,,,
arm,NCT04591626::arm::FG000,NCT04591626,1.5 Milligrams (mg) Dulaglutide,,,,,,,,,,FG000,"Participants received 1.5 mg Dulaglutide administered once weekly (QW) subcutaneously (SC) as add-on to titrated treat-to-target (TTT) dose of Insulin Glargine given SC, along with metformin and/or ac",,,
arm,NCT04591626::arm::FG001,NCT04591626,Placebo,,,,,,,,,,FG001,"Participants received placebo administered QW SC as add-on to titrated TTT dose of insulin glargine given SC, along with metformin and/or acarbose.",,,
period,NCT04591626::period::1,NCT04591626,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04591626::outcome::primary::1,NCT04591626,Change From Baseline in Hemoglobin A1c (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline, Week 28"
country,NCT04591626::country::China,NCT04591626,China,,,,,,,,,,,,,,
trial,NCT00707031,NCT00707031,"GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin",PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,639.0,2008-06,2010-11,18.0,18.0,,,,,
arm,NCT00707031::arm::FG000,NCT00707031,Lixisenatide,,,,,,,,,,FG000,"2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.",,,
arm,NCT00707031::arm::FG001,NCT00707031,Exenatide,,,,,,,,,,FG001,"1-step initiation regimen of exenatide: 5 mcg twice daily (BID) subcutaneously for 4 weeks, followed by 10 mcg BID up to the end of treatment.",,,
period,NCT00707031::period::1,NCT00707031,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00707031::outcome::primary::1,NCT00707031,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
country,NCT00707031::country::United States,NCT00707031,United States,,,,,,,,,,,,,,
country,NCT00707031::country::Argentina,NCT00707031,Argentina,,,,,,,,,,,,,,
country,NCT00707031::country::Austria,NCT00707031,Austria,,,,,,,,,,,,,,
country,NCT00707031::country::Brazil,NCT00707031,Brazil,,,,,,,,,,,,,,
country,NCT00707031::country::Colombia,NCT00707031,Colombia,,,,,,,,,,,,,,
country,NCT00707031::country::Denmark,NCT00707031,Denmark,,,,,,,,,,,,,,
country,NCT00707031::country::Finland,NCT00707031,Finland,,,,,,,,,,,,,,
country,NCT00707031::country::Germany,NCT00707031,Germany,,,,,,,,,,,,,,
country,NCT00707031::country::Greece,NCT00707031,Greece,,,,,,,,,,,,,,
country,NCT00707031::country::Hungary,NCT00707031,Hungary,,,,,,,,,,,,,,
country,NCT00707031::country::Italy,NCT00707031,Italy,,,,,,,,,,,,,,
country,NCT00707031::country::Netherlands,NCT00707031,Netherlands,,,,,,,,,,,,,,
country,NCT00707031::country::Norway,NCT00707031,Norway,,,,,,,,,,,,,,
country,NCT00707031::country::Poland,NCT00707031,Poland,,,,,,,,,,,,,,
country,NCT00707031::country::Puerto Rico,NCT00707031,Puerto Rico,,,,,,,,,,,,,,
country,NCT00707031::country::Russia,NCT00707031,Russia,,,,,,,,,,,,,,
country,NCT00707031::country::Spain,NCT00707031,Spain,,,,,,,,,,,,,,
country,NCT00707031::country::Sweden,NCT00707031,Sweden,,,,,,,,,,,,,,
trial,NCT01809327,NCT01809327,"A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise",PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,1186.0,2013-06-04,2014-12-02,13.0,129.0,,,,,
arm,NCT01809327::arm::FG000,NCT01809327,Metformin XR,,,,,,,,,,FG000,"Participants received metformin extended release (XR) tablets (in doses titrated over 9 weeks) once daily with the evening meal, plus one placebo capsule before the morning meal and one placebo capsul",,,
arm,NCT01809327::arm::FG001,NCT01809327,Canagliflozin 100 Milligram (mg),,,,,,,,,,FG001,Participants received one 100 milligram (mg) canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match t,,,
arm,NCT01809327::arm::FG002,NCT01809327,Canagliflozin 300 mg,,,,,,,,,,FG002,Participants received one 300 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin,,,
arm,NCT01809327::arm::FG003,NCT01809327,Canagliflozin 100 mg + Metformin XR,,,,,,,,,,FG003,Participants received one 100 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once da,,,
arm,NCT01809327::arm::FG004,NCT01809327,Canagliflozin 300 mg + Metformin XR,,,,,,,,,,FG004,Participants received one 300 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once da,,,
period,NCT01809327::period::1,NCT01809327,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01809327::outcome::primary::1,NCT01809327,Change in Glycated Hemoglobin (HbA1c) From Baseline at Week 26,,,,,,,,,,,,,PRIMARY,Day 1 (Baseline) and Week 26
country,NCT01809327::country::United States,NCT01809327,United States,,,,,,,,,,,,,,
country,NCT01809327::country::Russia,NCT01809327,Russia,,,,,,,,,,,,,,
country,NCT01809327::country::Ukraine,NCT01809327,Ukraine,,,,,,,,,,,,,,
country,NCT01809327::country::Argentina,NCT01809327,Argentina,,,,,,,,,,,,,,
country,NCT01809327::country::Mexico,NCT01809327,Mexico,,,,,,,,,,,,,,
country,NCT01809327::country::Slovakia,NCT01809327,Slovakia,,,,,,,,,,,,,,
country,NCT01809327::country::South Africa,NCT01809327,South Africa,,,,,,,,,,,,,,
country,NCT01809327::country::Hungary,NCT01809327,Hungary,,,,,,,,,,,,,,
country,NCT01809327::country::Romania,NCT01809327,Romania,,,,,,,,,,,,,,
country,NCT01809327::country::Czechia,NCT01809327,Czechia,,,,,,,,,,,,,,
country,NCT01809327::country::Puerto Rico,NCT01809327,Puerto Rico,,,,,,,,,,,,,,
country,NCT01809327::country::South Korea,NCT01809327,South Korea,,,,,,,,,,,,,,
country,NCT01809327::country::Brazil,NCT01809327,Brazil,,,,,,,,,,,,,,
trial,NCT02033889,NCT02033889,A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,621.0,2013-12-13,2017-08-03,0.0,0.0,,,,,
arm,NCT02033889::arm::FG000,NCT02033889,Placebo/Glimepiride,,,,,,,,,,FG000,"Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue crite",,,
arm,NCT02033889::arm::FG001,NCT02033889,Ertugliflozin 5 mg,,,,,,,,,,FG001,"Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria ag",,,
arm,NCT02033889::arm::FG002,NCT02033889,Ertugliflozin 15 mg,,,,,,,,,,FG002,"Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria a",,,
period,NCT02033889::period::1,NCT02033889,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02033889::outcome::primary::1,NCT02033889,Change From Baseline in A1C at Week 26 (Excluding Rescue Approach),,,,,,,,,,,,,PRIMARY,Baseline and Week 26
outcome,NCT02033889::outcome::primary::2,NCT02033889,Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach),,,,,,,,,,,,,PRIMARY,Up to Week 106
outcome,NCT02033889::outcome::primary::3,NCT02033889,Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach),,,,,,,,,,,,,PRIMARY,Up to Week 104
trial,NCT01499082,NCT01499082,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,807.0,2011-12,2013-09,13.0,193.0,,,,,
arm,NCT01499082::arm::FG000,NCT01499082,HOE901-U300,,,,,,,,,,FG000,HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily (evening) for 12 months on top of mealtime insulin analogue.,,,
arm,NCT01499082::arm::FG001,NCT01499082,Lantus,,,,,,,,,,FG001,"Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of mealtime insulin analogue.",,,
period,NCT01499082::period::1,NCT01499082,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01499082::outcome::primary::1,NCT01499082,Change in HbA1c From Baseline to Month 6 Endpoint,,,,,,,,,,,,,PRIMARY,"Baseline, Month 6"
country,NCT01499082::country::United States,NCT01499082,United States,,,,,,,,,,,,,,
country,NCT01499082::country::Canada,NCT01499082,Canada,,,,,,,,,,,,,,
country,NCT01499082::country::Hungary,NCT01499082,Hungary,,,,,,,,,,,,,,
country,NCT01499082::country::Czechia,NCT01499082,Czechia,,,,,,,,,,,,,,
country,NCT01499082::country::Romania,NCT01499082,Romania,,,,,,,,,,,,,,
country,NCT01499082::country::Netherlands,NCT01499082,Netherlands,,,,,,,,,,,,,,
country,NCT01499082::country::South Africa,NCT01499082,South Africa,,,,,,,,,,,,,,
country,NCT01499082::country::Estonia,NCT01499082,Estonia,,,,,,,,,,,,,,
country,NCT01499082::country::Latvia,NCT01499082,Latvia,,,,,,,,,,,,,,
country,NCT01499082::country::Mexico,NCT01499082,Mexico,,,,,,,,,,,,,,
country,NCT01499082::country::Finland,NCT01499082,Finland,,,,,,,,,,,,,,
country,NCT01499082::country::Germany,NCT01499082,Germany,,,,,,,,,,,,,,
country,NCT01499082::country::France,NCT01499082,France,,,,,,,,,,,,,,
trial,NCT01095653,NCT01095653,A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,1179.0,2010-06,2012-03,4.0,39.0,,,,,
arm,NCT01095653::arm::FG000,NCT01095653,Placebo,,,,,,,,,,FG000,Participants received dapagliflozin matching placebo once daily for up to 24 weeks (may include the addition of open-label metformin as rescue),,,
arm,NCT01095653::arm::FG001,NCT01095653,Dapagliflozin 5 mg,,,,,,,,,,FG001,Participants received dapagliflozin 5 mg once daily for up to 24 weeks (may include the addition of open-label metformin as rescue),,,
arm,NCT01095653::arm::FG002,NCT01095653,Dapagliflozin 10 mg,,,,,,,,,,FG002,Participants received dapagliflozin 10 mg once daily for up to 24 weeks (may include the addition of open-label metformin as rescue),,,
period,NCT01095653::period::1,NCT01095653,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01095653::outcome::primary::1,NCT01095653,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]),,,,,,,,,,,,,PRIMARY,From Baseline to Week 24
country,NCT01095653::country::China,NCT01095653,China,,,,,,,,,,,,,,
country,NCT01095653::country::South Korea,NCT01095653,South Korea,,,,,,,,,,,,,,
country,NCT01095653::country::Taiwan,NCT01095653,Taiwan,,,,,,,,,,,,,,
country,NCT01095653::country::India,NCT01095653,India,,,,,,,,,,,,,,
trial,NCT01214239,NCT01214239,"Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control",PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,300.0,2010-10,,3.0,19.0,,,,,
arm,NCT01214239::arm::FG000,NCT01214239,Placebo,,,,,,,,,,FG000,Placebo,,,
arm,NCT01214239::arm::FG001,NCT01214239,Linagliptin 5mg,,,,,,,,,,FG001,"Linagliptin 5mg, once daily tablets, oral",,,
period,NCT01214239::period::1,NCT01214239,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01214239::outcome::primary::1,NCT01214239,HbA1c Change From Baseline at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and at week 24
country,NCT01214239::country::China,NCT01214239,China,,,,,,,,,,,,,,
country,NCT01214239::country::Malaysia,NCT01214239,Malaysia,,,,,,,,,,,,,,
country,NCT01214239::country::Philippines,NCT01214239,Philippines,,,,,,,,,,,,,,
trial,NCT00518882,NCT00518882,Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,467.0,2007-08,2009-04,16.0,125.0,,,,,
arm,NCT00518882::arm::FG000,NCT00518882,Liraglutide -> Liraglutide -> Liraglutide,,,,,,,,,,FG000,"Liraglutide 1.8 mg once daily + OAD (metformin monotherapy, sulphonylurea (SU) monotherapy or a combination), Weeks 0-26 (double-blinded) continued to receive liraglutide 1.8 mg once daily + OAD in ex",,,
arm,NCT00518882::arm::FG001,NCT00518882,Exenatide -> Liraglutide -> Liraglutide,,,,,,,,,,FG001,"Exenatide 10 mcg twice daily + OAD (metformin monotherapy, sulphonylurea (SU) monotherapy or a combination), Weeks 0-26 (double-blinded) switched to receive liraglutide 1.8 mg once daily + OAD in exte",,,
period,NCT00518882::period::1,NCT00518882,"Double-Blind, Week 0-26",,,,,,,,,,,,1.0,,
period,NCT00518882::period::2,NCT00518882,"Open-Label Extension, Week 26-78",,,,,,,,,,,,2.0,,
outcome,NCT00518882::outcome::primary::1,NCT00518882,Change in Glycosylated A1c (HbA1c) at Week 26,,,,,,,,,,,,,PRIMARY,"week 0, week 26"
country,NCT00518882::country::United States,NCT00518882,United States,,,,,,,,,,,,,,
country,NCT00518882::country::Germany,NCT00518882,Germany,,,,,,,,,,,,,,
country,NCT00518882::country::Poland,NCT00518882,Poland,,,,,,,,,,,,,,
country,NCT00518882::country::Denmark,NCT00518882,Denmark,,,,,,,,,,,,,,
country,NCT00518882::country::France,NCT00518882,France,,,,,,,,,,,,,,
country,NCT00518882::country::Norway,NCT00518882,Norway,,,,,,,,,,,,,,
country,NCT00518882::country::Spain,NCT00518882,Spain,,,,,,,,,,,,,,
country,NCT00518882::country::Switzerland,NCT00518882,Switzerland,,,,,,,,,,,,,,
country,NCT00518882::country::Austria,NCT00518882,Austria,,,,,,,,,,,,,,
country,NCT00518882::country::Finland,NCT00518882,Finland,,,,,,,,,,,,,,
country,NCT00518882::country::Ireland,NCT00518882,Ireland,,,,,,,,,,,,,,
country,NCT00518882::country::Romania,NCT00518882,Romania,,,,,,,,,,,,,,
country,NCT00518882::country::Slovenia,NCT00518882,Slovenia,,,,,,,,,,,,,,
country,NCT00518882::country::Sweden,NCT00518882,Sweden,,,,,,,,,,,,,,
country,NCT00518882::country::North Macedonia,NCT00518882,North Macedonia,,,,,,,,,,,,,,
country,NCT00518882::country::Puerto Rico,NCT00518882,Puerto Rico,,,,,,,,,,,,,,
trial,NCT02036515,NCT02036515,Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,464.0,2014-03-12,2016-06-06,0.0,0.0,,,,,
arm,NCT02036515::arm::FG000,NCT02036515,Ertugliflozin 5 mg,,,,,,,,,,FG000,"Ertugliflozin, 5 mg, oral, once daily for 52 weeks",,,
arm,NCT02036515::arm::FG001,NCT02036515,Ertugliflozin 15 mg,,,,,,,,,,FG001,"Ertugliflozin, 15 mg, oral, once daily for 52 weeks",,,
arm,NCT02036515::arm::FG002,NCT02036515,Placebo,,,,,,,,,,FG002,"Matching placebo to ertuglifozin, oral, once daily for 52 weeks",,,
period,NCT02036515::period::1,NCT02036515,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02036515::outcome::primary::1,NCT02036515,Change From Baseline in Hemoglobin A1C at Week 26,,,,,,,,,,,,,PRIMARY,Baseline and Week 26
outcome,NCT02036515::outcome::primary::2,NCT02036515,Percentage of Participants Experiencing An Adverse Event (AE),,,,,,,,,,,,,PRIMARY,Up to Week 54
outcome,NCT02036515::outcome::primary::3,NCT02036515,Percentage of Participants Discontinuing Study Treatment Due to an AE,,,,,,,,,,,,,PRIMARY,Up to Week 52
trial,NCT00316082,NCT00316082,Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,PHASE3,diabetes type 2,Diabetes,INDUSTRY,365.0,2006-06,2008-11,4.0,74.0,,,,,
arm,NCT00316082::arm::FG000,NCT00316082,Saxagliptin 2.5 mg Once in the Morning (QAM),,,,,,,,,,FG000,The Saxagliptin 2.5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily.,,,
arm,NCT00316082::arm::FG001,NCT00316082,Saxagliptin 5 mg QAM,,,,,,,,,,FG001,The Saxagliptin 5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QAM daily.,,,
arm,NCT00316082::arm::FG002,NCT00316082,Saxagliptin 2.5/5 mg QAM,,,,,,,,,,FG002,"The Saxagliptin 2.5/5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily, with possible titration to 5 mg oral tablets Q",,,
arm,NCT00316082::arm::FG003,NCT00316082,Saxagliptin 5 mg Once in the Evening (QPM),,,,,,,,,,FG003,The Saxagliptin 5 mg QPM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QPM daily.,,,
arm,NCT00316082::arm::FG004,NCT00316082,Placebo,,,,,,,,,,FG004,The Placebo group includes data from subjects randomized to receive administration of placebo oral tablets daily.,,,
period,NCT00316082::period::1,NCT00316082,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00316082::outcome::primary::1,NCT00316082,Change From Baseline in Hemoglobin A1 (A1C) at Week 24,,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
country,NCT00316082::country::United States,NCT00316082,United States,,,,,,,,,,,,,,
country,NCT00316082::country::Russia,NCT00316082,Russia,,,,,,,,,,,,,,
country,NCT00316082::country::India,NCT00316082,India,,,,,,,,,,,,,,
country,NCT00316082::country::Taiwan,NCT00316082,Taiwan,,,,,,,,,,,,,,
trial,NCT00395343,NCT00395343,Sitagliptin Added-on to Insulin Study (0431-051),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,641.0,2006-12-11,2008-10-13,0.0,0.0,,,,,
arm,NCT00395343::arm::FG000,NCT00395343,Sitagliptin 100 mg q.d.,,,,,,,,,,FG000,The Sitagliptin 100 mg q.d. (q.d. = once daily) group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing tr,,,
arm,NCT00395343::arm::FG001,NCT00395343,Placebo,,,,,,,,,,FG001,The Placebo group includes data from patients randomized to receive treatment with a placebo of the sitagliptin 100 mg oral tablet once daily (blinded) in addition to ongoing treatment with insulin (p,,,
period,NCT00395343::period::1,NCT00395343,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00395343::outcome::primary::1,NCT00395343,Change From Baseline in A1C at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and Week 24
trial,NCT03376789,NCT03376789,Mylan Insulin Glargine Study,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 1",INDUSTRY,219.0,2017-11-29,2019-01-10,1.0,38.0,,,,,
arm,NCT03376789::arm::FG000,NCT03376789,MYL-1501D (Process V Product),,,,,,,,,,FG000,"MYL-1501D (Process V Product)

MYL-1501D: Process V or Process VI",,,
arm,NCT03376789::arm::FG001,NCT03376789,MYL-1501D (Process VI Product),,,,,,,,,,FG001,"MYL-1501D (Process VI Product)

MYL-1501D: Process V or Process VI",,,
period,NCT03376789::period::1,NCT03376789,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03376789::outcome::primary::1,NCT03376789,Change in HbA1c,,,,,,,,,,,,,PRIMARY,Baseline to Week 18
country,NCT03376789::country::United States,NCT03376789,United States,,,,,,,,,,,,,,
trial,NCT01468987,NCT01468987,A Study in Participants With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,1369.0,2011-12,2013-08,25.0,156.0,,,,,
arm,NCT01468987::arm::FG000,NCT01468987,LY2605541 + Insulin Lispro,,,,,,,,,,FG000,"Includes participants that were randomized to receive LY2605541 plus Insulin Lispro.

Participant-specific dose of LY2605541 was administered subcutaneously (SC) once daily at bedtime for 26 weeks.

P",,,
arm,NCT01468987::arm::FG001,NCT01468987,Insulin Glargine + Insulin Lispro,,,,,,,,,,FG001,"Includes participants that were randomized to receive Insulin Glargine plus Insulin Lispro.

Participant-specific dose of Insulin Glargine was administered SC once daily at bedtime for 26 weeks.

Part",,,
period,NCT01468987::period::1,NCT01468987,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01468987::outcome::primary::1,NCT01468987,Change From Baseline in Hemoglobin A1c (HbA1c) at 26 Weeks,,,,,,,,,,,,,PRIMARY,"Baseline, 26 weeks"
country,NCT01468987::country::United States,NCT01468987,United States,,,,,,,,,,,,,,
country,NCT01468987::country::Germany,NCT01468987,Germany,,,,,,,,,,,,,,
country,NCT01468987::country::Australia,NCT01468987,Australia,,,,,,,,,,,,,,
country,NCT01468987::country::Croatia,NCT01468987,Croatia,,,,,,,,,,,,,,
country,NCT01468987::country::Israel,NCT01468987,Israel,,,,,,,,,,,,,,
country,NCT01468987::country::Czechia,NCT01468987,Czechia,,,,,,,,,,,,,,
country,NCT01468987::country::Hungary,NCT01468987,Hungary,,,,,,,,,,,,,,
country,NCT01468987::country::Italy,NCT01468987,Italy,,,,,,,,,,,,,,
country,NCT01468987::country::Netherlands,NCT01468987,Netherlands,,,,,,,,,,,,,,
country,NCT01468987::country::Poland,NCT01468987,Poland,,,,,,,,,,,,,,
country,NCT01468987::country::Puerto Rico,NCT01468987,Puerto Rico,,,,,,,,,,,,,,
country,NCT01468987::country::Romania,NCT01468987,Romania,,,,,,,,,,,,,,
country,NCT01468987::country::Spain,NCT01468987,Spain,,,,,,,,,,,,,,
country,NCT01468987::country::Turkey (Türkiye),NCT01468987,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01468987::country::Greece,NCT01468987,Greece,,,,,,,,,,,,,,
country,NCT01468987::country::Russia,NCT01468987,Russia,,,,,,,,,,,,,,
country,NCT01468987::country::Slovakia,NCT01468987,Slovakia,,,,,,,,,,,,,,
country,NCT01468987::country::Taiwan,NCT01468987,Taiwan,,,,,,,,,,,,,,
country,NCT01468987::country::United Kingdom,NCT01468987,United Kingdom,,,,,,,,,,,,,,
country,NCT01468987::country::Denmark,NCT01468987,Denmark,,,,,,,,,,,,,,
country,NCT01468987::country::Japan,NCT01468987,Japan,,,,,,,,,,,,,,
country,NCT01468987::country::Mexico,NCT01468987,Mexico,,,,,,,,,,,,,,
country,NCT01468987::country::Austria,NCT01468987,Austria,,,,,,,,,,,,,,
country,NCT01468987::country::Brazil,NCT01468987,Brazil,,,,,,,,,,,,,,
country,NCT01468987::country::Lithuania,NCT01468987,Lithuania,,,,,,,,,,,,,,
trial,NCT00622284,NCT00622284,Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,1560.0,2008-02,,16.0,221.0,,,,,
arm,NCT00622284::arm::FG000,NCT00622284,Linagliptin,,,,,,,,,,FG000,Patients randomized to receive Linagliptin 5mg and metformin,,,
arm,NCT00622284::arm::FG001,NCT00622284,Glimepiride,,,,,,,,,,FG001,Patients randomized to receive Glimepiride 1-4mg and metformin,,,
period,NCT00622284::period::1,NCT00622284,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00622284::outcome::primary::1,NCT00622284,HbA1c Change From Baseline at Week 52,,,,,,,,,,,,,PRIMARY,Baseline and week 52
outcome,NCT00622284::outcome::primary::2,NCT00622284,HbA1c Change From Baseline at Week 104,,,,,,,,,,,,,PRIMARY,Baseline and week 104
country,NCT00622284::country::France,NCT00622284,France,,,,,,,,,,,,,,
country,NCT00622284::country::Germany,NCT00622284,Germany,,,,,,,,,,,,,,
country,NCT00622284::country::United States,NCT00622284,United States,,,,,,,,,,,,,,
country,NCT00622284::country::United Kingdom,NCT00622284,United Kingdom,,,,,,,,,,,,,,
country,NCT00622284::country::Italy,NCT00622284,Italy,,,,,,,,,,,,,,
country,NCT00622284::country::Netherlands,NCT00622284,Netherlands,,,,,,,,,,,,,,
country,NCT00622284::country::Poland,NCT00622284,Poland,,,,,,,,,,,,,,
country,NCT00622284::country::Hungary,NCT00622284,Hungary,,,,,,,,,,,,,,
country,NCT00622284::country::India,NCT00622284,India,,,,,,,,,,,,,,
country,NCT00622284::country::Denmark,NCT00622284,Denmark,,,,,,,,,,,,,,
country,NCT00622284::country::Ireland,NCT00622284,Ireland,,,,,,,,,,,,,,
country,NCT00622284::country::South Africa,NCT00622284,South Africa,,,,,,,,,,,,,,
country,NCT00622284::country::Bulgaria,NCT00622284,Bulgaria,,,,,,,,,,,,,,
country,NCT00622284::country::Norway,NCT00622284,Norway,,,,,,,,,,,,,,
country,NCT00622284::country::Sweden,NCT00622284,Sweden,,,,,,,,,,,,,,
country,NCT00622284::country::Hong Kong,NCT00622284,Hong Kong,,,,,,,,,,,,,,
trial,NCT00309751,NCT00309751,Study Comparing Pitavastatin and Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia,PHASE3,diabetes type 2,Type II Diabetes Mellitus; Dyslipidemia,INDUSTRY,418.0,2005-12,2007-06,6.0,35.0,,,,,
arm,NCT00309751::arm::FG000,NCT00309751,Pitavastatin 4 mg QD,,,,,,,,,,FG000,Pitavastatin 4 mg once daily,,,
arm,NCT00309751::arm::FG001,NCT00309751,Atorvastatin 20 mg QD,,,,,,,,,,FG001,Atorvastatin 20 mg once daily,,,
period,NCT00309751::period::1,NCT00309751,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00309751::outcome::primary::1,NCT00309751,Percent Change From Baseline Low Density Lipoprotein Cholesterol (LDL-C),,,,,,,,,,,,,PRIMARY,12 weeks
country,NCT00309751::country::Poland,NCT00309751,Poland,,,,,,,,,,,,,,
country,NCT00309751::country::Netherlands,NCT00309751,Netherlands,,,,,,,,,,,,,,
country,NCT00309751::country::Germany,NCT00309751,Germany,,,,,,,,,,,,,,
country,NCT00309751::country::India,NCT00309751,India,,,,,,,,,,,,,,
country,NCT00309751::country::United Kingdom,NCT00309751,United Kingdom,,,,,,,,,,,,,,
country,NCT00309751::country::Denmark,NCT00309751,Denmark,,,,,,,,,,,,,,
trial,NCT02229396,NCT02229396,Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo,PHASE3,diabetes type 2,Diabetes Mellitus,INDUSTRY,695.0,2014-09-04,2017-12-28,6.0,133.0,,,,,
arm,NCT02229396::arm::FG000,NCT02229396,Dapagliflozin + Placebo,,,,,,,,,,FG000,Dapagliflozin 10 milligram (mg) tablet administered orally once daily + matching placebo for exenatide administered as subcutaneous (SC) injection once weekly. Patients continued to administer the sam,,,
arm,NCT02229396::arm::FG001,NCT02229396,Exenatide + Dapagliflozin,,,,,,,,,,FG001,Exenatide once weekly (EQW) 2 mg administered as SC injection + dapagliflozin 10 mg tablet administered orally once daily. Patients continued to administer the same type and dose of metformin therapy ,,,
arm,NCT02229396::arm::FG002,NCT02229396,Exenatide + Placebo,,,,,,,,,,FG002,Exenatide once weekly (EQW) 2 mg administered as SC injection + matching placebo for dapagliflozin tablet administered orally once daily. Patients continued to administer the same type and dose of met,,,
period,NCT02229396::period::1,NCT02229396,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02229396::outcome::primary::1,NCT02229396,Change in HbA1c From Baseline to Week 28,,,,,,,,,,,,,PRIMARY,Baseline to Week 28
country,NCT02229396::country::United States,NCT02229396,United States,,,,,,,,,,,,,,
country,NCT02229396::country::Hungary,NCT02229396,Hungary,,,,,,,,,,,,,,
country,NCT02229396::country::Slovakia,NCT02229396,Slovakia,,,,,,,,,,,,,,
country,NCT02229396::country::Romania,NCT02229396,Romania,,,,,,,,,,,,,,
country,NCT02229396::country::Poland,NCT02229396,Poland,,,,,,,,,,,,,,
country,NCT02229396::country::South Africa,NCT02229396,South Africa,,,,,,,,,,,,,,
trial,NCT02501161,NCT02501161,A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,1012.0,2016-01-31,2018-10-03,16.0,143.0,,,,,
arm,NCT02501161::arm::FG000,NCT02501161,Insulin Degludec/Liraglutide,,,,,,,,,,FG000,Participants received subcutaneous (s.c.) injection of Insulin degludec/liraglutide (IDegLira) once daily up to 104 weeks. Participants received 10 dose steps (10 units IDeg/0.36 milligrams \[mg\] lir,,,
arm,NCT02501161::arm::FG001,NCT02501161,Insulin Glargine,,,,,,,,,,FG001,Participants received s.c. injection of insulin glargine (IGlar) once daily up to 104 weeks. Participants received 10 units of IGlar initially. The dose was then escalated twice weekly until the FPG t,,,
period,NCT02501161::period::1,NCT02501161,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02501161::outcome::primary::1,NCT02501161,Time From Randomisation to Inadequate Glycaemic Control and Need for Treatment Intensification,,,,,,,,,,,,,PRIMARY,Weeks 0-104 + 7 days follow-up-1 + 30 days follow-up-2
country,NCT02501161::country::United States,NCT02501161,United States,,,,,,,,,,,,,,
country,NCT02501161::country::India,NCT02501161,India,,,,,,,,,,,,,,
country,NCT02501161::country::South Africa,NCT02501161,South Africa,,,,,,,,,,,,,,
country,NCT02501161::country::United Kingdom,NCT02501161,United Kingdom,,,,,,,,,,,,,,
country,NCT02501161::country::Israel,NCT02501161,Israel,,,,,,,,,,,,,,
country,NCT02501161::country::Norway,NCT02501161,Norway,,,,,,,,,,,,,,
country,NCT02501161::country::Russia,NCT02501161,Russia,,,,,,,,,,,,,,
country,NCT02501161::country::Turkey (Türkiye),NCT02501161,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02501161::country::Italy,NCT02501161,Italy,,,,,,,,,,,,,,
country,NCT02501161::country::Hungary,NCT02501161,Hungary,,,,,,,,,,,,,,
country,NCT02501161::country::Slovakia,NCT02501161,Slovakia,,,,,,,,,,,,,,
country,NCT02501161::country::Argentina,NCT02501161,Argentina,,,,,,,,,,,,,,
country,NCT02501161::country::Czechia,NCT02501161,Czechia,,,,,,,,,,,,,,
country,NCT02501161::country::Mexico,NCT02501161,Mexico,,,,,,,,,,,,,,
country,NCT02501161::country::Poland,NCT02501161,Poland,,,,,,,,,,,,,,
country,NCT02501161::country::Brazil,NCT02501161,Brazil,,,,,,,,,,,,,,
trial,NCT05662332,NCT05662332,A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1),PHASE3,diabetes type 2,Type 2 Diabetes; T2D,INDUSTRY,795.0,2023-01-14,2024-07-19,4.0,71.0,,,,,
arm,NCT05662332::arm::FG000,NCT05662332,Insulin Efsitora Alfa,,,,,,,,,,FG000,"Participants received Insulin Efsitora Alfa (insulin efsitora; 500 U/ml) administered subcutaneously (SC) once weekly (QW) for 52 weeks, with titration using fixed-doses 100 U, 150 U, 250 U, and 400 U",,,
arm,NCT05662332::arm::FG001,NCT05662332,Insulin Glargine,,,,,,,,,,FG001,Participants received insulin glargine (100 U/ml) administered SC once daily (QD) for 52 weeks with titration by standard sliding-scale dose adjustments.,,,
period,NCT05662332::period::1,NCT05662332,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT05662332::outcome::primary::1,NCT05662332,Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis],,,,,,,,,,,,,PRIMARY,"Baseline, Week 52"
country,NCT05662332::country::United States,NCT05662332,United States,,,,,,,,,,,,,,
country,NCT05662332::country::Argentina,NCT05662332,Argentina,,,,,,,,,,,,,,
country,NCT05662332::country::Mexico,NCT05662332,Mexico,,,,,,,,,,,,,,
country,NCT05662332::country::Puerto Rico,NCT05662332,Puerto Rico,,,,,,,,,,,,,,
trial,NCT02284893,NCT02284893,Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,461.0,2014-09-09,2016-09-20,6.0,79.0,,,,,
arm,NCT02284893::arm::FG000,NCT02284893,SAXA + DAPA + MET,,,,,,,,,,FG000,Saxagliptin 5-mg tablet+Dapagliflozin 10-mg tablet+Placebo capsules matching the sitagliptin 100-mg capsules+Metformin background therapy,,,
arm,NCT02284893::arm::FG001,NCT02284893,SITA + MET,,,,,,,,,,FG001,Placebo tablet matching the saxagliptin 5-mg tablet +Placebo tablet matching the dapagliflozin 10-mg table+Sitagliptin 100-mg capsules +Metformin background therapy,,,
period,NCT02284893::period::1,NCT02284893,26 Week (Short Term),,,,,,,,,,,,1.0,,
period,NCT02284893::period::2,NCT02284893,52 Week (Long Term),,,,,,,,,,,,2.0,,
outcome,NCT02284893::outcome::primary::1,NCT02284893,Mean Change in HbA1c,,,,,,,,,,,,,PRIMARY,Baseline (randomization) to Week 26
country,NCT02284893::country::United States,NCT02284893,United States,,,,,,,,,,,,,,
country,NCT02284893::country::Poland,NCT02284893,Poland,,,,,,,,,,,,,,
country,NCT02284893::country::Romania,NCT02284893,Romania,,,,,,,,,,,,,,
country,NCT02284893::country::Hungary,NCT02284893,Hungary,,,,,,,,,,,,,,
country,NCT02284893::country::Mexico,NCT02284893,Mexico,,,,,,,,,,,,,,
country,NCT02284893::country::South Africa,NCT02284893,South Africa,,,,,,,,,,,,,,
trial,NCT00575588,NCT00575588,"52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period",PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,891.0,2007-12,2010-08,11.0,94.0,,,,,
arm,NCT00575588::arm::FG000,NCT00575588,Saxagliptin + Metformin,,,,,,,,,,FG000,Saxagliptin 5 mg tablets added on to open-label metformin,,,
arm,NCT00575588::arm::FG001,NCT00575588,Glipizide + Metformin,,,,,,,,,,FG001,Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks) added on to open-label metformin,,,
period,NCT00575588::period::1,NCT00575588,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00575588::outcome::primary::1,NCT00575588,Hemoglobin A1c (HbA1c) Change From Baseline to Week 52,,,,,,,,,,,,,PRIMARY,Baseline to 52 Weeks
country,NCT00575588::country::Germany,NCT00575588,Germany,,,,,,,,,,,,,,
country,NCT00575588::country::United Kingdom,NCT00575588,United Kingdom,,,,,,,,,,,,,,
country,NCT00575588::country::Hungary,NCT00575588,Hungary,,,,,,,,,,,,,,
country,NCT00575588::country::Norway,NCT00575588,Norway,,,,,,,,,,,,,,
country,NCT00575588::country::Netherlands,NCT00575588,Netherlands,,,,,,,,,,,,,,
country,NCT00575588::country::Finland,NCT00575588,Finland,,,,,,,,,,,,,,
country,NCT00575588::country::Slovakia,NCT00575588,Slovakia,,,,,,,,,,,,,,
country,NCT00575588::country::South Korea,NCT00575588,South Korea,,,,,,,,,,,,,,
country,NCT00575588::country::Russia,NCT00575588,Russia,,,,,,,,,,,,,,
country,NCT00575588::country::India,NCT00575588,India,,,,,,,,,,,,,,
country,NCT00575588::country::Vietnam,NCT00575588,Vietnam,,,,,,,,,,,,,,
trial,NCT00318461,NCT00318461,To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,1091.0,2006-05,2008-11,20.0,190.0,,,,,
arm,NCT00318461::arm::FG000,NCT00318461,Lira 0.6 + Met,,,,,,,,,,FG000,"Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 0.6 mg/day + metformin 1.5-2.0 g/day in the extension period (week",,,
arm,NCT00318461::arm::FG001,NCT00318461,Lira 1.2 + Met,,,,,,,,,,FG001,"Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.2 mg/day + metformin 1.5-2.0 g/day in the extension period (week",,,
arm,NCT00318461::arm::FG002,NCT00318461,Lira 1.8 + Met,,,,,,,,,,FG002,"Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.8 mg/day + metformin 1.5-2.0 g/day in the extension period (week",,,
arm,NCT00318461::arm::FG003,NCT00318461,Met Mono,,,,,,,,,,FG003,"Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo, weeks 0-26 (double-blinded period) and open-label metformin 1.5-2.0 g/day in the extension period (weeks 26-104)",,,
arm,NCT00318461::arm::FG004,NCT00318461,Met + Glim,,,,,,,,,,FG004,"Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo, weeks 0-26 (double-blinded period) and open-label glimepiride 4 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26",,,
period,NCT00318461::period::1,NCT00318461,"Double-Blind, 6 Months",,,,,,,,,,,,1.0,,
period,NCT00318461::period::2,NCT00318461,"Open-Label Extension, 18 Months",,,,,,,,,,,,2.0,,
outcome,NCT00318461::outcome::primary::1,NCT00318461,Change in Glycosylated A1c (HbA1c) at Week 26,,,,,,,,,,,,,PRIMARY,"week 0, week 26"
outcome,NCT00318461::outcome::primary::2,NCT00318461,Change in Glycosylated A1c (HbA1c) at Week 104,,,,,,,,,,,,,PRIMARY,"week 0, week 104"
country,NCT00318461::country::Germany,NCT00318461,Germany,,,,,,,,,,,,,,
country,NCT00318461::country::Australia,NCT00318461,Australia,,,,,,,,,,,,,,
country,NCT00318461::country::Spain,NCT00318461,Spain,,,,,,,,,,,,,,
country,NCT00318461::country::Italy,NCT00318461,Italy,,,,,,,,,,,,,,
country,NCT00318461::country::United Kingdom,NCT00318461,United Kingdom,,,,,,,,,,,,,,
country,NCT00318461::country::Denmark,NCT00318461,Denmark,,,,,,,,,,,,,,
country,NCT00318461::country::Norway,NCT00318461,Norway,,,,,,,,,,,,,,
country,NCT00318461::country::Sweden,NCT00318461,Sweden,,,,,,,,,,,,,,
country,NCT00318461::country::Hungary,NCT00318461,Hungary,,,,,,,,,,,,,,
country,NCT00318461::country::Slovakia,NCT00318461,Slovakia,,,,,,,,,,,,,,
country,NCT00318461::country::South Africa,NCT00318461,South Africa,,,,,,,,,,,,,,
country,NCT00318461::country::Belgium,NCT00318461,Belgium,,,,,,,,,,,,,,
country,NCT00318461::country::Russia,NCT00318461,Russia,,,,,,,,,,,,,,
country,NCT00318461::country::India,NCT00318461,India,,,,,,,,,,,,,,
country,NCT00318461::country::Argentina,NCT00318461,Argentina,,,,,,,,,,,,,,
country,NCT00318461::country::Ireland,NCT00318461,Ireland,,,,,,,,,,,,,,
country,NCT00318461::country::Netherlands,NCT00318461,Netherlands,,,,,,,,,,,,,,
country,NCT00318461::country::Romania,NCT00318461,Romania,,,,,,,,,,,,,,
country,NCT00318461::country::Bulgaria,NCT00318461,Bulgaria,,,,,,,,,,,,,,
country,NCT00318461::country::Croatia,NCT00318461,Croatia,,,,,,,,,,,,,,
trial,NCT00790205,NCT00790205,Sitagliptin Cardiovascular Outcomes Study (MK-0431-082),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,14671.0,2008-12-10,2015-03-30,0.0,0.0,,,,,
arm,NCT00790205::arm::FG000,NCT00790205,Sitagliptin,,,,,,,,,,FG000,Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years,,,
arm,NCT00790205::arm::FG001,NCT00790205,Placebo,,,,,,,,,,FG001,Matching placebo tablet taken orally once daily in the morning for up to approximately 5 years,,,
period,NCT00790205::period::1,NCT00790205,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00790205::outcome::primary::1,NCT00790205,Percentage of Participants With First Confirmed Cardiovascular (CV) Event of Major Adverse Cardiovascular Event (MACE) Plus (Per Protocol Population),,,,,,,,,,,,,PRIMARY,Up to 5 years
outcome,NCT00790205::outcome::primary::2,NCT00790205,Percentage of Participants With First Confirmed CV Event of Major Adverse Cardiovascular Event (MACE) Plus (Intent to Treat Population),,,,,,,,,,,,,PRIMARY,Up to 5 years
trial,NCT00707993,NCT00707993,Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics,PHASE3,diabetes type 2,Diabetes Mellitus,INDUSTRY,441.0,2008-06,2010-08,11.0,80.0,,,,,
arm,NCT00707993::arm::FG000,NCT00707993,Alogliptin 25 mg QD,,,,,,,,,,FG000,"Alogliptin 25 mg, tablets, orally, once daily and glipizide placebo matching tablets, orally, once daily for up to 52 weeks.",,,
arm,NCT00707993::arm::FG001,NCT00707993,Glipizide 5 mg QD,,,,,,,,,,FG001,"Alogliptin placebo-matching tablets, orally, once daily and glipizide 5 mg to 10 mg, tablets, orally, once daily up to 52 weeks.",,,
period,NCT00707993::period::1,NCT00707993,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00707993::outcome::primary::1,NCT00707993,Change From Baseline in Glycosylated Hemoglobin at Week 52.,,,,,,,,,,,,,PRIMARY,Baseline and Week 52.
country,NCT00707993::country::United States,NCT00707993,United States,,,,,,,,,,,,,,
country,NCT00707993::country::Mexico,NCT00707993,Mexico,,,,,,,,,,,,,,
country,NCT00707993::country::Israel,NCT00707993,Israel,,,,,,,,,,,,,,
country,NCT00707993::country::South Africa,NCT00707993,South Africa,,,,,,,,,,,,,,
country,NCT00707993::country::Romania,NCT00707993,Romania,,,,,,,,,,,,,,
country,NCT00707993::country::India,NCT00707993,India,,,,,,,,,,,,,,
country,NCT00707993::country::Hungary,NCT00707993,Hungary,,,,,,,,,,,,,,
country,NCT00707993::country::Peru,NCT00707993,Peru,,,,,,,,,,,,,,
country,NCT00707993::country::Poland,NCT00707993,Poland,,,,,,,,,,,,,,
country,NCT00707993::country::Russia,NCT00707993,Russia,,,,,,,,,,,,,,
country,NCT00707993::country::Ukraine,NCT00707993,Ukraine,,,,,,,,,,,,,,
trial,NCT00935532,NCT00935532,Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,427.0,2009-07,2011-07,1.0,22.0,,,,,
arm,NCT00935532::arm::FG000,NCT00935532,Exenatide Once Weekly,,,,,,,,,,FG000,"Subcutaneous injection, 2.0mg, once a week.",,,
arm,NCT00935532::arm::FG001,NCT00935532,Insulin Glargine,,,,,,,,,,FG001,"Subcutaneous injection, titrated to achieve fasting serum glucose target, once a day",,,
period,NCT00935532::period::1,NCT00935532,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00935532::outcome::primary::1,NCT00935532,Change in HbA1c From Baseline to Endpoint (Week 26),,,,,,,,,,,,,PRIMARY,"Baseline, Week 26"
country,NCT00935532::country::Japan,NCT00935532,Japan,,,,,,,,,,,,,,
trial,NCT01880736,NCT01880736,A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,458.0,2013-06,2014-04,1.0,40.0,,,,,
arm,NCT01880736::arm::FG000,NCT01880736,IDeg OD Fixed Dosing and Simple Titration (Arm A),,,,,,,,,,FG000,"The subjects received IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) OD subcutaneously, under the skin of the thigh, upper arm or abdomen for 26 weeks at the same time each day according to the fixed dos",,,
arm,NCT01880736::arm::FG001,NCT01880736,IDeg OD Fixed Dosing and Stepwise Titration (Arm B),,,,,,,,,,FG001,"The subjects received IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) OD subcutaneously, under the skin of the thigh, upper arm or abdomen for 26 weeks at the same time each day according to the fixed dos",,,
arm,NCT01880736::arm::FG002,NCT01880736,IDeg OD Flexible Dosing and Simple Titration (Arm C),,,,,,,,,,FG002,"The subjects received IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) once daily (OD) subcutaneously, under the skin of the thigh, upper arm or abdomen for 26 weeks with the option to vary time of adminis",,,
arm,NCT01880736::arm::FG003,NCT01880736,IDeg OD Flexible Dosing and Stepwise Titration (Arm D),,,,,,,,,,FG003,"The subjects received IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) once daily (OD) subcutaneously, under the skin of the thigh, upper arm or abdomen for 26 weeks with the option to vary time of adminis",,,
period,NCT01880736::period::1,NCT01880736,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01880736::outcome::primary::1,NCT01880736,Change From Baseline in HbA1c (%) Glycosylated Haemoglobin),,,,,,,,,,,,,PRIMARY,"Week 0, week 26"
country,NCT01880736::country::Japan,NCT01880736,Japan,,,,,,,,,,,,,,
trial,NCT02762578,NCT02762578,Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,543.0,2016-05-03,2017-06-19,1.0,42.0,,,,,
arm,NCT02762578::arm::FG000,NCT02762578,IDegAsp BID,,,,,,,,,,FG000,Subjects received subcutaneous (s.c.) injections of insulin degludec/insulin aspart (IDegAsp) twice daily (BID) for 26 weeks. Subjects started insulin treatment at dose corresponding to their pre-tria,,,
arm,NCT02762578::arm::FG001,NCT02762578,BIAsp 30 BID,,,,,,,,,,FG001,"Subjects received s.c. injections of biphasic insulin aspart 30 (BIAsp 30, a mixture of soluble insulin aspart \[IAsp\] 30% and protaminated IAsp 70%) BID for 26 weeks. Subjects started insulin treatm",,,
period,NCT02762578::period::1,NCT02762578,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02762578::outcome::primary::1,NCT02762578,Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin),,,,,,,,,,,,,PRIMARY,At 26 weeks
country,NCT02762578::country::China,NCT02762578,China,,,,,,,,,,,,,,
trial,NCT03211858,NCT03211858,Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine,PHASE3,diabetes type 2,Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus,INDUSTRY,597.0,2017-08-02,2019-01-12,7.0,82.0,,,,,
arm,NCT03211858::arm::FG000,NCT03211858,SAR341402,,,,,,,,,,FG000,"SAR341402 100 units per milliliter (U/mL) subcutaneous (SC) injection, before meals intake on top of once daily (QD) Insulin Glargine, up to Week 52.",,,
arm,NCT03211858::arm::FG001,NCT03211858,NovoLog/NovoRapid,,,,,,,,,,FG001,"NovoLog/NovoRapid 100 U/mL SC injection, before meals intake on top of QD Insulin Glargine,up to Week 52.",,,
period,NCT03211858::period::1,NCT03211858,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03211858::outcome::primary::1,NCT03211858,Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26,,,,,,,,,,,,,PRIMARY,"Baseline, Week 26"
country,NCT03211858::country::United States,NCT03211858,United States,,,,,,,,,,,,,,
country,NCT03211858::country::Hungary,NCT03211858,Hungary,,,,,,,,,,,,,,
country,NCT03211858::country::Japan,NCT03211858,Japan,,,,,,,,,,,,,,
country,NCT03211858::country::Poland,NCT03211858,Poland,,,,,,,,,,,,,,
country,NCT03211858::country::Germany,NCT03211858,Germany,,,,,,,,,,,,,,
country,NCT03211858::country::Finland,NCT03211858,Finland,,,,,,,,,,,,,,
country,NCT03211858::country::Russia,NCT03211858,Russia,,,,,,,,,,,,,,
trial,NCT02545049,NCT02545049,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease,PHASE3,diabetes type 2,Diabetic Kidney Disease,INDUSTRY,7352.0,2015-09-17,2021-02-02,48.0,975.0,,,,,
arm,NCT02545049::arm::FG000,NCT02545049,Finerenone,,,,,,,,,,FG000,Participants received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy,,,
arm,NCT02545049::arm::FG001,NCT02545049,Placebo,,,,,,,,,,FG001,Participants received matching placebo once daily in addition to standard of care therapy,,,
period,NCT02545049::period::1,NCT02545049,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02545049::outcome::primary::1,NCT02545049,"The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non Fatal Stroke, or Hospitalization for Heart Failure.",,,,,,,,,,,,,PRIMARY,"From randomization up until the first occurrence of the CV composite endpoint, or censoring at the end of the study, with an average study duration of 41 months."
country,NCT02545049::country::United States,NCT02545049,United States,,,,,,,,,,,,,,
country,NCT02545049::country::Japan,NCT02545049,Japan,,,,,,,,,,,,,,
country,NCT02545049::country::China,NCT02545049,China,,,,,,,,,,,,,,
country,NCT02545049::country::Russia,NCT02545049,Russia,,,,,,,,,,,,,,
country,NCT02545049::country::Germany,NCT02545049,Germany,,,,,,,,,,,,,,
country,NCT02545049::country::Canada,NCT02545049,Canada,,,,,,,,,,,,,,
country,NCT02545049::country::Spain,NCT02545049,Spain,,,,,,,,,,,,,,
country,NCT02545049::country::Brazil,NCT02545049,Brazil,,,,,,,,,,,,,,
country,NCT02545049::country::Poland,NCT02545049,Poland,,,,,,,,,,,,,,
country,NCT02545049::country::Czechia,NCT02545049,Czechia,,,,,,,,,,,,,,
country,NCT02545049::country::Italy,NCT02545049,Italy,,,,,,,,,,,,,,
country,NCT02545049::country::Ukraine,NCT02545049,Ukraine,,,,,,,,,,,,,,
country,NCT02545049::country::Hungary,NCT02545049,Hungary,,,,,,,,,,,,,,
country,NCT02545049::country::Israel,NCT02545049,Israel,,,,,,,,,,,,,,
country,NCT02545049::country::Mexico,NCT02545049,Mexico,,,,,,,,,,,,,,
country,NCT02545049::country::Colombia,NCT02545049,Colombia,,,,,,,,,,,,,,
country,NCT02545049::country::Romania,NCT02545049,Romania,,,,,,,,,,,,,,
country,NCT02545049::country::Bulgaria,NCT02545049,Bulgaria,,,,,,,,,,,,,,
country,NCT02545049::country::Portugal,NCT02545049,Portugal,,,,,,,,,,,,,,
country,NCT02545049::country::South Africa,NCT02545049,South Africa,,,,,,,,,,,,,,
country,NCT02545049::country::Australia,NCT02545049,Australia,,,,,,,,,,,,,,
country,NCT02545049::country::France,NCT02545049,France,,,,,,,,,,,,,,
country,NCT02545049::country::Denmark,NCT02545049,Denmark,,,,,,,,,,,,,,
country,NCT02545049::country::Argentina,NCT02545049,Argentina,,,,,,,,,,,,,,
country,NCT02545049::country::Turkey (Türkiye),NCT02545049,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02545049::country::Austria,NCT02545049,Austria,,,,,,,,,,,,,,
country,NCT02545049::country::Netherlands,NCT02545049,Netherlands,,,,,,,,,,,,,,
country,NCT02545049::country::South Korea,NCT02545049,South Korea,,,,,,,,,,,,,,
country,NCT02545049::country::Sweden,NCT02545049,Sweden,,,,,,,,,,,,,,
country,NCT02545049::country::Finland,NCT02545049,Finland,,,,,,,,,,,,,,
country,NCT02545049::country::United Kingdom,NCT02545049,United Kingdom,,,,,,,,,,,,,,
country,NCT02545049::country::Norway,NCT02545049,Norway,,,,,,,,,,,,,,
country,NCT02545049::country::Malaysia,NCT02545049,Malaysia,,,,,,,,,,,,,,
country,NCT02545049::country::Chile,NCT02545049,Chile,,,,,,,,,,,,,,
country,NCT02545049::country::Taiwan,NCT02545049,Taiwan,,,,,,,,,,,,,,
country,NCT02545049::country::Belgium,NCT02545049,Belgium,,,,,,,,,,,,,,
country,NCT02545049::country::Greece,NCT02545049,Greece,,,,,,,,,,,,,,
country,NCT02545049::country::New Zealand,NCT02545049,New Zealand,,,,,,,,,,,,,,
country,NCT02545049::country::Lithuania,NCT02545049,Lithuania,,,,,,,,,,,,,,
country,NCT02545049::country::Philippines,NCT02545049,Philippines,,,,,,,,,,,,,,
country,NCT02545049::country::Slovakia,NCT02545049,Slovakia,,,,,,,,,,,,,,
country,NCT02545049::country::Switzerland,NCT02545049,Switzerland,,,,,,,,,,,,,,
country,NCT02545049::country::Vietnam,NCT02545049,Vietnam,,,,,,,,,,,,,,
country,NCT02545049::country::Hong Kong,NCT02545049,Hong Kong,,,,,,,,,,,,,,
country,NCT02545049::country::Thailand,NCT02545049,Thailand,,,,,,,,,,,,,,
country,NCT02545049::country::Ireland,NCT02545049,Ireland,,,,,,,,,,,,,,
country,NCT02545049::country::Puerto Rico,NCT02545049,Puerto Rico,,,,,,,,,,,,,,
country,NCT02545049::country::Singapore,NCT02545049,Singapore,,,,,,,,,,,,,,
trial,NCT01986881,NCT01986881,"Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)",PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,8246.0,2013-11-04,2019-12-27,0.0,0.0,,,,,
arm,NCT01986881::arm::FG000,NCT01986881,Ertugliflozin 5 mg (Overall Cardiovascular Study),,,,,,,,,,FG000,"Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years",,,
arm,NCT01986881::arm::FG001,NCT01986881,Ertugliflozin 15 mg (Overall Cardiovascular Study),,,,,,,,,,FG001,"Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years",,,
arm,NCT01986881::arm::FG002,NCT01986881,Placebo (Overall Cardiovascular Study),,,,,,,,,,FG002,"Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years",,,
period,NCT01986881::period::1,NCT01986881,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01986881::outcome::primary::1,NCT01986881,"Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study)",,,,,,,,,,,,,PRIMARY,Up to approximately 6 years
outcome,NCT01986881::outcome::primary::2,NCT01986881,Baseline Hemoglobin A1C (A1C) (Insulin With or Without Metformin Add-on Glycemic Sub-study),,,,,,,,,,,,,PRIMARY,Baseline
outcome,NCT01986881::outcome::primary::3,NCT01986881,Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study),,,,,,,,,,,,,PRIMARY,Baseline and Week 18
outcome,NCT01986881::outcome::primary::4,NCT01986881,Baseline Hemoglobin A1C (A1C) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study),,,,,,,,,,,,,PRIMARY,Baseline
outcome,NCT01986881::outcome::primary::5,NCT01986881,Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study),,,,,,,,,,,,,PRIMARY,Baseline and Week 18
outcome,NCT01986881::outcome::primary::6,NCT01986881,Baseline Hemoglobin A1C (A1C) (Metformin With Sulfonylurea Add-on Glycemic Sub-study),,,,,,,,,,,,,PRIMARY,Baseline
outcome,NCT01986881::outcome::primary::7,NCT01986881,Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Metformin With Sulfonylurea Add-on Glycemic Sub-study),,,,,,,,,,,,,PRIMARY,Baseline and Week 18
trial,NCT00917267,NCT00917267,A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,691.0,2009-07,2011-04,5.0,42.0,,,,,
arm,NCT00917267::arm::FG000,NCT00917267,Exenatide Once Weekly,,,,,,,,,,FG000,"Subcutaneous injection of 2 mg exenatide, once a week",,,
arm,NCT00917267::arm::FG001,NCT00917267,Exenatide Twice Daily,,,,,,,,,,FG001,"Subcutaneous injection of exenatide, twice a day (5 mcg exenatide per dose for first 4 weeks, then 10 mcg exenatide per dose for 22 weeks)",,,
period,NCT00917267::period::1,NCT00917267,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00917267::outcome::primary::1,NCT00917267,Change in HbA1c From Baseline to Week 26.,,,,,,,,,,,,,PRIMARY,"Baseline, Week 26"
country,NCT00917267::country::Japan,NCT00917267,Japan,,,,,,,,,,,,,,
country,NCT00917267::country::India,NCT00917267,India,,,,,,,,,,,,,,
country,NCT00917267::country::Taiwan,NCT00917267,Taiwan,,,,,,,,,,,,,,
country,NCT00917267::country::China,NCT00917267,China,,,,,,,,,,,,,,
country,NCT00917267::country::South Korea,NCT00917267,South Korea,,,,,,,,,,,,,,
trial,NCT01068665,NCT01068665,Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,460.0,2010-03,2010-11,8.0,116.0,,,,,
arm,NCT01068665::arm::FG000,NCT01068665,IDeg 200 U/mL OD,,,,,,,,,,FG000,Insulin degludec (IDeg) 200U/mL was given once daily (OD) subcutaneously with the main evening meal in combination with metformin with or without dipeptidyl peptidase-4 (DPP-4) inhibitor treatment for,,,
arm,NCT01068665::arm::FG001,NCT01068665,IGlar OD,,,,,,,,,,FG001,Insulin glargine (IGlar) was given once daily (OD) subcutaneously according to approved labelling in combination with metformin with or without dipeptidyl peptidase-4 (DPP-4) inhibitor treatment for 2,,,
period,NCT01068665::period::1,NCT01068665,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01068665::outcome::primary::1,NCT01068665,Change in Glycosylated Haemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Week 0, Week 26"
country,NCT01068665::country::United States,NCT01068665,United States,,,,,,,,,,,,,,
country,NCT01068665::country::United Kingdom,NCT01068665,United Kingdom,,,,,,,,,,,,,,
country,NCT01068665::country::Canada,NCT01068665,Canada,,,,,,,,,,,,,,
country,NCT01068665::country::France,NCT01068665,France,,,,,,,,,,,,,,
country,NCT01068665::country::Russia,NCT01068665,Russia,,,,,,,,,,,,,,
country,NCT01068665::country::South Africa,NCT01068665,South Africa,,,,,,,,,,,,,,
country,NCT01068665::country::Ireland,NCT01068665,Ireland,,,,,,,,,,,,,,
country,NCT01068665::country::Ukraine,NCT01068665,Ukraine,,,,,,,,,,,,,,
trial,NCT03989232,NCT03989232,A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,961.0,2019-06-19,2020-11-09,11.0,129.0,,,,,
arm,NCT03989232::arm::FG000,NCT03989232,Semaglutide 1.0 mg,,,,,,,,,,FG000,"Participants received subcutaneous (s.c.) injection of semaglutide once-weekly for 40 weeks in a fixed-dose escalation regimen, with dose doubling every 4 weeks until the target dose of 1.0 mg was rea",,,
arm,NCT03989232::arm::FG001,NCT03989232,Semaglutide 2.0 mg,,,,,,,,,,FG001,"Participants received s.c. injection of semaglutide once-weekly for 40 weeks in a fixed-dose escalation regimen, with dose doubling every 4 weeks until the target maintenance dose of 2.0 mg was reache",,,
period,NCT03989232::period::1,NCT03989232,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03989232::outcome::primary::1,NCT03989232,Change in HbA1c,,,,,,,,,,,,,PRIMARY,"Week 0, week 40"
country,NCT03989232::country::United States,NCT03989232,United States,,,,,,,,,,,,,,
country,NCT03989232::country::Hungary,NCT03989232,Hungary,,,,,,,,,,,,,,
country,NCT03989232::country::Slovakia,NCT03989232,Slovakia,,,,,,,,,,,,,,
country,NCT03989232::country::Poland,NCT03989232,Poland,,,,,,,,,,,,,,
country,NCT03989232::country::Canada,NCT03989232,Canada,,,,,,,,,,,,,,
country,NCT03989232::country::Greece,NCT03989232,Greece,,,,,,,,,,,,,,
country,NCT03989232::country::Bulgaria,NCT03989232,Bulgaria,,,,,,,,,,,,,,
country,NCT03989232::country::Ukraine,NCT03989232,Ukraine,,,,,,,,,,,,,,
country,NCT03989232::country::Czechia,NCT03989232,Czechia,,,,,,,,,,,,,,
country,NCT03989232::country::Japan,NCT03989232,Japan,,,,,,,,,,,,,,
country,NCT03989232::country::Puerto Rico,NCT03989232,Puerto Rico,,,,,,,,,,,,,,
trial,NCT02964247,NCT02964247,LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,303.0,2017-03-03,2018-05-08,7.0,82.0,,,,,
arm,NCT02964247::arm::FG000,NCT02964247,Liraglutide,,,,,,,,,,FG000,"Eligible subjects were given liraglutide subcutaneously (s.c.), once daily (OD) for 26 weeks. Subjects received 0.6 mg dose of liraglutide in week 1, dose was escalated to 1.2 mg in week 2 and 1.8 mg ",,,
arm,NCT02964247::arm::FG001,NCT02964247,Placebo,,,,,,,,,,FG001,"Eligible subjects were given liraglutide placebo subcutaneously (s.c.), once daily (OD) for 26 weeks. Dose escalation for placebo matched that for liraglutide with regards to volume. Subjects remained",,,
period,NCT02964247::period::1,NCT02964247,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02964247::outcome::primary::1,NCT02964247,Change in HbA1c,,,,,,,,,,,,,PRIMARY,"Week 0, Week 26"
country,NCT02964247::country::United States,NCT02964247,United States,,,,,,,,,,,,,,
country,NCT02964247::country::India,NCT02964247,India,,,,,,,,,,,,,,
country,NCT02964247::country::Russia,NCT02964247,Russia,,,,,,,,,,,,,,
country,NCT02964247::country::Israel,NCT02964247,Israel,,,,,,,,,,,,,,
country,NCT02964247::country::United Arab Emirates,NCT02964247,United Arab Emirates,,,,,,,,,,,,,,
country,NCT02964247::country::Brazil,NCT02964247,Brazil,,,,,,,,,,,,,,
country,NCT02964247::country::Puerto Rico,NCT02964247,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01652716,NCT01652716,Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,377.0,2013-01,2014-08,1.0,58.0,,,,,
arm,NCT01652716::arm::FG000,NCT01652716,Experimental: Exenatide Once Weekly (QWS) Suspension,,,,,,,,,,FG000,Exenatide suspension 2 mg weekly subcutaneous injection for 52 weeks (28 weeks plus an additional 24 weeks),,,
arm,NCT01652716::arm::FG001,NCT01652716,Active Comparator: Exenatide Twice Daily (BID),,,,,,,,,,FG001,Exenatide 5 mcg BID for 4 weeks followed by 10 mcg BID for 24 weeks followed by a switch to Exenatide QWS 2mg for at least 24 weeks,,,
period,NCT01652716::period::1,NCT01652716,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01652716::outcome::primary::1,NCT01652716,Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28,,,,,,,,,,,,,PRIMARY,Baseline to Week 28
country,NCT01652716::country::United States,NCT01652716,United States,,,,,,,,,,,,,,
trial,NCT01059799,NCT01059799,Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,435.0,2010-02-01,2010-12-16,6.0,53.0,,,,,
arm,NCT01059799::arm::FG000,NCT01059799,IDeg OD,,,,,,,,,,FG000,Insulin degludec (IDeg) was given once daily (OD) subcutaneously (under the skin) in the evening in combination with pre-trial OADs (except DPP-4 inhibitors) for 26 weeks. Insulin doses were individua,,,
arm,NCT01059799::arm::FG001,NCT01059799,IGlar OD,,,,,,,,,,FG001,Insulin glargine (IGlar) was given once daily (OD) subcutaneously (under the skin) according to approved labelling in combination with pre-trial OADs (except DPP-4 inhibitors) for 26 weeks. Insulin do,,,
period,NCT01059799::period::1,NCT01059799,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01059799::outcome::primary::1,NCT01059799,Change in Glycosylated Haemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Week 0, Week 26"
country,NCT01059799::country::South Korea,NCT01059799,South Korea,,,,,,,,,,,,,,
country,NCT01059799::country::Japan,NCT01059799,Japan,,,,,,,,,,,,,,
country,NCT01059799::country::Malaysia,NCT01059799,Malaysia,,,,,,,,,,,,,,
country,NCT01059799::country::Taiwan,NCT01059799,Taiwan,,,,,,,,,,,,,,
country,NCT01059799::country::Thailand,NCT01059799,Thailand,,,,,,,,,,,,,,
country,NCT01059799::country::Hong Kong,NCT01059799,Hong Kong,,,,,,,,,,,,,,
trial,NCT02152371,NCT02152371,A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,300.0,2014-05,2015-10,7.0,40.0,,,,,
arm,NCT02152371::arm::FG000,NCT02152371,Dulaglutide + Insulin Glargine,,,,,,,,,,FG000,1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin shou,,,
arm,NCT02152371::arm::FG001,NCT02152371,Placebo + Insulin Glargine,,,,,,,,,,FG001,Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.,,,
period,NCT02152371::period::1,NCT02152371,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02152371::outcome::primary::1,NCT02152371,Change From Baseline to 28 Weeks in Hemoglobin A1c (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline, 28 Weeks"
country,NCT02152371::country::United States,NCT02152371,United States,,,,,,,,,,,,,,
country,NCT02152371::country::Puerto Rico,NCT02152371,Puerto Rico,,,,,,,,,,,,,,
country,NCT02152371::country::Czechia,NCT02152371,Czechia,,,,,,,,,,,,,,
country,NCT02152371::country::Spain,NCT02152371,Spain,,,,,,,,,,,,,,
country,NCT02152371::country::Italy,NCT02152371,Italy,,,,,,,,,,,,,,
country,NCT02152371::country::United Kingdom,NCT02152371,United Kingdom,,,,,,,,,,,,,,
country,NCT02152371::country::Hungary,NCT02152371,Hungary,,,,,,,,,,,,,,
trial,NCT01590797,NCT01590797,A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,467.0,2012-07-10,2014-06-25,0.0,0.0,,,,,
arm,NCT01590797::arm::FG000,NCT01590797,Sitagliptin,,,,,,,,,,FG000,"Participants treated with sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for ≥10 weeks before and throug",,,
arm,NCT01590797::arm::FG001,NCT01590797,Placebo,,,,,,,,,,FG001,"Participants treated with placebo to sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for ≥10 weeks before",,,
period,NCT01590797::period::1,NCT01590797,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01590797::outcome::primary::1,NCT01590797,Change From Baseline in Hemoglobin A1C (HbA1C) Levels at Week 24 in Participants Receiving Insulin Alone or in Combination With Metformin,,,,,,,,,,,,,PRIMARY,Baseline and Week 24
outcome,NCT01590797::outcome::primary::2,NCT01590797,Number of Participants With One or More Adverse Events,,,,,,,,,,,,,PRIMARY,Up to Week 26
outcome,NCT01590797::outcome::primary::3,NCT01590797,Number of Participants Discontinuing Study Medication Due to an AE,,,,,,,,,,,,,PRIMARY,Up to Week 24
trial,NCT01076088,NCT01076088,Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,744.0,2010-11-15,2012-12-24,0.0,0.0,,,,,
arm,NCT01076088::arm::FG000,NCT01076088,Sitagliptin 50 mg + Metformin 500 mg,,,,,,,,,,FG000,Sitagliptin 50 mg twice daily + metformin 500 mg twice daily,,,
arm,NCT01076088::arm::FG001,NCT01076088,Sitagliptin 50 mg + Metformin 850 mg,,,,,,,,,,FG001,Sitagliptin 50 mg twice daily + metformin 850 mg twice daily,,,
arm,NCT01076088::arm::FG002,NCT01076088,Metformin 500 mg,,,,,,,,,,FG002,Metformin 500 mg twice daily,,,
arm,NCT01076088::arm::FG003,NCT01076088,Metformin 850,,,,,,,,,,FG003,Metformin 850 mg twice daily,,,
arm,NCT01076088::arm::FG004,NCT01076088,Sitagliptin 100 mg,,,,,,,,,,FG004,Sitagliptin 100 mg once daily,,,
arm,NCT01076088::arm::FG005,NCT01076088,Placebo,,,,,,,,,,FG005,Matching placebo to sitagliptin and/or metformin. Population includes 1 participant who did not receive any study medication.,,,
period,NCT01076088::period::1,NCT01076088,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01076088::outcome::primary::1,NCT01076088,Change From Baseline in Hemoglobin A1C (A1C) at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and Week 24
trial,NCT00286442,NCT00286442,Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Diabetes Mellitus,INDUSTRY,527.0,2006-03,2007-06,17.0,56.0,,,,,
arm,NCT00286442::arm::FG000,NCT00286442,Alogliptin 12.5 mg QD,,,,,,,,,,FG000,"Alogliptin 12.5 mg, tablets, orally, once daily and metformin for up to 26 weeks.",,,
arm,NCT00286442::arm::FG001,NCT00286442,Alogliptin 25 mg QD,,,,,,,,,,FG001,"Alogliptin 25 mg, tablets, orally, once daily and metformin for up to 26 weeks.",,,
arm,NCT00286442::arm::FG002,NCT00286442,Placebo,,,,,,,,,,FG002,"Alogliptin placebo-matching tablets, orally, once daily and metformin for up to 26 weeks.",,,
period,NCT00286442::period::1,NCT00286442,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00286442::outcome::primary::1,NCT00286442,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.,,,,,,,,,,,,,PRIMARY,Baseline and Week 26.
country,NCT00286442::country::United States,NCT00286442,United States,,,,,,,,,,,,,,
country,NCT00286442::country::Argentina,NCT00286442,Argentina,,,,,,,,,,,,,,
country,NCT00286442::country::Australia,NCT00286442,Australia,,,,,,,,,,,,,,
country,NCT00286442::country::Brazil,NCT00286442,Brazil,,,,,,,,,,,,,,
country,NCT00286442::country::Chile,NCT00286442,Chile,,,,,,,,,,,,,,
country,NCT00286442::country::Czechia,NCT00286442,Czechia,,,,,,,,,,,,,,
country,NCT00286442::country::Germany,NCT00286442,Germany,,,,,,,,,,,,,,
country,NCT00286442::country::Guatemala,NCT00286442,Guatemala,,,,,,,,,,,,,,
country,NCT00286442::country::Hungary,NCT00286442,Hungary,,,,,,,,,,,,,,
country,NCT00286442::country::India,NCT00286442,India,,,,,,,,,,,,,,
country,NCT00286442::country::Mexico,NCT00286442,Mexico,,,,,,,,,,,,,,
country,NCT00286442::country::Netherlands,NCT00286442,Netherlands,,,,,,,,,,,,,,
country,NCT00286442::country::New Zealand,NCT00286442,New Zealand,,,,,,,,,,,,,,
country,NCT00286442::country::Peru,NCT00286442,Peru,,,,,,,,,,,,,,
country,NCT00286442::country::Poland,NCT00286442,Poland,,,,,,,,,,,,,,
country,NCT00286442::country::South Africa,NCT00286442,South Africa,,,,,,,,,,,,,,
country,NCT00286442::country::United Kingdom,NCT00286442,United Kingdom,,,,,,,,,,,,,,
trial,NCT00757588,NCT00757588,Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,455.0,2008-11,2010-04,10.0,80.0,,,,,
arm,NCT00757588::arm::FG000,NCT00757588,"Saxagliptin, 5 mg + Insulin",,,,,,,,,,FG000,"Saxagliptin, 5 mg, added to ongoing insulin with or without metformin therapy for up to 24 weeks in patients with type 2 diabetes",,,
arm,NCT00757588::arm::FG001,NCT00757588,Placebo + Insulin,,,,,,,,,,FG001,Placebo added to ongoing insulin with metformin therapy for up to 24 weeks in patients with type 2 diabetes,,,
period,NCT00757588::period::1,NCT00757588,Period 1: Short-term (24-week) Phase,,,,,,,,,,,,1.0,,
period,NCT00757588::period::2,NCT00757588,Period 2: Long-term (52-week) Phase,,,,,,,,,,,,2.0,,
outcome,NCT00757588::outcome::primary::1,NCT00757588,Adjusted Mean Change From Baseline in A1C Levels (Last Observation Carried Forward [LOCF]),,,,,,,,,,,,,PRIMARY,Baseline to Week 24
country,NCT00757588::country::United States,NCT00757588,United States,,,,,,,,,,,,,,
country,NCT00757588::country::Mexico,NCT00757588,Mexico,,,,,,,,,,,,,,
country,NCT00757588::country::Canada,NCT00757588,Canada,,,,,,,,,,,,,,
country,NCT00757588::country::Poland,NCT00757588,Poland,,,,,,,,,,,,,,
country,NCT00757588::country::Russia,NCT00757588,Russia,,,,,,,,,,,,,,
country,NCT00757588::country::India,NCT00757588,India,,,,,,,,,,,,,,
country,NCT00757588::country::Hungary,NCT00757588,Hungary,,,,,,,,,,,,,,
country,NCT00757588::country::South Africa,NCT00757588,South Africa,,,,,,,,,,,,,,
country,NCT00757588::country::United Kingdom,NCT00757588,United Kingdom,,,,,,,,,,,,,,
country,NCT00757588::country::France,NCT00757588,France,,,,,,,,,,,,,,
trial,NCT00770653,NCT00770653,Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.,PHASE3,diabetes type 2,Diabetes Mellitus; Dyslipidemias,INDUSTRY,305.0,2007-04,2009-05,1.0,64.0,,,,,
arm,NCT00770653::arm::FG000,NCT00770653,Pioglitazone 15 mg and Metformin 850 mg BID,,,,,,,,,,FG000,"Pioglitazone 15 mg/metformin 850 mg combination tablets, orally, twice daily and glimepiride placebo-matching tablets, orally, once daily and metformin placebo-matching tablets, orally, twice daily fo",,,
arm,NCT00770653::arm::FG001,NCT00770653,Glimepiride 2 mg and Metformin 850 mg BID,,,,,,,,,,FG001,"Pioglitazone/metformin placebo-matching combination tablets, orally, twice daily and glimepiride 2 mg, tablets, orally, once daily and metformin 850 mg, tablets, orally, twice daily for up to 24 weeks",,,
period,NCT00770653::period::1,NCT00770653,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00770653::outcome::primary::1,NCT00770653,The Mean Increase From Baseline in High-Density Lipoprotein Cholesterol.,,,,,,,,,,,,,PRIMARY,Baseline and Week 24.
country,NCT00770653::country::Germany,NCT00770653,Germany,,,,,,,,,,,,,,
trial,NCT01084005,NCT01084005,Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,241.0,2010-03,,5.0,34.0,,,,,
arm,NCT01084005::arm::FG000,NCT01084005,Placebo,,,,,,,,,,FG000,Patients randomized to receive treatment with matching placebo,,,
arm,NCT01084005::arm::FG001,NCT01084005,Linagliptin 5 mg,,,,,,,,,,FG001,Patients randomized to receive treatment with Linagliptin 5mg,,,
period,NCT01084005::period::1,NCT01084005,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01084005::outcome::primary::1,NCT01084005,HbA1c Change From Baseline to Week 24,,,,,,,,,,,,,PRIMARY,Baseline and week 24
country,NCT01084005::country::Canada,NCT01084005,Canada,,,,,,,,,,,,,,
country,NCT01084005::country::Denmark,NCT01084005,Denmark,,,,,,,,,,,,,,
country,NCT01084005::country::Australia,NCT01084005,Australia,,,,,,,,,,,,,,
country,NCT01084005::country::Netherlands,NCT01084005,Netherlands,,,,,,,,,,,,,,
country,NCT01084005::country::Sweden,NCT01084005,Sweden,,,,,,,,,,,,,,
trial,NCT01159600,NCT01159600,Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,1504.0,2010-07,,12.0,148.0,,,,,
arm,NCT01159600::arm::FG000,NCT01159600,Met: Placebo,,,,,,,,,,FG000,"A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 24 weeks in patients with background medication of metformin only.",,,
arm,NCT01159600::arm::FG001,NCT01159600,Met: Empa 10mg,,,,,,,,,,FG001,Single oral dose of empagliflozin (empa) 10mg taken once daily for 24 weeks in patients with background medication of metformin only.,,,
arm,NCT01159600::arm::FG002,NCT01159600,Met: Empa 25mg,,,,,,,,,,FG002,Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin only.,,,
arm,NCT01159600::arm::FG003,NCT01159600,Met: Empa 25mg Open Label,,,,,,,,,,FG003,Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin only.,,,
arm,NCT01159600::arm::FG004,NCT01159600,Met+SU: Placebo,,,,,,,,,,FG004,"A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).",,,
arm,NCT01159600::arm::FG005,NCT01159600,Met+SU: Empa 10mg,,,,,,,,,,FG005,Single oral dose of empagliflozin (empa) 10mg taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).,,,
arm,NCT01159600::arm::FG006,NCT01159600,Met+SU: Empa 25mg,,,,,,,,,,FG006,Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).,,,
arm,NCT01159600::arm::FG007,NCT01159600,Met+SU: Empa 25mg Open Label,,,,,,,,,,FG007,Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks in patients with background medication of metformin plus sulphonylurea (SU).,,,
period,NCT01159600::period::1,NCT01159600,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01159600::outcome::primary::1,NCT01159600,HbA1c Change From Baseline,,,,,,,,,,,,,PRIMARY,Baseline and 24 weeks
country,NCT01159600::country::China,NCT01159600,China,,,,,,,,,,,,,,
country,NCT01159600::country::United States,NCT01159600,United States,,,,,,,,,,,,,,
country,NCT01159600::country::Canada,NCT01159600,Canada,,,,,,,,,,,,,,
country,NCT01159600::country::France,NCT01159600,France,,,,,,,,,,,,,,
country,NCT01159600::country::South Korea,NCT01159600,South Korea,,,,,,,,,,,,,,
country,NCT01159600::country::Germany,NCT01159600,Germany,,,,,,,,,,,,,,
country,NCT01159600::country::Taiwan,NCT01159600,Taiwan,,,,,,,,,,,,,,
country,NCT01159600::country::Slovakia,NCT01159600,Slovakia,,,,,,,,,,,,,,
country,NCT01159600::country::Turkey (Türkiye),NCT01159600,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01159600::country::India,NCT01159600,India,,,,,,,,,,,,,,
country,NCT01159600::country::Mexico,NCT01159600,Mexico,,,,,,,,,,,,,,
country,NCT01159600::country::Slovenia,NCT01159600,Slovenia,,,,,,,,,,,,,,
trial,NCT02630706,NCT02630706,A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,506.0,2015-12-16,2017-12-27,0.0,0.0,,,,,
arm,NCT02630706::arm::FG000,NCT02630706,Ertugliflozin 5 mg,,,,,,,,,,FG000,"Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\>=1500 mg/day). Glycemic rescue therapy with open-la",,,
arm,NCT02630706::arm::FG001,NCT02630706,Ertugliflozin 15 mg,,,,,,,,,,FG001,"Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in par",,,
arm,NCT02630706::arm::FG002,NCT02630706,Placebo,,,,,,,,,,FG002,"Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initi",,,
period,NCT02630706::period::1,NCT02630706,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02630706::outcome::primary::1,NCT02630706,Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach),,,,,,,,,,,,,PRIMARY,Baseline and Week 26
outcome,NCT02630706::outcome::primary::2,NCT02630706,Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach) (China Subpopulation),,,,,,,,,,,,,PRIMARY,Baseline and Week 26
outcome,NCT02630706::outcome::primary::3,NCT02630706,Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach),,,,,,,,,,,,,PRIMARY,Up to 28 weeks
outcome,NCT02630706::outcome::primary::4,NCT02630706,Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach) (China Subpopulation),,,,,,,,,,,,,PRIMARY,Up to 28 weeks
outcome,NCT02630706::outcome::primary::5,NCT02630706,Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach),,,,,,,,,,,,,PRIMARY,Up to 26 weeks
outcome,NCT02630706::outcome::primary::6,NCT02630706,Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach) (China Subpopulation),,,,,,,,,,,,,PRIMARY,Up to 26 weeks
trial,NCT01648582,NCT01648582,A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,774.0,2012-07,2014-12,4.0,30.0,,,,,
arm,NCT01648582::arm::FG000,NCT01648582,1.5 mg Dulaglutide,,,,,,,,,,FG000,1.5 mg dulaglutide administered as 1 subcutaneous (SC) injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.,,,
arm,NCT01648582::arm::FG001,NCT01648582,0.75 mg Dulaglutide,,,,,,,,,,FG001,0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.,,,
arm,NCT01648582::arm::FG002,NCT01648582,Insulin Glargine,,,,,,,,,,FG002,Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and /or a sulfonylurea.,,,
period,NCT01648582::period::1,NCT01648582,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01648582::outcome::primary::1,NCT01648582,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks,,,,,,,,,,,,,PRIMARY,"Baseline, 26 Weeks"
country,NCT01648582::country::China,NCT01648582,China,,,,,,,,,,,,,,
country,NCT01648582::country::Russia,NCT01648582,Russia,,,,,,,,,,,,,,
country,NCT01648582::country::South Korea,NCT01648582,South Korea,,,,,,,,,,,,,,
country,NCT01648582::country::Mexico,NCT01648582,Mexico,,,,,,,,,,,,,,
trial,NCT01336023,NCT01336023,"Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes",PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,1663.0,2011-05-23,2012-11-22,20.0,302.0,,,,,
arm,NCT01336023::arm::FG000,NCT01336023,IDeg,,,,,,,,,,FG000,Insulin degludec (IDeg: 100 U/mL) was injected once daily (OD) subcutaneously (s.c.) for 26 weeks (main trial) + 26 weeks (extension trial). IDeg treatment was initiated at a dose of 10 units and titr,,,
arm,NCT01336023::arm::FG001,NCT01336023,IDegLira,,,,,,,,,,FG001,Insulin Degludec/Liraglutide (IDegLira: 100 U/3.6 mg per mL) was injected subcutaneously OD for 26 weeks(main trial) + 26 weeks (extension trial). IDegLira treatment was initiated at 10 dose steps (co,,,
arm,NCT01336023::arm::FG002,NCT01336023,Liraglutide,,,,,,,,,,FG002,"Liraglutide (6 mg/mL) was injected subcutaneously OD for 26 weeks (main trial). Liraglutide treatment was initiated at a dose of 0.6 mg/day, and subsequently increased by 0.6 mg in weekly dose escalat",,,
period,NCT01336023::period::1,NCT01336023,Week 0 to Week 26,,,,,,,,,,,,1.0,,
period,NCT01336023::period::2,NCT01336023,Week 27 to 52,,,,,,,,,,,,2.0,,
outcome,NCT01336023::outcome::primary::1,NCT01336023,Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26.,,,,,,,,,,,,,PRIMARY,"Week 0, week 26"
country,NCT01336023::country::United States,NCT01336023,United States,,,,,,,,,,,,,,
country,NCT01336023::country::India,NCT01336023,India,,,,,,,,,,,,,,
country,NCT01336023::country::United Kingdom,NCT01336023,United Kingdom,,,,,,,,,,,,,,
country,NCT01336023::country::Canada,NCT01336023,Canada,,,,,,,,,,,,,,
country,NCT01336023::country::Germany,NCT01336023,Germany,,,,,,,,,,,,,,
country,NCT01336023::country::South Africa,NCT01336023,South Africa,,,,,,,,,,,,,,
country,NCT01336023::country::Russia,NCT01336023,Russia,,,,,,,,,,,,,,
country,NCT01336023::country::Australia,NCT01336023,Australia,,,,,,,,,,,,,,
country,NCT01336023::country::Italy,NCT01336023,Italy,,,,,,,,,,,,,,
country,NCT01336023::country::Spain,NCT01336023,Spain,,,,,,,,,,,,,,
country,NCT01336023::country::Hungary,NCT01336023,Hungary,,,,,,,,,,,,,,
country,NCT01336023::country::Malaysia,NCT01336023,Malaysia,,,,,,,,,,,,,,
country,NCT01336023::country::Finland,NCT01336023,Finland,,,,,,,,,,,,,,
country,NCT01336023::country::Slovakia,NCT01336023,Slovakia,,,,,,,,,,,,,,
country,NCT01336023::country::Taiwan,NCT01336023,Taiwan,,,,,,,,,,,,,,
country,NCT01336023::country::Thailand,NCT01336023,Thailand,,,,,,,,,,,,,,
country,NCT01336023::country::Singapore,NCT01336023,Singapore,,,,,,,,,,,,,,
country,NCT01336023::country::Ireland,NCT01336023,Ireland,,,,,,,,,,,,,,
country,NCT01336023::country::Mexico,NCT01336023,Mexico,,,,,,,,,,,,,,
country,NCT01336023::country::Puerto Rico,NCT01336023,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01009580,NCT01009580,Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,447.0,2009-11-05,2010-08-23,10.0,53.0,,,,,
arm,NCT01009580::arm::FG000,NCT01009580,IDegAsp BID,,,,,,,,,,FG000,"Insulin degludec/insulin aspart (IDegAsp) was given subcutaneously twice daily (BID) with or without Metformin, DPP-4 inhibitor, Pioglitazone. IDegAsp was given with the breakfast meal and main evenin",,,
arm,NCT01009580::arm::FG001,NCT01009580,BIAsp 30 BID,,,,,,,,,,FG001,"Biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously twice daily (BID) with or without Metformin, DPP-4 inhibitor, Pioglitazone. BIAsp 30 was given with the breakfast meal and main evening m",,,
period,NCT01009580::period::1,NCT01009580,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01009580::outcome::primary::1,NCT01009580,Change in Glycosylated Haemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Week 0, Week 26"
country,NCT01009580::country::India,NCT01009580,India,,,,,,,,,,,,,,
country,NCT01009580::country::Denmark,NCT01009580,Denmark,,,,,,,,,,,,,,
country,NCT01009580::country::Poland,NCT01009580,Poland,,,,,,,,,,,,,,
country,NCT01009580::country::Sweden,NCT01009580,Sweden,,,,,,,,,,,,,,
country,NCT01009580::country::Australia,NCT01009580,Australia,,,,,,,,,,,,,,
country,NCT01009580::country::Finland,NCT01009580,Finland,,,,,,,,,,,,,,
country,NCT01009580::country::Malaysia,NCT01009580,Malaysia,,,,,,,,,,,,,,
country,NCT01009580::country::Thailand,NCT01009580,Thailand,,,,,,,,,,,,,,
country,NCT01009580::country::Turkey (Türkiye),NCT01009580,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01009580::country::Taiwan,NCT01009580,Taiwan,,,,,,,,,,,,,,
trial,NCT04657003,NCT04657003,A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight,PHASE3,diabetes type 2,Type 2 Diabetes; Overweight; Obesity,INDUSTRY,938.0,2021-03-29,2023-04-10,8.0,75.0,,,,,
arm,NCT04657003::arm::FG000,NCT04657003,Placebo,,,,,,,,,,FG000,Participants received Placebo administered subcutaneously (SC) once weekly (QW).,,,
arm,NCT04657003::arm::FG001,NCT04657003,10 Milligrams (mg) Tirzepatide,,,,,,,,,,FG001,Participants received 10 mg Tirzepatide administered SC QW,,,
arm,NCT04657003::arm::FG002,NCT04657003,15 mg Tirzepatide,,,,,,,,,,FG002,Participants received 15 mg Tirzepatide administered SC QW,,,
period,NCT04657003::period::1,NCT04657003,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04657003::outcome::primary::1,NCT04657003,Percent Change From Baseline in Body Weight,,,,,,,,,,,,,PRIMARY,"Baseline, Week 72"
outcome,NCT04657003::outcome::primary::2,NCT04657003,Percentage of Participants Who Achieve ≥5% Body Weight Reduction From Baseline,,,,,,,,,,,,,PRIMARY,Week 72
country,NCT04657003::country::United States,NCT04657003,United States,,,,,,,,,,,,,,
country,NCT04657003::country::Argentina,NCT04657003,Argentina,,,,,,,,,,,,,,
country,NCT04657003::country::Brazil,NCT04657003,Brazil,,,,,,,,,,,,,,
country,NCT04657003::country::Taiwan,NCT04657003,Taiwan,,,,,,,,,,,,,,
country,NCT04657003::country::Japan,NCT04657003,Japan,,,,,,,,,,,,,,
country,NCT04657003::country::Russia,NCT04657003,Russia,,,,,,,,,,,,,,
country,NCT04657003::country::Puerto Rico,NCT04657003,Puerto Rico,,,,,,,,,,,,,,
country,NCT04657003::country::India,NCT04657003,India,,,,,,,,,,,,,,
trial,NCT00972283,NCT00972283,Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,1006.0,2009-09-01,2010-10-28,12.0,136.0,,,,,
arm,NCT00972283::arm::FG000,NCT00972283,IDeg OD,,,,,,,,,,FG000,Insulin degludec (IDeg) was given subcutaneously once daily (OD) with main evening meal with insulin aspart (IAsp) as mealtime insulin with or without subject's pre-trial metformin with or without pio,,,
arm,NCT00972283::arm::FG001,NCT00972283,IGlar OD,,,,,,,,,,FG001,"Insulin glargine (IGlar) was given subcutaneously once daily (OD), according to labelling instructions with insulin aspart (IAsp) as mealtime insulin with or without subject's pre-trial metformin with",,,
period,NCT00972283::period::1,NCT00972283,Main: Week 0 to 52 (NN1250-3582),,,,,,,,,,,,1.0,,
period,NCT00972283::period::2,NCT00972283,Extension: Week 53 to 78 (NN1250-3667),,,,,,,,,,,,2.0,,
outcome,NCT00972283::outcome::primary::1,NCT00972283,Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment,,,,,,,,,,,,,PRIMARY,"Week 0, Week 52"
outcome,NCT00972283::outcome::primary::2,NCT00972283,Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes,,,,,,,,,,,,,PRIMARY,Week 0 to Week 78 + 7 days follow up
outcome,NCT00972283::outcome::primary::3,NCT00972283,Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,,,,,,,,,,,,PRIMARY,Week 0 to Week 78 + 7 days follow up
outcome,NCT00972283::outcome::primary::4,NCT00972283,Rate of Treatment Emergent Adverse Events (AEs),,,,,,,,,,,,,PRIMARY,Week 0 to Week 78 + 7 days follow up
country,NCT00972283::country::United States,NCT00972283,United States,,,,,,,,,,,,,,
country,NCT00972283::country::Italy,NCT00972283,Italy,,,,,,,,,,,,,,
country,NCT00972283::country::Spain,NCT00972283,Spain,,,,,,,,,,,,,,
country,NCT00972283::country::Germany,NCT00972283,Germany,,,,,,,,,,,,,,
country,NCT00972283::country::Russia,NCT00972283,Russia,,,,,,,,,,,,,,
country,NCT00972283::country::Bulgaria,NCT00972283,Bulgaria,,,,,,,,,,,,,,
country,NCT00972283::country::Romania,NCT00972283,Romania,,,,,,,,,,,,,,
country,NCT00972283::country::Ireland,NCT00972283,Ireland,,,,,,,,,,,,,,
country,NCT00972283::country::Slovakia,NCT00972283,Slovakia,,,,,,,,,,,,,,
country,NCT00972283::country::South Africa,NCT00972283,South Africa,,,,,,,,,,,,,,
country,NCT00972283::country::Turkey (Türkiye),NCT00972283,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00972283::country::Hong Kong,NCT00972283,Hong Kong,,,,,,,,,,,,,,
trial,NCT02273050,NCT02273050,Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,1136.0,2014-12,2016-08,1.0,17.0,,,,,
arm,NCT02273050::arm::FG000,NCT02273050,METFORMIN + PLACEBO 5MG QD,,,,,,,,,,FG000,,,,
arm,NCT02273050::arm::FG001,NCT02273050,SAXAGLIPTIN 5MG QD + METFORMIN,,,,,,,,,,FG001,,,,
arm,NCT02273050::arm::FG002,NCT02273050,SAXAGLIPTIN 5MG QD + PLACEBO,,,,,,,,,,FG002,,,,
period,NCT02273050::period::1,NCT02273050,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02273050::outcome::primary::1,NCT02273050,Change From Baseline in HbA1c From Baseline to Week 24 Provided That it is Prior to Rescue,,,,,,,,,,,,,PRIMARY,Baseline to Week 24 (prior to rescue)
country,NCT02273050::country::China,NCT02273050,China,,,,,,,,,,,,,,
trial,NCT01853072,NCT01853072,Nepafenac Once Daily for Macular Edema - Study 1,PHASE3,diabetes type 2,Non-Proliferative Diabetic Retinopathy; Cataract,INDUSTRY,881.0,2013-06,2015-05,0.0,0.0,,,,,
arm,NCT01853072::arm::FG000,NCT01853072,Nepafenac,,,,,,,,,,FG000,"Nepafenac Ophthalmic Suspension, 0.3%",,,
arm,NCT01853072::arm::FG001,NCT01853072,Vehicle,,,,,,,,,,FG001,Nepafenac Ophthalmic Suspension Vehicle,,,
period,NCT01853072::period::1,NCT01853072,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01853072::outcome::primary::1,NCT01853072,Percentage of Participants With Best-corrected Visual Acuity (BCVA) Improvement of ≥ 15 Letters From Preoperative Baseline to Day 14 and Maintained Through Day 90,,,,,,,,,,,,,PRIMARY,"Baseline to Day 14, and maintained through Day 90"
outcome,NCT01853072::outcome::primary::2,NCT01853072,Percentage of Participants Who Develop Macular Edema Within 90 Days Following Cataract Surgery (Day 0),,,,,,,,,,,,,PRIMARY,Day 0 to Day 90
trial,NCT00328627,NCT00328627,Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,1554.0,2006-05,2008-03,19.0,90.0,,,,,
arm,NCT00328627::arm::FG000,NCT00328627,Placebo,,,,,,,,,,FG000,"Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.",,,
arm,NCT00328627::arm::FG001,NCT00328627,Alogliptin 12.5 + Placebo,,,,,,,,,,FG001,"Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.",,,
arm,NCT00328627::arm::FG002,NCT00328627,Alogliptin 25 + Placebo,,,,,,,,,,FG002,"Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.",,,
arm,NCT00328627::arm::FG003,NCT00328627,Placebo + Pioglitazone 15,,,,,,,,,,FG003,"Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.",,,
arm,NCT00328627::arm::FG004,NCT00328627,Alogliptin 12.5 + Pioglitazone 15,,,,,,,,,,FG004,"Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.",,,
arm,NCT00328627::arm::FG005,NCT00328627,Alogliptin 25 + Pioglitazone 15,,,,,,,,,,FG005,"Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.",,,
arm,NCT00328627::arm::FG006,NCT00328627,Placebo + Pioglitazone 30,,,,,,,,,,FG006,"Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.",,,
arm,NCT00328627::arm::FG007,NCT00328627,Alogliptin 12.5 + Pioglitazone 30,,,,,,,,,,FG007,"Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.",,,
arm,NCT00328627::arm::FG008,NCT00328627,Alogliptin 25 + Pioglitazone 30,,,,,,,,,,FG008,"Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.",,,
arm,NCT00328627::arm::FG009,NCT00328627,Placebo + Pioglitazone 45,,,,,,,,,,FG009,"Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.",,,
arm,NCT00328627::arm::FG010,NCT00328627,Alogliptin 12.5 + Pioglitazone 45,,,,,,,,,,FG010,"Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.",,,
arm,NCT00328627::arm::FG011,NCT00328627,Alogliptin 25 + Pioglitazone 45,,,,,,,,,,FG011,"Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.",,,
period,NCT00328627::period::1,NCT00328627,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00328627::outcome::primary::1,NCT00328627,Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c) (Grouped Analysis),,,,,,,,,,,,,PRIMARY,Baseline and Week 26
outcome,NCT00328627::outcome::primary::2,NCT00328627,Change From Baseline to Week 26 in HbA1c,,,,,,,,,,,,,PRIMARY,Baseline and Week 26
country,NCT00328627::country::United States,NCT00328627,United States,,,,,,,,,,,,,,
country,NCT00328627::country::Australia,NCT00328627,Australia,,,,,,,,,,,,,,
country,NCT00328627::country::Brazil,NCT00328627,Brazil,,,,,,,,,,,,,,
country,NCT00328627::country::Bulgaria,NCT00328627,Bulgaria,,,,,,,,,,,,,,
country,NCT00328627::country::Chile,NCT00328627,Chile,,,,,,,,,,,,,,
country,NCT00328627::country::Croatia,NCT00328627,Croatia,,,,,,,,,,,,,,
country,NCT00328627::country::Estonia,NCT00328627,Estonia,,,,,,,,,,,,,,
country,NCT00328627::country::Guatemala,NCT00328627,Guatemala,,,,,,,,,,,,,,
country,NCT00328627::country::India,NCT00328627,India,,,,,,,,,,,,,,
country,NCT00328627::country::Israel,NCT00328627,Israel,,,,,,,,,,,,,,
country,NCT00328627::country::Latvia,NCT00328627,Latvia,,,,,,,,,,,,,,
country,NCT00328627::country::Mexico,NCT00328627,Mexico,,,,,,,,,,,,,,
country,NCT00328627::country::New Zealand,NCT00328627,New Zealand,,,,,,,,,,,,,,
country,NCT00328627::country::Peru,NCT00328627,Peru,,,,,,,,,,,,,,
country,NCT00328627::country::Romania,NCT00328627,Romania,,,,,,,,,,,,,,
country,NCT00328627::country::Russia,NCT00328627,Russia,,,,,,,,,,,,,,
country,NCT00328627::country::Serbia,NCT00328627,Serbia,,,,,,,,,,,,,,
country,NCT00328627::country::South Africa,NCT00328627,South Africa,,,,,,,,,,,,,,
country,NCT00328627::country::Ukraine,NCT00328627,Ukraine,,,,,,,,,,,,,,
trial,NCT03191396,NCT03191396,Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,577.0,2017-06-27,2018-08-13,12.0,92.0,,,,,
arm,NCT03191396::arm::FG000,NCT03191396,Semaglutide 1.0 mg,,,,,,,,,,FG000,"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm on",,,
arm,NCT03191396::arm::FG001,NCT03191396,Liraglutide 1.2 mg,,,,,,,,,,FG001,"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm onc",,,
period,NCT03191396::period::1,NCT03191396,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03191396::outcome::primary::1,NCT03191396,Change in HbA1c,,,,,,,,,,,,,PRIMARY,"Week 0, week 30"
country,NCT03191396::country::United Kingdom,NCT03191396,United Kingdom,,,,,,,,,,,,,,
country,NCT03191396::country::France,NCT03191396,France,,,,,,,,,,,,,,
country,NCT03191396::country::Bulgaria,NCT03191396,Bulgaria,,,,,,,,,,,,,,
country,NCT03191396::country::Finland,NCT03191396,Finland,,,,,,,,,,,,,,
country,NCT03191396::country::Hungary,NCT03191396,Hungary,,,,,,,,,,,,,,
country,NCT03191396::country::Germany,NCT03191396,Germany,,,,,,,,,,,,,,
country,NCT03191396::country::Spain,NCT03191396,Spain,,,,,,,,,,,,,,
country,NCT03191396::country::Sweden,NCT03191396,Sweden,,,,,,,,,,,,,,
country,NCT03191396::country::Czechia,NCT03191396,Czechia,,,,,,,,,,,,,,
country,NCT03191396::country::Italy,NCT03191396,Italy,,,,,,,,,,,,,,
country,NCT03191396::country::Slovenia,NCT03191396,Slovenia,,,,,,,,,,,,,,
country,NCT03191396::country::Poland,NCT03191396,Poland,,,,,,,,,,,,,,
trial,NCT00701090,NCT00701090,A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED),PHASE3,diabetes type 2,"Type 2 Diabetes Mellitus, Non Insulin Dependent; Diabetes Mellitus, Non-Insulin-Dependent",INDUSTRY,1035.0,2008-05,2009-10,0.0,0.0,,,,,
arm,NCT00701090::arm::FG000,NCT00701090,Sitagliptin,,,,,,,,,,FG000,The Sitagliptin 100 mg q.d. (q.d. = once daily) group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing tr,,,
arm,NCT00701090::arm::FG001,NCT00701090,Glimepiride,,,,,,,,,,FG001,The Glimepiride group includes data from patients randomized to receive treatment starting with 1 mg oral tablets of glimepiride (blinded) up-titrated until Week 18 as needed to a maximum dose of 6 mg,,,
period,NCT00701090::period::1,NCT00701090,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00701090::outcome::primary::1,NCT00701090,Change From Baseline in HbA1c at Week 30,,,,,,,,,,,,,PRIMARY,Week 0 to Week 30
trial,NCT00474630,NCT00474630,A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Obesity; Overweight; Diabetes Mellitus, Type 2",INDUSTRY,505.0,2007-05,2009-06,1.0,53.0,,,,,
arm,NCT00474630::arm::FG000,NCT00474630,NB32,,,,,,,,,,FG000,Naltrexone SR 32 mg/Bupropion SR 360 mg/day,,,
arm,NCT00474630::arm::FG001,NCT00474630,Placebo,,,,,,,,,,FG001,Placebo,,,
period,NCT00474630::period::1,NCT00474630,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00474630::outcome::primary::1,NCT00474630,Co-primary: Body Weight- Mean Percent Change,,,,,,,,,,,,,PRIMARY,"Baseline, 56 weeks"
outcome,NCT00474630::outcome::primary::2,NCT00474630,Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease,,,,,,,,,,,,,PRIMARY,"Baseline, 56 weeks"
country,NCT00474630::country::United States,NCT00474630,United States,,,,,,,,,,,,,,
trial,NCT00856284,NCT00856284,Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,2639.0,2009-03,2012-10,32.0,261.0,,,,,
arm,NCT00856284::arm::FG000,NCT00856284,Metformin + Alogliptin 12.5 mg,,,,,,,,,,FG000,"Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.",,,
arm,NCT00856284::arm::FG001,NCT00856284,Metformin + Alogliptin 25 mg,,,,,,,,,,FG001,"Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.",,,
arm,NCT00856284::arm::FG002,NCT00856284,Metformin + Glipizide,,,,,,,,,,FG002,"Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, partic",,,
period,NCT00856284::period::1,NCT00856284,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00856284::outcome::primary::1,NCT00856284,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 52,,,,,,,,,,,,,PRIMARY,Baseline and Week 52
outcome,NCT00856284::outcome::primary::2,NCT00856284,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 104,,,,,,,,,,,,,PRIMARY,Baseline and Week 104
country,NCT00856284::country::United States,NCT00856284,United States,,,,,,,,,,,,,,
country,NCT00856284::country::Israel,NCT00856284,Israel,,,,,,,,,,,,,,
country,NCT00856284::country::Canada,NCT00856284,Canada,,,,,,,,,,,,,,
country,NCT00856284::country::Ukraine,NCT00856284,Ukraine,,,,,,,,,,,,,,
country,NCT00856284::country::Hungary,NCT00856284,Hungary,,,,,,,,,,,,,,
country,NCT00856284::country::India,NCT00856284,India,,,,,,,,,,,,,,
country,NCT00856284::country::Latvia,NCT00856284,Latvia,,,,,,,,,,,,,,
country,NCT00856284::country::New Zealand,NCT00856284,New Zealand,,,,,,,,,,,,,,
country,NCT00856284::country::Germany,NCT00856284,Germany,,,,,,,,,,,,,,
country,NCT00856284::country::Lithuania,NCT00856284,Lithuania,,,,,,,,,,,,,,
country,NCT00856284::country::Malaysia,NCT00856284,Malaysia,,,,,,,,,,,,,,
country,NCT00856284::country::Poland,NCT00856284,Poland,,,,,,,,,,,,,,
country,NCT00856284::country::Russia,NCT00856284,Russia,,,,,,,,,,,,,,
country,NCT00856284::country::United Kingdom,NCT00856284,United Kingdom,,,,,,,,,,,,,,
country,NCT00856284::country::Mexico,NCT00856284,Mexico,,,,,,,,,,,,,,
country,NCT00856284::country::Romania,NCT00856284,Romania,,,,,,,,,,,,,,
country,NCT00856284::country::South Africa,NCT00856284,South Africa,,,,,,,,,,,,,,
country,NCT00856284::country::Brazil,NCT00856284,Brazil,,,,,,,,,,,,,,
country,NCT00856284::country::Australia,NCT00856284,Australia,,,,,,,,,,,,,,
country,NCT00856284::country::Thailand,NCT00856284,Thailand,,,,,,,,,,,,,,
country,NCT00856284::country::Hong Kong,NCT00856284,Hong Kong,,,,,,,,,,,,,,
country,NCT00856284::country::Italy,NCT00856284,Italy,,,,,,,,,,,,,,
country,NCT00856284::country::Peru,NCT00856284,Peru,,,,,,,,,,,,,,
country,NCT00856284::country::South Korea,NCT00856284,South Korea,,,,,,,,,,,,,,
country,NCT00856284::country::Spain,NCT00856284,Spain,,,,,,,,,,,,,,
country,NCT00856284::country::Austria,NCT00856284,Austria,,,,,,,,,,,,,,
country,NCT00856284::country::Chile,NCT00856284,Chile,,,,,,,,,,,,,,
country,NCT00856284::country::Puerto Rico,NCT00856284,Puerto Rico,,,,,,,,,,,,,,
country,NCT00856284::country::Argentina,NCT00856284,Argentina,,,,,,,,,,,,,,
country,NCT00856284::country::Guatemala,NCT00856284,Guatemala,,,,,,,,,,,,,,
country,NCT00856284::country::Philippines,NCT00856284,Philippines,,,,,,,,,,,,,,
country,NCT00856284::country::Singapore,NCT00856284,Singapore,,,,,,,,,,,,,,
trial,NCT01790438,NCT01790438,A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,641.0,2013-03,2014-05,11.0,63.0,,,,,
arm,NCT01790438::arm::FG000,NCT01790438,LY2605541,,,,,,,,,,FG000,Administered by subcutaneous (SC) injection once daily in the morning or at bedtime. Initial dose was 10 units and was adjusted weekly based on Fasting Blood Glucose (FBG). LY2605541 was given alone o,,,
arm,NCT01790438::arm::FG001,NCT01790438,Human Insulin NPH,,,,,,,,,,FG001,Administered by SC injection once daily at bedtime. Initial dose was 10 units and was adjusted weekly based on FBG. Human insulin isophane suspension (NPH) was used alone or in combination with up to ,,,
period,NCT01790438::period::1,NCT01790438,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01790438::outcome::primary::1,NCT01790438,Change From Baseline to 26 Weeks in Hemoglobin A1c (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline, 26 Weeks"
country,NCT01790438::country::United States,NCT01790438,United States,,,,,,,,,,,,,,
country,NCT01790438::country::Germany,NCT01790438,Germany,,,,,,,,,,,,,,
country,NCT01790438::country::Canada,NCT01790438,Canada,,,,,,,,,,,,,,
country,NCT01790438::country::Poland,NCT01790438,Poland,,,,,,,,,,,,,,
country,NCT01790438::country::South Korea,NCT01790438,South Korea,,,,,,,,,,,,,,
country,NCT01790438::country::Spain,NCT01790438,Spain,,,,,,,,,,,,,,
country,NCT01790438::country::Czechia,NCT01790438,Czechia,,,,,,,,,,,,,,
country,NCT01790438::country::Hungary,NCT01790438,Hungary,,,,,,,,,,,,,,
country,NCT01790438::country::Puerto Rico,NCT01790438,Puerto Rico,,,,,,,,,,,,,,
country,NCT01790438::country::Argentina,NCT01790438,Argentina,,,,,,,,,,,,,,
country,NCT01790438::country::Mexico,NCT01790438,Mexico,,,,,,,,,,,,,,
trial,NCT01558271,NCT01558271,A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,492.0,2012-03,2014-05,1.0,14.0,,,,,
arm,NCT01558271::arm::FG000,NCT01558271,LY2189265,,,,,,,,,,FG000,"Once-weekly subcutaneous (SC) injection of 0.75 milligrams (mg) of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of op",,,
arm,NCT01558271::arm::FG001,NCT01558271,Placebo/LY2189265,,,,,,,,,,FG001,"Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy.",,,
arm,NCT01558271::arm::FG002,NCT01558271,Liraglutide,,,,,,,,,,FG002,"Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy.",,,
period,NCT01558271::period::1,NCT01558271,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01558271::outcome::primary::1,NCT01558271,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks,,,,,,,,,,,,,PRIMARY,"Baseline, 26 weeks"
country,NCT01558271::country::Japan,NCT01558271,Japan,,,,,,,,,,,,,,
trial,NCT02897349,NCT02897349,Linagliptin Add-on to Insulin Background Therapy,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,206.0,2016-09-30,2019-01-18,1.0,25.0,,,,,
arm,NCT02897349::arm::FG000,NCT02897349,Placebo Matching Linagliptin,,,,,,,,,,FG000,Participants were administered placebo matching 5 milligram (mg) linagliptin tablet once daily per os (p.o.) for 24 weeks.,,,
arm,NCT02897349::arm::FG001,NCT02897349,Linagliptin,,,,,,,,,,FG001,Participants were administered 5 milligram (mg) linagliptin tablet once daily per os (p.o.) for 24 weeks.,,,
period,NCT02897349::period::1,NCT02897349,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02897349::outcome::primary::1,NCT02897349,Percentage Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment,,,,,,,,,,,,,PRIMARY,Baseline and week 24
country,NCT02897349::country::China,NCT02897349,China,,,,,,,,,,,,,,
trial,NCT00545584,NCT00545584,Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078),PHASE3,diabetes type 2,"Diabetes Mellitus, Non-Insulin-Dependent",INDUSTRY,1512.0,2007-04-01,2009-11-19,0.0,0.0,,,,,
arm,NCT00545584::arm::FG000,NCT00545584,Sitagliptin With Standard of Care,,,,,,,,,,FG000,"Subjects received sitagliptin 100 mg once daily for 26 Weeks,

and:

No specific intervention (standard recommendation) on physical exercise and diet.",,,
arm,NCT00545584::arm::FG001,NCT00545584,Sitagliptin With Diet Advice,,,,,,,,,,FG001,"Subjects received sitagliptin 100 mg once daily for 26 Weeks,

and:

Intervention on diet which includes advice on diet with a leaflet and a diary",,,
arm,NCT00545584::arm::FG002,NCT00545584,Sitagliptin With Diet and Physical Activity Advice,,,,,,,,,,FG002,"Subjects received sitagliptin 100 mg once daily for 26 Weeks,

and:

Intervention on diet + physical activity which includes advice on diet and physical activity with leaflets and diaries PLUS advice ",,,
period,NCT00545584::period::1,NCT00545584,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00545584::outcome::primary::1,NCT00545584,Hemoglobin A1c Measurement,,,,,,,,,,,,,PRIMARY,Baseline and Week 24
trial,NCT01045447,NCT01045447,"Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes",PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,465.0,2010-01,2010-10,9.0,65.0,,,,,
arm,NCT01045447::arm::FG000,NCT01045447,IDegAsp OD,,,,,,,,,,FG000,Insulin degludec/insulin aspart (IDegAsp) was given once daily (OD) subcutaneously (s.c.) with main evening meal or the largest meal of the day in combination with metformin±pioglitazone±DPP-4 inhibit,,,
arm,NCT01045447::arm::FG001,NCT01045447,IGlar OD,,,,,,,,,,FG001,Insulin glargine (IGlar) was given once daily (OD) subcutaneously according to approved labelling in combination with metformin±pioglitazone±DPP-4. inhibitor.,,,
period,NCT01045447::period::1,NCT01045447,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01045447::outcome::primary::1,NCT01045447,Change in Glycosylated Haemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Week 0, Week 26"
country,NCT01045447::country::United States,NCT01045447,United States,,,,,,,,,,,,,,
country,NCT01045447::country::India,NCT01045447,India,,,,,,,,,,,,,,
country,NCT01045447::country::France,NCT01045447,France,,,,,,,,,,,,,,
country,NCT01045447::country::South Korea,NCT01045447,South Korea,,,,,,,,,,,,,,
country,NCT01045447::country::Turkey (Türkiye),NCT01045447,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01045447::country::Sweden,NCT01045447,Sweden,,,,,,,,,,,,,,
country,NCT01045447::country::Poland,NCT01045447,Poland,,,,,,,,,,,,,,
country,NCT01045447::country::South Africa,NCT01045447,South Africa,,,,,,,,,,,,,,
country,NCT01045447::country::Croatia,NCT01045447,Croatia,,,,,,,,,,,,,,
trial,NCT02551874,NCT02551874,"A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin",PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,650.0,2015-10-20,2017-11-10,10.0,40.0,,,,,
arm,NCT02551874::arm::FG000,NCT02551874,Dapagliflozin + Saxagliptin + Metformin,,,,,,,,,,FG000,"Subjects received dapagliflozin 10 milligrams (mg) and saxagliptin 5 mg, administered orally once daily (QD) in the morning for the 52-week treatment period (24-week short-term period and 28-week long",,,
arm,NCT02551874::arm::FG001,NCT02551874,Titrated Insulin + Metformin,,,,,,,,,,FG001,"Subjects were to administer insulin glargine subcutaneously QD at the same time every day for the 52-week treatment period (24-week short-term period and 28-week long term period), following investiga",,,
period,NCT02551874::period::1,NCT02551874,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02551874::outcome::primary::1,NCT02551874,Mean Change From Baseline in HbA1c at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and Week 24
country,NCT02551874::country::United States,NCT02551874,United States,,,,,,,,,,,,,,
country,NCT02551874::country::Mexico,NCT02551874,Mexico,,,,,,,,,,,,,,
country,NCT02551874::country::Romania,NCT02551874,Romania,,,,,,,,,,,,,,
country,NCT02551874::country::Hungary,NCT02551874,Hungary,,,,,,,,,,,,,,
country,NCT02551874::country::Poland,NCT02551874,Poland,,,,,,,,,,,,,,
country,NCT02551874::country::Czechia,NCT02551874,Czechia,,,,,,,,,,,,,,
country,NCT02551874::country::Denmark,NCT02551874,Denmark,,,,,,,,,,,,,,
country,NCT02551874::country::South Africa,NCT02551874,South Africa,,,,,,,,,,,,,,
country,NCT02551874::country::Spain,NCT02551874,Spain,,,,,,,,,,,,,,
country,NCT02551874::country::Sweden,NCT02551874,Sweden,,,,,,,,,,,,,,
trial,NCT01422876,NCT01422876,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,1405.0,2011-08,2013-09,22.0,211.0,,,,,
arm,NCT01422876::arm::FG000,NCT01422876,Metformin Background: Empagliflozin 25 mg/Linagliptin 5 mg,,,,,,,,,,FG000,Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12,,,
arm,NCT01422876::arm::FG001,NCT01422876,Metformin Background: Empagliflozin 10 mg/Linagliptin 5 mg,,,,,,,,,,FG001,Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12,,,
arm,NCT01422876::arm::FG002,NCT01422876,Metformin Background: Empagliflozin 25 mg,,,,,,,,,,FG002,Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12,,,
arm,NCT01422876::arm::FG003,NCT01422876,Metformin Background: Empagliflozin 10 mg,,,,,,,,,,FG003,Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12,,,
arm,NCT01422876::arm::FG004,NCT01422876,Metformin Background: Linagliptin 5 mg,,,,,,,,,,FG004,Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12,,,
arm,NCT01422876::arm::FG005,NCT01422876,Treatment Naive: Empagliflozin 25 mg/Linagliptin 5 mg,,,,,,,,,,FG005,"Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.

Test product: Empagliflozin/linagliptin FDC table",,,
arm,NCT01422876::arm::FG006,NCT01422876,Treament Naive: Empagliflozin 10 mg/Linagliptin 5 mg,,,,,,,,,,FG006,"Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.

Test product: Empagliflozin/linagliptin FDC table",,,
arm,NCT01422876::arm::FG007,NCT01422876,Treatment Naive: Empagliflozin 25 mg,,,,,,,,,,FG007,"Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.

Reference therapy 1: Empagliflozin tablets dose: ",,,
arm,NCT01422876::arm::FG008,NCT01422876,Treatment Naive: Empagliflozin 10 mg,,,,,,,,,,FG008,"Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.

Reference therapy 1: Empagliflozin tablets dose: ",,,
arm,NCT01422876::arm::FG009,NCT01422876,Treatment Naive: Linagliptin 5 mg,,,,,,,,,,FG009,"Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.

Reference therapy 2: Linagliptin tablets dose: 5 ",,,
period,NCT01422876::period::1,NCT01422876,Week 24,,,,,,,,,,,,1.0,,
period,NCT01422876::period::2,NCT01422876,Week 52,,,,,,,,,,,,2.0,,
outcome,NCT01422876::outcome::primary::1,NCT01422876,Change From Baseline in Glycosylated Hemoglobin (HbA1c) for Metformin Background Patients,,,,,,,,,,,,,PRIMARY,Baseline and 24 weeks
outcome,NCT01422876::outcome::primary::2,NCT01422876,Change From Baseline in Glycosylated Hemoglobin (HbA1c) for Treatment Naive Patients,,,,,,,,,,,,,PRIMARY,Baseline and 24 weeks
country,NCT01422876::country::United States,NCT01422876,United States,,,,,,,,,,,,,,
country,NCT01422876::country::Romania,NCT01422876,Romania,,,,,,,,,,,,,,
country,NCT01422876::country::Canada,NCT01422876,Canada,,,,,,,,,,,,,,
country,NCT01422876::country::Taiwan,NCT01422876,Taiwan,,,,,,,,,,,,,,
country,NCT01422876::country::Lebanon,NCT01422876,Lebanon,,,,,,,,,,,,,,
country,NCT01422876::country::Philippines,NCT01422876,Philippines,,,,,,,,,,,,,,
country,NCT01422876::country::Russia,NCT01422876,Russia,,,,,,,,,,,,,,
country,NCT01422876::country::Argentina,NCT01422876,Argentina,,,,,,,,,,,,,,
country,NCT01422876::country::Estonia,NCT01422876,Estonia,,,,,,,,,,,,,,
country,NCT01422876::country::Mexico,NCT01422876,Mexico,,,,,,,,,,,,,,
country,NCT01422876::country::Peru,NCT01422876,Peru,,,,,,,,,,,,,,
country,NCT01422876::country::Spain,NCT01422876,Spain,,,,,,,,,,,,,,
country,NCT01422876::country::Colombia,NCT01422876,Colombia,,,,,,,,,,,,,,
country,NCT01422876::country::Italy,NCT01422876,Italy,,,,,,,,,,,,,,
country,NCT01422876::country::Poland,NCT01422876,Poland,,,,,,,,,,,,,,
country,NCT01422876::country::Brazil,NCT01422876,Brazil,,,,,,,,,,,,,,
country,NCT01422876::country::Bulgaria,NCT01422876,Bulgaria,,,,,,,,,,,,,,
country,NCT01422876::country::Denmark,NCT01422876,Denmark,,,,,,,,,,,,,,
country,NCT01422876::country::Hungary,NCT01422876,Hungary,,,,,,,,,,,,,,
country,NCT01422876::country::Sweden,NCT01422876,Sweden,,,,,,,,,,,,,,
country,NCT01422876::country::Australia,NCT01422876,Australia,,,,,,,,,,,,,,
country,NCT01422876::country::Malaysia,NCT01422876,Malaysia,,,,,,,,,,,,,,
trial,NCT02791490,NCT02791490,A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,458.0,2016-06-16,2018-02-01,0.0,0.0,,,,,
arm,NCT02791490::arm::FG000,NCT02791490,Sitagliptin,,,,,,,,,,FG000,"Participants received sitagliptin 100 mg once daily for 20 weeks. They also received immediate-release metformin (Met-IR), which was titrated from a baseline dose of 1000 mg/day (500 mg/twice a day \[",,,
arm,NCT02791490::arm::FG001,NCT02791490,Placebo,,,,,,,,,,FG001,"Participants received placebo matching sitagliptin once daily for 20 weeks. They also received Met-IR, which was titrated from baseline dose of 1000 mg/day (500 mg/b.i.d.) up to 2000 mg/day (1000 mg/b",,,
period,NCT02791490::period::1,NCT02791490,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02791490::outcome::primary::1,NCT02791490,Change From Baseline in Hemoglobin A1C at Week 20,,,,,,,,,,,,,PRIMARY,Baseline and Week 20
outcome,NCT02791490::outcome::primary::2,NCT02791490,Percentage of Participants Who Experienced at Least One Adverse Event (AE),,,,,,,,,,,,,PRIMARY,Up to 22 weeks
outcome,NCT02791490::outcome::primary::3,NCT02791490,Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event,,,,,,,,,,,,,PRIMARY,Up to 20 weeks
trial,NCT03436693,NCT03436693,Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy,PHASE3,diabetes type 2,Diabetic Nephropathy,INDUSTRY,308.0,2018-02-15,2021-01-21,1.0,26.0,,,,,
arm,NCT03436693::arm::FG000,NCT03436693,Canagliflozin 100mg,,,,,,,,,,FG000,Canagliflozin 100mg orally once daily for 104 Weeks,,,
arm,NCT03436693::arm::FG001,NCT03436693,Placebo,,,,,,,,,,FG001,Placebo orally once daily for 104 Weeks,,,
period,NCT03436693::period::1,NCT03436693,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03436693::outcome::primary::1,NCT03436693,Percentage of Participants With 30% Decline in Estimated Glomerular Filtration Rate (eGFR) From Baseline at Week 104,,,,,,,,,,,,,PRIMARY,Week 104
country,NCT03436693::country::Japan,NCT03436693,Japan,,,,,,,,,,,,,,
trial,NCT01485614,NCT01485614,Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083),PHASE3,diabetes type 2,Diabetes Mellitus; Type 2 Diabetes,INDUSTRY,200.0,2012-02-10,2019-10-09,0.0,0.0,,,,,
arm,NCT01485614::arm::FG000,NCT01485614,Sitagliptin,,,,,,,,,,FG000,Participants received 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Partici,,,
arm,NCT01485614::arm::FG001,NCT01485614,Placebo/Metformin,,,,,,,,,,FG001,Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during We,,,
arm,NCT01485614::arm::FG002,NCT01485614,Metformin,,,,,,,,,,FG002,Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Partici,,,
arm,NCT01485614::arm::FG003,NCT01485614,Placebo/Sitagliptin,,,,,,,,,,FG003,Participants received 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during We,,,
period,NCT01485614::period::1,NCT01485614,Randomization,,,,,,,,,,,,1.0,,
period,NCT01485614::period::2,NCT01485614,Weeks 0-20,,,,,,,,,,,,2.0,,
period,NCT01485614::period::3,NCT01485614,Weeks 20-54,,,,,,,,,,,,3.0,,
outcome,NCT01485614::outcome::primary::1,NCT01485614,Change From Baseline in Hemoglobin A1C (A1C) at Week 20,,,,,,,,,,,,,PRIMARY,Baseline and Week 20
outcome,NCT01485614::outcome::primary::2,NCT01485614,Baseline Glycated Hemoglobin (A1C) for the Placebo (Pooled) Arm,,,,,,,,,,,,,PRIMARY,Baseline
outcome,NCT01485614::outcome::primary::3,NCT01485614,Change From Baseline In A1C at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled)),,,,,,,,,,,,,PRIMARY,Baseline and Week 20
outcome,NCT01485614::outcome::primary::4,NCT01485614,Number of Participants Who Experienced ≥1 Adverse Event During Weeks 0-56,,,,,,,,,,,,,PRIMARY,Up to Week 56
outcome,NCT01485614::outcome::primary::5,NCT01485614,Percentage of Participants Who Experienced ≥1 Adverse Event During Weeks 0-56 (Analysis of Selected Arms: Sitagliptin and Placebo/Metformin),,,,,,,,,,,,,PRIMARY,Up to Week 56
outcome,NCT01485614::outcome::primary::6,NCT01485614,Number of Participants Who Discontinued Study Drug Due to an Adverse Event During Weeks 0-54,,,,,,,,,,,,,PRIMARY,Up to Week 54
outcome,NCT01485614::outcome::primary::7,NCT01485614,Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event During Weeks 0-54 (Analysis of Selected Arms: Sitagliptin and Placebo/Metformin),,,,,,,,,,,,,PRIMARY,Up to Week 54
trial,NCT01406717,NCT01406717,Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,360.0,2013-03-01,2015-11-04,1.0,34.0,,,,,
arm,NCT01406717::arm::FG000,NCT01406717,SPIL1033,,,,,,,,,,FG000,SPIL1033: 5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks. To be self-administered twice daily.,,,
arm,NCT01406717::arm::FG001,NCT01406717,Placebo,,,,,,,,,,FG001,Placebo: 5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks. To be self-administered twice daily.,,,
period,NCT01406717::period::1,NCT01406717,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01406717::outcome::primary::1,NCT01406717,Change From Baseline to End of Study in Hemoglobin A1c (HbA1c),,,,,,,,,,,,,PRIMARY,24 weeks
outcome,NCT01406717::outcome::primary::2,NCT01406717,Change From Baseline to End of Study in Fasting Plasma Glucose (FPG),,,,,,,,,,,,,PRIMARY,24 weeks
outcome,NCT01406717::outcome::primary::3,NCT01406717,Count and Percentage of Subjects Positive for Anti-exenatide Antibodies,,,,,,,,,,,,,PRIMARY,24 weeks
outcome,NCT01406717::outcome::primary::4,NCT01406717,Count and Percentage of Subjects With Potentially Immune-related Treatment-emergent Adverse Events (TEAEs),,,,,,,,,,,,,PRIMARY,24 weeks
country,NCT01406717::country::India,NCT01406717,India,,,,,,,,,,,,,,
trial,NCT01814748,NCT01814748,A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028),PHASE3,diabetes type 2,Diabetes Mellitus,INDUSTRY,203.0,2013-05-03,2015-09-14,0.0,0.0,,,,,
arm,NCT01814748::arm::FG000,NCT01814748,Omarigliptin 25 mg,,,,,,,,,,FG000,"Omarigliptin 25 mg, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.",,,
arm,NCT01814748::arm::FG001,NCT01814748,Placebo,,,,,,,,,,FG001,"Placebo to omarigliptin, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.",,,
period,NCT01814748::period::1,NCT01814748,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01814748::outcome::primary::1,NCT01814748,Change From Baseline in A1C at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and Week 24
outcome,NCT01814748::outcome::primary::2,NCT01814748,Percentage of Participants Who Experienced at Least One Adverse Event (AE),,,,,,,,,,,,,PRIMARY,Up to Week 27
outcome,NCT01814748::outcome::primary::3,NCT01814748,Percentage of Participants Who Discontinued Study Drug Due to an AE,,,,,,,,,,,,,PRIMARY,Up to Week 24
trial,NCT00131664,NCT00131664,Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,OTHER,391.0,2005-09,2008-01,1.0,1.0,,,,,
arm,NCT00131664::arm::FG000,NCT00131664,Avandia and Amaryl,,,,,,,,,,FG000,Avandia™ + Amaryl™ Arm: at month 2 initial dose of 4 mg + 1 mg once daily (OD) was titrated up to 8 mg + 1 mg OD; at month 4 it was further titrated up to 8 mg + 2 mg OD.,,,
arm,NCT00131664::arm::FG001,NCT00131664,Avandamet,,,,,,,,,,FG001,Avandamet™ Arm: at month 2 the initial dose of 2 mg / 500 mg twice daily (BID) was titrated up to 4 mg / 500 mg BID; at month 4 it was be further titrated up to 4 mg / 1000 mg BID.,,,
arm,NCT00131664::arm::FG002,NCT00131664,Metformin,,,,,,,,,,FG002,"Metformin Arm: initial dose of 500 mg twice daily (BID) was titrated up to 850 mg BID at month 2. At month 4, it was further titrated up to 1000 mg BID.",,,
arm,NCT00131664::arm::FG003,NCT00131664,"Avandia, Amaryl and Metformin",,,,,,,,,,FG003,"Avandia™ + Amaryl™ Arm: At month 6, if patients not achieving A1C target of less than 7 received additional specified drug therapy. Metformin was added and titrated up to 1000 mg twice daily (BID) max",,,
arm,NCT00131664::arm::FG004,NCT00131664,Avandamet and Amaryl,,,,,,,,,,FG004,"Avandamet™ Arm: At month 6, if patients not achieving A1C target of less than 7 received additional specified drug therapy. Amaryl™ was added and titrated up to 4 mg once daily maximum dose for an add",,,
arm,NCT00131664::arm::FG005,NCT00131664,Metformin and Amaryl,,,,,,,,,,FG005,"Metformin Arm: At month 6, if patients not achieving A1C target of less than 7 received additional specified drug therapy. Amaryl™ was added and titrated up to 4 mg once daily maximum dose for an addi",,,
period,NCT00131664::period::1,NCT00131664,First Period (First 6 Months),,,,,,,,,,,,1.0,,
period,NCT00131664::period::2,NCT00131664,Second Period (Additional Drug Added),,,,,,,,,,,,2.0,,
outcome,NCT00131664::outcome::primary::1,NCT00131664,Mean Change From Baseline in A1C at Month 6,,,,,,,,,,,,,PRIMARY,Baseline and Month 6
country,NCT00131664::country::Canada,NCT00131664,Canada,,,,,,,,,,,,,,
trial,NCT02226003,NCT02226003,Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,291.0,2014-09-23,2016-02-23,0.0,0.0,,,,,
arm,NCT02226003::arm::FG000,NCT02226003,Ertugliflozin 5 mg + Sitagliptin 100 mg,,,,,,,,,,FG000,"Ertugliflozin, 5 mg, administered orally, once daily for 26 weeks. Sitagliptin, 100 mg, administered orally, once daily for 26 weeks. Placebo to ertugliflozin, 10 mg, administered orally, once daily f",,,
arm,NCT02226003::arm::FG001,NCT02226003,Ertugliflozin 15 mg + Sitagliptin 100 mg,,,,,,,,,,FG001,"Ertugliflozin, 15 mg, administered orally, once daily for 26 weeks. Sitagliptin, 100 mg, administered orally, once daily for 26 weeks.",,,
arm,NCT02226003::arm::FG002,NCT02226003,Placebo,,,,,,,,,,FG002,"Placebo to ertugliflozin, 5 mg and 10 mg, administered orally, once daily for 26 weeks. Placebo to sitagliptin, 100 mg, administered orally, once daily for 26 weeks.",,,
period,NCT02226003::period::1,NCT02226003,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02226003::outcome::primary::1,NCT02226003,Change From Baseline in Hemoglobin A1C (HbA1C) at Week 26 - Full Analysis Set (FAS Population Excluding Rescue Approach,,,,,,,,,,,,,PRIMARY,Baseline and Week 26
outcome,NCT02226003::outcome::primary::2,NCT02226003,Percentage of Participants Who Experienced an Adverse Event (AE) - All Participants as Treated Excluding Rescue Approach,,,,,,,,,,,,,PRIMARY,Up to Week 28
outcome,NCT02226003::outcome::primary::3,NCT02226003,Percentage of Participants Who Discontinued Study Medication Due to an AE - All Participants as Treated Excluding Rescue Approach,,,,,,,,,,,,,PRIMARY,Up to Week 26
trial,NCT00975286,NCT00975286,24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,446.0,2009-10,2011-08,26.0,140.0,,,,,
arm,NCT00975286::arm::FG000,NCT00975286,Placebo,,,,,,,,,,FG000,"2-step initiation regimen of volume matching placebo: 10 microgram (mcg) once daily (QD) subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.",,,
arm,NCT00975286::arm::FG001,NCT00975286,Lixisenatide,,,,,,,,,,FG001,"2-step initiation regimen of lixisenatide: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.",,,
period,NCT00975286::period::1,NCT00975286,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00975286::outcome::primary::1,NCT00975286,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
country,NCT00975286::country::United States,NCT00975286,United States,,,,,,,,,,,,,,
country,NCT00975286::country::Canada,NCT00975286,Canada,,,,,,,,,,,,,,
country,NCT00975286::country::India,NCT00975286,India,,,,,,,,,,,,,,
country,NCT00975286::country::Romania,NCT00975286,Romania,,,,,,,,,,,,,,
country,NCT00975286::country::Argentina,NCT00975286,Argentina,,,,,,,,,,,,,,
country,NCT00975286::country::Hungary,NCT00975286,Hungary,,,,,,,,,,,,,,
country,NCT00975286::country::Poland,NCT00975286,Poland,,,,,,,,,,,,,,
country,NCT00975286::country::Chile,NCT00975286,Chile,,,,,,,,,,,,,,
country,NCT00975286::country::France,NCT00975286,France,,,,,,,,,,,,,,
country,NCT00975286::country::Mexico,NCT00975286,Mexico,,,,,,,,,,,,,,
country,NCT00975286::country::Sweden,NCT00975286,Sweden,,,,,,,,,,,,,,
country,NCT00975286::country::Ukraine,NCT00975286,Ukraine,,,,,,,,,,,,,,
country,NCT00975286::country::Brazil,NCT00975286,Brazil,,,,,,,,,,,,,,
country,NCT00975286::country::Estonia,NCT00975286,Estonia,,,,,,,,,,,,,,
country,NCT00975286::country::Israel,NCT00975286,Israel,,,,,,,,,,,,,,
country,NCT00975286::country::Taiwan,NCT00975286,Taiwan,,,,,,,,,,,,,,
country,NCT00975286::country::Colombia,NCT00975286,Colombia,,,,,,,,,,,,,,
country,NCT00975286::country::Denmark,NCT00975286,Denmark,,,,,,,,,,,,,,
country,NCT00975286::country::Germany,NCT00975286,Germany,,,,,,,,,,,,,,
country,NCT00975286::country::Netherlands,NCT00975286,Netherlands,,,,,,,,,,,,,,
country,NCT00975286::country::South Africa,NCT00975286,South Africa,,,,,,,,,,,,,,
country,NCT00975286::country::Czechia,NCT00975286,Czechia,,,,,,,,,,,,,,
country,NCT00975286::country::Italy,NCT00975286,Italy,,,,,,,,,,,,,,
country,NCT00975286::country::Malaysia,NCT00975286,Malaysia,,,,,,,,,,,,,,
country,NCT00975286::country::Puerto Rico,NCT00975286,Puerto Rico,,,,,,,,,,,,,,
country,NCT00975286::country::Russia,NCT00975286,Russia,,,,,,,,,,,,,,
trial,NCT02229383,NCT02229383,Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus,PHASE3,diabetes type 2,Diabetes Mellitus,INDUSTRY,464.0,2014-09-06,2016-08-29,6.0,123.0,,,,,
arm,NCT02229383::arm::FG000,NCT02229383,Exenatide,,,,,,,,,,FG000,Exenatide 2 milligram (mg) 1 time per week + titrated basal insulin glargine with or without metformin.,,,
arm,NCT02229383::arm::FG001,NCT02229383,Placebo,,,,,,,,,,FG001,Placebo (matching with exenatide) 1 time per week + titrated basal insulin glargine with or without metformin.,,,
period,NCT02229383::period::1,NCT02229383,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02229383::outcome::primary::1,NCT02229383,Change in HbA1c From Baseline to Week 28,,,,,,,,,,,,,PRIMARY,Baseline to Week 28
country,NCT02229383::country::United States,NCT02229383,United States,,,,,,,,,,,,,,
country,NCT02229383::country::Hungary,NCT02229383,Hungary,,,,,,,,,,,,,,
country,NCT02229383::country::Slovakia,NCT02229383,Slovakia,,,,,,,,,,,,,,
country,NCT02229383::country::Romania,NCT02229383,Romania,,,,,,,,,,,,,,
country,NCT02229383::country::Poland,NCT02229383,Poland,,,,,,,,,,,,,,
country,NCT02229383::country::South Africa,NCT02229383,South Africa,,,,,,,,,,,,,,
trial,NCT00763451,NCT00763451,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin",PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,484.0,2008-09,2011-01,15.0,15.0,,,,,
arm,NCT00763451::arm::FG000,NCT00763451,Placebo (Two-Step Titration),,,,,,,,,,FG000,"2-step initiation regimen of volume matching placebo: 10 microgram (mcg) once daily (QD) subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.",,,
arm,NCT00763451::arm::FG001,NCT00763451,Placebo (One-Step Titration),,,,,,,,,,FG001,"1-step initiation regimen of volume matching placebo: 10 mcg QD subcutaneously for 2 weeks, then 20 mcg QD up to the end of treatment.",,,
arm,NCT00763451::arm::FG002,NCT00763451,Lixisenatide (Two-Step Titration),,,,,,,,,,FG002,"2-step initiation regimen of lixisenatide: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.",,,
arm,NCT00763451::arm::FG003,NCT00763451,Lixisenatide (One-Step Titration),,,,,,,,,,FG003,"1-step initiation regimen of lixisenatide: 10 mcg QD subcutaneously for 2 weeks, then 20 mcg QD up to the end of treatment.",,,
period,NCT00763451::period::1,NCT00763451,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00763451::outcome::primary::1,NCT00763451,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
country,NCT00763451::country::United States,NCT00763451,United States,,,,,,,,,,,,,,
country,NCT00763451::country::Brazil,NCT00763451,Brazil,,,,,,,,,,,,,,
country,NCT00763451::country::Chile,NCT00763451,Chile,,,,,,,,,,,,,,
country,NCT00763451::country::Colombia,NCT00763451,Colombia,,,,,,,,,,,,,,
country,NCT00763451::country::Estonia,NCT00763451,Estonia,,,,,,,,,,,,,,
country,NCT00763451::country::Germany,NCT00763451,Germany,,,,,,,,,,,,,,
country,NCT00763451::country::Italy,NCT00763451,Italy,,,,,,,,,,,,,,
country,NCT00763451::country::Lithuania,NCT00763451,Lithuania,,,,,,,,,,,,,,
country,NCT00763451::country::Malaysia,NCT00763451,Malaysia,,,,,,,,,,,,,,
country,NCT00763451::country::Mexico,NCT00763451,Mexico,,,,,,,,,,,,,,
country,NCT00763451::country::Philippines,NCT00763451,Philippines,,,,,,,,,,,,,,
country,NCT00763451::country::Poland,NCT00763451,Poland,,,,,,,,,,,,,,
country,NCT00763451::country::Romania,NCT00763451,Romania,,,,,,,,,,,,,,
country,NCT00763451::country::Slovakia,NCT00763451,Slovakia,,,,,,,,,,,,,,
country,NCT00763451::country::Ukraine,NCT00763451,Ukraine,,,,,,,,,,,,,,
trial,NCT00256867,NCT00256867,A Study In Patients With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,369.0,2005-08-18,2006-10-31,6.0,85.0,,,,,
arm,NCT00256867::arm::FG000,NCT00256867,Fixed Dose Combination (FDC) 4/40 Milligram (mg),,,,,,,,,,FG000,Participants received FDC of rosiglitazone (RSG) 4.0 mg and simvastatin (SIMV) 40 mg (FDC 4/40) and matching placebo once a day for 16 weeks. In case of the participants who had Low Density Lipoprotei,,,
arm,NCT00256867::arm::FG001,NCT00256867,FDC 4/80 mg,,,,,,,,,,FG001,Participants received FDC RSG/SIMV 4/80 mg and SIMV 40 mg matching placebo once a day for 16 weeks.,,,
arm,NCT00256867::arm::FG002,NCT00256867,FDC 8/40 mg,,,,,,,,,,FG002,Participants received FDC RSG/SIMV 8/40 mg once a day and matching placebo once a day for 16 weeks. In case of the participants who had LDL-c \>130 mg/dL at Visit 4a (Week 6) the treatment doses were ,,,
arm,NCT00256867::arm::FG003,NCT00256867,FDC 8/80 mg,,,,,,,,,,FG003,Participants received FDC RSG/SIMV 8/80 mg and matching placebo once a day for 16 weeks.,,,
arm,NCT00256867::arm::FG004,NCT00256867,RSG 4mg,,,,,,,,,,FG004,"Participants received RSG 4.0 mg and matching placebo once a day for 16 weeks. In case of the participants who had LDL-c \>130 mg/dL evaluated at Visit 4a (Week 6), the treatment doses were titrated u",,,
arm,NCT00256867::arm::FG005,NCT00256867,RSG 8mg,,,,,,,,,,FG005,Participants received RSG 8.0 mg and matching placebo once a day for 16 weeks. In case of the participants who had LDL-c \>130 mg/dL at Visit 4a (Week 6) the treatment doses were up titrated to RSG/SI,,,
arm,NCT00256867::arm::FG006,NCT00256867,SIMV 40mg,,,,,,,,,,FG006,Participants received SIMV 40 mg and matching placebo once a day for 16 weeks. In case of the participants who had LDL-c \>130 mg/dL at Visit 4a (Week 6) the treatment doses were up titrated to SIMV/S,,,
arm,NCT00256867::arm::FG007,NCT00256867,SIMV 80mg,,,,,,,,,,FG007,Participants received SIMV/SIMV 40/40 mg once a day for 16 weeks.,,,
period,NCT00256867::period::1,NCT00256867,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00256867::outcome::primary::1,NCT00256867,Median Percent Change From Baseline to Week 6 in LDL-c in FDC and RSG Monotherapy,,,,,,,,,,,,,PRIMARY,Baseline (Week 0) and Week 6
country,NCT00256867::country::United States,NCT00256867,United States,,,,,,,,,,,,,,
country,NCT00256867::country::Canada,NCT00256867,Canada,,,,,,,,,,,,,,
country,NCT00256867::country::Australia,NCT00256867,Australia,,,,,,,,,,,,,,
country,NCT00256867::country::Mexico,NCT00256867,Mexico,,,,,,,,,,,,,,
country,NCT00256867::country::Philippines,NCT00256867,Philippines,,,,,,,,,,,,,,
country,NCT00256867::country::Puerto Rico,NCT00256867,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00086515,NCT00086515,Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED),PHASE3,diabetes type 2,"Diabetes Mellitus, Type II",INDUSTRY,701.0,2004-06-30,2007-02-02,0.0,0.0,,,,,
arm,NCT00086515::arm::FG000,NCT00086515,Sitagliptin 100 mg,,,,,,,,,,FG000,The Sitagliptin 100 mg group includes patients who were administered once-daily treatment with oral tablets of sitagliptin 100 mg during Phase A (Weeks 0-24) of the treatment period. During Phase B (W,,,
arm,NCT00086515::arm::FG001,NCT00086515,Placebo / Glipizide 5 mg,,,,,,,,,,FG001,"The Placebo/Glipizide 5 mg group includes patients who were administered once-daily treatment with oral

tablets of sitagliptin-matched placebo during Phase A (Weeks 0-24) of the treatment period. Dur",,,
period,NCT00086515::period::1,NCT00086515,Phase A (Weeks 0-24),,,,,,,,,,,,1.0,,
period,NCT00086515::period::2,NCT00086515,Phase A to Phase B Transition Period,,,,,,,,,,,,2.0,,
period,NCT00086515::period::3,NCT00086515,Phase B (Weeks 24-104),,,,,,,,,,,,3.0,,
outcome,NCT00086515::outcome::primary::1,NCT00086515,Change From Baseline in Hemoglobin A1C (A1C) at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and Week 24
trial,NCT01494987,NCT01494987,Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,431.0,2012-01,2013-08,12.0,140.0,,,,,
arm,NCT01494987::arm::FG000,NCT01494987,Placebo+Glimepiride,,,,,,,,,,FG000,"Glimepiride stabilization period (up to 8 weeks): participants not on stable glimepiride received glimepiride 2 mg once daily, and if tolerated the dose was increased on Day 8 (+ 2 days) to 4 mg once ",,,
arm,NCT01494987::arm::FG001,NCT01494987,Ranolazine+Glimepiride,,,,,,,,,,FG001,"Glimepiride stabilization period (up to 8 weeks): participants not on stable glimepiride received glimepiride 2 mg once daily, and if tolerated the dose was increased on Day 8 (+ 2 days) to 4 mg once ",,,
period,NCT01494987::period::1,NCT01494987,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01494987::outcome::primary::1,NCT01494987,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,,,,,,,,,,,,,PRIMARY,Baseline
country,NCT01494987::country::United States,NCT01494987,United States,,,,,,,,,,,,,,
country,NCT01494987::country::Russia,NCT01494987,Russia,,,,,,,,,,,,,,
country,NCT01494987::country::Romania,NCT01494987,Romania,,,,,,,,,,,,,,
country,NCT01494987::country::South Africa,NCT01494987,South Africa,,,,,,,,,,,,,,
country,NCT01494987::country::Ukraine,NCT01494987,Ukraine,,,,,,,,,,,,,,
country,NCT01494987::country::Poland,NCT01494987,Poland,,,,,,,,,,,,,,
country,NCT01494987::country::Hungary,NCT01494987,Hungary,,,,,,,,,,,,,,
country,NCT01494987::country::Slovakia,NCT01494987,Slovakia,,,,,,,,,,,,,,
country,NCT01494987::country::Thailand,NCT01494987,Thailand,,,,,,,,,,,,,,
country,NCT01494987::country::Serbia,NCT01494987,Serbia,,,,,,,,,,,,,,
country,NCT01494987::country::Czechia,NCT01494987,Czechia,,,,,,,,,,,,,,
country,NCT01494987::country::Malaysia,NCT01494987,Malaysia,,,,,,,,,,,,,,
trial,NCT00712673,NCT00712673,"GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin",PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,680.0,2008-06,2011-03,16.0,16.0,,,,,
arm,NCT00712673::arm::FG000,NCT00712673,Placebo (Morning Injection),,,,,,,,,,FG000,"2-step initiation morning regimen of volume matching placebo: 10 microgram (mcg) once daily (QD) subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.",,,
arm,NCT00712673::arm::FG001,NCT00712673,Placebo (Evening Injection),,,,,,,,,,FG001,"2-step initiation evening regimen of volume matching placebo: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.",,,
arm,NCT00712673::arm::FG002,NCT00712673,Lixisenatide (Morning Injection),,,,,,,,,,FG002,"2-step initiation morning regimen of lixisenatide: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.",,,
arm,NCT00712673::arm::FG003,NCT00712673,Lixisenatide (Evening Injection),,,,,,,,,,FG003,"2-step initiation evening regimen of lixisenatide: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.",,,
period,NCT00712673::period::1,NCT00712673,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00712673::outcome::primary::1,NCT00712673,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
country,NCT00712673::country::United States,NCT00712673,United States,,,,,,,,,,,,,,
country,NCT00712673::country::Australia,NCT00712673,Australia,,,,,,,,,,,,,,
country,NCT00712673::country::Canada,NCT00712673,Canada,,,,,,,,,,,,,,
country,NCT00712673::country::Chile,NCT00712673,Chile,,,,,,,,,,,,,,
country,NCT00712673::country::Croatia,NCT00712673,Croatia,,,,,,,,,,,,,,
country,NCT00712673::country::Czechia,NCT00712673,Czechia,,,,,,,,,,,,,,
country,NCT00712673::country::Germany,NCT00712673,Germany,,,,,,,,,,,,,,
country,NCT00712673::country::Mexico,NCT00712673,Mexico,,,,,,,,,,,,,,
country,NCT00712673::country::Morocco,NCT00712673,Morocco,,,,,,,,,,,,,,
country,NCT00712673::country::Philippines,NCT00712673,Philippines,,,,,,,,,,,,,,
country,NCT00712673::country::Romania,NCT00712673,Romania,,,,,,,,,,,,,,
country,NCT00712673::country::Russia,NCT00712673,Russia,,,,,,,,,,,,,,
country,NCT00712673::country::South Africa,NCT00712673,South Africa,,,,,,,,,,,,,,
country,NCT00712673::country::Spain,NCT00712673,Spain,,,,,,,,,,,,,,
country,NCT00712673::country::Ukraine,NCT00712673,Ukraine,,,,,,,,,,,,,,
country,NCT00712673::country::Venezuela,NCT00712673,Venezuela,,,,,,,,,,,,,,
trial,NCT00978627,NCT00978627,Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 1",INDUSTRY,548.0,2009-08,2010-05,10.0,81.0,,,,,
arm,NCT00978627::arm::FG000,NCT00978627,IDegAsp OD,,,,,,,,,,FG000,Insulin degludec/insulin aspart (IDegAsp) was given subcutaneously (s.c.) once daily (OD) with a main meal in combination with mealtime insulin aspart (IAsp) for the remaining meals. The regimen was g,,,
arm,NCT00978627::arm::FG001,NCT00978627,IDet,,,,,,,,,,FG001,Insulin detemir (Idet) was given subcutaneously (s.c) once daily (OD) in the evening or twice daily (BID) in combination with mealtime insulin aspart (Iasp). The regimen was given for 26 weeks in the ,,,
period,NCT00978627::period::1,NCT00978627,Main: Week 0 to 26 (NN5401-3594),,,,,,,,,,,,1.0,,
period,NCT00978627::period::2,NCT00978627,Extension: Week 27 to 52 (NN5401-3645),,,,,,,,,,,,2.0,,
outcome,NCT00978627::outcome::primary::1,NCT00978627,Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment,,,,,,,,,,,,,PRIMARY,"Week 0, Week 26"
outcome,NCT00978627::outcome::primary::2,NCT00978627,Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes,,,,,,,,,,,,,PRIMARY,Week 0 to Week 53 + 7 days follow up
outcome,NCT00978627::outcome::primary::3,NCT00978627,Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,,,,,,,,,,,,PRIMARY,Week 0 to Week 53 + 7 days follow up
outcome,NCT00978627::outcome::primary::4,NCT00978627,Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs),,,,,,,,,,,,,PRIMARY,Week 0 to Week 53 + 7 days of follow up
country,NCT00978627::country::United States,NCT00978627,United States,,,,,,,,,,,,,,
country,NCT00978627::country::Russia,NCT00978627,Russia,,,,,,,,,,,,,,
country,NCT00978627::country::Romania,NCT00978627,Romania,,,,,,,,,,,,,,
country,NCT00978627::country::United Kingdom,NCT00978627,United Kingdom,,,,,,,,,,,,,,
country,NCT00978627::country::Australia,NCT00978627,Australia,,,,,,,,,,,,,,
country,NCT00978627::country::Poland,NCT00978627,Poland,,,,,,,,,,,,,,
country,NCT00978627::country::France,NCT00978627,France,,,,,,,,,,,,,,
country,NCT00978627::country::Denmark,NCT00978627,Denmark,,,,,,,,,,,,,,
country,NCT00978627::country::Israel,NCT00978627,Israel,,,,,,,,,,,,,,
country,NCT00978627::country::Puerto Rico,NCT00978627,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00637273,NCT00637273,"A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)",PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,514.0,2008-01,2009-07,3.0,62.0,,,,,
arm,NCT00637273::arm::FG000,NCT00637273,Exenatide Once Weekly,,,,,,,,,,FG000,Exenatide once weekly 2 mg subcutaneous weekly plus placebo oral once daily in the morning,,,
arm,NCT00637273::arm::FG001,NCT00637273,Sitagliptin,,,,,,,,,,FG001,Sitagliptin 100 mg oral once daily in the morning plus placebo once weekly subcutaneous weekly,,,
arm,NCT00637273::arm::FG002,NCT00637273,Pioglitazone,,,,,,,,,,FG002,Pioglitazone 45 mg oral once daily in the morning plus placebo once weekly subcutaneous weekly,,,
period,NCT00637273::period::1,NCT00637273,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00637273::outcome::primary::1,NCT00637273,Change in HbA1c From Baseline to Week 26,,,,,,,,,,,,,PRIMARY,"Day 1, Week 26"
country,NCT00637273::country::United States,NCT00637273,United States,,,,,,,,,,,,,,
country,NCT00637273::country::Mexico,NCT00637273,Mexico,,,,,,,,,,,,,,
country,NCT00637273::country::India,NCT00637273,India,,,,,,,,,,,,,,
trial,NCT00604383,NCT00604383,Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study,PHASE3,diabetes type 2,Diabetic Retinopathy,INDUSTRY,685.0,2001-03,2005-06,1.0,1.0,,,,,
arm,NCT00604383::arm::FG000,NCT00604383,Ruboxistaurin,,,,,,,,,,FG000,"One 32-milligram (mg) tablet, orally, daily, for up to 42 months",,,
arm,NCT00604383::arm::FG001,NCT00604383,Placebo,,,,,,,,,,FG001,"1 tablet, orally, daily, for up to 42 months",,,
period,NCT00604383::period::1,NCT00604383,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00604383::outcome::primary::1,NCT00604383,Percentage of Participants Who Had Sustained Moderate Visual Loss (SMVL) as Defined as a Visual Acuity Loss of ≥15 Letters Measured Twice During a 6-month Period,,,,,,,,,,,,,PRIMARY,Baseline through 36 months
country,NCT00604383::country::United States,NCT00604383,United States,,,,,,,,,,,,,,
trial,NCT05963022,NCT05963022,A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO),PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,206.0,2023-08-21,2024-10-09,1.0,28.0,,,,,
arm,NCT05963022::arm::FG000,NCT05963022,5 Milligram (mg) Tirzepatide,,,,,,,,,,FG000,"Participants received 5 mg of tirzepatide administered as subcutaneous (SC) injection via a single-dose pen (SDP) once weekly (QW) for 40 weeks.

The starting dose of tirzepatide was 2.5 mg QW, which ",,,
arm,NCT05963022::arm::FG001,NCT05963022,10 mg Tirzepatide,,,,,,,,,,FG001,"Participants received 10 mg of tirzepatide administered as SC injection via a SDP QW for 40 weeks.

The starting dose of tirzepatide was 2.5 mg QW, which increased by 2.5 mg every 4 weeks (2.5 mg to 5",,,
arm,NCT05963022::arm::FG002,NCT05963022,15 mg Tirzepatide,,,,,,,,,,FG002,"Participants received 15 mg of tirzepatide administered as SC injection via a SDP QW for 40 weeks.

The starting dose of tirzepatide was 2.5 mg QW, which increased by 2.5 mg every 4 weeks (2.5 mg to 5",,,
arm,NCT05963022::arm::FG003,NCT05963022,Placebo,,,,,,,,,,FG003,Participants received tirzepatide matched placebo administered as SC injection via a SDP QW for 40 weeks.,,,
period,NCT05963022::period::1,NCT05963022,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT05963022::outcome::primary::1,NCT05963022,Change From Baseline in Hemoglobin A1c (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline, Week 40"
country,NCT05963022::country::China,NCT05963022,China,,,,,,,,,,,,,,
trial,NCT04298229,NCT04298229,Efficacy and Safety of Dapagliflozin in Acute Heart Failure,PHASE3,diabetes type 2,"Heart Failure; Diabetes Mellitus, Type 2",OTHER,240.0,2020-04-01,2023-05-17,1.0,6.0,,,,,
arm,NCT04298229::arm::FG000,NCT04298229,Structured Usual Care,,,,,,,,,,FG000,Protocolized Diuretic Therapy: Structured usual care arm with protocolized diuretic therapy based on urine output.,,,
arm,NCT04298229::arm::FG001,NCT04298229,Dapagliflozin Plus Structured Usual Care,,,,,,,,,,FG001,"Dapagliflozin 10 MG: SGLT2 inhibitors being investigated for its diuretic and natriuretic effects on top of protocolized diuretic therapy.

Protocolized Diuretic Therapy: Structured usual care arm wit",,,
period,NCT04298229::period::1,NCT04298229,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04298229::outcome::primary::1,NCT04298229,"Cumulative Change in Weight (Kilograms) Per 40mg of IV Furosemide Equivalents, Adjusted for Baseline Weight",,,,,,,,,,,,,PRIMARY,Baseline to Day 5 or discharge if earlier
country,NCT04298229::country::United States,NCT04298229,United States,,,,,,,,,,,,,,
trial,NCT01719003,NCT01719003,Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2; Hyperglycemia",INDUSTRY,1413.0,2012-10,2014-12,21.0,190.0,,,,,
arm,NCT01719003::arm::FG000,NCT01719003,Empagliflozin 12.5 mg Bid+ Metformin 1000 mg Bid,,,,,,,,,,FG000,Oral administration of Empagliflozin 12.5 mg and Metformin 1000 mg twice daily (bid),,,
arm,NCT01719003::arm::FG001,NCT01719003,Empagliflozin 12.5 mg Bid+ Metformin 500 mg Bid,,,,,,,,,,FG001,Oral administration of Empagliflozin 12.5 mg and Metformin 500 mg bid,,,
arm,NCT01719003::arm::FG002,NCT01719003,Empagliflozin 5 mg Bid + Metformin 1000 mg Bid,,,,,,,,,,FG002,Oral administration of Empagliflozin 5 mg and Metformin 1000 mg bid,,,
arm,NCT01719003::arm::FG003,NCT01719003,Empagliflozin 5 mg Bid + Metformin 500 mg Bid,,,,,,,,,,FG003,Oral administration of Empagliflozin 5 mg and Metformin 500 mg bid,,,
arm,NCT01719003::arm::FG004,NCT01719003,Empagliflozin 25 mg qd,,,,,,,,,,FG004,Oral administration of Empagliflozin 25 mg once daily (qd),,,
arm,NCT01719003::arm::FG005,NCT01719003,Empagliflozin 10 mg qd,,,,,,,,,,FG005,Oral administration of Empagliflozin 10 mg qd,,,
arm,NCT01719003::arm::FG006,NCT01719003,Metformin 1000 mg Bid,,,,,,,,,,FG006,Oral administration of Metformin 1000 mg bid,,,
arm,NCT01719003::arm::FG007,NCT01719003,Metformin 500 mg Bid,,,,,,,,,,FG007,Oral administration of Metformin 500 mg bid,,,
arm,NCT01719003::arm::FG008,NCT01719003,Empagliflozin 12.5 mg Bid + Metformin 1000 mg Bid OL,,,,,,,,,,FG008,Oral administration of Empagliflozin 12.5 mg and Metformin 1000 mg bid in an open label (OL),,,
period,NCT01719003::period::1,NCT01719003,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01719003::outcome::primary::1,NCT01719003,HbA1c (Glycosylated Haemoglobin) Change From Baseline at Week 24,,,,,,,,,,,,,PRIMARY,baseline and 24 weeks
country,NCT01719003::country::United States,NCT01719003,United States,,,,,,,,,,,,,,
country,NCT01719003::country::France,NCT01719003,France,,,,,,,,,,,,,,
country,NCT01719003::country::Russia,NCT01719003,Russia,,,,,,,,,,,,,,
country,NCT01719003::country::Canada,NCT01719003,Canada,,,,,,,,,,,,,,
country,NCT01719003::country::Germany,NCT01719003,Germany,,,,,,,,,,,,,,
country,NCT01719003::country::South Korea,NCT01719003,South Korea,,,,,,,,,,,,,,
country,NCT01719003::country::United Kingdom,NCT01719003,United Kingdom,,,,,,,,,,,,,,
country,NCT01719003::country::Philippines,NCT01719003,Philippines,,,,,,,,,,,,,,
country,NCT01719003::country::Brazil,NCT01719003,Brazil,,,,,,,,,,,,,,
country,NCT01719003::country::Serbia,NCT01719003,Serbia,,,,,,,,,,,,,,
country,NCT01719003::country::Spain,NCT01719003,Spain,,,,,,,,,,,,,,
country,NCT01719003::country::Czechia,NCT01719003,Czechia,,,,,,,,,,,,,,
country,NCT01719003::country::Mexico,NCT01719003,Mexico,,,,,,,,,,,,,,
country,NCT01719003::country::Taiwan,NCT01719003,Taiwan,,,,,,,,,,,,,,
country,NCT01719003::country::Turkey (Türkiye),NCT01719003,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01719003::country::Guatemala,NCT01719003,Guatemala,,,,,,,,,,,,,,
country,NCT01719003::country::Peru,NCT01719003,Peru,,,,,,,,,,,,,,
country,NCT01719003::country::Egypt,NCT01719003,Egypt,,,,,,,,,,,,,,
country,NCT01719003::country::Lebanon,NCT01719003,Lebanon,,,,,,,,,,,,,,
country,NCT01719003::country::Malaysia,NCT01719003,Malaysia,,,,,,,,,,,,,,
country,NCT01719003::country::Thailand,NCT01719003,Thailand,,,,,,,,,,,,,,
trial,NCT01619059,NCT01619059,Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,315.0,2012-06,2015-01,9.0,83.0,,,,,
arm,NCT01619059::arm::FG000,NCT01619059,Placebo + Dapagliflozin 10mg + Metformin,,,,,,,,,,FG000,"Participants received Saxagliptin-matching placebo, dapagliflozin 10mg once daily plus open-label metformin for up to 52 weeks",,,
arm,NCT01619059::arm::FG001,NCT01619059,Saxagliptin 5mg + Dapagliflozin 10mg + Metformin,,,,,,,,,,FG001,"Participants received Saxagliptin 5mg, dapagliflozin 10mg once daily plus open-label metformin for up to 52 weeks",,,
period,NCT01619059::period::1,NCT01619059,Short-Term (ST) Treatment Period,,,,,,,,,,,,1.0,,
period,NCT01619059::period::2,NCT01619059,Long-Term (LT) Treatment Period,,,,,,,,,,,,2.0,,
outcome,NCT01619059::outcome::primary::1,NCT01619059,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24,,,,,,,,,,,,,PRIMARY,From Baseline to Week 24
country,NCT01619059::country::United States,NCT01619059,United States,,,,,,,,,,,,,,
country,NCT01619059::country::Poland,NCT01619059,Poland,,,,,,,,,,,,,,
country,NCT01619059::country::Russia,NCT01619059,Russia,,,,,,,,,,,,,,
country,NCT01619059::country::Romania,NCT01619059,Romania,,,,,,,,,,,,,,
country,NCT01619059::country::Canada,NCT01619059,Canada,,,,,,,,,,,,,,
country,NCT01619059::country::Mexico,NCT01619059,Mexico,,,,,,,,,,,,,,
country,NCT01619059::country::Hungary,NCT01619059,Hungary,,,,,,,,,,,,,,
country,NCT01619059::country::Czechia,NCT01619059,Czechia,,,,,,,,,,,,,,
country,NCT01619059::country::Puerto Rico,NCT01619059,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01076075,NCT01076075,A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,427.0,2010-06-03,2012-01-19,0.0,0.0,,,,,
arm,NCT01076075::arm::FG000,NCT01076075,Sitagliptin,,,,,,,,,,FG000,Phase A (Weeks 0-24): Sitagliptin 100 mg; Phase B (Weeks 24-54): Sitagliptin 100 mg + Placebo to Pioglitazone,,,
arm,NCT01076075::arm::FG001,NCT01076075,Placebo/Pioglitazone,,,,,,,,,,FG001,Phase A (Weeks 0-24): Placebo to Sitagliptin 100 mg; Phase B (Weeks 24-54): Placebo to Sitagliptin 100 mg + Pioglitazone 30 mg,,,
period,NCT01076075::period::1,NCT01076075,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01076075::outcome::primary::1,NCT01076075,Change From Baseline in Hemoglobin A1C (%) at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and Week 24
outcome,NCT01076075::outcome::primary::2,NCT01076075,Number of Participants With One or More Adverse Events (AEs) - Week 0 to Week 54,,,,,,,,,,,,,PRIMARY,Week 0 to Week 54
outcome,NCT01076075::outcome::primary::3,NCT01076075,Number of Participants Discontinuing Study Drug Due to An Adverse Event,,,,,,,,,,,,,PRIMARY,Week 0 to Week 54
trial,NCT01364428,NCT01364428,Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,373.0,2011-06,2012-01,1.0,45.0,,,,,
arm,NCT01364428::arm::FG000,NCT01364428,IDeg 200 U/mL,,,,,,,,,,FG000,"Insulin degludec 200 U/mL (IDeg 200 U/mL) in a 3 mL prefilled pen PDS290 was given subcutaneously once daily in combination with pre-trial oral antidiabetic drug treatment(metformin, insulin secretago",,,
arm,NCT01364428::arm::FG001,NCT01364428,IDeg,,,,,,,,,,FG001,"Insulin degludec 100 U/mL (IDeg) in a 3 mL prefilled pen PDS290 was given subcutaneously once daily in combination with pre-trial oral antidiabetic drug treatment (metformin, insulin secretagogue \[su",,,
period,NCT01364428::period::1,NCT01364428,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01364428::outcome::primary::1,NCT01364428,Change in Glycosylated Haemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Week 0, Week 22"
country,NCT01364428::country::United States,NCT01364428,United States,,,,,,,,,,,,,,
trial,NCT01023581,NCT01023581,Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,784.0,2009-11,2011-06,13.0,201.0,,,,,
arm,NCT01023581::arm::FG000,NCT01023581,Placebo,,,,,,,,,,FG000,"Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.",,,
arm,NCT01023581::arm::FG001,NCT01023581,Alogliptin 25 QD,,,,,,,,,,FG001,"Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.",,,
arm,NCT01023581::arm::FG002,NCT01023581,Alogliptin 12.5 BID,,,,,,,,,,FG002,"Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.",,,
arm,NCT01023581::arm::FG003,NCT01023581,Metformin 500 BID,,,,,,,,,,FG003,"Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks.",,,
arm,NCT01023581::arm::FG004,NCT01023581,Metformin 1000 BID,,,,,,,,,,FG004,"Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks.",,,
arm,NCT01023581::arm::FG005,NCT01023581,Alogliptin 12.5 BID + Metformin 500 BID,,,,,,,,,,FG005,"Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks.",,,
arm,NCT01023581::arm::FG006,NCT01023581,Alogliptin 12.5 BID + Metformin 1000 BID,,,,,,,,,,FG006,"Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks.",,,
period,NCT01023581::period::1,NCT01023581,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01023581::outcome::primary::1,NCT01023581,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26,,,,,,,,,,,,,PRIMARY,Baseline and Week 26.
country,NCT01023581::country::United States,NCT01023581,United States,,,,,,,,,,,,,,
country,NCT01023581::country::Mexico,NCT01023581,Mexico,,,,,,,,,,,,,,
country,NCT01023581::country::Ukraine,NCT01023581,Ukraine,,,,,,,,,,,,,,
country,NCT01023581::country::Hungary,NCT01023581,Hungary,,,,,,,,,,,,,,
country,NCT01023581::country::Poland,NCT01023581,Poland,,,,,,,,,,,,,,
country,NCT01023581::country::Puerto Rico,NCT01023581,Puerto Rico,,,,,,,,,,,,,,
country,NCT01023581::country::Slovakia,NCT01023581,Slovakia,,,,,,,,,,,,,,
country,NCT01023581::country::Russia,NCT01023581,Russia,,,,,,,,,,,,,,
country,NCT01023581::country::Czechia,NCT01023581,Czechia,,,,,,,,,,,,,,
country,NCT01023581::country::Romania,NCT01023581,Romania,,,,,,,,,,,,,,
country,NCT01023581::country::South Africa,NCT01023581,South Africa,,,,,,,,,,,,,,
country,NCT01023581::country::Israel,NCT01023581,Israel,,,,,,,,,,,,,,
country,NCT01023581::country::Lithuania,NCT01023581,Lithuania,,,,,,,,,,,,,,
trial,NCT02104804,NCT02104804,Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,953.0,2014-05-07,2016-02-26,1.0,11.0,,,,,
arm,NCT02104804::arm::FG000,NCT02104804,Saxagliptin Plus Insulin,,,,,,,,,,FG000,Saxagliptin 5 mg plus insulin,,,
arm,NCT02104804::arm::FG001,NCT02104804,Vs. Placebo Plus Insulin,,,,,,,,,,FG001,Patients receiving placebo 5 mg plus insulin,,,
period,NCT02104804::period::1,NCT02104804,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02104804::outcome::primary::1,NCT02104804,Change in HbA1c From Baseline to Week 24,,,,,,,,,,,,,PRIMARY,Baseline to 24 weeks
country,NCT02104804::country::China,NCT02104804,China,,,,,,,,,,,,,,
trial,NCT01177384,NCT01177384,Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,380.0,2011-01-25,2013-03-25,0.0,0.0,,,,,
arm,NCT01177384::arm::FG000,NCT01177384,Sitagliptin,,,,,,,,,,FG000,Sitagliptin 100 mg daily (q.d.) + acarbose (continuing the current stable dose of at least 50 mg three times daily \[t.i.d.\]),,,
arm,NCT01177384::arm::FG001,NCT01177384,Placebo,,,,,,,,,,FG001,Placebo q.d. + acarbose (continuing the current stable dose of at least 50 mg t.i.d.),,,
period,NCT01177384::period::1,NCT01177384,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01177384::outcome::primary::1,NCT01177384,Change From Baseline in Hemoglobin A1c (A1C) at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and Week 24
outcome,NCT01177384::outcome::primary::2,NCT01177384,Number of Participants Who Experienced at Least One Adverse Event,,,,,,,,,,,,,PRIMARY,Up to Week 24 + 14 Day Post-Study Follow-up
outcome,NCT01177384::outcome::primary::3,NCT01177384,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,,,,,,,,,,,,,PRIMARY,Up to 24 Weeks
trial,NCT02773368,NCT02773368,A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,420.0,2016-05-23,2017-10-23,11.0,88.0,,,,,
arm,NCT02773368::arm::FG000,NCT02773368,IDegLira,,,,,,,,,,FG000,Subjects were administered with insulin degludec/liraglutide (IDegLira: 100 U/3.6 mg per mL) subcutaneously (s.c.) once daily for a duration of 26 weeks. IDegLira was supplied in a 3 mL prefilled PDS2,,,
arm,NCT02773368::arm::FG001,NCT02773368,IGlar,,,,,,,,,,FG001,Subjects were administered with insulin glargine (IGlar: 100 U/mL) subcutaneously (s.c.) once daily for a duration of 26 weeks. IGlar was supplied in a 3 mL pre-filled Solostar® pen at 100 U/mL soluti,,,
period,NCT02773368::period::1,NCT02773368,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02773368::outcome::primary::1,NCT02773368,Change in HbA1c (Glycosylated Haemoglobin),,,,,,,,,,,,,PRIMARY,"Week 0, Week 26"
country,NCT02773368::country::United States,NCT02773368,United States,,,,,,,,,,,,,,
country,NCT02773368::country::India,NCT02773368,India,,,,,,,,,,,,,,
country,NCT02773368::country::Switzerland,NCT02773368,Switzerland,,,,,,,,,,,,,,
country,NCT02773368::country::Russia,NCT02773368,Russia,,,,,,,,,,,,,,
country,NCT02773368::country::Spain,NCT02773368,Spain,,,,,,,,,,,,,,
country,NCT02773368::country::Canada,NCT02773368,Canada,,,,,,,,,,,,,,
country,NCT02773368::country::Finland,NCT02773368,Finland,,,,,,,,,,,,,,
country,NCT02773368::country::Hungary,NCT02773368,Hungary,,,,,,,,,,,,,,
country,NCT02773368::country::Slovakia,NCT02773368,Slovakia,,,,,,,,,,,,,,
country,NCT02773368::country::Slovenia,NCT02773368,Slovenia,,,,,,,,,,,,,,
country,NCT02773368::country::Argentina,NCT02773368,Argentina,,,,,,,,,,,,,,
trial,NCT01734785,NCT01734785,Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,607.0,2013-02-08,2015-03-23,11.0,90.0,,,,,
arm,NCT01734785::arm::FG000,NCT01734785,Empagliflozin 25 mg,,,,,,,,,,FG000,Patients received 1 fixed dose combination (FDC) Empagliflozin (empa) 25/lina 5 mg tablet and two placebo tablet (1 matching placebo tablet to lina 5 and 1 matching placebo tablet to FDC empa 10/lina ,,,
arm,NCT01734785::arm::FG001,NCT01734785,Empagliflozin 10 mg,,,,,,,,,,FG001,"Patients received 1 FDC empa 10/lina 5 mg tablet and two placebo tablet (1 matching placebo tablet to lina 5 and 1 matching placebo tablet to FDC empa 25/lina 5), administered orally, once every day f",,,
arm,NCT01734785::arm::FG002,NCT01734785,Placebo,,,,,,,,,,FG002,"Patients received 1 lina 5 mg tablet and two placebo tablet (1 matching placebo tablet to FDC empa 25/lina 5 and 1 matching placebo tablet to FDC empa 10/lina 5), administered orally, once every day f",,,
arm,NCT01734785::arm::FG003,NCT01734785,Linagliptin 5 mg,,,,,,,,,,FG003,"Patients received 5mg dose of Linagliptin (lina 5), administered orally, once daily for 16 weeks during the OL treatment period, thereafter patients received 1 matching placebo tablet to FDC empa 25/l",,,
period,NCT01734785::period::1,NCT01734785,Open-Label Period,,,,,,,,,,,,1.0,,
period,NCT01734785::period::2,NCT01734785,Double-Blind Period,,,,,,,,,,,,2.0,,
outcome,NCT01734785::outcome::primary::1,NCT01734785,HbA1c Change From Baseline After 24 Weeks Double-blind Randomized Treatment,,,,,,,,,,,,,PRIMARY,Baseline and 24 weeks
country,NCT01734785::country::United States,NCT01734785,United States,,,,,,,,,,,,,,
country,NCT01734785::country::South Korea,NCT01734785,South Korea,,,,,,,,,,,,,,
country,NCT01734785::country::Spain,NCT01734785,Spain,,,,,,,,,,,,,,
country,NCT01734785::country::New Zealand,NCT01734785,New Zealand,,,,,,,,,,,,,,
country,NCT01734785::country::France,NCT01734785,France,,,,,,,,,,,,,,
country,NCT01734785::country::Australia,NCT01734785,Australia,,,,,,,,,,,,,,
country,NCT01734785::country::Canada,NCT01734785,Canada,,,,,,,,,,,,,,
country,NCT01734785::country::Taiwan,NCT01734785,Taiwan,,,,,,,,,,,,,,
country,NCT01734785::country::Brazil,NCT01734785,Brazil,,,,,,,,,,,,,,
country,NCT01734785::country::Norway,NCT01734785,Norway,,,,,,,,,,,,,,
country,NCT01734785::country::El Salvador,NCT01734785,El Salvador,,,,,,,,,,,,,,
trial,NCT00960076,NCT00960076,An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,282.0,2009-08,2010-10,5.0,35.0,,,,,
arm,NCT00960076::arm::FG000,NCT00960076,Saxagliptin + Metformin,,,,,,,,,,FG000,Saxagliptin 5 mg (DB) + Metformin XR 1500 mg (OL),,,
arm,NCT00960076::arm::FG001,NCT00960076,Metformin (DB) + Metformin (OL),,,,,,,,,,FG001,Metformin XR 500 mg (DB) + Metformin XR 1500 mg (OL),,,
period,NCT00960076::period::1,NCT00960076,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00960076::outcome::primary::1,NCT00960076,Change in HbA1c Level From Baseline to Week 18 (LOCF),,,,,,,,,,,,,PRIMARY,Baseline to week 18
country,NCT00960076::country::United States,NCT00960076,United States,,,,,,,,,,,,,,
country,NCT00960076::country::Mexico,NCT00960076,Mexico,,,,,,,,,,,,,,
country,NCT00960076::country::Colombia,NCT00960076,Colombia,,,,,,,,,,,,,,
country,NCT00960076::country::Costa Rica,NCT00960076,Costa Rica,,,,,,,,,,,,,,
country,NCT00960076::country::Peru,NCT00960076,Peru,,,,,,,,,,,,,,
trial,NCT01999218,NCT01999218,Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,1326.0,2013-12-16,2017-04-18,0.0,0.0,,,,,
arm,NCT01999218::arm::FG000,NCT01999218,Ertugliflozin 5 mg,,,,,,,,,,FG000,Ertugliflozin 5 mg once daily (QD) from Day 1 to Week 104,,,
arm,NCT01999218::arm::FG001,NCT01999218,Ertugliflozin 15 mg,,,,,,,,,,FG001,Ertugliflozin 15 mg QD from Day 1 to Week 104,,,
arm,NCT01999218::arm::FG002,NCT01999218,Glimepiride,,,,,,,,,,FG002,Glimepiride to a maximum of 8 mg QD from Day 1 to Week 104,,,
period,NCT01999218::period::1,NCT01999218,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01999218::outcome::primary::1,NCT01999218,Change From Baseline in Hemoglobin A1C (A1C) at Week 52: Excluding Rescue Approach,,,,,,,,,,,,,PRIMARY,Baseline and Week 52
outcome,NCT01999218::outcome::primary::2,NCT01999218,Percentage of Participants Experiencing An Adverse Event (AE) Up to Week 106,,,,,,,,,,,,,PRIMARY,Up to Week 106
outcome,NCT01999218::outcome::primary::3,NCT01999218,Percentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 104,,,,,,,,,,,,,PRIMARY,Up to Week 104
trial,NCT00327015,NCT00327015,A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,PHASE3,diabetes type 2,Diabetes,INDUSTRY,1306.0,2006-05,2008-12,13.0,211.0,,,,,
arm,NCT00327015::arm::FG000,NCT00327015,Saxagliptin 5 mg + Metformin,,,,,,,,,,FG000,"The Saxagliptin 5 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 5 mg oral tablets and metformin IR 500 mg. Metformin Im",,,
arm,NCT00327015::arm::FG001,NCT00327015,Saxagliptin 10 mg + Metformin,,,,,,,,,,FG001,"The Saxagliptin 10 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 10 mg oral tablets and metformin IR 500 mg. Metformin ",,,
arm,NCT00327015::arm::FG002,NCT00327015,Saxagliptin 10 mg,,,,,,,,,,FG002,"The Saxagliptin 10 mg group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 10 mg oral tablets and placebo resembling metformin.",,,
arm,NCT00327015::arm::FG003,NCT00327015,Metformin,,,,,,,,,,FG003,"The Metformin group includes data from participants randomized to receive coadministration of metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2",,,
period,NCT00327015::period::1,NCT00327015,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00327015::outcome::primary::1,NCT00327015,"Change From Baseline in Hemoglobin A1c (A1C) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy",,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
outcome,NCT00327015::outcome::primary::2,NCT00327015,"Change From Baseline in A1C at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy",,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
country,NCT00327015::country::Russia,NCT00327015,Russia,,,,,,,,,,,,,,
country,NCT00327015::country::United States,NCT00327015,United States,,,,,,,,,,,,,,
country,NCT00327015::country::Argentina,NCT00327015,Argentina,,,,,,,,,,,,,,
country,NCT00327015::country::Germany,NCT00327015,Germany,,,,,,,,,,,,,,
country,NCT00327015::country::Mexico,NCT00327015,Mexico,,,,,,,,,,,,,,
country,NCT00327015::country::India,NCT00327015,India,,,,,,,,,,,,,,
country,NCT00327015::country::Brazil,NCT00327015,Brazil,,,,,,,,,,,,,,
country,NCT00327015::country::Ukraine,NCT00327015,Ukraine,,,,,,,,,,,,,,
country,NCT00327015::country::Poland,NCT00327015,Poland,,,,,,,,,,,,,,
country,NCT00327015::country::Philippines,NCT00327015,Philippines,,,,,,,,,,,,,,
country,NCT00327015::country::Puerto Rico,NCT00327015,Puerto Rico,,,,,,,,,,,,,,
country,NCT00327015::country::Hungary,NCT00327015,Hungary,,,,,,,,,,,,,,
country,NCT00327015::country::Italy,NCT00327015,Italy,,,,,,,,,,,,,,
trial,NCT01081834,NCT01081834,The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,678.0,2010-03,2012-03,18.0,78.0,,,,,
arm,NCT01081834::arm::FG000,NCT01081834,Main Study: Placebo/Sitagliptin,,,,,,,,,,FG000,"In the Main Study, each patient received matching placebo once daily for 26 weeks and were then switched from placebo to 100 mg of sitagliptin once daily until Week 52.",,,
arm,NCT01081834::arm::FG001,NCT01081834,Main Study: Canagliflozin 100 mg,,,,,,,,,,FG001,"In the Main Study, each patient received 100 mg of canagliflozin once daily for 52 weeks.",,,
arm,NCT01081834::arm::FG002,NCT01081834,Main Study: Canagliflozin 300 mg,,,,,,,,,,FG002,"In the Main Study, each patient received 300 mg of canagliflozin once daily for 52 weeks.",,,
arm,NCT01081834::arm::FG003,NCT01081834,High Glycemic Substudy: Canagliflozin 100 mg,,,,,,,,,,FG003,"In the High Glycemic Substudy, each patient received 100 mg of canagliflozin once daily for 26 weeks only. No patients received treatment during the period Week 26 to Week 52.",,,
arm,NCT01081834::arm::FG004,NCT01081834,High Glycemic Substudy: Canagliflozin 300 mg,,,,,,,,,,FG004,"In the High Glycemic Substudy, each patient received 300 mg of canagliflozin once daily for 26 weeks only. No patients received treatment during the period Week 26 to Week 52.",,,
period,NCT01081834::period::1,NCT01081834,Core Period: Baseline to Week 26,,,,,,,,,,,,1.0,,
period,NCT01081834::period::2,NCT01081834,Extension Period: Week 26 to Week 52,,,,,,,,,,,,2.0,,
outcome,NCT01081834::outcome::primary::1,NCT01081834,Change in HbA1c From Baseline to Week 26 (Main Study),,,,,,,,,,,,,PRIMARY,Day 1 (Baseline) and Week 26
outcome,NCT01081834::outcome::primary::2,NCT01081834,Change in HbA1c From Baseline to Week 26 (High Glycemic Substudy),,,,,,,,,,,,,PRIMARY,Day 1 (Baseline) and Week 26
country,NCT01081834::country::United States,NCT01081834,United States,,,,,,,,,,,,,,
country,NCT01081834::country::Lithuania,NCT01081834,Lithuania,,,,,,,,,,,,,,
country,NCT01081834::country::Mexico,NCT01081834,Mexico,,,,,,,,,,,,,,
country,NCT01081834::country::South Korea,NCT01081834,South Korea,,,,,,,,,,,,,,
country,NCT01081834::country::Philippines,NCT01081834,Philippines,,,,,,,,,,,,,,
country,NCT01081834::country::Romania,NCT01081834,Romania,,,,,,,,,,,,,,
country,NCT01081834::country::Spain,NCT01081834,Spain,,,,,,,,,,,,,,
country,NCT01081834::country::Sweden,NCT01081834,Sweden,,,,,,,,,,,,,,
country,NCT01081834::country::Austria,NCT01081834,Austria,,,,,,,,,,,,,,
country,NCT01081834::country::Estonia,NCT01081834,Estonia,,,,,,,,,,,,,,
country,NCT01081834::country::India,NCT01081834,India,,,,,,,,,,,,,,
country,NCT01081834::country::Poland,NCT01081834,Poland,,,,,,,,,,,,,,
country,NCT01081834::country::Puerto Rico,NCT01081834,Puerto Rico,,,,,,,,,,,,,,
country,NCT01081834::country::Colombia,NCT01081834,Colombia,,,,,,,,,,,,,,
country,NCT01081834::country::Malaysia,NCT01081834,Malaysia,,,,,,,,,,,,,,
country,NCT01081834::country::South Africa,NCT01081834,South Africa,,,,,,,,,,,,,,
country,NCT01081834::country::Guatemala,NCT01081834,Guatemala,,,,,,,,,,,,,,
country,NCT01081834::country::Iceland,NCT01081834,Iceland,,,,,,,,,,,,,,
trial,NCT01179048,NCT01179048,Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,9341.0,2010-08-31,2015-12-17,33.0,428.0,,,,,
arm,NCT01179048::arm::FG000,NCT01179048,Liraglutide,,,,,,,,,,FG000,"Subjects received liraglutide once daily by subcutaneous injection in the abdomen, thigh or upper arm, at any time of the day and irrespective of meals, for a treatment period of 42 to 60 months. It w",,,
arm,NCT01179048::arm::FG001,NCT01179048,Placebo,,,,,,,,,,FG001,"Subjects received placebo (matched to liraglutide) daily by subcutaneous injection in the abdomen, thigh or upper arm, at any time of the day and irrespective of meals, for a treatment period of 42 to",,,
period,NCT01179048::period::1,NCT01179048,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01179048::outcome::primary::1,NCT01179048,"Time From Randomisation to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)",,,,,,,,,,,,,PRIMARY,from randomisation (visit 3
country,NCT01179048::country::United States,NCT01179048,United States,,,,,,,,,,,,,,
country,NCT01179048::country::Brazil,NCT01179048,Brazil,,,,,,,,,,,,,,
country,NCT01179048::country::Germany,NCT01179048,Germany,,,,,,,,,,,,,,
country,NCT01179048::country::United Kingdom,NCT01179048,United Kingdom,,,,,,,,,,,,,,
country,NCT01179048::country::Canada,NCT01179048,Canada,,,,,,,,,,,,,,
country,NCT01179048::country::India,NCT01179048,India,,,,,,,,,,,,,,
country,NCT01179048::country::South Africa,NCT01179048,South Africa,,,,,,,,,,,,,,
country,NCT01179048::country::Turkey (Türkiye),NCT01179048,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01179048::country::Russia,NCT01179048,Russia,,,,,,,,,,,,,,
country,NCT01179048::country::Poland,NCT01179048,Poland,,,,,,,,,,,,,,
country,NCT01179048::country::Italy,NCT01179048,Italy,,,,,,,,,,,,,,
country,NCT01179048::country::Spain,NCT01179048,Spain,,,,,,,,,,,,,,
country,NCT01179048::country::Australia,NCT01179048,Australia,,,,,,,,,,,,,,
country,NCT01179048::country::Romania,NCT01179048,Romania,,,,,,,,,,,,,,
country,NCT01179048::country::Netherlands,NCT01179048,Netherlands,,,,,,,,,,,,,,
country,NCT01179048::country::China,NCT01179048,China,,,,,,,,,,,,,,
country,NCT01179048::country::Mexico,NCT01179048,Mexico,,,,,,,,,,,,,,
country,NCT01179048::country::Denmark,NCT01179048,Denmark,,,,,,,,,,,,,,
country,NCT01179048::country::Sweden,NCT01179048,Sweden,,,,,,,,,,,,,,
country,NCT01179048::country::Austria,NCT01179048,Austria,,,,,,,,,,,,,,
country,NCT01179048::country::Finland,NCT01179048,Finland,,,,,,,,,,,,,,
country,NCT01179048::country::Israel,NCT01179048,Israel,,,,,,,,,,,,,,
country,NCT01179048::country::Norway,NCT01179048,Norway,,,,,,,,,,,,,,
country,NCT01179048::country::South Korea,NCT01179048,South Korea,,,,,,,,,,,,,,
country,NCT01179048::country::Belgium,NCT01179048,Belgium,,,,,,,,,,,,,,
country,NCT01179048::country::France,NCT01179048,France,,,,,,,,,,,,,,
country,NCT01179048::country::Greece,NCT01179048,Greece,,,,,,,,,,,,,,
country,NCT01179048::country::Taiwan,NCT01179048,Taiwan,,,,,,,,,,,,,,
country,NCT01179048::country::Czechia,NCT01179048,Czechia,,,,,,,,,,,,,,
country,NCT01179048::country::Ireland,NCT01179048,Ireland,,,,,,,,,,,,,,
country,NCT01179048::country::Puerto Rico,NCT01179048,Puerto Rico,,,,,,,,,,,,,,
country,NCT01179048::country::United Arab Emirates,NCT01179048,United Arab Emirates,,,,,,,,,,,,,,
country,NCT01179048::country::Serbia,NCT01179048,Serbia,,,,,,,,,,,,,,
trial,NCT01289990,NCT01289990,Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,2705.0,2011-02,2013-05,19.0,243.0,,,,,
arm,NCT01289990::arm::FG000,NCT01289990,Empagliflozin 10 mg (Drug Naive),,,,,,,,,,FG000,"Patients rolled over from trial 1245.20

Empagliflozin 10 mg tablets once daily

Placebo: Placebo matching Sitagliptin

Placebo: Placebo matching Empagliflozin 25 mg",,,
arm,NCT01289990::arm::FG001,NCT01289990,Empagliflozin 25 mg (Drug Naive),,,,,,,,,,FG001,"Patients rolled over from trial 1245.20

Empagliflozin 25 mg tablets once daily

Placebo: Placebo matching Sitagliptin

Placebo: Placebo matching Empagliflozin 10 mg",,,
arm,NCT01289990::arm::FG002,NCT01289990,Placebo (Drug Naive),,,,,,,,,,FG002,"Patients rolled over from trial 1245.20

Placebo tablets matching Empagliflozin / Sitagliptin once daily

Placebo: Placebo matching Empagliflozin 10 mg

Placebo: Placebo matching Sitagliptin

Placebo:",,,
arm,NCT01289990::arm::FG003,NCT01289990,Sitagliptin 100mg (Drug Naive),,,,,,,,,,FG003,"Patients rolled over from trial 1245.20

Sitagliptin once daily

Placebo: Placebo matching Empagliflozin 25 mg

Placebo: Placebo matching Empagliflozin 10 mg

Sitagliptin 100mg: Sitagliptin once daily",,,
arm,NCT01289990::arm::FG004,NCT01289990,Empagliflozin 10 mg (Pioglitazone),,,,,,,,,,FG004,"Patients rolled over from trial 1245.19

Empagliflozin 10 mg tablets once daily

Empagliflozin 10 mg: Empagliflozin 10 mg tablets once daily

Placebo: Placebo matching Empagliflozin 25 mg",,,
arm,NCT01289990::arm::FG005,NCT01289990,Empagliflozin 25 mg (Pioglitazone),,,,,,,,,,FG005,"Patients rolled over from trial 1245.19

Empagliflozin 25 mg tablets once daily

Empagliflozin 25 mg: Empagliflozin 25 mg tablets once daily

Placebo: Placebo matching Empagliflozin 10 mg",,,
arm,NCT01289990::arm::FG006,NCT01289990,Placebo (Pioglitazone),,,,,,,,,,FG006,"Patients rolled over from trial 1245.19

Placebo tablets matching Empagliflozin once daily

Placebo: Placebo matching Empagliflozin 10 mg

Placebo: Placebo matching Empagliflozin 25 mg",,,
arm,NCT01289990::arm::FG007,NCT01289990,Empagliflozin 10 mg (Metformin),,,,,,,,,,FG007,"Patients rolled over from trial 1245.23

Empagliflozin 10 mg tablets once daily

Placebo: Placebo matching Empagliflozin 25 mg

Empagliflozin 10 mg: Empagliflozin 10 mg once daily",,,
arm,NCT01289990::arm::FG008,NCT01289990,Empagliflozin 25 mg (Metformin),,,,,,,,,,FG008,"Patients rolled over from trial 1245.23

Empagliflozin 25 mg tablets once daily

Empagliflozin 25 mg: Empagliflozin 25 mg tablets once daily

Placebo: Placebo matching Empagliflozin 10 mg",,,
arm,NCT01289990::arm::FG009,NCT01289990,Placebo (Metformin),,,,,,,,,,FG009,"Patients rolled over from trial 1245.23

Placebo tablets matching Empagliflozin once daily

Placebo: Placebo matching Empagliflozin 10 mg

Placebo: Placebo matching Empagliflozin 25 mg",,,
arm,NCT01289990::arm::FG010,NCT01289990,Empagliflozin 10 mg (Metformin+Sulfonylurea),,,,,,,,,,FG010,"Patients rolled over from trial 1245.23

Empagliflozin 10 mg tablets once daily

Empagliflozin 10 mg: Empagliflozin 10 mg tablets once daily

Placebo: Placebo matching Empagliflozin 25 mg",,,
arm,NCT01289990::arm::FG011,NCT01289990,Empagliflozin 25 mg (Metformin+Sulfonylurea),,,,,,,,,,FG011,"Patients rolled over from trial 1245.23

Empagliflozin 25 mg tablets once daily

Empagliflozin 25 mg: Empagliflozin 25 mg tablets once daily

Placebo: Placebo matching Empagliflozin 10 mg",,,
arm,NCT01289990::arm::FG012,NCT01289990,Placebo (Metformin+Sulfonylurea),,,,,,,,,,FG012,"Patients rolled over from trial 1245.23

Placebo tablets matching Empagliflozin

Placebo: Placebo matching Empagliflozin 10 mg

Placebo: Placebo matching Empagliflozin 25 mg",,,
period,NCT01289990::period::1,NCT01289990,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01289990::outcome::primary::1,NCT01289990,Changes From Baseline in Glycosylated Haemoglobin (HbA1c) (%) After 52 Weeks of Treatment,,,,,,,,,,,,,PRIMARY,Baseline and 52 weeks
outcome,NCT01289990::outcome::primary::2,NCT01289990,Changes From Baseline in HbA1c (%) After 76 Weeks of Treatment,,,,,,,,,,,,,PRIMARY,Baseline and 76 weeks
country,NCT01289990::country::United States,NCT01289990,United States,,,,,,,,,,,,,,
country,NCT01289990::country::Canada,NCT01289990,Canada,,,,,,,,,,,,,,
country,NCT01289990::country::China,NCT01289990,China,,,,,,,,,,,,,,
country,NCT01289990::country::Germany,NCT01289990,Germany,,,,,,,,,,,,,,
country,NCT01289990::country::India,NCT01289990,India,,,,,,,,,,,,,,
country,NCT01289990::country::France,NCT01289990,France,,,,,,,,,,,,,,
country,NCT01289990::country::South Korea,NCT01289990,South Korea,,,,,,,,,,,,,,
country,NCT01289990::country::Belgium,NCT01289990,Belgium,,,,,,,,,,,,,,
country,NCT01289990::country::Japan,NCT01289990,Japan,,,,,,,,,,,,,,
country,NCT01289990::country::Taiwan,NCT01289990,Taiwan,,,,,,,,,,,,,,
country,NCT01289990::country::Slovakia,NCT01289990,Slovakia,,,,,,,,,,,,,,
country,NCT01289990::country::Ireland,NCT01289990,Ireland,,,,,,,,,,,,,,
country,NCT01289990::country::Philippines,NCT01289990,Philippines,,,,,,,,,,,,,,
country,NCT01289990::country::Turkey (Türkiye),NCT01289990,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01289990::country::Ukraine,NCT01289990,Ukraine,,,,,,,,,,,,,,
country,NCT01289990::country::Mexico,NCT01289990,Mexico,,,,,,,,,,,,,,
country,NCT01289990::country::Slovenia,NCT01289990,Slovenia,,,,,,,,,,,,,,
country,NCT01289990::country::Switzerland,NCT01289990,Switzerland,,,,,,,,,,,,,,
country,NCT01289990::country::Greece,NCT01289990,Greece,,,,,,,,,,,,,,
trial,NCT01075282,NCT01075282,A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2),PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,810.0,2010-02,2012-11,20.0,78.0,,,,,
arm,NCT01075282::arm::FG000,NCT01075282,LY2189265 1.5 mg,,,,,,,,,,FG000,"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 78 weeks

Metformin: at least 1500 milligram per day (mg/day), oral, for 78 weeks

Glimepiride: at least 4 mg/day, oral",,,
arm,NCT01075282::arm::FG001,NCT01075282,LY2189265 0.75 mg,,,,,,,,,,FG001,"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 78 weeks

Metformin: at least 1500 milligram per day (mg/day), oral, for 78 weeks

Glimepiride: at least 4 mg/day, ora",,,
arm,NCT01075282::arm::FG002,NCT01075282,Insulin Glargine,,,,,,,,,,FG002,"Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 78 weeks

Metformin: at least 1500 milligram per day (mg/day), oral, for 78 weeks

Glimepiride: at l",,,
period,NCT01075282::period::1,NCT01075282,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01075282::outcome::primary::1,NCT01075282,Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline, 52 weeks"
country,NCT01075282::country::Canada,NCT01075282,Canada,,,,,,,,,,,,,,
country,NCT01075282::country::India,NCT01075282,India,,,,,,,,,,,,,,
country,NCT01075282::country::Poland,NCT01075282,Poland,,,,,,,,,,,,,,
country,NCT01075282::country::Taiwan,NCT01075282,Taiwan,,,,,,,,,,,,,,
country,NCT01075282::country::Australia,NCT01075282,Australia,,,,,,,,,,,,,,
country,NCT01075282::country::France,NCT01075282,France,,,,,,,,,,,,,,
country,NCT01075282::country::Argentina,NCT01075282,Argentina,,,,,,,,,,,,,,
country,NCT01075282::country::Hungary,NCT01075282,Hungary,,,,,,,,,,,,,,
country,NCT01075282::country::Mexico,NCT01075282,Mexico,,,,,,,,,,,,,,
country,NCT01075282::country::Romania,NCT01075282,Romania,,,,,,,,,,,,,,
country,NCT01075282::country::Spain,NCT01075282,Spain,,,,,,,,,,,,,,
country,NCT01075282::country::Sweden,NCT01075282,Sweden,,,,,,,,,,,,,,
country,NCT01075282::country::Belgium,NCT01075282,Belgium,,,,,,,,,,,,,,
country,NCT01075282::country::Croatia,NCT01075282,Croatia,,,,,,,,,,,,,,
country,NCT01075282::country::South Korea,NCT01075282,South Korea,,,,,,,,,,,,,,
country,NCT01075282::country::Brazil,NCT01075282,Brazil,,,,,,,,,,,,,,
country,NCT01075282::country::Czechia,NCT01075282,Czechia,,,,,,,,,,,,,,
country,NCT01075282::country::Italy,NCT01075282,Italy,,,,,,,,,,,,,,
country,NCT01075282::country::Greece,NCT01075282,Greece,,,,,,,,,,,,,,
country,NCT01075282::country::Slovakia,NCT01075282,Slovakia,,,,,,,,,,,,,,
trial,NCT01128894,NCT01128894,A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,841.0,2010-05,2011-09,8.0,173.0,,,,,
arm,NCT01128894::arm::FG000,NCT01128894,Albiglutide 50 mg,,,,,,,,,,FG000,Participants received albiglutide 30 milligrams (mg) once weekly subcutaneously (SC) from Baseline until Week 6 with up-titration to 50 mg weekly at Week 6.,,,
arm,NCT01128894::arm::FG001,NCT01128894,Liraglutide 1.8 mg,,,,,,,,,,FG001,"Participants received liraglutide 0.6 mg once daily (OD) SC from Baseline until Week 1. From Week 1 to Week 2 the dose was increased to 1.2 mg. At Week 2, the dose was increased to 1.8 mg.",,,
period,NCT01128894::period::1,NCT01128894,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01128894::outcome::primary::1,NCT01128894,Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 32,,,,,,,,,,,,,PRIMARY,Baseline and Week 32
country,NCT01128894::country::United States,NCT01128894,United States,,,,,,,,,,,,,,
country,NCT01128894::country::Australia,NCT01128894,Australia,,,,,,,,,,,,,,
country,NCT01128894::country::Peru,NCT01128894,Peru,,,,,,,,,,,,,,
country,NCT01128894::country::South Korea,NCT01128894,South Korea,,,,,,,,,,,,,,
country,NCT01128894::country::Philippines,NCT01128894,Philippines,,,,,,,,,,,,,,
country,NCT01128894::country::Spain,NCT01128894,Spain,,,,,,,,,,,,,,
country,NCT01128894::country::United Kingdom,NCT01128894,United Kingdom,,,,,,,,,,,,,,
country,NCT01128894::country::Israel,NCT01128894,Israel,,,,,,,,,,,,,,
trial,NCT01885208,NCT01885208,Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,813.0,2013-12-02,2015-07-13,13.0,146.0,,,,,
arm,NCT01885208::arm::FG000,NCT01885208,Semaglutide 1.0 mg,,,,,,,,,,FG000,"Subjects randomised to semaglutide followed a fixed dose-escalation regimen for a period of 56 weeks. Subjects started with once-weekly doses of 0.25 mg for 4 weeks, then escalated to doses of 0.5 mg ",,,
arm,NCT01885208::arm::FG001,NCT01885208,Exenatide ER 2.0 mg,,,,,,,,,,FG001,Subjects on exenatide extended release (ER) 2.0 mg (Bydureon®) were treated with the same 2.0 mg dose for a period of 56 weeks. Exenatide one vial of 2 mg exenatide ER was supplied in a pre-filled syr,,,
period,NCT01885208::period::1,NCT01885208,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01885208::outcome::primary::1,NCT01885208,Change From Baseline in HbA1c (Glycosylated Haemoglobin),,,,,,,,,,,,,PRIMARY,"Week 0, week 56"
country,NCT01885208::country::United States,NCT01885208,United States,,,,,,,,,,,,,,
country,NCT01885208::country::Netherlands,NCT01885208,Netherlands,,,,,,,,,,,,,,
country,NCT01885208::country::France,NCT01885208,France,,,,,,,,,,,,,,
country,NCT01885208::country::Germany,NCT01885208,Germany,,,,,,,,,,,,,,
country,NCT01885208::country::Italy,NCT01885208,Italy,,,,,,,,,,,,,,
country,NCT01885208::country::Greece,NCT01885208,Greece,,,,,,,,,,,,,,
country,NCT01885208::country::United Kingdom,NCT01885208,United Kingdom,,,,,,,,,,,,,,
country,NCT01885208::country::Argentina,NCT01885208,Argentina,,,,,,,,,,,,,,
country,NCT01885208::country::Croatia,NCT01885208,Croatia,,,,,,,,,,,,,,
country,NCT01885208::country::Finland,NCT01885208,Finland,,,,,,,,,,,,,,
country,NCT01885208::country::Switzerland,NCT01885208,Switzerland,,,,,,,,,,,,,,
country,NCT01885208::country::Serbia,NCT01885208,Serbia,,,,,,,,,,,,,,
country,NCT01885208::country::Puerto Rico,NCT01885208,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00877890,NCT00877890,"A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)",PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,254.0,2009-03,2010-01,1.0,41.0,,,,,
arm,NCT00877890::arm::FG000,NCT00877890,Exenatide Once Weekly,,,,,,,,,,FG000,"Subcutaneous injection of 2 mg exenatide, once a week",,,
arm,NCT00877890::arm::FG001,NCT00877890,Exenatide Twice Daily,,,,,,,,,,FG001,"Subcutaneous injection of exenatide, twice a day (5 mcg exenatide per dose for first 4 weeks, then 10 mcg exenatide per dose for 20 weeks)",,,
period,NCT00877890::period::1,NCT00877890,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00877890::outcome::primary::1,NCT00877890,Change in HbA1c From Baseline to Week 24,,,,,,,,,,,,,PRIMARY,"Day 1, Week 24"
country,NCT00877890::country::United States,NCT00877890,United States,,,,,,,,,,,,,,
trial,NCT01513590,NCT01513590,A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,394.0,2012-01-16,2012-11-19,10.0,49.0,,,,,
arm,NCT01513590::arm::FG000,NCT01513590,IDegAsp BID,,,,,,,,,,FG000,Insulin degludec/insulin aspart (IDegAsp) was given subcutaneously twice daily (BID) with metformin. IDegAsp was given with the breakfast meal and main evening meal.,,,
arm,NCT01513590::arm::FG001,NCT01513590,BIAsp 30 BID,,,,,,,,,,FG001,Biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously twice daily (BID) with metformin. BIAsp 30 was given with the breakfast meal and main evening meal.,,,
period,NCT01513590::period::1,NCT01513590,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01513590::outcome::primary::1,NCT01513590,Change From Baseline in HbA1c (Glycosylated Haemoglobin),,,,,,,,,,,,,PRIMARY,"Week 0, week 26"
country,NCT01513590::country::Bulgaria,NCT01513590,Bulgaria,,,,,,,,,,,,,,
country,NCT01513590::country::Ukraine,NCT01513590,Ukraine,,,,,,,,,,,,,,
country,NCT01513590::country::Germany,NCT01513590,Germany,,,,,,,,,,,,,,
country,NCT01513590::country::Croatia,NCT01513590,Croatia,,,,,,,,,,,,,,
country,NCT01513590::country::Poland,NCT01513590,Poland,,,,,,,,,,,,,,
country,NCT01513590::country::Romania,NCT01513590,Romania,,,,,,,,,,,,,,
country,NCT01513590::country::Turkey (Türkiye),NCT01513590,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01513590::country::Czechia,NCT01513590,Czechia,,,,,,,,,,,,,,
country,NCT01513590::country::Algeria,NCT01513590,Algeria,,,,,,,,,,,,,,
country,NCT01513590::country::Slovakia,NCT01513590,Slovakia,,,,,,,,,,,,,,
trial,NCT04017832,NCT04017832,A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,1441.0,2019-07-29,2021-10-27,9.0,93.0,,,,,
arm,NCT04017832::arm::FG000,NCT04017832,Oral Semaglutide 3 mg,,,,,,,,,,FG000,Participants received semaglutide 3 mg tablet and placebo tablet matched to sitagliptin orally once daily for 26 weeks.,,,
arm,NCT04017832::arm::FG001,NCT04017832,Oral Semaglutide 7 mg,,,,,,,,,,FG001,Participants received oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 26: 3 mg from week 0 to week 4 and 7 mg from week 5 to week 26. Participants also received pla,,,
arm,NCT04017832::arm::FG002,NCT04017832,Oral Semaglutide 14 mg,,,,,,,,,,FG002,"Participants received oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 26: 3 mg from week 1 to week 4, 7 mg from week 5 to week 8 and 14 mg from week 9 to week 26. P",,,
arm,NCT04017832::arm::FG003,NCT04017832,Sitagliptin 100 mg,,,,,,,,,,FG003,Participants received oral sitagliptin 100 mg tablet and placebo tablet matched to oral semaglutide orally once daily for 26 weeks.,,,
period,NCT04017832::period::1,NCT04017832,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04017832::outcome::primary::1,NCT04017832,Change From Baseline to Week 26 in Glycated Haemoglobin (HbA1c) (%),,,,,,,,,,,,,PRIMARY,From baseline to week 26
country,NCT04017832::country::China,NCT04017832,China,,,,,,,,,,,,,,
country,NCT04017832::country::South Africa,NCT04017832,South Africa,,,,,,,,,,,,,,
country,NCT04017832::country::Romania,NCT04017832,Romania,,,,,,,,,,,,,,
country,NCT04017832::country::Czechia,NCT04017832,Czechia,,,,,,,,,,,,,,
country,NCT04017832::country::Taiwan,NCT04017832,Taiwan,,,,,,,,,,,,,,
country,NCT04017832::country::Brazil,NCT04017832,Brazil,,,,,,,,,,,,,,
country,NCT04017832::country::Serbia,NCT04017832,Serbia,,,,,,,,,,,,,,
country,NCT04017832::country::Algeria,NCT04017832,Algeria,,,,,,,,,,,,,,
country,NCT04017832::country::Hong Kong,NCT04017832,Hong Kong,,,,,,,,,,,,,,
trial,NCT02540993,NCT02540993,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease,PHASE3,diabetes type 2,Chronic Kidney Disease,INDUSTRY,5734.0,2015-09-17,2020-04-14,48.0,978.0,,,,,
arm,NCT02540993::arm::FG000,NCT02540993,Finerenone,,,,,,,,,,FG000,Participants received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy,,,
arm,NCT02540993::arm::FG001,NCT02540993,Placebo,,,,,,,,,,FG001,Participants received matching placebo once daily in addition to standard of care therapy,,,
period,NCT02540993::period::1,NCT02540993,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02540993::outcome::primary::1,NCT02540993,"The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death",,,,,,,,,,,,,PRIMARY,"From randomization up until the first occurrence of the primary renal composite endpoint, or censoring at the end of the study, with an average follow-up time of 32 months"
country,NCT02540993::country::United States,NCT02540993,United States,,,,,,,,,,,,,,
country,NCT02540993::country::Japan,NCT02540993,Japan,,,,,,,,,,,,,,
country,NCT02540993::country::China,NCT02540993,China,,,,,,,,,,,,,,
country,NCT02540993::country::Russia,NCT02540993,Russia,,,,,,,,,,,,,,
country,NCT02540993::country::Germany,NCT02540993,Germany,,,,,,,,,,,,,,
country,NCT02540993::country::Canada,NCT02540993,Canada,,,,,,,,,,,,,,
country,NCT02540993::country::Spain,NCT02540993,Spain,,,,,,,,,,,,,,
country,NCT02540993::country::Brazil,NCT02540993,Brazil,,,,,,,,,,,,,,
country,NCT02540993::country::Poland,NCT02540993,Poland,,,,,,,,,,,,,,
country,NCT02540993::country::Czechia,NCT02540993,Czechia,,,,,,,,,,,,,,
country,NCT02540993::country::Italy,NCT02540993,Italy,,,,,,,,,,,,,,
country,NCT02540993::country::Ukraine,NCT02540993,Ukraine,,,,,,,,,,,,,,
country,NCT02540993::country::Israel,NCT02540993,Israel,,,,,,,,,,,,,,
country,NCT02540993::country::Bulgaria,NCT02540993,Bulgaria,,,,,,,,,,,,,,
country,NCT02540993::country::France,NCT02540993,France,,,,,,,,,,,,,,
country,NCT02540993::country::Hungary,NCT02540993,Hungary,,,,,,,,,,,,,,
country,NCT02540993::country::South Africa,NCT02540993,South Africa,,,,,,,,,,,,,,
country,NCT02540993::country::South Korea,NCT02540993,South Korea,,,,,,,,,,,,,,
country,NCT02540993::country::Portugal,NCT02540993,Portugal,,,,,,,,,,,,,,
country,NCT02540993::country::Mexico,NCT02540993,Mexico,,,,,,,,,,,,,,
country,NCT02540993::country::Romania,NCT02540993,Romania,,,,,,,,,,,,,,
country,NCT02540993::country::Colombia,NCT02540993,Colombia,,,,,,,,,,,,,,
country,NCT02540993::country::Netherlands,NCT02540993,Netherlands,,,,,,,,,,,,,,
country,NCT02540993::country::United Kingdom,NCT02540993,United Kingdom,,,,,,,,,,,,,,
country,NCT02540993::country::Denmark,NCT02540993,Denmark,,,,,,,,,,,,,,
country,NCT02540993::country::Sweden,NCT02540993,Sweden,,,,,,,,,,,,,,
country,NCT02540993::country::Argentina,NCT02540993,Argentina,,,,,,,,,,,,,,
country,NCT02540993::country::Australia,NCT02540993,Australia,,,,,,,,,,,,,,
country,NCT02540993::country::Austria,NCT02540993,Austria,,,,,,,,,,,,,,
country,NCT02540993::country::Finland,NCT02540993,Finland,,,,,,,,,,,,,,
country,NCT02540993::country::Chile,NCT02540993,Chile,,,,,,,,,,,,,,
country,NCT02540993::country::Malaysia,NCT02540993,Malaysia,,,,,,,,,,,,,,
country,NCT02540993::country::Norway,NCT02540993,Norway,,,,,,,,,,,,,,
country,NCT02540993::country::Belgium,NCT02540993,Belgium,,,,,,,,,,,,,,
country,NCT02540993::country::Taiwan,NCT02540993,Taiwan,,,,,,,,,,,,,,
country,NCT02540993::country::Turkey (Türkiye),NCT02540993,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02540993::country::Greece,NCT02540993,Greece,,,,,,,,,,,,,,
country,NCT02540993::country::New Zealand,NCT02540993,New Zealand,,,,,,,,,,,,,,
country,NCT02540993::country::Switzerland,NCT02540993,Switzerland,,,,,,,,,,,,,,
country,NCT02540993::country::Lithuania,NCT02540993,Lithuania,,,,,,,,,,,,,,
country,NCT02540993::country::Philippines,NCT02540993,Philippines,,,,,,,,,,,,,,
country,NCT02540993::country::Singapore,NCT02540993,Singapore,,,,,,,,,,,,,,
country,NCT02540993::country::Slovakia,NCT02540993,Slovakia,,,,,,,,,,,,,,
country,NCT02540993::country::Vietnam,NCT02540993,Vietnam,,,,,,,,,,,,,,
country,NCT02540993::country::Hong Kong,NCT02540993,Hong Kong,,,,,,,,,,,,,,
country,NCT02540993::country::Ireland,NCT02540993,Ireland,,,,,,,,,,,,,,
country,NCT02540993::country::Thailand,NCT02540993,Thailand,,,,,,,,,,,,,,
country,NCT02540993::country::Puerto Rico,NCT02540993,Puerto Rico,,,,,,,,,,,,,,
trial,NCT03268005,NCT03268005,"Research Study Comparing a New Medicine ""Fast-acting Insulin Aspart"" to Another Already Available Medicine ""NovoRapid""/""NovoLog"" in People With Type 2 Diabetes",PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,1264.0,2017-09-19,2019-01-29,18.0,167.0,,,,,
arm,NCT03268005::arm::FG000,NCT03268005,Faster Aspart,,,,,,,,,,FG000,Participants received Faster aspart along with insulin degludec (basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the inves,,,
arm,NCT03268005::arm::FG001,NCT03268005,NovoRapid,,,,,,,,,,FG001,Participants received insulin aspart (NovoRapid®/NovoLog®: basal-bolus regimen) with or without metformin for 16 weeks. Before the treatment period was a 12-week run-in period in which the investigato,,,
period,NCT03268005::period::1,NCT03268005,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03268005::outcome::primary::1,NCT03268005,Change in Glycosylated Haemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Week 0, week 16"
country,NCT03268005::country::United States,NCT03268005,United States,,,,,,,,,,,,,,
country,NCT03268005::country::Canada,NCT03268005,Canada,,,,,,,,,,,,,,
country,NCT03268005::country::South Korea,NCT03268005,South Korea,,,,,,,,,,,,,,
country,NCT03268005::country::Greece,NCT03268005,Greece,,,,,,,,,,,,,,
country,NCT03268005::country::Russia,NCT03268005,Russia,,,,,,,,,,,,,,
country,NCT03268005::country::Spain,NCT03268005,Spain,,,,,,,,,,,,,,
country,NCT03268005::country::Germany,NCT03268005,Germany,,,,,,,,,,,,,,
country,NCT03268005::country::Italy,NCT03268005,Italy,,,,,,,,,,,,,,
country,NCT03268005::country::Poland,NCT03268005,Poland,,,,,,,,,,,,,,
country,NCT03268005::country::Romania,NCT03268005,Romania,,,,,,,,,,,,,,
country,NCT03268005::country::Ukraine,NCT03268005,Ukraine,,,,,,,,,,,,,,
country,NCT03268005::country::Serbia,NCT03268005,Serbia,,,,,,,,,,,,,,
country,NCT03268005::country::Slovakia,NCT03268005,Slovakia,,,,,,,,,,,,,,
country,NCT03268005::country::Argentina,NCT03268005,Argentina,,,,,,,,,,,,,,
country,NCT03268005::country::Bulgaria,NCT03268005,Bulgaria,,,,,,,,,,,,,,
country,NCT03268005::country::Croatia,NCT03268005,Croatia,,,,,,,,,,,,,,
country,NCT03268005::country::Czechia,NCT03268005,Czechia,,,,,,,,,,,,,,
country,NCT03268005::country::Puerto Rico,NCT03268005,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01462266,NCT01462266,Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,660.0,2012-01-13,2013-06-07,0.0,0.0,,,,,
arm,NCT01462266::arm::FG000,NCT01462266,Sitagliptin,,,,,,,,,,FG000,Sitagliptin 100 mg administered orally once daily for 24 weeks.,,,
arm,NCT01462266::arm::FG001,NCT01462266,Placebo,,,,,,,,,,FG001,Placebo to sitagliptin administered orally once daily for 24 weeks.,,,
period,NCT01462266::period::1,NCT01462266,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01462266::outcome::primary::1,NCT01462266,Change From Baseline in Daily Insulin Dose at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and Week 24
trial,NCT03954834,NCT03954834,A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,478.0,2019-06-03,2020-10-28,5.0,53.0,,,,,
arm,NCT03954834::arm::FG000,NCT03954834,5 mg Tirzepatide,,,,,,,,,,FG000,Participants received 5 mg of tirzepatide as subcutaneous injection once a week.,,,
arm,NCT03954834::arm::FG001,NCT03954834,10 mg Tirzepatide,,,,,,,,,,FG001,Participants received 10mg of tirzepatide as subcutaneous injection once a week.,,,
arm,NCT03954834::arm::FG002,NCT03954834,15 mg Tirzepatide,,,,,,,,,,FG002,Participants received 15mg of tirzepatide as subcutaneous injection once a week.,,,
arm,NCT03954834::arm::FG003,NCT03954834,Placebo,,,,,,,,,,FG003,Participants received placebo as subcutaneous injection once a week.,,,
period,NCT03954834::period::1,NCT03954834,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03954834::outcome::primary::1,NCT03954834,Change From Baseline in Hemoglobin A1c (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline, Week 40"
country,NCT03954834::country::United States,NCT03954834,United States,,,,,,,,,,,,,,
country,NCT03954834::country::Japan,NCT03954834,Japan,,,,,,,,,,,,,,
country,NCT03954834::country::India,NCT03954834,India,,,,,,,,,,,,,,
country,NCT03954834::country::Mexico,NCT03954834,Mexico,,,,,,,,,,,,,,
country,NCT03954834::country::Puerto Rico,NCT03954834,Puerto Rico,,,,,,,,,,,,,,
trial,NCT02030600,NCT02030600,"A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes",PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,721.0,2014-01-06,2015-12-04,2.0,166.0,,,,,
arm,NCT02030600::arm::FG000,NCT02030600,Insulin Degludec/Insulin Glargine (IDeg/IGlar),,,,,,,,,,FG000,Subjects received insulin degludec (IDeg) in treatment period 1 and insulin glargine (IGlar) in treatment period 2. Each treatment period consisted of a 16-week titration period and a 16-week maintena,,,
arm,NCT02030600::arm::FG001,NCT02030600,Insulin Glargine/Insulin Degludec (IGlar/IDeg),,,,,,,,,,FG001,Subjects received IGlar in treatment period 1 and IDeg in treatment period 2. Each treatment period consisted of a 16-week titration period and a 16-week maintenance period (total 32 weeks for each tr,,,
period,NCT02030600::period::1,NCT02030600,Treatment Period 1,,,,,,,,,,,,1.0,,
period,NCT02030600::period::2,NCT02030600,Treatment Period 2,,,,,,,,,,,,2.0,,
outcome,NCT02030600::outcome::primary::1,NCT02030600,Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Maintenance Period,,,,,,,,,,,,,PRIMARY,"After 16 weeks of treatment, in each treatment period (Week 16-32 and Week 48-64)"
country,NCT02030600::country::United States,NCT02030600,United States,,,,,,,,,,,,,,
country,NCT02030600::country::Puerto Rico,NCT02030600,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00885352,NCT00885352,Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,313.0,2009-04-15,2010-11-10,0.0,0.0,,,,,
arm,NCT00885352::arm::FG000,NCT00885352,Sitagliptin,,,,,,,,,,FG000,Sitagliptin 100 mg once daily,,,
arm,NCT00885352::arm::FG001,NCT00885352,Placebo,,,,,,,,,,FG001,Placebo to sitagliptin once daily,,,
period,NCT00885352::period::1,NCT00885352,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00885352::outcome::primary::1,NCT00885352,Change From Baseline in Hemoglobin A1c (A1C) at Week 26,,,,,,,,,,,,,PRIMARY,Baseline and Week 26
trial,NCT00954447,NCT00954447,Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,1263.0,2009-08,,19.0,169.0,,,,,
arm,NCT00954447::arm::FG000,NCT00954447,Placebo,,,,,,,,,,FG000,"Patients randomized to receive treatment with matching placebo, orally taken, once daily. During the first 24 weeks of the randomised treatment period, the background dose of basal insulin and/or oral",,,
arm,NCT00954447::arm::FG001,NCT00954447,Linagliptin 5 mg,,,,,,,,,,FG001,"Patients randomized to receive treatment with Linagliptin 5mg, orally taken, once daily. During the first 24 weeks of the randomised treatment period, the background dose of basal insulin and/or oral ",,,
period,NCT00954447::period::1,NCT00954447,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00954447::outcome::primary::1,NCT00954447,Change From Baseline in HbA1c After 24 Weeks,,,,,,,,,,,,,PRIMARY,Baseline and 24 weeks
country,NCT00954447::country::United States,NCT00954447,United States,,,,,,,,,,,,,,
country,NCT00954447::country::Germany,NCT00954447,Germany,,,,,,,,,,,,,,
country,NCT00954447::country::Canada,NCT00954447,Canada,,,,,,,,,,,,,,
country,NCT00954447::country::South Korea,NCT00954447,South Korea,,,,,,,,,,,,,,
country,NCT00954447::country::Spain,NCT00954447,Spain,,,,,,,,,,,,,,
country,NCT00954447::country::Taiwan,NCT00954447,Taiwan,,,,,,,,,,,,,,
country,NCT00954447::country::Italy,NCT00954447,Italy,,,,,,,,,,,,,,
country,NCT00954447::country::Netherlands,NCT00954447,Netherlands,,,,,,,,,,,,,,
country,NCT00954447::country::Czechia,NCT00954447,Czechia,,,,,,,,,,,,,,
country,NCT00954447::country::Finland,NCT00954447,Finland,,,,,,,,,,,,,,
country,NCT00954447::country::Greece,NCT00954447,Greece,,,,,,,,,,,,,,
country,NCT00954447::country::Russia,NCT00954447,Russia,,,,,,,,,,,,,,
country,NCT00954447::country::Slovakia,NCT00954447,Slovakia,,,,,,,,,,,,,,
country,NCT00954447::country::Argentina,NCT00954447,Argentina,,,,,,,,,,,,,,
country,NCT00954447::country::Norway,NCT00954447,Norway,,,,,,,,,,,,,,
country,NCT00954447::country::Brazil,NCT00954447,Brazil,,,,,,,,,,,,,,
country,NCT00954447::country::Belgium,NCT00954447,Belgium,,,,,,,,,,,,,,
country,NCT00954447::country::Mexico,NCT00954447,Mexico,,,,,,,,,,,,,,
country,NCT00954447::country::Peru,NCT00954447,Peru,,,,,,,,,,,,,,
trial,NCT00918138,NCT00918138,Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,219.0,2009-08,2010-05,4.0,21.0,,,,,
arm,NCT00918138::arm::FG000,NCT00918138,Saxagliptin 5 mg + Metformin XR 1500 mg,,,,,,,,,,FG000,saxagliptin 5 mg plus metformin XR 1500 plus matching metformin XR 500 mg placebo,,,
arm,NCT00918138::arm::FG001,NCT00918138,Metformin 2000 mg,,,,,,,,,,FG001,metformin XR 500 mg plus metformin XR 1500 mg plus matching saxagliptin 5 mg placebo,,,
period,NCT00918138::period::1,NCT00918138,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00918138::outcome::primary::1,NCT00918138,Change From Baseline in 24-Hour Mean Weighted Glucose (MWG) at Week 4,,,,,,,,,,,,,PRIMARY,"Baseline, Week 4"
country,NCT00918138::country::United States,NCT00918138,United States,,,,,,,,,,,,,,
country,NCT00918138::country::Israel,NCT00918138,Israel,,,,,,,,,,,,,,
country,NCT00918138::country::Mexico,NCT00918138,Mexico,,,,,,,,,,,,,,
country,NCT00918138::country::Argentina,NCT00918138,Argentina,,,,,,,,,,,,,,
trial,NCT01652729,NCT01652729,"Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus",PHASE3,diabetes type 2,Diabetes Type 2,INDUSTRY,365.0,2013-02,2014-04,1.0,60.0,,,,,
arm,NCT01652729::arm::FG000,NCT01652729,Experimental: Exenatide,,,,,,,,,,FG000,Exenatide once weekly suspension 2mg subcutaneous injection,,,
arm,NCT01652729::arm::FG001,NCT01652729,Active Comparator: Sitagliptin,,,,,,,,,,FG001,Sitagliptin 100mg oral tablet once daily,,,
arm,NCT01652729::arm::FG002,NCT01652729,Placebo Comparator: Placebo,,,,,,,,,,FG002,Placebo oral tablet once daily,,,
period,NCT01652729::period::1,NCT01652729,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01652729::outcome::primary::1,NCT01652729,Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28,,,,,,,,,,,,,PRIMARY,Baseline to Week 28
country,NCT01652729::country::United States,NCT01652729,United States,,,,,,,,,,,,,,
trial,NCT00813995,NCT00813995,A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,395.0,2008-12-09,2010-08-09,0.0,0.0,,,,,
arm,NCT00813995::arm::FG000,NCT00813995,Sitagliptin,,,,,,,,,,FG000,Sitagliptin phosphate 100 mg tablets once daily (q.d.) and a stable dose of metformin therapy for 24 weeks.,,,
arm,NCT00813995::arm::FG001,NCT00813995,Placebo,,,,,,,,,,FG001,Placebo tablets q.d. and a stable dose of metformin therapy for 24 weeks.,,,
period,NCT00813995::period::1,NCT00813995,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00813995::outcome::primary::1,NCT00813995,Change From Baseline in Hemoglobin A1c (A1C) at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and Week 24
trial,NCT00397631,NCT00397631,Initial Combination With Pioglitazone Study (0431-064),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,520.0,2006-12-19,2008-06-28,0.0,0.0,,,,,
arm,NCT00397631::arm::FG000,NCT00397631,Sitagliptin 100 mg q.d. + Pioglitazone 30 mg q.d.,,,,,,,,,,FG000,The Sitagliptin 100 mg q.d. + Pioglitazone 30 mg q.d. (q.d. = once daily) group includes data from patients randomized to receive coadministration of sitagliptin 100 mg oral tablets and pioglitazone 3,,,
arm,NCT00397631::arm::FG001,NCT00397631,Pioglitazone 30 mg q.d.,,,,,,,,,,FG001,The Pioglitazone 30 mg q.d. (q.d. = once daily) group includes data from patients randomized to receive coadministration of pioglitazone 30 mg oral tablets and placebo to sitagliptin 100 mg oral table,,,
period,NCT00397631::period::1,NCT00397631,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00397631::outcome::primary::1,NCT00397631,Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and 24 weeks
trial,NCT02419612,NCT02419612,"A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone",PHASE3,diabetes type 2,Diabetes,INDUSTRY,444.0,2015-08-14,2019-09-18,10.0,84.0,,,,,
arm,NCT02419612::arm::FG000,NCT02419612,Dapagliflozin 10mg and Saxagliptin 5mg,,,,,,,,,,FG000,"Subjects received dapagliflozin 10 mg, saxagliptin 5 mg plus placebo for glimepiride, each administered orally once daily. Subjects also continued to receive their metformin dose of at least 1500 mg p",,,
arm,NCT02419612::arm::FG001,NCT02419612,Titrated Glimepiride,,,,,,,,,,FG001,"Subjects received titrated glimepiride 1, 2, 3, 4, or 6 mg plus placebo for saxagliptin and placebo for dapagliflozin, administered orally once daily. Subjects also continued to receive their metformi",,,
period,NCT02419612::period::1,NCT02419612,Short-term Treatment Period,,,,,,,,,,,,1.0,,
period,NCT02419612::period::2,NCT02419612,Long-term Treatment Period,,,,,,,,,,,,2.0,,
outcome,NCT02419612::outcome::primary::1,NCT02419612,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 52,,,,,,,,,,,,,PRIMARY,Baseline and Week 52
country,NCT02419612::country::United States,NCT02419612,United States,,,,,,,,,,,,,,
country,NCT02419612::country::Hungary,NCT02419612,Hungary,,,,,,,,,,,,,,
country,NCT02419612::country::Romania,NCT02419612,Romania,,,,,,,,,,,,,,
country,NCT02419612::country::Poland,NCT02419612,Poland,,,,,,,,,,,,,,
country,NCT02419612::country::Czechia,NCT02419612,Czechia,,,,,,,,,,,,,,
country,NCT02419612::country::Mexico,NCT02419612,Mexico,,,,,,,,,,,,,,
country,NCT02419612::country::Russia,NCT02419612,Russia,,,,,,,,,,,,,,
country,NCT02419612::country::Sweden,NCT02419612,Sweden,,,,,,,,,,,,,,
country,NCT02419612::country::Germany,NCT02419612,Germany,,,,,,,,,,,,,,
country,NCT02419612::country::United Kingdom,NCT02419612,United Kingdom,,,,,,,,,,,,,,
trial,NCT00377676,NCT00377676,Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,3095.0,2004-07,2007-01,0.0,0.0,,,,,
arm,NCT00377676::arm::FG000,NCT00377676,Cycloset,,,,,,,,,,FG000,"During the first week of the dose titration period, subjects were instructed to take 1 tablet of study drug daily (0.8 mg Cycloset). If the dose was tolerated, subjects were to have their dose of stud",,,
arm,NCT00377676::arm::FG001,NCT00377676,Placebo,,,,,,,,,,FG001,"During the first week of the dose titration period, subjects were instructed to take 1 tablet of study drug daily (1 placebo tablet). If the dose was tolerated, subjects were to have their dose of stu",,,
period,NCT00377676::period::1,NCT00377676,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00377676::outcome::primary::1,NCT00377676,Subjects Experiencing Serious Adverse Events,,,,,,,,,,,,,PRIMARY,From baseline to week 52.
trial,NCT00601250,NCT00601250,Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,701.0,2008-01,,10.0,82.0,,,,,
arm,NCT00601250::arm::FG000,NCT00601250,Placebo,,,,,,,,,,FG000,Patients randomized to receive treatment with matching placebo,,,
arm,NCT00601250::arm::FG001,NCT00601250,Linagliptin,,,,,,,,,,FG001,Patients randomized to receive treatment with Linagliptin 5 mg,,,
period,NCT00601250::period::1,NCT00601250,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00601250::outcome::primary::1,NCT00601250,HbA1c Change From Baseline at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and week 24
country,NCT00601250::country::United States,NCT00601250,United States,,,,,,,,,,,,,,
country,NCT00601250::country::India,NCT00601250,India,,,,,,,,,,,,,,
country,NCT00601250::country::Mexico,NCT00601250,Mexico,,,,,,,,,,,,,,
country,NCT00601250::country::Czechia,NCT00601250,Czechia,,,,,,,,,,,,,,
country,NCT00601250::country::Israel,NCT00601250,Israel,,,,,,,,,,,,,,
country,NCT00601250::country::Finland,NCT00601250,Finland,,,,,,,,,,,,,,
country,NCT00601250::country::Russia,NCT00601250,Russia,,,,,,,,,,,,,,
country,NCT00601250::country::New Zealand,NCT00601250,New Zealand,,,,,,,,,,,,,,
country,NCT00601250::country::Sweden,NCT00601250,Sweden,,,,,,,,,,,,,,
country,NCT00601250::country::Greece,NCT00601250,Greece,,,,,,,,,,,,,,
trial,NCT01059812,NCT01059812,A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,424.0,2010-02-01,2010-12-23,5.0,46.0,,,,,
arm,NCT01059812::arm::FG000,NCT01059812,IDegAsp BID,,,,,,,,,,FG000,Insulin degludec/insulin aspart (IDegAsp) was given twice daily (BID) with breakfast and evening meal with or without metformin.,,,
arm,NCT01059812::arm::FG001,NCT01059812,BIAsp 30 BID,,,,,,,,,,FG001,Biphasic insulin aspart (BIAsp 30) was given twice daily (BID) with breakfast and evening meal with or without metformin.,,,
period,NCT01059812::period::1,NCT01059812,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01059812::outcome::primary::1,NCT01059812,Change in HbA1c (Glycosylated Haemoglobin) After 26 Weeks of Treatment,,,,,,,,,,,,,PRIMARY,"Week 0, Week 26"
country,NCT01059812::country::Japan,NCT01059812,Japan,,,,,,,,,,,,,,
country,NCT01059812::country::South Korea,NCT01059812,South Korea,,,,,,,,,,,,,,
country,NCT01059812::country::Malaysia,NCT01059812,Malaysia,,,,,,,,,,,,,,
country,NCT01059812::country::Taiwan,NCT01059812,Taiwan,,,,,,,,,,,,,,
country,NCT01059812::country::Hong Kong,NCT01059812,Hong Kong,,,,,,,,,,,,,,
trial,NCT02305381,NCT02305381,Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,397.0,2014-12-01,2015-11-21,6.0,99.0,,,,,
arm,NCT02305381::arm::FG000,NCT02305381,Semaglutide 0.5 mg,,,,,,,,,,FG000,"Subjects received semaglutide 0.25 mg subcutaneous (sc) injection once weekly for 4 weeks followed by semaglutide 0.5 mg once weekly up to week 30. Semaglutide injection was administered in the thigh,",,,
arm,NCT02305381::arm::FG001,NCT02305381,Semaglutide 1.0 mg,,,,,,,,,,FG001,Subjects received semaglutide 0.25 mg sc injection once weekly for 4 weeks followed by semaglutide 0.5 mg once weekly for next 4 weeks and then semaglutide 1.0 mg once weekly up to week 30.Semaglutide,,,
arm,NCT02305381::arm::FG002,NCT02305381,Placebo,,,,,,,,,,FG002,"Subjects received placebo (matched to semaglutide) sc injection once weekly for 30 weeks. Placebo injection was administered in the thigh, abdomen or upper arm, at any time of day irrespective of meal",,,
period,NCT02305381::period::1,NCT02305381,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02305381::outcome::primary::1,NCT02305381,Change in HbA1c (Glycosylated Haemoglobin),,,,,,,,,,,,,PRIMARY,"Week 0, week 30"
country,NCT02305381::country::United States,NCT02305381,United States,,,,,,,,,,,,,,
country,NCT02305381::country::Germany,NCT02305381,Germany,,,,,,,,,,,,,,
country,NCT02305381::country::Japan,NCT02305381,Japan,,,,,,,,,,,,,,
country,NCT02305381::country::Slovakia,NCT02305381,Slovakia,,,,,,,,,,,,,,
country,NCT02305381::country::Serbia,NCT02305381,Serbia,,,,,,,,,,,,,,
country,NCT02305381::country::Puerto Rico,NCT02305381,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00789191,NCT00789191,Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,222.0,2008-11,2009-08,8.0,51.0,,,,,
arm,NCT00789191::arm::FG000,NCT00789191,Comb,,,,,,,,,,FG000,Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment,,,
arm,NCT00789191::arm::FG001,NCT00789191,Sita,,,,,,,,,,FG001,Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment,,,
period,NCT00789191::period::1,NCT00789191,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00789191::outcome::primary::1,NCT00789191,HbA1c (Glycosylated Haemoglobin A1c),,,,,,,,,,,,,PRIMARY,Week 26
country,NCT00789191::country::United States,NCT00789191,United States,,,,,,,,,,,,,,
country,NCT00789191::country::Canada,NCT00789191,Canada,,,,,,,,,,,,,,
country,NCT00789191::country::France,NCT00789191,France,,,,,,,,,,,,,,
country,NCT00789191::country::Finland,NCT00789191,Finland,,,,,,,,,,,,,,
country,NCT00789191::country::Slovakia,NCT00789191,Slovakia,,,,,,,,,,,,,,
country,NCT00789191::country::Hungary,NCT00789191,Hungary,,,,,,,,,,,,,,
country,NCT00789191::country::Turkey (Türkiye),NCT00789191,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00789191::country::South Korea,NCT00789191,South Korea,,,,,,,,,,,,,,
trial,NCT01064414,NCT01064414,"An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment",PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2; Renal Insufficiency",INDUSTRY,272.0,2010-06,2012-08,18.0,106.0,,,,,
arm,NCT01064414::arm::FG000,NCT01064414,Placebo,,,,,,,,,,FG000,Each patient received matching placebo once daily for 52 weeks. Data are presented for Baseline to Week 26 (Core Period) and for Week 26 to 52 (Extension Period).,,,
arm,NCT01064414::arm::FG001,NCT01064414,Canagliflozin 100 mg,,,,,,,,,,FG001,Each patient received 100 mg of canagliflozin once daily for 52 weeks. Data are presented for Baseline to Week 26 (Core Period) and for Week 26 to 52 (Extension Period).,,,
arm,NCT01064414::arm::FG002,NCT01064414,Canagliflozin 300 mg,,,,,,,,,,FG002,Each patient received 300 mg of canagliflozin once daily for 52 weeks.Data are presented for Baseline to Week 26 (Core Period) and for Week 26 to 52 (Extension Period).,,,
period,NCT01064414::period::1,NCT01064414,Core Period: Baseline to Week 26,,,,,,,,,,,,1.0,,
period,NCT01064414::period::2,NCT01064414,Extension Period: Week 26 to Week 52,,,,,,,,,,,,2.0,,
outcome,NCT01064414::outcome::primary::1,NCT01064414,Change in HbA1c From Baseline to Week 26,,,,,,,,,,,,,PRIMARY,Day 1 (Baseline) and Week 26
country,NCT01064414::country::United States,NCT01064414,United States,,,,,,,,,,,,,,
country,NCT01064414::country::Canada,NCT01064414,Canada,,,,,,,,,,,,,,
country,NCT01064414::country::Germany,NCT01064414,Germany,,,,,,,,,,,,,,
country,NCT01064414::country::Russia,NCT01064414,Russia,,,,,,,,,,,,,,
country,NCT01064414::country::France,NCT01064414,France,,,,,,,,,,,,,,
country,NCT01064414::country::Belgium,NCT01064414,Belgium,,,,,,,,,,,,,,
country,NCT01064414::country::Spain,NCT01064414,Spain,,,,,,,,,,,,,,
country,NCT01064414::country::Australia,NCT01064414,Australia,,,,,,,,,,,,,,
country,NCT01064414::country::Malaysia,NCT01064414,Malaysia,,,,,,,,,,,,,,
country,NCT01064414::country::Mexico,NCT01064414,Mexico,,,,,,,,,,,,,,
country,NCT01064414::country::New Zealand,NCT01064414,New Zealand,,,,,,,,,,,,,,
country,NCT01064414::country::India,NCT01064414,India,,,,,,,,,,,,,,
country,NCT01064414::country::Latvia,NCT01064414,Latvia,,,,,,,,,,,,,,
country,NCT01064414::country::Poland,NCT01064414,Poland,,,,,,,,,,,,,,
country,NCT01064414::country::South Africa,NCT01064414,South Africa,,,,,,,,,,,,,,
country,NCT01064414::country::Romania,NCT01064414,Romania,,,,,,,,,,,,,,
country,NCT01064414::country::South Korea,NCT01064414,South Korea,,,,,,,,,,,,,,
country,NCT01064414::country::Brazil,NCT01064414,Brazil,,,,,,,,,,,,,,
trial,NCT02453555,NCT02453555,Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,275.0,2015-05-14,2017-03-27,1.0,40.0,,,,,
arm,NCT02453555::arm::FG000,NCT02453555,Empagliflozin 10 Milligram (mg)/Linagliptin 5 Milligram (mg),,,,,,,,,,FG000,Patients were administered a fixed dose combination (FDC) of 10 mg Empagliflozin and 5 mg Linagliptin tablet along with matching placebo of Linagliptin 5 mg orally once daily for 24 weeks of double-bl,,,
arm,NCT02453555::arm::FG001,NCT02453555,Linagliptin 5 mg + Placebo 10 mg,,,,,,,,,,FG001,Patients were administered a matching placebo of FDC of 10 mg Empagliflozin and 5 mg Linagliptin tablet along with Linagliptin 5 mg orally once daily for 24 weeks of double-blind treatment period.,,,
arm,NCT02453555::arm::FG002,NCT02453555,Empagliflozin 25 mg/Linagliptin 5 mg (Extension Period),,,,,,,,,,FG002,Patients with insufficient response based on Glycosylated haemoglobin A1c (HbA1c) after 24-week of double-blind treatment period were up-titrated to a FDC of 25 mg Empagliflozin and 5 mg Linagliptin t,,,
arm,NCT02453555::arm::FG003,NCT02453555,Empagliflozin 10 mg/Linagliptin 5 mg (Extension Period),,,,,,,,,,FG003,Patients with sufficient response based on HbA1c after 24-week of double-blind treatment period were continued on a FDC of 10 mg Empagliflozin and 5 mg Linagliptin tablet along with matching placebo o,,,
arm,NCT02453555::arm::FG004,NCT02453555,Linagliptin 5 mg + Placebo 25 mg (Extension Period),,,,,,,,,,FG004,Patients with insufficient response based on HbA1c after 24-week of double-blind treatment period were up-titrated to receive a matching placebo of FDC of 25 mg Empagliflozin and 5 mg Linagliptin tabl,,,
arm,NCT02453555::arm::FG005,NCT02453555,Linagliptin 5 mg + Placebo 10 mg (Extension Period),,,,,,,,,,FG005,Patients with sufficient response based on HbA1c after 24-week of double-blind treatment period were continued on a matching placebo of FDC of 10 mg Empagliflozin and 5 mg Linagliptin tablet along wit,,,
period,NCT02453555::period::1,NCT02453555,24-week Double-blind Treatment Period,,,,,,,,,,,,1.0,,
period,NCT02453555::period::2,NCT02453555,Extension Period,,,,,,,,,,,,2.0,,
outcome,NCT02453555::outcome::primary::1,NCT02453555,Change of Glycosylated Haemoglobin A1c (Glycosylated Haemoglobin A1c After 24 Weeks of Double-blind Treatment From Baseline),,,,,,,,,,,,,PRIMARY,Baseline and 24 week
country,NCT02453555::country::Japan,NCT02453555,Japan,,,,,,,,,,,,,,
trial,NCT01664247,NCT01664247,The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,346.0,2012-10-01,2013-12-31,11.0,132.0,,,,,
arm,NCT01664247::arm::FG000,NCT01664247,IDeg,,,,,,,,,,FG000,"Liraglutide treatment was initiated on 0.6 mg daily for one week and increased further after the second week in the run-in period. In the randomized period, Insulin degludec (IDeg, 100 U/mL, in a 3 mL",,,
arm,NCT01664247::arm::FG001,NCT01664247,Placebo,,,,,,,,,,FG001,"Placebo treatment (3 mL prefilled pen) in combination with Liraglutide (Lira,1.8 mg/daily, 3 mL prefilled pen) once daily was given subcutaneously (under the skin) in the thigh, abdomen or upper arm (",,,
period,NCT01664247::period::1,NCT01664247,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01664247::outcome::primary::1,NCT01664247,Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%),,,,,,,,,,,,,PRIMARY,"Week 0, week 26"
country,NCT01664247::country::United States,NCT01664247,United States,,,,,,,,,,,,,,
country,NCT01664247::country::France,NCT01664247,France,,,,,,,,,,,,,,
country,NCT01664247::country::Germany,NCT01664247,Germany,,,,,,,,,,,,,,
country,NCT01664247::country::Canada,NCT01664247,Canada,,,,,,,,,,,,,,
country,NCT01664247::country::Italy,NCT01664247,Italy,,,,,,,,,,,,,,
country,NCT01664247::country::Israel,NCT01664247,Israel,,,,,,,,,,,,,,
country,NCT01664247::country::South Africa,NCT01664247,South Africa,,,,,,,,,,,,,,
country,NCT01664247::country::United Kingdom,NCT01664247,United Kingdom,,,,,,,,,,,,,,
country,NCT01664247::country::Ukraine,NCT01664247,Ukraine,,,,,,,,,,,,,,
country,NCT01664247::country::Serbia,NCT01664247,Serbia,,,,,,,,,,,,,,
country,NCT01664247::country::United Arab Emirates,NCT01664247,United Arab Emirates,,,,,,,,,,,,,,
trial,NCT03078478,NCT03078478,A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,1609.0,2017-03-13,2019-03-04,12.0,229.0,,,,,
arm,NCT03078478::arm::FG000,NCT03078478,Insulin Degludec U200,,,,,,,,,,FG000,"Participants received insulin degludec 200 units/mL once daily as subcutaneous injections (in the thigh, upper arm or abdomen) ± oral anti-diabetic drugs. The daily basal insulin dose was reduced by 2",,,
arm,NCT03078478::arm::FG001,NCT03078478,Insulin Glargine U300,,,,,,,,,,FG001,"Participants received insulin glargine 300 units/mL once daily as subcutaneous injections (in the thigh, upper arm or abdomen) ± pre-trial oral anti-diabetic drugs. The dose of IGlar U300 corresponded",,,
period,NCT03078478::period::1,NCT03078478,Titration Period (16 Weeks),,,,,,,,,,,,1.0,,
period,NCT03078478::period::2,NCT03078478,Maintenance Period 1 (36 Weeks),,,,,,,,,,,,2.0,,
period,NCT03078478::period::3,NCT03078478,Maintencance Period 2 (36 Weeks),,,,,,,,,,,,3.0,,
outcome,NCT03078478::outcome::primary::1,NCT03078478,Number of Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks),,,,,,,,,,,,,PRIMARY,36 Weeks
country,NCT03078478::country::United States,NCT03078478,United States,,,,,,,,,,,,,,
country,NCT03078478::country::Germany,NCT03078478,Germany,,,,,,,,,,,,,,
country,NCT03078478::country::Canada,NCT03078478,Canada,,,,,,,,,,,,,,
country,NCT03078478::country::Hungary,NCT03078478,Hungary,,,,,,,,,,,,,,
country,NCT03078478::country::Poland,NCT03078478,Poland,,,,,,,,,,,,,,
country,NCT03078478::country::Greece,NCT03078478,Greece,,,,,,,,,,,,,,
country,NCT03078478::country::Norway,NCT03078478,Norway,,,,,,,,,,,,,,
country,NCT03078478::country::Denmark,NCT03078478,Denmark,,,,,,,,,,,,,,
country,NCT03078478::country::Romania,NCT03078478,Romania,,,,,,,,,,,,,,
country,NCT03078478::country::Estonia,NCT03078478,Estonia,,,,,,,,,,,,,,
country,NCT03078478::country::Serbia,NCT03078478,Serbia,,,,,,,,,,,,,,
country,NCT03078478::country::Puerto Rico,NCT03078478,Puerto Rico,,,,,,,,,,,,,,
trial,NCT02128932,NCT02128932,Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,1089.0,2014-08-04,2015-09-03,15.0,231.0,,,,,
arm,NCT02128932::arm::FG000,NCT02128932,Semaglutide 0.5mg/Week,,,,,,,,,,FG000,Subjects on semaglutide followed a fixed dose-escalation. The maintenance dose of 0.5 mg was to be reached after 4 doses (4 weeks) of 0.25 mg semaglutide. Doses could not be changed during the trial a,,,
arm,NCT02128932::arm::FG001,NCT02128932,Semaglutide 1.0 mg/Week,,,,,,,,,,FG001,"Subjects randomised to semaglutide followed a fixed dose-escalation regimen. The maintenance dose of 1.0 mg was to be reached after 4 doses (4 weeks) of 0.25 mg, followed by 4 doses (4 weeks) of 0.5 m",,,
arm,NCT02128932::arm::FG002,NCT02128932,Insulin Glargine,,,,,,,,,,FG002,Subjects on insulin glargine were to start on 10 IU s.c. injected OD. The insulin dose adjustment had to aim to reach a pre-breakfast FPG of 4.0 to \<5.5 mmol/L (71- \<100 mg/dL). Once daily solution ,,,
period,NCT02128932::period::1,NCT02128932,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02128932::outcome::primary::1,NCT02128932,Change in HbA1c From Baseline,,,,,,,,,,,,,PRIMARY,"Week 0, week 30"
country,NCT02128932::country::United States,NCT02128932,United States,,,,,,,,,,,,,,
country,NCT02128932::country::France,NCT02128932,France,,,,,,,,,,,,,,
country,NCT02128932::country::India,NCT02128932,India,,,,,,,,,,,,,,
country,NCT02128932::country::United Kingdom,NCT02128932,United Kingdom,,,,,,,,,,,,,,
country,NCT02128932::country::Germany,NCT02128932,Germany,,,,,,,,,,,,,,
country,NCT02128932::country::Romania,NCT02128932,Romania,,,,,,,,,,,,,,
country,NCT02128932::country::Slovakia,NCT02128932,Slovakia,,,,,,,,,,,,,,
country,NCT02128932::country::South Africa,NCT02128932,South Africa,,,,,,,,,,,,,,
country,NCT02128932::country::Argentina,NCT02128932,Argentina,,,,,,,,,,,,,,
country,NCT02128932::country::Croatia,NCT02128932,Croatia,,,,,,,,,,,,,,
country,NCT02128932::country::Mexico,NCT02128932,Mexico,,,,,,,,,,,,,,
country,NCT02128932::country::Netherlands,NCT02128932,Netherlands,,,,,,,,,,,,,,
country,NCT02128932::country::Slovenia,NCT02128932,Slovenia,,,,,,,,,,,,,,
country,NCT02128932::country::North Macedonia,NCT02128932,North Macedonia,,,,,,,,,,,,,,
country,NCT02128932::country::Puerto Rico,NCT02128932,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00295633,NCT00295633,A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,565.0,2006-03,2008-10,8.0,133.0,,,,,
arm,NCT00295633::arm::FG000,NCT00295633,Saxagliptin 2.5 mg Plus Open-label Thiazolidinedione (TZD),,,,,,,,,,FG000,The Saxagliptin 2.5 mg + Open-Label TZD group includes data from subjects randomized to receive coadministration of blinded Saxagliptin 2.5 mg plus open-label pioglitazone 30 mg or 45 mg once daily (Q,,,
arm,NCT00295633::arm::FG001,NCT00295633,Saxagliptin 5 mg Plus Open-label TZD,,,,,,,,,,FG001,"The Saxagliptin 5 mg + Open-Label TZD group includes data from subjects randomized to receive coadministration of blinded Saxagliptin 5 mg plus pioglitazone 30 mg or 45 mg once daily (QD), or rosiglit",,,
arm,NCT00295633::arm::FG002,NCT00295633,Placebo Plus Open-label TZD,,,,,,,,,,FG002,"The placebo + open-label TZD group includes data from subjects randomized to receive coadministration of blinded placebo plus pioglitazone 30 mg or 45 mg once daily (QD), or rosiglitazone 4 mg QD, or ",,,
period,NCT00295633::period::1,NCT00295633,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00295633::outcome::primary::1,NCT00295633,Change From Baseline in Hemoglobin A1c (A1C) at Week 24,,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
country,NCT00295633::country::United States,NCT00295633,United States,,,,,,,,,,,,,,
country,NCT00295633::country::India,NCT00295633,India,,,,,,,,,,,,,,
country,NCT00295633::country::Argentina,NCT00295633,Argentina,,,,,,,,,,,,,,
country,NCT00295633::country::Canada,NCT00295633,Canada,,,,,,,,,,,,,,
country,NCT00295633::country::Mexico,NCT00295633,Mexico,,,,,,,,,,,,,,
country,NCT00295633::country::Peru,NCT00295633,Peru,,,,,,,,,,,,,,
country,NCT00295633::country::Philippines,NCT00295633,Philippines,,,,,,,,,,,,,,
country,NCT00295633::country::Puerto Rico,NCT00295633,Puerto Rico,,,,,,,,,,,,,,
trial,NCT04657016,NCT04657016,A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program,PHASE3,diabetes type 2,Obesity; Overweight,INDUSTRY,579.0,2021-03-29,2023-05-12,4.0,65.0,,,,,
arm,NCT04657016::arm::FG000,NCT04657016,Placebo,,,,,,,,,,FG000,Participants received matching placebo subcutaneously (SC) once weekly (QW).,,,
arm,NCT04657016::arm::FG001,NCT04657016,Tirzepatide,,,,,,,,,,FG001,"Participants received weekly doses of tirzepatide SC for 72 weeks, starting at 2.5 milligrams (mg) for 4 weeks. Subsequently, the dose was increased by 2.5 mg every 4 weeks up to the maximum tolerated",,,
period,NCT04657016::period::1,NCT04657016,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04657016::outcome::primary::1,NCT04657016,Percent Change From Baseline in Body Weight,,,,,,,,,,,,,PRIMARY,"Baseline, 72 Weeks"
outcome,NCT04657016::outcome::primary::2,NCT04657016,Percentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction,,,,,,,,,,,,,PRIMARY,Week 72
country,NCT04657016::country::United States,NCT04657016,United States,,,,,,,,,,,,,,
country,NCT04657016::country::Argentina,NCT04657016,Argentina,,,,,,,,,,,,,,
country,NCT04657016::country::Brazil,NCT04657016,Brazil,,,,,,,,,,,,,,
country,NCT04657016::country::Puerto Rico,NCT04657016,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00069784,NCT00069784,The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention),PHASE3,diabetes type 2,"Diabetes Mellitus, Non-Insulin-Dependent",INDUSTRY,12537.0,2003-08,2011-12,40.0,40.0,,,,,
arm,NCT00069784::arm::FG000,NCT00069784,Insulin Glargine,,,,,,,,,,FG000,Treatment with Insulin Glargine with or without omega-3 polyunsaturated fatty acids,,,
arm,NCT00069784::arm::FG001,NCT00069784,Standard Care,,,,,,,,,,FG001,Standard care with or without omega-3 polyunsaturated fatty acids,,,
period,NCT00069784::period::1,NCT00069784,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00069784::outcome::primary::1,NCT00069784,"Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI) or Nonfatal Stroke",,,,,,,,,,,,,PRIMARY,from randomization until study cut-off date (median duration of follow-up: 6.2 years)
outcome,NCT00069784::outcome::primary::2,NCT00069784,"Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Revascularization Procedure or Hospitalization for Heart Failure (HF)",,,,,,,,,,,,,PRIMARY,from randomization until study cut-off date (median duration of follow-up: 6.2 years)
country,NCT00069784::country::United States,NCT00069784,United States,,,,,,,,,,,,,,
country,NCT00069784::country::Argentina,NCT00069784,Argentina,,,,,,,,,,,,,,
country,NCT00069784::country::Australia,NCT00069784,Australia,,,,,,,,,,,,,,
country,NCT00069784::country::Austria,NCT00069784,Austria,,,,,,,,,,,,,,
country,NCT00069784::country::Belarus,NCT00069784,Belarus,,,,,,,,,,,,,,
country,NCT00069784::country::Bermuda,NCT00069784,Bermuda,,,,,,,,,,,,,,
country,NCT00069784::country::Brazil,NCT00069784,Brazil,,,,,,,,,,,,,,
country,NCT00069784::country::Canada,NCT00069784,Canada,,,,,,,,,,,,,,
country,NCT00069784::country::Chile,NCT00069784,Chile,,,,,,,,,,,,,,
country,NCT00069784::country::China,NCT00069784,China,,,,,,,,,,,,,,
country,NCT00069784::country::Colombia,NCT00069784,Colombia,,,,,,,,,,,,,,
country,NCT00069784::country::Croatia,NCT00069784,Croatia,,,,,,,,,,,,,,
country,NCT00069784::country::Denmark,NCT00069784,Denmark,,,,,,,,,,,,,,
country,NCT00069784::country::Estonia,NCT00069784,Estonia,,,,,,,,,,,,,,
country,NCT00069784::country::Finland,NCT00069784,Finland,,,,,,,,,,,,,,
country,NCT00069784::country::France,NCT00069784,France,,,,,,,,,,,,,,
country,NCT00069784::country::Germany,NCT00069784,Germany,,,,,,,,,,,,,,
country,NCT00069784::country::Hungary,NCT00069784,Hungary,,,,,,,,,,,,,,
country,NCT00069784::country::India,NCT00069784,India,,,,,,,,,,,,,,
country,NCT00069784::country::Ireland,NCT00069784,Ireland,,,,,,,,,,,,,,
country,NCT00069784::country::Israel,NCT00069784,Israel,,,,,,,,,,,,,,
country,NCT00069784::country::Italy,NCT00069784,Italy,,,,,,,,,,,,,,
country,NCT00069784::country::Latvia,NCT00069784,Latvia,,,,,,,,,,,,,,
country,NCT00069784::country::Lithuania,NCT00069784,Lithuania,,,,,,,,,,,,,,
country,NCT00069784::country::Mexico,NCT00069784,Mexico,,,,,,,,,,,,,,
country,NCT00069784::country::Netherlands,NCT00069784,Netherlands,,,,,,,,,,,,,,
country,NCT00069784::country::Norway,NCT00069784,Norway,,,,,,,,,,,,,,
country,NCT00069784::country::Philippines,NCT00069784,Philippines,,,,,,,,,,,,,,
country,NCT00069784::country::Poland,NCT00069784,Poland,,,,,,,,,,,,,,
country,NCT00069784::country::Romania,NCT00069784,Romania,,,,,,,,,,,,,,
country,NCT00069784::country::Russia,NCT00069784,Russia,,,,,,,,,,,,,,
country,NCT00069784::country::Slovakia,NCT00069784,Slovakia,,,,,,,,,,,,,,
country,NCT00069784::country::South Africa,NCT00069784,South Africa,,,,,,,,,,,,,,
country,NCT00069784::country::South Korea,NCT00069784,South Korea,,,,,,,,,,,,,,
country,NCT00069784::country::Spain,NCT00069784,Spain,,,,,,,,,,,,,,
country,NCT00069784::country::Sweden,NCT00069784,Sweden,,,,,,,,,,,,,,
country,NCT00069784::country::Switzerland,NCT00069784,Switzerland,,,,,,,,,,,,,,
country,NCT00069784::country::Turkey (Türkiye),NCT00069784,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00069784::country::United Kingdom,NCT00069784,United Kingdom,,,,,,,,,,,,,,
country,NCT00069784::country::Venezuela,NCT00069784,Venezuela,,,,,,,,,,,,,,
trial,NCT01582451,NCT01582451,A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,466.0,2012-05,2013-12,9.0,61.0,,,,,
arm,NCT01582451::arm::FG000,NCT01582451,LY2605541,,,,,,,,,,FG000,LY2605541 was administered by subcutaneous (SQ) injection once daily at bedtime for up to 52 weeks. Initial dose based on dose of prestudy basal insulin and adjusted based on fasting blood glucose (FB,,,
arm,NCT01582451::arm::FG001,NCT01582451,Insulin Glargine,,,,,,,,,,FG001,Insulin glargine was administered by SQ injection once daily at bedtime for up to 52 weeks. Initial dose based on dose of prestudy basal insulin and adjusted based on FBG.,,,
period,NCT01582451::period::1,NCT01582451,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01582451::outcome::primary::1,NCT01582451,Change From Baseline to 26-week Endpoint in Hemoglobin A1c (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline, 26 weeks"
country,NCT01582451::country::United States,NCT01582451,United States,,,,,,,,,,,,,,
country,NCT01582451::country::Germany,NCT01582451,Germany,,,,,,,,,,,,,,
country,NCT01582451::country::Israel,NCT01582451,Israel,,,,,,,,,,,,,,
country,NCT01582451::country::Spain,NCT01582451,Spain,,,,,,,,,,,,,,
country,NCT01582451::country::Czechia,NCT01582451,Czechia,,,,,,,,,,,,,,
country,NCT01582451::country::Romania,NCT01582451,Romania,,,,,,,,,,,,,,
country,NCT01582451::country::Russia,NCT01582451,Russia,,,,,,,,,,,,,,
country,NCT01582451::country::Greece,NCT01582451,Greece,,,,,,,,,,,,,,
country,NCT01582451::country::Puerto Rico,NCT01582451,Puerto Rico,,,,,,,,,,,,,,
trial,NCT02769481,NCT02769481,Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,426.0,2016-08-15,2019-06-14,4.0,45.0,,,,,
arm,NCT02769481::arm::FG000,NCT02769481,Bexagliflozin,,,,,,,,,,FG000,"Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for glimepiride for the duration of the study",,,
arm,NCT02769481::arm::FG001,NCT02769481,Glimepiride,,,,,,,,,,FG001,"Subjects will receive a glimepiride capsule, 2, 4 or 6 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of t",,,
period,NCT02769481::period::1,NCT02769481,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02769481::outcome::primary::1,NCT02769481,Change From Baseline in HbA1c at Week 60,,,,,,,,,,,,,PRIMARY,Baseline and Week 60
country,NCT02769481::country::Poland,NCT02769481,Poland,,,,,,,,,,,,,,
country,NCT02769481::country::United States,NCT02769481,United States,,,,,,,,,,,,,,
country,NCT02769481::country::Spain,NCT02769481,Spain,,,,,,,,,,,,,,
country,NCT02769481::country::Germany,NCT02769481,Germany,,,,,,,,,,,,,,
trial,NCT03987919,NCT03987919,A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,1879.0,2019-07-30,2021-02-15,9.0,127.0,,,,,
arm,NCT03987919::arm::FG000,NCT03987919,5 mg Tirzepatide,,,,,,,,,,FG000,5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.,,,
arm,NCT03987919::arm::FG001,NCT03987919,10 mg Tirzepatide,,,,,,,,,,FG001,10 mg tirzepatide administered SC once a week.,,,
arm,NCT03987919::arm::FG002,NCT03987919,15 mg Tirzepatide,,,,,,,,,,FG002,15 mg tirzepatide administered SC once a week.,,,
arm,NCT03987919::arm::FG003,NCT03987919,1 mg Semaglutide,,,,,,,,,,FG003,1 mg semaglutide administered SC once a week.,,,
period,NCT03987919::period::1,NCT03987919,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03987919::outcome::primary::1,NCT03987919,Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg),,,,,,,,,,,,,PRIMARY,"Baseline, Week 40"
country,NCT03987919::country::United States,NCT03987919,United States,,,,,,,,,,,,,,
country,NCT03987919::country::United Kingdom,NCT03987919,United Kingdom,,,,,,,,,,,,,,
country,NCT03987919::country::Argentina,NCT03987919,Argentina,,,,,,,,,,,,,,
country,NCT03987919::country::Australia,NCT03987919,Australia,,,,,,,,,,,,,,
country,NCT03987919::country::Israel,NCT03987919,Israel,,,,,,,,,,,,,,
country,NCT03987919::country::Canada,NCT03987919,Canada,,,,,,,,,,,,,,
country,NCT03987919::country::Mexico,NCT03987919,Mexico,,,,,,,,,,,,,,
country,NCT03987919::country::Brazil,NCT03987919,Brazil,,,,,,,,,,,,,,
country,NCT03987919::country::Puerto Rico,NCT03987919,Puerto Rico,,,,,,,,,,,,,,
trial,NCT02505334,NCT02505334,A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,635.0,2015-07-21,2017-11-09,1.0,47.0,,,,,
arm,NCT02505334::arm::FG000,NCT02505334,Liraglutide 1.8 mg,,,,,,,,,,FG000,"Subjects received liraglutide once daily subcutaneous (s.c.; under the skin) injections for 52 weeks (26-week main + 26-week extension treatment period). After the 12-week run-in period, liraglutide d",,,
arm,NCT02505334::arm::FG001,NCT02505334,Liraglutide 0.9 mg,,,,,,,,,,FG001,"Subjects received liraglutide once daily s.c. injections for 26 weeks (main treatment period). After the 12-week run-in period, subjects continued their liraglutide treatment unchanged (i.e., 0.9 mg/d",,,
period,NCT02505334::period::1,NCT02505334,Main Treatment Period,,,,,,,,,,,,1.0,,
period,NCT02505334::period::2,NCT02505334,Extension Treatment Period,,,,,,,,,,,,2.0,,
outcome,NCT02505334::outcome::primary::1,NCT02505334,Change in Glycosylated Haemoglobin (HbA1c) (Week 26),,,,,,,,,,,,,PRIMARY,"Week 0, Week 26"
country,NCT02505334::country::Japan,NCT02505334,Japan,,,,,,,,,,,,,,
trial,NCT00484198,NCT00484198,Study of Rivoglitazone in Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,1912.0,2007-04-23,2009-02-12,18.0,183.0,,,,,
arm,NCT00484198::arm::FG000,NCT00484198,Placebo,,,,,,,,,,FG000,"Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.

Extension",,,
arm,NCT00484198::arm::FG001,NCT00484198,Rivoglitazone 1.0 mg,,,,,,,,,,FG001,"Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.

Extension Period:

Participants with type 2 diabetes mellitus who were administ",,,
arm,NCT00484198::arm::FG002,NCT00484198,Rivoglitazone 1.5 mg,,,,,,,,,,FG002,"Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.

Extension Period:

Participants with type 2 diabetes mellitus who were administ",,,
arm,NCT00484198::arm::FG003,NCT00484198,Pioglitazone 45 mg,,,,,,,,,,FG003,"Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.

Extension Period:

Participants with type 2 diabetes mellitus w",,,
period,NCT00484198::period::1,NCT00484198,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00484198::outcome::primary::1,NCT00484198,Hemoglobin A1c at Baseline and Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus,,,,,,,,,,,,,PRIMARY,Baseline up to week 26 post-dose
outcome,NCT00484198::outcome::primary::2,NCT00484198,Change in Hemoglobin A1c From Baseline Through Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus,,,,,,,,,,,,,PRIMARY,Baseline up to 26 weeks post-dose
country,NCT00484198::country::United States,NCT00484198,United States,,,,,,,,,,,,,,
country,NCT00484198::country::India,NCT00484198,India,,,,,,,,,,,,,,
country,NCT00484198::country::Germany,NCT00484198,Germany,,,,,,,,,,,,,,
country,NCT00484198::country::Hungary,NCT00484198,Hungary,,,,,,,,,,,,,,
country,NCT00484198::country::Czechia,NCT00484198,Czechia,,,,,,,,,,,,,,
country,NCT00484198::country::Mexico,NCT00484198,Mexico,,,,,,,,,,,,,,
country,NCT00484198::country::Peru,NCT00484198,Peru,,,,,,,,,,,,,,
country,NCT00484198::country::Slovakia,NCT00484198,Slovakia,,,,,,,,,,,,,,
country,NCT00484198::country::United Kingdom,NCT00484198,United Kingdom,,,,,,,,,,,,,,
country,NCT00484198::country::Romania,NCT00484198,Romania,,,,,,,,,,,,,,
country,NCT00484198::country::Serbia,NCT00484198,Serbia,,,,,,,,,,,,,,
country,NCT00484198::country::Ukraine,NCT00484198,Ukraine,,,,,,,,,,,,,,
country,NCT00484198::country::Latvia,NCT00484198,Latvia,,,,,,,,,,,,,,
country,NCT00484198::country::Argentina,NCT00484198,Argentina,,,,,,,,,,,,,,
country,NCT00484198::country::Austria,NCT00484198,Austria,,,,,,,,,,,,,,
country,NCT00484198::country::Chile,NCT00484198,Chile,,,,,,,,,,,,,,
country,NCT00484198::country::Puerto Rico,NCT00484198,Puerto Rico,,,,,,,,,,,,,,
country,NCT00484198::country::South Africa,NCT00484198,South Africa,,,,,,,,,,,,,,
trial,NCT01243424,NCT01243424,CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,6103.0,2010-11-11,2018-08-21,43.0,613.0,,,,,
arm,NCT01243424::arm::FG000,NCT01243424,Linagliptin,,,,,,,,,,FG000,"After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of 5 milligram (mg) linagliptin plus 1 over-encapsulated tablet of placebo matching glimepiride, which was uptitrated in 4",,,
arm,NCT01243424::arm::FG001,NCT01243424,Glimepiride,,,,,,,,,,FG001,"After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of placebo matching linagliptin plus 1 over-encapsulated tablet of 1 to 4 mg glimepiride, which was uptitrated in 4-week i",,,
period,NCT01243424::period::1,NCT01243424,Discontinuation From Study (Treated Set),,,,,,,,,,,,1.0,,
period,NCT01243424::period::2,NCT01243424,Discontinuation From Treatment,,,,,,,,,,,,2.0,,
outcome,NCT01243424::outcome::primary::1,NCT01243424,The First 3-point Major Adverse Cardiovascular Events (3P-MACE),,,,,,,,,,,,,PRIMARY,"From randomization until individual day of trial completion, up to 432 weeks"
country,NCT01243424::country::United States,NCT01243424,United States,,,,,,,,,,,,,,
country,NCT01243424::country::Germany,NCT01243424,Germany,,,,,,,,,,,,,,
country,NCT01243424::country::France,NCT01243424,France,,,,,,,,,,,,,,
country,NCT01243424::country::India,NCT01243424,India,,,,,,,,,,,,,,
country,NCT01243424::country::Spain,NCT01243424,Spain,,,,,,,,,,,,,,
country,NCT01243424::country::Argentina,NCT01243424,Argentina,,,,,,,,,,,,,,
country,NCT01243424::country::Netherlands,NCT01243424,Netherlands,,,,,,,,,,,,,,
country,NCT01243424::country::South Korea,NCT01243424,South Korea,,,,,,,,,,,,,,
country,NCT01243424::country::Taiwan,NCT01243424,Taiwan,,,,,,,,,,,,,,
country,NCT01243424::country::Belgium,NCT01243424,Belgium,,,,,,,,,,,,,,
country,NCT01243424::country::Japan,NCT01243424,Japan,,,,,,,,,,,,,,
country,NCT01243424::country::Brazil,NCT01243424,Brazil,,,,,,,,,,,,,,
country,NCT01243424::country::Canada,NCT01243424,Canada,,,,,,,,,,,,,,
country,NCT01243424::country::Colombia,NCT01243424,Colombia,,,,,,,,,,,,,,
country,NCT01243424::country::Norway,NCT01243424,Norway,,,,,,,,,,,,,,
country,NCT01243424::country::Georgia,NCT01243424,Georgia,,,,,,,,,,,,,,
country,NCT01243424::country::Philippines,NCT01243424,Philippines,,,,,,,,,,,,,,
country,NCT01243424::country::South Africa,NCT01243424,South Africa,,,,,,,,,,,,,,
country,NCT01243424::country::Ukraine,NCT01243424,Ukraine,,,,,,,,,,,,,,
country,NCT01243424::country::United Kingdom,NCT01243424,United Kingdom,,,,,,,,,,,,,,
country,NCT01243424::country::Hungary,NCT01243424,Hungary,,,,,,,,,,,,,,
country,NCT01243424::country::Italy,NCT01243424,Italy,,,,,,,,,,,,,,
country,NCT01243424::country::Russia,NCT01243424,Russia,,,,,,,,,,,,,,
country,NCT01243424::country::Sweden,NCT01243424,Sweden,,,,,,,,,,,,,,
country,NCT01243424::country::Czechia,NCT01243424,Czechia,,,,,,,,,,,,,,
country,NCT01243424::country::Greece,NCT01243424,Greece,,,,,,,,,,,,,,
country,NCT01243424::country::Malaysia,NCT01243424,Malaysia,,,,,,,,,,,,,,
country,NCT01243424::country::Peru,NCT01243424,Peru,,,,,,,,,,,,,,
country,NCT01243424::country::Portugal,NCT01243424,Portugal,,,,,,,,,,,,,,
country,NCT01243424::country::Finland,NCT01243424,Finland,,,,,,,,,,,,,,
country,NCT01243424::country::Israel,NCT01243424,Israel,,,,,,,,,,,,,,
country,NCT01243424::country::Slovakia,NCT01243424,Slovakia,,,,,,,,,,,,,,
country,NCT01243424::country::Romania,NCT01243424,Romania,,,,,,,,,,,,,,
country,NCT01243424::country::Australia,NCT01243424,Australia,,,,,,,,,,,,,,
country,NCT01243424::country::Bulgaria,NCT01243424,Bulgaria,,,,,,,,,,,,,,
country,NCT01243424::country::Mexico,NCT01243424,Mexico,,,,,,,,,,,,,,
country,NCT01243424::country::Serbia,NCT01243424,Serbia,,,,,,,,,,,,,,
country,NCT01243424::country::Chile,NCT01243424,Chile,,,,,,,,,,,,,,
country,NCT01243424::country::Ireland,NCT01243424,Ireland,,,,,,,,,,,,,,
country,NCT01243424::country::New Zealand,NCT01243424,New Zealand,,,,,,,,,,,,,,
country,NCT01243424::country::Switzerland,NCT01243424,Switzerland,,,,,,,,,,,,,,
country,NCT01243424::country::Tunisia,NCT01243424,Tunisia,,,,,,,,,,,,,,
country,NCT01243424::country::Hong Kong,NCT01243424,Hong Kong,,,,,,,,,,,,,,
trial,NCT02738879,NCT02738879,Randomized Sitagliptin Withdrawal Study (MK-0431-845),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,746.0,2016-05-09,2018-01-30,0.0,0.0,,,,,
arm,NCT02738879::arm::FG000,NCT02738879,Sitagliptin,,,,,,,,,,FG000,"Sitagliptin 100 mg, oral, once daily for 30 weeks",,,
arm,NCT02738879::arm::FG001,NCT02738879,Placebo,,,,,,,,,,FG001,"Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks",,,
period,NCT02738879::period::1,NCT02738879,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02738879::outcome::primary::1,NCT02738879,Change From Baseline in A1C at Week 30,,,,,,,,,,,,,PRIMARY,Baseline and Week 30
outcome,NCT02738879::outcome::primary::2,NCT02738879,Event Rate of Documented Symptomatic Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L),,,,,,,,,,,,,PRIMARY,Up to 30 weeks
outcome,NCT02738879::outcome::primary::3,NCT02738879,Percentage of Participants Who Discontinued Study Drug Due to an AE,,,,,,,,,,,,,PRIMARY,Up to 30 weeks
outcome,NCT02738879::outcome::primary::4,NCT02738879,Percentage of Participants Who Experienced One or More Adverse Events (AEs),,,,,,,,,,,,,PRIMARY,Up to 32 weeks
trial,NCT01421459,NCT01421459,A Study in Adults With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,759.0,2011-09,2012-09,12.0,62.0,,,,,
arm,NCT01421459::arm::FG000,NCT01421459,LY2963016 + OAMs,,,,,,,,,,FG000,"LY2963016 titrated based on blood glucose (BG) readings, administered subcutaneously, once daily in combination with at least 2 oral antihyperglycemic medications (OAMs) administered per standard of c",,,
arm,NCT01421459::arm::FG001,NCT01421459,Lantus + OAMs,,,,,,,,,,FG001,"Lantus titrated based on BG readings, administered subcutaneously, once daily in combination with at least 2 OAMs administered per standard of care for 24 weeks",,,
period,NCT01421459::period::1,NCT01421459,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01421459::outcome::primary::1,NCT01421459,Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline, Endpoint (up to 24 weeks)"
country,NCT01421459::country::United States,NCT01421459,United States,,,,,,,,,,,,,,
country,NCT01421459::country::Germany,NCT01421459,Germany,,,,,,,,,,,,,,
country,NCT01421459::country::Mexico,NCT01421459,Mexico,,,,,,,,,,,,,,
country,NCT01421459::country::Poland,NCT01421459,Poland,,,,,,,,,,,,,,
country,NCT01421459::country::Puerto Rico,NCT01421459,Puerto Rico,,,,,,,,,,,,,,
country,NCT01421459::country::Spain,NCT01421459,Spain,,,,,,,,,,,,,,
country,NCT01421459::country::Taiwan,NCT01421459,Taiwan,,,,,,,,,,,,,,
country,NCT01421459::country::Czechia,NCT01421459,Czechia,,,,,,,,,,,,,,
country,NCT01421459::country::France,NCT01421459,France,,,,,,,,,,,,,,
country,NCT01421459::country::Hungary,NCT01421459,Hungary,,,,,,,,,,,,,,
country,NCT01421459::country::South Korea,NCT01421459,South Korea,,,,,,,,,,,,,,
country,NCT01421459::country::Greece,NCT01421459,Greece,,,,,,,,,,,,,,
trial,NCT00614120,NCT00614120,Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,929.0,2008-01,2009-02,3.0,50.0,,,,,
arm,NCT00614120::arm::FG000,NCT00614120,Lira 0.6 + Met,,,,,,,,,,FG000,Liraglutide 0.6 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo,,,
arm,NCT00614120::arm::FG001,NCT00614120,Lira 1.2 + Met,,,,,,,,,,FG001,Liraglutide 1.2 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo,,,
arm,NCT00614120::arm::FG002,NCT00614120,Lira 1.8 + Met,,,,,,,,,,FG002,Liraglutide 1.8 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo,,,
arm,NCT00614120::arm::FG003,NCT00614120,Glim + Met,,,,,,,,,,FG003,Glimepiride 4.0 mg + metformin 1.5-2.0 g daily + liraglutide placebo,,,
period,NCT00614120::period::1,NCT00614120,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00614120::outcome::primary::1,NCT00614120,Change in Glycosylated Haemoglobin A1c (HbA1c),,,,,,,,,,,,,PRIMARY,"week 0, week 16"
country,NCT00614120::country::India,NCT00614120,India,,,,,,,,,,,,,,
country,NCT00614120::country::China,NCT00614120,China,,,,,,,,,,,,,,
country,NCT00614120::country::South Korea,NCT00614120,South Korea,,,,,,,,,,,,,,
trial,NCT01318083,NCT01318083,Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,312.0,2008-08,2009-04,0.0,0.0,,,,,
arm,NCT01318083::arm::FG000,NCT01318083,Alogliptin 12.5 mg QD and Glimepiride QD or BID,,,,,,,,,,FG000,"Alogliptin 12.5 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.",,,
arm,NCT01318083::arm::FG001,NCT01318083,Alogliptin 25 mg QD and Glimepiride QD or BID,,,,,,,,,,FG001,"Alogliptin 25 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.",,,
arm,NCT01318083::arm::FG002,NCT01318083,"Glimepiride 1, 2, 3 or 4 mg QD or BID",,,,,,,,,,FG002,"Glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.",,,
period,NCT01318083::period::1,NCT01318083,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01318083::outcome::primary::1,NCT01318083,Change From Baseline in Glycosylated Hemoglobin (Week 12).,,,,,,,,,,,,,PRIMARY,Baseline and Week 12.
trial,NCT01191268,NCT01191268,A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4),PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,884.0,2010-11,2012-09,16.0,101.0,,,,,
arm,NCT01191268::arm::FG000,NCT01191268,1.5 mg LY2189265,,,,,,,,,,FG000,"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks

Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each m",,,
arm,NCT01191268::arm::FG001,NCT01191268,0.75 mg LY2189265,,,,,,,,,,FG001,"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks

Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each ",,,
arm,NCT01191268::arm::FG002,NCT01191268,Insulin Glargine,,,,,,,,,,FG002,"Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks

Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice ",,,
period,NCT01191268::period::1,NCT01191268,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01191268::outcome::primary::1,NCT01191268,Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline, 26 weeks"
country,NCT01191268::country::United States,NCT01191268,United States,,,,,,,,,,,,,,
country,NCT01191268::country::Hungary,NCT01191268,Hungary,,,,,,,,,,,,,,
country,NCT01191268::country::Spain,NCT01191268,Spain,,,,,,,,,,,,,,
country,NCT01191268::country::Canada,NCT01191268,Canada,,,,,,,,,,,,,,
country,NCT01191268::country::Denmark,NCT01191268,Denmark,,,,,,,,,,,,,,
country,NCT01191268::country::Taiwan,NCT01191268,Taiwan,,,,,,,,,,,,,,
country,NCT01191268::country::Argentina,NCT01191268,Argentina,,,,,,,,,,,,,,
country,NCT01191268::country::Belgium,NCT01191268,Belgium,,,,,,,,,,,,,,
country,NCT01191268::country::Brazil,NCT01191268,Brazil,,,,,,,,,,,,,,
country,NCT01191268::country::Greece,NCT01191268,Greece,,,,,,,,,,,,,,
country,NCT01191268::country::Mexico,NCT01191268,Mexico,,,,,,,,,,,,,,
country,NCT01191268::country::Poland,NCT01191268,Poland,,,,,,,,,,,,,,
country,NCT01191268::country::Puerto Rico,NCT01191268,Puerto Rico,,,,,,,,,,,,,,
country,NCT01191268::country::Australia,NCT01191268,Australia,,,,,,,,,,,,,,
country,NCT01191268::country::Russia,NCT01191268,Russia,,,,,,,,,,,,,,
country,NCT01191268::country::Sweden,NCT01191268,Sweden,,,,,,,,,,,,,,
trial,NCT01986855,NCT01986855,A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,468.0,2013-12-02,2016-09-28,0.0,0.0,,,,,
arm,NCT01986855::arm::FG000,NCT01986855,Ertugliflozin 5 mg,,,,,,,,,,FG000,"Ertugliflozin, oral, 5-mg tablet once daily for 52 weeks. Participants also received a 10-mg matching placebo tablet once daily for 52 weeks.",,,
arm,NCT01986855::arm::FG001,NCT01986855,Ertugliflozin 15 mg,,,,,,,,,,FG001,"Ertugliflozin, oral, 5-mg and 10-mg tablet once daily for 52 weeks",,,
arm,NCT01986855::arm::FG002,NCT01986855,Placebo,,,,,,,,,,FG002,"Placebo, oral, tablet, 5-mg or 5-mg and 10-mg tablet once daily for 52 weeks",,,
period,NCT01986855::period::1,NCT01986855,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01986855::outcome::primary::1,NCT01986855,Change From Baseline in A1C at Week 26 - Excluding Rescue Approach,,,,,,,,,,,,,PRIMARY,Baseline and Week 26
outcome,NCT01986855::outcome::primary::2,NCT01986855,Percentage of Participants Who Experienced an Adverse Event (AE),,,,,,,,,,,,,PRIMARY,Up to 54 weeks
outcome,NCT01986855::outcome::primary::3,NCT01986855,Percentage of Participants Who Discontinued Study Treatment Due to an AE,,,,,,,,,,,,,PRIMARY,Up to 52 weeks
trial,NCT00385697,NCT00385697,The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus,PHASE3,diabetes type 2,Type 1 Diabetes Mellitus,INDUSTRY,554.0,2006-10,2011-08,16.0,115.0,,,,,
arm,NCT00385697::arm::FG000,NCT00385697,Open-label Herold Regimen,,,,,,,,,,FG000,"Full dose of teplizumab IV for 14 days, repeated at Week 26 Teplizumab: Daily IV dosing for 14 days, repeated at Week 26",,,
arm,NCT00385697::arm::FG001,NCT00385697,Double-blind Herold Regimen,,,,,,,,,,FG001,"Full dose of teplizumab IV for 14 days, repeated at Week 26

Teplizumab: Daily IV dosing for 14 days, repeated at Week 26",,,
arm,NCT00385697::arm::FG002,NCT00385697,Double-blind 33.3% Herold Regimen,,,,,,,,,,FG002,"One third full dose of teplizumab IV for 14 days, repeated at Week 26

Teplizumab: Daily IV dosing for 14 days, repeated at Week 26",,,
arm,NCT00385697::arm::FG003,NCT00385697,Double-blind Curtailed Herold Regimen,,,,,,,,,,FG003,"Full dose of teplizumab IV for 6 days followed by placebo for 8 days, repeated at Week 26

Teplizumab: Daily IV dosing for 14 days, repeated at Week 26",,,
arm,NCT00385697::arm::FG004,NCT00385697,Double-blind Placebo,,,,,,,,,,FG004,"Placebo IV dosing daily for 14 days repeated at Week

Placebo: Daily IV dosing for 14 days, repeated at Week 26",,,
period,NCT00385697::period::1,NCT00385697,Open-label Segment 1,,,,,,,,,,,,1.0,,
period,NCT00385697::period::2,NCT00385697,Double-blind Segment 2,,,,,,,,,,,,2.0,,
period,NCT00385697::period::3,NCT00385697,Long-term Follow up Segment 3,,,,,,,,,,,,3.0,,
outcome,NCT00385697::outcome::primary::1,NCT00385697,Number of Subjects in Segment 2 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.,,,,,,,,,,,,,PRIMARY,52 weeks after randomization
outcome,NCT00385697::outcome::primary::2,NCT00385697,Number of Subjects in Segment 1 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.,,,,,,,,,,,,,PRIMARY,52 weeks after first dose
outcome,NCT00385697::outcome::primary::3,NCT00385697,Mean HbA1c Change From Baseline in Segment 2,,,,,,,,,,,,,PRIMARY,52 weeks after randomization
outcome,NCT00385697::outcome::primary::4,NCT00385697,Mean HbA1c Change From Baseline in Segment 1,,,,,,,,,,,,,PRIMARY,52 weeks after first dose
country,NCT00385697::country::United States,NCT00385697,United States,,,,,,,,,,,,,,
country,NCT00385697::country::India,NCT00385697,India,,,,,,,,,,,,,,
country,NCT00385697::country::Poland,NCT00385697,Poland,,,,,,,,,,,,,,
country,NCT00385697::country::Ukraine,NCT00385697,Ukraine,,,,,,,,,,,,,,
country,NCT00385697::country::Canada,NCT00385697,Canada,,,,,,,,,,,,,,
country,NCT00385697::country::Czechia,NCT00385697,Czechia,,,,,,,,,,,,,,
country,NCT00385697::country::Israel,NCT00385697,Israel,,,,,,,,,,,,,,
country,NCT00385697::country::Romania,NCT00385697,Romania,,,,,,,,,,,,,,
country,NCT00385697::country::Germany,NCT00385697,Germany,,,,,,,,,,,,,,
country,NCT00385697::country::Spain,NCT00385697,Spain,,,,,,,,,,,,,,
country,NCT00385697::country::Mexico,NCT00385697,Mexico,,,,,,,,,,,,,,
country,NCT00385697::country::Sweden,NCT00385697,Sweden,,,,,,,,,,,,,,
country,NCT00385697::country::Estonia,NCT00385697,Estonia,,,,,,,,,,,,,,
country,NCT00385697::country::United Kingdom,NCT00385697,United Kingdom,,,,,,,,,,,,,,
country,NCT00385697::country::Latvia,NCT00385697,Latvia,,,,,,,,,,,,,,
country,NCT00385697::country::Netherlands,NCT00385697,Netherlands,,,,,,,,,,,,,,
trial,NCT03353350,NCT03353350,Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,406.0,2017-12-05,2020-09-07,5.0,54.0,,,,,
arm,NCT03353350::arm::FG000,NCT03353350,Placebo,,,,,,,,,,FG000,"Matching placebo (Prefilled syringe) administered once weekly for 56 weeks

placebo: Pharmaceutical form: solution for injection

Route of administration: subcutaneous",,,
arm,NCT03353350::arm::FG001,NCT03353350,Efpeglenatide 2 mg,,,,,,,,,,FG001,"Efpeglenatide low dose (Prefilled syringe) administered once weekly for 56 weeks

efpeglenatide (SAR439977): Pharmaceutical form: solution for injection

Route of administration: subcutaneous",,,
arm,NCT03353350::arm::FG002,NCT03353350,Efpeglenatide 4 mg,,,,,,,,,,FG002,"Efpeglenatide middle dose (Prefilled syringe) administered once weekly for 56 weeks (including titration period)

efpeglenatide (SAR439977): Pharmaceutical form: solution for injection

Route of admin",,,
arm,NCT03353350::arm::FG003,NCT03353350,Efpeglenatide 6 mg,,,,,,,,,,FG003,"Efpeglenatide high dose (Prefilled syringe) administered once weekly for 56 weeks (including titration period)

efpeglenatide (SAR439977): Pharmaceutical form: solution for injection

Route of adminis",,,
period,NCT03353350::period::1,NCT03353350,30-week Core Treatment Period,,,,,,,,,,,,1.0,,
period,NCT03353350::period::2,NCT03353350,26-week Treatment Extension Period,,,,,,,,,,,,2.0,,
outcome,NCT03353350::outcome::primary::1,NCT03353350,Change in Glycated Hemoglobin (HbA1c) (%),,,,,,,,,,,,,PRIMARY,Baseline to Week 30
country,NCT03353350::country::United States,NCT03353350,United States,,,,,,,,,,,,,,
country,NCT03353350::country::United Kingdom,NCT03353350,United Kingdom,,,,,,,,,,,,,,
country,NCT03353350::country::Poland,NCT03353350,Poland,,,,,,,,,,,,,,
country,NCT03353350::country::Ukraine,NCT03353350,Ukraine,,,,,,,,,,,,,,
country,NCT03353350::country::Germany,NCT03353350,Germany,,,,,,,,,,,,,,
trial,NCT01126580,NCT01126580,A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3),PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,807.0,2010-05,2012-06,19.0,91.0,,,,,
arm,NCT01126580::arm::FG000,NCT01126580,1.5 mg LY2189265,,,,,,,,,,FG000,"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks

Placebo: orally, twice daily for 52 weeks",,,
arm,NCT01126580::arm::FG001,NCT01126580,0.75 mg LY2189265,,,,,,,,,,FG001,"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks

Placebo: orally, twice daily for 52 weeks",,,
arm,NCT01126580::arm::FG002,NCT01126580,Metformin,,,,,,,,,,FG002,"Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks

Placebo: subcutaneously (SC), once weekly for 52 weeks",,,
period,NCT01126580::period::1,NCT01126580,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01126580::outcome::primary::1,NCT01126580,Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline, 26 weeks"
country,NCT01126580::country::United States,NCT01126580,United States,,,,,,,,,,,,,,
country,NCT01126580::country::Canada,NCT01126580,Canada,,,,,,,,,,,,,,
country,NCT01126580::country::United Kingdom,NCT01126580,United Kingdom,,,,,,,,,,,,,,
country,NCT01126580::country::Germany,NCT01126580,Germany,,,,,,,,,,,,,,
country,NCT01126580::country::Croatia,NCT01126580,Croatia,,,,,,,,,,,,,,
country,NCT01126580::country::France,NCT01126580,France,,,,,,,,,,,,,,
country,NCT01126580::country::India,NCT01126580,India,,,,,,,,,,,,,,
country,NCT01126580::country::Romania,NCT01126580,Romania,,,,,,,,,,,,,,
country,NCT01126580::country::Czechia,NCT01126580,Czechia,,,,,,,,,,,,,,
country,NCT01126580::country::Mexico,NCT01126580,Mexico,,,,,,,,,,,,,,
country,NCT01126580::country::Poland,NCT01126580,Poland,,,,,,,,,,,,,,
country,NCT01126580::country::Puerto Rico,NCT01126580,Puerto Rico,,,,,,,,,,,,,,
country,NCT01126580::country::Slovakia,NCT01126580,Slovakia,,,,,,,,,,,,,,
country,NCT01126580::country::South Africa,NCT01126580,South Africa,,,,,,,,,,,,,,
country,NCT01126580::country::South Korea,NCT01126580,South Korea,,,,,,,,,,,,,,
country,NCT01126580::country::Spain,NCT01126580,Spain,,,,,,,,,,,,,,
country,NCT01126580::country::Argentina,NCT01126580,Argentina,,,,,,,,,,,,,,
country,NCT01126580::country::Brazil,NCT01126580,Brazil,,,,,,,,,,,,,,
country,NCT01126580::country::Finland,NCT01126580,Finland,,,,,,,,,,,,,,
trial,NCT02420262,NCT02420262,A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,506.0,2015-07-26,2016-10-05,12.0,117.0,,,,,
arm,NCT02420262::arm::FG000,NCT02420262,IDegLira,,,,,,,,,,FG000,Insulin Degludec/Liraglutide (IDegLira: 100 U/3.6 mg per mL) was injected subcutaneously once daily (OD) for a duration of 26 weeks. IDegLira was supplied in a 3 mL pre-filled PDS290 pen-injector with,,,
arm,NCT02420262::arm::FG001,NCT02420262,IGlar + IAsp,,,,,,,,,,FG001,"Subjects received insulin glargine plus prandial insulin aspart subcutaneously for duration of 26 weeks. A stable pre- trial OD dose of IGlar (20-50 units, in a 3 mL pre-filled Solostar®) was continue",,,
period,NCT02420262::period::1,NCT02420262,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02420262::outcome::primary::1,NCT02420262,Change in HbA1c (Glycosylated Haemoglobin),,,,,,,,,,,,,PRIMARY,"Week 0, Week 26"
country,NCT02420262::country::United States,NCT02420262,United States,,,,,,,,,,,,,,
country,NCT02420262::country::France,NCT02420262,France,,,,,,,,,,,,,,
country,NCT02420262::country::Russia,NCT02420262,Russia,,,,,,,,,,,,,,
country,NCT02420262::country::Czechia,NCT02420262,Czechia,,,,,,,,,,,,,,
country,NCT02420262::country::Greece,NCT02420262,Greece,,,,,,,,,,,,,,
country,NCT02420262::country::Israel,NCT02420262,Israel,,,,,,,,,,,,,,
country,NCT02420262::country::Spain,NCT02420262,Spain,,,,,,,,,,,,,,
country,NCT02420262::country::Turkey (Türkiye),NCT02420262,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02420262::country::Hungary,NCT02420262,Hungary,,,,,,,,,,,,,,
country,NCT02420262::country::Slovakia,NCT02420262,Slovakia,,,,,,,,,,,,,,
country,NCT02420262::country::Argentina,NCT02420262,Argentina,,,,,,,,,,,,,,
country,NCT02420262::country::Mexico,NCT02420262,Mexico,,,,,,,,,,,,,,
trial,NCT03338010,NCT03338010,A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,536.0,2018-03-22,2020-03-18,1.0,32.0,,,,,
arm,NCT03338010::arm::FG000,NCT03338010,LY2963016,,,,,,,,,,FG000,Insulin naive participants started on 10 units (U) LY2963016 given subcutaneously (SC) once a day (QD) for 24 weeks. Participants-driven titration was supervised by investigators through the course of,,,
arm,NCT03338010::arm::FG001,NCT03338010,Lantus®,,,,,,,,,,FG001,Insulin naive participants started on 10 U Lantus® given SC QD for 24 weeks. Participants-driven titration was supervised by investigators through the course of the study to maintain the FBG ≤100 mg/d,,,
period,NCT03338010::period::1,NCT03338010,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03338010::outcome::primary::1,NCT03338010,Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®),,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
country,NCT03338010::country::China,NCT03338010,China,,,,,,,,,,,,,,
trial,NCT02254291,NCT02254291,A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,308.0,2014-10-02,2015-11-11,1.0,25.0,,,,,
arm,NCT02254291::arm::FG000,NCT02254291,Semaglutide 0.5 mg,,,,,,,,,,FG000,"Subjects were randomized to receive semaglutide 0.5 mg once weekly subcutaneously (s.c.; under the skin) in the thigh, abdomen, or upper arm for a duration of 30 weeks. Subjects followed a fixed dose ",,,
arm,NCT02254291::arm::FG001,NCT02254291,Semaglutide 1.0 mg,,,,,,,,,,FG001,"Subjects were randomized to receive semaglutide 1.0 mg once weekly subcutaneously (s.c.; under the skin) in the thigh, abdomen, or upper arm for a duration of 30 weeks. Subjects followed a fixed dose ",,,
arm,NCT02254291::arm::FG002,NCT02254291,Sitagliptin,,,,,,,,,,FG002,"The subjects in this arm received oral fixed dose of sitagliptin 100 mg tablet once daily for a duration of 30 weeks. For subjects previously treated with OAD monotherapy, their pre-trial OAD was wash",,,
period,NCT02254291::period::1,NCT02254291,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02254291::outcome::primary::1,NCT02254291,Number of Treatment Emergent Adverse Events (TEAEs),,,,,,,,,,,,,PRIMARY,Weeks 0-30
country,NCT02254291::country::Japan,NCT02254291,Japan,,,,,,,,,,,,,,
trial,NCT05478252,NCT05478252,A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,388.0,2022-08-03,2023-09-18,5.0,104.0,,,,,
arm,NCT05478252::arm::FG000,NCT05478252,Semaglutide J,,,,,,,,,,FG000,Participants initially received 0.25 mg subcutaneous injections of semaglutide J once weekly and the dose was then escalated (0.25 mg in week 0 to week 4 and 0.5 mg in week 4 to week 8) once in 4 week,,,
arm,NCT05478252::arm::FG001,NCT05478252,Semaglutide B,,,,,,,,,,FG001,Participants initially received 0.25 mg subcutaneous injections of semaglutide B once weekly and the dose was then escalated (0.25 mg in week 0 to week 4 and 0.5 mg in week 4 to week 8) once in 4 week,,,
period,NCT05478252::period::1,NCT05478252,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT05478252::outcome::primary::1,NCT05478252,Change in Glycosylated Haemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,From baseline (week 0) to end of treatment (week 28)
country,NCT05478252::country::United States,NCT05478252,United States,,,,,,,,,,,,,,
country,NCT05478252::country::Canada,NCT05478252,Canada,,,,,,,,,,,,,,
country,NCT05478252::country::Poland,NCT05478252,Poland,,,,,,,,,,,,,,
country,NCT05478252::country::South Africa,NCT05478252,South Africa,,,,,,,,,,,,,,
country,NCT05478252::country::Slovakia,NCT05478252,Slovakia,,,,,,,,,,,,,,
trial,NCT03015220,NCT03015220,Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,458.0,2017-01-10,2018-07-12,1.0,34.0,,,,,
arm,NCT03015220::arm::FG000,NCT03015220,Oral Semaglutide 3 mg,,,,,,,,,,FG000,"Participants were to take oral semaglutide 3 mg tablets once-daily from week 0 to week 52. In addition, participants were to continue their pre-trial oral anti-diabetic drug (OAD) (either of sulphonyl",,,
arm,NCT03015220::arm::FG001,NCT03015220,Oral Semaglutide 7 mg,,,,,,,,,,FG001,"Participants were to take oral semaglutide tablets once-daily in a dose escalation manner from week 0 to week 52: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 52. In addition, participants ",,,
arm,NCT03015220::arm::FG002,NCT03015220,Oral Semaglutide 14 mg,,,,,,,,,,FG002,"Participants were to take oral semaglutide tablets once-daily in a dose escalation manner from week 0 to week 52: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 5",,,
arm,NCT03015220::arm::FG003,NCT03015220,Dulaglutide 0.75 mg,,,,,,,,,,FG003,"Participants were to take dulaglutide 0.75 mg subcutaneous (under the skin) injections once-weekly from week 0 to week 52. In addition, participants were to continue their pre-trial OAD (either of sul",,,
period,NCT03015220::period::1,NCT03015220,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03015220::outcome::primary::1,NCT03015220,Number of Treatment-emergent Adverse Events (TEAEs),,,,,,,,,,,,,PRIMARY,Weeks 0-57
country,NCT03015220::country::Japan,NCT03015220,Japan,,,,,,,,,,,,,,
trial,NCT04809220,NCT04809220,A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose Metabolism Disorders; Metabolic Disease; Endocrine System Diseases; Hypoglycemic Agents; Type 2 Diabetes Mellitus (T2DM)",INDUSTRY,591.0,2021-04-13,2023-04-26,1.0,44.0,,,,,
arm,NCT04809220::arm::FG000,NCT04809220,Dulaglutide 1.5 Milligram (mg),,,,,,,,,,FG000,Participants received 1.5 mg of dulaglutide given weekly SC during the 52-week treatment period. Dulaglutide will be given alone or in combination with 1 OAM. Participants on DPP-4i discontinued DPP-4,,,
arm,NCT04809220::arm::FG001,NCT04809220,Dulaglutide 0.75 mg,,,,,,,,,,FG001,Participants received 0.75 mg of dulaglutide given weekly SC during the 52-week treatment period. Dulaglutide will be given alone or in combination with 1 OAM. Participants on DPP-4i discontinued DPP-,,,
period,NCT04809220::period::1,NCT04809220,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04809220::outcome::primary::1,NCT04809220,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26,,,,,,,,,,,,,PRIMARY,"Baseline, Week 26"
country,NCT04809220::country::Japan,NCT04809220,Japan,,,,,,,,,,,,,,
trial,NCT03172494,NCT03172494,"A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)",PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,720.0,2017-05-26,2019-07-13,1.0,36.0,,,,,
arm,NCT03172494::arm::FG000,NCT03172494,Insulin Degludec/Liraglutide,,,,,,,,,,FG000,Participants were to receive Insulin degludec/liraglutide subcutaneous injection once daily in combination with metformin for 26 weeks. Participants received 10 dose steps (10 units insulin degludec a,,,
arm,NCT03172494::arm::FG001,NCT03172494,Insulin Degludec,,,,,,,,,,FG001,Participants were to receive Insulin degludec subcutaneous injection once daily in combination with metformin for 26 weeks. Participants received 10 units insulin degludec initially. The dose was then,,,
arm,NCT03172494::arm::FG002,NCT03172494,Liraglutide,,,,,,,,,,FG002,Participants were to receive liraglutide subcutaneous injection once daily in combination with metformin for 26 weeks. Participants received 0.6 mg initially. The dose was then escalated in weekly inc,,,
period,NCT03172494::period::1,NCT03172494,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03172494::outcome::primary::1,NCT03172494,Change in HbA1c,,,,,,,,,,,,,PRIMARY,"Week 0, week 26"
country,NCT03172494::country::China,NCT03172494,China,,,,,,,,,,,,,,
trial,NCT01272193,NCT01272193,Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,296.0,2011-01,2011-09,1.0,50.0,,,,,
arm,NCT01272193::arm::FG000,NCT01272193,IDegAsp OD,,,,,,,,,,FG000,Insulin degludec/insulin aspart (IDegAsp) was given subcutaneously once daily (OD) either as monotherapy or in combination with no more than 2 oral antidiabetic drugs (excluding sulphonylureas/DPP-4 i,,,
arm,NCT01272193::arm::FG001,NCT01272193,IGlar OD,,,,,,,,,,FG001,Insulin glargine (IGlar) was given once daily (OD) according to approved labelling either as monotherapy or in combination with no more than 2 oral antidiabetic drugs (excluding sulphonylureas/DPP-4 i,,,
period,NCT01272193::period::1,NCT01272193,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01272193::outcome::primary::1,NCT01272193,Change in Glycosylated Haemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Week 0, Week 26"
country,NCT01272193::country::Japan,NCT01272193,Japan,,,,,,,,,,,,,,
trial,NCT01098539,NCT01098539,A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,507.0,2010-05,2012-11,15.0,218.0,,,,,
arm,NCT01098539::arm::FG000,NCT01098539,Albiglutide 30 mg,,,,,,,,,,FG000,"Participants received albiglutide 30 milligrams (mg) once weekly subcutaneously from Baseline until Week 52, with optional up-titration to 50 mg if additional glycemic control was required. Albiglutid",,,
arm,NCT01098539::arm::FG001,NCT01098539,Sitagliptin 100 mg,,,,,,,,,,FG001,Participants with normal renal function (estimated glomerular filtration rate \[eGFR\] \>89 milliliters per minute \[mL/min\]) received a sitagliptin 100 mg overcoated tablet once daily orally from Ba,,,
period,NCT01098539::period::1,NCT01098539,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01098539::outcome::primary::1,NCT01098539,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26,,,,,,,,,,,,,PRIMARY,Baseline
country,NCT01098539::country::United States,NCT01098539,United States,,,,,,,,,,,,,,
country,NCT01098539::country::India,NCT01098539,India,,,,,,,,,,,,,,
country,NCT01098539::country::Australia,NCT01098539,Australia,,,,,,,,,,,,,,
country,NCT01098539::country::South Africa,NCT01098539,South Africa,,,,,,,,,,,,,,
country,NCT01098539::country::United Kingdom,NCT01098539,United Kingdom,,,,,,,,,,,,,,
country,NCT01098539::country::Peru,NCT01098539,Peru,,,,,,,,,,,,,,
country,NCT01098539::country::Israel,NCT01098539,Israel,,,,,,,,,,,,,,
country,NCT01098539::country::Spain,NCT01098539,Spain,,,,,,,,,,,,,,
country,NCT01098539::country::South Korea,NCT01098539,South Korea,,,,,,,,,,,,,,
country,NCT01098539::country::Germany,NCT01098539,Germany,,,,,,,,,,,,,,
country,NCT01098539::country::Philippines,NCT01098539,Philippines,,,,,,,,,,,,,,
country,NCT01098539::country::Brazil,NCT01098539,Brazil,,,,,,,,,,,,,,
country,NCT01098539::country::Russia,NCT01098539,Russia,,,,,,,,,,,,,,
country,NCT01098539::country::Colombia,NCT01098539,Colombia,,,,,,,,,,,,,,
country,NCT01098539::country::Taiwan,NCT01098539,Taiwan,,,,,,,,,,,,,,
trial,NCT01381900,NCT01381900,"A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea",PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,678.0,2011-08,2012-11,3.0,25.0,,,,,
arm,NCT01381900::arm::FG000,NCT01381900,Placebo,,,,,,,,,,FG000,Each participant received matching placebo once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.,,,
arm,NCT01381900::arm::FG001,NCT01381900,Canagliflozin 100 mg,,,,,,,,,,FG001,Each participant received 100 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.,,,
arm,NCT01381900::arm::FG002,NCT01381900,Canagliflozin 300 mg,,,,,,,,,,FG002,Each participant received 300 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.,,,
period,NCT01381900::period::1,NCT01381900,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01381900::outcome::primary::1,NCT01381900,Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 18,,,,,,,,,,,,,PRIMARY,Day 1 (Baseline) and Week 18
country,NCT01381900::country::China,NCT01381900,China,,,,,,,,,,,,,,
country,NCT01381900::country::Malaysia,NCT01381900,Malaysia,,,,,,,,,,,,,,
country,NCT01381900::country::Vietnam,NCT01381900,Vietnam,,,,,,,,,,,,,,
trial,NCT00434954,NCT00434954,Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,494.0,2007-02,2009-06,1.0,39.0,,,,,
arm,NCT00434954::arm::FG000,NCT00434954,Exenatide Twice Daily,,,,,,,,,,FG000,"Exenatide 5 mcg twice daily for 4 weeks, followed by 10 mcg twice daily for 26 weeks",,,
arm,NCT00434954::arm::FG001,NCT00434954,Premixed Insulin Aspart Twice Daily,,,,,,,,,,FG001,"Premixed insulin aspart (70% protamin crystallized, 30% soluble) twice daily, individually titrated to reach target blood glucose levels for 26 weeks",,,
period,NCT00434954::period::1,NCT00434954,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00434954::outcome::primary::1,NCT00434954,Change in Glycosylated Hemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,Baseline and 26 weeks
outcome,NCT00434954::outcome::primary::2,NCT00434954,Incidence of Hypoglycemia (Percentage of Participants With at Least One Hypoglycemic Episode),,,,,,,,,,,,,PRIMARY,26 weeks
country,NCT00434954::country::Germany,NCT00434954,Germany,,,,,,,,,,,,,,
trial,NCT04184622,NCT04184622,A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight,PHASE3,diabetes type 2,Overweight; Obesity,INDUSTRY,2539.0,2019-12-04,2024-07-06,10.0,118.0,,,,,
arm,NCT04184622::arm::FG000,NCT04184622,Placebo,,,,,,,,,,FG000,"* Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received once weekly (QW) subcutaneous (SC) doses of a matching placebo, admini",,,
arm,NCT04184622::arm::FG001,NCT04184622,5 mg Tirzepatide,,,,,,,,,,FG001,"* Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received QW SC doses of tirzepatide, starting at 2.5 milligrams (mg) and increa",,,
arm,NCT04184622::arm::FG002,NCT04184622,10 mg Tirzepatide,,,,,,,,,,FG002,"* Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received QW SC doses of tirzepatide, starting at 2.5 mg and increasing by 2.5 m",,,
arm,NCT04184622::arm::FG003,NCT04184622,15 mg Tirzepatide,,,,,,,,,,FG003,"* Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received QW SC doses of tirzepatide, starting at 2.5 mg and increasing by 2.5 m",,,
period,NCT04184622::period::1,NCT04184622,Primary Treatment Period,,,,,,,,,,,,1.0,,
period,NCT04184622::period::2,NCT04184622,Additional Treatment Period,,,,,,,,,,,,2.0,,
period,NCT04184622::period::3,NCT04184622,Safety Follow-up Period,,,,,,,,,,,,3.0,,
outcome,NCT04184622::outcome::primary::1,NCT04184622,Percent Change From Baseline in Body Weight (Primary Treatment Period),,,,,,,,,,,,,PRIMARY,"Baseline, Week 72"
outcome,NCT04184622::outcome::primary::2,NCT04184622,Percentage of Participants Who Achieve ≥5% Body Weight Reduction (Primary Treatment Period),,,,,,,,,,,,,PRIMARY,Week 72
country,NCT04184622::country::United States,NCT04184622,United States,,,,,,,,,,,,,,
country,NCT04184622::country::Mexico,NCT04184622,Mexico,,,,,,,,,,,,,,
country,NCT04184622::country::Argentina,NCT04184622,Argentina,,,,,,,,,,,,,,
country,NCT04184622::country::Russia,NCT04184622,Russia,,,,,,,,,,,,,,
country,NCT04184622::country::Brazil,NCT04184622,Brazil,,,,,,,,,,,,,,
country,NCT04184622::country::China,NCT04184622,China,,,,,,,,,,,,,,
country,NCT04184622::country::India,NCT04184622,India,,,,,,,,,,,,,,
country,NCT04184622::country::Japan,NCT04184622,Japan,,,,,,,,,,,,,,
country,NCT04184622::country::Puerto Rico,NCT04184622,Puerto Rico,,,,,,,,,,,,,,
country,NCT04184622::country::Taiwan,NCT04184622,Taiwan,,,,,,,,,,,,,,
trial,NCT00661362,NCT00661362,Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,570.0,2008-06,2009-09,3.0,30.0,,,,,
arm,NCT00661362::arm::FG000,NCT00661362,Saxagliptin 5 mg + Metformin,,,,,,,,,,FG000,"Saxagliptin 5 mg tablet, once daily (OD), added on to stable Metformin for 24 weeks",,,
arm,NCT00661362::arm::FG001,NCT00661362,Placebo + Metformin,,,,,,,,,,FG001,"Placebo tablet, OD, added on to stable Metformin for 24 weeks",,,
period,NCT00661362::period::1,NCT00661362,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00661362::outcome::primary::1,NCT00661362,Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline , Week 24"
country,NCT00661362::country::China,NCT00661362,China,,,,,,,,,,,,,,
country,NCT00661362::country::South Korea,NCT00661362,South Korea,,,,,,,,,,,,,,
country,NCT00661362::country::India,NCT00661362,India,,,,,,,,,,,,,,
trial,NCT00006305,NCT00006305,Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes,PHASE3,diabetes type 2,"Coronary Disease; Cardiovascular Diseases; Heart Diseases; Insulin Resistance; Diabetes Mellitus; Diabetes Mellitus, Non-Insulin-Dependent",OTHER,2368.0,2000-09,2009-03,0.0,0.0,,,,,
arm,NCT00006305::arm::FG000,NCT00006305,Revascularization and Insulin Providing (IP),,,,,,,,,,FG000,Prompt revascularization with intensive medical therapy and insulin providing glycemic control strategy,,,
arm,NCT00006305::arm::FG001,NCT00006305,Revascularization and Insulin Sensitizing (IS),,,,,,,,,,FG001,Prompt revascularization with intensive medical therapy and insulin sensitizing glycemic control strategy,,,
arm,NCT00006305::arm::FG002,NCT00006305,Medical Therapy and Insulin Providing (IP),,,,,,,,,,FG002,Intensive medical therapy with delayed revascularization if clinically indicated and insulin providing glycemic control strategy,,,
arm,NCT00006305::arm::FG003,NCT00006305,Medical Therapy and Insulin Sensitizing (IS),,,,,,,,,,FG003,Intensive medical therapy with delayed revascularization if clinically indicated and insulin sensitizing glycemic control strategy,,,
period,NCT00006305::period::1,NCT00006305,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00006305::outcome::primary::1,NCT00006305,Number of Participants With All-Cause Mortality,,,,,,,,,,,,,PRIMARY,five years
trial,NCT04795531,NCT04795531,"A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)",PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,588.0,2021-03-24,2022-06-23,12.0,93.0,,,,,
arm,NCT04795531::arm::FG000,NCT04795531,Insulin Icodec,,,,,,,,,,FG000,Participants were to receive once weekly subcutaneous (s.c.) injection of insulin icodec using PDS290 prefilled pen-injector at a starting dose of 70 units (U) and once weekly placebo for 26 weeks. Th,,,
arm,NCT04795531::arm::FG001,NCT04795531,Insulin Degludec,,,,,,,,,,FG001,Participants were to receive once daily s.c. injection of insulin degludec using PDS290 prefilled pen-injector at a starting dose of 10 U and once daily placebo for 26 weeks. The dose was then adjuste,,,
period,NCT04795531::period::1,NCT04795531,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04795531::outcome::primary::1,NCT04795531,Change in Glycated Haemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline (Week 0), Week 26"
country,NCT04795531::country::United States,NCT04795531,United States,,,,,,,,,,,,,,
country,NCT04795531::country::Canada,NCT04795531,Canada,,,,,,,,,,,,,,
country,NCT04795531::country::China,NCT04795531,China,,,,,,,,,,,,,,
country,NCT04795531::country::France,NCT04795531,France,,,,,,,,,,,,,,
country,NCT04795531::country::Czechia,NCT04795531,Czechia,,,,,,,,,,,,,,
country,NCT04795531::country::Austria,NCT04795531,Austria,,,,,,,,,,,,,,
country,NCT04795531::country::Taiwan,NCT04795531,Taiwan,,,,,,,,,,,,,,
country,NCT04795531::country::Argentina,NCT04795531,Argentina,,,,,,,,,,,,,,
country,NCT04795531::country::Brazil,NCT04795531,Brazil,,,,,,,,,,,,,,
country,NCT04795531::country::Denmark,NCT04795531,Denmark,,,,,,,,,,,,,,
country,NCT04795531::country::Mexico,NCT04795531,Mexico,,,,,,,,,,,,,,
country,NCT04795531::country::Puerto Rico,NCT04795531,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01318122,NCT01318122,Long-term Safety Study of Alogliptin Used in Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,336.0,2008-05,2009-08,0.0,0.0,,,,,
arm,NCT01318122::arm::FG000,NCT01318122,CCT/004 - 12.5 mg Dose Group* → 12.5 mg Combination Group,,,,,,,,,,FG000,"Alogliptin 12.5 mg, tablets, orally, once daily and Pioglitazone 15 mg or 30 mg, tablets, orally, once daily for up to 40 weeks.

\*for participants from the 12.5 mg combination dosing ARM of the SYR-",,,
arm,NCT01318122::arm::FG001,NCT01318122,CCT/004 - 25 mg Dose Group* → 25 mg Combination Dose Group,,,,,,,,,,FG001,"Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 mg or 30 mg, tablets, orally, once daily for up to 40 weeks.

\*for participants from the 25 mg combination dosing ARM of the SYR-322/",,,
arm,NCT01318122::arm::FG002,NCT01318122,Pioglitazone Monotherapy Group* → 12.5 mg Combination Group,,,,,,,,,,FG002,"Alogliptin 12.5 mg, tablets, orally, once daily and Pioglitazone 15 mg or 30 mg, tablets, orally, once daily for up to 40 weeks.

\*for participants from the pioglitazone 15 mg or 30 mg dosing ARM of ",,,
arm,NCT01318122::arm::FG003,NCT01318122,Pioglitazone Monotherapy Group* → 25 mg Combination Group,,,,,,,,,,FG003,"Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 mg or 30 mg, tablets, orally, once daily for up to 40 weeks.

\*for participants from the pioglitazone 15 mg or 30 mg dosing ARM of th",,,
period,NCT01318122::period::1,NCT01318122,Enrolled - Long-Term Extension Study,,,,,,,,,,,,1.0,,
period,NCT01318122::period::2,NCT01318122,Entered - Long-Term Extension Study,,,,,,,,,,,,2.0,,
outcome,NCT01318122::outcome::primary::1,NCT01318122,Number of Participants With Adverse Events.,,,,,,,,,,,,,PRIMARY,52 Weeks.
trial,NCT02715258,NCT02715258,Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,210.0,2016-03,2017-04,2.0,23.0,,,,,
arm,NCT02715258::arm::FG000,NCT02715258,"Bexagliflozin Tablets, 20 mg",,,,,,,,,,FG000,"Each subject will receive bexagliflozin tablets, 20 mg once daily for 24 weeks.",,,
arm,NCT02715258::arm::FG001,NCT02715258,Placebo Tablets,,,,,,,,,,FG001,Each subject will receive placebo (inactive tablet) once daily for 24 weeks.,,,
period,NCT02715258::period::1,NCT02715258,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02715258::outcome::primary::1,NCT02715258,Change in HbA1c From Baseline at Week 24,,,,,,,,,,,,,PRIMARY,24 weeks
country,NCT02715258::country::United States,NCT02715258,United States,,,,,,,,,,,,,,
country,NCT02715258::country::Canada,NCT02715258,Canada,,,,,,,,,,,,,,
trial,NCT01733758,NCT01733758,A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM),PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,494.0,2013-02,2015-02,1.0,74.0,,,,,
arm,NCT01733758::arm::FG000,NCT01733758,Placebo,,,,,,,,,,FG000,"Participants received double-blind matching albiglutide placebo as a subcutaneous injection weekly to Week 24. After Week 24, participants received albiglutide 30 milligrams (mg) as a subcutaneous inj",,,
arm,NCT01733758::arm::FG001,NCT01733758,Albiglutide 30 mg Weekly,,,,,,,,,,FG001,Participants received double-blind albiglutide 30 mg as a subcutaneous injection weekly to Week 52.,,,
arm,NCT01733758::arm::FG002,NCT01733758,Albiglutide 50 mg Weekly,,,,,,,,,,FG002,"Participants received double-blind albiglutide 30 mg as a subcutaneous injection weekly until Week 4. Starting at Week 4, participants received albiglutide 50 mg as a subcutaneous injection weekly to ",,,
arm,NCT01733758::arm::FG003,NCT01733758,Open Label Liraglutide 0.9 mg Daily,,,,,,,,,,FG003,Participants received open-label liraglutide as a subcutaneous injection daily at a dose of 0.3 mg with weekly forced uptitrations to a dose of 0.6 mg then a dose of 0.9 mg (maximum dose in Japan). Th,,,
period,NCT01733758::period::1,NCT01733758,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01733758::outcome::primary::1,NCT01733758,Model-adjusted Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and Week 24
outcome,NCT01733758::outcome::primary::2,NCT01733758,"Mean HbA1c at Baseline, Week 24, and Change From Baseline at Week 24",,,,,,,,,,,,,PRIMARY,Baseline and Week 24
country,NCT01733758::country::Japan,NCT01733758,Japan,,,,,,,,,,,,,,
trial,NCT02911948,NCT02911948,A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,210.0,2016-09-21,2017-11-22,1.0,38.0,,,,,
arm,NCT02911948::arm::FG000,NCT02911948,Insulin Degludec/Liraglutide,,,,,,,,,,FG000,Eligible subjects were treated with insulin degludec/liraglutide (IDegLira) in combination with metformin (at stable pre-trial dose and frequency level) for 26 weeks. The starting dose of IDegLira was,,,
arm,NCT02911948::arm::FG001,NCT02911948,Insulin Degludec,,,,,,,,,,FG001,"Eligible subjects were treated with insulin degludec (IDeg) in combination with metformin (at stable pre-trial dose and frequency level) for 26 weeks. The starting dose of IDeg was 10 units IDeg, with",,,
period,NCT02911948::period::1,NCT02911948,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02911948::outcome::primary::1,NCT02911948,Change in Glycosylated Haemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"week 0, week 26"
country,NCT02911948::country::Japan,NCT02911948,Japan,,,,,,,,,,,,,,
trial,NCT04039503,NCT04039503,A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,475.0,2019-08-30,2021-01-13,8.0,48.0,,,,,
arm,NCT04039503::arm::FG000,NCT04039503,5 mg Tirzepatide,,,,,,,,,,FG000,5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.,,,
arm,NCT04039503::arm::FG001,NCT04039503,10 mg Tirzepatide,,,,,,,,,,FG001,10 mg tirzepatide administered SC once a week.,,,
arm,NCT04039503::arm::FG002,NCT04039503,15 mg Tirzepatide,,,,,,,,,,FG002,15 mg tirzepatide administered SC once a week.,,,
arm,NCT04039503::arm::FG003,NCT04039503,Placebo,,,,,,,,,,FG003,Placebo administered SC once a week.,,,
period,NCT04039503::period::1,NCT04039503,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04039503::outcome::primary::1,NCT04039503,Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg),,,,,,,,,,,,,PRIMARY,"Baseline, Week 40"
country,NCT04039503::country::Germany,NCT04039503,Germany,,,,,,,,,,,,,,
country,NCT04039503::country::Japan,NCT04039503,Japan,,,,,,,,,,,,,,
country,NCT04039503::country::Czechia,NCT04039503,Czechia,,,,,,,,,,,,,,
country,NCT04039503::country::United States,NCT04039503,United States,,,,,,,,,,,,,,
country,NCT04039503::country::Slovakia,NCT04039503,Slovakia,,,,,,,,,,,,,,
country,NCT04039503::country::Spain,NCT04039503,Spain,,,,,,,,,,,,,,
country,NCT04039503::country::Poland,NCT04039503,Poland,,,,,,,,,,,,,,
country,NCT04039503::country::Puerto Rico,NCT04039503,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00839527,NCT00839527,A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,685.0,2009-02,2013-04,9.0,358.0,,,,,
arm,NCT00839527::arm::FG000,NCT00839527,Placebo + Metformin + Glimepiride,,,,,,,,,,FG000,Participants received albiglutide matching placebo as a subcutaneous injection weekly via a fully disposable pen injector system with open-label glimepiride (4 milligrams \[mg\] daily orally) with met,,,
arm,NCT00839527::arm::FG001,NCT00839527,Pioglitazone + Metformin + Glimepiride,,,,,,,,,,FG001,Participants received pioglitazone (30 mg daily orally; with treatment-masked uptitration if needed to 45 mg) and albiglutide-matching placebo weekly as a subcutaneous injection via a fully disposable,,,
arm,NCT00839527::arm::FG002,NCT00839527,Albiglutide + Metformin + Glimepiride,,,,,,,,,,FG002,Participants received pioglitazone-matching placebo daily orally and albiglutide (30 mg weekly; treatment-masked uptitration if needed to 50 mg weekly) as a subcutaneous injection via a fully disposab,,,
period,NCT00839527::period::1,NCT00839527,Treatment Period (TP) (156 Weeks),,,,,,,,,,,,1.0,,
period,NCT00839527::period::2,NCT00839527,Follow-up Period (FUP) (8 Weeks),,,,,,,,,,,,2.0,,
outcome,NCT00839527::outcome::primary::1,NCT00839527,Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52,,,,,,,,,,,,,PRIMARY,Baseline and Week 52
country,NCT00839527::country::United States,NCT00839527,United States,,,,,,,,,,,,,,
country,NCT00839527::country::Germany,NCT00839527,Germany,,,,,,,,,,,,,,
country,NCT00839527::country::Philippines,NCT00839527,Philippines,,,,,,,,,,,,,,
country,NCT00839527::country::India,NCT00839527,India,,,,,,,,,,,,,,
country,NCT00839527::country::Spain,NCT00839527,Spain,,,,,,,,,,,,,,
country,NCT00839527::country::Hong Kong,NCT00839527,Hong Kong,,,,,,,,,,,,,,
country,NCT00839527::country::Peru,NCT00839527,Peru,,,,,,,,,,,,,,
country,NCT00839527::country::United Kingdom,NCT00839527,United Kingdom,,,,,,,,,,,,,,
country,NCT00839527::country::Russia,NCT00839527,Russia,,,,,,,,,,,,,,
trial,NCT00998881,NCT00998881,Monotherapy Study of MP-513 in Patients With Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,203.0,2009-09,2010-06,1.0,1.0,,,,,
arm,NCT00998881::arm::FG000,NCT00998881,Placebo,,,,,,,,,,FG000,"Teneligliptin placebo-matching tablets, orally, once daily",,,
arm,NCT00998881::arm::FG001,NCT00998881,Teneligliptin 20 mg,,,,,,,,,,FG001,"Teneligliptin 20 mg, orally, once daily",,,
period,NCT00998881::period::1,NCT00998881,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00998881::outcome::primary::1,NCT00998881,Change From Baseline in HbA1c at Week 12,,,,,,,,,,,,,PRIMARY,12 weeks
country,NCT00998881::country::Japan,NCT00998881,Japan,,,,,,,,,,,,,,
trial,NCT00082407,NCT00082407,Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,505.0,2003-11,2008-07,12.0,69.0,,,,,
arm,NCT00082407::arm::FG000,NCT00082407,Exenatide Arm,,,,,,,,,,FG000,"subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks",,,
arm,NCT00082407::arm::FG001,NCT00082407,Biphasic Insulin Aspart Arm,,,,,,,,,,FG001,"subcutaneous injection, twice daily; titration to target blood glucose level",,,
period,NCT00082407::period::1,NCT00082407,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00082407::outcome::primary::1,NCT00082407,Change in Glcosylated Hemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"baseline, week 52"
country,NCT00082407::country::Germany,NCT00082407,Germany,,,,,,,,,,,,,,
country,NCT00082407::country::United Kingdom,NCT00082407,United Kingdom,,,,,,,,,,,,,,
country,NCT00082407::country::Russia,NCT00082407,Russia,,,,,,,,,,,,,,
country,NCT00082407::country::Italy,NCT00082407,Italy,,,,,,,,,,,,,,
country,NCT00082407::country::Spain,NCT00082407,Spain,,,,,,,,,,,,,,
country,NCT00082407::country::Greece,NCT00082407,Greece,,,,,,,,,,,,,,
country,NCT00082407::country::Croatia,NCT00082407,Croatia,,,,,,,,,,,,,,
country,NCT00082407::country::Portugal,NCT00082407,Portugal,,,,,,,,,,,,,,
country,NCT00082407::country::Taiwan,NCT00082407,Taiwan,,,,,,,,,,,,,,
country,NCT00082407::country::Netherlands,NCT00082407,Netherlands,,,,,,,,,,,,,,
country,NCT00082407::country::Romania,NCT00082407,Romania,,,,,,,,,,,,,,
country,NCT00082407::country::Slovenia,NCT00082407,Slovenia,,,,,,,,,,,,,,
trial,NCT01958671,NCT01958671,"A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)",PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,461.0,2013-10-09,2016-07-28,0.0,0.0,,,,,
arm,NCT01958671::arm::FG000,NCT01958671,Ertugliflozin 5 mg/Ertugliflozin 5 mg,,,,,,,,,,FG000,Phase A: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 5 mg administered once daily for 26 we,,,
arm,NCT01958671::arm::FG001,NCT01958671,Ertugliflozin 15 mg/Ertugliflozin 15 mg,,,,,,,,,,FG001,Phase A: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 15 mg administered once daily for 26 ,,,
arm,NCT01958671::arm::FG002,NCT01958671,Placebo/Metformin,,,,,,,,,,FG002,Phase A: Placebo to ertugliflozin administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Participants not rescued with open-label metfo,,,
period,NCT01958671::period::1,NCT01958671,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01958671::outcome::primary::1,NCT01958671,Change From Baseline In A1C at Week 26,,,,,,,,,,,,,PRIMARY,Baseline and Week 26
outcome,NCT01958671::outcome::primary::2,NCT01958671,Percentage of Participants Experiencing An Adverse Event (AE),,,,,,,,,,,,,PRIMARY,Up to 54 weeks (including 2 weeks following last dose)
outcome,NCT01958671::outcome::primary::3,NCT01958671,Percentage of Participants Discontinuing Study Treatment Due to an AE,,,,,,,,,,,,,PRIMARY,Up to 52 weeks
trial,NCT00976937,NCT00976937,24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,319.0,2009-08,2011-03,13.0,92.0,,,,,
arm,NCT00976937::arm::FG000,NCT00976937,Lixisenatide,,,,,,,,,,FG000,"2-step initiation regimen of lixisenatide along with sitagliptin placebo: lixisenatide 10 microgram (mcg) once daily (QD) subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up",,,
arm,NCT00976937::arm::FG001,NCT00976937,Sitagliptin,,,,,,,,,,FG001,Sitagliptin along with 2-step initiation regimen of volume matching lixisenatide placebo: sitagliptin 100 mg capsule orally QD up to Week 24 along with volume matching lixisenatide placebo 10 mcg QD s,,,
period,NCT00976937::period::1,NCT00976937,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00976937::outcome::primary::1,NCT00976937,Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% and at Least 5% Weight Loss From Baseline at Week 24,,,,,,,,,,,,,PRIMARY,Week 24
country,NCT00976937::country::United States,NCT00976937,United States,,,,,,,,,,,,,,
country,NCT00976937::country::Canada,NCT00976937,Canada,,,,,,,,,,,,,,
country,NCT00976937::country::Mexico,NCT00976937,Mexico,,,,,,,,,,,,,,
country,NCT00976937::country::Romania,NCT00976937,Romania,,,,,,,,,,,,,,
country,NCT00976937::country::Brazil,NCT00976937,Brazil,,,,,,,,,,,,,,
country,NCT00976937::country::Australia,NCT00976937,Australia,,,,,,,,,,,,,,
country,NCT00976937::country::Chile,NCT00976937,Chile,,,,,,,,,,,,,,
country,NCT00976937::country::Guatemala,NCT00976937,Guatemala,,,,,,,,,,,,,,
country,NCT00976937::country::Peru,NCT00976937,Peru,,,,,,,,,,,,,,
country,NCT00976937::country::Russia,NCT00976937,Russia,,,,,,,,,,,,,,
country,NCT00976937::country::Poland,NCT00976937,Poland,,,,,,,,,,,,,,
country,NCT00976937::country::Germany,NCT00976937,Germany,,,,,,,,,,,,,,
country,NCT00976937::country::Ukraine,NCT00976937,Ukraine,,,,,,,,,,,,,,
trial,NCT01617434,NCT01617434,The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,451.0,2012-09,2013-10,9.0,86.0,,,,,
arm,NCT01617434::arm::FG000,NCT01617434,Liraglutide,,,,,,,,,,FG000,"Liraglutide was administered subcutaneously (s.c. injection, under the skin) once daily (OD) for 26 weeks in combination with pre-trial basal insulin analogue regimen ± metformin. The starting dose of",,,
arm,NCT01617434::arm::FG001,NCT01617434,Placebo,,,,,,,,,,FG001,"Placebo was administered subcutaneously (s.c. injection, under the skin) once daily (OD) for 26 weeks in combination with pre-trial basal insulin analogue regimen ± metformin. The starting dose of the",,,
period,NCT01617434::period::1,NCT01617434,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01617434::outcome::primary::1,NCT01617434,Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 26,,,,,,,,,,,,,PRIMARY,Week 0 to Week 26
country,NCT01617434::country::United States,NCT01617434,United States,,,,,,,,,,,,,,
country,NCT01617434::country::Canada,NCT01617434,Canada,,,,,,,,,,,,,,
country,NCT01617434::country::Germany,NCT01617434,Germany,,,,,,,,,,,,,,
country,NCT01617434::country::Netherlands,NCT01617434,Netherlands,,,,,,,,,,,,,,
country,NCT01617434::country::India,NCT01617434,India,,,,,,,,,,,,,,
country,NCT01617434::country::Finland,NCT01617434,Finland,,,,,,,,,,,,,,
country,NCT01617434::country::Argentina,NCT01617434,Argentina,,,,,,,,,,,,,,
country,NCT01617434::country::Mexico,NCT01617434,Mexico,,,,,,,,,,,,,,
country,NCT01617434::country::Serbia,NCT01617434,Serbia,,,,,,,,,,,,,,
trial,NCT04760626,NCT04760626,"A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before",PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,1085.0,2021-03-01,2022-08-29,8.0,180.0,,,,,
arm,NCT04760626::arm::FG000,NCT04760626,Insulin Icodec,,,,,,,,,,FG000,"Participants were to receive once weekly subcutaneous (s.c.) injection of Insulin icodec guided by the DoseGuide app, for 52 weeks using PDS290 prefilled pen-injector. Participants were to perform onc",,,
arm,NCT04760626::arm::FG001,NCT04760626,Once Daily Basal Insulin Analogue,,,,,,,,,,FG001,Participants were to receive once daily basal insulin analogue of (Insulin degludec using PDS290 prefilled pen-injector) or (Insulin glargine U100 or Insulin glargine U300 using SoloSTAR® pre-filled p,,,
period,NCT04760626::period::1,NCT04760626,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04760626::outcome::primary::1,NCT04760626,Change in Glycated Haemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline (week 0), week 52"
country,NCT04760626::country::United States,NCT04760626,United States,,,,,,,,,,,,,,
country,NCT04760626::country::Canada,NCT04760626,Canada,,,,,,,,,,,,,,
country,NCT04760626::country::Germany,NCT04760626,Germany,,,,,,,,,,,,,,
country,NCT04760626::country::Turkey (Türkiye),NCT04760626,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT04760626::country::Greece,NCT04760626,Greece,,,,,,,,,,,,,,
country,NCT04760626::country::Hungary,NCT04760626,Hungary,,,,,,,,,,,,,,
country,NCT04760626::country::Poland,NCT04760626,Poland,,,,,,,,,,,,,,
country,NCT04760626::country::Puerto Rico,NCT04760626,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01720446,NCT01720446,Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,3297.0,2013-02-21,2016-03-15,21.0,253.0,,,,,
arm,NCT01720446::arm::FG000,NCT01720446,Semaglutide 0.5 mg,,,,,,,,,,FG000,"Subjects received once-weekly dose of semaglutide 0.5 mg as an add-on to their standard-of-care treatment. Injections were administered subcutaneously in the thigh, abdomen or upper arm, at any time o",,,
arm,NCT01720446::arm::FG001,NCT01720446,Semaglutide 1.0 mg,,,,,,,,,,FG001,"Subjects received once-weekly dose of semaglutide 1.0 mg as an add-on to their standard-of-care treatment. Injections were administered subcutaneously in the thigh, abdomen or upper arm, at any time o",,,
arm,NCT01720446::arm::FG002,NCT01720446,Placebo 0.5 mg,,,,,,,,,,FG002,"Subjects received once-weekly dose of placebo 0.5 mg as an add-on to their standard-of-care treatment. Injections were administered subcutaneously in the thigh, abdomen or upper arm, at any time of da",,,
arm,NCT01720446::arm::FG003,NCT01720446,Placebo 1.0 mg,,,,,,,,,,FG003,"Subjects received once-weekly dose of placebo 1.0 mg as an add-on to their standard-of-care treatment. Injections were administered subcutaneously in the thigh, abdomen or upper arm, at any time of da",,,
period,NCT01720446::period::1,NCT01720446,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01720446::outcome::primary::1,NCT01720446,"Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke",,,,,,,,,,,,,PRIMARY,Time from randomisation up to end of follow-up (scheduled at week 109)
country,NCT01720446::country::United States,NCT01720446,United States,,,,,,,,,,,,,,
country,NCT01720446::country::India,NCT01720446,India,,,,,,,,,,,,,,
country,NCT01720446::country::Canada,NCT01720446,Canada,,,,,,,,,,,,,,
country,NCT01720446::country::Russia,NCT01720446,Russia,,,,,,,,,,,,,,
country,NCT01720446::country::Mexico,NCT01720446,Mexico,,,,,,,,,,,,,,
country,NCT01720446::country::Turkey (Türkiye),NCT01720446,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01720446::country::Australia,NCT01720446,Australia,,,,,,,,,,,,,,
country,NCT01720446::country::Brazil,NCT01720446,Brazil,,,,,,,,,,,,,,
country,NCT01720446::country::Germany,NCT01720446,Germany,,,,,,,,,,,,,,
country,NCT01720446::country::United Kingdom,NCT01720446,United Kingdom,,,,,,,,,,,,,,
country,NCT01720446::country::Argentina,NCT01720446,Argentina,,,,,,,,,,,,,,
country,NCT01720446::country::Israel,NCT01720446,Israel,,,,,,,,,,,,,,
country,NCT01720446::country::Italy,NCT01720446,Italy,,,,,,,,,,,,,,
country,NCT01720446::country::Malaysia,NCT01720446,Malaysia,,,,,,,,,,,,,,
country,NCT01720446::country::Spain,NCT01720446,Spain,,,,,,,,,,,,,,
country,NCT01720446::country::Denmark,NCT01720446,Denmark,,,,,,,,,,,,,,
country,NCT01720446::country::Poland,NCT01720446,Poland,,,,,,,,,,,,,,
country,NCT01720446::country::Algeria,NCT01720446,Algeria,,,,,,,,,,,,,,
country,NCT01720446::country::Bulgaria,NCT01720446,Bulgaria,,,,,,,,,,,,,,
country,NCT01720446::country::Taiwan,NCT01720446,Taiwan,,,,,,,,,,,,,,
country,NCT01720446::country::Thailand,NCT01720446,Thailand,,,,,,,,,,,,,,
trial,NCT00252694,NCT00252694,DIabetic Retinopathy Candesartan Trials,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,4717.0,2001-08,2008-04,0.0,0.0,,,,,
arm,NCT00252694::arm::FG000,NCT00252694,Candesartan,,,,,,,,,,FG000,Candesartan cilexetil 32 mg once daily,,,
arm,NCT00252694::arm::FG001,NCT00252694,Placebo,,,,,,,,,,FG001,Placebo Comparator,,,
period,NCT00252694::period::1,NCT00252694,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00252694::outcome::primary::1,NCT00252694,Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale,,,,,,,,,,,,,PRIMARY,"From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year."
trial,NCT04429503,NCT04429503,Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease,PHASE3,diabetes type 2,Diabetic Macular Edema; Type 1 Diabetes Mellitus; Type 2 Diabetes Mellitus,INDUSTRY,660.0,2020-06-29,2024-06-18,8.0,138.0,,,,,
arm,NCT04429503::arm::FG000,NCT04429503,Aflibercept 2 mg Every 8 Weeks (2q8),,,,,,,,,,FG000,"Participants received 2 milligrams (mg) aflibercept every 8 weeks (2q8), following 5 initial monthly doses",,,
arm,NCT04429503::arm::FG001,NCT04429503,High-dose (HD) Aflibercept Every 12 Weeks (HDq12),,,,,,,,,,FG001,Participants received HD aflibercept (8 mg) every 12 weeks (HDq12) following 3 initial monthly doses,,,
arm,NCT04429503::arm::FG002,NCT04429503,HD Aflibercept Every 16 Weeks (HDq16),,,,,,,,,,FG002,Participants received HD aflibercept (8mg) every 16 weeks (HDq16) following 3 initial monthly doses,,,
arm,NCT04429503::arm::FG003,NCT04429503,2q8/HD Aflibercept (Extension),,,,,,,,,,FG003,Participants receiving aflibercept 2q8 switched to HD in the extension phase,,,
arm,NCT04429503::arm::FG004,NCT04429503,HDq12 Aflibercept (Extension),,,,,,,,,,FG004,Participants continued to receive HDq12 aflibercept during the extension phase,,,
arm,NCT04429503::arm::FG005,NCT04429503,HDq16 Aflibercept (Extension),,,,,,,,,,FG005,Participants continued to receive HDq16 aflibercept during the extension phase,,,
period,NCT04429503::period::1,NCT04429503,Main Study (Up to Wk 96),,,,,,,,,,,,1.0,,
period,NCT04429503::period::2,NCT04429503,Extension Phase (Wk 96 to Wk 156),,,,,,,,,,,,2.0,,
outcome,NCT04429503::outcome::primary::1,NCT04429503,Change From Baseline in Best Corrected Visual Acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] Letter Score) in the Study Eye at Week 48,,,,,,,,,,,,,PRIMARY,"Baseline, Week 48"
country,NCT04429503::country::United States,NCT04429503,United States,,,,,,,,,,,,,,
country,NCT04429503::country::Japan,NCT04429503,Japan,,,,,,,,,,,,,,
country,NCT04429503::country::Hungary,NCT04429503,Hungary,,,,,,,,,,,,,,
country,NCT04429503::country::Canada,NCT04429503,Canada,,,,,,,,,,,,,,
country,NCT04429503::country::Czechia,NCT04429503,Czechia,,,,,,,,,,,,,,
country,NCT04429503::country::Germany,NCT04429503,Germany,,,,,,,,,,,,,,
country,NCT04429503::country::United Kingdom,NCT04429503,United Kingdom,,,,,,,,,,,,,,
country,NCT04429503::country::Puerto Rico,NCT04429503,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01930188,NCT01930188,Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,1231.0,2013-12-02,2015-10-12,18.0,141.0,,,,,
arm,NCT01930188::arm::FG000,NCT01930188,Semaglutide 0.5 mg + Sitagliptin Placebo,,,,,,,,,,FG000,"Semaglutide 0.5 mg administered subcutaneously (s.c., under the skin) once weekly, in the thigh, abdomen, or upper arm, at any time of day irrespective of meals. Sitagliptin placebo (0 mg) administere",,,
arm,NCT01930188::arm::FG001,NCT01930188,Semaglutide 1.0 mg + Sitagliptin Placebo,,,,,,,,,,FG001,"Semaglutide 1.0 mg administered subcutaneously (s.c., under the skin) once weekly, in the thigh, abdomen, or upper arm, at any time of day irrespective of meals. Sitagliptin placebo (0 mg) administere",,,
arm,NCT01930188::arm::FG002,NCT01930188,Sitagliptin + Semaglutide Placebo,,,,,,,,,,FG002,Subjects were randomised to 2 different placebo arms (sitagliptin + semaglutide placebo 0.5 mg and sitagliptin + semaglutide placebo 1.0 mg). Both arms were pooled together for data analysis. Semaglut,,,
period,NCT01930188::period::1,NCT01930188,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01930188::outcome::primary::1,NCT01930188,Change in HbA1c (Glycosylated Haemoglobin) From Baseline,,,,,,,,,,,,,PRIMARY,"Week 0, week 56"
country,NCT01930188::country::India,NCT01930188,India,,,,,,,,,,,,,,
country,NCT01930188::country::Russia,NCT01930188,Russia,,,,,,,,,,,,,,
country,NCT01930188::country::Japan,NCT01930188,Japan,,,,,,,,,,,,,,
country,NCT01930188::country::Turkey (Türkiye),NCT01930188,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01930188::country::Bulgaria,NCT01930188,Bulgaria,,,,,,,,,,,,,,
country,NCT01930188::country::Portugal,NCT01930188,Portugal,,,,,,,,,,,,,,
country,NCT01930188::country::South Africa,NCT01930188,South Africa,,,,,,,,,,,,,,
country,NCT01930188::country::Spain,NCT01930188,Spain,,,,,,,,,,,,,,
country,NCT01930188::country::Ukraine,NCT01930188,Ukraine,,,,,,,,,,,,,,
country,NCT01930188::country::Czechia,NCT01930188,Czechia,,,,,,,,,,,,,,
country,NCT01930188::country::Hungary,NCT01930188,Hungary,,,,,,,,,,,,,,
country,NCT01930188::country::Mexico,NCT01930188,Mexico,,,,,,,,,,,,,,
country,NCT01930188::country::Norway,NCT01930188,Norway,,,,,,,,,,,,,,
country,NCT01930188::country::Romania,NCT01930188,Romania,,,,,,,,,,,,,,
country,NCT01930188::country::Argentina,NCT01930188,Argentina,,,,,,,,,,,,,,
country,NCT01930188::country::Sweden,NCT01930188,Sweden,,,,,,,,,,,,,,
country,NCT01930188::country::Thailand,NCT01930188,Thailand,,,,,,,,,,,,,,
country,NCT01930188::country::Hong Kong,NCT01930188,Hong Kong,,,,,,,,,,,,,,
trial,NCT00849056,NCT00849056,Safety and Efficacy of Albiglutide in Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,310.0,2009-01,2013-01,6.0,331.0,,,,,
arm,NCT00849056::arm::FG000,NCT00849056,Placebo + Pioglitazone With or Without Metformin,,,,,,,,,,FG000,"Participants received matching placebo as a subcutaneous injection weekly via a fully disposable pen injector system and pioglitazone (\>=30 milligrams \[mg\]/day, unless there was documented evidence",,,
arm,NCT00849056::arm::FG001,NCT00849056,Albiglutide 30 mg + Pioglitazone With or Without Metformin,,,,,,,,,,FG001,"Participants received albiglutide 30 milligrams (mg) as a subcutaneous injection weekly via a fully disposable pen injector system and pioglitazone (\>=30 mg/day, unless there was documented evidence ",,,
period,NCT00849056::period::1,NCT00849056,Treatment Period (TP) (156 Weeks),,,,,,,,,,,,1.0,,
period,NCT00849056::period::2,NCT00849056,Follow-up Period (FUP) (8 Weeks),,,,,,,,,,,,2.0,,
outcome,NCT00849056::outcome::primary::1,NCT00849056,Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52,,,,,,,,,,,,,PRIMARY,Baseline and Week 52
country,NCT00849056::country::United States,NCT00849056,United States,,,,,,,,,,,,,,
country,NCT00849056::country::United Kingdom,NCT00849056,United Kingdom,,,,,,,,,,,,,,
country,NCT00849056::country::Peru,NCT00849056,Peru,,,,,,,,,,,,,,
country,NCT00849056::country::South Africa,NCT00849056,South Africa,,,,,,,,,,,,,,
country,NCT00849056::country::India,NCT00849056,India,,,,,,,,,,,,,,
country,NCT00849056::country::South Korea,NCT00849056,South Korea,,,,,,,,,,,,,,
trial,NCT01164501,NCT01164501,Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2; Renal Insufficiency",INDUSTRY,741.0,2010-07,2012-07,15.0,127.0,,,,,
arm,NCT01164501::arm::FG000,NCT01164501,Placebo,,,,,,,,,,FG000,"Placebo tablets, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 52 weeks.",,,
arm,NCT01164501::arm::FG001,NCT01164501,Empa 10mg,,,,,,,,,,FG001,Single oral dose of empagliflozin (empa) 10mg plus a placebo tablet matching the 25mg empa dose were taken once daily for 52 weeks.,,,
arm,NCT01164501::arm::FG002,NCT01164501,Empa 25mg,,,,,,,,,,FG002,Single oral dose of empagliflozin (empa) 25mg plus a placebo tablet matching the 10mg empa dose were taken once daily for 52 weeks.,,,
period,NCT01164501::period::1,NCT01164501,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01164501::outcome::primary::1,NCT01164501,HbA1c Change From Baseline in Patients With Mild or Moderate Renal Impairment,,,,,,,,,,,,,PRIMARY,Baseline and 24 weeks
outcome,NCT01164501::outcome::primary::2,NCT01164501,HbA1c Change From Baseline in Patients With Mild Renal Impairment,,,,,,,,,,,,,PRIMARY,Baseline and 24 weeks
outcome,NCT01164501::outcome::primary::3,NCT01164501,HbA1c Change From Baseline in Patients With Moderate Renal Impairment,,,,,,,,,,,,,PRIMARY,Baseline and 24 weeks
country,NCT01164501::country::United States,NCT01164501,United States,,,,,,,,,,,,,,
country,NCT01164501::country::India,NCT01164501,India,,,,,,,,,,,,,,
country,NCT01164501::country::United Kingdom,NCT01164501,United Kingdom,,,,,,,,,,,,,,
country,NCT01164501::country::Malaysia,NCT01164501,Malaysia,,,,,,,,,,,,,,
country,NCT01164501::country::Spain,NCT01164501,Spain,,,,,,,,,,,,,,
country,NCT01164501::country::Canada,NCT01164501,Canada,,,,,,,,,,,,,,
country,NCT01164501::country::France,NCT01164501,France,,,,,,,,,,,,,,
country,NCT01164501::country::Netherlands,NCT01164501,Netherlands,,,,,,,,,,,,,,
country,NCT01164501::country::Poland,NCT01164501,Poland,,,,,,,,,,,,,,
country,NCT01164501::country::Philippines,NCT01164501,Philippines,,,,,,,,,,,,,,
country,NCT01164501::country::Russia,NCT01164501,Russia,,,,,,,,,,,,,,
country,NCT01164501::country::Slovakia,NCT01164501,Slovakia,,,,,,,,,,,,,,
country,NCT01164501::country::Hong Kong,NCT01164501,Hong Kong,,,,,,,,,,,,,,
country,NCT01164501::country::Portugal,NCT01164501,Portugal,,,,,,,,,,,,,,
country,NCT01164501::country::South Africa,NCT01164501,South Africa,,,,,,,,,,,,,,
trial,NCT01555164,NCT01555164,A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,442.0,2012-06,2013-10,11.0,146.0,,,,,
arm,NCT01555164::arm::FG000,NCT01555164,Placebo+Metformin,,,,,,,,,,FG000,Qualifying period: Metformin 1000 mg (2 x 500 mg tablets) twice daily plus placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening) an,,,
arm,NCT01555164::arm::FG001,NCT01555164,Ranolazine+Metformin,,,,,,,,,,FG001,Qualifying period: Metformin 1000 mg (2 x 500 mg tablets) twice daily plus placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening) an,,,
period,NCT01555164::period::1,NCT01555164,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01555164::outcome::primary::1,NCT01555164,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,,,,,,,,,,,,,PRIMARY,Baseline
country,NCT01555164::country::United States,NCT01555164,United States,,,,,,,,,,,,,,
country,NCT01555164::country::Russia,NCT01555164,Russia,,,,,,,,,,,,,,
country,NCT01555164::country::India,NCT01555164,India,,,,,,,,,,,,,,
country,NCT01555164::country::South Africa,NCT01555164,South Africa,,,,,,,,,,,,,,
country,NCT01555164::country::Ukraine,NCT01555164,Ukraine,,,,,,,,,,,,,,
country,NCT01555164::country::Hungary,NCT01555164,Hungary,,,,,,,,,,,,,,
country,NCT01555164::country::Canada,NCT01555164,Canada,,,,,,,,,,,,,,
country,NCT01555164::country::Poland,NCT01555164,Poland,,,,,,,,,,,,,,
country,NCT01555164::country::Israel,NCT01555164,Israel,,,,,,,,,,,,,,
country,NCT01555164::country::Czechia,NCT01555164,Czechia,,,,,,,,,,,,,,
country,NCT01555164::country::Mexico,NCT01555164,Mexico,,,,,,,,,,,,,,
trial,NCT02302716,NCT02302716,A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,493.0,2014-12,2016-07,7.0,44.0,,,,,
arm,NCT02302716::arm::FG000,NCT02302716,LY2963016,,,,,,,,,,FG000,"Insulin naive participants started on 10 units (U) LY2963016 given subcutaneously (SC) once a day (QD) for 24 weeks. Participants entering the study on LANTUS®, insulin detemir or neutral protamine Ha",,,
arm,NCT02302716::arm::FG001,NCT02302716,LANTUS®,,,,,,,,,,FG001,"Insulin naive participants started on 10 U LANTUS® given SC QD for 24 weeks. Participants entering the study on LANTUS®, insulin detemir or NPH QD were started at the same dose SC. Participants enteri",,,
period,NCT02302716::period::1,NCT02302716,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02302716::outcome::primary::1,NCT02302716,Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline, 24 weeks"
country,NCT02302716::country::India,NCT02302716,India,,,,,,,,,,,,,,
country,NCT02302716::country::United States,NCT02302716,United States,,,,,,,,,,,,,,
country,NCT02302716::country::South Korea,NCT02302716,South Korea,,,,,,,,,,,,,,
country,NCT02302716::country::Taiwan,NCT02302716,Taiwan,,,,,,,,,,,,,,
country,NCT02302716::country::Turkey (Türkiye),NCT02302716,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02302716::country::Russia,NCT02302716,Russia,,,,,,,,,,,,,,
country,NCT02302716::country::Puerto Rico,NCT02302716,Puerto Rico,,,,,,,,,,,,,,
trial,NCT05024032,NCT05024032,A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN),PHASE3,diabetes type 2,Obesity; Overweight; Metabolism and Nutrition Disorder,INDUSTRY,210.0,2021-09-01,2022-12-27,1.0,29.0,,,,,
arm,NCT05024032::arm::FG000,NCT05024032,10 Milligrams (mg) Tirzepatide,,,,,,,,,,FG000,"Participants received maintenance dose 10 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, and then 10 mg tirzepatide administered subcutaneously (SC) once weekly (QW).",,,
arm,NCT05024032::arm::FG001,NCT05024032,15 mg Tirzepatide,,,,,,,,,,FG001,"Participants received maintenance dose 15 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and then 15 mg tirzepatide administered SC QW.",,,
arm,NCT05024032::arm::FG002,NCT05024032,Placebo,,,,,,,,,,FG002,Participants received matching placebo SC QW.,,,
period,NCT05024032::period::1,NCT05024032,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT05024032::outcome::primary::1,NCT05024032,Mean Percent Change From Baseline in Body Weight,,,,,,,,,,,,,PRIMARY,"Baseline, Week 52"
outcome,NCT05024032::outcome::primary::2,NCT05024032,Percentage of Participants Who Achieve ≥5% Body Weight Reduction,,,,,,,,,,,,,PRIMARY,Week 52
country,NCT05024032::country::China,NCT05024032,China,,,,,,,,,,,,,,
trial,NCT00866658,NCT00866658,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)",PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,311.0,2009-03,2010-06,4.0,4.0,,,,,
arm,NCT00866658::arm::FG000,NCT00866658,Placebo,,,,,,,,,,FG000,"2-step initiation regimen of volume matching placebo: 10 microgram (mcg) once daily (QD) subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.",,,
arm,NCT00866658::arm::FG001,NCT00866658,Lixisenatide,,,,,,,,,,FG001,"2-step initiation regimen of lixisenatide: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.",,,
period,NCT00866658::period::1,NCT00866658,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00866658::outcome::primary::1,NCT00866658,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
country,NCT00866658::country::Japan,NCT00866658,Japan,,,,,,,,,,,,,,
country,NCT00866658::country::Philippines,NCT00866658,Philippines,,,,,,,,,,,,,,
country,NCT00866658::country::South Korea,NCT00866658,South Korea,,,,,,,,,,,,,,
country,NCT00866658::country::Taiwan,NCT00866658,Taiwan,,,,,,,,,,,,,,
trial,NCT03552757,NCT03552757,Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity,PHASE3,diabetes type 2,Obesity; Overweight,INDUSTRY,1210.0,2018-06-04,2020-05-01,13.0,147.0,,,,,
arm,NCT03552757::arm::FG000,NCT03552757,Semaglutide 1.0 mg,,,,,,,,,,FG000,"Participants received once-weekly subcutaneous (s.c; under the skin) semaglutide injections for 68 weeks: 0.25 mg from week 1-4, 0.5 mg from week 5-8 and 1.0 mg from week 9-68. Participants also recei",,,
arm,NCT03552757::arm::FG001,NCT03552757,Semaglutide 2.4 mg,,,,,,,,,,FG001,"Participants received once-weekly s.c semaglutide injections for 68 weeks: 0.25 mg from week 1-4, 0.5 mg from week 5-8, 1.0 mg from week 9-12, 1.7 mg from week 13-16 and 2.4 mg from week 17-68. Partic",,,
arm,NCT03552757::arm::FG002,NCT03552757,Placebo,,,,,,,,,,FG002,Participants received once-weekly s.c placebo injections (both placebo I (placebo matched to semaglutide 1.0 mg) and placebo II (placebo matched to semaglutide 2.4 mg) for 68 weeks. Participants recei,,,
period,NCT03552757::period::1,NCT03552757,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03552757::outcome::primary::1,NCT03552757,Change in Body Weight (%) - Semaglutide 2.4 mg Versus Placebo,,,,,,,,,,,,,PRIMARY,Baseline (week 0) to week 68
outcome,NCT03552757::outcome::primary::2,NCT03552757,Participants Who Achieve (Yes/no): Body Weight Reduction ≥5% - Semaglutide 2.4 mg Versus Placebo,,,,,,,,,,,,,PRIMARY,At week 68
country,NCT03552757::country::United States,NCT03552757,United States,,,,,,,,,,,,,,
country,NCT03552757::country::India,NCT03552757,India,,,,,,,,,,,,,,
country,NCT03552757::country::Japan,NCT03552757,Japan,,,,,,,,,,,,,,
country,NCT03552757::country::Canada,NCT03552757,Canada,,,,,,,,,,,,,,
country,NCT03552757::country::United Kingdom,NCT03552757,United Kingdom,,,,,,,,,,,,,,
country,NCT03552757::country::Germany,NCT03552757,Germany,,,,,,,,,,,,,,
country,NCT03552757::country::Russia,NCT03552757,Russia,,,,,,,,,,,,,,
country,NCT03552757::country::Spain,NCT03552757,Spain,,,,,,,,,,,,,,
country,NCT03552757::country::Greece,NCT03552757,Greece,,,,,,,,,,,,,,
country,NCT03552757::country::South Africa,NCT03552757,South Africa,,,,,,,,,,,,,,
country,NCT03552757::country::Argentina,NCT03552757,Argentina,,,,,,,,,,,,,,
country,NCT03552757::country::United Arab Emirates,NCT03552757,United Arab Emirates,,,,,,,,,,,,,,
country,NCT03552757::country::Puerto Rico,NCT03552757,Puerto Rico,,,,,,,,,,,,,,
trial,NCT02059187,NCT02059187,The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,531.0,2014-02-11,2015-03-11,0.0,0.0,,,,,
arm,NCT02059187::arm::FG000,NCT02059187,MK-1293,,,,,,,,,,FG000,MK-1293 administered subcutaneously once daily.,,,
arm,NCT02059187::arm::FG001,NCT02059187,Lantus™,,,,,,,,,,FG001,Lantus™ administered subcutaneously once daily.,,,
period,NCT02059187::period::1,NCT02059187,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02059187::outcome::primary::1,NCT02059187,Change From Baseline in Participant Hemoglobin A1C Level at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and Week 24
outcome,NCT02059187::outcome::primary::2,NCT02059187,Percentage of Participants With Confirmed Anti-Insulin Antibodies (AIA) up to Week 24,,,,,,,,,,,,,PRIMARY,Up to 24 weeks
trial,NCT01698775,NCT01698775,A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,213.0,2012-10-02,2016-01-19,0.0,0.0,,,,,
arm,NCT01698775::arm::FG000,NCT01698775,Omarigliptin (Phase A) → Omarigliptin (Phase B),,,,,,,,,,FG000,Phase A: omarigliptin 12.5 mg or 25 mg capsule orally once a week for 24 weeks. Phase B: omarigliptin 12.5 mg or 25 mg capsule orally once a week for 30 weeks. Participants who were not on background ,,,
arm,NCT01698775::arm::FG001,NCT01698775,Placebo to Omarigliptin (Phase A) → Glipizide (Phase B),,,,,,,,,,FG001,Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: matching placebo to omarigliptin orally once a week for 30 weeks. Participants who were not on background insulin th,,,
period,NCT01698775::period::1,NCT01698775,Phase A,,,,,,,,,,,,1.0,,
period,NCT01698775::period::2,NCT01698775,Phase B,,,,,,,,,,,,2.0,,
outcome,NCT01698775::outcome::primary::1,NCT01698775,Change From Baseline in Glycosylated Hemoglobin (A1C) at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and Week 24
outcome,NCT01698775::outcome::primary::2,NCT01698775,Percentage of Participants Who Experienced at Least One Adverse Event (Phase A: 24-week Placebo Controlled Period),,,,,,,,,,,,,PRIMARY,Up to 28 weeks (including 28 days following the last dose of study therapy for participants who discontinued study drug)
outcome,NCT01698775::outcome::primary::3,NCT01698775,Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (Phase A: 24-week Placebo Controlled Period),,,,,,,,,,,,,PRIMARY,Up to 24 weeks
outcome,NCT01698775::outcome::primary::4,NCT01698775,Percentage of Participants Who Experienced at Least One Adverse Event (Phase A: 24-week Placebo Controlled Period + Phase B: 30-week Active Controlled Period),,,,,,,,,,,,,PRIMARY,Up to 58 weeks (including 28 days following the last dose of study therapy)
outcome,NCT01698775::outcome::primary::5,NCT01698775,Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (Phase A: 24-week Placebo Controlled Period + Phase B: 30-week Active Controlled Period),,,,,,,,,,,,,PRIMARY,Up to 54 weeks
trial,NCT01499095,NCT01499095,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,811.0,2011-12,2013-11,13.0,213.0,,,,,
arm,NCT01499095::arm::FG000,NCT01499095,HOE901-U300,,,,,,,,,,FG000,HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily (evening) for 12 months in combination with oral antidiabetic drug(s).,,,
arm,NCT01499095::arm::FG001,NCT01499095,Lantus,,,,,,,,,,FG001,"Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months in combination with oral antidiabetic drug(s).",,,
period,NCT01499095::period::1,NCT01499095,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01499095::outcome::primary::1,NCT01499095,Change in HbA1c From Baseline to Month 6 Endpoint,,,,,,,,,,,,,PRIMARY,"Baseline, Month 6"
country,NCT01499095::country::United States,NCT01499095,United States,,,,,,,,,,,,,,
country,NCT01499095::country::Romania,NCT01499095,Romania,,,,,,,,,,,,,,
country,NCT01499095::country::Canada,NCT01499095,Canada,,,,,,,,,,,,,,
country,NCT01499095::country::Russia,NCT01499095,Russia,,,,,,,,,,,,,,
country,NCT01499095::country::Chile,NCT01499095,Chile,,,,,,,,,,,,,,
country,NCT01499095::country::Hungary,NCT01499095,Hungary,,,,,,,,,,,,,,
country,NCT01499095::country::South Africa,NCT01499095,South Africa,,,,,,,,,,,,,,
country,NCT01499095::country::Mexico,NCT01499095,Mexico,,,,,,,,,,,,,,
country,NCT01499095::country::France,NCT01499095,France,,,,,,,,,,,,,,
country,NCT01499095::country::Germany,NCT01499095,Germany,,,,,,,,,,,,,,
country,NCT01499095::country::Spain,NCT01499095,Spain,,,,,,,,,,,,,,
country,NCT01499095::country::Portugal,NCT01499095,Portugal,,,,,,,,,,,,,,
country,NCT01499095::country::Finland,NCT01499095,Finland,,,,,,,,,,,,,,
trial,NCT00680745,NCT00680745,Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,597.0,2008-04,2010-05,7.0,66.0,,,,,
arm,NCT00680745::arm::FG000,NCT00680745,Dapagliflozin 2.5mg + Glimepiride,,,,,,,,,,FG000,Dapagliflozin tablet 2.5 mg once daily plus glimepiride,,,
arm,NCT00680745::arm::FG001,NCT00680745,Dapagliflozin 5mg + Glimepiride,,,,,,,,,,FG001,Dapagliflozin tablet 5 mg once daily plus glimepiride,,,
arm,NCT00680745::arm::FG002,NCT00680745,Dapagliflozin 10mg + Glimepiride,,,,,,,,,,FG002,Dapagliflozin tablet 10 mg once daily plus glimepiride,,,
arm,NCT00680745::arm::FG003,NCT00680745,Placebo + Glimepiride,,,,,,,,,,FG003,Placebo comparator plus glimepiride,,,
period,NCT00680745::period::1,NCT00680745,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00680745::outcome::primary::1,NCT00680745,Adjusted Mean Change in HbA1c Levels,,,,,,,,,,,,,PRIMARY,Baseline to Week 24
country,NCT00680745::country::Poland,NCT00680745,Poland,,,,,,,,,,,,,,
country,NCT00680745::country::Hungary,NCT00680745,Hungary,,,,,,,,,,,,,,
country,NCT00680745::country::Czechia,NCT00680745,Czechia,,,,,,,,,,,,,,
country,NCT00680745::country::South Korea,NCT00680745,South Korea,,,,,,,,,,,,,,
country,NCT00680745::country::Ukraine,NCT00680745,Ukraine,,,,,,,,,,,,,,
country,NCT00680745::country::Philippines,NCT00680745,Philippines,,,,,,,,,,,,,,
country,NCT00680745::country::Thailand,NCT00680745,Thailand,,,,,,,,,,,,,,
trial,NCT00727857,NCT00727857,Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.,PHASE3,diabetes type 2,Diabetes Mellitus,INDUSTRY,600.0,2007-06,2008-08,4.0,77.0,,,,,
arm,NCT00727857::arm::FG000,NCT00727857,Pioglitazone 15 mg/Metformin 850 mg BID,,,,,,,,,,FG000,"Pioglitazone 15 mg /metformin 850 mg combination tablets, orally, twice daily for up to 24 weeks",,,
arm,NCT00727857::arm::FG001,NCT00727857,Pioglitazone 15 mg BID,,,,,,,,,,FG001,"Pioglitazone 15 mg, tablets, orally, twice daily for up to 24 weeks",,,
arm,NCT00727857::arm::FG002,NCT00727857,Metformin 850 mg BID,,,,,,,,,,FG002,"Metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.",,,
period,NCT00727857::period::1,NCT00727857,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00727857::outcome::primary::1,NCT00727857,Percent Change From Baseline in Glycosylated Hemoglobin,,,,,,,,,,,,,PRIMARY,Baseline and Week 24
country,NCT00727857::country::United States,NCT00727857,United States,,,,,,,,,,,,,,
country,NCT00727857::country::Puerto Rico,NCT00727857,Puerto Rico,,,,,,,,,,,,,,
country,NCT00727857::country::Chile,NCT00727857,Chile,,,,,,,,,,,,,,
country,NCT00727857::country::Mexico,NCT00727857,Mexico,,,,,,,,,,,,,,
trial,NCT00309244,NCT00309244,Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up,PHASE3,diabetes type 2,Diabetes Type 2,INDUSTRY,677.0,2006-02,2008-09,10.0,151.0,,,,,
arm,NCT00309244::arm::FG000,NCT00309244,TI + Insulin Glargine,,,,,,,,,,FG000,Technosphere® Insulin Inhalation Powder (administered at each meal) + subcutaneous insulin glargine (administered once daily at bedtime). Doses are individualized for each patient.,,,
arm,NCT00309244::arm::FG001,NCT00309244,BPR 70/30,,,,,,,,,,FG001,"70% insulin aspart protamine suspension and 30% insulin aspart subcutaneous injection (rDNA origin), administered twice daily (before breakfast and before main evening meal). Doses are individualized ",,,
period,NCT00309244::period::1,NCT00309244,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00309244::outcome::primary::1,NCT00309244,Change From Baseline in HbA1c to Week 52,,,,,,,,,,,,,PRIMARY,Baseline to Week 52
country,NCT00309244::country::United States,NCT00309244,United States,,,,,,,,,,,,,,
country,NCT00309244::country::Russia,NCT00309244,Russia,,,,,,,,,,,,,,
country,NCT00309244::country::Brazil,NCT00309244,Brazil,,,,,,,,,,,,,,
country,NCT00309244::country::Spain,NCT00309244,Spain,,,,,,,,,,,,,,
country,NCT00309244::country::Argentina,NCT00309244,Argentina,,,,,,,,,,,,,,
country,NCT00309244::country::Poland,NCT00309244,Poland,,,,,,,,,,,,,,
country,NCT00309244::country::Canada,NCT00309244,Canada,,,,,,,,,,,,,,
country,NCT00309244::country::Mexico,NCT00309244,Mexico,,,,,,,,,,,,,,
country,NCT00309244::country::Chile,NCT00309244,Chile,,,,,,,,,,,,,,
country,NCT00309244::country::United Kingdom,NCT00309244,United Kingdom,,,,,,,,,,,,,,
trial,NCT00763815,NCT00763815,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone",PHASE3,diabetes type 2,Diabetes Mellitus Type 2,INDUSTRY,484.0,2008-09,2011-06,13.0,150.0,,,,,
arm,NCT00763815::arm::FG000,NCT00763815,Placebo,,,,,,,,,,FG000,"2-step initiation regimen of volume matching placebo: 10 microgram (mcg) once daily (QD) subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.",,,
arm,NCT00763815::arm::FG001,NCT00763815,Lixisenatide,,,,,,,,,,FG001,"2-step initiation regimen of lixisenatide: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.",,,
period,NCT00763815::period::1,NCT00763815,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00763815::outcome::primary::1,NCT00763815,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
country,NCT00763815::country::United States,NCT00763815,United States,,,,,,,,,,,,,,
country,NCT00763815::country::Romania,NCT00763815,Romania,,,,,,,,,,,,,,
country,NCT00763815::country::Canada,NCT00763815,Canada,,,,,,,,,,,,,,
country,NCT00763815::country::Germany,NCT00763815,Germany,,,,,,,,,,,,,,
country,NCT00763815::country::Austria,NCT00763815,Austria,,,,,,,,,,,,,,
country,NCT00763815::country::France,NCT00763815,France,,,,,,,,,,,,,,
country,NCT00763815::country::Greece,NCT00763815,Greece,,,,,,,,,,,,,,
country,NCT00763815::country::Guatemala,NCT00763815,Guatemala,,,,,,,,,,,,,,
country,NCT00763815::country::India,NCT00763815,India,,,,,,,,,,,,,,
country,NCT00763815::country::Peru,NCT00763815,Peru,,,,,,,,,,,,,,
country,NCT00763815::country::Mexico,NCT00763815,Mexico,,,,,,,,,,,,,,
country,NCT00763815::country::Puerto Rico,NCT00763815,Puerto Rico,,,,,,,,,,,,,,
country,NCT00763815::country::Turkey (Türkiye),NCT00763815,Turkey (Türkiye),,,,,,,,,,,,,,
trial,NCT00393718,NCT00393718,Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,400.0,2006-11,2008-05,1.0,1.0,,,,,
arm,NCT00393718::arm::FG000,NCT00393718,Liraglutide,,,,,,,,,,FG000,Liraglutide 0.9 mg + glibenclamide placebo,,,
arm,NCT00393718::arm::FG001,NCT00393718,Glibenclamide,,,,,,,,,,FG001,Glibenclamide 1.25-2.5 mg + liraglutide placebo,,,
period,NCT00393718::period::1,NCT00393718,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00393718::outcome::primary::1,NCT00393718,Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment,,,,,,,,,,,,,PRIMARY,after 24 weeks of treatment
country,NCT00393718::country::Japan,NCT00393718,Japan,,,,,,,,,,,,,,
trial,NCT00289848,NCT00289848,MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,530.0,2006-03,2007-03,0.0,0.0,,,,,
arm,NCT00289848::arm::FG000,NCT00289848,Sitagliptin 100 mg,,,,,,,,,,FG000,The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily.,,,
arm,NCT00289848::arm::FG001,NCT00289848,Placebo,,,,,,,,,,FG001,The Placebo group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo once daily.,,,
period,NCT00289848::period::1,NCT00289848,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00289848::outcome::primary::1,NCT00289848,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 18,,,,,,,,,,,,,PRIMARY,Baseline and Week 18
trial,NCT03495102,NCT03495102,A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,1842.0,2018-04-05,2019-10-10,16.0,208.0,,,,,
arm,NCT03495102::arm::FG000,NCT03495102,Dulaglutide 1.5 mg,,,,,,,,,,FG000,Dulaglutide 1.5 mg administered subcutaneously (SC) once a week.,,,
arm,NCT03495102::arm::FG001,NCT03495102,Dulaglutide 3 mg,,,,,,,,,,FG001,Dulaglutide 3 mg administered SC once a week.,,,
arm,NCT03495102::arm::FG002,NCT03495102,Dulaglutide 4.5 mg,,,,,,,,,,FG002,Dulaglutide 4.5 mg administered SC once a week.,,,
period,NCT03495102::period::1,NCT03495102,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03495102::outcome::primary::1,NCT03495102,Change in Hemoglobin A1c (HbA1c) From Baseline,,,,,,,,,,,,,PRIMARY,"Baseline, Week 36"
country,NCT03495102::country::United States,NCT03495102,United States,,,,,,,,,,,,,,
country,NCT03495102::country::Argentina,NCT03495102,Argentina,,,,,,,,,,,,,,
country,NCT03495102::country::Romania,NCT03495102,Romania,,,,,,,,,,,,,,
country,NCT03495102::country::Poland,NCT03495102,Poland,,,,,,,,,,,,,,
country,NCT03495102::country::Spain,NCT03495102,Spain,,,,,,,,,,,,,,
country,NCT03495102::country::Greece,NCT03495102,Greece,,,,,,,,,,,,,,
country,NCT03495102::country::Hungary,NCT03495102,Hungary,,,,,,,,,,,,,,
country,NCT03495102::country::Israel,NCT03495102,Israel,,,,,,,,,,,,,,
country,NCT03495102::country::Italy,NCT03495102,Italy,,,,,,,,,,,,,,
country,NCT03495102::country::Slovakia,NCT03495102,Slovakia,,,,,,,,,,,,,,
country,NCT03495102::country::Austria,NCT03495102,Austria,,,,,,,,,,,,,,
country,NCT03495102::country::Canada,NCT03495102,Canada,,,,,,,,,,,,,,
country,NCT03495102::country::Russia,NCT03495102,Russia,,,,,,,,,,,,,,
country,NCT03495102::country::Puerto Rico,NCT03495102,Puerto Rico,,,,,,,,,,,,,,
country,NCT03495102::country::Taiwan,NCT03495102,Taiwan,,,,,,,,,,,,,,
country,NCT03495102::country::Mexico,NCT03495102,Mexico,,,,,,,,,,,,,,
trial,NCT00308737,NCT00308737,Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes, Type 1; Diabetes, Type 2",INDUSTRY,2053.0,2005-06,2008-10,8.0,176.0,,,,,
arm,NCT00308737::arm::FG000,NCT00308737,Technosphere® Insulin,,,,,,,,,,FG000,"Technosphere Insulin with or without basal insulin, or oral anti-diabetic medications, or any combination of the previous.",,,
arm,NCT00308737::arm::FG001,NCT00308737,Usual Care,,,,,,,,,,FG001,"Usual care may consist of oral anti-diabetic medications, basal insulin, subcutaneous prandial insulin, or any combination of the previous.",,,
arm,NCT00308737::arm::FG002,NCT00308737,Non-diabetes,,,,,,,,,,FG002,Subjects without abnormalities in glucose control,,,
period,NCT00308737::period::1,NCT00308737,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00308737::outcome::primary::1,NCT00308737,Change From Baseline to Month 24 in Forced Expiratory Volume in 1 Second (FEV1) by MMRM for TI vs Usual Care,,,,,,,,,,,,,PRIMARY,Baseline to Month 24
outcome,NCT00308737::outcome::primary::2,NCT00308737,FEV1 Decrease of ≥ 15% From Baseline Value at Last Measurement for TI vs Usual Care,,,,,,,,,,,,,PRIMARY,Baseline to Month 24
country,NCT00308737::country::United States,NCT00308737,United States,,,,,,,,,,,,,,
country,NCT00308737::country::Russia,NCT00308737,Russia,,,,,,,,,,,,,,
country,NCT00308737::country::Ukraine,NCT00308737,Ukraine,,,,,,,,,,,,,,
country,NCT00308737::country::Poland,NCT00308737,Poland,,,,,,,,,,,,,,
country,NCT00308737::country::United Kingdom,NCT00308737,United Kingdom,,,,,,,,,,,,,,
country,NCT00308737::country::Canada,NCT00308737,Canada,,,,,,,,,,,,,,
country,NCT00308737::country::Czechia,NCT00308737,Czechia,,,,,,,,,,,,,,
country,NCT00308737::country::Spain,NCT00308737,Spain,,,,,,,,,,,,,,
trial,NCT02054897,NCT02054897,Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,388.0,2014-02-03,2015-05-08,9.0,86.0,,,,,
arm,NCT02054897::arm::FG000,NCT02054897,Semaglutide 0.5 mg,,,,,,,,,,FG000,Subjects were given 0.25 mg semaglutide once weekly subcutaneous (s.c.; under the skin) injections for 4 weeks followed by 0.5 mg semaglutide once weekly for the remaining 26 weeks of the treatment pe,,,
arm,NCT02054897::arm::FG001,NCT02054897,Semaglutide 1.0 mg,,,,,,,,,,FG001,"Subjects were given 0.25 mg semaglutide once weekly s.c. injection for 4 weeks, 0.5 mg semaglutide once weekly s.c. injections for the next 4 weeks followed by 1.0 mg semaglutide once weekly s.c. inje",,,
arm,NCT02054897::arm::FG002,NCT02054897,Placebo,,,,,,,,,,FG002,"Subjects were randomised to either of the 2 placebo arms (i.e., semaglutide placebo 0.5 mg and semaglutide placebo 1.0 mg) and then pooled for data analysis.

1. Placebo 0.5 mg arm: Subjects were give",,,
period,NCT02054897::period::1,NCT02054897,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02054897::outcome::primary::1,NCT02054897,Change in HbA1c (Glycosylated Haemoglobin),,,,,,,,,,,,,PRIMARY,"Week 0, week 30"
country,NCT02054897::country::United States,NCT02054897,United States,,,,,,,,,,,,,,
country,NCT02054897::country::Russia,NCT02054897,Russia,,,,,,,,,,,,,,
country,NCT02054897::country::South Africa,NCT02054897,South Africa,,,,,,,,,,,,,,
country,NCT02054897::country::Canada,NCT02054897,Canada,,,,,,,,,,,,,,
country,NCT02054897::country::Italy,NCT02054897,Italy,,,,,,,,,,,,,,
country,NCT02054897::country::Japan,NCT02054897,Japan,,,,,,,,,,,,,,
country,NCT02054897::country::Romania,NCT02054897,Romania,,,,,,,,,,,,,,
country,NCT02054897::country::United Kingdom,NCT02054897,United Kingdom,,,,,,,,,,,,,,
country,NCT02054897::country::Mexico,NCT02054897,Mexico,,,,,,,,,,,,,,
trial,NCT01177813,NCT01177813,Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,986.0,2010-07,,9.0,124.0,,,,,
arm,NCT01177813::arm::FG000,NCT01177813,Placebo,,,,,,,,,,FG000,Patients receive tablets identical to those containing 10 mg and 25 mg Empagliflozin and to Sitagliptin 100 mg once daily in the morning.,,,
arm,NCT01177813::arm::FG001,NCT01177813,Empagliflozin10 mg,,,,,,,,,,FG001,Patients receive 10 mg Empagliflozin in tablets once daily in the morning.,,,
arm,NCT01177813::arm::FG002,NCT01177813,Empagliflozin 25 mg,,,,,,,,,,FG002,Patients receive 25 mg Empagliflozin in tablets once daily in the morning.,,,
arm,NCT01177813::arm::FG003,NCT01177813,Sitagliptin 100 mg,,,,,,,,,,FG003,Patients receive 100 mg Sitagliptin in tablets once daily in the morning.,,,
arm,NCT01177813::arm::FG004,NCT01177813,Empagliflozin 25 mg OL,,,,,,,,,,FG004,Patients receive 25 mg Empagliflozin in tablets open label (OL) once daily in the morning.,,,
period,NCT01177813::period::1,NCT01177813,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01177813::outcome::primary::1,NCT01177813,Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 24 Weeks,,,,,,,,,,,,,PRIMARY,Baseline and day 169
country,NCT01177813::country::United States,NCT01177813,United States,,,,,,,,,,,,,,
country,NCT01177813::country::China,NCT01177813,China,,,,,,,,,,,,,,
country,NCT01177813::country::Canada,NCT01177813,Canada,,,,,,,,,,,,,,
country,NCT01177813::country::Belgium,NCT01177813,Belgium,,,,,,,,,,,,,,
country,NCT01177813::country::Japan,NCT01177813,Japan,,,,,,,,,,,,,,
country,NCT01177813::country::Germany,NCT01177813,Germany,,,,,,,,,,,,,,
country,NCT01177813::country::India,NCT01177813,India,,,,,,,,,,,,,,
country,NCT01177813::country::Ireland,NCT01177813,Ireland,,,,,,,,,,,,,,
country,NCT01177813::country::Switzerland,NCT01177813,Switzerland,,,,,,,,,,,,,,
trial,NCT01195662,NCT01195662,A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,2245.0,2010-10,2013-02,16.0,298.0,,,,,
arm,NCT01195662::arm::FG000,NCT01195662,Placebo Matching Dapagliflozin,,,,,,,,,,FG000,"Placebo matching dapagliflozin: Tablets, Oral, 0 mg, once daily, Up to 12 weeks. Non-investigational medications used in this study were antidiabetic drug(s), including oral antidiabetic drugs and ins",,,
arm,NCT01195662::arm::FG001,NCT01195662,Dapagliflozin 10 mg,,,,,,,,,,FG001,"Dapagliflozin: Tablets, Oral, 10 mg, once daily, Up to 12 weeks. Non-investigational medications used in this study were antidiabetic drug(s), including oral antidiabetic drugs and insulin, angiotensi",,,
arm,NCT01195662::arm::FG002,NCT01195662,Dagagliflozin 5 mg (Arm Discontinued With Amendment 8),,,,,,,,,,FG002,"Dapagliflozin: Tablets, Oral, 5 mg, once a day for up to12 weeks. Non-investigational medications used in this study were antidiabetic drug(s), including oral antidiabetic drugs and insulin, angiotens",,,
period,NCT01195662::period::1,NCT01195662,Double Blind Treatment Period,,,,,,,,,,,,1.0,,
period,NCT01195662::period::2,NCT01195662,Follow-Up(Week 13/1 Week Post Last Dose),,,,,,,,,,,,2.0,,
outcome,NCT01195662::outcome::primary::1,NCT01195662,Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure for 12 Week Double-Blind Treatment Period - Randomized Participants,,,,,,,,,,,,,PRIMARY,Baseline to Week 12
outcome,NCT01195662::outcome::primary::2,NCT01195662,Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) for 12 Week Double-Blind Treatment Period - Randomized Participants,,,,,,,,,,,,,PRIMARY,Baseline to Week 12
country,NCT01195662::country::United States,NCT01195662,United States,,,,,,,,,,,,,,
country,NCT01195662::country::Poland,NCT01195662,Poland,,,,,,,,,,,,,,
country,NCT01195662::country::India,NCT01195662,India,,,,,,,,,,,,,,
country,NCT01195662::country::Germany,NCT01195662,Germany,,,,,,,,,,,,,,
country,NCT01195662::country::Mexico,NCT01195662,Mexico,,,,,,,,,,,,,,
country,NCT01195662::country::Romania,NCT01195662,Romania,,,,,,,,,,,,,,
country,NCT01195662::country::Hungary,NCT01195662,Hungary,,,,,,,,,,,,,,
country,NCT01195662::country::Czechia,NCT01195662,Czechia,,,,,,,,,,,,,,
country,NCT01195662::country::Canada,NCT01195662,Canada,,,,,,,,,,,,,,
country,NCT01195662::country::Colombia,NCT01195662,Colombia,,,,,,,,,,,,,,
country,NCT01195662::country::Denmark,NCT01195662,Denmark,,,,,,,,,,,,,,
country,NCT01195662::country::Finland,NCT01195662,Finland,,,,,,,,,,,,,,
country,NCT01195662::country::United Kingdom,NCT01195662,United Kingdom,,,,,,,,,,,,,,
country,NCT01195662::country::Australia,NCT01195662,Australia,,,,,,,,,,,,,,
country,NCT01195662::country::Puerto Rico,NCT01195662,Puerto Rico,,,,,,,,,,,,,,
country,NCT01195662::country::Ireland,NCT01195662,Ireland,,,,,,,,,,,,,,
trial,NCT01392573,NCT01392573,A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,413.0,2011-11-28,2012-10-04,7.0,86.0,,,,,
arm,NCT01392573::arm::FG000,NCT01392573,IDegLira,,,,,,,,,,FG000,"Insulin degludec/liraglutide (IDegLira) was injected subcutaneously (under the skin) once daily for 26 weeks in combination with metformin treatment. Metformin dose was maintained at the stable, pre-r",,,
arm,NCT01392573::arm::FG001,NCT01392573,IDeg,,,,,,,,,,FG001,"Insulin degludec (IDeg) was injected subcutaneously (under the skin) once daily for 26 weeks. Metformin dose was maintained at the stable, pre-randomisation dose and frequency level. Treatment with ID",,,
period,NCT01392573::period::1,NCT01392573,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01392573::outcome::primary::1,NCT01392573,Change From Baseline in HbA1c (Glycosylated Haemoglobin),,,,,,,,,,,,,PRIMARY,"Week 0, week 26"
country,NCT01392573::country::United States,NCT01392573,United States,,,,,,,,,,,,,,
country,NCT01392573::country::Bulgaria,NCT01392573,Bulgaria,,,,,,,,,,,,,,
country,NCT01392573::country::India,NCT01392573,India,,,,,,,,,,,,,,
country,NCT01392573::country::Switzerland,NCT01392573,Switzerland,,,,,,,,,,,,,,
country,NCT01392573::country::Hungary,NCT01392573,Hungary,,,,,,,,,,,,,,
country,NCT01392573::country::Denmark,NCT01392573,Denmark,,,,,,,,,,,,,,
country,NCT01392573::country::Slovenia,NCT01392573,Slovenia,,,,,,,,,,,,,,
trial,NCT00184600,NCT00184600,"Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes",PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,708.0,2004-11,2009-08,2.0,63.0,,,,,
arm,NCT00184600::arm::FG000,NCT00184600,Insulin Detemir (Basal Insulin),,,,,,,,,,FG000,"Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measuremen",,,
arm,NCT00184600::arm::FG001,NCT00184600,Insulin Aspart (Prandial Insulin),,,,,,,,,,FG001,"Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two c",,,
arm,NCT00184600::arm::FG002,NCT00184600,Biphasic Insulin Aspart 30 (Biphasic Insulin),,,,,,,,,,FG002,Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. At week 24 and therea,,,
period,NCT00184600::period::1,NCT00184600,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00184600::outcome::primary::1,NCT00184600,HbA1c (Glycosylated Haemoglobin) at Month 12,,,,,,,,,,,,,PRIMARY,"Baseline, Month 12"
outcome,NCT00184600::outcome::primary::2,NCT00184600,HbA1c (Glycosylated Haemoglobin) at Month 36,,,,,,,,,,,,,PRIMARY,"Baseline, Month 36"
country,NCT00184600::country::United Kingdom,NCT00184600,United Kingdom,,,,,,,,,,,,,,
country,NCT00184600::country::Ireland,NCT00184600,Ireland,,,,,,,,,,,,,,
trial,NCT00976391,NCT00976391,A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,586.0,2009-09,2012-05,14.0,209.0,,,,,
arm,NCT00976391::arm::FG000,NCT00976391,Albiglutide 30 mg With Insulin Glargine,,,,,,,,,,FG000,Participants received albiglutide 30 milligrams (mg) as a subcutaneous injection weekly (with uptitration to 50 mg weekly if needed) via a fully disposable pen injector system combined with insulin gl,,,
arm,NCT00976391::arm::FG001,NCT00976391,Preprandial Lispro Insulin With Insulin Glargine,,,,,,,,,,FG001,Participants received a combination of insulin glargine (with uptitration if needed) and preprandial lispro insulin (with uptitration as appropriate) as prescribed by their physician.Participants did ,,,
period,NCT00976391::period::1,NCT00976391,Treatment Period (52 Weeks),,,,,,,,,,,,1.0,,
period,NCT00976391::period::2,NCT00976391,Follow-up Period (8 Weeks),,,,,,,,,,,,2.0,,
outcome,NCT00976391::outcome::primary::1,NCT00976391,Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 26,,,,,,,,,,,,,PRIMARY,Baseline and Week 26
country,NCT00976391::country::United States,NCT00976391,United States,,,,,,,,,,,,,,
country,NCT00976391::country::South Africa,NCT00976391,South Africa,,,,,,,,,,,,,,
country,NCT00976391::country::South Korea,NCT00976391,South Korea,,,,,,,,,,,,,,
country,NCT00976391::country::Philippines,NCT00976391,Philippines,,,,,,,,,,,,,,
country,NCT00976391::country::Spain,NCT00976391,Spain,,,,,,,,,,,,,,
country,NCT00976391::country::India,NCT00976391,India,,,,,,,,,,,,,,
country,NCT00976391::country::Peru,NCT00976391,Peru,,,,,,,,,,,,,,
country,NCT00976391::country::Taiwan,NCT00976391,Taiwan,,,,,,,,,,,,,,
country,NCT00976391::country::Germany,NCT00976391,Germany,,,,,,,,,,,,,,
country,NCT00976391::country::United Kingdom,NCT00976391,United Kingdom,,,,,,,,,,,,,,
country,NCT00976391::country::Brazil,NCT00976391,Brazil,,,,,,,,,,,,,,
country,NCT00976391::country::Mexico,NCT00976391,Mexico,,,,,,,,,,,,,,
country,NCT00976391::country::France,NCT00976391,France,,,,,,,,,,,,,,
country,NCT00976391::country::Hong Kong,NCT00976391,Hong Kong,,,,,,,,,,,,,,
trial,NCT00960661,NCT00960661,"A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes",PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,1036.0,2009-09,2012-08,18.0,95.0,,,,,
arm,NCT00960661::arm::FG000,NCT00960661,Enrolled,,,,,,,,,,FG000,Patients who enrolled in the basal insulin optimization (BIO) phase,,,
arm,NCT00960661::arm::FG001,NCT00960661,Exenatide (BET),,,,,,,,,,FG001,"Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET)",,,
arm,NCT00960661::arm::FG002,NCT00960661,Insulin Lispro (BBT),,,,,,,,,,FG002,"Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT)",,,
period,NCT00960661::period::1,NCT00960661,Basal Insulin Optimization Phase (BIO),,,,,,,,,,,,1.0,,
period,NCT00960661::period::2,NCT00960661,Interventional Phase,,,,,,,,,,,,2.0,,
outcome,NCT00960661::outcome::primary::1,NCT00960661,Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 30,,,,,,,,,,,,,PRIMARY,"Baseline, 30 weeks"
country,NCT00960661::country::France,NCT00960661,France,,,,,,,,,,,,,,
country,NCT00960661::country::Argentina,NCT00960661,Argentina,,,,,,,,,,,,,,
country,NCT00960661::country::Germany,NCT00960661,Germany,,,,,,,,,,,,,,
country,NCT00960661::country::Netherlands,NCT00960661,Netherlands,,,,,,,,,,,,,,
country,NCT00960661::country::Sweden,NCT00960661,Sweden,,,,,,,,,,,,,,
country,NCT00960661::country::Italy,NCT00960661,Italy,,,,,,,,,,,,,,
country,NCT00960661::country::Romania,NCT00960661,Romania,,,,,,,,,,,,,,
country,NCT00960661::country::Spain,NCT00960661,Spain,,,,,,,,,,,,,,
country,NCT00960661::country::United Kingdom,NCT00960661,United Kingdom,,,,,,,,,,,,,,
country,NCT00960661::country::Belgium,NCT00960661,Belgium,,,,,,,,,,,,,,
country,NCT00960661::country::Mexico,NCT00960661,Mexico,,,,,,,,,,,,,,
country,NCT00960661::country::Finland,NCT00960661,Finland,,,,,,,,,,,,,,
country,NCT00960661::country::Portugal,NCT00960661,Portugal,,,,,,,,,,,,,,
country,NCT00960661::country::Russia,NCT00960661,Russia,,,,,,,,,,,,,,
country,NCT00960661::country::South Korea,NCT00960661,South Korea,,,,,,,,,,,,,,
country,NCT00960661::country::Estonia,NCT00960661,Estonia,,,,,,,,,,,,,,
country,NCT00960661::country::Greece,NCT00960661,Greece,,,,,,,,,,,,,,
country,NCT00960661::country::Puerto Rico,NCT00960661,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00654381,NCT00654381,Japanese P III vs Voglibose and Placebo,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,561.0,2008-04,,1.0,47.0,,,,,
arm,NCT00654381::arm::FG000,NCT00654381,Placebo - BI1356 (Linagliptin) 5mg - Linagliptin 5mg,,,,,,,,,,FG000,Placebo in Stage 1 - 5 mg in Stage 2 - 5 mg in Stage 3,,,
arm,NCT00654381::arm::FG001,NCT00654381,Placebo - Linagliptin 5mg - Linagliptin 10mg,,,,,,,,,,FG001,Placebo in Stage 1 - 10 mg in Stage 2 - 10 mg in Stage 3,,,
arm,NCT00654381::arm::FG002,NCT00654381,Linagliptin 5mg - Linagliptin 5mg - Linagliptin 5mg,,,,,,,,,,FG002,5 mg in Stage 1 - 5 mg in Stage 2 - 5 mg in Stage 3,,,
arm,NCT00654381::arm::FG003,NCT00654381,Linagliptin 10 mg - Linagliptin 10 mg - Linagliptin 10 mg,,,,,,,,,,FG003,10 mg in Stage 1 - 10 mg in Stage 2 - 10 mg in Stage 3,,,
arm,NCT00654381::arm::FG004,NCT00654381,Voglibose - Voglibose - Linagliptin 5mg,,,,,,,,,,FG004,Voglibose in Stage 1 - Voglibose in Stage 2 - 5 mg in Stage 3,,,
arm,NCT00654381::arm::FG005,NCT00654381,Voglibose - Voglibose - Linagliptin 10mg,,,,,,,,,,FG005,Voglibose in Stage 1 - Voglibose in Stage 2 - 10 mg in Stage 3,,,
period,NCT00654381::period::1,NCT00654381,1st Stage,,,,,,,,,,,,1.0,,
period,NCT00654381::period::2,NCT00654381,2nd Stage,,,,,,,,,,,,2.0,,
period,NCT00654381::period::3,NCT00654381,Extension Stage,,,,,,,,,,,,3.0,,
outcome,NCT00654381::outcome::primary::1,NCT00654381,Change From Baseline in HbA1c at Week 12,,,,,,,,,,,,,PRIMARY,12 weeks
outcome,NCT00654381::outcome::primary::2,NCT00654381,Change From Baseline in HbA1c at Week 26,,,,,,,,,,,,,PRIMARY,26 weeks
outcome,NCT00654381::outcome::primary::3,NCT00654381,Examination of Long-term Safety of Linagliptin (52-week Treatment),,,,,,,,,,,,,PRIMARY,52 weeks
country,NCT00654381::country::Japan,NCT00654381,Japan,,,,,,,,,,,,,,
trial,NCT00982644,NCT00982644,Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,1030.0,2009-09,2010-12,15.0,187.0,,,,,
arm,NCT00982644::arm::FG000,NCT00982644,IDeg OD,,,,,,,,,,FG000,Insulin degludec (IDeg) was given subcutaneously (s.c) once daily (OD) with the main evening meal in combination with metformin with or without DPP-IV inhibitors. IDeg was given for 52 weeks in the ma,,,
arm,NCT00982644::arm::FG001,NCT00982644,IGlar OD,,,,,,,,,,FG001,"Insulin glargine (IGlar) was given subcutaneously (s.c) once daily (OD), according to the local labelling in combination with metformin with or without DPP-IV inhibitors. IGlar was given for 52 weeks ",,,
period,NCT00982644::period::1,NCT00982644,Main: Week 0 to 52 (NN1250-3579),,,,,,,,,,,,1.0,,
period,NCT00982644::period::2,NCT00982644,Extension: Week 53 to 104 (NN1250-3643),,,,,,,,,,,,2.0,,
outcome,NCT00982644::outcome::primary::1,NCT00982644,Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment,,,,,,,,,,,,,PRIMARY,"Week 0, Week 52"
outcome,NCT00982644::outcome::primary::2,NCT00982644,Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes,,,,,,,,,,,,,PRIMARY,Week 0 to Week 104 + 7 days follow up
outcome,NCT00982644::outcome::primary::3,NCT00982644,Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,,,,,,,,,,,,PRIMARY,Week 0 to Week 104 + 7 days follow up
outcome,NCT00982644::outcome::primary::4,NCT00982644,Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs),,,,,,,,,,,,,PRIMARY,Week 0 to Week 104 + 7 days of follow up
country,NCT00982644::country::United States,NCT00982644,United States,,,,,,,,,,,,,,
country,NCT00982644::country::Germany,NCT00982644,Germany,,,,,,,,,,,,,,
country,NCT00982644::country::Canada,NCT00982644,Canada,,,,,,,,,,,,,,
country,NCT00982644::country::Spain,NCT00982644,Spain,,,,,,,,,,,,,,
country,NCT00982644::country::Norway,NCT00982644,Norway,,,,,,,,,,,,,,
country,NCT00982644::country::Austria,NCT00982644,Austria,,,,,,,,,,,,,,
country,NCT00982644::country::France,NCT00982644,France,,,,,,,,,,,,,,
country,NCT00982644::country::Denmark,NCT00982644,Denmark,,,,,,,,,,,,,,
country,NCT00982644::country::Finland,NCT00982644,Finland,,,,,,,,,,,,,,
country,NCT00982644::country::Belgium,NCT00982644,Belgium,,,,,,,,,,,,,,
country,NCT00982644::country::Czechia,NCT00982644,Czechia,,,,,,,,,,,,,,
country,NCT00982644::country::Serbia and Montenegro,NCT00982644,Serbia and Montenegro,,,,,,,,,,,,,,
country,NCT00982644::country::Serbia,NCT00982644,Serbia,,,,,,,,,,,,,,
country,NCT00982644::country::Slovenia,NCT00982644,Slovenia,,,,,,,,,,,,,,
country,NCT00982644::country::Puerto Rico,NCT00982644,Puerto Rico,,,,,,,,,,,,,,
trial,NCT03332771,NCT03332771,Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,954.0,2017-12-01,2019-09-06,4.0,142.0,,,,,
arm,NCT03332771::arm::FG000,NCT03332771,Placebo,,,,,,,,,,FG000,"Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind",,,
arm,NCT03332771::arm::FG001,NCT03332771,Sotagliflozin 400 mg,,,,,,,,,,FG001,"Following a 2-week run-in period, two Sotagliflozin 200 mg, tablets, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatme",,,
arm,NCT03332771::arm::FG002,NCT03332771,Sotagliflozin 200 mg,,,,,,,,,,FG002,"Following a 2-week run-in period, one Sotagliflozin 200 mg, tablet and one Sotagliflozin-matching placebo tablet, and two Glimepiride-matching placebo capsules, taken orally once daily before the firs",,,
arm,NCT03332771::arm::FG003,NCT03332771,Glimepiride,,,,,,,,,,FG003,"Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets, and combination of two Glimepiride capsules with adequate dose strengths per dose titration (titrated up to 6mg), taken or",,,
period,NCT03332771::period::1,NCT03332771,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03332771::outcome::primary::1,NCT03332771,Change From Baseline in Hemoglobin A1c at Week 52,,,,,,,,,,,,,PRIMARY,"Baseline, Week 52"
country,NCT03332771::country::United States,NCT03332771,United States,,,,,,,,,,,,,,
country,NCT03332771::country::Slovakia,NCT03332771,Slovakia,,,,,,,,,,,,,,
country,NCT03332771::country::Bulgaria,NCT03332771,Bulgaria,,,,,,,,,,,,,,
country,NCT03332771::country::Hungary,NCT03332771,Hungary,,,,,,,,,,,,,,
trial,NCT00485758,NCT00485758,Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069),PHASE3,diabetes type 2,Diabetes Mellitus Type 2,INDUSTRY,796.0,2007-07,2008-08,0.0,0.0,,,,,
arm,NCT00485758::arm::FG000,NCT00485758,Extended Release Niacin/Laropiprant,,,,,,,,,,FG000,"One tablet of Extended Release Niacin/Laropiprant (1 gram/20 milligram) in addition to lipid modifying therapy. After 4 weeks, advanced to Extended Release Niacin/Laropiprant (2 gram/40 milligram).

N",,,
arm,NCT00485758::arm::FG001,NCT00485758,Placebo,,,,,,,,,,FG001,Matching placebo added to lipid modifying regimen and continued on this regimen for remainder of the study.,,,
period,NCT00485758::period::1,NCT00485758,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00485758::outcome::primary::1,NCT00485758,Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes When Compared to Placebo,,,,,,,,,,,,,PRIMARY,Baseline and 12 Weeks
trial,NCT01131676,NCT01131676,BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,7064.0,2010-07,2015-04,42.0,615.0,,,,,
arm,NCT01131676::arm::FG000,NCT01131676,Placebo,,,,,,,,,,FG000,Oral administration of Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily),,,
arm,NCT01131676::arm::FG001,NCT01131676,Empagliflozin 10 mg,,,,,,,,,,FG001,Oral administration of Empagliflozin 10 mg (BI 10773) film coated tablets (1 tablet once daily),,,
arm,NCT01131676::arm::FG002,NCT01131676,Empagliflozin 25 mg,,,,,,,,,,FG002,Oral administration of Empagliflozin 25 mg (BI 10773) film coated tablets (1 tablet once daily),,,
period,NCT01131676::period::1,NCT01131676,Discontinuation From Treatment,,,,,,,,,,,,1.0,,
period,NCT01131676::period::2,NCT01131676,Discontinuation From Study (Treated Set),,,,,,,,,,,,2.0,,
outcome,NCT01131676::outcome::primary::1,NCT01131676,"Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke.",,,,,,,,,,,,,PRIMARY,"From randomisation to individual end of observation, up to 4.6 years"
country,NCT01131676::country::United States,NCT01131676,United States,,,,,,,,,,,,,,
country,NCT01131676::country::Brazil,NCT01131676,Brazil,,,,,,,,,,,,,,
country,NCT01131676::country::Russia,NCT01131676,Russia,,,,,,,,,,,,,,
country,NCT01131676::country::Spain,NCT01131676,Spain,,,,,,,,,,,,,,
country,NCT01131676::country::South Africa,NCT01131676,South Africa,,,,,,,,,,,,,,
country,NCT01131676::country::Netherlands,NCT01131676,Netherlands,,,,,,,,,,,,,,
country,NCT01131676::country::India,NCT01131676,India,,,,,,,,,,,,,,
country,NCT01131676::country::South Korea,NCT01131676,South Korea,,,,,,,,,,,,,,
country,NCT01131676::country::Belgium,NCT01131676,Belgium,,,,,,,,,,,,,,
country,NCT01131676::country::France,NCT01131676,France,,,,,,,,,,,,,,
country,NCT01131676::country::Italy,NCT01131676,Italy,,,,,,,,,,,,,,
country,NCT01131676::country::Japan,NCT01131676,Japan,,,,,,,,,,,,,,
country,NCT01131676::country::Portugal,NCT01131676,Portugal,,,,,,,,,,,,,,
country,NCT01131676::country::Canada,NCT01131676,Canada,,,,,,,,,,,,,,
country,NCT01131676::country::United Kingdom,NCT01131676,United Kingdom,,,,,,,,,,,,,,
country,NCT01131676::country::Argentina,NCT01131676,Argentina,,,,,,,,,,,,,,
country,NCT01131676::country::Peru,NCT01131676,Peru,,,,,,,,,,,,,,
country,NCT01131676::country::Poland,NCT01131676,Poland,,,,,,,,,,,,,,
country,NCT01131676::country::Austria,NCT01131676,Austria,,,,,,,,,,,,,,
country,NCT01131676::country::Malaysia,NCT01131676,Malaysia,,,,,,,,,,,,,,
country,NCT01131676::country::Philippines,NCT01131676,Philippines,,,,,,,,,,,,,,
country,NCT01131676::country::Taiwan,NCT01131676,Taiwan,,,,,,,,,,,,,,
country,NCT01131676::country::Romania,NCT01131676,Romania,,,,,,,,,,,,,,
country,NCT01131676::country::Georgia,NCT01131676,Georgia,,,,,,,,,,,,,,
country,NCT01131676::country::Greece,NCT01131676,Greece,,,,,,,,,,,,,,
country,NCT01131676::country::Hungary,NCT01131676,Hungary,,,,,,,,,,,,,,
country,NCT01131676::country::Indonesia,NCT01131676,Indonesia,,,,,,,,,,,,,,
country,NCT01131676::country::Norway,NCT01131676,Norway,,,,,,,,,,,,,,
country,NCT01131676::country::Colombia,NCT01131676,Colombia,,,,,,,,,,,,,,
country,NCT01131676::country::Israel,NCT01131676,Israel,,,,,,,,,,,,,,
country,NCT01131676::country::Mexico,NCT01131676,Mexico,,,,,,,,,,,,,,
country,NCT01131676::country::Ukraine,NCT01131676,Ukraine,,,,,,,,,,,,,,
country,NCT01131676::country::Croatia,NCT01131676,Croatia,,,,,,,,,,,,,,
country,NCT01131676::country::Denmark,NCT01131676,Denmark,,,,,,,,,,,,,,
country,NCT01131676::country::Sri Lanka,NCT01131676,Sri Lanka,,,,,,,,,,,,,,
country,NCT01131676::country::Thailand,NCT01131676,Thailand,,,,,,,,,,,,,,
country,NCT01131676::country::Estonia,NCT01131676,Estonia,,,,,,,,,,,,,,
country,NCT01131676::country::Czechia,NCT01131676,Czechia,,,,,,,,,,,,,,
country,NCT01131676::country::Hong Kong,NCT01131676,Hong Kong,,,,,,,,,,,,,,
country,NCT01131676::country::Australia,NCT01131676,Australia,,,,,,,,,,,,,,
country,NCT01131676::country::New Zealand,NCT01131676,New Zealand,,,,,,,,,,,,,,
country,NCT01131676::country::Singapore,NCT01131676,Singapore,,,,,,,,,,,,,,
trial,NCT01106625,NCT01106625,The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea),PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,469.0,2010-05,2012-04,12.0,76.0,,,,,
arm,NCT01106625::arm::FG000,NCT01106625,Placebo,,,,,,,,,,FG000,Each patient received matching placebo once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.,,,
arm,NCT01106625::arm::FG001,NCT01106625,Canagliflozin 100 mg,,,,,,,,,,FG001,Each patient received 100 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.,,,
arm,NCT01106625::arm::FG002,NCT01106625,Canagliflozin 300 mg,,,,,,,,,,FG002,Each patient received 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.,,,
period,NCT01106625::period::1,NCT01106625,Core Period: Baseline to Week 26,,,,,,,,,,,,1.0,,
period,NCT01106625::period::2,NCT01106625,Extension Period: Week 26 to Week 52,,,,,,,,,,,,2.0,,
outcome,NCT01106625::outcome::primary::1,NCT01106625,Change in HbA1c From Baseline to Week 26,,,,,,,,,,,,,PRIMARY,Day 1 (Baseline) and Week 26
country,NCT01106625::country::United States,NCT01106625,United States,,,,,,,,,,,,,,
country,NCT01106625::country::Australia,NCT01106625,Australia,,,,,,,,,,,,,,
country,NCT01106625::country::France,NCT01106625,France,,,,,,,,,,,,,,
country,NCT01106625::country::Spain,NCT01106625,Spain,,,,,,,,,,,,,,
country,NCT01106625::country::Belgium,NCT01106625,Belgium,,,,,,,,,,,,,,
country,NCT01106625::country::Hungary,NCT01106625,Hungary,,,,,,,,,,,,,,
country,NCT01106625::country::Israel,NCT01106625,Israel,,,,,,,,,,,,,,
country,NCT01106625::country::United Kingdom,NCT01106625,United Kingdom,,,,,,,,,,,,,,
country,NCT01106625::country::Russia,NCT01106625,Russia,,,,,,,,,,,,,,
country,NCT01106625::country::Mexico,NCT01106625,Mexico,,,,,,,,,,,,,,
country,NCT01106625::country::Puerto Rico,NCT01106625,Puerto Rico,,,,,,,,,,,,,,
country,NCT01106625::country::Guatemala,NCT01106625,Guatemala,,,,,,,,,,,,,,
trial,NCT00715624,NCT00715624,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin",PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,496.0,2008-07,2011-02,15.0,15.0,,,,,
arm,NCT00715624::arm::FG000,NCT00715624,Placebo,,,,,,,,,,FG000,"2-step initiation regimen of volume matching placebo: 10 microgram (mcg) once daily (QD) subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.",,,
arm,NCT00715624::arm::FG001,NCT00715624,Lixisenatide,,,,,,,,,,FG001,"2-step initiation regimen of lixisenatide: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.",,,
period,NCT00715624::period::1,NCT00715624,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00715624::outcome::primary::1,NCT00715624,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
country,NCT00715624::country::United States,NCT00715624,United States,,,,,,,,,,,,,,
country,NCT00715624::country::Brazil,NCT00715624,Brazil,,,,,,,,,,,,,,
country,NCT00715624::country::Canada,NCT00715624,Canada,,,,,,,,,,,,,,
country,NCT00715624::country::Chile,NCT00715624,Chile,,,,,,,,,,,,,,
country,NCT00715624::country::Egypt,NCT00715624,Egypt,,,,,,,,,,,,,,
country,NCT00715624::country::France,NCT00715624,France,,,,,,,,,,,,,,
country,NCT00715624::country::Germany,NCT00715624,Germany,,,,,,,,,,,,,,
country,NCT00715624::country::India,NCT00715624,India,,,,,,,,,,,,,,
country,NCT00715624::country::Italy,NCT00715624,Italy,,,,,,,,,,,,,,
country,NCT00715624::country::Mexico,NCT00715624,Mexico,,,,,,,,,,,,,,
country,NCT00715624::country::Puerto Rico,NCT00715624,Puerto Rico,,,,,,,,,,,,,,
country,NCT00715624::country::Russia,NCT00715624,Russia,,,,,,,,,,,,,,
country,NCT00715624::country::South Korea,NCT00715624,South Korea,,,,,,,,,,,,,,
country,NCT00715624::country::Turkey (Türkiye),NCT00715624,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00715624::country::United Kingdom,NCT00715624,United Kingdom,,,,,,,,,,,,,,
trial,NCT03199053,NCT03199053,Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,256.0,2017-10-11,2024-01-03,23.0,122.0,,,,,
arm,NCT03199053::arm::FG000,NCT03199053,Dapagliflozin,,,,,,,,,,FG000,"Participants were randomised to receive dapagliflozin 5 mg administered orally once daily (low-dose). At Week 14, participants with Week 12 glycated haemoglobin (HbA1c) values \< 7% remained on low-do",,,
arm,NCT03199053::arm::FG001,NCT03199053,Saxagliptin,,,,,,,,,,FG001,"Participants were randomised to receive saxagliptin 2.5 mg administered orally once daily (low-dose). At Week 14, participants with Week 12 HbA1c values \< 7% remained on low-dose saxagliptin. Partici",,,
arm,NCT03199053::arm::FG002,NCT03199053,Placebo,,,,,,,,,,FG002,"Participants were randomised to receive placebo administered orally once daily. At Week 14, all participants continued on placebo. To maintain blinding, all participants underwent a dummy second rando",,,
period,NCT03199053::period::1,NCT03199053,ST Period,,,,,,,,,,,,1.0,,
period,NCT03199053::period::2,NCT03199053,LT Period,,,,,,,,,,,,2.0,,
period,NCT03199053::period::3,NCT03199053,Non-treatment Follow-up Period,,,,,,,,,,,,3.0,,
outcome,NCT03199053::outcome::primary::1,NCT03199053,Dapagliflozin Versus Placebo: Adjusted Mean Change From Baseline in HbA1c at Week 26,,,,,,,,,,,,,PRIMARY,Baseline and Week 26
outcome,NCT03199053::outcome::primary::2,NCT03199053,Saxagliptin Versus Placebo: Adjusted Mean Change From Baseline in HbA1c at Week 26,,,,,,,,,,,,,PRIMARY,Baseline and Week 26
country,NCT03199053::country::United States,NCT03199053,United States,,,,,,,,,,,,,,
country,NCT03199053::country::Mexico,NCT03199053,Mexico,,,,,,,,,,,,,,
country,NCT03199053::country::India,NCT03199053,India,,,,,,,,,,,,,,
country,NCT03199053::country::Malaysia,NCT03199053,Malaysia,,,,,,,,,,,,,,
country,NCT03199053::country::Brazil,NCT03199053,Brazil,,,,,,,,,,,,,,
country,NCT03199053::country::Turkey (Türkiye),NCT03199053,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT03199053::country::Argentina,NCT03199053,Argentina,,,,,,,,,,,,,,
country,NCT03199053::country::United Kingdom,NCT03199053,United Kingdom,,,,,,,,,,,,,,
country,NCT03199053::country::Italy,NCT03199053,Italy,,,,,,,,,,,,,,
country,NCT03199053::country::New Zealand,NCT03199053,New Zealand,,,,,,,,,,,,,,
country,NCT03199053::country::Philippines,NCT03199053,Philippines,,,,,,,,,,,,,,
country,NCT03199053::country::Russia,NCT03199053,Russia,,,,,,,,,,,,,,
country,NCT03199053::country::South Korea,NCT03199053,South Korea,,,,,,,,,,,,,,
country,NCT03199053::country::Ukraine,NCT03199053,Ukraine,,,,,,,,,,,,,,
country,NCT03199053::country::Colombia,NCT03199053,Colombia,,,,,,,,,,,,,,
country,NCT03199053::country::Taiwan,NCT03199053,Taiwan,,,,,,,,,,,,,,
country,NCT03199053::country::Thailand,NCT03199053,Thailand,,,,,,,,,,,,,,
country,NCT03199053::country::Australia,NCT03199053,Australia,,,,,,,,,,,,,,
country,NCT03199053::country::Canada,NCT03199053,Canada,,,,,,,,,,,,,,
country,NCT03199053::country::Chile,NCT03199053,Chile,,,,,,,,,,,,,,
country,NCT03199053::country::Finland,NCT03199053,Finland,,,,,,,,,,,,,,
country,NCT03199053::country::Israel,NCT03199053,Israel,,,,,,,,,,,,,,
country,NCT03199053::country::Poland,NCT03199053,Poland,,,,,,,,,,,,,,
trial,NCT02648217,NCT02648217,"Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan",PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,263.0,2016-01-04,2016-09-05,6.0,32.0,,,,,
arm,NCT02648217::arm::FG000,NCT02648217,Insulin Degludec/Insulin Aspart,,,,,,,,,,FG000,"Subjects received insulin degludec/insulin aspart (IDegAsp) subcutaneously (s.c.; under the skin) in the thigh, upper arm or abdomen for a duration of 16-28 weeks (8-20 weeks treatment initiation peri",,,
arm,NCT02648217::arm::FG001,NCT02648217,Biphasic Insulin Aspart 30,,,,,,,,,,FG001,"Subjects received biphasic insulin aspart 30 (BIAsp 30) s.c. in the thigh, upper arm or abdomen for a duration of 16-28 weeks (8-20 weeks treatment initiation period \[pre-Ramadan\], 4-week Ramadan tr",,,
period,NCT02648217::period::1,NCT02648217,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02648217::outcome::primary::1,NCT02648217,Change in HbA1c (%) (Glycosylated Haemoglobin),,,,,,,,,,,,,PRIMARY,From week 0 to end of Ramadan (day 29 of Ramadan)
country,NCT02648217::country::India,NCT02648217,India,,,,,,,,,,,,,,
country,NCT02648217::country::South Africa,NCT02648217,South Africa,,,,,,,,,,,,,,
country,NCT02648217::country::Algeria,NCT02648217,Algeria,,,,,,,,,,,,,,
country,NCT02648217::country::United Arab Emirates,NCT02648217,United Arab Emirates,,,,,,,,,,,,,,
country,NCT02648217::country::Lebanon,NCT02648217,Lebanon,,,,,,,,,,,,,,
country,NCT02648217::country::Malaysia,NCT02648217,Malaysia,,,,,,,,,,,,,,
trial,NCT01006291,NCT01006291,Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,687.0,2009-11,2010-09,14.0,72.0,,,,,
arm,NCT01006291::arm::FG000,NCT01006291,IDeg OD FF,,,,,,,,,,FG000,Insulin degludec (IDeg) was given once daily (OD) subcutaneously (s.c.) with or without pre-trial OADs for 26 weeks with alternating morning and evening dosing according to a fixed flexible (FF) sched,,,
arm,NCT01006291::arm::FG001,NCT01006291,IDeg OD,,,,,,,,,,FG001,Insulin degludec (IDeg) was given once daily (OD) subcutaneously (s.c.) at main evening meal with or without pre-trial OADs for 26 weeks.,,,
arm,NCT01006291::arm::FG002,NCT01006291,IGlar OD,,,,,,,,,,FG002,Insulin glargine (IGlar) was given once daily (OD) subcutaneously (s.c.) according to local labelling with or without pre-trial OADs for 26 weeks.,,,
period,NCT01006291::period::1,NCT01006291,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01006291::outcome::primary::1,NCT01006291,Change in Glycosylated Haemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Week 0, Week 26"
country,NCT01006291::country::India,NCT01006291,India,,,,,,,,,,,,,,
country,NCT01006291::country::Israel,NCT01006291,Israel,,,,,,,,,,,,,,
country,NCT01006291::country::United Kingdom,NCT01006291,United Kingdom,,,,,,,,,,,,,,
country,NCT01006291::country::Finland,NCT01006291,Finland,,,,,,,,,,,,,,
country,NCT01006291::country::Russia,NCT01006291,Russia,,,,,,,,,,,,,,
country,NCT01006291::country::Norway,NCT01006291,Norway,,,,,,,,,,,,,,
country,NCT01006291::country::Malaysia,NCT01006291,Malaysia,,,,,,,,,,,,,,
country,NCT01006291::country::Argentina,NCT01006291,Argentina,,,,,,,,,,,,,,
country,NCT01006291::country::Hungary,NCT01006291,Hungary,,,,,,,,,,,,,,
country,NCT01006291::country::Taiwan,NCT01006291,Taiwan,,,,,,,,,,,,,,
country,NCT01006291::country::Mexico,NCT01006291,Mexico,,,,,,,,,,,,,,
country,NCT01006291::country::South Africa,NCT01006291,South Africa,,,,,,,,,,,,,,
country,NCT01006291::country::North Macedonia,NCT01006291,North Macedonia,,,,,,,,,,,,,,
country,NCT01006291::country::Serbia,NCT01006291,Serbia,,,,,,,,,,,,,,
trial,NCT00996658,NCT00996658,Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,278.0,2009-10,,4.0,52.0,,,,,
arm,NCT00996658::arm::FG000,NCT00996658,Placebo Tablet,,,,,,,,,,FG000,Placebo matching linagliptin 5 mg tablet,,,
arm,NCT00996658::arm::FG001,NCT00996658,Linagliptin 5 mg Tablet,,,,,,,,,,FG001,Linagliptin 5 mg (milligrams) tablet given by mouth once daily,,,
period,NCT00996658::period::1,NCT00996658,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00996658::outcome::primary::1,NCT00996658,Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 24 Weeks,,,,,,,,,,,,,PRIMARY,"baseline, 24 weeks"
country,NCT00996658::country::United States,NCT00996658,United States,,,,,,,,,,,,,,
country,NCT00996658::country::India,NCT00996658,India,,,,,,,,,,,,,,
country,NCT00996658::country::France,NCT00996658,France,,,,,,,,,,,,,,
country,NCT00996658::country::Philippines,NCT00996658,Philippines,,,,,,,,,,,,,,
trial,NCT00082381,NCT00082381,Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,551.0,2003-06,2008-07,13.0,91.0,,,,,
arm,NCT00082381::arm::FG000,NCT00082381,Exenatide Arm,,,,,,,,,,FG000,Exenatide subcutaneous injection twice daily for 26 weeks (5mcg for 4 weeks followed by 10mcg for 22 weeks),,,
arm,NCT00082381::arm::FG001,NCT00082381,Insulin Glargine Arm,,,,,,,,,,FG001,Insulin glargine subcutaneous injection once daily for 26 weeks (forced titration to target blood glucose level),,,
period,NCT00082381::period::1,NCT00082381,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00082381::outcome::primary::1,NCT00082381,Change in Glycosylated Hemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline, week 26"
country,NCT00082381::country::United States,NCT00082381,United States,,,,,,,,,,,,,,
country,NCT00082381::country::Australia,NCT00082381,Australia,,,,,,,,,,,,,,
country,NCT00082381::country::Germany,NCT00082381,Germany,,,,,,,,,,,,,,
country,NCT00082381::country::Poland,NCT00082381,Poland,,,,,,,,,,,,,,
country,NCT00082381::country::Belgium,NCT00082381,Belgium,,,,,,,,,,,,,,
country,NCT00082381::country::Puerto Rico,NCT00082381,Puerto Rico,,,,,,,,,,,,,,
country,NCT00082381::country::Sweden,NCT00082381,Sweden,,,,,,,,,,,,,,
country,NCT00082381::country::Netherlands,NCT00082381,Netherlands,,,,,,,,,,,,,,
country,NCT00082381::country::Norway,NCT00082381,Norway,,,,,,,,,,,,,,
country,NCT00082381::country::Spain,NCT00082381,Spain,,,,,,,,,,,,,,
country,NCT00082381::country::Brazil,NCT00082381,Brazil,,,,,,,,,,,,,,
country,NCT00082381::country::Portugal,NCT00082381,Portugal,,,,,,,,,,,,,,
country,NCT00082381::country::Finland,NCT00082381,Finland,,,,,,,,,,,,,,
trial,NCT02849080,NCT02849080,Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,504.0,2016-09-20,2019-03-27,10.0,83.0,,,,,
arm,NCT02849080::arm::FG000,NCT02849080,Oral Semaglutide Flex,,,,,,,,,,FG000,"Participants were to receive oral semaglutide tablets once daily from week 0 to week 52 (main phase): 3 milligrams (mg) for the first 8 weeks, 3 or 7 mg for next 8 weeks followed by 3, 7 or 14 mg for ",,,
arm,NCT02849080::arm::FG001,NCT02849080,Sitagliptin 100 mg- Main Phase,,,,,,,,,,FG001,"Participants were to receive 100 mg sitagliptin tablet once daily for 52 weeks (main phase). Participants were to continue their anti-diabetic background medication (metformin, sulphonylurea, thiazoli",,,
arm,NCT02849080::arm::FG002,NCT02849080,Oral Semaglutide Flex- Switch,,,,,,,,,,FG002,Participants who were still on sitagliptin 100 mg treatment at week 52 (end of main phase) were re-randomised to receive oral semaglutide tablets once daily from week 53 to week 104 (extension phase):,,,
arm,NCT02849080::arm::FG003,NCT02849080,Sitagliptin 100 mg- Switch,,,,,,,,,,FG003,Participants who were still on sitagliptin 100 mg treatment at week 52 (end of main phase) were re-randomised to continue sitagliptin in the extension phase (week 53 to week 104). Participants were to,,,
period,NCT02849080::period::1,NCT02849080,Main Phase: 0 - 52 Weeks,,,,,,,,,,,,1.0,,
period,NCT02849080::period::2,NCT02849080,Extension Phase: 53 - 104 Weeks,,,,,,,,,,,,2.0,,
outcome,NCT02849080::outcome::primary::1,NCT02849080,Participants Who Achieve HbA1c <7.0% (53 mmol/Mol) ADA Target (Yes/no),,,,,,,,,,,,,PRIMARY,Week 52
country,NCT02849080::country::United States,NCT02849080,United States,,,,,,,,,,,,,,
country,NCT02849080::country::Turkey (Türkiye),NCT02849080,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02849080::country::Switzerland,NCT02849080,Switzerland,,,,,,,,,,,,,,
country,NCT02849080::country::Belgium,NCT02849080,Belgium,,,,,,,,,,,,,,
country,NCT02849080::country::South Korea,NCT02849080,South Korea,,,,,,,,,,,,,,
country,NCT02849080::country::Norway,NCT02849080,Norway,,,,,,,,,,,,,,
country,NCT02849080::country::Argentina,NCT02849080,Argentina,,,,,,,,,,,,,,
country,NCT02849080::country::Austria,NCT02849080,Austria,,,,,,,,,,,,,,
country,NCT02849080::country::Egypt,NCT02849080,Egypt,,,,,,,,,,,,,,
country,NCT02849080::country::Brazil,NCT02849080,Brazil,,,,,,,,,,,,,,
trial,NCT02827708,NCT02827708,Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,324.0,2016-09-20,2018-05-15,8.0,117.0,,,,,
arm,NCT02827708::arm::FG000,NCT02827708,Oral Semaglutide 14 mg,,,,,,,,,,FG000,"Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 26: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 2",,,
arm,NCT02827708::arm::FG001,NCT02827708,Placebo,,,,,,,,,,FG001,Participants were to take oral semaglutide placebo tablets once daily from week 0 to week 26.,,,
period,NCT02827708::period::1,NCT02827708,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02827708::outcome::primary::1,NCT02827708,Change in HbA1c,,,,,,,,,,,,,PRIMARY,"Week 0, week 26"
country,NCT02827708::country::United States,NCT02827708,United States,,,,,,,,,,,,,,
country,NCT02827708::country::Russia,NCT02827708,Russia,,,,,,,,,,,,,,
country,NCT02827708::country::United Kingdom,NCT02827708,United Kingdom,,,,,,,,,,,,,,
country,NCT02827708::country::Denmark,NCT02827708,Denmark,,,,,,,,,,,,,,
country,NCT02827708::country::Finland,NCT02827708,Finland,,,,,,,,,,,,,,
country,NCT02827708::country::Israel,NCT02827708,Israel,,,,,,,,,,,,,,
country,NCT02827708::country::Sweden,NCT02827708,Sweden,,,,,,,,,,,,,,
country,NCT02827708::country::Poland,NCT02827708,Poland,,,,,,,,,,,,,,
trial,NCT00313313,NCT00313313,A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas,PHASE3,diabetes type 2,Diabetes,INDUSTRY,768.0,2006-04,2008-09,13.0,115.0,,,,,
arm,NCT00313313::arm::FG000,NCT00313313,Saxagliptin 2.5 mg + Glyburide 7.5 mg,,,,,,,,,,FG000,The Saxagliptin 2.5 mg + Glyburide 7.5 mg group includes data from subjects randomized to receive coadministration of blinded saxagliptin 2.5 mg oral tablets and open-label glyburide 7.5 mg oral table,,,
arm,NCT00313313::arm::FG001,NCT00313313,Saxagliptin 5 mg + Glyburide 7.5 mg,,,,,,,,,,FG001,The Saxagliptin 5 mg + Glyburide 7.5 mg group includes data from subjects randomized to receive coadministration of blinded saxagliptin 5 mg oral tablets and open-label glyburide 7.5 mg oral tables on,,,
arm,NCT00313313::arm::FG002,NCT00313313,Placebo + Glyburide 7.5 mg,,,,,,,,,,FG002,"The Placebo + Glyburide 7.5 mg group includes data from subjects randomized to receive coadministration of blinded placebo oral tablets, blinded glyburide 2.5 mg, and open-label glyburide 7.5 mg once ",,,
period,NCT00313313::period::1,NCT00313313,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00313313::outcome::primary::1,NCT00313313,Change From Baseline in Hemoglobin A1c (A1C) at Week 24,,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
country,NCT00313313::country::United States,NCT00313313,United States,,,,,,,,,,,,,,
country,NCT00313313::country::Brazil,NCT00313313,Brazil,,,,,,,,,,,,,,
country,NCT00313313::country::Mexico,NCT00313313,Mexico,,,,,,,,,,,,,,
country,NCT00313313::country::Israel,NCT00313313,Israel,,,,,,,,,,,,,,
country,NCT00313313::country::South Korea,NCT00313313,South Korea,,,,,,,,,,,,,,
country,NCT00313313::country::South Africa,NCT00313313,South Africa,,,,,,,,,,,,,,
country,NCT00313313::country::Argentina,NCT00313313,Argentina,,,,,,,,,,,,,,
country,NCT00313313::country::Peru,NCT00313313,Peru,,,,,,,,,,,,,,
country,NCT00313313::country::Puerto Rico,NCT00313313,Puerto Rico,,,,,,,,,,,,,,
country,NCT00313313::country::Philippines,NCT00313313,Philippines,,,,,,,,,,,,,,
country,NCT00313313::country::Taiwan,NCT00313313,Taiwan,,,,,,,,,,,,,,
country,NCT00313313::country::Hong Kong,NCT00313313,Hong Kong,,,,,,,,,,,,,,
country,NCT00313313::country::Singapore,NCT00313313,Singapore,,,,,,,,,,,,,,
trial,NCT00000620,NCT00000620,Action to Control Cardiovascular Risk in Diabetes (ACCORD),PHASE3,diabetes type 2,"Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia; Hypertension; Diabetes Mellitus, Type 2; Diabetes Mellitus; Coronary Disease",NIH,10251.0,1999-09,2012-12,2.0,7.0,,,,,
arm,NCT00000620::arm::FG000,NCT00000620,Glycemia Trial: Intensive Control/BP Trial: Intensive Control,,,,,,,,,,FG000,Glycemia Trial - Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels \<6.0%.,,,
arm,NCT00000620::arm::FG001,NCT00000620,Glycemia Trial: Intensive Control/BP Trial: Standard Control,,,,,,,,,,FG001,Glycemia Trial - Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels \<6.0%.,,,
arm,NCT00000620::arm::FG002,NCT00000620,Glycemia Trial: Intensive Control/Lipid Trial: Fenofibrate,,,,,,,,,,FG002,Glycemia Trial - Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels \<6.0%.,,,
arm,NCT00000620::arm::FG003,NCT00000620,Glycemia Trial: Intensive Control/Lipid Trial: Placebo,,,,,,,,,,FG003,Glycemia Trial - Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels \<6.0%.,,,
arm,NCT00000620::arm::FG004,NCT00000620,Glycemia Trial: Standard Control/BP Trial: Intensive Control,,,,,,,,,,FG004,Glycemia Trial - Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels of 7.0 ,,,
arm,NCT00000620::arm::FG005,NCT00000620,Glycemia Trial: Standard Control/BP Trial: Standard Control,,,,,,,,,,FG005,Glycemia Trial - Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels of 7.0 ,,,
arm,NCT00000620::arm::FG006,NCT00000620,Glycemia Trial: Standard Control/Lipid Trial: Fenofibrate,,,,,,,,,,FG006,Glycemia Trial - Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels of 7.0 ,,,
arm,NCT00000620::arm::FG007,NCT00000620,Glycemia Trial: Standard Control/Lipid Trial: Placebo,,,,,,,,,,FG007,Glycemia Trial - Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels of 7.0 ,,,
period,NCT00000620::period::1,NCT00000620,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00000620::outcome::primary::1,NCT00000620,First Occurrence of a Major Cardiovascular Event (MCE),,,,,,,,,,,,,PRIMARY,4.9 years
outcome,NCT00000620::outcome::primary::2,NCT00000620,"Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.",,,,,,,,,,,,,PRIMARY,4.7 years
outcome,NCT00000620::outcome::primary::3,NCT00000620,First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.,,,,,,,,,,,,,PRIMARY,4.7 years
outcome,NCT00000620::outcome::primary::4,NCT00000620,First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.,,,,,,,,,,,,,PRIMARY,
country,NCT00000620::country::United States,NCT00000620,United States,,,,,,,,,,,,,,
country,NCT00000620::country::Canada,NCT00000620,Canada,,,,,,,,,,,,,,
trial,NCT00765817,NCT00765817,Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,261.0,2008-10,2010-01,6.0,59.0,,,,,
arm,NCT00765817::arm::FG000,NCT00765817,Exenatide Arm,,,,,,,,,,FG000,"Exenatide 5mcg twice daily for 4 weeks, followed by exenatide 10mcg twice daily for 26 weeks (with a background of titrated insulin glargine and other oral antidiabetic agents)",,,
arm,NCT00765817::arm::FG001,NCT00765817,Placebo Arm,,,,,,,,,,FG001,Placebo volume equivalent to the active volume injected in the exenatide arm (with a background of titrated insulin glargine and other oral antidiabetic agents),,,
period,NCT00765817::period::1,NCT00765817,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00765817::outcome::primary::1,NCT00765817,Change in Glycosylated Hemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,baseline and 30 weeks
country,NCT00765817::country::United States,NCT00765817,United States,,,,,,,,,,,,,,
country,NCT00765817::country::United Kingdom,NCT00765817,United Kingdom,,,,,,,,,,,,,,
country,NCT00765817::country::Puerto Rico,NCT00765817,Puerto Rico,,,,,,,,,,,,,,
country,NCT00765817::country::Israel,NCT00765817,Israel,,,,,,,,,,,,,,
country,NCT00765817::country::Mexico,NCT00765817,Mexico,,,,,,,,,,,,,,
country,NCT00765817::country::Greece,NCT00765817,Greece,,,,,,,,,,,,,,
trial,NCT02294474,NCT02294474,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,505.0,2015-01,2016-02,12.0,103.0,,,,,
arm,NCT02294474::arm::FG000,NCT02294474,SAR342434,,,,,,,,,,FG000,"SAR342434 100 U/mL SC injection before meals intake on top of QD Insulin Glargine, up to Week 26.",,,
arm,NCT02294474::arm::FG001,NCT02294474,Humalog,,,,,,,,,,FG001,"Humalog 100 U/mL SC injection before meals intake on top of QD Insulin Glargine, up to Week 26.",,,
period,NCT02294474::period::1,NCT02294474,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02294474::outcome::primary::1,NCT02294474,Change in HbA1c From Baseline to Week 26,,,,,,,,,,,,,PRIMARY,"Baseline, Week 26"
country,NCT02294474::country::United States,NCT02294474,United States,,,,,,,,,,,,,,
country,NCT02294474::country::Romania,NCT02294474,Romania,,,,,,,,,,,,,,
country,NCT02294474::country::Hungary,NCT02294474,Hungary,,,,,,,,,,,,,,
country,NCT02294474::country::Germany,NCT02294474,Germany,,,,,,,,,,,,,,
country,NCT02294474::country::Argentina,NCT02294474,Argentina,,,,,,,,,,,,,,
country,NCT02294474::country::Russia,NCT02294474,Russia,,,,,,,,,,,,,,
country,NCT02294474::country::Italy,NCT02294474,Italy,,,,,,,,,,,,,,
country,NCT02294474::country::South Korea,NCT02294474,South Korea,,,,,,,,,,,,,,
country,NCT02294474::country::Turkey (Türkiye),NCT02294474,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02294474::country::Chile,NCT02294474,Chile,,,,,,,,,,,,,,
country,NCT02294474::country::Spain,NCT02294474,Spain,,,,,,,,,,,,,,
country,NCT02294474::country::Colombia,NCT02294474,Colombia,,,,,,,,,,,,,,
trial,NCT00121641,NCT00121641,Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,1035.0,2005-07,2010-02,6.0,134.0,,,,,
arm,NCT00121641::arm::FG000,NCT00121641,Saxagliptin 2.5 mg,,,,,,,,,,FG000,"Tablets, Oral, 2.5 mg, Once daily (24 weeks short term \[ST\], 42 months long term \[LT\]); Metformin 500-2000 mg (as needed for rescue).",,,
arm,NCT00121641::arm::FG001,NCT00121641,Saxagliptin 5 mg,,,,,,,,,,FG001,"Tablets, Oral, 5 mg, Once daily (24 weeks ST, 42 months LT); Metformin 500-2000 mg (as needed for rescue).",,,
arm,NCT00121641::arm::FG002,NCT00121641,Saxagliptin 10 mg,,,,,,,,,,FG002,"Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT); Metformin 500-2000 mg (as needed for rescue).",,,
arm,NCT00121641::arm::FG003,NCT00121641,Placebo,,,,,,,,,,FG003,"Tablets, Oral, 0mg, Once daily (24 weeks ST, 42 months LT); Metformin 500-2000 mg (as needed for rescue)",,,
arm,NCT00121641::arm::FG004,NCT00121641,Open-Label Treatment Cohort (Direct Enrollees),,,,,,,,,,FG004,"Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT); Metformin 500-2000 mg (as needed for rescue).",,,
period,NCT00121641::period::1,NCT00121641,24-week Short-term Treatment Period,,,,,,,,,,,,1.0,,
period,NCT00121641::period::2,NCT00121641,48-month Short Term + Long Term Period,,,,,,,,,,,,2.0,,
outcome,NCT00121641::outcome::primary::1,NCT00121641,Hemoglobin A1c (A1C) Changes From Baseline at Week 24,,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
outcome,NCT00121641::outcome::primary::2,NCT00121641,A1C Changes From Baseline at Week 24 - Open Label Cohort,,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
country,NCT00121641::country::United States,NCT00121641,United States,,,,,,,,,,,,,,
country,NCT00121641::country::Canada,NCT00121641,Canada,,,,,,,,,,,,,,
country,NCT00121641::country::Australia,NCT00121641,Australia,,,,,,,,,,,,,,
country,NCT00121641::country::Mexico,NCT00121641,Mexico,,,,,,,,,,,,,,
country,NCT00121641::country::Puerto Rico,NCT00121641,Puerto Rico,,,,,,,,,,,,,,
country,NCT00121641::country::Taiwan,NCT00121641,Taiwan,,,,,,,,,,,,,,
trial,NCT01676220,NCT01676220,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,878.0,2012-08,2014-03,16.0,217.0,,,,,
arm,NCT01676220::arm::FG000,NCT01676220,HOE901-U300,,,,,,,,,,FG000,HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily (evening) for 12 months in combination with non-insulin antihyperglycemic drug(s).,,,
arm,NCT01676220::arm::FG001,NCT01676220,Lantus (Insulin Glargine),,,,,,,,,,FG001,"Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months in combination with non-insulin antihyperglycemic drug(s).",,,
period,NCT01676220::period::1,NCT01676220,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01676220::outcome::primary::1,NCT01676220,Change in HbA1c From Baseline to Month 6 Endpoint,,,,,,,,,,,,,PRIMARY,"Baseline, Month 6"
country,NCT01676220::country::United States,NCT01676220,United States,,,,,,,,,,,,,,
country,NCT01676220::country::Canada,NCT01676220,Canada,,,,,,,,,,,,,,
country,NCT01676220::country::Japan,NCT01676220,Japan,,,,,,,,,,,,,,
country,NCT01676220::country::Romania,NCT01676220,Romania,,,,,,,,,,,,,,
country,NCT01676220::country::Denmark,NCT01676220,Denmark,,,,,,,,,,,,,,
country,NCT01676220::country::Hungary,NCT01676220,Hungary,,,,,,,,,,,,,,
country,NCT01676220::country::Netherlands,NCT01676220,Netherlands,,,,,,,,,,,,,,
country,NCT01676220::country::Puerto Rico,NCT01676220,Puerto Rico,,,,,,,,,,,,,,
country,NCT01676220::country::Slovakia,NCT01676220,Slovakia,,,,,,,,,,,,,,
country,NCT01676220::country::Bulgaria,NCT01676220,Bulgaria,,,,,,,,,,,,,,
country,NCT01676220::country::Czechia,NCT01676220,Czechia,,,,,,,,,,,,,,
country,NCT01676220::country::Finland,NCT01676220,Finland,,,,,,,,,,,,,,
country,NCT01676220::country::Latvia,NCT01676220,Latvia,,,,,,,,,,,,,,
country,NCT01676220::country::Lithuania,NCT01676220,Lithuania,,,,,,,,,,,,,,
country,NCT01676220::country::Sweden,NCT01676220,Sweden,,,,,,,,,,,,,,
country,NCT01676220::country::Estonia,NCT01676220,Estonia,,,,,,,,,,,,,,
trial,NCT00541450,NCT00541450,A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,492.0,2008-01-15,2010-01-16,0.0,0.0,,,,,
arm,NCT00541450::arm::FG000,NCT00541450,Sita/Met FDC,,,,,,,,,,FG000,"In Phase A (Treatment Day 1 up to Week 12), participants were administered 100 mg once daily (q.d.) of sitagliptin and matching placebo to pioglitazone.

In Phase B (Treatment Week 12 to Week 40), par",,,
arm,NCT00541450::arm::FG001,NCT00541450,Pioglitazone,,,,,,,,,,FG001,"In Phase A (Treatment Day 1 up to Week 12), participants in the pioglitazone group were administered 15 mg once daily (q.d.) of pioglitazone and matching placebo to sitagliptin. At Week 6, all partici",,,
period,NCT00541450::period::1,NCT00541450,Phase A,,,,,,,,,,,,1.0,,
period,NCT00541450::period::2,NCT00541450,Phase B,,,,,,,,,,,,2.0,,
outcome,NCT00541450::outcome::primary::1,NCT00541450,Change in Hemoglobin A1c (A1C) in the Sita/Met Fixed-Dose Combination (FDC) or Pioglitazone Groups at 40 Weeks,,,,,,,,,,,,,PRIMARY,Baseline to 40 weeks
outcome,NCT00541450::outcome::primary::2,NCT00541450,Change in Hemoglobin A1c (A1C) in Participants Treated With Sitagliptin or Pioglitazone at 12 Weeks,,,,,,,,,,,,,PRIMARY,Baseline to 12 weeks
trial,NCT01697592,NCT01697592,Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,585.0,2012-10-24,2014-05-08,0.0,0.0,,,,,
arm,NCT01697592::arm::FG000,NCT01697592,Omarigliptin 25 mg/Sulfonylureas (SU) (Phase A+B),,,,,,,,,,FG000,Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of SU throughout the duration o,,,
arm,NCT01697592::arm::FG001,NCT01697592,Omarigliptin 25 mg/Glinides (Gln) (Phase A+B),,,,,,,,,,FG001,Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of Gln throughout the duration ,,,
arm,NCT01697592::arm::FG002,NCT01697592,Omarigliptin 25 mg/Biguanides (BG) (Phase A+B),,,,,,,,,,FG002,Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of BG throughout the duration o,,,
arm,NCT01697592::arm::FG003,NCT01697592,Omarigliptin 25 mg/Thiazolidinediones (TZD) (Phase A+B),,,,,,,,,,FG003,Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of TZD throughout the duration ,,,
arm,NCT01697592::arm::FG004,NCT01697592,Omarigliptin 25 mg/α-GI (Phase A+B),,,,,,,,,,FG004,Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of α-glucosidase (α-GI) through,,,
arm,NCT01697592::arm::FG005,NCT01697592,Placebo/SU (Phase A) Switching to Omari. 25 mg/SU (Phase B),,,,,,,,,,FG005,Placebo to omarigliptin (omari.)administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg administered orally once weekly for 28 weeks during Phase B. Participants continued pre-,,,
arm,NCT01697592::arm::FG006,NCT01697592,Placebo/Gln. (Phase A) Switching to Omari. 25 mg/Gln (Phase B),,,,,,,,,,FG006,Placebo to omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg administered orally once weekly for 28 weeks during Phase B. Participants continued pre-study ba,,,
arm,NCT01697592::arm::FG007,NCT01697592,Placebo/BG (Phase A) Switching to Omari. 25 mg/BG (Phase B),,,,,,,,,,FG007,Placebo to Omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg administered orally once weekly for 28 weeks during Phase B. Participants continued pre-study ba,,,
arm,NCT01697592::arm::FG008,NCT01697592,Placebo/TZD (Phase A) Switching to Omari. 25 mg/TZ (Phase B),,,,,,,,,,FG008,Placebo to omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg administered orally once weekly for 28 weeks during Phase B. Participants continued pre-study ba,,,
arm,NCT01697592::arm::FG009,NCT01697592,Placebo/α-GI (Phase A) Switching to Omari. 25 mg/α-GI (Ph. B),,,,,,,,,,FG009,Placebo to omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg administered orally once weekly for 28 weeks during Phase B. Participants continued pre-study ba,,,
period,NCT01697592::period::1,NCT01697592,Phase A (Up to 24 Weeks),,,,,,,,,,,,1.0,,
period,NCT01697592::period::2,NCT01697592,Phase B (Week 25 to Week 52),,,,,,,,,,,,2.0,,
outcome,NCT01697592::outcome::primary::1,NCT01697592,Percentage of Participants Who Experienced at Least One Adverse Event Excluding Data After Glycemic Rescue During Phase A,,,,,,,,,,,,,PRIMARY,Up to 24 weeks
outcome,NCT01697592::outcome::primary::2,NCT01697592,Percentage of Participants Who Experienced at Least One Adverse Event Excluding Data After Glycemic Rescue During the Overall Study,,,,,,,,,,,,,PRIMARY,Up to 52 weeks
outcome,NCT01697592::outcome::primary::3,NCT01697592,Percentage of Participants Who Discontinued From the Study Due to an Adverse Event During Phase A,,,,,,,,,,,,,PRIMARY,Up to 24 weeks
outcome,NCT01697592::outcome::primary::4,NCT01697592,Percentage of Participants Who Discontinued From the Study Due to an Adverse Event During the Overall Study,,,,,,,,,,,,,PRIMARY,Up to 52 weeks
trial,NCT03018028,NCT03018028,"Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes",PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,243.0,2017-01-10,2018-08-15,1.0,16.0,,,,,
arm,NCT03018028::arm::FG000,NCT03018028,Oral Semaglutide 3 mg,,,,,,,,,,FG000,Participants received 3.0 milligrams (mg) of oral semaglutide tablets once daily in the morning in fasted state for 52 weeks. The oral semaglutide tablet was taken once daily in a fasting state at lea,,,
arm,NCT03018028::arm::FG001,NCT03018028,Oral Semaglutide 7 mg,,,,,,,,,,FG001,Participants received oral semaglutide tablets once daily in the morning in fasted state for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until ,,,
arm,NCT03018028::arm::FG002,NCT03018028,Oral Semaglutide 14 mg,,,,,,,,,,FG002,Participants received oral semaglutide tablets once daily in the morning in fasted state for 52 weeks. Participants started oral semaglutide at 3 mg and were dose escalated in 4-week increments until ,,,
arm,NCT03018028::arm::FG003,NCT03018028,Liraglutide 0.9 mg,,,,,,,,,,FG003,"Participants received liraglutide for 52 weeks. Liraglutide was administered once-daily as subcutaneous injection (under the skin) in the abdomen, thigh or upper arm and was taken with or without food",,,
arm,NCT03018028::arm::FG004,NCT03018028,Placebo,,,,,,,,,,FG004,Participants received placebo (for oral semaglutide) tablets once daily for 52 weeks. The placebo tablet was taken once daily in the morning in a fasting state at least 30 min before the first meal of,,,
period,NCT03018028::period::1,NCT03018028,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03018028::outcome::primary::1,NCT03018028,Change in HbA1c (Week 26),,,,,,,,,,,,,PRIMARY,"Week 0, week 26"
country,NCT03018028::country::Japan,NCT03018028,Japan,,,,,,,,,,,,,,
trial,NCT01755156,NCT01755156,"A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)",PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,402.0,2013-01-11,2016-03-16,0.0,0.0,,,,,
arm,NCT01755156::arm::FG000,NCT01755156,Omarigliptin (Phase A) → Omarigliptin (Phase B),,,,,,,,,,FG000,Phase A: Omarigliptin 25 mg capsule administered orally once weekly for 24 weeks. Phase B: Omarigliptin 25 mg capsule administered orally once weekly and matching placebo to glimepiride tablet/capsule,,,
arm,NCT01755156::arm::FG001,NCT01755156,Placebo to Omarigliptin (Phase A) → Glimepiride (Phase B),,,,,,,,,,FG001,Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: Matching placebo to omarigliptin capsule administered orally once weekly and glimepiride 1 or 2 mg tablet/capsule ad,,,
period,NCT01755156::period::1,NCT01755156,Phase A (Weeks 0-24),,,,,,,,,,,,1.0,,
period,NCT01755156::period::2,NCT01755156,Phase B (Weeks 24-104),,,,,,,,,,,,2.0,,
outcome,NCT01755156::outcome::primary::1,NCT01755156,Change From Baseline in Glycosylated Hemoglobin (A1C) at Week 24 (Phase A),,,,,,,,,,,,,PRIMARY,Baseline and Week 24
outcome,NCT01755156::outcome::primary::2,NCT01755156,Percentage of Participants Who Experienced at Least One Adverse Event (Phase A+B),,,,,,,,,,,,,PRIMARY,Up to 107 weeks
outcome,NCT01755156::outcome::primary::3,NCT01755156,Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (Phase A+B),,,,,,,,,,,,,PRIMARY,Up to 104 weeks
outcome,NCT01755156::outcome::primary::4,NCT01755156,Percentage of Participants Who Experienced an Adverse Event Which Were Included Under the System Order Class of Investigations (Phase A+B),,,,,,,,,,,,,PRIMARY,Up to 104 weeks
trial,NCT00968812,NCT00968812,CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,1452.0,2009-09,2013-01,20.0,138.0,,,,,
arm,NCT00968812::arm::FG000,NCT00968812,Canagliflozin 100 mg: Baseline to Week 104,,,,,,,,,,FG000,Each patient received 100 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.,,,
arm,NCT00968812::arm::FG001,NCT00968812,Canagliflozin 300 mg: Baseline to Week 104,,,,,,,,,,FG001,Each patient received 300 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.,,,
arm,NCT00968812::arm::FG002,NCT00968812,Glimepiride: Baseline to Week 104,,,,,,,,,,FG002,"Each patient received glimepiride, at protocol-specified doses, once daily in combination with protocol-specified doses of metformin for 104 weeks.",,,
period,NCT00968812::period::1,NCT00968812,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00968812::outcome::primary::1,NCT00968812,Change in HbA1c From Baseline to Week 52,,,,,,,,,,,,,PRIMARY,Day 1 (Baseline) and Week 52
country,NCT00968812::country::United States,NCT00968812,United States,,,,,,,,,,,,,,
country,NCT00968812::country::Poland,NCT00968812,Poland,,,,,,,,,,,,,,
country,NCT00968812::country::Canada,NCT00968812,Canada,,,,,,,,,,,,,,
country,NCT00968812::country::Israel,NCT00968812,Israel,,,,,,,,,,,,,,
country,NCT00968812::country::India,NCT00968812,India,,,,,,,,,,,,,,
country,NCT00968812::country::Romania,NCT00968812,Romania,,,,,,,,,,,,,,
country,NCT00968812::country::South Korea,NCT00968812,South Korea,,,,,,,,,,,,,,
country,NCT00968812::country::Germany,NCT00968812,Germany,,,,,,,,,,,,,,
country,NCT00968812::country::Ukraine,NCT00968812,Ukraine,,,,,,,,,,,,,,
country,NCT00968812::country::Finland,NCT00968812,Finland,,,,,,,,,,,,,,
country,NCT00968812::country::Russia,NCT00968812,Russia,,,,,,,,,,,,,,
country,NCT00968812::country::Bulgaria,NCT00968812,Bulgaria,,,,,,,,,,,,,,
country,NCT00968812::country::Denmark,NCT00968812,Denmark,,,,,,,,,,,,,,
country,NCT00968812::country::Philippines,NCT00968812,Philippines,,,,,,,,,,,,,,
country,NCT00968812::country::Slovakia,NCT00968812,Slovakia,,,,,,,,,,,,,,
country,NCT00968812::country::Argentina,NCT00968812,Argentina,,,,,,,,,,,,,,
country,NCT00968812::country::Mexico,NCT00968812,Mexico,,,,,,,,,,,,,,
country,NCT00968812::country::Costa Rica,NCT00968812,Costa Rica,,,,,,,,,,,,,,
country,NCT00968812::country::Norway,NCT00968812,Norway,,,,,,,,,,,,,,
country,NCT00968812::country::Puerto Rico,NCT00968812,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01167881,NCT01167881,Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,1549.0,2010-08,2015-08,23.0,182.0,,,,,
arm,NCT01167881::arm::FG000,NCT01167881,Empaglifozin 25 mg,,,,,,,,,,FG000,"Patients received one Empagliflozin 25 mg tablet and one placebo Glimepiride capsule orally once daily.

Empagliflozin: 25 mg once daily

Placebo: Placebo matching Glimepiride",,,
arm,NCT01167881::arm::FG001,NCT01167881,Glimepiride,,,,,,,,,,FG001,"Patients received one Glimepiride capsule and one placebo Empagliflozin tablet orally once daily.

Glimepiride: 1-4 mg once daily

Placebo: Placebo matching Empagliflozin",,,
period,NCT01167881::period::1,NCT01167881,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01167881::outcome::primary::1,NCT01167881,The Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 104 Weeks of Treatment.,,,,,,,,,,,,,PRIMARY,Baseline and 104 weeks
country,NCT01167881::country::United States,NCT01167881,United States,,,,,,,,,,,,,,
country,NCT01167881::country::Canada,NCT01167881,Canada,,,,,,,,,,,,,,
country,NCT01167881::country::United Kingdom,NCT01167881,United Kingdom,,,,,,,,,,,,,,
country,NCT01167881::country::India,NCT01167881,India,,,,,,,,,,,,,,
country,NCT01167881::country::Spain,NCT01167881,Spain,,,,,,,,,,,,,,
country,NCT01167881::country::South Africa,NCT01167881,South Africa,,,,,,,,,,,,,,
country,NCT01167881::country::Philippines,NCT01167881,Philippines,,,,,,,,,,,,,,
country,NCT01167881::country::Czechia,NCT01167881,Czechia,,,,,,,,,,,,,,
country,NCT01167881::country::Italy,NCT01167881,Italy,,,,,,,,,,,,,,
country,NCT01167881::country::Malaysia,NCT01167881,Malaysia,,,,,,,,,,,,,,
country,NCT01167881::country::Sweden,NCT01167881,Sweden,,,,,,,,,,,,,,
country,NCT01167881::country::Austria,NCT01167881,Austria,,,,,,,,,,,,,,
country,NCT01167881::country::Taiwan,NCT01167881,Taiwan,,,,,,,,,,,,,,
country,NCT01167881::country::Argentina,NCT01167881,Argentina,,,,,,,,,,,,,,
country,NCT01167881::country::Colombia,NCT01167881,Colombia,,,,,,,,,,,,,,
country,NCT01167881::country::Finland,NCT01167881,Finland,,,,,,,,,,,,,,
country,NCT01167881::country::Mexico,NCT01167881,Mexico,,,,,,,,,,,,,,
country,NCT01167881::country::Portugal,NCT01167881,Portugal,,,,,,,,,,,,,,
country,NCT01167881::country::Thailand,NCT01167881,Thailand,,,,,,,,,,,,,,
country,NCT01167881::country::Hong Kong,NCT01167881,Hong Kong,,,,,,,,,,,,,,
country,NCT01167881::country::Netherlands,NCT01167881,Netherlands,,,,,,,,,,,,,,
country,NCT01167881::country::Norway,NCT01167881,Norway,,,,,,,,,,,,,,
country,NCT01167881::country::Switzerland,NCT01167881,Switzerland,,,,,,,,,,,,,,
trial,NCT00542178,NCT00542178,Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study),PHASE3,diabetes type 2,Diabetic Retinopathy,NIH,3472.0,2003-10,2009-12,2.0,7.0,,,,,
arm,NCT00542178::arm::FG000,NCT00542178,Intensive Glycemia Control & Intensive Blood Pressure Control,,,,,,,,,,FG000,"Intensive Glycemia Control: A strategy of intensive glycemia treatment to HbA1c less than 6%

Intensive Blood Pressure Control: A strategy of BP treatment for SBP less than 120 mm Hg",,,
arm,NCT00542178::arm::FG001,NCT00542178,Standard Glycemia Control & Intensive Blood Pressure Control,,,,,,,,,,FG001,"Standard Glycemia Control: A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9%

Intensive Blood Pressure Control: A strategy of BP treatment for SBP less than 120 mm Hg",,,
arm,NCT00542178::arm::FG002,NCT00542178,Intensive Glycemia Control & Standard Blood Pressure Control,,,,,,,,,,FG002,"Intensive Glycemia Control: A strategy of intensive glycemia treatment to HbA1c less than 6%

Standard Blood Pressure Control: A strategy of BP treatment for SBP less than 140 mm Hg",,,
arm,NCT00542178::arm::FG003,NCT00542178,Standard Glycemia Control & Standard Blood Pressure Control,,,,,,,,,,FG003,"Standard Glycemia Control: A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9%

Standard Blood Pressure Control: A strategy of BP treatment for SBP less than 140 mm Hg",,,
arm,NCT00542178::arm::FG004,NCT00542178,Intensive Glycemia Control & Fibrate,,,,,,,,,,FG004,"Intensive Glycemia Control: A strategy of intensive glycemia treatment to HbA1c less than 6%

Fibrate: Blinded fenofibrate + simvastatin 20-40 mg/d",,,
arm,NCT00542178::arm::FG005,NCT00542178,Standard Glycemia Control & Fibrate,,,,,,,,,,FG005,"Standard Glycemia Control: A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9%

Fibrate: Blinded fenofibrate + simvastatin 20-40 mg/d",,,
arm,NCT00542178::arm::FG006,NCT00542178,Intensive Glycemia Control & Fibrate Placebo,,,,,,,,,,FG006,"Intensive Glycemia Control: A strategy of intensive glycemia treatment to HbA1c less than 6%

Fibrate Placebo: Blinded placebo + simvastatin 20-40 mg/d",,,
arm,NCT00542178::arm::FG007,NCT00542178,Standard Glycemia Control & Fibrate Placebo,,,,,,,,,,FG007,"Standard Glycemia Control: A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9%

Fibrate Placebo: Blinded placebo + simvastatin 20-40 mg/d",,,
period,NCT00542178::period::1,NCT00542178,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00542178::outcome::primary::1,NCT00542178,"Number of Participants With Progression of Diabetic Retinopathy of at Least 3 Stages on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale, or Development of Proliferative Diabetic Retinopathy Necessitating Photocoagulation Therapy or Vitrectomy",,,,,,,,,,,,,PRIMARY,Measured at Year 4
country,NCT00542178::country::United States,NCT00542178,United States,,,,,,,,,,,,,,
country,NCT00542178::country::Canada,NCT00542178,Canada,,,,,,,,,,,,,,
trial,NCT01676116,NCT01676116,The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,438.0,2012-08-29,2014-03-11,5.0,109.0,,,,,
arm,NCT01676116::arm::FG000,NCT01676116,Insulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs),,,,,,,,,,FG000,Subjects were treated with subcutaneous (under the skin) once daily (OD) insulin degludec/liraglutide. Treatment with insulin degludec/liraglutide was initiated at 16 dose steps containing 16 units of,,,
arm,NCT01676116::arm::FG001,NCT01676116,Liraglutide or Exenatide + OADs,,,,,,,,,,FG001,Subjects continued on their pre-trial GLP-1 receptor agonist treatment with subcutaneous (under the skin) liraglutide (Victoza®) or exenatide (Byetta®) in stable pre-trial dose without changing the fr,,,
period,NCT01676116::period::1,NCT01676116,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01676116::outcome::primary::1,NCT01676116,"Change in Glycosylated Haemoglobin (HbA1c) From Baseline (Randomisation, Visit 2)",,,,,,,,,,,,,PRIMARY,"Week 0, week 26"
country,NCT01676116::country::United States,NCT01676116,United States,,,,,,,,,,,,,,
country,NCT01676116::country::France,NCT01676116,France,,,,,,,,,,,,,,
country,NCT01676116::country::Slovakia,NCT01676116,Slovakia,,,,,,,,,,,,,,
country,NCT01676116::country::Australia,NCT01676116,Australia,,,,,,,,,,,,,,
country,NCT01676116::country::Hungary,NCT01676116,Hungary,,,,,,,,,,,,,,
trial,NCT01392677,NCT01392677,Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus; High HbA1c Level; Inadequate Glycaemic Control,INDUSTRY,311.0,2011-10,2013-08,6.0,42.0,,,,,
arm,NCT01392677::arm::FG000,NCT01392677,Placebo Plus Metformin Plus Sulfonylurea,,,,,,,,,,FG000,Placebo once daily plus background combination of metformin and sulfonylurea,,,
arm,NCT01392677::arm::FG001,NCT01392677,Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea,,,,,,,,,,FG001,Dapagliflozin 10mg once daily plus background combination of metformin and sulfonylurea,,,
period,NCT01392677::period::1,NCT01392677,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01392677::outcome::primary::1,NCT01392677,Adjusted Mean Change From Baseline in HbA1c Levels,,,,,,,,,,,,,PRIMARY,Baseline to week 24
country,NCT01392677::country::Canada,NCT01392677,Canada,,,,,,,,,,,,,,
country,NCT01392677::country::Spain,NCT01392677,Spain,,,,,,,,,,,,,,
country,NCT01392677::country::Czechia,NCT01392677,Czechia,,,,,,,,,,,,,,
country,NCT01392677::country::Germany,NCT01392677,Germany,,,,,,,,,,,,,,
country,NCT01392677::country::Poland,NCT01392677,Poland,,,,,,,,,,,,,,
country,NCT01392677::country::Slovakia,NCT01392677,Slovakia,,,,,,,,,,,,,,
trial,NCT00627445,NCT00627445,Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,441.0,2008-02,2009-01,1.0,1.0,,,,,
arm,NCT00627445::arm::FG000,NCT00627445,BIAsp 50-50-30,,,,,,,,,,FG000,Individual adjusted dose of biphasic insulin aspart 50 administered before breakfast and lunch and individual adjusted dose of biphasic insulin aspart 30 at dinner in combination with metformin 500-20,,,
arm,NCT00627445::arm::FG001,NCT00627445,BIAsp 30-30,,,,,,,,,,FG001,"Individual adjusted dose of biphasic insulin aspart 30 administered before breakfast and dinner in combination with metformin 500-2000 mg, up to three times daily",,,
period,NCT00627445::period::1,NCT00627445,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00627445::outcome::primary::1,NCT00627445,Change in Glycosylated Haemoglobin A1c (HbA1c),,,,,,,,,,,,,PRIMARY,"week 0, week 16"
country,NCT00627445::country::China,NCT00627445,China,,,,,,,,,,,,,,
trial,NCT00602472,NCT00602472,BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,1058.0,2008-02,,11.0,100.0,,,,,
arm,NCT00602472::arm::FG000,NCT00602472,Placebo,,,,,,,,,,FG000,Patients randomized to receive treatment with matching placebo,,,
arm,NCT00602472::arm::FG001,NCT00602472,Linagliptin,,,,,,,,,,FG001,Patients randomized to receive treatment with Linagliptin 5mg,,,
period,NCT00602472::period::1,NCT00602472,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00602472::outcome::primary::1,NCT00602472,HbA1c Change From Baseline to Week 24,,,,,,,,,,,,,PRIMARY,Baseline and week 24
country,NCT00602472::country::China,NCT00602472,China,,,,,,,,,,,,,,
country,NCT00602472::country::Argentina,NCT00602472,Argentina,,,,,,,,,,,,,,
country,NCT00602472::country::Canada,NCT00602472,Canada,,,,,,,,,,,,,,
country,NCT00602472::country::South Korea,NCT00602472,South Korea,,,,,,,,,,,,,,
country,NCT00602472::country::United Kingdom,NCT00602472,United Kingdom,,,,,,,,,,,,,,
country,NCT00602472::country::Germany,NCT00602472,Germany,,,,,,,,,,,,,,
country,NCT00602472::country::Taiwan,NCT00602472,Taiwan,,,,,,,,,,,,,,
country,NCT00602472::country::Belgium,NCT00602472,Belgium,,,,,,,,,,,,,,
country,NCT00602472::country::Philippines,NCT00602472,Philippines,,,,,,,,,,,,,,
country,NCT00602472::country::Russia,NCT00602472,Russia,,,,,,,,,,,,,,
country,NCT00602472::country::Turkey (Türkiye),NCT00602472,Turkey (Türkiye),,,,,,,,,,,,,,
trial,NCT00641043,NCT00641043,Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,389.0,2008-03,,7.0,43.0,,,,,
arm,NCT00641043::arm::FG000,NCT00641043,Placebo + Pioglitazone,,,,,,,,,,FG000,Patients randomized to receive treatment with matching placebo (to Linagliptin 5 mg) and Pioglitazone 30 mg,,,
arm,NCT00641043::arm::FG001,NCT00641043,Linagliptin + Pioglitazone,,,,,,,,,,FG001,Patients randomized to receive treatment with Linagliptin 5 mg and Pioglitazone 30 mg,,,
period,NCT00641043::period::1,NCT00641043,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00641043::outcome::primary::1,NCT00641043,HbA1c Change From Baseline to Week 24,,,,,,,,,,,,,PRIMARY,Baseline and week 24
country,NCT00641043::country::Spain,NCT00641043,Spain,,,,,,,,,,,,,,
country,NCT00641043::country::Greece,NCT00641043,Greece,,,,,,,,,,,,,,
country,NCT00641043::country::Hungary,NCT00641043,Hungary,,,,,,,,,,,,,,
country,NCT00641043::country::Japan,NCT00641043,Japan,,,,,,,,,,,,,,
country,NCT00641043::country::Romania,NCT00641043,Romania,,,,,,,,,,,,,,
country,NCT00641043::country::Austria,NCT00641043,Austria,,,,,,,,,,,,,,
country,NCT00641043::country::Portugal,NCT00641043,Portugal,,,,,,,,,,,,,,
trial,NCT01076647,NCT01076647,Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,467.0,2010-03,2010-12,7.0,105.0,,,,,
arm,NCT01076647::arm::FG000,NCT01076647,IDeg 3TW,,,,,,,,,,FG000,"Insulin degludec (IDeg) 200 U/ml was given thrice weekly on Mondays, Wednesdays and Fridays subcutaneously (s.c.) in the evening with pre-trial metformin and with or without pre-trial DPP-4 for 26 wee",,,
arm,NCT01076647::arm::FG001,NCT01076647,IGlar OD,,,,,,,,,,FG001,Insulin glargine (IGlar) was given once daily (OD) subcutaneously (s.c.) same time each day according to local labelling with pre-trial metformin and with or without pre-trial DPP-4 for 26 weeks.,,,
period,NCT01076647::period::1,NCT01076647,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01076647::outcome::primary::1,NCT01076647,Change in Glycosylated Haemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Week 0, Week 26"
country,NCT01076647::country::United States,NCT01076647,United States,,,,,,,,,,,,,,
country,NCT01076647::country::France,NCT01076647,France,,,,,,,,,,,,,,
country,NCT01076647::country::Netherlands,NCT01076647,Netherlands,,,,,,,,,,,,,,
country,NCT01076647::country::Canada,NCT01076647,Canada,,,,,,,,,,,,,,
country,NCT01076647::country::Hungary,NCT01076647,Hungary,,,,,,,,,,,,,,
country,NCT01076647::country::Romania,NCT01076647,Romania,,,,,,,,,,,,,,
country,NCT01076647::country::Bulgaria,NCT01076647,Bulgaria,,,,,,,,,,,,,,
trial,NCT04093752,NCT04093752,A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo),PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,917.0,2019-12-09,2021-11-24,4.0,67.0,,,,,
arm,NCT04093752::arm::FG000,NCT04093752,5 mg Tirzepatide,,,,,,,,,,FG000,Participants received 5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week (QW).,,,
arm,NCT04093752::arm::FG001,NCT04093752,10 mg Tirzepatide,,,,,,,,,,FG001,Participants received 10 mg tirzepatide administered SC QW.,,,
arm,NCT04093752::arm::FG002,NCT04093752,15 mg Tirzepatide,,,,,,,,,,FG002,Participants received 15 mg tirzepatide administered SC QW.,,,
arm,NCT04093752::arm::FG003,NCT04093752,Insulin Glargine,,,,,,,,,,FG003,"Participants received insulin glargine administered once daily (QD) SC. The starting dose of insulin glargine was 6 Insulin Units (IU)/day at bedtime, titrated to a fasting blood glucose (FBG) between",,,
period,NCT04093752::period::1,NCT04093752,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04093752::outcome::primary::1,NCT04093752,Mean Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg),,,,,,,,,,,,,PRIMARY,"Baseline, Week 40"
country,NCT04093752::country::China,NCT04093752,China,,,,,,,,,,,,,,
country,NCT04093752::country::South Korea,NCT04093752,South Korea,,,,,,,,,,,,,,
country,NCT04093752::country::Australia,NCT04093752,Australia,,,,,,,,,,,,,,
country,NCT04093752::country::India,NCT04093752,India,,,,,,,,,,,,,,
trial,NCT03914326,NCT03914326,A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,9651.0,2019-06-17,2024-08-23,34.0,492.0,,,,,
arm,NCT03914326::arm::FG000,NCT03914326,Oral Semaglutide,,,,,,,,,,FG000,"Participants were to receive once daily semaglutide tablets with a dose escalation every 4 weeks in doses 3 mg (week 0 to week 4), 7 mg (week 4 to week 8) until maintenance dose of 14 mg was reached a",,,
arm,NCT03914326::arm::FG001,NCT03914326,Placebo,,,,,,,,,,FG001,Participants were to receive once daily placebo matching oral semaglutide until end of the treatment visit (up to week 260).,,,
period,NCT03914326::period::1,NCT03914326,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03914326::outcome::primary::1,NCT03914326,"Number of Participants From Randomization to First Occurrence of a Major Adverse Cardiovascular Event (MACE), a Composite Endpoint Consisting of: Cardiovascular (CV) Death/Non-fatal Myocardial Infarction/Non-fatal Stroke",,,,,,,,,,,,,PRIMARY,From randomisation (week 0) up to week 265
country,NCT03914326::country::United States,NCT03914326,United States,,,,,,,,,,,,,,
country,NCT03914326::country::India,NCT03914326,India,,,,,,,,,,,,,,
country,NCT03914326::country::Japan,NCT03914326,Japan,,,,,,,,,,,,,,
country,NCT03914326::country::Russia,NCT03914326,Russia,,,,,,,,,,,,,,
country,NCT03914326::country::United Kingdom,NCT03914326,United Kingdom,,,,,,,,,,,,,,
country,NCT03914326::country::Canada,NCT03914326,Canada,,,,,,,,,,,,,,
country,NCT03914326::country::South Africa,NCT03914326,South Africa,,,,,,,,,,,,,,
country,NCT03914326::country::Spain,NCT03914326,Spain,,,,,,,,,,,,,,
country,NCT03914326::country::Turkey (Türkiye),NCT03914326,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT03914326::country::Germany,NCT03914326,Germany,,,,,,,,,,,,,,
country,NCT03914326::country::Italy,NCT03914326,Italy,,,,,,,,,,,,,,
country,NCT03914326::country::Malaysia,NCT03914326,Malaysia,,,,,,,,,,,,,,
country,NCT03914326::country::Argentina,NCT03914326,Argentina,,,,,,,,,,,,,,
country,NCT03914326::country::Slovakia,NCT03914326,Slovakia,,,,,,,,,,,,,,
country,NCT03914326::country::Israel,NCT03914326,Israel,,,,,,,,,,,,,,
country,NCT03914326::country::Romania,NCT03914326,Romania,,,,,,,,,,,,,,
country,NCT03914326::country::Thailand,NCT03914326,Thailand,,,,,,,,,,,,,,
country,NCT03914326::country::Croatia,NCT03914326,Croatia,,,,,,,,,,,,,,
country,NCT03914326::country::Czechia,NCT03914326,Czechia,,,,,,,,,,,,,,
country,NCT03914326::country::Mexico,NCT03914326,Mexico,,,,,,,,,,,,,,
country,NCT03914326::country::Netherlands,NCT03914326,Netherlands,,,,,,,,,,,,,,
country,NCT03914326::country::Ukraine,NCT03914326,Ukraine,,,,,,,,,,,,,,
country,NCT03914326::country::Brazil,NCT03914326,Brazil,,,,,,,,,,,,,,
country,NCT03914326::country::Belgium,NCT03914326,Belgium,,,,,,,,,,,,,,
country,NCT03914326::country::China,NCT03914326,China,,,,,,,,,,,,,,
country,NCT03914326::country::France,NCT03914326,France,,,,,,,,,,,,,,
country,NCT03914326::country::South Korea,NCT03914326,South Korea,,,,,,,,,,,,,,
country,NCT03914326::country::Serbia,NCT03914326,Serbia,,,,,,,,,,,,,,
country,NCT03914326::country::Algeria,NCT03914326,Algeria,,,,,,,,,,,,,,
country,NCT03914326::country::Colombia,NCT03914326,Colombia,,,,,,,,,,,,,,
country,NCT03914326::country::Austria,NCT03914326,Austria,,,,,,,,,,,,,,
country,NCT03914326::country::Denmark,NCT03914326,Denmark,,,,,,,,,,,,,,
country,NCT03914326::country::Taiwan,NCT03914326,Taiwan,,,,,,,,,,,,,,
country,NCT03914326::country::Hong Kong,NCT03914326,Hong Kong,,,,,,,,,,,,,,
trial,NCT04770532,NCT04770532,"A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin",PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,526.0,2021-03-05,2022-03-01,9.0,88.0,,,,,
arm,NCT04770532::arm::FG000,NCT04770532,Insulin Icodec,,,,,,,,,,FG000,"Participants were to receive once weekly subcutaneous (s.c.) injection of Insulin icodec for 26 weeks, using PDS290 prefilled pen-injector at a starting dose of 7 times the pre-trial total daily basal",,,
arm,NCT04770532::arm::FG001,NCT04770532,Insulin Degludec,,,,,,,,,,FG001,"Participants were to receive once daily s.c. injection of Insulin degludec for 26 weeks, using PDS290 prefilled pen-injector at a dose in accordance with local label. Participants were to perform once",,,
period,NCT04770532::period::1,NCT04770532,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04770532::outcome::primary::1,NCT04770532,Change in Glycated Haemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline (Week 0), Week 26"
country,NCT04770532::country::United States,NCT04770532,United States,,,,,,,,,,,,,,
country,NCT04770532::country::Japan,NCT04770532,Japan,,,,,,,,,,,,,,
country,NCT04770532::country::Germany,NCT04770532,Germany,,,,,,,,,,,,,,
country,NCT04770532::country::Portugal,NCT04770532,Portugal,,,,,,,,,,,,,,
country,NCT04770532::country::South Korea,NCT04770532,South Korea,,,,,,,,,,,,,,
country,NCT04770532::country::Bulgaria,NCT04770532,Bulgaria,,,,,,,,,,,,,,
country,NCT04770532::country::South Africa,NCT04770532,South Africa,,,,,,,,,,,,,,
country,NCT04770532::country::Ukraine,NCT04770532,Ukraine,,,,,,,,,,,,,,
country,NCT04770532::country::Poland,NCT04770532,Poland,,,,,,,,,,,,,,
trial,NCT01624259,NCT01624259,A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,599.0,2012-06,2013-11,10.0,57.0,,,,,
arm,NCT01624259::arm::FG000,NCT01624259,LY2189265,,,,,,,,,,FG000,"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 26 weeks

Metformin: at least 1500 mg/day, oral, for 26 weeks",,,
arm,NCT01624259::arm::FG001,NCT01624259,Liraglutide,,,,,,,,,,FG001,"Liraglutide: 0.6 mg, SC, once daily for 7 days, then titrated up to 1.2 mg, SC, once daily for 7 days, then titrated up to 1.8 mg, SC, once daily for 24 weeks

Metformin: at least 1500 mg/day, oral, f",,,
period,NCT01624259::period::1,NCT01624259,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01624259::outcome::primary::1,NCT01624259,Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline, 26 Weeks"
country,NCT01624259::country::United States,NCT01624259,United States,,,,,,,,,,,,,,
country,NCT01624259::country::Poland,NCT01624259,Poland,,,,,,,,,,,,,,
country,NCT01624259::country::Germany,NCT01624259,Germany,,,,,,,,,,,,,,
country,NCT01624259::country::Spain,NCT01624259,Spain,,,,,,,,,,,,,,
country,NCT01624259::country::Hungary,NCT01624259,Hungary,,,,,,,,,,,,,,
country,NCT01624259::country::Romania,NCT01624259,Romania,,,,,,,,,,,,,,
country,NCT01624259::country::Slovakia,NCT01624259,Slovakia,,,,,,,,,,,,,,
country,NCT01624259::country::Puerto Rico,NCT01624259,Puerto Rico,,,,,,,,,,,,,,
country,NCT01624259::country::Czechia,NCT01624259,Czechia,,,,,,,,,,,,,,
country,NCT01624259::country::Mexico,NCT01624259,Mexico,,,,,,,,,,,,,,
trial,NCT00411554,NCT00411554,A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED),PHASE3,diabetes type 2,"Diabetes Mellitus, Non-Insulin-Dependent",INDUSTRY,319.0,2007-01,2007-08,0.0,0.0,,,,,
arm,NCT00411554::arm::FG000,NCT00411554,Sitagliptin 50 mg QD,,,,,,,,,,FG000,The Sitagliptin group includes data from all patients randomized to receive treatment with sitagliptin 50 mg orally once daily (QD=once daily).,,,
arm,NCT00411554::arm::FG001,NCT00411554,Voglibose 0.2 mg TID,,,,,,,,,,FG001,The Voglibose group includes data from all patients randomized to receive treatment with voglibose 0.2 mg orally three times daily (TID= three times daily).,,,
period,NCT00411554::period::1,NCT00411554,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00411554::outcome::primary::1,NCT00411554,Change From Baseline in HbA1c at Week 12,,,,,,,,,,,,,PRIMARY,Baseline and Week 12
trial,NCT00220961,NCT00220961,Actos Now for Prevention of Diabetes (ACT NOW),PHASE3,diabetes type 2,Impaired Glucose Tolerance; Type 2 Diabetes,OTHER,602.0,2004-01,2010-04,1.0,8.0,,,,,
arm,NCT00220961::arm::FG000,NCT00220961,Placebo,,,,,,,,,,FG000,"Placebo tablet similar to pioglitazone tablet

Placebo: Placebo tablets similar to pioglitazone tablets - 1 tablet/day",,,
arm,NCT00220961::arm::FG001,NCT00220961,Pioglitazone,,,,,,,,,,FG001,"Pioglitazone tablet similar to placebo tablet

Pioglitazone: Pioglitazone tablets - 45mg/day tablet",,,
period,NCT00220961::period::1,NCT00220961,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00220961::outcome::primary::1,NCT00220961,Prevention of Type 2 Diabetes,,,,,,,,,,,,,PRIMARY,2.4 years
country,NCT00220961::country::United States,NCT00220961,United States,,,,,,,,,,,,,,
trial,NCT00560417,NCT00560417,Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,339.0,2007-11,2009-12,2.0,52.0,,,,,
arm,NCT00560417::arm::FG000,NCT00560417,ILPS,,,,,,,,,,FG000,Insulin Lispro Protamine Suspension (ILPS) administered subcutaneously once a day at bedtime for 24 weeks,,,
arm,NCT00560417::arm::FG001,NCT00560417,Glargine,,,,,,,,,,FG001,Insulin Glargine administered subcutaneously once a day at bedtime for 24 weeks,,,
period,NCT00560417::period::1,NCT00560417,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00560417::outcome::primary::1,NCT00560417,Change From Baseline in Hemoglobin A1C (HbA1c) at Endpoint (Last Observation Carried Forward [LOCF]),,,,,,,,,,,,,PRIMARY,"Baseline, Endpoint (LOCF) up to 24 weeks"
country,NCT00560417::country::United States,NCT00560417,United States,,,,,,,,,,,,,,
country,NCT00560417::country::Puerto Rico,NCT00560417,Puerto Rico,,,,,,,,,,,,,,
trial,NCT02739984,NCT02739984,Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia,PHASE3,diabetes type 2,Hypercholesterolemia; Mixed Dyslipidemia; Type 2 Diabetes,INDUSTRY,424.0,2016-05-17,2017-08-03,7.0,66.0,,,,,
arm,NCT02739984::arm::FG000,NCT02739984,Placebo,,,,,,,,,,FG000,Participants received placebo subcutaneous injection once every month (QM) for 12 weeks.,,,
arm,NCT02739984::arm::FG001,NCT02739984,Evolocumab,,,,,,,,,,FG001,Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks.,,,
period,NCT02739984::period::1,NCT02739984,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02739984::outcome::primary::1,NCT02739984,Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12,,,,,,,,,,,,,PRIMARY,Baseline and Weeks 10 and 12
outcome,NCT02739984::outcome::primary::2,NCT02739984,Percent Change From Baseline in LDL-C at Week 12,,,,,,,,,,,,,PRIMARY,Baseline and week 12
country,NCT02739984::country::United States,NCT02739984,United States,,,,,,,,,,,,,,
country,NCT02739984::country::Canada,NCT02739984,Canada,,,,,,,,,,,,,,
country,NCT02739984::country::Poland,NCT02739984,Poland,,,,,,,,,,,,,,
country,NCT02739984::country::Spain,NCT02739984,Spain,,,,,,,,,,,,,,
country,NCT02739984::country::Belgium,NCT02739984,Belgium,,,,,,,,,,,,,,
country,NCT02739984::country::Italy,NCT02739984,Italy,,,,,,,,,,,,,,
country,NCT02739984::country::Mexico,NCT02739984,Mexico,,,,,,,,,,,,,,
trial,NCT02648204,NCT02648204,Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,1201.0,2016-01-06,2017-05-19,17.0,209.0,,,,,
arm,NCT02648204::arm::FG000,NCT02648204,Semaglutide 0.5 mg,,,,,,,,,,FG000,"Subjects received subcutaneous (s.c., under the skin) injections of semaglutide once weekly (OW) for treatment duration of 40 weeks. Subjects received semaglutide 0.25 mg for 4 weeks (weeks 1 to 4) fo",,,
arm,NCT02648204::arm::FG001,NCT02648204,Semaglutide 1.0 mg,,,,,,,,,,FG001,Subjects received s.c. injections of semaglutide OW for treatment duration of 40 weeks. Subjects received semaglutide 0.25 mg for 4 weeks (week 1 to 4) followed by 0.5 mg for another 4 weeks (week 5 t,,,
arm,NCT02648204::arm::FG002,NCT02648204,Dulaglutide 0.75 mg,,,,,,,,,,FG002,Subjects received s.c. injections of dulaglutide 0.75 mg OW for treatment duration of 40 weeks. Subjects were followed for 5 weeks after completion of treatment period.,,,
arm,NCT02648204::arm::FG003,NCT02648204,Dulaglutide 1.5 mg,,,,,,,,,,FG003,Subjects received s.c. injections of dulaglutide 1.5 mg OW for treatment duration of 40 weeks. Subjects were followed for 5 weeks after completion of treatment period.,,,
period,NCT02648204::period::1,NCT02648204,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02648204::outcome::primary::1,NCT02648204,Change in HbA1c,,,,,,,,,,,,,PRIMARY,"Week 0, week 40"
country,NCT02648204::country::United States,NCT02648204,United States,,,,,,,,,,,,,,
country,NCT02648204::country::India,NCT02648204,India,,,,,,,,,,,,,,
country,NCT02648204::country::Spain,NCT02648204,Spain,,,,,,,,,,,,,,
country,NCT02648204::country::Greece,NCT02648204,Greece,,,,,,,,,,,,,,
country,NCT02648204::country::United Kingdom,NCT02648204,United Kingdom,,,,,,,,,,,,,,
country,NCT02648204::country::Germany,NCT02648204,Germany,,,,,,,,,,,,,,
country,NCT02648204::country::Romania,NCT02648204,Romania,,,,,,,,,,,,,,
country,NCT02648204::country::Croatia,NCT02648204,Croatia,,,,,,,,,,,,,,
country,NCT02648204::country::Finland,NCT02648204,Finland,,,,,,,,,,,,,,
country,NCT02648204::country::Portugal,NCT02648204,Portugal,,,,,,,,,,,,,,
country,NCT02648204::country::Slovakia,NCT02648204,Slovakia,,,,,,,,,,,,,,
country,NCT02648204::country::Bulgaria,NCT02648204,Bulgaria,,,,,,,,,,,,,,
country,NCT02648204::country::Ireland,NCT02648204,Ireland,,,,,,,,,,,,,,
country,NCT02648204::country::Lithuania,NCT02648204,Lithuania,,,,,,,,,,,,,,
country,NCT02648204::country::Latvia,NCT02648204,Latvia,,,,,,,,,,,,,,
country,NCT02648204::country::Hong Kong,NCT02648204,Hong Kong,,,,,,,,,,,,,,
country,NCT02648204::country::Puerto Rico,NCT02648204,Puerto Rico,,,,,,,,,,,,,,
trial,NCT03351478,NCT03351478,Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,770.0,2017-11-27,2019-05-16,12.0,160.0,,,,,
arm,NCT03351478::arm::FG000,NCT03351478,Sotagliflozin 400 mg,,,,,,,,,,FG000,"Following a 2-week run-in period, sotagliflozin 400 milligrams (mg) administered as two 200 mg tablets and one placebo capsule (identical to empagliflozin capsule in appearance), once daily before the",,,
arm,NCT03351478::arm::FG001,NCT03351478,Empagliflozin 25 mg,,,,,,,,,,FG001,"Following a 2-week run-in period, placebo matching sotagliflozin administered as two tablets (identical to sotagliflozin in appearance) and one capsule of empagliflozin 25 mg, once daily before the fi",,,
arm,NCT03351478::arm::FG002,NCT03351478,Placebo,,,,,,,,,,FG002,"Following a 2-week run-in period, placebo given as two placebo tablets (identical to sotagliflozin) and one placebo capsule (identical to empagliflozin) once daily before the first meal of the day for",,,
period,NCT03351478::period::1,NCT03351478,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03351478::outcome::primary::1,NCT03351478,Change From Baseline in Hemoglobin A1c (HbA1c) % at Week 26,,,,,,,,,,,,,PRIMARY,"Baseline, Week 26"
country,NCT03351478::country::United States,NCT03351478,United States,,,,,,,,,,,,,,
country,NCT03351478::country::Russia,NCT03351478,Russia,,,,,,,,,,,,,,
country,NCT03351478::country::Czechia,NCT03351478,Czechia,,,,,,,,,,,,,,
country,NCT03351478::country::Bulgaria,NCT03351478,Bulgaria,,,,,,,,,,,,,,
country,NCT03351478::country::Italy,NCT03351478,Italy,,,,,,,,,,,,,,
country,NCT03351478::country::Canada,NCT03351478,Canada,,,,,,,,,,,,,,
country,NCT03351478::country::Spain,NCT03351478,Spain,,,,,,,,,,,,,,
country,NCT03351478::country::Slovakia,NCT03351478,Slovakia,,,,,,,,,,,,,,
country,NCT03351478::country::Latvia,NCT03351478,Latvia,,,,,,,,,,,,,,
country,NCT03351478::country::United Kingdom,NCT03351478,United Kingdom,,,,,,,,,,,,,,
country,NCT03351478::country::France,NCT03351478,France,,,,,,,,,,,,,,
country,NCT03351478::country::Mexico,NCT03351478,Mexico,,,,,,,,,,,,,,
trial,NCT02058147,NCT02058147,Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,1170.0,2014-02,2015-06,23.0,273.0,,,,,
arm,NCT02058147::arm::FG000,NCT02058147,Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC),,,,,,,,,,FG000,FRC injected subcutaneously once daily (QD) for 30 weeks. Dose individually adjusted.,,,
arm,NCT02058147::arm::FG001,NCT02058147,Insulin Glargine,,,,,,,,,,FG001,Insulin glargine injected subcutaneously QD for 30 weeks. Dose individually adjusted.,,,
arm,NCT02058147::arm::FG002,NCT02058147,Lixisenatide,,,,,,,,,,FG002,"Lixisenatide 10 mcg injected subcutaneously QD for 2 weeks, then 20 mcg QD (maintenance dose).",,,
period,NCT02058147::period::1,NCT02058147,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02058147::outcome::primary::1,NCT02058147,Change in HbA1c From Baseline to Week 30,,,,,,,,,,,,,PRIMARY,"Baseline, Week 30"
country,NCT02058147::country::United States,NCT02058147,United States,,,,,,,,,,,,,,
country,NCT02058147::country::Czechia,NCT02058147,Czechia,,,,,,,,,,,,,,
country,NCT02058147::country::Russia,NCT02058147,Russia,,,,,,,,,,,,,,
country,NCT02058147::country::Chile,NCT02058147,Chile,,,,,,,,,,,,,,
country,NCT02058147::country::Spain,NCT02058147,Spain,,,,,,,,,,,,,,
country,NCT02058147::country::Hungary,NCT02058147,Hungary,,,,,,,,,,,,,,
country,NCT02058147::country::Romania,NCT02058147,Romania,,,,,,,,,,,,,,
country,NCT02058147::country::Mexico,NCT02058147,Mexico,,,,,,,,,,,,,,
country,NCT02058147::country::Poland,NCT02058147,Poland,,,,,,,,,,,,,,
country,NCT02058147::country::Ukraine,NCT02058147,Ukraine,,,,,,,,,,,,,,
country,NCT02058147::country::Germany,NCT02058147,Germany,,,,,,,,,,,,,,
country,NCT02058147::country::Lithuania,NCT02058147,Lithuania,,,,,,,,,,,,,,
country,NCT02058147::country::South Africa,NCT02058147,South Africa,,,,,,,,,,,,,,
country,NCT02058147::country::Denmark,NCT02058147,Denmark,,,,,,,,,,,,,,
country,NCT02058147::country::Italy,NCT02058147,Italy,,,,,,,,,,,,,,
country,NCT02058147::country::Sweden,NCT02058147,Sweden,,,,,,,,,,,,,,
country,NCT02058147::country::United Kingdom,NCT02058147,United Kingdom,,,,,,,,,,,,,,
country,NCT02058147::country::Australia,NCT02058147,Australia,,,,,,,,,,,,,,
country,NCT02058147::country::Estonia,NCT02058147,Estonia,,,,,,,,,,,,,,
country,NCT02058147::country::France,NCT02058147,France,,,,,,,,,,,,,,
country,NCT02058147::country::Latvia,NCT02058147,Latvia,,,,,,,,,,,,,,
country,NCT02058147::country::Belgium,NCT02058147,Belgium,,,,,,,,,,,,,,
country,NCT02058147::country::Canada,NCT02058147,Canada,,,,,,,,,,,,,,
trial,NCT02460978,NCT02460978,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,PHASE3,diabetes type 2,Type 1 Diabetes Mellitus,INDUSTRY,815.0,2015-07-08,2018-04-18,13.0,136.0,,,,,
arm,NCT02460978::arm::FG000,NCT02460978,DAPA 5 MG + INS,,,,,,,,,,FG000,Dapagliflozin 5 mg plus insulin,,,
arm,NCT02460978::arm::FG001,NCT02460978,DAPA 10 MG + INS,,,,,,,,,,FG001,Dapagliflozin 10 mg plus insulin,,,
arm,NCT02460978::arm::FG002,NCT02460978,PLA + INS,,,,,,,,,,FG002,Placebo plus insulin,,,
period,NCT02460978::period::1,NCT02460978,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02460978::outcome::primary::1,NCT02460978,Adjusted Mean Change From Baseline in HbA1c at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and 24 weeks
country,NCT02460978::country::United States,NCT02460978,United States,,,,,,,,,,,,,,
country,NCT02460978::country::Japan,NCT02460978,Japan,,,,,,,,,,,,,,
country,NCT02460978::country::Germany,NCT02460978,Germany,,,,,,,,,,,,,,
country,NCT02460978::country::Poland,NCT02460978,Poland,,,,,,,,,,,,,,
country,NCT02460978::country::Argentina,NCT02460978,Argentina,,,,,,,,,,,,,,
country,NCT02460978::country::Canada,NCT02460978,Canada,,,,,,,,,,,,,,
country,NCT02460978::country::United Kingdom,NCT02460978,United Kingdom,,,,,,,,,,,,,,
country,NCT02460978::country::Russia,NCT02460978,Russia,,,,,,,,,,,,,,
country,NCT02460978::country::Sweden,NCT02460978,Sweden,,,,,,,,,,,,,,
country,NCT02460978::country::Chile,NCT02460978,Chile,,,,,,,,,,,,,,
country,NCT02460978::country::Netherlands,NCT02460978,Netherlands,,,,,,,,,,,,,,
country,NCT02460978::country::Switzerland,NCT02460978,Switzerland,,,,,,,,,,,,,,
country,NCT02460978::country::Belgium,NCT02460978,Belgium,,,,,,,,,,,,,,
trial,NCT01646320,NCT01646320,Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,320.0,2012-09,2015-02,8.0,66.0,,,,,
arm,NCT01646320::arm::FG000,NCT01646320,Dapa+Saxa+Met,,,,,,,,,,FG000,"Participants received dapagliflozin, 10 mg, and open-label saxagliptin 5 mg and metformin ≥1500 mg per day for up to 52 weeks",,,
arm,NCT01646320::arm::FG001,NCT01646320,Pla+Saxa+Met,,,,,,,,,,FG001,Participants received dapagliflozin matching placebo and open-label saxagliptin 5 mg and metformin ≥1500 mg per day for up to 52 weeks,,,
period,NCT01646320::period::1,NCT01646320,Short-term Period (Day 1 to Week 24),,,,,,,,,,,,1.0,,
period,NCT01646320::period::2,NCT01646320,Long-term Period (Weeks 24 to 52),,,,,,,,,,,,2.0,,
outcome,NCT01646320::outcome::primary::1,NCT01646320,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24,,,,,,,,,,,,,PRIMARY,From Baseline to Week 24
country,NCT01646320::country::United States,NCT01646320,United States,,,,,,,,,,,,,,
country,NCT01646320::country::Russia,NCT01646320,Russia,,,,,,,,,,,,,,
country,NCT01646320::country::Poland,NCT01646320,Poland,,,,,,,,,,,,,,
country,NCT01646320::country::Mexico,NCT01646320,Mexico,,,,,,,,,,,,,,
country,NCT01646320::country::Romania,NCT01646320,Romania,,,,,,,,,,,,,,
country,NCT01646320::country::United Kingdom,NCT01646320,United Kingdom,,,,,,,,,,,,,,
country,NCT01646320::country::Czechia,NCT01646320,Czechia,,,,,,,,,,,,,,
country,NCT01646320::country::Puerto Rico,NCT01646320,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01106677,NCT01106677,The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial),PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,1284.0,2010-05,2012-05,22.0,125.0,,,,,
arm,NCT01106677::arm::FG000,NCT01106677,Placebo/Sitagliptin,,,,,,,,,,FG000,Each patient received matching placebo once daily for 26 weeks and were then switched from placebo to 100 mg of sitagliptin once daily until Week 52. Placebo and sitagliptin were given with protocol-s,,,
arm,NCT01106677::arm::FG001,NCT01106677,Canagliflozin 100 mg,,,,,,,,,,FG001,Each patient received 100 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin immediate release.,,,
arm,NCT01106677::arm::FG002,NCT01106677,Canagliflozin 300 mg,,,,,,,,,,FG002,Each patient received 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin immediate release.,,,
arm,NCT01106677::arm::FG003,NCT01106677,Sitagliptin 100 mg,,,,,,,,,,FG003,Each patient received 100 mg of sitagliptin once daily for 52 weeks with protocol-specified doses of metformin immediate release.,,,
period,NCT01106677::period::1,NCT01106677,Core Period: Baseline to Week 26,,,,,,,,,,,,1.0,,
period,NCT01106677::period::2,NCT01106677,Extension Period: Week 26 to Week 52,,,,,,,,,,,,2.0,,
outcome,NCT01106677::outcome::primary::1,NCT01106677,Change in HbA1c From Baseline to Week 26,,,,,,,,,,,,,PRIMARY,Day 1 (Baseline) and Week 26
country,NCT01106677::country::United States,NCT01106677,United States,,,,,,,,,,,,,,
country,NCT01106677::country::India,NCT01106677,India,,,,,,,,,,,,,,
country,NCT01106677::country::Russia,NCT01106677,Russia,,,,,,,,,,,,,,
country,NCT01106677::country::Ukraine,NCT01106677,Ukraine,,,,,,,,,,,,,,
country,NCT01106677::country::Czechia,NCT01106677,Czechia,,,,,,,,,,,,,,
country,NCT01106677::country::Mexico,NCT01106677,Mexico,,,,,,,,,,,,,,
country,NCT01106677::country::Poland,NCT01106677,Poland,,,,,,,,,,,,,,
country,NCT01106677::country::Slovakia,NCT01106677,Slovakia,,,,,,,,,,,,,,
country,NCT01106677::country::Turkey (Türkiye),NCT01106677,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01106677::country::Bulgaria,NCT01106677,Bulgaria,,,,,,,,,,,,,,
country,NCT01106677::country::Latvia,NCT01106677,Latvia,,,,,,,,,,,,,,
country,NCT01106677::country::Malaysia,NCT01106677,Malaysia,,,,,,,,,,,,,,
country,NCT01106677::country::Portugal,NCT01106677,Portugal,,,,,,,,,,,,,,
country,NCT01106677::country::Argentina,NCT01106677,Argentina,,,,,,,,,,,,,,
country,NCT01106677::country::Colombia,NCT01106677,Colombia,,,,,,,,,,,,,,
country,NCT01106677::country::Thailand,NCT01106677,Thailand,,,,,,,,,,,,,,
country,NCT01106677::country::Greece,NCT01106677,Greece,,,,,,,,,,,,,,
country,NCT01106677::country::Sweden,NCT01106677,Sweden,,,,,,,,,,,,,,
country,NCT01106677::country::Estonia,NCT01106677,Estonia,,,,,,,,,,,,,,
country,NCT01106677::country::Peru,NCT01106677,Peru,,,,,,,,,,,,,,
country,NCT01106677::country::Puerto Rico,NCT01106677,Puerto Rico,,,,,,,,,,,,,,
country,NCT01106677::country::Singapore,NCT01106677,Singapore,,,,,,,,,,,,,,
trial,NCT01194830,NCT01194830,Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,234.0,2010-09,2011-10,1.0,93.0,,,,,
arm,NCT01194830::arm::FG000,NCT01194830,Placebo Tablet,,,,,,,,,,FG000,Placebo matching linagliptin 5 mg tablet,,,
arm,NCT01194830::arm::FG001,NCT01194830,Linagliptin 5 mg Tablet,,,,,,,,,,FG001,Linagliptin 5 mg (milligrams) tablet given by mouth once daily,,,
period,NCT01194830::period::1,NCT01194830,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01194830::outcome::primary::1,NCT01194830,Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 24 Weeks,,,,,,,,,,,,,PRIMARY,"baseline, 24 weeks"
country,NCT01194830::country::United States,NCT01194830,United States,,,,,,,,,,,,,,
trial,NCT02314637,NCT02314637,Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,240.0,2009-08,2011-07,1.0,1.0,,,,,
arm,NCT02314637::arm::FG000,NCT02314637,Teneligliptin,,,,,,,,,,FG000,Teneligliptin for 52 weeks,,,
arm,NCT02314637::arm::FG001,NCT02314637,Teneligliptin + Sulfonylurea,,,,,,,,,,FG001,Teneligliptin for 52 weeks in combination with sulfonylurea (glimepiride),,,
period,NCT02314637::period::1,NCT02314637,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02314637::outcome::primary::1,NCT02314637,Number of Participants With Adverse Events,,,,,,,,,,,,,PRIMARY,52 weeks
country,NCT02314637::country::Japan,NCT02314637,Japan,,,,,,,,,,,,,,
trial,NCT00736099,NCT00736099,Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,2122.0,2008-08,,32.0,232.0,,,,,
arm,NCT00736099::arm::FG000,NCT00736099,Old Lina,,,,,,,,,,FG000,Patients pre-treated with linagliptin (BI 1356),,,
arm,NCT00736099::arm::FG001,NCT00736099,New Lina,,,,,,,,,,FG001,Patients pre-treated with placebo,,,
period,NCT00736099::period::1,NCT00736099,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00736099::outcome::primary::1,NCT00736099,Frequency of Patients With Adverse Events (AEs),,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::2,NCT00736099,Frequency of Patients With Investigator-defined Hypoglycaemic Adverse Events,,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::3,NCT00736099,Frequency of Patients With Significant Adverse Events Based on Standardised MedDRA Query (SMQ),,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::4,NCT00736099,Frequency of Patients With Adjudication of Cardiac and Cerebrovascular Events,,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::5,NCT00736099,Number of Patients With Abnormalities in Vital Signs,,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::6,NCT00736099,Number of Patients With Abnormalities in Haematology: Eosinophils,,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::7,NCT00736099,Number of Patients With Abnormalities in Haematology: Haemoglobin,,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::8,NCT00736099,Number of Patients With Abnormalities in Haematology: Haematocrit,,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::9,NCT00736099,Number of Patients With Abnormalities in Haematology: Red Blood Cell Count,,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::10,NCT00736099,Number of Patients With Abnormalities in Haematology: White Blood Cell Count,,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::11,NCT00736099,Number of Patients With Abnormalities in Haematology: Platelets,,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::12,NCT00736099,Number of Patients With Abnormalities in Clinical Chemistry: Potassium,,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::13,NCT00736099,Number of Patients With Abnormalities in Clinical Chemistry: Uric Acid,,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::14,NCT00736099,Number of Patients With Abnormalities in Clinical Chemistry: Triglycerides,,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::15,NCT00736099,Number of Patients With Abnormalities in Clinical Chemistry: Amylase,,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::16,NCT00736099,Number of Patients With Abnormalities in Clinical Chemistry: γ-Glutamyl-transferase (GGT),,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::17,NCT00736099,Number of Patients With Abnormalities in Clinical Chemistry: Creatinine,,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::18,NCT00736099,Number of Patients With Abnormalities in Clinical Chemistry: Creatinine Kinase,,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::19,NCT00736099,Number of Patients With Abnormalities in Clinical Chemistry: Phosphate,,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::20,NCT00736099,Number of Patients With Abnormalities in Clinical Chemistry: Calcium,,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::21,NCT00736099,Number of Patients With Abnormalities in Clinical Chemistry: Sodium,,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::22,NCT00736099,Number of Patients With Abnormalities in Clinical Chemistry: Alanine Transaminase (ALT),,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::23,NCT00736099,Number of Patients With Abnormalities in Clinical Chemistry: Aspartate Transaminase (AST),,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::24,NCT00736099,Number of Patients With Abnormalities in Clinical Chemistry: Glucose,,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::25,NCT00736099,Number of Patients With Abnormalities in Clinical Chemistry: Bilirubin,,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::26,NCT00736099,Number of Patients With Abnormalities in Clinical Chemistry: Alkaline Phosphatase (AP),,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::27,NCT00736099,Number of Patients With Abnormalities in Clinical Chemistry: Albumin,,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::28,NCT00736099,Number of Patients With Abnormalities in Clinical Chemistry: Lactate Dehydrogenase (LDH),,,,,,,,,,,,,PRIMARY,78 weeks
outcome,NCT00736099::outcome::primary::29,NCT00736099,Number of Patients With Abnormalities in Clinical Chemistry: Cholesterol,,,,,,,,,,,,,PRIMARY,78 weeks
country,NCT00736099::country::India,NCT00736099,India,,,,,,,,,,,,,,
country,NCT00736099::country::United States,NCT00736099,United States,,,,,,,,,,,,,,
country,NCT00736099::country::Canada,NCT00736099,Canada,,,,,,,,,,,,,,
country,NCT00736099::country::China,NCT00736099,China,,,,,,,,,,,,,,
country,NCT00736099::country::Spain,NCT00736099,Spain,,,,,,,,,,,,,,
country,NCT00736099::country::Ukraine,NCT00736099,Ukraine,,,,,,,,,,,,,,
country,NCT00736099::country::Russia,NCT00736099,Russia,,,,,,,,,,,,,,
country,NCT00736099::country::South Korea,NCT00736099,South Korea,,,,,,,,,,,,,,
country,NCT00736099::country::Mexico,NCT00736099,Mexico,,,,,,,,,,,,,,
country,NCT00736099::country::United Kingdom,NCT00736099,United Kingdom,,,,,,,,,,,,,,
country,NCT00736099::country::Germany,NCT00736099,Germany,,,,,,,,,,,,,,
country,NCT00736099::country::Taiwan,NCT00736099,Taiwan,,,,,,,,,,,,,,
country,NCT00736099::country::Belgium,NCT00736099,Belgium,,,,,,,,,,,,,,
country,NCT00736099::country::Greece,NCT00736099,Greece,,,,,,,,,,,,,,
country,NCT00736099::country::Israel,NCT00736099,Israel,,,,,,,,,,,,,,
country,NCT00736099::country::Romania,NCT00736099,Romania,,,,,,,,,,,,,,
country,NCT00736099::country::Czechia,NCT00736099,Czechia,,,,,,,,,,,,,,
country,NCT00736099::country::Hungary,NCT00736099,Hungary,,,,,,,,,,,,,,
country,NCT00736099::country::Malaysia,NCT00736099,Malaysia,,,,,,,,,,,,,,
country,NCT00736099::country::Slovakia,NCT00736099,Slovakia,,,,,,,,,,,,,,
country,NCT00736099::country::Finland,NCT00736099,Finland,,,,,,,,,,,,,,
country,NCT00736099::country::Japan,NCT00736099,Japan,,,,,,,,,,,,,,
country,NCT00736099::country::Netherlands,NCT00736099,Netherlands,,,,,,,,,,,,,,
country,NCT00736099::country::New Zealand,NCT00736099,New Zealand,,,,,,,,,,,,,,
country,NCT00736099::country::Philippines,NCT00736099,Philippines,,,,,,,,,,,,,,
country,NCT00736099::country::Argentina,NCT00736099,Argentina,,,,,,,,,,,,,,
country,NCT00736099::country::Italy,NCT00736099,Italy,,,,,,,,,,,,,,
country,NCT00736099::country::Sweden,NCT00736099,Sweden,,,,,,,,,,,,,,
country,NCT00736099::country::Poland,NCT00736099,Poland,,,,,,,,,,,,,,
country,NCT00736099::country::Austria,NCT00736099,Austria,,,,,,,,,,,,,,
country,NCT00736099::country::Croatia,NCT00736099,Croatia,,,,,,,,,,,,,,
country,NCT00736099::country::Thailand,NCT00736099,Thailand,,,,,,,,,,,,,,
trial,NCT01792518,NCT01792518,"MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin",PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,360.0,2013-02,2015-12,12.0,74.0,,,,,
arm,NCT01792518::arm::FG000,NCT01792518,Placebo,,,,,,,,,,FG000,"Patients received 1 matching placebo tablet to Linagliptin 5 mg, administered orally, once every day for 24 weeks during the double blind treatment period.",,,
arm,NCT01792518::arm::FG001,NCT01792518,Linagliptin 5 mg,,,,,,,,,,FG001,"Patients received 1 tablet of Linagliptin 5 mg, administered orally, once every day for 24 weeks during the double blind treatment period.",,,
period,NCT01792518::period::1,NCT01792518,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01792518::outcome::primary::1,NCT01792518,HbA1c Change From Baseline After 24 Weeks Double-blind Randomized Treatment,,,,,,,,,,,,,PRIMARY,Baseline and 24 weeks
country,NCT01792518::country::United States,NCT01792518,United States,,,,,,,,,,,,,,
country,NCT01792518::country::Canada,NCT01792518,Canada,,,,,,,,,,,,,,
country,NCT01792518::country::France,NCT01792518,France,,,,,,,,,,,,,,
country,NCT01792518::country::Germany,NCT01792518,Germany,,,,,,,,,,,,,,
country,NCT01792518::country::Japan,NCT01792518,Japan,,,,,,,,,,,,,,
country,NCT01792518::country::Taiwan,NCT01792518,Taiwan,,,,,,,,,,,,,,
country,NCT01792518::country::South Korea,NCT01792518,South Korea,,,,,,,,,,,,,,
country,NCT01792518::country::Spain,NCT01792518,Spain,,,,,,,,,,,,,,
country,NCT01792518::country::Denmark,NCT01792518,Denmark,,,,,,,,,,,,,,
country,NCT01792518::country::Finland,NCT01792518,Finland,,,,,,,,,,,,,,
country,NCT01792518::country::Philippines,NCT01792518,Philippines,,,,,,,,,,,,,,
country,NCT01792518::country::Vietnam,NCT01792518,Vietnam,,,,,,,,,,,,,,
trial,NCT00663260,NCT00663260,Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,631.0,2008-06,2011-06,13.0,96.0,,,,,
arm,NCT00663260::arm::FG000,NCT00663260,Placebo,,,,,,,,,,FG000,Participants received dapagliflozin matching placebo once daily for up to 24 weeks (Subjects were to continue their original pre-enrollment anti-diabetic therapy; may include the addition of open-labe,,,
arm,NCT00663260::arm::FG001,NCT00663260,Dapagliflozin 5 mg,,,,,,,,,,FG001,Participants received dapagliflozin 5 mg once daily for up to 24 weeks (Subjects were to continue their original pre-enrollment anti-diabetic therapy; may include the addition of open-label metformin ,,,
arm,NCT00663260::arm::FG002,NCT00663260,Dapagliflozin 10 mg,,,,,,,,,,FG002,Participants received dapagliflozin 10 mg once daily for up to 24 weeks (Subjects were to continue their original pre-enrollment anti-diabetic therapy; may include the addition of open-label metformin,,,
period,NCT00663260::period::1,NCT00663260,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00663260::outcome::primary::1,NCT00663260,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF],,,,,,,,,,,,,PRIMARY,From Baseline to Week 24
country,NCT00663260::country::United States,NCT00663260,United States,,,,,,,,,,,,,,
country,NCT00663260::country::Canada,NCT00663260,Canada,,,,,,,,,,,,,,
country,NCT00663260::country::Argentina,NCT00663260,Argentina,,,,,,,,,,,,,,
country,NCT00663260::country::Italy,NCT00663260,Italy,,,,,,,,,,,,,,
country,NCT00663260::country::India,NCT00663260,India,,,,,,,,,,,,,,
country,NCT00663260::country::Mexico,NCT00663260,Mexico,,,,,,,,,,,,,,
country,NCT00663260::country::France,NCT00663260,France,,,,,,,,,,,,,,
country,NCT00663260::country::Australia,NCT00663260,Australia,,,,,,,,,,,,,,
country,NCT00663260::country::Peru,NCT00663260,Peru,,,,,,,,,,,,,,
country,NCT00663260::country::Denmark,NCT00663260,Denmark,,,,,,,,,,,,,,
country,NCT00663260::country::Spain,NCT00663260,Spain,,,,,,,,,,,,,,
country,NCT00663260::country::Puerto Rico,NCT00663260,Puerto Rico,,,,,,,,,,,,,,
country,NCT00663260::country::Singapore,NCT00663260,Singapore,,,,,,,,,,,,,,
trial,NCT01512108,NCT01512108,Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,363.0,2012-01-10,2013-04-26,1.0,36.0,,,,,
arm,NCT01512108::arm::FG000,NCT01512108,Liraglutide 0.9 mg/Day,,,,,,,,,,FG000,"Liraglutide 0.9 mg/day was injected subcutaneously, once daily in morning or evening in addition to unchanged pre-trial oral anti-diabetic drug (OAD) (either glinide, metformin, α-glucosidase inhibito",,,
arm,NCT01512108::arm::FG001,NCT01512108,Additional OAD,,,,,,,,,,FG001,Subject's received additional OAD to pre-trial OAD. The type and dosage of additional OAD was chosen based on each individual's glycaemic control by the investigator as per Japanese labelling.,,,
period,NCT01512108::period::1,NCT01512108,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01512108::outcome::primary::1,NCT01512108,Incidence of Treatment Emergent Adverse Events (AEs),,,,,,,,,,,,,PRIMARY,Week 0 to Week 52 + 7 days
country,NCT01512108::country::Japan,NCT01512108,Japan,,,,,,,,,,,,,,
trial,NCT00666458,NCT00666458,18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D),PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,822.0,2008-04,2009-03,9.0,87.0,,,,,
arm,NCT00666458::arm::FG000,NCT00666458,Saxa + Met,,,,,,,,,,FG000,Saxagliptin 5 mg tablets added on to open-label metformin,,,
arm,NCT00666458::arm::FG001,NCT00666458,Sita + Met,,,,,,,,,,FG001,Sitagliptin 100 mg capsules added on to open-label metformin,,,
period,NCT00666458::period::1,NCT00666458,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00666458::outcome::primary::1,NCT00666458,Hemoglobin A1c (HbA1c) Change From Baseline to Week 18,,,,,,,,,,,,,PRIMARY,"Baseline, Week 18"
country,NCT00666458::country::Sweden,NCT00666458,Sweden,,,,,,,,,,,,,,
country,NCT00666458::country::Belgium,NCT00666458,Belgium,,,,,,,,,,,,,,
country,NCT00666458::country::France,NCT00666458,France,,,,,,,,,,,,,,
country,NCT00666458::country::Italy,NCT00666458,Italy,,,,,,,,,,,,,,
country,NCT00666458::country::Norway,NCT00666458,Norway,,,,,,,,,,,,,,
country,NCT00666458::country::South Africa,NCT00666458,South Africa,,,,,,,,,,,,,,
country,NCT00666458::country::Argentina,NCT00666458,Argentina,,,,,,,,,,,,,,
country,NCT00666458::country::Denmark,NCT00666458,Denmark,,,,,,,,,,,,,,
country,NCT00666458::country::Mexico,NCT00666458,Mexico,,,,,,,,,,,,,,
trial,NCT02924064,NCT02924064,Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,247.0,2016-09,,1.0,1.0,,,,,
arm,NCT02924064::arm::FG000,NCT02924064,Teneligliptin 20mg + Metformin,,,,,,,,,,FG000,Teneligliptin (20 mg once daily) for 24 weeks in combination with metformin.,,,
arm,NCT02924064::arm::FG001,NCT02924064,Placebo + Metformin,,,,,,,,,,FG001,Placebo for 24 weeks in combination with metformin.,,,
period,NCT02924064::period::1,NCT02924064,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02924064::outcome::primary::1,NCT02924064,The Changes in HbA1c at Week 24,,,,,,,,,,,,,PRIMARY,at Day 1(baseline) and Week 24
country,NCT02924064::country::China,NCT02924064,China,,,,,,,,,,,,,,
trial,NCT02916706,NCT02916706,Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,254.0,2016-09,,1.0,1.0,,,,,
arm,NCT02916706::arm::FG000,NCT02916706,Teneligliptin 20mg,,,,,,,,,,FG000,Teneligliptin (20mg once daily) for 24 weeks,,,
arm,NCT02916706::arm::FG001,NCT02916706,Placebo,,,,,,,,,,FG001,Placebo for 24 weeks,,,
period,NCT02916706::period::1,NCT02916706,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02916706::outcome::primary::1,NCT02916706,Change in HbA1c From Baseline to Week 24,,,,,,,,,,,,,PRIMARY,at Day 1(baseline) and Week 24
country,NCT02916706::country::China,NCT02916706,China,,,,,,,,,,,,,,
trial,NCT02561078,NCT02561078,An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,420.0,2015-10-20,2017-05-09,2.0,57.0,,,,,
arm,NCT02561078::arm::FG000,NCT02561078,Human Regular U-500 Insulin Administered by CSII,,,,,,,,,,FG000,Human regular U-500 insulin administered by continuous subcutaneous insulin infusion (CSII) and titrated based on blood glucose readings for 26 weeks with a 2-week multiple daily injections (MDI) lead,,,
arm,NCT02561078::arm::FG001,NCT02561078,Human Regular U-500 Insulin Administered by MDI,,,,,,,,,,FG001,Human regular U-500 insulin administered subcutaneously (SC) by multiple daily injections (MDI) three times a day and titrated based on blood glucose readings for 26 weeks.,,,
period,NCT02561078::period::1,NCT02561078,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02561078::outcome::primary::1,NCT02561078,Change From Baseline in Hemoglobin A1c (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline, 26 Weeks"
country,NCT02561078::country::United States,NCT02561078,United States,,,,,,,,,,,,,,
country,NCT02561078::country::Puerto Rico,NCT02561078,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00819091,NCT00819091,"Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug",PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,245.0,2008-12,,7.0,45.0,,,,,
arm,NCT00819091::arm::FG000,NCT00819091,Placebo,,,,,,,,,,FG000,Matching placebo tablet taken orally once daily,,,
arm,NCT00819091::arm::FG001,NCT00819091,Linagliptin (BI 1356) 5.0 mg,,,,,,,,,,FG001,Linagliptin 5.0 mg tablet taken orally once daily,,,
period,NCT00819091::period::1,NCT00819091,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00819091::outcome::primary::1,NCT00819091,Change From Baseline in HbA1c (Glycosylated Hemoglobin) at Week 18,,,,,,,,,,,,,PRIMARY,"Baseline, week 18"
country,NCT00819091::country::United States,NCT00819091,United States,,,,,,,,,,,,,,
country,NCT00819091::country::India,NCT00819091,India,,,,,,,,,,,,,,
country,NCT00819091::country::Russia,NCT00819091,Russia,,,,,,,,,,,,,,
country,NCT00819091::country::Hungary,NCT00819091,Hungary,,,,,,,,,,,,,,
country,NCT00819091::country::Poland,NCT00819091,Poland,,,,,,,,,,,,,,
country,NCT00819091::country::Argentina,NCT00819091,Argentina,,,,,,,,,,,,,,
country,NCT00819091::country::Japan,NCT00819091,Japan,,,,,,,,,,,,,,
trial,NCT03882970,NCT03882970,A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,1444.0,2019-04-01,2021-01-04,13.0,122.0,,,,,
arm,NCT03882970::arm::FG000,NCT03882970,5 mg Tirzepatide,,,,,,,,,,FG000,5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.,,,
arm,NCT03882970::arm::FG001,NCT03882970,10 mg Tirzepatide,,,,,,,,,,FG001,10 mg tirzepatide administered SC once a week.,,,
arm,NCT03882970::arm::FG002,NCT03882970,15 mg Tirzepatide,,,,,,,,,,FG002,15 mg tirzepatide administered SC once a week SC.,,,
arm,NCT03882970::arm::FG003,NCT03882970,Insulin Degludec,,,,,,,,,,FG003,"Insulin degludec administered SC once a day. Doses were individualized and titrated according to protocol-defined targets.

The starting dose of insulin degludec was 10 IU/day ideally at bedtime, titr",,,
period,NCT03882970::period::1,NCT03882970,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03882970::outcome::primary::1,NCT03882970,Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg),,,,,,,,,,,,,PRIMARY,"Baseline, Week 52"
country,NCT03882970::country::United States,NCT03882970,United States,,,,,,,,,,,,,,
country,NCT03882970::country::Greece,NCT03882970,Greece,,,,,,,,,,,,,,
country,NCT03882970::country::Romania,NCT03882970,Romania,,,,,,,,,,,,,,
country,NCT03882970::country::South Korea,NCT03882970,South Korea,,,,,,,,,,,,,,
country,NCT03882970::country::Argentina,NCT03882970,Argentina,,,,,,,,,,,,,,
country,NCT03882970::country::Taiwan,NCT03882970,Taiwan,,,,,,,,,,,,,,
country,NCT03882970::country::Hungary,NCT03882970,Hungary,,,,,,,,,,,,,,
country,NCT03882970::country::Poland,NCT03882970,Poland,,,,,,,,,,,,,,
country,NCT03882970::country::Spain,NCT03882970,Spain,,,,,,,,,,,,,,
country,NCT03882970::country::Italy,NCT03882970,Italy,,,,,,,,,,,,,,
country,NCT03882970::country::Austria,NCT03882970,Austria,,,,,,,,,,,,,,
country,NCT03882970::country::Ukraine,NCT03882970,Ukraine,,,,,,,,,,,,,,
country,NCT03882970::country::Puerto Rico,NCT03882970,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01318070,NCT01318070,Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,339.0,2007-11,2008-10,0.0,0.0,,,,,
arm,NCT01318070::arm::FG000,NCT01318070,Alogliptin 12.5 mg QD and Pioglitazone 15 or 30mg QD,,,,,,,,,,FG000,"Alogliptin 12.5mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.",,,
arm,NCT01318070::arm::FG001,NCT01318070,Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD,,,,,,,,,,FG001,"Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.",,,
arm,NCT01318070::arm::FG002,NCT01318070,Pioglitazone 15 mg or 30 mg QD,,,,,,,,,,FG002,"Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.",,,
period,NCT01318070::period::1,NCT01318070,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01318070::outcome::primary::1,NCT01318070,Change From Baseline in Glycosylated Hemoglobin (Week 12).,,,,,,,,,,,,,PRIMARY,Baseline and Week 12.
trial,NCT01890122,NCT01890122,Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes,PHASE3,diabetes type 2,Diabetes Mellitus,INDUSTRY,647.0,2013-09,2015-10,4.0,45.0,,,,,
arm,NCT01890122::arm::FG000,NCT01890122,Metformin HCl 500 mg,,,,,,,,,,FG000,"Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matchin",,,
arm,NCT01890122::arm::FG001,NCT01890122,Alogliptin 12.5 mg,,,,,,,,,,FG001,"Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 ",,,
arm,NCT01890122::arm::FG002,NCT01890122,Alogliptin 12.5 mg + Metformin HCl 500 mg FDC,,,,,,,,,,FG002,"Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up",,,
arm,NCT01890122::arm::FG003,NCT01890122,Placebo,,,,,,,,,,FG003,"Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to",,,
period,NCT01890122::period::1,NCT01890122,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01890122::outcome::primary::1,NCT01890122,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (or Early Termination),,,,,,,,,,,,,PRIMARY,Baseline and Week 26 (or Early termination)
country,NCT01890122::country::China,NCT01890122,China,,,,,,,,,,,,,,
country,NCT01890122::country::Malaysia,NCT01890122,Malaysia,,,,,,,,,,,,,,
country,NCT01890122::country::South Korea,NCT01890122,South Korea,,,,,,,,,,,,,,
country,NCT01890122::country::Taiwan,NCT01890122,Taiwan,,,,,,,,,,,,,,
trial,NCT03214380,NCT03214380,A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,933.0,2017-07-14,2019-03-13,16.0,141.0,,,,,
arm,NCT03214380::arm::FG000,NCT03214380,Insulin Lispro (Humalog) Lead-In,,,,,,,,,,FG000,100 U/mL Insulin lispro given SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and ,,,
arm,NCT03214380::arm::FG001,NCT03214380,Insulin Lispro (Humalog),,,,,,,,,,FG001,100 U/mL Insulin lispro given SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and ,,,
arm,NCT03214380::arm::FG002,NCT03214380,LY900014,,,,,,,,,,FG002,100 U/mL LY900014 SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated acc,,,
arm,NCT03214380::arm::FG003,NCT03214380,Insulin Lispro (Humalog) Lead-In Maximum Extended Enrollment,,,,,,,,,,FG003,100 U/mL Insulin lispro (Humalog) SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized ,,,
arm,NCT03214380::arm::FG004,NCT03214380,Insulin Lispro (Humalog) Maximum Extended Enrollment (MEE),,,,,,,,,,FG004,100 U/mL Insulin lispro (Humalog) SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized ,,,
arm,NCT03214380::arm::FG005,NCT03214380,LY900014 (MEE),,,,,,,,,,FG005,100 U/mL LY900014 SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated acc,,,
period,NCT03214380::period::1,NCT03214380,Lead-in,,,,,,,,,,,,1.0,,
period,NCT03214380::period::2,NCT03214380,Treatment Period,,,,,,,,,,,,2.0,,
outcome,NCT03214380::outcome::primary::1,NCT03214380,Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26,,,,,,,,,,,,,PRIMARY,"Baseline, Week 26"
country,NCT03214380::country::United States,NCT03214380,United States,,,,,,,,,,,,,,
country,NCT03214380::country::Japan,NCT03214380,Japan,,,,,,,,,,,,,,
country,NCT03214380::country::South Korea,NCT03214380,South Korea,,,,,,,,,,,,,,
country,NCT03214380::country::India,NCT03214380,India,,,,,,,,,,,,,,
country,NCT03214380::country::Germany,NCT03214380,Germany,,,,,,,,,,,,,,
country,NCT03214380::country::Argentina,NCT03214380,Argentina,,,,,,,,,,,,,,
country,NCT03214380::country::Russia,NCT03214380,Russia,,,,,,,,,,,,,,
country,NCT03214380::country::Australia,NCT03214380,Australia,,,,,,,,,,,,,,
country,NCT03214380::country::Czechia,NCT03214380,Czechia,,,,,,,,,,,,,,
country,NCT03214380::country::Puerto Rico,NCT03214380,Puerto Rico,,,,,,,,,,,,,,
country,NCT03214380::country::Slovakia,NCT03214380,Slovakia,,,,,,,,,,,,,,
country,NCT03214380::country::Taiwan,NCT03214380,Taiwan,,,,,,,,,,,,,,
country,NCT03214380::country::Hungary,NCT03214380,Hungary,,,,,,,,,,,,,,
country,NCT03214380::country::Mexico,NCT03214380,Mexico,,,,,,,,,,,,,,
country,NCT03214380::country::Spain,NCT03214380,Spain,,,,,,,,,,,,,,
country,NCT03214380::country::Italy,NCT03214380,Italy,,,,,,,,,,,,,,
trial,NCT00094770,NCT00094770,An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024),PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,1172.0,2004-09,2007-05,0.0,0.0,,,,,
arm,NCT00094770::arm::FG000,NCT00094770,Sitagliptin 100 mg,,,,,,,,,,FG000,The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily.,,,
arm,NCT00094770::arm::FG001,NCT00094770,Glipizide,,,,,,,,,,FG001,The Glipizide group includes data from patients randomized to receive treatment with glipizide initiated at a dose of 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of ,,,
period,NCT00094770::period::1,NCT00094770,Year 1 ( Week 0 to Week 52),,,,,,,,,,,,1.0,,
period,NCT00094770::period::2,NCT00094770,Year 2 (Week 0 to Week 104),,,,,,,,,,,,2.0,,
outcome,NCT00094770::outcome::primary::1,NCT00094770,Change From Baseline in HbA1c at Week 52,,,,,,,,,,,,,PRIMARY,Baseline and Week 52
trial,NCT00700817,NCT00700817,"The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus",PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,665.0,2008-06,2010-06,15.0,166.0,,,,,
arm,NCT00700817::arm::FG000,NCT00700817,Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg,,,,,,,,,,FG000,Once-daily subcutaneous dose of liraglutide 1.2 mg with at least 1500 mg metformin/day (tablets) for 26 weeks. First week for up-titration of liraglutide from 0.6 mg to 1.2 mg. Subjects continued to r,,,
arm,NCT00700817::arm::FG001,NCT00700817,Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg,,,,,,,,,,FG001,Once-daily subcutaneous dose of liraglutide 1.8 mg with at least 1500 mg metformin/day (tablets) for 26 weeks. First 2 weeks for up-titration of liraglutide from 0.6 mg to 1.8 mg. Subjects continued t,,,
arm,NCT00700817::arm::FG002,NCT00700817,Sita -> Sita,,,,,,,,,,FG002,Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-,,,
arm,NCT00700817::arm::FG003,NCT00700817,Sita -> Sita -> Lira 1.2 mg,,,,,,,,,,FG003,Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-,,,
arm,NCT00700817::arm::FG004,NCT00700817,Sita -> Sita -> Lira 1.8 mg,,,,,,,,,,FG004,Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-,,,
period,NCT00700817::period::1,NCT00700817,Week 0-26 (Main Period),,,,,,,,,,,,1.0,,
period,NCT00700817::period::2,NCT00700817,Week 26-52 (Extension Period 1),,,,,,,,,,,,2.0,,
period,NCT00700817::period::3,NCT00700817,Week 52-78 (Extension Period 2),,,,,,,,,,,,3.0,,
outcome,NCT00700817::outcome::primary::1,NCT00700817,Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 26,,,,,,,,,,,,,PRIMARY,"Week 0, Week 26"
outcome,NCT00700817::outcome::primary::2,NCT00700817,Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 52,,,,,,,,,,,,,PRIMARY,"Week 0, Week 52"
outcome,NCT00700817::outcome::primary::3,NCT00700817,Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 78,,,,,,,,,,,,,PRIMARY,"Week 0, Week 78"
outcome,NCT00700817::outcome::primary::4,NCT00700817,Mean Change in Glycosylated Haemoglobin A1c (HbA1c) From Week 52 to Week 78,,,,,,,,,,,,,PRIMARY,"Week 52, Week 78"
country,NCT00700817::country::United States,NCT00700817,United States,,,,,,,,,,,,,,
country,NCT00700817::country::United Kingdom,NCT00700817,United Kingdom,,,,,,,,,,,,,,
country,NCT00700817::country::Germany,NCT00700817,Germany,,,,,,,,,,,,,,
country,NCT00700817::country::Canada,NCT00700817,Canada,,,,,,,,,,,,,,
country,NCT00700817::country::Netherlands,NCT00700817,Netherlands,,,,,,,,,,,,,,
country,NCT00700817::country::Italy,NCT00700817,Italy,,,,,,,,,,,,,,
country,NCT00700817::country::Spain,NCT00700817,Spain,,,,,,,,,,,,,,
country,NCT00700817::country::France,NCT00700817,France,,,,,,,,,,,,,,
country,NCT00700817::country::Ireland,NCT00700817,Ireland,,,,,,,,,,,,,,
country,NCT00700817::country::Puerto Rico,NCT00700817,Puerto Rico,,,,,,,,,,,,,,
country,NCT00700817::country::Slovakia,NCT00700817,Slovakia,,,,,,,,,,,,,,
country,NCT00700817::country::Romania,NCT00700817,Romania,,,,,,,,,,,,,,
country,NCT00700817::country::Croatia,NCT00700817,Croatia,,,,,,,,,,,,,,
country,NCT00700817::country::Slovenia,NCT00700817,Slovenia,,,,,,,,,,,,,,
country,NCT00700817::country::Serbia and Montenegro,NCT00700817,Serbia and Montenegro,,,,,,,,,,,,,,
trial,NCT00087516,NCT00087516,Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021),PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,741.0,2004-06,2007-02,0.0,0.0,,,,,
arm,NCT00087516::arm::FG000,NCT00087516,Sitagliptin 100 mg/100 mg,,,,,,,,,,FG000,The Sitagliptin 100 mg/100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg q.d. (once daily) for up to 104 weeks (including the 24-week Pha,,,
arm,NCT00087516::arm::FG001,NCT00087516,Sitagliptin 200 mg/200 mg,,,,,,,,,,FG001,The Sitagliptin 200 mg/200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 200 mg q.d. for up to 104 weeks (including the 24-week Phase A study pe,,,
arm,NCT00087516::arm::FG002,NCT00087516,Placebo/Sitagliptin 100 mg,,,,,,,,,,FG002,The Placebo/Sitagliptin 100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study p,,,
arm,NCT00087516::arm::FG003,NCT00087516,Placebo/Sitagliptin 200 mg,,,,,,,,,,FG003,The Placebo/Sitagliptin 200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study p,,,
period,NCT00087516::period::1,NCT00087516,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00087516::outcome::primary::1,NCT00087516,Change From Baseline in A1C at Week 24,,,,,,,,,,,,,PRIMARY,Weeks 0-24
trial,NCT00305604,NCT00305604,Study of Sitagliptin in Older Type 2 Diabetics (0431-047)(COMPLETED),PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,206.0,2006-03-08,2008-03-12,0.0,0.0,,,,,
arm,NCT00305604::arm::FG000,NCT00305604,Sitagliptin,,,,,,,,,,FG000,Once-daily administration of sitagliptin 100 mg (or 50 mg based on creatinine clearance); Patients may be down-titrated (1 instead of 2 tablets) if there is a decrease in creatinine clearance to \< 50,,,
arm,NCT00305604::arm::FG001,NCT00305604,Placebo,,,,,,,,,,FG001,Sitagliptin-matching placebo tablets.,,,
period,NCT00305604::period::1,NCT00305604,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00305604::outcome::primary::1,NCT00305604,Change From Baseline in HbA1c (Hemoglobin A1c) at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and Week 24
trial,NCT03115112,NCT03115112,Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,386.0,2017-10-12,2018-10-31,6.0,56.0,,,,,
arm,NCT03115112::arm::FG000,NCT03115112,Bexagliflozin,,,,,,,,,,FG000,"Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for sitagliptin daily for the duration of the",,,
arm,NCT03115112::arm::FG001,NCT03115112,Sitagliptin,,,,,,,,,,FG001,"Subjects will receive a sitagliptin tablet, 100 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the stud",,,
period,NCT03115112::period::1,NCT03115112,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03115112::outcome::primary::1,NCT03115112,Change in HbA1c From Baseline to Week 24,,,,,,,,,,,,,PRIMARY,Baseline to week 24
country,NCT03115112::country::Poland,NCT03115112,Poland,,,,,,,,,,,,,,
country,NCT03115112::country::Japan,NCT03115112,Japan,,,,,,,,,,,,,,
country,NCT03115112::country::United States,NCT03115112,United States,,,,,,,,,,,,,,
country,NCT03115112::country::Spain,NCT03115112,Spain,,,,,,,,,,,,,,
country,NCT03115112::country::Hungary,NCT03115112,Hungary,,,,,,,,,,,,,,
country,NCT03115112::country::Czechia,NCT03115112,Czechia,,,,,,,,,,,,,,
trial,NCT01045707,NCT01045707,"Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes",PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,530.0,2010-01,2010-10,9.0,92.0,,,,,
arm,NCT01045707::arm::FG000,NCT01045707,IDegAsp OD,,,,,,,,,,FG000,Insulin degludec/insulin aspart (IDegAsp) was given subcutaneously (s.c.) once daily (OD) in combination with subject's pre-trial treatment of metformin. IDegAsp was given with breakfast for 26 weeks ,,,
arm,NCT01045707::arm::FG001,NCT01045707,IGlar OD,,,,,,,,,,FG001,Insulin glargine (IGlar) was given subcutaneously (s.c.) once daily (OD) according to approved labelling in combination with subject's pre-trial treatment of metformin. IGlar was given for 52 weeks (2,,,
period,NCT01045707::period::1,NCT01045707,Main: Week 0 to 26 (NN5401-3590),,,,,,,,,,,,1.0,,
period,NCT01045707::period::2,NCT01045707,Extension: Week 27 to 52 (NN5401-3726),,,,,,,,,,,,2.0,,
outcome,NCT01045707::outcome::primary::1,NCT01045707,Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment,,,,,,,,,,,,,PRIMARY,"Week 0, Week 26"
outcome,NCT01045707::outcome::primary::2,NCT01045707,Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes,,,,,,,,,,,,,PRIMARY,Week 0 to Week 53 + 7 days follow up
outcome,NCT01045707::outcome::primary::3,NCT01045707,Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,,,,,,,,,,,,PRIMARY,Week 0 to Week 53 + 7 days follow up
outcome,NCT01045707::outcome::primary::4,NCT01045707,Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs),,,,,,,,,,,,,PRIMARY,Week 0 to Week 53 + 7 days follow up
country,NCT01045707::country::United States,NCT01045707,United States,,,,,,,,,,,,,,
country,NCT01045707::country::Spain,NCT01045707,Spain,,,,,,,,,,,,,,
country,NCT01045707::country::Russia,NCT01045707,Russia,,,,,,,,,,,,,,
country,NCT01045707::country::Austria,NCT01045707,Austria,,,,,,,,,,,,,,
country,NCT01045707::country::India,NCT01045707,India,,,,,,,,,,,,,,
country,NCT01045707::country::Poland,NCT01045707,Poland,,,,,,,,,,,,,,
country,NCT01045707::country::Turkey (Türkiye),NCT01045707,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01045707::country::South Korea,NCT01045707,South Korea,,,,,,,,,,,,,,
country,NCT01045707::country::Puerto Rico,NCT01045707,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01289119,NCT01289119,Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,506.0,2010-12,2011-12,3.0,21.0,,,,,
arm,NCT01289119::arm::FG000,NCT01289119,Placebo,,,,,,,,,,FG000,"Participants received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks",,,
arm,NCT01289119::arm::FG001,NCT01289119,Alogliptin Monotherapy,,,,,,,,,,FG001,"Participants received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.",,,
arm,NCT01289119::arm::FG002,NCT01289119,Metformin,,,,,,,,,,FG002,"Participants continued to receive their stable dose of Metformin (≥1000 mg/day) and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.",,,
arm,NCT01289119::arm::FG003,NCT01289119,Metformin + Alogliptin Add-on Therapy,,,,,,,,,,FG003,"Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.",,,
arm,NCT01289119::arm::FG004,NCT01289119,Pioglitazone,,,,,,,,,,FG004,"Participants continued to receive their stable dose of pioglitazone with or without metformin and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.",,,
arm,NCT01289119::arm::FG005,NCT01289119,Pioglitazone + Alogliptin Add-on Therapy,,,,,,,,,,FG005,"Participants continued to receive their stable dose of pioglitazone with or without metformin and also received alogliptin, 25 mg tablets orally once daily for up to 16 weeks.",,,
period,NCT01289119::period::1,NCT01289119,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01289119::outcome::primary::1,NCT01289119,Change From Baseline in Glycosylated Hemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,Baseline and Week 16.
country,NCT01289119::country::China,NCT01289119,China,,,,,,,,,,,,,,
country,NCT01289119::country::Hong Kong,NCT01289119,Hong Kong,,,,,,,,,,,,,,
country,NCT01289119::country::Taiwan,NCT01289119,Taiwan,,,,,,,,,,,,,,
trial,NCT02371759,NCT02371759,Lidocaine + Clonidine for Intraoral Anesthesia in Patients With Diabetes Mellitus Type 2,PHASE3,diabetes type 2,Diabetes Mellitus; Local Anesthesia,OTHER,256.0,2013-06,2016-01,1.0,1.0,,,,,
arm,NCT02371759::arm::FG000,NCT02371759,Diabetics: L+C Maxillary Anesthesia,,,,,,,,,,FG000,"Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for maxillary infiltration anesthesia

L+C maxillary anesthesia: Maxillary anesthesia obtained by 2% lidocaine + ",,,
arm,NCT02371759::arm::FG001,NCT02371759,Diabetics: L+C Mandibular Anesthesia,,,,,,,,,,FG001,"Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for mandibular block anesthesia

L+C mandibular anesthesia: Mandibular anesthesia obtained by 2% lidocaine + clon",,,
arm,NCT02371759::arm::FG002,NCT02371759,Diabetics: L+E Maxillary Anesthesia,,,,,,,,,,FG002,"Single dose intraoral local anesthesia with 2ml lidocaine (2%)+ epinephrine (1:80.000) for maxillary infiltration anesthesia

L+E maxillary anesthesia: Maxillary anesthesia obtained by 2% lidocaine + ",,,
arm,NCT02371759::arm::FG003,NCT02371759,Diabetics: L+E Mandibular Anesthesia,,,,,,,,,,FG003,"Single dose intraoral local anesthesia with 2ml lidocaine (2%) + epinephrine (1:80.000) for mandibular block anesthesia

L+E mandibular anesthesia: Mandibular anesthesia obtained by 2% lidocaine + epi",,,
arm,NCT02371759::arm::FG004,NCT02371759,Healthy: L+C Maxillary Anesthesia,,,,,,,,,,FG004,"Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for maxillary infiltration anesthesia

L+C maxillary anesthesia: Maxillary anesthesia obtained by 2% lidocaine + ",,,
arm,NCT02371759::arm::FG005,NCT02371759,Healthy: L+C Mandibular Anesthesia,,,,,,,,,,FG005,"Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for mandibular block anesthesia

L+C mandibular anesthesia: Mandibular anesthesia obtained by 2% lidocaine + clon",,,
arm,NCT02371759::arm::FG006,NCT02371759,Healthy: L+E Maxillary Anesthesia,,,,,,,,,,FG006,"Single dose intraoral local anesthesia with 2ml lidocaine (2%)+ epinephrine (1:80.000) for maxillary infiltration anesthesia

L+E maxillary anesthesia: Maxillary anesthesia obtained by 2% lidocaine + ",,,
arm,NCT02371759::arm::FG007,NCT02371759,Healthy: L+E Mandibular Anesthesia,,,,,,,,,,FG007,"Single dose intraoral local anesthesia with 2ml lidocaine (2%) + epinephrine (1:80.000) for mandibular block anesthesia

L+E mandibular anesthesia: Mandibular anesthesia obtained by 2% lidocaine + epi",,,
period,NCT02371759::period::1,NCT02371759,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02371759::outcome::primary::1,NCT02371759,Duration of Intraoral Local Anesthesia,,,,,,,,,,,,,PRIMARY,Up to 6 hours after local anesthesia injection
outcome,NCT02371759::outcome::primary::2,NCT02371759,Intensity of Intraoral Local Anesthesia,,,,,,,,,,,,,PRIMARY,Up to 10 minutes after local anesthesia injection
outcome,NCT02371759::outcome::primary::3,NCT02371759,Baseline Systolic Blood Pressure,,,,,,,,,,,,,PRIMARY,"Baseline, 0 minutes"
outcome,NCT02371759::outcome::primary::4,NCT02371759,Systolic Blood Pressure at 10 Minutes,,,,,,,,,,,,,PRIMARY,10th minute
outcome,NCT02371759::outcome::primary::5,NCT02371759,Systolic Blood Pressure at 15 Minutes,,,,,,,,,,,,,PRIMARY,15th minute
outcome,NCT02371759::outcome::primary::6,NCT02371759,Systolic Blood Pressure at 20 Minutes,,,,,,,,,,,,,PRIMARY,20th minute
outcome,NCT02371759::outcome::primary::7,NCT02371759,Systolic Blood Pressure at 35 Minutes,,,,,,,,,,,,,PRIMARY,35th minute
outcome,NCT02371759::outcome::primary::8,NCT02371759,Baseline Diastolic Blood Pressure,,,,,,,,,,,,,PRIMARY,"baseline, 0 minutes"
outcome,NCT02371759::outcome::primary::9,NCT02371759,Diastolic Blood Pressure at 10 Minutes,,,,,,,,,,,,,PRIMARY,10th minute
outcome,NCT02371759::outcome::primary::10,NCT02371759,Diastolic Blood Pressure at 15 Minutes,,,,,,,,,,,,,PRIMARY,15th minute
outcome,NCT02371759::outcome::primary::11,NCT02371759,Diastolic Blood Pressure at 20 Minutes,,,,,,,,,,,,,PRIMARY,20th minute
outcome,NCT02371759::outcome::primary::12,NCT02371759,Diastolic Blood Pressure at 35 Minutes,,,,,,,,,,,,,PRIMARY,35th minute
outcome,NCT02371759::outcome::primary::13,NCT02371759,Baseline Values of Heart Rate,,,,,,,,,,,,,PRIMARY,"baseline, 0 minutes"
outcome,NCT02371759::outcome::primary::14,NCT02371759,Heart Rate at 10 Minutes,,,,,,,,,,,,,PRIMARY,10th minute
outcome,NCT02371759::outcome::primary::15,NCT02371759,Heart Rate at 15 Minutes,,,,,,,,,,,,,PRIMARY,15th minute
outcome,NCT02371759::outcome::primary::16,NCT02371759,Heart Rate at 20 Minutes,,,,,,,,,,,,,PRIMARY,20th minute
outcome,NCT02371759::outcome::primary::17,NCT02371759,Ceart Rate at 35 Minutes,,,,,,,,,,,,,PRIMARY,35th minute
outcome,NCT02371759::outcome::primary::18,NCT02371759,Baseline Electrocardiogram,,,,,,,,,,,,,PRIMARY,"baseline, 0 minutes"
outcome,NCT02371759::outcome::primary::19,NCT02371759,Electrocardiogram at 10 Minutes,,,,,,,,,,,,,PRIMARY,10th minute
outcome,NCT02371759::outcome::primary::20,NCT02371759,Electrocardiogram at 15 Minutes,,,,,,,,,,,,,PRIMARY,15th minute
outcome,NCT02371759::outcome::primary::21,NCT02371759,Electrocardiogram at 20 Minutes,,,,,,,,,,,,,PRIMARY,20th minute
country,NCT02371759::country::Serbia,NCT02371759,Serbia,,,,,,,,,,,,,,
trial,NCT01204294,NCT01204294,Comprehensive Add on Study in Japan,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,574.0,2010-09,2012-01,1.0,43.0,,,,,
arm,NCT01204294::arm::FG000,NCT01204294,Bigu+Lina,,,,,,,,,,FG000,biguanide plus linagliptin,,,
arm,NCT01204294::arm::FG001,NCT01204294,Glin+Lina,,,,,,,,,,FG001,glinide plus linagliptin,,,
arm,NCT01204294::arm::FG002,NCT01204294,Glit+Lina,,,,,,,,,,FG002,glitazone plus linagliptin,,,
arm,NCT01204294::arm::FG003,NCT01204294,SU+Lina,,,,,,,,,,FG003,sulfonylurea plus linagliptin,,,
arm,NCT01204294::arm::FG004,NCT01204294,A-GI+Lina,,,,,,,,,,FG004,alpha-glucosidase inhibitor plus linagliptin,,,
arm,NCT01204294::arm::FG005,NCT01204294,SU+Met,,,,,,,,,,FG005,sulfonylurea plus metformin,,,
arm,NCT01204294::arm::FG006,NCT01204294,A-GI+Met,,,,,,,,,,FG006,alpha-glucosidase inhibitor plus metformin,,,
period,NCT01204294::period::1,NCT01204294,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01204294::outcome::primary::1,NCT01204294,Incidence of Adverse Events (AEs),,,,,,,,,,,,,PRIMARY,"The first drug administration through 7 days after the last drug administration, up to 382 days"
country,NCT01204294::country::Japan,NCT01204294,Japan,,,,,,,,,,,,,,
trial,NCT00094757,NCT00094757,An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023),PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,521.0,2004-10-06,2006-04-28,0.0,0.0,,,,,
arm,NCT00094757::arm::FG000,NCT00094757,Sitagliptin 100 mg,,,,,,,,,,FG000,The Sitagliptin 100 mg got 1 sitagliptin 100 mg tablet and 1 sitagliptin matching placebo tablet once daily Weeks 0-54 and pioglitazone placebo once daily in Weeks 18-54.,,,
arm,NCT00094757::arm::FG001,NCT00094757,Sitagliptin 200 mg,,,,,,,,,,FG001,The Sitagliptin 200 mg got 2 sitagliptin 100 mg tablets once daily Weeks 0-54 and pioglitazone placebo once daily in Weeks 18-54.,,,
arm,NCT00094757::arm::FG002,NCT00094757,Placebo/Pioglitazone,,,,,,,,,,FG002,The Placebo/Pioglitazone got 2 sitagliptin matching placebo tablets once daily in Weeks 0- 54 and pioglitazone 30 mg/day once daily in Weeks 18-54.,,,
period,NCT00094757::period::1,NCT00094757,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00094757::outcome::primary::1,NCT00094757,Change From Baseline in A1C at Week 18,,,,,,,,,,,,,PRIMARY,Weeks 0-18
trial,NCT03021187,NCT03021187,Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,731.0,2017-02-02,2018-08-22,10.0,118.0,,,,,
arm,NCT03021187::arm::FG000,NCT03021187,Oral Semaglutide 3 mg,,,,,,,,,,FG000,Participants were to take oral semaglutide 3 mg tablets once-daily from week 0 to week 52.,,,
arm,NCT03021187::arm::FG001,NCT03021187,Oral Semaglutide 7 mg,,,,,,,,,,FG001,Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 52: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 52.,,,
arm,NCT03021187::arm::FG002,NCT03021187,Oral Semaglutide 14 mg,,,,,,,,,,FG002,"Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 52: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 5",,,
arm,NCT03021187::arm::FG003,NCT03021187,Placebo,,,,,,,,,,FG003,Participants were to take oral semaglutide placebo tablets once-daily for a period of 52 weeks.,,,
period,NCT03021187::period::1,NCT03021187,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03021187::outcome::primary::1,NCT03021187,Change in HbA1c (Week 26),,,,,,,,,,,,,PRIMARY,"Week 0, week 26"
country,NCT03021187::country::United States,NCT03021187,United States,,,,,,,,,,,,,,
country,NCT03021187::country::Japan,NCT03021187,Japan,,,,,,,,,,,,,,
country,NCT03021187::country::France,NCT03021187,France,,,,,,,,,,,,,,
country,NCT03021187::country::India,NCT03021187,India,,,,,,,,,,,,,,
country,NCT03021187::country::Canada,NCT03021187,Canada,,,,,,,,,,,,,,
country,NCT03021187::country::Greece,NCT03021187,Greece,,,,,,,,,,,,,,
country,NCT03021187::country::Russia,NCT03021187,Russia,,,,,,,,,,,,,,
country,NCT03021187::country::Poland,NCT03021187,Poland,,,,,,,,,,,,,,
country,NCT03021187::country::Mexico,NCT03021187,Mexico,,,,,,,,,,,,,,
country,NCT03021187::country::Puerto Rico,NCT03021187,Puerto Rico,,,,,,,,,,,,,,
trial,NCT02607306,NCT02607306,"A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.",PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,819.0,2015-11-18,2017-12-22,1.0,76.0,,,,,
arm,NCT02607306::arm::FG000,NCT02607306,Insulin Degludec/Liraglutide,,,,,,,,,,FG000,Eligible subjects were treated with insulin degludec/liraglutide (IDegLira) once daily (OD) in combination with pre-trial oral anti diabetic drugs (at stable dose level and dosing frequency; dose redu,,,
arm,NCT02607306::arm::FG001,NCT02607306,Insulin Degludec,,,,,,,,,,FG001,Eligible subjects were treated with insulin degludec (IDeg) once daily (OD) in combination with pre-trial oral anti diabetic drugs (at stable dose level and dosing frequency unless there were safety c,,,
arm,NCT02607306::arm::FG002,NCT02607306,Liraglutide,,,,,,,,,,FG002,"Eligible subjects were treated with liraglutide once daily (OD) in combination with pre-trial oral anti diabetic drugs (at stable dose level and dosing frequency unless there were safety concerns, in ",,,
period,NCT02607306::period::1,NCT02607306,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02607306::outcome::primary::1,NCT02607306,Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Non-inferiority of IDegLira vs IDeg and Superiority of IDegLira vs Lira,,,,,,,,,,,,,PRIMARY,"Week 0, Week 52"
country,NCT02607306::country::Japan,NCT02607306,Japan,,,,,,,,,,,,,,
trial,NCT01137812,NCT01137812,The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial),PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,756.0,2010-07,2012-03,17.0,184.0,,,,,
arm,NCT01137812::arm::FG000,NCT01137812,Canagliflozin 300 mg,,,,,,,,,,FG000,Each patient received 300 mg of canagliflozin once a day for 52 weeks with protocol-specified doses of metformin and sulphonylurea.,,,
arm,NCT01137812::arm::FG001,NCT01137812,Sitagliptin 100 mg,,,,,,,,,,FG001,Each patient received 100 mg of sitagliptin once a day for 52 weeks with protocol-specified doses of metformin and sulphonylurea.,,,
period,NCT01137812::period::1,NCT01137812,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01137812::outcome::primary::1,NCT01137812,Change in HbA1c From Baseline to Week 52,,,,,,,,,,,,,PRIMARY,Day 1 (Baseline) and Week 52
country,NCT01137812::country::United States,NCT01137812,United States,,,,,,,,,,,,,,
country,NCT01137812::country::Canada,NCT01137812,Canada,,,,,,,,,,,,,,
country,NCT01137812::country::Poland,NCT01137812,Poland,,,,,,,,,,,,,,
country,NCT01137812::country::Ukraine,NCT01137812,Ukraine,,,,,,,,,,,,,,
country,NCT01137812::country::Brazil,NCT01137812,Brazil,,,,,,,,,,,,,,
country,NCT01137812::country::France,NCT01137812,France,,,,,,,,,,,,,,
country,NCT01137812::country::India,NCT01137812,India,,,,,,,,,,,,,,
country,NCT01137812::country::Netherlands,NCT01137812,Netherlands,,,,,,,,,,,,,,
country,NCT01137812::country::Israel,NCT01137812,Israel,,,,,,,,,,,,,,
country,NCT01137812::country::Denmark,NCT01137812,Denmark,,,,,,,,,,,,,,
country,NCT01137812::country::Germany,NCT01137812,Germany,,,,,,,,,,,,,,
country,NCT01137812::country::New Zealand,NCT01137812,New Zealand,,,,,,,,,,,,,,
country,NCT01137812::country::South Korea,NCT01137812,South Korea,,,,,,,,,,,,,,
country,NCT01137812::country::Malaysia,NCT01137812,Malaysia,,,,,,,,,,,,,,
country,NCT01137812::country::Austria,NCT01137812,Austria,,,,,,,,,,,,,,
country,NCT01137812::country::Belgium,NCT01137812,Belgium,,,,,,,,,,,,,,
country,NCT01137812::country::Singapore,NCT01137812,Singapore,,,,,,,,,,,,,,
trial,NCT01713530,NCT01713530,A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,274.0,2013-02-21,2014-01-09,5.0,51.0,,,,,
arm,NCT01713530::arm::FG000,NCT01713530,IDegAsp BID,,,,,,,,,,FG000,"The subjects in this arm received insulin degludec/insulin aspart (IDegAsp) (100 U/mL, 3 mL prefilled pen PDS290) twice daily, subcutaneously in the abdomen, upper arm (deltoid area) or thigh either w",,,
arm,NCT01713530::arm::FG001,NCT01713530,IDeg OD+IAsp,,,,,,,,,,FG001,"The subjects in this arm received IDeg (100 U/mL, 3 mL prefilled pen PDS290) once daily, subcutaneously in the abdomen, upper arm (deltoid area) or thigh at any time of the day. The subjects in this a",,,
period,NCT01713530::period::1,NCT01713530,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01713530::outcome::primary::1,NCT01713530,Change From Baseline in HbA1c (%),,,,,,,,,,,,,PRIMARY,"Week 0, week 26"
country,NCT01713530::country::United States,NCT01713530,United States,,,,,,,,,,,,,,
country,NCT01713530::country::France,NCT01713530,France,,,,,,,,,,,,,,
country,NCT01713530::country::Austria,NCT01713530,Austria,,,,,,,,,,,,,,
country,NCT01713530::country::Norway,NCT01713530,Norway,,,,,,,,,,,,,,
country,NCT01713530::country::Algeria,NCT01713530,Algeria,,,,,,,,,,,,,,
trial,NCT05275400,NCT05275400,A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,986.0,2022-03-08,2024-05-15,10.0,127.0,,,,,
arm,NCT05275400::arm::FG000,NCT05275400,500 U/mL - Insulin Efsitora,,,,,,,,,,FG000,Participants received 500 units per milliliter (U/mL) Insulin Efsitora Alfa (insulin efsitora) administered subcutaneously (SC) once weekly (QW).,,,
arm,NCT05275400::arm::FG001,NCT05275400,100 U/mL - Insulin Degludec,,,,,,,,,,FG001,Participants received 100 U/mL insulin degludec administered SC once daily (QD).,,,
period,NCT05275400::period::1,NCT05275400,Treatment Period,,,,,,,,,,,,1.0,,
period,NCT05275400::period::2,NCT05275400,Follow-Up Period,,,,,,,,,,,,2.0,,
outcome,NCT05275400::outcome::primary::1,NCT05275400,Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority],,,,,,,,,,,,,PRIMARY,"Baseline, Week 26"
country,NCT05275400::country::United States,NCT05275400,United States,,,,,,,,,,,,,,
country,NCT05275400::country::Japan,NCT05275400,Japan,,,,,,,,,,,,,,
country,NCT05275400::country::Argentina,NCT05275400,Argentina,,,,,,,,,,,,,,
country,NCT05275400::country::South Korea,NCT05275400,South Korea,,,,,,,,,,,,,,
country,NCT05275400::country::Poland,NCT05275400,Poland,,,,,,,,,,,,,,
country,NCT05275400::country::Spain,NCT05275400,Spain,,,,,,,,,,,,,,
country,NCT05275400::country::Slovakia,NCT05275400,Slovakia,,,,,,,,,,,,,,
country,NCT05275400::country::Hungary,NCT05275400,Hungary,,,,,,,,,,,,,,
country,NCT05275400::country::Taiwan,NCT05275400,Taiwan,,,,,,,,,,,,,,
country,NCT05275400::country::Puerto Rico,NCT05275400,Puerto Rico,,,,,,,,,,,,,,
trial,NCT03819153,NCT03819153,A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,3533.0,2019-06-17,2024-01-09,28.0,413.0,,,,,
arm,NCT03819153::arm::FG000,NCT03819153,Semaglutide,,,,,,,,,,FG000,"Participants received a dose of semaglutide subcutaneously once weekly with dose escalation in every 4 weeks in doses 0.25 mg (weeks 0-3), 0.50 mg (weeks 4-7) until the maintenance dose of 1 mg was re",,,
arm,NCT03819153::arm::FG001,NCT03819153,Placebo,,,,,,,,,,FG001,Participants received placebo matching semaglutide subcutaneously once weekly along with standard of care until end of the study (week 238). Participants were followed up for 5 weeks after end of trea,,,
period,NCT03819153::period::1,NCT03819153,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03819153::outcome::primary::1,NCT03819153,Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI),,,,,,,,,,,,,PRIMARY,From Week 0 up to Week 234
outcome,NCT03819153::outcome::primary::2,NCT03819153,Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2,,,,,,,,,,,,,PRIMARY,
outcome,NCT03819153::outcome::primary::3,NCT03819153,Initiation of Chronic Renal Replacement Therapy,,,,,,,,,,,,,PRIMARY,
outcome,NCT03819153::outcome::primary::4,NCT03819153,Renal Death,,,,,,,,,,,,,PRIMARY,
outcome,NCT03819153::outcome::primary::5,NCT03819153,CV Death,,,,,,,,,,,,,PRIMARY,
country,NCT03819153::country::United States,NCT03819153,United States,,,,,,,,,,,,,,
country,NCT03819153::country::Canada,NCT03819153,Canada,,,,,,,,,,,,,,
country,NCT03819153::country::Japan,NCT03819153,Japan,,,,,,,,,,,,,,
country,NCT03819153::country::Russia,NCT03819153,Russia,,,,,,,,,,,,,,
country,NCT03819153::country::India,NCT03819153,India,,,,,,,,,,,,,,
country,NCT03819153::country::France,NCT03819153,France,,,,,,,,,,,,,,
country,NCT03819153::country::Hungary,NCT03819153,Hungary,,,,,,,,,,,,,,
country,NCT03819153::country::Greece,NCT03819153,Greece,,,,,,,,,,,,,,
country,NCT03819153::country::Turkey (Türkiye),NCT03819153,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT03819153::country::United Kingdom,NCT03819153,United Kingdom,,,,,,,,,,,,,,
country,NCT03819153::country::Slovakia,NCT03819153,Slovakia,,,,,,,,,,,,,,
country,NCT03819153::country::Belgium,NCT03819153,Belgium,,,,,,,,,,,,,,
country,NCT03819153::country::Germany,NCT03819153,Germany,,,,,,,,,,,,,,
country,NCT03819153::country::Italy,NCT03819153,Italy,,,,,,,,,,,,,,
country,NCT03819153::country::Netherlands,NCT03819153,Netherlands,,,,,,,,,,,,,,
country,NCT03819153::country::South Africa,NCT03819153,South Africa,,,,,,,,,,,,,,
country,NCT03819153::country::Australia,NCT03819153,Australia,,,,,,,,,,,,,,
country,NCT03819153::country::Brazil,NCT03819153,Brazil,,,,,,,,,,,,,,
country,NCT03819153::country::Poland,NCT03819153,Poland,,,,,,,,,,,,,,
country,NCT03819153::country::Argentina,NCT03819153,Argentina,,,,,,,,,,,,,,
country,NCT03819153::country::Bulgaria,NCT03819153,Bulgaria,,,,,,,,,,,,,,
country,NCT03819153::country::Spain,NCT03819153,Spain,,,,,,,,,,,,,,
country,NCT03819153::country::Thailand,NCT03819153,Thailand,,,,,,,,,,,,,,
country,NCT03819153::country::Ukraine,NCT03819153,Ukraine,,,,,,,,,,,,,,
country,NCT03819153::country::Malaysia,NCT03819153,Malaysia,,,,,,,,,,,,,,
country,NCT03819153::country::Mexico,NCT03819153,Mexico,,,,,,,,,,,,,,
country,NCT03819153::country::China,NCT03819153,China,,,,,,,,,,,,,,
country,NCT03819153::country::Israel,NCT03819153,Israel,,,,,,,,,,,,,,
trial,NCT01456195,NCT01456195,Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,421.0,2011-11,2013-07,8.0,95.0,,,,,
arm,NCT01456195::arm::FG000,NCT01456195,Placebo,,,,,,,,,,FG000,"Fasiglifam placebo-matching tablets, orally, once daily for up to 24 weeks.",,,
arm,NCT01456195::arm::FG001,NCT01456195,Fasiglifam 25 mg,,,,,,,,,,FG001,"Fasiglifam 25 mg, tablets, orally, once daily for up to 24 weeks.",,,
arm,NCT01456195::arm::FG002,NCT01456195,Fasiglifam 50 mg,,,,,,,,,,FG002,"Fasiglifam 50 mg, tablets, orally, once daily for up to 24 weeks.",,,
period,NCT01456195::period::1,NCT01456195,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01456195::outcome::primary::1,NCT01456195,Change From Baseline in Glycosylated Hemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,Baseline and Week 24
country,NCT01456195::country::United States,NCT01456195,United States,,,,,,,,,,,,,,
country,NCT01456195::country::Slovakia,NCT01456195,Slovakia,,,,,,,,,,,,,,
country,NCT01456195::country::Ukraine,NCT01456195,Ukraine,,,,,,,,,,,,,,
country,NCT01456195::country::Argentina,NCT01456195,Argentina,,,,,,,,,,,,,,
country,NCT01456195::country::Hungary,NCT01456195,Hungary,,,,,,,,,,,,,,
country,NCT01456195::country::Bulgaria,NCT01456195,Bulgaria,,,,,,,,,,,,,,
country,NCT01456195::country::Guatemala,NCT01456195,Guatemala,,,,,,,,,,,,,,
country,NCT01456195::country::Mexico,NCT01456195,Mexico,,,,,,,,,,,,,,
trial,NCT02298192,NCT02298192,A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,420.0,2014-11-21,2015-12-23,9.0,84.0,,,,,
arm,NCT02298192::arm::FG000,NCT02298192,IDegLira (1WT),,,,,,,,,,FG000,Subjects inadequately controlled on metformin either alone or in combination with pioglitazone were randomized in a 1:1 manner to receive IDegLira once daily. The subjects were stratified by their OAD,,,
arm,NCT02298192::arm::FG001,NCT02298192,IDegLira,,,,,,,,,,FG001,Subjects inadequately controlled on metformin either alone or in combination with pioglitazone were randomized in a 1:1 manner to receive IDegLira once daily. The subjects were stratified by their OAD,,,
period,NCT02298192::period::1,NCT02298192,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02298192::outcome::primary::1,NCT02298192,Change From Baseline in HbA1c,,,,,,,,,,,,,PRIMARY,"Week 0, week 32"
country,NCT02298192::country::United States,NCT02298192,United States,,,,,,,,,,,,,,
country,NCT02298192::country::Canada,NCT02298192,Canada,,,,,,,,,,,,,,
country,NCT02298192::country::Austria,NCT02298192,Austria,,,,,,,,,,,,,,
country,NCT02298192::country::Slovakia,NCT02298192,Slovakia,,,,,,,,,,,,,,
country,NCT02298192::country::Russia,NCT02298192,Russia,,,,,,,,,,,,,,
country,NCT02298192::country::Bulgaria,NCT02298192,Bulgaria,,,,,,,,,,,,,,
country,NCT02298192::country::Czechia,NCT02298192,Czechia,,,,,,,,,,,,,,
country,NCT02298192::country::Hungary,NCT02298192,Hungary,,,,,,,,,,,,,,
country,NCT02298192::country::Serbia,NCT02298192,Serbia,,,,,,,,,,,,,,
trial,NCT00528372,NCT00528372,A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,1067.0,2007-09,2010-07,4.0,78.0,,,,,
arm,NCT00528372::arm::FG000,NCT00528372,Group 1: Dapagliflozin Placebo,,,,,,,,,,FG000,"Participants with hemoglobin AIc (HbA1c) ≥7% and ≤10% at enrollment received dapagliflozin placebo once each morning and evening for up to 102 weeks. Participants also received metformin tablets, 500-",,,
arm,NCT00528372::arm::FG001,NCT00528372,"Group 1: Dapagliflozin, 2.5 mg AM",,,,,,,,,,FG001,"Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 2.5 mg, once each morning for up to 102 weeks. Participants also received metformin tablets, 500-2000 mg, orally as n",,,
arm,NCT00528372::arm::FG002,NCT00528372,"Group 1: Dapagliflozin, 5 mg AM",,,,,,,,,,FG002,"Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 5 mg, once each morning for up to 102 weeks. Participants also received metformin tablets, 500-2000 mg, orally as nee",,,
arm,NCT00528372::arm::FG003,NCT00528372,"Group 1: Dapagliflozin, 10 mg AM",,,,,,,,,,FG003,"Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 10 mg, once each morning for up to 102 weeks. Participants also received metformin tablets, 500-2000 mg, orally as ne",,,
arm,NCT00528372::arm::FG004,NCT00528372,"Group 1: Dapagliflozin, 2.5 mg PM",,,,,,,,,,FG004,"Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 2.5 mg, once each evening for up to 102 weeks. Participants also received metformin tablets, 500-2000 mg, orally as n",,,
arm,NCT00528372::arm::FG005,NCT00528372,"Group 1: Dapagliflozin, 5 mg PM",,,,,,,,,,FG005,"Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 5 mg, once each evening for up to 102 weeks. Participants also received metformin tablets, 500-2000 mg, orally as nee",,,
arm,NCT00528372::arm::FG006,NCT00528372,"Group 1: Dapagliflozin, 10 mg PM",,,,,,,,,,FG006,"Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 10 mg, once each evening for up to 102 weeks. Participants also received metformin tablets, 500-2000 mg, orally as ne",,,
arm,NCT00528372::arm::FG007,NCT00528372,"Group 2: Dapagliflozin, 5 mg AM",,,,,,,,,,FG007,"Participants with HbA1c ≥10.1% and ≤12% at enrollment received dapagliflozin tablets, 5 mg, once each morning for up to 102 weeks. Participants also received metformin tablets, 500-2000 mg, orally as ",,,
arm,NCT00528372::arm::FG008,NCT00528372,"Group 2: Dapagliflozin, 10 mg AM",,,,,,,,,,FG008,"Participants with HbA1c ≥10.1% and ≤12% at enrollment received dapagliflozin tablets, 10 mg, once each morning for up to 102 weeks. Participants also received metformin tablets, 500-2000 mg, orally as",,,
period,NCT00528372::period::1,NCT00528372,Short-term (ST) Period (Day 1-Week 24),,,,,,,,,,,,1.0,,
period,NCT00528372::period::2,NCT00528372,Long-term (LT) Period (Weeks 24-102),,,,,,,,,,,,2.0,,
outcome,NCT00528372::outcome::primary::1,NCT00528372,Adjusted Mean Change From Baseline to Week 24 in Hemoglobin A1C (HbA1c) (Last Observation Carried Forward [LOCF]): Group 1,,,,,,,,,,,,,PRIMARY,Baseline to Week 24 (end of Short-term Period)
outcome,NCT00528372::outcome::primary::2,NCT00528372,Adjusted Mean Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c) (Last Observation Carried Forward [LOCF]): Group 2,,,,,,,,,,,,,PRIMARY,Baseline to Week 24 (end of Short-term Period)
country,NCT00528372::country::United States,NCT00528372,United States,,,,,,,,,,,,,,
country,NCT00528372::country::Canada,NCT00528372,Canada,,,,,,,,,,,,,,
country,NCT00528372::country::Mexico,NCT00528372,Mexico,,,,,,,,,,,,,,
country,NCT00528372::country::Russia,NCT00528372,Russia,,,,,,,,,,,,,,
trial,NCT00838903,NCT00838903,Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,1049.0,2009-02,2013-04,11.0,386.0,,,,,
arm,NCT00838903::arm::FG000,NCT00838903,Placebo Plus Metformin,,,,,,,,,,FG000,Participants received metformin \>=1500 milligrams (mg) daily plus matching albiglutide placebo as a subcutaneous injection weekly via a fully disposable pen injector system plus matching sitagliptin ,,,
arm,NCT00838903::arm::FG001,NCT00838903,Sitagliptin 100 mg Plus Metformin,,,,,,,,,,FG001,Participants received sitagliptin 100 mg daily plus metformin \>=1500 mg daily plus matching albiglutide placebo as a subcutaneous injection weekly via a fully disposable pen injector system plus matc,,,
arm,NCT00838903::arm::FG002,NCT00838903,Glimepiride 2 mg Plus Metformin,,,,,,,,,,FG002,Participants received glimepiride 2 mg daily (with masked up-titration to 4 mg daily if required) plus metformin \>=1500 mg daily plus matching albiglutide placebo as a subcutaneous injection weekly v,,,
arm,NCT00838903::arm::FG003,NCT00838903,Albiglutide 30 mg Plus Metformin,,,,,,,,,,FG003,Participants received albiglutide 30 mg weekly (with masked up-titration to 50 mg weekly if required) as a subcutaneous injection via a fully disposable pen injector system plus metformin \>=1500 mg d,,,
period,NCT00838903::period::1,NCT00838903,Treatment Period (156 Weeks),,,,,,,,,,,,1.0,,
period,NCT00838903::period::2,NCT00838903,Follow-up Period (8 Weeks),,,,,,,,,,,,2.0,,
outcome,NCT00838903::outcome::primary::1,NCT00838903,Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 104,,,,,,,,,,,,,PRIMARY,Baseline and Week 104
country,NCT00838903::country::United States,NCT00838903,United States,,,,,,,,,,,,,,
country,NCT00838903::country::Mexico,NCT00838903,Mexico,,,,,,,,,,,,,,
country,NCT00838903::country::South Africa,NCT00838903,South Africa,,,,,,,,,,,,,,
country,NCT00838903::country::United Kingdom,NCT00838903,United Kingdom,,,,,,,,,,,,,,
country,NCT00838903::country::Germany,NCT00838903,Germany,,,,,,,,,,,,,,
country,NCT00838903::country::Russia,NCT00838903,Russia,,,,,,,,,,,,,,
country,NCT00838903::country::Peru,NCT00838903,Peru,,,,,,,,,,,,,,
country,NCT00838903::country::Philippines,NCT00838903,Philippines,,,,,,,,,,,,,,
country,NCT00838903::country::Hong Kong,NCT00838903,Hong Kong,,,,,,,,,,,,,,
country,NCT00838903::country::Spain,NCT00838903,Spain,,,,,,,,,,,,,,
country,NCT00838903::country::Albania,NCT00838903,Albania,,,,,,,,,,,,,,
trial,NCT01169779,NCT01169779,Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,391.0,2010-07,2011-12,4.0,35.0,,,,,
arm,NCT01169779::arm::FG000,NCT01169779,Placebo,,,,,,,,,,FG000,"1-step initiation regimen of volume matching placebo: 10 microgram (mcg) once daily (QD) subcutaneously for 2 weeks, followed by 20 mcg QD up to Week 24.",,,
arm,NCT01169779::arm::FG001,NCT01169779,Lixisenatide,,,,,,,,,,FG001,"1-step initiation regimen of lixisenatide: 10 mcg QD subcutaneously for 2 weeks, followed by 20 mcg QD up to Week 24.",,,
period,NCT01169779::period::1,NCT01169779,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01169779::outcome::primary::1,NCT01169779,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
country,NCT01169779::country::China,NCT01169779,China,,,,,,,,,,,,,,
country,NCT01169779::country::Hong Kong,NCT01169779,Hong Kong,,,,,,,,,,,,,,
country,NCT01169779::country::Malaysia,NCT01169779,Malaysia,,,,,,,,,,,,,,
country,NCT01169779::country::Thailand,NCT01169779,Thailand,,,,,,,,,,,,,,
trial,NCT02787551,NCT02787551,"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period",PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,514.0,2016-07-06,2018-11-17,9.0,124.0,,,,,
arm,NCT02787551::arm::FG000,NCT02787551,Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC),,,,,,,,,,FG000,"Core period: FRC injected subcutaneously QD for 26 weeks on top of oral anti-diabetic drug (OAD) therapy. Dose individually adjusted.

Single arm extension period: participants who completed core trea",,,
arm,NCT02787551::arm::FG001,NCT02787551,GLP-1 Receptor Agonist,,,,,,,,,,FG001,"Core Period: GLP-1 RA receptor agonist (liraglutide QD, exenatide BID, exenatide extended-release QW, albiglutide QW, or dulaglutide QW) injected subcutaneously for 26 weeks on top of OAD therapy. GLP",,,
period,NCT02787551::period::1,NCT02787551,Core Period: 26 Weeks,,,,,,,,,,,,1.0,,
period,NCT02787551::period::2,NCT02787551,Extension Period:26 Weeks(Upto 52 Weeks),,,,,,,,,,,,2.0,,
outcome,NCT02787551::outcome::primary::1,NCT02787551,Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 26: Core Period,,,,,,,,,,,,,PRIMARY,"Baseline, Week 26"
outcome,NCT02787551::outcome::primary::2,NCT02787551,Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 52: Single Arm Extension Period,,,,,,,,,,,,,PRIMARY,"Baseline, Week 52"
country,NCT02787551::country::United States,NCT02787551,United States,,,,,,,,,,,,,,
country,NCT02787551::country::Spain,NCT02787551,Spain,,,,,,,,,,,,,,
country,NCT02787551::country::Romania,NCT02787551,Romania,,,,,,,,,,,,,,
country,NCT02787551::country::Slovakia,NCT02787551,Slovakia,,,,,,,,,,,,,,
country,NCT02787551::country::Italy,NCT02787551,Italy,,,,,,,,,,,,,,
country,NCT02787551::country::Israel,NCT02787551,Israel,,,,,,,,,,,,,,
country,NCT02787551::country::Canada,NCT02787551,Canada,,,,,,,,,,,,,,
country,NCT02787551::country::Estonia,NCT02787551,Estonia,,,,,,,,,,,,,,
country,NCT02787551::country::Germany,NCT02787551,Germany,,,,,,,,,,,,,,
trial,NCT01468181,NCT01468181,A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,394.0,2011-11,2013-12,1.0,14.0,,,,,
arm,NCT01468181::arm::FG000,NCT01468181,LY2189265 + Sulfonylureas (SU),,,,,,,,,,FG000,"LY2189265: 0.75 milligrams (mg) administered subcutaneously (SC), once weekly for 52 weeks

Participants were to continue on their stable, pre-study, physician-prescribed dose of SU monotherapy throug",,,
arm,NCT01468181::arm::FG001,NCT01468181,LY2189265 + Biguanides (BG),,,,,,,,,,FG001,"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks

Participants were to continue on their stable, pre-study, physician-prescribed dose of BG monotherapy throughout the study.",,,
arm,NCT01468181::arm::FG002,NCT01468181,LY2189265 + Alpha-glucosidas e Inhibitor (a-GI),,,,,,,,,,FG002,"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks

Participants were to continue on their stable, pre-study, physician-prescribed dose of a-GI monotherapy throughout the study.",,,
arm,NCT01468181::arm::FG003,NCT01468181,LY2189265 + Thiazolidin Edione (TZD),,,,,,,,,,FG003,"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks

Participants were to continue on their stable, pre-study, physician-prescribed dose of TZD monotherapy throughout the study.",,,
arm,NCT01468181::arm::FG004,NCT01468181,LY2189265 + Glinides,,,,,,,,,,FG004,"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks

Participants were to continue on their stable, pre-study, physician-prescribed dose of glinides monotherapy throughout the study.",,,
period,NCT01468181::period::1,NCT01468181,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01468181::outcome::primary::1,NCT01468181,Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs),,,,,,,,,,,,,PRIMARY,Baseline through 52 Weeks
outcome,NCT01468181::outcome::primary::2,NCT01468181,Percentage of Participants With Hypoglycemic Episodes,,,,,,,,,,,,,PRIMARY,Baseline through 52 Weeks
country,NCT01468181::country::Japan,NCT01468181,Japan,,,,,,,,,,,,,,
trial,NCT01294436,NCT01294436,Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Type2 Diabetes; High Blood Sugar,INDUSTRY,728.0,2011-02,2012-09,1.0,38.0,,,,,
arm,NCT01294436::arm::FG000,NCT01294436,Monotherapy,,,,,,,,,,FG000,Dapagliflozin 5/10 mg only,,,
arm,NCT01294436::arm::FG001,NCT01294436,All Combination Therapies,,,,,,,,,,FG001,Dapagliflozin 5/10 mg in combination with any anti-diabetic drugs,,,
period,NCT01294436::period::1,NCT01294436,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01294436::outcome::primary::1,NCT01294436,Proportion of Participants With Adverse Events,,,,,,,,,,,,,PRIMARY,Long-term treatment up to 52 weeks
outcome,NCT01294436::outcome::primary::2,NCT01294436,Proportion of Participants With Serious Adverse Events,,,,,,,,,,,,,PRIMARY,Long-term treatment up to 52 weeks
outcome,NCT01294436::outcome::primary::3,NCT01294436,Proportion of Participants With At Least One Episode of Hypoglycemia,,,,,,,,,,,,,PRIMARY,Long-term treatment up to 52 weeks
outcome,NCT01294436::outcome::primary::4,NCT01294436,Mean Change in Hematocrit,,,,,,,,,,,,,PRIMARY,Baseline to Week 52
outcome,NCT01294436::outcome::primary::5,NCT01294436,Mean Change in Alanine Aminotransferase (ALT),,,,,,,,,,,,,PRIMARY,Baseline to Week 52
outcome,NCT01294436::outcome::primary::6,NCT01294436,Mean Change in Aspartate Aminotransferase (AST),,,,,,,,,,,,,PRIMARY,Baseline to Week 52
outcome,NCT01294436::outcome::primary::7,NCT01294436,Mean Change in Blood Urea Nitrogen (BUN),,,,,,,,,,,,,PRIMARY,Baseline to Week 52
outcome,NCT01294436::outcome::primary::8,NCT01294436,Mean Change in Magnesium,,,,,,,,,,,,,PRIMARY,Baseline to Week 52
outcome,NCT01294436::outcome::primary::9,NCT01294436,Mean Change in Serum Uric Acid,,,,,,,,,,,,,PRIMARY,Baseline to Week 52
outcome,NCT01294436::outcome::primary::10,NCT01294436,Mean Change in Seated Heart Rate,,,,,,,,,,,,,PRIMARY,Baseline to Week 52
outcome,NCT01294436::outcome::primary::11,NCT01294436,Mean Change in Seated Diastolic Blood Pressure,,,,,,,,,,,,,PRIMARY,Baseline to Week 52
outcome,NCT01294436::outcome::primary::12,NCT01294436,Mean Change in Seated Systolic Blood Pressure,,,,,,,,,,,,,PRIMARY,Baseline to Week 52
country,NCT01294436::country::Japan,NCT01294436,Japan,,,,,,,,,,,,,,
trial,NCT03175120,NCT03175120,A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD),PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,453.0,2017-05-26,2019-04-04,2.0,37.0,,,,,
arm,NCT03175120::arm::FG000,NCT03175120,Insulin Degludec/Liraglutide,,,,,,,,,,FG000,Participants were to receive Insulin degludec/liraglutide (IDegLira) subcutaneous injection once daily in combination with metformin for 26 weeks. Participants received 16 dose steps (16 units insulin,,,
arm,NCT03175120::arm::FG001,NCT03175120,Insulin Degludec,,,,,,,,,,FG001,Participants were to receive Insulin degludec (IDeg) subcutaneous injection once daily in combination with metformin for 26 weeks. Participants received 16 units insulin degludec initially. The dose w,,,
period,NCT03175120::period::1,NCT03175120,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03175120::outcome::primary::1,NCT03175120,Change in HbA1c,,,,,,,,,,,,,PRIMARY,"Week 0, week 26"
country,NCT03175120::country::China,NCT03175120,China,,,,,,,,,,,,,,
country,NCT03175120::country::Hong Kong,NCT03175120,Hong Kong,,,,,,,,,,,,,,
trial,NCT00360334,NCT00360334,A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,235.0,2006-06,2008-04,1.0,31.0,,,,,
arm,NCT00360334::arm::FG000,NCT00360334,Exenatide,,,,,,,,,,FG000,"5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks",,,
arm,NCT00360334::arm::FG001,NCT00360334,Insulin Glargine,,,,,,,,,,FG001,dosing based on treat to target protocol,,,
period,NCT00360334::period::1,NCT00360334,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00360334::outcome::primary::1,NCT00360334,Percent of Patients Who Achieved HbA1c ≤ 7.4% With Minimal Weight Gain (≤ 1kg),,,,,,,,,,,,,PRIMARY,26 weeks
country,NCT00360334::country::United Kingdom,NCT00360334,United Kingdom,,,,,,,,,,,,,,
trial,NCT01365507,NCT01365507,Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,276.0,2011-06,2012-04,7.0,42.0,,,,,
arm,NCT01365507::arm::FG000,NCT01365507,IDegAsp Simple,,,,,,,,,,FG000,Insulin degludec/insulin aspart (IDegAsp) was given once daily (OD) subcutaneously (3-4 days intervals between doses) with pre-trial metformin according to simple titration algorithm: self-titration w,,,
arm,NCT01365507::arm::FG001,NCT01365507,IDegAsp Step Wise,,,,,,,,,,FG001,Insulin degludec/insulin aspart (IDegAsp) was given once daily (OD) subcutaneously (at least 5 days intervals between doses) with pre-trial metformin according to step wise titration algorithm: self-t,,,
period,NCT01365507::period::1,NCT01365507,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01365507::outcome::primary::1,NCT01365507,Change in Glycosylated Haemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Week 0, week 26"
country,NCT01365507::country::United States,NCT01365507,United States,,,,,,,,,,,,,,
country,NCT01365507::country::South Korea,NCT01365507,South Korea,,,,,,,,,,,,,,
country,NCT01365507::country::Turkey (Türkiye),NCT01365507,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01365507::country::Malaysia,NCT01365507,Malaysia,,,,,,,,,,,,,,
country,NCT01365507::country::Mexico,NCT01365507,Mexico,,,,,,,,,,,,,,
country,NCT01365507::country::Thailand,NCT01365507,Thailand,,,,,,,,,,,,,,
country,NCT01365507::country::Puerto Rico,NCT01365507,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01451398,NCT01451398,Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,353.0,2011-11,2013-07,4.0,76.0,,,,,
arm,NCT01451398::arm::FG000,NCT01451398,TI Inhalation Powder + OADs,,,,,,,,,,FG000,"Technosphere Insulin powder administered via the Gen2 inhaler added to 2 or more stable Oral Antidiabetic Drugs (OADs), doses individualized for each patient",,,
arm,NCT01451398::arm::FG001,NCT01451398,Technosphere Powder,,,,,,,,,,FG001,"Technosphere powder (with no insulin) administered via the Gen2 inhaler added to 2 or more stable Oral Antidiabetic Drugs (OADs), doses individualized for each patient",,,
period,NCT01451398::period::1,NCT01451398,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01451398::outcome::primary::1,NCT01451398,Change From Baseline to Week 24 in HbA1c,,,,,,,,,,,,,PRIMARY,Baseline to Week 24
country,NCT01451398::country::United States,NCT01451398,United States,,,,,,,,,,,,,,
country,NCT01451398::country::Russia,NCT01451398,Russia,,,,,,,,,,,,,,
country,NCT01451398::country::Ukraine,NCT01451398,Ukraine,,,,,,,,,,,,,,
country,NCT01451398::country::Brazil,NCT01451398,Brazil,,,,,,,,,,,,,,
trial,NCT00306384,NCT00306384,Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Diabetes Mellitus,INDUSTRY,3323.0,2006-03,2011-11,12.0,114.0,,,,,
arm,NCT00306384::arm::FG000,NCT00306384,Alogliptin 12.5 mg,,,,,,,,,,FG000,"Participants who completed the previous double-blind study received alogliptin 12.5 tablet, orally, once daily for up to 4 years.",,,
arm,NCT00306384::arm::FG001,NCT00306384,Alogliptin 25 mg,,,,,,,,,,FG001,"Participants who completed the previous double-blind study received alogliptin 25 mg tablets orally, once daily for up to 4 years.",,,
arm,NCT00306384::arm::FG002,NCT00306384,Rescued: Alogliptin 25 mg,,,,,,,,,,FG002,"Participants rescued from the previous double-blind study received alogliptin 25 mg tablets, orally once daily for up to 4 years.",,,
period,NCT00306384::period::1,NCT00306384,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00306384::outcome::primary::1,NCT00306384,Percentage of Participants With Treatment-emergent Adverse Events (TEAEs),,,,,,,,,,,,,PRIMARY,4 years
country,NCT00306384::country::United States,NCT00306384,United States,,,,,,,,,,,,,,
country,NCT00306384::country::Germany,NCT00306384,Germany,,,,,,,,,,,,,,
country,NCT00306384::country::Argentina,NCT00306384,Argentina,,,,,,,,,,,,,,
country,NCT00306384::country::Brazil,NCT00306384,Brazil,,,,,,,,,,,,,,
country,NCT00306384::country::Netherlands,NCT00306384,Netherlands,,,,,,,,,,,,,,
country,NCT00306384::country::Poland,NCT00306384,Poland,,,,,,,,,,,,,,
country,NCT00306384::country::South Africa,NCT00306384,South Africa,,,,,,,,,,,,,,
country,NCT00306384::country::Czechia,NCT00306384,Czechia,,,,,,,,,,,,,,
country,NCT00306384::country::Peru,NCT00306384,Peru,,,,,,,,,,,,,,
country,NCT00306384::country::Chile,NCT00306384,Chile,,,,,,,,,,,,,,
country,NCT00306384::country::Dominican Republic,NCT00306384,Dominican Republic,,,,,,,,,,,,,,
country,NCT00306384::country::Guatemala,NCT00306384,Guatemala,,,,,,,,,,,,,,
trial,NCT01318109,NCT01318109,Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in Japan,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,288.0,2008-08,2009-04,0.0,0.0,,,,,
arm,NCT01318109::arm::FG000,NCT01318109,Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID,,,,,,,,,,FG000,"Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.",,,
arm,NCT01318109::arm::FG001,NCT01318109,Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID,,,,,,,,,,FG001,"Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.",,,
arm,NCT01318109::arm::FG002,NCT01318109,Metformin 500mg BID or 750mg TID,,,,,,,,,,FG002,"Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.",,,
period,NCT01318109::period::1,NCT01318109,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01318109::outcome::primary::1,NCT01318109,Change From Baseline in Glycosylated Hemoglobin (Week 12).,,,,,,,,,,,,,PRIMARY,Baseline and Week 12.
trial,NCT01064687,NCT01064687,A Study in Participants With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,978.0,2010-02,2012-05,4.0,89.0,,,,,
arm,NCT01064687::arm::FG000,NCT01064687,1.5 mg LY2189265,,,,,,,,,,FG000,"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks

Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks

Pioglitazone: at least 30 mg/day, o",,,
arm,NCT01064687::arm::FG001,NCT01064687,0.75 mg LY2189265,,,,,,,,,,FG001,"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks

Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks

Pioglitazone: at least 30 mg/day, ",,,
arm,NCT01064687::arm::FG002,NCT01064687,Exenatide,,,,,,,,,,FG002,"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks

Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks

P",,,
arm,NCT01064687::arm::FG003,NCT01064687,Placebo,,,,,,,,,,FG003,"Placebo: subcutaneous (SC), once weekly for 26 weeks

Metformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks

Pioglitazone: at least 30 mg/day, oral, for 26 weeks",,,
period,NCT01064687::period::1,NCT01064687,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01064687::outcome::primary::1,NCT01064687,Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline, 26 weeks"
country,NCT01064687::country::United States,NCT01064687,United States,,,,,,,,,,,,,,
country,NCT01064687::country::Puerto Rico,NCT01064687,Puerto Rico,,,,,,,,,,,,,,
country,NCT01064687::country::Mexico,NCT01064687,Mexico,,,,,,,,,,,,,,
country,NCT01064687::country::Argentina,NCT01064687,Argentina,,,,,,,,,,,,,,
trial,NCT01217892,NCT01217892,Evaluation of Dapagliflozin Taken Twice-daily,PHASE3,diabetes type 2,Type 2 Diabetes,INDUSTRY,400.0,2010-11,2011-08,7.0,55.0,,,,,
arm,NCT01217892::arm::FG000,NCT01217892,Dapagliflozin 2.5mg BID Plus Metformin,,,,,,,,,,FG000,"Dapagliflozin 2.5mg, oral, twice daily plus Metformin, oral, twice daily, \>=1500mg total daily dose",,,
arm,NCT01217892::arm::FG001,NCT01217892,Dapagliflozin 5mg BID Plus Metformin,,,,,,,,,,FG001,"Dapagliflozin 5mg, oral, twice daily plus Metformin, oral, twice daily, \>=1500mg total daily dose",,,
arm,NCT01217892::arm::FG002,NCT01217892,Dapagliflozin 10mg OD Plus Metformin,,,,,,,,,,FG002,"Dapagliflozin 10mg, oral, once daily plus Metformin, oral, twice daily, \>=1500mg total daily dose",,,
arm,NCT01217892::arm::FG003,NCT01217892,Placebo Plus Metformin,,,,,,,,,,FG003,"Placebo plus Metformin, oral, twice daily, \>=1500mg total daily dose",,,
period,NCT01217892::period::1,NCT01217892,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01217892::outcome::primary::1,NCT01217892,Adjusted Mean Change in HbA1c Levels,,,,,,,,,,,,,PRIMARY,Baseline to Week 16
country,NCT01217892::country::Germany,NCT01217892,Germany,,,,,,,,,,,,,,
country,NCT01217892::country::Slovakia,NCT01217892,Slovakia,,,,,,,,,,,,,,
country,NCT01217892::country::Hungary,NCT01217892,Hungary,,,,,,,,,,,,,,
country,NCT01217892::country::Switzerland,NCT01217892,Switzerland,,,,,,,,,,,,,,
country,NCT01217892::country::South Africa,NCT01217892,South Africa,,,,,,,,,,,,,,
country,NCT01217892::country::Romania,NCT01217892,Romania,,,,,,,,,,,,,,
country,NCT01217892::country::Ukraine,NCT01217892,Ukraine,,,,,,,,,,,,,,
trial,NCT00032487,NCT00032487,Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,FED,1791.0,2000-12-01,2008-05-30,2.0,21.0,,,,,
arm,NCT00032487::arm::FG000,NCT00032487,Standard Glycemic Control,,,,,,,,,,FG000,Standard glycemic control to maintain HbA1c between 8.0-9.0%. Metformin 500 mg Rosiglitazone 4 mg Glimepiride 2 mg Insulin 1 unit 9 lbs,,,
arm,NCT00032487::arm::FG001,NCT00032487,Intensive Glycemic Control,,,,,,,,,,FG001,Intensive glycemic control lower HbA1c below 6.0%. Metformin 500 mg (go up to 2000 mg) Rosiglitazone 4 mg bid Glimepiride 8 mg Insulin 1 unit 9 lbs add one injection to Arm 1,,,
period,NCT00032487::period::1,NCT00032487,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00032487::outcome::primary::1,NCT00032487,Primary Major Macrovascular Events,,,,,,,,,,,,,PRIMARY,Post baseline time to the first major macrovascular event up to 82 months
country,NCT00032487::country::United States,NCT00032487,United States,,,,,,,,,,,,,,
country,NCT00032487::country::Puerto Rico,NCT00032487,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01413204,NCT01413204,Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,272.0,2011-07,2012-08,1.0,5.0,,,,,
arm,NCT01413204::arm::FG000,NCT01413204,TA-7284 Low,,,,,,,,,,FG000,"TA-7284 low dose, once daily for 24 weeks",,,
arm,NCT01413204::arm::FG001,NCT01413204,TA-7284 High,,,,,,,,,,FG001,"TA-7284 high dose, once daily for 24 weeks",,,
arm,NCT01413204::arm::FG002,NCT01413204,Placebo,,,,,,,,,,FG002,"TA-7284 Placebo, once daily for 24 weeks",,,
period,NCT01413204::period::1,NCT01413204,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01413204::outcome::primary::1,NCT01413204,Change in Hemoglobin A1c (A1C) From Baseline (NGSP Value),,,,,,,,,,,,,PRIMARY,baseline and 24 weeks
country,NCT01413204::country::Japan,NCT01413204,Japan,,,,,,,,,,,,,,
trial,NCT00392678,NCT00392678,Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D),PHASE3,diabetes type 2,Type 2 Diabetes,OTHER,277.0,2006-10,2010-12,1.0,16.0,,,,,
arm,NCT00392678::arm::FG000,NCT00392678,3 Gram,,,,,,,,,,FG000,"Salsalate 3.0 g daily, divided",,,
arm,NCT00392678::arm::FG001,NCT00392678,3.5 Gram,,,,,,,,,,FG001,"Salsalate 3.5 g daily, divided",,,
arm,NCT00392678::arm::FG002,NCT00392678,4 Gram,,,,,,,,,,FG002,"Salsalate 4.0 g daily, divided",,,
arm,NCT00392678::arm::FG003,NCT00392678,Placebo,,,,,,,,,,FG003,Matched by appearance to active drug,,,
period,NCT00392678::period::1,NCT00392678,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00392678::outcome::primary::1,NCT00392678,Change in HbA1c Baseline to End of Trial in TINSAL-T2D Stage 1,,,,,,,,,,,,,PRIMARY,14 week
country,NCT00392678::country::United States,NCT00392678,United States,,,,,,,,,,,,,,
trial,NCT00487240,NCT00487240,Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 1",INDUSTRY,387.0,2007-06,2008-08,9.0,28.0,,,,,
arm,NCT00487240::arm::FG000,NCT00487240,Insulin Lispro Protamine Suspension,,,,,,,,,,FG000,"Patient specific dose insulin lispro protamine suspension, twice daily (BID), within 15 minutes before meals, subcutaneous (SC) injection x 32 weeks",,,
arm,NCT00487240::arm::FG001,NCT00487240,Detemir,,,,,,,,,,FG001,Patient specific dose insulin Levemir (detemir) twice daily (BID) subcutaneous (SC) injection x 32 weeks,,,
period,NCT00487240::period::1,NCT00487240,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00487240::outcome::primary::1,NCT00487240,Change in Hemoglobin A1c (HbA1c) From Baseline to Endpoint,,,,,,,,,,,,,PRIMARY,baseline and 32 weeks
country,NCT00487240::country::Hungary,NCT00487240,Hungary,,,,,,,,,,,,,,
country,NCT00487240::country::United States,NCT00487240,United States,,,,,,,,,,,,,,
country,NCT00487240::country::Romania,NCT00487240,Romania,,,,,,,,,,,,,,
country,NCT00487240::country::Russia,NCT00487240,Russia,,,,,,,,,,,,,,
country,NCT00487240::country::Mexico,NCT00487240,Mexico,,,,,,,,,,,,,,
country,NCT00487240::country::Argentina,NCT00487240,Argentina,,,,,,,,,,,,,,
country,NCT00487240::country::Australia,NCT00487240,Australia,,,,,,,,,,,,,,
country,NCT00487240::country::Brazil,NCT00487240,Brazil,,,,,,,,,,,,,,
country,NCT00487240::country::Greece,NCT00487240,Greece,,,,,,,,,,,,,,
trial,NCT04460885,NCT04460885,"A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before",PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,984.0,2020-11-25,2022-12-01,13.0,198.0,,,,,
arm,NCT04460885::arm::FG000,NCT04460885,Insulin Icodec,,,,,,,,,,FG000,Participants received once-weekly subcutaneous injection of insulin icodec at a starting dose of 70 U for 78 weeks using PDS 290 pre-filled injector in combination with non-insulin anti-diabetic drugs,,,
arm,NCT04460885::arm::FG001,NCT04460885,Insulin Glargine,,,,,,,,,,FG001,Participants received once daily subcutaneous injection of insulin glargine at a starting dose of 10 U for 78 weeks using SoloSTAR pre-filled pen injector in combination with non-insulin anti-diabetic,,,
period,NCT04460885::period::1,NCT04460885,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04460885::outcome::primary::1,NCT04460885,Change in Glycated Haemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline (week 0), Week 52"
country,NCT04460885::country::United States,NCT04460885,United States,,,,,,,,,,,,,,
country,NCT04460885::country::United Kingdom,NCT04460885,United Kingdom,,,,,,,,,,,,,,
country,NCT04460885::country::Japan,NCT04460885,Japan,,,,,,,,,,,,,,
country,NCT04460885::country::Russia,NCT04460885,Russia,,,,,,,,,,,,,,
country,NCT04460885::country::India,NCT04460885,India,,,,,,,,,,,,,,
country,NCT04460885::country::Poland,NCT04460885,Poland,,,,,,,,,,,,,,
country,NCT04460885::country::Slovakia,NCT04460885,Slovakia,,,,,,,,,,,,,,
country,NCT04460885::country::Israel,NCT04460885,Israel,,,,,,,,,,,,,,
country,NCT04460885::country::Spain,NCT04460885,Spain,,,,,,,,,,,,,,
country,NCT04460885::country::Italy,NCT04460885,Italy,,,,,,,,,,,,,,
country,NCT04460885::country::Croatia,NCT04460885,Croatia,,,,,,,,,,,,,,
country,NCT04460885::country::Mexico,NCT04460885,Mexico,,,,,,,,,,,,,,
country,NCT04460885::country::Puerto Rico,NCT04460885,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01028391,NCT01028391,30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064),PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,317.0,2007-09-01,2009-01-01,0.0,0.0,,,,,
arm,NCT01028391::arm::FG000,NCT01028391,Sitagliptin 100 mg q.d. + Pioglitazone 45 mg q.d.,,,,,,,,,,FG000,The Sitagliptin 100 mg q.d. + Pioglitazone 45 mg q.d. (q.d. = once daily) group includes extension study data from patients who received once-daily coadministered treatment with oral tablets of sitagl,,,
arm,NCT01028391::arm::FG001,NCT01028391,Pioglitazone 45 mg q.d.,,,,,,,,,,FG001,The Pioglitazone 45 mg q.d. (q.d. = once daily) group includes extension study data from patients who received once-daily coadministered treatment with oral tablets of placebo to sitagliptin 100 mg an,,,
period,NCT01028391::period::1,NCT01028391,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01028391::outcome::primary::1,NCT01028391,"Change From Baseline (i.e., Week 0 of the 24-week Base Study) in Hemoglobin A1c (HbA1c) at Week 54",,,,,,,,,,,,,PRIMARY,Baseline and 54 Weeks
trial,NCT02068443,NCT02068443,Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,374.0,2014-02,2015-02,1.0,27.0,,,,,
arm,NCT02068443::arm::FG000,NCT02068443,Alogliptin Alone,,,,,,,,,,FG000,"Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride placebo-matching, tablets, orally, 2 tablets after breakfast and 1 tablet after dinner for 24 weeks.",,,
arm,NCT02068443::arm::FG001,NCT02068443,Alogliptin + Metformin Hydrochloride QD,,,,,,,,,,FG001,"Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride 500 mg QD (250 mg x 2 tablets, once daily), tablets, orally, QD (once daily), after breakfast and 1 metformi",,,
arm,NCT02068443::arm::FG002,NCT02068443,Alogliptin + Metformin Hydrochloride BID,,,,,,,,,,FG002,"Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride 250 mg BID (twice daily), tablets, orally, 1 tablet after breakfast and 1 tablet after dinner and 1 metformi",,,
period,NCT02068443::period::1,NCT02068443,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02068443::outcome::primary::1,NCT02068443,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) National Glycohemoglobin Standardization Program (NGSP) at the End of Treatment (EOT) Period,,,,,,,,,,,,,PRIMARY,Baseline and End of Treatment (EOT) (Up to Week 24)
country,NCT02068443::country::Japan,NCT02068443,Japan,,,,,,,,,,,,,,
trial,NCT01620489,NCT01620489,Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,279.0,2012-06-14,2013-08-20,6.0,97.0,,,,,
arm,NCT01620489::arm::FG000,NCT01620489,Lira 1.8 mg,,,,,,,,,,FG000,"Subjects received subcutaneous (s.c) liraglutide 1.8 mg once daily, applying a 3-4 week dose escalation regimen with weekly increments of 0.6 mg until the maintenance dose of 1.8 mg was reached, as an",,,
arm,NCT01620489::arm::FG001,NCT01620489,Placebo,,,,,,,,,,FG001,"Subjects received s.c placebo 1.8 mg once daily, applying a 3-4 week dose escalation regimen with weekly increments of 0.6 mg until the maintenance dose of 1.8 mg was reached, as an add-on to the subj",,,
period,NCT01620489::period::1,NCT01620489,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01620489::outcome::primary::1,NCT01620489,Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in HbA1c (%) (Glycosylated Haemoglobin),,,,,,,,,,,,,PRIMARY,"Week 0, Week 26"
country,NCT01620489::country::United States,NCT01620489,United States,,,,,,,,,,,,,,
country,NCT01620489::country::Russia,NCT01620489,Russia,,,,,,,,,,,,,,
country,NCT01620489::country::United Kingdom,NCT01620489,United Kingdom,,,,,,,,,,,,,,
country,NCT01620489::country::Poland,NCT01620489,Poland,,,,,,,,,,,,,,
country,NCT01620489::country::France,NCT01620489,France,,,,,,,,,,,,,,
country,NCT01620489::country::Ukraine,NCT01620489,Ukraine,,,,,,,,,,,,,,
trial,NCT00666718,NCT00666718,A Comparison Study of Basal Bolus Therapies Together With Lispro Insulin in Type 2 Diabetes Patients,PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,374.0,2008-04,2010-02,10.0,50.0,,,,,
arm,NCT00666718::arm::FG000,NCT00666718,Glargine,,,,,,,,,,FG000,Glargine plus Insulin Lispro (2-3 injections) plus metformin,,,
arm,NCT00666718::arm::FG001,NCT00666718,ILPS,,,,,,,,,,FG001,Insulin Lispro Protamine Suspension plus Insulin Lispro (2-3 injections) plus metformin,,,
period,NCT00666718::period::1,NCT00666718,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00666718::outcome::primary::1,NCT00666718,Change From Baseline in Hemoglobin A1c (HbA1c) to Week 24,,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
country,NCT00666718::country::Germany,NCT00666718,Germany,,,,,,,,,,,,,,
country,NCT00666718::country::Poland,NCT00666718,Poland,,,,,,,,,,,,,,
country,NCT00666718::country::Italy,NCT00666718,Italy,,,,,,,,,,,,,,
country,NCT00666718::country::Czechia,NCT00666718,Czechia,,,,,,,,,,,,,,
country,NCT00666718::country::Romania,NCT00666718,Romania,,,,,,,,,,,,,,
country,NCT00666718::country::Slovakia,NCT00666718,Slovakia,,,,,,,,,,,,,,
country,NCT00666718::country::United Kingdom,NCT00666718,United Kingdom,,,,,,,,,,,,,,
country,NCT00666718::country::Belgium,NCT00666718,Belgium,,,,,,,,,,,,,,
country,NCT00666718::country::Greece,NCT00666718,Greece,,,,,,,,,,,,,,
country,NCT00666718::country::Turkey (Türkiye),NCT00666718,Turkey (Türkiye),,,,,,,,,,,,,,
trial,NCT01472185,NCT01472185,Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Type 2 Diabetes Mellitus,INDUSTRY,465.0,2011-11,2013-10,10.0,159.0,,,,,
arm,NCT01472185::arm::FG000,NCT01472185,Placebo,,,,,,,,,,FG000,"Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.

Treatment Period: Placebo to match ranolazine (Days 1-7: 1 tablet twice daily; 2 tablets twice daily thereafter) for",,,
arm,NCT01472185::arm::FG001,NCT01472185,Ranolazine,,,,,,,,,,FG001,"Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.

Treatment Period: Ranolazine tablets (Days 1-7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to",,,
period,NCT01472185::period::1,NCT01472185,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01472185::outcome::primary::1,NCT01472185,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,,,,,,,,,,,,,PRIMARY,Baseline
country,NCT01472185::country::United States,NCT01472185,United States,,,,,,,,,,,,,,
country,NCT01472185::country::Russia,NCT01472185,Russia,,,,,,,,,,,,,,
country,NCT01472185::country::Poland,NCT01472185,Poland,,,,,,,,,,,,,,
country,NCT01472185::country::Ukraine,NCT01472185,Ukraine,,,,,,,,,,,,,,
country,NCT01472185::country::Romania,NCT01472185,Romania,,,,,,,,,,,,,,
country,NCT01472185::country::South Africa,NCT01472185,South Africa,,,,,,,,,,,,,,
country,NCT01472185::country::Hungary,NCT01472185,Hungary,,,,,,,,,,,,,,
country,NCT01472185::country::Slovakia,NCT01472185,Slovakia,,,,,,,,,,,,,,
country,NCT01472185::country::Serbia,NCT01472185,Serbia,,,,,,,,,,,,,,
country,NCT01472185::country::Czechia,NCT01472185,Czechia,,,,,,,,,,,,,,
trial,NCT04880850,NCT04880850,"A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)",PHASE3,diabetes type 2,"Diabetes Mellitus, Type 2",INDUSTRY,582.0,2021-05-14,2022-06-16,9.0,116.0,,,,,
arm,NCT04880850::arm::FG000,NCT04880850,Insulin Icodec,,,,,,,,,,FG000,"Participants were to receive once weekly subcutaneous (s.c.) injection of Insulin icodec for 26 weeks, using PDS290 prefilled pen-injector in combination with insulin aspart at a starting dose of 7 ti",,,
arm,NCT04880850::arm::FG001,NCT04880850,Insulin Glargine,,,,,,,,,,FG001,"Participants were to receive once daily s.c. injection of Insulin glargine for 26 weeks, using SoloSTAR pre-filled pen-injector in combination with insulin aspart. Participants were to perform daily S",,,
period,NCT04880850::period::1,NCT04880850,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04880850::outcome::primary::1,NCT04880850,Change in Glycated Haemoglobin (HbA1c),,,,,,,,,,,,,PRIMARY,"Baseline (week 0), Week 26"
country,NCT04880850::country::United States,NCT04880850,United States,,,,,,,,,,,,,,
country,NCT04880850::country::India,NCT04880850,India,,,,,,,,,,,,,,
country,NCT04880850::country::Russia,NCT04880850,Russia,,,,,,,,,,,,,,
country,NCT04880850::country::Japan,NCT04880850,Japan,,,,,,,,,,,,,,
country,NCT04880850::country::Netherlands,NCT04880850,Netherlands,,,,,,,,,,,,,,
country,NCT04880850::country::Italy,NCT04880850,Italy,,,,,,,,,,,,,,
country,NCT04880850::country::Romania,NCT04880850,Romania,,,,,,,,,,,,,,
country,NCT04880850::country::Belgium,NCT04880850,Belgium,,,,,,,,,,,,,,
country,NCT04880850::country::Mexico,NCT04880850,Mexico,,,,,,,,,,,,,,
trial,NCT00286494,NCT00286494,Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,Diabetes Mellitus,INDUSTRY,493.0,2006-02,2007-08,14.0,77.0,,,,,
arm,NCT00286494::arm::FG000,NCT00286494,Placebo,,,,,,,,,,FG000,"Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks.",,,
arm,NCT00286494::arm::FG001,NCT00286494,Alogliptin 12.5 mg QD,,,,,,,,,,FG001,"Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks.",,,
arm,NCT00286494::arm::FG002,NCT00286494,Alogliptin 25 mg QD,,,,,,,,,,FG002,"Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks.",,,
period,NCT00286494::period::1,NCT00286494,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00286494::outcome::primary::1,NCT00286494,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.,,,,,,,,,,,,,PRIMARY,Baseline and Week 26.
country,NCT00286494::country::United States,NCT00286494,United States,,,,,,,,,,,,,,
country,NCT00286494::country::Argentina,NCT00286494,Argentina,,,,,,,,,,,,,,
country,NCT00286494::country::Australia,NCT00286494,Australia,,,,,,,,,,,,,,
country,NCT00286494::country::Brazil,NCT00286494,Brazil,,,,,,,,,,,,,,
country,NCT00286494::country::Czechia,NCT00286494,Czechia,,,,,,,,,,,,,,
country,NCT00286494::country::Germany,NCT00286494,Germany,,,,,,,,,,,,,,
country,NCT00286494::country::Guatemala,NCT00286494,Guatemala,,,,,,,,,,,,,,
country,NCT00286494::country::Hungary,NCT00286494,Hungary,,,,,,,,,,,,,,
country,NCT00286494::country::India,NCT00286494,India,,,,,,,,,,,,,,
country,NCT00286494::country::Mexico,NCT00286494,Mexico,,,,,,,,,,,,,,
country,NCT00286494::country::Netherlands,NCT00286494,Netherlands,,,,,,,,,,,,,,
country,NCT00286494::country::New Zealand,NCT00286494,New Zealand,,,,,,,,,,,,,,
country,NCT00286494::country::Peru,NCT00286494,Peru,,,,,,,,,,,,,,
country,NCT00286494::country::South Africa,NCT00286494,South Africa,,,,,,,,,,,,,,
trial,NCT01952145,NCT01952145,A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus,PHASE3,diabetes type 2,"Diabetes; Diabetes Mellitus, Type 2",INDUSTRY,557.0,2013-09-20,2014-11-04,10.0,91.0,,,,,
arm,NCT01952145::arm::FG000,NCT01952145,Insulin Degludec/Liraglutide (IDegLira),,,,,,,,,,FG000,Eligible subjects received IDegLira once daily (OD) subcutaneously for a duration of 26 weeks. The starting dose of IDegLira was 16 dose steps (16 units IDeg/0.6 mg liraglutide) and was titrated accor,,,
arm,NCT01952145::arm::FG001,NCT01952145,Insulin Glargine (IGlar),,,,,,,,,,FG001,"Eligible subjects received IGlar OD subcutaneously for a duration of 26 weeks. The treatment started with dose equal to the pre-trial daily dose (dose-to-dose switch), after which the dose was titrate",,,
period,NCT01952145::period::1,NCT01952145,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01952145::outcome::primary::1,NCT01952145,Change From Baseline in HbA1c (Glycosylated Haemoglobin),,,,,,,,,,,,,PRIMARY,"Week 0, week 26"
country,NCT01952145::country::United States,NCT01952145,United States,,,,,,,,,,,,,,
country,NCT01952145::country::Russia,NCT01952145,Russia,,,,,,,,,,,,,,
country,NCT01952145::country::Slovakia,NCT01952145,Slovakia,,,,,,,,,,,,,,
country,NCT01952145::country::Greece,NCT01952145,Greece,,,,,,,,,,,,,,
country,NCT01952145::country::Australia,NCT01952145,Australia,,,,,,,,,,,,,,
country,NCT01952145::country::Spain,NCT01952145,Spain,,,,,,,,,,,,,,
country,NCT01952145::country::Argentina,NCT01952145,Argentina,,,,,,,,,,,,,,
country,NCT01952145::country::Hungary,NCT01952145,Hungary,,,,,,,,,,,,,,
country,NCT01952145::country::Mexico,NCT01952145,Mexico,,,,,,,,,,,,,,
country,NCT01952145::country::South Africa,NCT01952145,South Africa,,,,,,,,,,,,,,
trial,NCT03439254,NCT03439254,Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis,PHASE3,NASH,Compensated Cirrhosis; Nonalcoholic Steatohepatitis,INDUSTRY,919.0,2017-08-30,2022-09-08,12.0,192.0,,,,,
arm,NCT03439254::arm::FG000,NCT03439254,DB: Placebo,,,,,,,,,,FG000,"Participants were randomized to receive placebo once daily orally with water, in conjunction with local standard of care.",,,
arm,NCT03439254::arm::FG001,NCT03439254,DB: OCA 10 Milligrams (mg),,,,,,,,,,FG001,"Participants were randomized to receive OCA 10 mg once daily dosing orally with water, in conjunction with local standard of care.",,,
arm,NCT03439254::arm::FG002,NCT03439254,DB: OCA 10 mg Titrated to OCA 25 mg,,,,,,,,,,FG002,"Participants were randomized to receive OCA 10 mg for the first 3 months prior to uptitrating to OCA 25 mg at Month 3, once daily dosing orally with water, in conjunction with local standard of care. ",,,
arm,NCT03439254::arm::FG003,NCT03439254,OLE: OCA 10 mg (DB Placebo),,,,,,,,,,FG003,Participants who completed the DB phase (and continued to receive investigational product) were eligible to enroll into the OLE phase. All participants received OCA upon entry into the OLE phase. Part,,,
arm,NCT03439254::arm::FG004,NCT03439254,OLE: OCA 10 mg (DB OCA 10 mg),,,,,,,,,,FG004,Participants who completed the DB phase (and continued to receive investigational product) were eligible to enroll into the OLE phase. All participants received OCA upon entry into the OLE phase. Part,,,
arm,NCT03439254::arm::FG005,NCT03439254,OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg),,,,,,,,,,FG005,Participants who completed the DB phase (and continued to receive investigational product) were eligible to enroll into the OLE phase. All participants received OCA upon entry into the OLE phase. Part,,,
period,NCT03439254::period::1,NCT03439254,Double-blind Phase (18 Months),,,,,,,,,,,,1.0,,
period,NCT03439254::period::2,NCT03439254,Open Label Extension Phase (12 Months),,,,,,,,,,,,2.0,,
outcome,NCT03439254::outcome::primary::1,NCT03439254,DB Phase: Number of Participants Who Were Responders and Showed Improvement in Fibrosis by at Least 1 Stage Without Worsening of Nonalcoholic Steatohepatitis (NASH),,,,,,,,,,,,,PRIMARY,Up to 18 months
outcome,NCT03439254::outcome::primary::2,NCT03439254,OLE Phase: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs),,,,,,,,,,,,,PRIMARY,Up to 12 months
outcome,NCT03439254::outcome::primary::3,NCT03439254,OLE Phase: Change From Baseline to Month 12 in Liver Stiffness Measurement (LSM),,,,,,,,,,,,,PRIMARY,Baseline and up to Month 12
outcome,NCT03439254::outcome::primary::4,NCT03439254,OLE Phase: Fibrosis-4 (FIB-4) at Baseline,,,,,,,,,,,,,PRIMARY,Baseline (Day 1)
outcome,NCT03439254::outcome::primary::5,NCT03439254,OLE Phase: Enhanced Liver Fibrosis (ELF) at Baseline,,,,,,,,,,,,,PRIMARY,Baseline (Day 1)
outcome,NCT03439254::outcome::primary::6,NCT03439254,OLE Phase: Number of Participants Reporting All-cause Mortality,,,,,,,,,,,,,PRIMARY,Up to Month 12
outcome,NCT03439254::outcome::primary::7,NCT03439254,"OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Ascites, Hepatocellular Carcinoma (HCC) and Non-liver Related Death",,,,,,,,,,,,,PRIMARY,Up to 12 months
outcome,NCT03439254::outcome::primary::8,NCT03439254,OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Worsening of Child-Pugh Score,,,,,,,,,,,,,PRIMARY,Up to 12 months
outcome,NCT03439254::outcome::primary::9,NCT03439254,OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Model for End-Stage Liver Disease (MELD) Score ≥15,,,,,,,,,,,,,PRIMARY,Up to 12 months
country,NCT03439254::country::United States,NCT03439254,United States,,,,,,,,,,,,,,
country,NCT03439254::country::France,NCT03439254,France,,,,,,,,,,,,,,
country,NCT03439254::country::Canada,NCT03439254,Canada,,,,,,,,,,,,,,
country,NCT03439254::country::United Kingdom,NCT03439254,United Kingdom,,,,,,,,,,,,,,
country,NCT03439254::country::Germany,NCT03439254,Germany,,,,,,,,,,,,,,
country,NCT03439254::country::Poland,NCT03439254,Poland,,,,,,,,,,,,,,
country,NCT03439254::country::Australia,NCT03439254,Australia,,,,,,,,,,,,,,
country,NCT03439254::country::Spain,NCT03439254,Spain,,,,,,,,,,,,,,
country,NCT03439254::country::New Zealand,NCT03439254,New Zealand,,,,,,,,,,,,,,
country,NCT03439254::country::Hungary,NCT03439254,Hungary,,,,,,,,,,,,,,
country,NCT03439254::country::Puerto Rico,NCT03439254,Puerto Rico,,,,,,,,,,,,,,
country,NCT03439254::country::Ukraine,NCT03439254,Ukraine,,,,,,,,,,,,,,
trial,NCT00063622,NCT00063622,Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS),PHASE3,NASH,Liver Diseases,NIH,247.0,2005-01,2009-09,1.0,8.0,,,,,
arm,NCT00063622::arm::FG000,NCT00063622,Pioglitazone,,,,,,,,,,FG000,Pioglitazone at a dose of 30 mg daily,,,
arm,NCT00063622::arm::FG001,NCT00063622,Vitamin E,,,,,,,,,,FG001,Vitamin E at a dose of 800 IU daily,,,
arm,NCT00063622::arm::FG002,NCT00063622,Placebo,,,,,,,,,,FG002,Placebo Pioglitazone and Placebo Vitamin E,,,
period,NCT00063622::period::1,NCT00063622,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00063622::outcome::primary::1,NCT00063622,Number of Participants With Improvement in Non-alcoholic Fatty Liver Disease (NAFLD) Activity Defined by Change in Standardized Scoring of Liver Biopsies at Baseline and After 96 Weeks of Treatment.,,,,,,,,,,,,,PRIMARY,baseline and 96 weeks
country,NCT00063622::country::United States,NCT00063622,United States,,,,,,,,,,,,,,
trial,NCT03640949,NCT03640949,Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest,PHASE3,cardiovascular disease,Heart Arrest,OTHER,501.0,2018-09-17,2022-01-21,1.0,10.0,,,,,
arm,NCT03640949::arm::FG000,NCT03640949,Vasopressin and Methylprednisolone,,,,,,,,,,FG000,"The study drugs will consist of 40 mg methylprednisolone (Solu-medrol®, Pfizer) and 20 IU of vasopressin (Empressin®, Amomed Pharma GmbH) given as soon as possible after the first dose of adrenaline. ",,,
arm,NCT03640949::arm::FG001,NCT03640949,Placebo,,,,,,,,,,FG001,"The placebo for vasopressin will consist of 1 mL of 9 mg/mL NaCl (""normal saline"") from 2 mL ampules identical to the vasopressin ampules. The placebo for methylprednisolone will also consist of 1 mL ",,,
period,NCT03640949::period::1,NCT03640949,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03640949::outcome::primary::1,NCT03640949,Number of Participants With Return of Spontaneous Circulation,,,,,,,,,,,,,PRIMARY,"During the cardiac arrest, an average of 20 minutes"
country,NCT03640949::country::Denmark,NCT03640949,Denmark,,,,,,,,,,,,,,
trial,NCT06834490,NCT06834490,Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia,PHASE3,cardiovascular disease,Chronic Cerebral Ischemia,INDUSTRY,318.0,2019-11-05,2020-12-08,2.0,14.0,,,,,
arm,NCT06834490::arm::FG000,NCT06834490,Main (Mexidol),,,,,,,,,,FG000,"Participants received Mexidol IV 500 mg (10 ml) once daily for 14 days, then Mexidol FORTE 250 orally 250 mg 1 tablet 3 times a day for 60 days",,,
arm,NCT06834490::arm::FG001,NCT06834490,Control (Placebo),,,,,,,,,,FG001,"Participants received Mexidol Placebo matching Mexidol IV 500 mg (10 ml) once daily for 14 days, then Mexidol Placebo matching Mexidol FORTE 250 orally 250 mg 1 tablet 3 times a day for 60 days",,,
period,NCT06834490::period::1,NCT06834490,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT06834490::outcome::primary::1,NCT06834490,Mean Score of Montreal Cognitive Assessment (MoCA) at Visit 5 in Comparison With Reference Score at Visit 0,,,,,,,,,,,,,PRIMARY,"Day 75+2 (Visit 5) compared with the baseline level (Visit 0, 7 days before treatment)"
country,NCT06834490::country::Russia,NCT06834490,Russia,,,,,,,,,,,,,,
country,NCT06834490::country::Uzbekistan,NCT06834490,Uzbekistan,,,,,,,,,,,,,,
trial,NCT02991118,NCT02991118,Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk,PHASE3,cardiovascular disease,Hypercholesterolemia; Atherosclerotic Cardiovascular Disease,INDUSTRY,779.0,2016-11-18,2018-08-22,1.0,2.0,,,,,
arm,NCT02991118::arm::FG000,NCT02991118,Placebo,,,,,,,,,,FG000,"Participants received a placebo tablet once daily by mouth for 4 weeks prior to the 52-week double-blind treatment period. During the treatment period, participants received placebo once daily by mout",,,
arm,NCT02991118::arm::FG001,NCT02991118,Bempedoic Acid,,,,,,,,,,FG001,"Participants received a placebo tablet once daily by mouth for 4 weeks prior to the 52-week double-blind treatment period. During the treatment period, participants received a bempedoic acid 180 milli",,,
period,NCT02991118::period::1,NCT02991118,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02991118::outcome::primary::1,NCT02991118,Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C),,,,,,,,,,,,,PRIMARY,Baseline
country,NCT02991118::country::United States,NCT02991118,United States,,,,,,,,,,,,,,
trial,NCT00347360,NCT00347360,The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,654.0,2006-07,2008-04,1.0,151.0,,,,,
arm,NCT00347360::arm::FG000,NCT00347360,Lisinopril 10,,,,,,,,,,FG000,lisinopril 10 milligrams (mg) once daily,,,
arm,NCT00347360::arm::FG001,NCT00347360,Lisinopril 20,,,,,,,,,,FG001,lisinopril 20 mg once daily,,,
arm,NCT00347360::arm::FG002,NCT00347360,Lisinopril 40,,,,,,,,,,FG002,lisinopril 40 mg once daily,,,
arm,NCT00347360::arm::FG003,NCT00347360,Carvedilol Controlled Release 20,,,,,,,,,,FG003,carvedilol controlled release (CR) 20 mg once daily,,,
arm,NCT00347360::arm::FG004,NCT00347360,Carvedilol Controlled Release 40,,,,,,,,,,FG004,carvedilol CR 40 mg once daily,,,
arm,NCT00347360::arm::FG005,NCT00347360,Carvedilol Controlled Release 80,,,,,,,,,,FG005,carvedilol CR 80 mg once daily,,,
arm,NCT00347360::arm::FG006,NCT00347360,Carvedilol Controlled Release 20 Lisinopril 10,,,,,,,,,,FG006,carvedilol CR 20 mg plus lisinopril 10 mg once daily,,,
arm,NCT00347360::arm::FG007,NCT00347360,Carvedilol Controlled Release 20 Lisinopril 20,,,,,,,,,,FG007,carvedilol CR 20 mg plus lisinopril 20 mg once daily,,,
arm,NCT00347360::arm::FG008,NCT00347360,Carvedilol Controlled Release 20 Lisinopril 40,,,,,,,,,,FG008,carvedilol CR 20 mg plus lisinopril 40 mg once daily,,,
arm,NCT00347360::arm::FG009,NCT00347360,Carvedilol Controlled Release 40 Lisinopril 10,,,,,,,,,,FG009,carvedilol CR 40 mg plus lisinopril 10 mg once daily,,,
arm,NCT00347360::arm::FG010,NCT00347360,Carvedilol Controlled Release 40 Lisinopril 20,,,,,,,,,,FG010,carvedilol CR 40 mg plus lisinopril 20 mg once daily,,,
arm,NCT00347360::arm::FG011,NCT00347360,Carvedilol Controlled Release 40 Lisinopril 40,,,,,,,,,,FG011,carvedilol CR 40 mg plus lisinopril 40 mg once daily,,,
arm,NCT00347360::arm::FG012,NCT00347360,Carvedilol Controlled Release 80 Lisinopril 10,,,,,,,,,,FG012,carvedilol CR 80 mg plus lisinopril 10 mg once daily,,,
arm,NCT00347360::arm::FG013,NCT00347360,Carvedilol Controlled Release 80 Lisinopril 20,,,,,,,,,,FG013,carvedilol CR 80 mg plus lisinopril 20 mg once daily,,,
arm,NCT00347360::arm::FG014,NCT00347360,Carvedilol Controlled Release 80 Lisinopril 40,,,,,,,,,,FG014,carvedilol CR 80 mg plus lisinopril 40 mg once daily,,,
period,NCT00347360::period::1,NCT00347360,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00347360::outcome::primary::1,NCT00347360,Change From Baseline to Week 6 in 24 Hour (hr) Mean Diastolic Blood Pressure,,,,,,,,,,,,,PRIMARY,"Baseline, Week 6."
outcome,NCT00347360::outcome::primary::2,NCT00347360,Change From Baseline to Week 6 in Trough Diastolic Blood Pressure,,,,,,,,,,,,,PRIMARY,"Baseline, Week 6"
country,NCT00347360::country::United States,NCT00347360,United States,,,,,,,,,,,,,,
trial,NCT02185417,NCT02185417,Diuretic Comparison Project,PHASE3,cardiovascular disease,Hypertension,FED,20723.0,2016-06-15,2022-12-29,2.0,70.0,,,,,
arm,NCT02185417::arm::FG000,NCT02185417,Hydrochlorothiazide,,,,,,,,,,FG000,Participants remained on the existing hydrochlorothiazide treatment regimen (a daily dose of 25 or 50 mg).,,,
arm,NCT02185417::arm::FG001,NCT02185417,Chlorthalidone,,,,,,,,,,FG001,Participants switched to an equivalent dose of chlorthalidone (a daily dose of 12.5 or 25 mg).,,,
arm,NCT02185417::arm::FG002,NCT02185417,Providers,,,,,,,,,,FG002,Providers were enrolled in order to contact their potentially eligible patients and were not included in the results,,,
period,NCT02185417::period::1,NCT02185417,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02185417::outcome::primary::1,NCT02185417,Time From Randomization to Composite Primary Outcome,,,,,,,,,,,,,PRIMARY,"Outcome data collection was performed from study randomization until the participants deceased, withdrawn, or reached end of study (Up to 5.4 years for the first patient enrolled and an average of 2.4 years for all participants)."
outcome,NCT02185417::outcome::primary::2,NCT02185417,Proportion of Participants Had a Composite Primary Outcome,,,,,,,,,,,,,PRIMARY,"Outcome data collection was performed from study randomization until the participants deceased, withdrawn, or reached end of study (Up to 5.4 years for the first patient enrolled and an average of 2.4 years for all participants)."
country,NCT02185417::country::United States,NCT02185417,United States,,,,,,,,,,,,,,
country,NCT02185417::country::Puerto Rico,NCT02185417,Puerto Rico,,,,,,,,,,,,,,
trial,NCT03036124,NCT03036124,Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure,PHASE3,cardiovascular disease,Chronic Heart Failure With Reduced Ejection Fraction (HFrEF),INDUSTRY,4744.0,2017-02-08,2019-07-17,20.0,419.0,,,,,
arm,NCT03036124::arm::FG000,NCT03036124,Dapa 10mg,,,,,,,,,,FG000,"Dapagliflozin 10 mg, given once daily per oral use.",,,
arm,NCT03036124::arm::FG001,NCT03036124,Placebo,,,,,,,,,,FG001,"Placebo tablet to match dapagliflozin 10 mg, given once daily per oral use.",,,
period,NCT03036124::period::1,NCT03036124,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03036124::outcome::primary::1,NCT03036124,"Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.",,,,,,,,,,,,,PRIMARY,Up to 27.8 months.
country,NCT03036124::country::United States,NCT03036124,United States,,,,,,,,,,,,,,
country,NCT03036124::country::Japan,NCT03036124,Japan,,,,,,,,,,,,,,
country,NCT03036124::country::China,NCT03036124,China,,,,,,,,,,,,,,
country,NCT03036124::country::Canada,NCT03036124,Canada,,,,,,,,,,,,,,
country,NCT03036124::country::Argentina,NCT03036124,Argentina,,,,,,,,,,,,,,
country,NCT03036124::country::Russia,NCT03036124,Russia,,,,,,,,,,,,,,
country,NCT03036124::country::Brazil,NCT03036124,Brazil,,,,,,,,,,,,,,
country,NCT03036124::country::Bulgaria,NCT03036124,Bulgaria,,,,,,,,,,,,,,
country,NCT03036124::country::India,NCT03036124,India,,,,,,,,,,,,,,
country,NCT03036124::country::Poland,NCT03036124,Poland,,,,,,,,,,,,,,
country,NCT03036124::country::Germany,NCT03036124,Germany,,,,,,,,,,,,,,
country,NCT03036124::country::Czechia,NCT03036124,Czechia,,,,,,,,,,,,,,
country,NCT03036124::country::Taiwan,NCT03036124,Taiwan,,,,,,,,,,,,,,
country,NCT03036124::country::Hungary,NCT03036124,Hungary,,,,,,,,,,,,,,
country,NCT03036124::country::Netherlands,NCT03036124,Netherlands,,,,,,,,,,,,,,
country,NCT03036124::country::Slovakia,NCT03036124,Slovakia,,,,,,,,,,,,,,
country,NCT03036124::country::United Kingdom,NCT03036124,United Kingdom,,,,,,,,,,,,,,
country,NCT03036124::country::Denmark,NCT03036124,Denmark,,,,,,,,,,,,,,
country,NCT03036124::country::Vietnam,NCT03036124,Vietnam,,,,,,,,,,,,,,
country,NCT03036124::country::Sweden,NCT03036124,Sweden,,,,,,,,,,,,,,
trial,NCT02555878,NCT02555878,A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants,PHASE3,cardiovascular disease,Neoplasms,INDUSTRY,841.0,2015-09-11,2018-08-24,10.0,151.0,,,,,
arm,NCT02555878::arm::FG000,NCT02555878,Placebo,,,,,,,,,,FG000,Participants received placebo tablet matched to rivaroxaban orally once daily for 180 days.,,,
arm,NCT02555878::arm::FG001,NCT02555878,Rivaroxaban 10 mg,,,,,,,,,,FG001,Participants received rivaroxaban 10 milligram (mg) tablet orally once daily for 180 days.,,,
period,NCT02555878::period::1,NCT02555878,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02555878::outcome::primary::1,NCT02555878,Percentage of Participants With Time to First Occurrence of Primary Efficacy Endpoint (Composite and Components),,,,,,,,,,,,,PRIMARY,Up to Day 180
outcome,NCT02555878::outcome::primary::2,NCT02555878,Percentage of Participants With Time to the First Occurrence of Major Bleeding Events as Defined by International Society of Thrombosis and Haemostasis (ISTH),,,,,,,,,,,,,PRIMARY,From first dose of study drug to 2 days after the last dose of the study drug (up to 32 weeks)
country,NCT02555878::country::United States,NCT02555878,United States,,,,,,,,,,,,,,
country,NCT02555878::country::Germany,NCT02555878,Germany,,,,,,,,,,,,,,
country,NCT02555878::country::Brazil,NCT02555878,Brazil,,,,,,,,,,,,,,
country,NCT02555878::country::Czechia,NCT02555878,Czechia,,,,,,,,,,,,,,
country,NCT02555878::country::France,NCT02555878,France,,,,,,,,,,,,,,
country,NCT02555878::country::Russia,NCT02555878,Russia,,,,,,,,,,,,,,
country,NCT02555878::country::Belgium,NCT02555878,Belgium,,,,,,,,,,,,,,
country,NCT02555878::country::United Kingdom,NCT02555878,United Kingdom,,,,,,,,,,,,,,
country,NCT02555878::country::Canada,NCT02555878,Canada,,,,,,,,,,,,,,
country,NCT02555878::country::Bulgaria,NCT02555878,Bulgaria,,,,,,,,,,,,,,
trial,NCT03057977,NCT03057977,EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced),PHASE3,cardiovascular disease,Heart Failure,INDUSTRY,3730.0,2017-03-06,2020-05-28,20.0,520.0,,,,,
arm,NCT03057977::arm::FG000,NCT03057977,Placebo,,,,,,,,,,FG000,1 film-coated tablet of matching placebo was administered orally once daily.,,,
arm,NCT03057977::arm::FG001,NCT03057977,10 mg Empagliflozin,,,,,,,,,,FG001,Film-coated tablet of 10 milligram (mg) Empagliflozin was administered orally once daily.,,,
period,NCT03057977::period::1,NCT03057977,Discontinuation From Treatment,,,,,,,,,,,,1.0,,
period,NCT03057977::period::2,NCT03057977,Discontinuation From Trial,,,,,,,,,,,,2.0,,
outcome,NCT03057977::outcome::primary::1,NCT03057977,Time to the First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF),,,,,,,,,,,,,PRIMARY,"From randomisation until completion of the planned treatment period, up to 1040 days."
country,NCT03057977::country::United States,NCT03057977,United States,,,,,,,,,,,,,,
country,NCT03057977::country::Japan,NCT03057977,Japan,,,,,,,,,,,,,,
country,NCT03057977::country::Argentina,NCT03057977,Argentina,,,,,,,,,,,,,,
country,NCT03057977::country::Brazil,NCT03057977,Brazil,,,,,,,,,,,,,,
country,NCT03057977::country::Poland,NCT03057977,Poland,,,,,,,,,,,,,,
country,NCT03057977::country::Germany,NCT03057977,Germany,,,,,,,,,,,,,,
country,NCT03057977::country::Canada,NCT03057977,Canada,,,,,,,,,,,,,,
country,NCT03057977::country::China,NCT03057977,China,,,,,,,,,,,,,,
country,NCT03057977::country::Netherlands,NCT03057977,Netherlands,,,,,,,,,,,,,,
country,NCT03057977::country::Czechia,NCT03057977,Czechia,,,,,,,,,,,,,,
country,NCT03057977::country::Hungary,NCT03057977,Hungary,,,,,,,,,,,,,,
country,NCT03057977::country::Mexico,NCT03057977,Mexico,,,,,,,,,,,,,,
country,NCT03057977::country::India,NCT03057977,India,,,,,,,,,,,,,,
country,NCT03057977::country::South Korea,NCT03057977,South Korea,,,,,,,,,,,,,,
country,NCT03057977::country::Spain,NCT03057977,Spain,,,,,,,,,,,,,,
country,NCT03057977::country::Belgium,NCT03057977,Belgium,,,,,,,,,,,,,,
country,NCT03057977::country::France,NCT03057977,France,,,,,,,,,,,,,,
country,NCT03057977::country::Italy,NCT03057977,Italy,,,,,,,,,,,,,,
country,NCT03057977::country::Australia,NCT03057977,Australia,,,,,,,,,,,,,,
country,NCT03057977::country::United Kingdom,NCT03057977,United Kingdom,,,,,,,,,,,,,,
trial,NCT01743001,NCT01743001,Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome,PHASE3,cardiovascular disease,Pulmonary Arterial Hypertension,INDUSTRY,226.0,2013-05-21,2016-12-01,21.0,55.0,,,,,
arm,NCT01743001::arm::FG000,NCT01743001,Macitentan,,,,,,,,,,FG000,"Subjects receive macitentan 10 mg, oral tablet, to be taken once daily",,,
arm,NCT01743001::arm::FG001,NCT01743001,Placebo,,,,,,,,,,FG001,"Subjects receive macitentan-matching placebo, oral tablet, to be taken once daily",,,
period,NCT01743001::period::1,NCT01743001,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01743001::outcome::primary::1,NCT01743001,"Change From Baseline to Week 16 in Exercise Capacity, as Measured by 6-minute Walk Distance (6MWD)",,,,,,,,,,,,,PRIMARY,From baseline to Week 16
country,NCT01743001::country::United States,NCT01743001,United States,,,,,,,,,,,,,,
country,NCT01743001::country::China,NCT01743001,China,,,,,,,,,,,,,,
country,NCT01743001::country::France,NCT01743001,France,,,,,,,,,,,,,,
country,NCT01743001::country::Bulgaria,NCT01743001,Bulgaria,,,,,,,,,,,,,,
country,NCT01743001::country::Germany,NCT01743001,Germany,,,,,,,,,,,,,,
country,NCT01743001::country::Mexico,NCT01743001,Mexico,,,,,,,,,,,,,,
country,NCT01743001::country::Poland,NCT01743001,Poland,,,,,,,,,,,,,,
country,NCT01743001::country::Romania,NCT01743001,Romania,,,,,,,,,,,,,,
country,NCT01743001::country::Russia,NCT01743001,Russia,,,,,,,,,,,,,,
country,NCT01743001::country::Serbia,NCT01743001,Serbia,,,,,,,,,,,,,,
country,NCT01743001::country::Spain,NCT01743001,Spain,,,,,,,,,,,,,,
country,NCT01743001::country::Vietnam,NCT01743001,Vietnam,,,,,,,,,,,,,,
country,NCT01743001::country::Chile,NCT01743001,Chile,,,,,,,,,,,,,,
country,NCT01743001::country::Portugal,NCT01743001,Portugal,,,,,,,,,,,,,,
country,NCT01743001::country::Austria,NCT01743001,Austria,,,,,,,,,,,,,,
country,NCT01743001::country::Greece,NCT01743001,Greece,,,,,,,,,,,,,,
country,NCT01743001::country::Israel,NCT01743001,Israel,,,,,,,,,,,,,,
country,NCT01743001::country::Malaysia,NCT01743001,Malaysia,,,,,,,,,,,,,,
country,NCT01743001::country::Philippines,NCT01743001,Philippines,,,,,,,,,,,,,,
country,NCT01743001::country::Turkey (Türkiye),NCT01743001,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01743001::country::United Kingdom,NCT01743001,United Kingdom,,,,,,,,,,,,,,
trial,NCT00090519,NCT00090519,Reduction in the Occurrence of Center-Involved Diabetic Macular Edema,PHASE3,cardiovascular disease,Diabetic Retinopathy,INDUSTRY,731.0,2004-02,2010-04,17.0,84.0,,,,,
arm,NCT00090519::arm::FG000,NCT00090519,Ruboxistaurin,,,,,,,,,,FG000,32 mg once daily (QD) oral for up to 36 months,,,
arm,NCT00090519::arm::FG001,NCT00090519,Placebo,,,,,,,,,,FG001,QD oral for up to 36 months,,,
period,NCT00090519::period::1,NCT00090519,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00090519::outcome::primary::1,NCT00090519,Mean Duration of Definite Center of Macula-involved Diabetic Macular Edema (DME),,,,,,,,,,,,,PRIMARY,6 Months through 36 Months
outcome,NCT00090519::outcome::primary::2,NCT00090519,Occurrence of Sustained Moderate Visual Loss (SMVL) in a Diabetic Retinopathy (DR) Study Eye,,,,,,,,,,,,,PRIMARY,"Baseline, 36 Months"
country,NCT00090519::country::United States,NCT00090519,United States,,,,,,,,,,,,,,
country,NCT00090519::country::Canada,NCT00090519,Canada,,,,,,,,,,,,,,
country,NCT00090519::country::Australia,NCT00090519,Australia,,,,,,,,,,,,,,
country,NCT00090519::country::United Kingdom,NCT00090519,United Kingdom,,,,,,,,,,,,,,
country,NCT00090519::country::Germany,NCT00090519,Germany,,,,,,,,,,,,,,
country,NCT00090519::country::Poland,NCT00090519,Poland,,,,,,,,,,,,,,
country,NCT00090519::country::Spain,NCT00090519,Spain,,,,,,,,,,,,,,
country,NCT00090519::country::Brazil,NCT00090519,Brazil,,,,,,,,,,,,,,
country,NCT00090519::country::France,NCT00090519,France,,,,,,,,,,,,,,
country,NCT00090519::country::India,NCT00090519,India,,,,,,,,,,,,,,
country,NCT00090519::country::Denmark,NCT00090519,Denmark,,,,,,,,,,,,,,
country,NCT00090519::country::Italy,NCT00090519,Italy,,,,,,,,,,,,,,
country,NCT00090519::country::Netherlands,NCT00090519,Netherlands,,,,,,,,,,,,,,
country,NCT00090519::country::Russia,NCT00090519,Russia,,,,,,,,,,,,,,
country,NCT00090519::country::Mexico,NCT00090519,Mexico,,,,,,,,,,,,,,
country,NCT00090519::country::Portugal,NCT00090519,Portugal,,,,,,,,,,,,,,
country,NCT00090519::country::Taiwan,NCT00090519,Taiwan,,,,,,,,,,,,,,
trial,NCT02111564,NCT02111564,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,PHASE3,cardiovascular disease,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,INDUSTRY,12024.0,2014-01-07,2018-05-03,37.0,595.0,,,,,
arm,NCT02111564::arm::FG000,NCT02111564,Rivaroxaban 10 mg or 7.5 mg,,,,,,,,,,FG000,Participants with a creatinine clearance (CrCl) greater than or equal to (\>=) 50 milliliter per minute (mL/min) received 10 milligram (mg) rivaroxaban tablet once daily orally and participants with a,,,
arm,NCT02111564::arm::FG001,NCT02111564,Placebo,,,,,,,,,,FG001,Participants received rivaroxaban matched placebo tablet once daily orally for 45 days.,,,
period,NCT02111564::period::1,NCT02111564,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02111564::outcome::primary::1,NCT02111564,Time From Randomization to First Occurrence of Composite of All Symptomatic Venous Thromboembolism (VTE) and VTE Related Death Adjudicated by Clinical Event Committee (CEC),,,,,,,,,,,,,PRIMARY,Up to Day 45
outcome,NCT02111564::outcome::primary::2,NCT02111564,Event Rate Based on Time From Randomization to the First Occurrence of Major Bleeding Adjudicated by CEC,,,,,,,,,,,,,PRIMARY,From randomization to 2 days after the last dose (Day 45)
country,NCT02111564::country::United States,NCT02111564,United States,,,,,,,,,,,,,,
country,NCT02111564::country::Spain,NCT02111564,Spain,,,,,,,,,,,,,,
country,NCT02111564::country::Hungary,NCT02111564,Hungary,,,,,,,,,,,,,,
country,NCT02111564::country::Czechia,NCT02111564,Czechia,,,,,,,,,,,,,,
country,NCT02111564::country::Poland,NCT02111564,Poland,,,,,,,,,,,,,,
country,NCT02111564::country::Russia,NCT02111564,Russia,,,,,,,,,,,,,,
country,NCT02111564::country::Australia,NCT02111564,Australia,,,,,,,,,,,,,,
country,NCT02111564::country::Brazil,NCT02111564,Brazil,,,,,,,,,,,,,,
country,NCT02111564::country::Bulgaria,NCT02111564,Bulgaria,,,,,,,,,,,,,,
country,NCT02111564::country::Netherlands,NCT02111564,Netherlands,,,,,,,,,,,,,,
country,NCT02111564::country::Ukraine,NCT02111564,Ukraine,,,,,,,,,,,,,,
country,NCT02111564::country::Germany,NCT02111564,Germany,,,,,,,,,,,,,,
country,NCT02111564::country::Argentina,NCT02111564,Argentina,,,,,,,,,,,,,,
country,NCT02111564::country::Serbia,NCT02111564,Serbia,,,,,,,,,,,,,,
country,NCT02111564::country::South Africa,NCT02111564,South Africa,,,,,,,,,,,,,,
country,NCT02111564::country::Canada,NCT02111564,Canada,,,,,,,,,,,,,,
country,NCT02111564::country::Israel,NCT02111564,Israel,,,,,,,,,,,,,,
country,NCT02111564::country::Romania,NCT02111564,Romania,,,,,,,,,,,,,,
country,NCT02111564::country::Croatia,NCT02111564,Croatia,,,,,,,,,,,,,,
country,NCT02111564::country::Greece,NCT02111564,Greece,,,,,,,,,,,,,,
country,NCT02111564::country::Denmark,NCT02111564,Denmark,,,,,,,,,,,,,,
country,NCT02111564::country::Latvia,NCT02111564,Latvia,,,,,,,,,,,,,,
country,NCT02111564::country::Colombia,NCT02111564,Colombia,,,,,,,,,,,,,,
country,NCT02111564::country::Lithuania,NCT02111564,Lithuania,,,,,,,,,,,,,,
country,NCT02111564::country::Portugal,NCT02111564,Portugal,,,,,,,,,,,,,,
country,NCT02111564::country::Turkey (Türkiye),NCT02111564,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02111564::country::United Kingdom,NCT02111564,United Kingdom,,,,,,,,,,,,,,
country,NCT02111564::country::Bosnia and Herzegovina,NCT02111564,Bosnia and Herzegovina,,,,,,,,,,,,,,
country,NCT02111564::country::Belarus,NCT02111564,Belarus,,,,,,,,,,,,,,
country,NCT02111564::country::Georgia,NCT02111564,Georgia,,,,,,,,,,,,,,
country,NCT02111564::country::Mexico,NCT02111564,Mexico,,,,,,,,,,,,,,
country,NCT02111564::country::Austria,NCT02111564,Austria,,,,,,,,,,,,,,
country,NCT02111564::country::North Macedonia,NCT02111564,North Macedonia,,,,,,,,,,,,,,
country,NCT02111564::country::Slovakia,NCT02111564,Slovakia,,,,,,,,,,,,,,
country,NCT02111564::country::Peru,NCT02111564,Peru,,,,,,,,,,,,,,
country,NCT02111564::country::Estonia,NCT02111564,Estonia,,,,,,,,,,,,,,
country,NCT02111564::country::Puerto Rico,NCT02111564,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01335399,NCT01335399,"Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma",PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,748.0,2011-08-04,2021-09-03,20.0,235.0,,,,,
arm,NCT01335399::arm::FG000,NCT01335399,E-Ld Cohort,,,,,,,,,,FG000,Participants receiving a combination of Elotuzumab (E) Lenalidomide (L) Dexamethasone (d) in a 28 day cycle,,,
arm,NCT01335399::arm::FG001,NCT01335399,Ld Cohort,,,,,,,,,,FG001,Participants receiving a combination of Lenalidomide (L) Dexamethasone (d) in a 28 day cycle,,,
period,NCT01335399::period::1,NCT01335399,Pre-treatment Period,,,,,,,,,,,,1.0,,
period,NCT01335399::period::2,NCT01335399,Treatment Period,,,,,,,,,,,,2.0,,
outcome,NCT01335399::outcome::primary::1,NCT01335399,Progression-Free Survival (PFS),,,,,,,,,,,,,PRIMARY,From randomization to date of first documented tumor progression or death due to any cause (up to 8 years)
country,NCT01335399::country::United States,NCT01335399,United States,,,,,,,,,,,,,,
country,NCT01335399::country::Italy,NCT01335399,Italy,,,,,,,,,,,,,,
country,NCT01335399::country::Germany,NCT01335399,Germany,,,,,,,,,,,,,,
country,NCT01335399::country::Australia,NCT01335399,Australia,,,,,,,,,,,,,,
country,NCT01335399::country::Poland,NCT01335399,Poland,,,,,,,,,,,,,,
country,NCT01335399::country::Spain,NCT01335399,Spain,,,,,,,,,,,,,,
country,NCT01335399::country::Canada,NCT01335399,Canada,,,,,,,,,,,,,,
country,NCT01335399::country::Israel,NCT01335399,Israel,,,,,,,,,,,,,,
country,NCT01335399::country::Belgium,NCT01335399,Belgium,,,,,,,,,,,,,,
country,NCT01335399::country::Romania,NCT01335399,Romania,,,,,,,,,,,,,,
country,NCT01335399::country::United Kingdom,NCT01335399,United Kingdom,,,,,,,,,,,,,,
country,NCT01335399::country::Greece,NCT01335399,Greece,,,,,,,,,,,,,,
country,NCT01335399::country::Hungary,NCT01335399,Hungary,,,,,,,,,,,,,,
country,NCT01335399::country::Austria,NCT01335399,Austria,,,,,,,,,,,,,,
country,NCT01335399::country::Switzerland,NCT01335399,Switzerland,,,,,,,,,,,,,,
country,NCT01335399::country::Turkey (Türkiye),NCT01335399,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01335399::country::Czechia,NCT01335399,Czechia,,,,,,,,,,,,,,
country,NCT01335399::country::Ireland,NCT01335399,Ireland,,,,,,,,,,,,,,
country,NCT01335399::country::Russia,NCT01335399,Russia,,,,,,,,,,,,,,
country,NCT01335399::country::Puerto Rico,NCT01335399,Puerto Rico,,,,,,,,,,,,,,
trial,NCT02076009,NCT02076009,"A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma",PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,569.0,2014-07-23,2024-11-21,18.0,145.0,,,,,
arm,NCT02076009::arm::FG000,NCT02076009,"Lenalidomide, Low-dose Dexamethasone (Rd)",,,,,,,,,,FG000,Participants received lenalidomide at a dose of 25 milligrams (mg) orally on Day 1 through Day 21 of each 28-day treatment cycle and low-dose dexamethasone at a total dose of 40 mg weekly (or 20 mg we,,,
arm,NCT02076009::arm::FG001,NCT02076009,"Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)",,,,,,,,,,FG001,"Participants received daratumumab 16 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion once a week during treatment cycles 1 and 2 (for 8 weeks, each 28-day cycle); every 2 weeks during ",,,
period,NCT02076009::period::1,NCT02076009,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02076009::outcome::primary::1,NCT02076009,Progression-free Survival (PFS),,,,,,,,,,,,,PRIMARY,From randomization to either disease progression or death whichever occurs first (up to 21 months)
country,NCT02076009::country::United States,NCT02076009,United States,,,,,,,,,,,,,,
country,NCT02076009::country::Japan,NCT02076009,Japan,,,,,,,,,,,,,,
country,NCT02076009::country::France,NCT02076009,France,,,,,,,,,,,,,,
country,NCT02076009::country::Germany,NCT02076009,Germany,,,,,,,,,,,,,,
country,NCT02076009::country::Canada,NCT02076009,Canada,,,,,,,,,,,,,,
country,NCT02076009::country::Russia,NCT02076009,Russia,,,,,,,,,,,,,,
country,NCT02076009::country::Poland,NCT02076009,Poland,,,,,,,,,,,,,,
country,NCT02076009::country::Belgium,NCT02076009,Belgium,,,,,,,,,,,,,,
country,NCT02076009::country::Israel,NCT02076009,Israel,,,,,,,,,,,,,,
country,NCT02076009::country::Spain,NCT02076009,Spain,,,,,,,,,,,,,,
country,NCT02076009::country::Sweden,NCT02076009,Sweden,,,,,,,,,,,,,,
country,NCT02076009::country::United Kingdom,NCT02076009,United Kingdom,,,,,,,,,,,,,,
country,NCT02076009::country::Australia,NCT02076009,Australia,,,,,,,,,,,,,,
country,NCT02076009::country::Taiwan,NCT02076009,Taiwan,,,,,,,,,,,,,,
country,NCT02076009::country::Netherlands,NCT02076009,Netherlands,,,,,,,,,,,,,,
country,NCT02076009::country::Denmark,NCT02076009,Denmark,,,,,,,,,,,,,,
country,NCT02076009::country::South Korea,NCT02076009,South Korea,,,,,,,,,,,,,,
country,NCT02076009::country::Greece,NCT02076009,Greece,,,,,,,,,,,,,,
trial,NCT01313676,NCT01313676,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,PHASE3,cardiovascular disease,"Pulmonary Disease, Chronic Obstructive",INDUSTRY,16568.0,2011-01-25,2015-07-15,44.0,1611.0,,,,,
arm,NCT01313676::arm::FG000,NCT01313676,Placebo,,,,,,,,,,FG000,Participants received placebo once daily (OD) in the morning from the dry powder inhaler (DPI) until the required number of events (death) was achieved. Participants were provided albuterol/salbutamol,,,
arm,NCT01313676::arm::FG001,NCT01313676,Fluticasone Furoate 100 µg,,,,,,,,,,FG001,Participants received Fluticasone Furoate (FF) 100 microgram (µg) inhalation powder OD in the morning from the DPI until the required number of events (death) was achieved. Participants were provided ,,,
arm,NCT01313676::arm::FG002,NCT01313676,Vilanterol 25 µg,,,,,,,,,,FG002,Participants received Vilanterol (VI) 25 µg inhalation powder OD in the morning from the DPI until the required number of events (death) was achieved. Participants were provided albuterol/salbutamol i,,,
arm,NCT01313676::arm::FG003,NCT01313676,Fluticasone Furoate/Vilanterol 100/25 µg,,,,,,,,,,FG003,Participants received FF/VI 100/25 µg inhalation powder OD in the morning from the DPI until the required number of events (death) was achieved. Participants were provided albuterol/salbutamol inhalat,,,
period,NCT01313676::period::1,NCT01313676,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01313676::outcome::primary::1,NCT01313676,"Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date",,,,,,,,,,,,,PRIMARY,From the date of randomization until date of death due to any cause (average of 2 study years)
country,NCT01313676::country::United States,NCT01313676,United States,,,,,,,,,,,,,,
country,NCT01313676::country::Russia,NCT01313676,Russia,,,,,,,,,,,,,,
country,NCT01313676::country::Poland,NCT01313676,Poland,,,,,,,,,,,,,,
country,NCT01313676::country::Germany,NCT01313676,Germany,,,,,,,,,,,,,,
country,NCT01313676::country::Argentina,NCT01313676,Argentina,,,,,,,,,,,,,,
country,NCT01313676::country::Ukraine,NCT01313676,Ukraine,,,,,,,,,,,,,,
country,NCT01313676::country::China,NCT01313676,China,,,,,,,,,,,,,,
country,NCT01313676::country::Romania,NCT01313676,Romania,,,,,,,,,,,,,,
country,NCT01313676::country::Czechia,NCT01313676,Czechia,,,,,,,,,,,,,,
country,NCT01313676::country::South Africa,NCT01313676,South Africa,,,,,,,,,,,,,,
country,NCT01313676::country::South Korea,NCT01313676,South Korea,,,,,,,,,,,,,,
country,NCT01313676::country::India,NCT01313676,India,,,,,,,,,,,,,,
country,NCT01313676::country::Bulgaria,NCT01313676,Bulgaria,,,,,,,,,,,,,,
country,NCT01313676::country::Hungary,NCT01313676,Hungary,,,,,,,,,,,,,,
country,NCT01313676::country::Spain,NCT01313676,Spain,,,,,,,,,,,,,,
country,NCT01313676::country::Croatia,NCT01313676,Croatia,,,,,,,,,,,,,,
country,NCT01313676::country::United Kingdom,NCT01313676,United Kingdom,,,,,,,,,,,,,,
country,NCT01313676::country::Bosnia and Herzegovina,NCT01313676,Bosnia and Herzegovina,,,,,,,,,,,,,,
country,NCT01313676::country::Japan,NCT01313676,Japan,,,,,,,,,,,,,,
country,NCT01313676::country::Canada,NCT01313676,Canada,,,,,,,,,,,,,,
country,NCT01313676::country::Indonesia,NCT01313676,Indonesia,,,,,,,,,,,,,,
country,NCT01313676::country::Philippines,NCT01313676,Philippines,,,,,,,,,,,,,,
country,NCT01313676::country::Latvia,NCT01313676,Latvia,,,,,,,,,,,,,,
country,NCT01313676::country::Mexico,NCT01313676,Mexico,,,,,,,,,,,,,,
country,NCT01313676::country::Taiwan,NCT01313676,Taiwan,,,,,,,,,,,,,,
country,NCT01313676::country::Georgia,NCT01313676,Georgia,,,,,,,,,,,,,,
country,NCT01313676::country::Thailand,NCT01313676,Thailand,,,,,,,,,,,,,,
country,NCT01313676::country::Turkey (Türkiye),NCT01313676,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01313676::country::Slovakia,NCT01313676,Slovakia,,,,,,,,,,,,,,
country,NCT01313676::country::Austria,NCT01313676,Austria,,,,,,,,,,,,,,
country,NCT01313676::country::Israel,NCT01313676,Israel,,,,,,,,,,,,,,
country,NCT01313676::country::Australia,NCT01313676,Australia,,,,,,,,,,,,,,
country,NCT01313676::country::Colombia,NCT01313676,Colombia,,,,,,,,,,,,,,
country,NCT01313676::country::Malaysia,NCT01313676,Malaysia,,,,,,,,,,,,,,
country,NCT01313676::country::North Macedonia,NCT01313676,North Macedonia,,,,,,,,,,,,,,
country,NCT01313676::country::Serbia,NCT01313676,Serbia,,,,,,,,,,,,,,
country,NCT01313676::country::Belarus,NCT01313676,Belarus,,,,,,,,,,,,,,
country,NCT01313676::country::Chile,NCT01313676,Chile,,,,,,,,,,,,,,
country,NCT01313676::country::Belgium,NCT01313676,Belgium,,,,,,,,,,,,,,
country,NCT01313676::country::France,NCT01313676,France,,,,,,,,,,,,,,
country,NCT01313676::country::Netherlands,NCT01313676,Netherlands,,,,,,,,,,,,,,
country,NCT01313676::country::Vietnam,NCT01313676,Vietnam,,,,,,,,,,,,,,
country,NCT01313676::country::Greece,NCT01313676,Greece,,,,,,,,,,,,,,
country,NCT01313676::country::Italy,NCT01313676,Italy,,,,,,,,,,,,,,
trial,NCT03452917,NCT03452917,Clinical Trial of Sodium Nitrite for Out of Hospital Cardiac Arrest,PHASE3,cardiovascular disease,Out-Of-Hospital Cardiac Arrest,OTHER,1502.0,2018-02-08,2020-04-30,1.0,1.0,,,,,
arm,NCT03452917::arm::FG000,NCT03452917,Placebo,,,,,,,,,,FG000,"2 ml of normal saline (n=500)

Placebo: 500 patients will 2 ml of normal saline",,,
arm,NCT03452917::arm::FG001,NCT03452917,Sodium Nitrite 45 mg,,,,,,,,,,FG001,45 mg IV of sodium nitrite (n=500),,,
arm,NCT03452917::arm::FG002,NCT03452917,Sodium Nitrite 60 mg,,,,,,,,,,FG002,sodium nitrite 60 mg (n=500),,,
period,NCT03452917::period::1,NCT03452917,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03452917::outcome::primary::1,NCT03452917,Number of Participants Who Survived to Hospital Admission,,,,,,,,,,,,,PRIMARY,within 24 hours after out of hospital cardiac arrest
country,NCT03452917::country::United States,NCT03452917,United States,,,,,,,,,,,,,,
trial,NCT00622336,NCT00622336,"A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma",PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,330.0,2003-04-01,2013-11-25,2.0,7.0,,,,,
arm,NCT00622336::arm::FG000,NCT00622336,Lenalidomide 25mg,,,,,,,,,,FG000,Lenalidomide 25mg by mouth (PO) daily on Days 1 to 21 in each 28 day cycle,,,
period,NCT00622336::period::1,NCT00622336,Treatment Phase,,,,,,,,,,,,1.0,,
period,NCT00622336::period::2,NCT00622336,Extension Phase,,,,,,,,,,,,2.0,,
outcome,NCT00622336::outcome::primary::1,NCT00622336,Number of Participants With Adverse Events (AE) During the Treatment Phase,,,,,,,,,,,,,PRIMARY,Until data cut-off of 22 Oct 2009
outcome,NCT00622336::outcome::primary::2,NCT00622336,Number of Participants With Adverse Events (AE) During the Extension Phase,,,,,,,,,,,,,PRIMARY,AEs/SAEs were recorded from informed consent to 30 days post treatment discontinuation visit. Maximum exposure to Lenalidomide treatment was 1260 days.
country,NCT00622336::country::Russia,NCT00622336,Russia,,,,,,,,,,,,,,
country,NCT00622336::country::Ukraine,NCT00622336,Ukraine,,,,,,,,,,,,,,
trial,NCT00091507,NCT00091507,"IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.",PHASE3,cardiovascular disease,"Angina, Unstable; Cardiovascular Diseases; Heart Diseases; Coronary Disease; Myocardial Infarction; Heart Failure, Congestive",OTHER,911.0,2006-11,2012-08,1.0,13.0,,,,,
arm,NCT00091507::arm::FG000,NCT00091507,GIK --,,,,,,,,,,FG000,GIK = glucose-insulin-potassium,,,
arm,NCT00091507::arm::FG001,NCT00091507,Placebo,,,,,,,,,,FG001,Dextrose 5%,,,
period,NCT00091507::period::1,NCT00091507,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00091507::outcome::primary::1,NCT00091507,Progression of Acute Coronary Syndrome to Myocardial Infarction,,,,,,,,,,,,,PRIMARY,24 hours
country,NCT00091507::country::United States,NCT00091507,United States,,,,,,,,,,,,,,
trial,NCT00089895,NCT00089895,EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED),PHASE3,cardiovascular disease,Myocardial Ischemia; Acute Coronary Syndrome,INDUSTRY,9406.0,2004-11-01,2008-11-01,0.0,0.0,,,,,
arm,NCT00089895::arm::FG000,NCT00089895,Eptifibatide,,,,,,,,,,FG000,"Eptifibatide in addition to standard of care which includes usage of aspirin, unfractionated heparin or low-molecular weight heparin.",,,
arm,NCT00089895::arm::FG001,NCT00089895,Placebo,,,,,,,,,,FG001,"Placebo in addition to standard of care which includes usage of aspirin, unfractionated heparin or low-molecular weight heparin.",,,
period,NCT00089895::period::1,NCT00089895,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00089895::outcome::primary::1,NCT00089895,"Incidence of the Composite of Death, Myocardial Infarction (MI), Recurrent Ischemia Requiring Urgent Revascularization (RI-UR), and Thrombotic Bail-out.",,,,,,,,,,,,,PRIMARY,96 hours after randomization
trial,NCT00996281,NCT00996281,Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension,PHASE3,cardiovascular disease,Essential Hypertension,INDUSTRY,837.0,2009-10,2011-11,5.0,26.0,,,,,
arm,NCT00996281::arm::FG000,NCT00996281,Azilsartan Medoxomil and Chlorthalidone,,,,,,,,,,FG000,"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily for up to 52 weeks. For participants who did not achieve target blood pressure by Week 4, titration to a ma",,,
arm,NCT00996281::arm::FG001,NCT00996281,Olmesartan Medoxomil and Hydrochlorothiazide,,,,,,,,,,FG001,"Participants in the United States: Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablet, orally, once daily for up to 52 weeks. For participants who did not achieve target blo",,,
period,NCT00996281::period::1,NCT00996281,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00996281::outcome::primary::1,NCT00996281,Percentage of Participants With at Least 1 Adverse Event,,,,,,,,,,,,,PRIMARY,From Week 0 (Day 1) to Week 52.
country,NCT00996281::country::Netherlands,NCT00996281,Netherlands,,,,,,,,,,,,,,
country,NCT00996281::country::Poland,NCT00996281,Poland,,,,,,,,,,,,,,
country,NCT00996281::country::United Kingdom,NCT00996281,United Kingdom,,,,,,,,,,,,,,
country,NCT00996281::country::Germany,NCT00996281,Germany,,,,,,,,,,,,,,
country,NCT00996281::country::Austria,NCT00996281,Austria,,,,,,,,,,,,,,
trial,NCT03472040,NCT03472040,A Long Term Safety Study of BCX7353 in Hereditary Angioedema,PHASE3,cardiovascular disease,Hereditary Angioedema; HAE; Prophylaxis,INDUSTRY,387.0,2018-02-16,2022-04-27,20.0,87.0,,,,,
arm,NCT03472040::arm::FG000,NCT03472040,110 mg Followed by 150 mg Berotralstat,,,,,,,,,,FG000,"Subjects were initially treated with berotralstat 110 mg per day (QD). Following the results from Part 1 of Study BCX7353-302, all subjects were transitioned to a berotralstat dose of 150 mg QD. Dosin",,,
arm,NCT03472040::arm::FG001,NCT03472040,150 mg Berotralstat,,,,,,,,,,FG001,Subjects were treated with berotralstat 150 mg QD. Dosing continued for up to 96 weeks (US) / 216 weeks (ROW).,,,
period,NCT03472040::period::1,NCT03472040,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03472040::outcome::primary::1,NCT03472040,Safety & Tolerability,,,,,,,,,,,,,PRIMARY,Up to 96 weeks (US) / 216 weeks (Rest of World (ROW)).
country,NCT03472040::country::United States,NCT03472040,United States,,,,,,,,,,,,,,
country,NCT03472040::country::Australia,NCT03472040,Australia,,,,,,,,,,,,,,
country,NCT03472040::country::United Kingdom,NCT03472040,United Kingdom,,,,,,,,,,,,,,
country,NCT03472040::country::Israel,NCT03472040,Israel,,,,,,,,,,,,,,
country,NCT03472040::country::South Korea,NCT03472040,South Korea,,,,,,,,,,,,,,
country,NCT03472040::country::France,NCT03472040,France,,,,,,,,,,,,,,
country,NCT03472040::country::Germany,NCT03472040,Germany,,,,,,,,,,,,,,
country,NCT03472040::country::Italy,NCT03472040,Italy,,,,,,,,,,,,,,
country,NCT03472040::country::Austria,NCT03472040,Austria,,,,,,,,,,,,,,
country,NCT03472040::country::New Zealand,NCT03472040,New Zealand,,,,,,,,,,,,,,
country,NCT03472040::country::Serbia,NCT03472040,Serbia,,,,,,,,,,,,,,
country,NCT03472040::country::Spain,NCT03472040,Spain,,,,,,,,,,,,,,
country,NCT03472040::country::Denmark,NCT03472040,Denmark,,,,,,,,,,,,,,
country,NCT03472040::country::Hong Kong,NCT03472040,Hong Kong,,,,,,,,,,,,,,
country,NCT03472040::country::Hungary,NCT03472040,Hungary,,,,,,,,,,,,,,
country,NCT03472040::country::North Macedonia,NCT03472040,North Macedonia,,,,,,,,,,,,,,
country,NCT03472040::country::Poland,NCT03472040,Poland,,,,,,,,,,,,,,
country,NCT03472040::country::Slovakia,NCT03472040,Slovakia,,,,,,,,,,,,,,
country,NCT03472040::country::South Africa,NCT03472040,South Africa,,,,,,,,,,,,,,
country,NCT03472040::country::Switzerland,NCT03472040,Switzerland,,,,,,,,,,,,,,
trial,NCT01151410,NCT01151410,"An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age",PHASE3,cardiovascular disease,Hypertension,INDUSTRY,208.0,2010-08,2015-08,7.0,36.0,,,,,
arm,NCT01151410::arm::FG000,NCT01151410,Aliskiren,,,,,,,,,,FG000,Patients will receive one of the following doses based on the their weight: Low weight (≥20 to \<50 kg) patients: Starting dose 37.5 mg with optional titration to 75 and then 150 mg Mid weight (≥50 to,,,
arm,NCT01151410::arm::FG001,NCT01151410,Enalapril,,,,,,,,,,FG001,Patients will receive one of the following doses based on their weight: Low weight (≥20 to \<50 kg) patients: Starting dose 2.5 mg with optional titration to 5 and then 10 mg Mid weight (≥50 to \<80 k,,,
period,NCT01151410::period::1,NCT01151410,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01151410::outcome::primary::1,NCT01151410,Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at to End of Study,,,,,,,,,,,,,PRIMARY,Baseline - end of study (Week 52 or Last observation carried forward (LOCF)
country,NCT01151410::country::United States,NCT01151410,United States,,,,,,,,,,,,,,
country,NCT01151410::country::Hungary,NCT01151410,Hungary,,,,,,,,,,,,,,
country,NCT01151410::country::Slovakia,NCT01151410,Slovakia,,,,,,,,,,,,,,
country,NCT01151410::country::Turkey (Türkiye),NCT01151410,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01151410::country::Guatemala,NCT01151410,Guatemala,,,,,,,,,,,,,,
country,NCT01151410::country::Poland,NCT01151410,Poland,,,,,,,,,,,,,,
country,NCT01151410::country::Puerto Rico,NCT01151410,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01656889,NCT01656889,Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers,PHASE3,cardiovascular disease,Venous Leg Ulcers,INDUSTRY,447.0,2012-08,2014-12,2.0,50.0,,,,,
arm,NCT01656889::arm::FG000,NCT01656889,HP802-247,,,,,,,,,,FG000,"HP802-247 (fibrinogen solution \& thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x 106 cell",,,
arm,NCT01656889::arm::FG001,NCT01656889,Vehicle,,,,,,,,,,FG001,"Vehicle Control (fibrinogen solution \& thrombin solution without cells)

Vehicle",,,
period,NCT01656889::period::1,NCT01656889,"Treatment Period, 12 Weeks",,,,,,,,,,,,1.0,,
period,NCT01656889::period::2,NCT01656889,"Post Treatment Follow-Up, 3 Months",,,,,,,,,,,,2.0,,
outcome,NCT01656889::outcome::primary::1,NCT01656889,Compare the Treatment Groups for the Proportion of Subjects With Complete Wound Closure Over the 12-Week Treatment Period From Baseline,,,,,,,,,,,,,PRIMARY,12 Weeks
country,NCT01656889::country::United States,NCT01656889,United States,,,,,,,,,,,,,,
country,NCT01656889::country::Canada,NCT01656889,Canada,,,,,,,,,,,,,,
trial,NCT06437626,NCT06437626,Efficacy and Safety of Mexidol® in Stroke Therapy,PHASE3,cardiovascular disease,Ischemic Stroke,INDUSTRY,304.0,2019-11-18,2023-08-18,3.0,17.0,,,,,
arm,NCT06437626::arm::FG000,NCT06437626,Mexidol®,,,,,,,,,,FG000,"Participants received Mexidol® IV 500 mg 2 times a day for 10 days, then Mexidol® FORTE 250 orally 250 mg 1 tablet 3 times a day for 60 days

Mexidol: 50 mg/ml IV solution, 250 mg tablets",,,
arm,NCT06437626::arm::FG001,NCT06437626,Placebo,,,,,,,,,,FG001,"Participants received Mexidol Placebo matching Mexidol® IV 500 mg 2 times a day for 10 days, then Mexidol® FORTE 250 orally 250 mg 1 tablet 3 times a day for 60 days

Placebo: Placebo IV solution, Pla",,,
period,NCT06437626::period::1,NCT06437626,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT06437626::outcome::primary::1,NCT06437626,Change From Baseline in the Modified Rankin Scale (mRS) Scores at the End of the Course of Therapy,,,,,,,,,,,,,PRIMARY,"Baseline, Day 71"
country,NCT06437626::country::Russia,NCT06437626,Russia,,,,,,,,,,,,,,
country,NCT06437626::country::Kazakhstan,NCT06437626,Kazakhstan,,,,,,,,,,,,,,
country,NCT06437626::country::Uzbekistan,NCT06437626,Uzbekistan,,,,,,,,,,,,,,
trial,NCT00097981,NCT00097981,A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma,PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,225.0,2005-01,2009-10,1.0,58.0,,,,,
arm,NCT00097981::arm::FG000,NCT00097981,Thalidomide + Dexamethasone,,,,,,,,,,FG000,"Participants received thalidomide every night (at bedtime) without food on Days 1 to 28 and dosing was gradually increased during Cycle 1 starting at 50 mg on Days 1 to 7, 100 mg on Days 8 to 14, 150 ",,,
arm,NCT00097981::arm::FG001,NCT00097981,DOXIL + Thalidomide + Dexamethasone,,,,,,,,,,FG001,DOXIL 40 mg/m2 was administered intravenously on Day 1 and thalidomide every night (at bedtime) without food on Days 1-28 and dosing was gradually increased during Cycle 1 starting at 50 mg on Days 1 ,,,
period,NCT00097981::period::1,NCT00097981,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00097981::outcome::primary::1,NCT00097981,Complete Response Rate: Number of Participants Who Achieved a Complete Response,,,,,,,,,,,,,PRIMARY,From Cycle 2 until 28 days following completion of treatment
country,NCT00097981::country::United States,NCT00097981,United States,,,,,,,,,,,,,,
trial,NCT00426751,NCT00426751,Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI),PHASE3,cardiovascular disease,"Infarction, Myocardial",INDUSTRY,429.0,2006-10,2007-12,2.0,24.0,,,,,
arm,NCT00426751::arm::FG000,NCT00426751,Eptifibatide,,,,,,,,,,FG000,Intravenous bolus of 180 micrograms (µg)/kilogram (kg) Eptifibatide followed immediately by a continuous infusion of 2 µg/kg/minute (min) for 20-24 hours (hr) after the end of percutaneous coronary in,,,
arm,NCT00426751::arm::FG001,NCT00426751,Abciximab,,,,,,,,,,FG001,Intravenous bolus of 0.25 mg/kg Abciximab followed by continuous intravenous infusion of 0.125 μg/kg/min (maximum 10 μg/min) for 12 hr after PCI,,,
period,NCT00426751::period::1,NCT00426751,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00426751::outcome::primary::1,NCT00426751,Number of Participants With Complete Sum ST Resolution (STR) 60 Minutes (Min) After Percutaneous Coronary Intervention (PCI) (Per Protocol Population),,,,,,,,,,,,,PRIMARY,Baseline (ECG I) and 60 min +/- 15 min after PCI (ECG III)
outcome,NCT00426751::outcome::primary::2,NCT00426751,Number of Participants With Complete Sum ST Resolution (STR) 60 Min After Percutaneous Coronary Intervention (PCI) (Intent-to-Treat Population),,,,,,,,,,,,,PRIMARY,Baseline (ECG I) and 60 min +/- 15 min after PCI (ECG III)
country,NCT00426751::country::France,NCT00426751,France,,,,,,,,,,,,,,
country,NCT00426751::country::Germany,NCT00426751,Germany,,,,,,,,,,,,,,
trial,NCT00437645,NCT00437645,Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension,PHASE3,cardiovascular disease,Essential Hypertension,INDUSTRY,1183.0,2007-01,2007-11,12.0,12.0,,,,,
arm,NCT00437645::arm::FG000,NCT00437645,Valsartan/Amlodipine 160/5 mg,,,,,,,,,,FG000,"Twelve (12) weeks treatment with the combination of valsartan/amlodipine 160/5 mg. Together with the active medication, patients received a placebo that matched amlodipine 5 mg. The three capsules wer",,,
arm,NCT00437645::arm::FG001,NCT00437645,Amlodipine 10 mg,,,,,,,,,,FG001,"Eight (8) weeks of treatment with amlodipine 10 mg (two 5 mg capsules). Together with the active medication, the patients received a placebo that matched valsartan 160 mg. At Week 8, patients were swi",,,
period,NCT00437645::period::1,NCT00437645,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00437645::outcome::primary::1,NCT00437645,Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 8,,,,,,,,,,,,,PRIMARY,Baseline to Week 8
outcome,NCT00437645::outcome::primary::2,NCT00437645,Percentage of Patients With Peripheral Edema From Baseline to Week 8,,,,,,,,,,,,,PRIMARY,Baseline to Week 8
country,NCT00437645::country::Argentina,NCT00437645,Argentina,,,,,,,,,,,,,,
country,NCT00437645::country::Chile,NCT00437645,Chile,,,,,,,,,,,,,,
country,NCT00437645::country::Ecuador,NCT00437645,Ecuador,,,,,,,,,,,,,,
country,NCT00437645::country::Finland,NCT00437645,Finland,,,,,,,,,,,,,,
country,NCT00437645::country::France,NCT00437645,France,,,,,,,,,,,,,,
country,NCT00437645::country::Germany,NCT00437645,Germany,,,,,,,,,,,,,,
country,NCT00437645::country::Italy,NCT00437645,Italy,,,,,,,,,,,,,,
country,NCT00437645::country::Norway,NCT00437645,Norway,,,,,,,,,,,,,,
country,NCT00437645::country::Spain,NCT00437645,Spain,,,,,,,,,,,,,,
country,NCT00437645::country::Sweden,NCT00437645,Sweden,,,,,,,,,,,,,,
country,NCT00437645::country::Switzerland,NCT00437645,Switzerland,,,,,,,,,,,,,,
country,NCT00437645::country::Turkey (Türkiye),NCT00437645,Turkey (Türkiye),,,,,,,,,,,,,,
trial,NCT01369069,NCT01369069,Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial,PHASE3,cardiovascular disease,Acute Ischemic Stroke; Diabetes; Hyperglycemia,OTHER,1151.0,2012-04,2018-11-19,1.0,70.0,,,,,
arm,NCT01369069::arm::FG000,NCT01369069,IV Insulin Drip With Target Glucose 80 mg/dL - 130 mg/dL,,,,,,,,,,FG000,"The intervention arm will have a targeted glucose concentration of 80-130 mg/dL. IV insulin drip will be titrated to keep glucose concentration in this range.

IV insulin to maintain target glucose co",,,
arm,NCT01369069::arm::FG001,NCT01369069,Sub Q Insulin to Keep Glucose Less Than 180 mg/dL,,,,,,,,,,FG001,"This standard care arm will get sub q insulin sliding scale to keep glucose concentration less than 180 mg/dL

Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL: Slidin",,,
period,NCT01369069::period::1,NCT01369069,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01369069::outcome::primary::1,NCT01369069,Number of Participants With a Favorable Modified Rankin Scale (Yes/No),,,,,,,,,,,,,PRIMARY,90 days (-14/+30 days)
outcome,NCT01369069::outcome::primary::2,NCT01369069,Number of Participants With Severe Hypoglycemia (Blood Glucose < 40mg/dL),,,,,,,,,,,,,PRIMARY,72 hours
country,NCT01369069::country::United States,NCT01369069,United States,,,,,,,,,,,,,,
trial,NCT00415623,NCT00415623,A Comparative Study Between Amlodipine 10mg And 5mg With Hypertension For Whom 5mg Is Insufficient,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,305.0,2007-01,2007-10,1.0,14.0,,,,,
arm,NCT00415623::arm::FG000,NCT00415623,Amlodipine 5 mg,,,,,,,,,,FG000,One amlodipine besilate 5 mg tablet and 1 amlodipine besilate 5 mg placebo tablet were administered once daily after breakfast for 8 weeks.,,,
arm,NCT00415623::arm::FG001,NCT00415623,Amlodipine 10 mg,,,,,,,,,,FG001,Two amlodipine besilate 5 mg tablets were administered once daily after breakfast for 8 weeks.,,,
period,NCT00415623::period::1,NCT00415623,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00415623::outcome::primary::1,NCT00415623,Change in Systolic Blood Pressure (SBP) From Baseline to Week 8,,,,,,,,,,,,,PRIMARY,Baseline to Week 8
country,NCT00415623::country::Japan,NCT00415623,Japan,,,,,,,,,,,,,,
trial,NCT00523978,NCT00523978,A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation,PHASE3,cardiovascular disease,Paroxysmal Atrial Fibrillation,INDUSTRY,245.0,2006-10,2011-07,2.0,26.0,,,,,
arm,NCT00523978::arm::FG000,NCT00523978,Cryoablation,,,,,,,,,,FG000,"an experimental group receiving cryoablation and, optionally, a previously failed Atrial Fibrillation Drug.3 Subjects withdrew consent 5 subjects were a screen failure. Therefore N=163 for Experimenta",,,
arm,NCT00523978::arm::FG001,NCT00523978,Standard Treatment With Drugs Only,,,,,,,,,,FG001,a control group receiving only an Atrial Fibrillation Drug. 4 Subject withdrew consent and 1 subject was a screen failure. Therefore- Control Treatment group N= 82.,,,
period,NCT00523978::period::1,NCT00523978,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00523978::outcome::primary::1,NCT00523978,Acute Procedural Success (APS),,,,,,,,,,,,,PRIMARY,371.4 Minutes (Average)
outcome,NCT00523978::outcome::primary::2,NCT00523978,Freedom From Chronic Treatment Failure (CTF),,,,,,,,,,,,,PRIMARY,12 month follow up period
outcome,NCT00523978::outcome::primary::3,NCT00523978,Treatment Success,,,,,,,,,,,,,PRIMARY,12 months
outcome,NCT00523978::outcome::primary::4,NCT00523978,Freedom From Major Atrial Fibrillation Events (MAFEs),,,,,,,,,,,,,PRIMARY,12 Months
outcome,NCT00523978::outcome::primary::5,NCT00523978,Cryoablation Procedure Events (CPEs),,,,,,,,,,,,,PRIMARY,To end of ablation procedure
country,NCT00523978::country::United States,NCT00523978,United States,,,,,,,,,,,,,,
country,NCT00523978::country::Canada,NCT00523978,Canada,,,,,,,,,,,,,,
trial,NCT00475852,NCT00475852,A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure,PHASE3,cardiovascular disease,Heart Decompensation,INDUSTRY,7141.0,2007-05,2011-03,28.0,328.0,,,,,
arm,NCT00475852::arm::FG000,NCT00475852,Nesiritide,,,,,,,,,,FG000,0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs,,,
arm,NCT00475852::arm::FG001,NCT00475852,Placebo,,,,,,,,,,FG001,Matching placebo infusion:0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs,,,
period,NCT00475852::period::1,NCT00475852,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00475852::outcome::primary::1,NCT00475852,Composite of Rehospitalization Due to Heart Failure and All-Cause Mortality,,,,,,,,,,,,,PRIMARY,Randomization to Day 30
outcome,NCT00475852::outcome::primary::2,NCT00475852,Dyspnea Self-Assessment at 6 Hours After Initiation of Study Drug,,,,,,,,,,,,,PRIMARY,6 hours after initiation of study drug
outcome,NCT00475852::outcome::primary::3,NCT00475852,Dyspnea Self-Assessment at 24 Hours After Initiation of Study Drug,,,,,,,,,,,,,PRIMARY,24 hours after study drug initiation
country,NCT00475852::country::United States,NCT00475852,United States,,,,,,,,,,,,,,
country,NCT00475852::country::Canada,NCT00475852,Canada,,,,,,,,,,,,,,
country,NCT00475852::country::Australia,NCT00475852,Australia,,,,,,,,,,,,,,
country,NCT00475852::country::Brazil,NCT00475852,Brazil,,,,,,,,,,,,,,
country,NCT00475852::country::China,NCT00475852,China,,,,,,,,,,,,,,
country,NCT00475852::country::France,NCT00475852,France,,,,,,,,,,,,,,
country,NCT00475852::country::India,NCT00475852,India,,,,,,,,,,,,,,
country,NCT00475852::country::Poland,NCT00475852,Poland,,,,,,,,,,,,,,
country,NCT00475852::country::Ukraine,NCT00475852,Ukraine,,,,,,,,,,,,,,
country,NCT00475852::country::Argentina,NCT00475852,Argentina,,,,,,,,,,,,,,
country,NCT00475852::country::Germany,NCT00475852,Germany,,,,,,,,,,,,,,
country,NCT00475852::country::Israel,NCT00475852,Israel,,,,,,,,,,,,,,
country,NCT00475852::country::Netherlands,NCT00475852,Netherlands,,,,,,,,,,,,,,
country,NCT00475852::country::New Zealand,NCT00475852,New Zealand,,,,,,,,,,,,,,
country,NCT00475852::country::Mexico,NCT00475852,Mexico,,,,,,,,,,,,,,
country,NCT00475852::country::Russia,NCT00475852,Russia,,,,,,,,,,,,,,
country,NCT00475852::country::Greece,NCT00475852,Greece,,,,,,,,,,,,,,
country,NCT00475852::country::Bulgaria,NCT00475852,Bulgaria,,,,,,,,,,,,,,
country,NCT00475852::country::Chile,NCT00475852,Chile,,,,,,,,,,,,,,
country,NCT00475852::country::Colombia,NCT00475852,Colombia,,,,,,,,,,,,,,
country,NCT00475852::country::Norway,NCT00475852,Norway,,,,,,,,,,,,,,
country,NCT00475852::country::Taiwan,NCT00475852,Taiwan,,,,,,,,,,,,,,
country,NCT00475852::country::Lithuania,NCT00475852,Lithuania,,,,,,,,,,,,,,
country,NCT00475852::country::Malaysia,NCT00475852,Malaysia,,,,,,,,,,,,,,
country,NCT00475852::country::South Korea,NCT00475852,South Korea,,,,,,,,,,,,,,
country,NCT00475852::country::Sweden,NCT00475852,Sweden,,,,,,,,,,,,,,
country,NCT00475852::country::Thailand,NCT00475852,Thailand,,,,,,,,,,,,,,
country,NCT00475852::country::Singapore,NCT00475852,Singapore,,,,,,,,,,,,,,
trial,NCT00657150,NCT00657150,Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty,PHASE3,cardiovascular disease,Venous Thromboembolism,INDUSTRY,2055.0,2008-03,,19.0,108.0,,,,,
arm,NCT00657150::arm::FG000,NCT00657150,Dabigatran 220mg,,,,,,,,,,FG000,qd (once daily) oral,,,
arm,NCT00657150::arm::FG001,NCT00657150,Enoxaparin,,,,,,,,,,FG001,40mg qd (once daily) subcutaneous,,,
period,NCT00657150::period::1,NCT00657150,Overall Study,,,,,,,,,,,,1.0,,
period,NCT00657150::period::2,NCT00657150,Treatment,,,,,,,,,,,,2.0,,
outcome,NCT00657150::outcome::primary::1,NCT00657150,Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period,,,,,,,,,,,,,PRIMARY,28-35 days
country,NCT00657150::country::India,NCT00657150,India,,,,,,,,,,,,,,
country,NCT00657150::country::United States,NCT00657150,United States,,,,,,,,,,,,,,
country,NCT00657150::country::Canada,NCT00657150,Canada,,,,,,,,,,,,,,
country,NCT00657150::country::Sweden,NCT00657150,Sweden,,,,,,,,,,,,,,
country,NCT00657150::country::Netherlands,NCT00657150,Netherlands,,,,,,,,,,,,,,
country,NCT00657150::country::Italy,NCT00657150,Italy,,,,,,,,,,,,,,
country,NCT00657150::country::Spain,NCT00657150,Spain,,,,,,,,,,,,,,
country,NCT00657150::country::Czechia,NCT00657150,Czechia,,,,,,,,,,,,,,
country,NCT00657150::country::Norway,NCT00657150,Norway,,,,,,,,,,,,,,
country,NCT00657150::country::Poland,NCT00657150,Poland,,,,,,,,,,,,,,
country,NCT00657150::country::Australia,NCT00657150,Australia,,,,,,,,,,,,,,
country,NCT00657150::country::Austria,NCT00657150,Austria,,,,,,,,,,,,,,
country,NCT00657150::country::Belgium,NCT00657150,Belgium,,,,,,,,,,,,,,
country,NCT00657150::country::Denmark,NCT00657150,Denmark,,,,,,,,,,,,,,
country,NCT00657150::country::Germany,NCT00657150,Germany,,,,,,,,,,,,,,
country,NCT00657150::country::Hungary,NCT00657150,Hungary,,,,,,,,,,,,,,
country,NCT00657150::country::Finland,NCT00657150,Finland,,,,,,,,,,,,,,
country,NCT00657150::country::South Africa,NCT00657150,South Africa,,,,,,,,,,,,,,
country,NCT00657150::country::New Zealand,NCT00657150,New Zealand,,,,,,,,,,,,,,
trial,NCT00765674,NCT00765674,Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,1191.0,2008-09,2009-08,12.0,12.0,,,,,
arm,NCT00765674::arm::FG000,NCT00765674,Aliskiren / Amlodipine,,,,,,,,,,FG000,Patients received an aliskiren 150 mg tablet plus an amlodipine 5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus amlodipine 10 mg for the remaining 4 weeks of the stud,,,
arm,NCT00765674::arm::FG001,NCT00765674,Aliskiren / Hydrochlorothiazide,,,,,,,,,,FG001,Patients received an aliskiren 150 mg tablet plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus hydrochlorothiazide 25 mg for the remaining,,,
arm,NCT00765674::arm::FG002,NCT00765674,Amlodipine / Hydrochlorothiazide,,,,,,,,,,FG002,Patients received an amlodipine 5 mg capsule plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to amlodipine 10 mg plus hydrochlorothiazide 25 mg for the remaining,,,
arm,NCT00765674::arm::FG003,NCT00765674,Aliskiren / Amlodipine / Hydrochlorothiazide,,,,,,,,,,FG003,"Patients received an aliskiren 150 mg tablet, a HCTZ 12.5 mg capsule and a placebo capsule for the first 3 days of treatment. Amlodipine 5 mg was then added for the remainder of the first 4 weeks of t",,,
period,NCT00765674::period::1,NCT00765674,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00765674::outcome::primary::1,NCT00765674,Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8),,,,,,,,,,,,,PRIMARY,Baseline to end of study (Week 8)
country,NCT00765674::country::United States,NCT00765674,United States,,,,,,,,,,,,,,
country,NCT00765674::country::Australia,NCT00765674,Australia,,,,,,,,,,,,,,
country,NCT00765674::country::Canada,NCT00765674,Canada,,,,,,,,,,,,,,
country,NCT00765674::country::Denmark,NCT00765674,Denmark,,,,,,,,,,,,,,
country,NCT00765674::country::Germany,NCT00765674,Germany,,,,,,,,,,,,,,
country,NCT00765674::country::Israel,NCT00765674,Israel,,,,,,,,,,,,,,
country,NCT00765674::country::Italy,NCT00765674,Italy,,,,,,,,,,,,,,
country,NCT00765674::country::Latvia,NCT00765674,Latvia,,,,,,,,,,,,,,
country,NCT00765674::country::Lithuania,NCT00765674,Lithuania,,,,,,,,,,,,,,
country,NCT00765674::country::Romania,NCT00765674,Romania,,,,,,,,,,,,,,
country,NCT00765674::country::Sweden,NCT00765674,Sweden,,,,,,,,,,,,,,
country,NCT00765674::country::Turkey (Türkiye),NCT00765674,Turkey (Türkiye),,,,,,,,,,,,,,
trial,NCT01885559,NCT01885559,HALT Progression of Polycystic Kidney Disease Study B,PHASE3,cardiovascular disease,"Kidney, Polycystic",NIH,486.0,2006-01,2014-06,1.0,7.0,,,,,
arm,NCT01885559::arm::FG000,NCT01885559,ACE-I + Placebo,,,,,,,,,,FG000,"ACE-I + placebo and standard blood pressure control of 110-130/80 mm Hg

Lisinopril and Placebo: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and placebo titrated to 40mg and 80mg, as tolerated by par",,,
arm,NCT01885559::arm::FG001,NCT01885559,ACE-I + Angiotensin Receptor Blocker (ARB),,,,,,,,,,FG001,"ACE-I + angiotensin receptor blocker (ARB) and standard blood pressure control of 110-130/80 mm Hg

Lisinopril and Telmisartan: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and telmisartan titrated to",,,
period,NCT01885559::period::1,NCT01885559,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01885559::outcome::primary::1,NCT01885559,"Number of Participants With 50% Reduction of Baseline eGFR, End Stage Renal Disease (ESRD, Initiation of Dialysis or Preemptive Transplant), or Death.",,,,,,,,,,,,,PRIMARY,Patients followed for 5-8 years with average of 6.5 years follow up
country,NCT01885559::country::United States,NCT01885559,United States,,,,,,,,,,,,,,
trial,NCT05888103,NCT05888103,Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.,PHASE3,cardiovascular disease,Primary Hypercholesterolemia or Mixed Dyslipidemia,INDUSTRY,207.0,2023-07-11,2024-10-24,1.0,28.0,,,,,
arm,NCT05888103::arm::FG000,NCT05888103,Inclisiran - Inclisiran,,,,,,,,,,FG000,"Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) s.c administered on Days 1, 90, and 270, and with matching placebo s.c administered on Day 180",,,
arm,NCT05888103::arm::FG001,NCT05888103,Placebo- Inclisiran,,,,,,,,,,FG001,Placebo s.c administered on Days 1 and 90 and Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) s.c administered on Days 180 and 270,,,
period,NCT05888103::period::1,NCT05888103,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT05888103::outcome::primary::1,NCT05888103,Percentage Change in Low-density Lipoprotein Cholesterol (LDL-C) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part,,,,,,,,,,,,,PRIMARY,"Baseline, Day 150"
country,NCT05888103::country::China,NCT05888103,China,,,,,,,,,,,,,,
trial,NCT00135707,NCT00135707,Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS),PHASE3,cardiovascular disease,Preeclampsia,OTHER,10154.0,2003-06,2009-01,1.0,16.0,,,,,
arm,NCT00135707::arm::FG000,NCT00135707,Vitamins,,,,,,,,,,FG000,Vitamins C \& E,,,
arm,NCT00135707::arm::FG001,NCT00135707,Placebo,,,,,,,,,,FG001,"Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell",,,
period,NCT00135707::period::1,NCT00135707,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00135707::outcome::primary::1,NCT00135707,Composite of Pregnancy-associated Hypertension and Serious Adverse Outcomes in the Mother or Fetus or Neonate,,,,,,,,,,,,,PRIMARY,20 weeks through discharge following delivery
outcome,NCT00135707::outcome::primary::2,NCT00135707,Severe Hypertension,,,,,,,,,,,,,PRIMARY,20 weeks through discharge following delivery
outcome,NCT00135707::outcome::primary::3,NCT00135707,Severe or Mild Pregnancy-associated Hypertension With Elevated Liver Enzyme Levels,,,,,,,,,,,,,PRIMARY,20 weeks through discharge following delivery
outcome,NCT00135707::outcome::primary::4,NCT00135707,Severe or Mild Pregnancy-associated Hypertension With Thrombocytopenia,,,,,,,,,,,,,PRIMARY,20 weeks through discharge following delivery
outcome,NCT00135707::outcome::primary::5,NCT00135707,Severe or Mild Pregnancy-associated Hypertension With an Elevated Serum Creatinine Level,,,,,,,,,,,,,PRIMARY,20 weeks through discharge following delivery
outcome,NCT00135707::outcome::primary::6,NCT00135707,Severe or Mild Pregnancy-associated Hypertension With an Eclamptic Seizure,,,,,,,,,,,,,PRIMARY,20 weeks through discharge following delivery
outcome,NCT00135707::outcome::primary::7,NCT00135707,Severe or Mild Pregnancy-associated Hypertension With an Indicated Preterm Birth Before 32 Weeks of Gestation Owing to Hypertension-related Disorders,,,,,,,,,,,,,PRIMARY,20 weeks through discharge following delivery
outcome,NCT00135707::outcome::primary::8,NCT00135707,Severe or Mild Pregnancy-associated Hypertension With a Fetus That Was Small for Gestational Age (Below the 3rd Percentile) Adjusted for Sex and Race or Ethnic Group,,,,,,,,,,,,,PRIMARY,20 weeks through discharge following delivery
outcome,NCT00135707::outcome::primary::9,NCT00135707,Severe or Mild Pregnancy-associated Hypertension With a Fetal Death After 20 Weeks of Gestation or Neonatal Death,,,,,,,,,,,,,PRIMARY,20 weeks through discharge or prior to discharge following delivery admission
country,NCT00135707::country::United States,NCT00135707,United States,,,,,,,,,,,,,,
trial,NCT03057951,NCT03057951,EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved),PHASE3,cardiovascular disease,Heart Failure,INDUSTRY,5988.0,2017-03-02,2021-04-26,23.0,619.0,,,,,
arm,NCT03057951::arm::FG000,NCT03057951,Placebo,,,,,,,,,,FG000,1 film-coated tablet of matching placebo was administered orally once daily in patients with chronic heart failure with preserved ejection fraction (HFpEF).,,,
arm,NCT03057951::arm::FG001,NCT03057951,10 mg Empagliflozin,,,,,,,,,,FG001,1 film-coated tablet of 10 milligram (mg) of empagliflozin was administered orally once daily in patients with chronic heart failure with preserved ejection fraction (HFpEF).,,,
period,NCT03057951::period::1,NCT03057951,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03057951::outcome::primary::1,NCT03057951,Time to First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF),,,,,,,,,,,,,PRIMARY,"From randomization until completion of the planned treatment phase, up to 1403 days."
country,NCT03057951::country::United States,NCT03057951,United States,,,,,,,,,,,,,,
country,NCT03057951::country::Japan,NCT03057951,Japan,,,,,,,,,,,,,,
country,NCT03057951::country::Argentina,NCT03057951,Argentina,,,,,,,,,,,,,,
country,NCT03057951::country::Brazil,NCT03057951,Brazil,,,,,,,,,,,,,,
country,NCT03057951::country::Germany,NCT03057951,Germany,,,,,,,,,,,,,,
country,NCT03057951::country::Poland,NCT03057951,Poland,,,,,,,,,,,,,,
country,NCT03057951::country::Canada,NCT03057951,Canada,,,,,,,,,,,,,,
country,NCT03057951::country::Czechia,NCT03057951,Czechia,,,,,,,,,,,,,,
country,NCT03057951::country::China,NCT03057951,China,,,,,,,,,,,,,,
country,NCT03057951::country::Hungary,NCT03057951,Hungary,,,,,,,,,,,,,,
country,NCT03057951::country::Netherlands,NCT03057951,Netherlands,,,,,,,,,,,,,,
country,NCT03057951::country::India,NCT03057951,India,,,,,,,,,,,,,,
country,NCT03057951::country::Mexico,NCT03057951,Mexico,,,,,,,,,,,,,,
country,NCT03057951::country::Romania,NCT03057951,Romania,,,,,,,,,,,,,,
country,NCT03057951::country::Australia,NCT03057951,Australia,,,,,,,,,,,,,,
country,NCT03057951::country::Colombia,NCT03057951,Colombia,,,,,,,,,,,,,,
country,NCT03057951::country::Italy,NCT03057951,Italy,,,,,,,,,,,,,,
country,NCT03057951::country::South Africa,NCT03057951,South Africa,,,,,,,,,,,,,,
country,NCT03057951::country::South Korea,NCT03057951,South Korea,,,,,,,,,,,,,,
country,NCT03057951::country::Spain,NCT03057951,Spain,,,,,,,,,,,,,,
country,NCT03057951::country::Belgium,NCT03057951,Belgium,,,,,,,,,,,,,,
country,NCT03057951::country::United Kingdom,NCT03057951,United Kingdom,,,,,,,,,,,,,,
country,NCT03057951::country::Singapore,NCT03057951,Singapore,,,,,,,,,,,,,,
trial,NCT01370616,NCT01370616,Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium for the Treatment of Diabetic Foot Infections in Chinese Adults (MK-0826-061),PHASE3,cardiovascular disease,Infection; Diabetic Foot,INDUSTRY,565.0,2011-09-02,2013-12-18,0.0,0.0,,,,,
arm,NCT01370616::arm::FG000,NCT01370616,Ertapenem Sodium,,,,,,,,,,FG000,"Participants received 1.0 g intravenous (IV) ertapenem sodium as a single daily dose at Hour 0 infused over a 30-minute interval , and IV piperacillin/tazobactam-matching placebo at Hours 8 and 16 inf",,,
arm,NCT01370616::arm::FG001,NCT01370616,Piperacillin/Tazobactam Sodium,,,,,,,,,,FG001,"Participants received 4.5 g IV piperacillin/tazobactam at Hours 0, 8, and 16 infused over a 30-minute interval, for 5 to 28 days. Participants may be switched to Amoxicillin/clavulunate potassium 625 ",,,
period,NCT01370616::period::1,NCT01370616,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01370616::outcome::primary::1,NCT01370616,Percentage of Participants With Favorable Clinical Response Assessments at Discontinuation of Intravenous (IV) Study Therapy (DCIV),,,,,,,,,,,,,PRIMARY,Day 5 up to Day 28
trial,NCT01413178,NCT01413178,A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma,PHASE3,cardiovascular disease,Myeloma,OTHER,205.0,2011-09-30,2019-03-10,1.0,1.0,,,,,
arm,NCT01413178::arm::FG000,NCT01413178,Busulfan + Melphalan,,,,,,,,,,FG000,Busulfan with a target daily area under the curve (AUC) of 5000 with Melphalan 70 mg/m2 followed by a stem cell transplant,,,
arm,NCT01413178::arm::FG001,NCT01413178,Melphalan,,,,,,,,,,FG001,High-dose Melphalan 200 mg/m2/day followed by a stem cell transplant,,,
period,NCT01413178::period::1,NCT01413178,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01413178::outcome::primary::1,NCT01413178,Progression-Free Survival (PFS),,,,,,,,,,,,,PRIMARY,3 years after transplant
country,NCT01413178::country::United States,NCT01413178,United States,,,,,,,,,,,,,,
trial,NCT00523744,NCT00523744,"Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension",PHASE3,cardiovascular disease,Hypertension,INDUSTRY,257.0,2007-07,2007-12,2.0,2.0,,,,,
arm,NCT00523744::arm::FG000,NCT00523744,"Amlodipine(AML)+Olmesartan, AML+Valsartan, AML+Valsartan+HCTZ",,,,,,,,,,FG000,"During the Treatment Phase 1, participants received 1 week of treatment with olmesartan 10 mg and amlodipine 5 mg once daily in free combination, followed by three weeks of treatment with olmesartan 2",,,
period,NCT00523744::period::1,NCT00523744,Phase 1 - Amlodipine+Olmesartan,,,,,,,,,,,,1.0,,
period,NCT00523744::period::2,NCT00523744,Phase 2 - Amlodipine+Valsartan,,,,,,,,,,,,2.0,,
period,NCT00523744::period::3,NCT00523744,Phase 3 - Amlodipine+Valsartan+HCTZ,,,,,,,,,,,,3.0,,
outcome,NCT00523744::outcome::primary::1,NCT00523744,Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the Study,,,,,,,,,,,,,PRIMARY,Baseline Phase 2 (Week 4) to end of Phase 2 (Week 8)
outcome,NCT00523744::outcome::primary::2,NCT00523744,Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Extension Phase of the Study,,,,,,,,,,,,,PRIMARY,Baseline Phase 3 (Week 8) to end of Phase 3 (Week 12)
country,NCT00523744::country::Germany,NCT00523744,Germany,,,,,,,,,,,,,,
country,NCT00523744::country::Unknown,NCT00523744,Unknown,,,,,,,,,,,,,,
trial,NCT00126438,NCT00126438,Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease,PHASE3,cardiovascular disease,"Heart Failure, Congestive",INDUSTRY,515.0,2005-07,2008-09,1.0,1.0,,,,,
arm,NCT00126438::arm::FG000,NCT00126438,AdreView - Heart Failure Group,,,,,,,,,,FG000,AdreView (123I-mIBG \[meta-iodobenzylguanidine\]): 10 milliCurie (mCi) as a single intravenous dose.,,,
arm,NCT00126438::arm::FG001,NCT00126438,Adreview - Control Group,,,,,,,,,,FG001,AdreView (123I-mIBG): 10 mCi as a single intravenous dose.,,,
period,NCT00126438::period::1,NCT00126438,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00126438::outcome::primary::1,NCT00126438,Relationship Between the Occurrence of Adverse Cardiac Event and 123I-mIBG Uptake on Planar Scintigraphy Categorized as High or Low Heart to Mediastinum (H/M) Ratio,,,,,,,,,,,,,PRIMARY,Approximately 24 months from the date of administration of 123I-mIBG
country,NCT00126438::country::United States,NCT00126438,United States,,,,,,,,,,,,,,
trial,NCT03514641,NCT03514641,An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension,PHASE3,cardiovascular disease,Essential Hypertension,INDUSTRY,673.0,2017-10-18,2018-11-30,1.0,87.0,,,,,
arm,NCT03514641::arm::FG000,NCT03514641,"603A: Bexagliflozin Tablets, 20 mg",,,,,,,,,,FG000,"Each subject will receive bexagliflozin tablets, 20 mg once daily for 12 weeks",,,
arm,NCT03514641::arm::FG001,NCT03514641,603A: Placebo Tablets,,,,,,,,,,FG001,Each subject will receive placebo (inactive tablet) once daily for 12 weeks.,,,
arm,NCT03514641::arm::FG002,NCT03514641,"603B: Bexagliflozin Tablets, 20 mg",,,,,,,,,,FG002,"Each subject will receive bexagliflozin tablets, 20 mg once daily for 12 weeks from week 24 to week 36 (cumulative)",,,
arm,NCT03514641::arm::FG003,NCT03514641,603B: Placebo Tablets,,,,,,,,,,FG003,Each subject will receive placebo (inactive tablet) once daily for 12 weeks from week 24 to week 36 (cumulative),,,
period,NCT03514641::period::1,NCT03514641,603A: 0-12 Week Study Period,,,,,,,,,,,,1.0,,
period,NCT03514641::period::2,NCT03514641,603B: 24-36 Week Study Period,,,,,,,,,,,,2.0,,
outcome,NCT03514641::outcome::primary::1,NCT03514641,Change of the 24 Hour Mean Systolic Blood Pressure From Baseline (Day 1) to Week 12,,,,,,,,,,,,,PRIMARY,Baseline (Day 1) to week 12
outcome,NCT03514641::outcome::primary::2,NCT03514641,Change of the 24 Hour Mean Systolic Blood Pressure From Cumulative Week 24 to Week 36,,,,,,,,,,,,,PRIMARY,Change from week 24 to week 36
country,NCT03514641::country::United States,NCT03514641,United States,,,,,,,,,,,,,,
trial,NCT01583218,NCT01583218,Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study),PHASE3,cardiovascular disease,Venous Thromboembolism (VTE),INDUSTRY,7513.0,2012-03,2016-01,34.0,462.0,,,,,
arm,NCT01583218::arm::FG000,NCT01583218,Betrixaban,,,,,,,,,,FG000,Daily oral (PO) betrixaban capsules for 35 to 42 days and subcutaneous (SQ) injections of enoxaparin placebo for 10 ± 4 days,,,
arm,NCT01583218::arm::FG001,NCT01583218,Enoxaparin,,,,,,,,,,FG001,Daily subcutaneous (SQ) injections of enoxaparin for 10 ± 4 days and oral (PO) betrixaban placebo capsules for 35 to 42 days,,,
period,NCT01583218::period::1,NCT01583218,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01583218::outcome::primary::1,NCT01583218,"Modified Intent-to-Treat (mITT) Cohort 1: Percentage of Participants Experiencing the Composite Event of Symptomatic Deep Vein Thrombosis (DVT), Non-fatal Pulmonary Emboli (PE), VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3",,,,,,,,,,,,,PRIMARY,mITT Cohort 1: Between randomization and Day 47 (max)
outcome,NCT01583218::outcome::primary::2,NCT01583218,"mITT Cohort 2: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3",,,,,,,,,,,,,PRIMARY,mITT Cohort 2: Between randomization and Day 47 (max)
outcome,NCT01583218::outcome::primary::3,NCT01583218,"mITT: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3",,,,,,,,,,,,,PRIMARY,mITT: Between randomization and Day 47 (max)
outcome,NCT01583218::outcome::primary::4,NCT01583218,Percentage of Participants Experiencing Major Bleeding Through Seven Days After Discontinuation of All Study Medication,,,,,,,,,,,,,PRIMARY,Between randomization and Day 49 (max)
country,NCT01583218::country::United States,NCT01583218,United States,,,,,,,,,,,,,,
country,NCT01583218::country::Russia,NCT01583218,Russia,,,,,,,,,,,,,,
country,NCT01583218::country::France,NCT01583218,France,,,,,,,,,,,,,,
country,NCT01583218::country::Ukraine,NCT01583218,Ukraine,,,,,,,,,,,,,,
country,NCT01583218::country::Germany,NCT01583218,Germany,,,,,,,,,,,,,,
country,NCT01583218::country::Czechia,NCT01583218,Czechia,,,,,,,,,,,,,,
country,NCT01583218::country::Hungary,NCT01583218,Hungary,,,,,,,,,,,,,,
country,NCT01583218::country::Spain,NCT01583218,Spain,,,,,,,,,,,,,,
country,NCT01583218::country::Brazil,NCT01583218,Brazil,,,,,,,,,,,,,,
country,NCT01583218::country::Italy,NCT01583218,Italy,,,,,,,,,,,,,,
country,NCT01583218::country::Romania,NCT01583218,Romania,,,,,,,,,,,,,,
country,NCT01583218::country::Bulgaria,NCT01583218,Bulgaria,,,,,,,,,,,,,,
country,NCT01583218::country::Poland,NCT01583218,Poland,,,,,,,,,,,,,,
country,NCT01583218::country::Lithuania,NCT01583218,Lithuania,,,,,,,,,,,,,,
country,NCT01583218::country::Canada,NCT01583218,Canada,,,,,,,,,,,,,,
country,NCT01583218::country::Denmark,NCT01583218,Denmark,,,,,,,,,,,,,,
country,NCT01583218::country::Israel,NCT01583218,Israel,,,,,,,,,,,,,,
country,NCT01583218::country::Argentina,NCT01583218,Argentina,,,,,,,,,,,,,,
country,NCT01583218::country::Austria,NCT01583218,Austria,,,,,,,,,,,,,,
country,NCT01583218::country::Australia,NCT01583218,Australia,,,,,,,,,,,,,,
country,NCT01583218::country::Croatia,NCT01583218,Croatia,,,,,,,,,,,,,,
country,NCT01583218::country::Finland,NCT01583218,Finland,,,,,,,,,,,,,,
country,NCT01583218::country::United Kingdom,NCT01583218,United Kingdom,,,,,,,,,,,,,,
country,NCT01583218::country::Chile,NCT01583218,Chile,,,,,,,,,,,,,,
country,NCT01583218::country::Peru,NCT01583218,Peru,,,,,,,,,,,,,,
country,NCT01583218::country::Serbia,NCT01583218,Serbia,,,,,,,,,,,,,,
country,NCT01583218::country::Belgium,NCT01583218,Belgium,,,,,,,,,,,,,,
country,NCT01583218::country::Latvia,NCT01583218,Latvia,,,,,,,,,,,,,,
country,NCT01583218::country::South Africa,NCT01583218,South Africa,,,,,,,,,,,,,,
country,NCT01583218::country::Estonia,NCT01583218,Estonia,,,,,,,,,,,,,,
country,NCT01583218::country::Georgia,NCT01583218,Georgia,,,,,,,,,,,,,,
country,NCT01583218::country::Singapore,NCT01583218,Singapore,,,,,,,,,,,,,,
country,NCT01583218::country::Slovakia,NCT01583218,Slovakia,,,,,,,,,,,,,,
country,NCT01583218::country::Montserrat,NCT01583218,Montserrat,,,,,,,,,,,,,,
trial,NCT00546052,NCT00546052,"A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)",PHASE3,cardiovascular disease,Hypertension; Metabolic Disorder,INDUSTRY,1738.0,2005-09-01,2008-01-01,0.0,0.0,,,,,
arm,NCT00546052::arm::FG000,NCT00546052,Losartan +/- Hydrochlorothiazide,,,,,,,,,,FG000,"Patients could be titrated up from Cozaar 50 mg to Cozaar 100mg to losartan 100 mg + Hydrochlorothiazide 12.5 mg and losartan 100mg/ Hydrochlorothiazide 25 mg, in sequence at any subsequent visits onl",,,
period,NCT00546052::period::1,NCT00546052,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00546052::outcome::primary::1,NCT00546052,Change in Hemoglobin A1c Between 52 Weeks and Baseline,,,,,,,,,,,,,PRIMARY,52 Weeks - Baseline
outcome,NCT00546052::outcome::primary::2,NCT00546052,Change in Fasting Blood Glucose Between Baseline and 52 Weeks Assessments,,,,,,,,,,,,,PRIMARY,52 Weeks - Baseline
trial,NCT00415532,NCT00415532,Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura,PHASE3,cardiovascular disease,Idiopathic Thrombocytopenic Purpura; Thrombocytopenia; Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenic Purpura,INDUSTRY,234.0,2006-12-01,2009-05-11,0.0,0.0,,,,,
arm,NCT00415532::arm::FG000,NCT00415532,Standard of Care,,,,,,,,,,FG000,Medical standard of care treatments were selected and prescribed by the investigator according to standard institutional practices or therapeutic guidelines and administered for up to 52 weeks.,,,
arm,NCT00415532::arm::FG001,NCT00415532,Romiplostim,,,,,,,,,,FG001,"Romiplostim administered by subcutaneous injection once weekly at a starting dose of 3 μg/kg, adjusted to a maximum dose of 10 μg/kg to maintain a platelet count between 50 and 200 x 10\^9/L for up to",,,
period,NCT00415532::period::1,NCT00415532,Treatment Period,,,,,,,,,,,,1.0,,
period,NCT00415532::period::2,NCT00415532,Safety Follow Up Period,,,,,,,,,,,,2.0,,
outcome,NCT00415532::outcome::primary::1,NCT00415532,Number of Participants With Splenectomy During 52-Week Treatment Period,,,,,,,,,,,,,PRIMARY,52 weeks
outcome,NCT00415532::outcome::primary::2,NCT00415532,Number of Participants With Treatment Failure During 52-Week Treatment Period,,,,,,,,,,,,,PRIMARY,52 weeks
trial,NCT00667719,NCT00667719,A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension,PHASE3,cardiovascular disease,Essential Hypertension,INDUSTRY,564.0,2008-06-05,2009-10-05,8.0,8.0,,,,,
arm,NCT00667719::arm::FG000,NCT00667719,Aliskiren /Amlodipine/Hydrochlorothiazide,,,,,,,,,,FG000,"Participants received aliskiren 300 milligrams (mg) plus hydrochlorothiazide 12.5 mg for one week, at Week 1 followed by combination of aliskiren 300 mg plus amlodipine 5 mg plus hydrochlorothiazide 1",,,
period,NCT00667719::period::1,NCT00667719,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00667719::outcome::primary::1,NCT00667719,"Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (SAEs) and Death",,,,,,,,,,,,,PRIMARY,54 weeks
country,NCT00667719::country::United States,NCT00667719,United States,,,,,,,,,,,,,,
country,NCT00667719::country::Belgium,NCT00667719,Belgium,,,,,,,,,,,,,,
country,NCT00667719::country::Egypt,NCT00667719,Egypt,,,,,,,,,,,,,,
country,NCT00667719::country::Germany,NCT00667719,Germany,,,,,,,,,,,,,,
country,NCT00667719::country::Poland,NCT00667719,Poland,,,,,,,,,,,,,,
country,NCT00667719::country::Slovakia,NCT00667719,Slovakia,,,,,,,,,,,,,,
country,NCT00667719::country::Spain,NCT00667719,Spain,,,,,,,,,,,,,,
country,NCT00667719::country::Turkey (Türkiye),NCT00667719,Turkey (Türkiye),,,,,,,,,,,,,,
trial,NCT02981407,NCT02981407,Myocardial Ischemia and Transfusion,PHASE3,cardiovascular disease,Myocardial Infarction; Anemia,OTHER,3506.0,2017-04-25,2023-10-20,6.0,133.0,,,,,
arm,NCT02981407::arm::FG000,NCT02981407,Liberal Transfusion Strategy,,,,,,,,,,FG000,Red blood cell transfusion - One unit of packed red cells is transfused following randomization followed by enough red blood cell units to raise the hemoglobin concentration above 10 g/dL any time the,,,
arm,NCT02981407::arm::FG001,NCT02981407,Restrictive Transfusion Strategy,,,,,,,,,,FG001,Permitted to receive a red blood cell transfusion if the blood count is below 8 g/dL and the physician believes it is in the patient's best interest. A transfusion will be strongly recommended if the ,,,
period,NCT02981407::period::1,NCT02981407,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02981407::outcome::primary::1,NCT02981407,Number of Participants With All-cause Mortality or Nonfatal Myocardial Reinfarction,,,,,,,,,,,,,PRIMARY,Within 30 days of randomization
country,NCT02981407::country::United States,NCT02981407,United States,,,,,,,,,,,,,,
country,NCT02981407::country::Canada,NCT02981407,Canada,,,,,,,,,,,,,,
country,NCT02981407::country::Brazil,NCT02981407,Brazil,,,,,,,,,,,,,,
country,NCT02981407::country::France,NCT02981407,France,,,,,,,,,,,,,,
country,NCT02981407::country::New Zealand,NCT02981407,New Zealand,,,,,,,,,,,,,,
country,NCT02981407::country::Australia,NCT02981407,Australia,,,,,,,,,,,,,,
trial,NCT02851407,NCT02851407,Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients,PHASE3,cardiovascular disease,Veno-occlusive Disease,INDUSTRY,372.0,2016-09-01,2020-10-20,14.0,114.0,,,,,
arm,NCT02851407::arm::FG000,NCT02851407,Defibrotide Prophylaxis,,,,,,,,,,FG000,Defibrotide was administered intravenously at a dose of 6.25mg/kg/day in 4 divided doses by IV infusion over 2 hours in addition to best supportive care within 24 hours before the first dose of the co,,,
arm,NCT02851407::arm::FG001,NCT02851407,Best Supportive Care,,,,,,,,,,FG001,"Best supportive care alone (without the addition of defibrotide) according to institutional guidelines and participant need, was administered on the first day of conditioning and continued until Day +",,,
period,NCT02851407::period::1,NCT02851407,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02851407::outcome::primary::1,NCT02851407,Veno-occlusive Disease (VOD)-Free Survival by Day +30 Post-Hematopoietic Stem Cell Transplant (HSCT) Per the Independent Endpoint Adjudication Committee (EPAC),,,,,,,,,,,,,PRIMARY,Day +30 Post-HSCT
country,NCT02851407::country::United States,NCT02851407,United States,,,,,,,,,,,,,,
country,NCT02851407::country::Japan,NCT02851407,Japan,,,,,,,,,,,,,,
country,NCT02851407::country::Spain,NCT02851407,Spain,,,,,,,,,,,,,,
country,NCT02851407::country::Germany,NCT02851407,Germany,,,,,,,,,,,,,,
country,NCT02851407::country::Turkey (Türkiye),NCT02851407,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02851407::country::Israel,NCT02851407,Israel,,,,,,,,,,,,,,
country,NCT02851407::country::Italy,NCT02851407,Italy,,,,,,,,,,,,,,
country,NCT02851407::country::United Kingdom,NCT02851407,United Kingdom,,,,,,,,,,,,,,
country,NCT02851407::country::Belgium,NCT02851407,Belgium,,,,,,,,,,,,,,
country,NCT02851407::country::France,NCT02851407,France,,,,,,,,,,,,,,
country,NCT02851407::country::South Korea,NCT02851407,South Korea,,,,,,,,,,,,,,
country,NCT02851407::country::Australia,NCT02851407,Australia,,,,,,,,,,,,,,
country,NCT02851407::country::Canada,NCT02851407,Canada,,,,,,,,,,,,,,
country,NCT02851407::country::New Zealand,NCT02851407,New Zealand,,,,,,,,,,,,,,
trial,NCT00461630,NCT00461630,Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE,PHASE3,cardiovascular disease,Cardiovascular Disease; Peripheral Arterial Disease; Diabetes Mellitus; Coronary Heart Disease,OTHER,25673.0,2007-01,2012-10,1.0,1.0,,,,,
arm,NCT00461630::arm::FG000,NCT00461630,ER Niacin/Laropiprant,,,,,,,,,,FG000,I g ER niacin plus 20mg laropiprant per tablet. 2 tablets orally per day. With either 40 mg simvastatin tablet or ezetimibe/simvastatin (10 mg/40 mg) in single tablet taken once daily,,,
arm,NCT00461630::arm::FG001,NCT00461630,Placebo,,,,,,,,,,FG001,Placebo (for ER niacin/laropiprant) 2 tablets orally per day. With either 40 mg simvastatin tablet orally per day or ezetimibe/simvastatin (10 mg/40 mg) in single tablet taken once daily,,,
period,NCT00461630::period::1,NCT00461630,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00461630::outcome::primary::1,NCT00461630,Major Vascular Event,,,,,,,,,,,,,PRIMARY,During scheduled treatment period (median duration 3.9 years)
country,NCT00461630::country::United Kingdom,NCT00461630,United Kingdom,,,,,,,,,,,,,,
trial,NCT02929329,NCT02929329,Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction,PHASE3,cardiovascular disease,Heart Failure,INDUSTRY,8256.0,2017-01-06,2020-09-14,36.0,1033.0,,,,,
arm,NCT02929329::arm::FG000,NCT02929329,Placebo,,,,,,,,,,FG000,Participants received matching placebo tablets twice a day (BID).,,,
arm,NCT02929329::arm::FG001,NCT02929329,Omecamtiv Mecarbil,,,,,,,,,,FG001,Participants received oral omecamtiv mecarbil BID. The starting dose was 25 mg; the dose may have been adjusted at week 4 to 37.5 or 50 mg based on the predose plasma concentration measured at week 2.,,,
period,NCT02929329::period::1,NCT02929329,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02929329::outcome::primary::1,NCT02929329,Time to Cardiovascular Death or First Heart Failure Event,,,,,,,,,,,,,PRIMARY,From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020)
country,NCT02929329::country::United States,NCT02929329,United States,,,,,,,,,,,,,,
country,NCT02929329::country::Japan,NCT02929329,Japan,,,,,,,,,,,,,,
country,NCT02929329::country::China,NCT02929329,China,,,,,,,,,,,,,,
country,NCT02929329::country::Russia,NCT02929329,Russia,,,,,,,,,,,,,,
country,NCT02929329::country::Argentina,NCT02929329,Argentina,,,,,,,,,,,,,,
country,NCT02929329::country::United Kingdom,NCT02929329,United Kingdom,,,,,,,,,,,,,,
country,NCT02929329::country::Poland,NCT02929329,Poland,,,,,,,,,,,,,,
country,NCT02929329::country::Brazil,NCT02929329,Brazil,,,,,,,,,,,,,,
country,NCT02929329::country::Canada,NCT02929329,Canada,,,,,,,,,,,,,,
country,NCT02929329::country::Czechia,NCT02929329,Czechia,,,,,,,,,,,,,,
country,NCT02929329::country::France,NCT02929329,France,,,,,,,,,,,,,,
country,NCT02929329::country::Italy,NCT02929329,Italy,,,,,,,,,,,,,,
country,NCT02929329::country::Hungary,NCT02929329,Hungary,,,,,,,,,,,,,,
country,NCT02929329::country::Germany,NCT02929329,Germany,,,,,,,,,,,,,,
country,NCT02929329::country::Spain,NCT02929329,Spain,,,,,,,,,,,,,,
country,NCT02929329::country::Ukraine,NCT02929329,Ukraine,,,,,,,,,,,,,,
country,NCT02929329::country::Netherlands,NCT02929329,Netherlands,,,,,,,,,,,,,,
country,NCT02929329::country::Turkey (Türkiye),NCT02929329,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02929329::country::Australia,NCT02929329,Australia,,,,,,,,,,,,,,
country,NCT02929329::country::Mexico,NCT02929329,Mexico,,,,,,,,,,,,,,
country,NCT02929329::country::Colombia,NCT02929329,Colombia,,,,,,,,,,,,,,
country,NCT02929329::country::Romania,NCT02929329,Romania,,,,,,,,,,,,,,
country,NCT02929329::country::Slovakia,NCT02929329,Slovakia,,,,,,,,,,,,,,
country,NCT02929329::country::Chile,NCT02929329,Chile,,,,,,,,,,,,,,
country,NCT02929329::country::Greece,NCT02929329,Greece,,,,,,,,,,,,,,
country,NCT02929329::country::Austria,NCT02929329,Austria,,,,,,,,,,,,,,
country,NCT02929329::country::Denmark,NCT02929329,Denmark,,,,,,,,,,,,,,
country,NCT02929329::country::South Africa,NCT02929329,South Africa,,,,,,,,,,,,,,
country,NCT02929329::country::Bulgaria,NCT02929329,Bulgaria,,,,,,,,,,,,,,
country,NCT02929329::country::Portugal,NCT02929329,Portugal,,,,,,,,,,,,,,
country,NCT02929329::country::Belgium,NCT02929329,Belgium,,,,,,,,,,,,,,
country,NCT02929329::country::Sweden,NCT02929329,Sweden,,,,,,,,,,,,,,
country,NCT02929329::country::Switzerland,NCT02929329,Switzerland,,,,,,,,,,,,,,
country,NCT02929329::country::Lithuania,NCT02929329,Lithuania,,,,,,,,,,,,,,
country,NCT02929329::country::New Zealand,NCT02929329,New Zealand,,,,,,,,,,,,,,
country,NCT02929329::country::Puerto Rico,NCT02929329,Puerto Rico,,,,,,,,,,,,,,
trial,NCT03725202,NCT03725202,A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis,PHASE3,cardiovascular disease,Giant Cell Arteritis (GCA),INDUSTRY,438.0,2019-02-06,2025-02-24,24.0,172.0,,,,,
arm,NCT03725202::arm::FG000,NCT03725202,Placebo + 52-week CS Taper,,,,,,,,,,FG000,Participants randomized to receive placebo tablets for upadacitinib administered orally once daily (QD) for 52 weeks and a 52-week corticosteroid (CS) taper regimen during Period 1.,,,
arm,NCT03725202::arm::FG001,NCT03725202,7.5 mg Upadacitinib + 26-week CS Taper,,,,,,,,,,FG001,Participants randomized to receive 7.5 mg upadacitinib tablets administered orally once daily (QD) for 52 weeks and a 26-week corticosteroid (CS) taper regimen during Period 1.,,,
arm,NCT03725202::arm::FG002,NCT03725202,15 mg Upadacitinib + 26-week CS Taper,,,,,,,,,,FG002,Participants randomized to receive 15 mg upadacitinib tablets administered orally once daily (QD) for 52 weeks and a 26-week corticosteroid (CS) taper regimen during Period 1.,,,
arm,NCT03725202::arm::FG003,NCT03725202,Placebo + 52-week CS Taper -> Placebo,,,,,,,,,,FG003,Participants who achieved sustained remission for at least 24 weeks prior to the Week 52 visit (at the end of Period 1) OR who had absence of GCA signs and symptoms and were CS-free at the Week 52 vis,,,
arm,NCT03725202::arm::FG004,NCT03725202,7.5 mg Upadacitinib + 26-week CS Taper -> 7.5 mg Upadacitinib,,,,,,,,,,FG004,Participants randomized to receive 7.5 mg upadacitinib tablets administered orally once daily (QD) in Period 2.,,,
arm,NCT03725202::arm::FG005,NCT03725202,7.5 mg Upadacitinib + 26-week CS Taper -> Placebo,,,,,,,,,,FG005,Participants randomized to receive placebo tablets for upadacitinib administered orally once daily (QD) in Period 2.,,,
arm,NCT03725202::arm::FG006,NCT03725202,15 mg Upadacitinib + 26-week CS Taper -> 15 mg Upadacitinib,,,,,,,,,,FG006,Participants randomized to receive 15 mg upadacitinib tablets administered orally once daily (QD) in Period 2.,,,
arm,NCT03725202::arm::FG007,NCT03725202,15 mg Upadacitinib + 26-week CS Taper -> Placebo,,,,,,,,,,FG007,Participants randomized to receive placebo tablets for upadacitinib administered orally once daily (QD) in Period 2.,,,
period,NCT03725202::period::1,NCT03725202,Period 1 (Baseline - Week 52),,,,,,,,,,,,1.0,,
period,NCT03725202::period::2,NCT03725202,Period 2 (Week 52 - Week 104),,,,,,,,,,,,2.0,,
outcome,NCT03725202::outcome::primary::1,NCT03725202,Percentage of Participants Achieving Sustained Remission at Week 52,,,,,,,,,,,,,PRIMARY,From Week 12 to Week 52
country,NCT03725202::country::United States,NCT03725202,United States,,,,,,,,,,,,,,
country,NCT03725202::country::France,NCT03725202,France,,,,,,,,,,,,,,
country,NCT03725202::country::Japan,NCT03725202,Japan,,,,,,,,,,,,,,
country,NCT03725202::country::Spain,NCT03725202,Spain,,,,,,,,,,,,,,
country,NCT03725202::country::United Kingdom,NCT03725202,United Kingdom,,,,,,,,,,,,,,
country,NCT03725202::country::Australia,NCT03725202,Australia,,,,,,,,,,,,,,
country,NCT03725202::country::Germany,NCT03725202,Germany,,,,,,,,,,,,,,
country,NCT03725202::country::Netherlands,NCT03725202,Netherlands,,,,,,,,,,,,,,
country,NCT03725202::country::New Zealand,NCT03725202,New Zealand,,,,,,,,,,,,,,
country,NCT03725202::country::Russia,NCT03725202,Russia,,,,,,,,,,,,,,
country,NCT03725202::country::Sweden,NCT03725202,Sweden,,,,,,,,,,,,,,
country,NCT03725202::country::Canada,NCT03725202,Canada,,,,,,,,,,,,,,
country,NCT03725202::country::Hungary,NCT03725202,Hungary,,,,,,,,,,,,,,
country,NCT03725202::country::Portugal,NCT03725202,Portugal,,,,,,,,,,,,,,
country,NCT03725202::country::Romania,NCT03725202,Romania,,,,,,,,,,,,,,
country,NCT03725202::country::Switzerland,NCT03725202,Switzerland,,,,,,,,,,,,,,
country,NCT03725202::country::Belgium,NCT03725202,Belgium,,,,,,,,,,,,,,
country,NCT03725202::country::Czechia,NCT03725202,Czechia,,,,,,,,,,,,,,
country,NCT03725202::country::Greece,NCT03725202,Greece,,,,,,,,,,,,,,
country,NCT03725202::country::Israel,NCT03725202,Israel,,,,,,,,,,,,,,
country,NCT03725202::country::Italy,NCT03725202,Italy,,,,,,,,,,,,,,
country,NCT03725202::country::Norway,NCT03725202,Norway,,,,,,,,,,,,,,
country,NCT03725202::country::Austria,NCT03725202,Austria,,,,,,,,,,,,,,
country,NCT03725202::country::Denmark,NCT03725202,Denmark,,,,,,,,,,,,,,
trial,NCT00366249,NCT00366249,Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.,PHASE3,cardiovascular disease,Bacterial Infections; Diabetic Foot; Osteomyelitis,INDUSTRY,1061.0,2007-01,2009-03,39.0,211.0,,,,,
arm,NCT00366249::arm::FG000,NCT00366249,Tigecycline,,,,,,,,,,FG000,Tigecycline 150 mg IV infusion every 24 hours,,,
arm,NCT00366249::arm::FG001,NCT00366249,Ertapenem,,,,,,,,,,FG001,"Ertapenem 1g IV infusion every 24 hours +/- vancomycin depending on culture results and at the discretion of investigator (for coverage of Methicillin-resistant Staphylococcus aureus (MRSA), coagulase",,,
period,NCT00366249::period::1,NCT00366249,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00366249::outcome::primary::1,NCT00366249,Number of Patients With Clinical Response of Cure Vs. Failure.,,,,,,,,,,,,,PRIMARY,Test of cure visit (TOC): Assessed at least 12 days post last dose
outcome,NCT00366249::outcome::primary::2,NCT00366249,Number of Patients With Clinical Response of Cure Vs. Failure/Indeterminate.,,,,,,,,,,,,,PRIMARY,Test of cure visit (TOC): Assessed at least 12 days post last dose
country,NCT00366249::country::Argentina,NCT00366249,Argentina,,,,,,,,,,,,,,
country,NCT00366249::country::United States,NCT00366249,United States,,,,,,,,,,,,,,
country,NCT00366249::country::Russia,NCT00366249,Russia,,,,,,,,,,,,,,
country,NCT00366249::country::Mexico,NCT00366249,Mexico,,,,,,,,,,,,,,
country,NCT00366249::country::Canada,NCT00366249,Canada,,,,,,,,,,,,,,
country,NCT00366249::country::Lithuania,NCT00366249,Lithuania,,,,,,,,,,,,,,
country,NCT00366249::country::Ukraine,NCT00366249,Ukraine,,,,,,,,,,,,,,
country,NCT00366249::country::Hungary,NCT00366249,Hungary,,,,,,,,,,,,,,
country,NCT00366249::country::Slovakia,NCT00366249,Slovakia,,,,,,,,,,,,,,
country,NCT00366249::country::Latvia,NCT00366249,Latvia,,,,,,,,,,,,,,
country,NCT00366249::country::Poland,NCT00366249,Poland,,,,,,,,,,,,,,
country,NCT00366249::country::Belgium,NCT00366249,Belgium,,,,,,,,,,,,,,
country,NCT00366249::country::China,NCT00366249,China,,,,,,,,,,,,,,
country,NCT00366249::country::Germany,NCT00366249,Germany,,,,,,,,,,,,,,
country,NCT00366249::country::Spain,NCT00366249,Spain,,,,,,,,,,,,,,
country,NCT00366249::country::United Kingdom,NCT00366249,United Kingdom,,,,,,,,,,,,,,
country,NCT00366249::country::Estonia,NCT00366249,Estonia,,,,,,,,,,,,,,
country,NCT00366249::country::India,NCT00366249,India,,,,,,,,,,,,,,
country,NCT00366249::country::Romania,NCT00366249,Romania,,,,,,,,,,,,,,
country,NCT00366249::country::South Korea,NCT00366249,South Korea,,,,,,,,,,,,,,
country,NCT00366249::country::Croatia,NCT00366249,Croatia,,,,,,,,,,,,,,
country,NCT00366249::country::Greece,NCT00366249,Greece,,,,,,,,,,,,,,
country,NCT00366249::country::Italy,NCT00366249,Italy,,,,,,,,,,,,,,
country,NCT00366249::country::South Africa,NCT00366249,South Africa,,,,,,,,,,,,,,
country,NCT00366249::country::Sweden,NCT00366249,Sweden,,,,,,,,,,,,,,
country,NCT00366249::country::Turkey (Türkiye),NCT00366249,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00366249::country::Australia,NCT00366249,Australia,,,,,,,,,,,,,,
country,NCT00366249::country::Brazil,NCT00366249,Brazil,,,,,,,,,,,,,,
country,NCT00366249::country::Chile,NCT00366249,Chile,,,,,,,,,,,,,,
country,NCT00366249::country::Colombia,NCT00366249,Colombia,,,,,,,,,,,,,,
country,NCT00366249::country::Finland,NCT00366249,Finland,,,,,,,,,,,,,,
country,NCT00366249::country::France,NCT00366249,France,,,,,,,,,,,,,,
country,NCT00366249::country::Peru,NCT00366249,Peru,,,,,,,,,,,,,,
country,NCT00366249::country::Portugal,NCT00366249,Portugal,,,,,,,,,,,,,,
country,NCT00366249::country::Switzerland,NCT00366249,Switzerland,,,,,,,,,,,,,,
country,NCT00366249::country::Taiwan,NCT00366249,Taiwan,,,,,,,,,,,,,,
country,NCT00366249::country::Austria,NCT00366249,Austria,,,,,,,,,,,,,,
country,NCT00366249::country::Denmark,NCT00366249,Denmark,,,,,,,,,,,,,,
country,NCT00366249::country::Panama,NCT00366249,Panama,,,,,,,,,,,,,,
trial,NCT00300274,NCT00300274,Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection,PHASE3,cardiovascular disease,Graft Rejection,INDUSTRY,721.0,2006-01,2011-07,15.0,64.0,,,,,
arm,NCT00300274::arm::FG000,NCT00300274,Everolimus 1.5 mg,,,,,,,,,,FG000,Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard co,,,
arm,NCT00300274::arm::FG001,NCT00300274,Everolimus 3.0 mg,,,,,,,,,,FG001,Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dos,,,
arm,NCT00300274::arm::FG002,NCT00300274,Mycophenolate Mofetil,,,,,,,,,,FG002,Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclospor,,,
period,NCT00300274::period::1,NCT00300274,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00300274::outcome::primary::1,NCT00300274,Percentage of Participants With Composite Efficacy Failure at 12 Months,,,,,,,,,,,,,PRIMARY,12 Months
country,NCT00300274::country::United States,NCT00300274,United States,,,,,,,,,,,,,,
country,NCT00300274::country::Germany,NCT00300274,Germany,,,,,,,,,,,,,,
country,NCT00300274::country::Italy,NCT00300274,Italy,,,,,,,,,,,,,,
country,NCT00300274::country::Canada,NCT00300274,Canada,,,,,,,,,,,,,,
country,NCT00300274::country::France,NCT00300274,France,,,,,,,,,,,,,,
country,NCT00300274::country::Australia,NCT00300274,Australia,,,,,,,,,,,,,,
country,NCT00300274::country::United Kingdom,NCT00300274,United Kingdom,,,,,,,,,,,,,,
country,NCT00300274::country::Argentina,NCT00300274,Argentina,,,,,,,,,,,,,,
country,NCT00300274::country::Spain,NCT00300274,Spain,,,,,,,,,,,,,,
country,NCT00300274::country::Austria,NCT00300274,Austria,,,,,,,,,,,,,,
country,NCT00300274::country::Belgium,NCT00300274,Belgium,,,,,,,,,,,,,,
country,NCT00300274::country::New Zealand,NCT00300274,New Zealand,,,,,,,,,,,,,,
country,NCT00300274::country::Norway,NCT00300274,Norway,,,,,,,,,,,,,,
country,NCT00300274::country::Puerto Rico,NCT00300274,Puerto Rico,,,,,,,,,,,,,,
country,NCT00300274::country::Taiwan,NCT00300274,Taiwan,,,,,,,,,,,,,,
trial,NCT02733185,NCT02733185,Trial to Assess Chelation Therapy 2,PHASE3,cardiovascular disease,Diabetes; Myocardial Infarction,OTHER,1000.0,2016-10-01,2023-06-30,1.0,1.0,,,,,
arm,NCT02733185::arm::FG000,NCT02733185,Active/Active,,,,,,,,,,FG000,"Active disodium EDTA (chelation) + Active Oral Multi Vitamins/Minerals (OMVM)

disodium EDTA

Oral Multi Vitamins/Minerals (OMVM)",,,
arm,NCT02733185::arm::FG001,NCT02733185,Active/Placebo,,,,,,,,,,FG001,"Active disodium EDTA (chelation) + Placebo Oral Multi Vitamins/Minerals (OMVM)

disodium EDTA

Placebo Oral Multi Vitamins/Minerals (OMVM)",,,
arm,NCT02733185::arm::FG002,NCT02733185,Placebo/ Active,,,,,,,,,,FG002,"Placebo disodium EDTA (chelation) + Active Oral Multi Vitamins/Minerals (OMVM)

Placebo disodium EDTA

Oral Multi Vitamins/Minerals (OMVM)",,,
arm,NCT02733185::arm::FG003,NCT02733185,Placebo/Placebo,,,,,,,,,,FG003,"Placebo disodium EDTA (chelation) + Placebo Oral Multi Vitamins/Minerals (OMVM)

Placebo disodium EDTA

Placebo Oral Multi Vitamins/Minerals (OMVM)",,,
period,NCT02733185::period::1,NCT02733185,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02733185::outcome::primary::1,NCT02733185,Primary Composite Outcome,,,,,,,,,,,,,PRIMARY,48 month follow-up (median)
country,NCT02733185::country::United States,NCT02733185,United States,,,,,,,,,,,,,,
trial,NCT00489736,NCT00489736,Efficacy & Safety of Dronedarone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation,PHASE3,cardiovascular disease,Atrial Fibrillation,INDUSTRY,504.0,2007-06,2008-10,23.0,23.0,,,,,
arm,NCT00489736::arm::FG000,NCT00489736,Dronedarone 400mg Bid,,,,,,,,,,FG000,dronedarone tablets 400mg twice daily (bid),,,
arm,NCT00489736::arm::FG001,NCT00489736,Amiodarone 600mg/200mg od,,,,,,,,,,FG001,"amiodarone 600mg once daily (od) for 28 days, then amiodarone 200mg once daily (od)",,,
period,NCT00489736::period::1,NCT00489736,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00489736::outcome::primary::1,NCT00489736,Treatment Failure,,,,,,,,,,,,,PRIMARY,minimum study duration is 6 months (+10 days)
country,NCT00489736::country::United States,NCT00489736,United States,,,,,,,,,,,,,,
country,NCT00489736::country::Argentina,NCT00489736,Argentina,,,,,,,,,,,,,,
country,NCT00489736::country::Australia,NCT00489736,Australia,,,,,,,,,,,,,,
country,NCT00489736::country::Austria,NCT00489736,Austria,,,,,,,,,,,,,,
country,NCT00489736::country::Belgium,NCT00489736,Belgium,,,,,,,,,,,,,,
country,NCT00489736::country::Canada,NCT00489736,Canada,,,,,,,,,,,,,,
country,NCT00489736::country::Chile,NCT00489736,Chile,,,,,,,,,,,,,,
country,NCT00489736::country::China,NCT00489736,China,,,,,,,,,,,,,,
country,NCT00489736::country::Czechia,NCT00489736,Czechia,,,,,,,,,,,,,,
country,NCT00489736::country::Estonia,NCT00489736,Estonia,,,,,,,,,,,,,,
country,NCT00489736::country::Finland,NCT00489736,Finland,,,,,,,,,,,,,,
country,NCT00489736::country::France,NCT00489736,France,,,,,,,,,,,,,,
country,NCT00489736::country::Germany,NCT00489736,Germany,,,,,,,,,,,,,,
country,NCT00489736::country::Italy,NCT00489736,Italy,,,,,,,,,,,,,,
country,NCT00489736::country::Mexico,NCT00489736,Mexico,,,,,,,,,,,,,,
country,NCT00489736::country::Morocco,NCT00489736,Morocco,,,,,,,,,,,,,,
country,NCT00489736::country::Netherlands,NCT00489736,Netherlands,,,,,,,,,,,,,,
country,NCT00489736::country::Poland,NCT00489736,Poland,,,,,,,,,,,,,,
country,NCT00489736::country::Russia,NCT00489736,Russia,,,,,,,,,,,,,,
country,NCT00489736::country::South Korea,NCT00489736,South Korea,,,,,,,,,,,,,,
country,NCT00489736::country::Sweden,NCT00489736,Sweden,,,,,,,,,,,,,,
country,NCT00489736::country::Tunisia,NCT00489736,Tunisia,,,,,,,,,,,,,,
country,NCT00489736::country::Turkey (Türkiye),NCT00489736,Turkey (Türkiye),,,,,,,,,,,,,,
trial,NCT00142584,NCT00142584,Evaluation of the Long-term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,336.0,2005-08,2008-03,1.0,1.0,,,,,
arm,NCT00142584::arm::FG000,NCT00142584,1-NEB,,,,,,,,,,FG000,"Nebivolol

Nebivolol: Patients randomized to nebivolol will initiate therapy with nebivolol 5 mg once daily for 4 weeks.",,,
arm,NCT00142584::arm::FG001,NCT00142584,2-MET,,,,,,,,,,FG001,"Metoprolol

Metoprolol: Patients randomized to metoprolol will initiate therapy with 100 mg once daily for 4 weeks.",,,
period,NCT00142584::period::1,NCT00142584,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00142584::outcome::primary::1,NCT00142584,Change in Average Sitting Diastolic Blood Pressure (DBP) Taken at Trough at the End of Treatment Compared to Baseline,,,,,,,,,,,,,PRIMARY,Through study duration (approximately 18 months)
country,NCT00142584::country::United States,NCT00142584,United States,,,,,,,,,,,,,,
trial,NCT01082874,NCT01082874,PeriOperative ISchemic Evaluation-2 Trial,PHASE3,cardiovascular disease,Cardiovascular Disease,OTHER,10010.0,2010-07,2015-01,23.0,23.0,,,,,
arm,NCT01082874::arm::FG000,NCT01082874,Active Clonidine and Active ASA,,,,,,,,,,FG000,"Active Clonidine: Pre-op (goal 2-4 hours): 2 x 0.1mg oral tablets and transdermal patch (0.2 mg/day). Patch to be removed 72 hours post-op.

Active ASA: Pre-op (goal 2-4 hours): 2 x 100mg oral tablets",,,
arm,NCT01082874::arm::FG001,NCT01082874,Active Clonidine and Placebo ASA,,,,,,,,,,FG001,"Active Clonidine: Pre-op (goal 2-4 hours): 2 x 0.1mg oral tablets and transdermal patch (0.2 mg/day). Patch to be removed 72 hours post-op.

Placebo ASA: Pre-op (goal 2-4 hours): 2 oral placebo tablet",,,
arm,NCT01082874::arm::FG002,NCT01082874,Placebo Clonidine and Active ASA,,,,,,,,,,FG002,"Placebo Clonidine: Pre-op (goal 2-4 hours): 2 oral placebo tablets and transdermal placebo patch. Patch to be removed 72 hours post-op.

Active ASA: Pre-op (goal 2-4 hours): 2 x 100mg oral tablets. Po",,,
arm,NCT01082874::arm::FG003,NCT01082874,Placebo Clonidine and Placebo ASA,,,,,,,,,,FG003,"Placebo Clonidine: Pre-op (goal 2-4 hours): 2 oral placebo tablets and transdermal placebo patch. Patch to be removed 72 hours post-op.

Placebo ASA: Pre-op (goal 2-4 hours): 2 oral placebo tablets. P",,,
period,NCT01082874::period::1,NCT01082874,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01082874::outcome::primary::1,NCT01082874,Composite of All-cause Mortality and Nonfatal MI,,,,,,,,,,,,,PRIMARY,30 days
outcome,NCT01082874::outcome::primary::2,NCT01082874,All-cause Mortality and Nonfatal MI,,,,,,,,,,,,,PRIMARY,1 year
country,NCT01082874::country::United States,NCT01082874,United States,,,,,,,,,,,,,,
country,NCT01082874::country::Argentina,NCT01082874,Argentina,,,,,,,,,,,,,,
country,NCT01082874::country::Australia,NCT01082874,Australia,,,,,,,,,,,,,,
country,NCT01082874::country::Austria,NCT01082874,Austria,,,,,,,,,,,,,,
country,NCT01082874::country::Belgium,NCT01082874,Belgium,,,,,,,,,,,,,,
country,NCT01082874::country::Brazil,NCT01082874,Brazil,,,,,,,,,,,,,,
country,NCT01082874::country::Canada,NCT01082874,Canada,,,,,,,,,,,,,,
country,NCT01082874::country::Chile,NCT01082874,Chile,,,,,,,,,,,,,,
country,NCT01082874::country::Colombia,NCT01082874,Colombia,,,,,,,,,,,,,,
country,NCT01082874::country::Denmark,NCT01082874,Denmark,,,,,,,,,,,,,,
country,NCT01082874::country::France,NCT01082874,France,,,,,,,,,,,,,,
country,NCT01082874::country::Germany,NCT01082874,Germany,,,,,,,,,,,,,,
country,NCT01082874::country::Hong Kong,NCT01082874,Hong Kong,,,,,,,,,,,,,,
country,NCT01082874::country::India,NCT01082874,India,,,,,,,,,,,,,,
country,NCT01082874::country::Italy,NCT01082874,Italy,,,,,,,,,,,,,,
country,NCT01082874::country::Malaysia,NCT01082874,Malaysia,,,,,,,,,,,,,,
country,NCT01082874::country::New Zealand,NCT01082874,New Zealand,,,,,,,,,,,,,,
country,NCT01082874::country::Pakistan,NCT01082874,Pakistan,,,,,,,,,,,,,,
country,NCT01082874::country::Peru,NCT01082874,Peru,,,,,,,,,,,,,,
country,NCT01082874::country::South Africa,NCT01082874,South Africa,,,,,,,,,,,,,,
country,NCT01082874::country::Spain,NCT01082874,Spain,,,,,,,,,,,,,,
country,NCT01082874::country::Switzerland,NCT01082874,Switzerland,,,,,,,,,,,,,,
country,NCT01082874::country::United Kingdom,NCT01082874,United Kingdom,,,,,,,,,,,,,,
trial,NCT00790335,NCT00790335,Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis,PHASE3,cardiovascular disease,Deep Vein Thrombosis; Venous Thrombosis; Postphlebitic Syndrome; Venous Thromboembolism; Post Thrombotic Syndrome,OTHER,692.0,2009-11,2017-01,1.0,56.0,,,,,
arm,NCT00790335::arm::FG000,NCT00790335,A-Intervention,,,,,,,,,,FG000,Pharmacomechanical catheter-directed thrombolysis (PCDT) with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initia,,,
arm,NCT00790335::arm::FG001,NCT00790335,B-Control,,,,,,,,,,FG001,"Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target international normalized ratio \[",,,
period,NCT00790335::period::1,NCT00790335,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00790335::outcome::primary::1,NCT00790335,Cumulative Incidence of Post-Thrombotic Syndrome (Villalta Scale),,,,,,,,,,,,,PRIMARY,Between 6 and 24 months after randomization
country,NCT00790335::country::United States,NCT00790335,United States,,,,,,,,,,,,,,
trial,NCT00649389,NCT00649389,Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,2500.0,2008-05,2009-12,2.0,232.0,,,,,
arm,NCT00649389::arm::FG000,NCT00649389,OM40/AML10,,,,,,,,,,FG000,"Double blind treatment olmesartan medoxomil (OM) 40 mg, Amlodipine (AML) 10 mg tablets once daily.",,,
arm,NCT00649389::arm::FG001,NCT00649389,OM40/HCTZ25,,,,,,,,,,FG001,"Double blind treatment olmesartan medoxomil (OM) 40 mg, Hydrochlorothiazide (HCTZ) 25 mg tablets once daily.",,,
arm,NCT00649389::arm::FG002,NCT00649389,AML10/HCTZ25,,,,,,,,,,FG002,"Double blind treatment Amlodipine (AML) 10 mg, Hydrochlorothiazide (HCTZ) 25 mg tablets once daily.",,,
arm,NCT00649389::arm::FG003,NCT00649389,OM40/AML10/HCTZ25,,,,,,,,,,FG003,"Double blind treatment olmesartan medoxomil (OM) 40 mg, Amlodipine (AML) 10 mg, Hydrochlorothiazide (HCTZ) 25 mg, tablets once daily.",,,
period,NCT00649389::period::1,NCT00649389,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00649389::outcome::primary::1,NCT00649389,Change From Baseline to Week 12 in Seated Diastolic Blood Pressure (SeDBP).,,,,,,,,,,,,,PRIMARY,baseline to 12 weeks
country,NCT00649389::country::United States,NCT00649389,United States,,,,,,,,,,,,,,
country,NCT00649389::country::Puerto Rico,NCT00649389,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01344460,NCT01344460,Gadobutrol Enhanced MRA of the Renal Arteries,PHASE3,cardiovascular disease,Renal Artery Obstruction,INDUSTRY,317.0,2011-05,2012-07,13.0,70.0,,,,,
arm,NCT01344460::arm::FG000,NCT01344460,"Gadobutrol (Gadavist, BAY 86-4875)",,,,,,,,,,FG000,"Gadobutrol was administered to all participants receiving study drug at the standard dose of 0.1 mmol/kg body weight (bw) by single intravenous (i.v.) bolus injection. During the course of the study, ",,,
period,NCT01344460::period::1,NCT01344460,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01344460::outcome::primary::1,NCT01344460,Percentage of Assessable Vascular Segments Using Gadobutrol-Enhanced MRA and Unenhanced MRA,,,,,,,,,,,,,PRIMARY,Images were taken pre-injection and post-injection
outcome,NCT01344460::outcome::primary::2,NCT01344460,Sensitivity for Detection of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA,,,,,,,,,,,,,PRIMARY,Images were taken pre-injection and post-injection
outcome,NCT01344460::outcome::primary::3,NCT01344460,Specificity for Exclusion of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA,,,,,,,,,,,,,PRIMARY,Images were taken pre-injection and post-injection
outcome,NCT01344460::outcome::primary::4,NCT01344460,Minimum Gadobutrol Performance for Sensitivity: Sensitivity More Than (>) 50%,,,,,,,,,,,,,PRIMARY,Images were taken pre-injection and post-injection
outcome,NCT01344460::outcome::primary::5,NCT01344460,Minimum Gadobutrol Performance for Specificity: Specificity > 50%,,,,,,,,,,,,,PRIMARY,Images were taken pre-injection and post-injection
country,NCT01344460::country::United States,NCT01344460,United States,,,,,,,,,,,,,,
country,NCT01344460::country::Germany,NCT01344460,Germany,,,,,,,,,,,,,,
country,NCT01344460::country::Brazil,NCT01344460,Brazil,,,,,,,,,,,,,,
country,NCT01344460::country::France,NCT01344460,France,,,,,,,,,,,,,,
country,NCT01344460::country::Czechia,NCT01344460,Czechia,,,,,,,,,,,,,,
country,NCT01344460::country::South Korea,NCT01344460,South Korea,,,,,,,,,,,,,,
country,NCT01344460::country::Taiwan,NCT01344460,Taiwan,,,,,,,,,,,,,,
country,NCT01344460::country::Colombia,NCT01344460,Colombia,,,,,,,,,,,,,,
country,NCT01344460::country::Poland,NCT01344460,Poland,,,,,,,,,,,,,,
country,NCT01344460::country::Switzerland,NCT01344460,Switzerland,,,,,,,,,,,,,,
country,NCT01344460::country::Argentina,NCT01344460,Argentina,,,,,,,,,,,,,,
country,NCT01344460::country::Austria,NCT01344460,Austria,,,,,,,,,,,,,,
country,NCT01344460::country::Turkey (Türkiye),NCT01344460,Turkey (Türkiye),,,,,,,,,,,,,,
trial,NCT00680186,NCT00680186,Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE),PHASE3,cardiovascular disease,Thromboembolism,INDUSTRY,2589.0,2008-04,,31.0,220.0,,,,,
arm,NCT00680186::arm::FG000,NCT00680186,Dabigatran 150 mg,,,,,,,,,,FG000,bid (twice daily) oral,,,
arm,NCT00680186::arm::FG001,NCT00680186,Warfarin,,,,,,,,,,FG001,PRN (as needed) to maintain an INR (international normalised ratio) of 2.0-3.0,,,
period,NCT00680186::period::1,NCT00680186,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00680186::outcome::primary::1,NCT00680186,Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE,,,,,,,,,,,,,PRIMARY,"For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180)"
country,NCT00680186::country::China,NCT00680186,China,,,,,,,,,,,,,,
country,NCT00680186::country::Canada,NCT00680186,Canada,,,,,,,,,,,,,,
country,NCT00680186::country::France,NCT00680186,France,,,,,,,,,,,,,,
country,NCT00680186::country::India,NCT00680186,India,,,,,,,,,,,,,,
country,NCT00680186::country::Czechia,NCT00680186,Czechia,,,,,,,,,,,,,,
country,NCT00680186::country::Israel,NCT00680186,Israel,,,,,,,,,,,,,,
country,NCT00680186::country::United States,NCT00680186,United States,,,,,,,,,,,,,,
country,NCT00680186::country::Brazil,NCT00680186,Brazil,,,,,,,,,,,,,,
country,NCT00680186::country::Russia,NCT00680186,Russia,,,,,,,,,,,,,,
country,NCT00680186::country::South Korea,NCT00680186,South Korea,,,,,,,,,,,,,,
country,NCT00680186::country::Netherlands,NCT00680186,Netherlands,,,,,,,,,,,,,,
country,NCT00680186::country::South Africa,NCT00680186,South Africa,,,,,,,,,,,,,,
country,NCT00680186::country::Turkey (Türkiye),NCT00680186,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00680186::country::Thailand,NCT00680186,Thailand,,,,,,,,,,,,,,
country,NCT00680186::country::Italy,NCT00680186,Italy,,,,,,,,,,,,,,
country,NCT00680186::country::Spain,NCT00680186,Spain,,,,,,,,,,,,,,
country,NCT00680186::country::Australia,NCT00680186,Australia,,,,,,,,,,,,,,
country,NCT00680186::country::Poland,NCT00680186,Poland,,,,,,,,,,,,,,
country,NCT00680186::country::Sweden,NCT00680186,Sweden,,,,,,,,,,,,,,
country,NCT00680186::country::Taiwan,NCT00680186,Taiwan,,,,,,,,,,,,,,
country,NCT00680186::country::United Kingdom,NCT00680186,United Kingdom,,,,,,,,,,,,,,
country,NCT00680186::country::Bulgaria,NCT00680186,Bulgaria,,,,,,,,,,,,,,
country,NCT00680186::country::Denmark,NCT00680186,Denmark,,,,,,,,,,,,,,
country,NCT00680186::country::Malaysia,NCT00680186,Malaysia,,,,,,,,,,,,,,
country,NCT00680186::country::New Zealand,NCT00680186,New Zealand,,,,,,,,,,,,,,
country,NCT00680186::country::Philippines,NCT00680186,Philippines,,,,,,,,,,,,,,
country,NCT00680186::country::Slovakia,NCT00680186,Slovakia,,,,,,,,,,,,,,
country,NCT00680186::country::Hungary,NCT00680186,Hungary,,,,,,,,,,,,,,
country,NCT00680186::country::Singapore,NCT00680186,Singapore,,,,,,,,,,,,,,
country,NCT00680186::country::Norway,NCT00680186,Norway,,,,,,,,,,,,,,
country,NCT00680186::country::Ukraine,NCT00680186,Ukraine,,,,,,,,,,,,,,
trial,NCT01850524,NCT01850524,IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma,PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,705.0,2013-04-29,2022-06-24,7.0,147.0,,,,,
arm,NCT01850524::arm::FG000,NCT01850524,Placebo + LenDex,,,,,,,,,,FG000,"Participants who were randomly assigned to receive placebo matching capsule single oral dose on Days 1, 8 and 15 along with standard regimen of LenDex (lenalidomide 25 mg capsules orally on Days 1-21 ",,,
arm,NCT01850524::arm::FG001,NCT01850524,Ixazomib + LenDex,,,,,,,,,,FG001,"Participants who were randomly assigned to receive Ixazomib 4.0 mg capsule single oral dose on Days 1, 8 and 15 along with standard regimen of LenDex (lenalidomide 25 mg capsules orally on Days 1-21 a",,,
period,NCT01850524::period::1,NCT01850524,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01850524::outcome::primary::1,NCT01850524,Progression Free Survival (PFS),,,,,,,,,,,,,PRIMARY,Up to approximately 79 months
country,NCT01850524::country::United States,NCT01850524,United States,,,,,,,,,,,,,,
country,NCT01850524::country::France,NCT01850524,France,,,,,,,,,,,,,,
country,NCT01850524::country::Canada,NCT01850524,Canada,,,,,,,,,,,,,,
country,NCT01850524::country::Belgium,NCT01850524,Belgium,,,,,,,,,,,,,,
country,NCT01850524::country::South Korea,NCT01850524,South Korea,,,,,,,,,,,,,,
country,NCT01850524::country::New Zealand,NCT01850524,New Zealand,,,,,,,,,,,,,,
country,NCT01850524::country::Russia,NCT01850524,Russia,,,,,,,,,,,,,,
trial,NCT00739973,NCT00739973,Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,2694.0,2008-09,2009-05,18.0,18.0,,,,,
arm,NCT00739973::arm::FG000,NCT00739973,Placebo,,,,,,,,,,FG000,"Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit pro",,,
arm,NCT00739973::arm::FG001,NCT00739973,Aliskiren 150 mg,,,,,,,,,,FG001,"Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit pro",,,
arm,NCT00739973::arm::FG002,NCT00739973,Aliskiren 300 mg,,,,,,,,,,FG002,"Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit pro",,,
arm,NCT00739973::arm::FG003,NCT00739973,Amlodipine 5 mg,,,,,,,,,,FG003,"Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit pro",,,
arm,NCT00739973::arm::FG004,NCT00739973,Amlodipine 10 mg,,,,,,,,,,FG004,"Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit pro",,,
arm,NCT00739973::arm::FG005,NCT00739973,Aliskiren/Amlodipine 150/5 mg,,,,,,,,,,FG005,"Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit pro",,,
arm,NCT00739973::arm::FG006,NCT00739973,Aliskiren/Amlodipine 150/10 mg,,,,,,,,,,FG006,"150/5 for 1 week, then up-titrated to 150/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medicatio",,,
arm,NCT00739973::arm::FG007,NCT00739973,Aliskiren/Amlodipine 300/5 mg,,,,,,,,,,FG007,"Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit pro",,,
arm,NCT00739973::arm::FG008,NCT00739973,Aliskiren/Amlodipine 300/10 mg Tablet,,,,,,,,,,FG008,"300/5 for 1 week, then up-titrated to 300/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medicatio",,,
period,NCT00739973::period::1,NCT00739973,Single-blind Period (2 to 4 Weeks),,,,,,,,,,,,1.0,,
period,NCT00739973::period::2,NCT00739973,Double-blind:Randomized Period (8 Weeks),,,,,,,,,,,,2.0,,
outcome,NCT00739973::outcome::primary::1,NCT00739973,Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Aliskiren 150 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP),,,,,,,,,,,,,PRIMARY,Baseline to end of study (Week 8)
outcome,NCT00739973::outcome::primary::2,NCT00739973,Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP),,,,,,,,,,,,,PRIMARY,Baseline to end of study (Week 8)
outcome,NCT00739973::outcome::primary::3,NCT00739973,Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP),,,,,,,,,,,,,PRIMARY,Baseline to end of study (Week 8)
outcome,NCT00739973::outcome::primary::4,NCT00739973,Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Aliskiren 150 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP),,,,,,,,,,,,,PRIMARY,Baseline to end of study (Week 8)
outcome,NCT00739973::outcome::primary::5,NCT00739973,Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP),,,,,,,,,,,,,PRIMARY,Baseline to end of study (Week 8)
outcome,NCT00739973::outcome::primary::6,NCT00739973,Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP),,,,,,,,,,,,,PRIMARY,Baseline to end of study (Week 8)
outcome,NCT00739973::outcome::primary::7,NCT00739973,Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Aliskiren 300 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP),,,,,,,,,,,,,PRIMARY,Baseline to end of study (Week 8)
outcome,NCT00739973::outcome::primary::8,NCT00739973,Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP),,,,,,,,,,,,,PRIMARY,Baseline to end of study (Week 8)
outcome,NCT00739973::outcome::primary::9,NCT00739973,Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP),,,,,,,,,,,,,PRIMARY,Baseline to end of study (Week 8)
outcome,NCT00739973::outcome::primary::10,NCT00739973,Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Aliskiren 300 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP),,,,,,,,,,,,,PRIMARY,Baseline to end of study (Week 8)
outcome,NCT00739973::outcome::primary::11,NCT00739973,Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP),,,,,,,,,,,,,PRIMARY,Baseline to end of study (Week 8)
outcome,NCT00739973::outcome::primary::12,NCT00739973,Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP),,,,,,,,,,,,,PRIMARY,Baseline to end of study (Week 8)
country,NCT00739973::country::United States,NCT00739973,United States,,,,,,,,,,,,,,
country,NCT00739973::country::Argentina,NCT00739973,Argentina,,,,,,,,,,,,,,
country,NCT00739973::country::Australia,NCT00739973,Australia,,,,,,,,,,,,,,
country,NCT00739973::country::Canada,NCT00739973,Canada,,,,,,,,,,,,,,
country,NCT00739973::country::Colombia,NCT00739973,Colombia,,,,,,,,,,,,,,
country,NCT00739973::country::Denmark,NCT00739973,Denmark,,,,,,,,,,,,,,
country,NCT00739973::country::Finland,NCT00739973,Finland,,,,,,,,,,,,,,
country,NCT00739973::country::Greece,NCT00739973,Greece,,,,,,,,,,,,,,
country,NCT00739973::country::Italy,NCT00739973,Italy,,,,,,,,,,,,,,
country,NCT00739973::country::Mexico,NCT00739973,Mexico,,,,,,,,,,,,,,
country,NCT00739973::country::Panama,NCT00739973,Panama,,,,,,,,,,,,,,
country,NCT00739973::country::Peru,NCT00739973,Peru,,,,,,,,,,,,,,
country,NCT00739973::country::Romania,NCT00739973,Romania,,,,,,,,,,,,,,
country,NCT00739973::country::Russia,NCT00739973,Russia,,,,,,,,,,,,,,
country,NCT00739973::country::South Africa,NCT00739973,South Africa,,,,,,,,,,,,,,
country,NCT00739973::country::Spain,NCT00739973,Spain,,,,,,,,,,,,,,
country,NCT00739973::country::Sweden,NCT00739973,Sweden,,,,,,,,,,,,,,
country,NCT00739973::country::Taiwan,NCT00739973,Taiwan,,,,,,,,,,,,,,
trial,NCT04157751,NCT04157751,A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure,PHASE3,cardiovascular disease,Heart Failure,INDUSTRY,530.0,2020-05-18,2021-06-02,15.0,118.0,,,,,
arm,NCT04157751::arm::FG000,NCT04157751,Placebo,,,,,,,,,,FG000,1 film-coated tablet of placebo matching 10 mg empagliflozin was administered orally once daily in patients with acute heart failure.,,,
arm,NCT04157751::arm::FG001,NCT04157751,10 mg Empagliflozin,,,,,,,,,,FG001,1 film-coated tablet of 10 milligram (mg) of empagliflozin was administered orally once daily in patients with acute heart failure.,,,
period,NCT04157751::period::1,NCT04157751,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04157751::outcome::primary::1,NCT04157751,"Percentage of Pairwise Comparisons With Wins of Clinical Benefit, a Composite of Death, Number of Heart Failure Events (HFEs), Time to the First HFE and ≥5-point Difference in CfB in KCCQ-TSS After 90 Days of Treatment",,,,,,,,,,,,,PRIMARY,Up to 90 days. For KCCQ-TSS: at baseline and at day 90.
country,NCT04157751::country::United States,NCT04157751,United States,,,,,,,,,,,,,,
country,NCT04157751::country::Germany,NCT04157751,Germany,,,,,,,,,,,,,,
country,NCT04157751::country::Italy,NCT04157751,Italy,,,,,,,,,,,,,,
country,NCT04157751::country::Netherlands,NCT04157751,Netherlands,,,,,,,,,,,,,,
country,NCT04157751::country::Japan,NCT04157751,Japan,,,,,,,,,,,,,,
country,NCT04157751::country::Belgium,NCT04157751,Belgium,,,,,,,,,,,,,,
country,NCT04157751::country::Spain,NCT04157751,Spain,,,,,,,,,,,,,,
country,NCT04157751::country::China,NCT04157751,China,,,,,,,,,,,,,,
country,NCT04157751::country::Denmark,NCT04157751,Denmark,,,,,,,,,,,,,,
country,NCT04157751::country::Hungary,NCT04157751,Hungary,,,,,,,,,,,,,,
country,NCT04157751::country::Norway,NCT04157751,Norway,,,,,,,,,,,,,,
country,NCT04157751::country::Czechia,NCT04157751,Czechia,,,,,,,,,,,,,,
country,NCT04157751::country::Poland,NCT04157751,Poland,,,,,,,,,,,,,,
country,NCT04157751::country::Canada,NCT04157751,Canada,,,,,,,,,,,,,,
country,NCT04157751::country::Sweden,NCT04157751,Sweden,,,,,,,,,,,,,,
trial,NCT00234832,NCT00234832,A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients,PHASE3,cardiovascular disease,Obesity,INDUSTRY,10777.0,2003-01,2009-11,1.0,1.0,,,,,
arm,NCT00234832::arm::FG000,NCT00234832,Randomized Sibutramine,,,,,,,,,,FG000,Subjects who completed the 6-week Lead-in Period and who were randomized and dispensed sibutramine during the Treatment Period and continued standard care for weight management. If sibutramine was pre,,,
arm,NCT00234832::arm::FG001,NCT00234832,Randomized Placebo,,,,,,,,,,FG001,Subjects who completed the 6-week Lead-in Period and who were randomized and dispensed placebo during the Treatment Period and continued standard care for weight management. If placebo was prematurely,,,
period,NCT00234832::period::1,NCT00234832,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00234832::outcome::primary::1,NCT00234832,"Risk of Experiencing a Primary Outcome Event (POE) (i.e., Nonfatal Myocardial Infarction [MI], Nonfatal Stroke, Resuscitated Cardiac Arrest, Cardiovascular [CV] Death)",,,,,,,,,,,,,PRIMARY,From randomization up to 6 years
country,NCT00234832::country::United States,NCT00234832,United States,,,,,,,,,,,,,,
trial,NCT00403767,NCT00403767,An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation,PHASE3,cardiovascular disease,Atrial Fibrillation; Stroke; Embolism,INDUSTRY,14269.0,2006-12,2010-09,44.0,932.0,,,,,
arm,NCT00403767::arm::FG000,NCT00403767,Rivaroxaban,,,,,,,,,,FG000,Rivaroxaban 15 mg p.o. once daily or Rivaroxaban 20 mg p.o. once daily,,,
arm,NCT00403767::arm::FG001,NCT00403767,Warfarin,,,,,,,,,,FG001,"Warfarin (1 mg, 2.5 mg, or 5 mg p.o. once daily)",,,
period,NCT00403767::period::1,NCT00403767,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00403767::outcome::primary::1,NCT00403767,The Composite Event of Stroke/Non-CNS Systemic Embolism: Primary Efficacy (Non-Inferiority),,,,,,,,,,,,,PRIMARY,Up to 4 years
outcome,NCT00403767::outcome::primary::2,NCT00403767,The Composite of Event of Stroke/Non-CNS Systemic Embolism: Primary Efficacy (Superiority),,,,,,,,,,,,,PRIMARY,Up to 4 years
outcome,NCT00403767::outcome::primary::3,NCT00403767,The Composite Event of Major/Non-major Clinically Relevant Bleeding Events: Primary Safety,,,,,,,,,,,,,PRIMARY,Up to 4 years
country,NCT00403767::country::United States,NCT00403767,United States,,,,,,,,,,,,,,
country,NCT00403767::country::Canada,NCT00403767,Canada,,,,,,,,,,,,,,
country,NCT00403767::country::Germany,NCT00403767,Germany,,,,,,,,,,,,,,
country,NCT00403767::country::Australia,NCT00403767,Australia,,,,,,,,,,,,,,
country,NCT00403767::country::Poland,NCT00403767,Poland,,,,,,,,,,,,,,
country,NCT00403767::country::United Kingdom,NCT00403767,United Kingdom,,,,,,,,,,,,,,
country,NCT00403767::country::France,NCT00403767,France,,,,,,,,,,,,,,
country,NCT00403767::country::Brazil,NCT00403767,Brazil,,,,,,,,,,,,,,
country,NCT00403767::country::Ukraine,NCT00403767,Ukraine,,,,,,,,,,,,,,
country,NCT00403767::country::Netherlands,NCT00403767,Netherlands,,,,,,,,,,,,,,
country,NCT00403767::country::China,NCT00403767,China,,,,,,,,,,,,,,
country,NCT00403767::country::Russia,NCT00403767,Russia,,,,,,,,,,,,,,
country,NCT00403767::country::Spain,NCT00403767,Spain,,,,,,,,,,,,,,
country,NCT00403767::country::Czechia,NCT00403767,Czechia,,,,,,,,,,,,,,
country,NCT00403767::country::India,NCT00403767,India,,,,,,,,,,,,,,
country,NCT00403767::country::Turkey (Türkiye),NCT00403767,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00403767::country::Hungary,NCT00403767,Hungary,,,,,,,,,,,,,,
country,NCT00403767::country::Israel,NCT00403767,Israel,,,,,,,,,,,,,,
country,NCT00403767::country::Belgium,NCT00403767,Belgium,,,,,,,,,,,,,,
country,NCT00403767::country::Argentina,NCT00403767,Argentina,,,,,,,,,,,,,,
country,NCT00403767::country::South Africa,NCT00403767,South Africa,,,,,,,,,,,,,,
country,NCT00403767::country::Chile,NCT00403767,Chile,,,,,,,,,,,,,,
country,NCT00403767::country::Denmark,NCT00403767,Denmark,,,,,,,,,,,,,,
country,NCT00403767::country::Norway,NCT00403767,Norway,,,,,,,,,,,,,,
country,NCT00403767::country::Colombia,NCT00403767,Colombia,,,,,,,,,,,,,,
country,NCT00403767::country::Mexico,NCT00403767,Mexico,,,,,,,,,,,,,,
country,NCT00403767::country::Romania,NCT00403767,Romania,,,,,,,,,,,,,,
country,NCT00403767::country::South Korea,NCT00403767,South Korea,,,,,,,,,,,,,,
country,NCT00403767::country::Greece,NCT00403767,Greece,,,,,,,,,,,,,,
country,NCT00403767::country::Taiwan,NCT00403767,Taiwan,,,,,,,,,,,,,,
country,NCT00403767::country::Bulgaria,NCT00403767,Bulgaria,,,,,,,,,,,,,,
country,NCT00403767::country::Finland,NCT00403767,Finland,,,,,,,,,,,,,,
country,NCT00403767::country::New Zealand,NCT00403767,New Zealand,,,,,,,,,,,,,,
country,NCT00403767::country::Thailand,NCT00403767,Thailand,,,,,,,,,,,,,,
country,NCT00403767::country::Austria,NCT00403767,Austria,,,,,,,,,,,,,,
country,NCT00403767::country::Lithuania,NCT00403767,Lithuania,,,,,,,,,,,,,,
country,NCT00403767::country::Philippines,NCT00403767,Philippines,,,,,,,,,,,,,,
country,NCT00403767::country::Sweden,NCT00403767,Sweden,,,,,,,,,,,,,,
country,NCT00403767::country::Hong Kong,NCT00403767,Hong Kong,,,,,,,,,,,,,,
country,NCT00403767::country::Switzerland,NCT00403767,Switzerland,,,,,,,,,,,,,,
country,NCT00403767::country::Malaysia,NCT00403767,Malaysia,,,,,,,,,,,,,,
country,NCT00403767::country::Peru,NCT00403767,Peru,,,,,,,,,,,,,,
country,NCT00403767::country::Venezuela,NCT00403767,Venezuela,,,,,,,,,,,,,,
country,NCT00403767::country::Singapore,NCT00403767,Singapore,,,,,,,,,,,,,,
trial,NCT00639158,NCT00639158,Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood,PHASE3,cardiovascular disease,Dyslipidemias; Coronary Heart Disease; Combined (Atherogenic) Dyslipidemia; Mixed Dyslipidemia,INDUSTRY,543.0,2008-02,,1.0,118.0,,,,,
arm,NCT00639158::arm::FG000,NCT00639158,ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe,,,,,,,,,,FG000,,,,
arm,NCT00639158::arm::FG001,NCT00639158,Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe,,,,,,,,,,FG001,,,,
period,NCT00639158::period::1,NCT00639158,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00639158::outcome::primary::1,NCT00639158,Median Percent Change in Triglycerides From Baseline to Final Visit,,,,,,,,,,,,,PRIMARY,Baseline to 12 Weeks (Final Visit)
outcome,NCT00639158::outcome::primary::2,NCT00639158,Mean Percent Change in High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Final Visit,,,,,,,,,,,,,PRIMARY,Baseline to 12 weeks (Final Visit)
country,NCT00639158::country::United States,NCT00639158,United States,,,,,,,,,,,,,,
trial,NCT02476006,NCT02476006,"Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)",PHASE3,cardiovascular disease,Hypercholesterolemia,INDUSTRY,998.0,2015-06-23,2019-04-12,16.0,153.0,,,,,
arm,NCT02476006::arm::FG000,NCT02476006,Alirocumab,,,,,,,,,,FG000,Participants received Alirocumab 150 milligram (mg) subcutaneously (SC) once every two weeks (Q2W) or 75 mg SC Q2W added to stable lipid modifying therapies (LMT) up to a maximum of 120 weeks. Alirocu,,,
period,NCT02476006::period::1,NCT02476006,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02476006::outcome::primary::1,NCT02476006,Percentage of Participants With Treatment Emergent Adverse Events (TEAEs),,,,,,,,,,,,,PRIMARY,From first injection of investigational medicinal product (IMP) up to 2 weeks after last dose of study drug (Week 120)
country,NCT02476006::country::France,NCT02476006,France,,,,,,,,,,,,,,
country,NCT02476006::country::Canada,NCT02476006,Canada,,,,,,,,,,,,,,
country,NCT02476006::country::Belgium,NCT02476006,Belgium,,,,,,,,,,,,,,
country,NCT02476006::country::Spain,NCT02476006,Spain,,,,,,,,,,,,,,
country,NCT02476006::country::Austria,NCT02476006,Austria,,,,,,,,,,,,,,
country,NCT02476006::country::Poland,NCT02476006,Poland,,,,,,,,,,,,,,
country,NCT02476006::country::Switzerland,NCT02476006,Switzerland,,,,,,,,,,,,,,
country,NCT02476006::country::Czechia,NCT02476006,Czechia,,,,,,,,,,,,,,
country,NCT02476006::country::Hungary,NCT02476006,Hungary,,,,,,,,,,,,,,
country,NCT02476006::country::Denmark,NCT02476006,Denmark,,,,,,,,,,,,,,
country,NCT02476006::country::Greece,NCT02476006,Greece,,,,,,,,,,,,,,
country,NCT02476006::country::Romania,NCT02476006,Romania,,,,,,,,,,,,,,
country,NCT02476006::country::Slovakia,NCT02476006,Slovakia,,,,,,,,,,,,,,
country,NCT02476006::country::Finland,NCT02476006,Finland,,,,,,,,,,,,,,
country,NCT02476006::country::Germany,NCT02476006,Germany,,,,,,,,,,,,,,
country,NCT02476006::country::Slovenia,NCT02476006,Slovenia,,,,,,,,,,,,,,
trial,NCT01023308,NCT01023308,Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma,PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,767.0,2009-12-21,2015-07-30,34.0,210.0,,,,,
arm,NCT01023308::arm::FG000,NCT01023308,Panobinostat + Bortezomib,,,,,,,,,,FG000,Panobinostat was given 20 mg hard gelatin capsules . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV)injection. Dexamethasone was given as an oral dose of 20 mg/day.,,,
arm,NCT01023308::arm::FG001,NCT01023308,Placebo + Bortezomib,,,,,,,,,,FG001,Placebo was given as a hard gelatin capsule in the image of Panobinostat . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV) injection. Dexamethasone was given as an oral dos,,,
period,NCT01023308::period::1,NCT01023308,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01023308::outcome::primary::1,NCT01023308,Progression-free Survival Events in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.,,,,,,,,,,,,,PRIMARY,45 months
outcome,NCT01023308::outcome::primary::2,NCT01023308,Progression Free Survival in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.,,,,,,,,,,,,,PRIMARY,45 months
country,NCT01023308::country::United States,NCT01023308,United States,,,,,,,,,,,,,,
country,NCT01023308::country::Germany,NCT01023308,Germany,,,,,,,,,,,,,,
country,NCT01023308::country::Japan,NCT01023308,Japan,,,,,,,,,,,,,,
country,NCT01023308::country::Italy,NCT01023308,Italy,,,,,,,,,,,,,,
country,NCT01023308::country::China,NCT01023308,China,,,,,,,,,,,,,,
country,NCT01023308::country::South Korea,NCT01023308,South Korea,,,,,,,,,,,,,,
country,NCT01023308::country::Spain,NCT01023308,Spain,,,,,,,,,,,,,,
country,NCT01023308::country::France,NCT01023308,France,,,,,,,,,,,,,,
country,NCT01023308::country::Brazil,NCT01023308,Brazil,,,,,,,,,,,,,,
country,NCT01023308::country::United Kingdom,NCT01023308,United Kingdom,,,,,,,,,,,,,,
country,NCT01023308::country::Australia,NCT01023308,Australia,,,,,,,,,,,,,,
country,NCT01023308::country::Norway,NCT01023308,Norway,,,,,,,,,,,,,,
country,NCT01023308::country::Canada,NCT01023308,Canada,,,,,,,,,,,,,,
country,NCT01023308::country::Denmark,NCT01023308,Denmark,,,,,,,,,,,,,,
country,NCT01023308::country::Sweden,NCT01023308,Sweden,,,,,,,,,,,,,,
country,NCT01023308::country::Israel,NCT01023308,Israel,,,,,,,,,,,,,,
country,NCT01023308::country::Taiwan,NCT01023308,Taiwan,,,,,,,,,,,,,,
country,NCT01023308::country::Argentina,NCT01023308,Argentina,,,,,,,,,,,,,,
country,NCT01023308::country::Belgium,NCT01023308,Belgium,,,,,,,,,,,,,,
country,NCT01023308::country::Czechia,NCT01023308,Czechia,,,,,,,,,,,,,,
country,NCT01023308::country::Hong Kong,NCT01023308,Hong Kong,,,,,,,,,,,,,,
country,NCT01023308::country::Netherlands,NCT01023308,Netherlands,,,,,,,,,,,,,,
country,NCT01023308::country::Thailand,NCT01023308,Thailand,,,,,,,,,,,,,,
country,NCT01023308::country::Turkey (Türkiye),NCT01023308,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01023308::country::Austria,NCT01023308,Austria,,,,,,,,,,,,,,
country,NCT01023308::country::Egypt,NCT01023308,Egypt,,,,,,,,,,,,,,
country,NCT01023308::country::Finland,NCT01023308,Finland,,,,,,,,,,,,,,
country,NCT01023308::country::Greece,NCT01023308,Greece,,,,,,,,,,,,,,
country,NCT01023308::country::Poland,NCT01023308,Poland,,,,,,,,,,,,,,
country,NCT01023308::country::Russia,NCT01023308,Russia,,,,,,,,,,,,,,
country,NCT01023308::country::South Africa,NCT01023308,South Africa,,,,,,,,,,,,,,
country,NCT01023308::country::Lebanon,NCT01023308,Lebanon,,,,,,,,,,,,,,
country,NCT01023308::country::Mexico,NCT01023308,Mexico,,,,,,,,,,,,,,
country,NCT01023308::country::Singapore,NCT01023308,Singapore,,,,,,,,,,,,,,
trial,NCT00514735,NCT00514735,Tailored Treatment of Permanent Atrial Fibrillation,PHASE3,cardiovascular disease,Atrial Fibrillation,INDUSTRY,210.0,2007-05,2010-11,2.0,24.0,,,,,
arm,NCT00514735::arm::FG000,NCT00514735,Ablation Management,,,,,,,,,,FG000,Pre- and post- procedure anticoagulation was managed according to the preference of the investigator. Left atrial access was obtained by a single transseptal puncture. No ablations were to occur until,,,
arm,NCT00514735::arm::FG001,NCT00514735,Medical Management,,,,,,,,,,FG001,"Medical Management subjects were prescribed Class I or III antiarrhythmic drugs. Changes in dosing, antiarrhythmic drugs or combinations of antiarrhythmic drugs were allowed. Direct current (DC) cardi",,,
period,NCT00514735::period::1,NCT00514735,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00514735::outcome::primary::1,NCT00514735,Chronic Effectiveness,,,,,,,,,,,,,PRIMARY,6 months
outcome,NCT00514735::outcome::primary::2,NCT00514735,Acute Safety,,,,,,,,,,,,,PRIMARY,7 days
outcome,NCT00514735::outcome::primary::3,NCT00514735,Chronic Safety,,,,,,,,,,,,,PRIMARY,6 months
country,NCT00514735::country::United States,NCT00514735,United States,,,,,,,,,,,,,,
country,NCT00514735::country::Netherlands,NCT00514735,Netherlands,,,,,,,,,,,,,,
trial,NCT02551094,NCT02551094,Colchicine Cardiovascular Outcomes Trial (COLCOT),PHASE3,cardiovascular disease,Coronary Artery Disease; Myocardial Infarction,OTHER,4745.0,2015-12-04,2019-07-17,1.0,1.0,,,,,
arm,NCT02551094::arm::FG000,NCT02551094,Colchicine,,,,,,,,,,FG000,"0.5 mg tablet of colchicine taken once a day

colchicine: 0.5 mg tablet taken once a day",,,
arm,NCT02551094::arm::FG001,NCT02551094,Colchicine Placebo,,,,,,,,,,FG001,"0.5 mg tablet of placebo taken once a day

colchicine placebo: sugar pill manufactured to mimic colchicine 0.5 mg tablet",,,
period,NCT02551094::period::1,NCT02551094,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02551094::outcome::primary::1,NCT02551094,"First Event of Cardiovascular Death, Resuscitated Cardiac Arrest, Acute Myocardial Infarction, Stroke, or Urgent Hospitalization for Angina Requiring Coronary Revascularization",,,,,,,,,,,,,PRIMARY,"From randomization to occurence of first event, assessed up to 3.5 years"
country,NCT02551094::country::Canada,NCT02551094,Canada,,,,,,,,,,,,,,
trial,NCT00180479,NCT00180479,SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS),PHASE3,cardiovascular disease,Stents; Coronary Artery Disease; Total Coronary Occlusion; Coronary Artery Restenosis; Stent Thrombosis; Vascular Disease; Myocardial Ischemia; Coronary Artery Stenosis,INDUSTRY,1002.0,2005-06,2011-11,1.0,65.0,,,,,
arm,NCT00180479::arm::FG000,NCT00180479,XIENCE V® EECSS,,,,,,,,,,FG000,XIENCE V® Everolimus Eluting Coronary Stent System,,,
arm,NCT00180479::arm::FG001,NCT00180479,TAXUS® EXPRESS2™ ECSS,,,,,,,,,,FG001,"TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.",,,
period,NCT00180479::period::1,NCT00180479,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00180479::outcome::primary::1,NCT00180479,Primary Endpoint: In-segment Late Loss (LL),,,,,,,,,,,,,PRIMARY,240 days
country,NCT00180479::country::United States,NCT00180479,United States,,,,,,,,,,,,,,
trial,NCT00091949,NCT00091949,Insulin Resistance Intervention After Stroke Trial,PHASE3,cardiovascular disease,Stroke; Myocardial Infarction; Diabetes,OTHER,3876.0,2005-02,2015-11,8.0,183.0,,,,,
arm,NCT00091949::arm::FG000,NCT00091949,Pioglitazone,,,,,,,,,,FG000,pioglitazone: a thiazolidinedione drug,,,
arm,NCT00091949::arm::FG001,NCT00091949,Placebo,,,,,,,,,,FG001,placebo: an inactive substance,,,
period,NCT00091949::period::1,NCT00091949,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00091949::outcome::primary::1,NCT00091949,"Recurrent Fatal or Non-fatal Stroke, or Fatal or Non-fatal Myocardial Infarction",,,,,,,,,,,,,PRIMARY,Up to 5 years
country,NCT00091949::country::United States,NCT00091949,United States,,,,,,,,,,,,,,
country,NCT00091949::country::United Kingdom,NCT00091949,United Kingdom,,,,,,,,,,,,,,
country,NCT00091949::country::Germany,NCT00091949,Germany,,,,,,,,,,,,,,
country,NCT00091949::country::Canada,NCT00091949,Canada,,,,,,,,,,,,,,
country,NCT00091949::country::Italy,NCT00091949,Italy,,,,,,,,,,,,,,
country,NCT00091949::country::Australia,NCT00091949,Australia,,,,,,,,,,,,,,
country,NCT00091949::country::Israel,NCT00091949,Israel,,,,,,,,,,,,,,
country,NCT00091949::country::Puerto Rico,NCT00091949,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00266695,NCT00266695,Treatment for Completers of the Study B7A-MC-MBCM,PHASE3,cardiovascular disease,Diabetic Retinopathy,INDUSTRY,203.0,2006-01,2008-08,1.0,29.0,,,,,
arm,NCT00266695::arm::FG000,NCT00266695,Ruboxistaurin,,,,,,,,,,FG000,32 milligrams (mg) given once daily as an oral tablet for 2 years.,,,
period,NCT00266695::period::1,NCT00266695,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00266695::outcome::primary::1,NCT00266695,Sustained Moderate Visual Loss (SMVL),,,,,,,,,,,,,PRIMARY,"Baseline, 18 months up to 24 months"
country,NCT00266695::country::United States,NCT00266695,United States,,,,,,,,,,,,,,
trial,NCT00439777,NCT00439777,Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study,PHASE3,cardiovascular disease,Pulmonary Embolism,INDUSTRY,4833.0,2007-03,2011-12,39.0,305.0,,,,,
arm,NCT00439777::arm::FG000,NCT00439777,"Rivaroxaban (Xarelto, BAY59-7939)",,,,,,,,,,FG000,"Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)",,,
arm,NCT00439777::arm::FG001,NCT00439777,Enoxaparin/VKA,,,,,,,,,,FG001,"Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (",,,
period,NCT00439777::period::1,NCT00439777,Treatment Period,,,,,,,,,,,,1.0,,
period,NCT00439777::period::2,NCT00439777,Observational Period,,,,,,,,,,,,2.0,,
outcome,NCT00439777::outcome::primary::1,NCT00439777,Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment,,,,,,,,,,,,,PRIMARY,"3-, 6-, or 12-month study treatment period"
country,NCT00439777::country::France,NCT00439777,France,,,,,,,,,,,,,,
country,NCT00439777::country::Germany,NCT00439777,Germany,,,,,,,,,,,,,,
country,NCT00439777::country::United States,NCT00439777,United States,,,,,,,,,,,,,,
country,NCT00439777::country::Australia,NCT00439777,Australia,,,,,,,,,,,,,,
country,NCT00439777::country::China,NCT00439777,China,,,,,,,,,,,,,,
country,NCT00439777::country::Italy,NCT00439777,Italy,,,,,,,,,,,,,,
country,NCT00439777::country::Belgium,NCT00439777,Belgium,,,,,,,,,,,,,,
country,NCT00439777::country::Israel,NCT00439777,Israel,,,,,,,,,,,,,,
country,NCT00439777::country::Hungary,NCT00439777,Hungary,,,,,,,,,,,,,,
country,NCT00439777::country::Poland,NCT00439777,Poland,,,,,,,,,,,,,,
country,NCT00439777::country::South Africa,NCT00439777,South Africa,,,,,,,,,,,,,,
country,NCT00439777::country::Brazil,NCT00439777,Brazil,,,,,,,,,,,,,,
country,NCT00439777::country::Spain,NCT00439777,Spain,,,,,,,,,,,,,,
country,NCT00439777::country::Czechia,NCT00439777,Czechia,,,,,,,,,,,,,,
country,NCT00439777::country::Austria,NCT00439777,Austria,,,,,,,,,,,,,,
country,NCT00439777::country::Netherlands,NCT00439777,Netherlands,,,,,,,,,,,,,,
country,NCT00439777::country::Switzerland,NCT00439777,Switzerland,,,,,,,,,,,,,,
country,NCT00439777::country::New Zealand,NCT00439777,New Zealand,,,,,,,,,,,,,,
country,NCT00439777::country::Sweden,NCT00439777,Sweden,,,,,,,,,,,,,,
country,NCT00439777::country::Canada,NCT00439777,Canada,,,,,,,,,,,,,,
country,NCT00439777::country::Indonesia,NCT00439777,Indonesia,,,,,,,,,,,,,,
country,NCT00439777::country::United Kingdom,NCT00439777,United Kingdom,,,,,,,,,,,,,,
country,NCT00439777::country::India,NCT00439777,India,,,,,,,,,,,,,,
country,NCT00439777::country::Norway,NCT00439777,Norway,,,,,,,,,,,,,,
country,NCT00439777::country::South Korea,NCT00439777,South Korea,,,,,,,,,,,,,,
country,NCT00439777::country::Taiwan,NCT00439777,Taiwan,,,,,,,,,,,,,,
country,NCT00439777::country::Denmark,NCT00439777,Denmark,,,,,,,,,,,,,,
country,NCT00439777::country::Thailand,NCT00439777,Thailand,,,,,,,,,,,,,,
country,NCT00439777::country::Finland,NCT00439777,Finland,,,,,,,,,,,,,,
country,NCT00439777::country::Hong Kong,NCT00439777,Hong Kong,,,,,,,,,,,,,,
country,NCT00439777::country::Lithuania,NCT00439777,Lithuania,,,,,,,,,,,,,,
country,NCT00439777::country::Philippines,NCT00439777,Philippines,,,,,,,,,,,,,,
country,NCT00439777::country::Singapore,NCT00439777,Singapore,,,,,,,,,,,,,,
country,NCT00439777::country::Andorra,NCT00439777,Andorra,,,,,,,,,,,,,,
country,NCT00439777::country::Estonia,NCT00439777,Estonia,,,,,,,,,,,,,,
country,NCT00439777::country::Ireland,NCT00439777,Ireland,,,,,,,,,,,,,,
country,NCT00439777::country::Latvia,NCT00439777,Latvia,,,,,,,,,,,,,,
country,NCT00439777::country::Malaysia,NCT00439777,Malaysia,,,,,,,,,,,,,,
country,NCT00439777::country::Puerto Rico,NCT00439777,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00358579,NCT00358579,Comparing Vasopressin and Adrenaline in Patients With Cardiac Arrest,PHASE3,cardiovascular disease,Cardiac Arrest,OTHER,727.0,2006-03,2010-01,1.0,4.0,,,,,
arm,NCT00358579::arm::FG000,NCT00358579,Adrenaline,,,,,,,,,,FG000,"1 mg Intravenous Adrenaline, administered as the first drug upon cardiac arrest patient's arrival at the Emergency Department",,,
arm,NCT00358579::arm::FG001,NCT00358579,Vasopressin,,,,,,,,,,FG001,"40 IU Intravenous Vasopressin, administered as the first drug upon cardiac arrest patient's arrival at the Emergency Department",,,
period,NCT00358579::period::1,NCT00358579,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00358579::outcome::primary::1,NCT00358579,Survival to Hospital Discharge.,,,,,,,,,,,,,PRIMARY,at 30 days post arrest
country,NCT00358579::country::Singapore,NCT00358579,Singapore,,,,,,,,,,,,,,
trial,NCT00916370,NCT00916370,SPIRIT PRIME Clinical Trial,PHASE3,cardiovascular disease,Myocardial Ischemia; Coronary Artery Stenosis; Coronary Disease; Coronary Artery Disease; Coronary Restenosis,INDUSTRY,525.0,2009-06,2014-02,2.0,62.0,,,,,
arm,NCT00916370::arm::FG000,NCT00916370,Core Size Registry,,,,,,,,,,FG000,Core size indicates the range of diameters of the stents used.,,,
arm,NCT00916370::arm::FG001,NCT00916370,Long Lesion Registry,,,,,,,,,,FG001,Use of long lesion stents.,,,
period,NCT00916370::period::1,NCT00916370,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00916370::outcome::primary::1,NCT00916370,Target Lesion Failure (TLF),,,,,,,,,,,,,PRIMARY,1 year
outcome,NCT00916370::outcome::primary::2,NCT00916370,Target Lesion Failure (TLF),,,,,,,,,,,,,PRIMARY,2 years
outcome,NCT00916370::outcome::primary::3,NCT00916370,Target Lesion Failure (TLF),,,,,,,,,,,,,PRIMARY,3 years
country,NCT00916370::country::United States,NCT00916370,United States,,,,,,,,,,,,,,
country,NCT00916370::country::Australia,NCT00916370,Australia,,,,,,,,,,,,,,
trial,NCT01663233,NCT01663233,Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine,PHASE3,cardiovascular disease,Essential Hypertension,INDUSTRY,266.0,2012-08,2013-05,6.0,28.0,,,,,
arm,NCT01663233::arm::FG000,NCT01663233,LCZ696 and Amlodipine,,,,,,,,,,FG000,"Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (an office msSBP ≥145 mmHg and \<180 mmHg) and who met all inclusion a",,,
arm,NCT01663233::arm::FG001,NCT01663233,Amlodipine,,,,,,,,,,FG001,"Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (an office msSBP ≥145 mmHg and \<180 mmHg) and who met all inclusion a",,,
period,NCT01663233::period::1,NCT01663233,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01663233::outcome::primary::1,NCT01663233,Change in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Systolic Blood Pressure (maSBP),,,,,,,,,,,,,PRIMARY,8 weeks
country,NCT01663233::country::Japan,NCT01663233,Japan,,,,,,,,,,,,,,
country,NCT01663233::country::South Korea,NCT01663233,South Korea,,,,,,,,,,,,,,
country,NCT01663233::country::Philippines,NCT01663233,Philippines,,,,,,,,,,,,,,
country,NCT01663233::country::China,NCT01663233,China,,,,,,,,,,,,,,
country,NCT01663233::country::Taiwan,NCT01663233,Taiwan,,,,,,,,,,,,,,
country,NCT01663233::country::Malaysia,NCT01663233,Malaysia,,,,,,,,,,,,,,
trial,NCT00323037,NCT00323037,A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure,PHASE3,cardiovascular disease,Congestive Heart Failure,INDUSTRY,318.0,2006-03,2008-06,1.0,75.0,,,,,
arm,NCT00323037::arm::FG000,NCT00323037,Coreg Immediate Release,,,,,,,,,,FG000,,,,
arm,NCT00323037::arm::FG001,NCT00323037,Coreg Controlled Release,,,,,,,,,,FG001,,,,
period,NCT00323037::period::1,NCT00323037,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00323037::outcome::primary::1,NCT00323037,Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI) Characterized by 2-D Echocardiography,,,,,,,,,,,,,PRIMARY,24 weeks after entry into the maintenance period
country,NCT00323037::country::United States,NCT00323037,United States,,,,,,,,,,,,,,
trial,NCT01674712,NCT01674712,A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease,PHASE3,cardiovascular disease,Dyslipidemia,INDUSTRY,575.0,2012-06,2013-10,7.0,69.0,,,,,
arm,NCT01674712::arm::FG000,NCT01674712,Fenofibrate/Simvastatin 145/20 mg,,,,,,,,,,FG000,"Fenofibrate/simvastatin 145/20 mg: Fenofibrate/simvastatin oval biconvex film-coated tablet, 145 mg / 20 mg, once daily, 12 weeks",,,
arm,NCT01674712::arm::FG001,NCT01674712,Simvastatin 20 mg,,,,,,,,,,FG001,"Simvastatin 20 mg: Simvastatin generic tablet over-encapsulated, 20 mg, once daily, 12 weeks",,,
arm,NCT01674712::arm::FG002,NCT01674712,Fenofibrate/Simvastatin 145/40 mg,,,,,,,,,,FG002,"Fenofibrate/simvastatin 145/40 mg: Fenofibrate/simvastatin film-coated tablet 145 mg / 40 mg, once daily, 12 weeks",,,
arm,NCT01674712::arm::FG003,NCT01674712,Simvastatin 40 mg,,,,,,,,,,FG003,"Simvastatin 40 mg: simvastatin, generic tablet over-encapsulated, 40 mg, once daily, 12 weeks",,,
arm,NCT01674712::arm::FG004,NCT01674712,Fenofibrate 145 mg,,,,,,,,,,FG004,"Fenofibrate 145 mg: Fenofibrate, tablet, 145 mg, once daily, 12 weeks",,,
period,NCT01674712::period::1,NCT01674712,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01674712::outcome::primary::1,NCT01674712,Percentage of Change of TG (Triglyceride),,,,,,,,,,,,,PRIMARY,from baseline to 12 weeks of treatment
outcome,NCT01674712::outcome::primary::2,NCT01674712,Percentage of Change of HDL-C (High Density Lipoprotein Cholesterol),,,,,,,,,,,,,PRIMARY,from baseline to 12 weeks of treatment
outcome,NCT01674712::outcome::primary::3,NCT01674712,Percentage of Change of LDL-C (Low Density Lipoprotein Cholesterol),,,,,,,,,,,,,PRIMARY,from baseline to 12 weeks of treatment
country,NCT01674712::country::Argentina,NCT01674712,Argentina,,,,,,,,,,,,,,
country,NCT01674712::country::Germany,NCT01674712,Germany,,,,,,,,,,,,,,
country,NCT01674712::country::Russia,NCT01674712,Russia,,,,,,,,,,,,,,
country,NCT01674712::country::Czechia,NCT01674712,Czechia,,,,,,,,,,,,,,
country,NCT01674712::country::Poland,NCT01674712,Poland,,,,,,,,,,,,,,
country,NCT01674712::country::Romania,NCT01674712,Romania,,,,,,,,,,,,,,
country,NCT01674712::country::Mexico,NCT01674712,Mexico,,,,,,,,,,,,,,
trial,NCT01732822,NCT01732822,A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease,PHASE3,cardiovascular disease,Peripheral Artery Disease,INDUSTRY,13885.0,2012-12-04,2016-09-26,28.0,776.0,,,,,
arm,NCT01732822::arm::FG000,NCT01732822,Ticagrelor 90 mg bd,,,,,,,,,,FG000,,,,
arm,NCT01732822::arm::FG001,NCT01732822,Clopidogrel 75 mg od,,,,,,,,,,FG001,,,,
period,NCT01732822::period::1,NCT01732822,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01732822::outcome::primary::1,NCT01732822,Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke,,,,,,,,,,,,,PRIMARY,"From randomization to PACD, an average of 2.5 years"
country,NCT01732822::country::United States,NCT01732822,United States,,,,,,,,,,,,,,
country,NCT01732822::country::Japan,NCT01732822,Japan,,,,,,,,,,,,,,
country,NCT01732822::country::Russia,NCT01732822,Russia,,,,,,,,,,,,,,
country,NCT01732822::country::Spain,NCT01732822,Spain,,,,,,,,,,,,,,
country,NCT01732822::country::Canada,NCT01732822,Canada,,,,,,,,,,,,,,
country,NCT01732822::country::Brazil,NCT01732822,Brazil,,,,,,,,,,,,,,
country,NCT01732822::country::France,NCT01732822,France,,,,,,,,,,,,,,
country,NCT01732822::country::Germany,NCT01732822,Germany,,,,,,,,,,,,,,
country,NCT01732822::country::China,NCT01732822,China,,,,,,,,,,,,,,
country,NCT01732822::country::Poland,NCT01732822,Poland,,,,,,,,,,,,,,
country,NCT01732822::country::Italy,NCT01732822,Italy,,,,,,,,,,,,,,
country,NCT01732822::country::Hungary,NCT01732822,Hungary,,,,,,,,,,,,,,
country,NCT01732822::country::Argentina,NCT01732822,Argentina,,,,,,,,,,,,,,
country,NCT01732822::country::Bulgaria,NCT01732822,Bulgaria,,,,,,,,,,,,,,
country,NCT01732822::country::Romania,NCT01732822,Romania,,,,,,,,,,,,,,
country,NCT01732822::country::Czechia,NCT01732822,Czechia,,,,,,,,,,,,,,
country,NCT01732822::country::Philippines,NCT01732822,Philippines,,,,,,,,,,,,,,
country,NCT01732822::country::Ukraine,NCT01732822,Ukraine,,,,,,,,,,,,,,
country,NCT01732822::country::Mexico,NCT01732822,Mexico,,,,,,,,,,,,,,
country,NCT01732822::country::South Korea,NCT01732822,South Korea,,,,,,,,,,,,,,
country,NCT01732822::country::Turkey (Türkiye),NCT01732822,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01732822::country::United Kingdom,NCT01732822,United Kingdom,,,,,,,,,,,,,,
country,NCT01732822::country::Chile,NCT01732822,Chile,,,,,,,,,,,,,,
country,NCT01732822::country::Netherlands,NCT01732822,Netherlands,,,,,,,,,,,,,,
country,NCT01732822::country::Sweden,NCT01732822,Sweden,,,,,,,,,,,,,,
country,NCT01732822::country::Slovakia,NCT01732822,Slovakia,,,,,,,,,,,,,,
country,NCT01732822::country::Thailand,NCT01732822,Thailand,,,,,,,,,,,,,,
country,NCT01732822::country::Vietnam,NCT01732822,Vietnam,,,,,,,,,,,,,,
trial,NCT02833948,NCT02833948,"Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)",PHASE3,cardiovascular disease,Aortic Valve Stenosis; Cardiovascular Diseases; Heart Valve Diseases; Ventricular Outflow Obstruction; Thrombosis,INDUSTRY,231.0,2016-05,2019-03-06,7.0,25.0,,,,,
arm,NCT02833948::arm::FG000,NCT02833948,ASA + Clopidogrel,,,,,,,,,,FG000,"ASA (Acetylsalicylic acid) 75-100mg + Clopidogrel 75mg for 90 days, followed by ASA 75-100mg monotherapy

Acetylsalicylic acid: Drug: Acetylsalicylic acid:

75 - 100 mg OD (for first 90 days only in a",,,
arm,NCT02833948::arm::FG001,NCT02833948,Rivaroxaban + ASA,,,,,,,,,,FG001,"Rivaroxaban 10mg + ASA 75-100mg for 90 days, followed by rivaroxaban 10mg monotherapy

Acetylsalicylic acid: Drug: Acetylsalicylic acid:

75 - 100 mg OD (for first 90 days only in arm 1)

Rivaroxaban:",,,
period,NCT02833948::period::1,NCT02833948,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02833948::outcome::primary::1,NCT02833948,Rate of Patients With at Least One Prosthetic Leaflet With >50% Motion Reduction as Assessed by Cardiac 4DCT-scan,,,,,,,,,,,,,PRIMARY,3 months
country,NCT02833948::country::Germany,NCT02833948,Germany,,,,,,,,,,,,,,
country,NCT02833948::country::United States,NCT02833948,United States,,,,,,,,,,,,,,
country,NCT02833948::country::Denmark,NCT02833948,Denmark,,,,,,,,,,,,,,
country,NCT02833948::country::Netherlands,NCT02833948,Netherlands,,,,,,,,,,,,,,
country,NCT02833948::country::Canada,NCT02833948,Canada,,,,,,,,,,,,,,
country,NCT02833948::country::Sweden,NCT02833948,Sweden,,,,,,,,,,,,,,
country,NCT02833948::country::Switzerland,NCT02833948,Switzerland,,,,,,,,,,,,,,
trial,NCT00129545,NCT00129545,WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation,PHASE3,cardiovascular disease,Atrial Fibrillation; Stroke,INDUSTRY,800.0,2005-02,2014-05,3.0,62.0,,,,,
arm,NCT00129545::arm::FG000,NCT00129545,Roll-in,,,,,,,,,,FG000,Investigational centers were allowed up to 3 roll in subjects before initiating the randomization phase,,,
arm,NCT00129545::arm::FG001,NCT00129545,WATCHMAN,,,,,,,,,,FG001,Randomized to receive implantation of the WATCHMAN left atrial appendage (LAA) closure Technology,,,
arm,NCT00129545::arm::FG002,NCT00129545,WARFARIN,,,,,,,,,,FG002,Randomized to receive Warfarin control,,,
period,NCT00129545::period::1,NCT00129545,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00129545::outcome::primary::1,NCT00129545,"Composite of Stroke, Systemic Embolism and Cardiovascular or Unexplained Death",,,,,,,,,,,,,PRIMARY,5 years
outcome,NCT00129545::outcome::primary::2,NCT00129545,"The Occurrence of Life-threatening Events, Including Device Embolization or Serious Bleeding Events",,,,,,,,,,,,,PRIMARY,5 years
country,NCT00129545::country::United States,NCT00129545,United States,,,,,,,,,,,,,,
country,NCT00129545::country::Germany,NCT00129545,Germany,,,,,,,,,,,,,,
country,NCT00129545::country::Czechia,NCT00129545,Czechia,,,,,,,,,,,,,,
trial,NCT01456169,NCT01456169,A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone,PHASE3,cardiovascular disease,Essential Hypertension,INDUSTRY,507.0,2011-10,2013-01,14.0,108.0,,,,,
arm,NCT01456169::arm::FG000,NCT01456169,Azilsartan Medoxomil 40 mg,,,,,,,,,,FG000,"Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.",,,
arm,NCT01456169::arm::FG001,NCT01456169,Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg,,,,,,,,,,FG001,"Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.",,,
arm,NCT01456169::arm::FG002,NCT01456169,Azilsartan Medoxomil + Chlorthalidone 40/25 mg,,,,,,,,,,FG002,"Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.",,,
period,NCT01456169::period::1,NCT01456169,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01456169::outcome::primary::1,NCT01456169,"Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure",,,,,,,,,,,,,PRIMARY,Baseline (of the double-blind treatment period) and Week 8
country,NCT01456169::country::Poland,NCT01456169,Poland,,,,,,,,,,,,,,
country,NCT01456169::country::Italy,NCT01456169,Italy,,,,,,,,,,,,,,
country,NCT01456169::country::Slovakia,NCT01456169,Slovakia,,,,,,,,,,,,,,
country,NCT01456169::country::Germany,NCT01456169,Germany,,,,,,,,,,,,,,
country,NCT01456169::country::Netherlands,NCT01456169,Netherlands,,,,,,,,,,,,,,
country,NCT01456169::country::Hungary,NCT01456169,Hungary,,,,,,,,,,,,,,
country,NCT01456169::country::Bulgaria,NCT01456169,Bulgaria,,,,,,,,,,,,,,
country,NCT01456169::country::United Kingdom,NCT01456169,United Kingdom,,,,,,,,,,,,,,
country,NCT01456169::country::France,NCT01456169,France,,,,,,,,,,,,,,
country,NCT01456169::country::Serbia,NCT01456169,Serbia,,,,,,,,,,,,,,
country,NCT01456169::country::Estonia,NCT01456169,Estonia,,,,,,,,,,,,,,
country,NCT01456169::country::Spain,NCT01456169,Spain,,,,,,,,,,,,,,
country,NCT01456169::country::Sweden,NCT01456169,Sweden,,,,,,,,,,,,,,
country,NCT01456169::country::Lithuania,NCT01456169,Lithuania,,,,,,,,,,,,,,
trial,NCT04915729,NCT04915729,A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity,PHASE3,cardiovascular disease,Stroke,INDUSTRY,1489.0,2021-06-22,2023-10-08,1.0,55.0,,,,,
arm,NCT04915729::arm::FG000,NCT04915729,Tenecteplase Treatment Group,,,,,,,,,,FG000,"Chinese patients with AIS were screened (visit 1) and randomised (visit 2a) when admitted. Patients received a single dose of tenecteplase, 0.25 mg/kg via intravenous (iv) bolus no later than 4.5 hour",,,
arm,NCT04915729::arm::FG001,NCT04915729,Alteplase Active Control Group,,,,,,,,,,FG001,"Chinese patients with AIS were screened (visit 1) and randomised (visit 2a) when admitted. Patients received a single dose of alteplase, 0.9 mg/kg, 10% via intravenous (iv) bolus and the remaining 90%",,,
period,NCT04915729::period::1,NCT04915729,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04915729::outcome::primary::1,NCT04915729,Percentage of Participants With Modified Rankin Scale (mRS) Score of 0 or 1,,,,,,,,,,,,,PRIMARY,At Day 90±7 days
country,NCT04915729::country::China,NCT04915729,China,,,,,,,,,,,,,,
trial,NCT00105027,NCT00105027,The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study,PHASE3,cardiovascular disease,"Macular Edema, Cystoid; Retinal Vein Occlusion",INDUSTRY,682.0,2004-10,2009-02,1.0,1.0,,,,,
arm,NCT00105027::arm::FG000,NCT00105027,CRVO Observation,,,,,,,,,,FG000,Standard care consists of observation of the macular edema.,,,
arm,NCT00105027::arm::FG001,NCT00105027,CRVO 1 mg Dose Triamcinolone Acetonide,,,,,,,,,,FG001,"Treatment administered at baseline. At each 4-month visit during follow-up, the investigator assessed whether persistent or recurrent macular edema was present that warranted retreatment with the 1 mg",,,
arm,NCT00105027::arm::FG002,NCT00105027,CRVO 4 mg Dose Triamcinolone Acetonide,,,,,,,,,,FG002,"Treatment administered at baseline. At each 4-month visit during follow-up, the investigator assessed whether persistent or recurrent macular edema was present that warranted retreatment with the 4 mg",,,
arm,NCT00105027::arm::FG003,NCT00105027,BRVO Standard Care,,,,,,,,,,FG003,Standard care was observation followed by grid laser photocoagulation if and when clearing of the hemorrhage permits grid laser photocoagulation. For study eyes of BRVO participants without a dense ma,,,
arm,NCT00105027::arm::FG004,NCT00105027,BRVO 1 mg Dose Triamcinolone Acetonide,,,,,,,,,,FG004,"Treatment administered at baseline. At each 4-month visit during follow-up, the investigator assessed whether persistent or recurrent macular edema was present that warranted retreatment with the 1 mg",,,
arm,NCT00105027::arm::FG005,NCT00105027,BRVO 4 mg Dose Triamcinolone Acetonide,,,,,,,,,,FG005,"Treatment administered at baseline. At each 4-month visit during follow-up, the investigator assessed whether persistent or recurrent macular edema was present that warranted retreatment with the 4 mg",,,
period,NCT00105027::period::1,NCT00105027,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00105027::outcome::primary::1,NCT00105027,The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit,,,,,,,,,,,,,PRIMARY,Change from baseline to 12 months
country,NCT00105027::country::United States,NCT00105027,United States,,,,,,,,,,,,,,
trial,NCT00368836,NCT00368836,Breath Analysis Technique to Diagnose Pulmonary Embolism,PHASE3,cardiovascular disease,Pulmonary Embolism,OTHER,475.0,2006-01,2008-06,1.0,1.0,,,,,
arm,NCT00368836::arm::FG000,NCT00368836,BreathScreen PE,,,,,,,,,,FG000,BreathScreen PE and D-Dimer collected on subjects scheduled for elective surgery,,,
period,NCT00368836::period::1,NCT00368836,Phase II,,,,,,,,,,,,1.0,,
period,NCT00368836::period::2,NCT00368836,Phase I Pre-op/Post-op,,,,,,,,,,,,2.0,,
outcome,NCT00368836::outcome::primary::1,NCT00368836,Phase I: Percentage Change in the Postoperative End Tidal CO2/O2 Ratio and D-dimer Concentration Relative to the Preoperative Measurement,,,,,,,,,,,,,PRIMARY,Pre-op measurement: the morning of surgery. Post-op measurement: the latter of postoperative day 3 or hospital discharge
outcome,NCT00368836::outcome::primary::2,NCT00368836,Phase II: Probability of Pulmonary Embolism Diagnosis by D-dimer Alone vs. D-Dimer Plus CO2/O2 for Pulmonary Embolism Diagnosed by CT Scan.,,,,,,,,,,,,,PRIMARY,Measured at 45 days
country,NCT00368836::country::United States,NCT00368836,United States,,,,,,,,,,,,,,
trial,NCT00081731,NCT00081731,Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions,PHASE3,cardiovascular disease,"Atherosclerosis; Cardiovascular Diseases; Hypertension, Renovascular; Renal Artery Obstruction",OTHER,947.0,2004-04,2013-09,1.0,1.0,,,,,
arm,NCT00081731::arm::FG000,NCT00081731,Optimal Medical Therapy,,,,,,,,,,FG000,"Optimal anti-hypertensive therapy

Atacand/HCT, Caduet: Atacand/HCT and caduet or optimal medical therapy for hypertension",,,
arm,NCT00081731::arm::FG001,NCT00081731,Stenting,,,,,,,,,,FG001,"Stent procedure plus optimal anti-hypertensive therapy

GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting): Angioplasty plus stenting of the renal artery GENESISTM Em",,,
period,NCT00081731::period::1,NCT00081731,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00081731::outcome::primary::1,NCT00081731,"Composite Endpoint: Death From Cardiovascular or Renal Causes, Stroke, Myocardial Infarction, Hospitalization for CHF, Progressive Renal Insufficiency, or Permanent Renal Replacement Therapy",,,,,,,,,,,,,PRIMARY,Measured at every 3 months for the first year and annually thereafter
outcome,NCT00081731::outcome::primary::2,NCT00081731,Cardiovascular or Renal Death,,,,,,,,,,,,,PRIMARY,Measured at every 3 months for the first year and annually thereafter
outcome,NCT00081731::outcome::primary::3,NCT00081731,Myocardial Infarction,,,,,,,,,,,,,PRIMARY,Measured at every 3 months for the first year and annually thereafter
outcome,NCT00081731::outcome::primary::4,NCT00081731,Hospitalization for Congestive Heart Failure,,,,,,,,,,,,,PRIMARY,Measured at every 3 months for the first year and annually thereafter
outcome,NCT00081731::outcome::primary::5,NCT00081731,Stroke,,,,,,,,,,,,,PRIMARY,Measured at every 3 months for the first year and annually thereafter
outcome,NCT00081731::outcome::primary::6,NCT00081731,"30% Reduction of eGFR From Baseline, Persisting for Greater Than or Equal to 60 Days",,,,,,,,,,,,,PRIMARY,Measured at every 3 months for the first year and annually thereafter
outcome,NCT00081731::outcome::primary::7,NCT00081731,Need for Renal Replacement Therapy,,,,,,,,,,,,,PRIMARY,Measured at every 3 months for the first year and annually thereafter
country,NCT00081731::country::United States,NCT00081731,United States,,,,,,,,,,,,,,
trial,NCT00550953,NCT00550953,Filtered Trial for Telmisartan 40mg Non-responder,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,314.0,2007-10,,1.0,5.0,,,,,
arm,NCT00550953::arm::FG000,NCT00550953,Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination,,,,,,,,,,FG000,"T40/A5 tablet, oral, once daily in the morning",,,
arm,NCT00550953::arm::FG001,NCT00550953,Telmisartan 40 mg Monotherapy,,,,,,,,,,FG001,"A5 capsule, oral, once daily in the morning",,,
period,NCT00550953::period::1,NCT00550953,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00550953::outcome::primary::1,NCT00550953,Decrease in Seated Diastolic Blood Pressure From Baseline to 8 Weeks,,,,,,,,,,,,,PRIMARY,Baseline and 8 Weeks
country,NCT00550953::country::Japan,NCT00550953,Japan,,,,,,,,,,,,,,
trial,NCT02525939,NCT02525939,Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS,PHASE3,cardiovascular disease,Acute Coronary Syndrome,INDUSTRY,6147.0,2016-04,2021-10,32.0,557.0,,,,,
arm,NCT02525939::arm::FG000,NCT02525939,Dalcetrapib,,,,,,,,,,FG000,"Participants received dalcetrapib 600 mg (two 300 mg tablets) orally once daily.

dalcetrapib: Cholesterol Ester Transfer Protein inhibitor, 300 mg tablets",,,
arm,NCT02525939::arm::FG001,NCT02525939,Placebo,,,,,,,,,,FG001,"Participants received dalcetrapib placebo tablets matching dalcetrapib orally once daily.

Placebo: dalcetrapib matching placebo tablets",,,
period,NCT02525939::period::1,NCT02525939,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02525939::outcome::primary::1,NCT02525939,"Composite of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, and Non-Fatal Stroke",,,,,,,,,,,,,PRIMARY,From randomization to the first occurrence of any component of the composite primary endpoint (median duration of follow-up was 39.9 months)
country,NCT02525939::country::United States,NCT02525939,United States,,,,,,,,,,,,,,
country,NCT02525939::country::United Kingdom,NCT02525939,United Kingdom,,,,,,,,,,,,,,
country,NCT02525939::country::Canada,NCT02525939,Canada,,,,,,,,,,,,,,
country,NCT02525939::country::Argentina,NCT02525939,Argentina,,,,,,,,,,,,,,
country,NCT02525939::country::Netherlands,NCT02525939,Netherlands,,,,,,,,,,,,,,
country,NCT02525939::country::Australia,NCT02525939,Australia,,,,,,,,,,,,,,
country,NCT02525939::country::Brazil,NCT02525939,Brazil,,,,,,,,,,,,,,
country,NCT02525939::country::Italy,NCT02525939,Italy,,,,,,,,,,,,,,
country,NCT02525939::country::Poland,NCT02525939,Poland,,,,,,,,,,,,,,
country,NCT02525939::country::Russia,NCT02525939,Russia,,,,,,,,,,,,,,
country,NCT02525939::country::Israel,NCT02525939,Israel,,,,,,,,,,,,,,
country,NCT02525939::country::Czechia,NCT02525939,Czechia,,,,,,,,,,,,,,
country,NCT02525939::country::France,NCT02525939,France,,,,,,,,,,,,,,
country,NCT02525939::country::Germany,NCT02525939,Germany,,,,,,,,,,,,,,
country,NCT02525939::country::Spain,NCT02525939,Spain,,,,,,,,,,,,,,
country,NCT02525939::country::Hungary,NCT02525939,Hungary,,,,,,,,,,,,,,
country,NCT02525939::country::New Zealand,NCT02525939,New Zealand,,,,,,,,,,,,,,
country,NCT02525939::country::Romania,NCT02525939,Romania,,,,,,,,,,,,,,
country,NCT02525939::country::Belgium,NCT02525939,Belgium,,,,,,,,,,,,,,
country,NCT02525939::country::Bulgaria,NCT02525939,Bulgaria,,,,,,,,,,,,,,
country,NCT02525939::country::Denmark,NCT02525939,Denmark,,,,,,,,,,,,,,
country,NCT02525939::country::South Africa,NCT02525939,South Africa,,,,,,,,,,,,,,
country,NCT02525939::country::Sweden,NCT02525939,Sweden,,,,,,,,,,,,,,
country,NCT02525939::country::Turkey (Türkiye),NCT02525939,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02525939::country::Portugal,NCT02525939,Portugal,,,,,,,,,,,,,,
country,NCT02525939::country::Austria,NCT02525939,Austria,,,,,,,,,,,,,,
country,NCT02525939::country::Slovakia,NCT02525939,Slovakia,,,,,,,,,,,,,,
country,NCT02525939::country::Finland,NCT02525939,Finland,,,,,,,,,,,,,,
country,NCT02525939::country::Chile,NCT02525939,Chile,,,,,,,,,,,,,,
country,NCT02525939::country::Puerto Rico,NCT02525939,Puerto Rico,,,,,,,,,,,,,,
country,NCT02525939::country::Switzerland,NCT02525939,Switzerland,,,,,,,,,,,,,,
country,NCT02525939::country::United Arab Emirates,NCT02525939,United Arab Emirates,,,,,,,,,,,,,,
trial,NCT02881957,NCT02881957,Hypovitaminosis D in Neurocritical Patients,PHASE3,cardiovascular disease,Craniocerebral Trauma; Intracranial Aneurysm; Brain Neoplasms; Spinal Cord Injuries; Seizures; Meningitis; Stroke; Intracranial Hemorrhages; Critical Illness; Vitamin d Deficiency,OTHER,274.0,2016-10-10,2018-10-10,1.0,1.0,,,,,
arm,NCT02881957::arm::FG000,NCT02881957,Placebo,,,,,,,,,,FG000,"Placebo control (simple oral syrup)

Placebo: Oral syrup placebo",,,
arm,NCT02881957::arm::FG001,NCT02881957,Vitamin D3,,,,,,,,,,FG001,"Cholecalciferol/Vitamin D3 (540,000 IU orally or by feeding tube once)

Cholecalciferol",,,
period,NCT02881957::period::1,NCT02881957,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02881957::outcome::primary::1,NCT02881957,Intent-to-treat Hospital Length-of-stay,,,,,,,,,,,,,PRIMARY,Until discharge
outcome,NCT02881957::outcome::primary::2,NCT02881957,As-treated Hospital Length of Stay,,,,,,,,,,,,,PRIMARY,Until discharge
country,NCT02881957::country::United States,NCT02881957,United States,,,,,,,,,,,,,,
trial,NCT00910429,NCT00910429,BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension,PHASE3,cardiovascular disease,Pulmonary Hypertension,INDUSTRY,237.0,2009-07-01,2019-08-19,26.0,73.0,,,,,
arm,NCT00910429::arm::FG000,NCT00910429,Riociguat-Former Riociguat 1.0-2.5 mg,,,,,,,,,,FG000,Participants were from the former riociguat (BAY 63-2521) treatment group of CHEST-1 on the same dose as they received on the last day of CHEST-1.,,,
arm,NCT00910429::arm::FG001,NCT00910429,Riociguat-Former Placebo,,,,,,,,,,FG001,Participants were from the former placebo group of CHEST-1. The starting dose in CHEST-2 was 1.0 mg riociguat three times one day.,,,
period,NCT00910429::period::1,NCT00910429,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00910429::outcome::primary::1,NCT00910429,Number of Participants With Treatment-emergent Adverse Events (TEAE),,,,,,,,,,,,,PRIMARY,"From administration of first dose of study medication up to 2 days after end of treatment with study medication, up to 10 years"
outcome,NCT00910429::outcome::primary::2,NCT00910429,Number of Participants With Death,,,,,,,,,,,,,PRIMARY,"From baseline to end of safety follow-up visit, up to 10 years (1 month more than End of study visit)"
country,NCT00910429::country::Japan,NCT00910429,Japan,,,,,,,,,,,,,,
country,NCT00910429::country::Germany,NCT00910429,Germany,,,,,,,,,,,,,,
country,NCT00910429::country::United States,NCT00910429,United States,,,,,,,,,,,,,,
country,NCT00910429::country::Canada,NCT00910429,Canada,,,,,,,,,,,,,,
country,NCT00910429::country::France,NCT00910429,France,,,,,,,,,,,,,,
country,NCT00910429::country::Brazil,NCT00910429,Brazil,,,,,,,,,,,,,,
country,NCT00910429::country::China,NCT00910429,China,,,,,,,,,,,,,,
country,NCT00910429::country::Mexico,NCT00910429,Mexico,,,,,,,,,,,,,,
country,NCT00910429::country::Turkey (Türkiye),NCT00910429,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00910429::country::Belgium,NCT00910429,Belgium,,,,,,,,,,,,,,
country,NCT00910429::country::Poland,NCT00910429,Poland,,,,,,,,,,,,,,
country,NCT00910429::country::Portugal,NCT00910429,Portugal,,,,,,,,,,,,,,
country,NCT00910429::country::Russia,NCT00910429,Russia,,,,,,,,,,,,,,
country,NCT00910429::country::South Korea,NCT00910429,South Korea,,,,,,,,,,,,,,
country,NCT00910429::country::United Kingdom,NCT00910429,United Kingdom,,,,,,,,,,,,,,
country,NCT00910429::country::Argentina,NCT00910429,Argentina,,,,,,,,,,,,,,
country,NCT00910429::country::Australia,NCT00910429,Australia,,,,,,,,,,,,,,
country,NCT00910429::country::Austria,NCT00910429,Austria,,,,,,,,,,,,,,
country,NCT00910429::country::Czechia,NCT00910429,Czechia,,,,,,,,,,,,,,
country,NCT00910429::country::Denmark,NCT00910429,Denmark,,,,,,,,,,,,,,
country,NCT00910429::country::Israel,NCT00910429,Israel,,,,,,,,,,,,,,
country,NCT00910429::country::Italy,NCT00910429,Italy,,,,,,,,,,,,,,
country,NCT00910429::country::Slovakia,NCT00910429,Slovakia,,,,,,,,,,,,,,
country,NCT00910429::country::Spain,NCT00910429,Spain,,,,,,,,,,,,,,
country,NCT00910429::country::Switzerland,NCT00910429,Switzerland,,,,,,,,,,,,,,
country,NCT00910429::country::Taiwan,NCT00910429,Taiwan,,,,,,,,,,,,,,
trial,NCT00249795,NCT00249795,Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I),PHASE3,cardiovascular disease,Atrial Fibrillation; Cardiovascular Disease,INDUSTRY,9016.0,2003-06,2009-08,30.0,30.0,,,,,
arm,NCT00249795::arm::FG000,NCT00249795,Irbesartan,,,,,,,,,,FG000,"150 mg for 2 weeks, then uptitrated to 300 mg up to final follow-up visit",,,
arm,NCT00249795::arm::FG001,NCT00249795,Placebo,,,,,,,,,,FG001,matching placebo up to final follow-up visit,,,
period,NCT00249795::period::1,NCT00249795,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00249795::outcome::primary::1,NCT00249795,"First Occurence of Any Component of the Composite of Myocardial Infarction, Stroke or Vascular Death as Per Adjudication",,,,,,,,,,,,,PRIMARY,Median follow-up of 4.5 years
outcome,NCT00249795::outcome::primary::2,NCT00249795,"First Occurence of Any Component of the Composite of Myocardial Infarction, Stroke, Vascular Death or Hospitalization for Heart Failure as Per Adjudication",,,,,,,,,,,,,PRIMARY,Median follow-up of 4.5 years
country,NCT00249795::country::United States,NCT00249795,United States,,,,,,,,,,,,,,
country,NCT00249795::country::Argentina,NCT00249795,Argentina,,,,,,,,,,,,,,
country,NCT00249795::country::Australia,NCT00249795,Australia,,,,,,,,,,,,,,
country,NCT00249795::country::Austria,NCT00249795,Austria,,,,,,,,,,,,,,
country,NCT00249795::country::Belgium,NCT00249795,Belgium,,,,,,,,,,,,,,
country,NCT00249795::country::Brazil,NCT00249795,Brazil,,,,,,,,,,,,,,
country,NCT00249795::country::Canada,NCT00249795,Canada,,,,,,,,,,,,,,
country,NCT00249795::country::Chile,NCT00249795,Chile,,,,,,,,,,,,,,
country,NCT00249795::country::Czechia,NCT00249795,Czechia,,,,,,,,,,,,,,
country,NCT00249795::country::Denmark,NCT00249795,Denmark,,,,,,,,,,,,,,
country,NCT00249795::country::Finland,NCT00249795,Finland,,,,,,,,,,,,,,
country,NCT00249795::country::France,NCT00249795,France,,,,,,,,,,,,,,
country,NCT00249795::country::Germany,NCT00249795,Germany,,,,,,,,,,,,,,
country,NCT00249795::country::Greece,NCT00249795,Greece,,,,,,,,,,,,,,
country,NCT00249795::country::Hong Kong,NCT00249795,Hong Kong,,,,,,,,,,,,,,
country,NCT00249795::country::Hungary,NCT00249795,Hungary,,,,,,,,,,,,,,
country,NCT00249795::country::Italy,NCT00249795,Italy,,,,,,,,,,,,,,
country,NCT00249795::country::Malaysia,NCT00249795,Malaysia,,,,,,,,,,,,,,
country,NCT00249795::country::Mexico,NCT00249795,Mexico,,,,,,,,,,,,,,
country,NCT00249795::country::Netherlands,NCT00249795,Netherlands,,,,,,,,,,,,,,
country,NCT00249795::country::Norway,NCT00249795,Norway,,,,,,,,,,,,,,
country,NCT00249795::country::Poland,NCT00249795,Poland,,,,,,,,,,,,,,
country,NCT00249795::country::Portugal,NCT00249795,Portugal,,,,,,,,,,,,,,
country,NCT00249795::country::Singapore,NCT00249795,Singapore,,,,,,,,,,,,,,
country,NCT00249795::country::South Africa,NCT00249795,South Africa,,,,,,,,,,,,,,
country,NCT00249795::country::Spain,NCT00249795,Spain,,,,,,,,,,,,,,
country,NCT00249795::country::Sweden,NCT00249795,Sweden,,,,,,,,,,,,,,
country,NCT00249795::country::Switzerland,NCT00249795,Switzerland,,,,,,,,,,,,,,
country,NCT00249795::country::Taiwan,NCT00249795,Taiwan,,,,,,,,,,,,,,
country,NCT00249795::country::United Kingdom,NCT00249795,United Kingdom,,,,,,,,,,,,,,
trial,NCT00000479,NCT00000479,Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer,PHASE3,cardiovascular disease,Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Heart Diseases; Myocardial Infarction; Myocardial Ischemia; Vascular Diseases,OTHER,39876.0,1992-09,2005-02,0.0,0.0,,,,,
arm,NCT00000479::arm::FG000,NCT00000479,Aspirin Only,,,,,,,,,,FG000,Aspirin(100 mg every other day)and placebo vitamin E,,,
arm,NCT00000479::arm::FG001,NCT00000479,Vitamin E Only,,,,,,,,,,FG001,Placebo aspirin and vitamin E (600 IU every other day,,,
arm,NCT00000479::arm::FG002,NCT00000479,Aspirin + Vitamin E,,,,,,,,,,FG002,Aspirin (100 mg every other day) and vitamin E (600 IU every other day),,,
arm,NCT00000479::arm::FG003,NCT00000479,Both Placebos,,,,,,,,,,FG003,Placebo aspirin and placebo vitamin E,,,
period,NCT00000479::period::1,NCT00000479,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00000479::outcome::primary::1,NCT00000479,"Number of Participants With Major Cardiovascular Events (a Combined Endpoint of Nonfatal Myocardial Infarction, Nonfatal Stroke, and Total Cardiovascular Death)",,,,,,,,,,,,,PRIMARY,Average follow-up 10.1 years
outcome,NCT00000479::outcome::primary::2,NCT00000479,"Number of Participants With Cancer, Excluding Nonmelanoma Skin Cancer",,,,,,,,,,,,,PRIMARY,Average follow-up 10.1 years
trial,NCT01508910,NCT01508910,Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina,PHASE3,cardiovascular disease,Chronic Myocardial Ischemia; Refractory Angina Pectoris; Advanced Coronary Heart Disease,INDUSTRY,291.0,2012-04,2015-11,1.0,41.0,,,,,
arm,NCT01508910::arm::FG000,NCT01508910,Treatment Arm,,,,,,,,,,FG000,Targeted intramyocardial delivery of 1 x 10\^5 Auto-CD34+ cells after granulocyte-colony stimulating factor (G-CSF) mobilization and apheresis.,,,
arm,NCT01508910::arm::FG001,NCT01508910,Active Control Arm,,,,,,,,,,FG001,Targeted intramyocardial delivery of placebo after granulocyte-colony stimulating factor (G-CSF) mobilization and apheresis.,,,
arm,NCT01508910::arm::FG002,NCT01508910,Unblinded Standard of Care (SOC) Arm,,,,,,,,,,FG002,No study-related procedures were performed.,,,
arm,NCT01508910::arm::FG003,NCT01508910,Not Injected Arm,,,,,,,,,,FG003,"Participants randomized into the Treatment Arm or Active Control Arm who did not undergo targeted intramyocardial delivery of 1 x 10\^5 Auto-CD34+ cells or placebo, respectively.",,,
period,NCT01508910::period::1,NCT01508910,Randomization,,,,,,,,,,,,1.0,,
period,NCT01508910::period::2,NCT01508910,Treatment,,,,,,,,,,,,2.0,,
outcome,NCT01508910::outcome::primary::1,NCT01508910,Change From Baseline in Total Exercise Time on Exercise Tolerance Test (ETT) Using the Modified Bruce Protocol,,,,,,,,,,,,,PRIMARY,Baseline and 12 month visit
country,NCT01508910::country::United States,NCT01508910,United States,,,,,,,,,,,,,,
trial,NCT00830960,NCT00830960,A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome,PHASE3,cardiovascular disease,Acute Coronary Syndrome,INDUSTRY,720.0,2009-02,2010-06,4.0,19.0,,,,,
arm,NCT00830960::arm::FG000,NCT00830960,Prasugrel 60/10 Primary,,,,,,,,,,FG000,Population includes participants randomly assigned to receive prasugrel 60-mg loading dose (LD) followed by prasugrel 10-mg maintenance dose (MD) daily in the primary cohort (participant weight ≥60 kg,,,
arm,NCT00830960::arm::FG001,NCT00830960,Prasugrel 30/7.5 Primary,,,,,,,,,,FG001,Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 7.5-mg MD daily in the primary cohort (participant weight ≥60 kg and age \<75 years),,,
arm,NCT00830960::arm::FG002,NCT00830960,Prasugrel 30/5 Primary,,,,,,,,,,FG002,Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the primary cohort (participant weight ≥60 kg and age \<75 years),,,
arm,NCT00830960::arm::FG003,NCT00830960,Clopidogrel 300/75 Primary,,,,,,,,,,FG003,Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by prasugrel 75-mg MD daily in the primary cohort (participant weight ≥60 kg and age \<75 years),,,
arm,NCT00830960::arm::FG004,NCT00830960,Prasugrel 30/5 Low Weight/Elderly,,,,,,,,,,FG004,Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the Low Weight/Elderly cohort (participant weight \<60 kg or age ≥75 years),,,
arm,NCT00830960::arm::FG005,NCT00830960,Clopidogrel 300/75 Low Weight/Elderly,,,,,,,,,,FG005,Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by prasugrel 75-mg MD daily in the Low Weight/Elderly cohort (participant weight \<60 kg or age ≥75 years),,,
period,NCT00830960::period::1,NCT00830960,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00830960::outcome::primary::1,NCT00830960,Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-mediated Platelet Aggregation (P2Y12 Reaction Units,,,,,,,,,,,,,PRIMARY,At 4 hours following LD administration
outcome,NCT00830960::outcome::primary::2,NCT00830960,PRU) Using the Accumetrics VerifyNow (VN) P2Y12 Assay at 4 Hours Post-Loading Dose (LD) in Primary Cohort (≥60 kg and <75 Years),,,,,,,,,,,,,PRIMARY,At 30 days during MD therapy
outcome,NCT00830960::outcome::primary::3,NCT00830960,Adenosine Diphosphate (ADP)-Induced P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNow (VN) P2Y12 Assay at 30 Days During Maintenance Dose (MD) Administration in Primary Cohort,,,,,,,,,,,,,PRIMARY,
country,NCT00830960::country::China,NCT00830960,China,,,,,,,,,,,,,,
country,NCT00830960::country::South Korea,NCT00830960,South Korea,,,,,,,,,,,,,,
country,NCT00830960::country::Taiwan,NCT00830960,Taiwan,,,,,,,,,,,,,,
country,NCT00830960::country::Thailand,NCT00830960,Thailand,,,,,,,,,,,,,,
trial,NCT00927862,NCT00927862,Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin,PHASE3,cardiovascular disease,Thromboembolism,OTHER,2415.0,2008-08,2011-06,1.0,1.0,,,,,
arm,NCT00927862::arm::FG000,NCT00927862,PG Dosing Patients,,,,,,,,,,FG000,"Patients who were enrolled in CoumaGen-II and thus, received their warfarin dosing by the PG-dosing algorithms were randomized to receive either standard or modified International Warfarin Pharmacogen",,,
arm,NCT00927862::arm::FG001,NCT00927862,Parellel/Historical Controls,,,,,,,,,,FG001,"A parallel, standard-dosing patient control cohort was identified by a query of the electronic medical records databases of the 3 participating hospitals for the time interval spanning enrollment of t",,,
period,NCT00927862::period::1,NCT00927862,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00927862::outcome::primary::1,NCT00927862,The Percent of Out of Range (OOR) International Normalized Prothrombin Time Ratio (INRs) in the Standard and Modified Pharmacogenetic Arms.,,,,,,,,,,,,,PRIMARY,1 month (from day 3 to day 30)
outcome,NCT00927862::outcome::primary::2,NCT00927862,The Percent of Out of Range (OOR) INRs in Pharmacogenetic-guided Patients and Parallel Controls,,,,,,,,,,,,,PRIMARY,1 month (from day 3 to day 30)
outcome,NCT00927862::outcome::primary::3,NCT00927862,The Percent of Time in Therapeutic Range (TTR) for the Standard and Modified Pharmacogenetic Algorithms.,,,,,,,,,,,,,PRIMARY,1 month (from baseline to day 30)
outcome,NCT00927862::outcome::primary::4,NCT00927862,The Time in Therapeutic Range (TTR) for the Pharmacogenetic-guided Patients and Parallel Controls,,,,,,,,,,,,,PRIMARY,1 month (from baseline to day 30)
country,NCT00927862::country::United States,NCT00927862,United States,,,,,,,,,,,,,,
trial,NCT01103960,NCT01103960,"An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy",PHASE3,cardiovascular disease,Hypertension,INDUSTRY,324.0,2010-07,,3.0,16.0,,,,,
arm,NCT01103960::arm::FG000,NCT01103960,A5 Alone,,,,,,,,,,FG000,Amlodipine 5mg monotherapy,,,
arm,NCT01103960::arm::FG001,NCT01103960,T80/A5,,,,,,,,,,FG001,Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination,,,
period,NCT01103960::period::1,NCT01103960,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01103960::outcome::primary::1,NCT01103960,Change From Baseline in DBP After 8 Weeks of Treatment,,,,,,,,,,,,,PRIMARY,Baseline and 8 weeks
outcome,NCT01103960::outcome::primary::2,NCT01103960,Change From Baseline in DBP After 8 Weeks of Treatment in Chinese Patients,,,,,,,,,,,,,PRIMARY,Baseline and 8 weeks
country,NCT01103960::country::China,NCT01103960,China,,,,,,,,,,,,,,
country,NCT01103960::country::Malaysia,NCT01103960,Malaysia,,,,,,,,,,,,,,
country,NCT01103960::country::Philippines,NCT01103960,Philippines,,,,,,,,,,,,,,
trial,NCT01225562,NCT01225562,"Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin",PHASE3,cardiovascular disease,Myocardial Infarction; Cardiovascular Death; Atherothrombosis; Stroke,INDUSTRY,21379.0,2010-10,2014-12,31.0,827.0,,,,,
arm,NCT01225562::arm::FG000,NCT01225562,Ticagrelor 90 mg,,,,,,,,,,FG000,Ticagrelor 90 mg twice daily (BD),,,
arm,NCT01225562::arm::FG001,NCT01225562,Ticagrelor 60 mg,,,,,,,,,,FG001,Ticagrelor 60 mg twice daily (BD),,,
arm,NCT01225562::arm::FG002,NCT01225562,Placebo,,,,,,,,,,FG002,Matching placebo,,,
period,NCT01225562::period::1,NCT01225562,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01225562::outcome::primary::1,NCT01225562,"Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death), Myocardial Infarction (MI) or Stroke Within 3 Years From Randomization",,,,,,,,,,,,,PRIMARY,Randomization up to 47 months
outcome,NCT01225562::outcome::primary::2,NCT01225562,Kaplan-Meier Estimate of the Percentage of Patients Who Experienced a TIMI Major Bleeding Within 3 Years From First Dose of Study Drug Units: Percentage of Patients,,,,,,,,,,,,,PRIMARY,First dosing up to 48 months
country,NCT01225562::country::United States,NCT01225562,United States,,,,,,,,,,,,,,
country,NCT01225562::country::Japan,NCT01225562,Japan,,,,,,,,,,,,,,
country,NCT01225562::country::Canada,NCT01225562,Canada,,,,,,,,,,,,,,
country,NCT01225562::country::Netherlands,NCT01225562,Netherlands,,,,,,,,,,,,,,
country,NCT01225562::country::Poland,NCT01225562,Poland,,,,,,,,,,,,,,
country,NCT01225562::country::Australia,NCT01225562,Australia,,,,,,,,,,,,,,
country,NCT01225562::country::Italy,NCT01225562,Italy,,,,,,,,,,,,,,
country,NCT01225562::country::Belgium,NCT01225562,Belgium,,,,,,,,,,,,,,
country,NCT01225562::country::Germany,NCT01225562,Germany,,,,,,,,,,,,,,
country,NCT01225562::country::France,NCT01225562,France,,,,,,,,,,,,,,
country,NCT01225562::country::United Kingdom,NCT01225562,United Kingdom,,,,,,,,,,,,,,
country,NCT01225562::country::Argentina,NCT01225562,Argentina,,,,,,,,,,,,,,
country,NCT01225562::country::Czechia,NCT01225562,Czechia,,,,,,,,,,,,,,
country,NCT01225562::country::Brazil,NCT01225562,Brazil,,,,,,,,,,,,,,
country,NCT01225562::country::Hungary,NCT01225562,Hungary,,,,,,,,,,,,,,
country,NCT01225562::country::Slovakia,NCT01225562,Slovakia,,,,,,,,,,,,,,
country,NCT01225562::country::Spain,NCT01225562,Spain,,,,,,,,,,,,,,
country,NCT01225562::country::Romania,NCT01225562,Romania,,,,,,,,,,,,,,
country,NCT01225562::country::South Africa,NCT01225562,South Africa,,,,,,,,,,,,,,
country,NCT01225562::country::China,NCT01225562,China,,,,,,,,,,,,,,
country,NCT01225562::country::Russia,NCT01225562,Russia,,,,,,,,,,,,,,
country,NCT01225562::country::Sweden,NCT01225562,Sweden,,,,,,,,,,,,,,
country,NCT01225562::country::South Korea,NCT01225562,South Korea,,,,,,,,,,,,,,
country,NCT01225562::country::Bulgaria,NCT01225562,Bulgaria,,,,,,,,,,,,,,
country,NCT01225562::country::Norway,NCT01225562,Norway,,,,,,,,,,,,,,
country,NCT01225562::country::Philippines,NCT01225562,Philippines,,,,,,,,,,,,,,
country,NCT01225562::country::Colombia,NCT01225562,Colombia,,,,,,,,,,,,,,
country,NCT01225562::country::Ukraine,NCT01225562,Ukraine,,,,,,,,,,,,,,
country,NCT01225562::country::Chile,NCT01225562,Chile,,,,,,,,,,,,,,
country,NCT01225562::country::Turkey (Türkiye),NCT01225562,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01225562::country::Peru,NCT01225562,Peru,,,,,,,,,,,,,,
trial,NCT01535261,NCT01535261,Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion,PHASE3,cardiovascular disease,Macular Edema; Central Retinal Vein Occlusion,INDUSTRY,357.0,2012-02,2015-03,18.0,78.0,,,,,
arm,NCT01535261::arm::FG000,NCT01535261,Ranibizumab Arm,,,,,,,,,,FG000,Intravitreal injection with standard dose of 0.5 mg/0.05mL PRN,,,
period,NCT01535261::period::1,NCT01535261,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01535261::outcome::primary::1,NCT01535261,Mean Change in Best Corrected Visual Acuity (BCVA) at Month 12 Compared to Baseline,,,,,,,,,,,,,PRIMARY,Baseline to month 12
country,NCT01535261::country::United Kingdom,NCT01535261,United Kingdom,,,,,,,,,,,,,,
country,NCT01535261::country::Spain,NCT01535261,Spain,,,,,,,,,,,,,,
country,NCT01535261::country::Italy,NCT01535261,Italy,,,,,,,,,,,,,,
country,NCT01535261::country::Canada,NCT01535261,Canada,,,,,,,,,,,,,,
country,NCT01535261::country::Greece,NCT01535261,Greece,,,,,,,,,,,,,,
country,NCT01535261::country::Poland,NCT01535261,Poland,,,,,,,,,,,,,,
country,NCT01535261::country::Portugal,NCT01535261,Portugal,,,,,,,,,,,,,,
country,NCT01535261::country::Netherlands,NCT01535261,Netherlands,,,,,,,,,,,,,,
country,NCT01535261::country::Australia,NCT01535261,Australia,,,,,,,,,,,,,,
country,NCT01535261::country::Hungary,NCT01535261,Hungary,,,,,,,,,,,,,,
country,NCT01535261::country::Slovakia,NCT01535261,Slovakia,,,,,,,,,,,,,,
country,NCT01535261::country::Switzerland,NCT01535261,Switzerland,,,,,,,,,,,,,,
country,NCT01535261::country::Austria,NCT01535261,Austria,,,,,,,,,,,,,,
country,NCT01535261::country::Czechia,NCT01535261,Czechia,,,,,,,,,,,,,,
country,NCT01535261::country::Ireland,NCT01535261,Ireland,,,,,,,,,,,,,,
country,NCT01535261::country::Denmark,NCT01535261,Denmark,,,,,,,,,,,,,,
country,NCT01535261::country::Sweden,NCT01535261,Sweden,,,,,,,,,,,,,,
country,NCT01535261::country::Turkey (Türkiye),NCT01535261,Turkey (Türkiye),,,,,,,,,,,,,,
trial,NCT02513303,NCT02513303,Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes,PHASE3,cardiovascular disease,Complication of Renal Dialysis; End Stage Renal Disease; End Stage Kidney Disease; ESRD; Chronic Kidney Failure; Complication of Hemodialysis; Vascular Access Complication; Arteriovenous Fistula,INDUSTRY,269.0,2015-11,2021-06,1.0,4.0,,,,,
arm,NCT02513303::arm::FG000,NCT02513303,Sirogen,,,,,,,,,,FG000,Participants received single administration of Sirolimus-eluting Collagen Implant (Sirogen) at the time of AV fistula surgery,,,
arm,NCT02513303::arm::FG001,NCT02513303,Control,,,,,,,,,,FG001,Participants underwent AV fistula surgery without an implant,,,
arm,NCT02513303::arm::FG002,NCT02513303,Run-in,,,,,,,,,,FG002,Participants received single administration of Sirolimus-eluting Collagen Implant (Sirogen) at the time of AV fistula surgery. The first subject enrolled by a participating surgeon was a run-in subjec,,,
period,NCT02513303::period::1,NCT02513303,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02513303::outcome::primary::1,NCT02513303,Fistula Suitability for Dialysis at 6 Months (FSD6),,,,,,,,,,,,,PRIMARY,6 months
country,NCT02513303::country::United States,NCT02513303,United States,,,,,,,,,,,,,,
trial,NCT01560624,NCT01560624,Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy,PHASE3,cardiovascular disease,Pulmonary Arterial Hypertension,INDUSTRY,690.0,2012-06-26,2018-06-24,23.0,155.0,,,,,
arm,NCT01560624::arm::FG000,NCT01560624,UT-15C,,,,,,,,,,FG000,"Treprostinil diolamine extended-release tablets (oral) 0.125 to 12 mg three times daily (TID)

Treprostinil Diolamine: Active",,,
arm,NCT01560624::arm::FG001,NCT01560624,Placebo,,,,,,,,,,FG001,"Matching placebo tablets (oral)

Placebo: Placebo",,,
period,NCT01560624::period::1,NCT01560624,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01560624::outcome::primary::1,NCT01560624,Time to First Clinical Worsening Event,,,,,,,,,,,,,PRIMARY,From randomization to approximately 4 years
country,NCT01560624::country::United States,NCT01560624,United States,,,,,,,,,,,,,,
country,NCT01560624::country::China,NCT01560624,China,,,,,,,,,,,,,,
country,NCT01560624::country::Germany,NCT01560624,Germany,,,,,,,,,,,,,,
country,NCT01560624::country::India,NCT01560624,India,,,,,,,,,,,,,,
country,NCT01560624::country::Australia,NCT01560624,Australia,,,,,,,,,,,,,,
country,NCT01560624::country::Brazil,NCT01560624,Brazil,,,,,,,,,,,,,,
country,NCT01560624::country::France,NCT01560624,France,,,,,,,,,,,,,,
country,NCT01560624::country::Argentina,NCT01560624,Argentina,,,,,,,,,,,,,,
country,NCT01560624::country::Israel,NCT01560624,Israel,,,,,,,,,,,,,,
country,NCT01560624::country::South Korea,NCT01560624,South Korea,,,,,,,,,,,,,,
country,NCT01560624::country::Canada,NCT01560624,Canada,,,,,,,,,,,,,,
country,NCT01560624::country::Italy,NCT01560624,Italy,,,,,,,,,,,,,,
country,NCT01560624::country::Poland,NCT01560624,Poland,,,,,,,,,,,,,,
country,NCT01560624::country::Taiwan,NCT01560624,Taiwan,,,,,,,,,,,,,,
country,NCT01560624::country::United Kingdom,NCT01560624,United Kingdom,,,,,,,,,,,,,,
country,NCT01560624::country::Austria,NCT01560624,Austria,,,,,,,,,,,,,,
country,NCT01560624::country::Chile,NCT01560624,Chile,,,,,,,,,,,,,,
country,NCT01560624::country::Denmark,NCT01560624,Denmark,,,,,,,,,,,,,,
country,NCT01560624::country::Greece,NCT01560624,Greece,,,,,,,,,,,,,,
country,NCT01560624::country::Mexico,NCT01560624,Mexico,,,,,,,,,,,,,,
country,NCT01560624::country::Netherlands,NCT01560624,Netherlands,,,,,,,,,,,,,,
country,NCT01560624::country::Singapore,NCT01560624,Singapore,,,,,,,,,,,,,,
country,NCT01560624::country::Sweden,NCT01560624,Sweden,,,,,,,,,,,,,,
trial,NCT00430508,NCT00430508,Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension,PHASE3,cardiovascular disease,Essential Hypertension,INDUSTRY,972.0,2007-02,2008-05,7.0,55.0,,,,,
arm,NCT00430508::arm::FG000,NCT00430508,OM/HCTZ 40/25mg + 20/12.5 Matching Placebo,,,,,,,,,,FG000,"olmesartan medoxomil/Hydrochlorothizaide 40/25mg tablets, once daily for 8 weeks",,,
arm,NCT00430508::arm::FG001,NCT00430508,OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo,,,,,,,,,,FG001,"olmesartan medoxomil/Hydrochlorothizaide 40/12.5mg tablets, once daily for 8 weeks",,,
arm,NCT00430508::arm::FG002,NCT00430508,OM/HCTZ 20/12.5mg + 40/0 Matching Placebo,,,,,,,,,,FG002,"olmesartan medoxomil/Hydrochlorothizaide 20/12.5mg tablets, once daily for 8 weeks",,,
arm,NCT00430508::arm::FG003,NCT00430508,OM/HCTZ 40/0mg + 20/12.5 Matching Placebo,,,,,,,,,,FG003,"olmesartan medoxomil/Hydrochlorothizaide 40/0mg tablets, once daily for 8 weeks",,,
period,NCT00430508::period::1,NCT00430508,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00430508::outcome::primary::1,NCT00430508,Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 16,,,,,,,,,,,,,PRIMARY,"8 weeks, change = week 16 - week 8"
country,NCT00430508::country::Czechia,NCT00430508,Czechia,,,,,,,,,,,,,,
country,NCT00430508::country::Poland,NCT00430508,Poland,,,,,,,,,,,,,,
country,NCT00430508::country::Germany,NCT00430508,Germany,,,,,,,,,,,,,,
country,NCT00430508::country::Ukraine,NCT00430508,Ukraine,,,,,,,,,,,,,,
country,NCT00430508::country::Spain,NCT00430508,Spain,,,,,,,,,,,,,,
country,NCT00430508::country::France,NCT00430508,France,,,,,,,,,,,,,,
country,NCT00430508::country::Bulgaria,NCT00430508,Bulgaria,,,,,,,,,,,,,,
trial,NCT00311402,NCT00311402,JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme,PHASE3,cardiovascular disease,Cerebrovascular Accident,INDUSTRY,1295.0,2006-04,,1.0,151.0,,,,,
arm,NCT00311402::arm::FG000,NCT00311402,Aggrenox Capsule,,,,,,,,,,FG000,"Aggrenox (extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule), 2 capsules twice daily",,,
arm,NCT00311402::arm::FG001,NCT00311402,Acetylsalicylic Acid (ASA) 81 mg Tablet,,,,,,,,,,FG001,"ASA 81 mg, 1 tablet once daily",,,
period,NCT00311402::period::1,NCT00311402,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00311402::outcome::primary::1,NCT00311402,Number of Patients With First Recurrent Cerebral Infarction (Fatal or Non-fatal),,,,,,,,,,,,,PRIMARY,Up to 124 weeks
country,NCT00311402::country::Japan,NCT00311402,Japan,,,,,,,,,,,,,,
trial,NCT01396057,NCT01396057,Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO),PHASE3,cardiovascular disease,Visual Impairment; Macular Edema; Branch Retinal Vein Occlusion,INDUSTRY,244.0,2011-07,2013-06,5.0,66.0,,,,,
arm,NCT01396057::arm::FG000,NCT01396057,Ranibizumab,,,,,,,,,,FG000,Injections consisted of 0.5 mg/0.05 ml solution to be injected intravitreally,,,
arm,NCT01396057::arm::FG001,NCT01396057,Dexamethasone,,,,,,,,,,FG001,Intravitreal implant as per commercial label (700 μg Dexamethasone; long acting release (LAR) over 6 months,,,
period,NCT01396057::period::1,NCT01396057,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01396057::outcome::primary::1,NCT01396057,Mean Average Best Corrected Visual Acuity (BCVA) Change From Month 1 Through Month 6 to Baseline,,,,,,,,,,,,,PRIMARY,"Baseline, month 6"
country,NCT01396057::country::Germany,NCT01396057,Germany,,,,,,,,,,,,,,
country,NCT01396057::country::United Kingdom,NCT01396057,United Kingdom,,,,,,,,,,,,,,
country,NCT01396057::country::Hungary,NCT01396057,Hungary,,,,,,,,,,,,,,
country,NCT01396057::country::Poland,NCT01396057,Poland,,,,,,,,,,,,,,
country,NCT01396057::country::Czechia,NCT01396057,Czechia,,,,,,,,,,,,,,
trial,NCT03087773,NCT03087773,Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction,PHASE3,cardiovascular disease,Acute Myocardial Infarction,OTHER,476.0,2017-05-11,2022-05-17,1.0,11.0,,,,,
arm,NCT03087773::arm::FG000,NCT03087773,Empagliflozin,,,,,,,,,,FG000,"The subjects will receive Empagliflozin 10mg.

Empagliflozin 10 mg: The subject will receive Empagliflozin 10 mg orally once daily for 26 weeks.",,,
arm,NCT03087773::arm::FG001,NCT03087773,Placebo Oral Tablet,,,,,,,,,,FG001,"The subjects will receive placebo.

Placebo Oral Tablet: The subject will receive Placebo orally once daily for 26 weeks.",,,
period,NCT03087773::period::1,NCT03087773,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03087773::outcome::primary::1,NCT03087773,Changes of Nt-proBNP (N-terminales Pro Brain Natriuretic Peptide) Levels,,,,,,,,,,,,,PRIMARY,26 weeks
country,NCT03087773::country::Austria,NCT03087773,Austria,,,,,,,,,,,,,,
trial,NCT01302392,NCT01302392,A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma,PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,315.0,2010-09,2015-09,19.0,68.0,,,,,
arm,NCT01302392::arm::FG000,NCT01302392,Best Supportive Care,,,,,,,,,,FG000,"Best Supportive Care: Corticosteroid (either prednisolone 30 mg orally (PO) every other day, dexamethasone 6 mg PO every other day, or other equivalent corticosteroid).

Optional cyclophosphamide 50 m",,,
arm,NCT01302392::arm::FG001,NCT01302392,Carfilzomib,,,,,,,,,,FG001,"Carfilzomib: 20mg/m² IV on Days 1 and 2 of Cycle 1, escalating to 27 mg/m² IV on Days 8,9,15,and 16 of Cycle 1 and continuing on Days 1,2,8,9,15,and 16 of Cycles 2 through Cycle 9. Cycles 10 and beyon",,,
period,NCT01302392::period::1,NCT01302392,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01302392::outcome::primary::1,NCT01302392,Overall Survival,,,,,,,,,,,,,PRIMARY,"From randomization through the final analysis data cutoff with longest follow-up time of approximately 45 months. Median follow up times were 27.8 months and 29.8 months for Carfilzomib and Best Supportive Care groups, respectively."
country,NCT01302392::country::Hungary,NCT01302392,Hungary,,,,,,,,,,,,,,
country,NCT01302392::country::Poland,NCT01302392,Poland,,,,,,,,,,,,,,
country,NCT01302392::country::Spain,NCT01302392,Spain,,,,,,,,,,,,,,
country,NCT01302392::country::Germany,NCT01302392,Germany,,,,,,,,,,,,,,
country,NCT01302392::country::Israel,NCT01302392,Israel,,,,,,,,,,,,,,
country,NCT01302392::country::Belgium,NCT01302392,Belgium,,,,,,,,,,,,,,
country,NCT01302392::country::Czechia,NCT01302392,Czechia,,,,,,,,,,,,,,
country,NCT01302392::country::Italy,NCT01302392,Italy,,,,,,,,,,,,,,
country,NCT01302392::country::United Kingdom,NCT01302392,United Kingdom,,,,,,,,,,,,,,
country,NCT01302392::country::Austria,NCT01302392,Austria,,,,,,,,,,,,,,
country,NCT01302392::country::France,NCT01302392,France,,,,,,,,,,,,,,
country,NCT01302392::country::Australia,NCT01302392,Australia,,,,,,,,,,,,,,
country,NCT01302392::country::Greece,NCT01302392,Greece,,,,,,,,,,,,,,
country,NCT01302392::country::Russia,NCT01302392,Russia,,,,,,,,,,,,,,
country,NCT01302392::country::Serbia,NCT01302392,Serbia,,,,,,,,,,,,,,
country,NCT01302392::country::South Korea,NCT01302392,South Korea,,,,,,,,,,,,,,
country,NCT01302392::country::New Zealand,NCT01302392,New Zealand,,,,,,,,,,,,,,
country,NCT01302392::country::Slovakia,NCT01302392,Slovakia,,,,,,,,,,,,,,
country,NCT01302392::country::Sweden,NCT01302392,Sweden,,,,,,,,,,,,,,
trial,NCT01299376,NCT01299376,MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356),PHASE3,cardiovascular disease,Hypertension,INDUSTRY,286.0,2011-01-24,2012-09-20,0.0,0.0,,,,,
arm,NCT01299376::arm::FG000,NCT01299376,L50/H12.5/A5→L50/H12.5/A5,,,,,,,,,,FG000,"One combination tablet containing L50 mg, H12.5 mg, and A5 mg, orally, once daily, for up to 8 weeks (double-blind treatment period). Participants continue with once daily L50/H12.5/A5 for 44 weeks du",,,
arm,NCT01299376::arm::FG001,NCT01299376,L50/H12.5→L50/H12.5/A5,,,,,,,,,,FG001,"One combination tablet containing L50 mg and H12.5 mg, orally, once daily, for up to 8 weeks during double-blind treatment period. Participants then receive once daily L50/H12.5/A5 for 44 weeks during",,,
period,NCT01299376::period::1,NCT01299376,Double-blind Treatment (Weeks 1 to 8),,,,,,,,,,,,1.0,,
period,NCT01299376::period::2,NCT01299376,Extension (Weeks 9 to 52),,,,,,,,,,,,2.0,,
outcome,NCT01299376::outcome::primary::1,NCT01299376,Change in Trough Sitting Diastolic Blood Pressure (SiDBP)-Double-Blind Treatment Period,,,,,,,,,,,,,PRIMARY,Baseline and Week 8
outcome,NCT01299376::outcome::primary::2,NCT01299376,Percentage of Participants Who Experience 1 or More Adverse Events (AEs)- Double-Blind Treatment Period,,,,,,,,,,,,,PRIMARY,up to Week 8
outcome,NCT01299376::outcome::primary::3,NCT01299376,Percentage of Participants Who Experience 1 or More Drug-Related AEs- Double-Blind Treatment Period,,,,,,,,,,,,,PRIMARY,up to Week 8
outcome,NCT01299376::outcome::primary::4,NCT01299376,Percentage of Participants Who Experience 1 or Serious Adverse Events (SAEs)- Double-Blind Treatment Period,,,,,,,,,,,,,PRIMARY,up to Week 8
outcome,NCT01299376::outcome::primary::5,NCT01299376,Percentage of Participants Who Experience 1 or More Drug-Related Serious Adverse Events (SAEs)- Double-Blind Treatment Period,,,,,,,,,,,,,PRIMARY,up to Week 8
outcome,NCT01299376::outcome::primary::6,NCT01299376,Percentage of Participants Who Had Study Drug Discontinued Due to an AE - Double Blind Treatment Period,,,,,,,,,,,,,PRIMARY,up to Week 8
outcome,NCT01299376::outcome::primary::7,NCT01299376,Percentage of Participants Who Experience 1 or More Adverse Events (AEs)- Long Term,,,,,,,,,,,,,PRIMARY,Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm
outcome,NCT01299376::outcome::primary::8,NCT01299376,Percentage of Participants Who Experience 1 or More Drug-related AEs- Long Term,,,,,,,,,,,,,PRIMARY,Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
outcome,NCT01299376::outcome::primary::9,NCT01299376,Percentage of Participants Who Experience 1 or More SAEs- Long Term,,,,,,,,,,,,,PRIMARY,Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm
outcome,NCT01299376::outcome::primary::10,NCT01299376,Percentage of Participants Who Experience 1 or More Drug-related SAEs- Long Term,,,,,,,,,,,,,PRIMARY,Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
outcome,NCT01299376::outcome::primary::11,NCT01299376,Percentage of Participants Who Had Study Drug Discontinued From the Study Due to an AE- Long Term,,,,,,,,,,,,,PRIMARY,Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm
trial,NCT00234533,NCT00234533,Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq,PHASE3,cardiovascular disease,"Turner Syndrome; Renal Insufficiency, Chronic; Pituitary Diseases; Dwarfism",INDUSTRY,251.0,2004-06,2008-07,14.0,45.0,,,,,
arm,NCT00234533::arm::FG000,NCT00234533,NutropinAq 10 mg/2 ml (30 IU),,,,,,,,,,FG000,"Patients received daily subcutaneous (s.c.) injections of NutropinAq 10 milligrams (mg)/ 2 milliliters (mL) for 6 months. The therapeutic daily doses administered were as follows:

* GHD patients: 0.0",,,
period,NCT00234533::period::1,NCT00234533,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00234533::outcome::primary::1,NCT00234533,Insulin-Like Growth Factor I (IGF-I) Levels Measured Using the Timed Capillary Blood Spot Samples,,,,,,,,,,,,,PRIMARY,"At Weeks 21, 22 and 23"
country,NCT00234533::country::France,NCT00234533,France,,,,,,,,,,,,,,
country,NCT00234533::country::Italy,NCT00234533,Italy,,,,,,,,,,,,,,
country,NCT00234533::country::Spain,NCT00234533,Spain,,,,,,,,,,,,,,
country,NCT00234533::country::Belgium,NCT00234533,Belgium,,,,,,,,,,,,,,
country,NCT00234533::country::Denmark,NCT00234533,Denmark,,,,,,,,,,,,,,
country,NCT00234533::country::Germany,NCT00234533,Germany,,,,,,,,,,,,,,
country,NCT00234533::country::Greece,NCT00234533,Greece,,,,,,,,,,,,,,
country,NCT00234533::country::Russia,NCT00234533,Russia,,,,,,,,,,,,,,
country,NCT00234533::country::Ukraine,NCT00234533,Ukraine,,,,,,,,,,,,,,
country,NCT00234533::country::United Kingdom,NCT00234533,United Kingdom,,,,,,,,,,,,,,
country,NCT00234533::country::Czechia,NCT00234533,Czechia,,,,,,,,,,,,,,
country,NCT00234533::country::Finland,NCT00234533,Finland,,,,,,,,,,,,,,
country,NCT00234533::country::Romania,NCT00234533,Romania,,,,,,,,,,,,,,
country,NCT00234533::country::Slovakia,NCT00234533,Slovakia,,,,,,,,,,,,,,
trial,NCT03036150,NCT03036150,A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease,PHASE3,cardiovascular disease,Chronic Kidney Disease,INDUSTRY,4304.0,2017-02-02,2020-06-12,21.0,390.0,,,,,
arm,NCT03036150::arm::FG000,NCT03036150,Dapagliflozin,,,,,,,,,,FG000,"Dapagliflozin 10 mg, given once daily per oral use",,,
arm,NCT03036150::arm::FG001,NCT03036150,Placebo,,,,,,,,,,FG001,"Placebo tablet to match dapagliflozin 10 mg, given once daily per oral use",,,
period,NCT03036150::period::1,NCT03036150,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03036150::outcome::primary::1,NCT03036150,Time to the First Occurrence of Any of the Components of the Composite: ≥50% Sustained Decline in eGFR or Reaching ESRD or CV Death or Renal Death.,,,,,,,,,,,,,PRIMARY,Up to 38.2 months
country,NCT03036150::country::United States,NCT03036150,United States,,,,,,,,,,,,,,
country,NCT03036150::country::Japan,NCT03036150,Japan,,,,,,,,,,,,,,
country,NCT03036150::country::China,NCT03036150,China,,,,,,,,,,,,,,
country,NCT03036150::country::Argentina,NCT03036150,Argentina,,,,,,,,,,,,,,
country,NCT03036150::country::Canada,NCT03036150,Canada,,,,,,,,,,,,,,
country,NCT03036150::country::Ukraine,NCT03036150,Ukraine,,,,,,,,,,,,,,
country,NCT03036150::country::Russia,NCT03036150,Russia,,,,,,,,,,,,,,
country,NCT03036150::country::India,NCT03036150,India,,,,,,,,,,,,,,
country,NCT03036150::country::Poland,NCT03036150,Poland,,,,,,,,,,,,,,
country,NCT03036150::country::South Korea,NCT03036150,South Korea,,,,,,,,,,,,,,
country,NCT03036150::country::Mexico,NCT03036150,Mexico,,,,,,,,,,,,,,
country,NCT03036150::country::Peru,NCT03036150,Peru,,,,,,,,,,,,,,
country,NCT03036150::country::Brazil,NCT03036150,Brazil,,,,,,,,,,,,,,
country,NCT03036150::country::Germany,NCT03036150,Germany,,,,,,,,,,,,,,
country,NCT03036150::country::Hungary,NCT03036150,Hungary,,,,,,,,,,,,,,
country,NCT03036150::country::Spain,NCT03036150,Spain,,,,,,,,,,,,,,
country,NCT03036150::country::Philippines,NCT03036150,Philippines,,,,,,,,,,,,,,
country,NCT03036150::country::United Kingdom,NCT03036150,United Kingdom,,,,,,,,,,,,,,
country,NCT03036150::country::Vietnam,NCT03036150,Vietnam,,,,,,,,,,,,,,
country,NCT03036150::country::Denmark,NCT03036150,Denmark,,,,,,,,,,,,,,
country,NCT03036150::country::Sweden,NCT03036150,Sweden,,,,,,,,,,,,,,
trial,NCT01178073,NCT01178073,A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH),PHASE3,cardiovascular disease,"Hypertension, Pulmonary",INDUSTRY,610.0,2010-10-01,2014-07-31,14.0,143.0,,,,,
arm,NCT01178073::arm::FG000,NCT01178073,Combination Therapy: Ambrisentan + Tadalafil,,,,,,,,,,FG000,Participants initially received one tablet of 5 milligrams (mg) ambrisentan (AMB) and one tablet of AMB matching placebo once daily (QD) for the first 8 weeks plus one tablet of 20 mg tadalafil (TAD) ,,,
arm,NCT01178073::arm::FG001,NCT01178073,Ambrisentan Monotherapy,,,,,,,,,,FG001,Participants initially received one tablet of 5 mg AMB and one tablet of AMB matching placebo QD for the first 8 weeks plus two tablets of TAD matching placebo. The AMB dose may have been uptitrated t,,,
arm,NCT01178073::arm::FG002,NCT01178073,Tadalafil Monotherapy,,,,,,,,,,FG002,Participants initially received one tablet of 20 mg TAD and one tablet of TAD matching placebo QD for the first 4 weeks plus two tablets of AMB matching placebo. The TAD dose was uptitrated to 40 mg (,,,
period,NCT01178073::period::1,NCT01178073,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01178073::outcome::primary::1,NCT01178073,"Number of Participants With First Adjudicated Clinical Failure (CF) Event, Death, Hospitalisation for Worsening PAH, Disease Progression, Unsatisfactory Long-term Clinical Response, All Through FAV",,,,,,,,,,,,,PRIMARY,From Baseline up to the Final Assessment Visit (FAV) (average of 609 days)
country,NCT01178073::country::United States,NCT01178073,United States,,,,,,,,,,,,,,
country,NCT01178073::country::Germany,NCT01178073,Germany,,,,,,,,,,,,,,
country,NCT01178073::country::Spain,NCT01178073,Spain,,,,,,,,,,,,,,
country,NCT01178073::country::France,NCT01178073,France,,,,,,,,,,,,,,
country,NCT01178073::country::Australia,NCT01178073,Australia,,,,,,,,,,,,,,
country,NCT01178073::country::Canada,NCT01178073,Canada,,,,,,,,,,,,,,
country,NCT01178073::country::Italy,NCT01178073,Italy,,,,,,,,,,,,,,
country,NCT01178073::country::Sweden,NCT01178073,Sweden,,,,,,,,,,,,,,
country,NCT01178073::country::United Kingdom,NCT01178073,United Kingdom,,,,,,,,,,,,,,
country,NCT01178073::country::Greece,NCT01178073,Greece,,,,,,,,,,,,,,
country,NCT01178073::country::Japan,NCT01178073,Japan,,,,,,,,,,,,,,
country,NCT01178073::country::Netherlands,NCT01178073,Netherlands,,,,,,,,,,,,,,
country,NCT01178073::country::Austria,NCT01178073,Austria,,,,,,,,,,,,,,
country,NCT01178073::country::Belgium,NCT01178073,Belgium,,,,,,,,,,,,,,
trial,NCT01323153,NCT01323153,A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE),PHASE3,cardiovascular disease,Coronary Heart Disease,INDUSTRY,300.0,2011-03,2012-03,4.0,33.0,,,,,
arm,NCT01323153::arm::FG000,NCT01323153,Dalcetrapib,,,,,,,,,,FG000,dalcetrapib: Oral doses of 600 mg once daily for 20 weeks,,,
arm,NCT01323153::arm::FG001,NCT01323153,Placebo,,,,,,,,,,FG001,placebo: Oral doses of matching placebo to dalcetrapib once daily for 20 weeks,,,
period,NCT01323153::period::1,NCT01323153,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01323153::outcome::primary::1,NCT01323153,Percent Change From Baseline in High-density Lipoprotein C (HDL-C) Levels After 4 Weeks of Treatment,,,,,,,,,,,,,PRIMARY,4 weeks
country,NCT01323153::country::Netherlands,NCT01323153,Netherlands,,,,,,,,,,,,,,
country,NCT01323153::country::Czechia,NCT01323153,Czechia,,,,,,,,,,,,,,
country,NCT01323153::country::United States,NCT01323153,United States,,,,,,,,,,,,,,
country,NCT01323153::country::United Kingdom,NCT01323153,United Kingdom,,,,,,,,,,,,,,
trial,NCT00603902,NCT00603902,BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management,PHASE3,cardiovascular disease,Obesity,INDUSTRY,4008.0,2008-01,2009-08,1.0,1.0,,,,,
arm,NCT00603902::arm::FG000,NCT00603902,Lorcaserin 10 mg QD,,,,,,,,,,FG000,lorcaserin 10 mg once daily (QD) tablets,,,
arm,NCT00603902::arm::FG001,NCT00603902,Lorcaserin 10 mg BID,,,,,,,,,,FG001,lorcaserin 10 mg twice a day (BID) tablets,,,
arm,NCT00603902::arm::FG002,NCT00603902,Matching Placebo,,,,,,,,,,FG002,matching placebo tablets,,,
period,NCT00603902::period::1,NCT00603902,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00603902::outcome::primary::1,NCT00603902,Co-primary Endpoint- Percentage of Participants Achieving Greater Than or Equal to 5% Weight Loss From Baseline to Week 52,,,,,,,,,,,,,PRIMARY,Baseline and Week 52
country,NCT00603902::country::United States,NCT00603902,United States,,,,,,,,,,,,,,
trial,NCT03772041,NCT03772041,Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure,PHASE3,cardiovascular disease,Congestive Heart Failure,INDUSTRY,294.0,2019-01-16,2020-07-29,1.0,1.0,,,,,
arm,NCT03772041::arm::FG000,NCT03772041,OPC-61815 Injection 16 mg,,,,,,,,,,FG000,"Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.",,,
arm,NCT03772041::arm::FG001,NCT03772041,Tolvaptan Tablet 15mg,,,,,,,,,,FG001,"Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.",,,
period,NCT03772041::period::1,NCT03772041,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03772041::outcome::primary::1,NCT03772041,Change From Baseline in Body Weight,,,,,,,,,,,,,PRIMARY,"Baseline, Day 6"
country,NCT03772041::country::Japan,NCT03772041,Japan,,,,,,,,,,,,,,
trial,NCT01028053,NCT01028053,Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease,PHASE3,cardiovascular disease,Mild Cognitive Impairment; Alzheimer's Disease,INDUSTRY,365.0,2009-12,2014-01,1.0,1.0,,,,,
arm,NCT01028053::arm::FG000,NCT01028053,Flutemetamol (18F) Injection,,,,,,,,,,FG000,Flutemetamol (18F) Injection: All subjects will receive an i.v. dose of (18F) flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of (18F) flutemetamol will be,,,
period,NCT01028053::period::1,NCT01028053,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01028053::outcome::primary::1,NCT01028053,Hazard Ratio (HR) by PET Scan Readers for Conversion to Probable Alzheimer's Disease Based on Visual Image Interpretation.,,,,,,,,,,,,,PRIMARY,Up to 36 months post flutemetamol administration
country,NCT01028053::country::United States,NCT01028053,United States,,,,,,,,,,,,,,
trial,NCT01591005,NCT01591005,SONOlysis in Prevention of Brain Infarctions dUring Carotid Stenting and caroTid EndaRterectomy,PHASE3,cardiovascular disease,Internal Carotid Artery Stenosis,OTHER,242.0,2010-10,2015-06,1.0,1.0,,,,,
arm,NCT01591005::arm::FG000,NCT01591005,CEA With Sonolysis,,,,,,,,,,FG000,"endarterectomy with sonolysis (continual transcranial Doppler monitoring)

sonolysis: continual transcranial Doppler monitoring with max. diagnostic intensity for 60 minutes

endarterectomy: carotid e",,,
arm,NCT01591005::arm::FG001,NCT01591005,CEA Without Sonolysis,,,,,,,,,,FG001,"endarterectomy without sonolysis

endarterectomy: carotid endarterectomy",,,
arm,NCT01591005::arm::FG002,NCT01591005,Carotid Stenting With Sonolysis,,,,,,,,,,FG002,"carotid stenting with sonolysis (continual transcranial Doppler monitoring)

sonolysis: continual transcranial Doppler monitoring with max. diagnostic intensity for 60 minutes

carotid stenting: percu",,,
arm,NCT01591005::arm::FG003,NCT01591005,Carotid Stenting Without Sonolysis,,,,,,,,,,FG003,"carotid stenting without sonolysis

carotid stenting: percutaneous transluminal angioplasty and stenting",,,
period,NCT01591005::period::1,NCT01591005,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01591005::outcome::primary::1,NCT01591005,Participants With a New Brain Infarction Detected Using Magnetic Resonance,,,,,,,,,,,,,PRIMARY,24 hours after intervention
country,NCT01591005::country::Czechia,NCT01591005,Czechia,,,,,,,,,,,,,,
trial,NCT00443053,NCT00443053,Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis),PHASE3,cardiovascular disease,"Thrombosis, Venous",INDUSTRY,3002.0,2007-03,2009-07,17.0,227.0,,,,,
arm,NCT00443053::arm::FG000,NCT00443053,Fondaparinux 2.5 mg,,,,,,,,,,FG000,Fondaparinux 2.5 milligrams (mg) administered subcutaneously (SC) once daily for 45 days,,,
arm,NCT00443053::arm::FG001,NCT00443053,Placebo,,,,,,,,,,FG001,Matching placebo,,,
period,NCT00443053::period::1,NCT00443053,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00443053::outcome::primary::1,NCT00443053,Number of Participants With at Least on Event of Venous Thromboembolism (VTE) and/or Death From Any Cause Recorded up to Day 47,,,,,,,,,,,,,PRIMARY,Baseline to Day 47
country,NCT00443053::country::Germany,NCT00443053,Germany,,,,,,,,,,,,,,
country,NCT00443053::country::Russia,NCT00443053,Russia,,,,,,,,,,,,,,
country,NCT00443053::country::France,NCT00443053,France,,,,,,,,,,,,,,
country,NCT00443053::country::Hungary,NCT00443053,Hungary,,,,,,,,,,,,,,
country,NCT00443053::country::Spain,NCT00443053,Spain,,,,,,,,,,,,,,
country,NCT00443053::country::Ukraine,NCT00443053,Ukraine,,,,,,,,,,,,,,
country,NCT00443053::country::Italy,NCT00443053,Italy,,,,,,,,,,,,,,
country,NCT00443053::country::Czechia,NCT00443053,Czechia,,,,,,,,,,,,,,
country,NCT00443053::country::Greece,NCT00443053,Greece,,,,,,,,,,,,,,
country,NCT00443053::country::Slovakia,NCT00443053,Slovakia,,,,,,,,,,,,,,
country,NCT00443053::country::Israel,NCT00443053,Israel,,,,,,,,,,,,,,
country,NCT00443053::country::Switzerland,NCT00443053,Switzerland,,,,,,,,,,,,,,
country,NCT00443053::country::Netherlands,NCT00443053,Netherlands,,,,,,,,,,,,,,
country,NCT00443053::country::Poland,NCT00443053,Poland,,,,,,,,,,,,,,
country,NCT00443053::country::Estonia,NCT00443053,Estonia,,,,,,,,,,,,,,
country,NCT00443053::country::Latvia,NCT00443053,Latvia,,,,,,,,,,,,,,
country,NCT00443053::country::Bulgaria,NCT00443053,Bulgaria,,,,,,,,,,,,,,
trial,NCT01467466,NCT01467466,Prevention of Serious Adverse Events Following Angiography,PHASE3,cardiovascular disease,Acute Renal Failure; Kidney Disease; Coronary Artery Disease,FED,5177.0,2013-10-07,2017-10-17,4.0,54.0,,,,,
arm,NCT01467466::arm::FG000,NCT01467466,Saline & oral placebo,,,,,,,,,,FG000,"IV isotonic saline and oral placebo drug capsule

IV isotonic saline: The investigators will administer 3 ml/kg of isotonic saline over 1 hour at an infusion rate of not less than 1 mL/kg per hour and",,,
arm,NCT01467466::arm::FG001,NCT01467466,Saline & oral N-acetylcysteine,,,,,,,,,,FG001,"IV isotonic saline and oral N-acetylcysteine (NAC) drug capsule

IV isotonic saline: The investigators will administer 3 ml/kg of isotonic saline over 1 hour at an infusion rate of not less than 1 mL/",,,
arm,NCT01467466::arm::FG002,NCT01467466,Bicarbonate & oral placebo,,,,,,,,,,FG002,"IV isotonic bicarbonate and oral placebo drug capsule

IV isotonic bicarbonate: The investigators will administer 3 ml/kg of isotonic bicarbonate over 1 hour at an infusion rate of not less than 1 mL/",,,
arm,NCT01467466::arm::FG003,NCT01467466,Bicarbonate & oral N-acetylcysteine,,,,,,,,,,FG003,"IV isotonic bicarbonate and oral N-acetylcysteine drug capsule

IV isotonic bicarbonate: The investigators will administer 3 ml/kg of isotonic bicarbonate over 1 hour at an infusion rate of not less t",,,
period,NCT01467466::period::1,NCT01467466,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01467466::outcome::primary::1,NCT01467466,"Number of Participants With Serious, Adverse, Patient-Centered Events, Including Death, Need for Acute Dialysis, or Persistent Decline in Kidney Function, Comparing Intravenous Sodium Bicarbonate With Intravenous Sodium Chloride.",,,,,,,,,,,,,PRIMARY,Within 90 days following angiography
outcome,NCT01467466::outcome::primary::2,NCT01467466,"Number of Participants With Serious, Adverse, Patient-Centered Events, Including Death, Need for Acute Dialysis, or Persistent Decline in Kidney Function, Comparing Oral N-Acetylcysteine With Oral Placebo.",,,,,,,,,,,,,PRIMARY,Within 90 days following angiography
country,NCT01467466::country::United States,NCT01467466,United States,,,,,,,,,,,,,,
country,NCT01467466::country::Australia,NCT01467466,Australia,,,,,,,,,,,,,,
country,NCT01467466::country::Malaysia,NCT01467466,Malaysia,,,,,,,,,,,,,,
country,NCT01467466::country::New Zealand,NCT01467466,New Zealand,,,,,,,,,,,,,,
trial,NCT02017171,NCT02017171,A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes,PHASE3,cardiovascular disease,Diabetic Nephropathies; Coronary Artery Disease,OTHER,530.0,2014-02,2019-08-31,3.0,30.0,,,,,
arm,NCT02017171::arm::FG000,NCT02017171,Allopurinol,,,,,,,,,,FG000,Oral allopurinol at a dose of 100 mg per day for 4 weeks and then at a dose ranging from 200 to 400 mg per day depending on kidney function,,,
arm,NCT02017171::arm::FG001,NCT02017171,Placebo,,,,,,,,,,FG001,Oral placebo tablets (Inactive oral tablets identical in appearance to allopurinol tablets),,,
period,NCT02017171::period::1,NCT02017171,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02017171::outcome::primary::1,NCT02017171,iGFR at the End of the Wash-out Period,,,,,,,,,,,,,PRIMARY,End of the 2-month wash-out period following the 3-year treatment period (week 164)
country,NCT02017171::country::United States,NCT02017171,United States,,,,,,,,,,,,,,
country,NCT02017171::country::Canada,NCT02017171,Canada,,,,,,,,,,,,,,
country,NCT02017171::country::Denmark,NCT02017171,Denmark,,,,,,,,,,,,,,
trial,NCT00843492,NCT00843492,A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery,PHASE3,cardiovascular disease,"Thrombosis, Venous",INDUSTRY,1351.0,2008-12,2010-06,6.0,122.0,,,,,
arm,NCT00843492::arm::FG000,NCT00843492,Nadroparin,,,,,,,,,,FG000,2850 anti-Xa International Units (IU) nadroparin calcium (in 0.3 milliliters \[ml\] in disposable prefilled syringes) was injected once daily subcutaneously after randomization (Day 1) until the end o,,,
arm,NCT00843492::arm::FG001,NCT00843492,Fondaparinux,,,,,,,,,,FG001,2.5 milligrams (mg) fondaparinux sodium (in 0.5 ml) or 1.5 mg fondaparinux (in 0.3 ml) (in participants with creatinine clearance between 30 and 50 ml per minute) was injected once daily subcutaneousl,,,
period,NCT00843492::period::1,NCT00843492,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00843492::outcome::primary::1,NCT00843492,Number of Participants With Venous Thromboembolism (VTE) or Death up to the Time of Complete Mobilization,,,,,,,,,,,,,PRIMARY,Day 1 to complete mobilization plus 2 days (average of 35.9 study days)
country,NCT00843492::country::France,NCT00843492,France,,,,,,,,,,,,,,
country,NCT00843492::country::Spain,NCT00843492,Spain,,,,,,,,,,,,,,
country,NCT00843492::country::Russia,NCT00843492,Russia,,,,,,,,,,,,,,
country,NCT00843492::country::Germany,NCT00843492,Germany,,,,,,,,,,,,,,
country,NCT00843492::country::Italy,NCT00843492,Italy,,,,,,,,,,,,,,
country,NCT00843492::country::Netherlands,NCT00843492,Netherlands,,,,,,,,,,,,,,
trial,NCT00221104,NCT00221104,Japan Statin Treatment Against Recurrent Stroke (J-STARS),PHASE3,cardiovascular disease,Ischemic Stroke,OTHER,1578.0,2004-03-01,,1.0,1.0,,,,,
arm,NCT00221104::arm::FG000,NCT00221104,Pravastatin Group,,,,,,,,,,FG000,"The administration was initiated within 1 month after randomization, and the treatment was continued until final observation. Diet and exercise therapies were reinforced when the total cholesterol lev",,,
arm,NCT00221104::arm::FG001,NCT00221104,Control Group,,,,,,,,,,FG001,"The administration of any statin was prohibited, although use of other non-statin drugs was allowed when necessary.",,,
period,NCT00221104::period::1,NCT00221104,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00221104::outcome::primary::1,NCT00221104,Incidence Rate of Stroke and TIA,,,,,,,,,,,,,PRIMARY,up to 5 years
country,NCT00221104::country::Japan,NCT00221104,Japan,,,,,,,,,,,,,,
trial,NCT00095238,NCT00095238,Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve),PHASE3,cardiovascular disease,Congestive Heart Failure,INDUSTRY,4128.0,2002-06,2008-07,25.0,229.0,,,,,
arm,NCT00095238::arm::FG000,NCT00095238,Irbesartan,,,,,,,,,,FG000,"titration from 75 to 300 mg, once daily (QD), up to 6 years",,,
arm,NCT00095238::arm::FG001,NCT00095238,Placebo,,,,,,,,,,FG001,"titration from 75 to 300 mg, once daily (QD), up to 6 years",,,
period,NCT00095238::period::1,NCT00095238,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00095238::outcome::primary::1,NCT00095238,Percentage of Participants With First Occurrence of the Composite Outcome of Death (All Cause) or Protocol-Specified Cardiovascular (CV) Hospitalization at Given Timepoints,,,,,,,,,,,,,PRIMARY,"Year 1, Year 2, Year 3, Year 4, Year 5"
country,NCT00095238::country::United States,NCT00095238,United States,,,,,,,,,,,,,,
country,NCT00095238::country::Netherlands,NCT00095238,Netherlands,,,,,,,,,,,,,,
country,NCT00095238::country::France,NCT00095238,France,,,,,,,,,,,,,,
country,NCT00095238::country::Germany,NCT00095238,Germany,,,,,,,,,,,,,,
country,NCT00095238::country::Canada,NCT00095238,Canada,,,,,,,,,,,,,,
country,NCT00095238::country::Australia,NCT00095238,Australia,,,,,,,,,,,,,,
country,NCT00095238::country::Italy,NCT00095238,Italy,,,,,,,,,,,,,,
country,NCT00095238::country::Spain,NCT00095238,Spain,,,,,,,,,,,,,,
country,NCT00095238::country::Belgium,NCT00095238,Belgium,,,,,,,,,,,,,,
country,NCT00095238::country::Sweden,NCT00095238,Sweden,,,,,,,,,,,,,,
country,NCT00095238::country::Argentina,NCT00095238,Argentina,,,,,,,,,,,,,,
country,NCT00095238::country::Brazil,NCT00095238,Brazil,,,,,,,,,,,,,,
country,NCT00095238::country::Poland,NCT00095238,Poland,,,,,,,,,,,,,,
country,NCT00095238::country::United Kingdom,NCT00095238,United Kingdom,,,,,,,,,,,,,,
country,NCT00095238::country::South Africa,NCT00095238,South Africa,,,,,,,,,,,,,,
country,NCT00095238::country::Hungary,NCT00095238,Hungary,,,,,,,,,,,,,,
country,NCT00095238::country::Mexico,NCT00095238,Mexico,,,,,,,,,,,,,,
country,NCT00095238::country::Norway,NCT00095238,Norway,,,,,,,,,,,,,,
country,NCT00095238::country::Russia,NCT00095238,Russia,,,,,,,,,,,,,,
country,NCT00095238::country::Switzerland,NCT00095238,Switzerland,,,,,,,,,,,,,,
country,NCT00095238::country::Czechia,NCT00095238,Czechia,,,,,,,,,,,,,,
country,NCT00095238::country::Denmark,NCT00095238,Denmark,,,,,,,,,,,,,,
country,NCT00095238::country::Greece,NCT00095238,Greece,,,,,,,,,,,,,,
country,NCT00095238::country::Ireland,NCT00095238,Ireland,,,,,,,,,,,,,,
country,NCT00095238::country::Portugal,NCT00095238,Portugal,,,,,,,,,,,,,,
trial,NCT01788358,NCT01788358,Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,508.0,2013-02-14,2014-05-01,6.0,82.0,,,,,
arm,NCT01788358::arm::FG000,NCT01788358,Nifedipine GITS/Candesartan Cilexetil FDC (BAY98-7106),,,,,,,,,,FG000,"Subjects received nifedipine gastrointestinal therapeutic system (GITS) / candesartan cilexetil fixed dose combination (FDC) (BAY98-7106) tablet orally, once daily in the morning of Visit 1 (Week 0) f",,,
period,NCT01788358::period::1,NCT01788358,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01788358::outcome::primary::1,NCT01788358,Number of Subjects With All Treatment-emergent Adverse Events (TEAEs) and Drug-related TEAEs up to Week 28,,,,,,,,,,,,,PRIMARY,From the time of first study drug administration up to Week 28
outcome,NCT01788358::outcome::primary::2,NCT01788358,Number of Subjects With Treatment-emergent Adverse Events (TEAEs) of Special Interest up to Week 28,,,,,,,,,,,,,PRIMARY,From the time of first study drug administration up to Week 28
outcome,NCT01788358::outcome::primary::3,NCT01788358,Number of Subjects With All Treatment-emergent Adverse Events (TEAEs) and Drug-related TEAEs up to Week 52/End of Study (EOS),,,,,,,,,,,,,PRIMARY,From the time of first study drug administration up to Week 52/EOS
outcome,NCT01788358::outcome::primary::4,NCT01788358,Number of Subjects With Treatment-emergent Adverse Events (TEAEs) of Special Interest up to Week 52/End of Study (EOS),,,,,,,,,,,,,PRIMARY,From the time of study treatment up to Week 52/EOS
country,NCT01788358::country::United States,NCT01788358,United States,,,,,,,,,,,,,,
country,NCT01788358::country::Canada,NCT01788358,Canada,,,,,,,,,,,,,,
country,NCT01788358::country::United Kingdom,NCT01788358,United Kingdom,,,,,,,,,,,,,,
country,NCT01788358::country::Germany,NCT01788358,Germany,,,,,,,,,,,,,,
country,NCT01788358::country::Belgium,NCT01788358,Belgium,,,,,,,,,,,,,,
country,NCT01788358::country::Poland,NCT01788358,Poland,,,,,,,,,,,,,,
trial,NCT00413049,NCT00413049,Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,698.0,2007-01,2007-11,1.0,12.0,,,,,
arm,NCT00413049::arm::FG000,NCT00413049,Valsartan/Amlodipine 80/5 mg,,,,,,,,,,FG000,"1 valsartan/amlodipine 80/5 mg tablet and 1 placebo capsule matching amlodipine 5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit,",,,
arm,NCT00413049::arm::FG001,NCT00413049,Amlodipine 5 mg,,,,,,,,,,FG001,"1 amlodipine 5 mg capsule and 1 placebo tablet matching valsartan/amlodipine 80/5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit,",,,
period,NCT00413049::period::1,NCT00413049,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00413049::outcome::primary::1,NCT00413049,Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8),,,,,,,,,,,,,PRIMARY,Baseline to end of study (Week 8)
country,NCT00413049::country::China,NCT00413049,China,,,,,,,,,,,,,,
trial,NCT04462536,NCT04462536,Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis,PHASE3,cardiovascular disease,"Stroke, Acute",INDUSTRY,850.0,2020-12-06,2023-08-31,9.0,81.0,,,,,
arm,NCT04462536::arm::FG000,NCT04462536,Placebo,,,,,,,,,,FG000,"Vehicle only

Placebo: Vehicle only",,,
arm,NCT04462536::arm::FG001,NCT04462536,Nerinetide,,,,,,,,,,FG001,"Single intravenous infusion of nerinetide 2.6 mg/kg (up to a maximum dose of 270 mg) over 10 ± 1 minutes

Nerinetide: Single intravenous infusion of nerinetide 2.6 mg/kg (up to a maximum dose of 270 m",,,
period,NCT04462536::period::1,NCT04462536,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04462536::outcome::primary::1,NCT04462536,"Number of Participants With Independent Functioning on the Modified Rankin Scale (mRS), as Defined by a Score of 0-2",,,,,,,,,,,,,PRIMARY,90 days
country,NCT04462536::country::Germany,NCT04462536,Germany,,,,,,,,,,,,,,
country,NCT04462536::country::United States,NCT04462536,United States,,,,,,,,,,,,,,
country,NCT04462536::country::Canada,NCT04462536,Canada,,,,,,,,,,,,,,
country,NCT04462536::country::Australia,NCT04462536,Australia,,,,,,,,,,,,,,
country,NCT04462536::country::Italy,NCT04462536,Italy,,,,,,,,,,,,,,
country,NCT04462536::country::Norway,NCT04462536,Norway,,,,,,,,,,,,,,
country,NCT04462536::country::Netherlands,NCT04462536,Netherlands,,,,,,,,,,,,,,
country,NCT04462536::country::Switzerland,NCT04462536,Switzerland,,,,,,,,,,,,,,
country,NCT04462536::country::Singapore,NCT04462536,Singapore,,,,,,,,,,,,,,
trial,NCT00696241,NCT00696241,Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,1275.0,2007-06,2008-10,3.0,85.0,,,,,
arm,NCT00696241::arm::FG000,NCT00696241,Azilsartan Medoxomil 20 mg QD,,,,,,,,,,FG000,"Azilsartan medoxomil 20 mg, tablets, orally, once daily for up to 6 weeks.",,,
arm,NCT00696241::arm::FG001,NCT00696241,Azilsartan Medoxomil 40 mg QD,,,,,,,,,,FG001,"Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 6 weeks.",,,
arm,NCT00696241::arm::FG002,NCT00696241,Azilsartan Medoxomil 80 mg QD,,,,,,,,,,FG002,"Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 6 weeks.",,,
arm,NCT00696241::arm::FG003,NCT00696241,Olmesartan 40 mg QD,,,,,,,,,,FG003,"Olmesartan 40 mg, tablets, orally, once daily for up to 6 weeks.",,,
arm,NCT00696241::arm::FG004,NCT00696241,Placebo QD,,,,,,,,,,FG004,"Placebo-matching tablets, orally, once daily for up to 6 weeks.",,,
period,NCT00696241::period::1,NCT00696241,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00696241::outcome::primary::1,NCT00696241,Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.,,,,,,,,,,,,,PRIMARY,Baseline and Week 6.
country,NCT00696241::country::United States,NCT00696241,United States,,,,,,,,,,,,,,
country,NCT00696241::country::Mexico,NCT00696241,Mexico,,,,,,,,,,,,,,
country,NCT00696241::country::Argentina,NCT00696241,Argentina,,,,,,,,,,,,,,
trial,NCT00766493,NCT00766493,GORE® Embolic Filter in Carotid Stenting for High Risk Surgical Subjects (EMBOLDEN),PHASE3,cardiovascular disease,Carotid Artery Stenosis,INDUSTRY,250.0,2009-01,2010-07,0.0,0.0,,,,,
arm,NCT00766493::arm::FG000,NCT00766493,EMBOLDEN,,,,,,,,,,FG000,GORE® Embolic Filter with carotid artery stenting,,,
period,NCT00766493::period::1,NCT00766493,Pre-Discharge,,,,,,,,,,,,1.0,,
period,NCT00766493::period::2,NCT00766493,30 Days Post-Procedure,,,,,,,,,,,,2.0,,
outcome,NCT00766493::outcome::primary::1,NCT00766493,"Composite Major Adverse Event (MAE) Rate of Death, Myocardial Infarction, and Stroke at 30 Days Postprocedure",,,,,,,,,,,,,PRIMARY,30 days
trial,NCT00808067,NCT00808067,RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial,PHASE3,cardiovascular disease,Atrial Fibrillation,INDUSTRY,5897.0,2008-11,2012-12,35.0,567.0,,,,,
arm,NCT00808067::arm::FG000,NCT00808067,Dabigatran 110 mg,,,,,,,,,,FG000,Dabigatran etexilate 110 mg twice daily,,,
arm,NCT00808067::arm::FG001,NCT00808067,Dabigatran 150 mg,,,,,,,,,,FG001,Dabigatran etexilate 150 mg twice daily,,,
period,NCT00808067::period::1,NCT00808067,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00808067::outcome::primary::1,NCT00808067,"Major Bleeding, Annualized Rate of Subjects With Major Bleeds",,,,,,,,,,,,,PRIMARY,up to 43 months
country,NCT00808067::country::United States,NCT00808067,United States,,,,,,,,,,,,,,
country,NCT00808067::country::Canada,NCT00808067,Canada,,,,,,,,,,,,,,
country,NCT00808067::country::Netherlands,NCT00808067,Netherlands,,,,,,,,,,,,,,
country,NCT00808067::country::France,NCT00808067,France,,,,,,,,,,,,,,
country,NCT00808067::country::Israel,NCT00808067,Israel,,,,,,,,,,,,,,
country,NCT00808067::country::Belgium,NCT00808067,Belgium,,,,,,,,,,,,,,
country,NCT00808067::country::Germany,NCT00808067,Germany,,,,,,,,,,,,,,
country,NCT00808067::country::India,NCT00808067,India,,,,,,,,,,,,,,
country,NCT00808067::country::Taiwan,NCT00808067,Taiwan,,,,,,,,,,,,,,
country,NCT00808067::country::Russia,NCT00808067,Russia,,,,,,,,,,,,,,
country,NCT00808067::country::China,NCT00808067,China,,,,,,,,,,,,,,
country,NCT00808067::country::Denmark,NCT00808067,Denmark,,,,,,,,,,,,,,
country,NCT00808067::country::South Korea,NCT00808067,South Korea,,,,,,,,,,,,,,
country,NCT00808067::country::Sweden,NCT00808067,Sweden,,,,,,,,,,,,,,
country,NCT00808067::country::United Kingdom,NCT00808067,United Kingdom,,,,,,,,,,,,,,
country,NCT00808067::country::Czechia,NCT00808067,Czechia,,,,,,,,,,,,,,
country,NCT00808067::country::Hungary,NCT00808067,Hungary,,,,,,,,,,,,,,
country,NCT00808067::country::Austria,NCT00808067,Austria,,,,,,,,,,,,,,
country,NCT00808067::country::Australia,NCT00808067,Australia,,,,,,,,,,,,,,
country,NCT00808067::country::Brazil,NCT00808067,Brazil,,,,,,,,,,,,,,
country,NCT00808067::country::Bulgaria,NCT00808067,Bulgaria,,,,,,,,,,,,,,
country,NCT00808067::country::Poland,NCT00808067,Poland,,,,,,,,,,,,,,
country,NCT00808067::country::Finland,NCT00808067,Finland,,,,,,,,,,,,,,
country,NCT00808067::country::Greece,NCT00808067,Greece,,,,,,,,,,,,,,
country,NCT00808067::country::Norway,NCT00808067,Norway,,,,,,,,,,,,,,
country,NCT00808067::country::Portugal,NCT00808067,Portugal,,,,,,,,,,,,,,
country,NCT00808067::country::Slovakia,NCT00808067,Slovakia,,,,,,,,,,,,,,
country,NCT00808067::country::Philippines,NCT00808067,Philippines,,,,,,,,,,,,,,
country,NCT00808067::country::Switzerland,NCT00808067,Switzerland,,,,,,,,,,,,,,
country,NCT00808067::country::Italy,NCT00808067,Italy,,,,,,,,,,,,,,
country,NCT00808067::country::Thailand,NCT00808067,Thailand,,,,,,,,,,,,,,
country,NCT00808067::country::Hong Kong,NCT00808067,Hong Kong,,,,,,,,,,,,,,
country,NCT00808067::country::Malaysia,NCT00808067,Malaysia,,,,,,,,,,,,,,
country,NCT00808067::country::Romania,NCT00808067,Romania,,,,,,,,,,,,,,
country,NCT00808067::country::Singapore,NCT00808067,Singapore,,,,,,,,,,,,,,
trial,NCT00923091,NCT00923091,"Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension",PHASE3,cardiovascular disease,Essential Hypertension,INDUSTRY,2689.0,2009-06,2011-03,15.0,133.0,,,,,
arm,NCT00923091::arm::FG000,NCT00923091,Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5mg,,,,,,,,,,FG000,Once a day the following tablets were taken: 1 tablet of olmesartan 20 mg/amlodipine 5 mg + 1 tablet of hydroclororthiazide 12.5 mg + one 12.5 mg hydrochlorothiazide placebo tablet. In Periods I/II pa,,,
arm,NCT00923091::arm::FG001,NCT00923091,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg,,,,,,,,,,FG001,Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 5 mg + 1 tablet of hydroclororthiazide 12.5 mg + one 12.5 mg hydrochlorothiazide placebo tablet. In Periods I/II pa,,,
arm,NCT00923091::arm::FG002,NCT00923091,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg,,,,,,,,,,FG002,Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 5 mg + 2 tablets of hydroclororthiazide 12.5 mg. In Periods I/II participants were randomized to this and the other,,,
arm,NCT00923091::arm::FG003,NCT00923091,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg,,,,,,,,,,FG003,Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 10 mg + 1 tablet of hydroclororthiazide 12.5 mg + one 12.5 mg hydrochlorothiazide placebo tablet. In Periods I/II p,,,
arm,NCT00923091::arm::FG004,NCT00923091,Olmesartan/Amlodipine/Hydrochlorothiazide(HCT) 40mg/10mg/25mg,,,,,,,,,,FG004,Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 10 mg + 2 tablets of hydroclororthiazide 12.5 mg. In Periods I/II participants were randomized to this and the othe,,,
arm,NCT00923091::arm::FG005,NCT00923091,Olmesartan(OM)20mg/Amlodipine (AML)5mg,,,,,,,,,,FG005,Once a day the following tablets were taken: 1 tablet of olmesartan 20 mg/amlodipine 5 mg + two 12.5 mg hydrochlorothiazide placebo tablets. In Periods I/II participants were randomized to this and th,,,
arm,NCT00923091::arm::FG006,NCT00923091,Olmesartan/Amlodipine 40mg/5mg,,,,,,,,,,FG006,Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 5 mg + two 12.5 mg hydrochlorothiazide placebo tablets. In Periods I/II participants were randomized to this and th,,,
arm,NCT00923091::arm::FG007,NCT00923091,Olmesartan/Amlodipine 40mg/10mg,,,,,,,,,,FG007,Once a day the following tablets were taken: 1 tablet of olmesartan 40 mg/amlodipine 10 mg + two 12.5 mg hydrochlorothiazide placebo tablets. In Periods I/II participants were randomized to this and t,,,
arm,NCT00923091::arm::FG008,NCT00923091,OM/AML/HCT 40/5/12.5mg Responder Continued on 40/5/12.5 mg,,,,,,,,,,FG008,In Period V responders continued on olmesartan/amlodipine/ hydrochlorothiazide 40mg/5mg/12.5 mg. A participant was considered a responder if their blood pressure was \<140/90 mm Hg; \<130/80 mm Hg if ,,,
arm,NCT00923091::arm::FG009,NCT00923091,OM/AML/HCT 40/5/12.5mg Non Responder Randomized to 40/5/12.5mg,,,,,,,,,,FG009,In Period V OLM/AML/HCTZ 40/5/12.5 non-responders were randomized to olmesartan/amlodipine/hydrochlorothiazide 40mg/5mg/12.5 mg or to 40mg/5mg/25 mg. A participant was considered a responder if their ,,,
arm,NCT00923091::arm::FG010,NCT00923091,OM/AML/HCT 40/5/12.5mg Non Responder Randomized to 40/5/25mg,,,,,,,,,,FG010,In Period V OLM/AML/HCTZ 40/5/12.5 non-responders were randomized to olmesartan/amlodipine/hydrochlorothiazide 40mg/5mg/12.5 mg or to 40mg/5mg/25 mg. A participant was considered a responder if their ,,,
arm,NCT00923091::arm::FG011,NCT00923091,OM/AML/HCT 20/5/12.5mg NonResponder Up Titrated to 40/5/12.5mg,,,,,,,,,,FG011,In Period V non-responders to olmesartan/amlodipine/hydrochlorothiazide 20mg/5mg/12.5 mg were up titrated to 40mg/5mg/12.5mg. A participant was considered a responder if their blood pressure was \<140,,,
arm,NCT00923091::arm::FG012,NCT00923091,20/5/12.5mg Responder Continued on 20/5/12.5 mg,,,,,,,,,,FG012,In Period V non-responders to olmesartan/amlodipine/hydrochlorothiazide 20mg/5mg/12.5 mg continued on 20mg/5mg/12.5mg. A participant was considered a responder if their blood pressure was \<140/90 mm ,,,
period,NCT00923091::period::1,NCT00923091,"PeriodI-II (Randomized, Double-Blind)",,,,,,,,,,,,1.0,,
period,NCT00923091::period::2,NCT00923091,Period III (Single-Blind),,,,,,,,,,,,2.0,,
period,NCT00923091::period::3,NCT00923091,Period IV (Double-Blind),,,,,,,,,,,,3.0,,
period,NCT00923091::period::4,NCT00923091,Period V (Double -Blind),,,,,,,,,,,,4.0,,
period,NCT00923091::period::5,NCT00923091,Period VI (Open-Label),,,,,,,,,,,,5.0,,
outcome,NCT00923091::outcome::primary::1,NCT00923091,Change in Seated Diastolic Blood Pressure (SeDBP).,,,,,,,,,,,,,PRIMARY,Baseline to week 10
country,NCT00923091::country::Germany,NCT00923091,Germany,,,,,,,,,,,,,,
country,NCT00923091::country::Italy,NCT00923091,Italy,,,,,,,,,,,,,,
country,NCT00923091::country::Poland,NCT00923091,Poland,,,,,,,,,,,,,,
country,NCT00923091::country::Hungary,NCT00923091,Hungary,,,,,,,,,,,,,,
country,NCT00923091::country::Ukraine,NCT00923091,Ukraine,,,,,,,,,,,,,,
country,NCT00923091::country::Belgium,NCT00923091,Belgium,,,,,,,,,,,,,,
country,NCT00923091::country::Czechia,NCT00923091,Czechia,,,,,,,,,,,,,,
country,NCT00923091::country::Romania,NCT00923091,Romania,,,,,,,,,,,,,,
country,NCT00923091::country::Spain,NCT00923091,Spain,,,,,,,,,,,,,,
country,NCT00923091::country::Latvia,NCT00923091,Latvia,,,,,,,,,,,,,,
country,NCT00923091::country::Bulgaria,NCT00923091,Bulgaria,,,,,,,,,,,,,,
country,NCT00923091::country::Netherlands,NCT00923091,Netherlands,,,,,,,,,,,,,,
country,NCT00923091::country::Russia,NCT00923091,Russia,,,,,,,,,,,,,,
country,NCT00923091::country::Slovakia,NCT00923091,Slovakia,,,,,,,,,,,,,,
country,NCT00923091::country::Denmark,NCT00923091,Denmark,,,,,,,,,,,,,,
trial,NCT01994720,NCT01994720,[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES],PHASE3,cardiovascular disease,Acute Ischaemic Stroke; Transient Ischaemic Attack,INDUSTRY,13307.0,2014-01-07,2016-03-02,33.0,521.0,,,,,
arm,NCT01994720::arm::FG000,NCT01994720,Ticagrelor 90 mg,,,,,,,,,,FG000,Ticagrelor 90 mg twice daily (BD),,,
arm,NCT01994720::arm::FG001,NCT01994720,ASA 100 mg,,,,,,,,,,FG001,ASA 100 mg once daily (OD),,,
period,NCT01994720::period::1,NCT01994720,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01994720::outcome::primary::1,NCT01994720,Number of Participants With Composite of Stroke/MI/Death,,,,,,,,,,,,,PRIMARY,From randomization up to 97 days
country,NCT01994720::country::United States,NCT01994720,United States,,,,,,,,,,,,,,
country,NCT01994720::country::Japan,NCT01994720,Japan,,,,,,,,,,,,,,
country,NCT01994720::country::China,NCT01994720,China,,,,,,,,,,,,,,
country,NCT01994720::country::France,NCT01994720,France,,,,,,,,,,,,,,
country,NCT01994720::country::Italy,NCT01994720,Italy,,,,,,,,,,,,,,
country,NCT01994720::country::Poland,NCT01994720,Poland,,,,,,,,,,,,,,
country,NCT01994720::country::Russia,NCT01994720,Russia,,,,,,,,,,,,,,
country,NCT01994720::country::Bulgaria,NCT01994720,Bulgaria,,,,,,,,,,,,,,
country,NCT01994720::country::Germany,NCT01994720,Germany,,,,,,,,,,,,,,
country,NCT01994720::country::Sweden,NCT01994720,Sweden,,,,,,,,,,,,,,
country,NCT01994720::country::Australia,NCT01994720,Australia,,,,,,,,,,,,,,
country,NCT01994720::country::Canada,NCT01994720,Canada,,,,,,,,,,,,,,
country,NCT01994720::country::Hungary,NCT01994720,Hungary,,,,,,,,,,,,,,
country,NCT01994720::country::Spain,NCT01994720,Spain,,,,,,,,,,,,,,
country,NCT01994720::country::Belgium,NCT01994720,Belgium,,,,,,,,,,,,,,
country,NCT01994720::country::Czechia,NCT01994720,Czechia,,,,,,,,,,,,,,
country,NCT01994720::country::Switzerland,NCT01994720,Switzerland,,,,,,,,,,,,,,
country,NCT01994720::country::Brazil,NCT01994720,Brazil,,,,,,,,,,,,,,
country,NCT01994720::country::Philippines,NCT01994720,Philippines,,,,,,,,,,,,,,
country,NCT01994720::country::Taiwan,NCT01994720,Taiwan,,,,,,,,,,,,,,
country,NCT01994720::country::Ukraine,NCT01994720,Ukraine,,,,,,,,,,,,,,
country,NCT01994720::country::Chile,NCT01994720,Chile,,,,,,,,,,,,,,
country,NCT01994720::country::South Korea,NCT01994720,South Korea,,,,,,,,,,,,,,
country,NCT01994720::country::Thailand,NCT01994720,Thailand,,,,,,,,,,,,,,
country,NCT01994720::country::Argentina,NCT01994720,Argentina,,,,,,,,,,,,,,
country,NCT01994720::country::Israel,NCT01994720,Israel,,,,,,,,,,,,,,
country,NCT01994720::country::Mexico,NCT01994720,Mexico,,,,,,,,,,,,,,
country,NCT01994720::country::Romania,NCT01994720,Romania,,,,,,,,,,,,,,
country,NCT01994720::country::Slovakia,NCT01994720,Slovakia,,,,,,,,,,,,,,
country,NCT01994720::country::Turkey (Türkiye),NCT01994720,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01994720::country::Peru,NCT01994720,Peru,,,,,,,,,,,,,,
country,NCT01994720::country::Hong Kong,NCT01994720,Hong Kong,,,,,,,,,,,,,,
country,NCT01994720::country::Vietnam,NCT01994720,Vietnam,,,,,,,,,,,,,,
trial,NCT00986154,NCT00986154,Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).,PHASE3,cardiovascular disease,Venous Thromboembolism; Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE); Thromboembolism; Venous Thrombosis,INDUSTRY,8292.0,2009-10,2013-04,38.0,454.0,,,,,
arm,NCT00986154::arm::FG000,NCT00986154,Heparin/Edoxaban Tosylate,,,,,,,,,,FG000,"edoxaban tosylate(DU-176b): edoxaban tosylate(DU-176b), film-coated tablet for oral use, 30 mg, two tablets (60 mg) once daily, maximum of 12 months treatment

low molecular weight heparin/unfractiona",,,
arm,NCT00986154::arm::FG001,NCT00986154,Heparin/Warfarin,,,,,,,,,,FG001,"low molecular weight heparin/unfractionated heparin: LMW heparin - subcutaneous injection, 1 mg/Kg twice daily or 1.5 mg/Kg once daily.

Unfractionated heparin - 5,000 IU bolus intravenous administrat",,,
period,NCT00986154::period::1,NCT00986154,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00986154::outcome::primary::1,NCT00986154,"Symptomatic Recurrent VTE, i.e., the Composite of DVT, Non-fatal PE, and Fatal PE",,,,,,,,,,,,,PRIMARY,12 months from time of randomization
country,NCT00986154::country::United States,NCT00986154,United States,,,,,,,,,,,,,,
country,NCT00986154::country::India,NCT00986154,India,,,,,,,,,,,,,,
country,NCT00986154::country::France,NCT00986154,France,,,,,,,,,,,,,,
country,NCT00986154::country::Japan,NCT00986154,Japan,,,,,,,,,,,,,,
country,NCT00986154::country::China,NCT00986154,China,,,,,,,,,,,,,,
country,NCT00986154::country::Russia,NCT00986154,Russia,,,,,,,,,,,,,,
country,NCT00986154::country::Hungary,NCT00986154,Hungary,,,,,,,,,,,,,,
country,NCT00986154::country::Germany,NCT00986154,Germany,,,,,,,,,,,,,,
country,NCT00986154::country::Brazil,NCT00986154,Brazil,,,,,,,,,,,,,,
country,NCT00986154::country::Israel,NCT00986154,Israel,,,,,,,,,,,,,,
country,NCT00986154::country::Australia,NCT00986154,Australia,,,,,,,,,,,,,,
country,NCT00986154::country::Italy,NCT00986154,Italy,,,,,,,,,,,,,,
country,NCT00986154::country::South Africa,NCT00986154,South Africa,,,,,,,,,,,,,,
country,NCT00986154::country::Netherlands,NCT00986154,Netherlands,,,,,,,,,,,,,,
country,NCT00986154::country::Ukraine,NCT00986154,Ukraine,,,,,,,,,,,,,,
country,NCT00986154::country::Czechia,NCT00986154,Czechia,,,,,,,,,,,,,,
country,NCT00986154::country::Mexico,NCT00986154,Mexico,,,,,,,,,,,,,,
country,NCT00986154::country::Poland,NCT00986154,Poland,,,,,,,,,,,,,,
country,NCT00986154::country::Argentina,NCT00986154,Argentina,,,,,,,,,,,,,,
country,NCT00986154::country::Canada,NCT00986154,Canada,,,,,,,,,,,,,,
country,NCT00986154::country::South Korea,NCT00986154,South Korea,,,,,,,,,,,,,,
country,NCT00986154::country::United Kingdom,NCT00986154,United Kingdom,,,,,,,,,,,,,,
country,NCT00986154::country::Austria,NCT00986154,Austria,,,,,,,,,,,,,,
country,NCT00986154::country::Belarus,NCT00986154,Belarus,,,,,,,,,,,,,,
country,NCT00986154::country::Denmark,NCT00986154,Denmark,,,,,,,,,,,,,,
country,NCT00986154::country::Switzerland,NCT00986154,Switzerland,,,,,,,,,,,,,,
country,NCT00986154::country::Sweden,NCT00986154,Sweden,,,,,,,,,,,,,,
country,NCT00986154::country::Taiwan,NCT00986154,Taiwan,,,,,,,,,,,,,,
country,NCT00986154::country::New Zealand,NCT00986154,New Zealand,,,,,,,,,,,,,,
country,NCT00986154::country::Philippines,NCT00986154,Philippines,,,,,,,,,,,,,,
country,NCT00986154::country::Turkey (Türkiye),NCT00986154,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00986154::country::Estonia,NCT00986154,Estonia,,,,,,,,,,,,,,
country,NCT00986154::country::Thailand,NCT00986154,Thailand,,,,,,,,,,,,,,
country,NCT00986154::country::Belgium,NCT00986154,Belgium,,,,,,,,,,,,,,
country,NCT00986154::country::Chile,NCT00986154,Chile,,,,,,,,,,,,,,
country,NCT00986154::country::Norway,NCT00986154,Norway,,,,,,,,,,,,,,
country,NCT00986154::country::Singapore,NCT00986154,Singapore,,,,,,,,,,,,,,
country,NCT00986154::country::Spain,NCT00986154,Spain,,,,,,,,,,,,,,
trial,NCT00841672,NCT00841672,Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension,PHASE3,cardiovascular disease,Moderate to Severe Hypertension,INDUSTRY,485.0,2009-01,2009-09,6.0,6.0,,,,,
arm,NCT00841672::arm::FG000,NCT00841672,Aliskiren/Amlodipine 300/10 mg Tablet,,,,,,,,,,FG000,"Aliskiren/amlodipine treatment regimen: At randomization, patients were treated with aliskiren/amlodipine 150/5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to",,,
arm,NCT00841672::arm::FG001,NCT00841672,Amlodipine 10 mg Capsule,,,,,,,,,,FG001,"Amlodipine treatment regimen: At randomization, patients were treated with amlodipine 5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive amlodipine 10 m",,,
period,NCT00841672::period::1,NCT00841672,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00841672::outcome::primary::1,NCT00841672,Mean Sitting Systolic Blood Pressure (msSBP),,,,,,,,,,,,,PRIMARY,Baseline to end of study (Week 8)
country,NCT00841672::country::Germany,NCT00841672,Germany,,,,,,,,,,,,,,
country,NCT00841672::country::Philippines,NCT00841672,Philippines,,,,,,,,,,,,,,
country,NCT00841672::country::Romania,NCT00841672,Romania,,,,,,,,,,,,,,
country,NCT00841672::country::Russia,NCT00841672,Russia,,,,,,,,,,,,,,
country,NCT00841672::country::Singapore,NCT00841672,Singapore,,,,,,,,,,,,,,
country,NCT00841672::country::Spain,NCT00841672,Spain,,,,,,,,,,,,,,
trial,NCT02680574,NCT02680574,Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD),PHASE3,cardiovascular disease,Anemia; Non-Dialysis-Dependent Chronic Kidney Disease,INDUSTRY,1725.0,2016-02,2020-07-31,30.0,503.0,,,,,
arm,NCT02680574::arm::FG000,NCT02680574,Vadadustat,,,,,,,,,,FG000,"Participants were randomized to receive Vadadustat at an initial oral dose of 300 milligrams per day (mg/day). Thereafter, Vadadustat was taken once daily on an outpatient basis. Up-and-down titration",,,
arm,NCT02680574::arm::FG001,NCT02680574,Darbepoetin Alfa,,,,,,,,,,FG001,"Participants were randomized to Darbepoetin alfa at an initial dose that was based on the current package insert for investigational sites in the United States (US), and the Summary of Product Charact",,,
period,NCT02680574::period::1,NCT02680574,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02680574::outcome::primary::1,NCT02680574,Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36),,,,,,,,,,,,,PRIMARY,Baseline
outcome,NCT02680574::outcome::primary::2,NCT02680574,Median Time to First Major Adverse Cardiovascular Event (MACE),,,,,,,,,,,,,PRIMARY,Weeks 24 to 36
country,NCT02680574::country::United States,NCT02680574,United States,,,,,,,,,,,,,,
country,NCT02680574::country::Brazil,NCT02680574,Brazil,,,,,,,,,,,,,,
country,NCT02680574::country::Argentina,NCT02680574,Argentina,,,,,,,,,,,,,,
country,NCT02680574::country::Mexico,NCT02680574,Mexico,,,,,,,,,,,,,,
country,NCT02680574::country::Spain,NCT02680574,Spain,,,,,,,,,,,,,,
country,NCT02680574::country::Ukraine,NCT02680574,Ukraine,,,,,,,,,,,,,,
country,NCT02680574::country::Bulgaria,NCT02680574,Bulgaria,,,,,,,,,,,,,,
country,NCT02680574::country::Hungary,NCT02680574,Hungary,,,,,,,,,,,,,,
country,NCT02680574::country::Australia,NCT02680574,Australia,,,,,,,,,,,,,,
country,NCT02680574::country::Italy,NCT02680574,Italy,,,,,,,,,,,,,,
country,NCT02680574::country::South Korea,NCT02680574,South Korea,,,,,,,,,,,,,,
country,NCT02680574::country::Russia,NCT02680574,Russia,,,,,,,,,,,,,,
country,NCT02680574::country::South Africa,NCT02680574,South Africa,,,,,,,,,,,,,,
country,NCT02680574::country::United Kingdom,NCT02680574,United Kingdom,,,,,,,,,,,,,,
country,NCT02680574::country::Colombia,NCT02680574,Colombia,,,,,,,,,,,,,,
country,NCT02680574::country::France,NCT02680574,France,,,,,,,,,,,,,,
country,NCT02680574::country::Romania,NCT02680574,Romania,,,,,,,,,,,,,,
country,NCT02680574::country::Serbia,NCT02680574,Serbia,,,,,,,,,,,,,,
country,NCT02680574::country::Germany,NCT02680574,Germany,,,,,,,,,,,,,,
country,NCT02680574::country::Israel,NCT02680574,Israel,,,,,,,,,,,,,,
country,NCT02680574::country::Slovakia,NCT02680574,Slovakia,,,,,,,,,,,,,,
country,NCT02680574::country::Turkey (Türkiye),NCT02680574,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02680574::country::Chile,NCT02680574,Chile,,,,,,,,,,,,,,
country,NCT02680574::country::Czechia,NCT02680574,Czechia,,,,,,,,,,,,,,
country,NCT02680574::country::Malaysia,NCT02680574,Malaysia,,,,,,,,,,,,,,
country,NCT02680574::country::Austria,NCT02680574,Austria,,,,,,,,,,,,,,
country,NCT02680574::country::New Zealand,NCT02680574,New Zealand,,,,,,,,,,,,,,
country,NCT02680574::country::Canada,NCT02680574,Canada,,,,,,,,,,,,,,
country,NCT02680574::country::Poland,NCT02680574,Poland,,,,,,,,,,,,,,
country,NCT02680574::country::Puerto Rico,NCT02680574,Puerto Rico,,,,,,,,,,,,,,
trial,NCT03444324,NCT03444324,Adjusted Fibrinogen Replacement Strategy,PHASE3,cardiovascular disease,Bleeding Disorder; Hypofibrinogenemia; Acquired,INDUSTRY,222.0,2018-04-03,2023-11-21,7.0,19.0,,,,,
arm,NCT03444324::arm::FG000,NCT03444324,BT524,,,,,,,,,,FG000,"Investigational Human Fibrinogen Concentrate

BT524: BT524 was administered intravenously at a patient specific dosage depending on the type of surgery, the extent of bleeding and the subject's clinic",,,
arm,NCT03444324::arm::FG001,NCT03444324,FFP/Cryo,,,,,,,,,,FG001,"Standard of Care

Fresh Frozen Plasma (FFP)/Cryoprecipitate (Cryo): FFP/Cryo was administered intravenously; dosage according to local standards. FFP, 15 mL per kg body weight (BW); Cryo, fixed dose o",,,
period,NCT03444324::period::1,NCT03444324,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03444324::outcome::primary::1,NCT03444324,Intra-operative Blood Loss,,,,,,,,,,,,,PRIMARY,"From decision to treat the subject with IMP until end of surgery, an average of 5 hours"
country,NCT03444324::country::Germany,NCT03444324,Germany,,,,,,,,,,,,,,
country,NCT03444324::country::Czechia,NCT03444324,Czechia,,,,,,,,,,,,,,
country,NCT03444324::country::Spain,NCT03444324,Spain,,,,,,,,,,,,,,
country,NCT03444324::country::Belgium,NCT03444324,Belgium,,,,,,,,,,,,,,
country,NCT03444324::country::Switzerland,NCT03444324,Switzerland,,,,,,,,,,,,,,
country,NCT03444324::country::Poland,NCT03444324,Poland,,,,,,,,,,,,,,
country,NCT03444324::country::United Kingdom,NCT03444324,United Kingdom,,,,,,,,,,,,,,
trial,NCT00371683,NCT00371683,Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery,PHASE3,cardiovascular disease,Deep Vein Thrombosis; Pulmonary Embolism,INDUSTRY,3608.0,2006-11,2008-05,13.0,107.0,,,,,
arm,NCT00371683::arm::FG000,NCT00371683,Apixaban 2.5mg BID,,,,,,,,,,FG000,"Apixaban 2.5 mg tablets twice a day (BID) plus matching placebo SC injection q 12 hours for 12 days, plus or minus 2 days. The study included a screening period that began no more than 30 days prior t",,,
arm,NCT00371683::arm::FG001,NCT00371683,Enoxaparin 30 mg SC Injection q 12 Hours,,,,,,,,,,FG001,"Enoxaparin 30 mg subcutaneous (SC) injection every (q) 12 hours (h) plus matching placebo tablets BID for 12 days, plus or minus 2 days. The study included a screening period that began no more than 3",,,
period,NCT00371683::period::1,NCT00371683,DB Treatment Period-Randomized Patients,,,,,,,,,,,,1.0,,
period,NCT00371683::period::2,NCT00371683,Follow-Up Period - Randomized Patients,,,,,,,,,,,,2.0,,
outcome,NCT00371683::outcome::primary::1,NCT00371683,Event Rate of the Composite of Adjudicated Venous Thromboembolism (VTE) Events and All-Cause Death With Onset During the Intended Treatment Period - Primary Subjects,,,,,,,,,,,,,PRIMARY,"From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization"
outcome,NCT00371683::outcome::primary::2,NCT00371683,"Event Rate for Participants With Major Bleeding, Clinically Relevant Non-Major Bleeding, Major or Clinically Relevant Non-Major Bleeding, Any Bleeding With Onset During the Treatment Period - Treated Population",,,,,,,,,,,,,PRIMARY,"First dose of study drug to last dose, plus 2 days post last dose"
outcome,NCT00371683::outcome::primary::3,NCT00371683,"Event Rate for Participants With Major Bleeding, Clinically Relevant (CR) Non-Major (N-M) Bleeding , Major or Clinically Relevant (CR) Non-Major (N-M) Bleeding, Any Bleeding With Onset During the Follow-Up Period",,,,,,,,,,,,,PRIMARY,Last dose of study drug to Day 72 (60 days)
country,NCT00371683::country::United States,NCT00371683,United States,,,,,,,,,,,,,,
country,NCT00371683::country::Canada,NCT00371683,Canada,,,,,,,,,,,,,,
country,NCT00371683::country::Mexico,NCT00371683,Mexico,,,,,,,,,,,,,,
country,NCT00371683::country::Australia,NCT00371683,Australia,,,,,,,,,,,,,,
country,NCT00371683::country::Israel,NCT00371683,Israel,,,,,,,,,,,,,,
country,NCT00371683::country::Argentina,NCT00371683,Argentina,,,,,,,,,,,,,,
country,NCT00371683::country::Poland,NCT00371683,Poland,,,,,,,,,,,,,,
country,NCT00371683::country::Brazil,NCT00371683,Brazil,,,,,,,,,,,,,,
country,NCT00371683::country::Turkey (Türkiye),NCT00371683,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00371683::country::Hungary,NCT00371683,Hungary,,,,,,,,,,,,,,
country,NCT00371683::country::Russia,NCT00371683,Russia,,,,,,,,,,,,,,
country,NCT00371683::country::Denmark,NCT00371683,Denmark,,,,,,,,,,,,,,
country,NCT00371683::country::Sweden,NCT00371683,Sweden,,,,,,,,,,,,,,
trial,NCT01363440,NCT01363440,Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema,PHASE3,cardiovascular disease,Diabetic Macular Edema,INDUSTRY,466.0,2011-05,2014-11,1.0,51.0,,,,,
arm,NCT01363440::arm::FG000,NCT01363440,Macular Laser Photocoagulation Treatment (Control),,,,,,,,,,FG000,"Participants received macular laser treatment at baseline and as-needed at visits at which laser re-treatment criteria were met, but no more frequently than every 12 weeks.",,,
arm,NCT01363440::arm::FG001,NCT01363440,Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4,,,,,,,,,,FG001,Participants received 2mg Intravitreal aflibercept injection (IAI) every 4 weeks.,,,
arm,NCT01363440::arm::FG002,NCT01363440,Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8,,,,,,,,,,FG002,Participants received 2mg Intravitreal aflibercept injection (IAI) every 4 weeks for 5 visits followed by injections every 8 weeks.,,,
period,NCT01363440::period::1,NCT01363440,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01363440::outcome::primary::1,NCT01363440,Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF),,,,,,,,,,,,,PRIMARY,Baseline and Week 52
country,NCT01363440::country::United States,NCT01363440,United States,,,,,,,,,,,,,,
trial,NCT00283686,NCT00283686,HALT Progression of Polycystic Kidney Disease Study A,PHASE3,cardiovascular disease,"Kidney, Polycystic",NIH,558.0,2006-01,2014-06,1.0,7.0,,,,,
arm,NCT00283686::arm::FG000,NCT00283686,ACE-I/ARB and Standard BP,,,,,,,,,,FG000,"ACE-I + angiotensin-receptor blocker (ARB) and standard blood pressure control of 120-130/70-80 mm Hg

Lisinopril and Telmisartan: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and telmisartan titrated",,,
arm,NCT00283686::arm::FG001,NCT00283686,ACE-I/ARB and Low BP,,,,,,,,,,FG001,"ACE-I + angiotensin-receptor blocker (ARB) and low blood pressure control of 95-110/60-75 mm Hg

Lisinopril and Telmisartan: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and telmisartan titrated to 40",,,
arm,NCT00283686::arm::FG002,NCT00283686,ACE-I/Placebo and Standard BP,,,,,,,,,,FG002,"ACE-I + Placebo and standard blood pressure control of 120-130/70-80 mm Hg

Lisinopril and Placebo: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and placebo titrated to 40mg and 80mg, as tolerated by ",,,
arm,NCT00283686::arm::FG003,NCT00283686,ACE-I/Placebo and Low BP,,,,,,,,,,FG003,"ACE-I + Placebo and low blood pressure control of 95-110/60-75 mm Hg

Lisinopril and Placebo: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and placebo titrated to 40mg and 80mg, as tolerated by partic",,,
period,NCT00283686::period::1,NCT00283686,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00283686::outcome::primary::1,NCT00283686,Study A: Percent Annual Change in Total Kidney Volume,,,,,,,,,,,,,PRIMARY,"Baseline and 2-, 4- and 5-year follow-up"
country,NCT00283686::country::United States,NCT00283686,United States,,,,,,,,,,,,,,
trial,NCT00078286,NCT00078286,Antidepressant Medication Treatment for Depression in Individuals With Chronic Heart Failure,PHASE3,cardiovascular disease,"Heart Failure, Congestive; Chronic Heart Failure; Depression",OTHER,469.0,2003-11,2008-09,1.0,1.0,,,,,
arm,NCT00078286::arm::FG000,NCT00078286,Sertraline,,,,,,,,,,FG000,Participants will take sertraline for 12 weeks,,,
arm,NCT00078286::arm::FG001,NCT00078286,Placebo,,,,,,,,,,FG001,Participants will take placebo for 12 weeks,,,
period,NCT00078286::period::1,NCT00078286,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00078286::outcome::primary::1,NCT00078286,Symptoms of Depression in Congestive Heart Failure Patients With Clinical Depression After Treatment With Sertraline or Placebo,,,,,,,,,,,,,PRIMARY,Measured at Week 12
country,NCT00078286::country::United States,NCT00078286,United States,,,,,,,,,,,,,,
trial,NCT01345019,NCT01345019,Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma,PHASE3,cardiovascular disease,Cancer; Hematologic Malignancies; Multiple Myeloma; Oncology; Bone Metastases; Multiple Myeloma Bone Lesions,INDUSTRY,1718.0,2012-05-17,2019-03-29,29.0,309.0,,,,,
arm,NCT01345019::arm::FG000,NCT01345019,Zoledronic Acid,,,,,,,,,,FG000,Participants randomized to receive zoledronic acid 4 mg intravenously plus placebo to denosumab subcutaneously (SC) once every 4 weeks (Q4W) in the double-blind treatment phase. In the open-label trea,,,
arm,NCT01345019::arm::FG001,NCT01345019,Denosumab,,,,,,,,,,FG001,Participants randomized to receive denosumab 120 mg subcutaneously (SC) plus placebo to zoledronic acid intravenously once every 4 weeks (Q4W) in the double-blind treatment phase. In the open-label tr,,,
period,NCT01345019::period::1,NCT01345019,Blinded Treatment Phase,,,,,,,,,,,,1.0,,
period,NCT01345019::period::2,NCT01345019,Open Label Treatment Phase,,,,,,,,,,,,2.0,,
outcome,NCT01345019::outcome::primary::1,NCT01345019,Time to First On-study Skeletal Related Event,,,,,,,,,,,,,PRIMARY,From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol)
outcome,NCT01345019::outcome::primary::2,NCT01345019,Percentage of Participants With an On-study Skeletal Related Event,,,,,,,,,,,,,PRIMARY,median time on study was 17.6 and 17.3 months in each treatment group respectively.
outcome,NCT01345019::outcome::primary::3,NCT01345019,Kaplan-Meier Estimate of Percentage of Participants With an On-study Skeletal Related Event,,,,,,,,,,,,,PRIMARY,From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol)
country,NCT01345019::country::United States,NCT01345019,United States,,,,,,,,,,,,,,
country,NCT01345019::country::France,NCT01345019,France,,,,,,,,,,,,,,
country,NCT01345019::country::Italy,NCT01345019,Italy,,,,,,,,,,,,,,
country,NCT01345019::country::Japan,NCT01345019,Japan,,,,,,,,,,,,,,
country,NCT01345019::country::Canada,NCT01345019,Canada,,,,,,,,,,,,,,
country,NCT01345019::country::Russia,NCT01345019,Russia,,,,,,,,,,,,,,
country,NCT01345019::country::South Korea,NCT01345019,South Korea,,,,,,,,,,,,,,
country,NCT01345019::country::Spain,NCT01345019,Spain,,,,,,,,,,,,,,
country,NCT01345019::country::Australia,NCT01345019,Australia,,,,,,,,,,,,,,
country,NCT01345019::country::Germany,NCT01345019,Germany,,,,,,,,,,,,,,
country,NCT01345019::country::Austria,NCT01345019,Austria,,,,,,,,,,,,,,
country,NCT01345019::country::Bulgaria,NCT01345019,Bulgaria,,,,,,,,,,,,,,
country,NCT01345019::country::Greece,NCT01345019,Greece,,,,,,,,,,,,,,
country,NCT01345019::country::Hungary,NCT01345019,Hungary,,,,,,,,,,,,,,
country,NCT01345019::country::Poland,NCT01345019,Poland,,,,,,,,,,,,,,
country,NCT01345019::country::Taiwan,NCT01345019,Taiwan,,,,,,,,,,,,,,
country,NCT01345019::country::Ukraine,NCT01345019,Ukraine,,,,,,,,,,,,,,
country,NCT01345019::country::United Kingdom,NCT01345019,United Kingdom,,,,,,,,,,,,,,
country,NCT01345019::country::Czechia,NCT01345019,Czechia,,,,,,,,,,,,,,
country,NCT01345019::country::Ireland,NCT01345019,Ireland,,,,,,,,,,,,,,
country,NCT01345019::country::Portugal,NCT01345019,Portugal,,,,,,,,,,,,,,
country,NCT01345019::country::Turkey (Türkiye),NCT01345019,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01345019::country::Malaysia,NCT01345019,Malaysia,,,,,,,,,,,,,,
country,NCT01345019::country::Singapore,NCT01345019,Singapore,,,,,,,,,,,,,,
country,NCT01345019::country::Slovakia,NCT01345019,Slovakia,,,,,,,,,,,,,,
country,NCT01345019::country::Switzerland,NCT01345019,Switzerland,,,,,,,,,,,,,,
country,NCT01345019::country::Hong Kong,NCT01345019,Hong Kong,,,,,,,,,,,,,,
country,NCT01345019::country::Lithuania,NCT01345019,Lithuania,,,,,,,,,,,,,,
country,NCT01345019::country::New Zealand,NCT01345019,New Zealand,,,,,,,,,,,,,,
trial,NCT00633893,NCT00633893,Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism,PHASE3,cardiovascular disease,Venous Thrombosis,INDUSTRY,2711.0,2008-05,2012-08,29.0,428.0,,,,,
arm,NCT00633893::arm::FG000,NCT00633893,Apixaban 2.5 mg,,,,,,,,,,FG000,Participants received 2.5 mg oral tablet apixaban twice a day (BID),,,
arm,NCT00633893::arm::FG001,NCT00633893,Apixaban 5 mg,,,,,,,,,,FG001,Participants received 5 mg oral tablet apixaban BID.,,,
arm,NCT00633893::arm::FG002,NCT00633893,Placebo,,,,,,,,,,FG002,Participants received matching placebo oral tablet BID.,,,
period,NCT00633893::period::1,NCT00633893,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00633893::outcome::primary::1,NCT00633893,"Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation",,,,,,,,,,,,,PRIMARY,Day 1 up to 12 Months
outcome,NCT00633893::outcome::primary::2,NCT00633893,"Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population Without Imputation",,,,,,,,,,,,,PRIMARY,Day 1 up to 12 months
country,NCT00633893::country::United States,NCT00633893,United States,,,,,,,,,,,,,,
country,NCT00633893::country::Brazil,NCT00633893,Brazil,,,,,,,,,,,,,,
country,NCT00633893::country::Poland,NCT00633893,Poland,,,,,,,,,,,,,,
country,NCT00633893::country::Italy,NCT00633893,Italy,,,,,,,,,,,,,,
country,NCT00633893::country::Argentina,NCT00633893,Argentina,,,,,,,,,,,,,,
country,NCT00633893::country::Germany,NCT00633893,Germany,,,,,,,,,,,,,,
country,NCT00633893::country::Spain,NCT00633893,Spain,,,,,,,,,,,,,,
country,NCT00633893::country::Mexico,NCT00633893,Mexico,,,,,,,,,,,,,,
country,NCT00633893::country::Russia,NCT00633893,Russia,,,,,,,,,,,,,,
country,NCT00633893::country::Australia,NCT00633893,Australia,,,,,,,,,,,,,,
country,NCT00633893::country::India,NCT00633893,India,,,,,,,,,,,,,,
country,NCT00633893::country::Canada,NCT00633893,Canada,,,,,,,,,,,,,,
country,NCT00633893::country::France,NCT00633893,France,,,,,,,,,,,,,,
country,NCT00633893::country::Israel,NCT00633893,Israel,,,,,,,,,,,,,,
country,NCT00633893::country::Czechia,NCT00633893,Czechia,,,,,,,,,,,,,,
country,NCT00633893::country::Ukraine,NCT00633893,Ukraine,,,,,,,,,,,,,,
country,NCT00633893::country::South Africa,NCT00633893,South Africa,,,,,,,,,,,,,,
country,NCT00633893::country::United Kingdom,NCT00633893,United Kingdom,,,,,,,,,,,,,,
country,NCT00633893::country::Denmark,NCT00633893,Denmark,,,,,,,,,,,,,,
country,NCT00633893::country::Chile,NCT00633893,Chile,,,,,,,,,,,,,,
country,NCT00633893::country::Norway,NCT00633893,Norway,,,,,,,,,,,,,,
country,NCT00633893::country::South Korea,NCT00633893,South Korea,,,,,,,,,,,,,,
country,NCT00633893::country::Austria,NCT00633893,Austria,,,,,,,,,,,,,,
country,NCT00633893::country::Romania,NCT00633893,Romania,,,,,,,,,,,,,,
country,NCT00633893::country::Philippines,NCT00633893,Philippines,,,,,,,,,,,,,,
country,NCT00633893::country::Hong Kong,NCT00633893,Hong Kong,,,,,,,,,,,,,,
country,NCT00633893::country::Portugal,NCT00633893,Portugal,,,,,,,,,,,,,,
country,NCT00633893::country::Puerto Rico,NCT00633893,Puerto Rico,,,,,,,,,,,,,,
country,NCT00633893::country::Singapore,NCT00633893,Singapore,,,,,,,,,,,,,,
trial,NCT00782184,NCT00782184,Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED),PHASE3,cardiovascular disease,Hypercholesterolemia,INDUSTRY,250.0,2008-11,2010-09,0.0,0.0,,,,,
arm,NCT00782184::arm::FG000,NCT00782184,Ezetimibe/Simvastatin 10/40,,,,,,,,,,FG000,"Participants received 20 mg open-label atorvastatin during a 5-week run-in period. Following this run-in period, ezetimibe/simvastatin 10/40 was administered once daily in tablet form during the 6-wee",,,
arm,NCT00782184::arm::FG001,NCT00782184,Atorvastatin 40 mg,,,,,,,,,,FG001,"Participants received 20 mg open-label atorvastatin during a 5-week run-in period. Following this run-in period, 40 mg atorvastatin was administered once daily in tablet form during the 6-week double-",,,
period,NCT00782184::period::1,NCT00782184,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00782184::outcome::primary::1,NCT00782184,Percent Change From Baseline in Low Density Lipoprotein (LDL)-C,,,,,,,,,,,,,PRIMARY,"Baseline (Treatment Day 1), Treatment Week 6"
trial,NCT00719563,NCT00719563,American Ginseng in Treating Patients With Fatigue Caused by Cancer,PHASE3,cardiovascular disease,"Chronic Myeloproliferative Disorders; Fatigue; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific",OTHER,364.0,2008-10,2013-08,1.0,326.0,,,,,
arm,NCT00719563::arm::FG000,NCT00719563,Ginseng,,,,,,,,,,FG000,"Patients received oral American ginseng twice daily for 14 days. This treatment was repeated every two weeks for 4 courses, for a total of 8 weeks of treatment.",,,
arm,NCT00719563::arm::FG001,NCT00719563,Placebo,,,,,,,,,,FG001,"Patients received oral placebo twice daily for 14 days. This treatment was repeated every two weeks for 4 courses, for a total of 8 weeks of treatment.",,,
period,NCT00719563::period::1,NCT00719563,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00719563::outcome::primary::1,NCT00719563,Change From Baseline to Week 4 in the General Subscale of the MFSI-SF,,,,,,,,,,,,,PRIMARY,Baseline and week 4
country,NCT00719563::country::United States,NCT00719563,United States,,,,,,,,,,,,,,
trial,NCT02993406,NCT02993406,"Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo",PHASE3,cardiovascular disease,Cardiovascular Diseases; Statin Adverse Reaction,INDUSTRY,13970.0,2016-12-22,2022-11-07,32.0,1319.0,,,,,
arm,NCT02993406::arm::FG000,NCT02993406,Bempedoic Acid 180 Milligrams (mg),,,,,,,,,,FG000,Participants were administered with Bempedoic acid 180 mg tablet once daily orally.,,,
arm,NCT02993406::arm::FG001,NCT02993406,Placebo Comparator,,,,,,,,,,FG001,Participants were administered with matching Placebo tablet once daily orally.,,,
period,NCT02993406::period::1,NCT02993406,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02993406::outcome::primary::1,NCT02993406,Number of Participants With First Occurrence of Four Component Major Adverse Cardiovascular Events (MACE),,,,,,,,,,,,,PRIMARY,Up to 68 months
country,NCT02993406::country::United States,NCT02993406,United States,,,,,,,,,,,,,,
country,NCT02993406::country::Brazil,NCT02993406,Brazil,,,,,,,,,,,,,,
country,NCT02993406::country::Poland,NCT02993406,Poland,,,,,,,,,,,,,,
country,NCT02993406::country::Argentina,NCT02993406,Argentina,,,,,,,,,,,,,,
country,NCT02993406::country::Russia,NCT02993406,Russia,,,,,,,,,,,,,,
country,NCT02993406::country::Netherlands,NCT02993406,Netherlands,,,,,,,,,,,,,,
country,NCT02993406::country::Germany,NCT02993406,Germany,,,,,,,,,,,,,,
country,NCT02993406::country::Ukraine,NCT02993406,Ukraine,,,,,,,,,,,,,,
country,NCT02993406::country::Romania,NCT02993406,Romania,,,,,,,,,,,,,,
country,NCT02993406::country::Mexico,NCT02993406,Mexico,,,,,,,,,,,,,,
country,NCT02993406::country::Hungary,NCT02993406,Hungary,,,,,,,,,,,,,,
country,NCT02993406::country::United Kingdom,NCT02993406,United Kingdom,,,,,,,,,,,,,,
country,NCT02993406::country::Czechia,NCT02993406,Czechia,,,,,,,,,,,,,,
country,NCT02993406::country::India,NCT02993406,India,,,,,,,,,,,,,,
country,NCT02993406::country::South Africa,NCT02993406,South Africa,,,,,,,,,,,,,,
country,NCT02993406::country::Bulgaria,NCT02993406,Bulgaria,,,,,,,,,,,,,,
country,NCT02993406::country::Australia,NCT02993406,Australia,,,,,,,,,,,,,,
country,NCT02993406::country::Slovakia,NCT02993406,Slovakia,,,,,,,,,,,,,,
country,NCT02993406::country::Canada,NCT02993406,Canada,,,,,,,,,,,,,,
country,NCT02993406::country::Colombia,NCT02993406,Colombia,,,,,,,,,,,,,,
country,NCT02993406::country::Belgium,NCT02993406,Belgium,,,,,,,,,,,,,,
country,NCT02993406::country::New Zealand,NCT02993406,New Zealand,,,,,,,,,,,,,,
country,NCT02993406::country::Spain,NCT02993406,Spain,,,,,,,,,,,,,,
country,NCT02993406::country::Croatia,NCT02993406,Croatia,,,,,,,,,,,,,,
country,NCT02993406::country::Denmark,NCT02993406,Denmark,,,,,,,,,,,,,,
country,NCT02993406::country::Turkey (Türkiye),NCT02993406,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02993406::country::Austria,NCT02993406,Austria,,,,,,,,,,,,,,
country,NCT02993406::country::Lithuania,NCT02993406,Lithuania,,,,,,,,,,,,,,
country,NCT02993406::country::Serbia,NCT02993406,Serbia,,,,,,,,,,,,,,
country,NCT02993406::country::Chile,NCT02993406,Chile,,,,,,,,,,,,,,
country,NCT02993406::country::Latvia,NCT02993406,Latvia,,,,,,,,,,,,,,
country,NCT02993406::country::Estonia,NCT02993406,Estonia,,,,,,,,,,,,,,
trial,NCT00402363,NCT00402363,"Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation",PHASE3,cardiovascular disease,"Fibrillation, Atrial",INDUSTRY,663.0,2006-11,2010-01,1.0,178.0,,,,,
arm,NCT00402363::arm::FG000,NCT00402363,"Paroxysmal AF, P-OM3",,,,,,,,,,FG000,"Participants with paroxysmal atrial fibrillation (AF) receiving P-OM3, 8 grams (g) per day for the first 7 days; 4 g per day thereafter through Week 24. Paroxysmal AF was defined as AF that had never ",,,
arm,NCT00402363::arm::FG001,NCT00402363,"Paroxysmal AF, Placebo",,,,,,,,,,FG001,Participants with paroxysmal AF receiving matching placebo. Paroxysmal AF was defined as AF that had never been treated with pharmacologic/electrical therapy to terminate an episode. A documented epis,,,
arm,NCT00402363::arm::FG002,NCT00402363,"Persistent AF, P-OM3",,,,,,,,,,FG002,"Participants with persistent AF receiving P-OM3, 8 g per day for the first 7 days; 4 g per day thereafter through Week 24. Persistent AF was defined as AF that had been terminated at least once with p",,,
arm,NCT00402363::arm::FG003,NCT00402363,"Persistent AF, Placebo",,,,,,,,,,FG003,Participants with persistent AF receiving matching placebo. Persistent AF was defined as AF that had been terminated at least once with pharmacologic/electrical cardioversion. A documented episode of ,,,
period,NCT00402363::period::1,NCT00402363,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00402363::outcome::primary::1,NCT00402363,Number of Participants With Paroxysmal AF With an Event of Documented Symptomatic Atrial Fibrillation (AF)/Flutter,,,,,,,,,,,,,PRIMARY,From first dose of study drug (Day 1) to the first symptomatic recurrence of AF/flutter (up to Week 24)
country,NCT00402363::country::United States,NCT00402363,United States,,,,,,,,,,,,,,
trial,NCT00810693,NCT00810693,A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH),PHASE3,cardiovascular disease,Pulmonary Hypertension,INDUSTRY,445.0,2008-12-17,2012-05-14,30.0,122.0,,,,,
arm,NCT00810693::arm::FG000,NCT00810693,"Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT",,,,,,,,,,FG000,Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 12 w,,,
arm,NCT00810693::arm::FG001,NCT00810693,"Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT",,,,,,,,,,FG001,Participants received Riociguat orally as a film-coated tablet up to 1.5mg three times daily (tid) (titration between 1.0 mg and 1.5 mg tid based on an individual dose titration (IDT) scheme) for 12 w,,,
arm,NCT00810693::arm::FG002,NCT00810693,Placebo,,,,,,,,,,FG002,Participants received Placebo orally as a film-coated tablet three times daily (tid) for 12 weeks,,,
period,NCT00810693::period::1,NCT00810693,Treatment Period,,,,,,,,,,,,1.0,,
period,NCT00810693::period::2,NCT00810693,Follow-up Period (FUP),,,,,,,,,,,,2.0,,
outcome,NCT00810693::outcome::primary::1,NCT00810693,6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 12,,,,,,,,,,,,,PRIMARY,Baseline and week 12
country,NCT00810693::country::United States,NCT00810693,United States,,,,,,,,,,,,,,
country,NCT00810693::country::Japan,NCT00810693,Japan,,,,,,,,,,,,,,
country,NCT00810693::country::Germany,NCT00810693,Germany,,,,,,,,,,,,,,
country,NCT00810693::country::France,NCT00810693,France,,,,,,,,,,,,,,
country,NCT00810693::country::Australia,NCT00810693,Australia,,,,,,,,,,,,,,
country,NCT00810693::country::Mexico,NCT00810693,Mexico,,,,,,,,,,,,,,
country,NCT00810693::country::China,NCT00810693,China,,,,,,,,,,,,,,
country,NCT00810693::country::Italy,NCT00810693,Italy,,,,,,,,,,,,,,
country,NCT00810693::country::Brazil,NCT00810693,Brazil,,,,,,,,,,,,,,
country,NCT00810693::country::Portugal,NCT00810693,Portugal,,,,,,,,,,,,,,
country,NCT00810693::country::South Korea,NCT00810693,South Korea,,,,,,,,,,,,,,
country,NCT00810693::country::United Kingdom,NCT00810693,United Kingdom,,,,,,,,,,,,,,
country,NCT00810693::country::Austria,NCT00810693,Austria,,,,,,,,,,,,,,
country,NCT00810693::country::Canada,NCT00810693,Canada,,,,,,,,,,,,,,
country,NCT00810693::country::Spain,NCT00810693,Spain,,,,,,,,,,,,,,
country,NCT00810693::country::Sweden,NCT00810693,Sweden,,,,,,,,,,,,,,
country,NCT00810693::country::Taiwan,NCT00810693,Taiwan,,,,,,,,,,,,,,
country,NCT00810693::country::Turkey (Türkiye),NCT00810693,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00810693::country::Belgium,NCT00810693,Belgium,,,,,,,,,,,,,,
country,NCT00810693::country::Russia,NCT00810693,Russia,,,,,,,,,,,,,,
country,NCT00810693::country::Singapore,NCT00810693,Singapore,,,,,,,,,,,,,,
country,NCT00810693::country::Thailand,NCT00810693,Thailand,,,,,,,,,,,,,,
country,NCT00810693::country::Argentina,NCT00810693,Argentina,,,,,,,,,,,,,,
country,NCT00810693::country::Czechia,NCT00810693,Czechia,,,,,,,,,,,,,,
country,NCT00810693::country::Denmark,NCT00810693,Denmark,,,,,,,,,,,,,,
country,NCT00810693::country::Greece,NCT00810693,Greece,,,,,,,,,,,,,,
country,NCT00810693::country::Israel,NCT00810693,Israel,,,,,,,,,,,,,,
country,NCT00810693::country::New Zealand,NCT00810693,New Zealand,,,,,,,,,,,,,,
country,NCT00810693::country::Poland,NCT00810693,Poland,,,,,,,,,,,,,,
country,NCT00810693::country::Switzerland,NCT00810693,Switzerland,,,,,,,,,,,,,,
trial,NCT00689611,NCT00689611,Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial,PHASE3,cardiovascular disease,Acute Coronary Syndrome; Myocardial Infarction; Smoking,OTHER,392.0,2005-12,2010-06,7.0,38.0,,,,,
arm,NCT00689611::arm::FG000,NCT00689611,Placebo,,,,,,,,,,FG000,Participants received placebo for 9 weeks.,,,
arm,NCT00689611::arm::FG001,NCT00689611,Bupropion,,,,,,,,,,FG001,"Participants received bupropion for 9 weeks.

Bupropion HCl ER: 150 mg tablets po qd for 3 days and then 150 mg po bid for remainder of 9 weeks.",,,
period,NCT00689611::period::1,NCT00689611,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00689611::outcome::primary::1,NCT00689611,Smoking Abstinence,,,,,,,,,,,,,PRIMARY,12 months
country,NCT00689611::country::Canada,NCT00689611,Canada,,,,,,,,,,,,,,
country,NCT00689611::country::United States,NCT00689611,United States,,,,,,,,,,,,,,
country,NCT00689611::country::Bangladesh,NCT00689611,Bangladesh,,,,,,,,,,,,,,
country,NCT00689611::country::India,NCT00689611,India,,,,,,,,,,,,,,
country,NCT00689611::country::Iran,NCT00689611,Iran,,,,,,,,,,,,,,
country,NCT00689611::country::Pakistan,NCT00689611,Pakistan,,,,,,,,,,,,,,
country,NCT00689611::country::Tunisia,NCT00689611,Tunisia,,,,,,,,,,,,,,
trial,NCT01217463,NCT01217463,The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Southern Europe The TRANS-South Study,PHASE3,cardiovascular disease,Diabetic Foot Ulcer of Neuropathic Origin,INDUSTRY,201.0,2010-11,2013-02,4.0,24.0,,,,,
arm,NCT01217463::arm::FG000,NCT01217463,Trafermin,,,,,,,,,,FG000,"Trafermin 0.01% spray: For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If ",,,
arm,NCT01217463::arm::FG001,NCT01217463,Placebo,,,,,,,,,,FG001,"Matching placebo spray: For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If",,,
period,NCT01217463::period::1,NCT01217463,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01217463::outcome::primary::1,NCT01217463,"Wound Closure Rate of Diabetic Foot Ulcers (DFUs) of Neuropathic Topical Daily Application of Trafermin 0.01% Spray Compared With Placebo, in Addition",,,,,,,,,,,,,PRIMARY,12 weeks
country,NCT01217463::country::Italy,NCT01217463,Italy,,,,,,,,,,,,,,
country,NCT01217463::country::Hungary,NCT01217463,Hungary,,,,,,,,,,,,,,
country,NCT01217463::country::Czechia,NCT01217463,Czechia,,,,,,,,,,,,,,
country,NCT01217463::country::France,NCT01217463,France,,,,,,,,,,,,,,
trial,NCT00661999,NCT00661999,Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer,PHASE3,cardiovascular disease,"Anemia; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific",OTHER,502.0,2006-01,2009-03,1.0,2.0,,,,,
arm,NCT00661999::arm::FG000,NCT00661999,DA + IV Iron,,,,,,,,,,FG000,Patients receive darbepoetin alfa (DA) subcutaneously and sodium ferric gluconate complex intravenously (IV) over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence,,,
arm,NCT00661999::arm::FG001,NCT00661999,DA + Oral Iron,,,,,,,,,,FG001,Patients receive darbepoetin alfa (DA) as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.,,,
arm,NCT00661999::arm::FG002,NCT00661999,DA + Placebo,,,,,,,,,,FG002,Patients receive darbepoetin alfa (DA) as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.,,,
period,NCT00661999::period::1,NCT00661999,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00661999::outcome::primary::1,NCT00661999,Hematopoietic Response Rate Defined as the Number of Participants Who Exhibit a Hematopoietic Response,,,,,,,,,,,,,PRIMARY,16 Weeks
country,NCT00661999::country::United States,NCT00661999,United States,,,,,,,,,,,,,,
trial,NCT01968954,NCT01968954,Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events,PHASE3,cardiovascular disease,Hyperlipidemia,INDUSTRY,711.0,2013-10,2016-04,9.0,103.0,,,,,
arm,NCT01968954::arm::FG000,NCT01968954,Placebo,,,,,,,,,,FG000,Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks.,,,
arm,NCT01968954::arm::FG001,NCT01968954,PF-04950615 150 mg,,,,,,,,,,FG001,Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks.,,,
period,NCT01968954::period::1,NCT01968954,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01968954::outcome::primary::1,NCT01968954,Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12,,,,,,,,,,,,,PRIMARY,"Baseline, Week 12"
country,NCT01968954::country::United States,NCT01968954,United States,,,,,,,,,,,,,,
country,NCT01968954::country::Poland,NCT01968954,Poland,,,,,,,,,,,,,,
country,NCT01968954::country::South Korea,NCT01968954,South Korea,,,,,,,,,,,,,,
country,NCT01968954::country::Canada,NCT01968954,Canada,,,,,,,,,,,,,,
country,NCT01968954::country::Italy,NCT01968954,Italy,,,,,,,,,,,,,,
country,NCT01968954::country::Germany,NCT01968954,Germany,,,,,,,,,,,,,,
country,NCT01968954::country::Australia,NCT01968954,Australia,,,,,,,,,,,,,,
country,NCT01968954::country::Czechia,NCT01968954,Czechia,,,,,,,,,,,,,,
country,NCT01968954::country::Hong Kong,NCT01968954,Hong Kong,,,,,,,,,,,,,,
trial,NCT02798471,NCT02798471,Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE),PHASE3,cardiovascular disease,Venous Thromboembolism (VTE); Pulmonary Embolism; Deep Vein Thrombosis (DVT),INDUSTRY,290.0,2017-03-27,2022-05-24,34.0,140.0,,,,,
arm,NCT02798471::arm::FG000,NCT02798471,Edoxaban,,,,,,,,,,FG000,"Pediatric patients who were randomized to edoxaban treatment. Edoxaban was administered as 15 or 30 mg tablets for participants 12 years of age to \<18, and 60 mg edoxaban suspension for oral administ",,,
arm,NCT02798471::arm::FG001,NCT02798471,Standard of Care,,,,,,,,,,FG001,"Pediatric patients who were randomized to standard of care (SOC) treatment. Standard of care may have included low molecular weight heparin (LMWH), vitamin K antagonist (VKA), or synthetic pentasaccha",,,
period,NCT02798471::period::1,NCT02798471,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02798471::outcome::primary::1,NCT02798471,Number of Participants With Symptomatic Recurrent Venous Thromboembolism During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite),,,,,,,,,,,,,PRIMARY,Randomization to Month 3
outcome,NCT02798471::outcome::primary::2,NCT02798471,Number of Participants Who Died as a Result of VTE During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite),,,,,,,,,,,,,PRIMARY,Randomization to Month 3
outcome,NCT02798471::outcome::primary::3,NCT02798471,Number of Participants With No Change or Extension of Thrombotic Burden During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite),,,,,,,,,,,,,PRIMARY,Randomization to Month 3
country,NCT02798471::country::United States,NCT02798471,United States,,,,,,,,,,,,,,
country,NCT02798471::country::Brazil,NCT02798471,Brazil,,,,,,,,,,,,,,
country,NCT02798471::country::Turkey (Türkiye),NCT02798471,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02798471::country::India,NCT02798471,India,,,,,,,,,,,,,,
country,NCT02798471::country::France,NCT02798471,France,,,,,,,,,,,,,,
country,NCT02798471::country::Thailand,NCT02798471,Thailand,,,,,,,,,,,,,,
country,NCT02798471::country::Taiwan,NCT02798471,Taiwan,,,,,,,,,,,,,,
country,NCT02798471::country::Bulgaria,NCT02798471,Bulgaria,,,,,,,,,,,,,,
country,NCT02798471::country::Croatia,NCT02798471,Croatia,,,,,,,,,,,,,,
country,NCT02798471::country::Czechia,NCT02798471,Czechia,,,,,,,,,,,,,,
country,NCT02798471::country::Hungary,NCT02798471,Hungary,,,,,,,,,,,,,,
country,NCT02798471::country::Israel,NCT02798471,Israel,,,,,,,,,,,,,,
country,NCT02798471::country::Portugal,NCT02798471,Portugal,,,,,,,,,,,,,,
country,NCT02798471::country::South Korea,NCT02798471,South Korea,,,,,,,,,,,,,,
country,NCT02798471::country::Spain,NCT02798471,Spain,,,,,,,,,,,,,,
country,NCT02798471::country::Canada,NCT02798471,Canada,,,,,,,,,,,,,,
country,NCT02798471::country::Lebanon,NCT02798471,Lebanon,,,,,,,,,,,,,,
country,NCT02798471::country::Ukraine,NCT02798471,Ukraine,,,,,,,,,,,,,,
country,NCT02798471::country::Argentina,NCT02798471,Argentina,,,,,,,,,,,,,,
country,NCT02798471::country::Chile,NCT02798471,Chile,,,,,,,,,,,,,,
country,NCT02798471::country::Germany,NCT02798471,Germany,,,,,,,,,,,,,,
country,NCT02798471::country::Guatemala,NCT02798471,Guatemala,,,,,,,,,,,,,,
country,NCT02798471::country::Panama,NCT02798471,Panama,,,,,,,,,,,,,,
country,NCT02798471::country::Russia,NCT02798471,Russia,,,,,,,,,,,,,,
country,NCT02798471::country::Serbia,NCT02798471,Serbia,,,,,,,,,,,,,,
country,NCT02798471::country::Singapore,NCT02798471,Singapore,,,,,,,,,,,,,,
country,NCT02798471::country::Denmark,NCT02798471,Denmark,,,,,,,,,,,,,,
country,NCT02798471::country::El Salvador,NCT02798471,El Salvador,,,,,,,,,,,,,,
country,NCT02798471::country::Kenya,NCT02798471,Kenya,,,,,,,,,,,,,,
country,NCT02798471::country::Malaysia,NCT02798471,Malaysia,,,,,,,,,,,,,,
country,NCT02798471::country::Netherlands,NCT02798471,Netherlands,,,,,,,,,,,,,,
country,NCT02798471::country::Norway,NCT02798471,Norway,,,,,,,,,,,,,,
country,NCT02798471::country::Romania,NCT02798471,Romania,,,,,,,,,,,,,,
country,NCT02798471::country::Slovenia,NCT02798471,Slovenia,,,,,,,,,,,,,,
trial,NCT01953328,NCT01953328,Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk,PHASE3,cardiovascular disease,Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events,INDUSTRY,409.0,2013-10,2014-06,1.0,54.0,,,,,
arm,NCT01953328::arm::FG000,NCT01953328,A5 Placebo Q2W,,,,,,,,,,FG000,Participants received atorvastatin 5 mg (A5) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.,,,
arm,NCT01953328::arm::FG001,NCT01953328,A5 Placebo QM,,,,,,,,,,FG001,Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.,,,
arm,NCT01953328::arm::FG002,NCT01953328,A5 Evolocumab Q2W,,,,,,,,,,FG002,Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.,,,
arm,NCT01953328::arm::FG003,NCT01953328,A5 Evolocumab QM,,,,,,,,,,FG003,Participants received atorvastatin 5 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.,,,
arm,NCT01953328::arm::FG004,NCT01953328,A20 Placebo Q2W,,,,,,,,,,FG004,Participants received atorvastatin 20 mg (A20) daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.,,,
arm,NCT01953328::arm::FG005,NCT01953328,A20 Placebo QM,,,,,,,,,,FG005,Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.,,,
arm,NCT01953328::arm::FG006,NCT01953328,A20 Evolocumab Q2W,,,,,,,,,,FG006,Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.,,,
arm,NCT01953328::arm::FG007,NCT01953328,A20 Evolocumab QM,,,,,,,,,,FG007,Participants received atorvastatin 20 mg daily during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.,,,
period,NCT01953328::period::1,NCT01953328,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01953328::outcome::primary::1,NCT01953328,Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at the Mean of Weeks 10 and 12,,,,,,,,,,,,,PRIMARY,Baseline and Weeks 10 and 12
outcome,NCT01953328::outcome::primary::2,NCT01953328,Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12,,,,,,,,,,,,,PRIMARY,Baseline and Week 12
country,NCT01953328::country::Japan,NCT01953328,Japan,,,,,,,,,,,,,,
trial,NCT03037931,NCT03037931,Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study,PHASE3,cardiovascular disease,Heart Failure; Iron-deficiency,INDUSTRY,3065.0,2017-03-15,2023-02-02,13.0,345.0,,,,,
arm,NCT03037931::arm::FG000,NCT03037931,Ferric Carboxymaltose,,,,,,,,,,FG000,Ferric Carboxymaltose 2 doses intravenously of 15mg/kg to a maximum individual dose of 750mg 7 days apart and a maximum combined dose of 1500mg - repeated every 6 months as indicated by the results of,,,
arm,NCT03037931::arm::FG001,NCT03037931,Placebo,,,,,,,,,,FG001,"Normal saline 15ml - 2 doses 7 days apart repeated every 6 months.

Placebo: Normal Saline Solution",,,
period,NCT03037931::period::1,NCT03037931,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03037931::outcome::primary::1,NCT03037931,Number of Deaths,,,,,,,,,,,,,PRIMARY,1 year
outcome,NCT03037931::outcome::primary::2,NCT03037931,Number of Hospitalizations for Heart Failure,,,,,,,,,,,,,PRIMARY,1 year
outcome,NCT03037931::outcome::primary::3,NCT03037931,Change in 6MWT (Six Minute Walk Test) Distance,,,,,,,,,,,,,PRIMARY,6 months
country,NCT03037931::country::United States,NCT03037931,United States,,,,,,,,,,,,,,
country,NCT03037931::country::Canada,NCT03037931,Canada,,,,,,,,,,,,,,
country,NCT03037931::country::Ukraine,NCT03037931,Ukraine,,,,,,,,,,,,,,
country,NCT03037931::country::Australia,NCT03037931,Australia,,,,,,,,,,,,,,
country,NCT03037931::country::Poland,NCT03037931,Poland,,,,,,,,,,,,,,
country,NCT03037931::country::Bulgaria,NCT03037931,Bulgaria,,,,,,,,,,,,,,
country,NCT03037931::country::New Zealand,NCT03037931,New Zealand,,,,,,,,,,,,,,
country,NCT03037931::country::Russia,NCT03037931,Russia,,,,,,,,,,,,,,
country,NCT03037931::country::Georgia,NCT03037931,Georgia,,,,,,,,,,,,,,
country,NCT03037931::country::Hungary,NCT03037931,Hungary,,,,,,,,,,,,,,
country,NCT03037931::country::Czechia,NCT03037931,Czechia,,,,,,,,,,,,,,
country,NCT03037931::country::Latvia,NCT03037931,Latvia,,,,,,,,,,,,,,
country,NCT03037931::country::Lithuania,NCT03037931,Lithuania,,,,,,,,,,,,,,
trial,NCT01608100,NCT01608100,Evaluation of a New Cardiac Biomarker Assay,PHASE3,cardiovascular disease,Acute Coronary Syndrome; Acute Myocardial Infarction,INDUSTRY,1101.0,2012-06,2014-09,1.0,12.0,,,,,
arm,NCT01608100::arm::FG000,NCT01608100,ARCHITECT STAT High Sensitive Troponin I Assay Testing,,,,,,,,,,FG000,"All subjects will have their blood tested by the investigational Troponin I assay.

ARCHITECT STAT High Sensitive Troponin I Assay: Test blood samples from the ARCHITECT STAT High Sensitive Troponin I",,,
period,NCT01608100::period::1,NCT01608100,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01608100::outcome::primary::1,NCT01608100,Clinical Performance - Area Under the Curve,,,,,,,,,,,,,PRIMARY,"Troponin value from three collection time points (0-2 hours, >2 and up to 4 hours, >4 hours and up to 9 hours) from subject presentation to the emergency department"
outcome,NCT01608100::outcome::primary::2,NCT01608100,Clinical Performance- Sensitivity,,,,,,,,,,,,,PRIMARY,"Troponin value from three collection time points (0-2 hours, >2 and up to 4 hours, >4 hours and up to 9 hours) from subject presentation to the emergency department"
outcome,NCT01608100::outcome::primary::3,NCT01608100,Clinical Performance- Specificity,,,,,,,,,,,,,PRIMARY,"Troponin value from three collection time points (0-2 hours, >2 and up to 4 hours, >4 hours and up to 9 hours) from subject presentation to the emergency department."
outcome,NCT01608100::outcome::primary::4,NCT01608100,Clinical Performance- Negative Predictive Value (NPV),,,,,,,,,,,,,PRIMARY,"Troponin value from three collection time points (0-2 hours, >2 and up to 4 hours, >4 hours and up to 9 hours) from subject presentation to the emergency department."
outcome,NCT01608100::outcome::primary::5,NCT01608100,Clinical Performance- Positive Predictive Value (PPV),,,,,,,,,,,,,PRIMARY,"Troponin value from three collection time points (0-2 hours, >2 and up to 4 hours, >4 hours and up to 9 hours) from subject presentation to the emergency department."
country,NCT01608100::country::United States,NCT01608100,United States,,,,,,,,,,,,,,
trial,NCT03470545,NCT03470545,Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy,PHASE3,cardiovascular disease,Obstructive Hypertrophic Cardiomyopathy,INDUSTRY,251.0,2018-05-29,2020-05-06,13.0,71.0,,,,,
arm,NCT03470545::arm::FG000,NCT03470545,Mavacamten (MYK-461),,,,,,,,,,FG000,"Mavacamten: mavacamten capsules

One mavacamten 2.5, 5, 10, or 15 mg capsule once daily by mouth for 30 weeks. The starting dose of mavacamten was 5 mg once daily by mouth. At Week 8 and Week 14, mava",,,
arm,NCT03470545::arm::FG001,NCT03470545,Placebo,,,,,,,,,,FG001,"Placebo: placebo capsule

One placebo-to-match mavacamten capsule once daily by mouth for 30 weeks. A universal placebo capsule to match all strengths of mavacamten had the same appearance as mavacamt",,,
period,NCT03470545::period::1,NCT03470545,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03470545::outcome::primary::1,NCT03470545,Percentage of Participants Achieving A Clinical Response,,,,,,,,,,,,,PRIMARY,30 weeks
country,NCT03470545::country::United States,NCT03470545,United States,,,,,,,,,,,,,,
country,NCT03470545::country::Germany,NCT03470545,Germany,,,,,,,,,,,,,,
country,NCT03470545::country::Israel,NCT03470545,Israel,,,,,,,,,,,,,,
country,NCT03470545::country::Spain,NCT03470545,Spain,,,,,,,,,,,,,,
country,NCT03470545::country::France,NCT03470545,France,,,,,,,,,,,,,,
country,NCT03470545::country::Poland,NCT03470545,Poland,,,,,,,,,,,,,,
country,NCT03470545::country::Belgium,NCT03470545,Belgium,,,,,,,,,,,,,,
country,NCT03470545::country::Denmark,NCT03470545,Denmark,,,,,,,,,,,,,,
country,NCT03470545::country::Czechia,NCT03470545,Czechia,,,,,,,,,,,,,,
country,NCT03470545::country::Netherlands,NCT03470545,Netherlands,,,,,,,,,,,,,,
country,NCT03470545::country::Portugal,NCT03470545,Portugal,,,,,,,,,,,,,,
country,NCT03470545::country::United Kingdom,NCT03470545,United Kingdom,,,,,,,,,,,,,,
country,NCT03470545::country::Italy,NCT03470545,Italy,,,,,,,,,,,,,,
trial,NCT00064753,NCT00064753,Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT),PHASE3,cardiovascular disease,Chronic Kidney Disease; Cardiovascular Disease; Death,NIH,4110.0,2002-05,2011-10,3.0,30.0,,,,,
arm,NCT00064753::arm::FG000,NCT00064753,High Dose Multivitamin,,,,,,,,,,FG000,"Multivitamin with increased folic acid, vitamin B6 and vitamin B12

High Dose Multivitamin: Vitamin B6 (Pyridoxine HCl): 50 mg Folic acid: 5.0 mg Vitamin B12: 1.0 mg Vitamin B1 (Thiamine HNO3): 1.5 mg",,,
arm,NCT00064753::arm::FG001,NCT00064753,Low Dose Multivitamin,,,,,,,,,,FG001,"Multivitamin devoid of folic acid and with estimated average requirement (EAR) amounts of vitamin B6 and vitamin B12

Low Dose Multivitamin: Vitamin B6 (Pyridoxine HCl): 1.4 mg Folic acid: 0.0 mg Vita",,,
period,NCT00064753::period::1,NCT00064753,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00064753::outcome::primary::1,NCT00064753,"Recurrent or de Novo Arteriosclerotic Cardiovascular Disease (CVD) Defined as the Occurrence of Non-fatal or Fatal Arteriosclerotic Outcomes Including Coronary Heart, Cerebrovascular, and Peripheral Vascular Disease Events",,,,,,,,,,,,,PRIMARY,Up to 6 years (mean 4 years)
country,NCT00064753::country::United States,NCT00064753,United States,,,,,,,,,,,,,,
country,NCT00064753::country::Canada,NCT00064753,Canada,,,,,,,,,,,,,,
country,NCT00064753::country::Brazil,NCT00064753,Brazil,,,,,,,,,,,,,,
trial,NCT01618669,NCT01618669,A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT),PHASE3,cardiovascular disease,Coronary Artery Disease (CAD),INDUSTRY,1147.0,2012-06,2014-12,4.0,69.0,,,,,
arm,NCT01618669::arm::FG000,NCT01618669,Regadenoson After Peak Exercise,,,,,,,,,,FG000,"On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT myocardial perfusion imaging (MPI). One to 14 da",,,
arm,NCT01618669::arm::FG001,NCT01618669,Regadenoson Alone,,,,,,,,,,FG001,"On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at re",,,
period,NCT01618669::period::1,NCT01618669,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01618669::outcome::primary::1,NCT01618669,Proportion of Participants With Majority Reader Self-agreement in Ischemia Assessment Between First and Second Stress Scans,,,,,,,,,,,,,PRIMARY,Day 1 (rest scan and first stress scan) and Day 2 -15 (second stress scan)
country,NCT01618669::country::United States,NCT01618669,United States,,,,,,,,,,,,,,
country,NCT01618669::country::Argentina,NCT01618669,Argentina,,,,,,,,,,,,,,
country,NCT01618669::country::Peru,NCT01618669,Peru,,,,,,,,,,,,,,
country,NCT01618669::country::Puerto Rico,NCT01618669,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00862251,NCT00862251,Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED),PHASE3,cardiovascular disease,Cardiovascular Disorder; Diabetes Mellitus,INDUSTRY,808.0,2009-04,2011-03,0.0,0.0,,,,,
arm,NCT00862251::arm::FG000,NCT00862251,Ezetimibe/Simvastatin,,,,,,,,,,FG000,"Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks",,,
arm,NCT00862251::arm::FG001,NCT00862251,Doubling Statin Dose,,,,,,,,,,FG001,"simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.",,,
arm,NCT00862251::arm::FG002,NCT00862251,Rosuvastatin,,,,,,,,,,FG002,"Rosuvastatin 10 mg tablets, taken once daily for six weeks.",,,
period,NCT00862251::period::1,NCT00862251,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00862251::outcome::primary::1,NCT00862251,Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Statin (Simvastatin or Atorvastatin).,,,,,,,,,,,,,PRIMARY,Baseline and Week 6
trial,NCT01827046,NCT01827046,Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III,PHASE3,cardiovascular disease,Intracerebral Hemorrhage,OTHER,499.0,2013-12-30,2018-09,9.0,84.0,,,,,
arm,NCT01827046::arm::FG000,NCT01827046,MIS Plus Rt-PA Management,,,,,,,,,,FG000,Subjects randomized to the Minimally Invasive Surgery (MIS) plus recombinant tissue plasminogen activator (rt-PA) management arm will undergo minimally invasive surgery followed by up to 9 doses of 1.,,,
arm,NCT01827046::arm::FG001,NCT01827046,Medical Management,,,,,,,,,,FG001,"Subjects randomized to medical management will receive the standard medical therapies for the treatment of intracerebral hemorrhage, which includes ICU care only and no planned surgical intervention.",,,
period,NCT01827046::period::1,NCT01827046,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01827046::outcome::primary::1,NCT01827046,"Dichotomized, Adjudicated Modified Rankin Scale Score 0-3 vs. 4-6 at 365 Days Post Ictus (Adjusted)",,,,,,,,,,,,,PRIMARY,Day 365
country,NCT01827046::country::United States,NCT01827046,United States,,,,,,,,,,,,,,
country,NCT01827046::country::Spain,NCT01827046,Spain,,,,,,,,,,,,,,
country,NCT01827046::country::Germany,NCT01827046,Germany,,,,,,,,,,,,,,
country,NCT01827046::country::United Kingdom,NCT01827046,United Kingdom,,,,,,,,,,,,,,
country,NCT01827046::country::Australia,NCT01827046,Australia,,,,,,,,,,,,,,
country,NCT01827046::country::Canada,NCT01827046,Canada,,,,,,,,,,,,,,
country,NCT01827046::country::China,NCT01827046,China,,,,,,,,,,,,,,
country,NCT01827046::country::Hungary,NCT01827046,Hungary,,,,,,,,,,,,,,
country,NCT01827046::country::Israel,NCT01827046,Israel,,,,,,,,,,,,,,
trial,NCT00103662,NCT00103662,Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients,PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,302.0,2005-01,2008-01,3.0,39.0,,,,,
arm,NCT00103662::arm::FG000,NCT00103662,G-CSF Plus Plerixafor,,,,,,,,,,FG000,"Participants underwent mobilization with G-CSF for 4 days. On the evening of Day 4, participants received a dose of plerixafor. On each subsequent day, participants received a morning dose of G-CSF fo",,,
arm,NCT00103662::arm::FG001,NCT00103662,G-CSF Plus Placebo,,,,,,,,,,FG001,"Participants underwent mobilization with G-CSF for 4 days. On the evening of Day 4, participants received a dose of placebo. On each subsequent day, participants received a morning dose of G-CSF follo",,,
period,NCT00103662::period::1,NCT00103662,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00103662::outcome::primary::1,NCT00103662,Proportion of Participants Achieving a Target of ≥ 6*10^6 CD34+ Cells/kg in 2 or Fewer Days of Apheresis.,,,,,,,,,,,,,PRIMARY,up to Day 6
country,NCT00103662::country::United States,NCT00103662,United States,,,,,,,,,,,,,,
country,NCT00103662::country::Canada,NCT00103662,Canada,,,,,,,,,,,,,,
country,NCT00103662::country::Germany,NCT00103662,Germany,,,,,,,,,,,,,,
trial,NCT02320669,NCT02320669,Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass,PHASE3,cardiovascular disease,Congenital Heart Defects,OTHER,220.0,2014-11,2019-10,1.0,3.0,,,,,
arm,NCT02320669::arm::FG000,NCT02320669,Triiodothyronine,,,,,,,,,,FG000,Active Medication - Synthetic Thyroid Hormone Triostat: Bolus of Triiodothyronine followed by infusion for 48 hours,,,
arm,NCT02320669::arm::FG001,NCT02320669,Placebo,,,,,,,,,,FG001,Placebo Control Placebo: Bolus of Placebo followed by infusion for 48 hours,,,
period,NCT02320669::period::1,NCT02320669,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02320669::outcome::primary::1,NCT02320669,Time To Extubation,,,,,,,,,,,,,PRIMARY,30 days
country,NCT02320669::country::United States,NCT02320669,United States,,,,,,,,,,,,,,
trial,NCT04740931,NCT04740931,A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion,PHASE3,cardiovascular disease,Macular Edema; Central Retinal Vein Occlusion; Hemiretinal Vein Occlusion,INDUSTRY,729.0,2021-03-02,2023-07-12,22.0,194.0,,,,,
arm,NCT04740931::arm::FG000,NCT04740931,"Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)",,,,,,,,,,FG000,"In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm A will receive faricimab 6 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 i",,,
arm,NCT04740931::arm::FG001,NCT04740931,"Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)",,,,,,,,,,FG001,"In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm B will receive aflibercept 2 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6",,,
period,NCT04740931::period::1,NCT04740931,Part 1 (Baseline up to Week 24),,,,,,,,,,,,1.0,,
period,NCT04740931::period::2,NCT04740931,Part 2 (Week 24 to Week 72),,,,,,,,,,,,2.0,,
outcome,NCT04740931::outcome::primary::1,NCT04740931,Part 1: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 24,,,,,,,,,,,,,PRIMARY,From Baseline through Week 24
country,NCT04740931::country::United States,NCT04740931,United States,,,,,,,,,,,,,,
country,NCT04740931::country::Japan,NCT04740931,Japan,,,,,,,,,,,,,,
country,NCT04740931::country::Poland,NCT04740931,Poland,,,,,,,,,,,,,,
country,NCT04740931::country::China,NCT04740931,China,,,,,,,,,,,,,,
country,NCT04740931::country::United Kingdom,NCT04740931,United Kingdom,,,,,,,,,,,,,,
country,NCT04740931::country::Argentina,NCT04740931,Argentina,,,,,,,,,,,,,,
country,NCT04740931::country::South Korea,NCT04740931,South Korea,,,,,,,,,,,,,,
country,NCT04740931::country::Spain,NCT04740931,Spain,,,,,,,,,,,,,,
country,NCT04740931::country::Australia,NCT04740931,Australia,,,,,,,,,,,,,,
country,NCT04740931::country::Brazil,NCT04740931,Brazil,,,,,,,,,,,,,,
country,NCT04740931::country::Hungary,NCT04740931,Hungary,,,,,,,,,,,,,,
country,NCT04740931::country::Israel,NCT04740931,Israel,,,,,,,,,,,,,,
country,NCT04740931::country::Russia,NCT04740931,Russia,,,,,,,,,,,,,,
country,NCT04740931::country::France,NCT04740931,France,,,,,,,,,,,,,,
country,NCT04740931::country::Germany,NCT04740931,Germany,,,,,,,,,,,,,,
country,NCT04740931::country::Portugal,NCT04740931,Portugal,,,,,,,,,,,,,,
country,NCT04740931::country::Taiwan,NCT04740931,Taiwan,,,,,,,,,,,,,,
country,NCT04740931::country::Austria,NCT04740931,Austria,,,,,,,,,,,,,,
country,NCT04740931::country::Czechia,NCT04740931,Czechia,,,,,,,,,,,,,,
country,NCT04740931::country::Hong Kong,NCT04740931,Hong Kong,,,,,,,,,,,,,,
country,NCT04740931::country::Italy,NCT04740931,Italy,,,,,,,,,,,,,,
country,NCT04740931::country::Singapore,NCT04740931,Singapore,,,,,,,,,,,,,,
trial,NCT01631227,NCT01631227,Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension,PHASE3,cardiovascular disease,Essential Hypertension,INDUSTRY,665.0,2012-06,2013-04,3.0,38.0,,,,,
arm,NCT01631227::arm::FG000,NCT01631227,Eprosartan,,,,,,,,,,FG000,Eprosartan 450 mg + Placebo Eprosartan Mesylate,,,
arm,NCT01631227::arm::FG001,NCT01631227,Eprosartan Mesylate,,,,,,,,,,FG001,Eprosartan Mesylate 600 mg + Placebo Eprosartan,,,
period,NCT01631227::period::1,NCT01631227,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01631227::outcome::primary::1,NCT01631227,Assess the Therapeutic Equivalence of Eprosartan (a New Formulation Containing Only the Active Moiety Eprosartan) With Eprosartan Mesylate (Currently Marketed Formulation) on Change of Sitting Diastolic Blood Pressure (DBP) From Baseline,,,,,,,,,,,,,PRIMARY,8 weeks
country,NCT01631227::country::Russia,NCT01631227,Russia,,,,,,,,,,,,,,
country,NCT01631227::country::Germany,NCT01631227,Germany,,,,,,,,,,,,,,
country,NCT01631227::country::United Kingdom,NCT01631227,United Kingdom,,,,,,,,,,,,,,
trial,NCT02235909,NCT02235909,An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,377.0,2015-03-30,2019-11-11,12.0,69.0,,,,,
arm,NCT02235909::arm::FG000,NCT02235909,Active Comparator: Double Blind Phase: Losartan,,,,,,,,,,FG000,"6-week, double-blind (DB), randomized, treatment phase (DB Phase): Starting at Losartan 25/50 and force titrated to 50/100 mg daily at Week 2.",,,
arm,NCT02235909::arm::FG001,NCT02235909,Experimental: Double-blind: Azilsartan Medoxomil - Low Dose,,,,,,,,,,FG001,"6-week, double-blind (DB), randomized, treatment phase (DB Phase): Azilsartan medoxomil Low-dose (AZM-L), 10 mg once daily.",,,
arm,NCT02235909::arm::FG002,NCT02235909,Experimental: Double-blind: Azilsartan Medoxomil - Medium Dose,,,,,,,,,,FG002,"6-week, double-blind (DB), randomized, treatment phase (DB Phase), Azilsartan medoxomil Medium-dose (AZM-M), 20 mg once daily at Week 2.",,,
arm,NCT02235909::arm::FG003,NCT02235909,Experimental: Double-blind: Azilsartan Medoxomil - High Dose,,,,,,,,,,FG003,"6-week, double-blind (DB), randomized, treatment phase (DB Phase): Azilsartan medoxomil High-dose (AZM-H), 40 mg AZM-M",,,
arm,NCT02235909::arm::FG004,NCT02235909,Placebo Comparator: Withdrawal Phase: PLACEBO,,,,,,,,,,FG004,"Placebo Arm In the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment or to be switched to placebo.",,,
arm,NCT02235909::arm::FG005,NCT02235909,Active Comparator: Withdrawal Phase: Losartan 50 mg,,,,,,,,,,FG005,"Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment or to be switched to placebo.",,,
arm,NCT02235909::arm::FG006,NCT02235909,Active Comparator: WITHDRAWAL Phase: Azilsartan Medoxomil LOW-dose,,,,,,,,,,FG006,"Experimental Arm in the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment ( Azilsartan medoxomil low dose) that was taken in Double blin",,,
arm,NCT02235909::arm::FG007,NCT02235909,Experimental: WITHDRAWAL Azilsartan Medoxomil - Medium Dose,,,,,,,,,,FG007,"Experimental Arm in the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment ( Azilsartan medoxomil MEDIUM dose) that was taken in Double b",,,
arm,NCT02235909::arm::FG008,NCT02235909,Experimental: WITHDRAWAL Azilsartan Medoxomil - High Dose,,,,,,,,,,FG008,"Experimental Arm in the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment ( Azilsartan medoxomil HIGH dose) that was taken in Double bli",,,
arm,NCT02235909::arm::FG009,NCT02235909,Azilsartan Medoxomil Alone,,,,,,,,,,FG009,"A subset of subjects taking AZM (10, 20, 40, or 80 mg) alone",,,
arm,NCT02235909::arm::FG010,NCT02235909,AZM Plus,,,,,,,,,,FG010,"A subset of subjects taking AZM (10, 20, 40, or 80 mg) plus additional antihypertensives as needed",,,
period,NCT02235909::period::1,NCT02235909,Double-Blind Phase,,,,,,,,,,,,1.0,,
period,NCT02235909::period::2,NCT02235909,Withdrawal Phase,,,,,,,,,,,,2.0,,
period,NCT02235909::period::3,NCT02235909,Open Label,,,,,,,,,,,,3.0,,
outcome,NCT02235909::outcome::primary::1,NCT02235909,Change in Seated Diastolic Blood Pressure Between AZM and Placebo,,,,,,,,,,,,,PRIMARY,From Week 6/Final Visit of DB Phase to Week 8/Final Visit of Withdrawal Phase
country,NCT02235909::country::United States,NCT02235909,United States,,,,,,,,,,,,,,
country,NCT02235909::country::Ukraine,NCT02235909,Ukraine,,,,,,,,,,,,,,
country,NCT02235909::country::Brazil,NCT02235909,Brazil,,,,,,,,,,,,,,
country,NCT02235909::country::South Africa,NCT02235909,South Africa,,,,,,,,,,,,,,
country,NCT02235909::country::Turkey (Türkiye),NCT02235909,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02235909::country::Colombia,NCT02235909,Colombia,,,,,,,,,,,,,,
country,NCT02235909::country::Hungary,NCT02235909,Hungary,,,,,,,,,,,,,,
country,NCT02235909::country::Mexico,NCT02235909,Mexico,,,,,,,,,,,,,,
country,NCT02235909::country::Poland,NCT02235909,Poland,,,,,,,,,,,,,,
country,NCT02235909::country::Argentina,NCT02235909,Argentina,,,,,,,,,,,,,,
country,NCT02235909::country::Italy,NCT02235909,Italy,,,,,,,,,,,,,,
country,NCT02235909::country::Bulgaria,NCT02235909,Bulgaria,,,,,,,,,,,,,,
trial,NCT01311687,NCT01311687,"A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study",PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,455.0,2011-03-11,2017-08-29,16.0,94.0,,,,,
arm,NCT01311687::arm::FG000,NCT01311687,Pomalidomide Plus Low-Dose Dexamethasone,,,,,,,,,,FG000,Participants received 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle and 40 mg dexamethasone (participants \> 75 years of age received 20 mg dexamethasone) adminis,,,
arm,NCT01311687::arm::FG001,NCT01311687,High-Dose Dexamethasone (HD-Dex),,,,,,,,,,FG001,"Participants received 40 mg dexamethasone (participants \> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1 through 4, 9 through 12, and 17 through 20 of a 28",,,
period,NCT01311687::period::1,NCT01311687,Treatment Phase,,,,,,,,,,,,1.0,,
period,NCT01311687::period::2,NCT01311687,PFS Follow-up Phase,,,,,,,,,,,,2.0,,
outcome,NCT01311687::outcome::primary::1,NCT01311687,Progression-free Survival (PFS) - Primary Analysis,,,,,,,,,,,,,PRIMARY,From randomization until the data cut-off date of 07 September 2012. Maximum duration of follow-up for PFS assessments was 57 weeks.
outcome,NCT01311687::outcome::primary::2,NCT01311687,Progression-free Survival (PFS) With a Later Cut-off Date,,,,,,,,,,,,,PRIMARY,From randomization until the data cut-off date of 01 March 2013. Maximum duration of follow-up for PFS assessments was 74 weeks.
country,NCT01311687::country::France,NCT01311687,France,,,,,,,,,,,,,,
country,NCT01311687::country::Australia,NCT01311687,Australia,,,,,,,,,,,,,,
country,NCT01311687::country::Canada,NCT01311687,Canada,,,,,,,,,,,,,,
country,NCT01311687::country::United Kingdom,NCT01311687,United Kingdom,,,,,,,,,,,,,,
country,NCT01311687::country::Germany,NCT01311687,Germany,,,,,,,,,,,,,,
country,NCT01311687::country::Italy,NCT01311687,Italy,,,,,,,,,,,,,,
country,NCT01311687::country::Spain,NCT01311687,Spain,,,,,,,,,,,,,,
country,NCT01311687::country::Sweden,NCT01311687,Sweden,,,,,,,,,,,,,,
country,NCT01311687::country::Denmark,NCT01311687,Denmark,,,,,,,,,,,,,,
country,NCT01311687::country::Russia,NCT01311687,Russia,,,,,,,,,,,,,,
country,NCT01311687::country::Belgium,NCT01311687,Belgium,,,,,,,,,,,,,,
country,NCT01311687::country::Netherlands,NCT01311687,Netherlands,,,,,,,,,,,,,,
country,NCT01311687::country::Switzerland,NCT01311687,Switzerland,,,,,,,,,,,,,,
country,NCT01311687::country::United States,NCT01311687,United States,,,,,,,,,,,,,,
country,NCT01311687::country::Czechia,NCT01311687,Czechia,,,,,,,,,,,,,,
country,NCT01311687::country::Greece,NCT01311687,Greece,,,,,,,,,,,,,,
trial,NCT03151993,NCT03151993,Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS,PHASE3,cardiovascular disease,Ischemic Stroke,INDUSTRY,336.0,2017-03-18,2019-06-20,1.0,18.0,,,,,
arm,NCT03151993::arm::FG000,NCT03151993,Recombinant Staphylokinase,,,,,,,,,,FG000,"Lyophilizate for solution making for intravenous injection, 5 mg (745000 ME). 10 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds

Recombinant ",,,
arm,NCT03151993::arm::FG001,NCT03151993,Actilyse,,,,,,,,,,FG001,"Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)

Alteplase: Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)",,,
period,NCT03151993::period::1,NCT03151993,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03151993::outcome::primary::1,NCT03151993,Good Functional Recovery,,,,,,,,,,,,,PRIMARY,within 90 days after fibrinolysis
country,NCT03151993::country::Russia,NCT03151993,Russia,,,,,,,,,,,,,,
trial,NCT00168818,NCT00168818,Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery,PHASE3,cardiovascular disease,"Thromboembolism; Arthroplasty, Replacement, Hip",INDUSTRY,3494.0,2004-11,,16.0,116.0,,,,,
arm,NCT00168818::arm::FG000,NCT00168818,Dabigatran 220mg,,,,,,,,,,FG000,Patients were treated with 220mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.,,,
arm,NCT00168818::arm::FG001,NCT00168818,Dabigatran 150mg,,,,,,,,,,FG001,Patients were treated with 150mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.,,,
arm,NCT00168818::arm::FG002,NCT00168818,Enoxaparin,,,,,,,,,,FG002,Patients were treated with 40mg Enoxaparin once daily for subcutaneous injection and placebo capsules. Placebo capsules matching the dabigatran capsules.,,,
period,NCT00168818::period::1,NCT00168818,Overall Study,,,,,,,,,,,,1.0,,
period,NCT00168818::period::2,NCT00168818,Treatment,,,,,,,,,,,,2.0,,
outcome,NCT00168818::outcome::primary::1,NCT00168818,Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period,,,,,,,,,,,,,PRIMARY,First administration until 31-38 days
country,NCT00168818::country::Poland,NCT00168818,Poland,,,,,,,,,,,,,,
country,NCT00168818::country::Germany,NCT00168818,Germany,,,,,,,,,,,,,,
country,NCT00168818::country::Spain,NCT00168818,Spain,,,,,,,,,,,,,,
country,NCT00168818::country::Australia,NCT00168818,Australia,,,,,,,,,,,,,,
country,NCT00168818::country::Czechia,NCT00168818,Czechia,,,,,,,,,,,,,,
country,NCT00168818::country::Sweden,NCT00168818,Sweden,,,,,,,,,,,,,,
country,NCT00168818::country::Belgium,NCT00168818,Belgium,,,,,,,,,,,,,,
country,NCT00168818::country::Hungary,NCT00168818,Hungary,,,,,,,,,,,,,,
country,NCT00168818::country::Netherlands,NCT00168818,Netherlands,,,,,,,,,,,,,,
country,NCT00168818::country::Norway,NCT00168818,Norway,,,,,,,,,,,,,,
country,NCT00168818::country::Denmark,NCT00168818,Denmark,,,,,,,,,,,,,,
country,NCT00168818::country::Finland,NCT00168818,Finland,,,,,,,,,,,,,,
country,NCT00168818::country::Austria,NCT00168818,Austria,,,,,,,,,,,,,,
country,NCT00168818::country::France,NCT00168818,France,,,,,,,,,,,,,,
country,NCT00168818::country::Italy,NCT00168818,Italy,,,,,,,,,,,,,,
country,NCT00168818::country::South Africa,NCT00168818,South Africa,,,,,,,,,,,,,,
trial,NCT00773747,NCT00773747,"Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)",PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,637.0,2008-12-01,2015-06-30,0.0,0.0,,,,,
arm,NCT00773747::arm::FG000,NCT00773747,Vorinostat + Bortezomib,,,,,,,,,,FG000,Participants will receive vorinostat four 100 mg capsules (400 mg total) orally 0-30 minutes after a meal on Days 1 through 14 of a 21-day treatment cycle and bortezomib 1.3 mg/m\^2 by intravenous inj,,,
arm,NCT00773747::arm::FG001,NCT00773747,Placebo + Bortezomib,,,,,,,,,,FG001,"Participants will receive four placebo capsules orally 0-30 minutes after a meal on Days 1 through 14 of a 21-day treatment cycle and bortezomib 1.3 mg/m\^2 by intravenous injection on Days 1, 4, 8, a",,,
period,NCT00773747::period::1,NCT00773747,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00773747::outcome::primary::1,NCT00773747,Progression-Free Survival (PFS),,,,,,,,,,,,,PRIMARY,From randomization to event of disease progression or death assessed up to 32 months (final study analysis)
trial,NCT00324350,NCT00324350,Intensive Glycemic Control and Skeletal Health Study,PHASE3,cardiovascular disease,Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia; Hypertension; Diabetes Mellitus; Coronary Disease,OTHER,7287.0,2003-10,2009-06,2.0,5.0,,,,,
arm,NCT00324350::arm::FG000,NCT00324350,Intensive Glycemic Control,,,,,,,,,,FG000,"intensive therapeutic strategy targeting normal glycated hemoglobin (A1C) levels (i.e., below 6.0%)in a population with long-standing type 2 diabetes and a history of cardiovascular disease or signifi",,,
arm,NCT00324350::arm::FG001,NCT00324350,Standard Glycemic Control,,,,,,,,,,FG001,standard strategy targeting A1C levels from 7.0 to 7.9% in a population with long-standing type 2 diabetes and a history of cardiovascular disease or significant cardiovascular risk factors,,,
period,NCT00324350::period::1,NCT00324350,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00324350::outcome::primary::1,NCT00324350,Number of Participants With at Least One Non-vertebral Fracture,,,,,,,,,,,,,PRIMARY,Average follow-up of 3.8 years
outcome,NCT00324350::outcome::primary::2,NCT00324350,Number of Participants With at Least One Fall,,,,,,,,,,,,,PRIMARY,Average follow-up of 2.0 years
country,NCT00324350::country::United States,NCT00324350,United States,,,,,,,,,,,,,,
country,NCT00324350::country::Canada,NCT00324350,Canada,,,,,,,,,,,,,,
trial,NCT00558259,NCT00558259,Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE,PHASE3,cardiovascular disease,Venous Thromboembolism,INDUSTRY,1353.0,2007-11,,21.0,147.0,,,,,
arm,NCT00558259::arm::FG000,NCT00558259,Dabigatran,,,,,,,,,,FG000,Dabigatran 150mg bid (twice daily),,,
arm,NCT00558259::arm::FG001,NCT00558259,Placebo,,,,,,,,,,FG001,Matching placebo,,,
period,NCT00558259::period::1,NCT00558259,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00558259::outcome::primary::1,NCT00558259,Centrally Confirmed Symptomatic Recurrent Venous Thrombotic Events (VTE) Including Unexplained Death During the Intended Treatment Period,,,,,,,,,,,,,PRIMARY,6 months
country,NCT00558259::country::United States,NCT00558259,United States,,,,,,,,,,,,,,
country,NCT00558259::country::Italy,NCT00558259,Italy,,,,,,,,,,,,,,
country,NCT00558259::country::Czechia,NCT00558259,Czechia,,,,,,,,,,,,,,
country,NCT00558259::country::Switzerland,NCT00558259,Switzerland,,,,,,,,,,,,,,
country,NCT00558259::country::Germany,NCT00558259,Germany,,,,,,,,,,,,,,
country,NCT00558259::country::Netherlands,NCT00558259,Netherlands,,,,,,,,,,,,,,
country,NCT00558259::country::Poland,NCT00558259,Poland,,,,,,,,,,,,,,
country,NCT00558259::country::South Korea,NCT00558259,South Korea,,,,,,,,,,,,,,
country,NCT00558259::country::Sweden,NCT00558259,Sweden,,,,,,,,,,,,,,
country,NCT00558259::country::Austria,NCT00558259,Austria,,,,,,,,,,,,,,
country,NCT00558259::country::Belgium,NCT00558259,Belgium,,,,,,,,,,,,,,
country,NCT00558259::country::Russia,NCT00558259,Russia,,,,,,,,,,,,,,
country,NCT00558259::country::Australia,NCT00558259,Australia,,,,,,,,,,,,,,
country,NCT00558259::country::Canada,NCT00558259,Canada,,,,,,,,,,,,,,
country,NCT00558259::country::South Africa,NCT00558259,South Africa,,,,,,,,,,,,,,
country,NCT00558259::country::Thailand,NCT00558259,Thailand,,,,,,,,,,,,,,
country,NCT00558259::country::Estonia,NCT00558259,Estonia,,,,,,,,,,,,,,
country,NCT00558259::country::Latvia,NCT00558259,Latvia,,,,,,,,,,,,,,
country,NCT00558259::country::Lithuania,NCT00558259,Lithuania,,,,,,,,,,,,,,
country,NCT00558259::country::New Zealand,NCT00558259,New Zealand,,,,,,,,,,,,,,
country,NCT00558259::country::Singapore,NCT00558259,Singapore,,,,,,,,,,,,,,
trial,NCT00402727,NCT00402727,Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection,PHASE3,cardiovascular disease,Abscess; Wound Infection; Diabetic Foot; Ulcer,INDUSTRY,813.0,2006-09,2008-06,20.0,123.0,,,,,
arm,NCT00402727::arm::FG000,NCT00402727,Moxifloxacin,,,,,,,,,,FG000,"Moxifloxacin (Avelox, BAY 12-8039) 400 mg intravenous (IV) once daily followed by Moxifloxacin 400 mg oral tablets once daily for a minimum of 7 days and a maximum of 21 days. Oral phase was not alway",,,
arm,NCT00402727::arm::FG001,NCT00402727,PIP/TAZ-AMC,,,,,,,,,,FG001,Piperacillin/Tacobactam 4.0/0.5 g (PIP/TAZ) administered intravenous three times daily followed by Amoxicillin/Clavulanic acid (AMC) oral tablets 875/125 mg twice daily for a minimum of 7 days and a m,,,
period,NCT00402727::period::1,NCT00402727,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00402727::outcome::primary::1,NCT00402727,Percentage of Cured Participants as Determined by the Data Review Committee (DRC) at Test of Cure Visit in the Per Protocol (PP) Population,,,,,,,,,,,,,PRIMARY,14 - 28 days after last dose of study medication
country,NCT00402727::country::Germany,NCT00402727,Germany,,,,,,,,,,,,,,
country,NCT00402727::country::Russia,NCT00402727,Russia,,,,,,,,,,,,,,
country,NCT00402727::country::France,NCT00402727,France,,,,,,,,,,,,,,
country,NCT00402727::country::United Kingdom,NCT00402727,United Kingdom,,,,,,,,,,,,,,
country,NCT00402727::country::Spain,NCT00402727,Spain,,,,,,,,,,,,,,
country,NCT00402727::country::Ukraine,NCT00402727,Ukraine,,,,,,,,,,,,,,
country,NCT00402727::country::Poland,NCT00402727,Poland,,,,,,,,,,,,,,
country,NCT00402727::country::Bulgaria,NCT00402727,Bulgaria,,,,,,,,,,,,,,
country,NCT00402727::country::Greece,NCT00402727,Greece,,,,,,,,,,,,,,
country,NCT00402727::country::Hungary,NCT00402727,Hungary,,,,,,,,,,,,,,
country,NCT00402727::country::Ireland,NCT00402727,Ireland,,,,,,,,,,,,,,
country,NCT00402727::country::Latvia,NCT00402727,Latvia,,,,,,,,,,,,,,
country,NCT00402727::country::South Africa,NCT00402727,South Africa,,,,,,,,,,,,,,
country,NCT00402727::country::Italy,NCT00402727,Italy,,,,,,,,,,,,,,
country,NCT00402727::country::Romania,NCT00402727,Romania,,,,,,,,,,,,,,
country,NCT00402727::country::Belgium,NCT00402727,Belgium,,,,,,,,,,,,,,
country,NCT00402727::country::Lithuania,NCT00402727,Lithuania,,,,,,,,,,,,,,
country,NCT00402727::country::Austria,NCT00402727,Austria,,,,,,,,,,,,,,
country,NCT00402727::country::Israel,NCT00402727,Israel,,,,,,,,,,,,,,
country,NCT00402727::country::Netherlands,NCT00402727,Netherlands,,,,,,,,,,,,,,
trial,NCT03585270,NCT03585270,"Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain",PHASE3,cardiovascular disease,Aneurysmal Subarachnoid Hemorrhage,INDUSTRY,409.0,2019-02-03,2022-11-18,15.0,80.0,,,,,
arm,NCT03585270::arm::FG000,NCT03585270,Clazosentan,,,,,,,,,,FG000,All participants from the randomized analysis set who started clazosentan 15 mg per hour infusion for up to 14 days.,,,
arm,NCT03585270::arm::FG001,NCT03585270,Placebo,,,,,,,,,,FG001,All participants from the randomized analysis set who started matching placebo infusion for up to 14 days.,,,
period,NCT03585270::period::1,NCT03585270,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03585270::outcome::primary::1,NCT03585270,Occurrence of Clinical Deterioration Due to Delayed Cerebral Ischemia (DCI) From Study Drug Initiation up to 14 Days Post-study Drug Initiation,,,,,,,,,,,,,PRIMARY,Up to 14 days post-study drug initiation
country,NCT03585270::country::United States,NCT03585270,United States,,,,,,,,,,,,,,
country,NCT03585270::country::Germany,NCT03585270,Germany,,,,,,,,,,,,,,
country,NCT03585270::country::Spain,NCT03585270,Spain,,,,,,,,,,,,,,
country,NCT03585270::country::France,NCT03585270,France,,,,,,,,,,,,,,
country,NCT03585270::country::Czechia,NCT03585270,Czechia,,,,,,,,,,,,,,
country,NCT03585270::country::Belgium,NCT03585270,Belgium,,,,,,,,,,,,,,
country,NCT03585270::country::Canada,NCT03585270,Canada,,,,,,,,,,,,,,
country,NCT03585270::country::Finland,NCT03585270,Finland,,,,,,,,,,,,,,
country,NCT03585270::country::Israel,NCT03585270,Israel,,,,,,,,,,,,,,
country,NCT03585270::country::Italy,NCT03585270,Italy,,,,,,,,,,,,,,
country,NCT03585270::country::Poland,NCT03585270,Poland,,,,,,,,,,,,,,
country,NCT03585270::country::Sweden,NCT03585270,Sweden,,,,,,,,,,,,,,
country,NCT03585270::country::Austria,NCT03585270,Austria,,,,,,,,,,,,,,
country,NCT03585270::country::Hungary,NCT03585270,Hungary,,,,,,,,,,,,,,
country,NCT03585270::country::Denmark,NCT03585270,Denmark,,,,,,,,,,,,,,
trial,NCT00023595,NCT00023595,Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease,PHASE3,cardiovascular disease,"Cardiovascular Diseases; Coronary Disease; Heart Failure, Congestive; Heart Diseases",OTHER,2136.0,2002-01,2015-11,1.0,1.0,,,,,
arm,NCT00023595::arm::FG000,NCT00023595,H01: Medication,,,,,,,,,,FG000,"50% of H01 patients were randomized to this medical therapy alone arm. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failur",,,
arm,NCT00023595::arm::FG001,NCT00023595,H01: Medication + CABG,,,,,,,,,,FG001,"50% of H01 patients were randomized to medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients",,,
arm,NCT00023595::arm::FG002,NCT00023595,H01+H02: Medication + CABG,,,,,,,,,,FG002,"This group includes those 76 patients who belong to both H01 and H02. These patients were randomized to medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary ar",,,
arm,NCT00023595::arm::FG003,NCT00023595,H02: Medication+CABG,,,,,,,,,,FG003,"50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for pat",,,
arm,NCT00023595::arm::FG004,NCT00023595,H02: Medication+CABG+SVR,,,,,,,,,,FG004,"50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the s",,,
period,NCT00023595::period::1,NCT00023595,5 Year Follow up,,,,,,,,,,,,1.0,,
period,NCT00023595::period::2,NCT00023595,10 Year Follow up,,,,,,,,,,,,2.0,,
outcome,NCT00023595::outcome::primary::1,NCT00023595,H01: All Cause Mortality,,,,,,,,,,,,,PRIMARY,5 years post randomization
outcome,NCT00023595::outcome::primary::2,NCT00023595,H01: All Cause Mortality,,,,,,,,,,,,,PRIMARY,10 years post randomization
outcome,NCT00023595::outcome::primary::3,NCT00023595,H02: All-cause Mortality or Cardiovascular Hospitalization,,,,,,,,,,,,,PRIMARY,5 years post randomization
country,NCT00023595::country::United States,NCT00023595,United States,,,,,,,,,,,,,,
trial,NCT01603615,NCT01603615,BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity,PHASE3,cardiovascular disease,Pediatrics; Muscle Spasticity; Cerebral Palsy; Stroke,INDUSTRY,220.0,2012-10-30,2018-09-03,9.0,48.0,,,,,
arm,NCT01603615::arm::FG000,NCT01603615,BOTOX®,,,,,,,,,,FG000,Participants received a maximum of 5 treatments of intramuscular injections of BOTOX® (botulinum toxin Type A) into upper limb and/or lower limb muscles at a minimum of 12 weeks apart. Treatment dosin,,,
period,NCT01603615::period::1,NCT01603615,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01603615::outcome::primary::1,NCT01603615,Percentage of Participants With at Least One Treatment- Emergent Adverse Event (TEAE),,,,,,,,,,,,,PRIMARY,From first dose of study drug up to 12 weeks post last dose (Up to 60 weeks)
country,NCT01603615::country::United States,NCT01603615,United States,,,,,,,,,,,,,,
country,NCT01603615::country::Poland,NCT01603615,Poland,,,,,,,,,,,,,,
country,NCT01603615::country::South Korea,NCT01603615,South Korea,,,,,,,,,,,,,,
country,NCT01603615::country::Russia,NCT01603615,Russia,,,,,,,,,,,,,,
country,NCT01603615::country::Thailand,NCT01603615,Thailand,,,,,,,,,,,,,,
country,NCT01603615::country::Philippines,NCT01603615,Philippines,,,,,,,,,,,,,,
country,NCT01603615::country::Canada,NCT01603615,Canada,,,,,,,,,,,,,,
country,NCT01603615::country::Hungary,NCT01603615,Hungary,,,,,,,,,,,,,,
country,NCT01603615::country::Turkey (Türkiye),NCT01603615,Turkey (Türkiye),,,,,,,,,,,,,,
trial,NCT01764633,NCT01764633,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,PHASE3,cardiovascular disease,Dyslipidemia,INDUSTRY,27564.0,2013-02-08,2016-11-11,49.0,1284.0,,,,,
arm,NCT01764633::arm::FG000,NCT01764633,Placebo,,,,,,,,,,FG000,Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference.,,,
arm,NCT01764633::arm::FG001,NCT01764633,Evolocumab,,,,,,,,,,FG001,Participants received evolocumab subcutaneous injections either 140 mg Q2W or 420 mg QM according to their own preference.,,,
period,NCT01764633::period::1,NCT01764633,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01764633::outcome::primary::1,NCT01764633,"Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization",,,,,,,,,,,,,PRIMARY,Events that occurred from randomization to the last confirmed survival status date
country,NCT01764633::country::United States,NCT01764633,United States,,,,,,,,,,,,,,
country,NCT01764633::country::United Kingdom,NCT01764633,United Kingdom,,,,,,,,,,,,,,
country,NCT01764633::country::Japan,NCT01764633,Japan,,,,,,,,,,,,,,
country,NCT01764633::country::Poland,NCT01764633,Poland,,,,,,,,,,,,,,
country,NCT01764633::country::Czechia,NCT01764633,Czechia,,,,,,,,,,,,,,
country,NCT01764633::country::Canada,NCT01764633,Canada,,,,,,,,,,,,,,
country,NCT01764633::country::China,NCT01764633,China,,,,,,,,,,,,,,
country,NCT01764633::country::Germany,NCT01764633,Germany,,,,,,,,,,,,,,
country,NCT01764633::country::Netherlands,NCT01764633,Netherlands,,,,,,,,,,,,,,
country,NCT01764633::country::Russia,NCT01764633,Russia,,,,,,,,,,,,,,
country,NCT01764633::country::France,NCT01764633,France,,,,,,,,,,,,,,
country,NCT01764633::country::South Africa,NCT01764633,South Africa,,,,,,,,,,,,,,
country,NCT01764633::country::Brazil,NCT01764633,Brazil,,,,,,,,,,,,,,
country,NCT01764633::country::Hungary,NCT01764633,Hungary,,,,,,,,,,,,,,
country,NCT01764633::country::Argentina,NCT01764633,Argentina,,,,,,,,,,,,,,
country,NCT01764633::country::Ukraine,NCT01764633,Ukraine,,,,,,,,,,,,,,
country,NCT01764633::country::Australia,NCT01764633,Australia,,,,,,,,,,,,,,
country,NCT01764633::country::Slovakia,NCT01764633,Slovakia,,,,,,,,,,,,,,
country,NCT01764633::country::Italy,NCT01764633,Italy,,,,,,,,,,,,,,
country,NCT01764633::country::Greece,NCT01764633,Greece,,,,,,,,,,,,,,
country,NCT01764633::country::India,NCT01764633,India,,,,,,,,,,,,,,
country,NCT01764633::country::Sweden,NCT01764633,Sweden,,,,,,,,,,,,,,
country,NCT01764633::country::Mexico,NCT01764633,Mexico,,,,,,,,,,,,,,
country,NCT01764633::country::South Korea,NCT01764633,South Korea,,,,,,,,,,,,,,
country,NCT01764633::country::Belgium,NCT01764633,Belgium,,,,,,,,,,,,,,
country,NCT01764633::country::Romania,NCT01764633,Romania,,,,,,,,,,,,,,
country,NCT01764633::country::Denmark,NCT01764633,Denmark,,,,,,,,,,,,,,
country,NCT01764633::country::Bulgaria,NCT01764633,Bulgaria,,,,,,,,,,,,,,
country,NCT01764633::country::Colombia,NCT01764633,Colombia,,,,,,,,,,,,,,
country,NCT01764633::country::Spain,NCT01764633,Spain,,,,,,,,,,,,,,
country,NCT01764633::country::Finland,NCT01764633,Finland,,,,,,,,,,,,,,
country,NCT01764633::country::Israel,NCT01764633,Israel,,,,,,,,,,,,,,
country,NCT01764633::country::Austria,NCT01764633,Austria,,,,,,,,,,,,,,
country,NCT01764633::country::Philippines,NCT01764633,Philippines,,,,,,,,,,,,,,
country,NCT01764633::country::Portugal,NCT01764633,Portugal,,,,,,,,,,,,,,
country,NCT01764633::country::Taiwan,NCT01764633,Taiwan,,,,,,,,,,,,,,
country,NCT01764633::country::Turkey (Türkiye),NCT01764633,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01764633::country::Latvia,NCT01764633,Latvia,,,,,,,,,,,,,,
country,NCT01764633::country::Malaysia,NCT01764633,Malaysia,,,,,,,,,,,,,,
country,NCT01764633::country::Norway,NCT01764633,Norway,,,,,,,,,,,,,,
country,NCT01764633::country::Switzerland,NCT01764633,Switzerland,,,,,,,,,,,,,,
country,NCT01764633::country::Chile,NCT01764633,Chile,,,,,,,,,,,,,,
country,NCT01764633::country::Estonia,NCT01764633,Estonia,,,,,,,,,,,,,,
country,NCT01764633::country::Lithuania,NCT01764633,Lithuania,,,,,,,,,,,,,,
country,NCT01764633::country::Ireland,NCT01764633,Ireland,,,,,,,,,,,,,,
country,NCT01764633::country::New Zealand,NCT01764633,New Zealand,,,,,,,,,,,,,,
country,NCT01764633::country::Singapore,NCT01764633,Singapore,,,,,,,,,,,,,,
country,NCT01764633::country::Hong Kong,NCT01764633,Hong Kong,,,,,,,,,,,,,,
country,NCT01764633::country::Iceland,NCT01764633,Iceland,,,,,,,,,,,,,,
trial,NCT00823212,NCT00823212,The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions,PHASE3,cardiovascular disease,Coronary Artery Disease,INDUSTRY,1530.0,2009-01,2014-12,17.0,133.0,,,,,
arm,NCT00823212::arm::FG000,NCT00823212,PROMUS,,,,,,,,,,FG000,Participants randomized to treatment with PROMUS everolimus-eluting stent (control device),,,
arm,NCT00823212::arm::FG001,NCT00823212,PROMUS Element,,,,,,,,,,FG001,Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device),,,
period,NCT00823212::period::1,NCT00823212,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00823212::outcome::primary::1,NCT00823212,Target Lesion Failure (TLF),,,,,,,,,,,,,PRIMARY,12-month post index procedure
country,NCT00823212::country::United States,NCT00823212,United States,,,,,,,,,,,,,,
country,NCT00823212::country::Japan,NCT00823212,Japan,,,,,,,,,,,,,,
country,NCT00823212::country::France,NCT00823212,France,,,,,,,,,,,,,,
country,NCT00823212::country::Germany,NCT00823212,Germany,,,,,,,,,,,,,,
country,NCT00823212::country::United Kingdom,NCT00823212,United Kingdom,,,,,,,,,,,,,,
country,NCT00823212::country::Australia,NCT00823212,Australia,,,,,,,,,,,,,,
country,NCT00823212::country::Belgium,NCT00823212,Belgium,,,,,,,,,,,,,,
country,NCT00823212::country::Netherlands,NCT00823212,Netherlands,,,,,,,,,,,,,,
country,NCT00823212::country::Poland,NCT00823212,Poland,,,,,,,,,,,,,,
country,NCT00823212::country::Finland,NCT00823212,Finland,,,,,,,,,,,,,,
country,NCT00823212::country::New Zealand,NCT00823212,New Zealand,,,,,,,,,,,,,,
country,NCT00823212::country::Denmark,NCT00823212,Denmark,,,,,,,,,,,,,,
country,NCT00823212::country::Malaysia,NCT00823212,Malaysia,,,,,,,,,,,,,,
country,NCT00823212::country::Austria,NCT00823212,Austria,,,,,,,,,,,,,,
country,NCT00823212::country::Latvia,NCT00823212,Latvia,,,,,,,,,,,,,,
country,NCT00823212::country::Portugal,NCT00823212,Portugal,,,,,,,,,,,,,,
country,NCT00823212::country::Singapore,NCT00823212,Singapore,,,,,,,,,,,,,,
trial,NCT00485836,NCT00485836,A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE),PHASE3,cardiovascular disease,Macular Edema; Retinal Vein Occlusion,INDUSTRY,392.0,2007-07,2009-12,0.0,0.0,,,,,
arm,NCT00485836::arm::FG000,NCT00485836,Sham Injection,,,,,,,,,,FG000,"Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.",,,
arm,NCT00485836::arm::FG001,NCT00485836,Ranibizumab Injection 0.3 mg,,,,,,,,,,FG001,"Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.",,,
arm,NCT00485836::arm::FG002,NCT00485836,Ranibizumab Injection 0.5 mg,,,,,,,,,,FG002,"Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.",,,
period,NCT00485836::period::1,NCT00485836,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00485836::outcome::primary::1,NCT00485836,Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at 6 Months,,,,,,,,,,,,,PRIMARY,Baseline and 6 months
trial,NCT00855465,NCT00855465,A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.,PHASE3,cardiovascular disease,Pulmonary Hypertension,INDUSTRY,262.0,2009-02-23,2012-06-27,26.0,89.0,,,,,
arm,NCT00855465::arm::FG000,NCT00855465,"Riociguat (Adempas, BAY63-2521)_individual Dose Titration",,,,,,,,,,FG000,Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 16 w,,,
arm,NCT00855465::arm::FG001,NCT00855465,Placebo,,,,,,,,,,FG001,Participants received Placebo orally as a film-coated tablet three times daily (tid) for 16 weeks,,,
period,NCT00855465::period::1,NCT00855465,Treatment Period,,,,,,,,,,,,1.0,,
period,NCT00855465::period::2,NCT00855465,Follow-up Period (FUP),,,,,,,,,,,,2.0,,
outcome,NCT00855465::outcome::primary::1,NCT00855465,6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 16,,,,,,,,,,,,,PRIMARY,Baseline and week 16
country,NCT00855465::country::Japan,NCT00855465,Japan,,,,,,,,,,,,,,
country,NCT00855465::country::Germany,NCT00855465,Germany,,,,,,,,,,,,,,
country,NCT00855465::country::United States,NCT00855465,United States,,,,,,,,,,,,,,
country,NCT00855465::country::France,NCT00855465,France,,,,,,,,,,,,,,
country,NCT00855465::country::Canada,NCT00855465,Canada,,,,,,,,,,,,,,
country,NCT00855465::country::China,NCT00855465,China,,,,,,,,,,,,,,
country,NCT00855465::country::Mexico,NCT00855465,Mexico,,,,,,,,,,,,,,
country,NCT00855465::country::Brazil,NCT00855465,Brazil,,,,,,,,,,,,,,
country,NCT00855465::country::Turkey (Türkiye),NCT00855465,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00855465::country::United Kingdom,NCT00855465,United Kingdom,,,,,,,,,,,,,,
country,NCT00855465::country::Austria,NCT00855465,Austria,,,,,,,,,,,,,,
country,NCT00855465::country::Belgium,NCT00855465,Belgium,,,,,,,,,,,,,,
country,NCT00855465::country::Poland,NCT00855465,Poland,,,,,,,,,,,,,,
country,NCT00855465::country::Russia,NCT00855465,Russia,,,,,,,,,,,,,,
country,NCT00855465::country::South Korea,NCT00855465,South Korea,,,,,,,,,,,,,,
country,NCT00855465::country::Spain,NCT00855465,Spain,,,,,,,,,,,,,,
country,NCT00855465::country::Argentina,NCT00855465,Argentina,,,,,,,,,,,,,,
country,NCT00855465::country::Australia,NCT00855465,Australia,,,,,,,,,,,,,,
country,NCT00855465::country::Czechia,NCT00855465,Czechia,,,,,,,,,,,,,,
country,NCT00855465::country::Denmark,NCT00855465,Denmark,,,,,,,,,,,,,,
country,NCT00855465::country::Italy,NCT00855465,Italy,,,,,,,,,,,,,,
country,NCT00855465::country::Netherlands,NCT00855465,Netherlands,,,,,,,,,,,,,,
country,NCT00855465::country::Portugal,NCT00855465,Portugal,,,,,,,,,,,,,,
country,NCT00855465::country::Slovakia,NCT00855465,Slovakia,,,,,,,,,,,,,,
country,NCT00855465::country::Switzerland,NCT00855465,Switzerland,,,,,,,,,,,,,,
country,NCT00855465::country::Taiwan,NCT00855465,Taiwan,,,,,,,,,,,,,,
trial,NCT00219141,NCT00219141,Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension,PHASE3,cardiovascular disease,Hypertension; Left Ventricular Hypertrophy; Overweight,INDUSTRY,460.0,2005-10,2007-11,9.0,9.0,,,,,
arm,NCT00219141::arm::FG000,NCT00219141,Aliskiren 300 mg,,,,,,,,,,FG000,Patients in this arm initially received 150 mg of aliskiren for two weeks and were then force-titrated up to 300 mg of aliskiren where they remained for 34 weeks.,,,
arm,NCT00219141::arm::FG001,NCT00219141,Losartan 100 mg,,,,,,,,,,FG001,Patients in this arm initially received 50 mg of losartan for two weeks and were then force-titrated up to 100 mg of losartan where they remained for 34 weeks.,,,
arm,NCT00219141::arm::FG002,NCT00219141,Aliskiren/Losartan 300/100 mg,,,,,,,,,,FG002,Patients in this arm initially received 150 mg of aliskiren in combination with 50 mg of losartan for two weeks and were then force-titrated up to 300 mg of aliskiren in combination with 100 mg of los,,,
period,NCT00219141::period::1,NCT00219141,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00219141::outcome::primary::1,NCT00219141,Change in Left Ventricular Mass Index (LVMI) From Baseline to End of Study (Week 36),,,,,,,,,,,,,PRIMARY,Baseline to end of study (Week 36)
country,NCT00219141::country::United States,NCT00219141,United States,,,,,,,,,,,,,,
country,NCT00219141::country::Argentina,NCT00219141,Argentina,,,,,,,,,,,,,,
country,NCT00219141::country::Colombia,NCT00219141,Colombia,,,,,,,,,,,,,,
country,NCT00219141::country::Finland,NCT00219141,Finland,,,,,,,,,,,,,,
country,NCT00219141::country::Germany,NCT00219141,Germany,,,,,,,,,,,,,,
country,NCT00219141::country::Italy,NCT00219141,Italy,,,,,,,,,,,,,,
country,NCT00219141::country::Russia,NCT00219141,Russia,,,,,,,,,,,,,,
country,NCT00219141::country::Spain,NCT00219141,Spain,,,,,,,,,,,,,,
country,NCT00219141::country::Sweden,NCT00219141,Sweden,,,,,,,,,,,,,,
trial,NCT02865850,NCT02865850,Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD),PHASE3,cardiovascular disease,Anemia; Dialysis-Dependent Chronic Kidney Disease,INDUSTRY,369.0,2016-07,2020-03-30,11.0,118.0,,,,,
arm,NCT02865850::arm::FG000,NCT02865850,Vadadustat,,,,,,,,,,FG000,"Participants were randomized to receive Vadadustat at an initial oral dose of 300 milligrams per day (mg/day). Thereafter, Vadadustat was taken once daily on an outpatient basis. Up-and-down titration",,,
arm,NCT02865850::arm::FG001,NCT02865850,Darbepoetin Alfa,,,,,,,,,,FG001,"Participants were randomized to Darbepoetin alfa at an initial dose that was based on the current package insert for investigational sites in the United States (US), and the Summary of Product Charact",,,
period,NCT02865850::period::1,NCT02865850,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02865850::outcome::primary::1,NCT02865850,Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36),,,,,,,,,,,,,PRIMARY,Baseline
outcome,NCT02865850::outcome::primary::2,NCT02865850,Median Time to First Major Adverse Cardiovascular Event (MACE),,,,,,,,,,,,,PRIMARY,Weeks 24 to 36
country,NCT02865850::country::United States,NCT02865850,United States,,,,,,,,,,,,,,
country,NCT02865850::country::Brazil,NCT02865850,Brazil,,,,,,,,,,,,,,
country,NCT02865850::country::Ukraine,NCT02865850,Ukraine,,,,,,,,,,,,,,
country,NCT02865850::country::Argentina,NCT02865850,Argentina,,,,,,,,,,,,,,
country,NCT02865850::country::Italy,NCT02865850,Italy,,,,,,,,,,,,,,
country,NCT02865850::country::Russia,NCT02865850,Russia,,,,,,,,,,,,,,
country,NCT02865850::country::South Korea,NCT02865850,South Korea,,,,,,,,,,,,,,
country,NCT02865850::country::Germany,NCT02865850,Germany,,,,,,,,,,,,,,
country,NCT02865850::country::Mexico,NCT02865850,Mexico,,,,,,,,,,,,,,
country,NCT02865850::country::Poland,NCT02865850,Poland,,,,,,,,,,,,,,
country,NCT02865850::country::Portugal,NCT02865850,Portugal,,,,,,,,,,,,,,
trial,NCT02145468,NCT02145468,A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60),PHASE3,cardiovascular disease,Acute Coronary Syndrome,INDUSTRY,3503.0,2014-06-03,2015-12-14,34.0,341.0,,,,,
arm,NCT02145468::arm::FG000,NCT02145468,Placebo,,,,,,,,,,FG000,"Participants received losmapimod matching placebo tablets via oral route, twice daily (BID), according to the randomization schedule for 12 weeks in addition to standard of care, and were followed for",,,
arm,NCT02145468::arm::FG001,NCT02145468,Losmapimod 7.5 Mllligrms BID,,,,,,,,,,FG001,"Participants received losmapimod 7.5 milligrams (mg) tablets via oral route, BID, according to the randomization schedule for 12 weeks in addition to standard of care, and were followed for an additio",,,
period,NCT02145468::period::1,NCT02145468,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02145468::outcome::primary::1,NCT02145468,Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12,,,,,,,,,,,,,PRIMARY,Up to 12 weeks
country,NCT02145468::country::United States,NCT02145468,United States,,,,,,,,,,,,,,
country,NCT02145468::country::Germany,NCT02145468,Germany,,,,,,,,,,,,,,
country,NCT02145468::country::Russia,NCT02145468,Russia,,,,,,,,,,,,,,
country,NCT02145468::country::Netherlands,NCT02145468,Netherlands,,,,,,,,,,,,,,
country,NCT02145468::country::Poland,NCT02145468,Poland,,,,,,,,,,,,,,
country,NCT02145468::country::Spain,NCT02145468,Spain,,,,,,,,,,,,,,
country,NCT02145468::country::Czechia,NCT02145468,Czechia,,,,,,,,,,,,,,
country,NCT02145468::country::Australia,NCT02145468,Australia,,,,,,,,,,,,,,
country,NCT02145468::country::Belgium,NCT02145468,Belgium,,,,,,,,,,,,,,
country,NCT02145468::country::France,NCT02145468,France,,,,,,,,,,,,,,
country,NCT02145468::country::Canada,NCT02145468,Canada,,,,,,,,,,,,,,
country,NCT02145468::country::South Korea,NCT02145468,South Korea,,,,,,,,,,,,,,
country,NCT02145468::country::Sweden,NCT02145468,Sweden,,,,,,,,,,,,,,
country,NCT02145468::country::Italy,NCT02145468,Italy,,,,,,,,,,,,,,
country,NCT02145468::country::Ukraine,NCT02145468,Ukraine,,,,,,,,,,,,,,
country,NCT02145468::country::Argentina,NCT02145468,Argentina,,,,,,,,,,,,,,
country,NCT02145468::country::Bulgaria,NCT02145468,Bulgaria,,,,,,,,,,,,,,
country,NCT02145468::country::Greece,NCT02145468,Greece,,,,,,,,,,,,,,
country,NCT02145468::country::New Zealand,NCT02145468,New Zealand,,,,,,,,,,,,,,
country,NCT02145468::country::South Africa,NCT02145468,South Africa,,,,,,,,,,,,,,
country,NCT02145468::country::United Kingdom,NCT02145468,United Kingdom,,,,,,,,,,,,,,
country,NCT02145468::country::Hungary,NCT02145468,Hungary,,,,,,,,,,,,,,
country,NCT02145468::country::Israel,NCT02145468,Israel,,,,,,,,,,,,,,
country,NCT02145468::country::Norway,NCT02145468,Norway,,,,,,,,,,,,,,
country,NCT02145468::country::Taiwan,NCT02145468,Taiwan,,,,,,,,,,,,,,
country,NCT02145468::country::Chile,NCT02145468,Chile,,,,,,,,,,,,,,
country,NCT02145468::country::Denmark,NCT02145468,Denmark,,,,,,,,,,,,,,
country,NCT02145468::country::Philippines,NCT02145468,Philippines,,,,,,,,,,,,,,
country,NCT02145468::country::Slovakia,NCT02145468,Slovakia,,,,,,,,,,,,,,
country,NCT02145468::country::Thailand,NCT02145468,Thailand,,,,,,,,,,,,,,
country,NCT02145468::country::Estonia,NCT02145468,Estonia,,,,,,,,,,,,,,
country,NCT02145468::country::Hong Kong,NCT02145468,Hong Kong,,,,,,,,,,,,,,
country,NCT02145468::country::Mexico,NCT02145468,Mexico,,,,,,,,,,,,,,
country,NCT02145468::country::Romania,NCT02145468,Romania,,,,,,,,,,,,,,
trial,NCT00526474,NCT00526474,Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737),PHASE3,cardiovascular disease,Atherosclerosis; Ischemia; Myocardial Infarction; Cerebrovascular Accident; Peripheral Arterial Disease,INDUSTRY,26449.0,2007-09-01,2011-12-01,0.0,0.0,,,,,
arm,NCT00526474::arm::FG000,NCT00526474,Placebo,,,,,,,,,,FG000,"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.",,,
arm,NCT00526474::arm::FG001,NCT00526474,Vorapaxar,,,,,,,,,,FG001,"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.",,,
period,NCT00526474::period::1,NCT00526474,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00526474::outcome::primary::1,NCT00526474,"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, or Urgent Coronary Revascularization (UCR) Within 3 Years From Randomization",,,,,,,,,,,,,PRIMARY,up to 3 years
trial,NCT00044213,NCT00044213,Trial to Assess Chelation Therapy (TACT),PHASE3,cardiovascular disease,Coronary Artery Disease,OTHER,1708.0,2003-09,2012-08,2.0,86.0,,,,,
arm,NCT00044213::arm::FG000,NCT00044213,EDTA + High Dose Vitamin,,,,,,,,,,FG000,Participants will receive 40 infusions of active EDTA chelation and active high-dose oral vitamins.,,,
arm,NCT00044213::arm::FG001,NCT00044213,EDTA + High Dose Vitamin Placebo,,,,,,,,,,FG001,Participants will receive 40 infusions of EDTA chelation and placebo high-dose oral vitamins.,,,
arm,NCT00044213::arm::FG002,NCT00044213,EDTA Placebo + High Dose Vitamin,,,,,,,,,,FG002,Participants will receive 40 infusions of placebo EDTA chelation and active high-dose oral vitamins.,,,
arm,NCT00044213::arm::FG003,NCT00044213,EDTA Placebo + High Dose Vitamin Placebo,,,,,,,,,,FG003,Participants will receive 40 infusions of placebo EDTA chelation and placebo high-dose oral vitamins.,,,
period,NCT00044213::period::1,NCT00044213,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00044213::outcome::primary::1,NCT00044213,"A Composite of Total Mortality, Recurrent Myocardial Infarction, Stroke, Coronary Revascularization, and Hospitalization for Angina.",,,,,,,,,,,,,PRIMARY,Measured over a maximum 5-year follow-up period- 55 month median
country,NCT00044213::country::United States,NCT00044213,United States,,,,,,,,,,,,,,
country,NCT00044213::country::Canada,NCT00044213,Canada,,,,,,,,,,,,,,
trial,NCT00516503,NCT00516503,Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer,PHASE3,cardiovascular disease,"Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neurotoxicity; Pain; Unspecified Adult Solid Tumor, Protocol Specific",OTHER,208.0,2008-02,2010-01,1.0,165.0,,,,,
arm,NCT00516503::arm::FG000,NCT00516503,Baclofen-amitriptyline Hydrochloride-ketamine,,,,,,,,,,FG000,"Patients apply 1 spoonful of baclofen-amitriptyline hydrochloride-ketamine gel topically to each area of pain, numbness, and/or tingling on the feet and/or hands twice daily for 4 weeks. Baclofen/amit",,,
arm,NCT00516503::arm::FG001,NCT00516503,Placebo,,,,,,,,,,FG001,"Patients apply 1 spoonful of placebo gel topically to each area of pain, numbness, and/or tingling on the feet and/or hands twice daily for 4 weeks. Placebo: Applied topically",,,
period,NCT00516503::period::1,NCT00516503,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00516503::outcome::primary::1,NCT00516503,Total Sensory Neuropathy as Measured by the European Organization for Research and Treatment of Cancer [EORTC] Quality of Life [QLQ] - Chemo-induced Peripheral Neuropathy [CIPN20],,,,,,,,,,,,,PRIMARY,From baseline to 4 weeks
country,NCT00516503::country::United States,NCT00516503,United States,,,,,,,,,,,,,,
trial,NCT01813435,NCT01813435,GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation,PHASE3,cardiovascular disease,Coronary Artery Disease (CAD),INDUSTRY,15991.0,2013-07-01,2018-04-26,18.0,130.0,,,,,
arm,NCT01813435::arm::FG000,NCT01813435,Experimental Treatment Strategy,,,,,,,,,,FG000,"All patients in the treatment group will receive acetylsalicylic acid (ASA) and ticagrelor for 1 month followed by 23 months of ticagrelor monotherapy.

Dosage and frequency:

Ticagrelor: 90 mg b.i.d.",,,
arm,NCT01813435::arm::FG001,NCT01813435,Reference Treatment Strategy,,,,,,,,,,FG001,"Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and Brilique(ticagrelor) for 12 months followed by 12 months of ASA monotherapy.

Stable Coronary Artery Disease (CAD) p",,,
period,NCT01813435::period::1,NCT01813435,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01813435::outcome::primary::1,NCT01813435,Number of Participants With a Composite of All-cause Mortality or Non-fatal New Q-wave Myocardial Infarction (MI),,,,,,,,,,,,,PRIMARY,2 year
country,NCT01813435::country::United Kingdom,NCT01813435,United Kingdom,,,,,,,,,,,,,,
country,NCT01813435::country::Germany,NCT01813435,Germany,,,,,,,,,,,,,,
country,NCT01813435::country::France,NCT01813435,France,,,,,,,,,,,,,,
country,NCT01813435::country::Netherlands,NCT01813435,Netherlands,,,,,,,,,,,,,,
country,NCT01813435::country::Spain,NCT01813435,Spain,,,,,,,,,,,,,,
country,NCT01813435::country::Bulgaria,NCT01813435,Bulgaria,,,,,,,,,,,,,,
country,NCT01813435::country::Hungary,NCT01813435,Hungary,,,,,,,,,,,,,,
country,NCT01813435::country::Poland,NCT01813435,Poland,,,,,,,,,,,,,,
country,NCT01813435::country::Belgium,NCT01813435,Belgium,,,,,,,,,,,,,,
country,NCT01813435::country::Italy,NCT01813435,Italy,,,,,,,,,,,,,,
country,NCT01813435::country::Switzerland,NCT01813435,Switzerland,,,,,,,,,,,,,,
country,NCT01813435::country::Austria,NCT01813435,Austria,,,,,,,,,,,,,,
country,NCT01813435::country::Brazil,NCT01813435,Brazil,,,,,,,,,,,,,,
country,NCT01813435::country::Portugal,NCT01813435,Portugal,,,,,,,,,,,,,,
country,NCT01813435::country::Australia,NCT01813435,Australia,,,,,,,,,,,,,,
country,NCT01813435::country::Canada,NCT01813435,Canada,,,,,,,,,,,,,,
country,NCT01813435::country::Denmark,NCT01813435,Denmark,,,,,,,,,,,,,,
country,NCT01813435::country::Singapore,NCT01813435,Singapore,,,,,,,,,,,,,,
trial,NCT01347710,NCT01347710,A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.,PHASE3,cardiovascular disease,Coronary Artery Disease,INDUSTRY,795.0,2011-06,2013-09,4.0,81.0,,,,,
arm,NCT01347710::arm::FG000,NCT01347710,Flurpiridaz F 18,,,,,,,,,,FG000,Open-label study of a single dose of Flurpiridaz F18 injection for PET MPI compared to SPECT MPI in patients with suspected or known coronary artery disease referred for coronary catheterization,,,
period,NCT01347710::period::1,NCT01347710,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01347710::outcome::primary::1,NCT01347710,Diagnostic Efficacy of Flurpiridaz F 18 PET Myocardial Perfusion Imaging (MPI) Sensitivity Versus SPECT Myocardial Perfusion Imaging Sensitivity,,,,,,,,,,,,,PRIMARY,60 days
outcome,NCT01347710::outcome::primary::2,NCT01347710,Diagnostic Efficacy of Flurpiridaz PET MPI Specificity Versus SPECT MPI Specificity,,,,,,,,,,,,,PRIMARY,60 days
country,NCT01347710::country::United States,NCT01347710,United States,,,,,,,,,,,,,,
country,NCT01347710::country::Canada,NCT01347710,Canada,,,,,,,,,,,,,,
country,NCT01347710::country::Finland,NCT01347710,Finland,,,,,,,,,,,,,,
country,NCT01347710::country::Puerto Rico,NCT01347710,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01599650,NCT01599650,Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion,PHASE3,cardiovascular disease,Branch Retinal Vein Occlusion,INDUSTRY,455.0,2012-05,2015-05,17.0,82.0,,,,,
arm,NCT01599650::arm::FG000,NCT01599650,1-ranibizumab Monotherapy,,,,,,,,,,FG000,laser therapy + Ranibizumab 0.5 mg,,,
arm,NCT01599650::arm::FG001,NCT01599650,2-ranibizumab With Laser,,,,,,,,,,FG001,Ranibizumab 0.5 mg + laser,,,
arm,NCT01599650::arm::FG002,NCT01599650,3-laser Monotherapy,,,,,,,,,,FG002,"after 6 months, laser patients could be treated with ranibizumab",,,
period,NCT01599650::period::1,NCT01599650,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01599650::outcome::primary::1,NCT01599650,Mean Change in Visual Acuity: BCVA Change at Month 6 Compared to Baseline in Patients With Visual Impairment Due to Branch Retinal Vein Occlusion (BRVO),,,,,,,,,,,,,PRIMARY,"Baseline, 6 Months"
country,NCT01599650::country::Spain,NCT01599650,Spain,,,,,,,,,,,,,,
country,NCT01599650::country::United Kingdom,NCT01599650,United Kingdom,,,,,,,,,,,,,,
country,NCT01599650::country::Italy,NCT01599650,Italy,,,,,,,,,,,,,,
country,NCT01599650::country::Canada,NCT01599650,Canada,,,,,,,,,,,,,,
country,NCT01599650::country::France,NCT01599650,France,,,,,,,,,,,,,,
country,NCT01599650::country::Greece,NCT01599650,Greece,,,,,,,,,,,,,,
country,NCT01599650::country::Poland,NCT01599650,Poland,,,,,,,,,,,,,,
country,NCT01599650::country::Portugal,NCT01599650,Portugal,,,,,,,,,,,,,,
country,NCT01599650::country::Australia,NCT01599650,Australia,,,,,,,,,,,,,,
country,NCT01599650::country::Slovakia,NCT01599650,Slovakia,,,,,,,,,,,,,,
country,NCT01599650::country::Switzerland,NCT01599650,Switzerland,,,,,,,,,,,,,,
country,NCT01599650::country::Hungary,NCT01599650,Hungary,,,,,,,,,,,,,,
country,NCT01599650::country::Netherlands,NCT01599650,Netherlands,,,,,,,,,,,,,,
country,NCT01599650::country::Czechia,NCT01599650,Czechia,,,,,,,,,,,,,,
country,NCT01599650::country::Ireland,NCT01599650,Ireland,,,,,,,,,,,,,,
country,NCT01599650::country::Denmark,NCT01599650,Denmark,,,,,,,,,,,,,,
country,NCT01599650::country::Sweden,NCT01599650,Sweden,,,,,,,,,,,,,,
trial,NCT00614380,NCT00614380,Open Label Study Telmisartan and Amlodipine in Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,976.0,2008-01,,12.0,122.0,,,,,
arm,NCT00614380::arm::FG000,NCT00614380,Telmisartan 40mg and Amlodipine 5mg,,,,,,,,,,FG000,,,,
arm,NCT00614380::arm::FG001,NCT00614380,Telmisartan 80mg and Amlodipine 5mg,,,,,,,,,,FG001,,,,
arm,NCT00614380::arm::FG002,NCT00614380,Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive,,,,,,,,,,FG002,,,,
arm,NCT00614380::arm::FG003,NCT00614380,Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive,,,,,,,,,,FG003,,,,
period,NCT00614380::period::1,NCT00614380,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00614380::outcome::primary::1,NCT00614380,Trough Seated Diastolic Blood Pressure (DBP) Control,,,,,,,,,,,,,PRIMARY,End of study (34 weeks or last value on treatment)
country,NCT00614380::country::France,NCT00614380,France,,,,,,,,,,,,,,
country,NCT00614380::country::Canada,NCT00614380,Canada,,,,,,,,,,,,,,
country,NCT00614380::country::South Africa,NCT00614380,South Africa,,,,,,,,,,,,,,
country,NCT00614380::country::Denmark,NCT00614380,Denmark,,,,,,,,,,,,,,
country,NCT00614380::country::Netherlands,NCT00614380,Netherlands,,,,,,,,,,,,,,
country,NCT00614380::country::Philippines,NCT00614380,Philippines,,,,,,,,,,,,,,
country,NCT00614380::country::South Korea,NCT00614380,South Korea,,,,,,,,,,,,,,
country,NCT00614380::country::Belgium,NCT00614380,Belgium,,,,,,,,,,,,,,
country,NCT00614380::country::Sweden,NCT00614380,Sweden,,,,,,,,,,,,,,
country,NCT00614380::country::Finland,NCT00614380,Finland,,,,,,,,,,,,,,
country,NCT00614380::country::Norway,NCT00614380,Norway,,,,,,,,,,,,,,
country,NCT00614380::country::Taiwan,NCT00614380,Taiwan,,,,,,,,,,,,,,
trial,NCT00232180,NCT00232180,A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines,PHASE3,cardiovascular disease,Heart Failure,INDUSTRY,2743.0,2006-03,2012-01,29.0,307.0,,,,,
arm,NCT00232180::arm::FG000,NCT00232180,Eplerenone: Double-blind Phase,,,,,,,,,,FG000,Eplerenone 25 milligram (mg) tablet orally once daily on top of standard heart failure therapy. Dose might have been increased at Week 4 to 50 mg once daily. For participants with an estimated glomeru,,,
arm,NCT00232180::arm::FG001,NCT00232180,Placebo: Double-blind Phase,,,,,,,,,,FG001,Placebo matching to eplerenone 25 mg orally once daily on top of standard heart failure therapy.,,,
arm,NCT00232180::arm::FG002,NCT00232180,Eplerenone: Open Label Phase,,,,,,,,,,FG002,Participants from double blind phase received eplerenone 25 mg tablet orally once daily on top of standard heart failure therapy for 12 months. Dose might have been increased at Week 4 to 50 mg once d,,,
period,NCT00232180::period::1,NCT00232180,Double-blind (DB) Phase,,,,,,,,,,,,1.0,,
period,NCT00232180::period::2,NCT00232180,Open Label Phase,,,,,,,,,,,,2.0,,
outcome,NCT00232180::outcome::primary::1,NCT00232180,Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated): Up to Cut-off Date,,,,,,,,,,,,,PRIMARY,Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010)
outcome,NCT00232180::outcome::primary::2,NCT00232180,Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated),,,,,,,,,,,,,PRIMARY,Baseline (30 March 2006) up to 59.5 months (complete DB phase: 18 March 2011)
country,NCT00232180::country::United States,NCT00232180,United States,,,,,,,,,,,,,,
country,NCT00232180::country::Germany,NCT00232180,Germany,,,,,,,,,,,,,,
country,NCT00232180::country::Ukraine,NCT00232180,Ukraine,,,,,,,,,,,,,,
country,NCT00232180::country::United Kingdom,NCT00232180,United Kingdom,,,,,,,,,,,,,,
country,NCT00232180::country::France,NCT00232180,France,,,,,,,,,,,,,,
country,NCT00232180::country::Italy,NCT00232180,Italy,,,,,,,,,,,,,,
country,NCT00232180::country::Netherlands,NCT00232180,Netherlands,,,,,,,,,,,,,,
country,NCT00232180::country::Sweden,NCT00232180,Sweden,,,,,,,,,,,,,,
country,NCT00232180::country::Czechia,NCT00232180,Czechia,,,,,,,,,,,,,,
country,NCT00232180::country::Portugal,NCT00232180,Portugal,,,,,,,,,,,,,,
country,NCT00232180::country::Belgium,NCT00232180,Belgium,,,,,,,,,,,,,,
country,NCT00232180::country::Canada,NCT00232180,Canada,,,,,,,,,,,,,,
country,NCT00232180::country::Poland,NCT00232180,Poland,,,,,,,,,,,,,,
country,NCT00232180::country::Greece,NCT00232180,Greece,,,,,,,,,,,,,,
country,NCT00232180::country::India,NCT00232180,India,,,,,,,,,,,,,,
country,NCT00232180::country::Russia,NCT00232180,Russia,,,,,,,,,,,,,,
country,NCT00232180::country::Slovakia,NCT00232180,Slovakia,,,,,,,,,,,,,,
country,NCT00232180::country::Hungary,NCT00232180,Hungary,,,,,,,,,,,,,,
country,NCT00232180::country::Mexico,NCT00232180,Mexico,,,,,,,,,,,,,,
country,NCT00232180::country::South Africa,NCT00232180,South Africa,,,,,,,,,,,,,,
country,NCT00232180::country::Spain,NCT00232180,Spain,,,,,,,,,,,,,,
country,NCT00232180::country::Ireland,NCT00232180,Ireland,,,,,,,,,,,,,,
country,NCT00232180::country::Argentina,NCT00232180,Argentina,,,,,,,,,,,,,,
country,NCT00232180::country::Australia,NCT00232180,Australia,,,,,,,,,,,,,,
country,NCT00232180::country::Hong Kong,NCT00232180,Hong Kong,,,,,,,,,,,,,,
country,NCT00232180::country::South Korea,NCT00232180,South Korea,,,,,,,,,,,,,,
country,NCT00232180::country::Venezuela,NCT00232180,Venezuela,,,,,,,,,,,,,,
country,NCT00232180::country::Singapore,NCT00232180,Singapore,,,,,,,,,,,,,,
country,NCT00232180::country::United Arab Emirates,NCT00232180,United Arab Emirates,,,,,,,,,,,,,,
trial,NCT00457002,NCT00457002,Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness,PHASE3,cardiovascular disease,Venous Thrombosis; Pulmonary Embolism,INDUSTRY,6758.0,2007-06,2011-05,35.0,296.0,,,,,
arm,NCT00457002::arm::FG000,NCT00457002,Apixaban 2.5 mg Oral,,,,,,,,,,FG000,Oral administration of 2.5 mg apixaban tablets twice daily (BID) for 30 days plus placebo matching enoxaparin 40 mg QD while in hospital and for a minimum of 6 days.,,,
arm,NCT00457002::arm::FG001,NCT00457002,Enoxaparin 40 mg Subcutaneous,,,,,,,,,,FG001,Subcutaneous (SC) administration of 40 mg enoxaparin once daily (QD) for a minimum of 6 days plus placebo tablets matching apixaban 2.5 mg for 30 days.,,,
period,NCT00457002::period::1,NCT00457002,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00457002::outcome::primary::1,NCT00457002,Incidence of Composite of Adjudicated Total Venous Thromboembolism (VTE) and VTE-related Death During the Intended Treatment Period - Primary Efficacy Population,,,,,,,,,,,,,PRIMARY,Intended Treatment Period
outcome,NCT00457002::outcome::primary::2,NCT00457002,Incidence of Major Bleeding During the Treatment Period in Treated Participants,,,,,,,,,,,,,PRIMARY,"Day 1, first dose of study drug, to last dose of study drug plus 2 days"
outcome,NCT00457002::outcome::primary::3,NCT00457002,Incidence of Clinically Relevant Non-Major (CRNM) Bleeding During the Treatment Period in Treated Participants,,,,,,,,,,,,,PRIMARY,"Day 1, first dose of study drug, to last dose of study drug plus 2 days"
outcome,NCT00457002::outcome::primary::4,NCT00457002,Incidence of Composite of Major or Clinically Relevant Non-Major (CRNM) Bleeding During the Treatment Period in Treated Participants,,,,,,,,,,,,,PRIMARY,"Day 1, first dose of study drug, to last dose of study drug plus 2 days"
outcome,NCT00457002::outcome::primary::5,NCT00457002,Incidence of All Bleeding During the Treatment Period in Treated Participants,,,,,,,,,,,,,PRIMARY,"Day 1, first dose of drug to last dose of drug plus 2 days"
country,NCT00457002::country::United States,NCT00457002,United States,,,,,,,,,,,,,,
country,NCT00457002::country::India,NCT00457002,India,,,,,,,,,,,,,,
country,NCT00457002::country::Russia,NCT00457002,Russia,,,,,,,,,,,,,,
country,NCT00457002::country::Ukraine,NCT00457002,Ukraine,,,,,,,,,,,,,,
country,NCT00457002::country::Argentina,NCT00457002,Argentina,,,,,,,,,,,,,,
country,NCT00457002::country::Brazil,NCT00457002,Brazil,,,,,,,,,,,,,,
country,NCT00457002::country::Denmark,NCT00457002,Denmark,,,,,,,,,,,,,,
country,NCT00457002::country::France,NCT00457002,France,,,,,,,,,,,,,,
country,NCT00457002::country::Germany,NCT00457002,Germany,,,,,,,,,,,,,,
country,NCT00457002::country::Spain,NCT00457002,Spain,,,,,,,,,,,,,,
country,NCT00457002::country::Canada,NCT00457002,Canada,,,,,,,,,,,,,,
country,NCT00457002::country::Poland,NCT00457002,Poland,,,,,,,,,,,,,,
country,NCT00457002::country::Australia,NCT00457002,Australia,,,,,,,,,,,,,,
country,NCT00457002::country::Czechia,NCT00457002,Czechia,,,,,,,,,,,,,,
country,NCT00457002::country::Israel,NCT00457002,Israel,,,,,,,,,,,,,,
country,NCT00457002::country::Italy,NCT00457002,Italy,,,,,,,,,,,,,,
country,NCT00457002::country::Mexico,NCT00457002,Mexico,,,,,,,,,,,,,,
country,NCT00457002::country::Peru,NCT00457002,Peru,,,,,,,,,,,,,,
country,NCT00457002::country::South Korea,NCT00457002,South Korea,,,,,,,,,,,,,,
country,NCT00457002::country::Belgium,NCT00457002,Belgium,,,,,,,,,,,,,,
country,NCT00457002::country::South Africa,NCT00457002,South Africa,,,,,,,,,,,,,,
country,NCT00457002::country::United Kingdom,NCT00457002,United Kingdom,,,,,,,,,,,,,,
country,NCT00457002::country::Philippines,NCT00457002,Philippines,,,,,,,,,,,,,,
country,NCT00457002::country::Chile,NCT00457002,Chile,,,,,,,,,,,,,,
country,NCT00457002::country::Hungary,NCT00457002,Hungary,,,,,,,,,,,,,,
country,NCT00457002::country::Colombia,NCT00457002,Colombia,,,,,,,,,,,,,,
country,NCT00457002::country::Malaysia,NCT00457002,Malaysia,,,,,,,,,,,,,,
country,NCT00457002::country::Turkey (Türkiye),NCT00457002,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00457002::country::Austria,NCT00457002,Austria,,,,,,,,,,,,,,
country,NCT00457002::country::Singapore,NCT00457002,Singapore,,,,,,,,,,,,,,
country,NCT00457002::country::Sweden,NCT00457002,Sweden,,,,,,,,,,,,,,
country,NCT00457002::country::Taiwan,NCT00457002,Taiwan,,,,,,,,,,,,,,
country,NCT00457002::country::Hong Kong,NCT00457002,Hong Kong,,,,,,,,,,,,,,
country,NCT00457002::country::Netherlands,NCT00457002,Netherlands,,,,,,,,,,,,,,
country,NCT00457002::country::Norway,NCT00457002,Norway,,,,,,,,,,,,,,
trial,NCT01154036,NCT01154036,MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162),PHASE3,cardiovascular disease,Hypercholesterolemia,INDUSTRY,1547.0,2010-07,2012-10,0.0,0.0,,,,,
arm,NCT01154036::arm::FG000,NCT01154036,Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg,,,,,,,,,,FG000,Co-administration of EZ 10 mg tablet + Atorva 10 mg tablet; once daily for 6 weeks,,,
arm,NCT01154036::arm::FG001,NCT01154036,Phase I: Atorvastatin 20 mg,,,,,,,,,,FG001,Atorvastatin 20 mg tablet once daily for 6 weeks,,,
arm,NCT01154036::arm::FG002,NCT01154036,Phase I: Rosuvastatin 10 mg,,,,,,,,,,FG002,Rosuvastatin 10 mg tablet once daily for 6 weeks;,,,
arm,NCT01154036::arm::FG003,NCT01154036,Phase II: EZ 10mg+Atorva 10mg,,,,,,,,,,FG003,Participants who had previously received EZ 10 mg + Atorva 10 mg in Phase I and continued on EZ 10 mg + Atorva 10 mg once daily for 6 weeks during Phase II regardless of whether or not LDL-C goals wer,,,
arm,NCT01154036::arm::FG004,NCT01154036,Phase II: EZ 10mg + Atorva 20mg [A],,,,,,,,,,FG004,Participants who had previously received Atorva 20 mg in Phase I and did not reach LDL-C goal and were switched to EZ 10 mg + Atorva 20 mg once daily for 6 weeks in Phase II,,,
arm,NCT01154036::arm::FG005,NCT01154036,Phase II: Atorva 40mg,,,,,,,,,,FG005,Participants who had previously received Atorva 20 mg in Phase I and did not reach LDL-C goal and were switched Atorva 40 mg once daily for 6 weeks in Phase II,,,
arm,NCT01154036::arm::FG006,NCT01154036,Phase II: EZ 10mg + Atorva 20mg [R],,,,,,,,,,FG006,Participants who had previously received Rosuvastatin 10 mg in Phase I and did not reach LDL-C goal and received EZ 10 mg + Atorva 20 mg once daily for 6 weeks in Phase II,,,
arm,NCT01154036::arm::FG007,NCT01154036,Phase II: Rosuvastatin 20mg,,,,,,,,,,FG007,Participants who had previously received Rosuvastatin 10 mg in Phase I and did not reach LDL-C goal and were switched to Rosuvastatin 20 mg once daily for 6 weeks in Phase II,,,
period,NCT01154036::period::1,NCT01154036,Phase I,,,,,,,,,,,,1.0,,
period,NCT01154036::period::2,NCT01154036,Phase II,,,,,,,,,,,,2.0,,
outcome,NCT01154036::outcome::primary::1,NCT01154036,Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I),,,,,,,,,,,,,PRIMARY,Baseline and Week 6 (end of Phase I )
trial,NCT00262600,NCT00262600,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,PHASE3,cardiovascular disease,Atrial Fibrillation; Stroke,INDUSTRY,18113.0,2005-12,,44.0,984.0,,,,,
arm,NCT00262600::arm::FG000,NCT00262600,Dabigatran 110 mg,,,,,,,,,,FG000,"110 mg twice daily, total daily dose 220 mg",,,
arm,NCT00262600::arm::FG001,NCT00262600,Dabigatran 150 mg,,,,,,,,,,FG001,"150 mg twice daily, total daily dose 300 mg",,,
arm,NCT00262600::arm::FG002,NCT00262600,Warfarin,,,,,,,,,,FG002,Target International Normalized Ratio (INR) of 2.0 to 3.0,,,
period,NCT00262600::period::1,NCT00262600,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00262600::outcome::primary::1,NCT00262600,Yearly Event Rate for Composite Endpoint of Stroke/SEE,,,,,,,,,,,,,PRIMARY,36 months
country,NCT00262600::country::United States,NCT00262600,United States,,,,,,,,,,,,,,
country,NCT00262600::country::Canada,NCT00262600,Canada,,,,,,,,,,,,,,
country,NCT00262600::country::Japan,NCT00262600,Japan,,,,,,,,,,,,,,
country,NCT00262600::country::France,NCT00262600,France,,,,,,,,,,,,,,
country,NCT00262600::country::Israel,NCT00262600,Israel,,,,,,,,,,,,,,
country,NCT00262600::country::Netherlands,NCT00262600,Netherlands,,,,,,,,,,,,,,
country,NCT00262600::country::Germany,NCT00262600,Germany,,,,,,,,,,,,,,
country,NCT00262600::country::Belgium,NCT00262600,Belgium,,,,,,,,,,,,,,
country,NCT00262600::country::India,NCT00262600,India,,,,,,,,,,,,,,
country,NCT00262600::country::Italy,NCT00262600,Italy,,,,,,,,,,,,,,
country,NCT00262600::country::United Kingdom,NCT00262600,United Kingdom,,,,,,,,,,,,,,
country,NCT00262600::country::Bulgaria,NCT00262600,Bulgaria,,,,,,,,,,,,,,
country,NCT00262600::country::Russia,NCT00262600,Russia,,,,,,,,,,,,,,
country,NCT00262600::country::Brazil,NCT00262600,Brazil,,,,,,,,,,,,,,
country,NCT00262600::country::Sweden,NCT00262600,Sweden,,,,,,,,,,,,,,
country,NCT00262600::country::Argentina,NCT00262600,Argentina,,,,,,,,,,,,,,
country,NCT00262600::country::China,NCT00262600,China,,,,,,,,,,,,,,
country,NCT00262600::country::Greece,NCT00262600,Greece,,,,,,,,,,,,,,
country,NCT00262600::country::Taiwan,NCT00262600,Taiwan,,,,,,,,,,,,,,
country,NCT00262600::country::South Korea,NCT00262600,South Korea,,,,,,,,,,,,,,
country,NCT00262600::country::Denmark,NCT00262600,Denmark,,,,,,,,,,,,,,
country,NCT00262600::country::Ukraine,NCT00262600,Ukraine,,,,,,,,,,,,,,
country,NCT00262600::country::Australia,NCT00262600,Australia,,,,,,,,,,,,,,
country,NCT00262600::country::Austria,NCT00262600,Austria,,,,,,,,,,,,,,
country,NCT00262600::country::Czechia,NCT00262600,Czechia,,,,,,,,,,,,,,
country,NCT00262600::country::Hungary,NCT00262600,Hungary,,,,,,,,,,,,,,
country,NCT00262600::country::Poland,NCT00262600,Poland,,,,,,,,,,,,,,
country,NCT00262600::country::Slovakia,NCT00262600,Slovakia,,,,,,,,,,,,,,
country,NCT00262600::country::Finland,NCT00262600,Finland,,,,,,,,,,,,,,
country,NCT00262600::country::Portugal,NCT00262600,Portugal,,,,,,,,,,,,,,
country,NCT00262600::country::South Africa,NCT00262600,South Africa,,,,,,,,,,,,,,
country,NCT00262600::country::Spain,NCT00262600,Spain,,,,,,,,,,,,,,
country,NCT00262600::country::Mexico,NCT00262600,Mexico,,,,,,,,,,,,,,
country,NCT00262600::country::Malaysia,NCT00262600,Malaysia,,,,,,,,,,,,,,
country,NCT00262600::country::Norway,NCT00262600,Norway,,,,,,,,,,,,,,
country,NCT00262600::country::Peru,NCT00262600,Peru,,,,,,,,,,,,,,
country,NCT00262600::country::Philippines,NCT00262600,Philippines,,,,,,,,,,,,,,
country,NCT00262600::country::Thailand,NCT00262600,Thailand,,,,,,,,,,,,,,
country,NCT00262600::country::Hong Kong,NCT00262600,Hong Kong,,,,,,,,,,,,,,
country,NCT00262600::country::Switzerland,NCT00262600,Switzerland,,,,,,,,,,,,,,
country,NCT00262600::country::Turkey (Türkiye),NCT00262600,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00262600::country::Colombia,NCT00262600,Colombia,,,,,,,,,,,,,,
country,NCT00262600::country::Romania,NCT00262600,Romania,,,,,,,,,,,,,,
country,NCT00262600::country::Singapore,NCT00262600,Singapore,,,,,,,,,,,,,,
trial,NCT05085275,NCT05085275,Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease,PHASE3,cardiovascular disease,"Anemia, Iron Deficiency; Hyperphosphatemia; Renal Insufficiency, Chronic; Renal Anemia; Disease Progression; Cardiovascular; Iron",NETWORK,289.0,2022-03-30,2024-01-24,1.0,23.0,,,,,
arm,NCT05085275::arm::FG000,NCT05085275,Ferric Citrate,,,,,,,,,,FG000,Supplied as tablets for oral administration containing 1 gram ferric citrate (210 milligrams of ferric iron). Administered orally with meals or snacks.,,,
arm,NCT05085275::arm::FG001,NCT05085275,Placebo,,,,,,,,,,FG001,"Tablets, matching in color and size to ferric citrate.",,,
period,NCT05085275::period::1,NCT05085275,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT05085275::outcome::primary::1,NCT05085275,Number of Participants Achieving a Composite Endpoint of Initiation of Maintenance Dialysis or All-cause Mortality,,,,,,,,,,,,,PRIMARY,9 months
country,NCT05085275::country::United States,NCT05085275,United States,,,,,,,,,,,,,,
trial,NCT03574597,NCT03574597,Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity,PHASE3,cardiovascular disease,Overweight; Obesity,INDUSTRY,17604.0,2018-10-24,2023-06-29,42.0,833.0,,,,,
arm,NCT03574597::arm::FG000,NCT03574597,Semaglutide,,,,,,,,,,FG000,"Participants received semaglutide subcutaneously once weekly in a fixed-dose escalation manner, with dose increases every 4 weeks for up to week 16 (0.25 milligrams \[mg\], 0.5 mg, 1.0 mg and 1.7 mg) ",,,
arm,NCT03574597::arm::FG001,NCT03574597,Placebo,,,,,,,,,,FG001,Participants received placebo (matched to semaglutide) subcutaneously once weekly up to the end of treatment period.,,,
period,NCT03574597::period::1,NCT03574597,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03574597::outcome::primary::1,NCT03574597,"Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke",,,,,,,,,,,,,PRIMARY,From randomisation (week 0) up to 240 weeks
country,NCT03574597::country::United States,NCT03574597,United States,,,,,,,,,,,,,,
country,NCT03574597::country::Japan,NCT03574597,Japan,,,,,,,,,,,,,,
country,NCT03574597::country::Russia,NCT03574597,Russia,,,,,,,,,,,,,,
country,NCT03574597::country::United Kingdom,NCT03574597,United Kingdom,,,,,,,,,,,,,,
country,NCT03574597::country::India,NCT03574597,India,,,,,,,,,,,,,,
country,NCT03574597::country::Germany,NCT03574597,Germany,,,,,,,,,,,,,,
country,NCT03574597::country::Canada,NCT03574597,Canada,,,,,,,,,,,,,,
country,NCT03574597::country::Romania,NCT03574597,Romania,,,,,,,,,,,,,,
country,NCT03574597::country::South Africa,NCT03574597,South Africa,,,,,,,,,,,,,,
country,NCT03574597::country::Italy,NCT03574597,Italy,,,,,,,,,,,,,,
country,NCT03574597::country::Poland,NCT03574597,Poland,,,,,,,,,,,,,,
country,NCT03574597::country::Turkey (Türkiye),NCT03574597,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT03574597::country::France,NCT03574597,France,,,,,,,,,,,,,,
country,NCT03574597::country::Ukraine,NCT03574597,Ukraine,,,,,,,,,,,,,,
country,NCT03574597::country::Bulgaria,NCT03574597,Bulgaria,,,,,,,,,,,,,,
country,NCT03574597::country::Brazil,NCT03574597,Brazil,,,,,,,,,,,,,,
country,NCT03574597::country::Greece,NCT03574597,Greece,,,,,,,,,,,,,,
country,NCT03574597::country::Australia,NCT03574597,Australia,,,,,,,,,,,,,,
country,NCT03574597::country::Malaysia,NCT03574597,Malaysia,,,,,,,,,,,,,,
country,NCT03574597::country::Czechia,NCT03574597,Czechia,,,,,,,,,,,,,,
country,NCT03574597::country::Israel,NCT03574597,Israel,,,,,,,,,,,,,,
country,NCT03574597::country::Spain,NCT03574597,Spain,,,,,,,,,,,,,,
country,NCT03574597::country::Argentina,NCT03574597,Argentina,,,,,,,,,,,,,,
country,NCT03574597::country::Netherlands,NCT03574597,Netherlands,,,,,,,,,,,,,,
country,NCT03574597::country::Mexico,NCT03574597,Mexico,,,,,,,,,,,,,,
country,NCT03574597::country::Norway,NCT03574597,Norway,,,,,,,,,,,,,,
country,NCT03574597::country::Thailand,NCT03574597,Thailand,,,,,,,,,,,,,,
country,NCT03574597::country::Latvia,NCT03574597,Latvia,,,,,,,,,,,,,,
country,NCT03574597::country::Austria,NCT03574597,Austria,,,,,,,,,,,,,,
country,NCT03574597::country::Belgium,NCT03574597,Belgium,,,,,,,,,,,,,,
country,NCT03574597::country::Colombia,NCT03574597,Colombia,,,,,,,,,,,,,,
country,NCT03574597::country::Croatia,NCT03574597,Croatia,,,,,,,,,,,,,,
country,NCT03574597::country::Finland,NCT03574597,Finland,,,,,,,,,,,,,,
country,NCT03574597::country::Denmark,NCT03574597,Denmark,,,,,,,,,,,,,,
country,NCT03574597::country::Hungary,NCT03574597,Hungary,,,,,,,,,,,,,,
country,NCT03574597::country::Ireland,NCT03574597,Ireland,,,,,,,,,,,,,,
country,NCT03574597::country::Portugal,NCT03574597,Portugal,,,,,,,,,,,,,,
country,NCT03574597::country::Serbia,NCT03574597,Serbia,,,,,,,,,,,,,,
country,NCT03574597::country::Sweden,NCT03574597,Sweden,,,,,,,,,,,,,,
country,NCT03574597::country::Algeria,NCT03574597,Algeria,,,,,,,,,,,,,,
country,NCT03574597::country::Taiwan,NCT03574597,Taiwan,,,,,,,,,,,,,,
country,NCT03574597::country::Puerto Rico,NCT03574597,Puerto Rico,,,,,,,,,,,,,,
trial,NCT02446990,NCT02446990,Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure,PHASE3,cardiovascular disease,Coronary Artery Disease,OTHER,19102.0,2009-09,2014-01,2.0,2.0,,,,,
arm,NCT02446990::arm::FG000,NCT02446990,Ivabradine,,,,,,,,,,FG000,"Ivabradine: 5 mg, 7.5 mg or 10 mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.",,,
arm,NCT02446990::arm::FG001,NCT02446990,Placebo,,,,,,,,,,FG001,"Placebo: Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.",,,
period,NCT02446990::period::1,NCT02446990,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02446990::outcome::primary::1,NCT02446990,Primary Composite Endpoint,,,,,,,,,,,,,PRIMARY,"The events are expressed as the time to occurrence of the first event, defined as the duration between the date of randomisation and the date of first occurrence of event, assessed up to 48 months."
country,NCT02446990::country::Italy,NCT02446990,Italy,,,,,,,,,,,,,,
country,NCT02446990::country::United Kingdom,NCT02446990,United Kingdom,,,,,,,,,,,,,,
trial,NCT00777946,NCT00777946,Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,818.0,2008-10,2009-05,9.0,9.0,,,,,
arm,NCT00777946::arm::FG000,NCT00777946,Aliskiren 300 mg/Amlodipine 10 mg,,,,,,,,,,FG000,Participants received 1 Aliskiren/Amlodipine 300/10mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks.,,,
arm,NCT00777946::arm::FG001,NCT00777946,Aliskiren 300 mg/Amlodipine 5 mg,,,,,,,,,,FG001,Participants received 1 Aliskiren/Amlodipine 300/5mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks.,,,
arm,NCT00777946::arm::FG002,NCT00777946,Aliskiren 300 mg,,,,,,,,,,FG002,Participants received 1 Aliskiren 300 mg tablet + 1 Placebo to Aliskiren/Amlodipine tablet orally once daily in the morning for 8 weeks.,,,
period,NCT00777946::period::1,NCT00777946,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00777946::outcome::primary::1,NCT00777946,Change From Baseline to End of Study in the Mean Sitting Diastolic Blood Pressure (msDBP),,,,,,,,,,,,,PRIMARY,"Baseline, End of Study (Week 8)"
country,NCT00777946::country::Estonia,NCT00777946,Estonia,,,,,,,,,,,,,,
country,NCT00777946::country::France,NCT00777946,France,,,,,,,,,,,,,,
country,NCT00777946::country::Iceland,NCT00777946,Iceland,,,,,,,,,,,,,,
country,NCT00777946::country::India,NCT00777946,India,,,,,,,,,,,,,,
country,NCT00777946::country::Italy,NCT00777946,Italy,,,,,,,,,,,,,,
country,NCT00777946::country::Lithuania,NCT00777946,Lithuania,,,,,,,,,,,,,,
country,NCT00777946::country::South Korea,NCT00777946,South Korea,,,,,,,,,,,,,,
country,NCT00777946::country::Spain,NCT00777946,Spain,,,,,,,,,,,,,,
country,NCT00777946::country::Venezuela,NCT00777946,Venezuela,,,,,,,,,,,,,,
trial,NCT00391872,NCT00391872,A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome,PHASE3,cardiovascular disease,Acute Coronary Syndrome,INDUSTRY,18624.0,2006-10,2009-03,44.0,672.0,,,,,
arm,NCT00391872::arm::FG000,NCT00391872,TICAGRELOR,,,,,,,,,,FG000,Ticagrelor 90 mg twice daily dose (BD),,,
arm,NCT00391872::arm::FG001,NCT00391872,CLOPIDOGREL,,,,,,,,,,FG001,Clopidogrel 75 mg once daily dose (ODD),,,
period,NCT00391872::period::1,NCT00391872,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00391872::outcome::primary::1,NCT00391872,"Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke",,,,,,,,,,,,,PRIMARY,Randomization up to 12 months
outcome,NCT00391872::outcome::primary::2,NCT00391872,Participants With Any Major Bleeding Event,,,,,,,,,,,,,PRIMARY,First dosing up to 12 months
country,NCT00391872::country::United States,NCT00391872,United States,,,,,,,,,,,,,,
country,NCT00391872::country::Germany,NCT00391872,Germany,,,,,,,,,,,,,,
country,NCT00391872::country::Netherlands,NCT00391872,Netherlands,,,,,,,,,,,,,,
country,NCT00391872::country::France,NCT00391872,France,,,,,,,,,,,,,,
country,NCT00391872::country::Poland,NCT00391872,Poland,,,,,,,,,,,,,,
country,NCT00391872::country::Italy,NCT00391872,Italy,,,,,,,,,,,,,,
country,NCT00391872::country::Canada,NCT00391872,Canada,,,,,,,,,,,,,,
country,NCT00391872::country::Denmark,NCT00391872,Denmark,,,,,,,,,,,,,,
country,NCT00391872::country::Russia,NCT00391872,Russia,,,,,,,,,,,,,,
country,NCT00391872::country::Brazil,NCT00391872,Brazil,,,,,,,,,,,,,,
country,NCT00391872::country::India,NCT00391872,India,,,,,,,,,,,,,,
country,NCT00391872::country::Sweden,NCT00391872,Sweden,,,,,,,,,,,,,,
country,NCT00391872::country::Norway,NCT00391872,Norway,,,,,,,,,,,,,,
country,NCT00391872::country::Czechia,NCT00391872,Czechia,,,,,,,,,,,,,,
country,NCT00391872::country::United Kingdom,NCT00391872,United Kingdom,,,,,,,,,,,,,,
country,NCT00391872::country::Argentina,NCT00391872,Argentina,,,,,,,,,,,,,,
country,NCT00391872::country::Belgium,NCT00391872,Belgium,,,,,,,,,,,,,,
country,NCT00391872::country::Portugal,NCT00391872,Portugal,,,,,,,,,,,,,,
country,NCT00391872::country::Bulgaria,NCT00391872,Bulgaria,,,,,,,,,,,,,,
country,NCT00391872::country::Hungary,NCT00391872,Hungary,,,,,,,,,,,,,,
country,NCT00391872::country::Israel,NCT00391872,Israel,,,,,,,,,,,,,,
country,NCT00391872::country::Spain,NCT00391872,Spain,,,,,,,,,,,,,,
country,NCT00391872::country::Romania,NCT00391872,Romania,,,,,,,,,,,,,,
country,NCT00391872::country::Slovakia,NCT00391872,Slovakia,,,,,,,,,,,,,,
country,NCT00391872::country::Australia,NCT00391872,Australia,,,,,,,,,,,,,,
country,NCT00391872::country::Finland,NCT00391872,Finland,,,,,,,,,,,,,,
country,NCT00391872::country::Austria,NCT00391872,Austria,,,,,,,,,,,,,,
country,NCT00391872::country::China,NCT00391872,China,,,,,,,,,,,,,,
country,NCT00391872::country::Greece,NCT00391872,Greece,,,,,,,,,,,,,,
country,NCT00391872::country::Indonesia,NCT00391872,Indonesia,,,,,,,,,,,,,,
country,NCT00391872::country::Mexico,NCT00391872,Mexico,,,,,,,,,,,,,,
country,NCT00391872::country::South Korea,NCT00391872,South Korea,,,,,,,,,,,,,,
country,NCT00391872::country::Switzerland,NCT00391872,Switzerland,,,,,,,,,,,,,,
country,NCT00391872::country::Philippines,NCT00391872,Philippines,,,,,,,,,,,,,,
country,NCT00391872::country::Turkey (Türkiye),NCT00391872,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00391872::country::Ukraine,NCT00391872,Ukraine,,,,,,,,,,,,,,
country,NCT00391872::country::South Africa,NCT00391872,South Africa,,,,,,,,,,,,,,
country,NCT00391872::country::Malaysia,NCT00391872,Malaysia,,,,,,,,,,,,,,
country,NCT00391872::country::Taiwan,NCT00391872,Taiwan,,,,,,,,,,,,,,
country,NCT00391872::country::Thailand,NCT00391872,Thailand,,,,,,,,,,,,,,
country,NCT00391872::country::Georgia,NCT00391872,Georgia,,,,,,,,,,,,,,
country,NCT00391872::country::Hong Kong,NCT00391872,Hong Kong,,,,,,,,,,,,,,
country,NCT00391872::country::Puerto Rico,NCT00391872,Puerto Rico,,,,,,,,,,,,,,
country,NCT00391872::country::Singapore,NCT00391872,Singapore,,,,,,,,,,,,,,
trial,NCT02181413,NCT02181413,A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant,PHASE3,cardiovascular disease,Multiple Myeloma; Autologous Stem Cell Transplant,INDUSTRY,656.0,2014-07-16,2023-09-08,33.0,227.0,,,,,
arm,NCT02181413::arm::FG000,NCT02181413,Placebo,,,,,,,,,,FG000,"Ixazomib citrate placebo-matching capsules, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 26 until progressive disease (PD), unacceptable toxicity, or discontinuation for alt",,,
arm,NCT02181413::arm::FG001,NCT02181413,Ixazomib Citrate,,,,,,,,,,FG001,"Ixazomib citrate 3 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib citrate 4 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cy",,,
period,NCT02181413::period::1,NCT02181413,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02181413::outcome::primary::1,NCT02181413,Progression Free Survival (PFS),,,,,,,,,,,,,PRIMARY,Randomization up to End of treatment (EOT) (24 months)
country,NCT02181413::country::Germany,NCT02181413,Germany,,,,,,,,,,,,,,
country,NCT02181413::country::Japan,NCT02181413,Japan,,,,,,,,,,,,,,
country,NCT02181413::country::Brazil,NCT02181413,Brazil,,,,,,,,,,,,,,
country,NCT02181413::country::Israel,NCT02181413,Israel,,,,,,,,,,,,,,
country,NCT02181413::country::Italy,NCT02181413,Italy,,,,,,,,,,,,,,
country,NCT02181413::country::Spain,NCT02181413,Spain,,,,,,,,,,,,,,
country,NCT02181413::country::United Kingdom,NCT02181413,United Kingdom,,,,,,,,,,,,,,
country,NCT02181413::country::Australia,NCT02181413,Australia,,,,,,,,,,,,,,
country,NCT02181413::country::South Korea,NCT02181413,South Korea,,,,,,,,,,,,,,
country,NCT02181413::country::Denmark,NCT02181413,Denmark,,,,,,,,,,,,,,
country,NCT02181413::country::Turkey (Türkiye),NCT02181413,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02181413::country::United States,NCT02181413,United States,,,,,,,,,,,,,,
country,NCT02181413::country::Argentina,NCT02181413,Argentina,,,,,,,,,,,,,,
country,NCT02181413::country::Belgium,NCT02181413,Belgium,,,,,,,,,,,,,,
country,NCT02181413::country::Czechia,NCT02181413,Czechia,,,,,,,,,,,,,,
country,NCT02181413::country::Poland,NCT02181413,Poland,,,,,,,,,,,,,,
country,NCT02181413::country::France,NCT02181413,France,,,,,,,,,,,,,,
country,NCT02181413::country::Hungary,NCT02181413,Hungary,,,,,,,,,,,,,,
country,NCT02181413::country::Netherlands,NCT02181413,Netherlands,,,,,,,,,,,,,,
country,NCT02181413::country::Sweden,NCT02181413,Sweden,,,,,,,,,,,,,,
country,NCT02181413::country::Taiwan,NCT02181413,Taiwan,,,,,,,,,,,,,,
country,NCT02181413::country::Austria,NCT02181413,Austria,,,,,,,,,,,,,,
country,NCT02181413::country::Greece,NCT02181413,Greece,,,,,,,,,,,,,,
country,NCT02181413::country::Norway,NCT02181413,Norway,,,,,,,,,,,,,,
country,NCT02181413::country::Portugal,NCT02181413,Portugal,,,,,,,,,,,,,,
country,NCT02181413::country::Colombia,NCT02181413,Colombia,,,,,,,,,,,,,,
country,NCT02181413::country::South Africa,NCT02181413,South Africa,,,,,,,,,,,,,,
country,NCT02181413::country::Canada,NCT02181413,Canada,,,,,,,,,,,,,,
country,NCT02181413::country::Mexico,NCT02181413,Mexico,,,,,,,,,,,,,,
country,NCT02181413::country::Singapore,NCT02181413,Singapore,,,,,,,,,,,,,,
country,NCT02181413::country::Switzerland,NCT02181413,Switzerland,,,,,,,,,,,,,,
country,NCT02181413::country::Thailand,NCT02181413,Thailand,,,,,,,,,,,,,,
country,NCT02181413::country::Ukraine,NCT02181413,Ukraine,,,,,,,,,,,,,,
trial,NCT00441350,NCT00441350,Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,1004.0,2007-07,2008-05,8.0,65.0,,,,,
arm,NCT00441350::arm::FG000,NCT00441350,Phase A/OM 40,,,,,,,,,,FG000,Olmesartanmedoxomil (OM)40 mg tablets. OM 40: Initially patients were to be treated with Olmesartanmedoxomil (OM)40 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrate,,,
arm,NCT00441350::arm::FG001,NCT00441350,Phase A/OM/HCTZ 40/12.5,,,,,,,,,,FG001,Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets. OM/HCTZ 40/12.5: Initially patients were to be treated with Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg table,,,
arm,NCT00441350::arm::FG002,NCT00441350,Phase B/ OM 40 mg Responders,,,,,,,,,,FG002,"Phase B (second double-blind treatment phase, 8 weeks duration):

Responders to OM 40 mg treatment were to continue treatment with OM 40 mg.",,,
arm,NCT00441350::arm::FG003,NCT00441350,Phase B/ OM 40 mg Non-responder,,,,,,,,,,FG003,"Phase B (second double-blind treatment phase, 8 weeks duration):

Non-responders to OM 40 mg treatment were to be up-titrated to OM/HCTZ 40/12.5 mg.",,,
arm,NCT00441350::arm::FG004,NCT00441350,Phase B OM/HCTZ 40/12.5 mg Responders,,,,,,,,,,FG004,"Phase B (second double-blind treatment phase, 8 weeks duration):

Responders to OM/HCTZ 40/12.5 mg treatment were to continue treatment with OM/HCTZ 40/12.5 mg.",,,
arm,NCT00441350::arm::FG005,NCT00441350,Phase B/ OM/HCTZ 40/12.5 mg Non-responders,,,,,,,,,,FG005,"Phase B (second double-blind treatment phase, 8 weeks duration):

Non-responders to OM/HCTZ 40/12.5 mg treatment were to be up- titrated to OM/HCTZ 40/25 mg.",,,
period,NCT00441350::period::1,NCT00441350,Phase A: Randomization to Week 8,,,,,,,,,,,,1.0,,
period,NCT00441350::period::2,NCT00441350,Phase B: Week 8 to Week 16,,,,,,,,,,,,2.0,,
outcome,NCT00441350::outcome::primary::1,NCT00441350,dBP Change After 8 Weeks Phase A,,,,,,,,,,,,,PRIMARY,Eight weeks
outcome,NCT00441350::outcome::primary::2,NCT00441350,sBP Change After 8 Weeks Phase A,,,,,,,,,,,,,PRIMARY,Eight weeks
country,NCT00441350::country::Germany,NCT00441350,Germany,,,,,,,,,,,,,,
country,NCT00441350::country::Czechia,NCT00441350,Czechia,,,,,,,,,,,,,,
country,NCT00441350::country::Israel,NCT00441350,Israel,,,,,,,,,,,,,,
country,NCT00441350::country::Italy,NCT00441350,Italy,,,,,,,,,,,,,,
country,NCT00441350::country::Poland,NCT00441350,Poland,,,,,,,,,,,,,,
country,NCT00441350::country::Croatia,NCT00441350,Croatia,,,,,,,,,,,,,,
country,NCT00441350::country::Romania,NCT00441350,Romania,,,,,,,,,,,,,,
country,NCT00441350::country::Denmark,NCT00441350,Denmark,,,,,,,,,,,,,,
trial,NCT00624923,NCT00624923,Targeting Inflammation Using Salsalate in CardioVascular Disease,PHASE3,cardiovascular disease,Coronary Artery Disease; Overweight,OTHER,340.0,2008-09,2016-07,1.0,5.0,,,,,
arm,NCT00624923::arm::FG000,NCT00624923,1- Active Pharmacologic,,,,,,,,,,FG000,"Salsalate

Salsalate: Salsalate, 500 mg, seven tablets daily by mouth, divided into two doses, for 30 months",,,
arm,NCT00624923::arm::FG001,NCT00624923,2- Placebo,,,,,,,,,,FG001,"Placebo

Placebo: Salsalate Placebo, seven tablets daily by mouth, divided into two doses, for 30 months",,,
period,NCT00624923::period::1,NCT00624923,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00624923::outcome::primary::1,NCT00624923,Change in Non-calcified Plaque Volume in the Coronary Arteries Assessed by MDCTA From Baseline to 30 Months,,,,,,,,,,,,,PRIMARY,Baseline to 30 months
country,NCT00624923::country::United States,NCT00624923,United States,,,,,,,,,,,,,,
trial,NCT00970489,NCT00970489,Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation,PHASE3,cardiovascular disease,Atrial Fibrillation,OTHER,1516.0,2010-08,2012-06,1.0,1.0,,,,,
arm,NCT00970489::arm::FG000,NCT00970489,Olive Oil Capsule,,,,,,,,,,FG000,"Placebo : Olive Oil capsules All patients were randomized to receive n-3 Polyunsaturated fatty acids (PUFA) or matched placebo in equal numbers using computer-generated numbers, stratified by medical ",,,
arm,NCT00970489::arm::FG001,NCT00970489,Omega-3 Fatty Acid Capsules,,,,,,,,,,FG001,"Omega -3 fatty acids : 10g dose of oral omega-3 fatty acid capsules over 3-5 days before surgery (or 8 g over 2 days before surgery), including the morning of surgery, followed by 2g/d after surgery f",,,
period,NCT00970489::period::1,NCT00970489,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00970489::outcome::primary::1,NCT00970489,Any First Post-op Atrial Fibrillation or Flutter (AF),,,,,,,,,,,,,PRIMARY,"up to 10 days post-surgery or discharge, whichever sooner"
country,NCT00970489::country::United States,NCT00970489,United States,,,,,,,,,,,,,,
trial,NCT00108082,NCT00108082,The CLEVER Study - Coreg And Left Ventricular Mass Regression,PHASE3,cardiovascular disease,"Hypertrophy, Left Ventricular",INDUSTRY,287.0,2005-01,2008-08,1.0,78.0,,,,,
arm,NCT00108082::arm::FG000,NCT00108082,Carvedilol CR,,,,,,,,,,FG000,Carvedilol controlled release (CR) 20 to 80 mg once daily (OD) plus lisinopril 20 mg OD. Participants were titrated from the starting dosage to higher dosages until their blood pressure was controlled,,,
arm,NCT00108082::arm::FG001,NCT00108082,Atenolol,,,,,,,,,,FG001,Atenolol 50 to 100 mg OD plus lisinopril 20 mg OD. Participants were titrated from the starting dosage to higher dosages until their blood pressure was controlled. Participants continued to receive li,,,
arm,NCT00108082::arm::FG002,NCT00108082,Lisinopril,,,,,,,,,,FG002,Lisinopril 10 to 40 mg OD plus lisinopril 20 mg OD. Participants were titrated from the starting dosage to higher dosages until their blood pressure was controlled. Participants continued to receive l,,,
period,NCT00108082::period::1,NCT00108082,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00108082::outcome::primary::1,NCT00108082,Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Magnetic Resonance Imaging (MRI) at Month 12,,,,,,,,,,,,,PRIMARY,"Baseline and Month 12 (If Month 12 data were not available, the Last Observation Carried Forward [LOCF] analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)"
country,NCT00108082::country::United States,NCT00108082,United States,,,,,,,,,,,,,,
trial,NCT00430950,NCT00430950,Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension,PHASE3,cardiovascular disease,Essential Hypertension,INDUSTRY,1011.0,2007-02,2008-10,4.0,41.0,,,,,
arm,NCT00430950::arm::FG000,NCT00430950,OM/HCTZ 40/25 mg + 20/25 mg Matching Placebo,,,,,,,,,,FG000,Olmesartan Medoxomil/Hydrochlorothiazide 40/25 mg with 20/25 mg matching placebo,,,
arm,NCT00430950::arm::FG001,NCT00430950,OM/HCTZ 20/25 mg + 40/25 mg Matching Placebo,,,,,,,,,,FG001,Olmesartan Medoxomil/Hydrochlorothiazide 20/25mg + 40/25mg matching placebo,,,
period,NCT00430950::period::1,NCT00430950,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00430950::outcome::primary::1,NCT00430950,Change in Mean Trough Sitting Diastolic Blood Pressure,,,,,,,,,,,,,PRIMARY,8 weeks
country,NCT00430950::country::Netherlands,NCT00430950,Netherlands,,,,,,,,,,,,,,
country,NCT00430950::country::Germany,NCT00430950,Germany,,,,,,,,,,,,,,
country,NCT00430950::country::Belgium,NCT00430950,Belgium,,,,,,,,,,,,,,
country,NCT00430950::country::Slovakia,NCT00430950,Slovakia,,,,,,,,,,,,,,
trial,NCT00882440,NCT00882440,A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011),PHASE3,cardiovascular disease,Hypertension,INDUSTRY,576.0,1990-12,1992-01,0.0,0.0,,,,,
arm,NCT00882440::arm::FG000,NCT00882440,Placebo,,,,,,,,,,FG000,Losartan and Enalapril placebo orally once daily for 8 weeks,,,
arm,NCT00882440::arm::FG001,NCT00882440,Losartan 10 mg,,,,,,,,,,FG001,Losartan 10 mg orally once daily for 8 weeks,,,
arm,NCT00882440::arm::FG002,NCT00882440,Losartan 25 mg,,,,,,,,,,FG002,Losartan 25 mg orally once daily for 8 weeks,,,
arm,NCT00882440::arm::FG003,NCT00882440,Losartan 50 mg,,,,,,,,,,FG003,Losartan 50 mg orally once daily for 8 weeks,,,
arm,NCT00882440::arm::FG004,NCT00882440,Losartan 100 mg,,,,,,,,,,FG004,Losartan 100 mg orally once daily for 8 weeks,,,
arm,NCT00882440::arm::FG005,NCT00882440,Losartan 150 mg,,,,,,,,,,FG005,Losartan 150 mg orally once daily for 8 weeks,,,
arm,NCT00882440::arm::FG006,NCT00882440,Enalapril 20,,,,,,,,,,FG006,Enalapril 20 mg orally once daily for 8 weeks,,,
period,NCT00882440::period::1,NCT00882440,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00882440::outcome::primary::1,NCT00882440,Mean Change From Baseline in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8,,,,,,,,,,,,,PRIMARY,24 hours post dose at Baseline and Week 8
trial,NCT00759681,NCT00759681,"ArterX Surgical Sealant, A Randomized Prospective Multicenter Trial",PHASE3,cardiovascular disease,Vascular Disease,INDUSTRY,217.0,2008-09,2010-03,1.0,1.0,,,,,
arm,NCT00759681::arm::FG000,NCT00759681,Control: Gelfoam and Thrombin,,,,,,,,,,FG000,Gelfoam PlusTM is used to seal suture lines of arterial grafts or patches made from PTFE and Dacron. Gelfoam is a sterile compressed sponge and Thrombin is the last enzyme in the clotting cascade.,,,
arm,NCT00759681::arm::FG001,NCT00759681,Investigational Device: ArterX Surgical Sealant,,,,,,,,,,FG001,ArterX is a two-component sealant provided in a double barreled syringe. The main components are bovine serum albumin and a polyaldehyde formed from polymerized glutaraldehyde. The solutions are dispe,,,
period,NCT00759681::period::1,NCT00759681,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00759681::outcome::primary::1,NCT00759681,Immediate Sealing Evidenced by no Bleeding on Clamp Release.,,,,,,,,,,,,,PRIMARY,Immediate at time of surgery
outcome,NCT00759681::outcome::primary::2,NCT00759681,"Cumulative Incidence of Significant Bleeding, Infection, Neurological Deficit or Inflammatory/Immune Allergic Response",,,,,,,,,,,,,PRIMARY,Treatment through 6 weeks
country,NCT00759681::country::United States,NCT00759681,United States,,,,,,,,,,,,,,
trial,NCT01507831,NCT01507831,Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term),PHASE3,cardiovascular disease,Hypercholesterolemia,INDUSTRY,2341.0,2012-01,2014-11,27.0,320.0,,,,,
arm,NCT01507831::arm::FG000,NCT01507831,Placebo Q2W,,,,,,,,,,FG000,Placebo (for alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable lipid modifying therapy (LMT) for 78 weeks.,,,
arm,NCT01507831::arm::FG001,NCT01507831,Alirocumab 150 mg Q2W,,,,,,,,,,FG001,Alirocumab 150 mg SC injection Q2W added to stable LMT for 78 weeks.,,,
period,NCT01507831::period::1,NCT01507831,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01507831::outcome::primary::1,NCT01507831,Percentage of Participants Who Experienced Adverse Events (AEs),,,,,,,,,,,,,PRIMARY,Up to 10 weeks after last study drug administration (maximum of 86 weeks)
country,NCT01507831::country::United States,NCT01507831,United States,,,,,,,,,,,,,,
country,NCT01507831::country::United Kingdom,NCT01507831,United Kingdom,,,,,,,,,,,,,,
country,NCT01507831::country::Germany,NCT01507831,Germany,,,,,,,,,,,,,,
country,NCT01507831::country::Canada,NCT01507831,Canada,,,,,,,,,,,,,,
country,NCT01507831::country::France,NCT01507831,France,,,,,,,,,,,,,,
country,NCT01507831::country::Netherlands,NCT01507831,Netherlands,,,,,,,,,,,,,,
country,NCT01507831::country::South Africa,NCT01507831,South Africa,,,,,,,,,,,,,,
country,NCT01507831::country::Ukraine,NCT01507831,Ukraine,,,,,,,,,,,,,,
country,NCT01507831::country::Hungary,NCT01507831,Hungary,,,,,,,,,,,,,,
country,NCT01507831::country::Bulgaria,NCT01507831,Bulgaria,,,,,,,,,,,,,,
country,NCT01507831::country::Poland,NCT01507831,Poland,,,,,,,,,,,,,,
country,NCT01507831::country::Italy,NCT01507831,Italy,,,,,,,,,,,,,,
country,NCT01507831::country::Spain,NCT01507831,Spain,,,,,,,,,,,,,,
country,NCT01507831::country::Mexico,NCT01507831,Mexico,,,,,,,,,,,,,,
country,NCT01507831::country::Russia,NCT01507831,Russia,,,,,,,,,,,,,,
country,NCT01507831::country::Argentina,NCT01507831,Argentina,,,,,,,,,,,,,,
country,NCT01507831::country::Colombia,NCT01507831,Colombia,,,,,,,,,,,,,,
country,NCT01507831::country::Denmark,NCT01507831,Denmark,,,,,,,,,,,,,,
country,NCT01507831::country::Norway,NCT01507831,Norway,,,,,,,,,,,,,,
country,NCT01507831::country::Sweden,NCT01507831,Sweden,,,,,,,,,,,,,,
country,NCT01507831::country::Belgium,NCT01507831,Belgium,,,,,,,,,,,,,,
country,NCT01507831::country::Chile,NCT01507831,Chile,,,,,,,,,,,,,,
country,NCT01507831::country::Finland,NCT01507831,Finland,,,,,,,,,,,,,,
country,NCT01507831::country::Israel,NCT01507831,Israel,,,,,,,,,,,,,,
country,NCT01507831::country::Portugal,NCT01507831,Portugal,,,,,,,,,,,,,,
country,NCT01507831::country::Romania,NCT01507831,Romania,,,,,,,,,,,,,,
country,NCT01507831::country::Czechia,NCT01507831,Czechia,,,,,,,,,,,,,,
trial,NCT00330759,NCT00330759,Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.,PHASE3,cardiovascular disease,Bone Metastases,INDUSTRY,1779.0,2006-06-01,2011-10-01,0.0,0.0,,,,,
arm,NCT00330759::arm::FG000,NCT00330759,Zoledronic Acid,,,,,,,,,,FG000,Zoledronic acid 4 mg by intravenous injection with a subcutaneous denosumab placebo once every 4 weeks,,,
arm,NCT00330759::arm::FG001,NCT00330759,Denosumab,,,,,,,,,,FG001,Denosumab 120 mg by subcutaneous injection with an intravenous zoledronic acid placebo once every 4 weeks,,,
period,NCT00330759::period::1,NCT00330759,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00330759::outcome::primary::1,NCT00330759,Time to the First On-Study Skeletal-Related Event (Non-Inferiority),,,,,,,,,,,,,PRIMARY,up to 33 months
trial,NCT02104817,NCT02104817,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,PHASE3,cardiovascular disease,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),INDUSTRY,13078.0,2014-10-30,2020-05-27,22.0,684.0,,,,,
arm,NCT02104817::arm::FG000,NCT02104817,Epanova,,,,,,,,,,FG000,Omega-3 carboxylic acid 4 x 1 gram capsule,,,
arm,NCT02104817::arm::FG001,NCT02104817,Placebo,,,,,,,,,,FG001,Corn oil 4 x 1 gram capsule,,,
period,NCT02104817::period::1,NCT02104817,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02104817::outcome::primary::1,NCT02104817,The Composite of Major Adverse Cardiovascular Events (MACE),,,,,,,,,,,,,PRIMARY,From the date of randomization and up to completion of the end-of-treatment visit (Month 60) or at study closure
country,NCT02104817::country::United States,NCT02104817,United States,,,,,,,,,,,,,,
country,NCT02104817::country::Japan,NCT02104817,Japan,,,,,,,,,,,,,,
country,NCT02104817::country::South Africa,NCT02104817,South Africa,,,,,,,,,,,,,,
country,NCT02104817::country::China,NCT02104817,China,,,,,,,,,,,,,,
country,NCT02104817::country::Hungary,NCT02104817,Hungary,,,,,,,,,,,,,,
country,NCT02104817::country::Poland,NCT02104817,Poland,,,,,,,,,,,,,,
country,NCT02104817::country::Russia,NCT02104817,Russia,,,,,,,,,,,,,,
country,NCT02104817::country::Ukraine,NCT02104817,Ukraine,,,,,,,,,,,,,,
country,NCT02104817::country::Netherlands,NCT02104817,Netherlands,,,,,,,,,,,,,,
country,NCT02104817::country::Czechia,NCT02104817,Czechia,,,,,,,,,,,,,,
country,NCT02104817::country::United Kingdom,NCT02104817,United Kingdom,,,,,,,,,,,,,,
country,NCT02104817::country::Canada,NCT02104817,Canada,,,,,,,,,,,,,,
country,NCT02104817::country::Italy,NCT02104817,Italy,,,,,,,,,,,,,,
country,NCT02104817::country::Australia,NCT02104817,Australia,,,,,,,,,,,,,,
country,NCT02104817::country::South Korea,NCT02104817,South Korea,,,,,,,,,,,,,,
country,NCT02104817::country::Belgium,NCT02104817,Belgium,,,,,,,,,,,,,,
country,NCT02104817::country::Lithuania,NCT02104817,Lithuania,,,,,,,,,,,,,,
country,NCT02104817::country::Mexico,NCT02104817,Mexico,,,,,,,,,,,,,,
country,NCT02104817::country::New Zealand,NCT02104817,New Zealand,,,,,,,,,,,,,,
country,NCT02104817::country::Denmark,NCT02104817,Denmark,,,,,,,,,,,,,,
country,NCT02104817::country::Estonia,NCT02104817,Estonia,,,,,,,,,,,,,,
country,NCT02104817::country::Taiwan,NCT02104817,Taiwan,,,,,,,,,,,,,,
trial,NCT00479713,NCT00479713,A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED),PHASE3,cardiovascular disease,Hypercholesterolemia,INDUSTRY,618.0,2007-02-01,2008-03-01,0.0,0.0,,,,,
arm,NCT00479713::arm::FG000,NCT00479713,Ezetemibe + Simvastatin,,,,,,,,,,FG000,Ezetemibe 10 mg + Simvastatin 20 mg plus a matching placebo for rosuvastatin 10 mg QD (once a day) for 6 weeks,,,
arm,NCT00479713::arm::FG001,NCT00479713,Rosuvastatin,,,,,,,,,,FG001,Rosuvastatin 10 mg plus a matching placebo for the combination tablet QD (once a day) for 6 weeks,,,
period,NCT00479713::period::1,NCT00479713,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00479713::outcome::primary::1,NCT00479713,Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) at Study Endpoint After Six Weeks of Treatment,,,,,,,,,,,,,PRIMARY,Baseline and 6 weeks
trial,NCT05142722,NCT05142722,Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies,PHASE3,cardiovascular disease,Dyslipidemias; High Cholesterol; Hypercholesterolemia; Familial Hypercholesterolemia; Atherosclerotic Cardiovascular Disease,INDUSTRY,2530.0,2021-12-15,2024-09-26,8.0,181.0,,,,,
arm,NCT05142722::arm::FG000,NCT05142722,Placebo,,,,,,,,,,FG000,"one placebo tablet once daily

Placebo: placebo tablet made to resemble active",,,
arm,NCT05142722::arm::FG001,NCT05142722,Obicetrapib 10mg,,,,,,,,,,FG001,"one 10mg obicetrapib tablet once daily

Obicetrapib: 10mg obicetrapib tablet",,,
period,NCT05142722::period::1,NCT05142722,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT05142722::outcome::primary::1,NCT05142722,Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC],,,,,,,,,,,,,PRIMARY,84 Days
country,NCT05142722::country::United States,NCT05142722,United States,,,,,,,,,,,,,,
country,NCT05142722::country::China,NCT05142722,China,,,,,,,,,,,,,,
country,NCT05142722::country::Poland,NCT05142722,Poland,,,,,,,,,,,,,,
country,NCT05142722::country::Netherlands,NCT05142722,Netherlands,,,,,,,,,,,,,,
country,NCT05142722::country::Japan,NCT05142722,Japan,,,,,,,,,,,,,,
country,NCT05142722::country::Czechia,NCT05142722,Czechia,,,,,,,,,,,,,,
country,NCT05142722::country::Georgia,NCT05142722,Georgia,,,,,,,,,,,,,,
country,NCT05142722::country::Denmark,NCT05142722,Denmark,,,,,,,,,,,,,,
trial,NCT01215253,NCT01215253,Ranolazine Implantable Cardioverter-Defibrillator Trial,PHASE3,cardiovascular disease,Ischemic Cardiomyopathy; Nonischemic Cardiomyopathy; Heart Failure,OTHER,1012.0,2011-09,2017-02-28,2.0,90.0,,,,,
arm,NCT01215253::arm::FG000,NCT01215253,Ranolazine,,,,,,,,,,FG000,"At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg t",,,
arm,NCT01215253::arm::FG001,NCT01215253,Placebo,,,,,,,,,,FG001,"Ranolazine: At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase ",,,
period,NCT01215253::period::1,NCT01215253,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01215253::outcome::primary::1,NCT01215253,Number of Patients With Ventricular Tachycardia (VT) or Ventricular Fibrillation (VF) or Death,,,,,,,,,,,,,PRIMARY,2 years of follow-up on average
country,NCT01215253::country::United States,NCT01215253,United States,,,,,,,,,,,,,,
country,NCT01215253::country::Canada,NCT01215253,Canada,,,,,,,,,,,,,,
trial,NCT00529451,NCT00529451,"Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg",PHASE3,cardiovascular disease,Hypertension,INDUSTRY,1613.0,2007-09,2008-07,3.0,3.0,,,,,
arm,NCT00529451::arm::FG000,NCT00529451,Aliskiren 300 mg,,,,,,,,,,FG000,Aliskiren 300 mg once daily,,,
arm,NCT00529451::arm::FG001,NCT00529451,Aliskiren 150 mg,,,,,,,,,,FG001,Aliskiren 150 mg once daily,,,
arm,NCT00529451::arm::FG002,NCT00529451,Aliskiren 75 mg,,,,,,,,,,FG002,Aliskiren 75 mg once daily,,,
arm,NCT00529451::arm::FG003,NCT00529451,Ramipril 5 mg,,,,,,,,,,FG003,Ramipril 5 mg once daily,,,
period,NCT00529451::period::1,NCT00529451,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00529451::outcome::primary::1,NCT00529451,Non-inferiority of Aliskiren 300 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP),,,,,,,,,,,,,PRIMARY,Baseline and Week 8
outcome,NCT00529451::outcome::primary::2,NCT00529451,Non-inferiority of Aliskiren 150 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP),,,,,,,,,,,,,PRIMARY,Baseline and Week 8
outcome,NCT00529451::outcome::primary::3,NCT00529451,Non-inferiority of Aliskiren 75 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP),,,,,,,,,,,,,PRIMARY,Baseline and Week 8
country,NCT00529451::country::China,NCT00529451,China,,,,,,,,,,,,,,
country,NCT00529451::country::India,NCT00529451,India,,,,,,,,,,,,,,
country,NCT00529451::country::Thailand,NCT00529451,Thailand,,,,,,,,,,,,,,
trial,NCT00424047,NCT00424047,A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma,PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,351.0,2003-01-01,2013-11-12,15.0,69.0,,,,,
arm,NCT00424047::arm::FG000,NCT00424047,Lenalidomide Plus Dexamethasone (Len/Dex),,,,,,,,,,FG000,"Lenalidomide 25 mg by mouth (PO) daily (QD) on Days 1 to 21 and a matching placebo capsule QD on Days 22 to 28 of each 28-day cycle.

Pulse dexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of eac",,,
arm,NCT00424047::arm::FG001,NCT00424047,Placebo Plus Dexamethasone,,,,,,,,,,FG001,"Placebo PO daily on Days 1 to 28 of each 28 day cycle.

Pulse dexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28-day cycle for Cycles 1 through 4. Beginning with Cycle 5, dexamethasone d",,,
period,NCT00424047::period::1,NCT00424047,Blinded Treatment (Up to 03 Aug 2005),,,,,,,,,,,,1.0,,
period,NCT00424047::period::2,NCT00424047,On Study at Time of Unblinding,,,,,,,,,,,,2.0,,
period,NCT00424047::period::3,NCT00424047,Long Term Extension (Up to 25 Jun 2013),,,,,,,,,,,,3.0,,
outcome,NCT00424047::outcome::primary::1,NCT00424047,Kaplan-Meier Estimate of Time to Tumor Progression (TTP),,,,,,,,,,,,,PRIMARY,From randomization up to cut-off date of 03 August 2005
outcome,NCT00424047::outcome::primary::2,NCT00424047,Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (Later Cut-off Date of 02 Mar 2008),,,,,,,,,,,,,PRIMARY,up to 24 months
country,NCT00424047::country::Australia,NCT00424047,Australia,,,,,,,,,,,,,,
country,NCT00424047::country::Germany,NCT00424047,Germany,,,,,,,,,,,,,,
country,NCT00424047::country::Ukraine,NCT00424047,Ukraine,,,,,,,,,,,,,,
country,NCT00424047::country::France,NCT00424047,France,,,,,,,,,,,,,,
country,NCT00424047::country::Italy,NCT00424047,Italy,,,,,,,,,,,,,,
country,NCT00424047::country::Spain,NCT00424047,Spain,,,,,,,,,,,,,,
country,NCT00424047::country::Ireland,NCT00424047,Ireland,,,,,,,,,,,,,,
country,NCT00424047::country::Israel,NCT00424047,Israel,,,,,,,,,,,,,,
country,NCT00424047::country::Poland,NCT00424047,Poland,,,,,,,,,,,,,,
country,NCT00424047::country::Switzerland,NCT00424047,Switzerland,,,,,,,,,,,,,,
country,NCT00424047::country::United Kingdom,NCT00424047,United Kingdom,,,,,,,,,,,,,,
country,NCT00424047::country::Austria,NCT00424047,Austria,,,,,,,,,,,,,,
country,NCT00424047::country::Belgium,NCT00424047,Belgium,,,,,,,,,,,,,,
country,NCT00424047::country::Greece,NCT00424047,Greece,,,,,,,,,,,,,,
country,NCT00424047::country::Sweden,NCT00424047,Sweden,,,,,,,,,,,,,,
trial,NCT00558428,NCT00558428,Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,1098.0,2007-10,,12.0,129.0,,,,,
arm,NCT00558428::arm::FG000,NCT00558428,Amlodipine 5mg,,,,,,,,,,FG000,,,,
arm,NCT00558428::arm::FG001,NCT00558428,Amlodipine 10mg,,,,,,,,,,FG001,,,,
arm,NCT00558428::arm::FG002,NCT00558428,Telmisartan 40mg and Amlodipine 5mg,,,,,,,,,,FG002,,,,
arm,NCT00558428::arm::FG003,NCT00558428,Telmisartan 80mg and Amlodipine 5mg,,,,,,,,,,FG003,,,,
period,NCT00558428::period::1,NCT00558428,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00558428::outcome::primary::1,NCT00558428,Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP),,,,,,,,,,,,,PRIMARY,End of study (8 weeks or last value on treatment)
outcome,NCT00558428::outcome::primary::2,NCT00558428,Number of Patients With Oedema,,,,,,,,,,,,,PRIMARY,"During randomised treatment period (8 weeks was the planned end of treatment, some of the measurements analysed as end of study can be at 4 weeks or at any point on randomised treatment)"
country,NCT00558428::country::France,NCT00558428,France,,,,,,,,,,,,,,
country,NCT00558428::country::Canada,NCT00558428,Canada,,,,,,,,,,,,,,
country,NCT00558428::country::Belgium,NCT00558428,Belgium,,,,,,,,,,,,,,
country,NCT00558428::country::South Africa,NCT00558428,South Africa,,,,,,,,,,,,,,
country,NCT00558428::country::Denmark,NCT00558428,Denmark,,,,,,,,,,,,,,
country,NCT00558428::country::Netherlands,NCT00558428,Netherlands,,,,,,,,,,,,,,
country,NCT00558428::country::Philippines,NCT00558428,Philippines,,,,,,,,,,,,,,
country,NCT00558428::country::South Korea,NCT00558428,South Korea,,,,,,,,,,,,,,
country,NCT00558428::country::Sweden,NCT00558428,Sweden,,,,,,,,,,,,,,
country,NCT00558428::country::Finland,NCT00558428,Finland,,,,,,,,,,,,,,
country,NCT00558428::country::Norway,NCT00558428,Norway,,,,,,,,,,,,,,
country,NCT00558428::country::Taiwan,NCT00558428,Taiwan,,,,,,,,,,,,,,
trial,NCT00558064,NCT00558064,Filtered Trial for Amlodipine Non-responder,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,531.0,2007-10,,1.0,41.0,,,,,
arm,NCT00558064::arm::FG000,NCT00558064,Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination,,,,,,,,,,FG000,"T40/A5 tablet, oral, once daily in the morning",,,
arm,NCT00558064::arm::FG001,NCT00558064,Amlodipine 5 mg Monotherapy,,,,,,,,,,FG001,"A5 capsule, oral, once daily in the morning",,,
period,NCT00558064::period::1,NCT00558064,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00558064::outcome::primary::1,NCT00558064,Reduction From Reference Baseline in Mean Seated Diastolic Blood Pressure at Trough (24-hour Post-dosing),,,,,,,,,,,,,PRIMARY,Baseline and 8 Weeks
country,NCT00558064::country::Japan,NCT00558064,Japan,,,,,,,,,,,,,,
trial,NCT02480764,NCT02480764,Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension,PHASE3,cardiovascular disease,Essential Hypertension,INDUSTRY,612.0,2015-08-27,2017-10-13,1.0,30.0,,,,,
arm,NCT02480764::arm::FG000,NCT02480764,Azilsartan Medoxomil 40 mg,,,,,,,,,,FG000,"Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 we",,,
arm,NCT02480764::arm::FG001,NCT02480764,Azilsartan Medoxomil 80 mg,,,,,,,,,,FG001,"Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 we",,,
arm,NCT02480764::arm::FG002,NCT02480764,Valsartan 160 mg,,,,,,,,,,FG002,"Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 we",,,
period,NCT02480764::period::1,NCT02480764,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02480764::outcome::primary::1,NCT02480764,Change From Baseline in Trough Sitting Clinic Systolic Blood Pressure (SBP),,,,,,,,,,,,,PRIMARY,Baseline and Week 8
country,NCT02480764::country::China,NCT02480764,China,,,,,,,,,,,,,,
trial,NCT00179647,NCT00179647,Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma,PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,1913.0,2005-09,2009-04,2.0,69.0,,,,,
arm,NCT00179647::arm::FG000,NCT00179647,Lenalidomide,,,,,,,,,,FG000,"This was a multicenter, non-randomized, open-label, uncontrolled, single-arm treatment study of lenalidomide as monotherapy or in combination with dexamethasone in subjects with previously treated rel",,,
period,NCT00179647::period::1,NCT00179647,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00179647::outcome::primary::1,NCT00179647,"Incidence of Adverse Events Summarized by System Organ Class, Preferred Term, Severity, Seriousness, and Relationship to Treatment.",,,,,,,,,,,,,PRIMARY,Median time-on-study=18.3 weeks
outcome,NCT00179647::outcome::primary::2,NCT00179647,Overall Incidence of Adverse Events,,,,,,,,,,,,,PRIMARY,Median time-on-study=18.3 weeks
country,NCT00179647::country::United States,NCT00179647,United States,,,,,,,,,,,,,,
country,NCT00179647::country::Canada,NCT00179647,Canada,,,,,,,,,,,,,,
trial,NCT03066804,NCT03066804,"A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients",PHASE3,cardiovascular disease,Heart Failure With Preserved Ejection Fraction,INDUSTRY,2572.0,2017-08-22,2019-10-28,32.0,380.0,,,,,
arm,NCT03066804::arm::FG000,NCT03066804,Sacubitril/Valsartan (LCZ696),,,,,,,,,,FG000,"All patients who fulfilled the inclusion/exclusion criteria were stratified before randomization based upon prior therapy for comorbidities to one of 3 strata: ACEi, ARB or no RASi.",,,
arm,NCT03066804::arm::FG001,NCT03066804,Individualized Medical Therapy (IMT) Comparator,,,,,,,,,,FG001,Patients randomized to the comparator arm received either enalapril (ACE stratum) valsartan (ARB stratum) or LCZ696 matching placebo (no RASi stratum).,,,
period,NCT03066804::period::1,NCT03066804,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03066804::outcome::primary::1,NCT03066804,Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) at Week 12,,,,,,,,,,,,,PRIMARY,"Baseline, week 12"
outcome,NCT03066804::outcome::primary::2,NCT03066804,Change From Baseline in 6 Minute Walk Distance (6MWD) at Week 24,,,,,,,,,,,,,PRIMARY,"Baseline, week 24"
country,NCT03066804::country::Germany,NCT03066804,Germany,,,,,,,,,,,,,,
country,NCT03066804::country::United States,NCT03066804,United States,,,,,,,,,,,,,,
country,NCT03066804::country::Russia,NCT03066804,Russia,,,,,,,,,,,,,,
country,NCT03066804::country::Slovakia,NCT03066804,Slovakia,,,,,,,,,,,,,,
country,NCT03066804::country::Argentina,NCT03066804,Argentina,,,,,,,,,,,,,,
country,NCT03066804::country::Czechia,NCT03066804,Czechia,,,,,,,,,,,,,,
country,NCT03066804::country::Spain,NCT03066804,Spain,,,,,,,,,,,,,,
country,NCT03066804::country::Romania,NCT03066804,Romania,,,,,,,,,,,,,,
country,NCT03066804::country::Turkey (Türkiye),NCT03066804,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT03066804::country::Brazil,NCT03066804,Brazil,,,,,,,,,,,,,,
country,NCT03066804::country::Bulgaria,NCT03066804,Bulgaria,,,,,,,,,,,,,,
country,NCT03066804::country::Italy,NCT03066804,Italy,,,,,,,,,,,,,,
country,NCT03066804::country::India,NCT03066804,India,,,,,,,,,,,,,,
country,NCT03066804::country::Netherlands,NCT03066804,Netherlands,,,,,,,,,,,,,,
country,NCT03066804::country::France,NCT03066804,France,,,,,,,,,,,,,,
country,NCT03066804::country::United Kingdom,NCT03066804,United Kingdom,,,,,,,,,,,,,,
country,NCT03066804::country::Portugal,NCT03066804,Portugal,,,,,,,,,,,,,,
country,NCT03066804::country::Peru,NCT03066804,Peru,,,,,,,,,,,,,,
country,NCT03066804::country::Colombia,NCT03066804,Colombia,,,,,,,,,,,,,,
country,NCT03066804::country::Israel,NCT03066804,Israel,,,,,,,,,,,,,,
country,NCT03066804::country::Thailand,NCT03066804,Thailand,,,,,,,,,,,,,,
country,NCT03066804::country::Austria,NCT03066804,Austria,,,,,,,,,,,,,,
country,NCT03066804::country::Belgium,NCT03066804,Belgium,,,,,,,,,,,,,,
country,NCT03066804::country::Canada,NCT03066804,Canada,,,,,,,,,,,,,,
country,NCT03066804::country::Hungary,NCT03066804,Hungary,,,,,,,,,,,,,,
country,NCT03066804::country::Serbia,NCT03066804,Serbia,,,,,,,,,,,,,,
country,NCT03066804::country::Guatemala,NCT03066804,Guatemala,,,,,,,,,,,,,,
country,NCT03066804::country::Latvia,NCT03066804,Latvia,,,,,,,,,,,,,,
country,NCT03066804::country::Mexico,NCT03066804,Mexico,,,,,,,,,,,,,,
country,NCT03066804::country::Denmark,NCT03066804,Denmark,,,,,,,,,,,,,,
country,NCT03066804::country::Estonia,NCT03066804,Estonia,,,,,,,,,,,,,,
country,NCT03066804::country::Lithuania,NCT03066804,Lithuania,,,,,,,,,,,,,,
trial,NCT00658515,NCT00658515,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,PHASE3,cardiovascular disease,Coronary Heart Disease,INDUSTRY,15871.0,2008-04,2012-09,29.0,1089.0,,,,,
arm,NCT00658515::arm::FG000,NCT00658515,Dalcetrapib (RO4607381),,,,,,,,,,FG000,"Dalcetrapib (RO4607381): 600mg po daily

Evidence-based medical care for Acute Coronary Syndrome: As prescribed",,,
arm,NCT00658515::arm::FG001,NCT00658515,Placebo,,,,,,,,,,FG001,"Evidence-based medical care for Acute Coronary Syndrome: As prescribed

Placebo: po daily",,,
period,NCT00658515::period::1,NCT00658515,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00658515::outcome::primary::1,NCT00658515,Incidence of Cardiovascular Mortality and Morbidity,,,,,,,,,,,,,PRIMARY,From date of randomization to first event up to 48 months
country,NCT00658515::country::United States,NCT00658515,United States,,,,,,,,,,,,,,
country,NCT00658515::country::Canada,NCT00658515,Canada,,,,,,,,,,,,,,
country,NCT00658515::country::Netherlands,NCT00658515,Netherlands,,,,,,,,,,,,,,
country,NCT00658515::country::Poland,NCT00658515,Poland,,,,,,,,,,,,,,
country,NCT00658515::country::Brazil,NCT00658515,Brazil,,,,,,,,,,,,,,
country,NCT00658515::country::Argentina,NCT00658515,Argentina,,,,,,,,,,,,,,
country,NCT00658515::country::Germany,NCT00658515,Germany,,,,,,,,,,,,,,
country,NCT00658515::country::China,NCT00658515,China,,,,,,,,,,,,,,
country,NCT00658515::country::United Kingdom,NCT00658515,United Kingdom,,,,,,,,,,,,,,
country,NCT00658515::country::Czechia,NCT00658515,Czechia,,,,,,,,,,,,,,
country,NCT00658515::country::France,NCT00658515,France,,,,,,,,,,,,,,
country,NCT00658515::country::Israel,NCT00658515,Israel,,,,,,,,,,,,,,
country,NCT00658515::country::Italy,NCT00658515,Italy,,,,,,,,,,,,,,
country,NCT00658515::country::Spain,NCT00658515,Spain,,,,,,,,,,,,,,
country,NCT00658515::country::Hungary,NCT00658515,Hungary,,,,,,,,,,,,,,
country,NCT00658515::country::Australia,NCT00658515,Australia,,,,,,,,,,,,,,
country,NCT00658515::country::South Korea,NCT00658515,South Korea,,,,,,,,,,,,,,
country,NCT00658515::country::South Africa,NCT00658515,South Africa,,,,,,,,,,,,,,
country,NCT00658515::country::Denmark,NCT00658515,Denmark,,,,,,,,,,,,,,
country,NCT00658515::country::Belgium,NCT00658515,Belgium,,,,,,,,,,,,,,
country,NCT00658515::country::Slovakia,NCT00658515,Slovakia,,,,,,,,,,,,,,
country,NCT00658515::country::New Zealand,NCT00658515,New Zealand,,,,,,,,,,,,,,
country,NCT00658515::country::Puerto Rico,NCT00658515,Puerto Rico,,,,,,,,,,,,,,
country,NCT00658515::country::Austria,NCT00658515,Austria,,,,,,,,,,,,,,
country,NCT00658515::country::Switzerland,NCT00658515,Switzerland,,,,,,,,,,,,,,
country,NCT00658515::country::Sweden,NCT00658515,Sweden,,,,,,,,,,,,,,
country,NCT00658515::country::Finland,NCT00658515,Finland,,,,,,,,,,,,,,
country,NCT00658515::country::Ireland,NCT00658515,Ireland,,,,,,,,,,,,,,
country,NCT00658515::country::Grenada,NCT00658515,Grenada,,,,,,,,,,,,,,
trial,NCT04264819,NCT04264819,Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration,PHASE3,cardiovascular disease,Neovascular Age-Related Macular Degeneration,INDUSTRY,295.0,2020-12-14,2023-05-10,1.0,51.0,,,,,
arm,NCT04264819::arm::FG000,NCT04264819,RTH258/Brolucizumab,,,,,,,,,,FG000,"This is a single arm study in which all patients are treated with brolucizumab 6mg; 3 loading injections (at Screening/Baseline, week 4 and week 8) followed by treat-to-control phase with adjustable t",,,
period,NCT04264819::period::1,NCT04264819,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04264819::outcome::primary::1,NCT04264819,Number of Patients With no Disease Activity at Week 16 in the Study Eye,,,,,,,,,,,,,PRIMARY,Week 16
country,NCT04264819::country::France,NCT04264819,France,,,,,,,,,,,,,,
trial,NCT00126425,NCT00126425,Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease,PHASE3,cardiovascular disease,"Heart Failure, Congestive",INDUSTRY,587.0,2005-07,2008-12,1.0,1.0,,,,,
arm,NCT00126425::arm::FG000,NCT00126425,AdreView--Heart Failure Group,,,,,,,,,,FG000,123I-mIBG (meta-iodobenzylguanidine): 10 mCi as a single intravenous dose.,,,
arm,NCT00126425::arm::FG001,NCT00126425,AdreView--Control Group,,,,,,,,,,FG001,123I-mIBG (meta-iodobenzylguanidine): 10 mCi as a single intravenous dose.,,,
period,NCT00126425::period::1,NCT00126425,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00126425::outcome::primary::1,NCT00126425,Relationship Between the Occurrence of Adverse Cardiac Event and 123I-mIBG Uptake on Planar Scintigraphy Categorized as High or Low Heart to Mediastinum (H/M) Ratio,,,,,,,,,,,,,PRIMARY,Approximately 24 months from the date of administration of 123I-mIBG
country,NCT00126425::country::United States,NCT00126425,United States,,,,,,,,,,,,,,
trial,NCT00202878,NCT00202878,IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103),PHASE3,cardiovascular disease,Hypercholesterolemia; Myocardial Infarction,INDUSTRY,18144.0,2005-10-17,2014-09-18,0.0,0.0,,,,,
arm,NCT00202878::arm::FG000,NCT00202878,Ezetimibe/Simvastatin,,,,,,,,,,FG000,One Ezetimibe 10 mg/simvastatin 40 mg combination tablet and two simvastatin 40 mg placebo tablets once per day.,,,
arm,NCT00202878::arm::FG001,NCT00202878,Simvastatin,,,,,,,,,,FG001,"One simvastatin 40 mg tablet, one ezetimibe/simvastatin combination 10/40 placebo tablet and one simvastatin 40 mg placebo tablet once per day.",,,
period,NCT00202878::period::1,NCT00202878,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00202878::outcome::primary::1,NCT00202878,"Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event)",,,,,,,,,,,,,PRIMARY,Up to approximately 9 years
trial,NCT03021343,NCT03021343,Effect of Colchicine on the Incidence of Atrial Fibrillation in Open Heart Surgery Patients,PHASE3,cardiovascular disease,Arrhythmia,OTHER,360.0,2012-10,2015-02,0.0,0.0,,,,,
arm,NCT03021343::arm::FG000,NCT03021343,Colchicine,,,,,,,,,,FG000,Colchicine 2 mg 12-24 hours prior to surgery and 1 mg 4 hours before or immediately after surgery and then continued at a dose of 0.5 mg twice daily until hospital discharge. Half the dose was given t,,,
arm,NCT03021343::arm::FG001,NCT03021343,No Colchicine,,,,,,,,,,FG001,In this arm no active medication was administered,,,
period,NCT03021343::period::1,NCT03021343,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03021343::outcome::primary::1,NCT03021343,The Number of Participants With Atrial Fibrillation,,,,,,,,,,,,,PRIMARY,"From date of randomization until the date of discharge, assessed up to 2 weeks"
outcome,NCT03021343::outcome::primary::2,NCT03021343,The Number of Participants With Colchicine Side Effects,,,,,,,,,,,,,PRIMARY,"From date of randomization until the date of discharge, assessed up to 2 weeks"
trial,NCT00152971,NCT00152971,Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement,PHASE3,cardiovascular disease,"Arthroplasty, Replacement, Knee; Thromboembolism",INDUSTRY,2615.0,2004-11,,4.0,94.0,,,,,
arm,NCT00152971::arm::FG000,NCT00152971,Dabigatran 220mg,,,,,,,,,,FG000,qd (once daily) oral,,,
arm,NCT00152971::arm::FG001,NCT00152971,Dabigatran 150mg,,,,,,,,,,FG001,qd (once daily) oral,,,
arm,NCT00152971::arm::FG002,NCT00152971,Enoxaparin,,,,,,,,,,FG002,30mg bid (twice daily) subcutaneous,,,
period,NCT00152971::period::1,NCT00152971,Overall Study,,,,,,,,,,,,1.0,,
period,NCT00152971::period::2,NCT00152971,Treatment,,,,,,,,,,,,2.0,,
outcome,NCT00152971::outcome::primary::1,NCT00152971,Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period,,,,,,,,,,,,,PRIMARY,First administration until 12-15 days
country,NCT00152971::country::United States,NCT00152971,United States,,,,,,,,,,,,,,
country,NCT00152971::country::Canada,NCT00152971,Canada,,,,,,,,,,,,,,
country,NCT00152971::country::Mexico,NCT00152971,Mexico,,,,,,,,,,,,,,
country,NCT00152971::country::United Kingdom,NCT00152971,United Kingdom,,,,,,,,,,,,,,
trial,NCT03354429,NCT03354429,THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death,PHASE3,cardiovascular disease,Acute Ischaemic Stroke; Transient Ischaemic Attack,INDUSTRY,11016.0,2018-01-22,2019-12-13,28.0,387.0,,,,,
arm,NCT03354429::arm::FG000,NCT03354429,TICAGRELOR,,,,,,,,,,FG000,"Ticagrelor 180 mg day 1, followed by 90 mg twice daily day 2-30",,,
arm,NCT03354429::arm::FG001,NCT03354429,PLACEBO,,,,,,,,,,FG001,"Placebo 180 mg day 1, followed by 90 mg twice daily day 2-30",,,
period,NCT03354429::period::1,NCT03354429,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03354429::outcome::primary::1,NCT03354429,Composite of Subsequent Stroke or Death,,,,,,,,,,,,,PRIMARY,From randomisation (day 1) to visit 3 (day 30-34)
country,NCT03354429::country::China,NCT03354429,China,,,,,,,,,,,,,,
country,NCT03354429::country::Russia,NCT03354429,Russia,,,,,,,,,,,,,,
country,NCT03354429::country::France,NCT03354429,France,,,,,,,,,,,,,,
country,NCT03354429::country::Poland,NCT03354429,Poland,,,,,,,,,,,,,,
country,NCT03354429::country::India,NCT03354429,India,,,,,,,,,,,,,,
country,NCT03354429::country::Italy,NCT03354429,Italy,,,,,,,,,,,,,,
country,NCT03354429::country::South Korea,NCT03354429,South Korea,,,,,,,,,,,,,,
country,NCT03354429::country::Thailand,NCT03354429,Thailand,,,,,,,,,,,,,,
country,NCT03354429::country::Hungary,NCT03354429,Hungary,,,,,,,,,,,,,,
country,NCT03354429::country::Taiwan,NCT03354429,Taiwan,,,,,,,,,,,,,,
country,NCT03354429::country::Spain,NCT03354429,Spain,,,,,,,,,,,,,,
country,NCT03354429::country::Argentina,NCT03354429,Argentina,,,,,,,,,,,,,,
country,NCT03354429::country::Ukraine,NCT03354429,Ukraine,,,,,,,,,,,,,,
country,NCT03354429::country::Belgium,NCT03354429,Belgium,,,,,,,,,,,,,,
country,NCT03354429::country::Germany,NCT03354429,Germany,,,,,,,,,,,,,,
country,NCT03354429::country::Slovakia,NCT03354429,Slovakia,,,,,,,,,,,,,,
country,NCT03354429::country::Bulgaria,NCT03354429,Bulgaria,,,,,,,,,,,,,,
country,NCT03354429::country::Mexico,NCT03354429,Mexico,,,,,,,,,,,,,,
country,NCT03354429::country::Sweden,NCT03354429,Sweden,,,,,,,,,,,,,,
country,NCT03354429::country::Brazil,NCT03354429,Brazil,,,,,,,,,,,,,,
country,NCT03354429::country::Peru,NCT03354429,Peru,,,,,,,,,,,,,,
country,NCT03354429::country::Romania,NCT03354429,Romania,,,,,,,,,,,,,,
country,NCT03354429::country::Czechia,NCT03354429,Czechia,,,,,,,,,,,,,,
country,NCT03354429::country::Australia,NCT03354429,Australia,,,,,,,,,,,,,,
country,NCT03354429::country::Canada,NCT03354429,Canada,,,,,,,,,,,,,,
country,NCT03354429::country::Saudi Arabia,NCT03354429,Saudi Arabia,,,,,,,,,,,,,,
country,NCT03354429::country::Vietnam,NCT03354429,Vietnam,,,,,,,,,,,,,,
country,NCT03354429::country::Hong Kong,NCT03354429,Hong Kong,,,,,,,,,,,,,,
trial,NCT01015287,NCT01015287,A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction,PHASE3,cardiovascular disease,Acute Coronary Syndromes,INDUSTRY,4033.0,2009-12,2013-02,19.0,153.0,,,,,
arm,NCT01015287::arm::FG000,NCT01015287,Non Pre-treatment,,,,,,,,,,FG000,A placebo oral loading dose (LD) was given at the time of diagnosis and a 60 milligrams (mg) oral LD of prasugrel was given at the time of percutaneous coronary intervention (PCI) followed by 5 mg or ,,,
arm,NCT01015287::arm::FG001,NCT01015287,Pre-treatment,,,,,,,,,,FG001,A 30 mg oral LD of prasugrel was given at diagnosis and a 30 mg oral dose of prasugrel was given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.,,,
period,NCT01015287::period::1,NCT01015287,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01015287::outcome::primary::1,NCT01015287,"The Percentage of Participants With Occurrence of Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, Urgent Revascularization (UR), or Glycoprotein (GP) IIb/IIIa Inhibitor Bailout",,,,,,,,,,,,,PRIMARY,First loading dose (LD) through 7 days after first LD
country,NCT01015287::country::France,NCT01015287,France,,,,,,,,,,,,,,
country,NCT01015287::country::Poland,NCT01015287,Poland,,,,,,,,,,,,,,
country,NCT01015287::country::Germany,NCT01015287,Germany,,,,,,,,,,,,,,
country,NCT01015287::country::Italy,NCT01015287,Italy,,,,,,,,,,,,,,
country,NCT01015287::country::Turkey (Türkiye),NCT01015287,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01015287::country::Israel,NCT01015287,Israel,,,,,,,,,,,,,,
country,NCT01015287::country::Netherlands,NCT01015287,Netherlands,,,,,,,,,,,,,,
country,NCT01015287::country::Belgium,NCT01015287,Belgium,,,,,,,,,,,,,,
country,NCT01015287::country::Canada,NCT01015287,Canada,,,,,,,,,,,,,,
country,NCT01015287::country::Czechia,NCT01015287,Czechia,,,,,,,,,,,,,,
country,NCT01015287::country::Austria,NCT01015287,Austria,,,,,,,,,,,,,,
country,NCT01015287::country::Hungary,NCT01015287,Hungary,,,,,,,,,,,,,,
country,NCT01015287::country::Portugal,NCT01015287,Portugal,,,,,,,,,,,,,,
country,NCT01015287::country::Lithuania,NCT01015287,Lithuania,,,,,,,,,,,,,,
country,NCT01015287::country::Slovakia,NCT01015287,Slovakia,,,,,,,,,,,,,,
country,NCT01015287::country::Latvia,NCT01015287,Latvia,,,,,,,,,,,,,,
country,NCT01015287::country::Romania,NCT01015287,Romania,,,,,,,,,,,,,,
country,NCT01015287::country::Finland,NCT01015287,Finland,,,,,,,,,,,,,,
country,NCT01015287::country::Sweden,NCT01015287,Sweden,,,,,,,,,,,,,,
trial,NCT01598831,NCT01598831,Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy,PHASE3,cardiovascular disease,Severe Sepsis; Coagulopathy,INDUSTRY,816.0,2012-10-29,2019-02-28,24.0,161.0,,,,,
arm,NCT01598831::arm::FG000,NCT01598831,ART-123,,,,,,,,,,FG000,"ART-123 (human recombinant thrombomodulin, thrombomodulin alfa) Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days",,,
arm,NCT01598831::arm::FG001,NCT01598831,Placebo,,,,,,,,,,FG001,Placebo Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days,,,
period,NCT01598831::period::1,NCT01598831,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01598831::outcome::primary::1,NCT01598831,Number of Participants With 28-Day All-cause Mortality,,,,,,,,,,,,,PRIMARY,28 days
outcome,NCT01598831::outcome::primary::2,NCT01598831,Number of Participants With On-Treatment Serious Major Bleeding Events,,,,,,,,,,,,,PRIMARY,Through Study Day 28
country,NCT01598831::country::United States,NCT01598831,United States,,,,,,,,,,,,,,
country,NCT01598831::country::France,NCT01598831,France,,,,,,,,,,,,,,
country,NCT01598831::country::India,NCT01598831,India,,,,,,,,,,,,,,
country,NCT01598831::country::Canada,NCT01598831,Canada,,,,,,,,,,,,,,
country,NCT01598831::country::Russia,NCT01598831,Russia,,,,,,,,,,,,,,
country,NCT01598831::country::Belgium,NCT01598831,Belgium,,,,,,,,,,,,,,
country,NCT01598831::country::Australia,NCT01598831,Australia,,,,,,,,,,,,,,
country,NCT01598831::country::Netherlands,NCT01598831,Netherlands,,,,,,,,,,,,,,
country,NCT01598831::country::Israel,NCT01598831,Israel,,,,,,,,,,,,,,
country,NCT01598831::country::Spain,NCT01598831,Spain,,,,,,,,,,,,,,
country,NCT01598831::country::Czechia,NCT01598831,Czechia,,,,,,,,,,,,,,
country,NCT01598831::country::United Kingdom,NCT01598831,United Kingdom,,,,,,,,,,,,,,
country,NCT01598831::country::Finland,NCT01598831,Finland,,,,,,,,,,,,,,
country,NCT01598831::country::New Zealand,NCT01598831,New Zealand,,,,,,,,,,,,,,
country,NCT01598831::country::South Korea,NCT01598831,South Korea,,,,,,,,,,,,,,
country,NCT01598831::country::Brazil,NCT01598831,Brazil,,,,,,,,,,,,,,
country,NCT01598831::country::Croatia,NCT01598831,Croatia,,,,,,,,,,,,,,
country,NCT01598831::country::Germany,NCT01598831,Germany,,,,,,,,,,,,,,
country,NCT01598831::country::Taiwan,NCT01598831,Taiwan,,,,,,,,,,,,,,
country,NCT01598831::country::Bulgaria,NCT01598831,Bulgaria,,,,,,,,,,,,,,
country,NCT01598831::country::Peru,NCT01598831,Peru,,,,,,,,,,,,,,
country,NCT01598831::country::Argentina,NCT01598831,Argentina,,,,,,,,,,,,,,
country,NCT01598831::country::Hungary,NCT01598831,Hungary,,,,,,,,,,,,,,
country,NCT01598831::country::Serbia,NCT01598831,Serbia,,,,,,,,,,,,,,
trial,NCT00168805,NCT00168805,RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery,PHASE3,cardiovascular disease,"Arthroplasty, Replacement, Knee; Thromboembolism",INDUSTRY,2101.0,2004-11,,15.0,105.0,,,,,
arm,NCT00168805::arm::FG000,NCT00168805,Dabigatran 220mg,,,,,,,,,,FG000,qd (once daily) oral,,,
arm,NCT00168805::arm::FG001,NCT00168805,Dabigatran 150mg,,,,,,,,,,FG001,qd (once daily) oral,,,
arm,NCT00168805::arm::FG002,NCT00168805,Enoxaparin,,,,,,,,,,FG002,40mg qd (once daily) subcutaneous,,,
period,NCT00168805::period::1,NCT00168805,Overall Study,,,,,,,,,,,,1.0,,
period,NCT00168805::period::2,NCT00168805,Treatment,,,,,,,,,,,,2.0,,
outcome,NCT00168805::outcome::primary::1,NCT00168805,Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period,,,,,,,,,,,,,PRIMARY,First administration until 6-10 days
country,NCT00168805::country::Australia,NCT00168805,Australia,,,,,,,,,,,,,,
country,NCT00168805::country::Spain,NCT00168805,Spain,,,,,,,,,,,,,,
country,NCT00168805::country::Czechia,NCT00168805,Czechia,,,,,,,,,,,,,,
country,NCT00168805::country::France,NCT00168805,France,,,,,,,,,,,,,,
country,NCT00168805::country::Germany,NCT00168805,Germany,,,,,,,,,,,,,,
country,NCT00168805::country::Sweden,NCT00168805,Sweden,,,,,,,,,,,,,,
country,NCT00168805::country::Belgium,NCT00168805,Belgium,,,,,,,,,,,,,,
country,NCT00168805::country::Hungary,NCT00168805,Hungary,,,,,,,,,,,,,,
country,NCT00168805::country::Italy,NCT00168805,Italy,,,,,,,,,,,,,,
country,NCT00168805::country::Netherlands,NCT00168805,Netherlands,,,,,,,,,,,,,,
country,NCT00168805::country::Denmark,NCT00168805,Denmark,,,,,,,,,,,,,,
country,NCT00168805::country::Austria,NCT00168805,Austria,,,,,,,,,,,,,,
country,NCT00168805::country::Finland,NCT00168805,Finland,,,,,,,,,,,,,,
country,NCT00168805::country::Poland,NCT00168805,Poland,,,,,,,,,,,,,,
country,NCT00168805::country::South Africa,NCT00168805,South Africa,,,,,,,,,,,,,,
trial,NCT00300456,NCT00300456,Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood,PHASE3,cardiovascular disease,Dyslipidemia; Coronary Heart Disease; Mixed Dyslipidemia,INDUSTRY,657.0,2006-03,,1.0,1.0,,,,,
arm,NCT00300456::arm::FG000,NCT00300456,ABT-335 + 20 mg Simvastatin,,,,,,,,,,FG000,ABT-335 + 20 mg simvastatin combination therapy once daily,,,
arm,NCT00300456::arm::FG001,NCT00300456,ABT-335 + 40 mg Simvastatin,,,,,,,,,,FG001,ABT-335 + 40 mg simvastatin combination therapy once daily,,,
arm,NCT00300456::arm::FG002,NCT00300456,ABT-335,,,,,,,,,,FG002,ABT-335 monotherapy once daily,,,
arm,NCT00300456::arm::FG003,NCT00300456,20 mg Simvastatin,,,,,,,,,,FG003,20 mg simvastatin monotherapy once daily,,,
arm,NCT00300456::arm::FG004,NCT00300456,40 mg Simvastatin,,,,,,,,,,FG004,40 mg simvastatin monotherapy once daily,,,
arm,NCT00300456::arm::FG005,NCT00300456,80 mg Simvastatin,,,,,,,,,,FG005,80 mg simvastatin monotherapy once daily,,,
period,NCT00300456::period::1,NCT00300456,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00300456::outcome::primary::1,NCT00300456,Mean Percent Change in Triglycerides From Baseline to Final Visit,,,,,,,,,,,,,PRIMARY,Baseline to 12 Weeks (Final Visit)
outcome,NCT00300456::outcome::primary::2,NCT00300456,Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Final Visit,,,,,,,,,,,,,PRIMARY,Baseline to 12 Weeks (Final Visit)
outcome,NCT00300456::outcome::primary::3,NCT00300456,Mean Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Final Visit,,,,,,,,,,,,,PRIMARY,Baseline to 12 Weeks (Final Visit)
country,NCT00300456::country::United States,NCT00300456,United States,,,,,,,,,,,,,,
trial,NCT03859427,NCT03859427,A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma,PHASE3,cardiovascular disease,Relapsed or Refractory Multiple Myeloma,INDUSTRY,454.0,2019-05-08,2023-03-31,17.0,108.0,,,,,
arm,NCT03859427::arm::FG000,NCT03859427,Twice-weekly Kyprolis (Carfilzomib) + Lenalidomide + Dexamethsone (KRd) 20/27 mg/m^2,,,,,,,,,,FG000,"Carfilzomib was administered twice-weekly intravenously as a 10 ± 5 minute infusion using an infusion pump on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. The dose was 20 mg/m\^2 on Days 1 and 2 ",,,
arm,NCT03859427::arm::FG001,NCT03859427,Once-weekly KRd 20/56 mg/m^2,,,,,,,,,,FG001,"Carfilzomib was administered once-weekly intravenously as a 30 ± 5 minute infusion using an infusion pump on Days 1, 8, and 15 of each 28-day cycle. The dose was 20 mg/m\^2 on Day 1 of Cycle 1 and 56 ",,,
period,NCT03859427::period::1,NCT03859427,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03859427::outcome::primary::1,NCT03859427,Overall Response Rate (ORR) Per International Myeloma Working Group Uniform Response Criteria (IMWG-URC),,,,,,,,,,,,,PRIMARY,Cycle 1 Day 1 up to approximately 12 months (cycle = 28 days)
country,NCT03859427::country::Japan,NCT03859427,Japan,,,,,,,,,,,,,,
country,NCT03859427::country::United States,NCT03859427,United States,,,,,,,,,,,,,,
country,NCT03859427::country::France,NCT03859427,France,,,,,,,,,,,,,,
country,NCT03859427::country::Romania,NCT03859427,Romania,,,,,,,,,,,,,,
country,NCT03859427::country::Greece,NCT03859427,Greece,,,,,,,,,,,,,,
country,NCT03859427::country::Turkey (Türkiye),NCT03859427,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT03859427::country::Russia,NCT03859427,Russia,,,,,,,,,,,,,,
country,NCT03859427::country::Spain,NCT03859427,Spain,,,,,,,,,,,,,,
country,NCT03859427::country::Germany,NCT03859427,Germany,,,,,,,,,,,,,,
country,NCT03859427::country::Sweden,NCT03859427,Sweden,,,,,,,,,,,,,,
country,NCT03859427::country::Czechia,NCT03859427,Czechia,,,,,,,,,,,,,,
country,NCT03859427::country::Bulgaria,NCT03859427,Bulgaria,,,,,,,,,,,,,,
country,NCT03859427::country::Finland,NCT03859427,Finland,,,,,,,,,,,,,,
country,NCT03859427::country::Netherlands,NCT03859427,Netherlands,,,,,,,,,,,,,,
country,NCT03859427::country::Lithuania,NCT03859427,Lithuania,,,,,,,,,,,,,,
country,NCT03859427::country::Austria,NCT03859427,Austria,,,,,,,,,,,,,,
country,NCT03859427::country::Slovakia,NCT03859427,Slovakia,,,,,,,,,,,,,,
trial,NCT00489541,NCT00489541,TAXUS PERSEUS Small Vessel,PHASE3,cardiovascular disease,Coronary Artery Disease,INDUSTRY,224.0,2007-07,2013-10,1.0,28.0,,,,,
arm,NCT00489541::arm::FG000,NCT00489541,TAXUS Element,,,,,,,,,,FG000,Paclitaxel-eluting stent (PES) implanted using standard percutaneous coronary intervention (PCI) technique,,,
arm,NCT00489541::arm::FG001,NCT00489541,Historical Control Bare Metal Stent (BMS),,,,,,,,,,FG001,The control group consists of 125 matched bare metal Express subjects from the TAXUS V trial (NCT00301522).,,,
period,NCT00489541::period::1,NCT00489541,12-Month Clinical Follow-up,,,,,,,,,,,,1.0,,
period,NCT00489541::period::2,NCT00489541,9-Month Angiographic Follow-up,,,,,,,,,,,,2.0,,
outcome,NCT00489541::outcome::primary::1,NCT00489541,In-stent Late Loss Measured by Quantitative Coronary Angiography (QCA),,,,,,,,,,,,,PRIMARY,9 months post-index procedure
country,NCT00489541::country::United States,NCT00489541,United States,,,,,,,,,,,,,,
trial,NCT00049673,NCT00049673,Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma,PHASE3,cardiovascular disease,Multiple Myeloma and Plasma Cell Neoplasm,NETWORK,332.0,2002-10-15,2013-09-19,1.0,18.0,,,,,
arm,NCT00049673::arm::FG000,NCT00049673,Prednisone,,,,,,,,,,FG000,"Patients receive oral thalidomide daily and oral prednisone every other day for 4 years in the absence of disease progression or unacceptable toxicity.

prednisone: Given orally

thalidomide: Given or",,,
arm,NCT00049673::arm::FG001,NCT00049673,Observation,,,,,,,,,,FG001,Patients undergo observation.,,,
period,NCT00049673::period::1,NCT00049673,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00049673::outcome::primary::1,NCT00049673,Overall Survival,,,,,,,,,,,,,PRIMARY,9 years
country,NCT00049673::country::Canada,NCT00049673,Canada,,,,,,,,,,,,,,
trial,NCT03917472,NCT03917472,Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema,PHASE3,cardiovascular disease,Diabetic Macular Edema,INDUSTRY,517.0,2019-07-17,2021-03-24,5.0,92.0,,,,,
arm,NCT03917472::arm::FG000,NCT03917472,Brolucizumab 6mg q4w,,,,,,,,,,FG000,Brolucizumab 6 mg/0.05 mL every 4 weeks.,,,
arm,NCT03917472::arm::FG001,NCT03917472,Aflibercept 2mg q4w,,,,,,,,,,FG001,Aflibercept 2mg/0.05 mL every 4 weeks,,,
period,NCT03917472::period::1,NCT03917472,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03917472::outcome::primary::1,NCT03917472,Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 52,,,,,,,,,,,,,PRIMARY,"Baseline, Week 52"
country,NCT03917472::country::United States,NCT03917472,United States,,,,,,,,,,,,,,
country,NCT03917472::country::Slovakia,NCT03917472,Slovakia,,,,,,,,,,,,,,
country,NCT03917472::country::Hungary,NCT03917472,Hungary,,,,,,,,,,,,,,
country,NCT03917472::country::Israel,NCT03917472,Israel,,,,,,,,,,,,,,
country,NCT03917472::country::Puerto Rico,NCT03917472,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00494871,NCT00494871,Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation,PHASE3,cardiovascular disease,Atrial Fibrillation,INDUSTRY,1280.0,2007-06,2010-01,1.0,165.0,,,,,
arm,NCT00494871::arm::FG000,NCT00494871,"Rivaroxaban (Xarelto, BAY59-7939)",,,,,,,,,,FG000,Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period,,,
arm,NCT00494871::arm::FG001,NCT00494871,Warfarin,,,,,,,,,,FG001,Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period,,,
period,NCT00494871::period::1,NCT00494871,Double-blind (DB) Treatment Period,,,,,,,,,,,,1.0,,
period,NCT00494871::period::2,NCT00494871,Follow-up (FU) Period,,,,,,,,,,,,2.0,,
outcome,NCT00494871::outcome::primary::1,NCT00494871,Event Rate of the Composite Endpoint of Adjudicated Major Bleeding or Adjudicated Non-major Clinically Relevant Bleeding,,,,,,,,,,,,,PRIMARY,Up to 2 days after the last dose
country,NCT00494871::country::Japan,NCT00494871,Japan,,,,,,,,,,,,,,
trial,NCT00092677,NCT00092677,An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED),PHASE3,cardiovascular disease,Aortic Stenosis,INDUSTRY,1873.0,2001-01,2008-04,0.0,0.0,,,,,
arm,NCT00092677::arm::FG000,NCT00092677,EZ/Simva 10/40 mg,,,,,,,,,,FG000,Ezetimibe 10 mg + Simvastatin 40 mg,,,
arm,NCT00092677::arm::FG001,NCT00092677,Placebo,,,,,,,,,,FG001,,,,
period,NCT00092677::period::1,NCT00092677,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00092677::outcome::primary::1,NCT00092677,Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of MCE (Major Cardiovascular Events),,,,,,,,,,,,,PRIMARY,Entire follow-up (median = 4.35 years)
trial,NCT03180736,NCT03180736,Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex,PHASE3,cardiovascular disease,Multiple Myeloma,NETWORK,304.0,2017-06-14,2024-11-30,10.0,40.0,,,,,
arm,NCT03180736::arm::FG000,NCT03180736,Daratumumab+Pomalidomide+Dexamethasone,,,,,,,,,,FG000,"Patients received Daratumumab subcutaneously (fixed dose of 1800 mg) or intravenously (16 mg/kg) weekly for cycles 1-2, every 2 weeks for cycles 3-6, and every 4 weeks thereafter. Pomalidomide was adm",,,
arm,NCT03180736::arm::FG001,NCT03180736,Pomalidomide + Dexamethasone,,,,,,,,,,FG001,"Patients received Pomalidomide at a dose of 4 mg orally every day on days 1 through 21, and dexamethasone 40 mg (or 20 mg for patients ≥75 years of age) orally weekly, in 28-day cycles",,,
period,NCT03180736::period::1,NCT03180736,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03180736::outcome::primary::1,NCT03180736,Comparison of Progression Free Survival Between Treatment Arms (Daratumumab /Pomalidomide /Dexamethasone vs Pomalidomide / Dexamethasone),,,,,,,,,,,,,PRIMARY,"PFS is assessed monthly from randomization until PD or death, whichever occurs first (approximately up to 3 years). PFS2 is assessed monthly from randomization until PD or death, whichever occurs first (approximately up to 5 years)."
country,NCT03180736::country::Germany,NCT03180736,Germany,,,,,,,,,,,,,,
country,NCT03180736::country::Italy,NCT03180736,Italy,,,,,,,,,,,,,,
country,NCT03180736::country::Spain,NCT03180736,Spain,,,,,,,,,,,,,,
country,NCT03180736::country::Turkey (Türkiye),NCT03180736,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT03180736::country::Belgium,NCT03180736,Belgium,,,,,,,,,,,,,,
country,NCT03180736::country::Greece,NCT03180736,Greece,,,,,,,,,,,,,,
country,NCT03180736::country::Czechia,NCT03180736,Czechia,,,,,,,,,,,,,,
country,NCT03180736::country::Denmark,NCT03180736,Denmark,,,,,,,,,,,,,,
country,NCT03180736::country::Netherlands,NCT03180736,Netherlands,,,,,,,,,,,,,,
country,NCT03180736::country::Serbia,NCT03180736,Serbia,,,,,,,,,,,,,,
trial,NCT03814187,NCT03814187,Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C,PHASE3,cardiovascular disease,ASCVD; Elevated Cholesterol; Heterozygous Familial Hypercholesterolemia; Homozygous Familial Hypercholesterolemia,INDUSTRY,3275.0,2019-04-16,2023-02-13,13.0,238.0,,,,,
arm,NCT03814187::arm::FG000,NCT03814187,Phase III Inclisiran-Inclisiran,,,,,,,,,,FG000,Subjects who received inclisiran (actual treatment) in studies ORION-9/ ORION-10/ORION-11,,,
arm,NCT03814187::arm::FG001,NCT03814187,Phase III Placebo-Inclisiran,,,,,,,,,,FG001,subjects who received placebo (actual treatment) in ORION-9/ORION-10/ORION-11,,,
arm,NCT03814187::arm::FG002,NCT03814187,ORION-3 Rollover,,,,,,,,,,FG002,Subjects rolling over from ORION-3 Phase II study,,,
period,NCT03814187::period::1,NCT03814187,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03814187::outcome::primary::1,NCT03814187,Proportion of Subjects Achieving Global Lipid Targets for Their Level of ASCVD Risk,,,,,,,,,,,,,PRIMARY,From ORION-8 Day 1 to the end of study (up to 1080 days)
outcome,NCT03814187::outcome::primary::2,NCT03814187,Incidence of Treatment-emergent Adverse Events (TEAEs),,,,,,,,,,,,,PRIMARY,From ORION-8 Day 1 to the end of study (up to 1080 days)
country,NCT03814187::country::United States,NCT03814187,United States,,,,,,,,,,,,,,
country,NCT03814187::country::United Kingdom,NCT03814187,United Kingdom,,,,,,,,,,,,,,
country,NCT03814187::country::Poland,NCT03814187,Poland,,,,,,,,,,,,,,
country,NCT03814187::country::South Africa,NCT03814187,South Africa,,,,,,,,,,,,,,
country,NCT03814187::country::Ukraine,NCT03814187,Ukraine,,,,,,,,,,,,,,
country,NCT03814187::country::Denmark,NCT03814187,Denmark,,,,,,,,,,,,,,
country,NCT03814187::country::Spain,NCT03814187,Spain,,,,,,,,,,,,,,
country,NCT03814187::country::Germany,NCT03814187,Germany,,,,,,,,,,,,,,
country,NCT03814187::country::Netherlands,NCT03814187,Netherlands,,,,,,,,,,,,,,
country,NCT03814187::country::Czechia,NCT03814187,Czechia,,,,,,,,,,,,,,
country,NCT03814187::country::Hungary,NCT03814187,Hungary,,,,,,,,,,,,,,
country,NCT03814187::country::Canada,NCT03814187,Canada,,,,,,,,,,,,,,
country,NCT03814187::country::Sweden,NCT03814187,Sweden,,,,,,,,,,,,,,
trial,NCT03337308,NCT03337308,"A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy",PHASE3,cardiovascular disease,Hyperlipidemias,INDUSTRY,382.0,2017-10-23,2018-07-18,1.0,5.0,,,,,
arm,NCT03337308::arm::FG000,NCT03337308,Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC,,,,,,,,,,FG000,Participants received bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 milligrams (mg)/10 mg tablets orally once daily for 12 weeks.,,,
arm,NCT03337308::arm::FG001,NCT03337308,Bempedoic Acid 180 mg,,,,,,,,,,FG001,Participants received bempedoic acid 180 mg tablets taken orally once daily for 12 weeks.,,,
arm,NCT03337308::arm::FG002,NCT03337308,Ezetimibe 10 mg,,,,,,,,,,FG002,Participants received ezetimibe 10 mg overencapsulated tablets orally once daily for 12 weeks.,,,
arm,NCT03337308::arm::FG003,NCT03337308,Placebo,,,,,,,,,,FG003,"Participants received placebo to match the bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, the bempedoic acid 180 mg tablet, or the ezetimibe 10 mg capsule, taken orally, ",,,
period,NCT03337308::period::1,NCT03337308,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03337308::outcome::primary::1,NCT03337308,Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C),,,,,,,,,,,,,PRIMARY,Baseline
country,NCT03337308::country::United States,NCT03337308,United States,,,,,,,,,,,,,,
trial,NCT00902174,NCT00902174,Imatinib (QTI571) in Pulmonary Arterial Hypertension,PHASE3,cardiovascular disease,Pulmonary Arterial Hypertension,INDUSTRY,202.0,2009-09,2011-05,14.0,95.0,,,,,
arm,NCT00902174::arm::FG000,NCT00902174,Imatinib Mesylate,,,,,,,,,,FG000,"Imatinib mesylate (QTI571) 200 mg once daily for two weeks, increased to 400 mg once daily if well tolerated. If 400 mg dose was not well tolerated, a down titration to 200 mg once daily was permitted",,,
arm,NCT00902174::arm::FG001,NCT00902174,Placebo,,,,,,,,,,FG001,Placebo to imatinib mesylate taken once daily. Participants receiving placebo were allowed to receive already approved PAH treatments.,,,
period,NCT00902174::period::1,NCT00902174,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00902174::outcome::primary::1,NCT00902174,Difference in Six-minute Walk Distance Test (6MWD) Between Imatinib and Placebo at 24 Weeks,,,,,,,,,,,,,PRIMARY,24 weeks
country,NCT00902174::country::United States,NCT00902174,United States,,,,,,,,,,,,,,
country,NCT00902174::country::Germany,NCT00902174,Germany,,,,,,,,,,,,,,
country,NCT00902174::country::Spain,NCT00902174,Spain,,,,,,,,,,,,,,
country,NCT00902174::country::Canada,NCT00902174,Canada,,,,,,,,,,,,,,
country,NCT00902174::country::Japan,NCT00902174,Japan,,,,,,,,,,,,,,
country,NCT00902174::country::United Kingdom,NCT00902174,United Kingdom,,,,,,,,,,,,,,
country,NCT00902174::country::Italy,NCT00902174,Italy,,,,,,,,,,,,,,
country,NCT00902174::country::Sweden,NCT00902174,Sweden,,,,,,,,,,,,,,
country,NCT00902174::country::Switzerland,NCT00902174,Switzerland,,,,,,,,,,,,,,
country,NCT00902174::country::Austria,NCT00902174,Austria,,,,,,,,,,,,,,
country,NCT00902174::country::Belgium,NCT00902174,Belgium,,,,,,,,,,,,,,
country,NCT00902174::country::France,NCT00902174,France,,,,,,,,,,,,,,
country,NCT00902174::country::Netherlands,NCT00902174,Netherlands,,,,,,,,,,,,,,
country,NCT00902174::country::South Korea,NCT00902174,South Korea,,,,,,,,,,,,,,
trial,NCT01818752,NCT01818752,"Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma",PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,955.0,2013-07-08,2016-11-04,30.0,213.0,,,,,
arm,NCT01818752::arm::FG000,NCT01818752,"Bortezomib, Melphalan, Prednisone",,,,,,,,,,FG000,Participants received bortezomib in combination with melphalan and prednisone for nine 42-day cycles. Bortezomib was administered either IV or subcutaneously at 1.3 mg/m² during cycles 1 to 4 on days ,,,
arm,NCT01818752::arm::FG001,NCT01818752,"Carfilzomib, Melphalan, Prednisone",,,,,,,,,,FG001,"Participants received carfilzomib administered in combination with melphalan and prednisone for nine 42-day cycles. Carfilzomib was administered as an intravenous (IV) infusion on days 1, 2, 8, 9, 22,",,,
period,NCT01818752::period::1,NCT01818752,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01818752::outcome::primary::1,NCT01818752,Progression-Free Survival (PFS),,,,,,,,,,,,,PRIMARY,From randomization until the data cut-off date of 15 July 2016
country,NCT01818752::country::China,NCT01818752,China,,,,,,,,,,,,,,
country,NCT01818752::country::France,NCT01818752,France,,,,,,,,,,,,,,
country,NCT01818752::country::Japan,NCT01818752,Japan,,,,,,,,,,,,,,
country,NCT01818752::country::United States,NCT01818752,United States,,,,,,,,,,,,,,
country,NCT01818752::country::South Korea,NCT01818752,South Korea,,,,,,,,,,,,,,
country,NCT01818752::country::Australia,NCT01818752,Australia,,,,,,,,,,,,,,
country,NCT01818752::country::Ukraine,NCT01818752,Ukraine,,,,,,,,,,,,,,
country,NCT01818752::country::Russia,NCT01818752,Russia,,,,,,,,,,,,,,
country,NCT01818752::country::Germany,NCT01818752,Germany,,,,,,,,,,,,,,
country,NCT01818752::country::Italy,NCT01818752,Italy,,,,,,,,,,,,,,
country,NCT01818752::country::Poland,NCT01818752,Poland,,,,,,,,,,,,,,
country,NCT01818752::country::Spain,NCT01818752,Spain,,,,,,,,,,,,,,
country,NCT01818752::country::United Kingdom,NCT01818752,United Kingdom,,,,,,,,,,,,,,
country,NCT01818752::country::Czechia,NCT01818752,Czechia,,,,,,,,,,,,,,
country,NCT01818752::country::Hungary,NCT01818752,Hungary,,,,,,,,,,,,,,
country,NCT01818752::country::Romania,NCT01818752,Romania,,,,,,,,,,,,,,
country,NCT01818752::country::Taiwan,NCT01818752,Taiwan,,,,,,,,,,,,,,
country,NCT01818752::country::Bulgaria,NCT01818752,Bulgaria,,,,,,,,,,,,,,
country,NCT01818752::country::Singapore,NCT01818752,Singapore,,,,,,,,,,,,,,
country,NCT01818752::country::Belgium,NCT01818752,Belgium,,,,,,,,,,,,,,
country,NCT01818752::country::Israel,NCT01818752,Israel,,,,,,,,,,,,,,
country,NCT01818752::country::Mexico,NCT01818752,Mexico,,,,,,,,,,,,,,
country,NCT01818752::country::Netherlands,NCT01818752,Netherlands,,,,,,,,,,,,,,
country,NCT01818752::country::New Zealand,NCT01818752,New Zealand,,,,,,,,,,,,,,
country,NCT01818752::country::Austria,NCT01818752,Austria,,,,,,,,,,,,,,
country,NCT01818752::country::Turkey (Türkiye),NCT01818752,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01818752::country::Argentina,NCT01818752,Argentina,,,,,,,,,,,,,,
country,NCT01818752::country::Greece,NCT01818752,Greece,,,,,,,,,,,,,,
country,NCT01818752::country::Switzerland,NCT01818752,Switzerland,,,,,,,,,,,,,,
country,NCT01818752::country::Canada,NCT01818752,Canada,,,,,,,,,,,,,,
trial,NCT00286741,NCT00286741,Can Group Visits Improve Outcomes of Veterans With Diabetes,PHASE3,cardiovascular disease,Diabetes; Hypertension,FED,239.0,2006-06,2009-01,1.0,2.0,,,,,
arm,NCT00286741::arm::FG000,NCT00286741,Medical Group Visits,,,,,,,,,,FG000,"Medical group visits

Diabetes Group Management Visits: Patients meet in groups and receive education about diabetes, reinforcing each other with their own experiences. Each patient also gets medicati",,,
arm,NCT00286741::arm::FG001,NCT00286741,Control,,,,,,,,,,FG001,control,,,
period,NCT00286741::period::1,NCT00286741,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00286741::outcome::primary::1,NCT00286741,Hemoglobin A1c,,,,,,,,,,,,,PRIMARY,12 months
outcome,NCT00286741::outcome::primary::2,NCT00286741,Systolic Blood Pressure,,,,,,,,,,,,,PRIMARY,12 months
country,NCT00286741::country::United States,NCT00286741,United States,,,,,,,,,,,,,,
trial,NCT01791153,NCT01791153,An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA),PHASE3,cardiovascular disease,Giant Cell Arteritis,INDUSTRY,251.0,2013-07-22,2018-06-04,14.0,78.0,,,,,
arm,NCT01791153::arm::FG000,NCT01791153,Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper,,,,,,,,,,FG000,Participants received tocilizumab at a dose of 162 milligrams (mg) as subcutaneous (SC) injection every week (qw) up to 52 weeks along with prednisone and/or prednisone placebo according to the protoc,,,
arm,NCT01791153::arm::FG001,NCT01791153,Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper,,,,,,,,,,FG001,Participants received tocilizumab at a dose of 162 mg as SC injection every 2 weeks (q2w) (and tocilizumab placebo q2w starting from Week 2) up to 52 weeks along with prednisone and/or prednisone plac,,,
arm,NCT01791153::arm::FG002,NCT01791153,Part 1: Placebo + 26 Weeks Prednisone Taper,,,,,,,,,,FG002,Participants received tocilizumab placebo as SC injection qw up to 52 weeks along with prednisone and/or prednisone placebo according to the protocol-defined schedule. Participants received prednisone,,,
arm,NCT01791153::arm::FG003,NCT01791153,Part 1: Placebo + 52 Weeks Prednisone Taper,,,,,,,,,,FG003,Participants received tocilizumab placebo as SC injection qw up to 52 weeks along with prednisone and/or prednisone placebo according to the protocol-defined schedule. Participants received prednisone,,,
arm,NCT01791153::arm::FG004,NCT01791153,Part 2: No Tocilizumab (Placebo in Part 1),,,,,,,,,,FG004,Participants did not receive tocilizumab in Part 2 from Week 52 up to Week 156. These participants received placebo during Part 1 (Weeks 1 to 52).,,,
arm,NCT01791153::arm::FG005,NCT01791153,Part 2: No Tocilizumab (Tocilizumab in Part 1),,,,,,,,,,FG005,Participants did not receive tocilizumab in Part 2 from Week 52 up to Week 156. These participants received tocilizumab during Part 1 (Weeks 1 to 52).,,,
arm,NCT01791153::arm::FG006,NCT01791153,Part 2: Tocilizumab (Placebo in Part 1),,,,,,,,,,FG006,Participants received open-label tocilizumab as determined by the investigator during Part 2 of the study (from Week 52 up to Week 156). These participants received placebo during Part 1 (Weeks 1 to 5,,,
arm,NCT01791153::arm::FG007,NCT01791153,Part 2: Tocilizumab (Tocilizumab in Part 1),,,,,,,,,,FG007,Participants received open-label tocilizumab as determined by the investigator during Part 2 of the study (from Week 52 up to Week 156). These participants received tocilizumab during Part 1 (Weeks 1 ,,,
period,NCT01791153::period::1,NCT01791153,Part 1: Blinded Period,,,,,,,,,,,,1.0,,
period,NCT01791153::period::2,NCT01791153,Part 2: Open-label Period,,,,,,,,,,,,2.0,,
outcome,NCT01791153::outcome::primary::1,NCT01791153,Percentage of Participants in Sustained Remission at Week 52 (Tocilizumab + 26 Weeks Prednisone Taper Versus Placebo + 26 Weeks Prednisone Taper),,,,,,,,,,,,,PRIMARY,Week 52
country,NCT01791153::country::United States,NCT01791153,United States,,,,,,,,,,,,,,
country,NCT01791153::country::Germany,NCT01791153,Germany,,,,,,,,,,,,,,
country,NCT01791153::country::United Kingdom,NCT01791153,United Kingdom,,,,,,,,,,,,,,
country,NCT01791153::country::Italy,NCT01791153,Italy,,,,,,,,,,,,,,
country,NCT01791153::country::France,NCT01791153,France,,,,,,,,,,,,,,
country,NCT01791153::country::Netherlands,NCT01791153,Netherlands,,,,,,,,,,,,,,
country,NCT01791153::country::Spain,NCT01791153,Spain,,,,,,,,,,,,,,
country,NCT01791153::country::Sweden,NCT01791153,Sweden,,,,,,,,,,,,,,
country,NCT01791153::country::Norway,NCT01791153,Norway,,,,,,,,,,,,,,
country,NCT01791153::country::Belgium,NCT01791153,Belgium,,,,,,,,,,,,,,
country,NCT01791153::country::Poland,NCT01791153,Poland,,,,,,,,,,,,,,
country,NCT01791153::country::Canada,NCT01791153,Canada,,,,,,,,,,,,,,
country,NCT01791153::country::Denmark,NCT01791153,Denmark,,,,,,,,,,,,,,
country,NCT01791153::country::Portugal,NCT01791153,Portugal,,,,,,,,,,,,,,
trial,NCT00090259,NCT00090259,"Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)",PHASE3,cardiovascular disease,Heart Failure,INDUSTRY,3834.0,2001-12-19,2009-05-13,0.0,0.0,,,,,
arm,NCT00090259::arm::FG000,NCT00090259,Losartan 50 mg,,,,,,,,,,FG000,,,,
arm,NCT00090259::arm::FG001,NCT00090259,Losartan 150 mg,,,,,,,,,,FG001,,,,
period,NCT00090259::period::1,NCT00090259,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00090259::outcome::primary::1,NCT00090259,Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure,,,,,,,,,,,,,PRIMARY,Entire follow-up (median = 4.7 years)
trial,NCT02161562,NCT02161562,OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients,PHASE3,cardiovascular disease,Chronic Spontaneous Urticaria,INDUSTRY,314.0,2014-08-01,2016-11-03,8.0,35.0,,,,,
arm,NCT02161562::arm::FG000,NCT02161562,Omalizumab 150mg (A),,,,,,,,,,FG000,Participants received 150mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period (at 150mg or 300mg) may have been implemented based on protocol-defined assessme,,,
arm,NCT02161562::arm::FG001,NCT02161562,Omalizumab 300mg (B),,,,,,,,,,FG001,Participants received 300mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period may have been implemented based on protocol-defined assessment criteria.,,,
period,NCT02161562::period::1,NCT02161562,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02161562::outcome::primary::1,NCT02161562,"Number of Participants Who Were Clinically Well-controlled (UAS7<=6) After the Initial Dosing Period, Relapsed (UAS7>=16) When Treatment Was Discontinued, and Who Achieved a UAS7 Score <=6 at the End of the Second Dosing Period (Retreatment A2 and B2)",,,,,,,,,,,,,PRIMARY,"Last 7 days of second dosing period, 44 weeks"
country,NCT02161562::country::Canada,NCT02161562,Canada,,,,,,,,,,,,,,
country,NCT02161562::country::Argentina,NCT02161562,Argentina,,,,,,,,,,,,,,
country,NCT02161562::country::Brazil,NCT02161562,Brazil,,,,,,,,,,,,,,
country,NCT02161562::country::Chile,NCT02161562,Chile,,,,,,,,,,,,,,
country,NCT02161562::country::Mexico,NCT02161562,Mexico,,,,,,,,,,,,,,
country,NCT02161562::country::Dominican Republic,NCT02161562,Dominican Republic,,,,,,,,,,,,,,
country,NCT02161562::country::Guatemala,NCT02161562,Guatemala,,,,,,,,,,,,,,
country,NCT02161562::country::Panama,NCT02161562,Panama,,,,,,,,,,,,,,
trial,NCT04740905,NCT04740905,A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion,PHASE3,cardiovascular disease,Macular Edema; Branch Retinal Vein Occlusion,INDUSTRY,553.0,2021-03-02,2023-06-12,22.0,150.0,,,,,
arm,NCT04740905::arm::FG000,NCT04740905,"Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)",,,,,,,,,,FG000,"In Part 1 (Day 1 through Week 24), participants were randomly assigned to Arm A to receive faricimab 6 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of ",,,
arm,NCT04740905::arm::FG001,NCT04740905,"Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)",,,,,,,,,,FG001,"In Part 1 (Day 1 through Week 24), participants were randomly assigned to Arm B to receive aflibercept 2 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total o",,,
period,NCT04740905::period::1,NCT04740905,Part 1 (Baseline up to Week 24),,,,,,,,,,,,1.0,,
period,NCT04740905::period::2,NCT04740905,Part 2 (Week 24 to Week 72),,,,,,,,,,,,2.0,,
outcome,NCT04740905::outcome::primary::1,NCT04740905,Part 1: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 24,,,,,,,,,,,,,PRIMARY,From Baseline through Week 24
country,NCT04740905::country::United States,NCT04740905,United States,,,,,,,,,,,,,,
country,NCT04740905::country::Japan,NCT04740905,Japan,,,,,,,,,,,,,,
country,NCT04740905::country::China,NCT04740905,China,,,,,,,,,,,,,,
country,NCT04740905::country::Poland,NCT04740905,Poland,,,,,,,,,,,,,,
country,NCT04740905::country::Argentina,NCT04740905,Argentina,,,,,,,,,,,,,,
country,NCT04740905::country::Australia,NCT04740905,Australia,,,,,,,,,,,,,,
country,NCT04740905::country::South Korea,NCT04740905,South Korea,,,,,,,,,,,,,,
country,NCT04740905::country::United Kingdom,NCT04740905,United Kingdom,,,,,,,,,,,,,,
country,NCT04740905::country::Israel,NCT04740905,Israel,,,,,,,,,,,,,,
country,NCT04740905::country::Spain,NCT04740905,Spain,,,,,,,,,,,,,,
country,NCT04740905::country::Brazil,NCT04740905,Brazil,,,,,,,,,,,,,,
country,NCT04740905::country::Czechia,NCT04740905,Czechia,,,,,,,,,,,,,,
country,NCT04740905::country::Hungary,NCT04740905,Hungary,,,,,,,,,,,,,,
country,NCT04740905::country::Taiwan,NCT04740905,Taiwan,,,,,,,,,,,,,,
country,NCT04740905::country::Germany,NCT04740905,Germany,,,,,,,,,,,,,,
country,NCT04740905::country::Italy,NCT04740905,Italy,,,,,,,,,,,,,,
country,NCT04740905::country::Portugal,NCT04740905,Portugal,,,,,,,,,,,,,,
country,NCT04740905::country::Russia,NCT04740905,Russia,,,,,,,,,,,,,,
country,NCT04740905::country::France,NCT04740905,France,,,,,,,,,,,,,,
country,NCT04740905::country::Hong Kong,NCT04740905,Hong Kong,,,,,,,,,,,,,,
country,NCT04740905::country::Singapore,NCT04740905,Singapore,,,,,,,,,,,,,,
country,NCT04740905::country::Austria,NCT04740905,Austria,,,,,,,,,,,,,,
trial,NCT00860262,NCT00860262,Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,858.0,2009-03,,11.0,137.0,,,,,
arm,NCT00860262::arm::FG000,NCT00860262,T80+A10,,,,,,,,,,FG000,Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10),,,
arm,NCT00860262::arm::FG001,NCT00860262,Telmisartan 80 mg,,,,,,,,,,FG001,Telmisartan 80 mg once daily (T80),,,
arm,NCT00860262::arm::FG002,NCT00860262,Amlodipine 10 mg,,,,,,,,,,FG002,Amlodipine 10 mg once daily (A10),,,
period,NCT00860262::period::1,NCT00860262,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00860262::outcome::primary::1,NCT00860262,Change From Baseline in Trough Seated Systolic Blood Pressure (SBP) at Week 8,,,,,,,,,,,,,PRIMARY,baseline and week 8
country,NCT00860262::country::France,NCT00860262,France,,,,,,,,,,,,,,
country,NCT00860262::country::United States,NCT00860262,United States,,,,,,,,,,,,,,
country,NCT00860262::country::Russia,NCT00860262,Russia,,,,,,,,,,,,,,
country,NCT00860262::country::Ukraine,NCT00860262,Ukraine,,,,,,,,,,,,,,
country,NCT00860262::country::Bulgaria,NCT00860262,Bulgaria,,,,,,,,,,,,,,
country,NCT00860262::country::Hungary,NCT00860262,Hungary,,,,,,,,,,,,,,
country,NCT00860262::country::Romania,NCT00860262,Romania,,,,,,,,,,,,,,
country,NCT00860262::country::Czechia,NCT00860262,Czechia,,,,,,,,,,,,,,
country,NCT00860262::country::South Korea,NCT00860262,South Korea,,,,,,,,,,,,,,
country,NCT00860262::country::Slovakia,NCT00860262,Slovakia,,,,,,,,,,,,,,
country,NCT00860262::country::Spain,NCT00860262,Spain,,,,,,,,,,,,,,
trial,NCT04072835,NCT04072835,Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303,PHASE3,cardiovascular disease,Paroxysmal Supraventricular Tachycardia,OTHER,1116.0,2019-09-23,2023-01-26,5.0,124.0,,,,,
arm,NCT04072835::arm::FG000,NCT04072835,All Participants,,,,,,,,,,FG000,"Participants self-administered etripamil NS 70 mg and after the implementation of protocol amendment 2.1, the participants had the option to administer a second dose of etripamil 70 mg 10 minutes late",,,
period,NCT04072835::period::1,NCT04072835,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04072835::outcome::primary::1,NCT04072835,Number of Participants With Adverse Events for Self-administered Etripamil NS Outside of the Clinical Setting.,,,,,,,,,,,,,PRIMARY,"From Baseline until a maximum of 4 episodes of perceived PSVT are treated with study drug, up to a maximum duration of 40 months."
country,NCT04072835::country::United States,NCT04072835,United States,,,,,,,,,,,,,,
country,NCT04072835::country::Brazil,NCT04072835,Brazil,,,,,,,,,,,,,,
country,NCT04072835::country::Argentina,NCT04072835,Argentina,,,,,,,,,,,,,,
country,NCT04072835::country::Canada,NCT04072835,Canada,,,,,,,,,,,,,,
country,NCT04072835::country::Colombia,NCT04072835,Colombia,,,,,,,,,,,,,,
trial,NCT00321919,NCT00321919,A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia,PHASE3,cardiovascular disease,Anemia,INDUSTRY,605.0,2000-07,2004-12,22.0,93.0,,,,,
arm,NCT00321919::arm::FG000,NCT00321919,Early Epoetin Beta Therapy,,,,,,,,,,FG000,"Participants received immediate epoetin beta therapy starting at 2000 IU, subcutaneously once weekly up to four years to reach a target Hemoglobin (Hb) level of 13-15 gram/decilitre (g/dL) with an ind",,,
arm,NCT00321919::arm::FG001,NCT00321919,Late Epoetin Beta Therapy,,,,,,,,,,FG001,"Participants received epoetin beta treatment starting at 2000 IU, subcutaneously once weekly up to four years only when a decline in Hb levels to \<10.5 g/dL has occurred in order to reach a target Hb",,,
period,NCT00321919::period::1,NCT00321919,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00321919::outcome::primary::1,NCT00321919,Median Time to First Cardiovascular Event,,,,,,,,,,,,,PRIMARY,Up to 4 years
country,NCT00321919::country::Italy,NCT00321919,Italy,,,,,,,,,,,,,,
country,NCT00321919::country::France,NCT00321919,France,,,,,,,,,,,,,,
country,NCT00321919::country::Sweden,NCT00321919,Sweden,,,,,,,,,,,,,,
country,NCT00321919::country::United Kingdom,NCT00321919,United Kingdom,,,,,,,,,,,,,,
country,NCT00321919::country::Russia,NCT00321919,Russia,,,,,,,,,,,,,,
country,NCT00321919::country::Spain,NCT00321919,Spain,,,,,,,,,,,,,,
country,NCT00321919::country::Czechia,NCT00321919,Czechia,,,,,,,,,,,,,,
country,NCT00321919::country::Denmark,NCT00321919,Denmark,,,,,,,,,,,,,,
country,NCT00321919::country::Poland,NCT00321919,Poland,,,,,,,,,,,,,,
country,NCT00321919::country::Portugal,NCT00321919,Portugal,,,,,,,,,,,,,,
country,NCT00321919::country::Taiwan,NCT00321919,Taiwan,,,,,,,,,,,,,,
country,NCT00321919::country::Belgium,NCT00321919,Belgium,,,,,,,,,,,,,,
country,NCT00321919::country::Germany,NCT00321919,Germany,,,,,,,,,,,,,,
country,NCT00321919::country::Greece,NCT00321919,Greece,,,,,,,,,,,,,,
country,NCT00321919::country::Turkey (Türkiye),NCT00321919,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00321919::country::Austria,NCT00321919,Austria,,,,,,,,,,,,,,
country,NCT00321919::country::Finland,NCT00321919,Finland,,,,,,,,,,,,,,
country,NCT00321919::country::Mexico,NCT00321919,Mexico,,,,,,,,,,,,,,
country,NCT00321919::country::Thailand,NCT00321919,Thailand,,,,,,,,,,,,,,
country,NCT00321919::country::Hong Kong,NCT00321919,Hong Kong,,,,,,,,,,,,,,
country,NCT00321919::country::Ireland,NCT00321919,Ireland,,,,,,,,,,,,,,
country,NCT00321919::country::Norway,NCT00321919,Norway,,,,,,,,,,,,,,
trial,NCT01729871,NCT01729871,A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy,PHASE3,cardiovascular disease,Atrial Fibrillation,INDUSTRY,253.0,2013-02,2014-10,5.0,44.0,,,,,
arm,NCT01729871::arm::FG000,NCT01729871,Rivaroxaban,,,,,,,,,,FG000,Participants were received Rivaroxaban 20 milligram (mg) orally once-daily administered preferably with the evening meal for 8-10 weeks.,,,
arm,NCT01729871::arm::FG001,NCT01729871,Vitamin K Antagonist,,,,,,,,,,FG001,Participants were received dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0 for 8-10 weeks.,,,
period,NCT01729871::period::1,NCT01729871,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01729871::outcome::primary::1,NCT01729871,Number of Participants With Incidence of Post-Procedure Major Bleeding Events,,,,,,,,,,,,,PRIMARY,Up to 30 plus or minus (+-) 5 days after the catheter ablation procedure
country,NCT01729871::country::United States,NCT01729871,United States,,,,,,,,,,,,,,
country,NCT01729871::country::Germany,NCT01729871,Germany,,,,,,,,,,,,,,
country,NCT01729871::country::Belgium,NCT01729871,Belgium,,,,,,,,,,,,,,
country,NCT01729871::country::France,NCT01729871,France,,,,,,,,,,,,,,
country,NCT01729871::country::United Kingdom,NCT01729871,United Kingdom,,,,,,,,,,,,,,
trial,NCT03296813,NCT03296813,TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure,PHASE3,cardiovascular disease,Heart Failure,OTHER,2973.0,2018-07-11,2022-07-29,1.0,60.0,,,,,
arm,NCT03296813::arm::FG000,NCT03296813,Torsemide,,,,,,,,,,FG000,"Oral dosing of torsemide compared to furosemide will be 1mg:2-4mg.

Torsemide: Loop diuretic",,,
arm,NCT03296813::arm::FG001,NCT03296813,Furosemide,,,,,,,,,,FG001,"Oral dosing of torsemide compared to furosemide will be 1mg:2-4mg.

For patients receiving loop diuretics other than furosemide, conversion to furosemide equivalents will be as follows:

1 mg oral tor",,,
period,NCT03296813::period::1,NCT03296813,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03296813::outcome::primary::1,NCT03296813,"All-cause Mortality, as Measured by Follow-up Phone Call or NDI",,,,,,,,,,,,,PRIMARY,up to 30 months
country,NCT03296813::country::United States,NCT03296813,United States,,,,,,,,,,,,,,
trial,NCT00358215,NCT00358215,RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial,PHASE3,cardiovascular disease,Heart Failure; Anemia; Cardiovascular Disease; Ventricular Dysfunction; Congestive Heart Failure,INDUSTRY,2278.0,2006-06-01,2012-10-11,36.0,754.0,,,,,
arm,NCT00358215::arm::FG000,NCT00358215,Placebo,,,,,,,,,,FG000,Participants received dose and administration schedule (every 2 weeks or once a month) changes that simulated the changes for participants receiving darbepoetin alfa.,,,
arm,NCT00358215::arm::FG001,NCT00358215,Darbepoetin Alfa,,,,,,,,,,FG001,"Starting dose of 0.75 µg/kg subcutaneously every 2 weeks until hemoglobin concentrations reach 13.0 g/dL on 2 consecutive visits, then monthly dosing, titrated to achieve hemoglobin target of 13.0 g/d",,,
period,NCT00358215::period::1,NCT00358215,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00358215::outcome::primary::1,NCT00358215,Time to All Cause Death or First Hospitalization for Worsening Heart Failure,,,,,,,,,,,,,PRIMARY,From randomization to the end of study
country,NCT00358215::country::United States,NCT00358215,United States,,,,,,,,,,,,,,
country,NCT00358215::country::Canada,NCT00358215,Canada,,,,,,,,,,,,,,
country,NCT00358215::country::India,NCT00358215,India,,,,,,,,,,,,,,
country,NCT00358215::country::Argentina,NCT00358215,Argentina,,,,,,,,,,,,,,
country,NCT00358215::country::Netherlands,NCT00358215,Netherlands,,,,,,,,,,,,,,
country,NCT00358215::country::Germany,NCT00358215,Germany,,,,,,,,,,,,,,
country,NCT00358215::country::Russia,NCT00358215,Russia,,,,,,,,,,,,,,
country,NCT00358215::country::United Kingdom,NCT00358215,United Kingdom,,,,,,,,,,,,,,
country,NCT00358215::country::Italy,NCT00358215,Italy,,,,,,,,,,,,,,
country,NCT00358215::country::France,NCT00358215,France,,,,,,,,,,,,,,
country,NCT00358215::country::Spain,NCT00358215,Spain,,,,,,,,,,,,,,
country,NCT00358215::country::Poland,NCT00358215,Poland,,,,,,,,,,,,,,
country,NCT00358215::country::Brazil,NCT00358215,Brazil,,,,,,,,,,,,,,
country,NCT00358215::country::Hungary,NCT00358215,Hungary,,,,,,,,,,,,,,
country,NCT00358215::country::Australia,NCT00358215,Australia,,,,,,,,,,,,,,
country,NCT00358215::country::Bulgaria,NCT00358215,Bulgaria,,,,,,,,,,,,,,
country,NCT00358215::country::Belgium,NCT00358215,Belgium,,,,,,,,,,,,,,
country,NCT00358215::country::Czechia,NCT00358215,Czechia,,,,,,,,,,,,,,
country,NCT00358215::country::Denmark,NCT00358215,Denmark,,,,,,,,,,,,,,
country,NCT00358215::country::Romania,NCT00358215,Romania,,,,,,,,,,,,,,
country,NCT00358215::country::South Africa,NCT00358215,South Africa,,,,,,,,,,,,,,
country,NCT00358215::country::Israel,NCT00358215,Israel,,,,,,,,,,,,,,
country,NCT00358215::country::Sweden,NCT00358215,Sweden,,,,,,,,,,,,,,
country,NCT00358215::country::Chile,NCT00358215,Chile,,,,,,,,,,,,,,
country,NCT00358215::country::Lithuania,NCT00358215,Lithuania,,,,,,,,,,,,,,
country,NCT00358215::country::Mexico,NCT00358215,Mexico,,,,,,,,,,,,,,
country,NCT00358215::country::Slovakia,NCT00358215,Slovakia,,,,,,,,,,,,,,
country,NCT00358215::country::Austria,NCT00358215,Austria,,,,,,,,,,,,,,
country,NCT00358215::country::Latvia,NCT00358215,Latvia,,,,,,,,,,,,,,
country,NCT00358215::country::Norway,NCT00358215,Norway,,,,,,,,,,,,,,
country,NCT00358215::country::Estonia,NCT00358215,Estonia,,,,,,,,,,,,,,
country,NCT00358215::country::Finland,NCT00358215,Finland,,,,,,,,,,,,,,
country,NCT00358215::country::Portugal,NCT00358215,Portugal,,,,,,,,,,,,,,
country,NCT00358215::country::Hong Kong,NCT00358215,Hong Kong,,,,,,,,,,,,,,
country,NCT00358215::country::Switzerland,NCT00358215,Switzerland,,,,,,,,,,,,,,
country,NCT00358215::country::Puerto Rico,NCT00358215,Puerto Rico,,,,,,,,,,,,,,
trial,NCT03451591,NCT03451591,LACunar Intervention (LACI-2) Trial-2,PHASE3,cardiovascular disease,"Cerebral Small Vessel Diseases; Stroke, Lacunar",OTHER,363.0,2018-01-08,2022-08-11,1.0,1.0,,,,,
arm,NCT03451591::arm::FG000,NCT03451591,Isosorbide Mononitrate XL (ISMN),,,,,,,,,,FG000,Oral Isotard® 25mg XL (Isosorbide Mononitrate) tablets. Oral Isotard® 25mg XL: Day 1-5 / 25mg daily morning dose. Day 6 to week 52 / 50mg daily morning dose. Week 53 / 25mg daily morning dose. Week 54,,,
arm,NCT03451591::arm::FG001,NCT03451591,Cilostazol,,,,,,,,,,FG001,Oral Cilostazol 100mg tablets. Day 1-5 / 50mg daily evening dose. Day 6-10 / 50mg twice daily morning \& evening. Day 11-15 / 50mg daily morning dose \& 100mg daily evening dose. Day 16 to week 52 / 1,,,
arm,NCT03451591::arm::FG002,NCT03451591,ISMN XL and Cilostazol,,,,,,,,,,FG002,Oral Isotard® 25 mg XL (ISMN) and oral Cilostazol 100mg tablets. Day 1-5 / ISMN - 25mg daily evening dose / Cilostazol - NIL. Day 6-10 / ISMN - 50mg daily morning dose and Cilostazol - NIL. Day 11-15 ,,,
arm,NCT03451591::arm::FG003,NCT03451591,Neither ISMN Nor Cilostazol,,,,,,,,,,FG003,"Neither isosorbide mononitrate nor Cilostazol is administered for the entire duration of the study.

Neither ISMN nor cilostazol: Neither isosorbide mononitrate nor Cilostazol administered for the ent",,,
period,NCT03451591::period::1,NCT03451591,Randomisation,,,,,,,,,,,,1.0,,
period,NCT03451591::period::2,NCT03451591,SAE Reporting - Exposure to IMP,,,,,,,,,,,,2.0,,
period,NCT03451591::period::3,NCT03451591,Randomisation to 12 Month Follow Up,,,,,,,,,,,,3.0,,
outcome,NCT03451591::outcome::primary::1,NCT03451591,Feasibility of Phase III Trial,,,,,,,,,,,,,PRIMARY,36 months (24 Months Recruitment + 12 months Follow Up)
country,NCT03451591::country::United Kingdom,NCT03451591,United Kingdom,,,,,,,,,,,,,,
trial,NCT02634333,NCT02634333,Anti-VEGF Treatment for Prevention of PDR/DME,PHASE3,cardiovascular disease,Diabetic Retinopathy; Diabetic Macular Edema,OTHER,399.0,2016-01,2022-05-11,2.0,85.0,,,,,
arm,NCT02634333::arm::FG000,NCT02634333,Aflibercept,,,,,,,,,,FG000,"Aflibercept injection in study eye at randomization and at visits at 1, 2, and 4 months and then every 4 months thereafter. More frequent aflibercept may be given if center-involved diabetic macular e",,,
arm,NCT02634333::arm::FG001,NCT02634333,Sham,,,,,,,,,,FG001,"Sham injection in study eye at randomization and at visits at 1, 2, and 4 months and then every 4 months thereafter. Deferred aflibercept may be given if center-involved diabetic macular edema or prol",,,
period,NCT02634333::period::1,NCT02634333,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02634333::outcome::primary::1,NCT02634333,Development of PDR and/or DME (Whichever Came First),,,,,,,,,,,,,PRIMARY,2 years
outcome,NCT02634333::outcome::primary::2,NCT02634333,Change in Visual Acuity From Baseline,,,,,,,,,,,,,PRIMARY,2 years
country,NCT02634333::country::United States,NCT02634333,United States,,,,,,,,,,,,,,
country,NCT02634333::country::Canada,NCT02634333,Canada,,,,,,,,,,,,,,
trial,NCT02648347,NCT02648347,Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease,PHASE3,cardiovascular disease,Anemia; Non-Dialysis-Dependent Chronic Kidney Disease,INDUSTRY,1751.0,2015-12,2020-07-31,20.0,439.0,,,,,
arm,NCT02648347::arm::FG000,NCT02648347,Vadadustat,,,,,,,,,,FG000,"Participants were randomized to receive Vadadustat at an initial oral dose of 300 milligrams per day (mg/day). Thereafter, Vadadustat was taken once daily on an outpatient basis. Up-and-down titration",,,
arm,NCT02648347::arm::FG001,NCT02648347,Darbepoetin Alfa,,,,,,,,,,FG001,"Participants were randomized to Darbepoetin alfa at an initial dose that was based on the current package insert for investigational sites in the United States (US), and the Summary of Product Charact",,,
period,NCT02648347::period::1,NCT02648347,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02648347::outcome::primary::1,NCT02648347,Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36),,,,,,,,,,,,,PRIMARY,Baseline
outcome,NCT02648347::outcome::primary::2,NCT02648347,Median Time to First Major Adverse Cardiovascular Event (MACE),,,,,,,,,,,,,PRIMARY,Weeks 24 to 36
country,NCT02648347::country::United States,NCT02648347,United States,,,,,,,,,,,,,,
country,NCT02648347::country::Brazil,NCT02648347,Brazil,,,,,,,,,,,,,,
country,NCT02648347::country::Argentina,NCT02648347,Argentina,,,,,,,,,,,,,,
country,NCT02648347::country::Ukraine,NCT02648347,Ukraine,,,,,,,,,,,,,,
country,NCT02648347::country::Mexico,NCT02648347,Mexico,,,,,,,,,,,,,,
country,NCT02648347::country::Bulgaria,NCT02648347,Bulgaria,,,,,,,,,,,,,,
country,NCT02648347::country::Russia,NCT02648347,Russia,,,,,,,,,,,,,,
country,NCT02648347::country::South Africa,NCT02648347,South Africa,,,,,,,,,,,,,,
country,NCT02648347::country::Hungary,NCT02648347,Hungary,,,,,,,,,,,,,,
country,NCT02648347::country::Italy,NCT02648347,Italy,,,,,,,,,,,,,,
country,NCT02648347::country::Spain,NCT02648347,Spain,,,,,,,,,,,,,,
country,NCT02648347::country::Australia,NCT02648347,Australia,,,,,,,,,,,,,,
country,NCT02648347::country::United Kingdom,NCT02648347,United Kingdom,,,,,,,,,,,,,,
country,NCT02648347::country::South Korea,NCT02648347,South Korea,,,,,,,,,,,,,,
country,NCT02648347::country::Israel,NCT02648347,Israel,,,,,,,,,,,,,,
country,NCT02648347::country::Poland,NCT02648347,Poland,,,,,,,,,,,,,,
country,NCT02648347::country::Malaysia,NCT02648347,Malaysia,,,,,,,,,,,,,,
country,NCT02648347::country::New Zealand,NCT02648347,New Zealand,,,,,,,,,,,,,,
country,NCT02648347::country::France,NCT02648347,France,,,,,,,,,,,,,,
country,NCT02648347::country::Puerto Rico,NCT02648347,Puerto Rico,,,,,,,,,,,,,,
trial,NCT04435626,NCT04435626,Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%,PHASE3,cardiovascular disease,Heart Failure,INDUSTRY,6016.0,2020-09-14,2024-06-14,37.0,661.0,,,,,
arm,NCT04435626::arm::FG000,NCT04435626,Finerenone (BAY94-8862),,,,,,,,,,FG000,"Participants received finerenone 10 mg, 20 mg or 40 mg once daily.",,,
arm,NCT04435626::arm::FG001,NCT04435626,Placebo,,,,,,,,,,FG001,Participants received matching placebo once daily.,,,
period,NCT04435626::period::1,NCT04435626,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04435626::outcome::primary::1,NCT04435626,Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events,,,,,,,,,,,,,PRIMARY,"From randomization up until the end of study, with an average study duration of 32 months"
outcome,NCT04435626::outcome::primary::2,NCT04435626,Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events,,,,,,,,,,,,,PRIMARY,"From randomization up until the end of study, with an average study duration of 32 months"
country,NCT04435626::country::United States,NCT04435626,United States,,,,,,,,,,,,,,
country,NCT04435626::country::Japan,NCT04435626,Japan,,,,,,,,,,,,,,
country,NCT04435626::country::China,NCT04435626,China,,,,,,,,,,,,,,
country,NCT04435626::country::Russia,NCT04435626,Russia,,,,,,,,,,,,,,
country,NCT04435626::country::Czechia,NCT04435626,Czechia,,,,,,,,,,,,,,
country,NCT04435626::country::Spain,NCT04435626,Spain,,,,,,,,,,,,,,
country,NCT04435626::country::Italy,NCT04435626,Italy,,,,,,,,,,,,,,
country,NCT04435626::country::Canada,NCT04435626,Canada,,,,,,,,,,,,,,
country,NCT04435626::country::Ukraine,NCT04435626,Ukraine,,,,,,,,,,,,,,
country,NCT04435626::country::Bulgaria,NCT04435626,Bulgaria,,,,,,,,,,,,,,
country,NCT04435626::country::Argentina,NCT04435626,Argentina,,,,,,,,,,,,,,
country,NCT04435626::country::Brazil,NCT04435626,Brazil,,,,,,,,,,,,,,
country,NCT04435626::country::Colombia,NCT04435626,Colombia,,,,,,,,,,,,,,
country,NCT04435626::country::Slovakia,NCT04435626,Slovakia,,,,,,,,,,,,,,
country,NCT04435626::country::Hungary,NCT04435626,Hungary,,,,,,,,,,,,,,
country,NCT04435626::country::Poland,NCT04435626,Poland,,,,,,,,,,,,,,
country,NCT04435626::country::Romania,NCT04435626,Romania,,,,,,,,,,,,,,
country,NCT04435626::country::Israel,NCT04435626,Israel,,,,,,,,,,,,,,
country,NCT04435626::country::United Kingdom,NCT04435626,United Kingdom,,,,,,,,,,,,,,
country,NCT04435626::country::Netherlands,NCT04435626,Netherlands,,,,,,,,,,,,,,
country,NCT04435626::country::Turkey (Türkiye),NCT04435626,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT04435626::country::Greece,NCT04435626,Greece,,,,,,,,,,,,,,
country,NCT04435626::country::Portugal,NCT04435626,Portugal,,,,,,,,,,,,,,
country,NCT04435626::country::Australia,NCT04435626,Australia,,,,,,,,,,,,,,
country,NCT04435626::country::South Korea,NCT04435626,South Korea,,,,,,,,,,,,,,
country,NCT04435626::country::Austria,NCT04435626,Austria,,,,,,,,,,,,,,
country,NCT04435626::country::Denmark,NCT04435626,Denmark,,,,,,,,,,,,,,
country,NCT04435626::country::Mexico,NCT04435626,Mexico,,,,,,,,,,,,,,
country,NCT04435626::country::Taiwan,NCT04435626,Taiwan,,,,,,,,,,,,,,
country,NCT04435626::country::Germany,NCT04435626,Germany,,,,,,,,,,,,,,
country,NCT04435626::country::Latvia,NCT04435626,Latvia,,,,,,,,,,,,,,
country,NCT04435626::country::Lithuania,NCT04435626,Lithuania,,,,,,,,,,,,,,
country,NCT04435626::country::Malaysia,NCT04435626,Malaysia,,,,,,,,,,,,,,
country,NCT04435626::country::New Zealand,NCT04435626,New Zealand,,,,,,,,,,,,,,
country,NCT04435626::country::India,NCT04435626,India,,,,,,,,,,,,,,
country,NCT04435626::country::Hong Kong,NCT04435626,Hong Kong,,,,,,,,,,,,,,
country,NCT04435626::country::Finland,NCT04435626,Finland,,,,,,,,,,,,,,
trial,NCT01182441,NCT01182441,Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy,PHASE3,cardiovascular disease,Atrial Fibrillation; Stroke,INDUSTRY,407.0,2010-11,2017-11,1.0,41.0,,,,,
arm,NCT01182441::arm::FG000,NCT01182441,WATCHMAN,,,,,,,,,,FG000,"Subjects assigned to receive the WATCHMAN device.

WATCHMAN Device: WATCHMAN Left Atrial Appendage Closure Technology",,,
arm,NCT01182441::arm::FG001,NCT01182441,Warfarin,,,,,,,,,,FG001,"Subjects assigned to warfarin therapy.

Warfarin: Warfarin dosage prescribed by study physician to adequately maintain an INR of 2.0-3.0",,,
period,NCT01182441::period::1,NCT01182441,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01182441::outcome::primary::1,NCT01182441,Primary Safety Endpoint (Device Group Only),,,,,,,,,,,,,PRIMARY,7-Day
outcome,NCT01182441::outcome::primary::2,NCT01182441,"Composite of Stroke, Systemic Embolism, and Death (Cardiovascular and Unknown)",,,,,,,,,,,,,PRIMARY,18 month rate
outcome,NCT01182441::outcome::primary::3,NCT01182441,Composite of Ischemic Stroke or Systemic Embolism,,,,,,,,,,,,,PRIMARY,Day 8 to 18-months
country,NCT01182441::country::United States,NCT01182441,United States,,,,,,,,,,,,,,
trial,NCT03158688,NCT03158688,"Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.",PHASE3,cardiovascular disease,Relapsed Multiple Myeloma; Refractory Multiple Myeloma,INDUSTRY,466.0,2017-06-13,2022-04-15,19.0,113.0,,,,,
arm,NCT03158688::arm::FG000,NCT03158688,Kd - Carfilzomib and Dexamethasone,,,,,,,,,,FG000,"Carfilzomib was administered intravenously (IV) at 20 mg/m\^2 in Cycle 1: days 1 and 2; at 56 mg/m\^2 in Cycle 1: days 8, 9, 15 and 16. The 56 mg/m\^2 dosage was continued in Cycles 2+ on days 1, 2, 8",,,
arm,NCT03158688::arm::FG001,NCT03158688,"KdD - Carfilzomib, Dexamethasone and Daratumumab",,,,,,,,,,FG001,"Carfilzomib was administered intravenously (IV) at 20 mg/m\^2 in Cycle 1: days 1 and 2; at 56 mg/m\^2 in Cycle 1: days 8, 9, 15 and 16. The 56 mg/m\^2 dosage was continued in Cycles 2+ on days 1, 2, 8",,,
period,NCT03158688::period::1,NCT03158688,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03158688::outcome::primary::1,NCT03158688,Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only),,,,,,,,,,,,,PRIMARY,From randomization until the PA DCO date of 14 July 2019
country,NCT03158688::country::Japan,NCT03158688,Japan,,,,,,,,,,,,,,
country,NCT03158688::country::United States,NCT03158688,United States,,,,,,,,,,,,,,
country,NCT03158688::country::Australia,NCT03158688,Australia,,,,,,,,,,,,,,
country,NCT03158688::country::France,NCT03158688,France,,,,,,,,,,,,,,
country,NCT03158688::country::Romania,NCT03158688,Romania,,,,,,,,,,,,,,
country,NCT03158688::country::South Korea,NCT03158688,South Korea,,,,,,,,,,,,,,
country,NCT03158688::country::Poland,NCT03158688,Poland,,,,,,,,,,,,,,
country,NCT03158688::country::Belgium,NCT03158688,Belgium,,,,,,,,,,,,,,
country,NCT03158688::country::Canada,NCT03158688,Canada,,,,,,,,,,,,,,
country,NCT03158688::country::Czechia,NCT03158688,Czechia,,,,,,,,,,,,,,
country,NCT03158688::country::Hungary,NCT03158688,Hungary,,,,,,,,,,,,,,
country,NCT03158688::country::Spain,NCT03158688,Spain,,,,,,,,,,,,,,
country,NCT03158688::country::Greece,NCT03158688,Greece,,,,,,,,,,,,,,
country,NCT03158688::country::Russia,NCT03158688,Russia,,,,,,,,,,,,,,
country,NCT03158688::country::Turkey (Türkiye),NCT03158688,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT03158688::country::Bulgaria,NCT03158688,Bulgaria,,,,,,,,,,,,,,
country,NCT03158688::country::United Kingdom,NCT03158688,United Kingdom,,,,,,,,,,,,,,
country,NCT03158688::country::Austria,NCT03158688,Austria,,,,,,,,,,,,,,
country,NCT03158688::country::Taiwan,NCT03158688,Taiwan,,,,,,,,,,,,,,
trial,NCT00818883,NCT00818883,Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension,PHASE3,cardiovascular disease,Essential Hypertension,INDUSTRY,609.0,2009-02,2009-11,2.0,53.0,,,,,
arm,NCT00818883::arm::FG000,NCT00818883,Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD,,,,,,,,,,FG000,"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 10 weeks.

For participants ",,,
arm,NCT00818883::arm::FG001,NCT00818883,Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD,,,,,,,,,,FG001,"Azilsartan medoxomil 40 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 10 weeks.

For participants who do not achieve target blood pressure by W",,,
period,NCT00818883::period::1,NCT00818883,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00818883::outcome::primary::1,NCT00818883,"Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure",,,,,,,,,,,,,PRIMARY,"Baseline, Week 6 and Week 10."
country,NCT00818883::country::United States,NCT00818883,United States,,,,,,,,,,,,,,
country,NCT00818883::country::Russia,NCT00818883,Russia,,,,,,,,,,,,,,
trial,NCT01977794,NCT01977794,Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,200.0,2014-03,2015-03,1.0,1.0,,,,,
arm,NCT01977794::arm::FG000,NCT01977794,Amlodipine Failed Group,,,,,,,,,,FG000,Subjects who failed monotherapy with amlodipine 5 milligram (mg) before trial inclusion were randomized to amlodipine failed group to receive Bisoprolol/Amlodipine fixed dose combination(FDC) tablet. ,,,
arm,NCT01977794::arm::FG001,NCT01977794,Bisoprolol Failed Group,,,,,,,,,,FG001,Subjects who failed monotherapy with bisoprolol 5 mg before trial inclusion were randomized to bisoprolol failed group to receive Bisoprolol/Amlodipine FDC tablet. Bisoprolol/Amlodipine FDC tablet was,,,
period,NCT01977794::period::1,NCT01977794,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01977794::outcome::primary::1,NCT01977794,Mean Reduction In Systolic Blood Pressure (SBP) After 18 Weeks of Treatment From Baseline,,,,,,,,,,,,,PRIMARY,"Baseline, Week 18"
country,NCT01977794::country::Germany,NCT01977794,Germany,,,,,,,,,,,,,,
trial,NCT01294163,NCT01294163,Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery,PHASE3,cardiovascular disease,Coronary Artery Disease; General Anesthetic Drug Allergy; Coronary Artery Bypass Graft Surgery,INDUSTRY,509.0,2011-04,2014-04,4.0,17.0,,,,,
arm,NCT01294163::arm::FG000,NCT01294163,Xenon Including Pilot Patients,,,,,,,,,,FG000,Anesthetic agent before and after CPB: xenon,,,
arm,NCT01294163::arm::FG001,NCT01294163,Sevoflurane,,,,,,,,,,FG001,Anesthetic agent before and after CPB: sevoflurane,,,
arm,NCT01294163::arm::FG002,NCT01294163,TIVA,,,,,,,,,,FG002,Anesthetic agent before and after CPB: propofol,,,
period,NCT01294163::period::1,NCT01294163,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01294163::outcome::primary::1,NCT01294163,Blood Level of Troponin I,,,,,,,,,,,,,PRIMARY,Sampling performed 24 hours after the end of the surgical procedure
outcome,NCT01294163::outcome::primary::2,NCT01294163,Log-transformed Blood Level of Troponin I,,,,,,,,,,,,,PRIMARY,Sampling performed 24 hours after the end of the surgical procedure
country,NCT01294163::country::France,NCT01294163,France,,,,,,,,,,,,,,
country,NCT01294163::country::Germany,NCT01294163,Germany,,,,,,,,,,,,,,
country,NCT01294163::country::Netherlands,NCT01294163,Netherlands,,,,,,,,,,,,,,
country,NCT01294163::country::Italy,NCT01294163,Italy,,,,,,,,,,,,,,
trial,NCT02307513,NCT02307513,"A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease",PHASE3,cardiovascular disease,Behçet's Syndrome,INDUSTRY,207.0,2014-12-30,2020-07-17,10.0,63.0,,,,,
arm,NCT02307513::arm::FG000,NCT02307513,Placebo/Apremilast,,,,,,,,,,FG000,Participants received identically appearing placebo tablets twice a day (BID) from weeks 0 to 12 during the placebo-controlled treatment phase. At week 12 participants were switched to apremilast 30 m,,,
arm,NCT02307513::arm::FG001,NCT02307513,Apremilast,,,,,,,,,,FG001,Participants received apremilast 30 mg tablets BID from weeks 0 to 12 during the placebo-controlled treatment phase and continued to receive apremilast 30 mg BID for 52 weeks during the active treatme,,,
period,NCT02307513::period::1,NCT02307513,Placebo Controlled Phase (Weeks 0-12),,,,,,,,,,,,1.0,,
period,NCT02307513::period::2,NCT02307513,Active Treatment Phase (Weeks 13-64),,,,,,,,,,,,2.0,,
period,NCT02307513::period::3,NCT02307513,Long-term Extension,,,,,,,,,,,,3.0,,
outcome,NCT02307513::outcome::primary::1,NCT02307513,Area Under the Curve (AUC) for the Number of Oral Ulcers From Baseline Through Week 12 (AUC W0-12),,,,,,,,,,,,,PRIMARY,"Oral ulcers were assessed at weeks 0 (baseline), 1, 2, 4, 6, 8, 10, and 12 during the placebo-controlled period."
country,NCT02307513::country::Japan,NCT02307513,Japan,,,,,,,,,,,,,,
country,NCT02307513::country::United States,NCT02307513,United States,,,,,,,,,,,,,,
country,NCT02307513::country::Israel,NCT02307513,Israel,,,,,,,,,,,,,,
country,NCT02307513::country::South Korea,NCT02307513,South Korea,,,,,,,,,,,,,,
country,NCT02307513::country::Turkey (Türkiye),NCT02307513,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02307513::country::France,NCT02307513,France,,,,,,,,,,,,,,
country,NCT02307513::country::Greece,NCT02307513,Greece,,,,,,,,,,,,,,
country,NCT02307513::country::Germany,NCT02307513,Germany,,,,,,,,,,,,,,
country,NCT02307513::country::Italy,NCT02307513,Italy,,,,,,,,,,,,,,
country,NCT02307513::country::Lebanon,NCT02307513,Lebanon,,,,,,,,,,,,,,
trial,NCT04518306,NCT04518306,Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,755.0,2021-06-14,2023-10-18,5.0,47.0,,,,,
arm,NCT04518306::arm::FG000,NCT04518306,Triple ¼ (GMRx2),,,,,,,,,,FG000,"Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg

Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg: Oral tablets

Over encapsulated Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.62",,,
arm,NCT04518306::arm::FG001,NCT04518306,Triple ½ (GMRx2),,,,,,,,,,FG001,"Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg

Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg: Oral tablets

Over encapsulated Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg o",,,
arm,NCT04518306::arm::FG002,NCT04518306,Placebo,,,,,,,,,,FG002,"Placebo

Placebo: Placebo

One tablet daily in the morning after home BP measurement from week 1 to week 4.",,,
period,NCT04518306::period::1,NCT04518306,Single-Blind Placebo Run-In Period,,,,,,,,,,,,1.0,,
period,NCT04518306::period::2,NCT04518306,Double-Blind Period,,,,,,,,,,,,2.0,,
outcome,NCT04518306::outcome::primary::1,NCT04518306,Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 4,,,,,,,,,,,,,PRIMARY,Randomization to Week 4
country,NCT04518306::country::United States,NCT04518306,United States,,,,,,,,,,,,,,
country,NCT04518306::country::United Kingdom,NCT04518306,United Kingdom,,,,,,,,,,,,,,
country,NCT04518306::country::Sri Lanka,NCT04518306,Sri Lanka,,,,,,,,,,,,,,
country,NCT04518306::country::Australia,NCT04518306,Australia,,,,,,,,,,,,,,
country,NCT04518306::country::Nigeria,NCT04518306,Nigeria,,,,,,,,,,,,,,
trial,NCT02924727,NCT02924727,Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI,PHASE3,cardiovascular disease,Acute Myocardial Infarction,INDUSTRY,5669.0,2016-12-09,2021-02-26,41.0,486.0,,,,,
arm,NCT02924727::arm::FG000,NCT02924727,LCZ696 (Sacubitril/Valsartan),,,,,,,,,,FG000,"Following randomization, patients received LCZ696 in titrated doses from level 1 up to level 3 (50, 100 and 200 mg twice daily).

Patients were required to take a total of two pills, (one tablet from ",,,
arm,NCT02924727::arm::FG001,NCT02924727,Ramipril,,,,,,,,,,FG001,"Following randomization, patients received Ramipril in titrated doses from level 1 up to level 3 (1.25, 2.5 and 5 mg twice daily).

Patients were required to take a total of two pills, (one capsule fr",,,
period,NCT02924727::period::1,NCT02924727,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02924727::outcome::primary::1,NCT02924727,Number of Participants With First CEC (Clinical Endpoint Committee) Confirmed Primary Composite Endpoint,,,,,,,,,,,,,PRIMARY,From randomization to first occurrence (up to approximately 43 months)
country,NCT02924727::country::United States,NCT02924727,United States,,,,,,,,,,,,,,
country,NCT02924727::country::Germany,NCT02924727,Germany,,,,,,,,,,,,,,
country,NCT02924727::country::China,NCT02924727,China,,,,,,,,,,,,,,
country,NCT02924727::country::Russia,NCT02924727,Russia,,,,,,,,,,,,,,
country,NCT02924727::country::Netherlands,NCT02924727,Netherlands,,,,,,,,,,,,,,
country,NCT02924727::country::Argentina,NCT02924727,Argentina,,,,,,,,,,,,,,
country,NCT02924727::country::Romania,NCT02924727,Romania,,,,,,,,,,,,,,
country,NCT02924727::country::Bulgaria,NCT02924727,Bulgaria,,,,,,,,,,,,,,
country,NCT02924727::country::India,NCT02924727,India,,,,,,,,,,,,,,
country,NCT02924727::country::Italy,NCT02924727,Italy,,,,,,,,,,,,,,
country,NCT02924727::country::United Kingdom,NCT02924727,United Kingdom,,,,,,,,,,,,,,
country,NCT02924727::country::Brazil,NCT02924727,Brazil,,,,,,,,,,,,,,
country,NCT02924727::country::Spain,NCT02924727,Spain,,,,,,,,,,,,,,
country,NCT02924727::country::Turkey (Türkiye),NCT02924727,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02924727::country::France,NCT02924727,France,,,,,,,,,,,,,,
country,NCT02924727::country::Portugal,NCT02924727,Portugal,,,,,,,,,,,,,,
country,NCT02924727::country::Hungary,NCT02924727,Hungary,,,,,,,,,,,,,,
country,NCT02924727::country::Canada,NCT02924727,Canada,,,,,,,,,,,,,,
country,NCT02924727::country::Czechia,NCT02924727,Czechia,,,,,,,,,,,,,,
country,NCT02924727::country::Greece,NCT02924727,Greece,,,,,,,,,,,,,,
country,NCT02924727::country::Sweden,NCT02924727,Sweden,,,,,,,,,,,,,,
country,NCT02924727::country::Taiwan,NCT02924727,Taiwan,,,,,,,,,,,,,,
country,NCT02924727::country::Austria,NCT02924727,Austria,,,,,,,,,,,,,,
country,NCT02924727::country::Belgium,NCT02924727,Belgium,,,,,,,,,,,,,,
country,NCT02924727::country::Denmark,NCT02924727,Denmark,,,,,,,,,,,,,,
country,NCT02924727::country::Mexico,NCT02924727,Mexico,,,,,,,,,,,,,,
country,NCT02924727::country::Australia,NCT02924727,Australia,,,,,,,,,,,,,,
country,NCT02924727::country::Colombia,NCT02924727,Colombia,,,,,,,,,,,,,,
country,NCT02924727::country::Israel,NCT02924727,Israel,,,,,,,,,,,,,,
country,NCT02924727::country::Slovakia,NCT02924727,Slovakia,,,,,,,,,,,,,,
country,NCT02924727::country::Poland,NCT02924727,Poland,,,,,,,,,,,,,,
country,NCT02924727::country::Singapore,NCT02924727,Singapore,,,,,,,,,,,,,,
country,NCT02924727::country::South Africa,NCT02924727,South Africa,,,,,,,,,,,,,,
country,NCT02924727::country::Peru,NCT02924727,Peru,,,,,,,,,,,,,,
country,NCT02924727::country::South Korea,NCT02924727,South Korea,,,,,,,,,,,,,,
country,NCT02924727::country::Switzerland,NCT02924727,Switzerland,,,,,,,,,,,,,,
country,NCT02924727::country::Thailand,NCT02924727,Thailand,,,,,,,,,,,,,,
country,NCT02924727::country::Croatia,NCT02924727,Croatia,,,,,,,,,,,,,,
country,NCT02924727::country::Finland,NCT02924727,Finland,,,,,,,,,,,,,,
country,NCT02924727::country::Norway,NCT02924727,Norway,,,,,,,,,,,,,,
country,NCT02924727::country::Philippines,NCT02924727,Philippines,,,,,,,,,,,,,,
trial,NCT00159861,NCT00159861,The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH,PHASE3,cardiovascular disease,Pulmonary Hypertension,INDUSTRY,267.0,2003-07,2006-01,11.0,52.0,,,,,
arm,NCT00159861::arm::FG000,NCT00159861,Placebo: Core Study / Sildenafil: Extension Study,,,,,,,,,,FG000,"Core Study: Placebo (16 weeks, or at least 4 weeks for subjects who required a change in epoprostenol dose due to clinical deterioration); Extension Study: Sildenafil (until last enrolled subject comp",,,
arm,NCT00159861::arm::FG001,NCT00159861,Sildenafil: Core Study / Sildenafil: Extension Study,,,,,,,,,,FG001,"Core Study (16 weeks, or at least 4 weeks for subjects who required a change in epoprostenol dose due to clinical deterioration): Sildenafil 20, 40, or 80 mg TID (3 times daily) based on toleration; E",,,
period,NCT00159861::period::1,NCT00159861,Core Study - 16 Weeks,,,,,,,,,,,,1.0,,
period,NCT00159861::period::2,NCT00159861,Extension Study - up to 3 Years,,,,,,,,,,,,2.0,,
outcome,NCT00159861::outcome::primary::1,NCT00159861,Categorized Change From Baseline in 6-Minute Walking Distance,,,,,,,,,,,,,PRIMARY,"1 Year, 2 Year, 3 Year"
country,NCT00159861::country::United States,NCT00159861,United States,,,,,,,,,,,,,,
country,NCT00159861::country::Canada,NCT00159861,Canada,,,,,,,,,,,,,,
country,NCT00159861::country::France,NCT00159861,France,,,,,,,,,,,,,,
country,NCT00159861::country::Netherlands,NCT00159861,Netherlands,,,,,,,,,,,,,,
country,NCT00159861::country::Spain,NCT00159861,Spain,,,,,,,,,,,,,,
country,NCT00159861::country::United Kingdom,NCT00159861,United Kingdom,,,,,,,,,,,,,,
country,NCT00159861::country::Belgium,NCT00159861,Belgium,,,,,,,,,,,,,,
country,NCT00159861::country::Czechia,NCT00159861,Czechia,,,,,,,,,,,,,,
country,NCT00159861::country::Denmark,NCT00159861,Denmark,,,,,,,,,,,,,,
country,NCT00159861::country::Israel,NCT00159861,Israel,,,,,,,,,,,,,,
country,NCT00159861::country::Italy,NCT00159861,Italy,,,,,,,,,,,,,,
trial,NCT02741596,NCT02741596,Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE,PHASE3,cardiovascular disease,Hereditary Angioedema (HAE),INDUSTRY,212.0,2016-05-26,2019-10-31,7.0,43.0,,,,,
arm,NCT02741596::arm::FG000,NCT02741596,Rollover Participants,,,,,,,,,,FG000,Participants who rolled from the DX-2930-03 (NCT02586805) study received 300 milligrams (mg) of DX-2930 subcutaneous (SC) injection on Day 0 followed by a second dose after participants reported their,,,
arm,NCT02741596::arm::FG001,NCT02741596,Non-rollover Participants,,,,,,,,,,FG001,Participants who directly entered in to this DX-2930-04 study received 300 mg of DX-2930 SC injection on Day 0 and continued to receive SC administrations of 300 mg DX-2930 every 2 weeks throughout th,,,
period,NCT02741596::period::1,NCT02741596,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02741596::outcome::primary::1,NCT02741596,Number of Participants With Treatment-emergent Adverse Events (TEAEs),,,,,,,,,,,,,PRIMARY,From start of the study up to follow-up (Day 952)
country,NCT02741596::country::United States,NCT02741596,United States,,,,,,,,,,,,,,
country,NCT02741596::country::Canada,NCT02741596,Canada,,,,,,,,,,,,,,
country,NCT02741596::country::Germany,NCT02741596,Germany,,,,,,,,,,,,,,
country,NCT02741596::country::Italy,NCT02741596,Italy,,,,,,,,,,,,,,
country,NCT02741596::country::Jordan,NCT02741596,Jordan,,,,,,,,,,,,,,
country,NCT02741596::country::Puerto Rico,NCT02741596,Puerto Rico,,,,,,,,,,,,,,
country,NCT02741596::country::United Kingdom,NCT02741596,United Kingdom,,,,,,,,,,,,,,
trial,NCT03277105,NCT03277105,A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma,PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,522.0,2017-10-27,2024-01-12,18.0,146.0,,,,,
arm,NCT03277105::arm::FG000,NCT03277105,Daratumumab IV,,,,,,,,,,FG000,"Participants received daratumumab intravenous infusion (Dara IV) 16 milligrams per kilogram (mg/kg) once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks thereafter until disease ",,,
arm,NCT03277105::arm::FG001,NCT03277105,Daratumumab SC,,,,,,,,,,FG001,"Participants received daratumumab 1800 mg subcutaneous injection (Dara SC) co-formulated with recombinant human hyaluronidase (rHuPH20) 2000 Units per milliliter (U/mL), once weekly in Cycle 1 and 2, ",,,
period,NCT03277105::period::1,NCT03277105,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03277105::outcome::primary::1,NCT03277105,Overall Response Rate (ORR),,,,,,,,,,,,,PRIMARY,Up to 1 year 8 months
outcome,NCT03277105::outcome::primary::2,NCT03277105,Maximum Trough Concentration (Ctrough) of Daratumumab,,,,,,,,,,,,,PRIMARY,Predose on Cycle 3 Day 1 (each cycle of 28 days)
country,NCT03277105::country::Japan,NCT03277105,Japan,,,,,,,,,,,,,,
country,NCT03277105::country::Spain,NCT03277105,Spain,,,,,,,,,,,,,,
country,NCT03277105::country::Brazil,NCT03277105,Brazil,,,,,,,,,,,,,,
country,NCT03277105::country::Russia,NCT03277105,Russia,,,,,,,,,,,,,,
country,NCT03277105::country::Ukraine,NCT03277105,Ukraine,,,,,,,,,,,,,,
country,NCT03277105::country::Poland,NCT03277105,Poland,,,,,,,,,,,,,,
country,NCT03277105::country::United Kingdom,NCT03277105,United Kingdom,,,,,,,,,,,,,,
country,NCT03277105::country::Australia,NCT03277105,Australia,,,,,,,,,,,,,,
country,NCT03277105::country::Italy,NCT03277105,Italy,,,,,,,,,,,,,,
country,NCT03277105::country::South Korea,NCT03277105,South Korea,,,,,,,,,,,,,,
country,NCT03277105::country::Canada,NCT03277105,Canada,,,,,,,,,,,,,,
country,NCT03277105::country::Czechia,NCT03277105,Czechia,,,,,,,,,,,,,,
country,NCT03277105::country::France,NCT03277105,France,,,,,,,,,,,,,,
country,NCT03277105::country::Israel,NCT03277105,Israel,,,,,,,,,,,,,,
country,NCT03277105::country::Sweden,NCT03277105,Sweden,,,,,,,,,,,,,,
country,NCT03277105::country::Taiwan,NCT03277105,Taiwan,,,,,,,,,,,,,,
country,NCT03277105::country::United States,NCT03277105,United States,,,,,,,,,,,,,,
country,NCT03277105::country::Greece,NCT03277105,Greece,,,,,,,,,,,,,,
trial,NCT01568866,NCT01568866,Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients,PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,929.0,2012-06-20,2018-02-05,27.0,241.0,,,,,
arm,NCT01568866::arm::FG000,NCT01568866,Bortezomib + DEX,,,,,,,,,,FG000,"Participants received bortezomib 1.3 mg/m² administered intravenously (IV) or subcutaneously (SC) on Days 1, 4, 8, and 11 of a 21-day cycle plus dexamethasone (DEX) 20 mg administered on Days 1, 2, 4,",,,
arm,NCT01568866::arm::FG001,NCT01568866,Carfilzomib + DEX,,,,,,,,,,FG001,"Participants received 20 mg/m² carfilzomib administered by IV infusion on Days 1 and 2 of Cycle 1, followed by 56 mg/m² on Days 8, 9, 15, and 16 of Cycle 1 and for each 28-day cycle thereafter. Additi",,,
period,NCT01568866::period::1,NCT01568866,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01568866::outcome::primary::1,NCT01568866,Progression-free Survival,,,,,,,,,,,,,PRIMARY,From randomization until the data cut-off date of 10 November 2014
country,NCT01568866::country::United States,NCT01568866,United States,,,,,,,,,,,,,,
country,NCT01568866::country::Japan,NCT01568866,Japan,,,,,,,,,,,,,,
country,NCT01568866::country::Australia,NCT01568866,Australia,,,,,,,,,,,,,,
country,NCT01568866::country::Germany,NCT01568866,Germany,,,,,,,,,,,,,,
country,NCT01568866::country::Italy,NCT01568866,Italy,,,,,,,,,,,,,,
country,NCT01568866::country::France,NCT01568866,France,,,,,,,,,,,,,,
country,NCT01568866::country::Ukraine,NCT01568866,Ukraine,,,,,,,,,,,,,,
country,NCT01568866::country::Spain,NCT01568866,Spain,,,,,,,,,,,,,,
country,NCT01568866::country::Brazil,NCT01568866,Brazil,,,,,,,,,,,,,,
country,NCT01568866::country::Russia,NCT01568866,Russia,,,,,,,,,,,,,,
country,NCT01568866::country::South Korea,NCT01568866,South Korea,,,,,,,,,,,,,,
country,NCT01568866::country::United Kingdom,NCT01568866,United Kingdom,,,,,,,,,,,,,,
country,NCT01568866::country::Canada,NCT01568866,Canada,,,,,,,,,,,,,,
country,NCT01568866::country::Hungary,NCT01568866,Hungary,,,,,,,,,,,,,,
country,NCT01568866::country::Poland,NCT01568866,Poland,,,,,,,,,,,,,,
country,NCT01568866::country::Belgium,NCT01568866,Belgium,,,,,,,,,,,,,,
country,NCT01568866::country::Czechia,NCT01568866,Czechia,,,,,,,,,,,,,,
country,NCT01568866::country::Taiwan,NCT01568866,Taiwan,,,,,,,,,,,,,,
country,NCT01568866::country::Israel,NCT01568866,Israel,,,,,,,,,,,,,,
country,NCT01568866::country::New Zealand,NCT01568866,New Zealand,,,,,,,,,,,,,,
country,NCT01568866::country::Romania,NCT01568866,Romania,,,,,,,,,,,,,,
country,NCT01568866::country::Bulgaria,NCT01568866,Bulgaria,,,,,,,,,,,,,,
country,NCT01568866::country::Austria,NCT01568866,Austria,,,,,,,,,,,,,,
country,NCT01568866::country::Singapore,NCT01568866,Singapore,,,,,,,,,,,,,,
country,NCT01568866::country::Thailand,NCT01568866,Thailand,,,,,,,,,,,,,,
country,NCT01568866::country::Greece,NCT01568866,Greece,,,,,,,,,,,,,,
country,NCT01568866::country::Slovakia,NCT01568866,Slovakia,,,,,,,,,,,,,,
trial,NCT01120405,NCT01120405,"Cardiovascular Safety of Xenon in General Anaesthesia, in Patient With Cardiovascular Risk in Non Cardiac Surgery",PHASE3,cardiovascular disease,Elevated Cardiac Risk; Coronary Arteries Disease Risk,INDUSTRY,600.0,2010-05,2012-07,1.0,13.0,,,,,
arm,NCT01120405::arm::FG000,NCT01120405,Xenon,,,,,,,,,,FG000,0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group A),,,
arm,NCT01120405::arm::FG001,NCT01120405,Sevoflurane,,,,,,,,,,FG001,0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group B),,,
period,NCT01120405::period::1,NCT01120405,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01120405::outcome::primary::1,NCT01120405,Number of Participants With Myocardial Necrosis (MN),,,,,,,,,,,,,PRIMARY,3 Postoperative Days
country,NCT01120405::country::France,NCT01120405,France,,,,,,,,,,,,,,
trial,NCT04252287,NCT04252287,"A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure",PHASE3,cardiovascular disease,Heart Failure,INDUSTRY,476.0,2020-03-10,2021-11-09,1.0,18.0,,,,,
arm,NCT04252287::arm::FG000,NCT04252287,Placebo,,,,,,,,,,FG000,Participants received placebo (matched to canagliflozin) capsule orally once daily for 12 weeks.,,,
arm,NCT04252287::arm::FG001,NCT04252287,Canagliflozin 100 mg,,,,,,,,,,FG001,"Participants received canagliflozin 100 milligrams (mg) immediate-release, over-encapsulated tablet (as capsule) orally once daily for 12 weeks.",,,
period,NCT04252287::period::1,NCT04252287,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04252287::outcome::primary::1,NCT04252287,Change From Baseline in Kansas City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 12,,,,,,,,,,,,,PRIMARY,"Baseline, Week 12"
country,NCT04252287::country::United States,NCT04252287,United States,,,,,,,,,,,,,,
trial,NCT00113087,NCT00113087,Trial of Angiotensin Converting Enzyme Inhibition in Infants With Single Ventricle--Pediatric Heart Network,PHASE3,cardiovascular disease,"Heart Defects, Congenital; Heart Failure, Congestive",NIH,230.0,2003-08,2008-07,2.0,9.0,,,,,
arm,NCT00113087::arm::FG000,NCT00113087,Enalapril,,,,,,,,,,FG000,"ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses",,,
arm,NCT00113087::arm::FG001,NCT00113087,Placebo,,,,,,,,,,FG001,Placebo suspension,,,
period,NCT00113087::period::1,NCT00113087,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00113087::outcome::primary::1,NCT00113087,Weight-for-age Z-score at 14 Months of Age,,,,,,,,,,,,,PRIMARY,"Measured at baseline, 2 weeks after starting study drug, just prior to the Glenn surgery, 7 days after restarting drug following the Glenn surgery, at 10 months of age, and at 14 months of age"
country,NCT00113087::country::United States,NCT00113087,United States,,,,,,,,,,,,,,
country,NCT00113087::country::Canada,NCT00113087,Canada,,,,,,,,,,,,,,
trial,NCT01898221,NCT01898221,Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation,PHASE3,cardiovascular disease,Ventricular Tachycardia; Atrial Fibrillation,OTHER,343.0,2013-10,2019-12,1.0,12.0,,,,,
arm,NCT01898221::arm::FG000,NCT01898221,Standard Catheter Ablation Patient Group,,,,,,,,,,FG000,"Patients will have a standard procedure ablation

Ablation: The doctor will perform only the standard procedure. Throughout the procedure, the researchers will document the following information for A",,,
arm,NCT01898221::arm::FG001,NCT01898221,Vein of Marshall and Standar Procedure,,,,,,,,,,FG001,"The doctor will inject Ethanol through a balloon catheter into the VOM

Ethanol: We enter the CS with a sheath advanced from the right internal jugular vein. A sub-selector catheter with a \~90° angle",,,
period,NCT01898221::period::1,NCT01898221,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01898221::outcome::primary::1,NCT01898221,Amount of Treated Subjects With Freedom of Symptomatic Post-procedural AF or Flutter at 12 and 15 Months Post Procedure and Less Than 1 Min/Day of AF or Flutter on 4-week EKG Monitor.,,,,,,,,,,,,,PRIMARY,15 months
country,NCT01898221::country::United States,NCT01898221,United States,,,,,,,,,,,,,,
trial,NCT02025621,NCT02025621,Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass,PHASE3,cardiovascular disease,Coronary Artery Bypass Grafting; Mitral Valve Surgery; Low Cardiac Output Syndrome,INDUSTRY,882.0,2014-07,2016-11,2.0,60.0,,,,,
arm,NCT02025621::arm::FG000,NCT02025621,Levosimendan,,,,,,,,,,FG000,"levosimendan 0.2 µg/kg/min for first hour, followed by 0.1 µg/kg/min for an additional 23 hours

Levosimendan",,,
arm,NCT02025621::arm::FG001,NCT02025621,Placebo,,,,,,,,,,FG001,"placebo 0.2 µg/kg/min for first hour, followed by 0.1 µg/kg/min for an additional 23 hours

Placebo: matching placebo",,,
period,NCT02025621::period::1,NCT02025621,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02025621::outcome::primary::1,NCT02025621,Number of Dual Efficacy Endpoint Events,,,,,,,,,,,,,PRIMARY,30 days
outcome,NCT02025621::outcome::primary::2,NCT02025621,Number of Quad Efficacy Endpoint Events,,,,,,,,,,,,,PRIMARY,30 days
country,NCT02025621::country::United States,NCT02025621,United States,,,,,,,,,,,,,,
country,NCT02025621::country::Canada,NCT02025621,Canada,,,,,,,,,,,,,,
trial,NCT00420849,NCT00420849,"A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma",PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,587.0,2006-11,2009-11,5.0,5.0,,,,,
arm,NCT00420849::arm::FG000,NCT00420849,Lenalidomide Plus Dexamethasone,,,,,,,,,,FG000,"Lenalidomide administered orally, 25 mg daily (QD) for the first 21 days of each 28-day cycle. Pulse dexamethasone administered orally, 40 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle d",,,
period,NCT00420849::period::1,NCT00420849,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00420849::outcome::primary::1,NCT00420849,"Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment",,,,,,,,,,,,,PRIMARY,up to 123 weeks
country,NCT00420849::country::Australia,NCT00420849,Australia,,,,,,,,,,,,,,
country,NCT00420849::country::Austria,NCT00420849,Austria,,,,,,,,,,,,,,
country,NCT00420849::country::Ireland,NCT00420849,Ireland,,,,,,,,,,,,,,
country,NCT00420849::country::Spain,NCT00420849,Spain,,,,,,,,,,,,,,
country,NCT00420849::country::United Kingdom,NCT00420849,United Kingdom,,,,,,,,,,,,,,
trial,NCT02990338,NCT02990338,"Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients",PHASE3,cardiovascular disease,Plasma Cell Myeloma,INDUSTRY,307.0,2016-12-22,2023-11-01,24.0,111.0,,,,,
arm,NCT02990338::arm::FG000,NCT02990338,Pd (Pomalidomide + Dexamethasone),,,,,,,,,,FG000,"Participants received pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treatment cycle plus dexamethasone 40 mg (participants \>= 75 years of age received 20 mg dexamethasone) PO on Days 1, 8, 15 a",,,
arm,NCT02990338::arm::FG001,NCT02990338,IPd (Isatuximab + Pomalidomide + Dexamethasone),,,,,,,,,,FG001,"Participants received isatuximab 10 mg/kg IV infusion on Days 1, 8, 15, and 22 at Cycle 1, and then on Days 1 and 15 of subsequent cycles plus pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treat",,,
period,NCT02990338::period::1,NCT02990338,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02990338::outcome::primary::1,NCT02990338,Progression Free Survival (PFS),,,,,,,,,,,,,PRIMARY,"From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration: 76.7 weeks)"
country,NCT02990338::country::France,NCT02990338,France,,,,,,,,,,,,,,
country,NCT02990338::country::Turkey (Türkiye),NCT02990338,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02990338::country::Italy,NCT02990338,Italy,,,,,,,,,,,,,,
country,NCT02990338::country::Japan,NCT02990338,Japan,,,,,,,,,,,,,,
country,NCT02990338::country::Spain,NCT02990338,Spain,,,,,,,,,,,,,,
country,NCT02990338::country::Australia,NCT02990338,Australia,,,,,,,,,,,,,,
country,NCT02990338::country::Czechia,NCT02990338,Czechia,,,,,,,,,,,,,,
country,NCT02990338::country::Greece,NCT02990338,Greece,,,,,,,,,,,,,,
country,NCT02990338::country::South Korea,NCT02990338,South Korea,,,,,,,,,,,,,,
country,NCT02990338::country::Belgium,NCT02990338,Belgium,,,,,,,,,,,,,,
country,NCT02990338::country::New Zealand,NCT02990338,New Zealand,,,,,,,,,,,,,,
country,NCT02990338::country::Poland,NCT02990338,Poland,,,,,,,,,,,,,,
country,NCT02990338::country::Taiwan,NCT02990338,Taiwan,,,,,,,,,,,,,,
country,NCT02990338::country::Canada,NCT02990338,Canada,,,,,,,,,,,,,,
country,NCT02990338::country::Hungary,NCT02990338,Hungary,,,,,,,,,,,,,,
country,NCT02990338::country::Portugal,NCT02990338,Portugal,,,,,,,,,,,,,,
country,NCT02990338::country::Russia,NCT02990338,Russia,,,,,,,,,,,,,,
country,NCT02990338::country::United Kingdom,NCT02990338,United Kingdom,,,,,,,,,,,,,,
country,NCT02990338::country::United States,NCT02990338,United States,,,,,,,,,,,,,,
country,NCT02990338::country::Sweden,NCT02990338,Sweden,,,,,,,,,,,,,,
country,NCT02990338::country::Denmark,NCT02990338,Denmark,,,,,,,,,,,,,,
country,NCT02990338::country::Germany,NCT02990338,Germany,,,,,,,,,,,,,,
country,NCT02990338::country::Norway,NCT02990338,Norway,,,,,,,,,,,,,,
country,NCT02990338::country::Slovakia,NCT02990338,Slovakia,,,,,,,,,,,,,,
trial,NCT00624052,NCT00624052,26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,838.0,2008-03,,12.0,92.0,,,,,
arm,NCT00624052::arm::FG000,NCT00624052,Telmisartan 40mg and Amlodipine 10mg,,,,,,,,,,FG000,Patients who were randomised to telmisartan 40mg and amlodipine 10mg and were on this dose at their last study visit,,,
arm,NCT00624052::arm::FG001,NCT00624052,Randomised Telmisartan 80mg and Amlodipine 10mg,,,,,,,,,,FG001,Patients who were randomised to telmisartan 80mg and amlodipine 10mg and were on this dose at their last study visit,,,
arm,NCT00624052::arm::FG002,NCT00624052,Titrated Telmisartan 80mg and Amlodipine 10mg,,,,,,,,,,FG002,Patients who were randomised to telmisartan 40mg and amlodipine 10mg but were titrated to telmisartan 80mg and amlodipine 10mg and were on this dose at their last study visit,,,
arm,NCT00624052::arm::FG003,NCT00624052,Telmisartan 40mg or 80mg and Amlodipine 10mg + add-on,,,,,,,,,,FG003,Patients who were on either telmisartan 40 mg or 80mg and amlodipine 10mg plus another antihypertensive medication at their last study visit,,,
period,NCT00624052::period::1,NCT00624052,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00624052::outcome::primary::1,NCT00624052,Trough Seated Diastolic Blood Pressure (DBP) Control,,,,,,,,,,,,,PRIMARY,End of study (34 weeks or last value on treatment)
country,NCT00624052::country::United Kingdom,NCT00624052,United Kingdom,,,,,,,,,,,,,,
country,NCT00624052::country::Ukraine,NCT00624052,Ukraine,,,,,,,,,,,,,,
country,NCT00624052::country::Spain,NCT00624052,Spain,,,,,,,,,,,,,,
country,NCT00624052::country::Bulgaria,NCT00624052,Bulgaria,,,,,,,,,,,,,,
country,NCT00624052::country::Russia,NCT00624052,Russia,,,,,,,,,,,,,,
country,NCT00624052::country::Czechia,NCT00624052,Czechia,,,,,,,,,,,,,,
country,NCT00624052::country::Slovakia,NCT00624052,Slovakia,,,,,,,,,,,,,,
country,NCT00624052::country::Australia,NCT00624052,Australia,,,,,,,,,,,,,,
country,NCT00624052::country::Austria,NCT00624052,Austria,,,,,,,,,,,,,,
country,NCT00624052::country::Ireland,NCT00624052,Ireland,,,,,,,,,,,,,,
country,NCT00624052::country::Italy,NCT00624052,Italy,,,,,,,,,,,,,,
country,NCT00624052::country::New Zealand,NCT00624052,New Zealand,,,,,,,,,,,,,,
trial,NCT01102426,NCT01102426,Aplidin - Dexamethasone in Relapsed/Refractory Myeloma,PHASE3,cardiovascular disease,Relapsed/Refractory Multiple Myeloma,INDUSTRY,255.0,2010-06,2017-11,19.0,82.0,,,,,
arm,NCT01102426::arm::FG000,NCT01102426,Plitidepsin+Dexamethasone,,,,,,,,,,FG000,"plitidepsin + dexamethasone combination

plitidepsin + dexamethasone: plitidepsin: powder and solvent for concentrate for solution for infusion. 2 mg vial + 4 ml ampoule. 5 mg/m2 intravenously (i.v.) ",,,
arm,NCT01102426::arm::FG001,NCT01102426,Dexamethasone,,,,,,,,,,FG001,"dexamethasone single agent

dexamethasone: 4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks.",,,
period,NCT01102426::period::1,NCT01102426,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01102426::outcome::primary::1,NCT01102426,Progression Free Survival (PFS) as Per Intention-to-treat (ITT),,,,,,,,,,,,,PRIMARY,"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years"
outcome,NCT01102426::outcome::primary::2,NCT01102426,Percentage of Participants With Progression Free Survival (PFS) as Per Intention-to-treat (ITT) at 6 Months,,,,,,,,,,,,,PRIMARY,"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months"
country,NCT01102426::country::Spain,NCT01102426,Spain,,,,,,,,,,,,,,
country,NCT01102426::country::South Korea,NCT01102426,South Korea,,,,,,,,,,,,,,
country,NCT01102426::country::Germany,NCT01102426,Germany,,,,,,,,,,,,,,
country,NCT01102426::country::Australia,NCT01102426,Australia,,,,,,,,,,,,,,
country,NCT01102426::country::Austria,NCT01102426,Austria,,,,,,,,,,,,,,
country,NCT01102426::country::Italy,NCT01102426,Italy,,,,,,,,,,,,,,
country,NCT01102426::country::United States,NCT01102426,United States,,,,,,,,,,,,,,
country,NCT01102426::country::Belgium,NCT01102426,Belgium,,,,,,,,,,,,,,
country,NCT01102426::country::France,NCT01102426,France,,,,,,,,,,,,,,
country,NCT01102426::country::United Kingdom,NCT01102426,United Kingdom,,,,,,,,,,,,,,
country,NCT01102426::country::Czechia,NCT01102426,Czechia,,,,,,,,,,,,,,
country,NCT01102426::country::Greece,NCT01102426,Greece,,,,,,,,,,,,,,
country,NCT01102426::country::Taiwan,NCT01102426,Taiwan,,,,,,,,,,,,,,
country,NCT01102426::country::Netherlands,NCT01102426,Netherlands,,,,,,,,,,,,,,
country,NCT01102426::country::New Zealand,NCT01102426,New Zealand,,,,,,,,,,,,,,
country,NCT01102426::country::Poland,NCT01102426,Poland,,,,,,,,,,,,,,
country,NCT01102426::country::Portugal,NCT01102426,Portugal,,,,,,,,,,,,,,
country,NCT01102426::country::Ireland,NCT01102426,Ireland,,,,,,,,,,,,,,
country,NCT01102426::country::Puerto Rico,NCT01102426,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01327846,NCT01327846,Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events),PHASE3,cardiovascular disease,Atherosclerosis,INDUSTRY,10066.0,2011-04-11,2019-04-14,40.0,1131.0,,,,,
arm,NCT01327846::arm::FG000,NCT01327846,Group I,,,,,,,,,,FG000,Core phase: Blinded Canakinumab 300 mg quarterly subcutaneous + standard of care (SoC) therapy Extension phase: Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care (SoC,,,
arm,NCT01327846::arm::FG001,NCT01327846,Group II,,,,,,,,,,FG001,Core phase: Blinded Canakinumab 150 mg quarterly subcutaneous + standard of care (SoC) therapy Extension phase: Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care (SoC,,,
arm,NCT01327846::arm::FG002,NCT01327846,Group III,,,,,,,,,,FG002,Core phase: Blinded Canakinumab 50 mg quarterly subcutaneous + standard of care (SoC) therapy Extension phase: Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care (SoC),,,
arm,NCT01327846::arm::FG003,NCT01327846,Group IV,,,,,,,,,,FG003,Core phase: Blinded matching placebo quarterly subcutaneous + standard of care (SoC) therapy Extension phase: Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care (SoC) ,,,
period,NCT01327846::period::1,NCT01327846,Core Phase,,,,,,,,,,,,1.0,,
period,NCT01327846::period::2,NCT01327846,Extension Phase,,,,,,,,,,,,2.0,,
outcome,NCT01327846::outcome::primary::1,NCT01327846,Analysis of Core Phase First CEC Confirmed Major Adverse Cardiovascular Events (MACE) and Its Components,,,,,,,,,,,,,PRIMARY,"From randomization, to end of treatment plus 30 days, up to approximately 6 years"
outcome,NCT01327846::outcome::primary::2,NCT01327846,Substudy 1 (Core Phase): Change From Baseline in Carotid Plaque Burden in the Bifurcation Region of the Index Carotid Artery,,,,,,,,,,,,,PRIMARY,24 months
outcome,NCT01327846::outcome::primary::3,NCT01327846,"Substudy 2 (Core Phase): Change From Baseline of the Insulin Secretion Rate (ISR) Relative to Glucose 0-30 Min Defined as Φ30 = AUCISR 0-30 / AUCGluc 0-30 Averaged Across the Year 3, 4, 5 Visits",,,,,,,,,,,,,PRIMARY,From randomization up to approximately 6 years
country,NCT01327846::country::United States,NCT01327846,United States,,,,,,,,,,,,,,
country,NCT01327846::country::Germany,NCT01327846,Germany,,,,,,,,,,,,,,
country,NCT01327846::country::Argentina,NCT01327846,Argentina,,,,,,,,,,,,,,
country,NCT01327846::country::Russia,NCT01327846,Russia,,,,,,,,,,,,,,
country,NCT01327846::country::India,NCT01327846,India,,,,,,,,,,,,,,
country,NCT01327846::country::Japan,NCT01327846,Japan,,,,,,,,,,,,,,
country,NCT01327846::country::Canada,NCT01327846,Canada,,,,,,,,,,,,,,
country,NCT01327846::country::Italy,NCT01327846,Italy,,,,,,,,,,,,,,
country,NCT01327846::country::Brazil,NCT01327846,Brazil,,,,,,,,,,,,,,
country,NCT01327846::country::China,NCT01327846,China,,,,,,,,,,,,,,
country,NCT01327846::country::United Kingdom,NCT01327846,United Kingdom,,,,,,,,,,,,,,
country,NCT01327846::country::Romania,NCT01327846,Romania,,,,,,,,,,,,,,
country,NCT01327846::country::Czechia,NCT01327846,Czechia,,,,,,,,,,,,,,
country,NCT01327846::country::Slovakia,NCT01327846,Slovakia,,,,,,,,,,,,,,
country,NCT01327846::country::Netherlands,NCT01327846,Netherlands,,,,,,,,,,,,,,
country,NCT01327846::country::Hungary,NCT01327846,Hungary,,,,,,,,,,,,,,
country,NCT01327846::country::Sweden,NCT01327846,Sweden,,,,,,,,,,,,,,
country,NCT01327846::country::Norway,NCT01327846,Norway,,,,,,,,,,,,,,
country,NCT01327846::country::Poland,NCT01327846,Poland,,,,,,,,,,,,,,
country,NCT01327846::country::Colombia,NCT01327846,Colombia,,,,,,,,,,,,,,
country,NCT01327846::country::Belgium,NCT01327846,Belgium,,,,,,,,,,,,,,
country,NCT01327846::country::South Korea,NCT01327846,South Korea,,,,,,,,,,,,,,
country,NCT01327846::country::Taiwan,NCT01327846,Taiwan,,,,,,,,,,,,,,
country,NCT01327846::country::Australia,NCT01327846,Australia,,,,,,,,,,,,,,
country,NCT01327846::country::Greece,NCT01327846,Greece,,,,,,,,,,,,,,
country,NCT01327846::country::South Africa,NCT01327846,South Africa,,,,,,,,,,,,,,
country,NCT01327846::country::Bulgaria,NCT01327846,Bulgaria,,,,,,,,,,,,,,
country,NCT01327846::country::Lithuania,NCT01327846,Lithuania,,,,,,,,,,,,,,
country,NCT01327846::country::Croatia,NCT01327846,Croatia,,,,,,,,,,,,,,
country,NCT01327846::country::Estonia,NCT01327846,Estonia,,,,,,,,,,,,,,
country,NCT01327846::country::Turkey (Türkiye),NCT01327846,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01327846::country::Austria,NCT01327846,Austria,,,,,,,,,,,,,,
country,NCT01327846::country::Mexico,NCT01327846,Mexico,,,,,,,,,,,,,,
country,NCT01327846::country::Puerto Rico,NCT01327846,Puerto Rico,,,,,,,,,,,,,,
country,NCT01327846::country::Latvia,NCT01327846,Latvia,,,,,,,,,,,,,,
country,NCT01327846::country::Guatemala,NCT01327846,Guatemala,,,,,,,,,,,,,,
country,NCT01327846::country::Peru,NCT01327846,Peru,,,,,,,,,,,,,,
country,NCT01327846::country::Serbia,NCT01327846,Serbia,,,,,,,,,,,,,,
country,NCT01327846::country::Iceland,NCT01327846,Iceland,,,,,,,,,,,,,,
country,NCT01327846::country::Slovenia,NCT01327846,Slovenia,,,,,,,,,,,,,,
trial,NCT04552041,NCT04552041,"Prospekta in the Treatment of Cognitive, Behavioral and Psychiatric Disorders in Patients With Vascular Dementia.",PHASE3,cardiovascular disease,Vascular Dementia,INDUSTRY,406.0,2020-12-03,2022-09-22,1.0,33.0,,,,,
arm,NCT04552041::arm::FG000,NCT04552041,Prospekta,,,,,,,,,,FG000,"Two tablets per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablets should be held in mouth until completely dis",,,
arm,NCT04552041::arm::FG001,NCT04552041,Placebo,,,,,,,,,,FG001,"Two tablets per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablets should be held in mouth until completely dis",,,
period,NCT04552041::period::1,NCT04552041,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04552041::outcome::primary::1,NCT04552041,Change in Mean Montreal Сognitive Assessment (MoCA) Score,,,,,,,,,,,,,PRIMARY,"Baseline, 24 weeks"
country,NCT04552041::country::Russia,NCT04552041,Russia,,,,,,,,,,,,,,
trial,NCT01217476,NCT01217476,The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North Study,PHASE3,cardiovascular disease,Diabetic Foot Ulcer of Neuropathic Origin,INDUSTRY,207.0,2010-12,2013-03,10.0,37.0,,,,,
arm,NCT01217476::arm::FG000,NCT01217476,Trafermin,,,,,,,,,,FG000,"Trafermin 0.01% spray: For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If ",,,
arm,NCT01217476::arm::FG001,NCT01217476,Placebo,,,,,,,,,,FG001,"Matching placebo spray: For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If",,,
period,NCT01217476::period::1,NCT01217476,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01217476::outcome::primary::1,NCT01217476,"Wound Closure Rate of Diabetic Foot Ulcers (DFUs) of Neuropathic Origin After a Maximum of 12 Weeks Topical Daily Application of Trafermin 0.01% Spray Compared With Placebo, in Addition to Best Local Cares",,,,,,,,,,,,,PRIMARY,12 weeks
country,NCT01217476::country::Poland,NCT01217476,Poland,,,,,,,,,,,,,,
country,NCT01217476::country::Germany,NCT01217476,Germany,,,,,,,,,,,,,,
country,NCT01217476::country::Netherlands,NCT01217476,Netherlands,,,,,,,,,,,,,,
country,NCT01217476::country::Slovakia,NCT01217476,Slovakia,,,,,,,,,,,,,,
country,NCT01217476::country::Belgium,NCT01217476,Belgium,,,,,,,,,,,,,,
country,NCT01217476::country::Croatia,NCT01217476,Croatia,,,,,,,,,,,,,,
country,NCT01217476::country::Hungary,NCT01217476,Hungary,,,,,,,,,,,,,,
country,NCT01217476::country::Sweden,NCT01217476,Sweden,,,,,,,,,,,,,,
country,NCT01217476::country::Bulgaria,NCT01217476,Bulgaria,,,,,,,,,,,,,,
country,NCT01217476::country::Denmark,NCT01217476,Denmark,,,,,,,,,,,,,,
trial,NCT01975246,NCT01975246,Add-on to Micamlo BP Trial,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,309.0,2013-11,2014-07,1.0,30.0,,,,,
arm,NCT01975246::arm::FG000,NCT01975246,Telmisartan and Amlodipine+HCTZ,,,,,,,,,,FG000,Subjects who were orally administered once daily with fixed dose combination (FDC) tablet of telmisartan 80 mg and amlodipine 5 mg+ hydrochlorothiazide (HCTZ) 12.5 mg tablet.,,,
arm,NCT01975246::arm::FG001,NCT01975246,Telmisartan+Amlodipine,,,,,,,,,,FG001,Subjects who were orally administered once daily with the fixed-dose combination tablet of telmisartan 80 mg and amlodipine 5 mg + placebo matching to hydrochlorothiazide 12.5 mg tablet,,,
period,NCT01975246::period::1,NCT01975246,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01975246::outcome::primary::1,NCT01975246,Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period.,,,,,,,,,,,,,PRIMARY,baseline and week 8
country,NCT01975246::country::Japan,NCT01975246,Japan,,,,,,,,,,,,,,
trial,NCT00445003,NCT00445003,Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy,PHASE3,cardiovascular disease,Proliferative Diabetic Retinopathy; Diabetic Macular Edema,OTHER,333.0,2007-03,2010-07,1.0,56.0,,,,,
arm,NCT00445003::arm::FG000,NCT00445003,Sham Injection,,,,,,,,,,FG000,Sham injection at baseline and 4 weeks,,,
arm,NCT00445003::arm::FG001,NCT00445003,0.5mg Ranibizumab,,,,,,,,,,FG001,Intravitreal injections of 0.5mg Ranibizumab at baseline and at 4 weeks,,,
arm,NCT00445003::arm::FG002,NCT00445003,4-mg Triamcinolone Acetonided,,,,,,,,,,FG002,4-mg Triamcinolone Acetonide at baseline and sham injection at 4 weeks,,,
period,NCT00445003::period::1,NCT00445003,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00445003::outcome::primary::1,NCT00445003,Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 14 Weeks,,,,,,,,,,,,,PRIMARY,baseline to 14 weeks
country,NCT00445003::country::United States,NCT00445003,United States,,,,,,,,,,,,,,
trial,NCT00425373,NCT00425373,Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension,PHASE3,cardiovascular disease,Essential Hypertension,INDUSTRY,1474.0,2006-11,2008-03,1.0,1.0,,,,,
arm,NCT00425373::arm::FG000,NCT00425373,Valsartan + Amlodipine 40/2.5 mg,,,,,,,,,,FG000,Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily,,,
arm,NCT00425373::arm::FG001,NCT00425373,Valsartan + Amlodipine 40/5 mg,,,,,,,,,,FG001,Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily,,,
arm,NCT00425373::arm::FG002,NCT00425373,Valsartan + Amlodipine 80/2.5 mg,,,,,,,,,,FG002,Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily,,,
arm,NCT00425373::arm::FG003,NCT00425373,Valsartan + Amlodipine 80/5 mg,,,,,,,,,,FG003,Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily,,,
arm,NCT00425373::arm::FG004,NCT00425373,Valsartan 40 mg,,,,,,,,,,FG004,Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily,,,
arm,NCT00425373::arm::FG005,NCT00425373,Valsartan 80 mg,,,,,,,,,,FG005,Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily,,,
arm,NCT00425373::arm::FG006,NCT00425373,Amlodipine 2.5 mg,,,,,,,,,,FG006,Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily,,,
arm,NCT00425373::arm::FG007,NCT00425373,Amlodipine 5 mg,,,,,,,,,,FG007,Amlodipine 5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily,,,
arm,NCT00425373::arm::FG008,NCT00425373,Placebo,,,,,,,,,,FG008,4 tablet and 2 capsule placebos taken once daily,,,
period,NCT00425373::period::1,NCT00425373,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00425373::outcome::primary::1,NCT00425373,Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to End of Study (Week 8),,,,,,,,,,,,,PRIMARY,Baseline to end of study (Week 8)
country,NCT00425373::country::Japan,NCT00425373,Japan,,,,,,,,,,,,,,
trial,NCT01176240,NCT01176240,A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease,PHASE3,cardiovascular disease,Orthostatic Hypotension; Parkinson's Disease,INDUSTRY,225.0,2010-06,2012-11,1.0,60.0,,,,,
arm,NCT01176240::arm::FG000,NCT01176240,Droxidopa,,,,,,,,,,FG000,"droxidopa active drug

Droxidopa: 100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment",,,
arm,NCT01176240::arm::FG001,NCT01176240,Placebo,,,,,,,,,,FG001,"Placebo matched control

Placebo: Placebo",,,
period,NCT01176240::period::1,NCT01176240,Study 306A,,,,,,,,,,,,1.0,,
period,NCT01176240::period::2,NCT01176240,Study 306B,,,,,,,,,,,,2.0,,
outcome,NCT01176240::outcome::primary::1,NCT01176240,306A Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ),,,,,,,,,,,,,PRIMARY,"Baseline, Week 8"
outcome,NCT01176240::outcome::primary::2,NCT01176240,306B Efficacy: Change in Dizziness/Lightheadedness/Feeling Faint/Feeling Like You Might Black Out (OHSA Item 1),,,,,,,,,,,,,PRIMARY,"Baseline, Week1"
country,NCT01176240::country::United States,NCT01176240,United States,,,,,,,,,,,,,,
trial,NCT04576988,NCT04576988,A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR),PHASE3,cardiovascular disease,Pulmonary Arterial Hypertension,INDUSTRY,324.0,2021-01-25,2022-12-06,21.0,120.0,,,,,
arm,NCT04576988::arm::FG000,NCT04576988,Sotatercept Plus Background PAH Therapy,,,,,,,,,,FG000,Participants received a starting dose of sotatercept 0.3 mg/kg titrated up to 0.7mg/kg by subcutaneous (SC) injection every 21 days plus background PAH therapy during the double-blind placebo controll,,,
arm,NCT04576988::arm::FG001,NCT04576988,Placebo Plus Background PAH Therapy,,,,,,,,,,FG001,Participants received dose matched placebo by SC injection every 21 days plus background PAH therapy during the DBPC period for up to approximately 24 weeks and the LTDB period for up to approximately,,,
period,NCT04576988::period::1,NCT04576988,Double Blind Placebo Controlled (DBPC),,,,,,,,,,,,1.0,,
period,NCT04576988::period::2,NCT04576988,Long Term Double Blind (LTDB),,,,,,,,,,,,2.0,,
outcome,NCT04576988::outcome::primary::1,NCT04576988,Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and Week 24
outcome,NCT04576988::outcome::primary::2,NCT04576988,Number of Participants Who Experienced an Adverse Event (AE),,,,,,,,,,,,,PRIMARY,Up to approximately 24 weeks
outcome,NCT04576988::outcome::primary::3,NCT04576988,Number of Participants Who Discontinued Study Treatment Due to an AE,,,,,,,,,,,,,PRIMARY,Up to approximately 24 weeks
country,NCT04576988::country::United States,NCT04576988,United States,,,,,,,,,,,,,,
country,NCT04576988::country::France,NCT04576988,France,,,,,,,,,,,,,,
country,NCT04576988::country::Germany,NCT04576988,Germany,,,,,,,,,,,,,,
country,NCT04576988::country::Spain,NCT04576988,Spain,,,,,,,,,,,,,,
country,NCT04576988::country::Australia,NCT04576988,Australia,,,,,,,,,,,,,,
country,NCT04576988::country::Argentina,NCT04576988,Argentina,,,,,,,,,,,,,,
country,NCT04576988::country::Israel,NCT04576988,Israel,,,,,,,,,,,,,,
country,NCT04576988::country::United Kingdom,NCT04576988,United Kingdom,,,,,,,,,,,,,,
country,NCT04576988::country::Brazil,NCT04576988,Brazil,,,,,,,,,,,,,,
country,NCT04576988::country::Canada,NCT04576988,Canada,,,,,,,,,,,,,,
country,NCT04576988::country::Czechia,NCT04576988,Czechia,,,,,,,,,,,,,,
country,NCT04576988::country::Mexico,NCT04576988,Mexico,,,,,,,,,,,,,,
country,NCT04576988::country::New Zealand,NCT04576988,New Zealand,,,,,,,,,,,,,,
country,NCT04576988::country::Poland,NCT04576988,Poland,,,,,,,,,,,,,,
country,NCT04576988::country::Serbia,NCT04576988,Serbia,,,,,,,,,,,,,,
country,NCT04576988::country::South Korea,NCT04576988,South Korea,,,,,,,,,,,,,,
country,NCT04576988::country::Belgium,NCT04576988,Belgium,,,,,,,,,,,,,,
country,NCT04576988::country::Netherlands,NCT04576988,Netherlands,,,,,,,,,,,,,,
country,NCT04576988::country::Sweden,NCT04576988,Sweden,,,,,,,,,,,,,,
country,NCT04576988::country::Switzerland,NCT04576988,Switzerland,,,,,,,,,,,,,,
country,NCT04576988::country::Italy,NCT04576988,Italy,,,,,,,,,,,,,,
trial,NCT01115855,NCT01115855,Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure,PHASE3,cardiovascular disease,Heart Failure,INDUSTRY,221.0,2010-07,2015-09,1.0,54.0,,,,,
arm,NCT01115855::arm::FG000,NCT01115855,Eplerenone,,,,,,,,,,FG000,Participants with estimated glomerular filtration rate (eGFR) greater than or equal to (\>=) 50 milliliter per minute divided by 1.73 squared meter (mL/min/1.73m\^2) received eplerenone 25 milligram (,,,
arm,NCT01115855::arm::FG001,NCT01115855,Placebo,,,,,,,,,,FG001,Participants with eGFR \>=50 mL/min/1.73m\^2 received placebo matched with eplerenone tablet orally once daily from up to Week 4 and participants with eGFR 30 to \<50 mL/min/1.73m\^2 received placebo ,,,
period,NCT01115855::period::1,NCT01115855,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01115855::outcome::primary::1,NCT01115855,Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF),,,,,,,,,,,,,PRIMARY,Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)
country,NCT01115855::country::Japan,NCT01115855,Japan,,,,,,,,,,,,,,
trial,NCT02440022,NCT02440022,Study Comparing Lutonix AV Drug Coated Balloon vs Standard Balloon for Treatment of Dysfunctional AV Fistulae,PHASE3,cardiovascular disease,Arteriovenous Fistula,INDUSTRY,285.0,2015-06,2018-06,1.0,23.0,,,,,
arm,NCT02440022::arm::FG000,NCT02440022,Lutonix DCB,,,,,,,,,,FG000,"Percutaneous transluminal angiography (PTA) will be performed using the Lutonix AV drug coated balloon.

Lutonix DCB

Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA)",,,
arm,NCT02440022::arm::FG001,NCT02440022,Standard Balloon Angioplasty Catheter,,,,,,,,,,FG001,"Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar mo",,,
period,NCT02440022::period::1,NCT02440022,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02440022::outcome::primary::1,NCT02440022,Percentage of Participants With Target Lesion Primary Patency (TLPP) at 6 Months Post Index Procedure,,,,,,,,,,,,,PRIMARY,6 months post index procedure
outcome,NCT02440022::outcome::primary::2,NCT02440022,Number of Participants With Freedom From Any Serious Adverse Event(s) Involving the AV Access Circuit at 30 Days Post Index Procedure.,,,,,,,,,,,,,PRIMARY,30 Days Post Index Procedure
country,NCT02440022::country::United States,NCT02440022,United States,,,,,,,,,,,,,,
trial,NCT00345631,NCT00345631,Safety and Effectiveness Study of the Ensure Medical Vascular Closure Device,PHASE3,cardiovascular disease,"Angioplasty, Transluminal, Percutaneous Coronary; Coronary Arteriosclerosis; Peripheral Arteriosclerosis",INDUSTRY,488.0,2007-02,2007-09,1.0,17.0,,,,,
arm,NCT00345631::arm::FG000,NCT00345631,Roll-In,,,,,,,,,,FG000,Roll-In patients were device training patients,,,
arm,NCT00345631::arm::FG001,NCT00345631,Vascular Closure Device,,,,,,,,,,FG001,"Ensure Medical Vascular Closure Device (VCD) have been developed to avoid manual compression, shorten bed rest, and allow earlier ambulation.",,,
arm,NCT00345631::arm::FG002,NCT00345631,Manual Compression,,,,,,,,,,FG002,Traditionally Hemostasis at the femoral artery access site after diagnostic or interventional procedures is typically achieved using either manual compression (with or without the use of adjunctive me,,,
period,NCT00345631::period::1,NCT00345631,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00345631::outcome::primary::1,NCT00345631,Time to Hemostasis (TTH),,,,,,,,,,,,,PRIMARY,From when the introducer sheath was removed to the time hemostasis was first observed
outcome,NCT00345631::outcome::primary::2,NCT00345631,Time to Ambulation (TTA),,,,,,,,,,,,,PRIMARY,From when the introducer sheath was removed to 30 days post-procedure
outcome,NCT00345631::outcome::primary::3,NCT00345631,Percentage of Patients Who Experience Any Vascular Closure Related Major Adverse Events During the 30 Days Post-procedure,,,,,,,,,,,,,PRIMARY,From post-procedure to 30 days follow up
country,NCT00345631::country::United States,NCT00345631,United States,,,,,,,,,,,,,,
trial,NCT01712789,NCT01712789,Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma,PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,682.0,2012-11-06,2019-12-11,20.0,112.0,,,,,
arm,NCT01712789::arm::FG000,NCT01712789,Pomalidomide Plus Low Dose Dexamethasone (LD-Dex),,,,,,,,,,FG000,Participants received 4 mg pomalidomide (POM) by mouth (PO) on Days 1 to 21 of each 28-day treatment cycle and low dose dexamethasone (LD-Dex) PO at the starting dose of 40 mg/day (≤ 75 years old) or ,,,
period,NCT01712789::period::1,NCT01712789,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01712789::outcome::primary::1,NCT01712789,Number of Participants With Treatment Emergent Adverse Events (TEAE),,,,,,,,,,,,,PRIMARY,From the first dose of study treatment up to 28 days following the last dose of study treatment. The median duration of treatment with pomalidomide and LD-dex was 21.4 weeks.
country,NCT01712789::country::Germany,NCT01712789,Germany,,,,,,,,,,,,,,
country,NCT01712789::country::Italy,NCT01712789,Italy,,,,,,,,,,,,,,
country,NCT01712789::country::Spain,NCT01712789,Spain,,,,,,,,,,,,,,
country,NCT01712789::country::France,NCT01712789,France,,,,,,,,,,,,,,
country,NCT01712789::country::United Kingdom,NCT01712789,United Kingdom,,,,,,,,,,,,,,
country,NCT01712789::country::Belgium,NCT01712789,Belgium,,,,,,,,,,,,,,
country,NCT01712789::country::Netherlands,NCT01712789,Netherlands,,,,,,,,,,,,,,
country,NCT01712789::country::Austria,NCT01712789,Austria,,,,,,,,,,,,,,
country,NCT01712789::country::Portugal,NCT01712789,Portugal,,,,,,,,,,,,,,
country,NCT01712789::country::Denmark,NCT01712789,Denmark,,,,,,,,,,,,,,
country,NCT01712789::country::Ireland,NCT01712789,Ireland,,,,,,,,,,,,,,
country,NCT01712789::country::Poland,NCT01712789,Poland,,,,,,,,,,,,,,
country,NCT01712789::country::Switzerland,NCT01712789,Switzerland,,,,,,,,,,,,,,
country,NCT01712789::country::Finland,NCT01712789,Finland,,,,,,,,,,,,,,
country,NCT01712789::country::Norway,NCT01712789,Norway,,,,,,,,,,,,,,
country,NCT01712789::country::Sweden,NCT01712789,Sweden,,,,,,,,,,,,,,
country,NCT01712789::country::Turkey (Türkiye),NCT01712789,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01712789::country::Estonia,NCT01712789,Estonia,,,,,,,,,,,,,,
country,NCT01712789::country::Greece,NCT01712789,Greece,,,,,,,,,,,,,,
country,NCT01712789::country::Slovakia,NCT01712789,Slovakia,,,,,,,,,,,,,,
trial,NCT04509674,NCT04509674,EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction),PHASE3,cardiovascular disease,Myocardial Infarction,INDUSTRY,6522.0,2020-12-16,2023-11-05,22.0,439.0,,,,,
arm,NCT04509674::arm::FG000,NCT04509674,Placebo,,,,,,,,,,FG000,"Patients with an acute myocardial infarction event took, on top of standard of care, one placebo matching-empagliflozin 10 milligrams (mg) film-coated tablet, orally, once daily, at the same time ever",,,
arm,NCT04509674::arm::FG001,NCT04509674,Empagliflozin 10 mg,,,,,,,,,,FG001,"Patients with an acute myocardial infarction event took, on top of standard of care, one empagliflozin (Jardiance®) 10 milligrams (mg) film-coated tablet, orally, once daily, at the same time every mo",,,
period,NCT04509674::period::1,NCT04509674,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04509674::outcome::primary::1,NCT04509674,Composite of Time to First Heart Failure Hospitalisation or All-cause Mortality,,,,,,,,,,,,,PRIMARY,"From randomisation or first study drug administration (if randomisation occurred after first drug administration), until individual day of trial completion. Up to 1004 days."
country,NCT04509674::country::United States,NCT04509674,United States,,,,,,,,,,,,,,
country,NCT04509674::country::Japan,NCT04509674,Japan,,,,,,,,,,,,,,
country,NCT04509674::country::Canada,NCT04509674,Canada,,,,,,,,,,,,,,
country,NCT04509674::country::Brazil,NCT04509674,Brazil,,,,,,,,,,,,,,
country,NCT04509674::country::Netherlands,NCT04509674,Netherlands,,,,,,,,,,,,,,
country,NCT04509674::country::Israel,NCT04509674,Israel,,,,,,,,,,,,,,
country,NCT04509674::country::Poland,NCT04509674,Poland,,,,,,,,,,,,,,
country,NCT04509674::country::Argentina,NCT04509674,Argentina,,,,,,,,,,,,,,
country,NCT04509674::country::Romania,NCT04509674,Romania,,,,,,,,,,,,,,
country,NCT04509674::country::China,NCT04509674,China,,,,,,,,,,,,,,
country,NCT04509674::country::Germany,NCT04509674,Germany,,,,,,,,,,,,,,
country,NCT04509674::country::Ukraine,NCT04509674,Ukraine,,,,,,,,,,,,,,
country,NCT04509674::country::Bulgaria,NCT04509674,Bulgaria,,,,,,,,,,,,,,
country,NCT04509674::country::Russia,NCT04509674,Russia,,,,,,,,,,,,,,
country,NCT04509674::country::Hungary,NCT04509674,Hungary,,,,,,,,,,,,,,
country,NCT04509674::country::Serbia,NCT04509674,Serbia,,,,,,,,,,,,,,
country,NCT04509674::country::India,NCT04509674,India,,,,,,,,,,,,,,
country,NCT04509674::country::Australia,NCT04509674,Australia,,,,,,,,,,,,,,
country,NCT04509674::country::France,NCT04509674,France,,,,,,,,,,,,,,
country,NCT04509674::country::South Korea,NCT04509674,South Korea,,,,,,,,,,,,,,
country,NCT04509674::country::Denmark,NCT04509674,Denmark,,,,,,,,,,,,,,
country,NCT04509674::country::Spain,NCT04509674,Spain,,,,,,,,,,,,,,
trial,NCT00617123,NCT00617123,Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183),PHASE3,cardiovascular disease,Atherosclerosis; Ischemia; Myocardial Infarction; Cerebrovascular Accident,INDUSTRY,258.0,2008-07-01,2010-10-01,0.0,0.0,,,,,
arm,NCT00617123::arm::FG000,NCT00617123,Vorapaxar,,,,,,,,,,FG000,Participants receive a vorapaxar 2.5 mg tablet administered orally once daily for 1 year,,,
arm,NCT00617123::arm::FG001,NCT00617123,Placebo,,,,,,,,,,FG001,Participants receive a matching placebo tablet to vorapaxar administered orally once daily for 1 year,,,
period,NCT00617123::period::1,NCT00617123,Referral Screening Period,,,,,,,,,,,,1.0,,
period,NCT00617123::period::2,NCT00617123,Study Treatment Period,,,,,,,,,,,,2.0,,
outcome,NCT00617123::outcome::primary::1,NCT00617123,Number of Participants Who Develop Vacuolization in the Inner Nuclear Layer (INL) of the Retina as Measured by Ocular Coherence Tomography (OCT),,,,,,,,,,,,,PRIMARY,Up to 12 months
trial,NCT00987389,NCT00987389,Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis,PHASE3,cardiovascular disease,Granulomatosis With Polyangiitis (Wegener's) (GPA); Microscopic Polyangiitis (MPA),OTHER,704.0,2010-05,2017-08,15.0,98.0,,,,,
arm,NCT00987389::arm::FG000,NCT00987389,Plasma Exchange With Standard Glucocorticoids,,,,,,,,,,FG000,"Plasma Exchange: Plasma exchange is a procedure whereby blood is taken from the body and separated by a machine into blood cells and plasma, which is the liquid part of blood. The plasma is discarded ",,,
arm,NCT00987389::arm::FG001,NCT00987389,Plasma Exchange With Reduced Glucocorticoids,,,,,,,,,,FG001,"Plasma Exchange: Plasma exchange is a procedure whereby blood is taken from the body and separated by a machine into blood cells and plasma, which is the liquid part of blood. The plasma is discarded ",,,
arm,NCT00987389::arm::FG002,NCT00987389,No Plasma Exchange With Standard Glucocorticoids,,,,,,,,,,FG002,"Participants in this arm do not undergo plasma exchange.

Glucocorticoids: During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All sub",,,
arm,NCT00987389::arm::FG003,NCT00987389,No Plasma Exchange With Reduced Glucocorticoid,,,,,,,,,,FG003,"Participants in this arm do not undergo plasma exchange.

All subjects' received the same glucocorticoids dose for the first two weeks, then the dose was decreased following a reduced glucocorticoid d",,,
period,NCT00987389::period::1,NCT00987389,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00987389::outcome::primary::1,NCT00987389,Composite of i) All-cause Mortality or ii) End-stage Renal Disease,,,,,,,,,,,,,PRIMARY,Time frame varied by subject: minimum of 1 year - maximum of 7 years
country,NCT00987389::country::United Kingdom,NCT00987389,United Kingdom,,,,,,,,,,,,,,
country,NCT00987389::country::Australia,NCT00987389,Australia,,,,,,,,,,,,,,
country,NCT00987389::country::France,NCT00987389,France,,,,,,,,,,,,,,
country,NCT00987389::country::United States,NCT00987389,United States,,,,,,,,,,,,,,
country,NCT00987389::country::Canada,NCT00987389,Canada,,,,,,,,,,,,,,
country,NCT00987389::country::Japan,NCT00987389,Japan,,,,,,,,,,,,,,
country,NCT00987389::country::Denmark,NCT00987389,Denmark,,,,,,,,,,,,,,
country,NCT00987389::country::New Zealand,NCT00987389,New Zealand,,,,,,,,,,,,,,
country,NCT00987389::country::Sweden,NCT00987389,Sweden,,,,,,,,,,,,,,
country,NCT00987389::country::Italy,NCT00987389,Italy,,,,,,,,,,,,,,
country,NCT00987389::country::Norway,NCT00987389,Norway,,,,,,,,,,,,,,
country,NCT00987389::country::Belgium,NCT00987389,Belgium,,,,,,,,,,,,,,
country,NCT00987389::country::Czechia,NCT00987389,Czechia,,,,,,,,,,,,,,
country,NCT00987389::country::Greece,NCT00987389,Greece,,,,,,,,,,,,,,
country,NCT00987389::country::Mexico,NCT00987389,Mexico,,,,,,,,,,,,,,
trial,NCT03735979,NCT03735979,Multi-arm Optimization of Stroke Thrombolysis,PHASE3,cardiovascular disease,Acute Ischemic Stroke,OTHER,514.0,2019-10-15,2024-10-31,1.0,61.0,,,,,
arm,NCT03735979::arm::FG000,NCT03735979,Argatroban,,,,,,,,,,FG000,100µg/kg bolus followed by 3µg/kg per minute for 12 hours,,,
arm,NCT03735979::arm::FG001,NCT03735979,Eptifibatide,,,,,,,,,,FG001,135µg/kg bolus followed by 0.75µg/kg/min infusion for two hours,,,
arm,NCT03735979::arm::FG002,NCT03735979,Placebo,,,,,,,,,,FG002,Placebo: IV placebo solution,,,
period,NCT03735979::period::1,NCT03735979,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03735979::outcome::primary::1,NCT03735979,90-day Utility Weighted Modified Rankin Scores (UW-mRS),,,,,,,,,,,,,PRIMARY,90 days after randomization
country,NCT03735979::country::United States,NCT03735979,United States,,,,,,,,,,,,,,
trial,NCT00249873,NCT00249873,Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A),PHASE3,cardiovascular disease,Atrial Fibrillation; Vascular Risk,INDUSTRY,7554.0,2003-06,2009-03,30.0,30.0,,,,,
arm,NCT00249873::arm::FG000,NCT00249873,Clopidogrel + ASA,,,,,,,,,,FG000,Clopidogrel 75 mg once daily (od) plus acetylsalicyclic acid (ASA) 75 to 100 mg od recommended (dose at the investigators' discretion),,,
arm,NCT00249873::arm::FG001,NCT00249873,Placebo + ASA,,,,,,,,,,FG001,Matching placebo of clopidogrel 75 mg od plus ASA 75 to 100 mg od recommended (dose at the investigators' discretion),,,
period,NCT00249873::period::1,NCT00249873,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00249873::outcome::primary::1,NCT00249873,"First Occurence of Any Component of the Composite of Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism, Myocardial Infarction or Vascular Death as Per Adjudication",,,,,,,,,,,,,PRIMARY,expected median follow-up of approximately 3 years
country,NCT00249873::country::United States,NCT00249873,United States,,,,,,,,,,,,,,
country,NCT00249873::country::Argentina,NCT00249873,Argentina,,,,,,,,,,,,,,
country,NCT00249873::country::Australia,NCT00249873,Australia,,,,,,,,,,,,,,
country,NCT00249873::country::Austria,NCT00249873,Austria,,,,,,,,,,,,,,
country,NCT00249873::country::Belgium,NCT00249873,Belgium,,,,,,,,,,,,,,
country,NCT00249873::country::Brazil,NCT00249873,Brazil,,,,,,,,,,,,,,
country,NCT00249873::country::Canada,NCT00249873,Canada,,,,,,,,,,,,,,
country,NCT00249873::country::Chile,NCT00249873,Chile,,,,,,,,,,,,,,
country,NCT00249873::country::Czechia,NCT00249873,Czechia,,,,,,,,,,,,,,
country,NCT00249873::country::Denmark,NCT00249873,Denmark,,,,,,,,,,,,,,
country,NCT00249873::country::Finland,NCT00249873,Finland,,,,,,,,,,,,,,
country,NCT00249873::country::France,NCT00249873,France,,,,,,,,,,,,,,
country,NCT00249873::country::Germany,NCT00249873,Germany,,,,,,,,,,,,,,
country,NCT00249873::country::Greece,NCT00249873,Greece,,,,,,,,,,,,,,
country,NCT00249873::country::Hong Kong,NCT00249873,Hong Kong,,,,,,,,,,,,,,
country,NCT00249873::country::Hungary,NCT00249873,Hungary,,,,,,,,,,,,,,
country,NCT00249873::country::Italy,NCT00249873,Italy,,,,,,,,,,,,,,
country,NCT00249873::country::Malaysia,NCT00249873,Malaysia,,,,,,,,,,,,,,
country,NCT00249873::country::Mexico,NCT00249873,Mexico,,,,,,,,,,,,,,
country,NCT00249873::country::Netherlands,NCT00249873,Netherlands,,,,,,,,,,,,,,
country,NCT00249873::country::Norway,NCT00249873,Norway,,,,,,,,,,,,,,
country,NCT00249873::country::Poland,NCT00249873,Poland,,,,,,,,,,,,,,
country,NCT00249873::country::Portugal,NCT00249873,Portugal,,,,,,,,,,,,,,
country,NCT00249873::country::Singapore,NCT00249873,Singapore,,,,,,,,,,,,,,
country,NCT00249873::country::South Africa,NCT00249873,South Africa,,,,,,,,,,,,,,
country,NCT00249873::country::Spain,NCT00249873,Spain,,,,,,,,,,,,,,
country,NCT00249873::country::Sweden,NCT00249873,Sweden,,,,,,,,,,,,,,
country,NCT00249873::country::Switzerland,NCT00249873,Switzerland,,,,,,,,,,,,,,
country,NCT00249873::country::Taiwan,NCT00249873,Taiwan,,,,,,,,,,,,,,
country,NCT00249873::country::United Kingdom,NCT00249873,United Kingdom,,,,,,,,,,,,,,
trial,NCT01499953,NCT01499953,Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux,PHASE3,cardiovascular disease,Superficial Vein Thrombosis,OTHER,472.0,2012-04,2016-05,1.0,23.0,,,,,
arm,NCT01499953::arm::FG000,NCT01499953,Fondaparinux,,,,,,,,,,FG000,"Fondaparinux for 45 days subcutaneous application: 2,5 mg OD

Fondaparinux: Fondaparinux Dose: 2.5 mg Duration: 45 (±5) days Frequency: once daily Application: subcutaneous",,,
arm,NCT01499953::arm::FG001,NCT01499953,Rivaroxaban,,,,,,,,,,FG001,"Rivaroxaban for 45 days oral dose: 10 mg OD

Rivaroxaban: Dose: 10 mg Duration: 45 (±5) days Frequency: once daily Application: oral",,,
period,NCT01499953::period::1,NCT01499953,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01499953::outcome::primary::1,NCT01499953,Rate of Objectively Confirmed VTE Complications,,,,,,,,,,,,,PRIMARY,45 +/- 5 days
country,NCT01499953::country::Germany,NCT01499953,Germany,,,,,,,,,,,,,,
trial,NCT00732641,NCT00732641,Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7),PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,244.0,2000-12,2010-11,0.0,0.0,,,,,
arm,NCT00732641::arm::FG000,NCT00732641,Peginterferon α-2b,,,,,,,,,,FG000,"Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.",,,
arm,NCT00732641::arm::FG001,NCT00732641,No Treatment,,,,,,,,,,FG001,Participants were observed and received no treatment,,,
period,NCT00732641::period::1,NCT00732641,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00732641::outcome::primary::1,NCT00732641,Number of Days With Progression Free Survival (PFS),,,,,,,,,,,,,PRIMARY,Baseline and up to 5 years (or to the date of the first documented tumor progression or relapse)
trial,NCT00240331,NCT00240331,AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD),PHASE3,cardiovascular disease,Renal Failure,INDUSTRY,2776.0,2003-01,2008-10,25.0,239.0,,,,,
arm,NCT00240331::arm::FG000,NCT00240331,Rosuvastatin 10mg,,,,,,,,,,FG000,Rosuvastatin 10 mg oral tablets,,,
arm,NCT00240331::arm::FG001,NCT00240331,Placebo,,,,,,,,,,FG001,Matching placebo,,,
period,NCT00240331::period::1,NCT00240331,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00240331::outcome::primary::1,NCT00240331,"Number of Randomised Participants With a Major Cardiovascular Event (Non-fatal Stroke, Non-fatal Myocardial Infarction or Cardiovascular Death)",,,,,,,,,,,,,PRIMARY,Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years
country,NCT00240331::country::France,NCT00240331,France,,,,,,,,,,,,,,
country,NCT00240331::country::Germany,NCT00240331,Germany,,,,,,,,,,,,,,
country,NCT00240331::country::Canada,NCT00240331,Canada,,,,,,,,,,,,,,
country,NCT00240331::country::United Kingdom,NCT00240331,United Kingdom,,,,,,,,,,,,,,
country,NCT00240331::country::Netherlands,NCT00240331,Netherlands,,,,,,,,,,,,,,
country,NCT00240331::country::Sweden,NCT00240331,Sweden,,,,,,,,,,,,,,
country,NCT00240331::country::Denmark,NCT00240331,Denmark,,,,,,,,,,,,,,
country,NCT00240331::country::Finland,NCT00240331,Finland,,,,,,,,,,,,,,
country,NCT00240331::country::Norway,NCT00240331,Norway,,,,,,,,,,,,,,
country,NCT00240331::country::Italy,NCT00240331,Italy,,,,,,,,,,,,,,
country,NCT00240331::country::Poland,NCT00240331,Poland,,,,,,,,,,,,,,
country,NCT00240331::country::Austria,NCT00240331,Austria,,,,,,,,,,,,,,
country,NCT00240331::country::Turkey (Türkiye),NCT00240331,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00240331::country::Czechia,NCT00240331,Czechia,,,,,,,,,,,,,,
country,NCT00240331::country::Hungary,NCT00240331,Hungary,,,,,,,,,,,,,,
country,NCT00240331::country::Mexico,NCT00240331,Mexico,,,,,,,,,,,,,,
country,NCT00240331::country::Belgium,NCT00240331,Belgium,,,,,,,,,,,,,,
country,NCT00240331::country::Switzerland,NCT00240331,Switzerland,,,,,,,,,,,,,,
country,NCT00240331::country::Greece,NCT00240331,Greece,,,,,,,,,,,,,,
country,NCT00240331::country::Bulgaria,NCT00240331,Bulgaria,,,,,,,,,,,,,,
country,NCT00240331::country::Australia,NCT00240331,Australia,,,,,,,,,,,,,,
country,NCT00240331::country::Brazil,NCT00240331,Brazil,,,,,,,,,,,,,,
country,NCT00240331::country::South Korea,NCT00240331,South Korea,,,,,,,,,,,,,,
country,NCT00240331::country::Iceland,NCT00240331,Iceland,,,,,,,,,,,,,,
country,NCT00240331::country::Ireland,NCT00240331,Ireland,,,,,,,,,,,,,,
trial,NCT01665053,NCT01665053,The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s),PHASE3,cardiovascular disease,Coronary Artery Disease,INDUSTRY,1684.0,2012-11,2018-12-22,16.0,126.0,,,,,
arm,NCT01665053::arm::FG000,NCT01665053,Promus Element Plus,,,,,,,,,,FG000,"PROMUS Element Plus is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of ",,,
arm,NCT01665053::arm::FG001,NCT01665053,SYNERGY,,,,,,,,,,FG001,"SYNERGY is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus c",,,
period,NCT01665053::period::1,NCT01665053,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01665053::outcome::primary::1,NCT01665053,Percentage of Participants With Target Lesion Failure (TLF) at 12 Months,,,,,,,,,,,,,PRIMARY,12 months
country,NCT01665053::country::United States,NCT01665053,United States,,,,,,,,,,,,,,
country,NCT01665053::country::Japan,NCT01665053,Japan,,,,,,,,,,,,,,
country,NCT01665053::country::France,NCT01665053,France,,,,,,,,,,,,,,
country,NCT01665053::country::Canada,NCT01665053,Canada,,,,,,,,,,,,,,
country,NCT01665053::country::Australia,NCT01665053,Australia,,,,,,,,,,,,,,
country,NCT01665053::country::Belgium,NCT01665053,Belgium,,,,,,,,,,,,,,
country,NCT01665053::country::New Zealand,NCT01665053,New Zealand,,,,,,,,,,,,,,
country,NCT01665053::country::Italy,NCT01665053,Italy,,,,,,,,,,,,,,
country,NCT01665053::country::Netherlands,NCT01665053,Netherlands,,,,,,,,,,,,,,
country,NCT01665053::country::Poland,NCT01665053,Poland,,,,,,,,,,,,,,
country,NCT01665053::country::Spain,NCT01665053,Spain,,,,,,,,,,,,,,
country,NCT01665053::country::Austria,NCT01665053,Austria,,,,,,,,,,,,,,
country,NCT01665053::country::Finland,NCT01665053,Finland,,,,,,,,,,,,,,
country,NCT01665053::country::Singapore,NCT01665053,Singapore,,,,,,,,,,,,,,
country,NCT01665053::country::Denmark,NCT01665053,Denmark,,,,,,,,,,,,,,
country,NCT01665053::country::Latvia,NCT01665053,Latvia,,,,,,,,,,,,,,
trial,NCT01492361,NCT01492361,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin,PHASE3,cardiovascular disease,Cardiovascular Diseases,INDUSTRY,8179.0,2011-11,2018-05,11.0,410.0,,,,,
arm,NCT01492361::arm::FG000,NCT01492361,AMR101,,,,,,,,,,FG000,AMR101: Parallel Assignment,,,
arm,NCT01492361::arm::FG001,NCT01492361,Placebo,,,,,,,,,,FG001,Placebo: Parallel Assignment,,,
period,NCT01492361::period::1,NCT01492361,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01492361::outcome::primary::1,NCT01492361,"Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization.",,,,,,,,,,,,,PRIMARY,Total follow-up time of up to approximately 6 years.
country,NCT01492361::country::United States,NCT01492361,United States,,,,,,,,,,,,,,
country,NCT01492361::country::Russia,NCT01492361,Russia,,,,,,,,,,,,,,
country,NCT01492361::country::Ukraine,NCT01492361,Ukraine,,,,,,,,,,,,,,
country,NCT01492361::country::Netherlands,NCT01492361,Netherlands,,,,,,,,,,,,,,
country,NCT01492361::country::South Africa,NCT01492361,South Africa,,,,,,,,,,,,,,
country,NCT01492361::country::Canada,NCT01492361,Canada,,,,,,,,,,,,,,
country,NCT01492361::country::India,NCT01492361,India,,,,,,,,,,,,,,
country,NCT01492361::country::Romania,NCT01492361,Romania,,,,,,,,,,,,,,
country,NCT01492361::country::Australia,NCT01492361,Australia,,,,,,,,,,,,,,
country,NCT01492361::country::Poland,NCT01492361,Poland,,,,,,,,,,,,,,
country,NCT01492361::country::New Zealand,NCT01492361,New Zealand,,,,,,,,,,,,,,
trial,NCT01012674,NCT01012674,Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF),PHASE3,cardiovascular disease,Cerebral Arterial Diseases,INDUSTRY,211.0,2009-10,2010-12,1.0,1.0,,,,,
arm,NCT01012674::arm::FG000,NCT01012674,TOF MRA Followed by Dotarem-enhanced MRA,,,,,,,,,,FG000,"Each patient will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem-enhanced MRA.

Each patient will be scheduled to undergo CTA either before TOF MRA or after ",,,
period,NCT01012674::period::1,NCT01012674,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01012674::outcome::primary::1,NCT01012674,Technical Failure Rate,,,,,,,,,,,,,PRIMARY,2 - 28 days
outcome,NCT01012674::outcome::primary::2,NCT01012674,Sensitivity,,,,,,,,,,,,,PRIMARY,2-42 days
outcome,NCT01012674::outcome::primary::3,NCT01012674,Specificity,,,,,,,,,,,,,PRIMARY,2 - 42 days
country,NCT01012674::country::United States,NCT01012674,United States,,,,,,,,,,,,,,
trial,NCT01627327,NCT01627327,Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease,PHASE3,cardiovascular disease,"Pulmonary Disease, Chronic Obstructive",INDUSTRY,623.0,2012-04-01,2012-12-21,6.0,54.0,,,,,
arm,NCT01627327::arm::FG000,NCT01627327,FF/VI 100/25 µg OD,,,,,,,,,,FG000,Participants received Fluticasone Furoate /Vilanterol (FF/VI) 100/25 micrograms (µg) inhalation once daily (OD) via a dry powder inhaler (DPI) and placebo inhalation OD via a HandiHaler in the morning,,,
arm,NCT01627327::arm::FG001,NCT01627327,TIO 18 µg OD,,,,,,,,,,FG001,Participants received tiotropium bromide (TIO) 18 µg inhalation OD via a HandiHaler and placebo inhalation OD via a DPI in the morning for 12 weeks.,,,
period,NCT01627327::period::1,NCT01627327,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01627327::outcome::primary::1,NCT01627327,Change From Baseline Trough in 24-hour Weighted Mean FEV1 on Treatment Day 84,,,,,,,,,,,,,PRIMARY,Baseline and Day 84
country,NCT01627327::country::Germany,NCT01627327,Germany,,,,,,,,,,,,,,
country,NCT01627327::country::United States,NCT01627327,United States,,,,,,,,,,,,,,
country,NCT01627327::country::Canada,NCT01627327,Canada,,,,,,,,,,,,,,
country,NCT01627327::country::Romania,NCT01627327,Romania,,,,,,,,,,,,,,
country,NCT01627327::country::Poland,NCT01627327,Poland,,,,,,,,,,,,,,
country,NCT01627327::country::Czechia,NCT01627327,Czechia,,,,,,,,,,,,,,
trial,NCT02197416,NCT02197416,Safety of Dabigatran Etexilate in Blood Clot Prevention in Children,PHASE3,cardiovascular disease,Venous Thromboembolism; Secondary Prevention,INDUSTRY,214.0,2014-09-29,2019-11-19,22.0,62.0,,,,,
arm,NCT02197416::arm::FG000,NCT02197416,Dabigatran Etexilate (0 to < 2 Years),,,,,,,,,,FG000,Single oral dose of dabigatran etexilate (DE) oral liquid formulation (OLF) ranging from 6.25 milligram(mg) to 143.75 mg was administrated twice daily in the morning and evening for participants aged ,,,
arm,NCT02197416::arm::FG001,NCT02197416,Dabigatran Etexilate (2 to <12 Years),,,,,,,,,,FG001,Single oral dose of DE pellets ranging from 20mg to 330mg was administrated twice daily in the morning and evening for participants aged less than 8 years and who cannot take capsules between 8 and \<,,,
arm,NCT02197416::arm::FG002,NCT02197416,Dabigatran Etexilate (12 to <18 Years),,,,,,,,,,FG002,"Single oral dose of DE capsule ranging from 50 mg to 330mg was administrated twice daily in the morning and evening for participants aged at least 8 years.

Dosage of DE was adjusted by age and weight",,,
period,NCT02197416::period::1,NCT02197416,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02197416::outcome::primary::1,NCT02197416,Event-free Probability of Recurrence of Venous Thromboembolism (VTE) at 6 and 12 Months,,,,,,,,,,,,,PRIMARY,At month 6 (Week 26) and 12 (Week 52) of on treatment period
outcome,NCT02197416::outcome::primary::2,NCT02197416,Event-free Probability of Major or Minor (Including Clinically Relevant Non-major (CRNM)) Bleeding Events at 6 and 12 Months,,,,,,,,,,,,,PRIMARY,At month 6 (Week 26) and month 12 (Week 52) of on treatment period
outcome,NCT02197416::outcome::primary::3,NCT02197416,Event-free Probability of Mortality Overall and Related to Thrombotic or Thromboembolic Events at 6 and 12 Months,,,,,,,,,,,,,PRIMARY,At month 6 (Week 26) and 12 (Week 52) of on treatment period
country,NCT02197416::country::United States,NCT02197416,United States,,,,,,,,,,,,,,
country,NCT02197416::country::Russia,NCT02197416,Russia,,,,,,,,,,,,,,
country,NCT02197416::country::Turkey (Türkiye),NCT02197416,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02197416::country::Czechia,NCT02197416,Czechia,,,,,,,,,,,,,,
country,NCT02197416::country::Canada,NCT02197416,Canada,,,,,,,,,,,,,,
country,NCT02197416::country::Italy,NCT02197416,Italy,,,,,,,,,,,,,,
country,NCT02197416::country::Belgium,NCT02197416,Belgium,,,,,,,,,,,,,,
country,NCT02197416::country::Brazil,NCT02197416,Brazil,,,,,,,,,,,,,,
country,NCT02197416::country::Germany,NCT02197416,Germany,,,,,,,,,,,,,,
country,NCT02197416::country::Ukraine,NCT02197416,Ukraine,,,,,,,,,,,,,,
country,NCT02197416::country::Norway,NCT02197416,Norway,,,,,,,,,,,,,,
country,NCT02197416::country::Austria,NCT02197416,Austria,,,,,,,,,,,,,,
country,NCT02197416::country::Denmark,NCT02197416,Denmark,,,,,,,,,,,,,,
country,NCT02197416::country::France,NCT02197416,France,,,,,,,,,,,,,,
country,NCT02197416::country::Hungary,NCT02197416,Hungary,,,,,,,,,,,,,,
country,NCT02197416::country::Israel,NCT02197416,Israel,,,,,,,,,,,,,,
country,NCT02197416::country::Lithuania,NCT02197416,Lithuania,,,,,,,,,,,,,,
country,NCT02197416::country::Mexico,NCT02197416,Mexico,,,,,,,,,,,,,,
country,NCT02197416::country::Sweden,NCT02197416,Sweden,,,,,,,,,,,,,,
country,NCT02197416::country::Switzerland,NCT02197416,Switzerland,,,,,,,,,,,,,,
country,NCT02197416::country::Taiwan,NCT02197416,Taiwan,,,,,,,,,,,,,,
country,NCT02197416::country::Thailand,NCT02197416,Thailand,,,,,,,,,,,,,,
trial,NCT00778921,NCT00778921,Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,847.0,2008-10,2009-06,7.0,7.0,,,,,
arm,NCT00778921::arm::FG000,NCT00778921,Aliskiren/Amlodipine 300/10 mg,,,,,,,,,,FG000,Oral tablets of combination aliskiren/amlodipine 300/10 mg taken once daily with water in the morning,,,
arm,NCT00778921::arm::FG001,NCT00778921,Aliskiren/Amlodipine 150/10 mg,,,,,,,,,,FG001,Oral tablets of combination aliskiren/amlodipine 150/10 mg taken once daily with water in the morning,,,
arm,NCT00778921::arm::FG002,NCT00778921,Amlodipine 10 mg,,,,,,,,,,FG002,Oral capsules of amlodipine 10 mg taken once daily with water in the morning,,,
period,NCT00778921::period::1,NCT00778921,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00778921::outcome::primary::1,NCT00778921,Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study,,,,,,,,,,,,,PRIMARY,Baseline and Week 8
country,NCT00778921::country::Argentina,NCT00778921,Argentina,,,,,,,,,,,,,,
country,NCT00778921::country::Germany,NCT00778921,Germany,,,,,,,,,,,,,,
country,NCT00778921::country::Norway,NCT00778921,Norway,,,,,,,,,,,,,,
country,NCT00778921::country::Poland,NCT00778921,Poland,,,,,,,,,,,,,,
country,NCT00778921::country::Slovakia,NCT00778921,Slovakia,,,,,,,,,,,,,,
country,NCT00778921::country::Sweden,NCT00778921,Sweden,,,,,,,,,,,,,,
country,NCT00778921::country::Turkey (Türkiye),NCT00778921,Turkey (Türkiye),,,,,,,,,,,,,,
trial,NCT02884206,NCT02884206,Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction,PHASE3,cardiovascular disease,Chronic Heart Failure (CHF),INDUSTRY,592.0,2016-11-23,2022-05-16,20.0,135.0,,,,,
arm,NCT02884206::arm::FG000,NCT02884206,Run-in Period,,,,,,,,,,FG000,"Treatment run-in consisted of valsartan 40 mg bid (if necessary), followed by valsartan 80 mg bid, and then followed by LCZ696 100 mg bid, over 3 to 8 weeks duration.",,,
arm,NCT02884206::arm::FG001,NCT02884206,LCZ696 200 mg Bid,,,,,,,,,,FG001,"Patients who were able to tolerate the treatment during the single-blind treatment run-in epoch. Following the run-in period, patients randomized in this arm were given LCZ696 at 200 mg twice daily fo",,,
arm,NCT02884206::arm::FG002,NCT02884206,Valsartan 160 mg Bid,,,,,,,,,,FG002,"Patients who were able to tolerate the treatment during the single-blind treatment run-in epoch. Following the run-in period, patients randomized in this arm were given valsartan at 160 mg twice daily",,,
period,NCT02884206::period::1,NCT02884206,Valsartan Run-in Period,,,,,,,,,,,,1.0,,
period,NCT02884206::period::2,NCT02884206,LCZ696 Run-in Period,,,,,,,,,,,,2.0,,
period,NCT02884206::period::3,NCT02884206,Double-Blind Period,,,,,,,,,,,,3.0,,
outcome,NCT02884206::outcome::primary::1,NCT02884206,Change From Baseline in the CogState Global Cognitive Composite Score (GCCS),,,,,,,,,,,,,PRIMARY,"Baseline, month 36"
country,NCT02884206::country::United States,NCT02884206,United States,,,,,,,,,,,,,,
country,NCT02884206::country::Germany,NCT02884206,Germany,,,,,,,,,,,,,,
country,NCT02884206::country::United Kingdom,NCT02884206,United Kingdom,,,,,,,,,,,,,,
country,NCT02884206::country::Italy,NCT02884206,Italy,,,,,,,,,,,,,,
country,NCT02884206::country::Poland,NCT02884206,Poland,,,,,,,,,,,,,,
country,NCT02884206::country::Spain,NCT02884206,Spain,,,,,,,,,,,,,,
country,NCT02884206::country::Argentina,NCT02884206,Argentina,,,,,,,,,,,,,,
country,NCT02884206::country::Russia,NCT02884206,Russia,,,,,,,,,,,,,,
country,NCT02884206::country::Australia,NCT02884206,Australia,,,,,,,,,,,,,,
country,NCT02884206::country::South Korea,NCT02884206,South Korea,,,,,,,,,,,,,,
country,NCT02884206::country::Taiwan,NCT02884206,Taiwan,,,,,,,,,,,,,,
country,NCT02884206::country::Bulgaria,NCT02884206,Bulgaria,,,,,,,,,,,,,,
country,NCT02884206::country::Canada,NCT02884206,Canada,,,,,,,,,,,,,,
country,NCT02884206::country::Croatia,NCT02884206,Croatia,,,,,,,,,,,,,,
country,NCT02884206::country::France,NCT02884206,France,,,,,,,,,,,,,,
country,NCT02884206::country::Lithuania,NCT02884206,Lithuania,,,,,,,,,,,,,,
country,NCT02884206::country::Netherlands,NCT02884206,Netherlands,,,,,,,,,,,,,,
country,NCT02884206::country::Turkey (Türkiye),NCT02884206,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02884206::country::Belgium,NCT02884206,Belgium,,,,,,,,,,,,,,
country,NCT02884206::country::Switzerland,NCT02884206,Switzerland,,,,,,,,,,,,,,
trial,NCT00003816,NCT00003816,Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer,PHASE3,cardiovascular disease,"Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonmalignant Neoplasm; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific",OTHER,361.0,1998-10-19,2019-07-12,1.0,1.0,,,,,
arm,NCT00003816::arm::FG000,NCT00003816,BuCy,,,,,,,,,,FG000,"Patients receive busulfan IV over 2 hours every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.

busulfan: Given IV

cyclophosphamide: Given IV",,,
arm,NCT00003816::arm::FG001,NCT00003816,CyTBI,,,,,,,,,,FG001,"Patients receive cyclophosphamide IV over 2 hours on days -5 and -4 and total-body irradiation (TBI) twice daily on days -3 to -1.

cyclophosphamide: Given IV

total-body irradiation: Given twice dail",,,
arm,NCT00003816::arm::FG002,NCT00003816,FluMel,,,,,,,,,,FG002,"Patients receive fludarabine IV over 30 minutes on days -6 to -2 and melphalan IV over 1 hour on days -3 and -2.

fludarabine phosphate: Given IV

melphalan: Given IV",,,
arm,NCT00003816::arm::FG003,NCT00003816,VpCyTBI,,,,,,,,,,FG003,"Patients receive etoposide IV over 26 hours beginning on day -5, cyclophosphamide IV over 2 hours on day -4, and TBI twice daily on days -3 to -1.

cyclophosphamide: Given IV

etoposide: Given IV

tot",,,
arm,NCT00003816::arm::FG004,NCT00003816,Other,,,,,,,,,,FG004,"Patients receive cyclophosphamide IV over 2 hours on days -5 and -4, TBI twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4-8 hours on days -3 to -1. OR Patients receive cyclophospham",,,
period,NCT00003816::period::1,NCT00003816,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00003816::outcome::primary::1,NCT00003816,CR Rate,,,,,,,,,,,,,PRIMARY,day 100
country,NCT00003816::country::United States,NCT00003816,United States,,,,,,,,,,,,,,
trial,NCT01890434,NCT01890434,Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD),PHASE3,cardiovascular disease,Coronary Artery Disease,INDUSTRY,478.0,2013-08-26,2016-11-10,4.0,24.0,,,,,
arm,NCT01890434::arm::FG000,NCT01890434,Gadobutrol 0.1 mmol/kg Body Weight,,,,,,,,,,FG000,Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress,,,
period,NCT01890434::period::1,NCT01890434,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01890434::outcome::primary::1,NCT01890434,Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Primary Analysis of Sensitivity Based on Blinded Readers' Assessment,,,,,,,,,,,,,PRIMARY,0 to 30/40 min post-injection
outcome,NCT01890434::outcome::primary::2,NCT01890434,Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Sensitivity Based on Blinded Readers' Assessment,,,,,,,,,,,,,PRIMARY,0 to 30/40 min post-injection
outcome,NCT01890434::outcome::primary::3,NCT01890434,Absence of Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Primary Analysis of Specificity Based on Blinded Readers' Assessment,,,,,,,,,,,,,PRIMARY,0 to 30/40 min post-injection
outcome,NCT01890434::outcome::primary::4,NCT01890434,Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Specificity Based on Blinded Readers' Assessment,,,,,,,,,,,,,PRIMARY,0 to 30/40 min post-injection
outcome,NCT01890434::outcome::primary::5,NCT01890434,Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Primary Analysis of Sensitivity Comparison Based on the Blinded Readers' Assessment,,,,,,,,,,,,,PRIMARY,0 to 30/40 min post-injection
outcome,NCT01890434::outcome::primary::6,NCT01890434,Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Additional Secondary Analysis of Sensitivity Comparison Based on the Blinded Readers' Assessment,,,,,,,,,,,,,PRIMARY,0 to 30/40 min post-injection
country,NCT01890434::country::United States,NCT01890434,United States,,,,,,,,,,,,,,
country,NCT01890434::country::Australia,NCT01890434,Australia,,,,,,,,,,,,,,
country,NCT01890434::country::Canada,NCT01890434,Canada,,,,,,,,,,,,,,
country,NCT01890434::country::Singapore,NCT01890434,Singapore,,,,,,,,,,,,,,
trial,NCT02158806,NCT02158806,Low Dose Aspirin for Venous Leg Ulcers,PHASE3,cardiovascular disease,Venous Leg Ulcer,OTHER,251.0,2015-03,2017-03-31,0.0,0.0,,,,,
arm,NCT02158806::arm::FG000,NCT02158806,Aspirin,,,,,,,,,,FG000,"150 mg capsule once daily for up to 24 weeks

Aspirin: 150 mg aspirin in capsule form once daily for up to 24 weeks",,,
arm,NCT02158806::arm::FG001,NCT02158806,Placebo,,,,,,,,,,FG001,"Matching inert capsule once daily for up to 24 weeks

Placebo: Matching placebo capsule containing inert bulking agent",,,
period,NCT02158806::period::1,NCT02158806,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02158806::outcome::primary::1,NCT02158806,Time to Complete Healing of Reference Ulcer,,,,,,,,,,,,,PRIMARY,24 weeks
trial,NCT00869206,NCT00869206,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",PHASE3,cardiovascular disease,Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,OTHER,1822.0,2009-03,2017-01,2.0,504.0,,,,,
arm,NCT00869206::arm::FG000,NCT00869206,Arm I (Zoledronic Acid Every 4 Weeks),,,,,,,,,,FG000,Patients receive zoledronic acid IV over at least 15 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.,,,
arm,NCT00869206::arm::FG001,NCT00869206,Arm II (Zoledronic Acid Every 12 Weeks),,,,,,,,,,FG001,Patients receive zoledronic acid IV over at least 15 minutes every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.,,,
period,NCT00869206::period::1,NCT00869206,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00869206::outcome::primary::1,NCT00869206,Percentage of Participants With at Least One Skeletal-related Event (SRE) Within 2 Years After Randomization,,,,,,,,,,,,,PRIMARY,2 years
country,NCT00869206::country::United States,NCT00869206,United States,,,,,,,,,,,,,,
country,NCT00869206::country::Puerto Rico,NCT00869206,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00282984,NCT00282984,Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking,PHASE3,cardiovascular disease,Smoking Cessation,INDUSTRY,714.0,2006-02,2008-08,15.0,39.0,,,,,
arm,NCT00282984::arm::FG000,NCT00282984,Varenicline (Var),,,,,,,,,,FG000,1 week titration followed by 11 weeks of 1 milligram (mg) twice daily (BID) dosing. Study medication was discontinued at the Week 12 visit and participants' smoking status was followed through the non,,,
arm,NCT00282984::arm::FG001,NCT00282984,Placebo (Pbo),,,,,,,,,,FG001,1 week titration followed by 11 weeks of placebo (pbo). Study medication was discontinued at the Week 12 visit and participants' smoking status was followed through the non-treatment period to Week 52,,,
period,NCT00282984::period::1,NCT00282984,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00282984::outcome::primary::1,NCT00282984,Number of Responders With Carbon Monoxide (CO) Confirmed 4-week Continuous Quit Rate (CQR) for Last 4 Weeks of Treatment (Trtmt),,,,,,,,,,,,,PRIMARY,weeks 9 through 12
country,NCT00282984::country::Canada,NCT00282984,Canada,,,,,,,,,,,,,,
country,NCT00282984::country::South Korea,NCT00282984,South Korea,,,,,,,,,,,,,,
country,NCT00282984::country::United Kingdom,NCT00282984,United Kingdom,,,,,,,,,,,,,,
country,NCT00282984::country::United States,NCT00282984,United States,,,,,,,,,,,,,,
country,NCT00282984::country::France,NCT00282984,France,,,,,,,,,,,,,,
country,NCT00282984::country::Germany,NCT00282984,Germany,,,,,,,,,,,,,,
country,NCT00282984::country::Argentina,NCT00282984,Argentina,,,,,,,,,,,,,,
country,NCT00282984::country::Australia,NCT00282984,Australia,,,,,,,,,,,,,,
country,NCT00282984::country::Brazil,NCT00282984,Brazil,,,,,,,,,,,,,,
country,NCT00282984::country::Czechia,NCT00282984,Czechia,,,,,,,,,,,,,,
country,NCT00282984::country::Denmark,NCT00282984,Denmark,,,,,,,,,,,,,,
country,NCT00282984::country::Greece,NCT00282984,Greece,,,,,,,,,,,,,,
country,NCT00282984::country::Mexico,NCT00282984,Mexico,,,,,,,,,,,,,,
country,NCT00282984::country::Netherlands,NCT00282984,Netherlands,,,,,,,,,,,,,,
country,NCT00282984::country::Taiwan,NCT00282984,Taiwan,,,,,,,,,,,,,,
trial,NCT01237223,NCT01237223,Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension,PHASE3,cardiovascular disease,Essential Hypertension,INDUSTRY,1342.0,2010-10,2011-05,1.0,11.0,,,,,
arm,NCT01237223::arm::FG000,NCT01237223,Placebo,,,,,,,,,,FG000,"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. In single blind run-in (4 weeks) and double blind t",,,
arm,NCT01237223::arm::FG001,NCT01237223,Aliskiren 150 mg,,,,,,,,,,FG001,"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.

Patients received Aliskiren 150 mg tablet once dai",,,
arm,NCT01237223::arm::FG002,NCT01237223,Amlodipine 2.5 mg,,,,,,,,,,FG002,"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.

Patients received Amlodipine 2.5 mg capsule once d",,,
arm,NCT01237223::arm::FG003,NCT01237223,Amlodipine 5 mg,,,,,,,,,,FG003,"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.

Patients received amlodipine 5 mg (two amlodipine ",,,
arm,NCT01237223::arm::FG004,NCT01237223,Aliskiren/Amlodipine 150/2.5 mg,,,,,,,,,,FG004,"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.

Patients received aliskiren/amlodipine 150/2.5 mg ",,,
arm,NCT01237223::arm::FG005,NCT01237223,Aliskiren/Amlodipine 150/5 mg,,,,,,,,,,FG005,"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.

Patients received aliskiren/amlodipine 150/5 mg ta",,,
period,NCT01237223::period::1,NCT01237223,"Single Blind(Run-in Period, 4 Weeks)",,,,,,,,,,,,1.0,,
period,NCT01237223::period::2,NCT01237223,"Double Blind (Treatment Period, 8 Weeks)",,,,,,,,,,,,2.0,,
outcome,NCT01237223::outcome::primary::1,NCT01237223,Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) to End of Study (Week 8),,,,,,,,,,,,,PRIMARY,"Baseline, Week 8"
country,NCT01237223::country::Japan,NCT01237223,Japan,,,,,,,,,,,,,,
trial,NCT03682185,NCT03682185,The Healthy Patterns Sleep Study,PHASE3,cardiovascular disease,Dementia; Alzheimer Disease; Circadian Rhythm Disorders; Circadian Rhythm Sleep Disorder; Insomnia; Hypersomnia; Cognitive Impairment; Cognitive Decline; Mild Cognitive Impairment; Frontotemporal Dementia; Neurocognitive Disorders; Vascular Dementia; Sleep Disorder; Memory Impairment,OTHER,421.0,2016-05-01,2021-05-31,1.0,1.0,,,,,
arm,NCT03682185::arm::FG000,NCT03682185,Caregivers of Persons Living With Dementia: Timed Activity Intervention Protocol,,,,,,,,,,FG000,"The timed activity group will be delivered to caregivers and persons living with dementia, and will involve 4 in-home visits and 4 brief telephone education sessions provided over 4 weeks. The timed a",,,
arm,NCT03682185::arm::FG001,NCT03682185,Caregivers of Persons Living With Dementia: Attention-Control Condition,,,,,,,,,,FG001,"The attention control group sessions will be delivered to caregivers and persons living with dementia.

This condition will contain no active elements beyond its nonspecific components, and no theoret",,,
arm,NCT03682185::arm::FG002,NCT03682185,People Living With Dementia: Timed Activity Intervention Protocol,,,,,,,,,,FG002,"The timed activity group will be delivered to caregivers and persons living with dementia, and will involve 4 in-home visits and 4 brief telephone education sessions provided over 4 weeks. The timed a",,,
arm,NCT03682185::arm::FG003,NCT03682185,Persons Living With Dementia: Attention-Control Condition,,,,,,,,,,FG003,"The attention control group sessions will be delivered to caregivers and persons living with dementia.

This condition will contain no active elements beyond its nonspecific components, and no theoret",,,
arm,NCT03682185::arm::FG004,NCT03682185,Unrandomized,,,,,,,,,,FG004,Unrandomized Participants who were consented but didn't move forward in the intervention.,,,
period,NCT03682185::period::1,NCT03682185,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03682185::outcome::primary::1,NCT03682185,Change in the Quality of Life in Alzheimer's Disease (QOL-AD) Scale,,,,,,,,,,,,,PRIMARY,Baseline and 1 month
country,NCT03682185::country::United States,NCT03682185,United States,,,,,,,,,,,,,,
trial,NCT00141778,NCT00141778,"Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)",PHASE3,cardiovascular disease,Atrial Fibrillation,OTHER,455.0,2005-04,2010-08,1.0,1.0,,,,,
arm,NCT00141778::arm::FG000,NCT00141778,Placebo,,,,,,,,,,FG000,Placebo Group,,,
arm,NCT00141778::arm::FG001,NCT00141778,Ramipril,,,,,,,,,,FG001,"Angiotensin-Converting Enzyme Inhibitor Group. Ramipril was given as 2.5 mg the first 3 days followed by 5 mg/day, with the dose reduced to 2.5 mg/day on the first postoperative day only.",,,
arm,NCT00141778::arm::FG002,NCT00141778,Spironolactone,,,,,,,,,,FG002,Mineralocorticoid Receptor (MR) Antagonist Group.Spironolactone was given as 25 mg/day.,,,
period,NCT00141778::period::1,NCT00141778,Randomization Prior to Study Med,,,,,,,,,,,,1.0,,
period,NCT00141778::period::2,NCT00141778,Started Study Medication,,,,,,,,,,,,2.0,,
outcome,NCT00141778::outcome::primary::1,NCT00141778,Postoperative Atrial Fibrillation,,,,,,,,,,,,,PRIMARY,Measured from admission to the ICU until discharge from hospital
country,NCT00141778::country::United States,NCT00141778,United States,,,,,,,,,,,,,,
trial,NCT00412984,NCT00412984,Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation,PHASE3,cardiovascular disease,Atrial Fibrillation; Atrial Flutter,INDUSTRY,20976.0,2006-12-31,2011-05-25,41.0,1111.0,,,,,
arm,NCT00412984::arm::FG000,NCT00412984,Apixaban,,,,,,,,,,FG000,Participants received apixaban and warfarin-placebo following randomization during a titration phase using a dosing algorithm for warfarin- placebo; apixaban was dosed at 5 mg twice daily (BID) \[or 2,,,
arm,NCT00412984::arm::FG001,NCT00412984,Warfarin,,,,,,,,,,FG001,Participants received apixaban-placebo and warfarin following randomization during a titration phase using a dosing algorithm for warfarin; apixaban-placebo was dosed at 5 mg twice daily (BID) \[or 2.,,,
period,NCT00412984::period::1,NCT00412984,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00412984::outcome::primary::1,NCT00412984,"Number of Participants With First Event of Ischemic/Unspecified Stroke, Hemorrhagic Stroke, or Systemic Embolism (SE) During the Intended Treatment Period",,,,,,,,,,,,,PRIMARY,"Time to first event in ""Intended Treatment Period"": started on day of randomization, ended at efficacy cut-off date (date target number of primary efficacy events [448] was expected to have occurred"
outcome,NCT00412984::outcome::primary::2,NCT00412984,Rate of Adjudicated Stroke or Systemic Embolism (SE) During the Intended Treatment Period,,,,,,,,,,,,,PRIMARY,"set to 30-Jan-2011, prior to unblinding)."
country,NCT00412984::country::United States,NCT00412984,United States,,,,,,,,,,,,,,
country,NCT00412984::country::Brazil,NCT00412984,Brazil,,,,,,,,,,,,,,
country,NCT00412984::country::Russia,NCT00412984,Russia,,,,,,,,,,,,,,
country,NCT00412984::country::Canada,NCT00412984,Canada,,,,,,,,,,,,,,
country,NCT00412984::country::Argentina,NCT00412984,Argentina,,,,,,,,,,,,,,
country,NCT00412984::country::Japan,NCT00412984,Japan,,,,,,,,,,,,,,
country,NCT00412984::country::Germany,NCT00412984,Germany,,,,,,,,,,,,,,
country,NCT00412984::country::United Kingdom,NCT00412984,United Kingdom,,,,,,,,,,,,,,
country,NCT00412984::country::India,NCT00412984,India,,,,,,,,,,,,,,
country,NCT00412984::country::China,NCT00412984,China,,,,,,,,,,,,,,
country,NCT00412984::country::Ukraine,NCT00412984,Ukraine,,,,,,,,,,,,,,
country,NCT00412984::country::Poland,NCT00412984,Poland,,,,,,,,,,,,,,
country,NCT00412984::country::Australia,NCT00412984,Australia,,,,,,,,,,,,,,
country,NCT00412984::country::Belgium,NCT00412984,Belgium,,,,,,,,,,,,,,
country,NCT00412984::country::Hungary,NCT00412984,Hungary,,,,,,,,,,,,,,
country,NCT00412984::country::Mexico,NCT00412984,Mexico,,,,,,,,,,,,,,
country,NCT00412984::country::Spain,NCT00412984,Spain,,,,,,,,,,,,,,
country,NCT00412984::country::Denmark,NCT00412984,Denmark,,,,,,,,,,,,,,
country,NCT00412984::country::Italy,NCT00412984,Italy,,,,,,,,,,,,,,
country,NCT00412984::country::Israel,NCT00412984,Israel,,,,,,,,,,,,,,
country,NCT00412984::country::Romania,NCT00412984,Romania,,,,,,,,,,,,,,
country,NCT00412984::country::South Korea,NCT00412984,South Korea,,,,,,,,,,,,,,
country,NCT00412984::country::Netherlands,NCT00412984,Netherlands,,,,,,,,,,,,,,
country,NCT00412984::country::Sweden,NCT00412984,Sweden,,,,,,,,,,,,,,
country,NCT00412984::country::Czechia,NCT00412984,Czechia,,,,,,,,,,,,,,
country,NCT00412984::country::Norway,NCT00412984,Norway,,,,,,,,,,,,,,
country,NCT00412984::country::Peru,NCT00412984,Peru,,,,,,,,,,,,,,
country,NCT00412984::country::South Africa,NCT00412984,South Africa,,,,,,,,,,,,,,
country,NCT00412984::country::Chile,NCT00412984,Chile,,,,,,,,,,,,,,
country,NCT00412984::country::Finland,NCT00412984,Finland,,,,,,,,,,,,,,
country,NCT00412984::country::Philippines,NCT00412984,Philippines,,,,,,,,,,,,,,
country,NCT00412984::country::Colombia,NCT00412984,Colombia,,,,,,,,,,,,,,
country,NCT00412984::country::France,NCT00412984,France,,,,,,,,,,,,,,
country,NCT00412984::country::Taiwan,NCT00412984,Taiwan,,,,,,,,,,,,,,
country,NCT00412984::country::Malaysia,NCT00412984,Malaysia,,,,,,,,,,,,,,
country,NCT00412984::country::Austria,NCT00412984,Austria,,,,,,,,,,,,,,
country,NCT00412984::country::Puerto Rico,NCT00412984,Puerto Rico,,,,,,,,,,,,,,
country,NCT00412984::country::Turkey (Türkiye),NCT00412984,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00412984::country::Hong Kong,NCT00412984,Hong Kong,,,,,,,,,,,,,,
country,NCT00412984::country::Switzerland,NCT00412984,Switzerland,,,,,,,,,,,,,,
country,NCT00412984::country::Singapore,NCT00412984,Singapore,,,,,,,,,,,,,,
trial,NCT04362085,NCT04362085,Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care,PHASE3,cardiovascular disease,COVID-19,OTHER,465.0,2020-05-11,2021-10-14,1.0,1.0,,,,,
arm,NCT04362085::arm::FG000,NCT04362085,Therapeutic Anticoagulation,,,,,,,,,,FG000,Therapeutic anticoagulation with LMWH or UFH (high dose nomogram). The choice of LMWH versus UFH will be at the clinician's discretion and dependent on local institutional supply. Therapeutic anticoag,,,
arm,NCT04362085::arm::FG001,NCT04362085,Standard Care,,,,,,,,,,FG001,"Administration of LMWH, UFH or fondaparinux at thromboprophylactic doses for acutely ill hospitalized medical patients, in the absence of contraindication, is considered standard care.",,,
period,NCT04362085::period::1,NCT04362085,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04362085::outcome::primary::1,NCT04362085,"Composite Outcome of ICU Admission, Non-invasive Positive Pressure Ventilation, Invasive Mechanical Ventilation, or All-cause Death up to 28 Days.",,,,,,,,,,,,,PRIMARY,Up to 28 days
country,NCT04362085::country::Canada,NCT04362085,Canada,,,,,,,,,,,,,,
trial,NCT02100514,NCT02100514,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events,PHASE3,cardiovascular disease,Hyperlipidemia,INDUSTRY,746.0,2014-10-28,2017-07-10,12.0,223.0,,,,,
arm,NCT02100514::arm::FG000,NCT02100514,Treatment Period: Placebo,,,,,,,,,,FG000,Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once every 2 weeks up to Week 52. Participants were followed up to Week 58.,,,
arm,NCT02100514::arm::FG001,NCT02100514,Treatment Period: Bococizumab 150 mg,,,,,,,,,,FG001,Participants received Bococizumab (PF-04950615) 150 milligram (mg) subcutaneous injection once every 2 weeks up to Week 52. Participants were followed up to Week 58.,,,
arm,NCT02100514::arm::FG002,NCT02100514,Extension Period: Placebo,,,,,,,,,,FG002,"Participants randomized to Placebo arm in treatment period and consented for extension period after Week 58 follow-up visit, were followed for SAEs and concomitant medications up to Week 110.",,,
arm,NCT02100514::arm::FG003,NCT02100514,Extension Period: Bococizumab ADA Positive,,,,,,,,,,FG003,"Participants randomized to Bococizumab in treatment period were classified as either ADA positive or ADA negative based on their ADA assessment at Week 58 follow-up visit. In extension period, partici",,,
arm,NCT02100514::arm::FG004,NCT02100514,Extension Period: Bococizumab ADA Negative,,,,,,,,,,FG004,Participants randomized to Bococizumab in treatment period were classified as either ADA positive or ADA negative based on their Week 58 follow-up ADA assessment. Participants who were ADA negative an,,,
period,NCT02100514::period::1,NCT02100514,Treatment Period,,,,,,,,,,,,1.0,,
period,NCT02100514::period::2,NCT02100514,Extension Period,,,,,,,,,,,,2.0,,
outcome,NCT02100514::outcome::primary::1,NCT02100514,Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12,,,,,,,,,,,,,PRIMARY,"Baseline, Week 12"
country,NCT02100514::country::United States,NCT02100514,United States,,,,,,,,,,,,,,
country,NCT02100514::country::Canada,NCT02100514,Canada,,,,,,,,,,,,,,
country,NCT02100514::country::Czechia,NCT02100514,Czechia,,,,,,,,,,,,,,
country,NCT02100514::country::Poland,NCT02100514,Poland,,,,,,,,,,,,,,
country,NCT02100514::country::Netherlands,NCT02100514,Netherlands,,,,,,,,,,,,,,
country,NCT02100514::country::United Kingdom,NCT02100514,United Kingdom,,,,,,,,,,,,,,
country,NCT02100514::country::Sweden,NCT02100514,Sweden,,,,,,,,,,,,,,
country,NCT02100514::country::South Korea,NCT02100514,South Korea,,,,,,,,,,,,,,
country,NCT02100514::country::Norway,NCT02100514,Norway,,,,,,,,,,,,,,
country,NCT02100514::country::Puerto Rico,NCT02100514,Puerto Rico,,,,,,,,,,,,,,
country,NCT02100514::country::Finland,NCT02100514,Finland,,,,,,,,,,,,,,
country,NCT02100514::country::Singapore,NCT02100514,Singapore,,,,,,,,,,,,,,
trial,NCT02207634,NCT02207634,Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects,PHASE3,cardiovascular disease,Dyslipidemia,INDUSTRY,1974.0,2014-09-10,2016-11-11,30.0,416.0,,,,,
arm,NCT02207634::arm::FG000,NCT02207634,Placebo,,,,,,,,,,FG000,Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference. Participants continued with their background statin therap,,,
arm,NCT02207634::arm::FG001,NCT02207634,Evolocumab,,,,,,,,,,FG001,Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference. Participants continued with their background statin therapy during the course of the,,,
period,NCT02207634::period::1,NCT02207634,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02207634::outcome::primary::1,NCT02207634,Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score,,,,,,,,,,,,,PRIMARY,"Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months)."
country,NCT02207634::country::United States,NCT02207634,United States,,,,,,,,,,,,,,
country,NCT02207634::country::Poland,NCT02207634,Poland,,,,,,,,,,,,,,
country,NCT02207634::country::Japan,NCT02207634,Japan,,,,,,,,,,,,,,
country,NCT02207634::country::United Kingdom,NCT02207634,United Kingdom,,,,,,,,,,,,,,
country,NCT02207634::country::Czechia,NCT02207634,Czechia,,,,,,,,,,,,,,
country,NCT02207634::country::Russia,NCT02207634,Russia,,,,,,,,,,,,,,
country,NCT02207634::country::Germany,NCT02207634,Germany,,,,,,,,,,,,,,
country,NCT02207634::country::Canada,NCT02207634,Canada,,,,,,,,,,,,,,
country,NCT02207634::country::Slovakia,NCT02207634,Slovakia,,,,,,,,,,,,,,
country,NCT02207634::country::South Africa,NCT02207634,South Africa,,,,,,,,,,,,,,
country,NCT02207634::country::Australia,NCT02207634,Australia,,,,,,,,,,,,,,
country,NCT02207634::country::Hungary,NCT02207634,Hungary,,,,,,,,,,,,,,
country,NCT02207634::country::Belgium,NCT02207634,Belgium,,,,,,,,,,,,,,
country,NCT02207634::country::Finland,NCT02207634,Finland,,,,,,,,,,,,,,
country,NCT02207634::country::Denmark,NCT02207634,Denmark,,,,,,,,,,,,,,
country,NCT02207634::country::France,NCT02207634,France,,,,,,,,,,,,,,
country,NCT02207634::country::Greece,NCT02207634,Greece,,,,,,,,,,,,,,
country,NCT02207634::country::Latvia,NCT02207634,Latvia,,,,,,,,,,,,,,
country,NCT02207634::country::Norway,NCT02207634,Norway,,,,,,,,,,,,,,
country,NCT02207634::country::Spain,NCT02207634,Spain,,,,,,,,,,,,,,
country,NCT02207634::country::Sweden,NCT02207634,Sweden,,,,,,,,,,,,,,
country,NCT02207634::country::Turkey (Türkiye),NCT02207634,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02207634::country::Netherlands,NCT02207634,Netherlands,,,,,,,,,,,,,,
country,NCT02207634::country::Estonia,NCT02207634,Estonia,,,,,,,,,,,,,,
country,NCT02207634::country::Portugal,NCT02207634,Portugal,,,,,,,,,,,,,,
country,NCT02207634::country::Malaysia,NCT02207634,Malaysia,,,,,,,,,,,,,,
country,NCT02207634::country::New Zealand,NCT02207634,New Zealand,,,,,,,,,,,,,,
country,NCT02207634::country::Hong Kong,NCT02207634,Hong Kong,,,,,,,,,,,,,,
country,NCT02207634::country::Italy,NCT02207634,Italy,,,,,,,,,,,,,,
country,NCT02207634::country::Lithuania,NCT02207634,Lithuania,,,,,,,,,,,,,,
trial,NCT00307047,NCT00307047,SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System,PHASE3,cardiovascular disease,Coronary Artery Disease,INDUSTRY,3687.0,2006-08,2012-05,1.0,65.0,,,,,
arm,NCT00307047::arm::FG000,NCT00307047,XIENCE V®,,,,,,,,,,FG000,Patients recieving the XIENCE V® stent,,,
arm,NCT00307047::arm::FG001,NCT00307047,TAXUS™ EXPRESS 2™,,,,,,,,,,FG001,Patients receiving the TAXUS™ EXPRESS 2™ stent,,,
period,NCT00307047::period::1,NCT00307047,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00307047::outcome::primary::1,NCT00307047,Ischemia Driven Target Lesion Failure (TLF),,,,,,,,,,,,,PRIMARY,1 year
country,NCT00307047::country::United States,NCT00307047,United States,,,,,,,,,,,,,,
trial,NCT01294462,NCT01294462,Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS),PHASE3,cardiovascular disease,Acute Coronary Syndrome; Percutaneous Coronary Intervention,INDUSTRY,801.0,2011-02,2012-07,3.0,87.0,,,,,
arm,NCT01294462::arm::FG000,NCT01294462,Ticagrelor (AZD6140),,,,,,,,,,FG000,Ticagrelor (AZD6140) 90 mg bid,,,
arm,NCT01294462::arm::FG001,NCT01294462,Clopidogrel,,,,,,,,,,FG001,Clopidogrel 75mg od,,,
period,NCT01294462::period::1,NCT01294462,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01294462::outcome::primary::1,NCT01294462,Major Bleeding,,,,,,,,,,,,,PRIMARY,Ongoing up to12 months
outcome,NCT01294462::outcome::primary::2,NCT01294462,Major Adverse Cardiac Events (MACE),,,,,,,,,,,,,PRIMARY,Ongoing up to 12 months
country,NCT01294462::country::Japan,NCT01294462,Japan,,,,,,,,,,,,,,
country,NCT01294462::country::South Korea,NCT01294462,South Korea,,,,,,,,,,,,,,
country,NCT01294462::country::Taiwan,NCT01294462,Taiwan,,,,,,,,,,,,,,
trial,NCT02319005,NCT02319005,ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC),PHASE3,cardiovascular disease,"Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC); Amyloidosis, Hereditary; Amyloid Neuropathies, Familial; Amyloid Neuropathies; Amyloidosis, Hereditary, Transthyretin-Related; Familial Transthyretin Cardiac Amyloidosis",INDUSTRY,206.0,2014-12,2017-03-30,9.0,61.0,,,,,
arm,NCT02319005::arm::FG000,NCT02319005,Revusiran (ALN-TTRSC),,,,,,,,,,FG000,All patients who received at least 1 dose of revusiran,,,
arm,NCT02319005::arm::FG001,NCT02319005,Placebo,,,,,,,,,,FG001,All patients who received at least 1 dose of placebo,,,
period,NCT02319005::period::1,NCT02319005,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02319005::outcome::primary::1,NCT02319005,6 Minute Walk Distance (6-MWD),,,,,,,,,,,,,PRIMARY,18 months
outcome,NCT02319005::outcome::primary::2,NCT02319005,Serum TTR Levels,,,,,,,,,,,,,PRIMARY,18 months
country,NCT02319005::country::United States,NCT02319005,United States,,,,,,,,,,,,,,
country,NCT02319005::country::France,NCT02319005,France,,,,,,,,,,,,,,
country,NCT02319005::country::Belgium,NCT02319005,Belgium,,,,,,,,,,,,,,
country,NCT02319005::country::Italy,NCT02319005,Italy,,,,,,,,,,,,,,
country,NCT02319005::country::Spain,NCT02319005,Spain,,,,,,,,,,,,,,
country,NCT02319005::country::United Kingdom,NCT02319005,United Kingdom,,,,,,,,,,,,,,
country,NCT02319005::country::Germany,NCT02319005,Germany,,,,,,,,,,,,,,
country,NCT02319005::country::Canada,NCT02319005,Canada,,,,,,,,,,,,,,
country,NCT02319005::country::Sweden,NCT02319005,Sweden,,,,,,,,,,,,,,
trial,NCT03067441,NCT03067441,Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE),PHASE3,cardiovascular disease,Hypercholesterolemia; Atherosclerotic Cardiovascular Disease,INDUSTRY,1462.0,2017-02-03,2019-11-05,1.0,3.0,,,,,
arm,NCT03067441::arm::FG000,NCT03067441,Placebo; Bempedoic Acid,,,,,,,,,,FG000,"In the parent study (Study 1002-040), participants received placebo tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), includi",,,
arm,NCT03067441::arm::FG001,NCT03067441,Bempedoic Acid; Bempedoic Acid,,,,,,,,,,FG001,"In the parent study, participants received bempedoic acid 180 mg tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including ",,,
period,NCT03067441::period::1,NCT03067441,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03067441::outcome::primary::1,NCT03067441,Number of Participants With Treatment-Emergent Adverse Events (TEAEs),,,,,,,,,,,,,PRIMARY,Up to Week 82
country,NCT03067441::country::United States,NCT03067441,United States,,,,,,,,,,,,,,
trial,NCT00662831,NCT00662831,Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients,PHASE3,cardiovascular disease,Diabetic Foot Ulcer,INDUSTRY,276.0,2008-04,2010-10,17.0,63.0,,,,,
arm,NCT00662831::arm::FG000,NCT00662831,Dalteparin,,,,,,,,,,FG000,Dalteparin 5000 International Units (IU) (0.2 milliliter \[mL\]) subcutaneously (s.c.) once daily for 24 weeks or early termination (ET).,,,
arm,NCT00662831::arm::FG001,NCT00662831,Placebo,,,,,,,,,,FG001,Placebo (0.2 mL normal saline) administered s.c. once daily for 24 weeks or ET.,,,
period,NCT00662831::period::1,NCT00662831,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00662831::outcome::primary::1,NCT00662831,Number of Participants With Greater Than or Equal to 50 Percent Reduction in Ulcer Surface Area Including Intact Skin Healing,,,,,,,,,,,,,PRIMARY,Week 24 [end of treatment (EOT)] or early termination
country,NCT00662831::country::United Kingdom,NCT00662831,United Kingdom,,,,,,,,,,,,,,
country,NCT00662831::country::Sweden,NCT00662831,Sweden,,,,,,,,,,,,,,
country,NCT00662831::country::Denmark,NCT00662831,Denmark,,,,,,,,,,,,,,
country,NCT00662831::country::Russia,NCT00662831,Russia,,,,,,,,,,,,,,
country,NCT00662831::country::Poland,NCT00662831,Poland,,,,,,,,,,,,,,
country,NCT00662831::country::Greece,NCT00662831,Greece,,,,,,,,,,,,,,
country,NCT00662831::country::Italy,NCT00662831,Italy,,,,,,,,,,,,,,
country,NCT00662831::country::Ukraine,NCT00662831,Ukraine,,,,,,,,,,,,,,
country,NCT00662831::country::Austria,NCT00662831,Austria,,,,,,,,,,,,,,
country,NCT00662831::country::Czechia,NCT00662831,Czechia,,,,,,,,,,,,,,
country,NCT00662831::country::Lithuania,NCT00662831,Lithuania,,,,,,,,,,,,,,
country,NCT00662831::country::Spain,NCT00662831,Spain,,,,,,,,,,,,,,
country,NCT00662831::country::Canada,NCT00662831,Canada,,,,,,,,,,,,,,
country,NCT00662831::country::Belgium,NCT00662831,Belgium,,,,,,,,,,,,,,
country,NCT00662831::country::Finland,NCT00662831,Finland,,,,,,,,,,,,,,
country,NCT00662831::country::Germany,NCT00662831,Germany,,,,,,,,,,,,,,
country,NCT00662831::country::Norway,NCT00662831,Norway,,,,,,,,,,,,,,
trial,NCT02414841,NCT02414841,A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2),PHASE3,cardiovascular disease,Chronic Kidney Disease,INDUSTRY,696.0,2015-08,2019-05-01,2.0,41.0,,,,,
arm,NCT02414841::arm::FG000,NCT02414841,Vonapanitase,,,,,,,,,,FG000,"Vonapanitase administered at the time of radiocephalic fistula creation

vonapanitase",,,
arm,NCT02414841::arm::FG001,NCT02414841,Placebo,,,,,,,,,,FG001,"Placebo administered at the time of radiocephalic fistula creation

Placebo",,,
period,NCT02414841::period::1,NCT02414841,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02414841::outcome::primary::1,NCT02414841,Kaplan-Meier Estimate of Secondary AVF Patency,,,,,,,,,,,,,PRIMARY,"Median time from AVF creation to AVF abandonment (secondary patency), assessed up to 1 year."
outcome,NCT02414841::outcome::primary::2,NCT02414841,Number of Participants With AVF Use for Hemodialysis,,,,,,,,,,,,,PRIMARY,Assessed at up to 12 Months
country,NCT02414841::country::United States,NCT02414841,United States,,,,,,,,,,,,,,
country,NCT02414841::country::Canada,NCT02414841,Canada,,,,,,,,,,,,,,
trial,NCT04592419,NCT04592419,"A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)",PHASE3,cardiovascular disease,Macular Edema; Retinal Vein Occlusion,INDUSTRY,568.0,2020-09-25,2023-01-19,12.0,141.0,,,,,
arm,NCT04592419::arm::FG000,NCT04592419,KSI-301 (Arm A),,,,,,,,,,FG000,"Intravitreal injection of KSI-301 (5 mg) at Day 1, Week 4, and once every 8 weeks through Week 20 followed by an individualized dosing regimen of Intravitreal injection of KSI-301 (5 mg) from Week 24 ",,,
arm,NCT04592419::arm::FG001,NCT04592419,Aflibercept (Arm B),,,,,,,,,,FG001,Intravitreal injection of aflibercept (2 mg) once every 4 weeks through Week 20 followed by an individualized dosing regimen of Intravitreal injection of Aflibercept (2 mg) once every 4 weeks from Wee,,,
period,NCT04592419::period::1,NCT04592419,Primary Study (Through Year 1),,,,,,,,,,,,1.0,,
period,NCT04592419::period::2,NCT04592419,Open-Label Extension Period,,,,,,,,,,,,2.0,,
outcome,NCT04592419::outcome::primary::1,NCT04592419,Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to Week 24 in BRVO Participants.,,,,,,,,,,,,,PRIMARY,Day 1 to Week 24
outcome,NCT04592419::outcome::primary::2,NCT04592419,Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to Week 24 in All RVO Patients.,,,,,,,,,,,,,PRIMARY,Day 1 to Week 24
country,NCT04592419::country::United States,NCT04592419,United States,,,,,,,,,,,,,,
country,NCT04592419::country::Spain,NCT04592419,Spain,,,,,,,,,,,,,,
country,NCT04592419::country::Israel,NCT04592419,Israel,,,,,,,,,,,,,,
country,NCT04592419::country::France,NCT04592419,France,,,,,,,,,,,,,,
country,NCT04592419::country::Poland,NCT04592419,Poland,,,,,,,,,,,,,,
country,NCT04592419::country::Hungary,NCT04592419,Hungary,,,,,,,,,,,,,,
country,NCT04592419::country::Italy,NCT04592419,Italy,,,,,,,,,,,,,,
country,NCT04592419::country::Slovakia,NCT04592419,Slovakia,,,,,,,,,,,,,,
country,NCT04592419::country::Germany,NCT04592419,Germany,,,,,,,,,,,,,,
country,NCT04592419::country::Latvia,NCT04592419,Latvia,,,,,,,,,,,,,,
country,NCT04592419::country::Czechia,NCT04592419,Czechia,,,,,,,,,,,,,,
country,NCT04592419::country::Puerto Rico,NCT04592419,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00124072,NCT00124072,Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine,PHASE3,cardiovascular disease,Cardiovascular Disease,OTHER,12064.0,1998-07,2008-05,1.0,1.0,,,,,
arm,NCT00124072::arm::FG000,NCT00124072,Simvastatin 20 mg + Folic Acid and B12,,,,,,,,,,FG000,"Participants received 20 mg simvastatin once daily, and 2 mg folic acid with 1 mg vitamin B12 once daily",,,
arm,NCT00124072::arm::FG001,NCT00124072,Simvastatin 80 mg + Folic Acid and B12,,,,,,,,,,FG001,"Participants received 80 mg simvastatin once daily, and 2 mg folic acid with 1 mg vitamin B12 once daily",,,
arm,NCT00124072::arm::FG002,NCT00124072,Simvastatin 20 mg + Placebo,,,,,,,,,,FG002,"Participants received 20 mg simvastatin once daily, and placebo folic acid with placebo vitamin B12 once daily",,,
arm,NCT00124072::arm::FG003,NCT00124072,Simvastatin 80 mg + Placebo,,,,,,,,,,FG003,"Participants received 80 mg simvastatin once daily, and placebo folic acid with placebo vitamin B12 once daily",,,
period,NCT00124072::period::1,NCT00124072,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00124072::outcome::primary::1,NCT00124072,Major Vascular Events (MVE),,,,,,,,,,,,,PRIMARY,6.7 years median follow-up
country,NCT00124072::country::United Kingdom,NCT00124072,United Kingdom,,,,,,,,,,,,,,
trial,NCT02809131,NCT02809131,Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.,PHASE3,cardiovascular disease,Sick Sinus Syndrome; Complete Heart Block; Syncope; Chronic Systolic Heart Failure,OTHER,1010.0,2016-04-01,2021-09-30,1.0,1.0,,,,,
arm,NCT02809131::arm::FG000,NCT02809131,Saline Irrigation,,,,,,,,,,FG000,Saline Irrigation in patients undergoing a cardiac implantable electronic devices (CIED) procedure who have at least 2 CIED infection risk factors,,,
arm,NCT02809131::arm::FG001,NCT02809131,Antibiotic Irrigation and Oral Antibiotics,,,,,,,,,,FG001,"Antibacterial irrigant (polymyxinB/bacitracin) and postoperative oral antibiotics (cephalexin, clindamycin, or levofloxacin) in patients undergoing a cardiac implantable electronic devices (CIED) proc",,,
period,NCT02809131::period::1,NCT02809131,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02809131::outcome::primary::1,NCT02809131,Number of Patients With a Major Cardiac Implantable Electronic Devices (CIED) Infection,,,,,,,,,,,,,PRIMARY,6 months
country,NCT02809131::country::United States,NCT02809131,United States,,,,,,,,,,,,,,
trial,NCT00616772,NCT00616772,"Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood",PHASE3,cardiovascular disease,Coronary Artery Disease; Coronary Heart Disease; Dyslipidemia,INDUSTRY,682.0,2008-02,2012-09,1.0,124.0,,,,,
arm,NCT00616772::arm::FG000,NCT00616772,ABT-335 + Atorvastatin,,,,,,,,,,FG000,ABT-335 (135 mg) and atorvastatin (up to 40 mg) once daily for 2 years.,,,
arm,NCT00616772::arm::FG001,NCT00616772,Placebo + Atorvastatin,,,,,,,,,,FG001,Placebo and atorvastatin (up to 40 mg) once daily for 2 years.,,,
period,NCT00616772::period::1,NCT00616772,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00616772::outcome::primary::1,NCT00616772,Rate of Change in Mean Posterior-wall Carotid Intima-media Thickness (cIMT),,,,,,,,,,,,,PRIMARY,"Baseline, 6 months, 12 months, 18 months, and 24 months"
country,NCT00616772::country::United States,NCT00616772,United States,,,,,,,,,,,,,,
trial,NCT00628498,NCT00628498,Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study,PHASE3,cardiovascular disease,Hepatic Veno-Occlusive Disease,INDUSTRY,1206.0,2007-12,2016-09,1.0,125.0,,,,,
arm,NCT00628498::arm::FG000,NCT00628498,Defibrotide,,,,,,,,,,FG000,Defibrotide 25 mg/kg day given in 4 divided doses approximately every 6 hours,,,
period,NCT00628498::period::1,NCT00628498,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00628498::outcome::primary::1,NCT00628498,Survival by Day+100 Post Stem Cell Transplant or Chemotherapy,,,,,,,,,,,,,PRIMARY,Day +100 from HSCT or 100 days from start of chemotherapy
country,NCT00628498::country::United States,NCT00628498,United States,,,,,,,,,,,,,,
trial,NCT01307033,NCT01307033,A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351),PHASE3,cardiovascular disease,Hypertension,INDUSTRY,278.0,2011-03-29,2012-12-04,0.0,0.0,,,,,
arm,NCT01307033::arm::FG000,NCT01307033,MK-0954H (L50/H12.5) Double Blind Period (Period 1),,,,,,,,,,FG000,"One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 50 mg (L50) and 12.5 mg of hydrochlorothiazide (H12.5)",,,
arm,NCT01307033::arm::FG001,NCT01307033,MK-0954A (L100/H12.5) Double Blind Period (Period 1),,,,,,,,,,FG001,"One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 100 mg (L100) and 12.5 mg of hydrochlorothiazide (H12.5)",,,
arm,NCT01307033::arm::FG002,NCT01307033,L50/H12.5→L100/H12.5 Open Label (Period 2),,,,,,,,,,FG002,"One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 50 mg (L50) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will then receive open label MK-0954A (L100/H12.5)",,,
arm,NCT01307033::arm::FG003,NCT01307033,L100/H12.5→L100/H12.5 Open Label (Period 2),,,,,,,,,,FG003,"One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 100 mg (L100) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will continue to receive MK-0954A orally, once d",,,
period,NCT01307033::period::1,NCT01307033,8-week Double-blind Period,,,,,,,,,,,,1.0,,
period,NCT01307033::period::2,NCT01307033,44-week Open-label Extension,,,,,,,,,,,,2.0,,
outcome,NCT01307033::outcome::primary::1,NCT01307033,Percentage of Participants Who Experienced an Adverse Event When Receiving MK-0954A (L100/H12.5) During Study (8-week Double-blind and/or 44-week Open-label Extension),,,,,,,,,,,,,PRIMARY,Up to 52 weeks
trial,NCT03001076,NCT03001076,Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility),PHASE3,cardiovascular disease,Hypercholesterolemia; Atherosclerosis; Statin Adverse Reaction,INDUSTRY,269.0,2016-11-29,2018-02-12,1.0,1.0,,,,,
arm,NCT03001076::arm::FG000,NCT03001076,Placebo,,,,,,,,,,FG000,"Participants received placebo tablet, once-daily by mouth and ezetimibe 10 mg capsules, once-daily by mouth for 4 weeks prior to the 12-week treatment period. During the treatment period, participants",,,
arm,NCT03001076::arm::FG001,NCT03001076,Bempedoic Acid,,,,,,,,,,FG001,"Participants received placebo tablet, once-daily by mouth and ezetimibe 10 mg capsules, once-daily by mouth for 4 weeks prior to the 12-week treatment period. During the treatment period, participants",,,
period,NCT03001076::period::1,NCT03001076,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03001076::outcome::primary::1,NCT03001076,Percent Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol (LDL-C),,,,,,,,,,,,,PRIMARY,Week 12
country,NCT03001076::country::United States,NCT03001076,United States,,,,,,,,,,,,,,
trial,NCT00591578,NCT00591578,Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,984.0,2007-12,2010-03,4.0,88.0,,,,,
arm,NCT00591578::arm::FG000,NCT00591578,Azilsartan Medoxomil 40 mg QD,,,,,,,,,,FG000,"Azilsartan medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 40 mg, tablets, orally, once daily for up to 22 weeks.

Open Label Extension: At Week 24/completion of the double-blind",,,
arm,NCT00591578::arm::FG001,NCT00591578,Azilsartan Medoxomil 80 mg QD,,,,,,,,,,FG001,"Azilsartan medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 80 mg, tablets, orally, once daily for up to 22 weeks.

Open Label Extension: At Week 24/completion of the double-blind",,,
arm,NCT00591578::arm::FG002,NCT00591578,Valsartan 320 mg QD,,,,,,,,,,FG002,"Valsartan 80 mg, tablets, orally, once daily for 2 weeks; titrated to 320 mg, tablets, orally, once daily for up to 22 weeks.

Open Label Extension: At Week 24/completion of the double-blind treatment",,,
period,NCT00591578::period::1,NCT00591578,Double-Blind Treatment Phase,,,,,,,,,,,,1.0,,
period,NCT00591578::period::2,NCT00591578,Open-Label Extension Phase,,,,,,,,,,,,2.0,,
outcome,NCT00591578::outcome::primary::1,NCT00591578,Change From Baseline in 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.,,,,,,,,,,,,,PRIMARY,Baseline and Week 24.
country,NCT00591578::country::United States,NCT00591578,United States,,,,,,,,,,,,,,
country,NCT00591578::country::Mexico,NCT00591578,Mexico,,,,,,,,,,,,,,
country,NCT00591578::country::Chile,NCT00591578,Chile,,,,,,,,,,,,,,
country,NCT00591578::country::Peru,NCT00591578,Peru,,,,,,,,,,,,,,
trial,NCT03399370,NCT03399370,Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol,PHASE3,cardiovascular disease,ASCVD; Elevated Cholesterol,INDUSTRY,1561.0,2017-12-21,2019-09-17,1.0,145.0,,,,,
arm,NCT03399370::arm::FG000,NCT03399370,Inclisiran,,,,,,,,,,FG000,"Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection on Day 1, Day 90, then every 6 months.

Inclisiran Sodium: Inclisiran is a small interfering ribonucleic acid (RNA) that in",,,
arm,NCT03399370::arm::FG001,NCT03399370,Saline Solution,,,,,,,,,,FG001,"Placebo will be administered as a SC injection of saline solution on Day 1, Day 90, then every 6 months.

Placebo: Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for ",,,
period,NCT03399370::period::1,NCT03399370,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03399370::outcome::primary::1,NCT03399370,Percentage Change in LDL-C From Baseline to Day 510,,,,,,,,,,,,,PRIMARY,"Baseline, Day 510"
outcome,NCT03399370::outcome::primary::2,NCT03399370,Time-adjusted Percentage Change in LDL-C Levels From Baseline After Day 90 and up to Day 540,,,,,,,,,,,,,PRIMARY,"Baseline, Day 90 to Day 540"
country,NCT03399370::country::United States,NCT03399370,United States,,,,,,,,,,,,,,
trial,NCT02322320,NCT02322320,"Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)",PHASE3,cardiovascular disease,Multiple Myeloma,NIH,273.0,2015-03,2019-06-07,1.0,42.0,,,,,
arm,NCT02322320::arm::FG000,NCT02322320,Tandem Auto Transplant,,,,,,,,,,FG000,"Initial autologous transplant followed by a second autologous transplant and lenalidomide maintenance

Lenalidomide: In BMT CTN 0702, maintenance therapy with lenalidomide started at 10 mg daily for t",,,
arm,NCT02322320::arm::FG001,NCT02322320,RVD Consolidation,,,,,,,,,,FG001,"Initial autologous transplant followed by lenalidomide, bortezomib and dexamethasone (RVD) consolidation and lenalidomide maintenance

Lenalidomide: In BMT CTN 0702, maintenance therapy with lenalidom",,,
arm,NCT02322320::arm::FG002,NCT02322320,Lenalidomide Maintenance,,,,,,,,,,FG002,"Initial autologous transplant followed by lenalidomide maintenance

Lenalidomide: In BMT CTN 0702, maintenance therapy with lenalidomide started at 10 mg daily for three months and increased to 15 mg ",,,
period,NCT02322320::period::1,NCT02322320,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02322320::outcome::primary::1,NCT02322320,Percentage of Participants With Progression-free Survival (PFS),,,,,,,,,,,,,PRIMARY,5 years post-randomization in BMT CTN 0702
country,NCT02322320::country::United States,NCT02322320,United States,,,,,,,,,,,,,,
trial,NCT00368277,NCT00368277,"A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly",PHASE3,cardiovascular disease,Hypertension,INDUSTRY,901.0,2006-09,2008-02,1.0,1.0,,,,,
arm,NCT00368277::arm::FG000,NCT00368277,Aliskiren Based Treatment Regimen,,,,,,,,,,FG000,Aliskiren 150 mg; aliskiren 300 mg; aliskiren 300mg + hydrochlorothiazide 12.5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; aliskir,,,
arm,NCT00368277::arm::FG001,NCT00368277,Ramipril Based Treatment Regimen,,,,,,,,,,FG001,Ramipril 5 mg; Ramipril 10 mg; Ramipril 10 mg + hydrochlorothiazide 12.5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; Ramipril 10 mg + ,,,
period,NCT00368277::period::1,NCT00368277,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00368277::outcome::primary::1,NCT00368277,Change From Baseline in Mean Sitting Systolic Blood Pressure to Week 12,,,,,,,,,,,,,PRIMARY,Baseline and Week 12
country,NCT00368277::country::United States,NCT00368277,United States,,,,,,,,,,,,,,
trial,NCT01895777,NCT01895777,Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE),PHASE3,cardiovascular disease,Venous Thromboembolism,INDUSTRY,267.0,2013-09-25,2019-11-14,26.0,65.0,,,,,
arm,NCT01895777::arm::FG000,NCT01895777,Dabigatran Etexilate,,,,,,,,,,FG000,"Oral administration of dabigatran etexilate (DE) twice daily. Patients aged ≥8 years: age- and weight-adjusted DE dosing via capsules using 50 milligram (mg), 75 mg, 110 mg, and 150 mg capsules. Patie",,,
arm,NCT01895777::arm::FG001,NCT01895777,Standard of Care,,,,,,,,,,FG001,Investigators decided on SoC treatment at time of randomisation: either low molecular weight heparin (LMWH) or vitamin K antagonists (VKA) or fondaparinux.,,,
period,NCT01895777::period::1,NCT01895777,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01895777::outcome::primary::1,NCT01895777,Composite Primary Endpoint,,,,,,,,,,,,,PRIMARY,"From the time of randomisation until Week 12, 84 days after randomisation including a visit window of 7 days."
country,NCT01895777::country::United States,NCT01895777,United States,,,,,,,,,,,,,,
country,NCT01895777::country::Russia,NCT01895777,Russia,,,,,,,,,,,,,,
country,NCT01895777::country::Turkey (Türkiye),NCT01895777,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01895777::country::Czechia,NCT01895777,Czechia,,,,,,,,,,,,,,
country,NCT01895777::country::Brazil,NCT01895777,Brazil,,,,,,,,,,,,,,
country,NCT01895777::country::Belgium,NCT01895777,Belgium,,,,,,,,,,,,,,
country,NCT01895777::country::Canada,NCT01895777,Canada,,,,,,,,,,,,,,
country,NCT01895777::country::Austria,NCT01895777,Austria,,,,,,,,,,,,,,
country,NCT01895777::country::Germany,NCT01895777,Germany,,,,,,,,,,,,,,
country,NCT01895777::country::Italy,NCT01895777,Italy,,,,,,,,,,,,,,
country,NCT01895777::country::Mexico,NCT01895777,Mexico,,,,,,,,,,,,,,
country,NCT01895777::country::Norway,NCT01895777,Norway,,,,,,,,,,,,,,
country,NCT01895777::country::Sweden,NCT01895777,Sweden,,,,,,,,,,,,,,
country,NCT01895777::country::Ukraine,NCT01895777,Ukraine,,,,,,,,,,,,,,
country,NCT01895777::country::Argentina,NCT01895777,Argentina,,,,,,,,,,,,,,
country,NCT01895777::country::Denmark,NCT01895777,Denmark,,,,,,,,,,,,,,
country,NCT01895777::country::Finland,NCT01895777,Finland,,,,,,,,,,,,,,
country,NCT01895777::country::France,NCT01895777,France,,,,,,,,,,,,,,
country,NCT01895777::country::Greece,NCT01895777,Greece,,,,,,,,,,,,,,
country,NCT01895777::country::Hungary,NCT01895777,Hungary,,,,,,,,,,,,,,
country,NCT01895777::country::Israel,NCT01895777,Israel,,,,,,,,,,,,,,
country,NCT01895777::country::Lithuania,NCT01895777,Lithuania,,,,,,,,,,,,,,
country,NCT01895777::country::Spain,NCT01895777,Spain,,,,,,,,,,,,,,
country,NCT01895777::country::Switzerland,NCT01895777,Switzerland,,,,,,,,,,,,,,
country,NCT01895777::country::Taiwan,NCT01895777,Taiwan,,,,,,,,,,,,,,
country,NCT01895777::country::Thailand,NCT01895777,Thailand,,,,,,,,,,,,,,
trial,NCT00151775,NCT00151775,Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,362.0,2005-05,2008-09,11.0,65.0,,,,,
arm,NCT00151775::arm::FG000,NCT00151775,"Cohort A: High Dose OM in Periods 2, 3",,,,,,,,,,FG000,Subgroup of Cohort A (6-16 years old with a limit on the number of Black participants) given a high dose (20 mg or 40 mg) of olmesartan medoxomil suspension (OM) depending on weight during Period 2 (d,,,
arm,NCT00151775::arm::FG001,NCT00151775,"Cohort A: Low Dose OM in Periods 2, 3",,,,,,,,,,FG001,Subgroup of Cohort A (6-16 years old with a limit on the number of Black participants) given a low dose (2.5 mg or 5.0 mg) of olmesartan medoxomil suspension (OM) depending on weight during Period 2 (,,,
arm,NCT00151775::arm::FG002,NCT00151775,Cohort A: Placebo in Period 3 (From High Dose in Period 2),,,,,,,,,,FG002,"Subgroup of Cohort A (6-16 years old with a limit on the number of Black participants) given placebo during Period 3 (double-blind, placebo-controlled period from week 3 to week 5) instead of the prev",,,
arm,NCT00151775::arm::FG003,NCT00151775,Cohort A: Placebo in Period 3 (From Low Dose in Period 2),,,,,,,,,,FG003,"Subgroup of Cohort A (6-16 years old with a limit on the number of Black participants) given placebo during Period 3 (double-blind, placebo-controlled period from week 3 to week 5) instead of the prev",,,
arm,NCT00151775::arm::FG004,NCT00151775,Cohort A: Period 4 Open-label OM,,,,,,,,,,FG004,All members of Cohort A (6-16 years old with a limit on the number of Black participants) were given 10 mg to 40 mg of olmesartan (OM) administered as oral suspension or tablets depending on participa,,,
arm,NCT00151775::arm::FG005,NCT00151775,"Cohort B: High Dose OM in Periods 2, 3",,,,,,,,,,FG005,Subgroup of Cohort B (6-16 years old comprised exclusively of Black participants) given a high dose (20 mg or 40 mg) of olmesartan medoxomil suspension (OM) depending on weight during Period 2 (double,,,
arm,NCT00151775::arm::FG006,NCT00151775,"Cohort B: Low Dose OM in Periods 2, 3",,,,,,,,,,FG006,Subgroup of Cohort B (6-16 years old comprised exclusively of Black participants) given a low dose (2.5 mg or 5.0 mg) of olmesartan medoxomil suspension (OM) depending on weight during Period 2 (doubl,,,
arm,NCT00151775::arm::FG007,NCT00151775,Cohort B: Placebo in Period 3 (From High Dose in Period 2),,,,,,,,,,FG007,"Subgroup of Cohort B (6-16 years old comprised exclusively of Black participants) given placebo during Period 3 (double-blind, placebo-controlled period from week 3 to week 5) instead of the previous ",,,
arm,NCT00151775::arm::FG008,NCT00151775,Cohort B: Placebo in Period 3 (From Low Dose in Period 2),,,,,,,,,,FG008,"Subgroup of Cohort B (6-16 years old comprised exclusively of Black participants) given placebo during Period 3 (double-blind, placebo-controlled period from week 3 to week 5) instead of the previous ",,,
arm,NCT00151775::arm::FG009,NCT00151775,Cohort B: Period 4 Open-label OM,,,,,,,,,,FG009,All members of Cohort B (6-16 years old comprised exclusively of Black participants) were given 10 mg to 40 mg of olmesartan (OM) administered as oral suspension or tablets depending on participant we,,,
arm,NCT00151775::arm::FG010,NCT00151775,"Cohort C: OM in Periods 2, 3, 4",,,,,,,,,,FG010,Cohort C (1-5 years old) was given olmesartan medoxomil (OM) 0.3 mg/kg in Period 2 (open-label period from day 0 to week 3) and a subgroup of Cohort C was given that dose of OM during Period 3 (double,,,
arm,NCT00151775::arm::FG011,NCT00151775,Cohort C: Placebo in Period 3 (From OM in Period 2),,,,,,,,,,FG011,"Subgroup of Cohort C (1-5 years old) given placebo during Period 3 (double-blind, placebo-controlled period from week 3 to week 5).",,,
period,NCT00151775::period::1,NCT00151775,Period 2 - Double-Blind Dose Response,,,,,,,,,,,,1.0,,
period,NCT00151775::period::2,NCT00151775,"Period 3: Double-blind, Withdrawal",,,,,,,,,,,,2.0,,
period,NCT00151775::period::3,NCT00151775,Period 4: Open Label,,,,,,,,,,,,3.0,,
outcome,NCT00151775::outcome::primary::1,NCT00151775,Least Squares Mean Change From Baseline in Seated Systolic Blood Pressure to the End of Period 2 (3 Weeks),,,,,,,,,,,,,PRIMARY,Day 0 to 3 weeks
outcome,NCT00151775::outcome::primary::2,NCT00151775,Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 2 (3 Weeks),,,,,,,,,,,,,PRIMARY,Day 0 (baseline) to 3 weeks
country,NCT00151775::country::United States,NCT00151775,United States,,,,,,,,,,,,,,
country,NCT00151775::country::South Africa,NCT00151775,South Africa,,,,,,,,,,,,,,
country,NCT00151775::country::India,NCT00151775,India,,,,,,,,,,,,,,
country,NCT00151775::country::Argentina,NCT00151775,Argentina,,,,,,,,,,,,,,
country,NCT00151775::country::Brazil,NCT00151775,Brazil,,,,,,,,,,,,,,
country,NCT00151775::country::Colombia,NCT00151775,Colombia,,,,,,,,,,,,,,
country,NCT00151775::country::Zambia,NCT00151775,Zambia,,,,,,,,,,,,,,
country,NCT00151775::country::Chile,NCT00151775,Chile,,,,,,,,,,,,,,
country,NCT00151775::country::Kenya,NCT00151775,Kenya,,,,,,,,,,,,,,
country,NCT00151775::country::Peru,NCT00151775,Peru,,,,,,,,,,,,,,
country,NCT00151775::country::Uganda,NCT00151775,Uganda,,,,,,,,,,,,,,
trial,NCT01556997,NCT01556997,Perindopril Amlodipine for the Treatment of Hypertension,PHASE3,cardiovascular disease,Essential Hypertension,INDUSTRY,837.0,2012-02,2013-02,1.0,48.0,,,,,
arm,NCT01556997::arm::FG000,NCT01556997,XOMA 985,,,,,,,,,,FG000,"fixed-dose combination of perindopril arginine/amlodipine besylate(PERa/AMLb)

XOMA 985: PERa/AMLb capsule taken once daily by mouth for six weeks",,,
arm,NCT01556997::arm::FG001,NCT01556997,Amlodipine Besylate (AMLb),,,,,,,,,,FG001,Amlodipine Besylate: AMLb capsule taken once daily by mouth for six weeks,,,
arm,NCT01556997::arm::FG002,NCT01556997,Perindopril Erbumine (PERe),,,,,,,,,,FG002,Perindopril Erbumine: PERe capsule taken once daily by mouth for six weeks,,,
period,NCT01556997::period::1,NCT01556997,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01556997::outcome::primary::1,NCT01556997,Change From Baseline to End of Treatment in the Mean Seated Trough Cuff Diastolic Blood Pressure (DBP).,,,,,,,,,,,,,PRIMARY,Day 0 to Day 42
country,NCT01556997::country::United States,NCT01556997,United States,,,,,,,,,,,,,,
trial,NCT00902538,NCT00902538,Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension,PHASE3,cardiovascular disease,Essential Hypertension,INDUSTRY,2204.0,2009-04,2010-10,14.0,117.0,,,,,
arm,NCT00902538::arm::FG000,NCT00902538,Olmesartan(OLM) 40 Mg-Amlodipine(AML) 10 mg,,,,,,,,,,FG000,"The participants in this arm received Olmesartan(OLM) 40 mg-Amlodipine(AML) 10 mg oral tablets, once a day, for the 8-week, single-blind, run-in Period 1. Then in Period 2, participants would be rando",,,
arm,NCT00902538::arm::FG001,NCT00902538,OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5,,,,,,,,,,FG001,"Participants could start receiving OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5 oral tablets given once daily in randomized, double-blind, 8-week Period 2. This combination was continued into single-",,,
arm,NCT00902538::arm::FG002,NCT00902538,OLM 40-AML 10-HCTZ 25,,,,,,,,,,FG002,"Participants could start receiving OLM 40-AML 10-HCTZ 25 oral tablets, given once daily, in randomized, double-blind, 8- week Period 2.",,,
arm,NCT00902538::arm::FG003,NCT00902538,OLM 40-AML 10-HCTZ 12.5 (Responders),,,,,,,,,,FG003,"Participants who meet their blood pressure goals (responded) in Period 3 and continued into 8-week, double-blind Period 4 continued to receive OLM 40-AML 10-HCTZ 12.5 oral tablets given once daily.",,,
arm,NCT00902538::arm::FG004,NCT00902538,OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5 (Non-responders),,,,,,,,,,FG004,"Participants finishing Period 3, but, who did not meet their blood pressure goals (non-responders) could receive OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5 oral tablets, given once daily, in double",,,
arm,NCT00902538::arm::FG005,NCT00902538,OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 25 (Non-responders),,,,,,,,,,FG005,"Participants finishing Period 3, but, who did not meet their blood pressure goals (non-responders) could receive OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 25 oral tablets, given once daily, in double-b",,,
period,NCT00902538::period::1,NCT00902538,"1-Single-blind, Run-in, Single-Treatment",,,,,,,,,,,,1.0,,
period,NCT00902538::period::2,NCT00902538,2-Randomized Double-blind 3 Treatments,,,,,,,,,,,,2.0,,
period,NCT00902538::period::3,NCT00902538,"3-Single-blind, Single Treatment",,,,,,,,,,,,3.0,,
period,NCT00902538::period::4,NCT00902538,4-Randomized Double-blind 2 Treatments,,,,,,,,,,,,4.0,,
outcome,NCT00902538::outcome::primary::1,NCT00902538,Change in Seated Diastolic Blood Pressure (SeDBP) of the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg vs. OM/AML 40/10 mg,,,,,,,,,,,,,PRIMARY,baseline (8 weeks) to 16 weeks
country,NCT00902538::country::France,NCT00902538,France,,,,,,,,,,,,,,
country,NCT00902538::country::Spain,NCT00902538,Spain,,,,,,,,,,,,,,
country,NCT00902538::country::Ukraine,NCT00902538,Ukraine,,,,,,,,,,,,,,
country,NCT00902538::country::Poland,NCT00902538,Poland,,,,,,,,,,,,,,
country,NCT00902538::country::Russia,NCT00902538,Russia,,,,,,,,,,,,,,
country,NCT00902538::country::Czechia,NCT00902538,Czechia,,,,,,,,,,,,,,
country,NCT00902538::country::Germany,NCT00902538,Germany,,,,,,,,,,,,,,
country,NCT00902538::country::Romania,NCT00902538,Romania,,,,,,,,,,,,,,
country,NCT00902538::country::Belgium,NCT00902538,Belgium,,,,,,,,,,,,,,
country,NCT00902538::country::Netherlands,NCT00902538,Netherlands,,,,,,,,,,,,,,
country,NCT00902538::country::Slovakia,NCT00902538,Slovakia,,,,,,,,,,,,,,
country,NCT00902538::country::Bulgaria,NCT00902538,Bulgaria,,,,,,,,,,,,,,
country,NCT00902538::country::Denmark,NCT00902538,Denmark,,,,,,,,,,,,,,
country,NCT00902538::country::Austria,NCT00902538,Austria,,,,,,,,,,,,,,
trial,NCT01709513,NCT01709513,"Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)",PHASE3,cardiovascular disease,Hypercholesterolemia,INDUSTRY,314.0,2012-09-30,2017-05-31,8.0,70.0,,,,,
arm,NCT01709513::arm::FG000,NCT01709513,Atorvastatin (Statin Rechallenge Arm),,,,,,,,,,FG000,Atorvastatin 20 mg over-encapsulated tablets orally once daily (QD) for 24 weeks and placebo (for alirocumab) subcutaneous (SC) injection every two weeks (Q2W) for 24 weeks added to stable LMT.,,,
arm,NCT01709513::arm::FG001,NCT01709513,Ezetimibe (Active Comparator),,,,,,,,,,FG001,Ezetimibe 10 mg over-encapsulated tablets orally QD for 24 weeks and placebo (for alirocumab) SC injection Q2W for 24 weeks added to stable LMT.,,,
arm,NCT01709513::arm::FG002,NCT01709513,Alirocumab 75 mg/ up to 150 mg,,,,,,,,,,FG002,Alirocumab 75 mg SC injection Q2W for 24 weeks and placebo (for atorvastatin/ezetimibe) over-encapsulated tablets orally QD for 24 weeks added to stable LMT. Alirocumab dose up-titrated to 150 mg Q2W ,,,
period,NCT01709513::period::1,NCT01709513,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01709513::outcome::primary::1,NCT01709513,Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--To-Treat (ITT) Analysis,,,,,,,,,,,,,PRIMARY,From Baseline to Week 24
country,NCT01709513::country::United States,NCT01709513,United States,,,,,,,,,,,,,,
country,NCT01709513::country::United Kingdom,NCT01709513,United Kingdom,,,,,,,,,,,,,,
country,NCT01709513::country::France,NCT01709513,France,,,,,,,,,,,,,,
country,NCT01709513::country::Israel,NCT01709513,Israel,,,,,,,,,,,,,,
country,NCT01709513::country::Italy,NCT01709513,Italy,,,,,,,,,,,,,,
country,NCT01709513::country::Austria,NCT01709513,Austria,,,,,,,,,,,,,,
country,NCT01709513::country::Canada,NCT01709513,Canada,,,,,,,,,,,,,,
country,NCT01709513::country::Norway,NCT01709513,Norway,,,,,,,,,,,,,,
trial,NCT00508820,NCT00508820,An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP,PHASE3,cardiovascular disease,Idiopathic Thrombocytopenic Purpura; Thrombocytopenia; Thrombocytopenic Purpura,INDUSTRY,407.0,2005-02-01,2011-03-01,0.0,0.0,,,,,
arm,NCT00508820::arm::FG000,NCT00508820,Romiplostim (AMG 531) Cohort 1,,,,,,,,,,FG000,Romiplostim administered to participants subcutaneously weekly based on platelet counts. Participants were enrolled under the original protocol or protocol amendments 1-3 where starting dose was 3mcg/,,,
arm,NCT00508820::arm::FG001,NCT00508820,Romiplostim (AMG 531) Cohort 2,,,,,,,,,,FG001,Romiplostim administered to participants subcutaneously weekly based on platelet counts. Participants were enrolled under protocol amendments 4 where starting dose was 1mcg/kg.,,,
period,NCT00508820::period::1,NCT00508820,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00508820::outcome::primary::1,NCT00508820,Adverse Events,,,,,,,,,,,,,PRIMARY,Duration of Treatment plus 30 days or End of Study (whichever is later). Approximately 205 weeks.
trial,NCT02892149,NCT02892149,Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD),PHASE3,cardiovascular disease,Anemia; Dialysis-Dependent Chronic Kidney Disease,INDUSTRY,3554.0,2016-08,2020-03-30,18.0,278.0,,,,,
arm,NCT02892149::arm::FG000,NCT02892149,Vadadustat,,,,,,,,,,FG000,"Participants were randomized to receive Vadadustat at an initial oral dose of 300 milligrams per day (mg/day). Thereafter, Vadadustat was taken once daily on an outpatient basis. Up-and-down titration",,,
arm,NCT02892149::arm::FG001,NCT02892149,Darbepoetin Alfa,,,,,,,,,,FG001,"Participants were randomized to Darbepoetin alfa at an initial dose that was based on the current package insert for investigational sites in the United States (US), and the Summary of Product Charact",,,
period,NCT02892149::period::1,NCT02892149,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02892149::outcome::primary::1,NCT02892149,Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36),,,,,,,,,,,,,PRIMARY,Baseline
outcome,NCT02892149::outcome::primary::2,NCT02892149,Median Time to First Major Adverse Cardiovascular Event (MACE),,,,,,,,,,,,,PRIMARY,Weeks 24 to 36
country,NCT02892149::country::United States,NCT02892149,United States,,,,,,,,,,,,,,
country,NCT02892149::country::Brazil,NCT02892149,Brazil,,,,,,,,,,,,,,
country,NCT02892149::country::Bulgaria,NCT02892149,Bulgaria,,,,,,,,,,,,,,
country,NCT02892149::country::South Korea,NCT02892149,South Korea,,,,,,,,,,,,,,
country,NCT02892149::country::Russia,NCT02892149,Russia,,,,,,,,,,,,,,
country,NCT02892149::country::Ukraine,NCT02892149,Ukraine,,,,,,,,,,,,,,
country,NCT02892149::country::Argentina,NCT02892149,Argentina,,,,,,,,,,,,,,
country,NCT02892149::country::Australia,NCT02892149,Australia,,,,,,,,,,,,,,
country,NCT02892149::country::Poland,NCT02892149,Poland,,,,,,,,,,,,,,
country,NCT02892149::country::Serbia,NCT02892149,Serbia,,,,,,,,,,,,,,
country,NCT02892149::country::Canada,NCT02892149,Canada,,,,,,,,,,,,,,
country,NCT02892149::country::France,NCT02892149,France,,,,,,,,,,,,,,
country,NCT02892149::country::Israel,NCT02892149,Israel,,,,,,,,,,,,,,
country,NCT02892149::country::Italy,NCT02892149,Italy,,,,,,,,,,,,,,
country,NCT02892149::country::United Kingdom,NCT02892149,United Kingdom,,,,,,,,,,,,,,
country,NCT02892149::country::Germany,NCT02892149,Germany,,,,,,,,,,,,,,
country,NCT02892149::country::Mexico,NCT02892149,Mexico,,,,,,,,,,,,,,
country,NCT02892149::country::Portugal,NCT02892149,Portugal,,,,,,,,,,,,,,
trial,NCT02107898,NCT02107898,Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN),PHASE3,cardiovascular disease,Hypercholesterolemia,INDUSTRY,216.0,2014-03,2015-09,1.0,32.0,,,,,
arm,NCT02107898::arm::FG000,NCT02107898,Placebo Q2W,,,,,,,,,,FG000,Placebo (for alirocumab) subcutaneous (SC) injection every two weeks (Q2W) added to stable lipid-modifying therapy (LMT) for 52 weeks.,,,
arm,NCT02107898::arm::FG001,NCT02107898,Alirocumab 75 mg/Up to 150 mg Q2W,,,,,,,,,,FG001,Alirocumab 75 mg SC injection Q2W added to stable LMT for 52 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when low-density lipoprotein cholesterol (LDL-C) levels ≥ 100 mg/dL (2.59 mmol/L),,,
period,NCT02107898::period::1,NCT02107898,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02107898::outcome::primary::1,NCT02107898,Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis),,,,,,,,,,,,,PRIMARY,From Baseline to Week 24
country,NCT02107898::country::Japan,NCT02107898,Japan,,,,,,,,,,,,,,
trial,NCT00273052,NCT00273052,COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,514.0,2006-01-05,2007-12-28,3.0,120.0,,,,,
arm,NCT00273052::arm::FG000,NCT00273052,Coreg CR,,,,,,,,,,FG000,"Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)",,,
arm,NCT00273052::arm::FG001,NCT00273052,Toprol XL,,,,,,,,,,FG001,"Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)",,,
period,NCT00273052::period::1,NCT00273052,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00273052::outcome::primary::1,NCT00273052,Change From Baseline in Triglycerides Levels by Treatment Group at Maintenance Month 6,,,,,,,,,,,,,PRIMARY,Baseline and Month 6
outcome,NCT00273052::outcome::primary::2,NCT00273052,Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) Levels by Treatment Group at Maintenance Month 6,,,,,,,,,,,,,PRIMARY,Baseline and Month 6
country,NCT00273052::country::United States,NCT00273052,United States,,,,,,,,,,,,,,
country,NCT00273052::country::Canada,NCT00273052,Canada,,,,,,,,,,,,,,
country,NCT00273052::country::Puerto Rico,NCT00273052,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00335452,NCT00335452,Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS,PHASE3,cardiovascular disease,Acute Coronary Disease; Angina Unstable,INDUSTRY,25086.0,2006-06,2009-09,38.0,38.0,,,,,
arm,NCT00335452::arm::FG000,NCT00335452,Clopidogrel 300/75/75 mg + ASA Low Dose,,,,,,,,,,FG000,"Day 1: Clopidogrel 300 mg loading dose + ASA ≥ 300 mg

Day 2 to Day 7: Clopidogrel 75 mg + ASA 75-100 mg

Day 8 to Day 30: Clopidogrel 75 mg + ASA 75-100 mg",,,
arm,NCT00335452::arm::FG001,NCT00335452,Clopidogrel 300/75/75 mg + ASA High Dose,,,,,,,,,,FG001,"Day 1: Clopidogrel 300 mg loading dose + ASA ≥ 300 mg

Day 2 to Day 7: Clopidogrel 75 mg + ASA 300-325 mg

Day 8 to Day 30: Clopidogrel 75 mg + ASA 300-325 mg",,,
arm,NCT00335452::arm::FG002,NCT00335452,Clopidogrel 600/150/75 mg + ASA Low Dose,,,,,,,,,,FG002,"Day 1: Clopidogrel 600 mg loading dose + ASA ≥ 300 mg

Day 2 to Day 7: Clopidogrel 150 mg + ASA 75-100 mg

Day 8 to Day 30: Clopidogrel 75 mg + ASA 75-100 mg",,,
arm,NCT00335452::arm::FG003,NCT00335452,Clopidogrel 600/150/75 mg + ASA High Dose,,,,,,,,,,FG003,"Day 1: Clopidogrel 600 mg loading dose + ASA ≥ 300 mg

Day 2 to Day 7: Clopidogrel 150 mg + ASA 300-325 mg

Day 8 to Day 30: Clopidogrel 75 mg + ASA 300-325 mg",,,
period,NCT00335452::period::1,NCT00335452,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00335452::outcome::primary::1,NCT00335452,First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison,,,,,,,,,,,,,PRIMARY,30 days
outcome,NCT00335452::outcome::primary::2,NCT00335452,First Occurrence of CV Death / MI / Stroke - ASA Dose Comparison,,,,,,,,,,,,,PRIMARY,30 days
outcome,NCT00335452::outcome::primary::3,NCT00335452,First Occurrence of CV Death / MI / Stroke - Interaction Clopidogrel Treatment Regimen and ASA Dose Level,,,,,,,,,,,,,PRIMARY,30 days
outcome,NCT00335452::outcome::primary::4,NCT00335452,First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison in PCI Subgroup,,,,,,,,,,,,,PRIMARY,30 days
country,NCT00335452::country::United States,NCT00335452,United States,,,,,,,,,,,,,,
country,NCT00335452::country::Argentina,NCT00335452,Argentina,,,,,,,,,,,,,,
country,NCT00335452::country::Australia,NCT00335452,Australia,,,,,,,,,,,,,,
country,NCT00335452::country::Austria,NCT00335452,Austria,,,,,,,,,,,,,,
country,NCT00335452::country::Belgium,NCT00335452,Belgium,,,,,,,,,,,,,,
country,NCT00335452::country::Brazil,NCT00335452,Brazil,,,,,,,,,,,,,,
country,NCT00335452::country::Bulgaria,NCT00335452,Bulgaria,,,,,,,,,,,,,,
country,NCT00335452::country::Canada,NCT00335452,Canada,,,,,,,,,,,,,,
country,NCT00335452::country::Chile,NCT00335452,Chile,,,,,,,,,,,,,,
country,NCT00335452::country::China,NCT00335452,China,,,,,,,,,,,,,,
country,NCT00335452::country::Croatia,NCT00335452,Croatia,,,,,,,,,,,,,,
country,NCT00335452::country::Czechia,NCT00335452,Czechia,,,,,,,,,,,,,,
country,NCT00335452::country::Estonia,NCT00335452,Estonia,,,,,,,,,,,,,,
country,NCT00335452::country::Finland,NCT00335452,Finland,,,,,,,,,,,,,,
country,NCT00335452::country::France,NCT00335452,France,,,,,,,,,,,,,,
country,NCT00335452::country::Germany,NCT00335452,Germany,,,,,,,,,,,,,,
country,NCT00335452::country::Greece,NCT00335452,Greece,,,,,,,,,,,,,,
country,NCT00335452::country::India,NCT00335452,India,,,,,,,,,,,,,,
country,NCT00335452::country::Ireland,NCT00335452,Ireland,,,,,,,,,,,,,,
country,NCT00335452::country::Israel,NCT00335452,Israel,,,,,,,,,,,,,,
country,NCT00335452::country::Italy,NCT00335452,Italy,,,,,,,,,,,,,,
country,NCT00335452::country::Latvia,NCT00335452,Latvia,,,,,,,,,,,,,,
country,NCT00335452::country::Lithuania,NCT00335452,Lithuania,,,,,,,,,,,,,,
country,NCT00335452::country::Malaysia,NCT00335452,Malaysia,,,,,,,,,,,,,,
country,NCT00335452::country::Mexico,NCT00335452,Mexico,,,,,,,,,,,,,,
country,NCT00335452::country::Netherlands,NCT00335452,Netherlands,,,,,,,,,,,,,,
country,NCT00335452::country::Poland,NCT00335452,Poland,,,,,,,,,,,,,,
country,NCT00335452::country::Romania,NCT00335452,Romania,,,,,,,,,,,,,,
country,NCT00335452::country::Russia,NCT00335452,Russia,,,,,,,,,,,,,,
country,NCT00335452::country::Singapore,NCT00335452,Singapore,,,,,,,,,,,,,,
country,NCT00335452::country::Slovakia,NCT00335452,Slovakia,,,,,,,,,,,,,,
country,NCT00335452::country::South Africa,NCT00335452,South Africa,,,,,,,,,,,,,,
country,NCT00335452::country::South Korea,NCT00335452,South Korea,,,,,,,,,,,,,,
country,NCT00335452::country::Spain,NCT00335452,Spain,,,,,,,,,,,,,,
country,NCT00335452::country::Sweden,NCT00335452,Sweden,,,,,,,,,,,,,,
country,NCT00335452::country::Switzerland,NCT00335452,Switzerland,,,,,,,,,,,,,,
country,NCT00335452::country::Turkey (Türkiye),NCT00335452,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00335452::country::United Kingdom,NCT00335452,United Kingdom,,,,,,,,,,,,,,
trial,NCT00744848,NCT00744848,Study to Evaluate Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy,PHASE3,cardiovascular disease,Hemorrhoids,INDUSTRY,204.0,2008-08,2009-02,1.0,20.0,,,,,
arm,NCT00744848::arm::FG000,NCT00744848,Bupivacaine HCl,,,,,,,,,,FG000,"100 mg Bupivacaine HCl (e.g., Marcaine with epinephrine 1:200,000) is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402.",,,
arm,NCT00744848::arm::FG001,NCT00744848,SKY0402,,,,,,,,,,FG001,Single administration 300 mg SKY0402 in a 40-mL injection volume via local infiltration.,,,
period,NCT00744848::period::1,NCT00744848,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00744848::outcome::primary::1,NCT00744848,Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores,,,,,,,,,,,,,PRIMARY,through 96 hours
country,NCT00744848::country::United States,NCT00744848,United States,,,,,,,,,,,,,,
trial,NCT03961360,NCT03961360,Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida,PHASE3,cardiovascular disease,Pre-Eclampsia; Hypertension in Pregnancy; Obesity,OTHER,220.0,2019-05-06,2023-04-10,1.0,1.0,,,,,
arm,NCT03961360::arm::FG000,NCT03961360,162 mg/Day Aspirin,,,,,,,,,,FG000,Aspirin 162 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia,,,
arm,NCT03961360::arm::FG001,NCT03961360,81 mg/Day Aspirin,,,,,,,,,,FG001,Aspirin 81 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia,,,
period,NCT03961360::period::1,NCT03961360,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03961360::outcome::primary::1,NCT03961360,Number of Participants With Preeclampsia Diagnosis With Severe Features Based on Clinician Diagnosis,,,,,,,,,,,,,PRIMARY,3-7 months
country,NCT03961360::country::United States,NCT03961360,United States,,,,,,,,,,,,,,
trial,NCT01239797,NCT01239797,Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma,PHASE3,cardiovascular disease,Lymphoma; Multiple Myeloma,INDUSTRY,646.0,2011-06-20,2021-04-21,23.0,216.0,,,,,
arm,NCT01239797::arm::FG000,NCT01239797,Lenalidomide + Dexamethasone + Elotuzumab,,,,,,,,,,FG000,"Lenalidomide: Capsules, Oral, 25 mg, once daily, on Days 1-21 Repeat every 28 days until participants met criteria for discontinuation of study drug Dexamethasone (Oral): On weeks without Elotuzumab d",,,
arm,NCT01239797::arm::FG001,NCT01239797,Lenalidomide + Dexamethasone,,,,,,,,,,FG001,"Lenalidomide: Capsules, Oral, 25 mg, once daily, on Days 1-21 Regimen repeated every 28 days until participants met criteria for discontinuation of study drug Dexamethasone: Tablets, Oral, 40 mg, week",,,
period,NCT01239797::period::1,NCT01239797,Randomized Participants,,,,,,,,,,,,1.0,,
period,NCT01239797::period::2,NCT01239797,Treated Participants,,,,,,,,,,,,2.0,,
outcome,NCT01239797::outcome::primary::1,NCT01239797,Median Progression Free Survival (PFS),,,,,,,,,,,,,PRIMARY,From randomization up to 326 events (up to approximately 38 months)
outcome,NCT01239797::outcome::primary::2,NCT01239797,Objective Response Rate (ORR),,,,,,,,,,,,,PRIMARY,From randomization up to approximately 38 months
country,NCT01239797::country::United States,NCT01239797,United States,,,,,,,,,,,,,,
country,NCT01239797::country::Germany,NCT01239797,Germany,,,,,,,,,,,,,,
country,NCT01239797::country::Japan,NCT01239797,Japan,,,,,,,,,,,,,,
country,NCT01239797::country::France,NCT01239797,France,,,,,,,,,,,,,,
country,NCT01239797::country::Italy,NCT01239797,Italy,,,,,,,,,,,,,,
country,NCT01239797::country::Canada,NCT01239797,Canada,,,,,,,,,,,,,,
country,NCT01239797::country::United Kingdom,NCT01239797,United Kingdom,,,,,,,,,,,,,,
country,NCT01239797::country::Australia,NCT01239797,Australia,,,,,,,,,,,,,,
country,NCT01239797::country::Belgium,NCT01239797,Belgium,,,,,,,,,,,,,,
country,NCT01239797::country::Poland,NCT01239797,Poland,,,,,,,,,,,,,,
country,NCT01239797::country::Spain,NCT01239797,Spain,,,,,,,,,,,,,,
country,NCT01239797::country::Israel,NCT01239797,Israel,,,,,,,,,,,,,,
country,NCT01239797::country::Austria,NCT01239797,Austria,,,,,,,,,,,,,,
country,NCT01239797::country::Czechia,NCT01239797,Czechia,,,,,,,,,,,,,,
country,NCT01239797::country::Hungary,NCT01239797,Hungary,,,,,,,,,,,,,,
country,NCT01239797::country::Romania,NCT01239797,Romania,,,,,,,,,,,,,,
country,NCT01239797::country::Turkey (Türkiye),NCT01239797,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01239797::country::Denmark,NCT01239797,Denmark,,,,,,,,,,,,,,
country,NCT01239797::country::Greece,NCT01239797,Greece,,,,,,,,,,,,,,
country,NCT01239797::country::Ireland,NCT01239797,Ireland,,,,,,,,,,,,,,
country,NCT01239797::country::Puerto Rico,NCT01239797,Puerto Rico,,,,,,,,,,,,,,
country,NCT01239797::country::Switzerland,NCT01239797,Switzerland,,,,,,,,,,,,,,
country,NCT01239797::country::United Arab Emirates,NCT01239797,United Arab Emirates,,,,,,,,,,,,,,
trial,NCT02930018,NCT02930018,Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke,PHASE3,cardiovascular disease,"Stroke, Acute",INDUSTRY,1105.0,2017-03-01,2019-11-20,8.0,50.0,,,,,
arm,NCT02930018::arm::FG000,NCT02930018,Placebo,,,,,,,,,,FG000,"Drug vehicle only

Placebo: Placebo Comparator: Placebo",,,
arm,NCT02930018::arm::FG001,NCT02930018,"Nerinetide (NA-1), 2.6 mg/kg",,,,,,,,,,FG001,Single intravenous infusion of nerinetide over 10 ± 1 minutes,,,
period,NCT02930018::period::1,NCT02930018,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02930018::outcome::primary::1,NCT02930018,Number of Subjects With mRS Score of 0 to 2,,,,,,,,,,,,,PRIMARY,90 Days
country,NCT02930018::country::United States,NCT02930018,United States,,,,,,,,,,,,,,
country,NCT02930018::country::Canada,NCT02930018,Canada,,,,,,,,,,,,,,
country,NCT02930018::country::Germany,NCT02930018,Germany,,,,,,,,,,,,,,
country,NCT02930018::country::South Korea,NCT02930018,South Korea,,,,,,,,,,,,,,
country,NCT02930018::country::Australia,NCT02930018,Australia,,,,,,,,,,,,,,
country,NCT02930018::country::Ireland,NCT02930018,Ireland,,,,,,,,,,,,,,
country,NCT02930018::country::Sweden,NCT02930018,Sweden,,,,,,,,,,,,,,
country,NCT02930018::country::United Kingdom,NCT02930018,United Kingdom,,,,,,,,,,,,,,
trial,NCT03064126,NCT03064126,RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty,PHASE3,cardiovascular disease,"Peripheral Artery Disease; Atherosclerosis; Artery Diseases, Peripheral; Plaque, Atherosclerotic; Occlusive Arterial Disease",INDUSTRY,440.0,2017-03-02,2023-10-25,6.0,67.0,,,,,
arm,NCT03064126::arm::FG000,NCT03064126,RANGER™ Paclitaxel Coated Balloon RCT,,,,,,,,,,FG000,"RANGER™ Paclitaxel Coated Balloon Catheter angioplasty in the SFA/PPA at the index procedure.

Subjects will be randomized 3:1 to the drug coated or standard angioplasty balloon.

RANGER™ Paclitaxel C",,,
arm,NCT03064126::arm::FG001,NCT03064126,Standard Balloon Angioplasty RCT,,,,,,,,,,FG001,"Standard Balloon Catheter angioplasty in the SFA/PPA at the index procedure. Subjects will be randomized 3:1 to the drug coated or standard angioplasty balloon.

Standard Balloon Angioplasty: A proced",,,
arm,NCT03064126::arm::FG002,NCT03064126,Long Balloon (LB) Substudy,,,,,,,,,,FG002,"The Long Balloon substudy cohort will evaluate the safety and effectiveness of the Ranger DCB in the 120, 150 and 200 mm lengths for treating SFA and/or PPA lesions.",,,
arm,NCT03064126::arm::FG003,NCT03064126,Pharmacokinetics (PK) Substudy,,,,,,,,,,FG003,The PK substudy cohort will evaluate the safety and pharmacokinetics of the levels of paclitaxel in the systemic circulation of subjects at multiple time points after treatment with the Ranger DCB. Ti,,,
period,NCT03064126::period::1,NCT03064126,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03064126::outcome::primary::1,NCT03064126,Number of Participants With Primary Lesion Patency,,,,,,,,,,,,,PRIMARY,12 months (RCT)
outcome,NCT03064126::outcome::primary::2,NCT03064126,Major Adverse Events (MAEs) (Primary Safety Endpoint),,,,,,,,,,,,,PRIMARY,6 months (LB substudy)
country,NCT03064126::country::United States,NCT03064126,United States,,,,,,,,,,,,,,
country,NCT03064126::country::Japan,NCT03064126,Japan,,,,,,,,,,,,,,
country,NCT03064126::country::Canada,NCT03064126,Canada,,,,,,,,,,,,,,
country,NCT03064126::country::Austria,NCT03064126,Austria,,,,,,,,,,,,,,
country,NCT03064126::country::Belgium,NCT03064126,Belgium,,,,,,,,,,,,,,
country,NCT03064126::country::New Zealand,NCT03064126,New Zealand,,,,,,,,,,,,,,
trial,NCT01080391,NCT01080391,"Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma",PHASE3,cardiovascular disease,Relapsed Multiple Myeloma,INDUSTRY,792.0,2010-07-14,2017-12-05,20.0,127.0,,,,,
arm,NCT01080391::arm::FG000,NCT01080391,Lenalidomide and Dexamethasone (Rd),,,,,,,,,,FG000,Participants received their randomized study treatment in 28-day cycles until disease progression or unacceptable toxicity. Lenalidomide 25 mg was administered orally on days 1 to 21 and dexamethasone,,,
arm,NCT01080391::arm::FG001,NCT01080391,"Carfilzomib, Lenalidomide, and Dexamethasone (CRd)",,,,,,,,,,FG001,Participants received their randomized study treatment in 28-day cycles until disease progression or unacceptable toxicity. Carfilzomib 20 mg/m² was administered intravenously (IV) on days 1 and 2 of ,,,
period,NCT01080391::period::1,NCT01080391,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01080391::outcome::primary::1,NCT01080391,Progression-free Survival (PFS),,,,,,,,,,,,,PRIMARY,From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.
country,NCT01080391::country::United States,NCT01080391,United States,,,,,,,,,,,,,,
country,NCT01080391::country::France,NCT01080391,France,,,,,,,,,,,,,,
country,NCT01080391::country::Russia,NCT01080391,Russia,,,,,,,,,,,,,,
country,NCT01080391::country::Canada,NCT01080391,Canada,,,,,,,,,,,,,,
country,NCT01080391::country::Germany,NCT01080391,Germany,,,,,,,,,,,,,,
country,NCT01080391::country::Poland,NCT01080391,Poland,,,,,,,,,,,,,,
country,NCT01080391::country::Hungary,NCT01080391,Hungary,,,,,,,,,,,,,,
country,NCT01080391::country::Belgium,NCT01080391,Belgium,,,,,,,,,,,,,,
country,NCT01080391::country::Israel,NCT01080391,Israel,,,,,,,,,,,,,,
country,NCT01080391::country::Spain,NCT01080391,Spain,,,,,,,,,,,,,,
country,NCT01080391::country::United Kingdom,NCT01080391,United Kingdom,,,,,,,,,,,,,,
country,NCT01080391::country::Bulgaria,NCT01080391,Bulgaria,,,,,,,,,,,,,,
country,NCT01080391::country::Czechia,NCT01080391,Czechia,,,,,,,,,,,,,,
country,NCT01080391::country::Italy,NCT01080391,Italy,,,,,,,,,,,,,,
country,NCT01080391::country::Serbia,NCT01080391,Serbia,,,,,,,,,,,,,,
country,NCT01080391::country::Romania,NCT01080391,Romania,,,,,,,,,,,,,,
country,NCT01080391::country::Sweden,NCT01080391,Sweden,,,,,,,,,,,,,,
country,NCT01080391::country::Austria,NCT01080391,Austria,,,,,,,,,,,,,,
country,NCT01080391::country::Greece,NCT01080391,Greece,,,,,,,,,,,,,,
country,NCT01080391::country::Netherlands,NCT01080391,Netherlands,,,,,,,,,,,,,,
trial,NCT00618774,NCT00618774,"An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination",PHASE3,cardiovascular disease,Hypertension,INDUSTRY,259.0,2008-01,,1.0,7.0,,,,,
arm,NCT00618774::arm::FG000,NCT00618774,Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination,,,,,,,,,,FG000,,,,
arm,NCT00618774::arm::FG001,NCT00618774,Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination,,,,,,,,,,FG001,,,,
period,NCT00618774::period::1,NCT00618774,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00618774::outcome::primary::1,NCT00618774,Percentage of Participants Who Experienced Adverse Events,,,,,,,,,,,,,PRIMARY,52 weeks
outcome,NCT00618774::outcome::primary::2,NCT00618774,"Clinically Relevant Abnormalities for Changes in Blood Pressure and Pulse Rate Due to Position Change, Seated Pulse Rate, Laboratory Parameters and ECG",,,,,,,,,,,,,PRIMARY,First administration of study treatment to 24 hours post last dosing of study treatment.
country,NCT00618774::country::Japan,NCT00618774,Japan,,,,,,,,,,,,,,
trial,NCT00687882,NCT00687882,Evaluation of the Duration of Therapy for Thrombosis in Children,PHASE3,cardiovascular disease,Venous Thrombosis,OTHER,532.0,2008-03,2022-02-15,6.0,63.0,,,,,
arm,NCT00687882::arm::FG000,NCT00687882,Intervention: A (Shortened Duration (6 Weeks) of Anticoagulant Therapy),,,,,,,,,,FG000,"Patients with non-occlusive thrombus or resolved thrombosis at 6 weeks.

Shortened duration (6 weeks) of anticoagulant therapy: Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks ",,,
arm,NCT00687882::arm::FG001,NCT00687882,Intervention: B (Conventional Duration (3 Months) of Anticoagulant Therapy),,,,,,,,,,FG001,"Patients with non-occlusive thrombus or resolved thrombosis at 6 weeks.

Conventional duration (3 months) of anticoagulant therapy: Subjects with evidence of non-occlusive or resolved thrombus at 6 we",,,
arm,NCT00687882::arm::FG002,NCT00687882,Parallel Cohort: Persistent Occlusive Thrombosis,,,,,,,,,,FG002,"Patients with completely occlusive thrombosis at 6 weeks.

No Intervention: Subjects with evidence of persistent thrombus at 6 weeks time will remain on anticoagulant therapy for 3-6 months at the dis",,,
arm,NCT00687882::arm::FG003,NCT00687882,Parallel Cohort: Persistent Antiphospholipid Antibody,,,,,,,,,,FG003,"Patients with persistent Positive Antiphospholipid Antibody at 6 weeks.

No Intervention: Subjects with evidence of persistent antiphospholipid antibody at 6 weeks will remain on anticoagulant therapy",,,
period,NCT00687882::period::1,NCT00687882,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00687882::outcome::primary::1,NCT00687882,Efficacy Outcome - Occurrence of Symptomatic Recurrent Venous Thromboembolism,,,,,,,,,,,,,PRIMARY,1 Year
outcome,NCT00687882::outcome::primary::2,NCT00687882,Safety Outcome - Occurrence of Clinically-relevant (i.e. Major Plus Clinically-relevant Non-major (CRNM),,,,,,,,,,,,,PRIMARY,1 year
country,NCT00687882::country::United States,NCT00687882,United States,,,,,,,,,,,,,,
country,NCT00687882::country::Canada,NCT00687882,Canada,,,,,,,,,,,,,,
country,NCT00687882::country::Israel,NCT00687882,Israel,,,,,,,,,,,,,,
country,NCT00687882::country::Australia,NCT00687882,Australia,,,,,,,,,,,,,,
country,NCT00687882::country::Austria,NCT00687882,Austria,,,,,,,,,,,,,,
country,NCT00687882::country::Netherlands,NCT00687882,Netherlands,,,,,,,,,,,,,,
trial,NCT00300482,NCT00300482,Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood,PHASE3,cardiovascular disease,Dyslipidemia; Coronary Heart Disease; Mixed Dyslipidemia,INDUSTRY,1445.0,2006-03,,1.0,1.0,,,,,
arm,NCT00300482::arm::FG000,NCT00300482,ABT-335 + 10 mg Rosuvastatin,,,,,,,,,,FG000,ABT-335 + 10 mg rosuvastatin combination therapy once daily,,,
arm,NCT00300482::arm::FG001,NCT00300482,ABT-335 + 20 mg Rosuvastatin,,,,,,,,,,FG001,ABT-335 + 20 mg rosuvastatin combination therapy once daily,,,
arm,NCT00300482::arm::FG002,NCT00300482,ABT-335,,,,,,,,,,FG002,ABT-335 monotherapy once daily,,,
arm,NCT00300482::arm::FG003,NCT00300482,10 mg Rosuvastatin,,,,,,,,,,FG003,10 mg rosuvastatin monotherapy once daily,,,
arm,NCT00300482::arm::FG004,NCT00300482,20 mg Rosuvastatin,,,,,,,,,,FG004,20 mg rosuvastatin monotherapy once daily,,,
arm,NCT00300482::arm::FG005,NCT00300482,40 mg Rosuvastatin,,,,,,,,,,FG005,40 mg rosuvastatin monotherapy once daily,,,
period,NCT00300482::period::1,NCT00300482,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00300482::outcome::primary::1,NCT00300482,Mean Percent Change in Triglycerides From Baseline to Final Visit,,,,,,,,,,,,,PRIMARY,Baseline to 12 Weeks
outcome,NCT00300482::outcome::primary::2,NCT00300482,Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Final Visit,,,,,,,,,,,,,PRIMARY,Baseline to 12 Weeks
outcome,NCT00300482::outcome::primary::3,NCT00300482,Mean Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Final Visit,,,,,,,,,,,,,PRIMARY,Baseline to 12 Weeks
country,NCT00300482::country::United States,NCT00300482,United States,,,,,,,,,,,,,,
trial,NCT01776424,NCT01776424,Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease,PHASE3,cardiovascular disease,Prevention & Control,INDUSTRY,27395.0,2013-02-28,2021-06-15,33.0,565.0,,,,,
arm,NCT01776424::arm::FG000,NCT01776424,Rivaroxaban 2.5mg + Aspirin 100mg,,,,,,,,,,FG000,Participants received rivaroxaban 2.5 mg twice daily (bid) and aspirin 100 mg once daily (od). All doses were provided in tablet form for oral administration. Participants who did not have a continuou,,,
arm,NCT01776424::arm::FG001,NCT01776424,Rivaroxaban 5mg + Aspirin Placebo,,,,,,,,,,FG001,"Participants received rivaroxaban 5 mg bid and aspirin placebo od. All doses were provided in tablet form for oral administration. Participants who did not have a continuous need to take a PPI, were a",,,
arm,NCT01776424::arm::FG002,NCT01776424,Rivaroxaban Placebo + Aspirin 100mg,,,,,,,,,,FG002,"Participants received rivaroxaban placebo bid and aspirin 100 mg od. All doses were provided in tablet form for oral administration. Participants who did not have a continuous need to take a PPI, were",,,
period,NCT01776424::period::1,NCT01776424,Antithrombotic Part (Double Blind),,,,,,,,,,,,1.0,,
period,NCT01776424::period::2,NCT01776424,LTOLE Part (Open Label),,,,,,,,,,,,2.0,,
outcome,NCT01776424::outcome::primary::1,NCT01776424,"The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death",,,,,,,,,,,,,PRIMARY,"For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days."
outcome,NCT01776424::outcome::primary::2,NCT01776424,The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria,,,,,,,,,,,,,PRIMARY,"For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days."
country,NCT01776424::country::United States,NCT01776424,United States,,,,,,,,,,,,,,
country,NCT01776424::country::Japan,NCT01776424,Japan,,,,,,,,,,,,,,
country,NCT01776424::country::Canada,NCT01776424,Canada,,,,,,,,,,,,,,
country,NCT01776424::country::Argentina,NCT01776424,Argentina,,,,,,,,,,,,,,
country,NCT01776424::country::China,NCT01776424,China,,,,,,,,,,,,,,
country,NCT01776424::country::Netherlands,NCT01776424,Netherlands,,,,,,,,,,,,,,
country,NCT01776424::country::Czechia,NCT01776424,Czechia,,,,,,,,,,,,,,
country,NCT01776424::country::Brazil,NCT01776424,Brazil,,,,,,,,,,,,,,
country,NCT01776424::country::Italy,NCT01776424,Italy,,,,,,,,,,,,,,
country,NCT01776424::country::Australia,NCT01776424,Australia,,,,,,,,,,,,,,
country,NCT01776424::country::Germany,NCT01776424,Germany,,,,,,,,,,,,,,
country,NCT01776424::country::Philippines,NCT01776424,Philippines,,,,,,,,,,,,,,
country,NCT01776424::country::Romania,NCT01776424,Romania,,,,,,,,,,,,,,
country,NCT01776424::country::Ukraine,NCT01776424,Ukraine,,,,,,,,,,,,,,
country,NCT01776424::country::United Kingdom,NCT01776424,United Kingdom,,,,,,,,,,,,,,
country,NCT01776424::country::Colombia,NCT01776424,Colombia,,,,,,,,,,,,,,
country,NCT01776424::country::Russia,NCT01776424,Russia,,,,,,,,,,,,,,
country,NCT01776424::country::Belgium,NCT01776424,Belgium,,,,,,,,,,,,,,
country,NCT01776424::country::Chile,NCT01776424,Chile,,,,,,,,,,,,,,
country,NCT01776424::country::Hungary,NCT01776424,Hungary,,,,,,,,,,,,,,
country,NCT01776424::country::Sweden,NCT01776424,Sweden,,,,,,,,,,,,,,
country,NCT01776424::country::France,NCT01776424,France,,,,,,,,,,,,,,
country,NCT01776424::country::Israel,NCT01776424,Israel,,,,,,,,,,,,,,
country,NCT01776424::country::South Korea,NCT01776424,South Korea,,,,,,,,,,,,,,
country,NCT01776424::country::Denmark,NCT01776424,Denmark,,,,,,,,,,,,,,
country,NCT01776424::country::Poland,NCT01776424,Poland,,,,,,,,,,,,,,
country,NCT01776424::country::South Africa,NCT01776424,South Africa,,,,,,,,,,,,,,
country,NCT01776424::country::Ireland,NCT01776424,Ireland,,,,,,,,,,,,,,
country,NCT01776424::country::Malaysia,NCT01776424,Malaysia,,,,,,,,,,,,,,
country,NCT01776424::country::Slovakia,NCT01776424,Slovakia,,,,,,,,,,,,,,
country,NCT01776424::country::Finland,NCT01776424,Finland,,,,,,,,,,,,,,
country,NCT01776424::country::Ecuador,NCT01776424,Ecuador,,,,,,,,,,,,,,
country,NCT01776424::country::Switzerland,NCT01776424,Switzerland,,,,,,,,,,,,,,
trial,NCT00794573,NCT00794573,Evaluation of Varenicline (Champix) in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) Trial,PHASE3,cardiovascular disease,Acute Coronary Syndrome,OTHER,302.0,2009-09,2015-12,1.0,4.0,,,,,
arm,NCT00794573::arm::FG000,NCT00794573,Varenicline,,,,,,,,,,FG000,"0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.",,,
arm,NCT00794573::arm::FG001,NCT00794573,Placebo,,,,,,,,,,FG001,"placebo for 0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.",,,
period,NCT00794573::period::1,NCT00794573,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00794573::outcome::primary::1,NCT00794573,7-Day Point Prevalence Smoking Abstinence,,,,,,,,,,,,,PRIMARY,24 weeks
outcome,NCT00794573::outcome::primary::2,NCT00794573,Continuous Smoking Abstinence,,,,,,,,,,,,,PRIMARY,24 weeks
country,NCT00794573::country::Canada,NCT00794573,Canada,,,,,,,,,,,,,,
trial,NCT01734928,NCT01734928,"Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma",PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,559.0,2013-01-07,2022-05-13,22.0,321.0,,,,,
arm,NCT01734928::arm::FG000,NCT01734928,Treatment 1: POM+BTZ+LD-DEX,,,,,,,,,,FG000,"POM (Pomalidomide)

* 4 mg/day on Days 1 to 14 of each 21-day treatment cycle BTZ (Bortezomib)
* For Cycles 1 - 8: 1.3 mg/m2/dose on Days 1, 4, 8, and 11 of a 21-day cycle
* For Cycles 9 onwards: 1.3 ",,,
arm,NCT01734928::arm::FG001,NCT01734928,Treatment 2: BTZ+LD-DEX,,,,,,,,,,FG001,"BTZ ((Bortezomib)

* For Cycles 1 - 8: 1.3 mg/m2/dose on Days 1, 4, 8, and 11 of a 21-day cycle
* For Cycles 9 onwards: 1.3 mg/m2/dose on Days 1 and 8 of a 21-day cycle DEX (Dexamethasone)
* For Cycle",,,
period,NCT01734928::period::1,NCT01734928,Randomization,,,,,,,,,,,,1.0,,
period,NCT01734928::period::2,NCT01734928,Treatment Period,,,,,,,,,,,,2.0,,
outcome,NCT01734928::outcome::primary::1,NCT01734928,Progression Free Survival by Independent Response Adjudication Committee (IRAC),,,,,,,,,,,,,PRIMARY,"From randomization to progressive disease or death during the IRAC assessment period, up to approximately 42 months"
country,NCT01734928::country::United States,NCT01734928,United States,,,,,,,,,,,,,,
country,NCT01734928::country::Italy,NCT01734928,Italy,,,,,,,,,,,,,,
country,NCT01734928::country::United Kingdom,NCT01734928,United Kingdom,,,,,,,,,,,,,,
country,NCT01734928::country::France,NCT01734928,France,,,,,,,,,,,,,,
country,NCT01734928::country::Turkey (Türkiye),NCT01734928,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01734928::country::Poland,NCT01734928,Poland,,,,,,,,,,,,,,
country,NCT01734928::country::Spain,NCT01734928,Spain,,,,,,,,,,,,,,
country,NCT01734928::country::Germany,NCT01734928,Germany,,,,,,,,,,,,,,
country,NCT01734928::country::Portugal,NCT01734928,Portugal,,,,,,,,,,,,,,
country,NCT01734928::country::Japan,NCT01734928,Japan,,,,,,,,,,,,,,
country,NCT01734928::country::Canada,NCT01734928,Canada,,,,,,,,,,,,,,
country,NCT01734928::country::Sweden,NCT01734928,Sweden,,,,,,,,,,,,,,
country,NCT01734928::country::Denmark,NCT01734928,Denmark,,,,,,,,,,,,,,
country,NCT01734928::country::Greece,NCT01734928,Greece,,,,,,,,,,,,,,
country,NCT01734928::country::Israel,NCT01734928,Israel,,,,,,,,,,,,,,
country,NCT01734928::country::Russia,NCT01734928,Russia,,,,,,,,,,,,,,
country,NCT01734928::country::Austria,NCT01734928,Austria,,,,,,,,,,,,,,
country,NCT01734928::country::Ireland,NCT01734928,Ireland,,,,,,,,,,,,,,
country,NCT01734928::country::Netherlands,NCT01734928,Netherlands,,,,,,,,,,,,,,
country,NCT01734928::country::Finland,NCT01734928,Finland,,,,,,,,,,,,,,
country,NCT01734928::country::Norway,NCT01734928,Norway,,,,,,,,,,,,,,
country,NCT01734928::country::Puerto Rico,NCT01734928,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00243919,NCT00243919,Locomotor Experience Applied Post Stroke Trial,PHASE3,cardiovascular disease,Stroke,OTHER,408.0,2006-04,2012-06,1.0,8.0,,,,,
arm,NCT00243919::arm::FG000,NCT00243919,Early Locomotor Training Program,,,,,,,,,,FG000,"Stepping on a treadmill with partial body weight support and manual assistance as needed for 20-30 minutes at 2.0 mph, followed by a progressive overground walking program for 20 minutes delivered at ",,,
arm,NCT00243919::arm::FG001,NCT00243919,Late Locomotor Training Program,,,,,,,,,,FG001,"Stepping on a treadmill with partial body weight support and manual assistance as needed for 20-30 minutes at 2.0 mph, followed by a progressive overground walking program for 20 minutes delivered at ",,,
arm,NCT00243919::arm::FG002,NCT00243919,Home Exercise Program,,,,,,,,,,FG002,"Home Exercise Program (HEP) was designed as an active control. The exercise program was progressed by a study physical therapist in the home to enhance flexibility, joint range of motion, upper- and l",,,
period,NCT00243919::period::1,NCT00243919,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00243919::outcome::primary::1,NCT00243919,Percentage of Patients Who Successfully Improved Functional Level of Walking at 1 Year Post-stroke,,,,,,,,,,,,,PRIMARY,12 months post-stroke
outcome,NCT00243919::outcome::primary::2,NCT00243919,Walking Speed: Measured During a 10-meter Walk,,,,,,,,,,,,,PRIMARY,Baseline and 12 months post-stroke
country,NCT00243919::country::United States,NCT00243919,United States,,,,,,,,,,,,,,
trial,NCT02239120,NCT02239120,Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS),PHASE3,cardiovascular disease,Stroke; Secondary Prevention,INDUSTRY,5390.0,2014-11-27,2018-08-14,42.0,569.0,,,,,
arm,NCT02239120::arm::FG000,NCT02239120,Dabigatran Etexilate 110 or 150 Milligram (mg),,,,,,,,,,FG000,Participants were orally administered one 110 mg (for participants aged ≥75 years or with a creatinine clearance (CrCl) of 30 to \<50 millilitre/ minute (mL/min)) or one 150 mg (for participants aged ,,,
arm,NCT02239120::arm::FG001,NCT02239120,"Acetylsalicylic Acid, Aspirin (ASA) 100 mg",,,,,,,,,,FG001,Participants were orally administered one 100 mg Aspirin non-enteric coated tablet once daily.,,,
period,NCT02239120::period::1,NCT02239120,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02239120::outcome::primary::1,NCT02239120,Adjudicated Recurrent Stroke,,,,,,,,,,,,,PRIMARY,"From randomisation until full follow up period, approximately 43 months."
outcome,NCT02239120::outcome::primary::2,NCT02239120,First Major Bleed (Adjudicated),,,,,,,,,,,,,PRIMARY,"Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months."
country,NCT02239120::country::United States,NCT02239120,United States,,,,,,,,,,,,,,
country,NCT02239120::country::Germany,NCT02239120,Germany,,,,,,,,,,,,,,
country,NCT02239120::country::Japan,NCT02239120,Japan,,,,,,,,,,,,,,
country,NCT02239120::country::Italy,NCT02239120,Italy,,,,,,,,,,,,,,
country,NCT02239120::country::China,NCT02239120,China,,,,,,,,,,,,,,
country,NCT02239120::country::Spain,NCT02239120,Spain,,,,,,,,,,,,,,
country,NCT02239120::country::Canada,NCT02239120,Canada,,,,,,,,,,,,,,
country,NCT02239120::country::South Korea,NCT02239120,South Korea,,,,,,,,,,,,,,
country,NCT02239120::country::Belgium,NCT02239120,Belgium,,,,,,,,,,,,,,
country,NCT02239120::country::Turkey (Türkiye),NCT02239120,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02239120::country::Australia,NCT02239120,Australia,,,,,,,,,,,,,,
country,NCT02239120::country::France,NCT02239120,France,,,,,,,,,,,,,,
country,NCT02239120::country::Russia,NCT02239120,Russia,,,,,,,,,,,,,,
country,NCT02239120::country::Taiwan,NCT02239120,Taiwan,,,,,,,,,,,,,,
country,NCT02239120::country::Portugal,NCT02239120,Portugal,,,,,,,,,,,,,,
country,NCT02239120::country::India,NCT02239120,India,,,,,,,,,,,,,,
country,NCT02239120::country::Poland,NCT02239120,Poland,,,,,,,,,,,,,,
country,NCT02239120::country::Austria,NCT02239120,Austria,,,,,,,,,,,,,,
country,NCT02239120::country::Ukraine,NCT02239120,Ukraine,,,,,,,,,,,,,,
country,NCT02239120::country::Czechia,NCT02239120,Czechia,,,,,,,,,,,,,,
country,NCT02239120::country::Greece,NCT02239120,Greece,,,,,,,,,,,,,,
country,NCT02239120::country::Switzerland,NCT02239120,Switzerland,,,,,,,,,,,,,,
country,NCT02239120::country::Argentina,NCT02239120,Argentina,,,,,,,,,,,,,,
country,NCT02239120::country::Brazil,NCT02239120,Brazil,,,,,,,,,,,,,,
country,NCT02239120::country::Hungary,NCT02239120,Hungary,,,,,,,,,,,,,,
country,NCT02239120::country::Sweden,NCT02239120,Sweden,,,,,,,,,,,,,,
country,NCT02239120::country::Mexico,NCT02239120,Mexico,,,,,,,,,,,,,,
country,NCT02239120::country::Colombia,NCT02239120,Colombia,,,,,,,,,,,,,,
country,NCT02239120::country::Croatia,NCT02239120,Croatia,,,,,,,,,,,,,,
country,NCT02239120::country::Estonia,NCT02239120,Estonia,,,,,,,,,,,,,,
country,NCT02239120::country::Israel,NCT02239120,Israel,,,,,,,,,,,,,,
country,NCT02239120::country::Serbia,NCT02239120,Serbia,,,,,,,,,,,,,,
country,NCT02239120::country::Thailand,NCT02239120,Thailand,,,,,,,,,,,,,,
country,NCT02239120::country::Chile,NCT02239120,Chile,,,,,,,,,,,,,,
country,NCT02239120::country::Hong Kong,NCT02239120,Hong Kong,,,,,,,,,,,,,,
country,NCT02239120::country::Malaysia,NCT02239120,Malaysia,,,,,,,,,,,,,,
country,NCT02239120::country::New Zealand,NCT02239120,New Zealand,,,,,,,,,,,,,,
country,NCT02239120::country::Singapore,NCT02239120,Singapore,,,,,,,,,,,,,,
country,NCT02239120::country::Slovenia,NCT02239120,Slovenia,,,,,,,,,,,,,,
country,NCT02239120::country::Peru,NCT02239120,Peru,,,,,,,,,,,,,,
country,NCT02239120::country::Slovakia,NCT02239120,Slovakia,,,,,,,,,,,,,,
country,NCT02239120::country::South Africa,NCT02239120,South Africa,,,,,,,,,,,,,,
trial,NCT02427802,NCT02427802,Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers,PHASE3,cardiovascular disease,"Foot Ulcer, Diabetic; Infection",INDUSTRY,612.0,2015-05,2016-10,1.0,86.0,,,,,
arm,NCT02427802::arm::FG000,NCT02427802,Gentamicin Sponge Group,,,,,,,,,,FG000,"Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic ther",,,
arm,NCT02427802::arm::FG001,NCT02427802,Placebo Sponge Group,,,,,,,,,,FG001,"Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.

Placebo: Matching collagen sponge",,,
arm,NCT02427802::arm::FG002,NCT02427802,No Sponge Group,,,,,,,,,,FG002,Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.,,,
period,NCT02427802::period::1,NCT02427802,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02427802::outcome::primary::1,NCT02427802,Clinical Cure (Resolution of All Clinical Signs and Symptoms of Infection),,,,,,,,,,,,,PRIMARY,approximately 10 days after end of treatment
country,NCT02427802::country::United States,NCT02427802,United States,,,,,,,,,,,,,,
trial,NCT00046228,NCT00046228,A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse),PHASE3,cardiovascular disease,Myocardial Infarction,INDUSTRY,2461.0,2002-08,2008-01,19.0,227.0,,,,,
arm,NCT00046228::arm::FG000,NCT00046228,Primary PCI Group,,,,,,,,,,FG000,Abciximab (bolus + 12 hr infusion) initiated just prior to primary percutaneous coronary intervention (PCI),,,
arm,NCT00046228::arm::FG001,NCT00046228,Abciximab Facilitated PCI Group,,,,,,,,,,FG001,"Abciximab (bolus) administered as soon as possible after randomization, 12 hour infusion initiated prior to PCI",,,
arm,NCT00046228::arm::FG002,NCT00046228,Reteplase/Abciximab Facilitated PCI Group,,,,,,,,,,FG002,"Abciximab (bolus) + reteplase (5 U + 5 U double bolus for subjects \< 75 years of age; 5 U single bolus for subjects ≥ 75 years of age), abciximab 12 hour infusion initiated prior to PCI",,,
period,NCT00046228::period::1,NCT00046228,90 Days,,,,,,,,,,,,1.0,,
period,NCT00046228::period::2,NCT00046228,1 Year,,,,,,,,,,,,2.0,,
outcome,NCT00046228::outcome::primary::1,NCT00046228,The Composite of All-Cause Mortality or Complications of MI at 90 Days.,,,,,,,,,,,,,PRIMARY,90 days
country,NCT00046228::country::United States,NCT00046228,United States,,,,,,,,,,,,,,
country,NCT00046228::country::Czechia,NCT00046228,Czechia,,,,,,,,,,,,,,
country,NCT00046228::country::Poland,NCT00046228,Poland,,,,,,,,,,,,,,
country,NCT00046228::country::Germany,NCT00046228,Germany,,,,,,,,,,,,,,
country,NCT00046228::country::United Kingdom,NCT00046228,United Kingdom,,,,,,,,,,,,,,
country,NCT00046228::country::Denmark,NCT00046228,Denmark,,,,,,,,,,,,,,
country,NCT00046228::country::Belgium,NCT00046228,Belgium,,,,,,,,,,,,,,
country,NCT00046228::country::France,NCT00046228,France,,,,,,,,,,,,,,
country,NCT00046228::country::Argentina,NCT00046228,Argentina,,,,,,,,,,,,,,
country,NCT00046228::country::Austria,NCT00046228,Austria,,,,,,,,,,,,,,
country,NCT00046228::country::Spain,NCT00046228,Spain,,,,,,,,,,,,,,
country,NCT00046228::country::Bulgaria,NCT00046228,Bulgaria,,,,,,,,,,,,,,
country,NCT00046228::country::Romania,NCT00046228,Romania,,,,,,,,,,,,,,
country,NCT00046228::country::Canada,NCT00046228,Canada,,,,,,,,,,,,,,
country,NCT00046228::country::South Africa,NCT00046228,South Africa,,,,,,,,,,,,,,
country,NCT00046228::country::Switzerland,NCT00046228,Switzerland,,,,,,,,,,,,,,
country,NCT00046228::country::Israel,NCT00046228,Israel,,,,,,,,,,,,,,
country,NCT00046228::country::Netherlands,NCT00046228,Netherlands,,,,,,,,,,,,,,
country,NCT00046228::country::Sweden,NCT00046228,Sweden,,,,,,,,,,,,,,
trial,NCT00643201,NCT00643201,Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism,PHASE3,cardiovascular disease,Venous Thrombosis,INDUSTRY,5614.0,2008-07,2013-03,31.0,381.0,,,,,
arm,NCT00643201::arm::FG000,NCT00643201,Apixaban,,,,,,,,,,FG000,"apixaban: tablets, oral, 10 milligram (mg) tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months.

Placebo for enoxaparin: solution, subcutaneous, 1milligram per kilogram (",,,
arm,NCT00643201::arm::FG001,NCT00643201,Enoxaparin + Warfarin,,,,,,,,,,FG001,"Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2.

Warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months

Placebo for apixaban: tablets, oral, 10 mg ",,,
period,NCT00643201::period::1,NCT00643201,"Randomized, Completed 6 Months of Study",,,,,,,,,,,,1.0,,
period,NCT00643201::period::2,NCT00643201,Completed Study Follow Up,,,,,,,,,,,,2.0,,
outcome,NCT00643201::outcome::primary::1,NCT00643201,"Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment",,,,,,,,,,,,,PRIMARY,Day 1 to Week 24 + 2 Days or 355 days (Discontinued Early)
country,NCT00643201::country::United States,NCT00643201,United States,,,,,,,,,,,,,,
country,NCT00643201::country::Russia,NCT00643201,Russia,,,,,,,,,,,,,,
country,NCT00643201::country::Brazil,NCT00643201,Brazil,,,,,,,,,,,,,,
country,NCT00643201::country::France,NCT00643201,France,,,,,,,,,,,,,,
country,NCT00643201::country::Canada,NCT00643201,Canada,,,,,,,,,,,,,,
country,NCT00643201::country::Germany,NCT00643201,Germany,,,,,,,,,,,,,,
country,NCT00643201::country::China,NCT00643201,China,,,,,,,,,,,,,,
country,NCT00643201::country::Israel,NCT00643201,Israel,,,,,,,,,,,,,,
country,NCT00643201::country::Italy,NCT00643201,Italy,,,,,,,,,,,,,,
country,NCT00643201::country::Poland,NCT00643201,Poland,,,,,,,,,,,,,,
country,NCT00643201::country::Australia,NCT00643201,Australia,,,,,,,,,,,,,,
country,NCT00643201::country::India,NCT00643201,India,,,,,,,,,,,,,,
country,NCT00643201::country::Czechia,NCT00643201,Czechia,,,,,,,,,,,,,,
country,NCT00643201::country::Ukraine,NCT00643201,Ukraine,,,,,,,,,,,,,,
country,NCT00643201::country::Mexico,NCT00643201,Mexico,,,,,,,,,,,,,,
country,NCT00643201::country::Norway,NCT00643201,Norway,,,,,,,,,,,,,,
country,NCT00643201::country::South Africa,NCT00643201,South Africa,,,,,,,,,,,,,,
country,NCT00643201::country::Spain,NCT00643201,Spain,,,,,,,,,,,,,,
country,NCT00643201::country::Hungary,NCT00643201,Hungary,,,,,,,,,,,,,,
country,NCT00643201::country::Argentina,NCT00643201,Argentina,,,,,,,,,,,,,,
country,NCT00643201::country::Denmark,NCT00643201,Denmark,,,,,,,,,,,,,,
country,NCT00643201::country::Austria,NCT00643201,Austria,,,,,,,,,,,,,,
country,NCT00643201::country::Chile,NCT00643201,Chile,,,,,,,,,,,,,,
country,NCT00643201::country::Romania,NCT00643201,Romania,,,,,,,,,,,,,,
country,NCT00643201::country::Malaysia,NCT00643201,Malaysia,,,,,,,,,,,,,,
country,NCT00643201::country::Portugal,NCT00643201,Portugal,,,,,,,,,,,,,,
country,NCT00643201::country::South Korea,NCT00643201,South Korea,,,,,,,,,,,,,,
country,NCT00643201::country::Singapore,NCT00643201,Singapore,,,,,,,,,,,,,,
country,NCT00643201::country::Hong Kong,NCT00643201,Hong Kong,,,,,,,,,,,,,,
country,NCT00643201::country::Puerto Rico,NCT00643201,Puerto Rico,,,,,,,,,,,,,,
country,NCT00643201::country::United Kingdom,NCT00643201,United Kingdom,,,,,,,,,,,,,,
trial,NCT02072434,NCT02072434,Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF),PHASE3,cardiovascular disease,Atrial Fibrillation,INDUSTRY,2199.0,2014-03-25,2016-02-03,19.0,228.0,,,,,
arm,NCT02072434::arm::FG000,NCT02072434,Edoxaban,,,,,,,,,,FG000,Participants randomized to receive Edoxaban,,,
arm,NCT02072434::arm::FG001,NCT02072434,Warfarin,,,,,,,,,,FG001,Participants randomized to receive Warfarin,,,
period,NCT02072434::period::1,NCT02072434,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02072434::outcome::primary::1,NCT02072434,"Percentage of Participants With Composite Endpoint of Stroke, Systemic Embolic Stroke (SEE), Myocardial Infarction (MI) and Cardiovascular (CV) Mortality From Randomization to End of Follow up",,,,,,,,,,,,,PRIMARY,Randomization to end of follow-up (within 2 years)
outcome,NCT02072434::outcome::primary::2,NCT02072434,Percentage of Participants With Composite Endpoints of Major and Clinically-relevant Non-major (CRNM) Bleeding,,,,,,,,,,,,,PRIMARY,During treatment period (within 2 years)
country,NCT02072434::country::United States,NCT02072434,United States,,,,,,,,,,,,,,
country,NCT02072434::country::United Kingdom,NCT02072434,United Kingdom,,,,,,,,,,,,,,
country,NCT02072434::country::Germany,NCT02072434,Germany,,,,,,,,,,,,,,
country,NCT02072434::country::Hungary,NCT02072434,Hungary,,,,,,,,,,,,,,
country,NCT02072434::country::France,NCT02072434,France,,,,,,,,,,,,,,
country,NCT02072434::country::Spain,NCT02072434,Spain,,,,,,,,,,,,,,
country,NCT02072434::country::Denmark,NCT02072434,Denmark,,,,,,,,,,,,,,
country,NCT02072434::country::Romania,NCT02072434,Romania,,,,,,,,,,,,,,
country,NCT02072434::country::Italy,NCT02072434,Italy,,,,,,,,,,,,,,
country,NCT02072434::country::Belgium,NCT02072434,Belgium,,,,,,,,,,,,,,
country,NCT02072434::country::Czechia,NCT02072434,Czechia,,,,,,,,,,,,,,
country,NCT02072434::country::Bulgaria,NCT02072434,Bulgaria,,,,,,,,,,,,,,
country,NCT02072434::country::Israel,NCT02072434,Israel,,,,,,,,,,,,,,
country,NCT02072434::country::Ukraine,NCT02072434,Ukraine,,,,,,,,,,,,,,
country,NCT02072434::country::Poland,NCT02072434,Poland,,,,,,,,,,,,,,
country,NCT02072434::country::Netherlands,NCT02072434,Netherlands,,,,,,,,,,,,,,
country,NCT02072434::country::Russia,NCT02072434,Russia,,,,,,,,,,,,,,
country,NCT02072434::country::Austria,NCT02072434,Austria,,,,,,,,,,,,,,
country,NCT02072434::country::Sweden,NCT02072434,Sweden,,,,,,,,,,,,,,
trial,NCT01456000,NCT01456000,HeartLight Ablation in Patients With Paroxysmal Atrial Fibrillation (PAF),PHASE3,cardiovascular disease,Paroxysmal Atrial Fibrillation,INDUSTRY,405.0,2012-01,2016-01,1.0,21.0,,,,,
arm,NCT01456000::arm::FG000,NCT01456000,EAS-AC (HeartLight),,,,,,,,,,FG000,"Treatment with the EAS-AC.

EAS-AC (HeartLight): Pulmonary vien isolation

ITT Population 178 participants",,,
arm,NCT01456000::arm::FG001,NCT01456000,Control Arm Ablation,,,,,,,,,,FG001,"Treatment with standard ablation.

Control Arm Ablation: Treatment with standard ablation.

ITT Population 175 Participants",,,
period,NCT01456000::period::1,NCT01456000,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01456000::outcome::primary::1,NCT01456000,Number of Participants That Meeting the Efficacy Success Criteria as Described in the Outcome Measure Description,,,,,,,,,,,,,PRIMARY,1 year
country,NCT01456000::country::United States,NCT01456000,United States,,,,,,,,,,,,,,
trial,NCT01786993,NCT01786993,MultiPoint Pacing IDE Study,PHASE3,cardiovascular disease,Heart Failure,INDUSTRY,506.0,2013-04,2016-06,1.0,49.0,,,,,
arm,NCT01786993::arm::FG000,NCT01786993,Multi-point Pacing Arm,,,,,,,,,,FG000,Subjects were programmed to MPP between 3 and 9 months. MPP programming was stipulated by the Echocardiographic measurements (e.g. EA VTI) during an acute hemodynamic assessment at the 3-month visit i,,,
arm,NCT01786993::arm::FG001,NCT01786993,Biventricular Arm,,,,,,,,,,FG001,Subjects were programmed to Quadripolar BiV pacing between 3 and 9 months using any of the 10 vectors available.,,,
period,NCT01786993::period::1,NCT01786993,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01786993::outcome::primary::1,NCT01786993,Freedom From System-related Complications Through 9 Months Compared to an Objective Performance Criterion,,,,,,,,,,,,,PRIMARY,Implant to 9 months
outcome,NCT01786993::outcome::primary::2,NCT01786993,Percentage of Non-responders With MPP Compared to Biventricular Pacing,,,,,,,,,,,,,PRIMARY,3 months to 9 months
country,NCT01786993::country::United States,NCT01786993,United States,,,,,,,,,,,,,,
trial,NCT00103506,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,646.0,2004-12,2014-06,17.0,108.0,,,,,
arm,NCT00103506::arm::FG000,NCT00103506,Velcade (Bortezomib) Monotherapy,,,,,,,,,,FG000,"Velcade (bortezomib) 1.3 milligram/meter per square (mg/m\^2) by rapid (bolus) intravenous (IV) administration given on Day 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.",,,
arm,NCT00103506::arm::FG001,NCT00103506,Doxil/Caelyx Plus Velcade (Bortezomib),,,,,,,,,,FG001,"Velcade (bortezomib) 1.3 mg/m\^2 by rapid (bolus) IV administration given on Day 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Doxorubicin hydrochloride (DOXIL/CAELYX) 30 mg/m\^2 by IV infu",,,
period,NCT00103506::period::1,NCT00103506,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00103506::outcome::primary::1,NCT00103506,Time to Progression (TTP),,,,,,,,,,,,,PRIMARY,Up to 1 year and 4 months (From date of first participant randomization [20 December 2004] up to interim analysis cut-off date [28 April 2006])
country,NCT00103506::country::United States,NCT00103506,United States,,,,,,,,,,,,,,
country,NCT00103506::country::Netherlands,NCT00103506,Netherlands,,,,,,,,,,,,,,
country,NCT00103506::country::France,NCT00103506,France,,,,,,,,,,,,,,
country,NCT00103506::country::Russia,NCT00103506,Russia,,,,,,,,,,,,,,
country,NCT00103506::country::Canada,NCT00103506,Canada,,,,,,,,,,,,,,
country,NCT00103506::country::Israel,NCT00103506,Israel,,,,,,,,,,,,,,
country,NCT00103506::country::Poland,NCT00103506,Poland,,,,,,,,,,,,,,
country,NCT00103506::country::Australia,NCT00103506,Australia,,,,,,,,,,,,,,
country,NCT00103506::country::Austria,NCT00103506,Austria,,,,,,,,,,,,,,
country,NCT00103506::country::South Africa,NCT00103506,South Africa,,,,,,,,,,,,,,
country,NCT00103506::country::Argentina,NCT00103506,Argentina,,,,,,,,,,,,,,
country,NCT00103506::country::Belgium,NCT00103506,Belgium,,,,,,,,,,,,,,
country,NCT00103506::country::Czechia,NCT00103506,Czechia,,,,,,,,,,,,,,
country,NCT00103506::country::Portugal,NCT00103506,Portugal,,,,,,,,,,,,,,
country,NCT00103506::country::Spain,NCT00103506,Spain,,,,,,,,,,,,,,
country,NCT00103506::country::United Kingdom,NCT00103506,United Kingdom,,,,,,,,,,,,,,
country,NCT00103506::country::Singapore,NCT00103506,Singapore,,,,,,,,,,,,,,
trial,NCT01644175,NCT01644175,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I),PHASE3,cardiovascular disease,Hypercholesterolemia,INDUSTRY,316.0,2012-07,2014-04,1.0,76.0,,,,,
arm,NCT01644175::arm::FG000,NCT01644175,Placebo Q2W,,,,,,,,,,FG000,Placebo (for alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 52 weeks.,,,
arm,NCT01644175::arm::FG001,NCT01644175,Alirocumab 75/150 mg Q2W,,,,,,,,,,FG001,Alirocumab 75 mg SC injection Q2W added to stable LMT for 52 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.,,,
period,NCT01644175::period::1,NCT01644175,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01644175::outcome::primary::1,NCT01644175,Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis,,,,,,,,,,,,,PRIMARY,From Baseline to Week 52
country,NCT01644175::country::United States,NCT01644175,United States,,,,,,,,,,,,,,
trial,NCT01181102,NCT01181102,"A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty",PHASE3,cardiovascular disease,Venous Thromboembolism,INDUSTRY,716.0,2009-03,2010-02,2.0,3.0,,,,,
arm,NCT01181102::arm::FG000,NCT01181102,DU-176b,,,,,,,,,,FG000,"DU-176b oral tablets, 30 mg., taken once daily for 2 weeks

edoxaban",,,
arm,NCT01181102::arm::FG001,NCT01181102,Enoxaparin Sodium,,,,,,,,,,FG001,"enoxaparin sodium 20mg(=2000IU)/0.2ml twice daily, subcutaneous injection for 2 weeks

enoxaparin sodium",,,
period,NCT01181102::period::1,NCT01181102,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01181102::outcome::primary::1,NCT01181102,Incidence of Subjects With Venous Thromboembolism Events.,,,,,,,,,,,,,PRIMARY,2 weeks
country,NCT01181102::country::Japan,NCT01181102,Japan,,,,,,,,,,,,,,
country,NCT01181102::country::Taiwan,NCT01181102,Taiwan,,,,,,,,,,,,,,
trial,NCT02136134,NCT02136134,Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma,PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,498.0,2014-08-15,2024-01-10,15.0,105.0,,,,,
arm,NCT02136134::arm::FG000,NCT02136134,Bortezomib + Dexamethasone (Vd),,,,,,,,,,FG000,"Participants received bortezomib 1.3 milligrams per square meter (mg/m\^2) subcutaneous (SC) injection on Days 1, 4, 8, and 11 of each 21-day cycle (8 treatment cycles) and dexamethasone 20 milligrams",,,
arm,NCT02136134::arm::FG001,NCT02136134,Daratumumab + Bortezomib and Dexamethasone (DVd),,,,,,,,,,FG001,"Participants received daratumumab 16 mg/kg IV infusion weekly or daratumumab SC injection (1800 mg fixed dose) for the first 3 cycles, on Day 1 of Cycles 4-8, and then every 4 weeks thereafter, bortez",,,
period,NCT02136134::period::1,NCT02136134,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02136134::outcome::primary::1,NCT02136134,Progression-free Survival (PFS),,,,,,,,,,,,,PRIMARY,"From the date of randomization to either progressive disease or death, whichever occurred first (approximately 1 year 4 months)"
country,NCT02136134::country::United States,NCT02136134,United States,,,,,,,,,,,,,,
country,NCT02136134::country::Germany,NCT02136134,Germany,,,,,,,,,,,,,,
country,NCT02136134::country::Russia,NCT02136134,Russia,,,,,,,,,,,,,,
country,NCT02136134::country::Netherlands,NCT02136134,Netherlands,,,,,,,,,,,,,,
country,NCT02136134::country::Sweden,NCT02136134,Sweden,,,,,,,,,,,,,,
country,NCT02136134::country::Ukraine,NCT02136134,Ukraine,,,,,,,,,,,,,,
country,NCT02136134::country::Australia,NCT02136134,Australia,,,,,,,,,,,,,,
country,NCT02136134::country::Turkey (Türkiye),NCT02136134,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02136134::country::Hungary,NCT02136134,Hungary,,,,,,,,,,,,,,
country,NCT02136134::country::Poland,NCT02136134,Poland,,,,,,,,,,,,,,
country,NCT02136134::country::South Korea,NCT02136134,South Korea,,,,,,,,,,,,,,
country,NCT02136134::country::Spain,NCT02136134,Spain,,,,,,,,,,,,,,
country,NCT02136134::country::Brazil,NCT02136134,Brazil,,,,,,,,,,,,,,
country,NCT02136134::country::Czechia,NCT02136134,Czechia,,,,,,,,,,,,,,
country,NCT02136134::country::Mexico,NCT02136134,Mexico,,,,,,,,,,,,,,
trial,NCT02271230,NCT02271230,Intervention With Vitamin D and Omega-3 Supplements and Incident Heart Failure,PHASE3,cardiovascular disease,Heart Failure,OTHER,25871.0,2014-08,2019-12,1.0,1.0,,,,,
arm,NCT02271230::arm::FG000,NCT02271230,Active Vitamin D + Active Omega-3 Fatty Acids,,,,,,,,,,FG000,"Active Vitamin D = Vitamin D3, one 2000 IU capsule/day; Active Omega-3 Fatty Acids = Omacor, one 1-gram capsule/day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 m",,,
arm,NCT02271230::arm::FG001,NCT02271230,Active Vitamin D + Placebo Omega-3 Fatty Acids,,,,,,,,,,FG001,"Active Vitamin D = Vitamin D3, one 2000 IU capsule/day; Placebo Omega-3 Fatty Acids, one capsule/day",,,
arm,NCT02271230::arm::FG002,NCT02271230,Placebo Vitamin D + Active Omega-3 Fatty Acids,,,,,,,,,,FG002,"Placebo Vitamin D, one capsule/day; Active Omega-3 Fatty Acids = Omacor, one 1-gram capsule/day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoi",,,
arm,NCT02271230::arm::FG003,NCT02271230,Placebo Vitamin D + Placebo Omega-3 Fatty Acids,,,,,,,,,,FG003,"Placebo Vitamin D, one capsule/day; Placebo Omega-3 Fatty Acids, one capsule/day",,,
period,NCT02271230::period::1,NCT02271230,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02271230::outcome::primary::1,NCT02271230,Number of Participants With New Heart Failure Hospitalization,,,,,,,,,,,,,PRIMARY,5 years
country,NCT02271230::country::United States,NCT02271230,United States,,,,,,,,,,,,,,
trial,NCT01976338,NCT01976338,Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO),PHASE3,cardiovascular disease,Macular Edema Secondary to Branch Retinal Vein Occlusion,INDUSTRY,283.0,2013-11-12,2016-03-28,6.0,33.0,,,,,
arm,NCT01976338::arm::FG000,NCT01976338,Ranibizumab 0.5 mg,,,,,,,,,,FG000,PRN Intravitreal injection,,,
arm,NCT01976338::arm::FG001,NCT01976338,Sham Injection,,,,,,,,,,FG001,As of Month 6 ranibizumab 0.5 mg PRN intravitreal injection,,,
period,NCT01976338::period::1,NCT01976338,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01976338::outcome::primary::1,NCT01976338,Average Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 1 Through Month 6,,,,,,,,,,,,,PRIMARY,Baseline to Month 1 through Month 6
country,NCT01976338::country::China,NCT01976338,China,,,,,,,,,,,,,,
country,NCT01976338::country::Taiwan,NCT01976338,Taiwan,,,,,,,,,,,,,,
country,NCT01976338::country::Indonesia,NCT01976338,Indonesia,,,,,,,,,,,,,,
country,NCT01976338::country::Philippines,NCT01976338,Philippines,,,,,,,,,,,,,,
country,NCT01976338::country::Vietnam,NCT01976338,Vietnam,,,,,,,,,,,,,,
country,NCT01976338::country::Hong Kong,NCT01976338,Hong Kong,,,,,,,,,,,,,,
trial,NCT01830543,NCT01830543,A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention,PHASE3,cardiovascular disease,Atrial Fibrillation; Percutaneous Coronary Intervention,INDUSTRY,2124.0,2013-05-10,2016-07-28,25.0,348.0,,,,,
arm,NCT01830543::arm::FG000,NCT01830543,Rivaroxaban 15 mg,,,,,,,,,,FG000,Participants received rivaroxaban 15 milligram (mg) or 10 mg (for participants with moderate renal impairment \[creatinine clearance (CrCl): 30 to less than (\<) 50 milliliter per minute (mL/min)\]) o,,,
arm,NCT01830543::arm::FG001,NCT01830543,Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD),,,,,,,,,,FG001,Participants received rivaroxaban 2.5 mg twice daily plus background dual antiplatelet therapy (DAPT) with low-dose acetylsalicylic acid (ASA) 75 to 100 mg per day and clopidogrel 75 mg once daily (or,,,
arm,NCT01830543::arm::FG002,NCT01830543,Vitamin K Antagonist (VKA),,,,,,,,,,FG002,"Participants received dose adjusted (to a target of international normalized ratio \[INR\] 2.0 to 3.0 \[or target INR 2.0 to 2.5\]) vitamin K antagonist (VKA) \[example warfarin, acenocoumarol; assign",,,
period,NCT01830543::period::1,NCT01830543,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01830543::outcome::primary::1,NCT01830543,Percentage of Participants With Clinically Significant Bleeding,,,,,,,,,,,,,PRIMARY,Up to Month 12
country,NCT01830543::country::United States,NCT01830543,United States,,,,,,,,,,,,,,
country,NCT01830543::country::United Kingdom,NCT01830543,United Kingdom,,,,,,,,,,,,,,
country,NCT01830543::country::Poland,NCT01830543,Poland,,,,,,,,,,,,,,
country,NCT01830543::country::Germany,NCT01830543,Germany,,,,,,,,,,,,,,
country,NCT01830543::country::Russia,NCT01830543,Russia,,,,,,,,,,,,,,
country,NCT01830543::country::Canada,NCT01830543,Canada,,,,,,,,,,,,,,
country,NCT01830543::country::France,NCT01830543,France,,,,,,,,,,,,,,
country,NCT01830543::country::Brazil,NCT01830543,Brazil,,,,,,,,,,,,,,
country,NCT01830543::country::Belgium,NCT01830543,Belgium,,,,,,,,,,,,,,
country,NCT01830543::country::Czechia,NCT01830543,Czechia,,,,,,,,,,,,,,
country,NCT01830543::country::Denmark,NCT01830543,Denmark,,,,,,,,,,,,,,
country,NCT01830543::country::Netherlands,NCT01830543,Netherlands,,,,,,,,,,,,,,
country,NCT01830543::country::Ukraine,NCT01830543,Ukraine,,,,,,,,,,,,,,
country,NCT01830543::country::Argentina,NCT01830543,Argentina,,,,,,,,,,,,,,
country,NCT01830543::country::Mexico,NCT01830543,Mexico,,,,,,,,,,,,,,
country,NCT01830543::country::South Korea,NCT01830543,South Korea,,,,,,,,,,,,,,
country,NCT01830543::country::Turkey (Türkiye),NCT01830543,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01830543::country::Bulgaria,NCT01830543,Bulgaria,,,,,,,,,,,,,,
country,NCT01830543::country::Sweden,NCT01830543,Sweden,,,,,,,,,,,,,,
country,NCT01830543::country::Australia,NCT01830543,Australia,,,,,,,,,,,,,,
country,NCT01830543::country::Chile,NCT01830543,Chile,,,,,,,,,,,,,,
country,NCT01830543::country::Taiwan,NCT01830543,Taiwan,,,,,,,,,,,,,,
country,NCT01830543::country::Malaysia,NCT01830543,Malaysia,,,,,,,,,,,,,,
country,NCT01830543::country::Romania,NCT01830543,Romania,,,,,,,,,,,,,,
country,NCT01830543::country::South Africa,NCT01830543,South Africa,,,,,,,,,,,,,,
trial,NCT02504216,NCT02504216,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,PHASE3,cardiovascular disease,Peripheral Artery Disease,INDUSTRY,6564.0,2015-08-18,2020-01-09,34.0,532.0,,,,,
arm,NCT02504216::arm::FG000,NCT02504216,Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od,,,,,,,,,,FG000,Participants were treated with Rivaroxaban 2.5 mg twice-daily (bid) and aspirin (ASA: Acetylsalicylic Acid) 100 mg once-daily (od),,,
arm,NCT02504216::arm::FG001,NCT02504216,Rivaroxaban Placebo Bid + Aspirin 100 mg od,,,,,,,,,,FG001,Participants were treated with Rivaroxaban-placebo twice-daily and aspirin (ASA: Acetylsalicylic Acid) 100 mg once-daily,,,
period,NCT02504216::period::1,NCT02504216,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02504216::outcome::primary::1,NCT02504216,"Primary Efficacy Outcome: Number of Participants With Composite of Myocardial Infarction (MI), Ischemic Stroke, Cardiovascular Death, Acute Limb Ischemia (ALI) and Major Amputation Due to a Vascular Etiology",,,,,,,,,,,,,PRIMARY,"For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean time in follow-up survival time until ECOD that date was 1109.76 days."
outcome,NCT02504216::outcome::primary::2,NCT02504216,Primary Safety Outcome: Number of Participants With TIMI (Thrombolysis in Myocardial Infarction) Major Bleeding,,,,,,,,,,,,,PRIMARY,"For each participant, the first occurrence of the primary safety outcome after randomization up until 2 days after permanent stop of study drug (rivaroxaban or rivaroxaban placebo)."
country,NCT02504216::country::United States,NCT02504216,United States,,,,,,,,,,,,,,
country,NCT02504216::country::Japan,NCT02504216,Japan,,,,,,,,,,,,,,
country,NCT02504216::country::Germany,NCT02504216,Germany,,,,,,,,,,,,,,
country,NCT02504216::country::China,NCT02504216,China,,,,,,,,,,,,,,
country,NCT02504216::country::Argentina,NCT02504216,Argentina,,,,,,,,,,,,,,
country,NCT02504216::country::Brazil,NCT02504216,Brazil,,,,,,,,,,,,,,
country,NCT02504216::country::Russia,NCT02504216,Russia,,,,,,,,,,,,,,
country,NCT02504216::country::France,NCT02504216,France,,,,,,,,,,,,,,
country,NCT02504216::country::Italy,NCT02504216,Italy,,,,,,,,,,,,,,
country,NCT02504216::country::United Kingdom,NCT02504216,United Kingdom,,,,,,,,,,,,,,
country,NCT02504216::country::Canada,NCT02504216,Canada,,,,,,,,,,,,,,
country,NCT02504216::country::Poland,NCT02504216,Poland,,,,,,,,,,,,,,
country,NCT02504216::country::South Korea,NCT02504216,South Korea,,,,,,,,,,,,,,
country,NCT02504216::country::Bulgaria,NCT02504216,Bulgaria,,,,,,,,,,,,,,
country,NCT02504216::country::Czechia,NCT02504216,Czechia,,,,,,,,,,,,,,
country,NCT02504216::country::Hungary,NCT02504216,Hungary,,,,,,,,,,,,,,
country,NCT02504216::country::Spain,NCT02504216,Spain,,,,,,,,,,,,,,
country,NCT02504216::country::Slovakia,NCT02504216,Slovakia,,,,,,,,,,,,,,
country,NCT02504216::country::Austria,NCT02504216,Austria,,,,,,,,,,,,,,
country,NCT02504216::country::Romania,NCT02504216,Romania,,,,,,,,,,,,,,
country,NCT02504216::country::Ukraine,NCT02504216,Ukraine,,,,,,,,,,,,,,
country,NCT02504216::country::Switzerland,NCT02504216,Switzerland,,,,,,,,,,,,,,
country,NCT02504216::country::Belgium,NCT02504216,Belgium,,,,,,,,,,,,,,
country,NCT02504216::country::Netherlands,NCT02504216,Netherlands,,,,,,,,,,,,,,
country,NCT02504216::country::Taiwan,NCT02504216,Taiwan,,,,,,,,,,,,,,
country,NCT02504216::country::Portugal,NCT02504216,Portugal,,,,,,,,,,,,,,
country,NCT02504216::country::Thailand,NCT02504216,Thailand,,,,,,,,,,,,,,
country,NCT02504216::country::Denmark,NCT02504216,Denmark,,,,,,,,,,,,,,
country,NCT02504216::country::Lithuania,NCT02504216,Lithuania,,,,,,,,,,,,,,
country,NCT02504216::country::Sweden,NCT02504216,Sweden,,,,,,,,,,,,,,
country,NCT02504216::country::Latvia,NCT02504216,Latvia,,,,,,,,,,,,,,
country,NCT02504216::country::Serbia,NCT02504216,Serbia,,,,,,,,,,,,,,
country,NCT02504216::country::Estonia,NCT02504216,Estonia,,,,,,,,,,,,,,
country,NCT02504216::country::Finland,NCT02504216,Finland,,,,,,,,,,,,,,
trial,NCT01785472,NCT01785472,Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension,PHASE3,cardiovascular disease,Essential Hypertension,INDUSTRY,1438.0,2013-04,2014-08,7.0,50.0,,,,,
arm,NCT01785472::arm::FG000,NCT01785472,LCZ696 200 mg,,,,,,,,,,FG000,Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily.,,,
arm,NCT01785472::arm::FG001,NCT01785472,LCZ696 400 mg,,,,,,,,,,FG001,"Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablet",,,
arm,NCT01785472::arm::FG002,NCT01785472,Olmesartan 20 mg,,,,,,,,,,FG002,Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily.,,,
period,NCT01785472::period::1,NCT01785472,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01785472::outcome::primary::1,NCT01785472,Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 200 mg Versus Olmesartan 20 mg,,,,,,,,,,,,,PRIMARY,"baseline, 8 weeks"
country,NCT01785472::country::China,NCT01785472,China,,,,,,,,,,,,,,
country,NCT01785472::country::Taiwan,NCT01785472,Taiwan,,,,,,,,,,,,,,
country,NCT01785472::country::South Korea,NCT01785472,South Korea,,,,,,,,,,,,,,
country,NCT01785472::country::Thailand,NCT01785472,Thailand,,,,,,,,,,,,,,
country,NCT01785472::country::Philippines,NCT01785472,Philippines,,,,,,,,,,,,,,
country,NCT01785472::country::Hong Kong,NCT01785472,Hong Kong,,,,,,,,,,,,,,
country,NCT01785472::country::Singapore,NCT01785472,Singapore,,,,,,,,,,,,,,
trial,NCT01330628,NCT01330628,Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis,PHASE3,cardiovascular disease,Peripheral Arterial Disease,INDUSTRY,252.0,2011-06,2015-05,2.0,34.0,,,,,
arm,NCT01330628::arm::FG000,NCT01330628,Laser Atherectomy and PTA,,,,,,,,,,FG000,"laser, then balloon angioplasty

Turbo Elite Laser and Turbo Tandem Laser Guide Catheters: application of laser energy to remove blockage followed by standard balloon angioplasty",,,
arm,NCT01330628::arm::FG001,NCT01330628,Balloon Angioplasty,,,,,,,,,,FG001,Balloon angioplasty: standard balloon catheters for PTA,,,
period,NCT01330628::period::1,NCT01330628,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01330628::outcome::primary::1,NCT01330628,Freedom From Target Lesion Revascularization (TLR),,,,,,,,,,,,,PRIMARY,6 months
outcome,NCT01330628::outcome::primary::2,NCT01330628,Freedom From Major Adverse Events (MAE),,,,,,,,,,,,,PRIMARY,30 days
country,NCT01330628::country::United States,NCT01330628,United States,,,,,,,,,,,,,,
country,NCT01330628::country::Puerto Rico,NCT01330628,Puerto Rico,,,,,,,,,,,,,,
trial,NCT02666664,NCT02666664,Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony),PHASE3,cardiovascular disease,Hypercholesterolemia; Atherosclerotic Cardiovascular Diseases,INDUSTRY,2230.0,2016-01-21,2018-03-28,6.0,104.0,,,,,
arm,NCT02666664::arm::FG000,NCT02666664,Placebo,,,,,,,,,,FG000,"During the double-blind treatment period, participants received placebo tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies) incl",,,
arm,NCT02666664::arm::FG001,NCT02666664,Bempedoic Acid,,,,,,,,,,FG001,"During the double-blind treatment period, participants received bempedoic acid 180 mg tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying the",,,
period,NCT02666664::period::1,NCT02666664,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02666664::outcome::primary::1,NCT02666664,Percentage of Participants With Treatment-emergent Adverse Events (TEAEs),,,,,,,,,,,,,PRIMARY,Up to approximately 52 weeks
outcome,NCT02666664::outcome::primary::2,NCT02666664,Percentage of Participants With Adjudicated Major Adverse Cardiovascular Event,,,,,,,,,,,,,PRIMARY,Up to approximately 52 weeks
outcome,NCT02666664::outcome::primary::3,NCT02666664,Percentage of Participants With the Indicated Event of Special Interest: Creatine Kinase Elevations,,,,,,,,,,,,,PRIMARY,Up to approximately 52 weeks
outcome,NCT02666664::outcome::primary::4,NCT02666664,Percentage of Participants With the Indicated Event of Special Interest: Hepatic Disorders,,,,,,,,,,,,,PRIMARY,Up to approximately 52 weeks
outcome,NCT02666664::outcome::primary::5,NCT02666664,Percentage of Participants With the Indicated Event of Special Interest: Hypoglycemia,,,,,,,,,,,,,PRIMARY,Up to approximately 52 weeks
outcome,NCT02666664::outcome::primary::6,NCT02666664,Percentage of Participants With the Indicated Event of Special Interest: Metabolic Acidosis,,,,,,,,,,,,,PRIMARY,Up to approximately 52 weeks
outcome,NCT02666664::outcome::primary::7,NCT02666664,Percentage of Participants With the Indicated Event of Special Interest: Muscular Disorder,,,,,,,,,,,,,PRIMARY,Up to approximately 52 weeks
outcome,NCT02666664::outcome::primary::8,NCT02666664,Percentage of Participants With the Indicated Event of Special Interest: Neurocognitive Disorder,,,,,,,,,,,,,PRIMARY,Up to approximately 52 weeks
outcome,NCT02666664::outcome::primary::9,NCT02666664,Percentage of Participants With the Indicated Event of Special Interest: New Onset or Worsening Diabetes Mellitus,,,,,,,,,,,,,PRIMARY,Up to approximately 52 weeks
outcome,NCT02666664::outcome::primary::10,NCT02666664,Percentage of Participants With the Indicated Event of Special Interest: Renal Disorder,,,,,,,,,,,,,PRIMARY,Up to approximately 52 weeks
outcome,NCT02666664::outcome::primary::11,NCT02666664,Change From Baseline to Week 52 in Uric Acid (Urate) Level,,,,,,,,,,,,,PRIMARY,Baseline and Week 52
outcome,NCT02666664::outcome::primary::12,NCT02666664,Change From Baseline to Week 52 in Creatinine Level,,,,,,,,,,,,,PRIMARY,Baseline and Week 52
outcome,NCT02666664::outcome::primary::13,NCT02666664,Change From Baseline to Week 52 in Hemoglobin Level,,,,,,,,,,,,,PRIMARY,Baseline and Week 52
country,NCT02666664::country::United States,NCT02666664,United States,,,,,,,,,,,,,,
country,NCT02666664::country::Canada,NCT02666664,Canada,,,,,,,,,,,,,,
country,NCT02666664::country::United Kingdom,NCT02666664,United Kingdom,,,,,,,,,,,,,,
country,NCT02666664::country::Netherlands,NCT02666664,Netherlands,,,,,,,,,,,,,,
country,NCT02666664::country::Poland,NCT02666664,Poland,,,,,,,,,,,,,,
country,NCT02666664::country::Germany,NCT02666664,Germany,,,,,,,,,,,,,,
trial,NCT00041938,NCT00041938,Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial,PHASE3,cardiovascular disease,Heart Disease; Stroke; Ischemic Heart Disease; Myocardial Infarction,OTHER,2305.0,2002-10,2014-07,2.0,64.0,,,,,
arm,NCT00041938::arm::FG000,NCT00041938,Aspirin,,,,,,,,,,FG000,Aspirin : 325 mg per day,,,
arm,NCT00041938::arm::FG001,NCT00041938,Warfarin,,,,,,,,,,FG001,Warfarin : International Normalized Ratio (INR) 2.5-3.0; target INR 2.75,,,
period,NCT00041938::period::1,NCT00041938,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00041938::outcome::primary::1,NCT00041938,"Event Rate Per 100 Patient Years for Composite Endpoint of Ischemic Stroke, Intracerebral Hemorrhage, or Death",,,,,,,,,,,,,PRIMARY,"From date of randomization until the date of the first to occur of ischemic stroke, intracerebral hemorrhage, or death, up to 6 years"
country,NCT00041938::country::United States,NCT00041938,United States,,,,,,,,,,,,,,
country,NCT00041938::country::Canada,NCT00041938,Canada,,,,,,,,,,,,,,
trial,NCT03053440,NCT03053440,A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM),PHASE3,cardiovascular disease,Waldenström's Macroglobulinemia,INDUSTRY,201.0,2017-01-25,2022-06-21,12.0,58.0,,,,,
arm,NCT03053440::arm::FG000,NCT03053440,Arm A: Ibrutinib,,,,,,,,,,FG000,"Participants diagnosed with Waldenström's Macroglobulinemia (WM) with mutated MYD88 gene received 420 mg ibrutinib once daily orally until progressive disease, unacceptable toxicity, death, withdrawal",,,
arm,NCT03053440::arm::FG001,NCT03053440,Arm B: Zanubrutinib,,,,,,,,,,FG001,"Participants diagnosed with WM with mutated MYD88 gene received 160 milligrams (mg) zanubrutinib twice daily orally until progressive disease, unacceptable toxicity, death, withdrawal of consent, or s",,,
period,NCT03053440::period::1,NCT03053440,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03053440::outcome::primary::1,NCT03053440,Percentage of Participants Achieving Either a Complete Response (CR) or Very Good Partial Response (VGPR) Using an Adaptation of the Response Criteria Updated at the Sixth International Workshop on WM as Assessed by an Independent Review Committee (IRC),,,,,,,,,,,,,PRIMARY,Up to approximately 2 years and 7 months
country,NCT03053440::country::Australia,NCT03053440,Australia,,,,,,,,,,,,,,
country,NCT03053440::country::Italy,NCT03053440,Italy,,,,,,,,,,,,,,
country,NCT03053440::country::Spain,NCT03053440,Spain,,,,,,,,,,,,,,
country,NCT03053440::country::United States,NCT03053440,United States,,,,,,,,,,,,,,
country,NCT03053440::country::United Kingdom,NCT03053440,United Kingdom,,,,,,,,,,,,,,
country,NCT03053440::country::Poland,NCT03053440,Poland,,,,,,,,,,,,,,
country,NCT03053440::country::Czechia,NCT03053440,Czechia,,,,,,,,,,,,,,
country,NCT03053440::country::Germany,NCT03053440,Germany,,,,,,,,,,,,,,
country,NCT03053440::country::Netherlands,NCT03053440,Netherlands,,,,,,,,,,,,,,
country,NCT03053440::country::France,NCT03053440,France,,,,,,,,,,,,,,
country,NCT03053440::country::Greece,NCT03053440,Greece,,,,,,,,,,,,,,
country,NCT03053440::country::Sweden,NCT03053440,Sweden,,,,,,,,,,,,,,
trial,NCT02412878,NCT02412878,Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma,PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,478.0,2015-09-09,2019-01-07,20.0,140.0,,,,,
arm,NCT02412878::arm::FG000,NCT02412878,Twice-weekly Carfilzomib 20/27 mg/m² + Dexamethasone,,,,,,,,,,FG000,"Participants received carfilzomib administered by intravenous (IV) infusion on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle (20 mg/m² on days 1 and 2 of cycle 1 and 27 mg/m² thereafter).

Particip",,,
arm,NCT02412878::arm::FG001,NCT02412878,Once-weekly Carfilzomib 20/70 mg/m² + Dexamethasone,,,,,,,,,,FG001,"Participants received carfilzomib administered by IV infusion on days 1, 8, and 15 of each 28-day cycle (20 mg/m² on day 1 of cycle 1 and 70 mg/m² thereafter).

Participants also received 40 mg dexame",,,
period,NCT02412878::period::1,NCT02412878,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02412878::outcome::primary::1,NCT02412878,Progression Free Survival,,,,,,,,,,,,,PRIMARY,From randomization until the data cut-off date of 15 June 2017
country,NCT02412878::country::Japan,NCT02412878,Japan,,,,,,,,,,,,,,
country,NCT02412878::country::Italy,NCT02412878,Italy,,,,,,,,,,,,,,
country,NCT02412878::country::United States,NCT02412878,United States,,,,,,,,,,,,,,
country,NCT02412878::country::Spain,NCT02412878,Spain,,,,,,,,,,,,,,
country,NCT02412878::country::Poland,NCT02412878,Poland,,,,,,,,,,,,,,
country,NCT02412878::country::Canada,NCT02412878,Canada,,,,,,,,,,,,,,
country,NCT02412878::country::France,NCT02412878,France,,,,,,,,,,,,,,
country,NCT02412878::country::United Kingdom,NCT02412878,United Kingdom,,,,,,,,,,,,,,
country,NCT02412878::country::Belgium,NCT02412878,Belgium,,,,,,,,,,,,,,
country,NCT02412878::country::Czechia,NCT02412878,Czechia,,,,,,,,,,,,,,
country,NCT02412878::country::Sweden,NCT02412878,Sweden,,,,,,,,,,,,,,
country,NCT02412878::country::Germany,NCT02412878,Germany,,,,,,,,,,,,,,
country,NCT02412878::country::Australia,NCT02412878,Australia,,,,,,,,,,,,,,
country,NCT02412878::country::Denmark,NCT02412878,Denmark,,,,,,,,,,,,,,
country,NCT02412878::country::Hungary,NCT02412878,Hungary,,,,,,,,,,,,,,
country,NCT02412878::country::Finland,NCT02412878,Finland,,,,,,,,,,,,,,
country,NCT02412878::country::Greece,NCT02412878,Greece,,,,,,,,,,,,,,
country,NCT02412878::country::New Zealand,NCT02412878,New Zealand,,,,,,,,,,,,,,
country,NCT02412878::country::Norway,NCT02412878,Norway,,,,,,,,,,,,,,
country,NCT02412878::country::Romania,NCT02412878,Romania,,,,,,,,,,,,,,
trial,NCT01286558,NCT01286558,Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg),PHASE3,cardiovascular disease,Hypertension,INDUSTRY,225.0,2011-01,,1.0,8.0,,,,,
arm,NCT01286558::arm::FG000,NCT01286558,80 mg Telmisartan and 5 mg Amlodipine FDC,,,,,,,,,,FG000,,,,
arm,NCT01286558::arm::FG001,NCT01286558,40 mg Telmisartan and 5 mg Amlodipine FDC,,,,,,,,,,FG001,,,,
period,NCT01286558::period::1,NCT01286558,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01286558::outcome::primary::1,NCT01286558,Reduction From the Reference Baseline in Mean Seated Diastolic Blood Pressure (DBP) at Trough,,,,,,,,,,,,,PRIMARY,"Reference baseline, 8 weeks"
country,NCT01286558::country::Japan,NCT01286558,Japan,,,,,,,,,,,,,,
trial,NCT03815292,NCT03815292,Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke,PHASE3,cardiovascular disease,Mild Cognitive Impairment; Ischemic Stroke,INDUSTRY,276.0,2018-10-19,2020-01-27,1.0,28.0,,,,,
arm,NCT03815292::arm::FG000,NCT03815292,MMH-MAP,,,,,,,,,,FG000,Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets/day). The tablets should be held in mouth without chewing until complete dissolution. The duration of treatmen,,,
arm,NCT03815292::arm::FG001,NCT03815292,Placebo,,,,,,,,,,FG001,"Placebo for 24 weeks, according to the MMH-MAP dosing regimen.

Placebo: Oral administration",,,
period,NCT03815292::period::1,NCT03815292,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03815292::outcome::primary::1,NCT03815292,Percentage of Patients With Improved Cognitive Function (The Montreal Cognitive Assessment Test Total Score of the Baseline +1 or More),,,,,,,,,,,,,PRIMARY,24 weeks of the treatment as compared to the baseline
country,NCT03815292::country::Russia,NCT03815292,Russia,,,,,,,,,,,,,,
trial,NCT00143598,NCT00143598,The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome,PHASE3,cardiovascular disease,Deep Venous Thrombosis,OTHER,806.0,2004-06,2012-02,2.0,25.0,,,,,
arm,NCT00143598::arm::FG000,NCT00143598,Active ECS,,,,,,,,,,FG000,Active Elastic Compression Stockings. 30-40 mm Hg,,,
arm,NCT00143598::arm::FG001,NCT00143598,Placebo ECS,,,,,,,,,,FG001,Placebo stockings with identical appearance but less than 5 mm Hg compression at the ankle.,,,
period,NCT00143598::period::1,NCT00143598,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00143598::outcome::primary::1,NCT00143598,Incidence of Post-thrombotic Syndrome (PTS),,,,,,,,,,,,,PRIMARY,During 2-year follow up
country,NCT00143598::country::Canada,NCT00143598,Canada,,,,,,,,,,,,,,
country,NCT00143598::country::United States,NCT00143598,United States,,,,,,,,,,,,,,
trial,NCT04518293,NCT04518293,Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,1385.0,2021-07-09,2023-09-01,7.0,89.0,,,,,
arm,NCT04518293::arm::FG000,NCT04518293,GMRx2,,,,,,,,,,FG000,"Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg

Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25",,,
arm,NCT04518293::arm::FG001,NCT04518293,Dual - TA,,,,,,,,,,FG001,"Telmisartan 20 mg/amlodipine 2.5 mg . At week 6 visit, forced up-titration to telmisartan 40 mg/amlodipine 5 mg

Telmisartan 20 mg/amlodipine 2.5 mg .: oral tablet

telmisartan 40 mg/amlodipine 5 mg: ",,,
arm,NCT04518293::arm::FG002,NCT04518293,Dual - TI,,,,,,,,,,FG002,"Telmisartan 20 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to telmisartan 40 mg/indapamide 2.5 mg

Telmisartan 20 mg/indapamide 1.25 mg: oral tablet

telmisartan 40 mg/indapamide 2.5 m",,,
arm,NCT04518293::arm::FG003,NCT04518293,Dual - AI,,,,,,,,,,FG003,"Amlodipine 2.5 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to amlodipine 5 mg/indapamide 2.5 mg

Amlodipine 2.5 mg/indapamide 1.25 mg: oral tablet

amlodipine 5 mg/indapamide 2.5 mg: o",,,
period,NCT04518293::period::1,NCT04518293,"Single, Active run-in (4 Weeks)",,,,,,,,,,,,1.0,,
period,NCT04518293::period::2,NCT04518293,Double-blind,,,,,,,,,,,,2.0,,
outcome,NCT04518293::outcome::primary::1,NCT04518293,Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 12,,,,,,,,,,,,,PRIMARY,Week 12
country,NCT04518293::country::United States,NCT04518293,United States,,,,,,,,,,,,,,
country,NCT04518293::country::United Kingdom,NCT04518293,United Kingdom,,,,,,,,,,,,,,
country,NCT04518293::country::Poland,NCT04518293,Poland,,,,,,,,,,,,,,
country,NCT04518293::country::Sri Lanka,NCT04518293,Sri Lanka,,,,,,,,,,,,,,
country,NCT04518293::country::Australia,NCT04518293,Australia,,,,,,,,,,,,,,
country,NCT04518293::country::Czechia,NCT04518293,Czechia,,,,,,,,,,,,,,
country,NCT04518293::country::New Zealand,NCT04518293,New Zealand,,,,,,,,,,,,,,
trial,NCT01545232,NCT01545232,"Pragmatic, Randomized Optimal Platelet and Plasma Ratios",PHASE3,cardiovascular disease,Trauma,OTHER,680.0,2012-08,2013-12,2.0,12.0,,,,,
arm,NCT01545232::arm::FG000,NCT01545232,1:1:1 Blood Transfusion Ratio,,,,,,,,,,FG000,"1:1:1 Blood Transfusion Ratio: Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets ",,,
arm,NCT01545232::arm::FG001,NCT01545232,1:1:2 Blood Transfusion Ratio,,,,,,,,,,FG001,"1:1:2 Blood Transfusion Ratio: Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units plate",,,
period,NCT01545232::period::1,NCT01545232,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01545232::outcome::primary::1,NCT01545232,24-hour Mortality,,,,,,,,,,,,,PRIMARY,First 24 hours after ED admission
outcome,NCT01545232::outcome::primary::2,NCT01545232,30-day Mortality,,,,,,,,,,,,,PRIMARY,First 30 days after ED admission
outcome,NCT01545232::outcome::primary::3,NCT01545232,Coagulation as Indicated by Number of Participants With Reported Venous Thrombolic Events (VTE),,,,,,,,,,,,,PRIMARY,"From time of ED admission, for up to 72 hours"
country,NCT01545232::country::United States,NCT01545232,United States,,,,,,,,,,,,,,
country,NCT01545232::country::Canada,NCT01545232,Canada,,,,,,,,,,,,,,
trial,NCT02630316,NCT02630316,Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE,PHASE3,cardiovascular disease,Pulmonary Hypertension; Interstitial Lung Disease; Combined Pulmonary Fibrosis and Emphysema,INDUSTRY,326.0,2017-02-03,2019-12-26,2.0,97.0,,,,,
arm,NCT02630316::arm::FG000,NCT02630316,Placebo,,,,,,,,,,FG000,"Matching placebo inhaled using an ultrasonic nebulizer four times daily

Placebo: Placebo administered four times daily",,,
arm,NCT02630316::arm::FG001,NCT02630316,Inhaled Treprostinil,,,,,,,,,,FG001,Active Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled four times daily and titrated up to a maximu,,,
period,NCT02630316::period::1,NCT02630316,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02630316::outcome::primary::1,NCT02630316,Change in 6-minute Walk Distance (6MWD) Measured at Peak Exposure From Baseline to Week 16,,,,,,,,,,,,,PRIMARY,Baseline and Week 16
country,NCT02630316::country::United States,NCT02630316,United States,,,,,,,,,,,,,,
country,NCT02630316::country::Puerto Rico,NCT02630316,Puerto Rico,,,,,,,,,,,,,,
trial,NCT01877915,NCT01877915,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",PHASE3,cardiovascular disease,Heart Failure; Coronary Artery Disease,INDUSTRY,5081.0,2013-09-10,2018-04-19,32.0,563.0,,,,,
arm,NCT01877915::arm::FG000,NCT01877915,Rivaroxaban,,,,,,,,,,FG000,Participants received 2.5 milligram (mg) tablet of rivaroxaban orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physi,,,
arm,NCT01877915::arm::FG001,NCT01877915,Placebo,,,,,,,,,,FG001,Participants received matching placebo orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).,,,
period,NCT01877915::period::1,NCT01877915,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01877915::outcome::primary::1,NCT01877915,"Event Rate of All-Cause Mortality, Myocardial Infarction (MI), or Stroke",,,,,,,,,,,,,PRIMARY,Up to Global treatment end date (approximately 54 months)
outcome,NCT01877915::outcome::primary::2,NCT01877915,Event Rate of Either Fatal Bleeding or Bleeding Into a Critical Space With Potential for Permanent Disability,,,,,,,,,,,,,PRIMARY,Up to 227 Weeks
country,NCT01877915::country::United States,NCT01877915,United States,,,,,,,,,,,,,,
country,NCT01877915::country::Japan,NCT01877915,Japan,,,,,,,,,,,,,,
country,NCT01877915::country::Poland,NCT01877915,Poland,,,,,,,,,,,,,,
country,NCT01877915::country::China,NCT01877915,China,,,,,,,,,,,,,,
country,NCT01877915::country::Russia,NCT01877915,Russia,,,,,,,,,,,,,,
country,NCT01877915::country::Spain,NCT01877915,Spain,,,,,,,,,,,,,,
country,NCT01877915::country::Brazil,NCT01877915,Brazil,,,,,,,,,,,,,,
country,NCT01877915::country::Germany,NCT01877915,Germany,,,,,,,,,,,,,,
country,NCT01877915::country::Czechia,NCT01877915,Czechia,,,,,,,,,,,,,,
country,NCT01877915::country::Argentina,NCT01877915,Argentina,,,,,,,,,,,,,,
country,NCT01877915::country::Mexico,NCT01877915,Mexico,,,,,,,,,,,,,,
country,NCT01877915::country::Romania,NCT01877915,Romania,,,,,,,,,,,,,,
country,NCT01877915::country::Ukraine,NCT01877915,Ukraine,,,,,,,,,,,,,,
country,NCT01877915::country::United Kingdom,NCT01877915,United Kingdom,,,,,,,,,,,,,,
country,NCT01877915::country::Netherlands,NCT01877915,Netherlands,,,,,,,,,,,,,,
country,NCT01877915::country::Bulgaria,NCT01877915,Bulgaria,,,,,,,,,,,,,,
country,NCT01877915::country::France,NCT01877915,France,,,,,,,,,,,,,,
country,NCT01877915::country::Canada,NCT01877915,Canada,,,,,,,,,,,,,,
country,NCT01877915::country::Portugal,NCT01877915,Portugal,,,,,,,,,,,,,,
country,NCT01877915::country::Turkey (Türkiye),NCT01877915,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01877915::country::Australia,NCT01877915,Australia,,,,,,,,,,,,,,
country,NCT01877915::country::Hungary,NCT01877915,Hungary,,,,,,,,,,,,,,
country,NCT01877915::country::Malaysia,NCT01877915,Malaysia,,,,,,,,,,,,,,
country,NCT01877915::country::Slovakia,NCT01877915,Slovakia,,,,,,,,,,,,,,
country,NCT01877915::country::South Korea,NCT01877915,South Korea,,,,,,,,,,,,,,
country,NCT01877915::country::South Africa,NCT01877915,South Africa,,,,,,,,,,,,,,
country,NCT01877915::country::Latvia,NCT01877915,Latvia,,,,,,,,,,,,,,
country,NCT01877915::country::Lithuania,NCT01877915,Lithuania,,,,,,,,,,,,,,
country,NCT01877915::country::Denmark,NCT01877915,Denmark,,,,,,,,,,,,,,
country,NCT01877915::country::Greece,NCT01877915,Greece,,,,,,,,,,,,,,
country,NCT01877915::country::Sweden,NCT01877915,Sweden,,,,,,,,,,,,,,
country,NCT01877915::country::Estonia,NCT01877915,Estonia,,,,,,,,,,,,,,
trial,NCT00781391,NCT00781391,Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation,PHASE3,cardiovascular disease,Stroke; Atrial Fibrillation; Embolism,INDUSTRY,21105.0,2008-11,2013-05,46.0,1009.0,,,,,
arm,NCT00781391::arm::FG000,NCT00781391,Warfarin/Placebo Edoxaban,,,,,,,,,,FG000,"Warfarin tablets plus placebo Edoxaban tablets

warfarin tablets: Warfarin tablets plus Edoxaban placebo tablets each taken once daily for 24 months

placebo edoxaban: placebo edoxaban",,,
arm,NCT00781391::arm::FG001,NCT00781391,High Dose Edoxaban/Placebo Warfarin,,,,,,,,,,FG001,"Edoxaban tablets plus warfarin placebo tablets

60mg Edoxaban tablets (high dose regimen): Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months

placebo warfarin: placebo",,,
arm,NCT00781391::arm::FG002,NCT00781391,Low Dose Edoxaban/Placebo Warfarin,,,,,,,,,,FG002,"Edoxaban tablets plus warfarin placebo tablets

30mg Edoxaban tablets (low dose regimen): Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months

placebo warfarin: placebo ",,,
period,NCT00781391::period::1,NCT00781391,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00781391::outcome::primary::1,NCT00781391,Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).,,,,,,,,,,,,,PRIMARY,on-treatment period 2.5 years of median study drug exposure and 2.8 year of median follow-up
outcome,NCT00781391::outcome::primary::2,NCT00781391,Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).,,,,,,,,,,,,,PRIMARY,overall study period 2.5 years of median study drug exposure and 2.8 year of median follow-up
outcome,NCT00781391::outcome::primary::3,NCT00781391,Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).,,,,,,,,,,,,,PRIMARY,on-treatment period 2.5 years of median study drug exposure and 2.8 year of median follow-up
outcome,NCT00781391::outcome::primary::4,NCT00781391,Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).,,,,,,,,,,,,,PRIMARY,overall study period 2.5 years of median study drug exposure and 2.8 year of median follow-up
outcome,NCT00781391::outcome::primary::5,NCT00781391,Compare Edoxaban to Warfarin for Superiority for Composite of Stroke and Systemic Embolic Events (SEE).,,,,,,,,,,,,,PRIMARY,overall study period 2.5 years of median study drug exposure and 2.8 year of median follow-up
country,NCT00781391::country::United States,NCT00781391,United States,,,,,,,,,,,,,,
country,NCT00781391::country::Germany,NCT00781391,Germany,,,,,,,,,,,,,,
country,NCT00781391::country::Canada,NCT00781391,Canada,,,,,,,,,,,,,,
country,NCT00781391::country::Japan,NCT00781391,Japan,,,,,,,,,,,,,,
country,NCT00781391::country::India,NCT00781391,India,,,,,,,,,,,,,,
country,NCT00781391::country::Poland,NCT00781391,Poland,,,,,,,,,,,,,,
country,NCT00781391::country::United Kingdom,NCT00781391,United Kingdom,,,,,,,,,,,,,,
country,NCT00781391::country::Czechia,NCT00781391,Czechia,,,,,,,,,,,,,,
country,NCT00781391::country::Italy,NCT00781391,Italy,,,,,,,,,,,,,,
country,NCT00781391::country::China,NCT00781391,China,,,,,,,,,,,,,,
country,NCT00781391::country::Brazil,NCT00781391,Brazil,,,,,,,,,,,,,,
country,NCT00781391::country::Russia,NCT00781391,Russia,,,,,,,,,,,,,,
country,NCT00781391::country::Hungary,NCT00781391,Hungary,,,,,,,,,,,,,,
country,NCT00781391::country::Israel,NCT00781391,Israel,,,,,,,,,,,,,,
country,NCT00781391::country::Ukraine,NCT00781391,Ukraine,,,,,,,,,,,,,,
country,NCT00781391::country::Argentina,NCT00781391,Argentina,,,,,,,,,,,,,,
country,NCT00781391::country::Sweden,NCT00781391,Sweden,,,,,,,,,,,,,,
country,NCT00781391::country::Belgium,NCT00781391,Belgium,,,,,,,,,,,,,,
country,NCT00781391::country::France,NCT00781391,France,,,,,,,,,,,,,,
country,NCT00781391::country::Spain,NCT00781391,Spain,,,,,,,,,,,,,,
country,NCT00781391::country::Romania,NCT00781391,Romania,,,,,,,,,,,,,,
country,NCT00781391::country::Australia,NCT00781391,Australia,,,,,,,,,,,,,,
country,NCT00781391::country::South Africa,NCT00781391,South Africa,,,,,,,,,,,,,,
country,NCT00781391::country::Croatia,NCT00781391,Croatia,,,,,,,,,,,,,,
country,NCT00781391::country::Netherlands,NCT00781391,Netherlands,,,,,,,,,,,,,,
country,NCT00781391::country::Slovakia,NCT00781391,Slovakia,,,,,,,,,,,,,,
country,NCT00781391::country::Turkey (Türkiye),NCT00781391,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00781391::country::Chile,NCT00781391,Chile,,,,,,,,,,,,,,
country,NCT00781391::country::Colombia,NCT00781391,Colombia,,,,,,,,,,,,,,
country,NCT00781391::country::Mexico,NCT00781391,Mexico,,,,,,,,,,,,,,
country,NCT00781391::country::Portugal,NCT00781391,Portugal,,,,,,,,,,,,,,
country,NCT00781391::country::South Korea,NCT00781391,South Korea,,,,,,,,,,,,,,
country,NCT00781391::country::Bulgaria,NCT00781391,Bulgaria,,,,,,,,,,,,,,
country,NCT00781391::country::Denmark,NCT00781391,Denmark,,,,,,,,,,,,,,
country,NCT00781391::country::Greece,NCT00781391,Greece,,,,,,,,,,,,,,
country,NCT00781391::country::Guatemala,NCT00781391,Guatemala,,,,,,,,,,,,,,
country,NCT00781391::country::New Zealand,NCT00781391,New Zealand,,,,,,,,,,,,,,
country,NCT00781391::country::Taiwan,NCT00781391,Taiwan,,,,,,,,,,,,,,
country,NCT00781391::country::Thailand,NCT00781391,Thailand,,,,,,,,,,,,,,
country,NCT00781391::country::Finland,NCT00781391,Finland,,,,,,,,,,,,,,
country,NCT00781391::country::Serbia,NCT00781391,Serbia,,,,,,,,,,,,,,
country,NCT00781391::country::Estonia,NCT00781391,Estonia,,,,,,,,,,,,,,
country,NCT00781391::country::Norway,NCT00781391,Norway,,,,,,,,,,,,,,
country,NCT00781391::country::Philippines,NCT00781391,Philippines,,,,,,,,,,,,,,
country,NCT00781391::country::Peru,NCT00781391,Peru,,,,,,,,,,,,,,
country,NCT00781391::country::Switzerland,NCT00781391,Switzerland,,,,,,,,,,,,,,
trial,NCT00325403,NCT00325403,FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH),PHASE3,cardiovascular disease,Pulmonary Hypertension,INDUSTRY,349.0,2006-10,2011-04,13.0,77.0,,,,,
arm,NCT00325403::arm::FG000,NCT00325403,Placebo,,,,,,,,,,FG000,These subjects were randomly allocated to receive matching oral placebo twice daily (every 12 hours +/- 1 hour) and were included in the primary analysis population. Dose increases were made in the ab,,,
arm,NCT00325403::arm::FG001,NCT00325403,UT-15C (Oral Treprostinil),,,,,,,,,,FG001,These subjects were randomly allocated to receive oral treprostinil twice daily (every 12 hours +/- 1 hour) and were included in the primary analysis population. Dose increases were made in the absenc,,,
period,NCT00325403::period::1,NCT00325403,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00325403::outcome::primary::1,NCT00325403,Six Minute Walk Distance (6MWD),,,,,,,,,,,,,PRIMARY,Baseline and Week 12
country,NCT00325403::country::United States,NCT00325403,United States,,,,,,,,,,,,,,
country,NCT00325403::country::India,NCT00325403,India,,,,,,,,,,,,,,
country,NCT00325403::country::Canada,NCT00325403,Canada,,,,,,,,,,,,,,
country,NCT00325403::country::China,NCT00325403,China,,,,,,,,,,,,,,
country,NCT00325403::country::Israel,NCT00325403,Israel,,,,,,,,,,,,,,
country,NCT00325403::country::Mexico,NCT00325403,Mexico,,,,,,,,,,,,,,
country,NCT00325403::country::Poland,NCT00325403,Poland,,,,,,,,,,,,,,
country,NCT00325403::country::Belgium,NCT00325403,Belgium,,,,,,,,,,,,,,
country,NCT00325403::country::Austria,NCT00325403,Austria,,,,,,,,,,,,,,
country,NCT00325403::country::France,NCT00325403,France,,,,,,,,,,,,,,
country,NCT00325403::country::Italy,NCT00325403,Italy,,,,,,,,,,,,,,
country,NCT00325403::country::Netherlands,NCT00325403,Netherlands,,,,,,,,,,,,,,
country,NCT00325403::country::Puerto Rico,NCT00325403,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00853827,NCT00853827,Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients,PHASE3,cardiovascular disease,Coronary Artery Disease (CAD); Coronary Atherosclerosis,INDUSTRY,613.0,2009-03,2013-01,11.0,129.0,,,,,
arm,NCT00853827::arm::FG000,NCT00853827,Aliskiren,,,,,,,,,,FG000,"Period 1(Screening Period) visit 1(Day -42 to Day -1) eligibility for study participation was assessed. Period 2: Visit 2 to 3, single blind for 1 week: patients received aliskiren 150 mg. Period 3: v",,,
arm,NCT00853827::arm::FG001,NCT00853827,Placebo,,,,,,,,,,FG001,"Period 1(Screening Period) visit 1(Day -42 to Day -1) eligibility for study participation was assessed. Period 2: visit 2 to 3, single blind for 1 week: patients received 1 tablet aliskiren 150 mg, 1 ",,,
period,NCT00853827::period::1,NCT00853827,Single Blind Period (1 Week),,,,,,,,,,,,1.0,,
period,NCT00853827::period::2,NCT00853827,Double Blind Period (103 Weeks),,,,,,,,,,,,2.0,,
outcome,NCT00853827::outcome::primary::1,NCT00853827,Change From Baseline in Percent Atheroma Volume(PAV) After 104 Weeks of Treatment,,,,,,,,,,,,,PRIMARY,"Baseline, 104 weeks"
country,NCT00853827::country::United States,NCT00853827,United States,,,,,,,,,,,,,,
country,NCT00853827::country::Spain,NCT00853827,Spain,,,,,,,,,,,,,,
country,NCT00853827::country::Italy,NCT00853827,Italy,,,,,,,,,,,,,,
country,NCT00853827::country::Canada,NCT00853827,Canada,,,,,,,,,,,,,,
country,NCT00853827::country::Germany,NCT00853827,Germany,,,,,,,,,,,,,,
country,NCT00853827::country::Argentina,NCT00853827,Argentina,,,,,,,,,,,,,,
country,NCT00853827::country::Belgium,NCT00853827,Belgium,,,,,,,,,,,,,,
country,NCT00853827::country::Australia,NCT00853827,Australia,,,,,,,,,,,,,,
country,NCT00853827::country::Hungary,NCT00853827,Hungary,,,,,,,,,,,,,,
country,NCT00853827::country::France,NCT00853827,France,,,,,,,,,,,,,,
country,NCT00853827::country::Poland,NCT00853827,Poland,,,,,,,,,,,,,,
trial,NCT02234843,NCT02234843,EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis,PHASE3,cardiovascular disease,Venous Thromboembolism,INDUSTRY,500.0,2014-11-13,2019-01-30,28.0,109.0,,,,,
arm,NCT02234843::arm::FG000,NCT02234843,"Rivaroxaban, Aged 12-<18",,,,,,,,,,FG000,Children aged 12-\<18 years randomized to rivaroxaban received either tablet or oral suspension after at least 5 days administration of initial therapy with UFH/LMWH/fondaparinux . Children with body ,,,
arm,NCT02234843::arm::FG001,NCT02234843,"Rivaroxaban, Aged 6-<12",,,,,,,,,,FG001,Children aged 6-\<12 years randomized to rivaroxaban received either tablet or oral suspension after at least 5 days administration of initial therapy with UFH/LMWH/fondaparinux . Children with body w,,,
arm,NCT02234843::arm::FG002,NCT02234843,"Rivaroxaban, Aged 2-<6",,,,,,,,,,FG002,Children aged 2-\<6 years randomized to rivaroxaban received oral suspension after at least 5 days administration of initial therapy with UFH/LMWH/fondaparinux . Children with body weight of ≥ 20 kg r,,,
arm,NCT02234843::arm::FG003,NCT02234843,"Rivaroxaban, Aged 0.5-<2",,,,,,,,,,FG003,Children aged 0.5-\<2 years randomized to rivaroxaban received oral suspension after at least 5 days administration of initial therapy with UFH/LMWH/fondaparinux . Children with body weight of \< 20 k,,,
arm,NCT02234843::arm::FG004,NCT02234843,"Rivaroxaban, Aged Birth-<0.5",,,,,,,,,,FG004,Children aged birth-\<0.5 years randomized to rivaroxaban received oral suspension after at least 5 days administration of initial therapy with UFH/LMWH/fondaparinux . Children with body weight of \< ,,,
arm,NCT02234843::arm::FG005,NCT02234843,"Comparator, Aged 12-<18",,,,,,,,,,FG005,"Children aged 12-\<18 years randomized to the comparator group continued with unfractionated heparin (UFH), low molecular weight heparin (LMWH) or fondaparinux or may switch to Vitamin K Antagonist (V",,,
arm,NCT02234843::arm::FG006,NCT02234843,"Comparator, Aged 6-<12",,,,,,,,,,FG006,"Children aged 6-\<12 years randomized to the comparator group continued with unfractionated heparin (UFH), low molecular weight heparin (LMWH) or fondaparinux or may switch to VKA therapy. VKA dosages",,,
arm,NCT02234843::arm::FG007,NCT02234843,"Comparator, Aged 2-<6",,,,,,,,,,FG007,"Children aged 2-\<6 years randomized to the comparator group continued with unfractionated heparin (UFH), low molecular weight heparin (LMWH) or fondaparinux or may switch to VKA therapy. VKA dosages ",,,
arm,NCT02234843::arm::FG008,NCT02234843,"Comparator, Aged 0.5-<2",,,,,,,,,,FG008,"Children aged 0.5-\<2 years randomized to the comparator group continued with unfractionated heparin (UFH), low molecular weight heparin (LMWH) or fondaparinux or may switch to VKA therapy. VKA dosage",,,
arm,NCT02234843::arm::FG009,NCT02234843,"Comparator, Aged Birth-<0.5",,,,,,,,,,FG009,"Children aged birth-\<0.5 years randomized to the comparator group continued with unfractionated heparin (UFH), low molecular weight heparin (LMWH) or fondaparinux or may switch to VKA therapy. VKA do",,,
period,NCT02234843::period::1,NCT02234843,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02234843::outcome::primary::1,NCT02234843,Incidence Rates of All Symptomatic Recurrent Venous Thromboembolism During the Main Treatment Period,,,,,,,,,,,,,PRIMARY,"During the main study treatment period (i.e., 3 months, except for children with central venous catheter venous thromboembolism (CVC-VTE) aged <2 years for whom it was 1 month)"
outcome,NCT02234843::outcome::primary::2,NCT02234843,Incidence Rates of All Symptomatic Recurrent Venous Thromboembolism During the Main Treatment Period,,,,,,,,,,,,,PRIMARY,"During the main study treatment period (i.e., 3 months, except for children with CVC-VTE aged <2 years for whom it was 1 month)"
outcome,NCT02234843::outcome::primary::3,NCT02234843,Incidence Rates of All Symptomatic Recurrent Venous Thromboembolism During Extended Treatment Period,,,,,,,,,,,,,PRIMARY,During extended treatment period: up to month 12.
outcome,NCT02234843::outcome::primary::4,NCT02234843,Number of Subjects With the Composite of All Symptomatic Recurrent Venous Thromboembolism During the 30 Days Post-study Treatment Period (i.e. >2 and ≤ 30 Days After Stop of Study Medication),,,,,,,,,,,,,PRIMARY,More than 2 and up to 30 days after stop of study medication
outcome,NCT02234843::outcome::primary::5,NCT02234843,Incidence Rates of the Composite of Treatment Emergent Overt Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding During Main Treatment Period,,,,,,,,,,,,,PRIMARY,"During the main study treatment period (i.e., 3 months, except for children with CVC-VTE aged <2 years for whom it was 1 month)"
outcome,NCT02234843::outcome::primary::6,NCT02234843,Incidence Rates of the Composite of Treatment Emergent Overt Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding During Main Treatment Period,,,,,,,,,,,,,PRIMARY,"During the main study treatment period (i.e., 3 months, except for children with CVC-VTE aged <2 years for whom it was 1 month)"
outcome,NCT02234843::outcome::primary::7,NCT02234843,Incidence Rates of the Composite of Treatment Emergent Overt Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding During Extended Treatment Period,,,,,,,,,,,,,PRIMARY,During extended treatment period: up to month 12.
country,NCT02234843::country::United States,NCT02234843,United States,,,,,,,,,,,,,,
country,NCT02234843::country::Russia,NCT02234843,Russia,,,,,,,,,,,,,,
country,NCT02234843::country::United Kingdom,NCT02234843,United Kingdom,,,,,,,,,,,,,,
country,NCT02234843::country::Canada,NCT02234843,Canada,,,,,,,,,,,,,,
country,NCT02234843::country::Netherlands,NCT02234843,Netherlands,,,,,,,,,,,,,,
country,NCT02234843::country::Austria,NCT02234843,Austria,,,,,,,,,,,,,,
country,NCT02234843::country::Brazil,NCT02234843,Brazil,,,,,,,,,,,,,,
country,NCT02234843::country::China,NCT02234843,China,,,,,,,,,,,,,,
country,NCT02234843::country::Germany,NCT02234843,Germany,,,,,,,,,,,,,,
country,NCT02234843::country::Israel,NCT02234843,Israel,,,,,,,,,,,,,,
country,NCT02234843::country::Belgium,NCT02234843,Belgium,,,,,,,,,,,,,,
country,NCT02234843::country::France,NCT02234843,France,,,,,,,,,,,,,,
country,NCT02234843::country::Italy,NCT02234843,Italy,,,,,,,,,,,,,,
country,NCT02234843::country::Japan,NCT02234843,Japan,,,,,,,,,,,,,,
country,NCT02234843::country::Spain,NCT02234843,Spain,,,,,,,,,,,,,,
country,NCT02234843::country::Switzerland,NCT02234843,Switzerland,,,,,,,,,,,,,,
country,NCT02234843::country::Turkey (Türkiye),NCT02234843,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02234843::country::Australia,NCT02234843,Australia,,,,,,,,,,,,,,
country,NCT02234843::country::Mexico,NCT02234843,Mexico,,,,,,,,,,,,,,
country,NCT02234843::country::Singapore,NCT02234843,Singapore,,,,,,,,,,,,,,
country,NCT02234843::country::Argentina,NCT02234843,Argentina,,,,,,,,,,,,,,
country,NCT02234843::country::Finland,NCT02234843,Finland,,,,,,,,,,,,,,
country,NCT02234843::country::Hong Kong,NCT02234843,Hong Kong,,,,,,,,,,,,,,
country,NCT02234843::country::Hungary,NCT02234843,Hungary,,,,,,,,,,,,,,
country,NCT02234843::country::Ireland,NCT02234843,Ireland,,,,,,,,,,,,,,
country,NCT02234843::country::Portugal,NCT02234843,Portugal,,,,,,,,,,,,,,
country,NCT02234843::country::Slovakia,NCT02234843,Slovakia,,,,,,,,,,,,,,
country,NCT02234843::country::Sweden,NCT02234843,Sweden,,,,,,,,,,,,,,
trial,NCT02988115,NCT02988115,Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant,PHASE3,cardiovascular disease,Hypercholesterolemia; Atherosclerotic Cardiovascular Disease; Statin Adverse Reaction,INDUSTRY,345.0,2016-11-16,2018-03-16,2.0,67.0,,,,,
arm,NCT02988115::arm::FG000,NCT02988115,Bempedoic Acid,,,,,,,,,,FG000,Participants received a bempedoic acid 180 milligram (mg) tablet taken orally once a day.,,,
arm,NCT02988115::arm::FG001,NCT02988115,Placebo,,,,,,,,,,FG001,Participants received matching oral placebo once a day.,,,
period,NCT02988115::period::1,NCT02988115,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02988115::outcome::primary::1,NCT02988115,Percent Change From Baseline (PCFB) in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12,,,,,,,,,,,,,PRIMARY,Baseline
country,NCT02988115::country::United States,NCT02988115,United States,,,,,,,,,,,,,,
country,NCT02988115::country::Canada,NCT02988115,Canada,,,,,,,,,,,,,,
trial,NCT00577135,NCT00577135,Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study),PHASE3,cardiovascular disease,Heart Failure,OTHER,308.0,2008-02,2010-02,2.0,9.0,,,,,
arm,NCT00577135::arm::FG000,NCT00577135,Q12 Hours Bolus & Low Intensification,,,,,,,,,,FG000,Low intensification (1 x oral dose) IV furosemide by Q12 hours bolus,,,
arm,NCT00577135::arm::FG001,NCT00577135,Q12 Hours Bolus & High Intensification,,,,,,,,,,FG001,High intensification (2.5 x oral dose) IV furosemide by Q12 hours bolus,,,
arm,NCT00577135::arm::FG002,NCT00577135,Continuous Infusion & Low Intensification,,,,,,,,,,FG002,Low intensification (1 x oral dose) IV furosemide by continuous infusion,,,
arm,NCT00577135::arm::FG003,NCT00577135,Continuous Infusion & High Intensification,,,,,,,,,,FG003,High intensification (2.5 x oral dose) IV furosemide by continuous infusion,,,
period,NCT00577135::period::1,NCT00577135,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00577135::outcome::primary::1,NCT00577135,"Patient Well Being, as Determined by a Visual Analog Scale",,,,,,,,,,,,,PRIMARY,Measured at 72 hours
outcome,NCT00577135::outcome::primary::2,NCT00577135,Change in Serum Creatinine,,,,,,,,,,,,,PRIMARY,Measured at baseline and 72 hours
country,NCT00577135::country::United States,NCT00577135,United States,,,,,,,,,,,,,,
country,NCT00577135::country::Canada,NCT00577135,Canada,,,,,,,,,,,,,,
trial,NCT04807400,NCT04807400,Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support,PHASE3,cardiovascular disease,Atherosclerotic Cardiovascular Disease; Atherosclerotic Cardiovascular Disease Risk Equivelents; Elevated Low Density Lipoprotein Cholesterol,INDUSTRY,892.0,2021-07-07,2023-01-13,1.0,17.0,,,,,
arm,NCT04807400::arm::FG000,NCT04807400,Inclisiran,,,,,,,,,,FG000,"Participants continue to receive their background lipid lowering therapy, plus inclisiran for injection (delivered in an injection-only model).",,,
arm,NCT04807400::arm::FG001,NCT04807400,Inclisiran + BS,,,,,,,,,,FG001,"Participants continued to receive their background lipid lowering therapy, plus inclisiran for injection, plus behavioural support.",,,
arm,NCT04807400::arm::FG002,NCT04807400,Control+ BS,,,,,,,,,,FG002,Participants continued to receive their background lipid lowering therapy plus behavioural support (BS).,,,
period,NCT04807400::period::1,NCT04807400,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04807400::outcome::primary::1,NCT04807400,Percentage Change in LDL-C From Baseline to Day 270,,,,,,,,,,,,,PRIMARY,"Baseline, Day 270"
country,NCT04807400::country::United Kingdom,NCT04807400,United Kingdom,,,,,,,,,,,,,,
trial,NCT01181167,NCT01181167,"A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty",PHASE3,cardiovascular disease,Prevention; Venous Thromboembolism,INDUSTRY,610.0,2009-05,2010-03,1.0,2.0,,,,,
arm,NCT01181167::arm::FG000,NCT01181167,DU-176b,,,,,,,,,,FG000,"DU-176b oral tablets, 30 mg., taken once daily for 2 weeks

edoxaban",,,
arm,NCT01181167::arm::FG001,NCT01181167,Enoxaparin Sodium,,,,,,,,,,FG001,"enoxaparin sodium 20mg(=2000IU)/0.2ml twice daily, subcutaneous injection for 2 weeks

enoxaparin sodium",,,
period,NCT01181167::period::1,NCT01181167,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01181167::outcome::primary::1,NCT01181167,Incidence of Subjects With Venous Thromboembolism Events,,,,,,,,,,,,,PRIMARY,2 weeks
country,NCT01181167::country::Japan,NCT01181167,Japan,,,,,,,,,,,,,,
trial,NCT00846365,NCT00846365,Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension,PHASE3,cardiovascular disease,Essential Hypertension,INDUSTRY,1085.0,2009-03,2010-06,3.0,80.0,,,,,
arm,NCT00846365::arm::FG000,NCT00846365,Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD,,,,,,,,,,FG000,"Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.

If participant does not achieve target blo",,,
arm,NCT00846365::arm::FG001,NCT00846365,Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD,,,,,,,,,,FG001,"Azilsartan medoxomil 40 mg and chlorthalidone 12.5, mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.

If participant does not achieve target bl",,,
arm,NCT00846365::arm::FG002,NCT00846365,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,,,,,,,,,,FG002,"Olmesartan medoxomil 20 mg/hydrochlorothiazide 12.5 mg, tablets, orally, and Azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for 8 weeks.

If participant does not ",,,
period,NCT00846365::period::1,NCT00846365,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00846365::outcome::primary::1,NCT00846365,"Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure.",,,,,,,,,,,,,PRIMARY,Baseline and Week 8.
country,NCT00846365::country::United States,NCT00846365,United States,,,,,,,,,,,,,,
country,NCT00846365::country::Chile,NCT00846365,Chile,,,,,,,,,,,,,,
country,NCT00846365::country::Mexico,NCT00846365,Mexico,,,,,,,,,,,,,,
trial,NCT01920711,NCT01920711,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",PHASE3,cardiovascular disease,Heart Failure With Preserved Ejection Fraction,INDUSTRY,4822.0,2014-07-18,2019-06-07,43.0,715.0,,,,,
arm,NCT01920711::arm::FG000,NCT01920711,LCZ696,,,,,,,,,,FG000,Single Blind Run-in Period (3-8 weeks): Prior optional valsartan run-in 40 mg bid for 1-2 weeks for some patients followed by Valsartan 80 mg bid for 1-2 weeks followed by LCZ696 100 mg bid for 2-4 we,,,
arm,NCT01920711::arm::FG001,NCT01920711,Valsartan,,,,,,,,,,FG001,"Single Blind Run-in Period (3-8 weeks): Prior optional valsartan run-in 40 mg bid for 1-2 weeks for some patients, followed by Valsartan 80 mg bid. for 1-2 weeks followed by LCZ696 100 mg bid for 2-4 ",,,
period,NCT01920711::period::1,NCT01920711,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01920711::outcome::primary::1,NCT01920711,Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations.,,,,,,,,,,,,,PRIMARY,Total follow up time (up to 57 months)
country,NCT01920711::country::United States,NCT01920711,United States,,,,,,,,,,,,,,
country,NCT01920711::country::Germany,NCT01920711,Germany,,,,,,,,,,,,,,
country,NCT01920711::country::China,NCT01920711,China,,,,,,,,,,,,,,
country,NCT01920711::country::Spain,NCT01920711,Spain,,,,,,,,,,,,,,
country,NCT01920711::country::United Kingdom,NCT01920711,United Kingdom,,,,,,,,,,,,,,
country,NCT01920711::country::Russia,NCT01920711,Russia,,,,,,,,,,,,,,
country,NCT01920711::country::Italy,NCT01920711,Italy,,,,,,,,,,,,,,
country,NCT01920711::country::Slovakia,NCT01920711,Slovakia,,,,,,,,,,,,,,
country,NCT01920711::country::Argentina,NCT01920711,Argentina,,,,,,,,,,,,,,
country,NCT01920711::country::Czechia,NCT01920711,Czechia,,,,,,,,,,,,,,
country,NCT01920711::country::Bulgaria,NCT01920711,Bulgaria,,,,,,,,,,,,,,
country,NCT01920711::country::Japan,NCT01920711,Japan,,,,,,,,,,,,,,
country,NCT01920711::country::Canada,NCT01920711,Canada,,,,,,,,,,,,,,
country,NCT01920711::country::India,NCT01920711,India,,,,,,,,,,,,,,
country,NCT01920711::country::Poland,NCT01920711,Poland,,,,,,,,,,,,,,
country,NCT01920711::country::Netherlands,NCT01920711,Netherlands,,,,,,,,,,,,,,
country,NCT01920711::country::Brazil,NCT01920711,Brazil,,,,,,,,,,,,,,
country,NCT01920711::country::France,NCT01920711,France,,,,,,,,,,,,,,
country,NCT01920711::country::Hungary,NCT01920711,Hungary,,,,,,,,,,,,,,
country,NCT01920711::country::Romania,NCT01920711,Romania,,,,,,,,,,,,,,
country,NCT01920711::country::Belgium,NCT01920711,Belgium,,,,,,,,,,,,,,
country,NCT01920711::country::South Africa,NCT01920711,South Africa,,,,,,,,,,,,,,
country,NCT01920711::country::South Korea,NCT01920711,South Korea,,,,,,,,,,,,,,
country,NCT01920711::country::Israel,NCT01920711,Israel,,,,,,,,,,,,,,
country,NCT01920711::country::Mexico,NCT01920711,Mexico,,,,,,,,,,,,,,
country,NCT01920711::country::Taiwan,NCT01920711,Taiwan,,,,,,,,,,,,,,
country,NCT01920711::country::Austria,NCT01920711,Austria,,,,,,,,,,,,,,
country,NCT01920711::country::Greece,NCT01920711,Greece,,,,,,,,,,,,,,
country,NCT01920711::country::Sweden,NCT01920711,Sweden,,,,,,,,,,,,,,
country,NCT01920711::country::Turkey (Türkiye),NCT01920711,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01920711::country::Denmark,NCT01920711,Denmark,,,,,,,,,,,,,,
country,NCT01920711::country::Australia,NCT01920711,Australia,,,,,,,,,,,,,,
country,NCT01920711::country::Colombia,NCT01920711,Colombia,,,,,,,,,,,,,,
country,NCT01920711::country::Peru,NCT01920711,Peru,,,,,,,,,,,,,,
country,NCT01920711::country::Singapore,NCT01920711,Singapore,,,,,,,,,,,,,,
country,NCT01920711::country::Switzerland,NCT01920711,Switzerland,,,,,,,,,,,,,,
country,NCT01920711::country::Croatia,NCT01920711,Croatia,,,,,,,,,,,,,,
country,NCT01920711::country::Guatemala,NCT01920711,Guatemala,,,,,,,,,,,,,,
country,NCT01920711::country::Norway,NCT01920711,Norway,,,,,,,,,,,,,,
country,NCT01920711::country::Philippines,NCT01920711,Philippines,,,,,,,,,,,,,,
country,NCT01920711::country::Serbia,NCT01920711,Serbia,,,,,,,,,,,,,,
country,NCT01920711::country::Finland,NCT01920711,Finland,,,,,,,,,,,,,,
country,NCT01920711::country::Slovenia,NCT01920711,Slovenia,,,,,,,,,,,,,,
trial,NCT01651780,NCT01651780,"Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH",PHASE3,cardiovascular disease,Severe Aortic Stenosis; Transcatheter Aortic Valve Replacement; Aortic Valve Replacement,INDUSTRY,803.0,2012-10,2015-06,7.0,33.0,,,,,
arm,NCT01651780::arm::FG000,NCT01651780,Bivalirudin,,,,,,,,,,FG000,Bivalirudin administered as a bolus and intravenous (IV) infusion during transcatheter aortic valve replacement (TAVR). It was recommended that the bolus (0.75 milligrams per kilogram \[mg/kg\]) be di,,,
arm,NCT01651780::arm::FG001,NCT01651780,Unfractionated Heparin (UFH),,,,,,,,,,FG001,"The dose of UFH adhered to the standard institutional practice. An activated clotting time (ACT) target ≥250 seconds was recommended. All wires, catheters, and sheaths were to be flushed with heparini",,,
period,NCT01651780::period::1,NCT01651780,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01651780::outcome::primary::1,NCT01651780,Major Bleeding (BARC ≥3b) at 48 Hours or Before Hospital Discharge,,,,,,,,,,,,,PRIMARY,"at 48 hours or discharge, whichever occurs first"
outcome,NCT01651780::outcome::primary::2,NCT01651780,Net Adverse Clinical Events (NACE) at up to 30 Days,,,,,,,,,,,,,PRIMARY,up to 30 days after procedure
country,NCT01651780::country::Germany,NCT01651780,Germany,,,,,,,,,,,,,,
country,NCT01651780::country::France,NCT01651780,France,,,,,,,,,,,,,,
country,NCT01651780::country::Italy,NCT01651780,Italy,,,,,,,,,,,,,,
country,NCT01651780::country::Canada,NCT01651780,Canada,,,,,,,,,,,,,,
country,NCT01651780::country::Netherlands,NCT01651780,Netherlands,,,,,,,,,,,,,,
country,NCT01651780::country::Switzerland,NCT01651780,Switzerland,,,,,,,,,,,,,,
country,NCT01651780::country::United Kingdom,NCT01651780,United Kingdom,,,,,,,,,,,,,,
trial,NCT01565941,NCT01565941,Heart And Lung Failure - Pediatric INsulin Titration Trial,PHASE3,cardiovascular disease,Heart Failure; Respiratory Failure,OTHER,713.0,2012-04,2018-02,3.0,35.0,,,,,
arm,NCT01565941::arm::FG000,NCT01565941,Tight Glycemic Control 1 (TGC-1),,,,,,,,,,FG000,Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be admini,,,
arm,NCT01565941::arm::FG001,NCT01565941,Tight Glycemic Control 2 (TGC-2),,,,,,,,,,FG001,Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be admin,,,
period,NCT01565941::period::1,NCT01565941,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01565941::outcome::primary::1,NCT01565941,ICU-Free Days,,,,,,,,,,,,,PRIMARY,Study day 28
country,NCT01565941::country::United States,NCT01565941,United States,,,,,,,,,,,,,,
country,NCT01565941::country::Australia,NCT01565941,Australia,,,,,,,,,,,,,,
country,NCT01565941::country::Canada,NCT01565941,Canada,,,,,,,,,,,,,,
trial,NCT02447172,NCT02447172,Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers,PHASE3,cardiovascular disease,"Foot Ulcer, Diabetic; Infection",INDUSTRY,524.0,2015-06,2016-09,16.0,91.0,,,,,
arm,NCT02447172::arm::FG000,NCT02447172,Gentamicin Sponge Group,,,,,,,,,,FG000,"Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic ther",,,
arm,NCT02447172::arm::FG001,NCT02447172,Placebo Sponge Group,,,,,,,,,,FG001,"Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.

Placebo: Matching placebo sponge",,,
arm,NCT02447172::arm::FG002,NCT02447172,No Sponge Group,,,,,,,,,,FG002,Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.,,,
period,NCT02447172::period::1,NCT02447172,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02447172::outcome::primary::1,NCT02447172,Percent of Patients With a Clinical Outcome of Clinical Cure (Resolution of All Clinical Signs and Symptoms of Infection),,,,,,,,,,,,,PRIMARY,approximately 10 days after end of treatment
country,NCT02447172::country::United Kingdom,NCT02447172,United Kingdom,,,,,,,,,,,,,,
country,NCT02447172::country::Poland,NCT02447172,Poland,,,,,,,,,,,,,,
country,NCT02447172::country::Germany,NCT02447172,Germany,,,,,,,,,,,,,,
country,NCT02447172::country::Czechia,NCT02447172,Czechia,,,,,,,,,,,,,,
country,NCT02447172::country::Spain,NCT02447172,Spain,,,,,,,,,,,,,,
country,NCT02447172::country::Netherlands,NCT02447172,Netherlands,,,,,,,,,,,,,,
country,NCT02447172::country::Hungary,NCT02447172,Hungary,,,,,,,,,,,,,,
country,NCT02447172::country::Slovakia,NCT02447172,Slovakia,,,,,,,,,,,,,,
country,NCT02447172::country::Belgium,NCT02447172,Belgium,,,,,,,,,,,,,,
country,NCT02447172::country::Italy,NCT02447172,Italy,,,,,,,,,,,,,,
country,NCT02447172::country::Austria,NCT02447172,Austria,,,,,,,,,,,,,,
country,NCT02447172::country::Sweden,NCT02447172,Sweden,,,,,,,,,,,,,,
country,NCT02447172::country::United States,NCT02447172,United States,,,,,,,,,,,,,,
country,NCT02447172::country::Australia,NCT02447172,Australia,,,,,,,,,,,,,,
country,NCT02447172::country::Denmark,NCT02447172,Denmark,,,,,,,,,,,,,,
country,NCT02447172::country::Ireland,NCT02447172,Ireland,,,,,,,,,,,,,,
trial,NCT00618956,NCT00618956,A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring,PHASE3,cardiovascular disease,Fibromyalgia,INDUSTRY,321.0,2007-10,,1.0,38.0,,,,,
arm,NCT00618956::arm::FG000,NCT00618956,Placebo,,,,,,,,,,FG000,"ITT N= 93, OC analyzed n=89",,,
arm,NCT00618956::arm::FG001,NCT00618956,Milnacipran,,,,,,,,,,FG001,"Milnacipran 100 to 200 mg/day tablet, oral administration, BID.",,,
period,NCT00618956::period::1,NCT00618956,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00618956::outcome::primary::1,NCT00618956,Change From Baseline in Mean Systolic Blood Pressure Following 12-hour Period Post-AM Dose at Visit 4,,,,,,,,,,,,,PRIMARY,"4 weeks (1 week of dose-escalation, 3 weeks of 100 mg/d)"
outcome,NCT00618956::outcome::primary::2,NCT00618956,Change From Baseline in Mean Systolic Blood Pressure Following 12-hour Period Post-AM Dose at Visit 6,,,,,,,,,,,,,PRIMARY,"7 weeks (1 week of dose-escalation, 3 weeks of 100 mg/d, followed by 1 week at 150 mg/d and 2 weeks of 200 mg/d)"
country,NCT00618956::country::United States,NCT00618956,United States,,,,,,,,,,,,,,
trial,NCT00909870,NCT00909870,Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers,PHASE3,cardiovascular disease,Venous Leg Ulcer,INDUSTRY,537.0,2009-06,2011-08,8.0,70.0,,,,,
arm,NCT00909870::arm::FG000,NCT00909870,Investigational Treatment (Dermagraft Plus Standard-of-Care),,,,,,,,,,FG000,"Weekly applications of Dermagraft and compression dressings, in combination with systematic surgical wound debridement.",,,
arm,NCT00909870::arm::FG001,NCT00909870,Active Control (Standard-of-Care),,,,,,,,,,FG001,"Weekly application of compression dressings only, in combination with systematic surgical wound debridement.",,,
period,NCT00909870::period::1,NCT00909870,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00909870::outcome::primary::1,NCT00909870,Complete Healing of the Study Ulcer by Week 16.,,,,,,,,,,,,,PRIMARY,16 weeks
country,NCT00909870::country::United States,NCT00909870,United States,,,,,,,,,,,,,,
country,NCT00909870::country::South Africa,NCT00909870,South Africa,,,,,,,,,,,,,,
country,NCT00909870::country::Poland,NCT00909870,Poland,,,,,,,,,,,,,,
country,NCT00909870::country::United Kingdom,NCT00909870,United Kingdom,,,,,,,,,,,,,,
country,NCT00909870::country::Austria,NCT00909870,Austria,,,,,,,,,,,,,,
country,NCT00909870::country::Germany,NCT00909870,Germany,,,,,,,,,,,,,,
country,NCT00909870::country::Sweden,NCT00909870,Sweden,,,,,,,,,,,,,,
country,NCT00909870::country::Estonia,NCT00909870,Estonia,,,,,,,,,,,,,,
trial,NCT01001572,NCT01001572,Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension,PHASE3,cardiovascular disease,Essential Hypertension,INDUSTRY,932.0,2009-09,2010-05,1.0,2.0,,,,,
arm,NCT01001572::arm::FG000,NCT01001572,Single-Blind Run -In Valsartan 160 mg,,,,,,,,,,FG000,Single-Blind Run-In treatment with one capsule Valsartan 160 mg taken orally once daily at approximately 9:00 AM for 4 weeks.,,,
arm,NCT01001572::arm::FG001,NCT01001572,Valsartan/Amlodipine 160/5 mg,,,,,,,,,,FG001,One film-coated tablet Valsartan/amlodipine 160/5 mg and 1 capsule Placebo to Valsartan taken orally once daily at approximately 9:00 AM for 8 weeks.,,,
arm,NCT01001572::arm::FG002,NCT01001572,Valsartan 160 mg,,,,,,,,,,FG002,One capsule Valsartan 160 mg and 1 tablet placebo to Valsartan/Amlodipine taken orally once daily at approximately 9:00 AM for 8 weeks,,,
period,NCT01001572::period::1,NCT01001572,Single-Blind Valsartan 160 mg,,,,,,,,,,,,1.0,,
period,NCT01001572::period::2,NCT01001572,Double-Blind Treatment Phase,,,,,,,,,,,,2.0,,
outcome,NCT01001572::outcome::primary::1,NCT01001572,Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to Week 8 Endpoint,,,,,,,,,,,,,PRIMARY,Baseline and Week 8
country,NCT01001572::country::Unknown,NCT01001572,Unknown,,,,,,,,,,,,,,
trial,NCT01084239,NCT01084239,Multicenter Study to Rule Out Myocardial Infarction by Cardiac Computed Tomography,PHASE3,cardiovascular disease,Acute Coronary Syndrome; Myocardial Infarction; Unstable Angina Pectoris,OTHER,1000.0,2010-04,2012-03,1.0,1.0,,,,,
arm,NCT01084239::arm::FG000,NCT01084239,Cardiac CT,,,,,,,,,,FG000,"Subjects in this arm (50% of the total cohort) were randomized to receive a cardiac computed tomography scan as part of the initial evaluation of acute chest pain symptoms, upon presentation to the em",,,
arm,NCT01084239::arm::FG001,NCT01084239,Standard of Care,,,,,,,,,,FG001,"Subjects in this arm (50% of the total cohort) continued to receive standard non-invasive evaluation of acute chest pain symptoms in the emergency department - mostly comprising of, but not limited to",,,
period,NCT01084239::period::1,NCT01084239,Randomization - Index Hospitalization,,,,,,,,,,,,1.0,,
period,NCT01084239::period::2,NCT01084239,28-Day Follow-up,,,,,,,,,,,,2.0,,
outcome,NCT01084239::outcome::primary::1,NCT01084239,Length of Hospital Stay,,,,,,,,,,,,,PRIMARY,Duration of stay in the hospital during the initial visit
country,NCT01084239::country::United States,NCT01084239,United States,,,,,,,,,,,,,,
trial,NCT01959243,NCT01959243,"Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants",PHASE3,cardiovascular disease,Hyperemia,INDUSTRY,507.0,2014-02-22,2014-06-23,1.0,4.0,,,,,
arm,NCT01959243::arm::FG000,NCT01959243,Brimonidine Tartrate,,,,,,,,,,FG000,Participants applied 1 drop of brimonidine tartrate ophthalmic solution 0.025% into each eye 4 times daily for up to 4 consecutive weeks.,,,
arm,NCT01959243::arm::FG001,NCT01959243,Brimonidine Tartrate Vehicle,,,,,,,,,,FG001,Participants applied 1 drop of the vehicle of brimonidine tartrate ophthalmic solution into each eye 4 times daily for up to 4 consecutive weeks.,,,
period,NCT01959243::period::1,NCT01959243,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01959243::outcome::primary::1,NCT01959243,Number of Participants With Treatment Emergent Adverse Events (TEAEs),,,,,,,,,,,,,PRIMARY,Baseline up to Day 29
country,NCT01959243::country::United States,NCT01959243,United States,,,,,,,,,,,,,,
trial,NCT03473223,NCT03473223,Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome,PHASE3,cardiovascular disease,Acute Coronary Syndrome,INDUSTRY,18226.0,2018-03-21,2023-11-17,49.0,903.0,,,,,
arm,NCT03473223::arm::FG000,NCT03473223,CSL112,,,,,,,,,,FG000,Participants received 6 grams of CSL112 (Apolipoprotein A-I \[human\] (apoA-I) purified from human plasma) once weekly via intravenous (IV) infusion for up to 4 weeks.,,,
arm,NCT03473223::arm::FG001,NCT03473223,Placebo,,,,,,,,,,FG001,Participants received placebo (25% albumin solution diluted to 4.4%) once weekly via IV infusion for up to 4 weeks.,,,
period,NCT03473223::period::1,NCT03473223,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03473223::outcome::primary::1,NCT03473223,"Number of Participants With First Occurrence of Any Component of Composite MACE (CV Death, MI, or Stroke)",,,,,,,,,,,,,PRIMARY,From the time of randomization through 90 days
country,NCT03473223::country::United States,NCT03473223,United States,,,,,,,,,,,,,,
country,NCT03473223::country::Brazil,NCT03473223,Brazil,,,,,,,,,,,,,,
country,NCT03473223::country::Japan,NCT03473223,Japan,,,,,,,,,,,,,,
country,NCT03473223::country::Canada,NCT03473223,Canada,,,,,,,,,,,,,,
country,NCT03473223::country::Argentina,NCT03473223,Argentina,,,,,,,,,,,,,,
country,NCT03473223::country::Russia,NCT03473223,Russia,,,,,,,,,,,,,,
country,NCT03473223::country::Netherlands,NCT03473223,Netherlands,,,,,,,,,,,,,,
country,NCT03473223::country::Germany,NCT03473223,Germany,,,,,,,,,,,,,,
country,NCT03473223::country::Poland,NCT03473223,Poland,,,,,,,,,,,,,,
country,NCT03473223::country::Ukraine,NCT03473223,Ukraine,,,,,,,,,,,,,,
country,NCT03473223::country::Belgium,NCT03473223,Belgium,,,,,,,,,,,,,,
country,NCT03473223::country::Australia,NCT03473223,Australia,,,,,,,,,,,,,,
country,NCT03473223::country::Bulgaria,NCT03473223,Bulgaria,,,,,,,,,,,,,,
country,NCT03473223::country::France,NCT03473223,France,,,,,,,,,,,,,,
country,NCT03473223::country::Israel,NCT03473223,Israel,,,,,,,,,,,,,,
country,NCT03473223::country::Mexico,NCT03473223,Mexico,,,,,,,,,,,,,,
country,NCT03473223::country::Romania,NCT03473223,Romania,,,,,,,,,,,,,,
country,NCT03473223::country::Hungary,NCT03473223,Hungary,,,,,,,,,,,,,,
country,NCT03473223::country::Italy,NCT03473223,Italy,,,,,,,,,,,,,,
country,NCT03473223::country::Serbia,NCT03473223,Serbia,,,,,,,,,,,,,,
country,NCT03473223::country::Spain,NCT03473223,Spain,,,,,,,,,,,,,,
country,NCT03473223::country::United Kingdom,NCT03473223,United Kingdom,,,,,,,,,,,,,,
country,NCT03473223::country::South Korea,NCT03473223,South Korea,,,,,,,,,,,,,,
country,NCT03473223::country::Turkey (Türkiye),NCT03473223,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT03473223::country::Czechia,NCT03473223,Czechia,,,,,,,,,,,,,,
country,NCT03473223::country::Denmark,NCT03473223,Denmark,,,,,,,,,,,,,,
country,NCT03473223::country::Colombia,NCT03473223,Colombia,,,,,,,,,,,,,,
country,NCT03473223::country::Georgia,NCT03473223,Georgia,,,,,,,,,,,,,,
country,NCT03473223::country::Greece,NCT03473223,Greece,,,,,,,,,,,,,,
country,NCT03473223::country::Portugal,NCT03473223,Portugal,,,,,,,,,,,,,,
country,NCT03473223::country::Malaysia,NCT03473223,Malaysia,,,,,,,,,,,,,,
country,NCT03473223::country::South Africa,NCT03473223,South Africa,,,,,,,,,,,,,,
country,NCT03473223::country::Taiwan,NCT03473223,Taiwan,,,,,,,,,,,,,,
country,NCT03473223::country::New Zealand,NCT03473223,New Zealand,,,,,,,,,,,,,,
country,NCT03473223::country::Thailand,NCT03473223,Thailand,,,,,,,,,,,,,,
country,NCT03473223::country::Croatia,NCT03473223,Croatia,,,,,,,,,,,,,,
country,NCT03473223::country::Austria,NCT03473223,Austria,,,,,,,,,,,,,,
country,NCT03473223::country::Chile,NCT03473223,Chile,,,,,,,,,,,,,,
country,NCT03473223::country::Latvia,NCT03473223,Latvia,,,,,,,,,,,,,,
country,NCT03473223::country::Lithuania,NCT03473223,Lithuania,,,,,,,,,,,,,,
country,NCT03473223::country::Slovakia,NCT03473223,Slovakia,,,,,,,,,,,,,,
country,NCT03473223::country::Norway,NCT03473223,Norway,,,,,,,,,,,,,,
country,NCT03473223::country::Sweden,NCT03473223,Sweden,,,,,,,,,,,,,,
country,NCT03473223::country::Estonia,NCT03473223,Estonia,,,,,,,,,,,,,,
country,NCT03473223::country::Hong Kong,NCT03473223,Hong Kong,,,,,,,,,,,,,,
country,NCT03473223::country::Peru,NCT03473223,Peru,,,,,,,,,,,,,,
country,NCT03473223::country::Switzerland,NCT03473223,Switzerland,,,,,,,,,,,,,,
country,NCT03473223::country::Finland,NCT03473223,Finland,,,,,,,,,,,,,,
country,NCT03473223::country::Singapore,NCT03473223,Singapore,,,,,,,,,,,,,,
trial,NCT04564742,NCT04564742,Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.,PHASE3,cardiovascular disease,Acute Myocardial Infarction; Heart Failure,INDUSTRY,4017.0,2020-12-22,2023-07-05,2.0,103.0,,,,,
arm,NCT04564742::arm::FG000,NCT04564742,Dapa 10 mg,,,,,,,,,,FG000,"Active, Green, plain, diamond shaped, film coated tablet, 10 mg once daily",,,
arm,NCT04564742::arm::FG001,NCT04564742,Placebo,,,,,,,,,,FG001,"Control, Green, plain, diamond shaped, film coated tablets, once daily",,,
period,NCT04564742::period::1,NCT04564742,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04564742::outcome::primary::1,NCT04564742,Analysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set),,,,,,,,,,,,,PRIMARY,29 months
country,NCT04564742::country::United Kingdom,NCT04564742,United Kingdom,,,,,,,,,,,,,,
country,NCT04564742::country::Sweden,NCT04564742,Sweden,,,,,,,,,,,,,,
trial,NCT02073682,NCT02073682,Cancer Venous Thromboembolism (VTE),PHASE3,cardiovascular disease,Venous Thromboembolism (VTE); Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE); Cancer,INDUSTRY,1046.0,2015-07-16,2017-09-15,6.0,9.0,,,,,
arm,NCT02073682::arm::FG000,NCT02073682,Edoxaban Group,,,,,,,,,,FG000,"After 5 days of low molecular weight heparin (LMWH), participants received edoxaban treatment daily",,,
arm,NCT02073682::arm::FG001,NCT02073682,Dalteparin Group,,,,,,,,,,FG001,Participants received dalteparin daily,,,
period,NCT02073682::period::1,NCT02073682,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02073682::outcome::primary::1,NCT02073682,Number of Participants With Adjudicated Recurrent Venous Thromboembolism (VTE) or Major Bleeding Event,,,,,,,,,,,,,PRIMARY,12 months
country,NCT02073682::country::United States,NCT02073682,United States,,,,,,,,,,,,,,
country,NCT02073682::country::Belgium,NCT02073682,Belgium,,,,,,,,,,,,,,
country,NCT02073682::country::France,NCT02073682,France,,,,,,,,,,,,,,
country,NCT02073682::country::Hungary,NCT02073682,Hungary,,,,,,,,,,,,,,
country,NCT02073682::country::Italy,NCT02073682,Italy,,,,,,,,,,,,,,
country,NCT02073682::country::Netherlands,NCT02073682,Netherlands,,,,,,,,,,,,,,
trial,NCT00501059,NCT00501059,A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease,PHASE3,cardiovascular disease,Moderate Risk of CVD,INDUSTRY,12546.0,2007-07-05,2016-11-15,8.0,466.0,,,,,
arm,NCT00501059::arm::FG000,NCT00501059,"Acetylsalicylic Acid (Aspirin, BAYE4465)",,,,,,,,,,FG000,Subjects received 1 tablet of enteric-coated acetylsalicylic acid \[100 milligram (mg)\] orally once daily.,,,
arm,NCT00501059::arm::FG001,NCT00501059,Placebo,,,,,,,,,,FG001,Subjects received 1 tablets of matching placebo orally once daily.,,,
period,NCT00501059::period::1,NCT00501059,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00501059::outcome::primary::1,NCT00501059,"Time to the First Occurrence of the Composite Outcome of MI (Myocardial Infarction), Stroke, Cardiovascular Death, UA (Unstable Angina) or TIA (Transient Ischemic Attack)",,,,,,,,,,,,,PRIMARY,Until follow-up (approximate 6 years)
country,NCT00501059::country::United Kingdom,NCT00501059,United Kingdom,,,,,,,,,,,,,,
country,NCT00501059::country::Germany,NCT00501059,Germany,,,,,,,,,,,,,,
country,NCT00501059::country::United States,NCT00501059,United States,,,,,,,,,,,,,,
country,NCT00501059::country::Poland,NCT00501059,Poland,,,,,,,,,,,,,,
country,NCT00501059::country::Spain,NCT00501059,Spain,,,,,,,,,,,,,,
country,NCT00501059::country::Italy,NCT00501059,Italy,,,,,,,,,,,,,,
country,NCT00501059::country::Ireland,NCT00501059,Ireland,,,,,,,,,,,,,,
country,NCT00501059::country::Puerto Rico,NCT00501059,Puerto Rico,,,,,,,,,,,,,,
trial,NCT03275285,NCT03275285,"Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients",PHASE3,cardiovascular disease,Plasma Cell Myeloma,INDUSTRY,302.0,2017-10-25,2025-01-03,16.0,70.0,,,,,
arm,NCT03275285::arm::FG000,NCT03275285,Carfilzomib + Dexamethasone (Kd),,,,,,,,,,FG000,"Participants received carfilzomib 20 milligrams per meter square (mg/m\^2), intravenous (IV) infusion on Days 1, and 2 in Cycle 1, and then escalated to 56 mg/m\^2 on Days 8, 9, 15 and 16 of Cycle 1 a",,,
arm,NCT03275285::arm::FG001,NCT03275285,Isatuximab + Carfilzomib + Dexamethasone (IKd),,,,,,,,,,FG001,"Participants received isatuximab 10 milligrams per kilogram (mg/kg), IV infusion on Days 1, 8, 15 and 22 in Cycle 1, and then on Days 1 and 15 of each 28-day treatment cycle plus carfilzomib 20 mg/m\^",,,
period,NCT03275285::period::1,NCT03275285,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03275285::outcome::primary::1,NCT03275285,Progression Free Survival (PFS) As Determined by Independent Response Committee (IRC): Primary Analysis,,,,,,,,,,,,,PRIMARY,From randomization until the primary analysis data cut-off date of 7 Feb 2020 (median duration of follow-up was 20.73 months)
outcome,NCT03275285::outcome::primary::2,NCT03275285,Progression Free Survival as Determined by Independent Response Committee: [Event Censored if Occurred >8 Weeks From Last Disease Assessment]: Primary Analysis,,,,,,,,,,,,,PRIMARY,From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
outcome,NCT03275285::outcome::primary::3,NCT03275285,Progression Free Survival as Determined by Independent Response Committee: Final Analysis,,,,,,,,,,,,,PRIMARY,From randomization until the final analysis data cut-off date of 14 January 2022 (the median duration of follow-up was 43.96 months)
outcome,NCT03275285::outcome::primary::4,NCT03275285,Progression Free Survival as Determined by Independent Response Committee [Event Censored if Occurred >8 Weeks From Last Disease Assessment]: Final Analysis,,,,,,,,,,,,,PRIMARY,From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)
country,NCT03275285::country::Australia,NCT03275285,Australia,,,,,,,,,,,,,,
country,NCT03275285::country::Japan,NCT03275285,Japan,,,,,,,,,,,,,,
country,NCT03275285::country::France,NCT03275285,France,,,,,,,,,,,,,,
country,NCT03275285::country::Brazil,NCT03275285,Brazil,,,,,,,,,,,,,,
country,NCT03275285::country::Greece,NCT03275285,Greece,,,,,,,,,,,,,,
country,NCT03275285::country::South Korea,NCT03275285,South Korea,,,,,,,,,,,,,,
country,NCT03275285::country::Spain,NCT03275285,Spain,,,,,,,,,,,,,,
country,NCT03275285::country::Turkey (Türkiye),NCT03275285,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT03275285::country::Czechia,NCT03275285,Czechia,,,,,,,,,,,,,,
country,NCT03275285::country::Hungary,NCT03275285,Hungary,,,,,,,,,,,,,,
country,NCT03275285::country::Italy,NCT03275285,Italy,,,,,,,,,,,,,,
country,NCT03275285::country::Canada,NCT03275285,Canada,,,,,,,,,,,,,,
country,NCT03275285::country::Russia,NCT03275285,Russia,,,,,,,,,,,,,,
country,NCT03275285::country::United Kingdom,NCT03275285,United Kingdom,,,,,,,,,,,,,,
country,NCT03275285::country::United States,NCT03275285,United States,,,,,,,,,,,,,,
country,NCT03275285::country::New Zealand,NCT03275285,New Zealand,,,,,,,,,,,,,,
trial,NCT01969708,NCT01969708,Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2),PHASE3,cardiovascular disease,Central Retinal Vein Occlusion,INDUSTRY,362.0,2014-09,2021-03,1.0,72.0,,,,,
arm,NCT01969708::arm::FG000,NCT01969708,Aflibercept,,,,,,,,,,FG000,"2.0 mg aflibercept every 4 weeks

aflibercept",,,
arm,NCT01969708::arm::FG001,NCT01969708,Bevacizumab,,,,,,,,,,FG001,"1.25 mg bevacizumab every 4 weeks

bevacizumab",,,
period,NCT01969708::period::1,NCT01969708,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01969708::outcome::primary::1,NCT01969708,Mean Change From Baseline in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Letter Score at Month 6,,,,,,,,,,,,,PRIMARY,Month 0 to 6
country,NCT01969708::country::United States,NCT01969708,United States,,,,,,,,,,,,,,
trial,NCT01976312,NCT01976312,Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO),PHASE3,cardiovascular disease,Central Retinal Vein Occlusion,INDUSTRY,252.0,2013-11-12,2016-03-14,7.0,34.0,,,,,
arm,NCT01976312::arm::FG000,NCT01976312,Ranibizumab 0.5 mg,,,,,,,,,,FG000,PRN intravitreal injection,,,
arm,NCT01976312::arm::FG001,NCT01976312,Sham Injection,,,,,,,,,,FG001,"As of Month 3, ranibizumab 0.5 mg PRN intravitreal injections",,,
period,NCT01976312::period::1,NCT01976312,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01976312::outcome::primary::1,NCT01976312,Average Change in Visual Acuity (Letters) From Baseline to Month 1 Through Month 3,,,,,,,,,,,,,PRIMARY,"Baseline, 3 Months"
country,NCT01976312::country::China,NCT01976312,China,,,,,,,,,,,,,,
country,NCT01976312::country::India,NCT01976312,India,,,,,,,,,,,,,,
country,NCT01976312::country::Indonesia,NCT01976312,Indonesia,,,,,,,,,,,,,,
country,NCT01976312::country::Philippines,NCT01976312,Philippines,,,,,,,,,,,,,,
country,NCT01976312::country::Taiwan,NCT01976312,Taiwan,,,,,,,,,,,,,,
country,NCT01976312::country::Vietnam,NCT01976312,Vietnam,,,,,,,,,,,,,,
country,NCT01976312::country::Hong Kong,NCT01976312,Hong Kong,,,,,,,,,,,,,,
trial,NCT00429364,NCT00429364,Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome,PHASE3,cardiovascular disease,Marfan Syndrome,OTHER,608.0,2007-01,2014-02,3.0,26.0,,,,,
arm,NCT00429364::arm::FG000,NCT00429364,Atenolol,,,,,,,,,,FG000,"Participants with Marfan's syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mea",,,
arm,NCT00429364::arm::FG001,NCT00429364,Losartan,,,,,,,,,,FG001,Participants with Marfan's syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).,,,
period,NCT00429364::period::1,NCT00429364,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00429364::outcome::primary::1,NCT00429364,Annual Rate of Change in Aortic Root (Sinuses of Valsalva) Body-surface-area-adjusted Z-score,,,,,,,,,,,,,PRIMARY,Up to 3 years following randomization.
country,NCT00429364::country::United States,NCT00429364,United States,,,,,,,,,,,,,,
country,NCT00429364::country::Belgium,NCT00429364,Belgium,,,,,,,,,,,,,,
country,NCT00429364::country::Canada,NCT00429364,Canada,,,,,,,,,,,,,,
trial,NCT01031095,NCT01031095,(A Novel Pharmacologic Regime for Elective Percutaneous Coronary Intervention),PHASE3,cardiovascular disease,Coronary Artery Disease,OTHER,200.0,2009-06,2010-06,1.0,1.0,,,,,
arm,NCT01031095::arm::FG000,NCT01031095,Low Dose Intracoronary Heparin,,,,,,,,,,FG000,Low dose intracoronary heparin treatment arm,,,
arm,NCT01031095::arm::FG001,NCT01031095,Standard Therapy,,,,,,,,,,FG001,standard unfractionated heparin (UFH) treatment,,,
period,NCT01031095::period::1,NCT01031095,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01031095::outcome::primary::1,NCT01031095,Major Adverse Cardiac Events,,,,,,,,,,,,,PRIMARY,30 days
outcome,NCT01031095::outcome::primary::2,NCT01031095,Major Adverse Cardiac Event,,,,,,,,,,,,,PRIMARY,30 days
country,NCT01031095::country::Turkey (Türkiye),NCT01031095,Turkey (Türkiye),,,,,,,,,,,,,,
trial,NCT04873934,NCT04873934,Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome,PHASE3,cardiovascular disease,Acute Coronary Syndrome,INDUSTRY,400.0,2021-06-24,2024-08-07,1.0,88.0,,,,,
arm,NCT04873934::arm::FG000,NCT04873934,Inclisiran With Usual Care,,,,,,,,,,FG000,Inclisiran sodium 300 mg / 1.5 ml (equivalent to 284 mg of inclisiran) + usual care,,,
arm,NCT04873934::arm::FG001,NCT04873934,Usual Care,,,,,,,,,,FG001,Usual Care Alone,,,
period,NCT04873934::period::1,NCT04873934,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04873934::outcome::primary::1,NCT04873934,Percent Change From Baseline to Day 330 in LDL-C,,,,,,,,,,,,,PRIMARY,Baseline and Day 330
outcome,NCT04873934::outcome::primary::2,NCT04873934,Achievement of LDL-C < 70 mg/dL at Day 330,,,,,,,,,,,,,PRIMARY,Day 330
country,NCT04873934::country::United States,NCT04873934,United States,,,,,,,,,,,,,,
trial,NCT00423319,NCT00423319,Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3),PHASE3,cardiovascular disease,Deep Vein Thrombosis; Pulmonary Embolism,INDUSTRY,5407.0,2007-03,2009-09,21.0,143.0,,,,,
arm,NCT00423319::arm::FG000,NCT00423319,"Apixaban, 2.5 mg BID Plus Placebo",,,,,,,,,,FG000,"Participants received apixaban, 2.5 mg twice daily (BID), as oral tablets, and matching enoxaparin-placebo injection once daily (QD)",,,
arm,NCT00423319::arm::FG001,NCT00423319,"Enoxaparin, 40 mg QD Plus Placebo",,,,,,,,,,FG001,"Participants received enoxaparin, 40 mg QD subcutaneously, and matching apixaban-placebo tablets BID",,,
period,NCT00423319::period::1,NCT00423319,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00423319::outcome::primary::1,NCT00423319,Rate of Composite of Adjudicated Venous Thromboembolic Event (VTE)-Related (Pulmonary Embolism and Symptomatic and Asymptomatic Deep Vein Thrombosis[DVT]) and All-cause Death During the Intended Treatment Period,,,,,,,,,,,,,PRIMARY,Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
country,NCT00423319::country::United States,NCT00423319,United States,,,,,,,,,,,,,,
country,NCT00423319::country::Canada,NCT00423319,Canada,,,,,,,,,,,,,,
country,NCT00423319::country::Russia,NCT00423319,Russia,,,,,,,,,,,,,,
country,NCT00423319::country::Australia,NCT00423319,Australia,,,,,,,,,,,,,,
country,NCT00423319::country::Mexico,NCT00423319,Mexico,,,,,,,,,,,,,,
country,NCT00423319::country::China,NCT00423319,China,,,,,,,,,,,,,,
country,NCT00423319::country::Denmark,NCT00423319,Denmark,,,,,,,,,,,,,,
country,NCT00423319::country::Ukraine,NCT00423319,Ukraine,,,,,,,,,,,,,,
country,NCT00423319::country::Argentina,NCT00423319,Argentina,,,,,,,,,,,,,,
country,NCT00423319::country::France,NCT00423319,France,,,,,,,,,,,,,,
country,NCT00423319::country::Poland,NCT00423319,Poland,,,,,,,,,,,,,,
country,NCT00423319::country::Belgium,NCT00423319,Belgium,,,,,,,,,,,,,,
country,NCT00423319::country::India,NCT00423319,India,,,,,,,,,,,,,,
country,NCT00423319::country::Israel,NCT00423319,Israel,,,,,,,,,,,,,,
country,NCT00423319::country::Norway,NCT00423319,Norway,,,,,,,,,,,,,,
country,NCT00423319::country::Spain,NCT00423319,Spain,,,,,,,,,,,,,,
country,NCT00423319::country::Hungary,NCT00423319,Hungary,,,,,,,,,,,,,,
country,NCT00423319::country::Germany,NCT00423319,Germany,,,,,,,,,,,,,,
country,NCT00423319::country::United Kingdom,NCT00423319,United Kingdom,,,,,,,,,,,,,,
country,NCT00423319::country::Romania,NCT00423319,Romania,,,,,,,,,,,,,,
country,NCT00423319::country::Sweden,NCT00423319,Sweden,,,,,,,,,,,,,,
trial,NCT00887978,NCT00887978,Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension,PHASE3,cardiovascular disease,Pulmonary Hypertension,INDUSTRY,310.0,2009-06,2011-07,12.0,62.0,,,,,
arm,NCT00887978::arm::FG000,NCT00887978,UT-15C SR,,,,,,,,,,FG000,"Doses were initiated at 0.25 mg BID and increased by 0.25 mg BID every three days (as clinically indicated based on tolerability and symptoms of PAH), to a max dose of 16 mg BID.",,,
arm,NCT00887978::arm::FG001,NCT00887978,Placebo,,,,,,,,,,FG001,"Identical placebo tablets to UT-15C, doses were titrated in the same manner",,,
period,NCT00887978::period::1,NCT00887978,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00887978::outcome::primary::1,NCT00887978,6-minute Walk Distance (6MWD),,,,,,,,,,,,,PRIMARY,Baseline and 16 weeks
country,NCT00887978::country::United States,NCT00887978,United States,,,,,,,,,,,,,,
country,NCT00887978::country::Canada,NCT00887978,Canada,,,,,,,,,,,,,,
country,NCT00887978::country::France,NCT00887978,France,,,,,,,,,,,,,,
country,NCT00887978::country::Germany,NCT00887978,Germany,,,,,,,,,,,,,,
country,NCT00887978::country::Israel,NCT00887978,Israel,,,,,,,,,,,,,,
country,NCT00887978::country::Spain,NCT00887978,Spain,,,,,,,,,,,,,,
country,NCT00887978::country::Belgium,NCT00887978,Belgium,,,,,,,,,,,,,,
country,NCT00887978::country::Italy,NCT00887978,Italy,,,,,,,,,,,,,,
country,NCT00887978::country::Netherlands,NCT00887978,Netherlands,,,,,,,,,,,,,,
country,NCT00887978::country::Portugal,NCT00887978,Portugal,,,,,,,,,,,,,,
country,NCT00887978::country::Sweden,NCT00887978,Sweden,,,,,,,,,,,,,,
country,NCT00887978::country::United Kingdom,NCT00887978,United Kingdom,,,,,,,,,,,,,,
trial,NCT02867813,NCT02867813,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension,PHASE3,cardiovascular disease,Dyslipidemia,INDUSTRY,5035.0,2016-09-02,2022-03-21,7.0,198.0,,,,,
arm,NCT02867813::arm::FG000,NCT02867813,Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study,,,,,,,,,,FG000,"Participants in the parent study who received placebo subcutaneous injections either Q2W or QM, and received evolocumab 140 mg every 2 weeks Q2W or 420 mg monthly QM in the open label extension, accor",,,
arm,NCT02867813::arm::FG001,NCT02867813,Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study,,,,,,,,,,FG001,"Participants in the parent study who received evolocumab subcutaneous injections either Q2W or QM, and received evolocumab 140 mg Q2W or 420 mg QM in the open label extension according to the particip",,,
period,NCT02867813::period::1,NCT02867813,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02867813::outcome::primary::1,NCT02867813,Number of Participants Who Experienced an Adverse Event,,,,,,,,,,,,,PRIMARY,Up to 5 years
country,NCT02867813::country::United States,NCT02867813,United States,,,,,,,,,,,,,,
country,NCT02867813::country::Poland,NCT02867813,Poland,,,,,,,,,,,,,,
country,NCT02867813::country::Czechia,NCT02867813,Czechia,,,,,,,,,,,,,,
country,NCT02867813::country::Russia,NCT02867813,Russia,,,,,,,,,,,,,,
country,NCT02867813::country::Hungary,NCT02867813,Hungary,,,,,,,,,,,,,,
country,NCT02867813::country::Slovakia,NCT02867813,Slovakia,,,,,,,,,,,,,,
country,NCT02867813::country::Ukraine,NCT02867813,Ukraine,,,,,,,,,,,,,,
trial,NCT00786474,NCT00786474,Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study),PHASE3,cardiovascular disease,Arterial Thromboembolic Events; Atrial Fibrillation,OTHER,1884.0,2009-07,2015-02,1.0,1.0,,,,,
arm,NCT00786474::arm::FG000,NCT00786474,Placebo,,,,,,,,,,FG000,"Placebo: Normal saline solution, dosage determined by weight, self-administered by patient twice a day",,,
arm,NCT00786474::arm::FG001,NCT00786474,Dalteparin,,,,,,,,,,FG001,"Dalteparin: Low molecular weight heparin (LMWH), dosage determined by weight, self-administered by patient twice a day",,,
period,NCT00786474::period::1,NCT00786474,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00786474::outcome::primary::1,NCT00786474,Number of Arterial Thromboembolic Events,,,,,,,,,,,,,PRIMARY,from subject signing of the consent until completed the study (Day -30 to Day +37)
outcome,NCT00786474::outcome::primary::2,NCT00786474,Major Bleeding,,,,,,,,,,,,,PRIMARY,from subject signing of the consent until completed the study (Day -30 to Day +37)
country,NCT00786474::country::United States,NCT00786474,United States,,,,,,,,,,,,,,
trial,NCT00890409,NCT00890409,Safety and Efficacy of Hypothermia to Treat Neonatal Hypoxic-Ischemic Encephalopathy,PHASE3,cardiovascular disease,Hypoxic-Ischemic Encephalopathy,OTHER,256.0,2002-05,2005-08,1.0,1.0,,,,,
arm,NCT00890409::arm::FG000,NCT00890409,Normothermia,,,,,,,,,,FG000,Rectal temperature in the group was maintained at 36 to 37.5 degree C.,,,
arm,NCT00890409::arm::FG001,NCT00890409,Hypothermia,,,,,,,,,,FG001,The group was fitted with a cooling cap around the head for 72 hours. The temperature of the cap could be adjusted between 5 to 20 degree C and was automatically regulated by a servo-controlled temper,,,
period,NCT00890409::period::1,NCT00890409,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00890409::outcome::primary::1,NCT00890409,Death,,,,,,,,,,,,,PRIMARY,18 months
outcome,NCT00890409::outcome::primary::2,NCT00890409,Severe Neurodevelopmental Disability,,,,,,,,,,,,,PRIMARY,18 months
country,NCT00890409::country::China,NCT00890409,China,,,,,,,,,,,,,,
trial,NCT03400800,NCT03400800,Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol,PHASE3,cardiovascular disease,"ASCVD; Risk Factor, Cardiovascular; Elevated Cholesterol",INDUSTRY,1617.0,2017-11-01,2019-08-27,7.0,70.0,,,,,
arm,NCT03400800::arm::FG000,NCT03400800,Inclisiran,,,,,,,,,,FG000,"Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) in 1.5 milliliters (mL) will be administered as a SC injection on Day 1, Day 90, and then every 6 months

Inclisiran Sodium: Inc",,,
arm,NCT03400800::arm::FG001,NCT03400800,Placebo,,,,,,,,,,FG001,"Placebo (1.5 mL) will be administered as a SC injection of saline solution on Day 1, Day 90, and then every 6 months

Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water f",,,
period,NCT03400800::period::1,NCT03400800,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03400800::outcome::primary::1,NCT03400800,Percentage Change in LDL-C From Baseline to Day 510,,,,,,,,,,,,,PRIMARY,"Baseline, Day 510"
outcome,NCT03400800::outcome::primary::2,NCT03400800,Time-adjusted Percent Change in LDL-C Levels From Baseline After Day 90 and up to Day 540,,,,,,,,,,,,,PRIMARY,"Baseline, Day 90 to Day 540"
country,NCT03400800::country::United Kingdom,NCT03400800,United Kingdom,,,,,,,,,,,,,,
country,NCT03400800::country::Poland,NCT03400800,Poland,,,,,,,,,,,,,,
country,NCT03400800::country::Ukraine,NCT03400800,Ukraine,,,,,,,,,,,,,,
country,NCT03400800::country::South Africa,NCT03400800,South Africa,,,,,,,,,,,,,,
country,NCT03400800::country::Germany,NCT03400800,Germany,,,,,,,,,,,,,,
country,NCT03400800::country::Hungary,NCT03400800,Hungary,,,,,,,,,,,,,,
country,NCT03400800::country::Czechia,NCT03400800,Czechia,,,,,,,,,,,,,,
trial,NCT00624065,NCT00624065,Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,348.0,2008-03,2008-08,1.0,76.0,,,,,
arm,NCT00624065::arm::FG000,NCT00624065,Lisinopril,,,,,,,,,,FG000,"Lisinopril monotherapy (10, 20, or 40 mg once daily)",,,
arm,NCT00624065::arm::FG001,NCT00624065,Carvedilol CR + Lisinopril,,,,,,,,,,FG001,"Carvedilol controlled release (CR) + lisinopril (20 + 10, 20 + 20, or 40 + 20 mg once daily)",,,
period,NCT00624065::period::1,NCT00624065,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00624065::outcome::primary::1,NCT00624065,Number of Participants With Mean Sitting Cuff Blood Pressure <140/90 mmHg at the End of 6 Weeks of Treatment,,,,,,,,,,,,,PRIMARY,Week 6
country,NCT00624065::country::United States,NCT00624065,United States,,,,,,,,,,,,,,
trial,NCT01644188,NCT01644188,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II),PHASE3,cardiovascular disease,Hypercholesterolemia,INDUSTRY,720.0,2012-08,2015-07,10.0,126.0,,,,,
arm,NCT01644188::arm::FG000,NCT01644188,Alirocumab 75 /up to 150 mg Q2W,,,,,,,,,,FG000,Subcutaneous injection of alirocumab 75 mg every 2 weeks (Q2W) and oral placebo capsule for ezetimibe daily added to stable Lipid- Modifying Therapy (LMT) for 104 weeks. Alirocumab dose up-titrated to,,,
arm,NCT01644188::arm::FG001,NCT01644188,Ezetimibe 10 mg,,,,,,,,,,FG001,Oral ezetimibe 10 mg capsule daily and subcutaneous placebo injection for alirocumab Q2W added to stable LMT for 104 weeks.,,,
period,NCT01644188::period::1,NCT01644188,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01644188::outcome::primary::1,NCT01644188,Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis,,,,,,,,,,,,,PRIMARY,From Baseline to Week 52
country,NCT01644188::country::United States,NCT01644188,United States,,,,,,,,,,,,,,
country,NCT01644188::country::Russia,NCT01644188,Russia,,,,,,,,,,,,,,
country,NCT01644188::country::South Korea,NCT01644188,South Korea,,,,,,,,,,,,,,
country,NCT01644188::country::Denmark,NCT01644188,Denmark,,,,,,,,,,,,,,
country,NCT01644188::country::South Africa,NCT01644188,South Africa,,,,,,,,,,,,,,
country,NCT01644188::country::Israel,NCT01644188,Israel,,,,,,,,,,,,,,
country,NCT01644188::country::Hungary,NCT01644188,Hungary,,,,,,,,,,,,,,
country,NCT01644188::country::Canada,NCT01644188,Canada,,,,,,,,,,,,,,
country,NCT01644188::country::France,NCT01644188,France,,,,,,,,,,,,,,
country,NCT01644188::country::Ukraine,NCT01644188,Ukraine,,,,,,,,,,,,,,
trial,NCT02541383,NCT02541383,A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma,PHASE3,cardiovascular disease,Multiple Myeloma,NETWORK,1085.0,2015-09,2023-09-01,3.0,107.0,,,,,
arm,NCT02541383::arm::FG000,NCT02541383,VTd Only,,,,,,,,,,FG000,"All patients randomized to the VTd group (Bortezomib (VELCADE), Thalidomide, and Dexamethasone) at rando 1 (even those who didn't receive any study treatment), not re-randomized in maintenance phase.",,,
arm,NCT02541383::arm::FG001,NCT02541383,DVTd Only * Arm/Group Title: Characters Remaining: 91,,,,,,,,,,FG001,"All patients randomized to the DVTd group (Daratumumab, Bortezomib (VELCADE), Thalidomide, and Dexamethasone) at rando 1 (even those who didn't receive any study treatment), not re-randomized in maint",,,
arm,NCT02541383::arm::FG002,NCT02541383,VTd-OBS,,,,,,,,,,FG002,"All patients randomized to the VTd group (Bortezomib (VELCADE), Thalidomide, and Dexamethasone) at rando 1 (even those who didn't receive any study treatment), re-randomized to observation",,,
arm,NCT02541383::arm::FG003,NCT02541383,VTd-DARA,,,,,,,,,,FG003,"All patients randomized to the VTd group (Bortezomib (VELCADE), Thalidomide, and Dexamethasone) at rando 1 (even those who didn't receive any study treatment), re-randomized to daratumumab monotherapy",,,
arm,NCT02541383::arm::FG004,NCT02541383,DVTd-OBS,,,,,,,,,,FG004,"All patients randomized to the DVTd group (Daratumumab, Bortezomib (VELCADE), Thalidomide, and Dexamethasone) at rando 1 (even those who didn't receive any study treatment), re-randomized to observati",,,
arm,NCT02541383::arm::FG005,NCT02541383,DVTd-DARA,,,,,,,,,,FG005,"All patients randomized to the DVTd group (Daratumumab, Bortezomib (VELCADE), Thalidomide, and Dexamethasone) at rando 1 (even those who didn't receive any study treatment), re-randomized to daratumum",,,
period,NCT02541383::period::1,NCT02541383,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02541383::outcome::primary::1,NCT02541383,Post-Consolidation Stringent Complete Response (sCR) Rate,,,,,,,,,,,,,PRIMARY,"At day 100 post Autologous Stem Cell Transplant (ASCT), up to 114 days post ASCT"
outcome,NCT02541383::outcome::primary::2,NCT02541383,Progression Free Survival (PFS) Post Completion of Maintenance Therapy,,,,,,,,,,,,,PRIMARY,"From the date of second randomization to either progressive disease or death which ever occurred first, with a median follow-up time of 35.4 months (cut-off for analysis was 26 months after the last rando 2 date)."
country,NCT02541383::country::France,NCT02541383,France,,,,,,,,,,,,,,
country,NCT02541383::country::Netherlands,NCT02541383,Netherlands,,,,,,,,,,,,,,
country,NCT02541383::country::Belgium,NCT02541383,Belgium,,,,,,,,,,,,,,
trial,NCT01615198,NCT01615198,Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension,PHASE3,cardiovascular disease,Essential Hypertension,INDUSTRY,588.0,2012-08,2013-07,7.0,79.0,,,,,
arm,NCT01615198::arm::FG000,NCT01615198,LCZ696,,,,,,,,,,FG000,Participants were treated with one LCZ696 100 mg tablet and one placebo of LCZ696 every day (qd) for 4 weeks along with placebo of Olmesartan 10 mg capsule qd. Participants were then up-titrated to LC,,,
arm,NCT01615198::arm::FG001,NCT01615198,Olmesartan,,,,,,,,,,FG001,Participants were treated with olmesartan 10 mg qd for 4 weeks along with 2 placebo of LCZ696 tablets qd. Participants were then uptitrated to olmesartan 20 mg qd for 6 weeks along with 2 placebo of L,,,
period,NCT01615198::period::1,NCT01615198,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01615198::outcome::primary::1,NCT01615198,Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP),,,,,,,,,,,,,PRIMARY,"Baseline, 10 weeks"
country,NCT01615198::country::Japan,NCT01615198,Japan,,,,,,,,,,,,,,
country,NCT01615198::country::South Korea,NCT01615198,South Korea,,,,,,,,,,,,,,
country,NCT01615198::country::China,NCT01615198,China,,,,,,,,,,,,,,
country,NCT01615198::country::Taiwan,NCT01615198,Taiwan,,,,,,,,,,,,,,
country,NCT01615198::country::Philippines,NCT01615198,Philippines,,,,,,,,,,,,,,
country,NCT01615198::country::Hong Kong,NCT01615198,Hong Kong,,,,,,,,,,,,,,
country,NCT01615198::country::Thailand,NCT01615198,Thailand,,,,,,,,,,,,,,
trial,NCT00620542,NCT00620542,CRESTOR Athero Imaging Head to Head IVUS Study,PHASE3,cardiovascular disease,Coronary Atherosclerosis,INDUSTRY,2333.0,2008-01,2011-06,14.0,195.0,,,,,
arm,NCT00620542::arm::FG000,NCT00620542,Rosuvastatin 20 mg,,,,,,,,,,FG000,2 week run-in period,,,
arm,NCT00620542::arm::FG001,NCT00620542,Atorvastatin 40 mg,,,,,,,,,,FG001,2 week run-in period,,,
arm,NCT00620542::arm::FG002,NCT00620542,Rosuvastatin 40 mg,,,,,,,,,,FG002,2 year core study,,,
arm,NCT00620542::arm::FG003,NCT00620542,Atorvastatin 80 mg,,,,,,,,,,FG003,2 year core study,,,
period,NCT00620542::period::1,NCT00620542,Part A (Run-in - 2 Weeks),,,,,,,,,,,,1.0,,
period,NCT00620542::period::2,NCT00620542,Part B (2 Year Core Study),,,,,,,,,,,,2.0,,
outcome,NCT00620542::outcome::primary::1,NCT00620542,Change From Baseline to End of Study (Week 104) in Percent Atheroma Volume (PAV),,,,,,,,,,,,,PRIMARY,End of study (Week 104)
country,NCT00620542::country::United States,NCT00620542,United States,,,,,,,,,,,,,,
country,NCT00620542::country::Canada,NCT00620542,Canada,,,,,,,,,,,,,,
country,NCT00620542::country::Netherlands,NCT00620542,Netherlands,,,,,,,,,,,,,,
country,NCT00620542::country::France,NCT00620542,France,,,,,,,,,,,,,,
country,NCT00620542::country::Italy,NCT00620542,Italy,,,,,,,,,,,,,,
country,NCT00620542::country::Brazil,NCT00620542,Brazil,,,,,,,,,,,,,,
country,NCT00620542::country::Poland,NCT00620542,Poland,,,,,,,,,,,,,,
country,NCT00620542::country::Mexico,NCT00620542,Mexico,,,,,,,,,,,,,,
country,NCT00620542::country::Argentina,NCT00620542,Argentina,,,,,,,,,,,,,,
country,NCT00620542::country::Belgium,NCT00620542,Belgium,,,,,,,,,,,,,,
country,NCT00620542::country::Spain,NCT00620542,Spain,,,,,,,,,,,,,,
country,NCT00620542::country::Australia,NCT00620542,Australia,,,,,,,,,,,,,,
country,NCT00620542::country::Russia,NCT00620542,Russia,,,,,,,,,,,,,,
country,NCT00620542::country::Hungary,NCT00620542,Hungary,,,,,,,,,,,,,,
trial,NCT00689936,NCT00689936,"Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma",PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,1623.0,2008-08-21,2016-07-14,19.0,288.0,,,,,
arm,NCT00689936::arm::FG000,NCT00689936,Lenalidomide and Low-Dose Dexamethasone (Rd),,,,,,,,,,FG000,"Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle u",,,
arm,NCT00689936::arm::FG001,NCT00689936,Lenalidomide and Dexamethasone Rd18,,,,,,,,,,FG001,"Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles ",,,
arm,NCT00689936::arm::FG002,NCT00689936,Melphalan + Prednisone + Thalidomide (MPT),,,,,,,,,,FG002,Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on d,,,
period,NCT00689936::period::1,NCT00689936,Active Treatment Phase,,,,,,,,,,,,1.0,,
period,NCT00689936::period::2,NCT00689936,Progression Free Survival-PFS-Follow-Up,,,,,,,,,,,,2.0,,
period,NCT00689936::period::3,NCT00689936,Long-Term Follow Up Phase,,,,,,,,,,,,3.0,,
outcome,NCT00689936::outcome::primary::1,NCT00689936,Kaplan-Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Independent Review Adjudication Committee (IRAC),,,,,,,,,,,,,PRIMARY,From date of randomization until the data cut-off date of 24 May 2013. Median follow-up time for all participants was 17.1 months.
outcome,NCT00689936::outcome::primary::2,NCT00689936,Kaplan-Meier Estimates of PFS Based on the Response Assessment by the Investigator At the Time of Final Analysis,,,,,,,,,,,,,PRIMARY,From date of randomization to date of data cut-off date of 21 January 2016
country,NCT00689936::country::France,NCT00689936,France,,,,,,,,,,,,,,
country,NCT00689936::country::United States,NCT00689936,United States,,,,,,,,,,,,,,
country,NCT00689936::country::Canada,NCT00689936,Canada,,,,,,,,,,,,,,
country,NCT00689936::country::Spain,NCT00689936,Spain,,,,,,,,,,,,,,
country,NCT00689936::country::Italy,NCT00689936,Italy,,,,,,,,,,,,,,
country,NCT00689936::country::Australia,NCT00689936,Australia,,,,,,,,,,,,,,
country,NCT00689936::country::Germany,NCT00689936,Germany,,,,,,,,,,,,,,
country,NCT00689936::country::United Kingdom,NCT00689936,United Kingdom,,,,,,,,,,,,,,
country,NCT00689936::country::South Korea,NCT00689936,South Korea,,,,,,,,,,,,,,
country,NCT00689936::country::Belgium,NCT00689936,Belgium,,,,,,,,,,,,,,
country,NCT00689936::country::Austria,NCT00689936,Austria,,,,,,,,,,,,,,
country,NCT00689936::country::Switzerland,NCT00689936,Switzerland,,,,,,,,,,,,,,
country,NCT00689936::country::Greece,NCT00689936,Greece,,,,,,,,,,,,,,
country,NCT00689936::country::Portugal,NCT00689936,Portugal,,,,,,,,,,,,,,
country,NCT00689936::country::China,NCT00689936,China,,,,,,,,,,,,,,
country,NCT00689936::country::Sweden,NCT00689936,Sweden,,,,,,,,,,,,,,
country,NCT00689936::country::Ireland,NCT00689936,Ireland,,,,,,,,,,,,,,
country,NCT00689936::country::New Zealand,NCT00689936,New Zealand,,,,,,,,,,,,,,
country,NCT00689936::country::Taiwan,NCT00689936,Taiwan,,,,,,,,,,,,,,
trial,NCT00433836,NCT00433836,Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,300.0,2007-01,2009-02,11.0,11.0,,,,,
arm,NCT00433836::arm::FG000,NCT00433836,Valsartan,,,,,,,,,,FG000,"Weight stratified dosages given by mouth, once daily, of valsartan 80/160/320 mg.",,,
arm,NCT00433836::arm::FG001,NCT00433836,Enalapril,,,,,,,,,,FG001,"Weight stratified dosages given by mouth, once daily, of enalapril 10/20/40 mg.",,,
period,NCT00433836::period::1,NCT00433836,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00433836::outcome::primary::1,NCT00433836,Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP),,,,,,,,,,,,,PRIMARY,Baseline and Week 12
country,NCT00433836::country::United States,NCT00433836,United States,,,,,,,,,,,,,,
country,NCT00433836::country::Belgium,NCT00433836,Belgium,,,,,,,,,,,,,,
country,NCT00433836::country::France,NCT00433836,France,,,,,,,,,,,,,,
country,NCT00433836::country::Germany,NCT00433836,Germany,,,,,,,,,,,,,,
country,NCT00433836::country::Hungary,NCT00433836,Hungary,,,,,,,,,,,,,,
country,NCT00433836::country::India,NCT00433836,India,,,,,,,,,,,,,,
country,NCT00433836::country::Italy,NCT00433836,Italy,,,,,,,,,,,,,,
country,NCT00433836::country::Poland,NCT00433836,Poland,,,,,,,,,,,,,,
country,NCT00433836::country::Slovakia,NCT00433836,Slovakia,,,,,,,,,,,,,,
country,NCT00433836::country::Sweden,NCT00433836,Sweden,,,,,,,,,,,,,,
country,NCT00433836::country::Turkey (Türkiye),NCT00433836,Turkey (Türkiye),,,,,,,,,,,,,,
trial,NCT00143507,NCT00143507,The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction,PHASE3,cardiovascular disease,"Coronary Disease; Ventricular Dysfunction, Left",OTHER,10917.0,2004-12,2008-02,1.0,1.0,,,,,
arm,NCT00143507::arm::FG000,NCT00143507,Ivabradine,,,,,,,,,,FG000,"Patients received ivabradine at starting dose of 5 mg twice daily, with a target dose, if HR tolerance criteria were met after two weeks (at the D15 visit), of 7.5 mg twice daily.",,,
arm,NCT00143507::arm::FG001,NCT00143507,Placebo,,,,,,,,,,FG001,Patients received placebo twice daily.,,,
period,NCT00143507::period::1,NCT00143507,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00143507::outcome::primary::1,NCT00143507,Primary Composite Endpoint,,,,,,,,,,,,,PRIMARY,"From the date of randomisation to the date of the first occurrence of the first event, up to 3 years."
country,NCT00143507::country::United Kingdom,NCT00143507,United Kingdom,,,,,,,,,,,,,,
trial,NCT00591266,NCT00591266,"Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension",PHASE3,cardiovascular disease,Hypertension,INDUSTRY,566.0,2007-10,2009-04,1.0,50.0,,,,,
arm,NCT00591266::arm::FG000,NCT00591266,Azilsartan Medoxomil 40 mg QD Amlodipine 5 mg QD,,,,,,,,,,FG000,"Azilsartan Medoxomil 40 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.",,,
arm,NCT00591266::arm::FG001,NCT00591266,Azilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QD,,,,,,,,,,FG001,"Azilsartan Medoxomil 80 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.",,,
arm,NCT00591266::arm::FG002,NCT00591266,Amlodipine 5 mg QD,,,,,,,,,,FG002,"Amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.",,,
period,NCT00591266::period::1,NCT00591266,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00591266::outcome::primary::1,NCT00591266,Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.,,,,,,,,,,,,,PRIMARY,Baseline and Week 6.
country,NCT00591266::country::United States,NCT00591266,United States,,,,,,,,,,,,,,
trial,NCT00496769,NCT00496769,A Phase III Study of Apixaban in Patients With Atrial Fibrillation,PHASE3,cardiovascular disease,Atrial Fibrillation,INDUSTRY,6421.0,2007-08-31,2017-05-25,36.0,503.0,,,,,
arm,NCT00496769::arm::FG000,NCT00496769,"Apixaban, 2.5 or 5 mg Twice Daily",,,,,,,,,,FG000,"Patients received 5 mg of apixaban twice daily. Participants who fulfilled any 2 of the following criteria at baseline received apixaban, 2.5 mg twice daily: age older than 80 years, body weight of 60",,,
arm,NCT00496769::arm::FG001,NCT00496769,"Acetylsalicylic Acid, 81-324 mg Once Daily",,,,,,,,,,FG001,"Patients received 81 to 324 mg of acetylsalicylic acid once daily, with dosage based on investigator discretion Participants who completed the double-blind treatment period and met eligibility criteri",,,
arm,NCT00496769::arm::FG002,NCT00496769,Open Label Apixaban,,,,,,,,,,FG002,Participants who completed the double-blind treatment period and met eligibility criteria had the option of enrolling in the Long Term Open Label Extension to receive open-label apixaban.,,,
period,NCT00496769::period::1,NCT00496769,Double Blind,,,,,,,,,,,,1.0,,
period,NCT00496769::period::2,NCT00496769,Open Label,,,,,,,,,,,,2.0,,
outcome,NCT00496769::outcome::primary::1,NCT00496769,Event Rate of Stroke/Systemic Embolism During the Intended-treatment Period,,,,,,,,,,,,,PRIMARY,"Randomization to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)"
country,NCT00496769::country::United States,NCT00496769,United States,,,,,,,,,,,,,,
country,NCT00496769::country::Russia,NCT00496769,Russia,,,,,,,,,,,,,,
country,NCT00496769::country::Brazil,NCT00496769,Brazil,,,,,,,,,,,,,,
country,NCT00496769::country::Canada,NCT00496769,Canada,,,,,,,,,,,,,,
country,NCT00496769::country::Argentina,NCT00496769,Argentina,,,,,,,,,,,,,,
country,NCT00496769::country::Germany,NCT00496769,Germany,,,,,,,,,,,,,,
country,NCT00496769::country::Poland,NCT00496769,Poland,,,,,,,,,,,,,,
country,NCT00496769::country::India,NCT00496769,India,,,,,,,,,,,,,,
country,NCT00496769::country::Mexico,NCT00496769,Mexico,,,,,,,,,,,,,,
country,NCT00496769::country::United Kingdom,NCT00496769,United Kingdom,,,,,,,,,,,,,,
country,NCT00496769::country::China,NCT00496769,China,,,,,,,,,,,,,,
country,NCT00496769::country::Czechia,NCT00496769,Czechia,,,,,,,,,,,,,,
country,NCT00496769::country::Ukraine,NCT00496769,Ukraine,,,,,,,,,,,,,,
country,NCT00496769::country::Israel,NCT00496769,Israel,,,,,,,,,,,,,,
country,NCT00496769::country::Australia,NCT00496769,Australia,,,,,,,,,,,,,,
country,NCT00496769::country::Chile,NCT00496769,Chile,,,,,,,,,,,,,,
country,NCT00496769::country::Indonesia,NCT00496769,Indonesia,,,,,,,,,,,,,,
country,NCT00496769::country::South Korea,NCT00496769,South Korea,,,,,,,,,,,,,,
country,NCT00496769::country::Belgium,NCT00496769,Belgium,,,,,,,,,,,,,,
country,NCT00496769::country::Italy,NCT00496769,Italy,,,,,,,,,,,,,,
country,NCT00496769::country::France,NCT00496769,France,,,,,,,,,,,,,,
country,NCT00496769::country::Philippines,NCT00496769,Philippines,,,,,,,,,,,,,,
country,NCT00496769::country::South Africa,NCT00496769,South Africa,,,,,,,,,,,,,,
country,NCT00496769::country::Spain,NCT00496769,Spain,,,,,,,,,,,,,,
country,NCT00496769::country::Sweden,NCT00496769,Sweden,,,,,,,,,,,,,,
country,NCT00496769::country::Malaysia,NCT00496769,Malaysia,,,,,,,,,,,,,,
country,NCT00496769::country::Taiwan,NCT00496769,Taiwan,,,,,,,,,,,,,,
country,NCT00496769::country::Colombia,NCT00496769,Colombia,,,,,,,,,,,,,,
country,NCT00496769::country::Finland,NCT00496769,Finland,,,,,,,,,,,,,,
country,NCT00496769::country::Austria,NCT00496769,Austria,,,,,,,,,,,,,,
country,NCT00496769::country::Norway,NCT00496769,Norway,,,,,,,,,,,,,,
country,NCT00496769::country::Singapore,NCT00496769,Singapore,,,,,,,,,,,,,,
country,NCT00496769::country::Turkey (Türkiye),NCT00496769,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00496769::country::Denmark,NCT00496769,Denmark,,,,,,,,,,,,,,
country,NCT00496769::country::Greece,NCT00496769,Greece,,,,,,,,,,,,,,
country,NCT00496769::country::Hong Kong,NCT00496769,Hong Kong,,,,,,,,,,,,,,
trial,NCT00433966,NCT00433966,Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction,PHASE3,cardiovascular disease,Myocardial Infarction,OTHER,3602.0,2005-03,2010-11,1.0,1.0,,,,,
arm,NCT00433966::arm::FG000,NCT00433966,Pharmacology Arm - Bivalirudin,,,,,,,,,,FG000,To establish the safety and efficacy of the use of bivalirudin in patients with acute myocardial infarction undergoing a primary angioplasty strategy by showing that compared to unfractionated heparin,,,
arm,NCT00433966::arm::FG001,NCT00433966,Pharmacology Arm - Unfractionated Heparin,,,,,,,,,,FG001,To establish the safety and efficacy of the use of bivalirudin in patients with acute myocardial infarction undergoing a primary angioplasty strategy by showing that compared to unfractionated heparin,,,
arm,NCT00433966::arm::FG002,NCT00433966,Stent Arm - Paclitaxel-Eluting Stent,,,,,,,,,,FG002,"To establish the safety and efficacy of the paclitaxel-eluting TAXUS™ stent by showing that compared to an otherwise identical bare metal EXPRESS2™ stent, the TAXUS™ stent results in:

1. reduced rate",,,
arm,NCT00433966::arm::FG003,NCT00433966,Stent Arm - Bare Metal Stent,,,,,,,,,,FG003,"To establish the safety and efficacy of the paclitaxel-eluting TAXUS™ stent by showing that compared to an otherwise identical bare metal EXPRESS2™ stent, the TAXUS™ stent results in:

1. reduced rate",,,
period,NCT00433966::period::1,NCT00433966,Pharmacology Intervention/Randomization,,,,,,,,,,,,1.0,,
period,NCT00433966::period::2,NCT00433966,Stent Intervention/Randomization,,,,,,,,,,,,2.0,,
outcome,NCT00433966::outcome::primary::1,NCT00433966,Pharmacology Arm - Major Adverse Ischemic Cardiac Events and Major Bleeding Events,,,,,,,,,,,,,PRIMARY,30 Days
outcome,NCT00433966::outcome::primary::2,NCT00433966,Stent Arm - Ischemic Target Lesion Revascularization,,,,,,,,,,,,,PRIMARY,1 year
outcome,NCT00433966::outcome::primary::3,NCT00433966,"Stent Arm - Death, Reinfarction, Stroke, or Stent Thrombosis",,,,,,,,,,,,,PRIMARY,1 year
country,NCT00433966::country::United States,NCT00433966,United States,,,,,,,,,,,,,,
trial,NCT01663402,NCT01663402,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,PHASE3,cardiovascular disease,Atherosclerotic Cardiovascular Disease,INDUSTRY,18924.0,2012-10,2018-01-23,57.0,1388.0,,,,,
arm,NCT01663402::arm::FG000,NCT01663402,Placebo,,,,,,,,,,FG000,Placebo (for alirocumab) SC injection every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for up to 64 months.,,,
arm,NCT01663402::arm::FG001,NCT01663402,Alirocumab 75 mg Q2W/Up to 150 mg Q2W,,,,,,,,,,FG001,Alirocumab 75 mg SC injection Q2W added to stable LMT for up to 64 months. Alirocumab dose up-titrated to 150 mg Q2W from Month 2 when LDL-C levels \>=50 mg/dL (1.29 mmol/L) at Month 1; or if up-titra,,,
period,NCT01663402::period::1,NCT01663402,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01663402::outcome::primary::1,NCT01663402,Time to First Occurrence of Major Adverse Cardiovascular Event (MACE),,,,,,,,,,,,,PRIMARY,From randomization up to 64 months
outcome,NCT01663402::outcome::primary::2,NCT01663402,Percentage of Observed Participants With Outcome Measure Events During the Study,,,,,,,,,,,,,PRIMARY,
country,NCT01663402::country::United States,NCT01663402,United States,,,,,,,,,,,,,,
country,NCT01663402::country::China,NCT01663402,China,,,,,,,,,,,,,,
country,NCT01663402::country::India,NCT01663402,India,,,,,,,,,,,,,,
country,NCT01663402::country::Argentina,NCT01663402,Argentina,,,,,,,,,,,,,,
country,NCT01663402::country::Russia,NCT01663402,Russia,,,,,,,,,,,,,,
country,NCT01663402::country::Canada,NCT01663402,Canada,,,,,,,,,,,,,,
country,NCT01663402::country::Germany,NCT01663402,Germany,,,,,,,,,,,,,,
country,NCT01663402::country::Brazil,NCT01663402,Brazil,,,,,,,,,,,,,,
country,NCT01663402::country::Spain,NCT01663402,Spain,,,,,,,,,,,,,,
country,NCT01663402::country::Japan,NCT01663402,Japan,,,,,,,,,,,,,,
country,NCT01663402::country::Poland,NCT01663402,Poland,,,,,,,,,,,,,,
country,NCT01663402::country::United Kingdom,NCT01663402,United Kingdom,,,,,,,,,,,,,,
country,NCT01663402::country::Netherlands,NCT01663402,Netherlands,,,,,,,,,,,,,,
country,NCT01663402::country::Ukraine,NCT01663402,Ukraine,,,,,,,,,,,,,,
country,NCT01663402::country::Israel,NCT01663402,Israel,,,,,,,,,,,,,,
country,NCT01663402::country::Australia,NCT01663402,Australia,,,,,,,,,,,,,,
country,NCT01663402::country::Italy,NCT01663402,Italy,,,,,,,,,,,,,,
country,NCT01663402::country::Czechia,NCT01663402,Czechia,,,,,,,,,,,,,,
country,NCT01663402::country::France,NCT01663402,France,,,,,,,,,,,,,,
country,NCT01663402::country::Belgium,NCT01663402,Belgium,,,,,,,,,,,,,,
country,NCT01663402::country::South Africa,NCT01663402,South Africa,,,,,,,,,,,,,,
country,NCT01663402::country::Mexico,NCT01663402,Mexico,,,,,,,,,,,,,,
country,NCT01663402::country::Peru,NCT01663402,Peru,,,,,,,,,,,,,,
country,NCT01663402::country::Slovakia,NCT01663402,Slovakia,,,,,,,,,,,,,,
country,NCT01663402::country::Bulgaria,NCT01663402,Bulgaria,,,,,,,,,,,,,,
country,NCT01663402::country::Chile,NCT01663402,Chile,,,,,,,,,,,,,,
country,NCT01663402::country::Serbia,NCT01663402,Serbia,,,,,,,,,,,,,,
country,NCT01663402::country::Colombia,NCT01663402,Colombia,,,,,,,,,,,,,,
country,NCT01663402::country::Denmark,NCT01663402,Denmark,,,,,,,,,,,,,,
country,NCT01663402::country::Romania,NCT01663402,Romania,,,,,,,,,,,,,,
country,NCT01663402::country::Croatia,NCT01663402,Croatia,,,,,,,,,,,,,,
country,NCT01663402::country::Hungary,NCT01663402,Hungary,,,,,,,,,,,,,,
country,NCT01663402::country::Philippines,NCT01663402,Philippines,,,,,,,,,,,,,,
country,NCT01663402::country::South Korea,NCT01663402,South Korea,,,,,,,,,,,,,,
country,NCT01663402::country::Sweden,NCT01663402,Sweden,,,,,,,,,,,,,,
country,NCT01663402::country::Taiwan,NCT01663402,Taiwan,,,,,,,,,,,,,,
country,NCT01663402::country::Greece,NCT01663402,Greece,,,,,,,,,,,,,,
country,NCT01663402::country::New Zealand,NCT01663402,New Zealand,,,,,,,,,,,,,,
country,NCT01663402::country::Turkey (Türkiye),NCT01663402,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01663402::country::Bosnia and Herzegovina,NCT01663402,Bosnia and Herzegovina,,,,,,,,,,,,,,
country,NCT01663402::country::Thailand,NCT01663402,Thailand,,,,,,,,,,,,,,
country,NCT01663402::country::Sri Lanka,NCT01663402,Sri Lanka,,,,,,,,,,,,,,
country,NCT01663402::country::Lithuania,NCT01663402,Lithuania,,,,,,,,,,,,,,
country,NCT01663402::country::Norway,NCT01663402,Norway,,,,,,,,,,,,,,
country,NCT01663402::country::Portugal,NCT01663402,Portugal,,,,,,,,,,,,,,
country,NCT01663402::country::Estonia,NCT01663402,Estonia,,,,,,,,,,,,,,
country,NCT01663402::country::Georgia,NCT01663402,Georgia,,,,,,,,,,,,,,
country,NCT01663402::country::Malaysia,NCT01663402,Malaysia,,,,,,,,,,,,,,
country,NCT01663402::country::Austria,NCT01663402,Austria,,,,,,,,,,,,,,
country,NCT01663402::country::Latvia,NCT01663402,Latvia,,,,,,,,,,,,,,
country,NCT01663402::country::North Macedonia,NCT01663402,North Macedonia,,,,,,,,,,,,,,
country,NCT01663402::country::Slovenia,NCT01663402,Slovenia,,,,,,,,,,,,,,
country,NCT01663402::country::Finland,NCT01663402,Finland,,,,,,,,,,,,,,
country,NCT01663402::country::Guatemala,NCT01663402,Guatemala,,,,,,,,,,,,,,
country,NCT01663402::country::Switzerland,NCT01663402,Switzerland,,,,,,,,,,,,,,
country,NCT01663402::country::Singapore,NCT01663402,Singapore,,,,,,,,,,,,,,
country,NCT01663402::country::Hong Kong,NCT01663402,Hong Kong,,,,,,,,,,,,,,
trial,NCT02344290,NCT02344290,Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults,PHASE3,cardiovascular disease,HIV; Cardiovascular Diseases,NIH,7769.0,2015-03-26,2023-08-21,13.0,137.0,,,,,
arm,NCT02344290::arm::FG000,NCT02344290,Pitavastatin,,,,,,,,,,FG000,"Participants received pitavastatin once a day for the entire time they were in study follow-up.

Pitavastatin: One tablet (4 mg) taken once daily, orally with or without food",,,
arm,NCT02344290::arm::FG001,NCT02344290,Placebo,,,,,,,,,,FG001,"Participants received placebo for pitavastatin once a day for the entire time they were in study follow-up.

Placebo: One tablet taken once daily, orally with or without food",,,
period,NCT02344290::period::1,NCT02344290,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02344290::outcome::primary::1,NCT02344290,Incidence Rate of Major Adverse Cardiovascular Event (MACE),,,,,,,,,,,,,PRIMARY,From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
country,NCT02344290::country::United States,NCT02344290,United States,,,,,,,,,,,,,,
country,NCT02344290::country::Spain,NCT02344290,Spain,,,,,,,,,,,,,,
country,NCT02344290::country::Brazil,NCT02344290,Brazil,,,,,,,,,,,,,,
country,NCT02344290::country::Canada,NCT02344290,Canada,,,,,,,,,,,,,,
country,NCT02344290::country::South Africa,NCT02344290,South Africa,,,,,,,,,,,,,,
country,NCT02344290::country::Haiti,NCT02344290,Haiti,,,,,,,,,,,,,,
country,NCT02344290::country::India,NCT02344290,India,,,,,,,,,,,,,,
country,NCT02344290::country::Peru,NCT02344290,Peru,,,,,,,,,,,,,,
country,NCT02344290::country::Thailand,NCT02344290,Thailand,,,,,,,,,,,,,,
country,NCT02344290::country::Botswana,NCT02344290,Botswana,,,,,,,,,,,,,,
country,NCT02344290::country::Puerto Rico,NCT02344290,Puerto Rico,,,,,,,,,,,,,,
country,NCT02344290::country::Uganda,NCT02344290,Uganda,,,,,,,,,,,,,,
country,NCT02344290::country::Zimbabwe,NCT02344290,Zimbabwe,,,,,,,,,,,,,,
trial,NCT00075829,NCT00075829,Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102),PHASE3,cardiovascular disease,Multiple Myeloma,NIH,710.0,2003-12,2013-03,1.0,36.0,,,,,
arm,NCT00075829::arm::FG000,NCT00075829,Auto-Auto Standard Risk,,,,,,,,,,FG000,Tandem autologous transplant plus thalidomide/dexamethasone (Thal-Dex) or observation (Obs) for standard risk patients PFS and OS did not differ between the Thal-Dex and the Obs arms and were thus poo,,,
arm,NCT00075829::arm::FG001,NCT00075829,Auto-Allo Standard Risk,,,,,,,,,,FG001,Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients,,,
arm,NCT00075829::arm::FG002,NCT00075829,Auto-Auto High Risk,,,,,,,,,,FG002,"Tandem autologous transplant plus thalidomide/dexamethasone (Thal-Dex) or observation (Obs) for high risk patients

PFS and OS did not differ between the Thal-Dex and the Obs arms and were thus pooled",,,
arm,NCT00075829::arm::FG003,NCT00075829,Auto-Allo High Risk,,,,,,,,,,FG003,Autologous transplant plus non-myeloablative allogeneic transplant for high risk patients,,,
period,NCT00075829::period::1,NCT00075829,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00075829::outcome::primary::1,NCT00075829,Progression-Free Survival (PFS),,,,,,,,,,,,,PRIMARY,Year 3
country,NCT00075829::country::United States,NCT00075829,United States,,,,,,,,,,,,,,
trial,NCT04404166,NCT04404166,Phone-based Intervention Under Nurse Guidance After Stroke 2,PHASE3,cardiovascular disease,Blood Pressure; Stroke; Cardiovascular Diseases,OTHER,500.0,2020-10-23,2024-04-05,1.0,10.0,,,,,
arm,NCT04404166::arm::FG000,NCT04404166,PINGS 2,,,,,,,,,,FG000,"Participants received a multicomponent, 12-month nurse-led intervention in addition to usual post-stroke care.

Components included:

* Home blood pressure monitoring at least once weekly with nurse n",,,
arm,NCT04404166::arm::FG001,NCT04404166,Standard of Care,,,,,,,,,,FG001,"Participants received standard secondary prevention after stroke, according to local guidelines.

This typically included:

* Physician follow-up visits approximately every 2 months.
* Prescriptions f",,,
period,NCT04404166::period::1,NCT04404166,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04404166::outcome::primary::1,NCT04404166,Systolic Blood Pressure,,,,,,,,,,,,,PRIMARY,12 months
country,NCT04404166::country::Ghana,NCT04404166,Ghana,,,,,,,,,,,,,,
trial,NCT02064439,NCT02064439,Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism),PHASE3,cardiovascular disease,Pulmonary Embolism; Thromboembolism; Thrombosis; Venous Thrombosis; Venous Thromboembolism,INDUSTRY,3365.0,2014-03-05,2016-11-04,31.0,266.0,,,,,
arm,NCT02064439::arm::FG000,NCT02064439,"Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD",,,,,,,,,,FG000,"Participants were randomized, stratified by country and by index event, to receive rivaroxaban 10 mg tablet or matching placebo once daily (OD) with food for 12, or 9 to less than 12, or 6 months depe",,,
arm,NCT02064439::arm::FG001,NCT02064439,"Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD",,,,,,,,,,FG001,"Participants were randomized, stratified by country and by index event, to receive rivaroxaban 20 mg tablet or matching placebo OD with food for 12, or 9 to less than 12, or 6 months depending on the ",,,
arm,NCT02064439::arm::FG002,NCT02064439,"Acetylsalicylic (ASA) 100 mg, OD",,,,,,,,,,FG002,"Participants were randomized, stratified by country and by index event, to receive ASA 100 mg tablet or matching placebo OD with food for 12, or 9 to less than 12, or 6 months depending on the date of",,,
period,NCT02064439::period::1,NCT02064439,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02064439::outcome::primary::1,NCT02064439,Number of Participants With the Composite of Fatal or Non-fatal Symptomatic Recurrent Venous Thromboembolism,,,,,,,,,,,,,PRIMARY,"Up to 12 months, at least 6 months"
outcome,NCT02064439::outcome::primary::2,NCT02064439,Number of Participants With First Treatment-emergent Major Bleeding,,,,,,,,,,,,,PRIMARY,"Up to 12 months, at least 6 months"
country,NCT02064439::country::China,NCT02064439,China,,,,,,,,,,,,,,
country,NCT02064439::country::United States,NCT02064439,United States,,,,,,,,,,,,,,
country,NCT02064439::country::France,NCT02064439,France,,,,,,,,,,,,,,
country,NCT02064439::country::Canada,NCT02064439,Canada,,,,,,,,,,,,,,
country,NCT02064439::country::Australia,NCT02064439,Australia,,,,,,,,,,,,,,
country,NCT02064439::country::Germany,NCT02064439,Germany,,,,,,,,,,,,,,
country,NCT02064439::country::Russia,NCT02064439,Russia,,,,,,,,,,,,,,
country,NCT02064439::country::Hungary,NCT02064439,Hungary,,,,,,,,,,,,,,
country,NCT02064439::country::Netherlands,NCT02064439,Netherlands,,,,,,,,,,,,,,
country,NCT02064439::country::Brazil,NCT02064439,Brazil,,,,,,,,,,,,,,
country,NCT02064439::country::Czechia,NCT02064439,Czechia,,,,,,,,,,,,,,
country,NCT02064439::country::Israel,NCT02064439,Israel,,,,,,,,,,,,,,
country,NCT02064439::country::Italy,NCT02064439,Italy,,,,,,,,,,,,,,
country,NCT02064439::country::Mexico,NCT02064439,Mexico,,,,,,,,,,,,,,
country,NCT02064439::country::Denmark,NCT02064439,Denmark,,,,,,,,,,,,,,
country,NCT02064439::country::South Africa,NCT02064439,South Africa,,,,,,,,,,,,,,
country,NCT02064439::country::New Zealand,NCT02064439,New Zealand,,,,,,,,,,,,,,
country,NCT02064439::country::South Korea,NCT02064439,South Korea,,,,,,,,,,,,,,
country,NCT02064439::country::Switzerland,NCT02064439,Switzerland,,,,,,,,,,,,,,
country,NCT02064439::country::Belgium,NCT02064439,Belgium,,,,,,,,,,,,,,
country,NCT02064439::country::Poland,NCT02064439,Poland,,,,,,,,,,,,,,
country,NCT02064439::country::Spain,NCT02064439,Spain,,,,,,,,,,,,,,
country,NCT02064439::country::United Kingdom,NCT02064439,United Kingdom,,,,,,,,,,,,,,
country,NCT02064439::country::Austria,NCT02064439,Austria,,,,,,,,,,,,,,
country,NCT02064439::country::Taiwan,NCT02064439,Taiwan,,,,,,,,,,,,,,
country,NCT02064439::country::Norway,NCT02064439,Norway,,,,,,,,,,,,,,
country,NCT02064439::country::Sweden,NCT02064439,Sweden,,,,,,,,,,,,,,
country,NCT02064439::country::Thailand,NCT02064439,Thailand,,,,,,,,,,,,,,
country,NCT02064439::country::Turkey (Türkiye),NCT02064439,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02064439::country::Vietnam,NCT02064439,Vietnam,,,,,,,,,,,,,,
country,NCT02064439::country::Philippines,NCT02064439,Philippines,,,,,,,,,,,,,,
trial,NCT00386607,NCT00386607,"A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.",PHASE3,cardiovascular disease,Hypertension,INDUSTRY,601.0,2006-10,2008-07,4.0,4.0,,,,,
arm,NCT00386607::arm::FG000,NCT00386607,Core Treatment,,,,,,,,,,FG000,"Oral pills of aliskiren 150 mg /valsartan 160 mg in combination for 2-weeks. The aliskiren 300 mg /valsartan 320 mg in combiniation for 52-weeks, optional addition of HCTZ 12.5 mg starting from Week 1",,,
arm,NCT00386607::arm::FG001,NCT00386607,Extension Treatment,,,,,,,,,,FG001,"For patients entering into extension, those previously treated with HCTZ (12.5 or 25 mg) in addition to aliskiren 300 mg/valsartan 320 mg were treated with aliskiren 300 mg/valsartan 320 mg/HCTZ 25 mg",,,
period,NCT00386607::period::1,NCT00386607,Core,,,,,,,,,,,,1.0,,
period,NCT00386607::period::2,NCT00386607,Extension,,,,,,,,,,,,2.0,,
outcome,NCT00386607::outcome::primary::1,NCT00386607,Overall Percentage of Patients With Adverse Events,,,,,,,,,,,,,PRIMARY,Month 12
outcome,NCT00386607::outcome::primary::2,NCT00386607,Overall Percentage of Patients With Adverse Events,,,,,,,,,,,,,PRIMARY,Month 18
country,NCT00386607::country::United States,NCT00386607,United States,,,,,,,,,,,,,,
country,NCT00386607::country::Canada,NCT00386607,Canada,,,,,,,,,,,,,,
country,NCT00386607::country::Germany,NCT00386607,Germany,,,,,,,,,,,,,,
country,NCT00386607::country::Netherlands,NCT00386607,Netherlands,,,,,,,,,,,,,,
trial,NCT00699998,NCT00699998,A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects,PHASE3,cardiovascular disease,Acute Coronary Syndrome,INDUSTRY,9326.0,2008-06,2012-04,53.0,688.0,,,,,
arm,NCT00699998::arm::FG000,NCT00699998,Prasugrel: <75 Years of Age,,,,,,,,,,FG000,"Prasugrel and Low-dose Commercially-available Aspirin in participants less than (\<) 75 years of age.

Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of",,,
arm,NCT00699998::arm::FG001,NCT00699998,Prasugrel: 75 Years of Age or Older,,,,,,,,,,FG001,"Prasugrel and Low-dose Commercially-available Aspirin in participants 75 years of age or older.

Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of study",,,
arm,NCT00699998::arm::FG002,NCT00699998,Clopidogrel: <75 Years of Age,,,,,,,,,,FG002,"Clopidogrel and Low-Dose Commercially-available Aspirin in participants less than (\<) 75 years of age.

Commercially-available Aspirin : Low-dose aspirin, oral, as prescribed by physician through end",,,
arm,NCT00699998::arm::FG003,NCT00699998,Clopidogrel: 75 Years of Age or Older,,,,,,,,,,FG003,"Clopidogrel and Low-Dose Commercially-available Aspirin in participants 75 years of age or older.

Commercially-available Aspirin: Low-dose aspirin, oral, as prescribed by physician through end of stu",,,
period,NCT00699998::period::1,NCT00699998,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00699998::outcome::primary::1,NCT00699998,"Percentage of Participants With a Composite Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), or Stroke",,,,,,,,,,,,,PRIMARY,Randomization through end of study (30-month visit)
country,NCT00699998::country::United States,NCT00699998,United States,,,,,,,,,,,,,,
country,NCT00699998::country::India,NCT00699998,India,,,,,,,,,,,,,,
country,NCT00699998::country::United Kingdom,NCT00699998,United Kingdom,,,,,,,,,,,,,,
country,NCT00699998::country::Brazil,NCT00699998,Brazil,,,,,,,,,,,,,,
country,NCT00699998::country::Italy,NCT00699998,Italy,,,,,,,,,,,,,,
country,NCT00699998::country::China,NCT00699998,China,,,,,,,,,,,,,,
country,NCT00699998::country::Poland,NCT00699998,Poland,,,,,,,,,,,,,,
country,NCT00699998::country::Argentina,NCT00699998,Argentina,,,,,,,,,,,,,,
country,NCT00699998::country::France,NCT00699998,France,,,,,,,,,,,,,,
country,NCT00699998::country::Netherlands,NCT00699998,Netherlands,,,,,,,,,,,,,,
country,NCT00699998::country::Ukraine,NCT00699998,Ukraine,,,,,,,,,,,,,,
country,NCT00699998::country::Russia,NCT00699998,Russia,,,,,,,,,,,,,,
country,NCT00699998::country::Canada,NCT00699998,Canada,,,,,,,,,,,,,,
country,NCT00699998::country::Israel,NCT00699998,Israel,,,,,,,,,,,,,,
country,NCT00699998::country::Turkey (Türkiye),NCT00699998,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00699998::country::Germany,NCT00699998,Germany,,,,,,,,,,,,,,
country,NCT00699998::country::Australia,NCT00699998,Australia,,,,,,,,,,,,,,
country,NCT00699998::country::Hungary,NCT00699998,Hungary,,,,,,,,,,,,,,
country,NCT00699998::country::Romania,NCT00699998,Romania,,,,,,,,,,,,,,
country,NCT00699998::country::Bulgaria,NCT00699998,Bulgaria,,,,,,,,,,,,,,
country,NCT00699998::country::Croatia,NCT00699998,Croatia,,,,,,,,,,,,,,
country,NCT00699998::country::Czechia,NCT00699998,Czechia,,,,,,,,,,,,,,
country,NCT00699998::country::Mexico,NCT00699998,Mexico,,,,,,,,,,,,,,
country,NCT00699998::country::Philippines,NCT00699998,Philippines,,,,,,,,,,,,,,
country,NCT00699998::country::South Korea,NCT00699998,South Korea,,,,,,,,,,,,,,
country,NCT00699998::country::Malaysia,NCT00699998,Malaysia,,,,,,,,,,,,,,
country,NCT00699998::country::South Africa,NCT00699998,South Africa,,,,,,,,,,,,,,
country,NCT00699998::country::Portugal,NCT00699998,Portugal,,,,,,,,,,,,,,
country,NCT00699998::country::Slovakia,NCT00699998,Slovakia,,,,,,,,,,,,,,
country,NCT00699998::country::Spain,NCT00699998,Spain,,,,,,,,,,,,,,
country,NCT00699998::country::Chile,NCT00699998,Chile,,,,,,,,,,,,,,
country,NCT00699998::country::Greece,NCT00699998,Greece,,,,,,,,,,,,,,
country,NCT00699998::country::Tunisia,NCT00699998,Tunisia,,,,,,,,,,,,,,
country,NCT00699998::country::Colombia,NCT00699998,Colombia,,,,,,,,,,,,,,
country,NCT00699998::country::Thailand,NCT00699998,Thailand,,,,,,,,,,,,,,
country,NCT00699998::country::Belgium,NCT00699998,Belgium,,,,,,,,,,,,,,
country,NCT00699998::country::Egypt,NCT00699998,Egypt,,,,,,,,,,,,,,
country,NCT00699998::country::Serbia,NCT00699998,Serbia,,,,,,,,,,,,,,
country,NCT00699998::country::Lithuania,NCT00699998,Lithuania,,,,,,,,,,,,,,
country,NCT00699998::country::New Zealand,NCT00699998,New Zealand,,,,,,,,,,,,,,
country,NCT00699998::country::Peru,NCT00699998,Peru,,,,,,,,,,,,,,
country,NCT00699998::country::Denmark,NCT00699998,Denmark,,,,,,,,,,,,,,
country,NCT00699998::country::Panama,NCT00699998,Panama,,,,,,,,,,,,,,
country,NCT00699998::country::Puerto Rico,NCT00699998,Puerto Rico,,,,,,,,,,,,,,
country,NCT00699998::country::Sweden,NCT00699998,Sweden,,,,,,,,,,,,,,
country,NCT00699998::country::Austria,NCT00699998,Austria,,,,,,,,,,,,,,
country,NCT00699998::country::Ireland,NCT00699998,Ireland,,,,,,,,,,,,,,
country,NCT00699998::country::Malta,NCT00699998,Malta,,,,,,,,,,,,,,
country,NCT00699998::country::Switzerland,NCT00699998,Switzerland,,,,,,,,,,,,,,
country,NCT00699998::country::Taiwan,NCT00699998,Taiwan,,,,,,,,,,,,,,
country,NCT00699998::country::Costa Rica,NCT00699998,Costa Rica,,,,,,,,,,,,,,
country,NCT00699998::country::Finland,NCT00699998,Finland,,,,,,,,,,,,,,
country,NCT00699998::country::Singapore,NCT00699998,Singapore,,,,,,,,,,,,,,
trial,NCT00497146,NCT00497146,The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4,PHASE3,cardiovascular disease,Chronic Kidney Disease; Left Ventricular Hypertrophy,INDUSTRY,227.0,2008-02,2012-03,12.0,71.0,,,,,
arm,NCT00497146::arm::FG000,NCT00497146,Paricalcitol,,,,,,,,,,FG000,"Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-ter",,,
arm,NCT00497146::arm::FG001,NCT00497146,Placebo,,,,,,,,,,FG001,Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 mo,,,
period,NCT00497146::period::1,NCT00497146,Treatment Period,,,,,,,,,,,,1.0,,
period,NCT00497146::period::2,NCT00497146,Long-term Follow-up Period,,,,,,,,,,,,2.0,,
outcome,NCT00497146::outcome::primary::1,NCT00497146,Change From Baseline in Left Ventricular Mass Index (LVMI) Over 48 Weeks Measured by Cardiac Magnetic Resonance Imaging (MRI),,,,,,,,,,,,,PRIMARY,Baseline to 48 weeks
country,NCT00497146::country::United States,NCT00497146,United States,,,,,,,,,,,,,,
country,NCT00497146::country::Australia,NCT00497146,Australia,,,,,,,,,,,,,,
country,NCT00497146::country::Puerto Rico,NCT00497146,Puerto Rico,,,,,,,,,,,,,,
country,NCT00497146::country::Germany,NCT00497146,Germany,,,,,,,,,,,,,,
country,NCT00497146::country::Spain,NCT00497146,Spain,,,,,,,,,,,,,,
country,NCT00497146::country::Russia,NCT00497146,Russia,,,,,,,,,,,,,,
country,NCT00497146::country::Taiwan,NCT00497146,Taiwan,,,,,,,,,,,,,,
country,NCT00497146::country::Czechia,NCT00497146,Czechia,,,,,,,,,,,,,,
country,NCT00497146::country::Italy,NCT00497146,Italy,,,,,,,,,,,,,,
country,NCT00497146::country::Romania,NCT00497146,Romania,,,,,,,,,,,,,,
country,NCT00497146::country::Poland,NCT00497146,Poland,,,,,,,,,,,,,,
country,NCT00497146::country::United Kingdom,NCT00497146,United Kingdom,,,,,,,,,,,,,,
trial,NCT00004562,NCT00004562,Occluded Artery Trial (OAT),PHASE3,cardiovascular disease,"Cardiovascular Diseases; Heart Diseases; Myocardial Infarction; Heart Failure, Congestive; Heart Failure",OTHER,2201.0,1999-09,2011-06,1.0,1.0,,,,,
arm,NCT00004562::arm::FG000,NCT00004562,Percutaneous Coronary Intervention Group,,,,,,,,,,FG000,Percutaneous Coronary Intervention with stent placement and optimal medical therapy,,,
arm,NCT00004562::arm::FG001,NCT00004562,Medical Therapy Group,,,,,,,,,,FG001,"Conventional medical management, including aspirin, beta blockers, angiotensin converting enzyme (ACE) inhibitors, and risk factor modification, plus percutaneous coronary intervention and coronary st",,,
period,NCT00004562::period::1,NCT00004562,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00004562::outcome::primary::1,NCT00004562,"Number of Patients That Had a First Occurrence of the Primary End Point (Composite of Death From Any Cause, Nonfatal MI, or Class IV HF)",,,,,,,,,,,,,PRIMARY,Measured over a maximum 9-year follow-up period - 6 year median
country,NCT00004562::country::United States,NCT00004562,United States,,,,,,,,,,,,,,
trial,NCT01000727,NCT01000727,The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial,PHASE3,cardiovascular disease,Acute Coronary Syndrome,INDUSTRY,13026.0,2009-12-01,2014-04-24,36.0,914.0,,,,,
arm,NCT01000727::arm::FG000,NCT01000727,Placebo,,,,,,,,,,FG000,Participants were randomized to receive matching placebo once daily.,,,
arm,NCT01000727::arm::FG001,NCT01000727,Darapladib 160 mg,,,,,,,,,,FG001,Participants were randomized to receive darapladib 160 milligram (mg) enteric-coated tablets once daily.,,,
period,NCT01000727::period::1,NCT01000727,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01000727::outcome::primary::1,NCT01000727,Number of Participants With First Occurrence of Any Event in the Composite of Major Coronary Events During the Time Period for Follow-up (FU) of Cardiovascular (CV) Event,,,,,,,,,,,,,PRIMARY,From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 3.80 years)
country,NCT01000727::country::United States,NCT01000727,United States,,,,,,,,,,,,,,
country,NCT01000727::country::Russia,NCT01000727,Russia,,,,,,,,,,,,,,
country,NCT01000727::country::Netherlands,NCT01000727,Netherlands,,,,,,,,,,,,,,
country,NCT01000727::country::Germany,NCT01000727,Germany,,,,,,,,,,,,,,
country,NCT01000727::country::Poland,NCT01000727,Poland,,,,,,,,,,,,,,
country,NCT01000727::country::Brazil,NCT01000727,Brazil,,,,,,,,,,,,,,
country,NCT01000727::country::Canada,NCT01000727,Canada,,,,,,,,,,,,,,
country,NCT01000727::country::India,NCT01000727,India,,,,,,,,,,,,,,
country,NCT01000727::country::China,NCT01000727,China,,,,,,,,,,,,,,
country,NCT01000727::country::Argentina,NCT01000727,Argentina,,,,,,,,,,,,,,
country,NCT01000727::country::Japan,NCT01000727,Japan,,,,,,,,,,,,,,
country,NCT01000727::country::France,NCT01000727,France,,,,,,,,,,,,,,
country,NCT01000727::country::Italy,NCT01000727,Italy,,,,,,,,,,,,,,
country,NCT01000727::country::Ukraine,NCT01000727,Ukraine,,,,,,,,,,,,,,
country,NCT01000727::country::Denmark,NCT01000727,Denmark,,,,,,,,,,,,,,
country,NCT01000727::country::Israel,NCT01000727,Israel,,,,,,,,,,,,,,
country,NCT01000727::country::South Africa,NCT01000727,South Africa,,,,,,,,,,,,,,
country,NCT01000727::country::Hungary,NCT01000727,Hungary,,,,,,,,,,,,,,
country,NCT01000727::country::United Kingdom,NCT01000727,United Kingdom,,,,,,,,,,,,,,
country,NCT01000727::country::Czechia,NCT01000727,Czechia,,,,,,,,,,,,,,
country,NCT01000727::country::Romania,NCT01000727,Romania,,,,,,,,,,,,,,
country,NCT01000727::country::Spain,NCT01000727,Spain,,,,,,,,,,,,,,
country,NCT01000727::country::Australia,NCT01000727,Australia,,,,,,,,,,,,,,
country,NCT01000727::country::Bulgaria,NCT01000727,Bulgaria,,,,,,,,,,,,,,
country,NCT01000727::country::Belgium,NCT01000727,Belgium,,,,,,,,,,,,,,
country,NCT01000727::country::New Zealand,NCT01000727,New Zealand,,,,,,,,,,,,,,
country,NCT01000727::country::Chile,NCT01000727,Chile,,,,,,,,,,,,,,
country,NCT01000727::country::South Korea,NCT01000727,South Korea,,,,,,,,,,,,,,
country,NCT01000727::country::Colombia,NCT01000727,Colombia,,,,,,,,,,,,,,
country,NCT01000727::country::Sweden,NCT01000727,Sweden,,,,,,,,,,,,,,
country,NCT01000727::country::Slovakia,NCT01000727,Slovakia,,,,,,,,,,,,,,
country,NCT01000727::country::Peru,NCT01000727,Peru,,,,,,,,,,,,,,
country,NCT01000727::country::Philippines,NCT01000727,Philippines,,,,,,,,,,,,,,
country,NCT01000727::country::Taiwan,NCT01000727,Taiwan,,,,,,,,,,,,,,
country,NCT01000727::country::Thailand,NCT01000727,Thailand,,,,,,,,,,,,,,
country,NCT01000727::country::Turkey (Türkiye),NCT01000727,Turkey (Türkiye),,,,,,,,,,,,,,
trial,NCT03551496,NCT03551496,The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia,PHASE3,cardiovascular disease,Critical Limb Ischemia,INDUSTRY,201.0,2018-08-31,2023-12-20,5.0,42.0,,,,,
arm,NCT03551496::arm::FG000,NCT03551496,DES BTK,,,,,,,,,,FG000,"Treatment with DES BTK

Drug Eluting Stent - Below the Knee: Treatment arm with DES-BTK, starting with one size of the device - 3.5 mm X 80 mm",,,
arm,NCT03551496::arm::FG001,NCT03551496,Conventional PTA,,,,,,,,,,FG001,"Treatment with standard PTA

Standard PTA Control Arm: The PTA device used must be market-released in the investigational center's geography and the size (ie, diameter, balloon length and catheter len",,,
period,NCT03551496::period::1,NCT03551496,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03551496::outcome::primary::1,NCT03551496,Number of Participants With Primary Patency,,,,,,,,,,,,,PRIMARY,12 months
outcome,NCT03551496::outcome::primary::2,NCT03551496,Number of Participants Free From Major Adverse Events (MAE),,,,,,,,,,,,,PRIMARY,12 months
country,NCT03551496::country::United States,NCT03551496,United States,,,,,,,,,,,,,,
country,NCT03551496::country::Japan,NCT03551496,Japan,,,,,,,,,,,,,,
country,NCT03551496::country::France,NCT03551496,France,,,,,,,,,,,,,,
country,NCT03551496::country::Belgium,NCT03551496,Belgium,,,,,,,,,,,,,,
country,NCT03551496::country::Netherlands,NCT03551496,Netherlands,,,,,,,,,,,,,,
trial,NCT00549302,NCT00549302,Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs,PHASE3,cardiovascular disease,"Hypertension, Pulmonary",INDUSTRY,357.0,2005-12,2012-02,10.0,10.0,,,,,
arm,NCT00549302::arm::FG000,NCT00549302,Tadalafil 20 mg Double Blind,,,,,,,,,,FG000,"Tadalafil, 20 milligram (mg) administered orally as 1 tadalafil tablet and 1 matched placebo tablet once daily from Day 1 up to 52 weeks of treatment.",,,
arm,NCT00549302::arm::FG001,NCT00549302,Tadalafil 40 mg Double-Blind,,,,,,,,,,FG001,"Tadalafil, 40 mg (two 20 mg tablets) administered orally once daily from Day 1 up to 52 weeks of treatment.",,,
arm,NCT00549302::arm::FG002,NCT00549302,Tadalafil 40 mg Open-Label,,,,,,,,,,FG002,"Tadalafil, 40 mg (two 20 mg tablets) administered orally once daily from Week 53 up to Week 243.",,,
period,NCT00549302::period::1,NCT00549302,Double-Blind,,,,,,,,,,,,1.0,,
period,NCT00549302::period::2,NCT00549302,Open-Label,,,,,,,,,,,,2.0,,
outcome,NCT00549302::outcome::primary::1,NCT00549302,Number of Participants With Adverse Events (AEs),,,,,,,,,,,,,PRIMARY,Baseline (Double-Blind Period) up to Week 243 (End of Open-Label Period)
country,NCT00549302::country::United States,NCT00549302,United States,,,,,,,,,,,,,,
country,NCT00549302::country::Belgium,NCT00549302,Belgium,,,,,,,,,,,,,,
country,NCT00549302::country::Canada,NCT00549302,Canada,,,,,,,,,,,,,,
country,NCT00549302::country::France,NCT00549302,France,,,,,,,,,,,,,,
country,NCT00549302::country::Germany,NCT00549302,Germany,,,,,,,,,,,,,,
country,NCT00549302::country::Ireland,NCT00549302,Ireland,,,,,,,,,,,,,,
country,NCT00549302::country::Italy,NCT00549302,Italy,,,,,,,,,,,,,,
country,NCT00549302::country::Japan,NCT00549302,Japan,,,,,,,,,,,,,,
country,NCT00549302::country::Spain,NCT00549302,Spain,,,,,,,,,,,,,,
country,NCT00549302::country::United Kingdom,NCT00549302,United Kingdom,,,,,,,,,,,,,,
trial,NCT03354273,NCT03354273,An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD),PHASE3,cardiovascular disease,Coronary Artery Disease (CAD),INDUSTRY,730.0,2018-06-05,2022-05-05,7.0,53.0,,,,,
arm,NCT03354273::arm::FG000,NCT03354273,Flurpiridaz (18F): All Participants,,,,,,,,,,FG000,Participants received 2 intravenous (IV) boluses of Flurpiridaz (18F) Injection in a large peripheral vein: 1 at rest then 1 during stress on the same day within 60 days prior to the invasive coronary,,,
period,NCT03354273::period::1,NCT03354273,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03354273::outcome::primary::1,NCT03354273,Sensitivity and Specificity of Flurpiridaz (18F) Injection Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) in the Detection of Significant Coronary Artery Disease (CAD) as Defined by Cardiac Catheterization,,,,,,,,,,,,,PRIMARY,Up to 60 days
country,NCT03354273::country::United States,NCT03354273,United States,,,,,,,,,,,,,,
country,NCT03354273::country::Netherlands,NCT03354273,Netherlands,,,,,,,,,,,,,,
country,NCT03354273::country::Canada,NCT03354273,Canada,,,,,,,,,,,,,,
country,NCT03354273::country::France,NCT03354273,France,,,,,,,,,,,,,,
country,NCT03354273::country::Germany,NCT03354273,Germany,,,,,,,,,,,,,,
country,NCT03354273::country::Switzerland,NCT03354273,Switzerland,,,,,,,,,,,,,,
country,NCT03354273::country::Finland,NCT03354273,Finland,,,,,,,,,,,,,,
trial,NCT00763867,NCT00763867,Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study),PHASE3,cardiovascular disease,Heart Failure,OTHER,216.0,2008-09,2012-09,2.0,10.0,,,,,
arm,NCT00763867::arm::FG000,NCT00763867,Placebo,,,,,,,,,,FG000,placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks,,,
arm,NCT00763867::arm::FG001,NCT00763867,Sildenafil,,,,,,,,,,FG001,sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks,,,
period,NCT00763867::period::1,NCT00763867,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00763867::outcome::primary::1,NCT00763867,"Exercise Capacity, as Determined by Peak Oxygen Uptake",,,,,,,,,,,,,PRIMARY,Change from Baseline to Week 24
country,NCT00763867::country::United States,NCT00763867,United States,,,,,,,,,,,,,,
country,NCT00763867::country::Canada,NCT00763867,Canada,,,,,,,,,,,,,,
trial,NCT00065806,NCT00065806,Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE),PHASE3,cardiovascular disease,"Lupus Erythematosus, Systemic",OTHER,221.0,2003-09,2009-12,1.0,1.0,,,,,
arm,NCT00065806::arm::FG000,NCT00065806,1 Atorvastatin,,,,,,,,,,FG000,"Patients will be treated with dietary intervention (AHA Therapeutic Lifestyle Changes \[TLC\] diet, \[http://www.nhlbi.nih.gov/cgi-bin/chd/step2intro.cgi\]), cardiovascular risk factor reduction couns",,,
arm,NCT00065806::arm::FG001,NCT00065806,2 Placebo,,,,,,,,,,FG001,"Patients will be treated with dietary intervention (AHA Therapeutic Lifestyle Changes \[TLC\] diet, \[http://www.nhlbi.nih.gov/cgi-bin/chd/step2intro.cgi\]), cardiovascular risk factor reduction couns",,,
period,NCT00065806::period::1,NCT00065806,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00065806::outcome::primary::1,NCT00065806,Change in Mean-Mean Common Carotid IMT (CIMT),,,,,,,,,,,,,PRIMARY,Change from baseline to 36 months
country,NCT00065806::country::United States,NCT00065806,United States,,,,,,,,,,,,,,
trial,NCT00696436,NCT00696436,An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,1291.0,2008-04,2009-08,6.0,131.0,,,,,
arm,NCT00696436::arm::FG000,NCT00696436,Azilsartan Medoxomil 40 mg QD,,,,,,,,,,FG000,"Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.

Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily",,,
arm,NCT00696436::arm::FG001,NCT00696436,Azilsartan Medoxomil 80 mg QD,,,,,,,,,,FG001,"Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.

Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once dai",,,
arm,NCT00696436::arm::FG002,NCT00696436,Valsartan 320 mg QD,,,,,,,,,,FG002,"Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.

Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four",,,
arm,NCT00696436::arm::FG003,NCT00696436,Olmesartan 40 mg QD,,,,,,,,,,FG003,"Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.

Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four ",,,
arm,NCT00696436::arm::FG004,NCT00696436,Placebo QD,,,,,,,,,,FG004,"Matching placebo, orally, once daily for up to six weeks.",,,
period,NCT00696436::period::1,NCT00696436,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00696436::outcome::primary::1,NCT00696436,Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.,,,,,,,,,,,,,PRIMARY,Baseline and Week 6.
country,NCT00696436::country::United States,NCT00696436,United States,,,,,,,,,,,,,,
country,NCT00696436::country::Argentina,NCT00696436,Argentina,,,,,,,,,,,,,,
country,NCT00696436::country::Mexico,NCT00696436,Mexico,,,,,,,,,,,,,,
country,NCT00696436::country::Brazil,NCT00696436,Brazil,,,,,,,,,,,,,,
country,NCT00696436::country::Peru,NCT00696436,Peru,,,,,,,,,,,,,,
country,NCT00696436::country::Puerto Rico,NCT00696436,Puerto Rico,,,,,,,,,,,,,,
trial,NCT03683030,NCT03683030,Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation,PHASE3,cardiovascular disease,Atrial Fibrillation,INDUSTRY,397.0,2018-10-22,2022-02-18,3.0,41.0,,,,,
arm,NCT03683030::arm::FG000,NCT03683030,Roll-in Phase,,,,,,,,,,FG000,"Participants enrolled in the roll-in phase with drug refractory, symptomatic paroxysmal atrial fibrillation (PAF) and were treated with the HELIOSTAR catheter in conjunction with the LassoStar cathete",,,
arm,NCT03683030::arm::FG001,NCT03683030,Main Study,,,,,,,,,,FG001,"Participants enrolled in the main phase with drug refractory, symptomatic PAF, met eligibility criteria and had insertion of the HELIOSTAR catheter (with or without delivery of RF) in conjunction with",,,
period,NCT03683030::period::1,NCT03683030,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03683030::outcome::primary::1,NCT03683030,Number of Participants With Any Primary Adverse Events (PAE) That Occurred Within 7 Days Following Atrial Fibrillation (AF) Ablation Procedure Using HELIOSTAR Catheter,,,,,,,,,,,,,PRIMARY,Within 7 days post-procedure (Day of procedure = Day 0)
outcome,NCT03683030::outcome::primary::2,NCT03683030,Number of Participants With Effectiveness Success,,,,,,,,,,,,,PRIMARY,From Day 91 up to Day 365 post-procedure (Day of procedure = Day 0)
country,NCT03683030::country::United States,NCT03683030,United States,,,,,,,,,,,,,,
country,NCT03683030::country::China,NCT03683030,China,,,,,,,,,,,,,,
country,NCT03683030::country::Italy,NCT03683030,Italy,,,,,,,,,,,,,,
trial,NCT01156571,NCT01156571,A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX),PHASE3,cardiovascular disease,Atherosclerosis; Percutaneous Coronary Intervention; Acute Coronary Syndrome,INDUSTRY,11145.0,2010-09,2012-12,1.0,1.0,,,,,
arm,NCT01156571::arm::FG000,NCT01156571,Cangrelor Treatment Arm,,,,,,,,,,FG000,"Cangrelor was administered as a 30 µg/kg bolus followed by a 4.0 µg/kg/min cangrelor IV infusion for a minimum of 2 hours or until conclusion of the index procedure, whichever is longer. At the discre",,,
arm,NCT01156571::arm::FG001,NCT01156571,Clopidogrel Treatment Arm,,,,,,,,,,FG001,"Oral clopidogrel was administered as soon as possible following randomization at investigator discretion at a loading dose of either 600 mg or 300 mg as specified by the investigator.

Patients in the",,,
period,NCT01156571::period::1,NCT01156571,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01156571::outcome::primary::1,NCT01156571,"The Composite Incidence of All-cause Mortality, Myocardial Infarction (MI), Ischemia-driven Revascularization (IDR) and Stent Thrombosis (ST)",,,,,,,,,,,,,PRIMARY,48 hours after randomization
country,NCT01156571::country::United States,NCT01156571,United States,,,,,,,,,,,,,,
trial,NCT00446511,NCT00446511,"Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension",PHASE3,cardiovascular disease,Hypertension,INDUSTRY,250.0,2007-06,2009-06,9.0,9.0,,,,,
arm,NCT00446511::arm::FG000,NCT00446511,CKD Patients: Valsartan+Enalapril,,,,,,,,,,FG000,"Chronic kidney disease (CKD) patients assigned to valsartan in the core study received combination therapy of valsartan and enalapril in the extension: Valsartan+enalapril (80/10, 160/20, 320/40 mg, w",,,
arm,NCT00446511::arm::FG001,NCT00446511,CKD Patients: Enalapril,,,,,,,,,,FG001,"Chronic kidney disease (CKD) patients assigned to enalapril in the core study received enalapril and valsartan placebo in the extension: Enalapril (10, 20, 40, weight stratified) and matching placebo ",,,
arm,NCT00446511::arm::FG002,NCT00446511,Non-CKD Patients: Valsartan,,,,,,,,,,FG002,"Non-chronic kidney disease (CKD) patients assigned to valsartan in the core study continued their valsartan monotherapy treatment in the extension: Valsartan (80, 160, 320 mg, weight stratified)+enala",,,
arm,NCT00446511::arm::FG003,NCT00446511,Non-CKD Patients: Enalapril,,,,,,,,,,FG003,"Non-chronic kidney disease (CKD) patients assigned to enalapril in the core study continued their enalapril monotherapy treatment in the extension: Enalapril (10, 20, 40, weight stratified)+valsartan ",,,
period,NCT00446511::period::1,NCT00446511,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00446511::outcome::primary::1,NCT00446511,Number of Patients With Adverse Events,,,,,,,,,,,,,PRIMARY,Start of extension (week 13) to end of study (Week 26 in non-CKD patients and Week 50 in CKD patients)
country,NCT00446511::country::United States,NCT00446511,United States,,,,,,,,,,,,,,
country,NCT00446511::country::Belgium,NCT00446511,Belgium,,,,,,,,,,,,,,
country,NCT00446511::country::France,NCT00446511,France,,,,,,,,,,,,,,
country,NCT00446511::country::Germany,NCT00446511,Germany,,,,,,,,,,,,,,
country,NCT00446511::country::Hungary,NCT00446511,Hungary,,,,,,,,,,,,,,
country,NCT00446511::country::India,NCT00446511,India,,,,,,,,,,,,,,
country,NCT00446511::country::Italy,NCT00446511,Italy,,,,,,,,,,,,,,
country,NCT00446511::country::Poland,NCT00446511,Poland,,,,,,,,,,,,,,
country,NCT00446511::country::Turkey (Türkiye),NCT00446511,Turkey (Türkiye),,,,,,,,,,,,,,
trial,NCT02866175,NCT02866175,Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention,PHASE3,cardiovascular disease,Atrial Fibrillation,INDUSTRY,1506.0,2017-02-24,2019-06-06,18.0,200.0,,,,,
arm,NCT02866175::arm::FG000,NCT02866175,Edoxaban Regimen,,,,,,,,,,FG000,Participants who were randomized to Edoxaban 60 mg once-daily or 30 mg once-daily and clopidogrel 75 mg once-daily (or in the presence of a documented clinical need prasugrel \[5 mg or 10 mg once-dail,,,
arm,NCT02866175::arm::FG001,NCT02866175,Vitamin K Antagonist Regimen,,,,,,,,,,FG001,Participants who were randomized to VKA in combination with clopidogrel 75 mg once-daily (or in the presence of a documented clinical need prasugrel \[5 mg or 10 mg once-daily\] or ticagrelor \[90 mg ,,,
period,NCT02866175::period::1,NCT02866175,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02866175::outcome::primary::1,NCT02866175,Number of Participants With Adjudicated Major or Clinically Relevant Non-major Bleeding As First Event Defined by International Society on Thrombosis and Haemostasis Following Edoxaban-based Regimen Compared With Vitamin K Antagonist (VKA)-Based Regimen,,,,,,,,,,,,,PRIMARY,Day 1 to 12 months postdose
country,NCT02866175::country::Germany,NCT02866175,Germany,,,,,,,,,,,,,,
country,NCT02866175::country::Ukraine,NCT02866175,Ukraine,,,,,,,,,,,,,,
country,NCT02866175::country::Italy,NCT02866175,Italy,,,,,,,,,,,,,,
country,NCT02866175::country::South Korea,NCT02866175,South Korea,,,,,,,,,,,,,,
country,NCT02866175::country::Spain,NCT02866175,Spain,,,,,,,,,,,,,,
country,NCT02866175::country::Hungary,NCT02866175,Hungary,,,,,,,,,,,,,,
country,NCT02866175::country::Poland,NCT02866175,Poland,,,,,,,,,,,,,,
country,NCT02866175::country::France,NCT02866175,France,,,,,,,,,,,,,,
country,NCT02866175::country::Taiwan,NCT02866175,Taiwan,,,,,,,,,,,,,,
country,NCT02866175::country::Belgium,NCT02866175,Belgium,,,,,,,,,,,,,,
country,NCT02866175::country::Romania,NCT02866175,Romania,,,,,,,,,,,,,,
country,NCT02866175::country::Portugal,NCT02866175,Portugal,,,,,,,,,,,,,,
country,NCT02866175::country::United Kingdom,NCT02866175,United Kingdom,,,,,,,,,,,,,,
country,NCT02866175::country::Serbia,NCT02866175,Serbia,,,,,,,,,,,,,,
country,NCT02866175::country::Austria,NCT02866175,Austria,,,,,,,,,,,,,,
country,NCT02866175::country::Lithuania,NCT02866175,Lithuania,,,,,,,,,,,,,,
country,NCT02866175::country::Netherlands,NCT02866175,Netherlands,,,,,,,,,,,,,,
country,NCT02866175::country::Switzerland,NCT02866175,Switzerland,,,,,,,,,,,,,,
trial,NCT00708435,NCT00708435,Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy,PHASE3,cardiovascular disease,Blood Coagulation Disorders; Acute Major Bleeding,INDUSTRY,216.0,2008-06,2010-11,6.0,69.0,,,,,
arm,NCT00708435::arm::FG000,NCT00708435,Beriplex® P/N,,,,,,,,,,FG000,"Beriplex® P/N : Single intravenous infusion as required to treat acute major bleeding; dosage 25, 35 or 50 units/kg depending on baseline INR, amount of coagulation factor IX and body weight.",,,
arm,NCT00708435::arm::FG001,NCT00708435,Fresh Frozen Plasma,,,,,,,,,,FG001,"Fresh frozen plasma : Single intravenous infusion as required to treat acute major bleeding; dosage 10, 12, or 15 mL/kg depending on baseline INR and body weight.",,,
period,NCT00708435::period::1,NCT00708435,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00708435::outcome::primary::1,NCT00708435,Percentage of Participants Achieving Hemostatic Efficacy of Stopping an Ongoing Major Bleed,,,,,,,,,,,,,PRIMARY,At 1 and 4 hours after the end of infusion
outcome,NCT00708435::outcome::primary::2,NCT00708435,Percentage of Participants Who Had a Rapid Decrease of the International Normalized Ratio (INR),,,,,,,,,,,,,PRIMARY,30 minutes after end of infusion
country,NCT00708435::country::United States,NCT00708435,United States,,,,,,,,,,,,,,
country,NCT00708435::country::Russia,NCT00708435,Russia,,,,,,,,,,,,,,
country,NCT00708435::country::Bulgaria,NCT00708435,Bulgaria,,,,,,,,,,,,,,
country,NCT00708435::country::Romania,NCT00708435,Romania,,,,,,,,,,,,,,
country,NCT00708435::country::Belarus,NCT00708435,Belarus,,,,,,,,,,,,,,
country,NCT00708435::country::Ukraine,NCT00708435,Ukraine,,,,,,,,,,,,,,
trial,NCT02994927,NCT02994927,A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis,PHASE3,cardiovascular disease,ANCA-Associated Vasculitis,INDUSTRY,331.0,2017-03-15,2019-11-01,20.0,198.0,,,,,
arm,NCT02994927::arm::FG000,NCT02994927,Prednisone Group,,,,,,,,,,FG000,Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone,,,
arm,NCT02994927::arm::FG001,NCT02994927,Avacopan Group,,,,,,,,,,FG001,Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo,,,
period,NCT02994927::period::1,NCT02994927,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02994927::outcome::primary::1,NCT02994927,Percentage of Subjects Achieving Disease Remission at Week 26,,,,,,,,,,,,,PRIMARY,Week 26
outcome,NCT02994927::outcome::primary::2,NCT02994927,Percentage of Subjects Achieving Sustained Disease Remission at Week 52,,,,,,,,,,,,,PRIMARY,Week 52
country,NCT02994927::country::United States,NCT02994927,United States,,,,,,,,,,,,,,
country,NCT02994927::country::United Kingdom,NCT02994927,United Kingdom,,,,,,,,,,,,,,
country,NCT02994927::country::Germany,NCT02994927,Germany,,,,,,,,,,,,,,
country,NCT02994927::country::Japan,NCT02994927,Japan,,,,,,,,,,,,,,
country,NCT02994927::country::Australia,NCT02994927,Australia,,,,,,,,,,,,,,
country,NCT02994927::country::France,NCT02994927,France,,,,,,,,,,,,,,
country,NCT02994927::country::Italy,NCT02994927,Italy,,,,,,,,,,,,,,
country,NCT02994927::country::Canada,NCT02994927,Canada,,,,,,,,,,,,,,
country,NCT02994927::country::Spain,NCT02994927,Spain,,,,,,,,,,,,,,
country,NCT02994927::country::Switzerland,NCT02994927,Switzerland,,,,,,,,,,,,,,
country,NCT02994927::country::Denmark,NCT02994927,Denmark,,,,,,,,,,,,,,
country,NCT02994927::country::New Zealand,NCT02994927,New Zealand,,,,,,,,,,,,,,
country,NCT02994927::country::Sweden,NCT02994927,Sweden,,,,,,,,,,,,,,
country,NCT02994927::country::Belgium,NCT02994927,Belgium,,,,,,,,,,,,,,
country,NCT02994927::country::Austria,NCT02994927,Austria,,,,,,,,,,,,,,
country,NCT02994927::country::Netherlands,NCT02994927,Netherlands,,,,,,,,,,,,,,
country,NCT02994927::country::Norway,NCT02994927,Norway,,,,,,,,,,,,,,
country,NCT02994927::country::Czechia,NCT02994927,Czechia,,,,,,,,,,,,,,
country,NCT02994927::country::Hungary,NCT02994927,Hungary,,,,,,,,,,,,,,
country,NCT02994927::country::Ireland,NCT02994927,Ireland,,,,,,,,,,,,,,
trial,NCT01539083,NCT01539083,Velcade (Bortezomib) Consolidation After Transplant,PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,256.0,2012-01-13,2018-01-09,3.0,23.0,,,,,
arm,NCT01539083::arm::FG000,NCT01539083,Bortezomib + Cyclophosphamide + Dexamethasone (VCD Induction),,,,,,,,,,FG000,"Participants received bortezomib (Velcade) 1.3 milligram per square meter (mg/m\^2) subcutaneously (SC) on Days 1, 4, 8, and 11; cyclophosphamide 300 mg/m\^2 orally on Days 1, 8, and 15; and dexametha",,,
arm,NCT01539083::arm::FG001,NCT01539083,Thalidomide + Prednisolone (TP Consolidation),,,,,,,,,,FG001,"Participants who completed induction phase entered in the consolidated treatment phase and received thalidomide 100 mg orally, once daily until disease progression (up to maximum of 12 months) and pre",,,
arm,NCT01539083::arm::FG002,NCT01539083,Bortezomib + Thalidomide + Prednisolone (VTP Consolidation),,,,,,,,,,FG002,"Participants who completed induction phase entered in the consolidated treatment phase and received bortezomib 1.3 mg/m\^2 SC every 2 weeks for 32 weeks in addition to thalidomide 100 mg orally, once ",,,
period,NCT01539083::period::1,NCT01539083,Before Randomization (VCD Induction),,,,,,,,,,,,1.0,,
period,NCT01539083::period::2,NCT01539083,After Randomization (TP and VTP),,,,,,,,,,,,2.0,,
outcome,NCT01539083::outcome::primary::1,NCT01539083,Consolidation Phase: Percentage of Participants With Complete Response (CR) and Very Good Partial Response (VGPR) at Month 12,,,,,,,,,,,,,PRIMARY,Month 12
country,NCT01539083::country::Australia,NCT01539083,Australia,,,,,,,,,,,,,,
country,NCT01539083::country::China,NCT01539083,China,,,,,,,,,,,,,,
country,NCT01539083::country::South Korea,NCT01539083,South Korea,,,,,,,,,,,,,,
trial,NCT01582854,NCT01582854,Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI),PHASE3,cardiovascular disease,Post-Stroke Cognitive Impairment (PSCI),INDUSTRY,503.0,2012-06,2014-11,3.0,14.0,,,,,
arm,NCT01582854::arm::FG000,NCT01582854,Actovegin,,,,,,,,,,FG000,"Actovegin 2000 mg solution, intravenous (IV) infusion for up to 20 days followed by 2 actovegin 200 mg, tablets, orally, 3 times a day for up to 6 months.",,,
arm,NCT01582854::arm::FG001,NCT01582854,Placebo,,,,,,,,,,FG001,"Actovegin placebo-matching solution, intravenous (IV) infusion for up to 20 days followed by 2 actovegin placebo-matching, tablets, orally, 3 times a day for up to 6 months.",,,
period,NCT01582854::period::1,NCT01582854,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01582854::outcome::primary::1,NCT01582854,Change From Baseline in Alzheimer's Disease Assessment Scale + Cognitive Subscale Extended Version (ADAS-cog+) at Month 6,,,,,,,,,,,,,PRIMARY,Baseline and Month 6
country,NCT01582854::country::Russia,NCT01582854,Russia,,,,,,,,,,,,,,
country,NCT01582854::country::Belarus,NCT01582854,Belarus,,,,,,,,,,,,,,
country,NCT01582854::country::Kazakhstan,NCT01582854,Kazakhstan,,,,,,,,,,,,,,
trial,NCT04986202,NCT04986202,Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%,PHASE3,cardiovascular disease,Heart Failure With Preserved Ejection Fraction,INDUSTRY,711.0,2021-06-30,2024-03-27,18.0,171.0,,,,,
arm,NCT04986202::arm::FG000,NCT04986202,AZD4831 2.5 mg,,,,,,,,,,FG000,Once-daily oral dosing of AZD4831 2.5 mg,,,
arm,NCT04986202::arm::FG001,NCT04986202,AZD4831 5 mg,,,,,,,,,,FG001,Once-daily oral dosing of AZD4831 5 mg,,,
arm,NCT04986202::arm::FG002,NCT04986202,Placebo,,,,,,,,,,FG002,Once-daily oral dosing of placebo,,,
period,NCT04986202::period::1,NCT04986202,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04986202::outcome::primary::1,NCT04986202,Kansas City Cardiomyopathy Questionnaire -Total Symptom Score,,,,,,,,,,,,,PRIMARY,Baseline - 16 weeks
outcome,NCT04986202::outcome::primary::2,NCT04986202,Six Minute Walk Distance,,,,,,,,,,,,,PRIMARY,Baseline - 16 weeks
country,NCT04986202::country::United States,NCT04986202,United States,,,,,,,,,,,,,,
country,NCT04986202::country::Japan,NCT04986202,Japan,,,,,,,,,,,,,,
country,NCT04986202::country::France,NCT04986202,France,,,,,,,,,,,,,,
country,NCT04986202::country::Taiwan,NCT04986202,Taiwan,,,,,,,,,,,,,,
country,NCT04986202::country::Brazil,NCT04986202,Brazil,,,,,,,,,,,,,,
country,NCT04986202::country::Bulgaria,NCT04986202,Bulgaria,,,,,,,,,,,,,,
country,NCT04986202::country::Poland,NCT04986202,Poland,,,,,,,,,,,,,,
country,NCT04986202::country::Czechia,NCT04986202,Czechia,,,,,,,,,,,,,,
country,NCT04986202::country::Russia,NCT04986202,Russia,,,,,,,,,,,,,,
country,NCT04986202::country::Canada,NCT04986202,Canada,,,,,,,,,,,,,,
country,NCT04986202::country::Sweden,NCT04986202,Sweden,,,,,,,,,,,,,,
country,NCT04986202::country::Belgium,NCT04986202,Belgium,,,,,,,,,,,,,,
country,NCT04986202::country::Denmark,NCT04986202,Denmark,,,,,,,,,,,,,,
country,NCT04986202::country::Slovakia,NCT04986202,Slovakia,,,,,,,,,,,,,,
country,NCT04986202::country::Netherlands,NCT04986202,Netherlands,,,,,,,,,,,,,,
country,NCT04986202::country::Australia,NCT04986202,Australia,,,,,,,,,,,,,,
country,NCT04986202::country::Hungary,NCT04986202,Hungary,,,,,,,,,,,,,,
country,NCT04986202::country::Turkey (Türkiye),NCT04986202,Turkey (Türkiye),,,,,,,,,,,,,,
trial,NCT02813265,NCT02813265,Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease,PHASE3,cardiovascular disease,Dry Eye Syndromes; Keratoconjunctivitis Sicca,INDUSTRY,918.0,2016-06,2017-10,1.0,60.0,,,,,
arm,NCT02813265::arm::FG000,NCT02813265,KPI-121 0.25% Ophthalmic Suspension,,,,,,,,,,FG000,Participants randomized to KPI-121 0.25% Ophthalmic Suspension,,,
arm,NCT02813265::arm::FG001,NCT02813265,Vehicle of KPI-121 0.25% Ophthalmic Suspension,,,,,,,,,,FG001,Participants randomized to Vehicle of KPI-121 0.25% Ophthalmic Suspension,,,
period,NCT02813265::period::1,NCT02813265,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02813265::outcome::primary::1,NCT02813265,Change From Baseline/Visit 2 (Day 1) in Bulbar Conjunctival Hyperemia at Visit 4 (Day 15),,,,,,,,,,,,,PRIMARY,Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)
outcome,NCT02813265::outcome::primary::2,NCT02813265,Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 4 (Day 15),,,,,,,,,,,,,PRIMARY,Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)
outcome,NCT02813265::outcome::primary::3,NCT02813265,Change From Baseline/Visit 2 (Day 1) in Corneal Fluorescein Staining Score at Visit 4 (Day 15),,,,,,,,,,,,,PRIMARY,Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)
outcome,NCT02813265::outcome::primary::4,NCT02813265,Change From Baseline/Visit 2 (Day 1) Ocular Discomfort Severity at Visit 4 (Day 15) in the Subgroup of Participants With More Severe Ocular Discomfort,,,,,,,,,,,,,PRIMARY,Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)
country,NCT02813265::country::United States,NCT02813265,United States,,,,,,,,,,,,,,
trial,NCT00094302,NCT00094302,Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function,PHASE3,cardiovascular disease,"Cardiovascular Diseases; Heart Diseases; Heart Failure, Congestive",OTHER,3445.0,2006-08,2013-06,6.0,270.0,,,,,
arm,NCT00094302::arm::FG000,NCT00094302,Placebo,,,,,,,,,,FG000,Placebo of spironolactone,,,
arm,NCT00094302::arm::FG001,NCT00094302,Spironolactone,,,,,,,,,,FG001,Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (tw,,,
period,NCT00094302::period::1,NCT00094302,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00094302::outcome::primary::1,NCT00094302,"Composite Outcome of Cardiovascular Mortality, Aborted Cardiac Arrest, or Hospitalization for the Management of Heart Failure, Whichever Occurred First",,,,,,,,,,,,,PRIMARY,"Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject."
country,NCT00094302::country::United States,NCT00094302,United States,,,,,,,,,,,,,,
country,NCT00094302::country::Russia,NCT00094302,Russia,,,,,,,,,,,,,,
country,NCT00094302::country::Canada,NCT00094302,Canada,,,,,,,,,,,,,,
country,NCT00094302::country::Argentina,NCT00094302,Argentina,,,,,,,,,,,,,,
country,NCT00094302::country::Brazil,NCT00094302,Brazil,,,,,,,,,,,,,,
country,NCT00094302::country::Georgia,NCT00094302,Georgia,,,,,,,,,,,,,,
trial,NCT01150357,NCT01150357,Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,267.0,2010-06,2014-08,9.0,48.0,,,,,
arm,NCT01150357::arm::FG000,NCT01150357,Aliskiren Low (6.25/12.5/25 mg),,,,,,,,,,FG000,During Phase 1: Participants received body-weight stratified dose of aliskiren capsules (6.25/12.5/25 mg) once daily. Participants whose body weight ≥ 20 kilogram (kg) to less than \< 50 kg received 6,,,
arm,NCT01150357::arm::FG001,NCT01150357,Aliskiren Mid (37.5/75/150 mg),,,,,,,,,,FG001,During Phase 1: Participants received body-weight stratified dose of aliskiren capsules (37.5/75/150 mg) once daily. Participants whose body weight ≥ 20 kg to \< 50 kg received 37.5 mg; ≥50 kg and \< ,,,
arm,NCT01150357::arm::FG002,NCT01150357,Aliskiren High (150/300/600 mg),,,,,,,,,,FG002,During Phase 1: Participants received body-weight stratified dose of aliskiren capsules (150/300/600 mg) once daily. Participants whose body weight ≥ 20 kg to \< 50 kg received 150 mg; ≥50 kg and \< 8,,,
period,NCT01150357::period::1,NCT01150357,Dose Response Phase (Phase 1),,,,,,,,,,,,1.0,,
period,NCT01150357::period::2,NCT01150357,Placebo-controlled Withdrawal (Phase 2),,,,,,,,,,,,2.0,,
outcome,NCT01150357::outcome::primary::1,NCT01150357,Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Endpoint (Phase 1),,,,,,,,,,,,,PRIMARY,Baseline to endpoint (Week 4 or Last observation carried forward (LOCF))
outcome,NCT01150357::outcome::primary::2,NCT01150357,Change in Mean Sitting Systolic Blood Pressure (msSBP) From Week 4 to Endpoint (Phase 2),,,,,,,,,,,,,PRIMARY,Week 4 to endpoint (Week 8 or LOCF)
country,NCT01150357::country::United States,NCT01150357,United States,,,,,,,,,,,,,,
country,NCT01150357::country::Hungary,NCT01150357,Hungary,,,,,,,,,,,,,,
country,NCT01150357::country::Slovakia,NCT01150357,Slovakia,,,,,,,,,,,,,,
country,NCT01150357::country::Belgium,NCT01150357,Belgium,,,,,,,,,,,,,,
country,NCT01150357::country::Turkey (Türkiye),NCT01150357,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01150357::country::Germany,NCT01150357,Germany,,,,,,,,,,,,,,
country,NCT01150357::country::Guatemala,NCT01150357,Guatemala,,,,,,,,,,,,,,
country,NCT01150357::country::Poland,NCT01150357,Poland,,,,,,,,,,,,,,
country,NCT01150357::country::Puerto Rico,NCT01150357,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00444600,NCT00444600,Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema,PHASE3,cardiovascular disease,Diabetic Retinopathy; Diabetic Macular Edema,OTHER,691.0,2007-03,2014-02,1.0,50.0,,,,,
arm,NCT00444600::arm::FG000,NCT00444600,Sham+Prompt Laser,,,,,,,,,,FG000,Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment st,,,
arm,NCT00444600::arm::FG001,NCT00444600,0.5 mg Ranibizumab+Prompt Laser,,,,,,,,,,FG001,0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 week,,,
arm,NCT00444600::arm::FG002,NCT00444600,0.5 mg Ranibizumab+Deferred Laser,,,,,,,,,,FG002,"0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser",,,
arm,NCT00444600::arm::FG003,NCT00444600,4 mg Triamcinolone+Prompt Laser,,,,,,,,,,FG003,"4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at",,,
period,NCT00444600::period::1,NCT00444600,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00444600::outcome::primary::1,NCT00444600,Mean Change in Visual Acuity (Letters) From Baseline to 1 Year Adjusted for Baseline Visual Acuity,,,,,,,,,,,,,PRIMARY,from baseline to 1 Year
outcome,NCT00444600::outcome::primary::2,NCT00444600,Distribution of Change in Visual Acuity (Letters) From Baseline to 1 Year,,,,,,,,,,,,,PRIMARY,from baseline to 1 Year
outcome,NCT00444600::outcome::primary::3,NCT00444600,Change in Visual Acuity From Baseline to 1 Year Among Eyes That Were Pseudophakic at Baseline,,,,,,,,,,,,,PRIMARY,from baseline to 1 Year
outcome,NCT00444600::outcome::primary::4,NCT00444600,Change in Visual Acuity From Baseline to 1 Year Among Eyes That Had Prior Treatment for Diabetic Macular Edema,,,,,,,,,,,,,PRIMARY,from baseline to 1 Year
outcome,NCT00444600::outcome::primary::5,NCT00444600,Change in Visual Acuity From Baseline to 1 Year Grouped by Baseline Visual Acuity Letter Score,,,,,,,,,,,,,PRIMARY,from baseline to 1 Year
outcome,NCT00444600::outcome::primary::6,NCT00444600,Change in Visual Acuity From Baseline to 1 Year Grouped by Optical Coherence Tomography Central Subfield Thickness,,,,,,,,,,,,,PRIMARY,from baseline to 1 Year
outcome,NCT00444600::outcome::primary::7,NCT00444600,Change in Visual Acuity From Baseline to 1 Year Grouped by Diabetic Retinopathy Severity,,,,,,,,,,,,,PRIMARY,from baseline to 1 Year
outcome,NCT00444600::outcome::primary::8,NCT00444600,Change in Visual Acuity From Baseline to 1 Year Grouped by Diffuse vs. Focal Edema as Characterized by the Investigator,,,,,,,,,,,,,PRIMARY,from baseline to 1 Year
country,NCT00444600::country::United States,NCT00444600,United States,,,,,,,,,,,,,,
trial,NCT00291330,NCT00291330,Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism,PHASE3,cardiovascular disease,Thromboembolism,INDUSTRY,2564.0,2006-02,,29.0,250.0,,,,,
arm,NCT00291330::arm::FG000,NCT00291330,Dabigatran 150 mg,,,,,,,,,,FG000,bid (twice daily) oral,,,
arm,NCT00291330::arm::FG001,NCT00291330,Warfarin,,,,,,,,,,FG001,PRN to maintain an INR of 2.0-3.0,,,
period,NCT00291330::period::1,NCT00291330,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00291330::outcome::primary::1,NCT00291330,Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE,,,,,,,,,,,,,PRIMARY,"For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180)"
country,NCT00291330::country::France,NCT00291330,France,,,,,,,,,,,,,,
country,NCT00291330::country::United States,NCT00291330,United States,,,,,,,,,,,,,,
country,NCT00291330::country::Canada,NCT00291330,Canada,,,,,,,,,,,,,,
country,NCT00291330::country::Russia,NCT00291330,Russia,,,,,,,,,,,,,,
country,NCT00291330::country::India,NCT00291330,India,,,,,,,,,,,,,,
country,NCT00291330::country::Czechia,NCT00291330,Czechia,,,,,,,,,,,,,,
country,NCT00291330::country::Brazil,NCT00291330,Brazil,,,,,,,,,,,,,,
country,NCT00291330::country::Spain,NCT00291330,Spain,,,,,,,,,,,,,,
country,NCT00291330::country::Hungary,NCT00291330,Hungary,,,,,,,,,,,,,,
country,NCT00291330::country::Israel,NCT00291330,Israel,,,,,,,,,,,,,,
country,NCT00291330::country::South Africa,NCT00291330,South Africa,,,,,,,,,,,,,,
country,NCT00291330::country::Netherlands,NCT00291330,Netherlands,,,,,,,,,,,,,,
country,NCT00291330::country::Sweden,NCT00291330,Sweden,,,,,,,,,,,,,,
country,NCT00291330::country::Turkey (Türkiye),NCT00291330,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00291330::country::United Kingdom,NCT00291330,United Kingdom,,,,,,,,,,,,,,
country,NCT00291330::country::Argentina,NCT00291330,Argentina,,,,,,,,,,,,,,
country,NCT00291330::country::Australia,NCT00291330,Australia,,,,,,,,,,,,,,
country,NCT00291330::country::Belgium,NCT00291330,Belgium,,,,,,,,,,,,,,
country,NCT00291330::country::Denmark,NCT00291330,Denmark,,,,,,,,,,,,,,
country,NCT00291330::country::Germany,NCT00291330,Germany,,,,,,,,,,,,,,
country,NCT00291330::country::Italy,NCT00291330,Italy,,,,,,,,,,,,,,
country,NCT00291330::country::Portugal,NCT00291330,Portugal,,,,,,,,,,,,,,
country,NCT00291330::country::Slovakia,NCT00291330,Slovakia,,,,,,,,,,,,,,
country,NCT00291330::country::New Zealand,NCT00291330,New Zealand,,,,,,,,,,,,,,
country,NCT00291330::country::Norway,NCT00291330,Norway,,,,,,,,,,,,,,
country,NCT00291330::country::Austria,NCT00291330,Austria,,,,,,,,,,,,,,
country,NCT00291330::country::Greece,NCT00291330,Greece,,,,,,,,,,,,,,
country,NCT00291330::country::Mexico,NCT00291330,Mexico,,,,,,,,,,,,,,
country,NCT00291330::country::Ukraine,NCT00291330,Ukraine,,,,,,,,,,,,,,
trial,NCT00847626,NCT00847626,Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,1711.0,2009-01,2010-07,5.0,99.0,,,,,
arm,NCT00847626::arm::FG000,NCT00847626,Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD,,,,,,,,,,FG000,"Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.",,,
arm,NCT00847626::arm::FG001,NCT00847626,Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD,,,,,,,,,,FG001,"Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.",,,
arm,NCT00847626::arm::FG002,NCT00847626,Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD,,,,,,,,,,FG002,"Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.",,,
arm,NCT00847626::arm::FG003,NCT00847626,Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD,,,,,,,,,,FG003,"Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.",,,
arm,NCT00847626::arm::FG004,NCT00847626,Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD,,,,,,,,,,FG004,"Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.",,,
arm,NCT00847626::arm::FG005,NCT00847626,Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD,,,,,,,,,,FG005,"Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.",,,
arm,NCT00847626::arm::FG006,NCT00847626,Chlorthalidone 12.5 mg QD,,,,,,,,,,FG006,"Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.",,,
arm,NCT00847626::arm::FG007,NCT00847626,Chlorthalidone 25 mg QD,,,,,,,,,,FG007,"Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.",,,
arm,NCT00847626::arm::FG008,NCT00847626,Azilsartan Medoxomil 20 mg QD,,,,,,,,,,FG008,"Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.",,,
arm,NCT00847626::arm::FG009,NCT00847626,Azilsartan Medoxomil 40 mg QD,,,,,,,,,,FG009,"Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.",,,
arm,NCT00847626::arm::FG010,NCT00847626,Azilsartan Medoxomil 80 mg QD,,,,,,,,,,FG010,"Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.",,,
period,NCT00847626::period::1,NCT00847626,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00847626::outcome::primary::1,NCT00847626,"Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pooled Analysis)",,,,,,,,,,,,,PRIMARY,Baseline and Week 8.
outcome,NCT00847626::outcome::primary::2,NCT00847626,"Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pairwise Analysis)",,,,,,,,,,,,,PRIMARY,Baseline and Week 8.
country,NCT00847626::country::United States,NCT00847626,United States,,,,,,,,,,,,,,
country,NCT00847626::country::Peru,NCT00847626,Peru,,,,,,,,,,,,,,
country,NCT00847626::country::Mexico,NCT00847626,Mexico,,,,,,,,,,,,,,
country,NCT00847626::country::Chile,NCT00847626,Chile,,,,,,,,,,,,,,
country,NCT00847626::country::Russia,NCT00847626,Russia,,,,,,,,,,,,,,
trial,NCT01101035,NCT01101035,Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES),PHASE3,cardiovascular disease,Cardiovascular Disease,INDUSTRY,6198.0,2010-04-23,2017-07-18,2.0,203.0,,,,,
arm,NCT01101035::arm::FG000,NCT01101035,Febuxostat,,,,,,,,,,FG000,"Febuxostat 40 mg (or 80 mg beginning on week 4 if serum uric acid level was ≥6.0 mg/dL), tablets, orally, once daily for up to approximately 82 months.",,,
arm,NCT01101035::arm::FG001,NCT01101035,Allopurinol,,,,,,,,,,FG001,"Allopurinol 300 mg to 600 mg (increased in 100 mg increments each month until serum uric acid was \<6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with mildl",,,
period,NCT01101035::period::1,NCT01101035,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01101035::outcome::primary::1,NCT01101035,Percentage of Participants With Primary Major Adverse Cardiovascular Events (MACE) Composite (75% Interim Analysis),,,,,,,,,,,,,PRIMARY,Up to last dose of study drug (approximately 83 months)
outcome,NCT01101035::outcome::primary::2,NCT01101035,Percentage of Participants With Primary MACE Composite (Final Analysis),,,,,,,,,,,,,PRIMARY,Up to last dose of study drug (approximately 83 months)
country,NCT01101035::country::United States,NCT01101035,United States,,,,,,,,,,,,,,
country,NCT01101035::country::Mexico,NCT01101035,Mexico,,,,,,,,,,,,,,
trial,NCT00922480,NCT00922480,Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,506.0,2008-12,2009-09,0.0,0.0,,,,,
arm,NCT00922480::arm::FG000,NCT00922480,Control: Losartan,,,,,,,,,,FG000,"Losartan group

Losartan (Control): Losartan 50 mg \~ 100 mg/po, take one tablets once a day",,,
arm,NCT00922480::arm::FG001,NCT00922480,Test: Fimasartan,,,,,,,,,,FG001,"Fimasartan 60mg, 120mg

Fimasartan: Fimasartan 60 \~ 120mg/po take one tablets once a day",,,
period,NCT00922480::period::1,NCT00922480,Main Study,,,,,,,,,,,,1.0,,
period,NCT00922480::period::2,NCT00922480,Extension Study,,,,,,,,,,,,2.0,,
outcome,NCT00922480::outcome::primary::1,NCT00922480,Diastolic Blood Pressure Change,,,,,,,,,,,,,PRIMARY,baseline and 12 weeks
trial,NCT00300469,NCT00300469,Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood,PHASE3,cardiovascular disease,Mixed Dyslipidemia; Coronary Heart Disease; Dyslipidemia,INDUSTRY,613.0,2006-03,,1.0,1.0,,,,,
arm,NCT00300469::arm::FG000,NCT00300469,ABT-335 + 20 mg Atorvastatin,,,,,,,,,,FG000,ABT-335 + 20 mg atorvastatin combination therapy once daily,,,
arm,NCT00300469::arm::FG001,NCT00300469,ABT-335 + 40 mg Atorvastatin,,,,,,,,,,FG001,ABT-335 + 40 mg atorvastatin combination therapy once daily,,,
arm,NCT00300469::arm::FG002,NCT00300469,ABT-335,,,,,,,,,,FG002,ABT-335 monotherapy once daily,,,
arm,NCT00300469::arm::FG003,NCT00300469,20 mg Atorvastatin,,,,,,,,,,FG003,20 mg atorvastatin monotherapy once daily,,,
arm,NCT00300469::arm::FG004,NCT00300469,40 mg Atorvastatin,,,,,,,,,,FG004,40 mg atorvastatin monotherapy once daily,,,
arm,NCT00300469::arm::FG005,NCT00300469,80 mg Atorvastatin,,,,,,,,,,FG005,80 mg atorvastatin monotherapy once daily,,,
period,NCT00300469::period::1,NCT00300469,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00300469::outcome::primary::1,NCT00300469,Mean Percent Change in Triglycerides From Baseline to Final Visit,,,,,,,,,,,,,PRIMARY,Baseline to 12 Weeks (Final Visit)
outcome,NCT00300469::outcome::primary::2,NCT00300469,Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Final Visit,,,,,,,,,,,,,PRIMARY,Baseline to 12 Weeks (Final Visit)
outcome,NCT00300469::outcome::primary::3,NCT00300469,Mean Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Final Visit,,,,,,,,,,,,,PRIMARY,Baseline to 12 Weeks (Final Visit)
country,NCT00300469::country::United States,NCT00300469,United States,,,,,,,,,,,,,,
trial,NCT00797862,NCT00797862,Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,1254.0,2008-11,2010-11,10.0,10.0,,,,,
arm,NCT00797862::arm::FG000,NCT00797862,Aliskiren+Amlodipine,,,,,,,,,,FG000,"Eligible participants received oral aliskiren 150 mg + amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of the combination treatment increased to aliskiren 300 mg + amlodipine 10 mg dai",,,
arm,NCT00797862::arm::FG001,NCT00797862,Aliskiren Start-Amlodipine Add On,,,,,,,,,,FG001,"Eligible participants received oral aliskiren 150 mg daily from week 1-8. From week 8 - 16, the dose of aliskiren increased to 300 mg daily. From week 16-24, amlodipine 10 mg was added to the aliskire",,,
arm,NCT00797862::arm::FG002,NCT00797862,Amlodipine Start-Aliskiren Add On,,,,,,,,,,FG002,"Eligible participants received oral amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of amlodipine increased to 10 mg daily. From week 16-24, aliskiren 300 mg was added to the amlodipin",,,
period,NCT00797862::period::1,NCT00797862,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00797862::outcome::primary::1,NCT00797862,"Overall Mean Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Over 8, 16 and 24 Weeks",,,,,,,,,,,,,PRIMARY,"Baseline, 8 weeks, 16 weeks, and 24 weeks"
outcome,NCT00797862::outcome::primary::2,NCT00797862,Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Week 24,,,,,,,,,,,,,PRIMARY,Baseline to 24 weeks
country,NCT00797862::country::Canada,NCT00797862,Canada,,,,,,,,,,,,,,
country,NCT00797862::country::Costa Rica,NCT00797862,Costa Rica,,,,,,,,,,,,,,
country,NCT00797862::country::France,NCT00797862,France,,,,,,,,,,,,,,
country,NCT00797862::country::Germany,NCT00797862,Germany,,,,,,,,,,,,,,
country,NCT00797862::country::Greece,NCT00797862,Greece,,,,,,,,,,,,,,
country,NCT00797862::country::Guatemala,NCT00797862,Guatemala,,,,,,,,,,,,,,
country,NCT00797862::country::South Africa,NCT00797862,South Africa,,,,,,,,,,,,,,
country,NCT00797862::country::Switzerland,NCT00797862,Switzerland,,,,,,,,,,,,,,
country,NCT00797862::country::United Kingdom,NCT00797862,United Kingdom,,,,,,,,,,,,,,
country,NCT00797862::country::Venezuela,NCT00797862,Venezuela,,,,,,,,,,,,,,
trial,NCT00434161,NCT00434161,A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma,PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,281.0,2006-12,2012-05,1.0,1.0,,,,,
arm,NCT00434161::arm::FG000,NCT00434161,Palifermin Before Only,,,,,,,,,,FG000,Subjects to receive palifermin before-high dose chemotherapy (total 3 doses) and matched placebo after-high dose chemotherapy (total 3 doses). Daily dose of intravenous (IV) 60 µg/kg/day of palifermin,,,
arm,NCT00434161::arm::FG001,NCT00434161,Placebo,,,,,,,,,,FG001,"Subjects to receive matched placebo before- and after-high dose chemotherapy (total of 6 doses). Daily dose of intravenous (IV) 60 µg/kg/day of placebo as 1 bolus IV injection on Days -6, 5 and -4 bef",,,
arm,NCT00434161::arm::FG002,NCT00434161,Palifermin Before and After,,,,,,,,,,FG002,"Subjects to receive palifermin before- and after-high dose chemotherapy (total of 6 doses). Daily dose of intravenous (IV) 60 µg/kg/day of palifermin as 1 bolus IV injection on Days -6, 5 and -4 befor",,,
period,NCT00434161::period::1,NCT00434161,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00434161::outcome::primary::1,NCT00434161,"Maximum Severity of Oral Mucositis (World Health Organization (WHO) Grades 0/1, 2, 3, or 4)",,,,,,,,,,,,,PRIMARY,at Day 32
outcome,NCT00434161::outcome::primary::2,NCT00434161,Incidence of Cataract Development or Progression at Month 12.,,,,,,,,,,,,,PRIMARY,12 months
country,NCT00434161::country::Germany,NCT00434161,Germany,,,,,,,,,,,,,,
trial,NCT01396083,NCT01396083,Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO),PHASE3,cardiovascular disease,Visual Impairment; Macular Edema; Central Retinal Vein Occlusion,INDUSTRY,243.0,2011-08,2014-01,4.0,64.0,,,,,
arm,NCT01396083::arm::FG000,NCT01396083,Ranibizumab,,,,,,,,,,FG000,Injections consisted of 0.5 mg/0.05 ml solution to be injected intravitreally,,,
arm,NCT01396083::arm::FG001,NCT01396083,Dexamethasone,,,,,,,,,,FG001,Intravitreal implant as per commercial label (700 μg Dexamethasone; long acting release (LAR) over 6 months,,,
period,NCT01396083::period::1,NCT01396083,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01396083::outcome::primary::1,NCT01396083,Mean Average BCVA Change From Month 1 Through Month 6 to Baseline,,,,,,,,,,,,,PRIMARY,"Baseline, month 6"
country,NCT01396083::country::Germany,NCT01396083,Germany,,,,,,,,,,,,,,
country,NCT01396083::country::United Kingdom,NCT01396083,United Kingdom,,,,,,,,,,,,,,
country,NCT01396083::country::Hungary,NCT01396083,Hungary,,,,,,,,,,,,,,
country,NCT01396083::country::Poland,NCT01396083,Poland,,,,,,,,,,,,,,
trial,NCT00553267,NCT00553267,Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,947.0,2007-11,,14.0,97.0,,,,,
arm,NCT00553267::arm::FG000,NCT00553267,Amlodipine 10mg,,,,,,,,,,FG000,,,,
arm,NCT00553267::arm::FG001,NCT00553267,Telmisartan 40mg and Amlodipine 10mg,,,,,,,,,,FG001,,,,
arm,NCT00553267::arm::FG002,NCT00553267,Telmisartan 80mg and Amlodipine 10mg,,,,,,,,,,FG002,,,,
period,NCT00553267::period::1,NCT00553267,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00553267::outcome::primary::1,NCT00553267,Change From Baseline in Trough Seated Diastolic Blood Pressure,,,,,,,,,,,,,PRIMARY,Baseline and end of study (8 weeks or last value on treatment)
country,NCT00553267::country::United Kingdom,NCT00553267,United Kingdom,,,,,,,,,,,,,,
country,NCT00553267::country::Ukraine,NCT00553267,Ukraine,,,,,,,,,,,,,,
country,NCT00553267::country::Bulgaria,NCT00553267,Bulgaria,,,,,,,,,,,,,,
country,NCT00553267::country::Russia,NCT00553267,Russia,,,,,,,,,,,,,,
country,NCT00553267::country::Czechia,NCT00553267,Czechia,,,,,,,,,,,,,,
country,NCT00553267::country::Slovakia,NCT00553267,Slovakia,,,,,,,,,,,,,,
country,NCT00553267::country::Spain,NCT00553267,Spain,,,,,,,,,,,,,,
country,NCT00553267::country::Austria,NCT00553267,Austria,,,,,,,,,,,,,,
country,NCT00553267::country::Ireland,NCT00553267,Ireland,,,,,,,,,,,,,,
country,NCT00553267::country::Australia,NCT00553267,Australia,,,,,,,,,,,,,,
country,NCT00553267::country::Turkey (Türkiye),NCT00553267,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00553267::country::Italy,NCT00553267,Italy,,,,,,,,,,,,,,
country,NCT00553267::country::New Zealand,NCT00553267,New Zealand,,,,,,,,,,,,,,
country,NCT00553267::country::Switzerland,NCT00553267,Switzerland,,,,,,,,,,,,,,
trial,NCT01217307,NCT01217307,Metformin to Reduce Heart Failure After Myocardial Infarction,PHASE3,cardiovascular disease,ST Elevation Myocardial Infarction (STEMI); Coronary Artery Disease; Heart Failure; Diabetes,OTHER,380.0,2011-01,2015-10,1.0,1.0,,,,,
arm,NCT01217307::arm::FG000,NCT01217307,Metformin,,,,,,,,,,FG000,"metformin 500mg twice daily during 4 months

Metformin: Metformin 500mg twice daily during 4 months",,,
arm,NCT01217307::arm::FG001,NCT01217307,Placebo,,,,,,,,,,FG001,"Placebo twice daily during 4 months

Placebo: Placebo twice daily during 4 months",,,
period,NCT01217307::period::1,NCT01217307,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01217307::outcome::primary::1,NCT01217307,Improvement in Left Ventricular Ejection Fraction,,,,,,,,,,,,,PRIMARY,4 months
country,NCT01217307::country::Netherlands,NCT01217307,Netherlands,,,,,,,,,,,,,,
trial,NCT00525824,NCT00525824,"12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe",PHASE3,cardiovascular disease,Hypercholesterolemia; Coronary Heart Disease; Atherosclerosis,INDUSTRY,1743.0,2007-08,2008-09,9.0,9.0,,,,,
arm,NCT00525824::arm::FG000,NCT00525824,R10 to R10 + E10,,,,,,,,,,FG000,Rosuvastatin 10 mg followed by Rosuvastatin 10 mg + Ezetimibe 10 mg,,,
arm,NCT00525824::arm::FG001,NCT00525824,R20 to R20 + E10,,,,,,,,,,FG001,Rosuvastatin 20 mg followed by Rosuvastatin 20 mg + Ezetimibe 10 mg,,,
arm,NCT00525824::arm::FG002,NCT00525824,S40 to S40 + E10,,,,,,,,,,FG002,Simvastatin 40 mg followed by Simvastatin 40 mg + Ezetimibe 10 mg,,,
arm,NCT00525824::arm::FG003,NCT00525824,S80 to S80 + E10,,,,,,,,,,FG003,Simvastatin 80 mg followed by Simvastatin 80 mg + Ezetimibe 10 mg,,,
period,NCT00525824::period::1,NCT00525824,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00525824::outcome::primary::1,NCT00525824,Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks Combination Treatment,,,,,,,,,,,,,PRIMARY,Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)
country,NCT00525824::country::United States,NCT00525824,United States,,,,,,,,,,,,,,
country,NCT00525824::country::Argentina,NCT00525824,Argentina,,,,,,,,,,,,,,
country,NCT00525824::country::Brazil,NCT00525824,Brazil,,,,,,,,,,,,,,
country,NCT00525824::country::Chile,NCT00525824,Chile,,,,,,,,,,,,,,
country,NCT00525824::country::Colombia,NCT00525824,Colombia,,,,,,,,,,,,,,
country,NCT00525824::country::Lithuania,NCT00525824,Lithuania,,,,,,,,,,,,,,
country,NCT00525824::country::Netherlands,NCT00525824,Netherlands,,,,,,,,,,,,,,
country,NCT00525824::country::Peru,NCT00525824,Peru,,,,,,,,,,,,,,
country,NCT00525824::country::Venezuela,NCT00525824,Venezuela,,,,,,,,,,,,,,
trial,NCT03381742,NCT03381742,Efficacy and Safety of Low-dose Ticagrelor,PHASE3,cardiovascular disease,Coronary Artery Disease,OTHER,3043.0,2017-12-13,2019-02-13,1.0,1.0,,,,,
arm,NCT03381742::arm::FG000,NCT03381742,Ticagrelor 45mg Bidpo.,,,,,,,,,,FG000,"To observe the efficacy and safety of ticagrelor 45mg bidpo. in patients with coronary artery disease.

Ticagrelor: ticagrelor 45 mg twice daily for 5 consecutive days at least.",,,
arm,NCT03381742::arm::FG001,NCT03381742,Ticagrelor 90mg Bidpo.,,,,,,,,,,FG001,"To observe the efficacy and safety of ticagrelor 90mg bidpo. in patients with coronary artery disease.

ticagrelor: ticagrelor 90 mg twice daily for 5 consecutive days at least.",,,
arm,NCT03381742::arm::FG002,NCT03381742,Clopidogrel 75mg Qdpo.,,,,,,,,,,FG002,"To observe the efficacy and safety of clopidogrel 75mg qdpo. in patients with coronary artery disease.

clopidogrel: clopidogrel 75 mg once daily for 5 consecutive days at least.",,,
arm,NCT03381742::arm::FG003,NCT03381742,Ticagrelor 90mg Qdpo.,,,,,,,,,,FG003,"To observe the efficacy and safety of ticagrelor 90mg qdpo. in patients with coronary artery disease.

Ticagrelor: ticagrelor 90 mg once daily for 5 consecutive days at least.",,,
period,NCT03381742::period::1,NCT03381742,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03381742::outcome::primary::1,NCT03381742,ADP-induced Inhibition of Platelet Aggregation,,,,,,,,,,,,,PRIMARY,up to 5 days
outcome,NCT03381742::outcome::primary::2,NCT03381742,Number of Participants With Bleeding (Major or Minor Bleeding),,,,,,,,,,,,,PRIMARY,up to 5 days
country,NCT03381742::country::China,NCT03381742,China,,,,,,,,,,,,,,
trial,NCT00075088,NCT00075088,Tele-Electrocardiography in Emergency Cardiac Care,PHASE3,cardiovascular disease,Myocardial Infarction; Chest Pain,OTHER,794.0,2003-09,2009-06,1.0,1.0,,,,,
arm,NCT00075088::arm::FG000,NCT00075088,Electrocardiogram (ECG) Intervention,,,,,,,,,,FG000,Patients randomized to the experimental group had their ECGs printed out in the target ED with an audible voice alarm. Print-out of the pre-hospital ECG in the target ED was the intervention.,,,
arm,NCT00075088::arm::FG001,NCT00075088,Routine Clinical Practice,,,,,,,,,,FG001,"Control patients had an ECG conducted after hospital arrival, as was the standard of care in the county.",,,
period,NCT00075088::period::1,NCT00075088,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00075088::outcome::primary::1,NCT00075088,Hospital Time to Treatment for Patients With Unstable Angina/Non-STEMI,,,,,,,,,,,,,PRIMARY,Day 1
outcome,NCT00075088::outcome::primary::2,NCT00075088,Hospital Time to Treatment for Patients With ST-elevation Myocardial Infarction (STEMI),,,,,,,,,,,,,PRIMARY,Day 1
country,NCT00075088::country::United States,NCT00075088,United States,,,,,,,,,,,,,,
trial,NCT00281580,NCT00281580,Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,1461.0,2006-04,,5.0,136.0,,,,,
arm,NCT00281580::arm::FG000,NCT00281580,Placebo (Pl),,,,,,,,,,FG000,"placebo tablet plus encapsulated placebo tablet, QD in morning",,,
arm,NCT00281580::arm::FG001,NCT00281580,Telmisartan 20 mg (T20),,,,,,,,,,FG001,"Telmisartan 20mg tablet, QD in morning",,,
arm,NCT00281580::arm::FG002,NCT00281580,Telmisartan 40 mg (T40),,,,,,,,,,FG002,"Telmisartan 40mg tablet, QD in morning",,,
arm,NCT00281580::arm::FG003,NCT00281580,Telmisartan 80 mg (T80),,,,,,,,,,FG003,"Telmisartan 80mg tablet, QD in morning",,,
arm,NCT00281580::arm::FG004,NCT00281580,Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5),,,,,,,,,,FG004,"T20mg tab plus encapsulated A2.5mg capsule, QD in morning",,,
arm,NCT00281580::arm::FG005,NCT00281580,Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5),,,,,,,,,,FG005,"T20mg tab plus encapsulated A5mg capsule, QD in morning",,,
arm,NCT00281580::arm::FG006,NCT00281580,Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10),,,,,,,,,,FG006,"T20mg tab plus 2 encapsulated A5mg capsule, QD in morning",,,
arm,NCT00281580::arm::FG007,NCT00281580,Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5),,,,,,,,,,FG007,"T40mg tab plus encapsulated A2.5mg capsule, QD in morning",,,
arm,NCT00281580::arm::FG008,NCT00281580,Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5),,,,,,,,,,FG008,"T40mg tab plus encapsulated A5mg capsule, QD in morning",,,
arm,NCT00281580::arm::FG009,NCT00281580,Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10),,,,,,,,,,FG009,"T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning",,,
arm,NCT00281580::arm::FG010,NCT00281580,Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5),,,,,,,,,,FG010,"T80mg tab plus encapsulated A2.5mg capsule, QD in morning",,,
arm,NCT00281580::arm::FG011,NCT00281580,Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5),,,,,,,,,,FG011,"T80mg tab plus encapsulated A5mg capsule, QD in morning",,,
arm,NCT00281580::arm::FG012,NCT00281580,Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10),,,,,,,,,,FG012,"T80mg tab plus 2 encapsulated A5mg capsule, QD in morning",,,
arm,NCT00281580::arm::FG013,NCT00281580,Amlodipine 2.5 mg (A2.5),,,,,,,,,,FG013,"encapsulated Amlodipine 2.5 mg capsule, QD in morning",,,
arm,NCT00281580::arm::FG014,NCT00281580,Amlodipine 5 mg (A5),,,,,,,,,,FG014,"encapsulated Amlodipine 5 mg capsule, QD in morning",,,
arm,NCT00281580::arm::FG015,NCT00281580,Amlodipine 10 mg (A10),,,,,,,,,,FG015,"2 encapsulated Amlodipine 5 mg capsule, QD in morning",,,
period,NCT00281580::period::1,NCT00281580,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00281580::outcome::primary::1,NCT00281580,Change From Baseline at 8 Weeks in Seated Trough Cuff Mean Diastolic Blood Pressure (DBP) (Observed Telmisartan Effect),,,,,,,,,,,,,PRIMARY,Baseline to end-of-study (up to 8 weeks) visit (Last Observation Carried Forward (LOCF))
outcome,NCT00281580::outcome::primary::2,NCT00281580,Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Telmisartan Effects),,,,,,,,,,,,,PRIMARY,Baseline to end-of-study (up to 8 weeks) visit (LOCF)
outcome,NCT00281580::outcome::primary::3,NCT00281580,Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Observed Amlodipine Effects),,,,,,,,,,,,,PRIMARY,Baseline to end-of-study (up to 8 weeks) visit (LOCF)
outcome,NCT00281580::outcome::primary::4,NCT00281580,Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Amlodipine Effects),,,,,,,,,,,,,PRIMARY,Baseline to end-of-study (up to 8 weeks) visit (LOCF)
outcome,NCT00281580::outcome::primary::5,NCT00281580,Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Observed Treatment Effects),,,,,,,,,,,,,PRIMARY,End-of-study visit (LOCF)
outcome,NCT00281580::outcome::primary::6,NCT00281580,Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects),,,,,,,,,,,,,PRIMARY,Baseline to end-of-study (up to 8 weeks) visit (LOCF)
outcome,NCT00281580::outcome::primary::7,NCT00281580,"Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects, Excluding Pl)",,,,,,,,,,,,,PRIMARY,Baseline to end-of-study (up to 8 weeks) visit (LOCF)
outcome,NCT00281580::outcome::primary::8,NCT00281580,Change From Baseline in Seated Trough Cuff Mean DBP (Observed Telmisartan Effect),,,,,,,,,,,,,PRIMARY,Baseline to end-of-study (up to 8 weeks) visit (LOCF)
outcome,NCT00281580::outcome::primary::9,NCT00281580,Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Telmisartan Effects),,,,,,,,,,,,,PRIMARY,Baseline to end-of-study (up to 8 weeks) visit (LOCF)
outcome,NCT00281580::outcome::primary::10,NCT00281580,Change From Baseline in Seated Trough Cuff Mean DBP (Observed Amlodipine Effects),,,,,,,,,,,,,PRIMARY,Up to 8 weeks (LOCF)
outcome,NCT00281580::outcome::primary::11,NCT00281580,Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Amlodipine Effects),,,,,,,,,,,,,PRIMARY,Up to 8 weeks (LOCF)
outcome,NCT00281580::outcome::primary::12,NCT00281580,Change From Baseline in Seated Trough Cuff Mean DBP (Observed Treatment Effects),,,,,,,,,,,,,PRIMARY,Up to 8 weeks (LOCF)
outcome,NCT00281580::outcome::primary::13,NCT00281580,Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects),,,,,,,,,,,,,PRIMARY,Up to 8 weeks (LOCF)
outcome,NCT00281580::outcome::primary::14,NCT00281580,"Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects, Excluding Pl)",,,,,,,,,,,,,PRIMARY,Up to 8 weeks (LOCF)
country,NCT00281580::country::United States,NCT00281580,United States,,,,,,,,,,,,,,
country,NCT00281580::country::South Africa,NCT00281580,South Africa,,,,,,,,,,,,,,
country,NCT00281580::country::Mexico,NCT00281580,Mexico,,,,,,,,,,,,,,
country,NCT00281580::country::Argentina,NCT00281580,Argentina,,,,,,,,,,,,,,
country,NCT00281580::country::Brazil,NCT00281580,Brazil,,,,,,,,,,,,,,
trial,NCT00591773,NCT00591773,Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,551.0,2007-09,2009-03,1.0,46.0,,,,,
arm,NCT00591773::arm::FG000,NCT00591773,Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD,,,,,,,,,,FG000,"Azilsartan medoxomil 40 mg, tablets, orally, once daily and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.",,,
arm,NCT00591773::arm::FG001,NCT00591773,Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD,,,,,,,,,,FG001,"Azilsartan medoxomil 80 mg, tablets, orally, once daily and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.",,,
arm,NCT00591773::arm::FG002,NCT00591773,Chlorthalidone 25 mg QD,,,,,,,,,,FG002,"Chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.",,,
period,NCT00591773::period::1,NCT00591773,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00591773::outcome::primary::1,NCT00591773,Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.,,,,,,,,,,,,,PRIMARY,Baseline and Week 6.
country,NCT00591773::country::United States,NCT00591773,United States,,,,,,,,,,,,,,
trial,NCT02195479,NCT02195479,A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma,PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,706.0,2014-12-09,2024-08-07,24.0,160.0,,,,,
arm,NCT02195479::arm::FG000,NCT02195479,"Velcade, Melphalan and Prednisone (VMP)",,,,,,,,,,FG000,"Participants received Velcade (bortezomib) 1.3 milligrams per square meter (mg/m\^2) as subcutaneous (SC) injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, ",,,
arm,NCT02195479::arm::FG001,NCT02195479,"Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)",,,,,,,,,,FG001,"Participants received Velcade 1.3 mg/m\^2 as SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m\^2, orally o",,,
period,NCT02195479::period::1,NCT02195479,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02195479::outcome::primary::1,NCT02195479,Progression Free Survival (PFS),,,,,,,,,,,,,PRIMARY,From randomization (Day -3) up to 2.4 years
country,NCT02195479::country::Japan,NCT02195479,Japan,,,,,,,,,,,,,,
country,NCT02195479::country::Spain,NCT02195479,Spain,,,,,,,,,,,,,,
country,NCT02195479::country::Poland,NCT02195479,Poland,,,,,,,,,,,,,,
country,NCT02195479::country::United States,NCT02195479,United States,,,,,,,,,,,,,,
country,NCT02195479::country::Australia,NCT02195479,Australia,,,,,,,,,,,,,,
country,NCT02195479::country::Brazil,NCT02195479,Brazil,,,,,,,,,,,,,,
country,NCT02195479::country::Russia,NCT02195479,Russia,,,,,,,,,,,,,,
country,NCT02195479::country::Belgium,NCT02195479,Belgium,,,,,,,,,,,,,,
country,NCT02195479::country::United Kingdom,NCT02195479,United Kingdom,,,,,,,,,,,,,,
country,NCT02195479::country::Germany,NCT02195479,Germany,,,,,,,,,,,,,,
country,NCT02195479::country::Turkey (Türkiye),NCT02195479,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02195479::country::Ukraine,NCT02195479,Ukraine,,,,,,,,,,,,,,
country,NCT02195479::country::South Korea,NCT02195479,South Korea,,,,,,,,,,,,,,
country,NCT02195479::country::Bulgaria,NCT02195479,Bulgaria,,,,,,,,,,,,,,
country,NCT02195479::country::Czechia,NCT02195479,Czechia,,,,,,,,,,,,,,
country,NCT02195479::country::Serbia,NCT02195479,Serbia,,,,,,,,,,,,,,
country,NCT02195479::country::Argentina,NCT02195479,Argentina,,,,,,,,,,,,,,
country,NCT02195479::country::Greece,NCT02195479,Greece,,,,,,,,,,,,,,
country,NCT02195479::country::Hungary,NCT02195479,Hungary,,,,,,,,,,,,,,
country,NCT02195479::country::Romania,NCT02195479,Romania,,,,,,,,,,,,,,
country,NCT02195479::country::Croatia,NCT02195479,Croatia,,,,,,,,,,,,,,
country,NCT02195479::country::Portugal,NCT02195479,Portugal,,,,,,,,,,,,,,
country,NCT02195479::country::Georgia,NCT02195479,Georgia,,,,,,,,,,,,,,
country,NCT02195479::country::North Macedonia,NCT02195479,North Macedonia,,,,,,,,,,,,,,
trial,NCT01976988,NCT01976988,Prospective Study on Preoperative Versus Postoperative Venous Thromboprophylaxis in Patients Undergoing Major Colorectal Surgery,PHASE3,cardiovascular disease,Venous Thromboembolism,OTHER,410.0,2013-09,2015-05,1.0,1.0,,,,,
arm,NCT01976988::arm::FG000,NCT01976988,Post-op Heparin,,,,,,,,,,FG000,Postoperative venous thromboprophylaxis (Control Arm/current standard practice: subcutaneous Heparin 5000 units started 23 hours after the end of surgery and continued every 8 hours for the remainder ,,,
arm,NCT01976988::arm::FG001,NCT01976988,Pre-op Heparin,,,,,,,,,,FG001,"Treatment arm: subcutaneous Heparin 5000 Units given in the preoperative area prior to surgery, then 8 hours after surgery and continued every 8 hours for the remainder of the patients hospital course",,,
period,NCT01976988::period::1,NCT01976988,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01976988::outcome::primary::1,NCT01976988,Number of Participants With Postoperative VTE Within 48 Hours After Surgery,,,,,,,,,,,,,PRIMARY,48 hour postop period
country,NCT01976988::country::United States,NCT01976988,United States,,,,,,,,,,,,,,
trial,NCT00300430,NCT00300430,"Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.",PHASE3,cardiovascular disease,Dyslipidemia; Coronary Heart Disease; Mixed Dyslipidemia,INDUSTRY,1911.0,2006-09,,1.0,1.0,,,,,
arm,NCT00300430::arm::FG000,NCT00300430,ABT-335 + 20 mg Rosuvastatin,,,,,,,,,,FG000,ABT-335 and 20 mg rosuvastatin combination therapy,,,
arm,NCT00300430::arm::FG001,NCT00300430,ABT-335 + 40 mg Simvastatin,,,,,,,,,,FG001,ABT-335 and 40 mg simvastatin combination therapy,,,
arm,NCT00300430::arm::FG002,NCT00300430,ABT-335 + 40 mg Atorvastatin,,,,,,,,,,FG002,ABT-335 and 40 mg atorvastatin combination therapy,,,
period,NCT00300430::period::1,NCT00300430,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00300430::outcome::primary::1,NCT00300430,"Percentage of Subjects Reporting Adverse Events During Combination Therapy, Either in the Preceding Double-blind Studies or in This Open-label Study",,,,,,,,,,,,,PRIMARY,Anytime after initiation of combination therapy (either in the double-blind or open-label study) to within 30 days after the last dose of combination therapy
country,NCT00300430::country::United States,NCT00300430,United States,,,,,,,,,,,,,,
trial,NCT00168298,NCT00168298,A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion,PHASE3,cardiovascular disease,Macular Edema; Retinal Vein Occlusion,INDUSTRY,668.0,2004-11-01,2008-09-05,13.0,13.0,,,,,
arm,NCT00168298::arm::FG000,NCT00168298,700 µg Dexamethasone,,,,,,,,,,FG000,700 µg dexamethasone intravitreal implant administered on Day 0 and Day 180.,,,
arm,NCT00168298::arm::FG001,NCT00168298,350 µg Dexamethasone Followed by 700 µg Dexamethasone,,,,,,,,,,FG001,350 µg dexamethasone intravitreal implant administered on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.,,,
arm,NCT00168298::arm::FG002,NCT00168298,Sham Injection Followed by 700 µg Dexamethasone,,,,,,,,,,FG002,Sham injection on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.,,,
period,NCT00168298::period::1,NCT00168298,Double-Blind Period,,,,,,,,,,,,1.0,,
period,NCT00168298::period::2,NCT00168298,Open-Label Period,,,,,,,,,,,,2.0,,
outcome,NCT00168298::outcome::primary::1,NCT00168298,Number of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity (BCVA) in the Study Eye,,,,,,,,,,,,,PRIMARY,Day 180
country,NCT00168298::country::United States,NCT00168298,United States,,,,,,,,,,,,,,
country,NCT00168298::country::Brazil,NCT00168298,Brazil,,,,,,,,,,,,,,
country,NCT00168298::country::Canada,NCT00168298,Canada,,,,,,,,,,,,,,
country,NCT00168298::country::Colombia,NCT00168298,Colombia,,,,,,,,,,,,,,
country,NCT00168298::country::Hong Kong,NCT00168298,Hong Kong,,,,,,,,,,,,,,
country,NCT00168298::country::India,NCT00168298,India,,,,,,,,,,,,,,
country,NCT00168298::country::Italy,NCT00168298,Italy,,,,,,,,,,,,,,
country,NCT00168298::country::New Zealand,NCT00168298,New Zealand,,,,,,,,,,,,,,
country,NCT00168298::country::Poland,NCT00168298,Poland,,,,,,,,,,,,,,
country,NCT00168298::country::Singapore,NCT00168298,Singapore,,,,,,,,,,,,,,
country,NCT00168298::country::South Korea,NCT00168298,South Korea,,,,,,,,,,,,,,
country,NCT00168298::country::Spain,NCT00168298,Spain,,,,,,,,,,,,,,
country,NCT00168298::country::United Kingdom,NCT00168298,United Kingdom,,,,,,,,,,,,,,
trial,NCT00414609,NCT00414609,Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE),PHASE3,cardiovascular disease,Myocardial Infarction,INDUSTRY,820.0,2006-12,2011-07,23.0,23.0,,,,,
arm,NCT00414609::arm::FG000,NCT00414609,Placebo_Core,,,,,,,,,,FG000,Placebo for 36 weeks once daily in the morning,,,
arm,NCT00414609::arm::FG001,NCT00414609,Aliskiren_Core,,,,,,,,,,FG001,"Aliskiren ascending doses: 75 mg tablet for 1st week, 150 mg for 2nd week, 300 mg for the next 34 weeks orally once daily in the morning.",,,
arm,NCT00414609::arm::FG002,NCT00414609,Aliskiren_Extension,,,,,,,,,,FG002,"Patients from both the arms of the core study who completed core study and signed informed consent form were included in this arm of extension study.

Patients received 150 mg aliskiren tablet orally ",,,
period,NCT00414609::period::1,NCT00414609,Core Study,,,,,,,,,,,,1.0,,
period,NCT00414609::period::2,NCT00414609,Extension Study,,,,,,,,,,,,2.0,,
outcome,NCT00414609::outcome::primary::1,NCT00414609,Core Study: Change From Baseline in Left Ventricular End Systolic Volume (LVESV) as Measured by Echocardiography at End of Study.,,,,,,,,,,,,,PRIMARY,Baseline and final visit (after 26 to 36 weeks of treatment)
outcome,NCT00414609::outcome::primary::2,NCT00414609,"Extension Study: Percentage of Participants With Deaths, Serious Adverse Events (SAEs), Discontinuation for Adverse Events (AEs) and Discontinuations for Abnormal Lab Values",,,,,,,,,,,,,PRIMARY,Extension study (24 weeks)
country,NCT00414609::country::United States,NCT00414609,United States,,,,,,,,,,,,,,
country,NCT00414609::country::Argentina,NCT00414609,Argentina,,,,,,,,,,,,,,
country,NCT00414609::country::Belgium,NCT00414609,Belgium,,,,,,,,,,,,,,
country,NCT00414609::country::Canada,NCT00414609,Canada,,,,,,,,,,,,,,
country,NCT00414609::country::Colombia,NCT00414609,Colombia,,,,,,,,,,,,,,
country,NCT00414609::country::Czechia,NCT00414609,Czechia,,,,,,,,,,,,,,
country,NCT00414609::country::Denmark,NCT00414609,Denmark,,,,,,,,,,,,,,
country,NCT00414609::country::Germany,NCT00414609,Germany,,,,,,,,,,,,,,
country,NCT00414609::country::Hungary,NCT00414609,Hungary,,,,,,,,,,,,,,
country,NCT00414609::country::India,NCT00414609,India,,,,,,,,,,,,,,
country,NCT00414609::country::Israel,NCT00414609,Israel,,,,,,,,,,,,,,
country,NCT00414609::country::Italy,NCT00414609,Italy,,,,,,,,,,,,,,
country,NCT00414609::country::Netherlands,NCT00414609,Netherlands,,,,,,,,,,,,,,
country,NCT00414609::country::Norway,NCT00414609,Norway,,,,,,,,,,,,,,
country,NCT00414609::country::Poland,NCT00414609,Poland,,,,,,,,,,,,,,
country,NCT00414609::country::Russia,NCT00414609,Russia,,,,,,,,,,,,,,
country,NCT00414609::country::Slovakia,NCT00414609,Slovakia,,,,,,,,,,,,,,
country,NCT00414609::country::South Korea,NCT00414609,South Korea,,,,,,,,,,,,,,
country,NCT00414609::country::Spain,NCT00414609,Spain,,,,,,,,,,,,,,
country,NCT00414609::country::Sweden,NCT00414609,Sweden,,,,,,,,,,,,,,
country,NCT00414609::country::Turkey (Türkiye),NCT00414609,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00414609::country::United Kingdom,NCT00414609,United Kingdom,,,,,,,,,,,,,,
country,NCT00414609::country::Venezuela,NCT00414609,Venezuela,,,,,,,,,,,,,,
trial,NCT00888355,NCT00888355,MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,428.0,1992-05,1993-02,0.0,0.0,,,,,
arm,NCT00888355::arm::FG000,NCT00888355,Placebo,,,,,,,,,,FG000,Losartan placebo orally once daily for 12 weeks,,,
arm,NCT00888355::arm::FG001,NCT00888355,Losartan 25 mg q.d.,,,,,,,,,,FG001,Losartan 25 mg orally once daily (q.d.) for 12 weeks,,,
arm,NCT00888355::arm::FG002,NCT00888355,Losartan 50 mg q.d.,,,,,,,,,,FG002,Losartan 50 mg orally once daily (q.d.) for 12 weeks,,,
arm,NCT00888355::arm::FG003,NCT00888355,Losartan 25 mg (b.i.d.),,,,,,,,,,FG003,Losartan 25 mg orally twice daily (b.i.d.) for 12 weeks,,,
period,NCT00888355::period::1,NCT00888355,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00888355::outcome::primary::1,NCT00888355,Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12,,,,,,,,,,,,,PRIMARY,"At baseline, and at 12 weeks (24 hours after last morning dose and 12 hours after last PM dose)"
trial,NCT02596126,NCT02596126,Secondary Prevention of Cardiovascular Disease in the Elderly Trial,PHASE3,cardiovascular disease,Myocardial Infarction; Cardiovascular Disease,OTHER,2499.0,2016-07,2022-03-31,7.0,113.0,,,,,
arm,NCT02596126::arm::FG000,NCT02596126,Treatment Prevention for Secondary CV,,,,,,,,,,FG000,Patients allocated to the usual care arm will receive standard of care therapies for secondary prevention according to the ESC guidelines. Drugs and doses will be left at the discretion of the treatin,,,
arm,NCT02596126::arm::FG001,NCT02596126,Cardiovascular Polypill,,,,,,,,,,FG001,"Patients allocated to the experimental arm will receive a cardiovascular polypill containing aspirin 100 mg, atorvastatin (40 or 20 mg) and ramipril (2.5, 5 or 10 mg) taken orally once a day.

Cardiov",,,
period,NCT02596126::period::1,NCT02596126,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02596126::outcome::primary::1,NCT02596126,Major Cardiovascular Adverse Events (MACE),,,,,,,,,,,,,PRIMARY,Up to 5 years
country,NCT02596126::country::Spain,NCT02596126,Spain,,,,,,,,,,,,,,
country,NCT02596126::country::Italy,NCT02596126,Italy,,,,,,,,,,,,,,
country,NCT02596126::country::Germany,NCT02596126,Germany,,,,,,,,,,,,,,
country,NCT02596126::country::France,NCT02596126,France,,,,,,,,,,,,,,
country,NCT02596126::country::Poland,NCT02596126,Poland,,,,,,,,,,,,,,
country,NCT02596126::country::Czechia,NCT02596126,Czechia,,,,,,,,,,,,,,
country,NCT02596126::country::Hungary,NCT02596126,Hungary,,,,,,,,,,,,,,
trial,NCT02900378,NCT02900378,randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure,PHASE3,cardiovascular disease,Chronic Heart Failure With Reduced Ejection Fraction,INDUSTRY,621.0,2016-12-20,2018-04-11,19.0,119.0,,,,,
arm,NCT02900378::arm::FG000,NCT02900378,LCZ696 (Sacubitril/Valsartan),,,,,,,,,,FG000,LCZ696 (Sacubitril/Valsartan) or its matching placebo twice a day for 12 weeks. Patients began study treatment (Sacubitril/Valsartan) at a specific dose level according to their pre-study ACEI/ARB dos,,,
arm,NCT02900378::arm::FG001,NCT02900378,Enalapril,,,,,,,,,,FG001,"Enalapril or its matching placebo twice a day for 12 weeks. Patients began study treatment (Enalapril) at a specific dose level according to their pre-study ACEI/ARB dose (1 (2.5 mg), 2a (5 mg)) or ma",,,
period,NCT02900378::period::1,NCT02900378,Randomization (Visit 2),,,,,,,,,,,,1.0,,
period,NCT02900378::period::2,NCT02900378,Treatment Phase,,,,,,,,,,,,2.0,,
outcome,NCT02900378::outcome::primary::1,NCT02900378,Change From Baseline (Week 0) in the Six Minute Walk Test (6MWT) at End of Study (Week 12),,,,,,,,,,,,,PRIMARY,"Baseline, Week 12"
outcome,NCT02900378::outcome::primary::2,NCT02900378,Change From Baseline (Week 0) in Mean Daily Non-sedentary Daytime Activity at End of Study (Week 12),,,,,,,,,,,,,PRIMARY,"Baseline, Week 12"
country,NCT02900378::country::Germany,NCT02900378,Germany,,,,,,,,,,,,,,
country,NCT02900378::country::Spain,NCT02900378,Spain,,,,,,,,,,,,,,
country,NCT02900378::country::United Kingdom,NCT02900378,United Kingdom,,,,,,,,,,,,,,
country,NCT02900378::country::Czechia,NCT02900378,Czechia,,,,,,,,,,,,,,
country,NCT02900378::country::Netherlands,NCT02900378,Netherlands,,,,,,,,,,,,,,
country,NCT02900378::country::Belgium,NCT02900378,Belgium,,,,,,,,,,,,,,
country,NCT02900378::country::Bulgaria,NCT02900378,Bulgaria,,,,,,,,,,,,,,
country,NCT02900378::country::Denmark,NCT02900378,Denmark,,,,,,,,,,,,,,
country,NCT02900378::country::Greece,NCT02900378,Greece,,,,,,,,,,,,,,
country,NCT02900378::country::Latvia,NCT02900378,Latvia,,,,,,,,,,,,,,
country,NCT02900378::country::Poland,NCT02900378,Poland,,,,,,,,,,,,,,
country,NCT02900378::country::Estonia,NCT02900378,Estonia,,,,,,,,,,,,,,
country,NCT02900378::country::France,NCT02900378,France,,,,,,,,,,,,,,
country,NCT02900378::country::Lithuania,NCT02900378,Lithuania,,,,,,,,,,,,,,
country,NCT02900378::country::Sweden,NCT02900378,Sweden,,,,,,,,,,,,,,
country,NCT02900378::country::Finland,NCT02900378,Finland,,,,,,,,,,,,,,
country,NCT02900378::country::Iceland,NCT02900378,Iceland,,,,,,,,,,,,,,
country,NCT02900378::country::Ireland,NCT02900378,Ireland,,,,,,,,,,,,,,
country,NCT02900378::country::Norway,NCT02900378,Norway,,,,,,,,,,,,,,
trial,NCT02757872,NCT02757872,Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives,PHASE3,cardiovascular disease,Hypertension; Kidney Diseases,OTHER,2232.0,2016-04,2022-03-31,1.0,1.0,,,,,
arm,NCT02757872::arm::FG000,NCT02757872,Vitamin D and Omega-3 Fatty Acids,,,,,,,,,,FG000,"Dietary Supplement: Vitamin D Vitamin D3 (cholecalciferol), one 2000 IU capsule per day.

Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams",,,
arm,NCT02757872::arm::FG001,NCT02757872,Vitamin D and Omega-3 Fatty Acid Placebo,,,,,,,,,,FG001,"Dietary Supplement: Vitamin D Vitamin D3 (cholecalciferol), one 2000 IU capsule per day.

Dietary Supplement: Omega-3 fatty acid placebo (Fish oil placebo)",,,
arm,NCT02757872::arm::FG002,NCT02757872,Vitamin D Placebo and Omega-3 Fatty Acids,,,,,,,,,,FG002,"Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of doco",,,
arm,NCT02757872::arm::FG003,NCT02757872,Vitamin D Placebo and Omega-3 Fatty Acids Placebo,,,,,,,,,,FG003,"Dietary Supplement: Vitamin D placebo. One capsule per day Vitamin D3 placebo

Dietary Supplement: Omega-3 Fatty acid Placebo (Fish oil placebo). One capsule per day",,,
period,NCT02757872::period::1,NCT02757872,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02757872::outcome::primary::1,NCT02757872,Change in Estimated Glomerular Filtration Rate,,,,,,,,,,,,,PRIMARY,Baseline and 4 years
country,NCT02757872::country::United States,NCT02757872,United States,,,,,,,,,,,,,,
trial,NCT00440193,NCT00440193,Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study,PHASE3,cardiovascular disease,Venous Thrombosis,INDUSTRY,3449.0,2007-03,2010-04,34.0,324.0,,,,,
arm,NCT00440193::arm::FG000,NCT00440193,"Rivaroxaban (Xarelto, BAY59-7939)",,,,,,,,,,FG000,"Participants were to receive rivaroxaban 15 mg oral tablet twice daily for 3 weeks, followed by 20 mg once daily",,,
arm,NCT00440193::arm::FG001,NCT00440193,Enoxaparin/VKA,,,,,,,,,,FG001,"Participants were to receive 1.0 mg/kg enoxaparin twice daily (subcutaneous) for at least 5 days, plus vitamin K antagonist (VKA) (oral) at individually titrated doses to achieve a target internationa",,,
period,NCT00440193::period::1,NCT00440193,Treatment Period,,,,,,,,,,,,1.0,,
period,NCT00440193::period::2,NCT00440193,Observational Period,,,,,,,,,,,,2.0,,
outcome,NCT00440193::outcome::primary::1,NCT00440193,Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment,,,,,,,,,,,,,PRIMARY,"3-, 6- or 12-month study treatment period"
country,NCT00440193::country::France,NCT00440193,France,,,,,,,,,,,,,,
country,NCT00440193::country::Germany,NCT00440193,Germany,,,,,,,,,,,,,,
country,NCT00440193::country::United States,NCT00440193,United States,,,,,,,,,,,,,,
country,NCT00440193::country::Australia,NCT00440193,Australia,,,,,,,,,,,,,,
country,NCT00440193::country::China,NCT00440193,China,,,,,,,,,,,,,,
country,NCT00440193::country::Italy,NCT00440193,Italy,,,,,,,,,,,,,,
country,NCT00440193::country::Poland,NCT00440193,Poland,,,,,,,,,,,,,,
country,NCT00440193::country::Israel,NCT00440193,Israel,,,,,,,,,,,,,,
country,NCT00440193::country::Belgium,NCT00440193,Belgium,,,,,,,,,,,,,,
country,NCT00440193::country::South Africa,NCT00440193,South Africa,,,,,,,,,,,,,,
country,NCT00440193::country::Brazil,NCT00440193,Brazil,,,,,,,,,,,,,,
country,NCT00440193::country::Netherlands,NCT00440193,Netherlands,,,,,,,,,,,,,,
country,NCT00440193::country::Czechia,NCT00440193,Czechia,,,,,,,,,,,,,,
country,NCT00440193::country::Spain,NCT00440193,Spain,,,,,,,,,,,,,,
country,NCT00440193::country::Hungary,NCT00440193,Hungary,,,,,,,,,,,,,,
country,NCT00440193::country::Austria,NCT00440193,Austria,,,,,,,,,,,,,,
country,NCT00440193::country::India,NCT00440193,India,,,,,,,,,,,,,,
country,NCT00440193::country::New Zealand,NCT00440193,New Zealand,,,,,,,,,,,,,,
country,NCT00440193::country::South Korea,NCT00440193,South Korea,,,,,,,,,,,,,,
country,NCT00440193::country::Sweden,NCT00440193,Sweden,,,,,,,,,,,,,,
country,NCT00440193::country::Switzerland,NCT00440193,Switzerland,,,,,,,,,,,,,,
country,NCT00440193::country::United Kingdom,NCT00440193,United Kingdom,,,,,,,,,,,,,,
country,NCT00440193::country::Canada,NCT00440193,Canada,,,,,,,,,,,,,,
country,NCT00440193::country::Indonesia,NCT00440193,Indonesia,,,,,,,,,,,,,,
country,NCT00440193::country::Taiwan,NCT00440193,Taiwan,,,,,,,,,,,,,,
country,NCT00440193::country::Denmark,NCT00440193,Denmark,,,,,,,,,,,,,,
country,NCT00440193::country::Norway,NCT00440193,Norway,,,,,,,,,,,,,,
country,NCT00440193::country::Thailand,NCT00440193,Thailand,,,,,,,,,,,,,,
country,NCT00440193::country::Hong Kong,NCT00440193,Hong Kong,,,,,,,,,,,,,,
country,NCT00440193::country::Philippines,NCT00440193,Philippines,,,,,,,,,,,,,,
country,NCT00440193::country::Singapore,NCT00440193,Singapore,,,,,,,,,,,,,,
country,NCT00440193::country::Finland,NCT00440193,Finland,,,,,,,,,,,,,,
country,NCT00440193::country::Malaysia,NCT00440193,Malaysia,,,,,,,,,,,,,,
country,NCT00440193::country::Puerto Rico,NCT00440193,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00093015,NCT00093015,Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT),PHASE3,cardiovascular disease,Kidney Disease; Diabetes Mellitus; Anemia,INDUSTRY,4038.0,2004-08-01,2009-07-01,0.0,0.0,,,,,
arm,NCT00093015::arm::FG000,NCT00093015,Placebo,,,,,,,,,,FG000,Subcutaneous placebo when hemoglobin concentration was ≥ 9.0 g/dL. Received subcutaneous rescue therapy (once monthly) with darbepoetin alfa in a blinded fashion if the hemoglobin concentration was \<,,,
arm,NCT00093015::arm::FG001,NCT00093015,Darbepoetin Alfa,,,,,,,,,,FG001,"Subcutaneous darbepoetin alfa at a starting dose of 75 mcg/kg once every 2 weeks, titrated to maintain a hemoglobin concentration of 13.0 g/dL. Dosing was switched to once monthly when two consecutive",,,
period,NCT00093015::period::1,NCT00093015,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00093015::outcome::primary::1,NCT00093015,"Time to All-cause Mortality or Cardiovascular (CV) Events Including Hospitalization Due to Acute Myocardial Ischemia, Congestive Heart Failure (CHF), Myocardial Infarction (MI), and Cerebrovascular Accident (CVA)",,,,,,,,,,,,,PRIMARY,"Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first"
outcome,NCT00093015::outcome::primary::2,NCT00093015,Time to All-cause Mortality or End Stage Renal Disease (ESRD),,,,,,,,,,,,,PRIMARY,"Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first"
trial,NCT00002850,NCT00002850,Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy,PHASE3,cardiovascular disease,Infection; Multiple Myeloma,OTHER,212.0,1997-03,2012-01,3.0,45.0,,,,,
arm,NCT00002850::arm::FG000,NCT00002850,Ciprofloxacin or Ofloxacin,,,,,,,,,,FG000,ciprofloxacin: Begin oral ciprofloxacin when they start chemotherapy for multiple myeloma. Assigned treatment consists of ciprofloxacin (Cipro® 500 mg po tablet every 12 hours for two months. The pati,,,
arm,NCT00002850::arm::FG001,NCT00002850,TMP-SMX,,,,,,,,,,FG001,trimethoprim-sulfamethoxazole: Begin oral Trimethoprim-sulfamethoxazole when they start chemotherapy for multiple myeloma. Assigned treatment consists of TMP-SMX (Septra® or Bactrim®) 1 DS tablet \[TM,,,
arm,NCT00002850::arm::FG002,NCT00002850,Observation,,,,,,,,,,FG002,Patients observed without intervention and evaluated for SBI for the first 2 months of treatment.,,,
period,NCT00002850::period::1,NCT00002850,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00002850::outcome::primary::1,NCT00002850,Proportion of Patients Experiencing a Serious Bacterial Infection,,,,,,,,,,,,,PRIMARY,First three months of chemotherapy
country,NCT00002850::country::United States,NCT00002850,United States,,,,,,,,,,,,,,
country,NCT00002850::country::Peru,NCT00002850,Peru,,,,,,,,,,,,,,
country,NCT00002850::country::South Africa,NCT00002850,South Africa,,,,,,,,,,,,,,
trial,NCT01302691,NCT01302691,MK-0954E Study in Participants With Hypertension (MK-0954E-357),PHASE3,cardiovascular disease,Hypertension,INDUSTRY,327.0,2011-01-01,2012-04-01,0.0,0.0,,,,,
arm,NCT01302691::arm::FG000,NCT01302691,L50/H12.5/A5,,,,,,,,,,FG000,"Participants receive 1 tablet, containing 50 mg losartan potassium (L50), 12.5 mg hydrochlorothiazide (H12.5), and 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks.",,,
arm,NCT01302691::arm::FG001,NCT01302691,L50 + A5,,,,,,,,,,FG001,"Participants receive tablet, containing 50 mg losartan potassium (L50), and tablet containing 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks.",,,
period,NCT01302691::period::1,NCT01302691,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01302691::outcome::primary::1,NCT01302691,Change in Mean Trough Sitting Diastolic Blood Pressure (SiDBP),,,,,,,,,,,,,PRIMARY,Baseline and Week 8
outcome,NCT01302691::outcome::primary::2,NCT01302691,Percentage of Participants Who Experience ≥1 Adverse Event (AE),,,,,,,,,,,,,PRIMARY,up to 14 days after last dose of study drug (up to 10 weeks)
outcome,NCT01302691::outcome::primary::3,NCT01302691,Percentage of Participants Who Experience ≥1 Drug-related AE,,,,,,,,,,,,,PRIMARY,up to 14 days after last dose of study drug (up to 10 weeks)
outcome,NCT01302691::outcome::primary::4,NCT01302691,Percentage of Participants Who Experience ≥1 Serious Adverse Event (SAE),,,,,,,,,,,,,PRIMARY,up to 14 days after last dose of study drug (up to 10 weeks)
outcome,NCT01302691::outcome::primary::5,NCT01302691,Percentage of Participants Who Experience ≥1 Drug-related SAE,,,,,,,,,,,,,PRIMARY,up to 14 days after last dose of study drug (up to 10 weeks)
outcome,NCT01302691::outcome::primary::6,NCT01302691,Percentage of Participants Who Had Study Drug Stopped Due to an AE,,,,,,,,,,,,,PRIMARY,up to 8 weeks
trial,NCT00695955,NCT00695955,One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,669.0,2007-06,2010-05,3.0,41.0,,,,,
arm,NCT00695955::arm::FG000,NCT00695955,Azilsartan Medoxomil,,,,,,,,,,FG000,"Cohort 1: Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tol",,,
period,NCT00695955::period::1,NCT00695955,Cohort 1,,,,,,,,,,,,1.0,,
period,NCT00695955::period::2,NCT00695955,Cohort 2,,,,,,,,,,,,2.0,,
outcome,NCT00695955::outcome::primary::1,NCT00695955,Number of Participants Reporting One or More Treatment-emergent Adverse Events From Day 1 Through End of the Study - Cohort 1.,,,,,,,,,,,,,PRIMARY,56 weeks.
outcome,NCT00695955::outcome::primary::2,NCT00695955,Number of Participants Reporting One or More Treatment-emergent Adverse Events From Day 1 Through End of the Study - Cohort 2.,,,,,,,,,,,,,PRIMARY,56 weeks.
country,NCT00695955::country::United States,NCT00695955,United States,,,,,,,,,,,,,,
country,NCT00695955::country::Chile,NCT00695955,Chile,,,,,,,,,,,,,,
country,NCT00695955::country::Mexico,NCT00695955,Mexico,,,,,,,,,,,,,,
trial,NCT02715726,NCT02715726,Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia,PHASE3,cardiovascular disease,Hypercholesterolemia,INDUSTRY,615.0,2016-07-27,2018-08-06,3.0,62.0,,,,,
arm,NCT02715726::arm::FG000,NCT02715726,Ezetimibe 10 mg,,,,,,,,,,FG000,Oral ezetimibe 10 mg capsule once daily with or without food for 24 Weeks and subcutaneous placebo injection for alirocumab every 2 weeks (Q2W) for 22 weeks added to lipid modifying therapy (LMT).,,,
arm,NCT02715726::arm::FG001,NCT02715726,Alirocumab 75 mg Q2W/up to 150 mg Q2W,,,,,,,,,,FG001,Subcutaneous injection of alirocumab 75 mg Q2W and oral placebo capsule for ezetimibe once daily with or without food added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from W,,,
period,NCT02715726::period::1,NCT02715726,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02715726::outcome::primary::1,NCT02715726,Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: Intent-to-treat (ITT) Analysis,,,,,,,,,,,,,PRIMARY,From Baseline to Week 24
country,NCT02715726::country::China,NCT02715726,China,,,,,,,,,,,,,,
country,NCT02715726::country::India,NCT02715726,India,,,,,,,,,,,,,,
country,NCT02715726::country::Thailand,NCT02715726,Thailand,,,,,,,,,,,,,,
trial,NCT00887250,NCT00887250,A Study to Investigate the Antihypertensive Efficacy of MK0954,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,366.0,1991-12,1992-11,0.0,0.0,,,,,
arm,NCT00887250::arm::FG000,NCT00887250,Placebo,,,,,,,,,,FG000,Losartan placebo orally once daily for 12 weeks,,,
arm,NCT00887250::arm::FG001,NCT00887250,Losartan 50 mg,,,,,,,,,,FG001,Losartan 50 mg orally once daily for 12 weeks,,,
arm,NCT00887250::arm::FG002,NCT00887250,Losartan 50/100 mg,,,,,,,,,,FG002,"Losartan orally once daily for 12 weeks, initiated as 50 mg and titrated to 100 mg for nonresponders (SiDBP ≥90 mm Hg) after 6 weeks",,,
period,NCT00887250::period::1,NCT00887250,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00887250::outcome::primary::1,NCT00887250,Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12,,,,,,,,,,,,,PRIMARY,At baseline and at 12 weeks (24 hours post dose)
trial,NCT02592824,NCT02592824,Glutamate for Metabolic Intervention in Coronary Surgery II,PHASE3,cardiovascular disease,Coronary Artery Bypass Surgery; Postoperative Complications; Heart Failure,OTHER,321.0,2015-11-15,2020-10-30,1.0,4.0,,,,,
arm,NCT02592824::arm::FG000,NCT02592824,Intravenous Glutamate Infusion,,,,,,,,,,FG000,Intravenous infusion of 0.125M L-glutamic acid solution at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for tw,,,
arm,NCT02592824::arm::FG001,NCT02592824,Intravenous Saline Infusion,,,,,,,,,,FG001,Intravenous infusion of saline at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping ,,,
period,NCT02592824::period::1,NCT02592824,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02592824::outcome::primary::1,NCT02592824,Postoperative Increase of Plasma NT-proBNP,,,,,,,,,,,,,PRIMARY,from the day before surgery to the third postoperative day
country,NCT02592824::country::Sweden,NCT02592824,Sweden,,,,,,,,,,,,,,
trial,NCT03080883,NCT03080883,Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy,PHASE3,cardiovascular disease,Cerebral Vein Thrombosis; Deep Vein Thrombosis; Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Pulmonary Embolism; Splanchnic Vein Thrombosis,OTHER,370.0,2017-07-14,2025-05-09,1.0,32.0,,,,,
arm,NCT03080883::arm::FG000,NCT03080883,Group I (2.5mg Dose Apixaban),,,,,,,,,,FG000,"Patients receive lower dose apixaban PO BID for 365 days. \>

\> Apixaban: Given PO",,,
arm,NCT03080883::arm::FG001,NCT03080883,Group II (5mg Dose Apixaban),,,,,,,,,,FG001,"Patients receive higher dose apixaban PO BID for 365 days. \>

\> Apixaban: Given PO",,,
period,NCT03080883::period::1,NCT03080883,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03080883::outcome::primary::1,NCT03080883,CIF of Major or Clinically Relevant Non-major Bleeding Combined With Death as Competing Risk,,,,,,,,,,,,,PRIMARY,12 months
country,NCT03080883::country::United States,NCT03080883,United States,,,,,,,,,,,,,,
trial,NCT00391469,NCT00391469,Induction of Mild Hypothermia Following Out-of-hospital Cardiac Arrest,PHASE3,cardiovascular disease,Out-of-hospital Cardiac Arrest,OTHER,1359.0,2007-12,2013-08,1.0,1.0,,,,,
arm,NCT00391469::arm::FG000,NCT00391469,Intervention,,,,,,,,,,FG000,Rapid infusion of 2 liters of 4oC normal saline: Patients randomized to mild hypothermia will receive a rapid infusion of 2 liters of 4oC normal saline prior to arrival in the emergency room. Patients,,,
arm,NCT00391469::arm::FG001,NCT00391469,Control,,,,,,,,,,FG001,standard of care,,,
period,NCT00391469::period::1,NCT00391469,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00391469::outcome::primary::1,NCT00391469,Number Alive at Hospital Discharge,,,,,,,,,,,,,PRIMARY,at hospital discharge
country,NCT00391469::country::United States,NCT00391469,United States,,,,,,,,,,,,,,
trial,NCT01307046,NCT01307046,MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352),PHASE3,cardiovascular disease,Hypertension,INDUSTRY,336.0,2011-03-29,2012-02-07,0.0,0.0,,,,,
arm,NCT01307046::arm::FG000,NCT01307046,MK-0954A,,,,,,,,,,FG000,"Participants administered MK-0954A, Placebo for Losartan 50 mg , and Placebo for Losartan 100 mg orally, once daily for 8 weeks.",,,
arm,NCT01307046::arm::FG001,NCT01307046,Losartan,,,,,,,,,,FG001,"Participants administered Losartan 100 mg, Placebo for MK-0954A, and Placebo for Losartan 50 mg orally, once daily for 8 weeks.",,,
period,NCT01307046::period::1,NCT01307046,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01307046::outcome::primary::1,NCT01307046,Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP),,,,,,,,,,,,,PRIMARY,Baseline and Week 8
outcome,NCT01307046::outcome::primary::2,NCT01307046,Percentage of Participants Who Experienced at Least One Adverse Event (AE),,,,,,,,,,,,,PRIMARY,8 weeks
trial,NCT00782340,NCT00782340,A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa,PHASE3,cardiovascular disease,Symptomatic Neurogenic Orthostatic Hypotension (NOH); Non-diabetic Neuropathy; Primary Autonomic Failure; Dopamine Beta Hydroxylase Deficiency,INDUSTRY,263.0,2008-09,2010-09,2.0,21.0,,,,,
arm,NCT00782340::arm::FG000,NCT00782340,Open-Label Titration,,,,,,,,,,FG000,All patients titrated to their optimal dose of droxidopa for up to 2 weeks during open-label dose titration.,,,
arm,NCT00782340::arm::FG001,NCT00782340,Droxidopa,,,,,,,,,,FG001,"100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per ",,,
arm,NCT00782340::arm::FG002,NCT00782340,Placebo,,,,,,,,,,FG002,"100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per ",,,
period,NCT00782340::period::1,NCT00782340,Open Label Titration,,,,,,,,,,,,1.0,,
period,NCT00782340::period::2,NCT00782340,Randomized Double Blind,,,,,,,,,,,,2.0,,
outcome,NCT00782340::outcome::primary::1,NCT00782340,Change in Orthostatic Hypotension Questionnaire Score (OHQ),,,,,,,,,,,,,PRIMARY,7 days
country,NCT00782340::country::United States,NCT00782340,United States,,,,,,,,,,,,,,
country,NCT00782340::country::Canada,NCT00782340,Canada,,,,,,,,,,,,,,
trial,NCT03860935,NCT03860935,Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy,PHASE3,cardiovascular disease,Amyloidosis; Amyloid Cardiomyopathy; Transthyretin Amyloidosis; Cardiomyopathies; Heart Diseases,INDUSTRY,632.0,2019-03-19,2023-05-11,18.0,104.0,,,,,
arm,NCT03860935::arm::FG000,NCT03860935,Acoramidis HCl 800 mg,,,,,,,,,,FG000,"Participants with symptomatic ATTR-CM received 800 mg acoramidis HCl BID (two 400 mg acoramidis HCl tablets, each equivalent to 356 mg acoramidis \[active moiety\])",,,
arm,NCT03860935::arm::FG001,NCT03860935,Placebo,,,,,,,,,,FG001,Participants with symptomatic ATTR-CM received matching placebo (two matching placebo tablets BID),,,
period,NCT03860935::period::1,NCT03860935,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03860935::outcome::primary::1,NCT03860935,"A Hierarchical Combination of All-Cause Mortality, Cumulative Frequency of CV-related Hospitalization, Change From Baseline in NT-proBNP and Change From Baseline in 6MWT at the Last Available Visit Where Both Subjects Had Non-missing Assessments.",,,,,,,,,,,,,PRIMARY,Baseline up to Month 30
country,NCT03860935::country::United States,NCT03860935,United States,,,,,,,,,,,,,,
country,NCT03860935::country::Canada,NCT03860935,Canada,,,,,,,,,,,,,,
country,NCT03860935::country::Spain,NCT03860935,Spain,,,,,,,,,,,,,,
country,NCT03860935::country::Italy,NCT03860935,Italy,,,,,,,,,,,,,,
country,NCT03860935::country::Australia,NCT03860935,Australia,,,,,,,,,,,,,,
country,NCT03860935::country::Belgium,NCT03860935,Belgium,,,,,,,,,,,,,,
country,NCT03860935::country::Brazil,NCT03860935,Brazil,,,,,,,,,,,,,,
country,NCT03860935::country::Czechia,NCT03860935,Czechia,,,,,,,,,,,,,,
country,NCT03860935::country::Netherlands,NCT03860935,Netherlands,,,,,,,,,,,,,,
country,NCT03860935::country::Ireland,NCT03860935,Ireland,,,,,,,,,,,,,,
country,NCT03860935::country::Israel,NCT03860935,Israel,,,,,,,,,,,,,,
country,NCT03860935::country::New Zealand,NCT03860935,New Zealand,,,,,,,,,,,,,,
country,NCT03860935::country::Portugal,NCT03860935,Portugal,,,,,,,,,,,,,,
country,NCT03860935::country::South Korea,NCT03860935,South Korea,,,,,,,,,,,,,,
country,NCT03860935::country::United Kingdom,NCT03860935,United Kingdom,,,,,,,,,,,,,,
country,NCT03860935::country::Denmark,NCT03860935,Denmark,,,,,,,,,,,,,,
country,NCT03860935::country::Greece,NCT03860935,Greece,,,,,,,,,,,,,,
country,NCT03860935::country::Poland,NCT03860935,Poland,,,,,,,,,,,,,,
trial,NCT00168324,NCT00168324,A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion,PHASE3,cardiovascular disease,Macular Edema; Retinal Vein Occlusion,INDUSTRY,599.0,2004-10-01,2008-10-01,13.0,13.0,,,,,
arm,NCT00168324::arm::FG000,NCT00168324,700 µg Dexamethasone,,,,,,,,,,FG000,700 µg dexamethasone intravitreal implant administered on Day 0 and Day 180.,,,
arm,NCT00168324::arm::FG001,NCT00168324,350 µg Dexamethasone Followed by 700 µg Dexamethasone,,,,,,,,,,FG001,350 µg dexamethasone intravitreal implant administered on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.,,,
arm,NCT00168324::arm::FG002,NCT00168324,Sham Injection Followed by 700 µg Dexamethasone,,,,,,,,,,FG002,Sham injection on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.,,,
period,NCT00168324::period::1,NCT00168324,Double-Blind Period,,,,,,,,,,,,1.0,,
period,NCT00168324::period::2,NCT00168324,Open-Label Period,,,,,,,,,,,,2.0,,
outcome,NCT00168324::outcome::primary::1,NCT00168324,Cumulative Response Rate of 15 or More Letter Improvement,,,,,,,,,,,,,PRIMARY,Up to 180 Days
country,NCT00168324::country::United States,NCT00168324,United States,,,,,,,,,,,,,,
country,NCT00168324::country::Australia,NCT00168324,Australia,,,,,,,,,,,,,,
country,NCT00168324::country::Austria,NCT00168324,Austria,,,,,,,,,,,,,,
country,NCT00168324::country::Canada,NCT00168324,Canada,,,,,,,,,,,,,,
country,NCT00168324::country::Czechia,NCT00168324,Czechia,,,,,,,,,,,,,,
country,NCT00168324::country::France,NCT00168324,France,,,,,,,,,,,,,,
country,NCT00168324::country::Germany,NCT00168324,Germany,,,,,,,,,,,,,,
country,NCT00168324::country::Israel,NCT00168324,Israel,,,,,,,,,,,,,,
country,NCT00168324::country::Mexico,NCT00168324,Mexico,,,,,,,,,,,,,,
country,NCT00168324::country::Philippines,NCT00168324,Philippines,,,,,,,,,,,,,,
country,NCT00168324::country::Portugal,NCT00168324,Portugal,,,,,,,,,,,,,,
country,NCT00168324::country::South Africa,NCT00168324,South Africa,,,,,,,,,,,,,,
country,NCT00168324::country::Taiwan,NCT00168324,Taiwan,,,,,,,,,,,,,,
trial,NCT03355664,NCT03355664,Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and Vietnam,PHASE3,cardiovascular disease,"Malaria, Falciparum",OTHER,310.0,2018-03-19,2020-03-04,2.0,4.0,,,,,
arm,NCT03355664::arm::FG000,NCT03355664,Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24,,,,,,,,,,FG000,ACT: Artemether-lumefantrine (20/120 mg) as a fixed dose combination twice daily for 3 days according to weight plus low dose primaquine at hour 24,,,
arm,NCT03355664::arm::FG001,NCT03355664,Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24,,,,,,,,,,FG001,TACT: Artemether-lumefantrine (20/120 mg) as a fixed dose combination twice daily for 3 days according to weight plus Amodiaquine (150mg) twice daily for 3 days according to weight plus low dose prima,,,
period,NCT03355664::period::1,NCT03355664,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03355664::outcome::primary::1,NCT03355664,Polymerase Chain Reaction Corrected Efficacy Defined as Adequate Clinical and Parasitological Response (ACPR) by Study Arm,,,,,,,,,,,,,PRIMARY,42 days
country,NCT03355664::country::Cambodia,NCT03355664,Cambodia,,,,,,,,,,,,,,
country,NCT03355664::country::Vietnam,NCT03355664,Vietnam,,,,,,,,,,,,,,
trial,NCT00289887,NCT00289887,Obese Hypertension Study (0954-315),PHASE3,cardiovascular disease,Hypertension,INDUSTRY,261.0,2006-02,2007-03,0.0,0.0,,,,,
arm,NCT00289887::arm::FG000,NCT00289887,Losartan,,,,,,,,,,FG000,"Once-daily losartan 50 mg titrated at 4-week intervals to losartan 100 mg, losartan 100 mg/Hydrochlorothiazide (HCTZ) 12.5 mg, and losartan 100 mg/HCTZ 25 mg",,,
arm,NCT00289887::arm::FG001,NCT00289887,Placebo,,,,,,,,,,FG001,"Once-daily matching placebo for losartan 50 mg titrated at 4-week intervals to matching placebo for losartan 100 mg, matching placebo for losartan 100 mg/HCTZ 12.5 mg, and matching placebo for losarta",,,
period,NCT00289887::period::1,NCT00289887,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00289887::outcome::primary::1,NCT00289887,Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8,,,,,,,,,,,,,PRIMARY,"At baseline and at 8 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)"
outcome,NCT00289887::outcome::primary::2,NCT00289887,Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 8,,,,,,,,,,,,,PRIMARY,"At baseline and at 8 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)"
outcome,NCT00289887::outcome::primary::3,NCT00289887,Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12,,,,,,,,,,,,,PRIMARY,"At baseline and at 12 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)"
outcome,NCT00289887::outcome::primary::4,NCT00289887,Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 12,,,,,,,,,,,,,PRIMARY,"At baseline and at 12 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)"
outcome,NCT00289887::outcome::primary::5,NCT00289887,Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 16,,,,,,,,,,,,,PRIMARY,"At baseline and at 16 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)"
outcome,NCT00289887::outcome::primary::6,NCT00289887,Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 16,,,,,,,,,,,,,PRIMARY,"At baseline and at 16 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)"
trial,NCT03888066,NCT03888066,Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND),PHASE3,cardiovascular disease,Hyperkalemia,INDUSTRY,1195.0,2019-04-24,2021-09-02,21.0,415.0,,,,,
arm,NCT03888066::arm::FG000,NCT03888066,Patiromer,,,,,,,,,,FG000,"Randomized participants who received a daily dose of patiromer, with possible dose adjustments based on subsequent local serum potassium level, during the Treatment Phase.

The starting dose of patiro",,,
arm,NCT03888066::arm::FG001,NCT03888066,Placebo,,,,,,,,,,FG001,"Randomized participants who received a daily dose of placebo, with possible dose adjustments based on subsequent local serum potassium level, during the Treatment Phase.

The starting dose of placebo ",,,
period,NCT03888066::period::1,NCT03888066,Run-in Phase,,,,,,,,,,,,1.0,,
period,NCT03888066::period::2,NCT03888066,Treatment Phase (Overall Study),,,,,,,,,,,,2.0,,
outcome,NCT03888066::outcome::primary::1,NCT03888066,Changes in Serum K+ Levels From Baseline,,,,,,,,,,,,,PRIMARY,Mean duration of exposure: 227.9 days for Patiromer and 234.5 days for Placebo
country,NCT03888066::country::United States,NCT03888066,United States,,,,,,,,,,,,,,
country,NCT03888066::country::Spain,NCT03888066,Spain,,,,,,,,,,,,,,
country,NCT03888066::country::Brazil,NCT03888066,Brazil,,,,,,,,,,,,,,
country,NCT03888066::country::Germany,NCT03888066,Germany,,,,,,,,,,,,,,
country,NCT03888066::country::France,NCT03888066,France,,,,,,,,,,,,,,
country,NCT03888066::country::Argentina,NCT03888066,Argentina,,,,,,,,,,,,,,
country,NCT03888066::country::Russia,NCT03888066,Russia,,,,,,,,,,,,,,
country,NCT03888066::country::Ukraine,NCT03888066,Ukraine,,,,,,,,,,,,,,
country,NCT03888066::country::Israel,NCT03888066,Israel,,,,,,,,,,,,,,
country,NCT03888066::country::Poland,NCT03888066,Poland,,,,,,,,,,,,,,
country,NCT03888066::country::Czechia,NCT03888066,Czechia,,,,,,,,,,,,,,
country,NCT03888066::country::Netherlands,NCT03888066,Netherlands,,,,,,,,,,,,,,
country,NCT03888066::country::Georgia,NCT03888066,Georgia,,,,,,,,,,,,,,
country,NCT03888066::country::United Kingdom,NCT03888066,United Kingdom,,,,,,,,,,,,,,
country,NCT03888066::country::Italy,NCT03888066,Italy,,,,,,,,,,,,,,
country,NCT03888066::country::Belgium,NCT03888066,Belgium,,,,,,,,,,,,,,
country,NCT03888066::country::Canada,NCT03888066,Canada,,,,,,,,,,,,,,
country,NCT03888066::country::Mexico,NCT03888066,Mexico,,,,,,,,,,,,,,
country,NCT03888066::country::Bulgaria,NCT03888066,Bulgaria,,,,,,,,,,,,,,
country,NCT03888066::country::Serbia,NCT03888066,Serbia,,,,,,,,,,,,,,
country,NCT03888066::country::Hungary,NCT03888066,Hungary,,,,,,,,,,,,,,
trial,NCT00546754,NCT00546754,BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333),PHASE3,cardiovascular disease,Hypertension,INDUSTRY,808.0,2007-05-01,2009-05-01,0.0,0.0,,,,,
arm,NCT00546754::arm::FG000,NCT00546754,Losartan 50 mg/HCTZ 12.5 mg,,,,,,,,,,FG000,Patients could be titrated up from losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg to losartan 100 mg/HCTZ 25 mg only if needed to achieve target blood pressure.,,,
arm,NCT00546754::arm::FG001,NCT00546754,Valsartan 80 mg/HCTZ 12.5 mg,,,,,,,,,,FG001,Patients could be titrated up from valsartan 80 mg/HCTZ 12.5 mg to valsartan 160 mg/HCTZ 25 mg only if needed to achieve target blood pressure.,,,
period,NCT00546754::period::1,NCT00546754,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00546754::outcome::primary::1,NCT00546754,Change in Systolic Blood Pressure From Baseline to Week 12,,,,,,,,,,,,,PRIMARY,Baseline and Week 12
outcome,NCT00546754::outcome::primary::2,NCT00546754,Change in Diastolic Blood Pressure From Baseline to Week 12,,,,,,,,,,,,,PRIMARY,Baseline and Week 12
trial,NCT00396877,NCT00396877,Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation,PHASE3,cardiovascular disease,"Heart Defects, Congenital",INDUSTRY,906.0,2006-11,2010-02,31.0,31.0,,,,,
arm,NCT00396877::arm::FG000,NCT00396877,Placebo,,,,,,,,,,FG000,Reconstituted solution using Clopidogrel matching placebo powder administered once daily with a graduated syringe in the mouth or via a feeding tube.,,,
arm,NCT00396877::arm::FG001,NCT00396877,Clopidogrel 0.2 mg/kg/Day,,,,,,,,,,FG001,"Reconstituted solution using Clopidogrel powder administered once daily with a graduated syringe in the mouth or via a feeding tube.

Route: oral or enteric

Frequency: once daily

Dose: daily dose ad",,,
period,NCT00396877::period::1,NCT00396877,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00396877::outcome::primary::1,NCT00396877,Number of Participants Reaching Primary Endpoint Criteria (First Occurrence of Death / Shunt Thrombosis / Cardiac Procedure < 120 Days Considered of Thrombotic Nature),,,,,,,,,,,,,PRIMARY,Median follow-up of 5.8 months (up to a maximum of 12 months after randomization)
country,NCT00396877::country::United States,NCT00396877,United States,,,,,,,,,,,,,,
country,NCT00396877::country::Argentina,NCT00396877,Argentina,,,,,,,,,,,,,,
country,NCT00396877::country::Belgium,NCT00396877,Belgium,,,,,,,,,,,,,,
country,NCT00396877::country::Brazil,NCT00396877,Brazil,,,,,,,,,,,,,,
country,NCT00396877::country::Canada,NCT00396877,Canada,,,,,,,,,,,,,,
country,NCT00396877::country::China,NCT00396877,China,,,,,,,,,,,,,,
country,NCT00396877::country::Denmark,NCT00396877,Denmark,,,,,,,,,,,,,,
country,NCT00396877::country::Egypt,NCT00396877,Egypt,,,,,,,,,,,,,,
country,NCT00396877::country::Finland,NCT00396877,Finland,,,,,,,,,,,,,,
country,NCT00396877::country::France,NCT00396877,France,,,,,,,,,,,,,,
country,NCT00396877::country::Germany,NCT00396877,Germany,,,,,,,,,,,,,,
country,NCT00396877::country::Hong Kong,NCT00396877,Hong Kong,,,,,,,,,,,,,,
country,NCT00396877::country::Hungary,NCT00396877,Hungary,,,,,,,,,,,,,,
country,NCT00396877::country::India,NCT00396877,India,,,,,,,,,,,,,,
country,NCT00396877::country::Israel,NCT00396877,Israel,,,,,,,,,,,,,,
country,NCT00396877::country::Italy,NCT00396877,Italy,,,,,,,,,,,,,,
country,NCT00396877::country::Malaysia,NCT00396877,Malaysia,,,,,,,,,,,,,,
country,NCT00396877::country::Mexico,NCT00396877,Mexico,,,,,,,,,,,,,,
country,NCT00396877::country::Netherlands,NCT00396877,Netherlands,,,,,,,,,,,,,,
country,NCT00396877::country::Norway,NCT00396877,Norway,,,,,,,,,,,,,,
country,NCT00396877::country::Poland,NCT00396877,Poland,,,,,,,,,,,,,,
country,NCT00396877::country::Portugal,NCT00396877,Portugal,,,,,,,,,,,,,,
country,NCT00396877::country::Russia,NCT00396877,Russia,,,,,,,,,,,,,,
country,NCT00396877::country::Singapore,NCT00396877,Singapore,,,,,,,,,,,,,,
country,NCT00396877::country::South Africa,NCT00396877,South Africa,,,,,,,,,,,,,,
country,NCT00396877::country::South Korea,NCT00396877,South Korea,,,,,,,,,,,,,,
country,NCT00396877::country::Spain,NCT00396877,Spain,,,,,,,,,,,,,,
country,NCT00396877::country::Sweden,NCT00396877,Sweden,,,,,,,,,,,,,,
country,NCT00396877::country::Taiwan,NCT00396877,Taiwan,,,,,,,,,,,,,,
country,NCT00396877::country::Thailand,NCT00396877,Thailand,,,,,,,,,,,,,,
country,NCT00396877::country::United Kingdom,NCT00396877,United Kingdom,,,,,,,,,,,,,,
trial,NCT01932112,NCT01932112,Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial),PHASE3,cardiovascular disease,Atrial Fibrillation; Persistent Common Pulmonary Vein,OTHER,378.0,2012-11,2015-05,1.0,1.0,,,,,
arm,NCT01932112::arm::FG000,NCT01932112,Adenosine Arm,,,,,,,,,,FG000,"After pulmonary vein isolation, 20mg Iv adenosine will be given to treatment group, will evaluate pulmonary vein reconnection.

Adenosine arm: After pulmonary vein isolation, 20mg Iv adenosine will be",,,
period,NCT01932112::period::1,NCT01932112,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01932112::outcome::primary::1,NCT01932112,Reconnection of Pulmonary Vein Electrogram After Adenosine Infusion,,,,,,,,,,,,,PRIMARY,5 minutes after IV adenosine
country,NCT01932112::country::South Korea,NCT01932112,South Korea,,,,,,,,,,,,,,
trial,NCT00452530,NCT00452530,Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery,PHASE3,cardiovascular disease,Deep Vein Thrombosis; Pulmonary Embolism,INDUSTRY,3221.0,2007-06,2009-01,27.0,122.0,,,,,
arm,NCT00452530::arm::FG000,NCT00452530,"Apixaban, 2.5 mg BID + Placebo",,,,,,,,,,FG000,"Participants received apixaban, 2.5 mg twice daily (BID), as oral tablets, and matching enoxaparin-placebo injection once daily (QD)",,,
arm,NCT00452530::arm::FG001,NCT00452530,"Enoxaparin, 40 mg QD + Placebo",,,,,,,,,,FG001,"Participants received enoxaparin, 40 mg QD subcutaneously, and matching apixaban-placebo tablets BID",,,
period,NCT00452530::period::1,NCT00452530,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00452530::outcome::primary::1,NCT00452530,Rate of Adjudicated Venous Thromboembolic Event-related and All-cause Deaths With Onset During the Intended-treatment Period,,,,,,,,,,,,,PRIMARY,Day of randomization to later of 2 days after last dose or 14 days after first dose
country,NCT00452530::country::Germany,NCT00452530,Germany,,,,,,,,,,,,,,
country,NCT00452530::country::Russia,NCT00452530,Russia,,,,,,,,,,,,,,
country,NCT00452530::country::Austria,NCT00452530,Austria,,,,,,,,,,,,,,
country,NCT00452530::country::South Africa,NCT00452530,South Africa,,,,,,,,,,,,,,
country,NCT00452530::country::Spain,NCT00452530,Spain,,,,,,,,,,,,,,
country,NCT00452530::country::Ukraine,NCT00452530,Ukraine,,,,,,,,,,,,,,
country,NCT00452530::country::China,NCT00452530,China,,,,,,,,,,,,,,
country,NCT00452530::country::France,NCT00452530,France,,,,,,,,,,,,,,
country,NCT00452530::country::Czechia,NCT00452530,Czechia,,,,,,,,,,,,,,
country,NCT00452530::country::India,NCT00452530,India,,,,,,,,,,,,,,
country,NCT00452530::country::Israel,NCT00452530,Israel,,,,,,,,,,,,,,
country,NCT00452530::country::Italy,NCT00452530,Italy,,,,,,,,,,,,,,
country,NCT00452530::country::Mexico,NCT00452530,Mexico,,,,,,,,,,,,,,
country,NCT00452530::country::Colombia,NCT00452530,Colombia,,,,,,,,,,,,,,
country,NCT00452530::country::Denmark,NCT00452530,Denmark,,,,,,,,,,,,,,
country,NCT00452530::country::Poland,NCT00452530,Poland,,,,,,,,,,,,,,
country,NCT00452530::country::South Korea,NCT00452530,South Korea,,,,,,,,,,,,,,
country,NCT00452530::country::Norway,NCT00452530,Norway,,,,,,,,,,,,,,
country,NCT00452530::country::Philippines,NCT00452530,Philippines,,,,,,,,,,,,,,
country,NCT00452530::country::Belgium,NCT00452530,Belgium,,,,,,,,,,,,,,
country,NCT00452530::country::Brazil,NCT00452530,Brazil,,,,,,,,,,,,,,
country,NCT00452530::country::Chile,NCT00452530,Chile,,,,,,,,,,,,,,
country,NCT00452530::country::Hungary,NCT00452530,Hungary,,,,,,,,,,,,,,
country,NCT00452530::country::Malaysia,NCT00452530,Malaysia,,,,,,,,,,,,,,
country,NCT00452530::country::Singapore,NCT00452530,Singapore,,,,,,,,,,,,,,
country,NCT00452530::country::United Kingdom,NCT00452530,United Kingdom,,,,,,,,,,,,,,
country,NCT00452530::country::Sweden,NCT00452530,Sweden,,,,,,,,,,,,,,
trial,NCT01685567,NCT01685567,Safety and Efficacy Study for Reverse Flow Used During Carotid Artery Stenting Procedure,PHASE3,cardiovascular disease,Carotid Artery Disease,INDUSTRY,219.0,2012-11,2016-07,2.0,21.0,,,,,
arm,NCT01685567::arm::FG000,NCT01685567,Intention-to-Treat (ITT),,,,,,,,,,FG000,All patients who were enrolled in the pivotal phase of the study are included. Lead-in patients are not included in this group.,,,
period,NCT01685567::period::1,NCT01685567,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01685567::outcome::primary::1,NCT01685567,"Hierarchical Composite of Stroke, Myocardial Infarction, and Death",,,,,,,,,,,,,PRIMARY,30-day post-procedure
country,NCT01685567::country::United States,NCT01685567,United States,,,,,,,,,,,,,,
country,NCT01685567::country::Spain,NCT01685567,Spain,,,,,,,,,,,,,,
trial,NCT01344447,NCT01344447,Gadobutrol Enhanced MRA of the Supra-aortic Vessels,PHASE3,cardiovascular disease,Carotid Stenosis,INDUSTRY,479.0,2011-05-12,2014-05-28,14.0,56.0,,,,,
arm,NCT01344447::arm::FG000,NCT01344447,"Gadobutrol (Gadavist, BAY 86-4875)",,,,,,,,,,FG000,Gadobutrol was administered to all participants receiving study drug at the standard dose of 0.1 millimole per kilogram (mmol/kg) body weight (BW) by single intravenous (IV) bolus injection. During th,,,
period,NCT01344447::period::1,NCT01344447,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01344447::outcome::primary::1,NCT01344447,Percentage of Assessable Vascular Segments Using Gadobutrol-Enhanced MRA and Unenhanced MRA,,,,,,,,,,,,,PRIMARY,Images were taken pre-injection and post-injection
outcome,NCT01344447::outcome::primary::2,NCT01344447,Sensitivity for Detection of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA,,,,,,,,,,,,,PRIMARY,Images were taken pre-injection and post-injection
outcome,NCT01344447::outcome::primary::3,NCT01344447,Specificity for Exclusion of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA,,,,,,,,,,,,,PRIMARY,Images were taken pre-injection and post-injection
outcome,NCT01344447::outcome::primary::4,NCT01344447,Minimum Gadobutrol Performance for Sensitivity: Sensitivity > 50%,,,,,,,,,,,,,PRIMARY,Images were taken pre-injection and post-injection
outcome,NCT01344447::outcome::primary::5,NCT01344447,Minimum Gadobutrol Performance for Specificity: Specificity > 50%,,,,,,,,,,,,,PRIMARY,Images were taken pre-injection and post-injection
country,NCT01344447::country::United States,NCT01344447,United States,,,,,,,,,,,,,,
country,NCT01344447::country::Italy,NCT01344447,Italy,,,,,,,,,,,,,,
country,NCT01344447::country::France,NCT01344447,France,,,,,,,,,,,,,,
country,NCT01344447::country::Germany,NCT01344447,Germany,,,,,,,,,,,,,,
country,NCT01344447::country::Poland,NCT01344447,Poland,,,,,,,,,,,,,,
country,NCT01344447::country::South Korea,NCT01344447,South Korea,,,,,,,,,,,,,,
country,NCT01344447::country::Argentina,NCT01344447,Argentina,,,,,,,,,,,,,,
country,NCT01344447::country::Australia,NCT01344447,Australia,,,,,,,,,,,,,,
country,NCT01344447::country::Turkey (Türkiye),NCT01344447,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01344447::country::Austria,NCT01344447,Austria,,,,,,,,,,,,,,
country,NCT01344447::country::China,NCT01344447,China,,,,,,,,,,,,,,
country,NCT01344447::country::Sweden,NCT01344447,Sweden,,,,,,,,,,,,,,
country,NCT01344447::country::Czechia,NCT01344447,Czechia,,,,,,,,,,,,,,
country,NCT01344447::country::Switzerland,NCT01344447,Switzerland,,,,,,,,,,,,,,
trial,NCT02301910,NCT02301910,Single Bolus Recombinant Nonimmunogenic Staphylokinase Versus Single Bolus Tenecteplase (Metalyse) in STEMI,PHASE3,cardiovascular disease,Myocardial Infarction,INDUSTRY,382.0,2014-05-16,2016-12-01,1.0,17.0,,,,,
arm,NCT02301910::arm::FG000,NCT02301910,Recombinant Staphylokinase,,,,,,,,,,FG000,"Lyophilizate for solution making for intravenous injection, 5 mg (745000 ME). 15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds

Recombinant ",,,
arm,NCT02301910::arm::FG001,NCT02301910,Tenecteplase,,,,,,,,,,FG001,"50 mg of drug reconstituted in 10 ml sterile water for injection given as single weight-adjusted i.v. bolus over 5 - 10 seconds Weight (kg) Dose (mg) Dose (ml)

* 55 to \<60 30 mg 6 ml
* 60 to \<70 35",,,
period,NCT02301910::period::1,NCT02301910,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02301910::outcome::primary::1,NCT02301910,The Number of Participants With Reperfusion,,,,,,,,,,,,,PRIMARY,90 min after fibrinolysis
country,NCT02301910::country::Russia,NCT02301910,Russia,,,,,,,,,,,,,,
trial,NCT00536744,NCT00536744,Effectiveness of dermaPACE™ Device and Standard Treatment Compared to Standard Treatment Alone for Diabetic Foot Ulcers,PHASE3,cardiovascular disease,Diabetic Foot Ulcers,INDUSTRY,206.0,2007-10,2010-09,3.0,23.0,,,,,
arm,NCT00536744::arm::FG000,NCT00536744,dermaPACE Application + Standard of Care,,,,,,,,,,FG000,"dermaPACE application + standard of care

dermaPACE: dermaPACE + Standard of care wound dressing.",,,
arm,NCT00536744::arm::FG001,NCT00536744,Non-energized (Inactive) Application + Standard of Care,,,,,,,,,,FG001,"Non-energized (inactive) application + standard of care

Sham: Sham treatment + Standard of care wound dressing.",,,
period,NCT00536744::period::1,NCT00536744,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00536744::outcome::primary::1,NCT00536744,The Primary Variable for Effectiveness of the dermaPACE Device Will be Assessed by Comparing the Incidence of Complete Wound Closure of the dermaPACE and Control Groups 12 Weeks Post Initial Application.,,,,,,,,,,,,,PRIMARY,12 weeks post initial application
country,NCT00536744::country::United States,NCT00536744,United States,,,,,,,,,,,,,,
country,NCT00536744::country::Germany,NCT00536744,Germany,,,,,,,,,,,,,,
country,NCT00536744::country::United Kingdom,NCT00536744,United Kingdom,,,,,,,,,,,,,,
trial,NCT00071032,NCT00071032,Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease,PHASE3,cardiovascular disease,Anemia; Hematologic Diseases; Cardiovascular Diseases; Heart Diseases; Myocardial Infarction; Thromboembolism; Pneumonia; Cerebrovascular Accident,OTHER,2016.0,2003-07,2009-05,1.0,1.0,,,,,
arm,NCT00071032::arm::FG000,NCT00071032,Liberal (10 g/dL) Transfusion Strategy,,,,,,,,,,FG000,Transfusion strategy that maintains postoperative Hgb levels \>= 10 g/dL,,,
arm,NCT00071032::arm::FG001,NCT00071032,Restrictive Strategy,,,,,,,,,,FG001,Blood transfusion is withheld until the patient develops symptoms of anemia or at physician discretion of the hemoglobin level falls below 8 g/dL,,,
period,NCT00071032::period::1,NCT00071032,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00071032::outcome::primary::1,NCT00071032,Inability to Walk 10 Feet or Across a Room Without Human Assistance or Death,,,,,,,,,,,,,PRIMARY,60 days after randomization
country,NCT00071032::country::United States,NCT00071032,United States,,,,,,,,,,,,,,
trial,NCT02984384,NCT02984384,PREVENTion of Clot in Orthopaedic Trauma,PHASE3,cardiovascular disease,Blood Clot; Trauma,OTHER,12424.0,2017-04-24,2022-02-18,2.0,21.0,,,,,
arm,NCT02984384::arm::FG000,NCT02984384,Low Molecular Weight Heparin (LMWH)-Enoxaparin,,,,,,,,,,FG000,"Injection of 30 mg enoxaparin, twice a day via injection

Low Molecular Weight Heparin (LMWH): The LMWH intervention will be 30 mg enoxaparin subcutaneous (under the skin) twice a day with variations ",,,
arm,NCT02984384::arm::FG001,NCT02984384,Acetylsalicylic Acid (ASA)-Aspirin,,,,,,,,,,FG001,"Enteral ingestion or administration of 81 mg ASA, twice a day

Acetylsalicylic acid: The Aspirin intervention will be 81 mg enteral (by mouth, feeding tube or rectal) twice a day with no variation in ",,,
period,NCT02984384::period::1,NCT02984384,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02984384::outcome::primary::1,NCT02984384,Number of Participants With All-cause Mortality,,,,,,,,,,,,,PRIMARY,90 days
country,NCT02984384::country::United States,NCT02984384,United States,,,,,,,,,,,,,,
country,NCT02984384::country::Canada,NCT02984384,Canada,,,,,,,,,,,,,,
trial,NCT00623623,NCT00623623,STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction,PHASE3,cardiovascular disease,Myocardial Infarction,INDUSTRY,1899.0,2008-03-01,2012-09-01,16.0,201.0,,,,,
arm,NCT00623623::arm::FG000,NCT00623623,Tenecteplase (Group A),,,,,,,,,,FG000,Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention ,,,
arm,NCT00623623::arm::FG001,NCT00623623,Primary PCI (Group B),,,,,,,,,,FG001,"Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.

Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be give",,,
period,NCT00623623::period::1,NCT00623623,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00623623::outcome::primary::1,NCT00623623,"Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.",,,,,,,,,,,,,PRIMARY,30 days
country,NCT00623623::country::France,NCT00623623,France,,,,,,,,,,,,,,
country,NCT00623623::country::Russia,NCT00623623,Russia,,,,,,,,,,,,,,
country,NCT00623623::country::Italy,NCT00623623,Italy,,,,,,,,,,,,,,
country,NCT00623623::country::Brazil,NCT00623623,Brazil,,,,,,,,,,,,,,
country,NCT00623623::country::Greece,NCT00623623,Greece,,,,,,,,,,,,,,
country,NCT00623623::country::Serbia,NCT00623623,Serbia,,,,,,,,,,,,,,
country,NCT00623623::country::Austria,NCT00623623,Austria,,,,,,,,,,,,,,
country,NCT00623623::country::United Kingdom,NCT00623623,United Kingdom,,,,,,,,,,,,,,
country,NCT00623623::country::Chile,NCT00623623,Chile,,,,,,,,,,,,,,
country,NCT00623623::country::Germany,NCT00623623,Germany,,,,,,,,,,,,,,
country,NCT00623623::country::Spain,NCT00623623,Spain,,,,,,,,,,,,,,
country,NCT00623623::country::Belgium,NCT00623623,Belgium,,,,,,,,,,,,,,
country,NCT00623623::country::Poland,NCT00623623,Poland,,,,,,,,,,,,,,
country,NCT00623623::country::Canada,NCT00623623,Canada,,,,,,,,,,,,,,
country,NCT00623623::country::Norway,NCT00623623,Norway,,,,,,,,,,,,,,
country,NCT00623623::country::Peru,NCT00623623,Peru,,,,,,,,,,,,,,
trial,NCT00362232,NCT00362232,Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.,PHASE3,cardiovascular disease,Venous Thromboembolism,INDUSTRY,3148.0,2006-06,2008-01,13.0,124.0,,,,,
arm,NCT00362232::arm::FG000,NCT00362232,"Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939)",,,,,,,,,,FG000,"Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening plus placebo syringes of enoxaparin twice a day (bid) administered once in the morning and once in the evenin",,,
arm,NCT00362232::arm::FG001,NCT00362232,Enoxaparin 30 mg Twice a Day (Bid),,,,,,,,,,FG001,Placebo tablet of rivaroxaban administered once daily in the evening plus syringes of enoxaparin active substance 30 mg twice a day administered once in the morning and once in the evening.,,,
period,NCT00362232::period::1,NCT00362232,Treatment (12 +/- 2 Days),,,,,,,,,,,,1.0,,
period,NCT00362232::period::2,NCT00362232,Follow-up (30 (+ 5) Days),,,,,,,,,,,,2.0,,
outcome,NCT00362232::outcome::primary::1,NCT00362232,"Composite Endpoint of Total Venous Thrombo Embolism (VTE) i.e.: Any Deep Vein Thromboembolism (DVT) (Proximal and/or Distal), Non Fatal Pulmonary Embolism (PE), Death of All Causes Per Protocol Population",,,,,,,,,,,,,PRIMARY,Up to 16 days after surgery
outcome,NCT00362232::outcome::primary::2,NCT00362232,"Composite Endpoint of Total VTE i.e.: Any DVT (Proximal and/or Distal), Non Fatal PE, Death of All Causes Per Modified Intent to Treat Population.",,,,,,,,,,,,,PRIMARY,Up to 16 days after surgery
country,NCT00362232::country::United States,NCT00362232,United States,,,,,,,,,,,,,,
country,NCT00362232::country::Canada,NCT00362232,Canada,,,,,,,,,,,,,,
country,NCT00362232::country::India,NCT00362232,India,,,,,,,,,,,,,,
country,NCT00362232::country::Poland,NCT00362232,Poland,,,,,,,,,,,,,,
country,NCT00362232::country::Mexico,NCT00362232,Mexico,,,,,,,,,,,,,,
country,NCT00362232::country::Denmark,NCT00362232,Denmark,,,,,,,,,,,,,,
country,NCT00362232::country::Israel,NCT00362232,Israel,,,,,,,,,,,,,,
country,NCT00362232::country::Sweden,NCT00362232,Sweden,,,,,,,,,,,,,,
country,NCT00362232::country::Lithuania,NCT00362232,Lithuania,,,,,,,,,,,,,,
country,NCT00362232::country::Norway,NCT00362232,Norway,,,,,,,,,,,,,,
country,NCT00362232::country::Bulgaria,NCT00362232,Bulgaria,,,,,,,,,,,,,,
country,NCT00362232::country::Sri Lanka,NCT00362232,Sri Lanka,,,,,,,,,,,,,,
country,NCT00362232::country::Pakistan,NCT00362232,Pakistan,,,,,,,,,,,,,,
trial,NCT03469349,NCT03469349,Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB,PHASE3,cardiovascular disease,Peripheral Arterial Diseases,INDUSTRY,366.0,2018-05-01,2019-08-28,3.0,20.0,,,,,
arm,NCT03469349::arm::FG000,NCT03469349,Placebo,,,,,,,,,,FG000,"Actovegin placebo-matching infusion, intravenously, once daily for up to 2 weeks followed by actovegin placebo-matching tablets, orally, thrice daily for up to 10 weeks.",,,
arm,NCT03469349::arm::FG001,NCT03469349,Actovegin 1200 mg,,,,,,,,,,FG001,"Actovegin 1200 milligram (mg), infusion, intravenously, once daily for up to 2 weeks followed by actovegin 200 mg, tablets, orally, thrice daily (1200 mg/day) for up to 10 weeks.",,,
period,NCT03469349::period::1,NCT03469349,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03469349::outcome::primary::1,NCT03469349,Percent Change From Baseline in Initial Claudication Distance (ICD) at Week 12,,,,,,,,,,,,,PRIMARY,Baseline up to Week 12
country,NCT03469349::country::Russia,NCT03469349,Russia,,,,,,,,,,,,,,
country,NCT03469349::country::Georgia,NCT03469349,Georgia,,,,,,,,,,,,,,
country,NCT03469349::country::Kazakhstan,NCT03469349,Kazakhstan,,,,,,,,,,,,,,
trial,NCT06005597,NCT06005597,Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies,PHASE3,cardiovascular disease,Dyslipidemias; Hypercholesterolemia; Familial Hypercholesterolemia; ASCVD; High Cholesterol,INDUSTRY,407.0,2024-03-01,2024-10-16,1.0,45.0,,,,,
arm,NCT06005597::arm::FG000,NCT06005597,Fixed Dose Combination,,,,,,,,,,FG000,"once-daily obicetrapib 10 mg and ezetimibe 10 mg fixed dose combination tablet, placebo tablet, placebo capsule

Fixed Dose Combination: tablet; 10mg obicetrapib and 10mg ezetimibe fixed does combinat",,,
arm,NCT06005597::arm::FG001,NCT06005597,Monotherapy Obicetrapib,,,,,,,,,,FG001,"once-daily obicetrapib 10 mg, placebo tablet, placebo capsule

Monotherapy obicetrapib: tablet; 10mg obicetrapib

Combination Therapy placebo: tablet; no active ingredient

Ezetimibe Placebo: capsule;",,,
arm,NCT06005597::arm::FG002,NCT06005597,Monotherapy Ezetimibe,,,,,,,,,,FG002,"once-daily ezetimibe 10 mg capsule, 2 placebo tablets

Monotherapy ezetimibe: capsule; 10mg ezetimibe

Combination Therapy placebo: tablet; no active ingredient

Obicetrapib Placebo: tablet; no active",,,
arm,NCT06005597::arm::FG003,NCT06005597,Placebo,,,,,,,,,,FG003,"once-daily placebo tablets (2), placebo capsule

Combination Therapy placebo: tablet; no active ingredient

Obicetrapib Placebo: tablet; no active ingredient

Ezetimibe Placebo: capsule; no active ing",,,
period,NCT06005597::period::1,NCT06005597,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT06005597::outcome::primary::1,NCT06005597,Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C,,,,,,,,,,,,,PRIMARY,84 Days
outcome,NCT06005597::outcome::primary::2,NCT06005597,Effect of Fixed Dose Combination (FDC) Compared to Ezetimibe Monotherapy on LDL-C,,,,,,,,,,,,,PRIMARY,84 Days
outcome,NCT06005597::outcome::primary::3,NCT06005597,Effect of Fixed Dose Combination (FDC) Compared to Obicetrapib Monotherapy on LDL-C,,,,,,,,,,,,,PRIMARY,84 Days
outcome,NCT06005597::outcome::primary::4,NCT06005597,Effect of Obicetrapib Monotherapy Compared to Placebo on LDL-C,,,,,,,,,,,,,PRIMARY,84 Days
country,NCT06005597::country::United States,NCT06005597,United States,,,,,,,,,,,,,,
trial,NCT00739674,NCT00739674,SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335),PHASE3,cardiovascular disease,Hypertension,INDUSTRY,992.0,2008-02-01,2010-01-01,0.0,0.0,,,,,
arm,NCT00739674::arm::FG000,NCT00739674,Losartan-Based Regimen Alone (L Group),,,,,,,,,,FG000,Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including hydrochlorothiazide (HCTZ) 12.5 mg or 25 mg and calcium channel blocker (CCB) as needed to achieve ,,,
arm,NCT00739674::arm::FG001,NCT00739674,Diet Management and Losartan-Based Regimen (DML Group),,,,,,,,,,FG001,Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt Die,,,
period,NCT00739674::period::1,NCT00739674,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00739674::outcome::primary::1,NCT00739674,Number of Patients Achieving Target Blood Pressure at Week 14 From Baseline,,,,,,,,,,,,,PRIMARY,14 Weeks
outcome,NCT00739674::outcome::primary::2,NCT00739674,Change in Systolic Blood Pressure From Baseline to Week 14,,,,,,,,,,,,,PRIMARY,14 Weeks
outcome,NCT00739674::outcome::primary::3,NCT00739674,Change in Diastolic Blood Pressure From Baseline to Week 14,,,,,,,,,,,,,PRIMARY,14 Weeks
trial,NCT00083551,NCT00083551,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,PHASE3,cardiovascular disease,Multiple Myeloma,OTHER,668.0,1998-08,2014-08,1.0,1.0,,,,,
arm,NCT00083551::arm::FG000,NCT00083551,Thalidomide,,,,,,,,,,FG000,"Thalidomide 400 QD during induction, 100 mg QD between transplants, 200 mg QD post transplant, 100 mg QD during year one of maintenance, and 50 mg QD during second year of maintenance.",,,
arm,NCT00083551::arm::FG001,NCT00083551,No Thalidomide,,,,,,,,,,FG001,"Patient received no thalidomide during induction, consolidation, and maintenance therapy.",,,
period,NCT00083551::period::1,NCT00083551,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00083551::outcome::primary::1,NCT00083551,Overall Survival,,,,,,,,,,,,,PRIMARY,6 Years
country,NCT00083551::country::United States,NCT00083551,United States,,,,,,,,,,,,,,
trial,NCT03448419,NCT03448419,This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms,PHASE3,cardiovascular disease,Heart Failure,INDUSTRY,312.0,2018-03-20,2019-10-07,11.0,109.0,,,,,
arm,NCT03448419::arm::FG000,NCT03448419,Placebo,,,,,,,,,,FG000,1 film-coated tablet of Placebo matching empagliflozin was administered orally once daily for 12 weeks in participants with chronic Heart Failure (CHF) with reduced left ventricular ejection fraction ,,,
arm,NCT03448419::arm::FG001,NCT03448419,10 mg Empagliflozin,,,,,,,,,,FG001,1 film-coated tablet of 10 milligram (mg) of Empagliflozin was administered orally once daily for 12 weeks in participants with chronic Heart Failure (CHF) with reduced left ventricular ejection fract,,,
period,NCT03448419::period::1,NCT03448419,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03448419::outcome::primary::1,NCT03448419,Change From Baseline to Week 12 in Exercise Capacity as Measured by the 6-Minutes-Walking-Test (6MWT) Distance,,,,,,,,,,,,,PRIMARY,At baseline and at week 12
country,NCT03448419::country::United States,NCT03448419,United States,,,,,,,,,,,,,,
country,NCT03448419::country::Germany,NCT03448419,Germany,,,,,,,,,,,,,,
country,NCT03448419::country::Poland,NCT03448419,Poland,,,,,,,,,,,,,,
country,NCT03448419::country::Portugal,NCT03448419,Portugal,,,,,,,,,,,,,,
country,NCT03448419::country::Spain,NCT03448419,Spain,,,,,,,,,,,,,,
country,NCT03448419::country::Greece,NCT03448419,Greece,,,,,,,,,,,,,,
country,NCT03448419::country::Italy,NCT03448419,Italy,,,,,,,,,,,,,,
country,NCT03448419::country::Australia,NCT03448419,Australia,,,,,,,,,,,,,,
country,NCT03448419::country::Norway,NCT03448419,Norway,,,,,,,,,,,,,,
country,NCT03448419::country::Canada,NCT03448419,Canada,,,,,,,,,,,,,,
country,NCT03448419::country::Sweden,NCT03448419,Sweden,,,,,,,,,,,,,,
trial,NCT02774265,NCT02774265,A Different Approach to Preventing Thrombosis,PHASE3,cardiovascular disease,Venous Thromboembolism; Pulmonary Embolism,OTHER,329.0,2016-01,2017-09,1.0,1.0,,,,,
arm,NCT02774265::arm::FG000,NCT02774265,VTE Prophylaxis With Enoxaparin 30mg BID,,,,,,,,,,FG000,"The group receiving VTE prophylaxis with enoxaparin 30mg subcutaneous BID.

VTE prophylaxis with Enoxaparin 30mg BID: Patients will receive Enoxaparin 30mg BID for DVT prophylaxis and will be followed",,,
arm,NCT02774265::arm::FG001,NCT02774265,VTE Prophylaxis With Aspirin 81mg BID,,,,,,,,,,FG001,"The group receiving VTE prophylaxis with ASA 81mg PO BID

VTE prophylaxis with Aspirin 81mg BID: Patients will receive Aspirin 81mg BID for DVT prophylaxis and will be followed to determine the effica",,,
period,NCT02774265::period::1,NCT02774265,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02774265::outcome::primary::1,NCT02774265,Number of Participants With Treatment-related Bleeding Events as Assessed by the Need for Blood Transfusions and Procedures for Bleeding Complications After Initiation of the Study Medication.,,,,,,,,,,,,,PRIMARY,90 days
country,NCT02774265::country::United States,NCT02774265,United States,,,,,,,,,,,,,,
trial,NCT01908816,NCT01908816,An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.,PHASE3,cardiovascular disease,"Choroidal Neovascularization; Macular Edema; Glaucoma, Neovascular; Diabetic Retinopathy",INDUSTRY,270.0,2013-09-26,2016-01-08,1.0,39.0,,,,,
arm,NCT01908816::arm::FG000,NCT01908816,CNV (Choroidal Neovascularization),,,,,,,,,,FG000,All patients received 0.5 mg ranibizumab IVT injection,,,
arm,NCT01908816::arm::FG001,NCT01908816,ME (Macular Edema),,,,,,,,,,FG001,All patients received 0.5 mg ranibizumab IVT injection,,,
arm,NCT01908816::arm::FG002,NCT01908816,RI/NVG (Rubeosis Iridis and Neovacular Glaucoma),,,,,,,,,,FG002,All patients received 0.5 mg ranibizumab IVT injection,,,
arm,NCT01908816::arm::FG003,NCT01908816,PDR/V,,,,,,,,,,FG003,(Proliferative Diabetic Retinopathy requiring Vitrectomy). All patients received 0.5 mg ranibizumab IVT injection,,,
period,NCT01908816::period::1,NCT01908816,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01908816::outcome::primary::1,NCT01908816,Number of Participants With Adverse Events as a Measure of Safety and Tolerability,,,,,,,,,,,,,PRIMARY,24 months
country,NCT01908816::country::France,NCT01908816,France,,,,,,,,,,,,,,
trial,NCT00507416,NCT00507416,"Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone",PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,502.0,2007-06,2013-03,2.0,235.0,,,,,
arm,NCT00507416::arm::FG000,NCT00507416,Bortezomib and Dexamethasone,,,,,,,,,,FG000,"Participants received bortezomib (Velcade) 1.3 mg/m\^2 administered as a bolus intravenous (IV) injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 fo",,,
arm,NCT00507416::arm::FG001,NCT00507416,"Bortezomib, Thalidomide, and Dexamethasone",,,,,,,,,,FG001,"Participants received bortezomib 1.3 mg/m\^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12, and thalidomide 100 mg or",,,
arm,NCT00507416::arm::FG002,NCT00507416,"Bortezomib, Melphalan and Prednisone",,,,,,,,,,FG002,"Participants received bortezomib 1.3 mg/m\^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and melphalan 9 mg/m\^2 orally on Days 1-4 every other cycle and prednisone 60 mg/m\^2 orally",,,
period,NCT00507416::period::1,NCT00507416,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00507416::outcome::primary::1,NCT00507416,Progression Free Survival (PFS),,,,,,,,,,,,,PRIMARY,From randomization until disease progression. Median follow-up time was 43 months.
country,NCT00507416::country::United States,NCT00507416,United States,,,,,,,,,,,,,,
country,NCT00507416::country::Puerto Rico,NCT00507416,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00696384,NCT00696384,A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,418.0,2007-06,2009-04,3.0,45.0,,,,,
arm,NCT00696384::arm::FG000,NCT00696384,Azilsartan Medoxomil QD - Open Label Phase,,,,,,,,,,FG000,"All subjects initiated azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks, force-titrated to 80 mg, tablets, orally, once daily. After Week 8, chlorthalidone, 25 mg, tablets, orall",,,
arm,NCT00696384::arm::FG001,NCT00696384,Azilsartan Medoxomil QD - Double-Blind Reversal Phase,,,,,,,,,,FG001,"Azilsartan medoxomil at the final dose received during the open-label phase: (20 mg, 40 mg or 80 mg), tablets, orally, once daily with or without chlorthalidone 25 mg, tablets, orally once daily and o",,,
arm,NCT00696384::arm::FG002,NCT00696384,Placebo QD - Double-Blind Reversal Phase,,,,,,,,,,FG002,"Azilsartan medoxomil placebo-matching tablets, orally, once daily with or without chlorthalidone 25 mg, orally once daily or other non-ARB antihypertensive (if currently taking), tablets, orally, once",,,
period,NCT00696384::period::1,NCT00696384,Open Label Phase,,,,,,,,,,,,1.0,,
period,NCT00696384::period::2,NCT00696384,Double Blind Phase,,,,,,,,,,,,2.0,,
outcome,NCT00696384::outcome::primary::1,NCT00696384,Change From Double-blind Baseline (Week 26) in Sitting Clinic Diastolic Blood Pressure to Week 32,,,,,,,,,,,,,PRIMARY,Double-blind Baseline (Week 26) and Week 32.
country,NCT00696384::country::United States,NCT00696384,United States,,,,,,,,,,,,,,
country,NCT00696384::country::Mexico,NCT00696384,Mexico,,,,,,,,,,,,,,
country,NCT00696384::country::Argentina,NCT00696384,Argentina,,,,,,,,,,,,,,
trial,NCT00705575,NCT00705575,Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,688.0,2008-06,2009-04,8.0,8.0,,,,,
arm,NCT00705575::arm::FG000,NCT00705575,Aliskiren/Hydrochlorothiazide (HCTZ) (300/25 mg),,,,,,,,,,FG000,"During the titration period, patients received aliskiren/hydrochlorothiazide (HCTZ) 150/12.5 mg for 1 week. Subsequently, patients were up-titrated and received aliskiren/HCTZ 300/25 mg.",,,
arm,NCT00705575::arm::FG001,NCT00705575,Aliskiren (300 mg),,,,,,,,,,FG001,"During the titration period, patients received aliskiren 150 mg for one week. Subsequently, patients were up-titrated and received aliskiren 300 mg.",,,
period,NCT00705575::period::1,NCT00705575,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00705575::outcome::primary::1,NCT00705575,Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 12),,,,,,,,,,,,,PRIMARY,Baseline to end of study (Week 12)
country,NCT00705575::country::United States,NCT00705575,United States,,,,,,,,,,,,,,
country,NCT00705575::country::Argentina,NCT00705575,Argentina,,,,,,,,,,,,,,
country,NCT00705575::country::Ecuador,NCT00705575,Ecuador,,,,,,,,,,,,,,
country,NCT00705575::country::Germany,NCT00705575,Germany,,,,,,,,,,,,,,
country,NCT00705575::country::Guatemala,NCT00705575,Guatemala,,,,,,,,,,,,,,
country,NCT00705575::country::Italy,NCT00705575,Italy,,,,,,,,,,,,,,
country,NCT00705575::country::Switzerland,NCT00705575,Switzerland,,,,,,,,,,,,,,
country,NCT00705575::country::Turkey (Türkiye),NCT00705575,Turkey (Türkiye),,,,,,,,,,,,,,
trial,NCT00894387,NCT00894387,"Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure",PHASE3,cardiovascular disease,Acute Decompensated Heart Failure; Congestive Heart Failure,INDUSTRY,1639.0,2009-05,2012-08,24.0,308.0,,,,,
arm,NCT00894387::arm::FG000,NCT00894387,Aliskiren,,,,,,,,,,FG000,"Randomized patients in this arm received, Aliskiren 150 mg once daily for 2 weeks. From week 2 upto 6 months , patients who could tolerate study medication were up-titrated to aliskiren 300 mg once da",,,
arm,NCT00894387::arm::FG001,NCT00894387,Placebo,,,,,,,,,,FG001,"Randomized patients in this arm received matching placebo of Aliskiren. At week 2, Patients who could tolerate study medication were up-titrated to matching placebo of 300 mg aliskiren.",,,
period,NCT00894387::period::1,NCT00894387,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00894387::outcome::primary::1,NCT00894387,Time to Event Analysis: Number of Patients Experienced the First Confirmed Occurrence of Either Cardiovascular Death or Heart Failure (HF) Re-hospitalization Within 6 Months,,,,,,,,,,,,,PRIMARY,6 months
country,NCT00894387::country::Germany,NCT00894387,Germany,,,,,,,,,,,,,,
country,NCT00894387::country::United States,NCT00894387,United States,,,,,,,,,,,,,,
country,NCT00894387::country::Italy,NCT00894387,Italy,,,,,,,,,,,,,,
country,NCT00894387::country::Russia,NCT00894387,Russia,,,,,,,,,,,,,,
country,NCT00894387::country::Argentina,NCT00894387,Argentina,,,,,,,,,,,,,,
country,NCT00894387::country::India,NCT00894387,India,,,,,,,,,,,,,,
country,NCT00894387::country::Poland,NCT00894387,Poland,,,,,,,,,,,,,,
country,NCT00894387::country::Slovakia,NCT00894387,Slovakia,,,,,,,,,,,,,,
country,NCT00894387::country::Czechia,NCT00894387,Czechia,,,,,,,,,,,,,,
country,NCT00894387::country::Spain,NCT00894387,Spain,,,,,,,,,,,,,,
country,NCT00894387::country::Turkey (Türkiye),NCT00894387,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00894387::country::Belgium,NCT00894387,Belgium,,,,,,,,,,,,,,
country,NCT00894387::country::Brazil,NCT00894387,Brazil,,,,,,,,,,,,,,
country,NCT00894387::country::Hungary,NCT00894387,Hungary,,,,,,,,,,,,,,
country,NCT00894387::country::France,NCT00894387,France,,,,,,,,,,,,,,
country,NCT00894387::country::Colombia,NCT00894387,Colombia,,,,,,,,,,,,,,
country,NCT00894387::country::Israel,NCT00894387,Israel,,,,,,,,,,,,,,
country,NCT00894387::country::Canada,NCT00894387,Canada,,,,,,,,,,,,,,
country,NCT00894387::country::Romania,NCT00894387,Romania,,,,,,,,,,,,,,
country,NCT00894387::country::Taiwan,NCT00894387,Taiwan,,,,,,,,,,,,,,
country,NCT00894387::country::Sweden,NCT00894387,Sweden,,,,,,,,,,,,,,
country,NCT00894387::country::Philippines,NCT00894387,Philippines,,,,,,,,,,,,,,
country,NCT00894387::country::Singapore,NCT00894387,Singapore,,,,,,,,,,,,,,
country,NCT00894387::country::Finland,NCT00894387,Finland,,,,,,,,,,,,,,
trial,NCT00484315,NCT00484315,TAXUS PERSEUS Workhorse,PHASE3,cardiovascular disease,Coronary Artery Disease,INDUSTRY,1264.0,2007-07,2013-10,4.0,90.0,,,,,
arm,NCT00484315::arm::FG000,NCT00484315,TAXUS Element,,,,,,,,,,FG000,Participants randomized to treatment with TAXUS Element paclitaxel-eluting stent (investigational device),,,
arm,NCT00484315::arm::FG001,NCT00484315,TAXUS Express,,,,,,,,,,FG001,Participants randomized to treatment with TAXUS Express paclitaxel-eluting stent (control device),,,
period,NCT00484315::period::1,NCT00484315,12-Month Clinical Follow-up,,,,,,,,,,,,1.0,,
period,NCT00484315::period::2,NCT00484315,9-Month Angiographic Follow-up,,,,,,,,,,,,2.0,,
outcome,NCT00484315::outcome::primary::1,NCT00484315,"Target Lesion Failure (TLF) at 12 Months Post-index Procedure. TLF is Defined as Any Ischemia-driven Revascularization of the Target Lesion, Myocardial Infarction (Q-wave and Non-Q-wave), or Death Related to the Target Vessel.",,,,,,,,,,,,,PRIMARY,12 months post-index procedure
country,NCT00484315::country::United States,NCT00484315,United States,,,,,,,,,,,,,,
country,NCT00484315::country::New Zealand,NCT00484315,New Zealand,,,,,,,,,,,,,,
country,NCT00484315::country::Australia,NCT00484315,Australia,,,,,,,,,,,,,,
country,NCT00484315::country::Singapore,NCT00484315,Singapore,,,,,,,,,,,,,,
trial,NCT02585713,NCT02585713,Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism,PHASE3,cardiovascular disease,Cerebral Vein Thrombosis; Deep Vein Thrombosis; Gonadal Thrombosis; Hepatic Thrombosis; Malignant Neoplasm; Mesenteric Thrombosis; Metastatic Malignant Neoplasm; Portal Vein Thrombosis; Pulmonary Embolism; Renal Vein Thrombosis; Splenic Thrombosis; Venous Thromboembolism,OTHER,300.0,2015-11-20,2019-12-24,1.0,18.0,,,,,
arm,NCT02585713::arm::FG000,NCT02585713,Arm A (Apixaban),,,,,,,,,,FG000,Patients receive apixaban 10 mg PO BID on days 1-7 and lower-dose apixaban 5 mg PO BID on days 8-180.,,,
arm,NCT02585713::arm::FG001,NCT02585713,Arm B (Dalteparin),,,,,,,,,,FG001,Patients receive dalteparin 200 IU/kg/day SC QD on days 1-30 and lower-dose dalteparin 150 IU/kg/day SC QD on days 31-180.,,,
period,NCT02585713::period::1,NCT02585713,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02585713::outcome::primary::1,NCT02585713,6 Month Bleeding Rate,,,,,,,,,,,,,PRIMARY,Up to 6 months
country,NCT02585713::country::United States,NCT02585713,United States,,,,,,,,,,,,,,
trial,NCT03110562,NCT03110562,"Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma",PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,402.0,2017-05-24,2022-05-12,21.0,157.0,,,,,
arm,NCT03110562::arm::FG000,NCT03110562,SVd Arm: Selinexor + Bortezomib + Dexamethasone,,,,,,,,,,FG000,"Participants received a fixed oral dose of 100 milligrams (mg) selinexor tablets (5 tablets of 20 mg each) once weekly (QW) on Days 1, 8, 15, 22, and 29 of each 35-day cycle, along with subcutaneous (",,,
arm,NCT03110562::arm::FG001,NCT03110562,Vd Arm: Bortezomib + Dexamethasone,,,,,,,,,,FG001,"Participants received SC injection of 1.3 mg/m\^2 bortezomib on Days 1, 4, 8, and 11 of each 21-day cycle for the first 8 cycles, followed by greater than or equal to (\>=) 9 cycles on Days 1, 8, 15, ",,,
arm,NCT03110562::arm::FG002,NCT03110562,SVdX Arm: Selinexor + Bortezomib + Dexamethasone,,,,,,,,,,FG002,Participants in the VD arm who had IRC-confirmed PD and were able to tolerate continued bortezomib treatment had crossed over to receive fixed oral dose of 100 mg selinexor tablets (5 tablets of 20 mg,,,
arm,NCT03110562::arm::FG003,NCT03110562,SdX Arm: Selinexor + Dexamethasone,,,,,,,,,,FG003,Participants in the VD arm who had IRC-confirmed PD and were unable to tolerate continued bortezomib treatment had crossed over to receive fixed oral dose of 100 mg selinexor tablets (5 tablets of 20 ,,,
period,NCT03110562::period::1,NCT03110562,Initial Treatment Period,,,,,,,,,,,,1.0,,
period,NCT03110562::period::2,NCT03110562,Crossover Period,,,,,,,,,,,,2.0,,
outcome,NCT03110562::outcome::primary::1,NCT03110562,SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC),,,,,,,,,,,,,PRIMARY,"From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 33 months)"
country,NCT03110562::country::United States,NCT03110562,United States,,,,,,,,,,,,,,
country,NCT03110562::country::India,NCT03110562,India,,,,,,,,,,,,,,
country,NCT03110562::country::United Kingdom,NCT03110562,United Kingdom,,,,,,,,,,,,,,
country,NCT03110562::country::Canada,NCT03110562,Canada,,,,,,,,,,,,,,
country,NCT03110562::country::Italy,NCT03110562,Italy,,,,,,,,,,,,,,
country,NCT03110562::country::Australia,NCT03110562,Australia,,,,,,,,,,,,,,
country,NCT03110562::country::France,NCT03110562,France,,,,,,,,,,,,,,
country,NCT03110562::country::Poland,NCT03110562,Poland,,,,,,,,,,,,,,
country,NCT03110562::country::Ukraine,NCT03110562,Ukraine,,,,,,,,,,,,,,
country,NCT03110562::country::Czechia,NCT03110562,Czechia,,,,,,,,,,,,,,
country,NCT03110562::country::Spain,NCT03110562,Spain,,,,,,,,,,,,,,
country,NCT03110562::country::Austria,NCT03110562,Austria,,,,,,,,,,,,,,
country,NCT03110562::country::Belgium,NCT03110562,Belgium,,,,,,,,,,,,,,
country,NCT03110562::country::Hungary,NCT03110562,Hungary,,,,,,,,,,,,,,
country,NCT03110562::country::Serbia,NCT03110562,Serbia,,,,,,,,,,,,,,
country,NCT03110562::country::Greece,NCT03110562,Greece,,,,,,,,,,,,,,
country,NCT03110562::country::Israel,NCT03110562,Israel,,,,,,,,,,,,,,
country,NCT03110562::country::Russia,NCT03110562,Russia,,,,,,,,,,,,,,
country,NCT03110562::country::Bulgaria,NCT03110562,Bulgaria,,,,,,,,,,,,,,
country,NCT03110562::country::Germany,NCT03110562,Germany,,,,,,,,,,,,,,
country,NCT03110562::country::Romania,NCT03110562,Romania,,,,,,,,,,,,,,
trial,NCT00147199,NCT00147199,Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH),PHASE3,cardiovascular disease,Pulmonary Hypertension,INDUSTRY,235.0,2005-06,2007-10,10.0,30.0,,,,,
arm,NCT00147199::arm::FG000,NCT00147199,Inhaled Treprostinil,,,,,,,,,,FG000,"Initial dose: 3 breaths. Titrated to 9 breaths, four times daily.",,,
arm,NCT00147199::arm::FG001,NCT00147199,Placebo,,,,,,,,,,FG001,Identical placebo inhalation solution,,,
period,NCT00147199::period::1,NCT00147199,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00147199::outcome::primary::1,NCT00147199,Peak 6-minute Walk Distance,,,,,,,,,,,,,PRIMARY,12 weeks
country,NCT00147199::country::United States,NCT00147199,United States,,,,,,,,,,,,,,
country,NCT00147199::country::Israel,NCT00147199,Israel,,,,,,,,,,,,,,
country,NCT00147199::country::United Kingdom,NCT00147199,United Kingdom,,,,,,,,,,,,,,
country,NCT00147199::country::Austria,NCT00147199,Austria,,,,,,,,,,,,,,
country,NCT00147199::country::Belgium,NCT00147199,Belgium,,,,,,,,,,,,,,
country,NCT00147199::country::France,NCT00147199,France,,,,,,,,,,,,,,
country,NCT00147199::country::Germany,NCT00147199,Germany,,,,,,,,,,,,,,
country,NCT00147199::country::Ireland,NCT00147199,Ireland,,,,,,,,,,,,,,
country,NCT00147199::country::Italy,NCT00147199,Italy,,,,,,,,,,,,,,
country,NCT00147199::country::Spain,NCT00147199,Spain,,,,,,,,,,,,,,
trial,NCT02861534,NCT02861534,A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001),PHASE3,cardiovascular disease,Heart Failure; Chronic Heart Failure With Reduced Ejection Fraction,INDUSTRY,5050.0,2016-09-20,2019-09-02,0.0,0.0,,,,,
arm,NCT02861534::arm::FG000,NCT02861534,Vericiguat,,,,,,,,,,FG000,"Participants received a starting dose of 2.5 mg of vericiguat taken orally once daily with food, on a background of heart failure (HF) standard of care. The vericiguat dose was uptitrated to 5 mg and ",,,
arm,NCT02861534::arm::FG001,NCT02861534,Placebo,,,,,,,,,,FG001,"Participants received a starting matching placebo dose of 2.5 mg taken orally once daily with food, on a background of HF standard of care. The matching placebo dose was uptitrated to 5 mg and to 10 m",,,
period,NCT02861534::period::1,NCT02861534,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02861534::outcome::primary::1,NCT02861534,Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization,,,,,,,,,,,,,PRIMARY,Up to approximately 33 months (through primary analysis database cutoff date of 18-June-2019)
trial,NCT02819284,NCT02819284,Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease,PHASE3,cardiovascular disease,Dry Eye Syndromes; Keratoconjunctivitis Sicca,INDUSTRY,909.0,2016-06,2017-09,1.0,62.0,,,,,
arm,NCT02819284::arm::FG000,NCT02819284,KPI-121 0.25% Ophthalmic Suspension,,,,,,,,,,FG000,Participants randomized to KPI-121 0.25% Ophthalmic Suspension,,,
arm,NCT02819284::arm::FG001,NCT02819284,Vehicle of KPI-121 0.25% Ophthalmic Suspension,,,,,,,,,,FG001,Participants randomized to Vehicle of KPI-121 0.25% Ophthalmic Suspension,,,
period,NCT02819284::period::1,NCT02819284,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02819284::outcome::primary::1,NCT02819284,Change From Baseline/Visit 2 (Day 1) in Bulbar Conjunctival Hyperemia at Visit 4 (Day 15),,,,,,,,,,,,,PRIMARY,Baseline/Visit 2 (Day 1) - Visit 4 (Day 15)
outcome,NCT02819284::outcome::primary::2,NCT02819284,Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 4 (Day 15),,,,,,,,,,,,,PRIMARY,Baseline/Visit 2 (Day 1) - Visit 4 (Day 15)
country,NCT02819284::country::United States,NCT02819284,United States,,,,,,,,,,,,,,
trial,NCT00434967,NCT00434967,Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,2207.0,2007-01,2008-01,6.0,27.0,,,,,
arm,NCT00434967::arm::FG000,NCT00434967,Placebo,,,,,,,,,,FG000,"given as 2 placebo tablets corresponding to candesartan/HCT 16/12.5 mg tablets, 1 placebo tablet corresponding to a candesartan 32 mg tablet and 2 placebo tablets corresponding to HCT 12.5 mg tablets ",,,
arm,NCT00434967::arm::FG001,NCT00434967,Candesartan 32 mg,,,,,,,,,,FG001,candesartan 32 mg (given as 1 candesartan 32 mg tablet plus 2 placebo tablets corresponding to candesartan/Hydrochlorothiazide (HCT) 16/12.5 mg tablets and 2 placebo tablets corresponding to HCT 12.5 ,,,
arm,NCT00434967::arm::FG002,NCT00434967,HCT 25 mg,,,,,,,,,,FG002,HCT 25 mg (given as 2 HCT 12.5 mg tablets plus 2 placebo tablets corresponding to candesartan/HCT 16/12.5 mg tablets and 1 placebo tablet corresponding to a candesartan 32 mg tablet for double dummy b,,,
arm,NCT00434967::arm::FG003,NCT00434967,Candesartan/HCT 32/25 mg,,,,,,,,,,FG003,"candesartan/HCT 32/25 mg (given as 2 candesartan/HCT 16/12.5 mg tablets, plus 1 placebo tablet corresponding to candesartan 32 mg tablet and 2 placebo tablets corresponding to HCT 12.5 mg tablets for ",,,
period,NCT00434967::period::1,NCT00434967,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00434967::outcome::primary::1,NCT00434967,Change in Sitting Diastolic Blood Pressure (DBP) From Baseline to the End of the Study (From Baseline to 8 Weeks).,,,,,,,,,,,,,PRIMARY,8 weeks
outcome,NCT00434967::outcome::primary::2,NCT00434967,Change in Sitting Systolic Blood Pressure (SBP) From Baseline to the End of the Study (Baseline to 8 Weeks),,,,,,,,,,,,,PRIMARY,8 weeks
country,NCT00434967::country::Belgium,NCT00434967,Belgium,,,,,,,,,,,,,,
country,NCT00434967::country::Romania,NCT00434967,Romania,,,,,,,,,,,,,,
country,NCT00434967::country::Slovakia,NCT00434967,Slovakia,,,,,,,,,,,,,,
country,NCT00434967::country::Latvia,NCT00434967,Latvia,,,,,,,,,,,,,,
country,NCT00434967::country::Malta,NCT00434967,Malta,,,,,,,,,,,,,,
country,NCT00434967::country::Russia,NCT00434967,Russia,,,,,,,,,,,,,,
trial,NCT00953212,NCT00953212,Prophylaxis to Reduce Postoperative Atrial Fibrillation in Cardiac Surgery,PHASE3,cardiovascular disease,Atrial Fibrillation; Atrial Flutter,OTHER,304.0,2009-08,2012-02,1.0,1.0,,,,,
arm,NCT00953212::arm::FG000,NCT00953212,"Beta Blockers, Ascorbic Acid and Amiodarone",,,,,,,,,,FG000,"beta blockers: metoprolol 25mg by mouth every 6 hours

amiodarone: amiodarone 600mg by mouth evening before surgery amiodarone 600mg by mouth morning of surgery amiodarone 400mg by mouth every 12 hour",,,
arm,NCT00953212::arm::FG001,NCT00953212,Beta Blockers and Ascorbic Acid,,,,,,,,,,FG001,"Beta Blockers and Ascorbic Acid beta blockers: metoprolol 25mg by mouth every 6 hours

ascorbic acid: ascorbic acid 2,000mg by mouth evening before surgery ascorbic acid 2,000mg by mouth morning of su",,,
arm,NCT00953212::arm::FG002,NCT00953212,Beta Blockers and Amiodarone,,,,,,,,,,FG002,"Beta Blockers and Amiodarone

beta blockers: metoprolol 25mg by mouth every 6 hours

amiodarone: amiodarone 600mg by mouth evening before surgery amiodarone 600mg by mouth morning of surgery amiodaron",,,
arm,NCT00953212::arm::FG003,NCT00953212,Beta Blockers Alone,,,,,,,,,,FG003,"Beta Blockers alone

beta blockers: metoprolol 25mg by mouth every 6 hours",,,
period,NCT00953212::period::1,NCT00953212,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00953212::outcome::primary::1,NCT00953212,Occurrence of Post-operative Atrial Fibrillation Requiring Treatment After Open Heart Surgery,,,,,,,,,,,,,PRIMARY,5 postoperative days
country,NCT00953212::country::United States,NCT00953212,United States,,,,,,,,,,,,,,
trial,NCT00439725,NCT00439725,Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study,PHASE3,cardiovascular disease,Venous Thromboembolism,INDUSTRY,1197.0,2007-02,2009-09,33.0,322.0,,,,,
arm,NCT00439725::arm::FG000,NCT00439725,"Rivaroxaban (Xarelto, BAY59-7939)",,,,,,,,,,FG000,Participants were to receive rivaroxaban 20 mg oral tablet once daily,,,
arm,NCT00439725::arm::FG001,NCT00439725,Placebo,,,,,,,,,,FG001,Participants were to receive matching placebo oral tablet once daily,,,
period,NCT00439725::period::1,NCT00439725,Treatment Period,,,,,,,,,,,,1.0,,
period,NCT00439725::period::2,NCT00439725,Observational Period,,,,,,,,,,,,2.0,,
outcome,NCT00439725::outcome::primary::1,NCT00439725,Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment,,,,,,,,,,,,,PRIMARY,6- or 12-month study treatment period
country,NCT00439725::country::France,NCT00439725,France,,,,,,,,,,,,,,
country,NCT00439725::country::Germany,NCT00439725,Germany,,,,,,,,,,,,,,
country,NCT00439725::country::United States,NCT00439725,United States,,,,,,,,,,,,,,
country,NCT00439725::country::Australia,NCT00439725,Australia,,,,,,,,,,,,,,
country,NCT00439725::country::China,NCT00439725,China,,,,,,,,,,,,,,
country,NCT00439725::country::Poland,NCT00439725,Poland,,,,,,,,,,,,,,
country,NCT00439725::country::Belgium,NCT00439725,Belgium,,,,,,,,,,,,,,
country,NCT00439725::country::Israel,NCT00439725,Israel,,,,,,,,,,,,,,
country,NCT00439725::country::South Africa,NCT00439725,South Africa,,,,,,,,,,,,,,
country,NCT00439725::country::Brazil,NCT00439725,Brazil,,,,,,,,,,,,,,
country,NCT00439725::country::Italy,NCT00439725,Italy,,,,,,,,,,,,,,
country,NCT00439725::country::Netherlands,NCT00439725,Netherlands,,,,,,,,,,,,,,
country,NCT00439725::country::Czechia,NCT00439725,Czechia,,,,,,,,,,,,,,
country,NCT00439725::country::United Kingdom,NCT00439725,United Kingdom,,,,,,,,,,,,,,
country,NCT00439725::country::Hungary,NCT00439725,Hungary,,,,,,,,,,,,,,
country,NCT00439725::country::India,NCT00439725,India,,,,,,,,,,,,,,
country,NCT00439725::country::Spain,NCT00439725,Spain,,,,,,,,,,,,,,
country,NCT00439725::country::Switzerland,NCT00439725,Switzerland,,,,,,,,,,,,,,
country,NCT00439725::country::Austria,NCT00439725,Austria,,,,,,,,,,,,,,
country,NCT00439725::country::South Korea,NCT00439725,South Korea,,,,,,,,,,,,,,
country,NCT00439725::country::Sweden,NCT00439725,Sweden,,,,,,,,,,,,,,
country,NCT00439725::country::New Zealand,NCT00439725,New Zealand,,,,,,,,,,,,,,
country,NCT00439725::country::Taiwan,NCT00439725,Taiwan,,,,,,,,,,,,,,
country,NCT00439725::country::Denmark,NCT00439725,Denmark,,,,,,,,,,,,,,
country,NCT00439725::country::Indonesia,NCT00439725,Indonesia,,,,,,,,,,,,,,
country,NCT00439725::country::Norway,NCT00439725,Norway,,,,,,,,,,,,,,
country,NCT00439725::country::Thailand,NCT00439725,Thailand,,,,,,,,,,,,,,
country,NCT00439725::country::Canada,NCT00439725,Canada,,,,,,,,,,,,,,
country,NCT00439725::country::Philippines,NCT00439725,Philippines,,,,,,,,,,,,,,
country,NCT00439725::country::Singapore,NCT00439725,Singapore,,,,,,,,,,,,,,
country,NCT00439725::country::Finland,NCT00439725,Finland,,,,,,,,,,,,,,
country,NCT00439725::country::Hong Kong,NCT00439725,Hong Kong,,,,,,,,,,,,,,
country,NCT00439725::country::Malaysia,NCT00439725,Malaysia,,,,,,,,,,,,,,
trial,NCT01876368,NCT01876368,Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,376.0,2013-09,2014-08,7.0,51.0,,,,,
arm,NCT01876368::arm::FG000,NCT01876368,LCZ696 200 mg,,,,,,,,,,FG000,Patients will be treated with one LCZ696 200 mg tablet and one placebo of olmesartan 20 mg capsule once daily for 8 weeks.,,,
arm,NCT01876368::arm::FG001,NCT01876368,Olmesartan 20 mg,,,,,,,,,,FG001,Patients will be treated with one placebo of LCZ696 200 mg tablet and one olmesartan 20 mg capsule once daily for 8 weeks.,,,
period,NCT01876368::period::1,NCT01876368,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01876368::outcome::primary::1,NCT01876368,Change From Baseline in 24-hour Mean Ambulatory Systolic Blood Pressure (maSBP),,,,,,,,,,,,,PRIMARY,"baseline, 8 weeks"
country,NCT01876368::country::United States,NCT01876368,United States,,,,,,,,,,,,,,
country,NCT01876368::country::Argentina,NCT01876368,Argentina,,,,,,,,,,,,,,
country,NCT01876368::country::Russia,NCT01876368,Russia,,,,,,,,,,,,,,
country,NCT01876368::country::Spain,NCT01876368,Spain,,,,,,,,,,,,,,
country,NCT01876368::country::Philippines,NCT01876368,Philippines,,,,,,,,,,,,,,
country,NCT01876368::country::Puerto Rico,NCT01876368,Puerto Rico,,,,,,,,,,,,,,
country,NCT01876368::country::Guatemala,NCT01876368,Guatemala,,,,,,,,,,,,,,
trial,NCT01603602,NCT01603602,BOTOX® Treatment in Pediatric Upper Limb Spasticity,PHASE3,cardiovascular disease,Pediatrics; Muscle Spasticity; Cerebral Palsy; Stroke,INDUSTRY,235.0,2012-07-12,2017-07-06,9.0,45.0,,,,,
arm,NCT01603602::arm::FG000,NCT01603602,BOTOX® 6 U/kg,,,,,,,,,,FG000,Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 6 U/kg into specified muscles of the upper limb on Day 1. Participants received weekly occupational therapy (OT).,,,
arm,NCT01603602::arm::FG001,NCT01603602,BOTOX® 3 U/kg,,,,,,,,,,FG001,Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 U/kg into specified muscles of the upper limb on Day 1. Participants received weekly OT.,,,
arm,NCT01603602::arm::FG002,NCT01603602,Placebo,,,,,,,,,,FG002,Participants received intramuscular injections of normal saline (placebo) into specified muscles of the upper limb on Day 1. Participants received weekly OT.,,,
period,NCT01603602::period::1,NCT01603602,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01603602::outcome::primary::1,NCT01603602,Average Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Score of the Principal Muscle Group at Weeks 4 and 6,,,,,,,,,,,,,PRIMARY,Baseline (Day 1) to Weeks 4 and 6
outcome,NCT01603602::outcome::primary::2,NCT01603602,Average Clinical Global Impression (CGI) of Overall Change by Physician at Weeks 4 and 6,,,,,,,,,,,,,PRIMARY,Weeks 4 and 6
country,NCT01603602::country::United States,NCT01603602,United States,,,,,,,,,,,,,,
country,NCT01603602::country::Poland,NCT01603602,Poland,,,,,,,,,,,,,,
country,NCT01603602::country::South Korea,NCT01603602,South Korea,,,,,,,,,,,,,,
country,NCT01603602::country::Russia,NCT01603602,Russia,,,,,,,,,,,,,,
country,NCT01603602::country::Thailand,NCT01603602,Thailand,,,,,,,,,,,,,,
country,NCT01603602::country::Philippines,NCT01603602,Philippines,,,,,,,,,,,,,,
country,NCT01603602::country::Turkey (Türkiye),NCT01603602,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01603602::country::Canada,NCT01603602,Canada,,,,,,,,,,,,,,
country,NCT01603602::country::Hungary,NCT01603602,Hungary,,,,,,,,,,,,,,
trial,NCT01231373,NCT01231373,Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence,PHASE3,cardiovascular disease,Varicose Veins,INDUSTRY,235.0,2010-11,2014-08,1.0,12.0,,,,,
arm,NCT01231373::arm::FG000,NCT01231373,Vehicle,,,,,,,,,,FG000,Vehicle: Injection of vehicle comparator,,,
arm,NCT01231373::arm::FG001,NCT01231373,"Polidocanol Injectable Foam, 0.125%",,,,,,,,,,FG001,active placebo for blinding of therapeutic polidocanol dose,,,
arm,NCT01231373::arm::FG002,NCT01231373,"Polidocanol Injectable Foam, 0.5%",,,,,,,,,,FG002,lower experimental polidocanol dose,,,
arm,NCT01231373::arm::FG003,NCT01231373,"Polidocanol Injectable Foam, 1.0%",,,,,,,,,,FG003,1.0% polidocanol foam injection,,,
period,NCT01231373::period::1,NCT01231373,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01231373::outcome::primary::1,NCT01231373,Change in Patient-Reported Symptoms of Varicose Veins (VVSymQ Score),,,,,,,,,,,,,PRIMARY,8 weeks
country,NCT01231373::country::United States,NCT01231373,United States,,,,,,,,,,,,,,
trial,NCT02546323,NCT02546323,A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis,PHASE3,cardiovascular disease,Atherosclerosis,INDUSTRY,543.0,2015-09-17,2019-01-29,1.0,24.0,,,,,
arm,NCT02546323::arm::FG000,NCT02546323,Rosuvastatin 20 mg,,,,,,,,,,FG000,"Rosuvastatin 20 mg was administered in oral tablet form, once daily, for a 104-week (2-year) treatment period.",,,
arm,NCT02546323::arm::FG001,NCT02546323,Placebo,,,,,,,,,,FG001,"Placebo was administered in oral tablet form, once daily, for a 104-week (2-year) treatment period.",,,
period,NCT02546323::period::1,NCT02546323,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02546323::outcome::primary::1,NCT02546323,Annualized Rate of Change in Mean of the Maximum (MeanMax) CIMT Measurements From Each of the 12 Carotid Artery Sites Based on All Scans Performed During the 104-Week Study Period,,,,,,,,,,,,,PRIMARY,From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).
country,NCT02546323::country::China,NCT02546323,China,,,,,,,,,,,,,,
trial,NCT00276380,NCT00276380,A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke,PHASE3,cardiovascular disease,"Stroke, Acute; Neurological Impairment",INDUSTRY,204.0,2003-02,2009-03,4.0,10.0,,,,,
arm,NCT00276380::arm::FG000,NCT00276380,EGb761®,,,,,,,,,,FG000,"Subjects received EGb761® 240 milligrams (mg)/day for 6 months administered orally, in association with acetylsalicylic acid (325 mg/day).

The test treatment consisted of 6 tablets/day. 2 tablets (ea",,,
arm,NCT00276380::arm::FG001,NCT00276380,Placebo,,,,,,,,,,FG001,"Subjects received placebo for 6 months, administered orally, in association with acetylsalicylic acid (325 mg/day).

The placebo consisted of 6 tablets/day. 2 tablets were taken orally with half a gla",,,
period,NCT00276380::period::1,NCT00276380,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00276380::outcome::primary::1,NCT00276380,Percentage of Subjects With Modified Rankin Score of Less Than 3 at the End of Study Period.,,,,,,,,,,,,,PRIMARY,Day 168
country,NCT00276380::country::Poland,NCT00276380,Poland,,,,,,,,,,,,,,
country,NCT00276380::country::Russia,NCT00276380,Russia,,,,,,,,,,,,,,
country,NCT00276380::country::Czechia,NCT00276380,Czechia,,,,,,,,,,,,,,
country,NCT00276380::country::Romania,NCT00276380,Romania,,,,,,,,,,,,,,
trial,NCT04401293,NCT04401293,Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients,PHASE3,cardiovascular disease,Sars-CoV2; COVID,OTHER,257.0,2020-04-26,2021-05-14,1.0,6.0,,,,,
arm,NCT04401293::arm::FG000,NCT04401293,Full Dose LMWH Anticoagulation Therapy,,,,,,,,,,FG000,Subjects in this study arm will be treated with therapeutic doses of subcutaneous low-molecular-weight heparin (enoxaparin). Enoxaparin 1mg/kg SQ BID for CrCl ≥ 30ml/min (or Enoxaparin 0.5mg/kg SQ BID,,,
arm,NCT04401293::arm::FG001,NCT04401293,Prophylactic/Intermediate Dose LMWH or UFH Therapy,,,,,,,,,,FG001,"Subjects in this study arm will be treated with Local institutional standard-of-care for prophylactic-dose or intermediate-dose UFH or LMWH. Regimens allowed are UFH up to 22,500 IU daily in BID or TI",,,
period,NCT04401293::period::1,NCT04401293,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04401293::outcome::primary::1,NCT04401293,"Composite Outcome of Arterial Thromboembolic Events, Venous Thromboembolic Events and All-cause Mortality at Day 30 ± 2 Days.",,,,,,,,,,,,,PRIMARY,Day 30 ± 2 days
country,NCT04401293::country::United States,NCT04401293,United States,,,,,,,,,,,,,,
trial,NCT01401647,NCT01401647,"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia",PHASE3,cardiovascular disease,Cardiac Arrest,OTHER,3024.0,2012-05,2016-01,2.0,9.0,,,,,
arm,NCT01401647::arm::FG000,NCT01401647,Amiodarone,,,,,,,,,,FG000,"Intravenous (IV) or intraosseous (IO) administration of amiodarone if VF/pulseless VT reoccurs after initial defibrillation.

amiodarone: 300 mg will be given IV/IO push for reoccurrence of ventricula",,,
arm,NCT01401647::arm::FG001,NCT01401647,Lidocaine,,,,,,,,,,FG001,"IV or IO administration of lidocaine if VF/pulseless VT reoccurs after initial defibrillation.

Lidocaine: 120 mg will be given IV/IO push with reoccurrence of ventricular fibrillation or pulseless ve",,,
arm,NCT01401647::arm::FG002,NCT01401647,Normal Saline,,,,,,,,,,FG002,"IV or IO administration of normal saline if VF/pulseless VT reoccurs after initial defibrillation.

Normal saline: 6 cc of normal saline (NS) will be given IV/IO push for reoccurrence of ventricular f",,,
period,NCT01401647::period::1,NCT01401647,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01401647::outcome::primary::1,NCT01401647,Number of Participants Who Survive From the Time of Cardiac Arrest to Hospital Discharge,,,,,,,,,,,,,PRIMARY,"Patients will be followed from the time of the cardiac arrest until death, hospital discharge, or December 31, 2015, whichever occurs first."
country,NCT01401647::country::United States,NCT01401647,United States,,,,,,,,,,,,,,
country,NCT01401647::country::Canada,NCT01401647,Canada,,,,,,,,,,,,,,
trial,NCT01968967,NCT01968967,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,PHASE3,cardiovascular disease,Hyperlipidemia,INDUSTRY,2139.0,2013-10-29,2017-07-10,12.0,249.0,,,,,
arm,NCT01968967::arm::FG000,NCT01968967,Placebo (Treatment Period),,,,,,,,,,FG000,Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once every 2 weeks up to Week 52. Participants were followed up to Week 58.,,,
arm,NCT01968967::arm::FG001,NCT01968967,Bococizumab 150 mg (Treatment Period),,,,,,,,,,FG001,Participants received Bococizumab (PF-04950615) 150 milligram (mg) subcutaneous injection once every 2 weeks up to Week 52. Participants were followed up to Week 58.,,,
arm,NCT01968967::arm::FG002,NCT01968967,Placebo (Extension Period),,,,,,,,,,FG002,"Participants randomized to Placebo arm in treatment period and consented for extension period after Week 58 follow-up visit, were followed for SAEs and concomitant medications up to Week 110.",,,
arm,NCT01968967::arm::FG003,NCT01968967,Bococizumab ADA Positive (Extension Period),,,,,,,,,,FG003,"Participants randomized to Bococizumab in treatment period were classified as either ADA positive or ADA negative based on their ADA assessment at Week 58 follow-up visit. In extension period, partici",,,
arm,NCT01968967::arm::FG004,NCT01968967,Bococizumab ADA Negative (Extension Period),,,,,,,,,,FG004,Participants randomized to Bococizumab in treatment period were classified as either ADA positive or ADA negative based on their Week 58 follow-up ADA assessment. Participants who were ADA negative an,,,
period,NCT01968967::period::1,NCT01968967,Treatment Period,,,,,,,,,,,,1.0,,
period,NCT01968967::period::2,NCT01968967,Extension Period,,,,,,,,,,,,2.0,,
outcome,NCT01968967::outcome::primary::1,NCT01968967,Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12,,,,,,,,,,,,,PRIMARY,"Baseline, Week 12"
country,NCT01968967::country::United States,NCT01968967,United States,,,,,,,,,,,,,,
country,NCT01968967::country::United Kingdom,NCT01968967,United Kingdom,,,,,,,,,,,,,,
country,NCT01968967::country::Canada,NCT01968967,Canada,,,,,,,,,,,,,,
country,NCT01968967::country::Colombia,NCT01968967,Colombia,,,,,,,,,,,,,,
country,NCT01968967::country::Hungary,NCT01968967,Hungary,,,,,,,,,,,,,,
country,NCT01968967::country::Mexico,NCT01968967,Mexico,,,,,,,,,,,,,,
country,NCT01968967::country::Spain,NCT01968967,Spain,,,,,,,,,,,,,,
country,NCT01968967::country::Russia,NCT01968967,Russia,,,,,,,,,,,,,,
country,NCT01968967::country::France,NCT01968967,France,,,,,,,,,,,,,,
country,NCT01968967::country::Romania,NCT01968967,Romania,,,,,,,,,,,,,,
country,NCT01968967::country::Lithuania,NCT01968967,Lithuania,,,,,,,,,,,,,,
country,NCT01968967::country::Taiwan,NCT01968967,Taiwan,,,,,,,,,,,,,,
trial,NCT02252172,NCT02252172,"Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma",PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,737.0,2015-02-16,2024-10-02,13.0,206.0,,,,,
arm,NCT02252172::arm::FG000,NCT02252172,Lenalidomide + Dexamethasone (Rd),,,,,,,,,,FG000,"Participants received Lenalidomide 25 milligrams (mg) capsule orally daily on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously (IV) once a week (QW) until disease",,,
arm,NCT02252172::arm::FG001,NCT02252172,Daratumumab + Lenalidomide + Dexamethasone (DRd),,,,,,,,,,FG001,"Participants received Daratumumab 16 milligrams per kilograms (mg/kg) IV QW for the first 8 weeks (cycles 1-2) and then every 2 weeks (Q2W) for 16 weeks (Cycle 3-6), then every 4 weeks (Q4W) (from Cyc",,,
period,NCT02252172::period::1,NCT02252172,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02252172::outcome::primary::1,NCT02252172,Progression-free Survival (PFS),,,,,,,,,,,,,PRIMARY,"From randomization (Day -3) to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or clinical cut-off (CCO) whichever occurs first (up to 3.5 years)"
country,NCT02252172::country::United States,NCT02252172,United States,,,,,,,,,,,,,,
country,NCT02252172::country::France,NCT02252172,France,,,,,,,,,,,,,,
country,NCT02252172::country::Germany,NCT02252172,Germany,,,,,,,,,,,,,,
country,NCT02252172::country::United Kingdom,NCT02252172,United Kingdom,,,,,,,,,,,,,,
country,NCT02252172::country::Australia,NCT02252172,Australia,,,,,,,,,,,,,,
country,NCT02252172::country::Sweden,NCT02252172,Sweden,,,,,,,,,,,,,,
country,NCT02252172::country::Canada,NCT02252172,Canada,,,,,,,,,,,,,,
country,NCT02252172::country::Israel,NCT02252172,Israel,,,,,,,,,,,,,,
country,NCT02252172::country::Austria,NCT02252172,Austria,,,,,,,,,,,,,,
country,NCT02252172::country::Belgium,NCT02252172,Belgium,,,,,,,,,,,,,,
country,NCT02252172::country::Netherlands,NCT02252172,Netherlands,,,,,,,,,,,,,,
country,NCT02252172::country::Denmark,NCT02252172,Denmark,,,,,,,,,,,,,,
country,NCT02252172::country::Ireland,NCT02252172,Ireland,,,,,,,,,,,,,,
trial,NCT03325556,NCT03325556,Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis,PHASE3,cardiovascular disease,Dementia-related Psychosis,INDUSTRY,392.0,2017-09-27,2019-10-30,13.0,83.0,,,,,
arm,NCT03325556::arm::FG000,NCT03325556,Pimavanserin Open-Label Period,,,,,,,,,,FG000,"Pimavanserin 34 mg once daily, with the possibility to adjust to pimavanserin 20 mg once daily between Weeks 1 and 4 based on tolerability. After Week 4, the dose of study drug remained fixed at eithe",,,
arm,NCT03325556::arm::FG001,NCT03325556,Pimavanserin Double-Blind Period,,,,,,,,,,FG001,Pimavanserin 34 mg once daily or pimavanserin 20 mg once daily (the dose at which patients completed the Open-Label Period) for 26 weeks or until relapse,,,
arm,NCT03325556::arm::FG002,NCT03325556,Placebo Double-Blind Period,,,,,,,,,,FG002,Placebo once daily for 26 weeks or until relapse,,,
period,NCT03325556::period::1,NCT03325556,Open-label Period,,,,,,,,,,,,1.0,,
period,NCT03325556::period::2,NCT03325556,Double-blind Period,,,,,,,,,,,,2.0,,
outcome,NCT03325556::outcome::primary::1,NCT03325556,Time From Randomization to Relapse in the Double-blind (DB) Period,,,,,,,,,,,,,PRIMARY,From randomization in the DB period through 26 weeks
country,NCT03325556::country::United States,NCT03325556,United States,,,,,,,,,,,,,,
country,NCT03325556::country::Ukraine,NCT03325556,Ukraine,,,,,,,,,,,,,,
country,NCT03325556::country::Poland,NCT03325556,Poland,,,,,,,,,,,,,,
country,NCT03325556::country::Serbia,NCT03325556,Serbia,,,,,,,,,,,,,,
country,NCT03325556::country::Italy,NCT03325556,Italy,,,,,,,,,,,,,,
country,NCT03325556::country::Slovakia,NCT03325556,Slovakia,,,,,,,,,,,,,,
country,NCT03325556::country::Spain,NCT03325556,Spain,,,,,,,,,,,,,,
country,NCT03325556::country::Czechia,NCT03325556,Czechia,,,,,,,,,,,,,,
country,NCT03325556::country::United Kingdom,NCT03325556,United Kingdom,,,,,,,,,,,,,,
country,NCT03325556::country::Chile,NCT03325556,Chile,,,,,,,,,,,,,,
country,NCT03325556::country::France,NCT03325556,France,,,,,,,,,,,,,,
country,NCT03325556::country::Bulgaria,NCT03325556,Bulgaria,,,,,,,,,,,,,,
country,NCT03325556::country::Germany,NCT03325556,Germany,,,,,,,,,,,,,,
trial,NCT02226120,NCT02226120,Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction,PHASE3,cardiovascular disease,Chronic Heart Failure With Reduced Ejection Fraction,INDUSTRY,1980.0,2014-10-16,2017-12-28,41.0,394.0,,,,,
arm,NCT02226120::arm::FG000,NCT02226120,LCZ696,,,,,,,,,,FG000,Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid,,,
period,NCT02226120::period::1,NCT02226120,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02226120::outcome::primary::1,NCT02226120,"Percentage of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths as a Measure of Safety and Tolerability of LCZ696",,,,,,,,,,,,,PRIMARY,"From first dose of study treatment to 30 days after last dose of study treatment, up to 30 months."
country,NCT02226120::country::Russia,NCT02226120,Russia,,,,,,,,,,,,,,
country,NCT02226120::country::Germany,NCT02226120,Germany,,,,,,,,,,,,,,
country,NCT02226120::country::United Kingdom,NCT02226120,United Kingdom,,,,,,,,,,,,,,
country,NCT02226120::country::United States,NCT02226120,United States,,,,,,,,,,,,,,
country,NCT02226120::country::Argentina,NCT02226120,Argentina,,,,,,,,,,,,,,
country,NCT02226120::country::Brazil,NCT02226120,Brazil,,,,,,,,,,,,,,
country,NCT02226120::country::India,NCT02226120,India,,,,,,,,,,,,,,
country,NCT02226120::country::Italy,NCT02226120,Italy,,,,,,,,,,,,,,
country,NCT02226120::country::Netherlands,NCT02226120,Netherlands,,,,,,,,,,,,,,
country,NCT02226120::country::Spain,NCT02226120,Spain,,,,,,,,,,,,,,
country,NCT02226120::country::South Africa,NCT02226120,South Africa,,,,,,,,,,,,,,
country,NCT02226120::country::Czechia,NCT02226120,Czechia,,,,,,,,,,,,,,
country,NCT02226120::country::Slovakia,NCT02226120,Slovakia,,,,,,,,,,,,,,
country,NCT02226120::country::Bulgaria,NCT02226120,Bulgaria,,,,,,,,,,,,,,
country,NCT02226120::country::Hungary,NCT02226120,Hungary,,,,,,,,,,,,,,
country,NCT02226120::country::Romania,NCT02226120,Romania,,,,,,,,,,,,,,
country,NCT02226120::country::Canada,NCT02226120,Canada,,,,,,,,,,,,,,
country,NCT02226120::country::Israel,NCT02226120,Israel,,,,,,,,,,,,,,
country,NCT02226120::country::South Korea,NCT02226120,South Korea,,,,,,,,,,,,,,
country,NCT02226120::country::Denmark,NCT02226120,Denmark,,,,,,,,,,,,,,
country,NCT02226120::country::Peru,NCT02226120,Peru,,,,,,,,,,,,,,
country,NCT02226120::country::Portugal,NCT02226120,Portugal,,,,,,,,,,,,,,
country,NCT02226120::country::Taiwan,NCT02226120,Taiwan,,,,,,,,,,,,,,
country,NCT02226120::country::Turkey (Türkiye),NCT02226120,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02226120::country::Belgium,NCT02226120,Belgium,,,,,,,,,,,,,,
country,NCT02226120::country::Philippines,NCT02226120,Philippines,,,,,,,,,,,,,,
country,NCT02226120::country::Sweden,NCT02226120,Sweden,,,,,,,,,,,,,,
country,NCT02226120::country::Guatemala,NCT02226120,Guatemala,,,,,,,,,,,,,,
country,NCT02226120::country::Lithuania,NCT02226120,Lithuania,,,,,,,,,,,,,,
country,NCT02226120::country::Mexico,NCT02226120,Mexico,,,,,,,,,,,,,,
country,NCT02226120::country::Poland,NCT02226120,Poland,,,,,,,,,,,,,,
country,NCT02226120::country::Thailand,NCT02226120,Thailand,,,,,,,,,,,,,,
country,NCT02226120::country::Estonia,NCT02226120,Estonia,,,,,,,,,,,,,,
country,NCT02226120::country::France,NCT02226120,France,,,,,,,,,,,,,,
country,NCT02226120::country::Hong Kong,NCT02226120,Hong Kong,,,,,,,,,,,,,,
country,NCT02226120::country::Latvia,NCT02226120,Latvia,,,,,,,,,,,,,,
country,NCT02226120::country::Malaysia,NCT02226120,Malaysia,,,,,,,,,,,,,,
country,NCT02226120::country::Panama,NCT02226120,Panama,,,,,,,,,,,,,,
country,NCT02226120::country::Singapore,NCT02226120,Singapore,,,,,,,,,,,,,,
country,NCT02226120::country::Chile,NCT02226120,Chile,,,,,,,,,,,,,,
country,NCT02226120::country::Finland,NCT02226120,Finland,,,,,,,,,,,,,,
trial,NCT01644331,NCT01644331,Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure,PHASE3,cardiovascular disease,Heart Failure; Dyspnea,OTHER,257.0,2012-10,2016-02,1.0,18.0,,,,,
arm,NCT01644331::arm::FG000,NCT01644331,Tolvaptan,,,,,,,,,,FG000,"IV furosemide (1 x oral dose given IV in Q12 hours divided doses or 40 mg IV Q12 hours, whichever is greater) plus oral Tolvaptan (given at 0, 12, 24 and 48 hours)

Tolvaptan: Tolvaptan (given at 0, 1",,,
arm,NCT01644331::arm::FG001,NCT01644331,Placebo,,,,,,,,,,FG001,"IV furosemide (1 x oral dose given IV Q12 divided doses or 40mg IV Q12 hours, whichever is greater) plus oral placebo (given at O, 24, 48 hours)

Placebo: IV furosemide (1 x oral dose given IV in Q12 ",,,
period,NCT01644331::period::1,NCT01644331,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01644331::outcome::primary::1,NCT01644331,Dyspnea Improvement Measured by Likert Scale at 8 and 24 Hours,,,,,,,,,,,,,PRIMARY,8 and 24 hours
country,NCT01644331::country::United States,NCT01644331,United States,,,,,,,,,,,,,,
trial,NCT03448406,NCT03448406,This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.,PHASE3,cardiovascular disease,Heart Failure,INDUSTRY,315.0,2018-03-20,2019-10-09,11.0,108.0,,,,,
arm,NCT03448406::arm::FG000,NCT03448406,Placebo,,,,,,,,,,FG000,1 film-coated tablet of Placebo matching Empagliflozin was administered orally once daily for 12 weeks in participants with chronic Heart Failure (CHF) with preserved ejection fraction (LVEF \> 40%).,,,
arm,NCT03448406::arm::FG001,NCT03448406,10 mg Empagliflozin,,,,,,,,,,FG001,1 film-coated tablet of 10 milligram (mg) of Empagliflozin was administered orally once daily for 12 weeks in participants with chronic Heart Failure (CHF) with with preserved ejection fraction (LVEF ,,,
period,NCT03448406::period::1,NCT03448406,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03448406::outcome::primary::1,NCT03448406,Change From Baseline to Week 12 in Exercise Capacity as Measured by the Distance Walked in 6 Minutes in Standardised Conditions (6MWTD),,,,,,,,,,,,,PRIMARY,At baseline and at Week 12
country,NCT03448406::country::United States,NCT03448406,United States,,,,,,,,,,,,,,
country,NCT03448406::country::Germany,NCT03448406,Germany,,,,,,,,,,,,,,
country,NCT03448406::country::Poland,NCT03448406,Poland,,,,,,,,,,,,,,
country,NCT03448406::country::Spain,NCT03448406,Spain,,,,,,,,,,,,,,
country,NCT03448406::country::Italy,NCT03448406,Italy,,,,,,,,,,,,,,
country,NCT03448406::country::Portugal,NCT03448406,Portugal,,,,,,,,,,,,,,
country,NCT03448406::country::Greece,NCT03448406,Greece,,,,,,,,,,,,,,
country,NCT03448406::country::Canada,NCT03448406,Canada,,,,,,,,,,,,,,
country,NCT03448406::country::Norway,NCT03448406,Norway,,,,,,,,,,,,,,
country,NCT03448406::country::Sweden,NCT03448406,Sweden,,,,,,,,,,,,,,
country,NCT03448406::country::Australia,NCT03448406,Australia,,,,,,,,,,,,,,
trial,NCT04415658,NCT04415658,Intravenous Thyroxine for Heart-Eligible Organ Donors,PHASE3,cardiovascular disease,Brain Death; Heart Failure,OTHER,838.0,2020-12-01,2022-12-06,1.0,14.0,,,,,
arm,NCT04415658::arm::FG000,NCT04415658,Thyroxine,,,,,,,,,,FG000,"Intravenous thyroxine infusion

Thyroxine: Infusion prepared by mixing 500 μg of drug in 500-ml of normal saline (i.e. concentration of 1 μg/ml) and enclosing the bag in an opaque sleeve. Infusion sta",,,
arm,NCT04415658::arm::FG001,NCT04415658,Saline Placebo,,,,,,,,,,FG001,"Intravenous saline infusion

Saline: The placebo will be a 500-ml bag of normal saline (without active drug) also enclosed in an opaque sleeve. This infusion will also be started at 30 ml/hour for twe",,,
period,NCT04415658::period::1,NCT04415658,Initial Study Period (12 Hours),,,,,,,,,,,,1.0,,
period,NCT04415658::period::2,NCT04415658,Open-Label (T4 Beyond 12 Hours),,,,,,,,,,,,2.0,,
outcome,NCT04415658::outcome::primary::1,NCT04415658,Heart Transplanted,,,,,,,,,,,,,PRIMARY,One week
outcome,NCT04415658::outcome::primary::2,NCT04415658,Graft Function,,,,,,,,,,,,,PRIMARY,30 days
country,NCT04415658::country::United States,NCT04415658,United States,,,,,,,,,,,,,,
trial,NCT00809965,NCT00809965,An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome,PHASE3,cardiovascular disease,Acute Coronary Syndrome; Myocardial Infarction; Myocardial Ischemia; Unstable Angina,INDUSTRY,15526.0,2008-11,2011-09,43.0,556.0,,,,,
arm,NCT00809965::arm::FG000,NCT00809965,Placebo,,,,,,,,,,FG000,One placebo tablet twice daily,,,
arm,NCT00809965::arm::FG001,NCT00809965,Rivaroxaban 2.5 mg Bid,,,,,,,,,,FG001,One rivaroxaban 2.5 mg tablet twice daily,,,
arm,NCT00809965::arm::FG002,NCT00809965,Rivaroxaban 5 mg Bid,,,,,,,,,,FG002,One rivaroxaban 5 mg tablet twice daily,,,
period,NCT00809965::period::1,NCT00809965,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00809965::outcome::primary::1,NCT00809965,"The Percentage of Patients With the Composite Endpoint of Cardiovascular Death, Myocardial Infarction, or Stroke",,,,,,,,,,,,,PRIMARY,From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)
country,NCT00809965::country::United States,NCT00809965,United States,,,,,,,,,,,,,,
country,NCT00809965::country::Japan,NCT00809965,Japan,,,,,,,,,,,,,,
country,NCT00809965::country::Russia,NCT00809965,Russia,,,,,,,,,,,,,,
country,NCT00809965::country::India,NCT00809965,India,,,,,,,,,,,,,,
country,NCT00809965::country::Poland,NCT00809965,Poland,,,,,,,,,,,,,,
country,NCT00809965::country::Germany,NCT00809965,Germany,,,,,,,,,,,,,,
country,NCT00809965::country::Canada,NCT00809965,Canada,,,,,,,,,,,,,,
country,NCT00809965::country::Czechia,NCT00809965,Czechia,,,,,,,,,,,,,,
country,NCT00809965::country::Ukraine,NCT00809965,Ukraine,,,,,,,,,,,,,,
country,NCT00809965::country::United Kingdom,NCT00809965,United Kingdom,,,,,,,,,,,,,,
country,NCT00809965::country::Spain,NCT00809965,Spain,,,,,,,,,,,,,,
country,NCT00809965::country::Australia,NCT00809965,Australia,,,,,,,,,,,,,,
country,NCT00809965::country::Netherlands,NCT00809965,Netherlands,,,,,,,,,,,,,,
country,NCT00809965::country::Argentina,NCT00809965,Argentina,,,,,,,,,,,,,,
country,NCT00809965::country::China,NCT00809965,China,,,,,,,,,,,,,,
country,NCT00809965::country::Mexico,NCT00809965,Mexico,,,,,,,,,,,,,,
country,NCT00809965::country::Brazil,NCT00809965,Brazil,,,,,,,,,,,,,,
country,NCT00809965::country::Chile,NCT00809965,Chile,,,,,,,,,,,,,,
country,NCT00809965::country::France,NCT00809965,France,,,,,,,,,,,,,,
country,NCT00809965::country::Bulgaria,NCT00809965,Bulgaria,,,,,,,,,,,,,,
country,NCT00809965::country::Israel,NCT00809965,Israel,,,,,,,,,,,,,,
country,NCT00809965::country::Hungary,NCT00809965,Hungary,,,,,,,,,,,,,,
country,NCT00809965::country::Portugal,NCT00809965,Portugal,,,,,,,,,,,,,,
country,NCT00809965::country::Sweden,NCT00809965,Sweden,,,,,,,,,,,,,,
country,NCT00809965::country::Turkey (Türkiye),NCT00809965,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00809965::country::Belgium,NCT00809965,Belgium,,,,,,,,,,,,,,
country,NCT00809965::country::Colombia,NCT00809965,Colombia,,,,,,,,,,,,,,
country,NCT00809965::country::Denmark,NCT00809965,Denmark,,,,,,,,,,,,,,
country,NCT00809965::country::Romania,NCT00809965,Romania,,,,,,,,,,,,,,
country,NCT00809965::country::New Zealand,NCT00809965,New Zealand,,,,,,,,,,,,,,
country,NCT00809965::country::Lithuania,NCT00809965,Lithuania,,,,,,,,,,,,,,
country,NCT00809965::country::Malaysia,NCT00809965,Malaysia,,,,,,,,,,,,,,
country,NCT00809965::country::South Korea,NCT00809965,South Korea,,,,,,,,,,,,,,
country,NCT00809965::country::Egypt,NCT00809965,Egypt,,,,,,,,,,,,,,
country,NCT00809965::country::Greece,NCT00809965,Greece,,,,,,,,,,,,,,
country,NCT00809965::country::Serbia,NCT00809965,Serbia,,,,,,,,,,,,,,
country,NCT00809965::country::Thailand,NCT00809965,Thailand,,,,,,,,,,,,,,
country,NCT00809965::country::Croatia,NCT00809965,Croatia,,,,,,,,,,,,,,
country,NCT00809965::country::Latvia,NCT00809965,Latvia,,,,,,,,,,,,,,
country,NCT00809965::country::Morocco,NCT00809965,Morocco,,,,,,,,,,,,,,
country,NCT00809965::country::Philippines,NCT00809965,Philippines,,,,,,,,,,,,,,
country,NCT00809965::country::Slovakia,NCT00809965,Slovakia,,,,,,,,,,,,,,
country,NCT00809965::country::Tunisia,NCT00809965,Tunisia,,,,,,,,,,,,,,
trial,NCT00032630,NCT00032630,Outcomes Following Myocardial Revascularization: On and Off Cardiopulmonary Bypass,PHASE3,cardiovascular disease,Ischemic Heart Disease,FED,2203.0,2002-04,2008-04,1.0,17.0,,,,,
arm,NCT00032630::arm::FG000,NCT00032630,On Pump,,,,,,,,,,FG000,Coronary artery bypass performed on a non beating heart using a heart-lung machine,,,
arm,NCT00032630::arm::FG001,NCT00032630,Off Pump,,,,,,,,,,FG001,Coronary artery bypass performed on a beating heart with no heart-lung machine,,,
period,NCT00032630::period::1,NCT00032630,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00032630::outcome::primary::1,NCT00032630,Short-term End Point,,,,,,,,,,,,,PRIMARY,30 day
outcome,NCT00032630::outcome::primary::2,NCT00032630,Long-term Composite,,,,,,,,,,,,,PRIMARY,one-year
country,NCT00032630::country::United States,NCT00032630,United States,,,,,,,,,,,,,,
trial,NCT00417963,NCT00417963,ViVEXX Carotid Revascularization Trial (VIVA),PHASE3,cardiovascular disease,Carotid Artery Stenosis,INDUSTRY,407.0,2005-10,2010-03,0.0,0.0,,,,,
arm,NCT00417963::arm::FG000,NCT00417963,ViVexx Carotid Stent Group,,,,,,,,,,FG000,placement of a bare metal stent for treatment of carotid artery stenosis,,,
period,NCT00417963::period::1,NCT00417963,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00417963::outcome::primary::1,NCT00417963,Percentage of Patients Experiencing Major Adverse Events (MAE),,,,,,,,,,,,,PRIMARY,365 days from implantation
trial,NCT02312258,NCT02312258,A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT),PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,706.0,2015-04-09,2022-08-26,35.0,275.0,,,,,
arm,NCT02312258::arm::FG000,NCT02312258,Placebo,,,,,,,,,,FG000,"Ixazomib placebo-matching capsule, orally, once on Days 1, 8, and 15 of each 28-day cycle from Cycles 1 through 26.",,,
arm,NCT02312258::arm::FG001,NCT02312258,Ixazomib,,,,,,,,,,FG001,"Ixazomib 3 mg, capsule, orally, once on Days 1, 8, and 15 of each 28-day cycle from Cycles 1 to 4 that may have been escalated to 4 mg thereafter up to Cycle 26.",,,
period,NCT02312258::period::1,NCT02312258,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02312258::outcome::primary::1,NCT02312258,Progression Free Survival (PFS),,,,,,,,,,,,,PRIMARY,From randomization until PD or death (up to 52 months)
country,NCT02312258::country::Brazil,NCT02312258,Brazil,,,,,,,,,,,,,,
country,NCT02312258::country::United Kingdom,NCT02312258,United Kingdom,,,,,,,,,,,,,,
country,NCT02312258::country::United States,NCT02312258,United States,,,,,,,,,,,,,,
country,NCT02312258::country::Japan,NCT02312258,Japan,,,,,,,,,,,,,,
country,NCT02312258::country::Germany,NCT02312258,Germany,,,,,,,,,,,,,,
country,NCT02312258::country::Italy,NCT02312258,Italy,,,,,,,,,,,,,,
country,NCT02312258::country::Spain,NCT02312258,Spain,,,,,,,,,,,,,,
country,NCT02312258::country::China,NCT02312258,China,,,,,,,,,,,,,,
country,NCT02312258::country::France,NCT02312258,France,,,,,,,,,,,,,,
country,NCT02312258::country::Israel,NCT02312258,Israel,,,,,,,,,,,,,,
country,NCT02312258::country::Portugal,NCT02312258,Portugal,,,,,,,,,,,,,,
country,NCT02312258::country::Czechia,NCT02312258,Czechia,,,,,,,,,,,,,,
country,NCT02312258::country::Greece,NCT02312258,Greece,,,,,,,,,,,,,,
country,NCT02312258::country::South Korea,NCT02312258,South Korea,,,,,,,,,,,,,,
country,NCT02312258::country::Argentina,NCT02312258,Argentina,,,,,,,,,,,,,,
country,NCT02312258::country::Mexico,NCT02312258,Mexico,,,,,,,,,,,,,,
country,NCT02312258::country::Russia,NCT02312258,Russia,,,,,,,,,,,,,,
country,NCT02312258::country::Austria,NCT02312258,Austria,,,,,,,,,,,,,,
country,NCT02312258::country::Canada,NCT02312258,Canada,,,,,,,,,,,,,,
country,NCT02312258::country::Chile,NCT02312258,Chile,,,,,,,,,,,,,,
country,NCT02312258::country::Denmark,NCT02312258,Denmark,,,,,,,,,,,,,,
country,NCT02312258::country::Hungary,NCT02312258,Hungary,,,,,,,,,,,,,,
country,NCT02312258::country::Poland,NCT02312258,Poland,,,,,,,,,,,,,,
country,NCT02312258::country::Serbia,NCT02312258,Serbia,,,,,,,,,,,,,,
country,NCT02312258::country::Sweden,NCT02312258,Sweden,,,,,,,,,,,,,,
country,NCT02312258::country::Turkey (Türkiye),NCT02312258,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02312258::country::Australia,NCT02312258,Australia,,,,,,,,,,,,,,
country,NCT02312258::country::Belgium,NCT02312258,Belgium,,,,,,,,,,,,,,
country,NCT02312258::country::Colombia,NCT02312258,Colombia,,,,,,,,,,,,,,
country,NCT02312258::country::Croatia,NCT02312258,Croatia,,,,,,,,,,,,,,
country,NCT02312258::country::South Africa,NCT02312258,South Africa,,,,,,,,,,,,,,
country,NCT02312258::country::Taiwan,NCT02312258,Taiwan,,,,,,,,,,,,,,
country,NCT02312258::country::Thailand,NCT02312258,Thailand,,,,,,,,,,,,,,
country,NCT02312258::country::Singapore,NCT02312258,Singapore,,,,,,,,,,,,,,
country,NCT02312258::country::Switzerland,NCT02312258,Switzerland,,,,,,,,,,,,,,
trial,NCT02270736,NCT02270736,Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability,PHASE3,cardiovascular disease,Chronic Troublesome Sialorrhea; Cerebral Palsy; Stroke; Traumatic Brain Injury; Intellectual Disability,INDUSTRY,256.0,2015-02-09,2019-05-07,6.0,31.0,,,,,
arm,NCT02270736::arm::FG000,NCT02270736,Double-blind MP: Placebo (Age 6 to 17 Years),,,,,,,,,,FG000,"Participants received placebo via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period ",,,
arm,NCT02270736::arm::FG001,NCT02270736,"Double-blind, MP: NT 201 (Age 6 to 17 Years)",,,,,,,,,,FG001,Participants received NT 201 (up to 2.5 Units per kilogram \[U/kg\] body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Vis,,,
arm,NCT02270736::arm::FG002,NCT02270736,"Open-label, MP: NT 201 (Age 2 to 5 Years)",,,,,,,,,,FG002,"Participants received NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, foll",,,
arm,NCT02270736::arm::FG003,NCT02270736,OLEX: NT 201 (Age 6 to 17 Years),,,,,,,,,,FG003,"Participants received NT 201 (up to 2.5 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (V",,,
arm,NCT02270736::arm::FG004,NCT02270736,OLEX: NT 201 (Age 2 to 5 Years),,,,,,,,,,FG004,"Participants received NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth ",,,
period,NCT02270736::period::1,NCT02270736,Main Period (MP) (up to 16 Weeks),,,,,,,,,,,,1.0,,
period,NCT02270736::period::2,NCT02270736,OLEX Period (up to 48 Weeks),,,,,,,,,,,,2.0,,
outcome,NCT02270736::outcome::primary::1,NCT02270736,Change From Baseline in Unstimulated Salivary Flow Rate (uSFR) at Week 4,,,,,,,,,,,,,PRIMARY,Baseline and Week 4
outcome,NCT02270736::outcome::primary::2,NCT02270736,Global Impression of Change Scale (GICS) at Week 4 Assessed by the Carer/Parent(s),,,,,,,,,,,,,PRIMARY,Week 4
outcome,NCT02270736::outcome::primary::3,NCT02270736,Occurrence of Treatment Emergent Adverse Events (TEAEs) Overall and Per Injection Cycle,,,,,,,,,,,,,PRIMARY,Baseline up to Week 64
country,NCT02270736::country::Russia,NCT02270736,Russia,,,,,,,,,,,,,,
country,NCT02270736::country::Ukraine,NCT02270736,Ukraine,,,,,,,,,,,,,,
country,NCT02270736::country::Hungary,NCT02270736,Hungary,,,,,,,,,,,,,,
country,NCT02270736::country::Poland,NCT02270736,Poland,,,,,,,,,,,,,,
country,NCT02270736::country::Georgia,NCT02270736,Georgia,,,,,,,,,,,,,,
country,NCT02270736::country::Serbia,NCT02270736,Serbia,,,,,,,,,,,,,,
trial,NCT00878644,NCT00878644,Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-OH [Out of Hospital] Trial,PHASE3,cardiovascular disease,Cardiac Arrest,OTHER,295.0,2009-09,2014-06,2.0,34.0,,,,,
arm,NCT00878644::arm::FG000,NCT00878644,Therapeutic Hypothermia,,,,,,,,,,FG000,"Participants will receive therapeutic hypothermia after experiencing cardiac arrest.

Therapeutic Hypothermia: Participants who are assigned to receive hypothermia will be cooled to a target temperatu",,,
arm,NCT00878644::arm::FG001,NCT00878644,Therapeutic Normothermia,,,,,,,,,,FG001,"Participants will receive therapeutic normothermia after experiencing cardiac arrest.

Therapeutic Normothermia: Participants who are assigned to receive therapeutic normothermia will have their tempe",,,
period,NCT00878644::period::1,NCT00878644,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00878644::outcome::primary::1,NCT00878644,Survival With Good Neurobehavioral Outcome,,,,,,,,,,,,,PRIMARY,Survival was assessed at one-year anniversary of cardiac arrest
country,NCT00878644::country::United States,NCT00878644,United States,,,,,,,,,,,,,,
country,NCT00878644::country::Canada,NCT00878644,Canada,,,,,,,,,,,,,,
trial,NCT02110901,NCT02110901,A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1),PHASE3,cardiovascular disease,Chronic Kidney Disease,INDUSTRY,349.0,2014-07,2018-12,1.0,35.0,,,,,
arm,NCT02110901::arm::FG000,NCT02110901,Vonapanitase,,,,,,,,,,FG000,Vonapanitase administered at the time of radiocephalic fistula creation,,,
arm,NCT02110901::arm::FG001,NCT02110901,Placebo,,,,,,,,,,FG001,Placebo administered at the time of radiocephalic fistula creation,,,
period,NCT02110901::period::1,NCT02110901,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02110901::outcome::primary::1,NCT02110901,Time to AVF Primary Unassisted Patency,,,,,,,,,,,,,PRIMARY,"Days from AVF creation until the first occurrence of either access thrombosis or procedure to restore or maintain patency, assessed up to 1 year"
outcome,NCT02110901::outcome::primary::2,NCT02110901,Kaplan-Meier Estimate of Secondary AVF Patency,,,,,,,,,,,,,PRIMARY,"Median time from AVF creation until AVF abandonment (secondary patency), assessed up to 1 year"
country,NCT02110901::country::United States,NCT02110901,United States,,,,,,,,,,,,,,
trial,NCT01010932,NCT01010932,Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF),PHASE3,cardiovascular disease,Cerebral Arterial Diseases,INDUSTRY,222.0,2009-10,2010-12,1.0,1.0,,,,,
arm,NCT01010932::arm::FG000,NCT01010932,TOF MRA Followed by Dotarem-enhanced MRA,,,,,,,,,,FG000,"Each patient will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem-enhanced MRA.

Each patient will be scheduled to undergo CTA either before TOF MRA or after ",,,
period,NCT01010932::period::1,NCT01010932,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01010932::outcome::primary::1,NCT01010932,Technical Failure Rate,,,,,,,,,,,,,PRIMARY,2 - 28 days
outcome,NCT01010932::outcome::primary::2,NCT01010932,Sensitivity,,,,,,,,,,,,,PRIMARY,2-42 days
outcome,NCT01010932::outcome::primary::3,NCT01010932,Specificity,,,,,,,,,,,,,PRIMARY,2 - 42 days
country,NCT01010932::country::United States,NCT01010932,United States,,,,,,,,,,,,,,
trial,NCT00162032,NCT00162032,A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease,PHASE3,cardiovascular disease,Kawasaki Disease,INDUSTRY,445.0,2005-08,2010-12,7.0,50.0,,,,,
arm,NCT00162032::arm::FG000,NCT00162032,Children (Ages 4-11),,,,,,,,,,FG000,Arm A children 4-11 years of age,,,
arm,NCT00162032::arm::FG001,NCT00162032,Adolescents (Ages 12-16),,,,,,,,,,FG001,Arm B children 12-16 years of age,,,
period,NCT00162032::period::1,NCT00162032,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00162032::outcome::primary::1,NCT00162032,Determine the Predictive Value of Cardiolite® Rest and Stress MPI to Define Pediatric Populations With Kawasaki Disease at High and Low Risk of Developing Cardiac Events.,,,,,,,,,,,,,PRIMARY,3 years
country,NCT00162032::country::United States,NCT00162032,United States,,,,,,,,,,,,,,
country,NCT00162032::country::Brazil,NCT00162032,Brazil,,,,,,,,,,,,,,
country,NCT00162032::country::South Korea,NCT00162032,South Korea,,,,,,,,,,,,,,
country,NCT00162032::country::Canada,NCT00162032,Canada,,,,,,,,,,,,,,
country,NCT00162032::country::Taiwan,NCT00162032,Taiwan,,,,,,,,,,,,,,
country,NCT00162032::country::Thailand,NCT00162032,Thailand,,,,,,,,,,,,,,
country,NCT00162032::country::Philippines,NCT00162032,Philippines,,,,,,,,,,,,,,
trial,NCT02164864,NCT02164864,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),PHASE3,cardiovascular disease,Atrial Fibrillation; Percutaneous Coronary Intervention,INDUSTRY,2725.0,2014-07-22,2017-06-05,41.0,421.0,,,,,
arm,NCT02164864::arm::FG000,NCT02164864,Dabigatran Etexilate 110mg,,,,,,,,,,FG000,Patients were orally administered Dabigatran Etexilate 110mg capsule twice daily (BID) for at least 6 months.,,,
arm,NCT02164864::arm::FG001,NCT02164864,Dabigatran Etexilate 150mg,,,,,,,,,,FG001,Patients were orally administered Dabigatran Etexilate 150mg capsule twice daily (BID) for at least 6 months.,,,
arm,NCT02164864::arm::FG002,NCT02164864,Warfarin,,,,,,,,,,FG002,"Patients were orally administered warfarin 1 mg, 3 mg, or 5 mg tablets once daily for at least 6 months. The warfarin dose was titrated as needed to maintain the target International normalised ratio ",,,
period,NCT02164864::period::1,NCT02164864,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02164864::outcome::primary::1,NCT02164864,Time to First Adjudicated ISTH MBE or CRNMBE,,,,,,,,,,,,,PRIMARY,up to 30 months
country,NCT02164864::country::Germany,NCT02164864,Germany,,,,,,,,,,,,,,
country,NCT02164864::country::United States,NCT02164864,United States,,,,,,,,,,,,,,
country,NCT02164864::country::Japan,NCT02164864,Japan,,,,,,,,,,,,,,
country,NCT02164864::country::Turkey (Türkiye),NCT02164864,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02164864::country::Italy,NCT02164864,Italy,,,,,,,,,,,,,,
country,NCT02164864::country::Russia,NCT02164864,Russia,,,,,,,,,,,,,,
country,NCT02164864::country::Spain,NCT02164864,Spain,,,,,,,,,,,,,,
country,NCT02164864::country::South Korea,NCT02164864,South Korea,,,,,,,,,,,,,,
country,NCT02164864::country::Czechia,NCT02164864,Czechia,,,,,,,,,,,,,,
country,NCT02164864::country::France,NCT02164864,France,,,,,,,,,,,,,,
country,NCT02164864::country::United Kingdom,NCT02164864,United Kingdom,,,,,,,,,,,,,,
country,NCT02164864::country::Canada,NCT02164864,Canada,,,,,,,,,,,,,,
country,NCT02164864::country::Belgium,NCT02164864,Belgium,,,,,,,,,,,,,,
country,NCT02164864::country::Greece,NCT02164864,Greece,,,,,,,,,,,,,,
country,NCT02164864::country::Poland,NCT02164864,Poland,,,,,,,,,,,,,,
country,NCT02164864::country::Argentina,NCT02164864,Argentina,,,,,,,,,,,,,,
country,NCT02164864::country::India,NCT02164864,India,,,,,,,,,,,,,,
country,NCT02164864::country::Australia,NCT02164864,Australia,,,,,,,,,,,,,,
country,NCT02164864::country::Brazil,NCT02164864,Brazil,,,,,,,,,,,,,,
country,NCT02164864::country::Netherlands,NCT02164864,Netherlands,,,,,,,,,,,,,,
country,NCT02164864::country::Sweden,NCT02164864,Sweden,,,,,,,,,,,,,,
country,NCT02164864::country::Taiwan,NCT02164864,Taiwan,,,,,,,,,,,,,,
country,NCT02164864::country::Hungary,NCT02164864,Hungary,,,,,,,,,,,,,,
country,NCT02164864::country::Portugal,NCT02164864,Portugal,,,,,,,,,,,,,,
country,NCT02164864::country::Bulgaria,NCT02164864,Bulgaria,,,,,,,,,,,,,,
country,NCT02164864::country::Colombia,NCT02164864,Colombia,,,,,,,,,,,,,,
country,NCT02164864::country::Israel,NCT02164864,Israel,,,,,,,,,,,,,,
country,NCT02164864::country::Croatia,NCT02164864,Croatia,,,,,,,,,,,,,,
country,NCT02164864::country::Norway,NCT02164864,Norway,,,,,,,,,,,,,,
country,NCT02164864::country::Chile,NCT02164864,Chile,,,,,,,,,,,,,,
country,NCT02164864::country::Finland,NCT02164864,Finland,,,,,,,,,,,,,,
country,NCT02164864::country::Hong Kong,NCT02164864,Hong Kong,,,,,,,,,,,,,,
country,NCT02164864::country::Ireland,NCT02164864,Ireland,,,,,,,,,,,,,,
country,NCT02164864::country::Mexico,NCT02164864,Mexico,,,,,,,,,,,,,,
country,NCT02164864::country::Slovakia,NCT02164864,Slovakia,,,,,,,,,,,,,,
country,NCT02164864::country::Slovenia,NCT02164864,Slovenia,,,,,,,,,,,,,,
country,NCT02164864::country::Thailand,NCT02164864,Thailand,,,,,,,,,,,,,,
country,NCT02164864::country::Austria,NCT02164864,Austria,,,,,,,,,,,,,,
country,NCT02164864::country::Singapore,NCT02164864,Singapore,,,,,,,,,,,,,,
country,NCT02164864::country::Denmark,NCT02164864,Denmark,,,,,,,,,,,,,,
country,NCT02164864::country::New Zealand,NCT02164864,New Zealand,,,,,,,,,,,,,,
trial,NCT02398656,NCT02398656,A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion,PHASE3,cardiovascular disease,"Stroke, Acute",OTHER,1274.0,2015-04-01,2024-04-10,10.0,61.0,,,,,
arm,NCT02398656::arm::FG000,NCT02398656,Tenecteplase (tNK),,,,,,,,,,FG000,"Experimental: TNK-tPA (0.25mg/kg) given as a single, intravenous bolus immediately upon randomization. Experimental treatment will be administered as a single intravenous bolus over 1-2 minutes as per",,,
arm,NCT02398656::arm::FG001,NCT02398656,Control (Antiplatelet Agents),,,,,,,,,,FG001,Control: Patients will be treated with standard of care based antiplatelet treatment - choice at the discretion of the investigator. Low dose aspirin (single agent) will be the choice of most physicia,,,
period,NCT02398656::period::1,NCT02398656,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02398656::outcome::primary::1,NCT02398656,Number of Participants With Return to Baseline Neurological Functioning Measured by the Modified Rankin Scale (mRS),,,,,,,,,,,,,PRIMARY,90 Days
country,NCT02398656::country::Canada,NCT02398656,Canada,,,,,,,,,,,,,,
country,NCT02398656::country::Brazil,NCT02398656,Brazil,,,,,,,,,,,,,,
country,NCT02398656::country::United Kingdom,NCT02398656,United Kingdom,,,,,,,,,,,,,,
country,NCT02398656::country::Australia,NCT02398656,Australia,,,,,,,,,,,,,,
country,NCT02398656::country::Spain,NCT02398656,Spain,,,,,,,,,,,,,,
country,NCT02398656::country::Austria,NCT02398656,Austria,,,,,,,,,,,,,,
country,NCT02398656::country::Ireland,NCT02398656,Ireland,,,,,,,,,,,,,,
country,NCT02398656::country::Singapore,NCT02398656,Singapore,,,,,,,,,,,,,,
country,NCT02398656::country::Finland,NCT02398656,Finland,,,,,,,,,,,,,,
country,NCT02398656::country::New Zealand,NCT02398656,New Zealand,,,,,,,,,,,,,,
trial,NCT00722566,NCT00722566,A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma,PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,222.0,2008-07,2010-09,3.0,3.0,,,,,
arm,NCT00722566::arm::FG000,NCT00722566,VELCADE Subcutaneous,,,,,,,,,,FG000,"VELCADE 1.3 mg/m\^2 administered by subcutaneous injection on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles.",,,
arm,NCT00722566::arm::FG001,NCT00722566,VELCADE Intravenous,,,,,,,,,,FG001,"VELCADE 1.3 mg/m\^2 administered by intravenous infusion on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles.",,,
period,NCT00722566::period::1,NCT00722566,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00722566::outcome::primary::1,NCT00722566,Number of Patients With Overall Response (Complete Response + Partial Response),,,,,,,,,,,,,PRIMARY,Over 4 cycles (prior to the addition of dexamethasone)
country,NCT00722566::country::Belgium,NCT00722566,Belgium,,,,,,,,,,,,,,
country,NCT00722566::country::France,NCT00722566,France,,,,,,,,,,,,,,
country,NCT00722566::country::Germany,NCT00722566,Germany,,,,,,,,,,,,,,
trial,NCT01898923,NCT01898923,Evaluate the Efficacy and Safety of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers,PHASE3,cardiovascular disease,Diabetic Foot,INDUSTRY,236.0,2012-11-23,2020-05-11,3.0,21.0,,,,,
arm,NCT01898923::arm::FG000,NCT01898923,ON101 Cream,,,,,,,,,,FG000,"ON101 Cream (1.25%),15g ointment per tube. Twice daily for up to 16 weeks.

ON101 Cream",,,
arm,NCT01898923::arm::FG001,NCT01898923,Aquacel® Hydrofiber® Dressing,,,,,,,,,,FG001,"Aquacel® Hydrofiber® dressings will be changed daily, on alternate days or three times a week according to need, but not longer than 7 days.

Aquacel® Hydrofiber® dressing",,,
period,NCT01898923::period::1,NCT01898923,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01898923::outcome::primary::1,NCT01898923,Number of Participants With Complete Ulcer Closure,,,,,,,,,,,,,PRIMARY,16 weeks
country,NCT01898923::country::Taiwan,NCT01898923,Taiwan,,,,,,,,,,,,,,
country,NCT01898923::country::China,NCT01898923,China,,,,,,,,,,,,,,
country,NCT01898923::country::United States,NCT01898923,United States,,,,,,,,,,,,,,
trial,NCT00594100,NCT00594100,GORE Embolic Protection With Reverse Flow,PHASE3,cardiovascular disease,Carotid Artery Stenosis,INDUSTRY,245.0,2006-07,2008-09,1.0,2.0,,,,,
arm,NCT00594100::arm::FG000,NCT00594100,GFRS Pivotal Subjects,,,,,,,,,,FG000,All non-training subjects using the GORE Flow Reversal System for embolic protection during carotid artery stenting (all subjects other than first two subjects accounted for in Training Cases).,,,
period,NCT00594100::period::1,NCT00594100,Procedure,,,,,,,,,,,,1.0,,
period,NCT00594100::period::2,NCT00594100,Follow-up Through 30 Days Post Procedure,,,,,,,,,,,,2.0,,
outcome,NCT00594100::outcome::primary::1,NCT00594100,Composite Major Adverse Event (MAE) Rate,,,,,,,,,,,,,PRIMARY,Treatment through 30-day visit window
country,NCT00594100::country::United States,NCT00594100,United States,,,,,,,,,,,,,,
trial,NCT00345839,NCT00345839,E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events,PHASE3,cardiovascular disease,Secondary Hyperparathyroidism; Chronic Kidney Disease,INDUSTRY,3883.0,2006-08-22,2012-04-10,0.0,0.0,,,,,
arm,NCT00345839::arm::FG000,NCT00345839,Cinacalcet,,,,,,,,,,FG000,"Cinacalcet administered orally in doses of 30, 60, 90, 120 or 180 mg per day. Participants could be titrated up to maximum dose based on PTH (parathyroid hormone), serum calcium and safety assessments",,,
arm,NCT00345839::arm::FG001,NCT00345839,Placebo,,,,,,,,,,FG001,Participants were given matching placebo tablets compared to the cinacalcet group.,,,
period,NCT00345839::period::1,NCT00345839,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00345839::outcome::primary::1,NCT00345839,"Time to Primary Composite Endpoint (All-cause Mortality, Myocardial Infarction, Hospitalization for Unstable Angina, Heart Failure or Peripheral Vascular Event)",,,,,,,,,,,,,PRIMARY,"From date of randomization until date of first confirmed primary composite endpoint event, assessed up to 5.4 years"
trial,NCT01033071,NCT01033071,Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.,PHASE3,cardiovascular disease,Essential Hypertension,INDUSTRY,1071.0,2010-01,2010-11,2.0,94.0,,,,,
arm,NCT01033071::arm::FG000,NCT01033071,Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD,,,,,,,,,,FG000,"Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.

Pa",,,
arm,NCT01033071::arm::FG001,NCT01033071,Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD,,,,,,,,,,FG001,"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.

Pa",,,
arm,NCT01033071::arm::FG002,NCT01033071,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,,,,,,,,,,FG002,"Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily and azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for up to 4 ",,,
period,NCT01033071::period::1,NCT01033071,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01033071::outcome::primary::1,NCT01033071,"Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure.",,,,,,,,,,,,,PRIMARY,Baseline and Week 12.
country,NCT01033071::country::United States,NCT01033071,United States,,,,,,,,,,,,,,
country,NCT01033071::country::Canada,NCT01033071,Canada,,,,,,,,,,,,,,
trial,NCT00799903,NCT00799903,The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial,PHASE3,cardiovascular disease,Atherosclerosis,INDUSTRY,15828.0,2008-12-01,2013-10-17,39.0,650.0,,,,,
arm,NCT00799903::arm::FG000,NCT00799903,Placebo,,,,,,,,,,FG000,Participants were randomized to receive matching placebo once daily.,,,
arm,NCT00799903::arm::FG001,NCT00799903,Darapladib,,,,,,,,,,FG001,Participants were randomized to receive darapladib 160 milligram (mg) enteric-coated tablets once daily.,,,
period,NCT00799903::period::1,NCT00799903,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00799903::outcome::primary::1,NCT00799903,"Number of Participants With First Occurrence of Any Component of the Composite of Major Adverse Cardiovascular Events (Cardiovascular [CV] Death, Non-fatal Myocardial Infarction [MI] or Non-fatal Stroke) During the Time Period for Follow-up of CV Events",,,,,,,,,,,,,PRIMARY,From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 4.25 years/average of 3.51 years)
country,NCT00799903::country::United States,NCT00799903,United States,,,,,,,,,,,,,,
country,NCT00799903::country::Germany,NCT00799903,Germany,,,,,,,,,,,,,,
country,NCT00799903::country::Canada,NCT00799903,Canada,,,,,,,,,,,,,,
country,NCT00799903::country::France,NCT00799903,France,,,,,,,,,,,,,,
country,NCT00799903::country::Russia,NCT00799903,Russia,,,,,,,,,,,,,,
country,NCT00799903::country::Spain,NCT00799903,Spain,,,,,,,,,,,,,,
country,NCT00799903::country::Japan,NCT00799903,Japan,,,,,,,,,,,,,,
country,NCT00799903::country::Argentina,NCT00799903,Argentina,,,,,,,,,,,,,,
country,NCT00799903::country::Poland,NCT00799903,Poland,,,,,,,,,,,,,,
country,NCT00799903::country::Brazil,NCT00799903,Brazil,,,,,,,,,,,,,,
country,NCT00799903::country::United Kingdom,NCT00799903,United Kingdom,,,,,,,,,,,,,,
country,NCT00799903::country::Australia,NCT00799903,Australia,,,,,,,,,,,,,,
country,NCT00799903::country::China,NCT00799903,China,,,,,,,,,,,,,,
country,NCT00799903::country::Czechia,NCT00799903,Czechia,,,,,,,,,,,,,,
country,NCT00799903::country::South Korea,NCT00799903,South Korea,,,,,,,,,,,,,,
country,NCT00799903::country::India,NCT00799903,India,,,,,,,,,,,,,,
country,NCT00799903::country::Netherlands,NCT00799903,Netherlands,,,,,,,,,,,,,,
country,NCT00799903::country::South Africa,NCT00799903,South Africa,,,,,,,,,,,,,,
country,NCT00799903::country::Sweden,NCT00799903,Sweden,,,,,,,,,,,,,,
country,NCT00799903::country::Ukraine,NCT00799903,Ukraine,,,,,,,,,,,,,,
country,NCT00799903::country::Hungary,NCT00799903,Hungary,,,,,,,,,,,,,,
country,NCT00799903::country::Italy,NCT00799903,Italy,,,,,,,,,,,,,,
country,NCT00799903::country::New Zealand,NCT00799903,New Zealand,,,,,,,,,,,,,,
country,NCT00799903::country::Belgium,NCT00799903,Belgium,,,,,,,,,,,,,,
country,NCT00799903::country::Greece,NCT00799903,Greece,,,,,,,,,,,,,,
country,NCT00799903::country::Bulgaria,NCT00799903,Bulgaria,,,,,,,,,,,,,,
country,NCT00799903::country::Romania,NCT00799903,Romania,,,,,,,,,,,,,,
country,NCT00799903::country::Chile,NCT00799903,Chile,,,,,,,,,,,,,,
country,NCT00799903::country::Pakistan,NCT00799903,Pakistan,,,,,,,,,,,,,,
country,NCT00799903::country::Philippines,NCT00799903,Philippines,,,,,,,,,,,,,,
country,NCT00799903::country::Taiwan,NCT00799903,Taiwan,,,,,,,,,,,,,,
country,NCT00799903::country::Denmark,NCT00799903,Denmark,,,,,,,,,,,,,,
country,NCT00799903::country::Mexico,NCT00799903,Mexico,,,,,,,,,,,,,,
country,NCT00799903::country::Norway,NCT00799903,Norway,,,,,,,,,,,,,,
country,NCT00799903::country::Slovakia,NCT00799903,Slovakia,,,,,,,,,,,,,,
country,NCT00799903::country::Thailand,NCT00799903,Thailand,,,,,,,,,,,,,,
country,NCT00799903::country::Estonia,NCT00799903,Estonia,,,,,,,,,,,,,,
country,NCT00799903::country::Peru,NCT00799903,Peru,,,,,,,,,,,,,,
country,NCT00799903::country::Hong Kong,NCT00799903,Hong Kong,,,,,,,,,,,,,,
trial,NCT00413413,NCT00413413,Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,1134.0,2007-01,2007-11,1.0,19.0,,,,,
arm,NCT00413413::arm::FG000,NCT00413413,Valsartan/Amlodipine 80/5 mg,,,,,,,,,,FG000,"1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily",,,
arm,NCT00413413::arm::FG001,NCT00413413,Valsartan 80 mg,,,,,,,,,,FG001,"1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily",,,
arm,NCT00413413::arm::FG002,NCT00413413,Valsartan 160 mg,,,,,,,,,,FG002,"1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily",,,
period,NCT00413413::period::1,NCT00413413,Single-Blind,,,,,,,,,,,,1.0,,
period,NCT00413413::period::2,NCT00413413,Double-Blind,,,,,,,,,,,,2.0,,
outcome,NCT00413413::outcome::primary::1,NCT00413413,Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8),,,,,,,,,,,,,PRIMARY,Baseline to end of study (Week 8)
country,NCT00413413::country::China,NCT00413413,China,,,,,,,,,,,,,,
trial,NCT01426425,NCT01426425,Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia,PHASE3,cardiovascular disease,AtrioVentricular Nodal Reentrant Tachycardia; Supraventricular Tachycardia; Heart Disease,INDUSTRY,572.0,2012-05,2016-09,2.0,34.0,,,,,
arm,NCT01426425::arm::FG000,NCT01426425,All Participants,,,,,,,,,,FG000,All subjects enrolled into the study.,,,
period,NCT01426425::period::1,NCT01426425,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01426425::outcome::primary::1,NCT01426425,Chronic Effectiveness (Through 6 Months) of the Freezor Xtra Catheter for the Treatment of AVNRT Using an Endocardial Approach.,,,,,,,,,,,,,PRIMARY,6 months
outcome,NCT01426425::outcome::primary::2,NCT01426425,Chronic Safety (Through 6 Months) of the Freezor Xtra Catheter When Used for the Treatment of AVNRT Using an Endocardial Approach.,,,,,,,,,,,,,PRIMARY,6 Months
country,NCT01426425::country::United States,NCT01426425,United States,,,,,,,,,,,,,,
country,NCT01426425::country::Canada,NCT01426425,Canada,,,,,,,,,,,,,,
trial,NCT02755597,NCT02755597,A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy,PHASE3,cardiovascular disease,Relapsed/Refractory Multiple Myeloma,INDUSTRY,291.0,2016-07-11,2022-08-15,16.0,97.0,,,,,
arm,NCT02755597::arm::FG000,NCT02755597,Venetoclax + Bortezomib and Dexamethasone,,,,,,,,,,FG000,"Cycles 1-8: Venetoclax 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m\^2 subcutaneously or IV on Days 1, 4, 8 \& 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 \&",,,
arm,NCT02755597::arm::FG001,NCT02755597,Placebo + Bortezomib and Dexamethasone,,,,,,,,,,FG001,"Cycles 1-8: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m\^2 subcutaneously or IV on Days 1, 4, 8 \& 11 and dexamethasone 20 mg orall",,,
period,NCT02755597::period::1,NCT02755597,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02755597::outcome::primary::1,NCT02755597,Progression-free Survival (PFS),,,,,,,,,,,,,PRIMARY,Median duration of follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group
country,NCT02755597::country::Japan,NCT02755597,Japan,,,,,,,,,,,,,,
country,NCT02755597::country::Australia,NCT02755597,Australia,,,,,,,,,,,,,,
country,NCT02755597::country::United Kingdom,NCT02755597,United Kingdom,,,,,,,,,,,,,,
country,NCT02755597::country::South Korea,NCT02755597,South Korea,,,,,,,,,,,,,,
country,NCT02755597::country::Russia,NCT02755597,Russia,,,,,,,,,,,,,,
country,NCT02755597::country::Brazil,NCT02755597,Brazil,,,,,,,,,,,,,,
country,NCT02755597::country::France,NCT02755597,France,,,,,,,,,,,,,,
country,NCT02755597::country::Hungary,NCT02755597,Hungary,,,,,,,,,,,,,,
country,NCT02755597::country::Italy,NCT02755597,Italy,,,,,,,,,,,,,,
country,NCT02755597::country::United States,NCT02755597,United States,,,,,,,,,,,,,,
country,NCT02755597::country::Spain,NCT02755597,Spain,,,,,,,,,,,,,,
country,NCT02755597::country::Taiwan,NCT02755597,Taiwan,,,,,,,,,,,,,,
country,NCT02755597::country::Germany,NCT02755597,Germany,,,,,,,,,,,,,,
country,NCT02755597::country::Ukraine,NCT02755597,Ukraine,,,,,,,,,,,,,,
country,NCT02755597::country::Canada,NCT02755597,Canada,,,,,,,,,,,,,,
country,NCT02755597::country::Ireland,NCT02755597,Ireland,,,,,,,,,,,,,,
trial,NCT01408303,NCT01408303,[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL,PHASE3,cardiovascular disease,Hypertriglyceridemia; Cardiovascular Disease,INDUSTRY,646.0,2011-08,2012-06,1.0,89.0,,,,,
arm,NCT01408303::arm::FG000,NCT01408303,"Epanova, 2 g + Statin",,,,,,,,,,FG000,"omega-3 carboxylic acids, 1 g capsule

omega-3 carboxylic acids + olive oil: omega-3 carboxylic acids 2 x 1 g capsule + olive oil 2 x 1 g capsule daily for 6 weeks

prescribe statin",,,
arm,NCT01408303::arm::FG001,NCT01408303,"Epanova, 4 g + Statin",,,,,,,,,,FG001,"omega-3 carboxylic acids, 1 g capsule

omega-3 carboxylic acids: omega-3 carboxylic acids 4 x 1 g capsule daily for 6 weeks

prescribed statin",,,
arm,NCT01408303::arm::FG002,NCT01408303,Olive Oil + Statin,,,,,,,,,,FG002,"olive oil, 1 g capsule

olive oil: 4 x 1 g capsule daily for 6 weeks

prescribed statin",,,
period,NCT01408303::period::1,NCT01408303,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01408303::outcome::primary::1,NCT01408303,Serum Non-HDL Cholesterol,,,,,,,,,,,,,PRIMARY,6 weeks
country,NCT01408303::country::United States,NCT01408303,United States,,,,,,,,,,,,,,
trial,NCT01087723,NCT01087723,European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial,PHASE3,cardiovascular disease,Acute Coronary Syndrome,INDUSTRY,2198.0,2010-03,2014-08,9.0,145.0,,,,,
arm,NCT01087723::arm::FG000,NCT01087723,Bivalirudin,,,,,,,,,,FG000,"Given immediately upon enrolment as an intravenous (IV) bolus of 0.75 milligrams/kilogram (mg/kg), followed immediately by an infusion of 1.75 mg/kg/hour (mg/kg/h). This infusion was to be run continu",,,
arm,NCT01087723::arm::FG001,NCT01087723,Standard of Care: Heparins With Optional GPI,,,,,,,,,,FG001,"Standard-of-care anti-thrombotic therapy as outlined in the European Society of Cardiology Dosing Guidelines for Management of ST segment elevation acute coronary syndrome (STE-ACS ), not including bi",,,
period,NCT01087723::period::1,NCT01087723,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01087723::outcome::primary::1,NCT01087723,The Composite Incidence of Death and Non-coronary Artery Bypass Graft (CABG) Major Bleeding,,,,,,,,,,,,,PRIMARY,Within 30 days
country,NCT01087723::country::France,NCT01087723,France,,,,,,,,,,,,,,
country,NCT01087723::country::Poland,NCT01087723,Poland,,,,,,,,,,,,,,
country,NCT01087723::country::Netherlands,NCT01087723,Netherlands,,,,,,,,,,,,,,
country,NCT01087723::country::Germany,NCT01087723,Germany,,,,,,,,,,,,,,
country,NCT01087723::country::Slovenia,NCT01087723,Slovenia,,,,,,,,,,,,,,
country,NCT01087723::country::Italy,NCT01087723,Italy,,,,,,,,,,,,,,
country,NCT01087723::country::Denmark,NCT01087723,Denmark,,,,,,,,,,,,,,
country,NCT01087723::country::Austria,NCT01087723,Austria,,,,,,,,,,,,,,
country,NCT01087723::country::Czechia,NCT01087723,Czechia,,,,,,,,,,,,,,
trial,NCT04058067,NCT04058067,To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema,PHASE3,cardiovascular disease,Diabetic Macular Edema,INDUSTRY,266.0,2019-08-23,2023-01-31,1.0,24.0,,,,,
arm,NCT04058067::arm::FG000,NCT04058067,Brolucizumab 6 mg,,,,,,,,,,FG000,5 x every 6 weeks loading then every 12 weeks or every 8 weeks maintenance,,,
arm,NCT04058067::arm::FG001,NCT04058067,Aflibercept 2 mg,,,,,,,,,,FG001,5 x every 4 weeks loading then every 8 weeks maintenance,,,
period,NCT04058067::period::1,NCT04058067,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04058067::outcome::primary::1,NCT04058067,Change From Baseline at Week 52 in Best-corrected Visual Acuity (BCVA) for the Study Eye.,,,,,,,,,,,,,PRIMARY,Baseline to Week 52
outcome,NCT04058067::outcome::primary::2,NCT04058067,Best-corrected Visual Acuity (BCVA) - Average Change From Baseline Over the Period Week 40 Through Week 52 for the Study Eye,,,,,,,,,,,,,PRIMARY,Week 40 to Week 52
country,NCT04058067::country::China,NCT04058067,China,,,,,,,,,,,,,,
trial,NCT00591253,NCT00591253,Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,413.0,2007-10,2009-04,2.0,64.0,,,,,
arm,NCT00591253::arm::FG000,NCT00591253,Azilsartan Medoxomil 40 mg QD,,,,,,,,,,FG000,"Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 6 weeks.",,,
arm,NCT00591253::arm::FG001,NCT00591253,Azilsartan Medoxomil 80 mg QD,,,,,,,,,,FG001,"Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 6 weeks.",,,
arm,NCT00591253::arm::FG002,NCT00591253,Placebo QD,,,,,,,,,,FG002,"Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 6 weeks.",,,
period,NCT00591253::period::1,NCT00591253,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00591253::outcome::primary::1,NCT00591253,Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.,,,,,,,,,,,,,PRIMARY,Baseline and Week 6.
country,NCT00591253::country::United States,NCT00591253,United States,,,,,,,,,,,,,,
country,NCT00591253::country::Puerto Rico,NCT00591253,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00699192,NCT00699192,"Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension",PHASE3,cardiovascular disease,Hypertension,INDUSTRY,965.0,2008-05,2009-05,10.0,18.0,,,,,
arm,NCT00699192::arm::FG000,NCT00699192,Amlodipine/Valsartan 5/80 mg,,,,,,,,,,FG000,"1 capsule amlodipine 5 mg, 1 capsule valsartan 80 mg once daily",,,
arm,NCT00699192::arm::FG001,NCT00699192,Amlodipine/Valsartan 5/40 mg,,,,,,,,,,FG001,"1 capsule amlodipine 5 mg, 1 capsule valsartan 40 mg once daily",,,
arm,NCT00699192::arm::FG002,NCT00699192,Amlodipine 5 mg,,,,,,,,,,FG002,"1 capsule amlodipine 5 mg, 1 capsule placebo to match valsartan once daily",,,
period,NCT00699192::period::1,NCT00699192,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00699192::outcome::primary::1,NCT00699192,Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8),,,,,,,,,,,,,PRIMARY,Baseline to end of study (Week 8)
country,NCT00699192::country::Czechia,NCT00699192,Czechia,,,,,,,,,,,,,,
country,NCT00699192::country::Finland,NCT00699192,Finland,,,,,,,,,,,,,,
country,NCT00699192::country::France,NCT00699192,France,,,,,,,,,,,,,,
country,NCT00699192::country::Germany,NCT00699192,Germany,,,,,,,,,,,,,,
country,NCT00699192::country::Hungary,NCT00699192,Hungary,,,,,,,,,,,,,,
country,NCT00699192::country::Italy,NCT00699192,Italy,,,,,,,,,,,,,,
country,NCT00699192::country::Poland,NCT00699192,Poland,,,,,,,,,,,,,,
country,NCT00699192::country::Slovakia,NCT00699192,Slovakia,,,,,,,,,,,,,,
country,NCT00699192::country::Spain,NCT00699192,Spain,,,,,,,,,,,,,,
country,NCT00699192::country::Sweden,NCT00699192,Sweden,,,,,,,,,,,,,,
trial,NCT02361944,NCT02361944,Risk of Oxygen During Cardiac Surgery Trial,PHASE3,cardiovascular disease,Cardiac Surgery,OTHER,213.0,2016-04-05,2021-01-08,1.0,1.0,,,,,
arm,NCT02361944::arm::FG000,NCT02361944,Normoxia,,,,,,,,,,FG000,"Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.

Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen satur",,,
arm,NCT02361944::arm::FG001,NCT02361944,Hyperoxia,,,,,,,,,,FG001,"Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.

Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above ",,,
period,NCT02361944::period::1,NCT02361944,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02361944::outcome::primary::1,NCT02361944,Intraoperative Systemic Oxidative Damage,,,,,,,,,,,,,PRIMARY,separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)
outcome,NCT02361944::outcome::primary::2,NCT02361944,Acute Kidney Injury,,,,,,,,,,,,,PRIMARY,baseline to postoperative day 2
country,NCT02361944::country::United States,NCT02361944,United States,,,,,,,,,,,,,,
trial,NCT03785405,NCT03785405,Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF,PHASE3,cardiovascular disease,Heart Failure,INDUSTRY,216.0,2019-05-02,2023-12-29,27.0,79.0,,,,,
arm,NCT03785405::arm::FG000,NCT03785405,Age Group 1,,,,,,,,,,FG000,Patients 6 years and older receiving open label sacubitril/valsartan 3.1 mg/kg bid,,,
arm,NCT03785405::arm::FG001,NCT03785405,Age Group 2,,,,,,,,,,FG001,Patients 1 year to \< 6 years receiving open label sacubitril/valsartan 3.1 mg/kg bid,,,
period,NCT03785405::period::1,NCT03785405,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03785405::outcome::primary::1,NCT03785405,Number of Participants With Adverse Events,,,,,,,,,,,,,PRIMARY,"to end of study, up to 4,5 years"
outcome,NCT03785405::outcome::primary::2,NCT03785405,Number of Participants With Serious Adverse Events,,,,,,,,,,,,,PRIMARY,"to end of study, up to 4.5 years"
outcome,NCT03785405::outcome::primary::3,NCT03785405,Duration of Drug Exposure,,,,,,,,,,,,,PRIMARY,Up to 4.5 years
country,NCT03785405::country::United States,NCT03785405,United States,,,,,,,,,,,,,,
country,NCT03785405::country::Japan,NCT03785405,Japan,,,,,,,,,,,,,,
country,NCT03785405::country::Italy,NCT03785405,Italy,,,,,,,,,,,,,,
country,NCT03785405::country::Germany,NCT03785405,Germany,,,,,,,,,,,,,,
country,NCT03785405::country::Spain,NCT03785405,Spain,,,,,,,,,,,,,,
country,NCT03785405::country::India,NCT03785405,India,,,,,,,,,,,,,,
country,NCT03785405::country::South Korea,NCT03785405,South Korea,,,,,,,,,,,,,,
country,NCT03785405::country::Portugal,NCT03785405,Portugal,,,,,,,,,,,,,,
country,NCT03785405::country::Turkey (Türkiye),NCT03785405,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT03785405::country::Canada,NCT03785405,Canada,,,,,,,,,,,,,,
country,NCT03785405::country::Lebanon,NCT03785405,Lebanon,,,,,,,,,,,,,,
country,NCT03785405::country::Poland,NCT03785405,Poland,,,,,,,,,,,,,,
country,NCT03785405::country::Russia,NCT03785405,Russia,,,,,,,,,,,,,,
country,NCT03785405::country::Singapore,NCT03785405,Singapore,,,,,,,,,,,,,,
country,NCT03785405::country::Taiwan,NCT03785405,Taiwan,,,,,,,,,,,,,,
country,NCT03785405::country::Thailand,NCT03785405,Thailand,,,,,,,,,,,,,,
country,NCT03785405::country::Argentina,NCT03785405,Argentina,,,,,,,,,,,,,,
country,NCT03785405::country::Austria,NCT03785405,Austria,,,,,,,,,,,,,,
country,NCT03785405::country::Bulgaria,NCT03785405,Bulgaria,,,,,,,,,,,,,,
country,NCT03785405::country::Croatia,NCT03785405,Croatia,,,,,,,,,,,,,,
country,NCT03785405::country::Czechia,NCT03785405,Czechia,,,,,,,,,,,,,,
country,NCT03785405::country::Finland,NCT03785405,Finland,,,,,,,,,,,,,,
country,NCT03785405::country::France,NCT03785405,France,,,,,,,,,,,,,,
country,NCT03785405::country::Hungary,NCT03785405,Hungary,,,,,,,,,,,,,,
country,NCT03785405::country::Israel,NCT03785405,Israel,,,,,,,,,,,,,,
country,NCT03785405::country::South Africa,NCT03785405,South Africa,,,,,,,,,,,,,,
country,NCT03785405::country::Switzerland,NCT03785405,Switzerland,,,,,,,,,,,,,,
trial,NCT01564537,NCT01564537,A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma,PHASE3,cardiovascular disease,Relapsed Multiple Myeloma; Refractory Multiple Myeloma,INDUSTRY,722.0,2012-08-01,2022-02-08,2.0,24.0,,,,,
arm,NCT01564537::arm::FG000,NCT01564537,Ixazomib+ Lenalidomide + Dexamethasone,,,,,,,,,,FG000,"Ixazomib 4 mg, capsules, orally, once, on Days 1, 8 and 15; plus lenalidomide 25 mg, orally, once, on Days 1 through 21; and dexamethasone 40 mg, orally, once, on Days 1, 8, 15 and 22 of a 28-day cycl",,,
arm,NCT01564537::arm::FG001,NCT01564537,Placebo + Lenalidomide + Dexamethasone,,,,,,,,,,FG001,"Ixazomib placebo-matching capsules, orally, once, on Days 1, 8 and 15; plus lenalidomide 25 mg, orally, once, on Days 1 through 21; and dexamethasone 40 mg, orally, once, on Days 1, 8, 15 and 22 of a ",,,
period,NCT01564537::period::1,NCT01564537,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01564537::outcome::primary::1,NCT01564537,Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC),,,,,,,,,,,,,PRIMARY,From date of randomization until disease progression or death up to approximately 27 months (approximate median follow-up 15 months)
country,NCT01564537::country::United States,NCT01564537,United States,,,,,,,,,,,,,,
country,NCT01564537::country::Canada,NCT01564537,Canada,,,,,,,,,,,,,,
trial,NCT01072877,NCT01072877,Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence,PHASE3,cardiovascular disease,Varicose Veins,INDUSTRY,279.0,2010-12,2012-11,1.0,20.0,,,,,
arm,NCT01072877::arm::FG000,NCT01072877,Vehicle,,,,,,,,,,FG000,"Injection of vehicle comparator

Placebo Vehicle: Placebo vehicle",,,
arm,NCT01072877::arm::FG001,NCT01072877,Polidocanol Endovenous Microfoam 0.125%,,,,,,,,,,FG001,"Polidocanol endovenous microfoam 0.125%

Polidocanol Endovenous Microfoam (PEM): Injection of Polidocanol Endovenous Microfoam",,,
arm,NCT01072877::arm::FG002,NCT01072877,Polidocanol Endovenous Microfoam 0.5%,,,,,,,,,,FG002,"Polidocanol endovenous microfoam 0.5%

Polidocanol Endovenous Microfoam (PEM): Injection of Polidocanol Endovenous Microfoam",,,
arm,NCT01072877::arm::FG003,NCT01072877,Polidocanol Endovenous Microfoam 1.0%,,,,,,,,,,FG003,"Polidocanol endovenous microfoam 1.0%

Polidocanol Endovenous Microfoam (PEM): Injection of Polidocanol Endovenous Microfoam",,,
arm,NCT01072877::arm::FG004,NCT01072877,Polidocanol Endovenous Microfoam 2.0%,,,,,,,,,,FG004,"Polidocanol endovenous microfoam 2.0%

Polidocanol Endovenous Microfoam (PEM): Injection of Polidocanol Endovenous Microfoam",,,
period,NCT01072877::period::1,NCT01072877,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01072877::outcome::primary::1,NCT01072877,Change in Patient-reported Symptoms of Varicose Veins (VVSymQ Score),,,,,,,,,,,,,PRIMARY,Week 8
country,NCT01072877::country::United States,NCT01072877,United States,,,,,,,,,,,,,,
trial,NCT00212992,NCT00212992,Biphasic Defibrillation Study: Trial to Compare Fixed Versus Escalating Energy,PHASE3,cardiovascular disease,Cardiac Arrest,OTHER,221.0,2001-03,2006-07,1.0,1.0,,,,,
arm,NCT00212992::arm::FG000,NCT00212992,Fixed Lower-energy,,,,,,,,,,FG000,Out-of-hospital cardiac arrest patients undergoing defibrillation received a fixed lower-energy regimen of 150 J for all shocks,,,
arm,NCT00212992::arm::FG001,NCT00212992,Escalating Higher-energy,,,,,,,,,,FG001,"Out-of-hospital cardiac arrest patients undergoing defibrillation received an escalating higher-energy regimen beginning with 200 J, proceeding to 300 J for the second shock and 360 J for all remainin",,,
period,NCT00212992::period::1,NCT00212992,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00212992::outcome::primary::1,NCT00212992,Successful Conversion to an Organized Heart Rhythm,,,,,,,,,,,,,PRIMARY,Termination of defibrillation
country,NCT00212992::country::Canada,NCT00212992,Canada,,,,,,,,,,,,,,
trial,NCT00729430,NCT00729430,Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging,PHASE3,cardiovascular disease,"Myocardial Infarction; Death, Sudden, Cardiac",OTHER,358.0,2008-08,2014-07,1.0,1.0,,,,,
arm,NCT00729430::arm::FG000,NCT00729430,High Dose Omega-3 Fatty Acid Arm,,,,,,,,,,FG000,"Participants will receive a highly purified form of omega-3 fatty acids for 6 months.

Omega-3 Fatty Acids (Fish Oil Supplements): 4 grams of omega-3 fatty acids taken orally once per day for 6 months",,,
arm,NCT00729430::arm::FG001,NCT00729430,Placebo Arm,,,,,,,,,,FG001,"Participants will receive placebo for 6 months.

Placebo: Placebo tablets taken orally once per day for 6 months",,,
period,NCT00729430::period::1,NCT00729430,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00729430::outcome::primary::1,NCT00729430,Effect of Omega-3 Fatty Acids on Adverse Left Ventricular Remodeling,,,,,,,,,,,,,PRIMARY,Before and after study treatments
country,NCT00729430::country::United States,NCT00729430,United States,,,,,,,,,,,,,,
trial,NCT01134393,NCT01134393,TElmisartan and AMlodipine Single Pill sTudy With Patients Not on Goal With Mono rAas Therapy-switch,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,502.0,2010-05,,5.0,47.0,,,,,
arm,NCT01134393::arm::FG000,NCT01134393,T80/A5,,,,,,,,,,FG000,Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination,,,
period,NCT01134393::period::1,NCT01134393,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01134393::outcome::primary::1,NCT01134393,Percentage of Patients Achieving Blood Pressure (BP) Control After 12 Weeks of Treatment Using In-clinic BP Measurements.,,,,,,,,,,,,,PRIMARY,12 weeks
country,NCT01134393::country::Poland,NCT01134393,Poland,,,,,,,,,,,,,,
country,NCT01134393::country::Germany,NCT01134393,Germany,,,,,,,,,,,,,,
country,NCT01134393::country::Netherlands,NCT01134393,Netherlands,,,,,,,,,,,,,,
country,NCT01134393::country::Italy,NCT01134393,Italy,,,,,,,,,,,,,,
country,NCT01134393::country::Mexico,NCT01134393,Mexico,,,,,,,,,,,,,,
trial,NCT03045406,NCT03045406,Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer,PHASE3,cardiovascular disease,Venous Thromboembolism,OTHER,1170.0,2017-04-13,2019-12-01,11.0,127.0,,,,,
arm,NCT03045406::arm::FG000,NCT03045406,Apixaban,,,,,,,,,,FG000,"orally administered, at the dose of 10 mg bid for 7 days, followed by 5 mg bid (total period of treatment: six months)

Apixaban: Tablets",,,
arm,NCT03045406::arm::FG001,NCT03045406,Dalteparin,,,,,,,,,,FG001,"subcutaneously administered, at a dose of 200 IU/kg SC o.i.d for 1 month. Thereafter, dalteparin will be administered at a dose of 150 IU/kg o.i.d. for 5 months

Dalteparin: Injections",,,
period,NCT03045406::period::1,NCT03045406,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03045406::outcome::primary::1,NCT03045406,Recurrent Venous Thromboembolism,,,,,,,,,,,,,PRIMARY,6 months
country,NCT03045406::country::Italy,NCT03045406,Italy,,,,,,,,,,,,,,
country,NCT03045406::country::Spain,NCT03045406,Spain,,,,,,,,,,,,,,
country,NCT03045406::country::United States,NCT03045406,United States,,,,,,,,,,,,,,
country,NCT03045406::country::France,NCT03045406,France,,,,,,,,,,,,,,
country,NCT03045406::country::Netherlands,NCT03045406,Netherlands,,,,,,,,,,,,,,
country,NCT03045406::country::Israel,NCT03045406,Israel,,,,,,,,,,,,,,
country,NCT03045406::country::Poland,NCT03045406,Poland,,,,,,,,,,,,,,
country,NCT03045406::country::Germany,NCT03045406,Germany,,,,,,,,,,,,,,
country,NCT03045406::country::United Kingdom,NCT03045406,United Kingdom,,,,,,,,,,,,,,
country,NCT03045406::country::Portugal,NCT03045406,Portugal,,,,,,,,,,,,,,
country,NCT03045406::country::Belgium,NCT03045406,Belgium,,,,,,,,,,,,,,
trial,NCT00576693,NCT00576693,Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis,PHASE3,cardiovascular disease,Ischemic Stroke,OTHER,451.0,2008-10,2013-04,1.0,50.0,,,,,
arm,NCT00576693::arm::FG000,NCT00576693,Intensive Medical Management Plus Stenting,,,,,,,,,,FG000,"intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg pe",,,
arm,NCT00576693::arm::FG001,NCT00576693,Intensive Medical Management Alone,,,,,,,,,,FG001,"Intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days f",,,
period,NCT00576693::period::1,NCT00576693,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00576693::outcome::primary::1,NCT00576693,Any Stroke or Death Within 30 Days of Enrollment or Any Revascularization Procedure OR an Ischemic Stroke in the Territory of the Symptomatic Intracranial Artery Beyond 30 Days After Enrollment.,,,,,,,,,,,,,PRIMARY,Mean length of follow-up was 2.4 years
country,NCT00576693::country::United States,NCT00576693,United States,,,,,,,,,,,,,,
trial,NCT00760214,NCT00760214,Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,885.0,2008-01,2009-04,10.0,72.0,,,,,
arm,NCT00760214::arm::FG000,NCT00760214,Azilsartan Medoxomil 40 mg QD,,,,,,,,,,FG000,"Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 40 mg, tablets, orally, once daily for up to 22 weeks.",,,
arm,NCT00760214::arm::FG001,NCT00760214,Azilsartan Medoxomil 80 mg QD,,,,,,,,,,FG001,"Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 80 mg, tablets, orally, once daily for up to 22 weeks.",,,
arm,NCT00760214::arm::FG002,NCT00760214,Ramipril 10 mg QD,,,,,,,,,,FG002,"Ramipril 2.5 mg, tablets, orally, once daily for two weeks; then increased to 10 mg, tablets, orally, once daily for up to 22 weeks.",,,
period,NCT00760214::period::1,NCT00760214,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00760214::outcome::primary::1,NCT00760214,Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.,,,,,,,,,,,,,PRIMARY,Baseline and Week 24.
country,NCT00760214::country::Germany,NCT00760214,Germany,,,,,,,,,,,,,,
country,NCT00760214::country::Poland,NCT00760214,Poland,,,,,,,,,,,,,,
country,NCT00760214::country::Netherlands,NCT00760214,Netherlands,,,,,,,,,,,,,,
country,NCT00760214::country::Sweden,NCT00760214,Sweden,,,,,,,,,,,,,,
country,NCT00760214::country::Bulgaria,NCT00760214,Bulgaria,,,,,,,,,,,,,,
country,NCT00760214::country::Slovakia,NCT00760214,Slovakia,,,,,,,,,,,,,,
country,NCT00760214::country::Estonia,NCT00760214,Estonia,,,,,,,,,,,,,,
country,NCT00760214::country::Finland,NCT00760214,Finland,,,,,,,,,,,,,,
country,NCT00760214::country::Serbia,NCT00760214,Serbia,,,,,,,,,,,,,,
country,NCT00760214::country::Russia,NCT00760214,Russia,,,,,,,,,,,,,,
trial,NCT03481634,NCT03481634,Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema,PHASE3,cardiovascular disease,Diabetic Macular Edema,INDUSTRY,566.0,2018-07-23,2021-10-18,14.0,116.0,,,,,
arm,NCT03481634::arm::FG000,NCT03481634,Brolucizumab 3 mg,,,,,,,,,,FG000,"Brolucizumab 3 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule",,,
arm,NCT03481634::arm::FG001,NCT03481634,Brolucizumab 6 mg,,,,,,,,,,FG001,"Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule",,,
arm,NCT03481634::arm::FG002,NCT03481634,Aflibercept 2 mg,,,,,,,,,,FG002,"Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks",,,
period,NCT03481634::period::1,NCT03481634,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03481634::outcome::primary::1,NCT03481634,Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 52,,,,,,,,,,,,,PRIMARY,"Baseline, Week 52"
country,NCT03481634::country::United States,NCT03481634,United States,,,,,,,,,,,,,,
country,NCT03481634::country::Japan,NCT03481634,Japan,,,,,,,,,,,,,,
country,NCT03481634::country::Australia,NCT03481634,Australia,,,,,,,,,,,,,,
country,NCT03481634::country::Israel,NCT03481634,Israel,,,,,,,,,,,,,,
country,NCT03481634::country::Portugal,NCT03481634,Portugal,,,,,,,,,,,,,,
country,NCT03481634::country::Italy,NCT03481634,Italy,,,,,,,,,,,,,,
country,NCT03481634::country::Spain,NCT03481634,Spain,,,,,,,,,,,,,,
country,NCT03481634::country::Argentina,NCT03481634,Argentina,,,,,,,,,,,,,,
country,NCT03481634::country::United Kingdom,NCT03481634,United Kingdom,,,,,,,,,,,,,,
country,NCT03481634::country::Canada,NCT03481634,Canada,,,,,,,,,,,,,,
country,NCT03481634::country::Austria,NCT03481634,Austria,,,,,,,,,,,,,,
country,NCT03481634::country::Colombia,NCT03481634,Colombia,,,,,,,,,,,,,,
country,NCT03481634::country::Netherlands,NCT03481634,Netherlands,,,,,,,,,,,,,,
country,NCT03481634::country::Puerto Rico,NCT03481634,Puerto Rico,,,,,,,,,,,,,,
trial,NCT00826280,NCT00826280,Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI),PHASE3,cardiovascular disease,Coronary Artery Disease (CAD),INDUSTRY,347.0,2009-03-24,2010-07-15,1.0,25.0,,,,,
arm,NCT00826280::arm::FG000,NCT00826280,Placebo Plus Regadenoson,,,,,,,,,,FG000,Two Placebo capsules plus 0.4 mg regadenoson per 5mL intravenous (IV) bolus injection,,,
arm,NCT00826280::arm::FG001,NCT00826280,Caffeine 200 mg Plus Regadenoson,,,,,,,,,,FG001,One 200 mg Caffeine capsule and one placebo capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection,,,
arm,NCT00826280::arm::FG002,NCT00826280,Caffeine 400 mg Plus Regadenoson,,,,,,,,,,FG002,Two 200 mg Caffeine capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection,,,
period,NCT00826280::period::1,NCT00826280,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00826280::outcome::primary::1,NCT00826280,Change in Number of Reversible Defects,,,,,,,,,,,,,PRIMARY,Day 3 and Day 5
country,NCT00826280::country::United States,NCT00826280,United States,,,,,,,,,,,,,,
trial,NCT01442038,NCT01442038,Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI),PHASE3,cardiovascular disease,Coronary Artery Disease; Angina Pectoris,INDUSTRY,2651.0,2011-10,2015-02,15.0,218.0,,,,,
arm,NCT01442038::arm::FG000,NCT01442038,Ranolazine,,,,,,,,,,FG000,"Ranolazine 500 mg (1 x 500 mg tablet) twice daily for 7 days, followed by ranolazine 1000 mg (2 x 500 mg tablet) twice daily for the duration of the study (participants receiving a moderate CYP3A4 inh",,,
arm,NCT01442038::arm::FG001,NCT01442038,Placebo,,,,,,,,,,FG001,"Ranolazine placebo (1 tablet) for 7 days, followed by ranolazine placebo (2 tablets) twice daily for the duration of the study (participants receiving a moderate CYP3A4 inhibitor continued to receive ",,,
period,NCT01442038::period::1,NCT01442038,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01442038::outcome::primary::1,NCT01442038,Kaplan-Meier Estimates for Time From Randomization to First Occurrence of Ischemia-driven Revascularization or Ischemia-driven Hospitalization Without Revascularization,,,,,,,,,,,,,PRIMARY,Baseline through end of study (average 90 weeks)
country,NCT01442038::country::United States,NCT01442038,United States,,,,,,,,,,,,,,
country,NCT01442038::country::Russia,NCT01442038,Russia,,,,,,,,,,,,,,
country,NCT01442038::country::Poland,NCT01442038,Poland,,,,,,,,,,,,,,
country,NCT01442038::country::Israel,NCT01442038,Israel,,,,,,,,,,,,,,
country,NCT01442038::country::Canada,NCT01442038,Canada,,,,,,,,,,,,,,
country,NCT01442038::country::Spain,NCT01442038,Spain,,,,,,,,,,,,,,
country,NCT01442038::country::Italy,NCT01442038,Italy,,,,,,,,,,,,,,
country,NCT01442038::country::Czechia,NCT01442038,Czechia,,,,,,,,,,,,,,
country,NCT01442038::country::Germany,NCT01442038,Germany,,,,,,,,,,,,,,
country,NCT01442038::country::Austria,NCT01442038,Austria,,,,,,,,,,,,,,
country,NCT01442038::country::United Kingdom,NCT01442038,United Kingdom,,,,,,,,,,,,,,
country,NCT01442038::country::Belgium,NCT01442038,Belgium,,,,,,,,,,,,,,
country,NCT01442038::country::France,NCT01442038,France,,,,,,,,,,,,,,
country,NCT01442038::country::Netherlands,NCT01442038,Netherlands,,,,,,,,,,,,,,
country,NCT01442038::country::Sweden,NCT01442038,Sweden,,,,,,,,,,,,,,
trial,NCT01422304,NCT01422304,Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038),PHASE3,cardiovascular disease,"Neuromuscular Blockade; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Coagulation; Antithrombotic Agents",INDUSTRY,1198.0,2011-10-12,2012-09-26,0.0,0.0,,,,,
arm,NCT01422304::arm::FG000,NCT01422304,Sugammadex,,,,,,,,,,FG000,For participants in this Arm assigned to planned active reversal of neuromuscular blockade: single intravenous (IV) administration of sugammadex 4 mg/kg and single IV administration of placebo (normal,,,
arm,NCT01422304::arm::FG001,NCT01422304,Usual Care,,,,,,,,,,FG001,For participants in this Arm assigned to planned active reversal of neuromuscular blockade: single IV administration of neostigmine (up to a maximum dose of 5 mg) with glycopyrrolate or atropine and s,,,
period,NCT01422304::period::1,NCT01422304,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01422304::outcome::primary::1,NCT01422304,Number of Participants With One or More Adjudicated Events of Bleeding (Major or Non-major) With Onset Within 24 Hours After Study Drug Administration,,,,,,,,,,,,,PRIMARY,Up to 24 hours post study drug administration
trial,NCT00174785,NCT00174785,A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation,PHASE3,cardiovascular disease,Atrial Fibrillation; Atrial Flutter,INDUSTRY,4628.0,2005-06,2008-03,37.0,37.0,,,,,
arm,NCT00174785::arm::FG000,NCT00174785,Dronedarone 400mg Bid,,,,,,,,,,FG000,dronedarone tablets 400mg twice daily,,,
arm,NCT00174785::arm::FG001,NCT00174785,Placebo,,,,,,,,,,FG001,matching placebo tablets,,,
period,NCT00174785::period::1,NCT00174785,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00174785::outcome::primary::1,NCT00174785,First Hospitalization for Cardiovascular Reason or Death From Any Cause,,,,,,,,,,,,,PRIMARY,minimum follow-up duration: 1 year 
country,NCT00174785::country::United States,NCT00174785,United States,,,,,,,,,,,,,,
country,NCT00174785::country::Argentina,NCT00174785,Argentina,,,,,,,,,,,,,,
country,NCT00174785::country::Australia,NCT00174785,Australia,,,,,,,,,,,,,,
country,NCT00174785::country::Austria,NCT00174785,Austria,,,,,,,,,,,,,,
country,NCT00174785::country::Belgium,NCT00174785,Belgium,,,,,,,,,,,,,,
country,NCT00174785::country::Canada,NCT00174785,Canada,,,,,,,,,,,,,,
country,NCT00174785::country::Chile,NCT00174785,Chile,,,,,,,,,,,,,,
country,NCT00174785::country::China,NCT00174785,China,,,,,,,,,,,,,,
country,NCT00174785::country::Czechia,NCT00174785,Czechia,,,,,,,,,,,,,,
country,NCT00174785::country::Finland,NCT00174785,Finland,,,,,,,,,,,,,,
country,NCT00174785::country::Germany,NCT00174785,Germany,,,,,,,,,,,,,,
country,NCT00174785::country::Greece,NCT00174785,Greece,,,,,,,,,,,,,,
country,NCT00174785::country::Hong Kong,NCT00174785,Hong Kong,,,,,,,,,,,,,,
country,NCT00174785::country::Hungary,NCT00174785,Hungary,,,,,,,,,,,,,,
country,NCT00174785::country::India,NCT00174785,India,,,,,,,,,,,,,,
country,NCT00174785::country::Israel,NCT00174785,Israel,,,,,,,,,,,,,,
country,NCT00174785::country::Italy,NCT00174785,Italy,,,,,,,,,,,,,,
country,NCT00174785::country::Malaysia,NCT00174785,Malaysia,,,,,,,,,,,,,,
country,NCT00174785::country::Mexico,NCT00174785,Mexico,,,,,,,,,,,,,,
country,NCT00174785::country::Morocco,NCT00174785,Morocco,,,,,,,,,,,,,,
country,NCT00174785::country::Netherlands,NCT00174785,Netherlands,,,,,,,,,,,,,,
country,NCT00174785::country::New Zealand,NCT00174785,New Zealand,,,,,,,,,,,,,,
country,NCT00174785::country::Norway,NCT00174785,Norway,,,,,,,,,,,,,,
country,NCT00174785::country::Philippines,NCT00174785,Philippines,,,,,,,,,,,,,,
country,NCT00174785::country::Poland,NCT00174785,Poland,,,,,,,,,,,,,,
country,NCT00174785::country::Portugal,NCT00174785,Portugal,,,,,,,,,,,,,,
country,NCT00174785::country::Russia,NCT00174785,Russia,,,,,,,,,,,,,,
country,NCT00174785::country::Singapore,NCT00174785,Singapore,,,,,,,,,,,,,,
country,NCT00174785::country::South Africa,NCT00174785,South Africa,,,,,,,,,,,,,,
country,NCT00174785::country::South Korea,NCT00174785,South Korea,,,,,,,,,,,,,,
country,NCT00174785::country::Spain,NCT00174785,Spain,,,,,,,,,,,,,,
country,NCT00174785::country::Sweden,NCT00174785,Sweden,,,,,,,,,,,,,,
country,NCT00174785::country::Taiwan,NCT00174785,Taiwan,,,,,,,,,,,,,,
country,NCT00174785::country::Thailand,NCT00174785,Thailand,,,,,,,,,,,,,,
country,NCT00174785::country::Tunisia,NCT00174785,Tunisia,,,,,,,,,,,,,,
country,NCT00174785::country::Turkey (Türkiye),NCT00174785,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00174785::country::United Kingdom,NCT00174785,United Kingdom,,,,,,,,,,,,,,
trial,NCT00486018,NCT00486018,A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO),PHASE3,cardiovascular disease,Macular Edema; Retinal Vein Occlusion,INDUSTRY,397.0,2007-07,2009-11,0.0,0.0,,,,,
arm,NCT00486018::arm::FG000,NCT00486018,Sham Injection,,,,,,,,,,FG000,"Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.",,,
arm,NCT00486018::arm::FG001,NCT00486018,Ranibizumab Injection 0.3 mg,,,,,,,,,,FG001,"Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.",,,
arm,NCT00486018::arm::FG002,NCT00486018,Ranibizumab Injection 0.5 mg,,,,,,,,,,FG002,"Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.",,,
period,NCT00486018::period::1,NCT00486018,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00486018::outcome::primary::1,NCT00486018,Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at 6 Months,,,,,,,,,,,,,PRIMARY,Baseline and 6 months
trial,NCT00097591,NCT00097591,A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention,PHASE3,cardiovascular disease,Coronary Arteriosclerosis; Acute Coronary Syndromes,INDUSTRY,13619.0,2004-11,2007-07,1.0,1.0,,,,,
arm,NCT00097591::arm::FG000,NCT00097591,Prasugrel,,,,,,,,,,FG000,"Oral loading dose of six 10 mg prasugrel tablets and four placebo tablets matched to clopidogrel, followed by an oral maintenance dose of prasugrel one 10 mg tablet and one placebo tablet matched to c",,,
arm,NCT00097591::arm::FG001,NCT00097591,Clopidogrel,,,,,,,,,,FG001,"Oral loading dose of four 75 mg clopidogrel tablets and six placebo tablets matched to prasugrel, followed by an oral maintenance dose of one 75 mg clopidogrel tablet and one placebo tablet matched to",,,
period,NCT00097591::period::1,NCT00097591,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00097591::outcome::primary::1,NCT00097591,"Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke",,,,,,,,,,,,,PRIMARY,Randomization up to 15 months
country,NCT00097591::country::United States,NCT00097591,United States,,,,,,,,,,,,,,
trial,NCT02277691,NCT02277691,A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension,PHASE3,cardiovascular disease,Essential Hypertension,INDUSTRY,341.0,2014-11-07,2016-04-25,1.0,38.0,,,,,
arm,NCT02277691::arm::FG000,NCT02277691,TAK-536TCH,,,,,,,,,,FG000,"For 4 weeks during the run-in period, one tablet of TAK-536CCB (as TAK-536/AML, 20 mg/5 mg, respectively) orally, once daily, before or after breakfast.

For 48 weeks during 52 weeks of the treatment ",,,
period,NCT02277691::period::1,NCT02277691,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02277691::outcome::primary::1,NCT02277691,Number of Participants Who Experience at Least One Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs),,,,,,,,,,,,,PRIMARY,Baseline up to Week 52
outcome,NCT02277691::outcome::primary::2,NCT02277691,Number of Participants With Markedly Abnormal Vital Signs Values,,,,,,,,,,,,,PRIMARY,Baseline up to Week 52
outcome,NCT02277691::outcome::primary::3,NCT02277691,Number of Participants With Treatment Emergent Adverse Event (TEAE) Related to Body Weight,,,,,,,,,,,,,PRIMARY,Baseline up to Week 52
outcome,NCT02277691::outcome::primary::4,NCT02277691,Number of Participants With Treatment Emergent Adverse Event (TEAE) Related to Electrocardiogram (ECG),,,,,,,,,,,,,PRIMARY,Baseline up to Week 52
outcome,NCT02277691::outcome::primary::5,NCT02277691,Number of Participants With Markedly Abnormal Clinical Laboratory Tests,,,,,,,,,,,,,PRIMARY,Baseline up to Week 52
country,NCT02277691::country::Japan,NCT02277691,Japan,,,,,,,,,,,,,,
trial,NCT01599104,NCT01599104,Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension,PHASE3,cardiovascular disease,Essential Hypertension,INDUSTRY,1161.0,2012-06,2013-04,1.0,61.0,,,,,
arm,NCT01599104::arm::FG000,NCT01599104,LCZ696 200 mg,,,,,,,,,,FG000,LCZ696 200 mg tablet and a placebo tablet once daily for eight weeks,,,
arm,NCT01599104::arm::FG001,NCT01599104,LCZ696 400 mg,,,,,,,,,,FG001,"LCZ696 200 mg tablet and a placebo tablet once daily for one week, then up-titrated to 400 mg once daily for the remaining 7 weeks",,,
arm,NCT01599104::arm::FG002,NCT01599104,Olmesartan 20 mg,,,,,,,,,,FG002,Olmesartan 20 mg tablet and a placebo tablet once daily for 8 weeks,,,
period,NCT01599104::period::1,NCT01599104,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01599104::outcome::primary::1,NCT01599104,Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP),,,,,,,,,,,,,PRIMARY,"Baseline, 8 weeks"
country,NCT01599104::country::Japan,NCT01599104,Japan,,,,,,,,,,,,,,
trial,NCT03459287,NCT03459287,Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients,PHASE3,cardiovascular disease,Anemia,INDUSTRY,581.0,2018-12-05,2024-03-05,1.0,18.0,,,,,
arm,NCT03459287::arm::FG000,NCT03459287,INTERCEPT (Test),,,,,,,,,,FG000,The INTERCEPT treatment process uses amustaline and glutathione together with a processing solution in a single-use disposable set and results in pathogen and leukocyte inactivated RBCs suspended in S,,,
arm,NCT03459287::arm::FG001,NCT03459287,Conventional (Control),,,,,,,,,,FG001,"The control transfusion component is a conventional leukocyte-reduced RBC component in an FDA approved additive solution (AS-1, AS-3 or AS-5) stored at 1°C to 6°C for up to 35 days post-donation and a",,,
period,NCT03459287::period::1,NCT03459287,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03459287::outcome::primary::1,NCT03459287,Percentage of Patients Who Have Received at Least One Study Transfusion With a Diagnosis of Renal Impairment Defined as:,,,,,,,,,,,,,PRIMARY,Within 48±4 hours of the end of surgery
outcome,NCT03459287::outcome::primary::2,NCT03459287,Percentage of Patients With Related Adverse Events,,,,,,,,,,,,,PRIMARY,From the start of the first study transfusion to 28 days after the last study transfusion (between 29 and 35 days depending on the day of the last study transfusion).
outcome,NCT03459287::outcome::primary::3,NCT03459287,Percentage of Patients With Treatment Emergent Antibodies,,,,,,,,,,,,,PRIMARY,From the start of the first study transfusion to 75 days after the last study transfusion (between 76-82 days depending on the day of the last study transfusion).
country,NCT03459287::country::United States,NCT03459287,United States,,,,,,,,,,,,,,
trial,NCT00706134,NCT00706134,"Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study",PHASE3,cardiovascular disease,Hypertension,INDUSTRY,756.0,2008-05,2009-04,8.0,8.0,,,,,
arm,NCT00706134::arm::FG000,NCT00706134,Placebo,,,,,,,,,,FG000,Placebo tablet taken once daily in the morning with a light meal.,,,
arm,NCT00706134::arm::FG001,NCT00706134,Aliskiren 75 mg,,,,,,,,,,FG001,Aliskiren 75 mg tablet taken once daily in the morning with a light meal.,,,
arm,NCT00706134::arm::FG002,NCT00706134,Aliskiren 150 mg,,,,,,,,,,FG002,Aliskiren 150 mg tablet taken once daily in the morning with a light meal.,,,
arm,NCT00706134::arm::FG003,NCT00706134,Aliskiren 300 mg,,,,,,,,,,FG003,Aliskiren 300 mg tablet taken once daily in the morning with a light meal.,,,
period,NCT00706134::period::1,NCT00706134,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00706134::outcome::primary::1,NCT00706134,Change in Mean Sitting Systolic Blood Pressure (msSBP)From Baseline to End of Study (Week 8),,,,,,,,,,,,,PRIMARY,Baseline to end of study (Week 8)
country,NCT00706134::country::Argentina,NCT00706134,Argentina,,,,,,,,,,,,,,
country,NCT00706134::country::Czechia,NCT00706134,Czechia,,,,,,,,,,,,,,
country,NCT00706134::country::Germany,NCT00706134,Germany,,,,,,,,,,,,,,
country,NCT00706134::country::Iceland,NCT00706134,Iceland,,,,,,,,,,,,,,
country,NCT00706134::country::Italy,NCT00706134,Italy,,,,,,,,,,,,,,
country,NCT00706134::country::Netherlands,NCT00706134,Netherlands,,,,,,,,,,,,,,
country,NCT00706134::country::Poland,NCT00706134,Poland,,,,,,,,,,,,,,
country,NCT00706134::country::Slovakia,NCT00706134,Slovakia,,,,,,,,,,,,,,
trial,NCT01890421,NCT01890421,Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD),PHASE3,cardiovascular disease,Coronary Artery Disease,INDUSTRY,426.0,2013-07-19,2017-08-31,7.0,23.0,,,,,
arm,NCT01890421::arm::FG000,NCT01890421,Gadobutrol 0.1 mmol/kg Body Weight,,,,,,,,,,FG000,Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress,,,
period,NCT01890421::period::1,NCT01890421,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01890421::outcome::primary::1,NCT01890421,Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI (Based on RPS) - Primary Analysis of Sensitivity Based on Blinded Readers' Assessment,,,,,,,,,,,,,PRIMARY,0 to 30/40 minute (min) post-injection
outcome,NCT01890421::outcome::primary::2,NCT01890421,Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI (Based on RPS) - Additional Secondary Analysis of Sensitivity Based on the Blinded Readers' Assessment,,,,,,,,,,,,,PRIMARY,0 to 30/40 min post-injection
outcome,NCT01890421::outcome::primary::3,NCT01890421,Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI (Based on RPS) - Primary Analysis of Specificity Based on the Blinded Readers' Assessment,,,,,,,,,,,,,PRIMARY,0 to 30/40 min post-injection
outcome,NCT01890421::outcome::primary::4,NCT01890421,Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI (Based on RPS) - Additional Secondary Analysis of Specificity Based on the Blinded Readers' Assessment,,,,,,,,,,,,,PRIMARY,0 to 30/40 min post-injection
outcome,NCT01890421::outcome::primary::5,NCT01890421,Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Primary Analysis of Sensitivity Comparison Based on the Blinded Readers' Assessment,,,,,,,,,,,,,PRIMARY,0 to 30/40 min post-injection
outcome,NCT01890421::outcome::primary::6,NCT01890421,Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Additional Secondary Analysis of Sensitivity Comparison Based on the Blinded Readers' Assessment,,,,,,,,,,,,,PRIMARY,0 to 30/40 min post-injection
country,NCT01890421::country::Germany,NCT01890421,Germany,,,,,,,,,,,,,,
country,NCT01890421::country::South Korea,NCT01890421,South Korea,,,,,,,,,,,,,,
country,NCT01890421::country::United Kingdom,NCT01890421,United Kingdom,,,,,,,,,,,,,,
country,NCT01890421::country::France,NCT01890421,France,,,,,,,,,,,,,,
country,NCT01890421::country::United States,NCT01890421,United States,,,,,,,,,,,,,,
country,NCT01890421::country::New Zealand,NCT01890421,New Zealand,,,,,,,,,,,,,,
country,NCT01890421::country::Switzerland,NCT01890421,Switzerland,,,,,,,,,,,,,,
trial,NCT02942576,NCT02942576,Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation,PHASE3,cardiovascular disease,Atrial Fibrillation,INDUSTRY,632.0,2017-03-21,2018-09-24,11.0,75.0,,,,,
arm,NCT02942576::arm::FG000,NCT02942576,Edoxaban-based Regimen,,,,,,,,,,FG000,"Edoxaban-based regimen for 21 days pre- and 90 days post-ablation period.

Edoxaban: Edoxaban 60 mg once-daily or 30 mg once-daily in selected subjects.",,,
arm,NCT02942576::arm::FG001,NCT02942576,VKA-based Regimen,,,,,,,,,,FG001,"VKA-based regimen for 21 days pre- and 90 days post-ablation period (control regimen)

VKA-Based Regimen: Dosed at International Normalised Ratio (INR) levels, which is a test of how long it takes for",,,
period,NCT02942576::period::1,NCT02942576,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02942576::outcome::primary::1,NCT02942576,"Number of Participants Who Experienced the Composite of All-cause Death, Stroke (VARC-2), and Major Bleeding (ISTH) in the Edoxaban Group Compared With Vitamin K Antagonist (VKA) Group in Participants Undergoing Catheter Ablation (Adjudicated Data)",,,,,,,,,,,,,PRIMARY,Day 1 to Day 90
outcome,NCT02942576::outcome::primary::2,NCT02942576,Number of Participants Who Experienced Major Bleeding (International Society on Thrombosis and Hemostasis [ISTH]) in the Edoxaban Group Compared With VKA Group Among Participants Undergoing Catheter Ablation (Adjudicated Data),,,,,,,,,,,,,PRIMARY,Day 1 to Day 90
country,NCT02942576::country::Germany,NCT02942576,Germany,,,,,,,,,,,,,,
country,NCT02942576::country::Italy,NCT02942576,Italy,,,,,,,,,,,,,,
country,NCT02942576::country::Czechia,NCT02942576,Czechia,,,,,,,,,,,,,,
country,NCT02942576::country::Hungary,NCT02942576,Hungary,,,,,,,,,,,,,,
country,NCT02942576::country::United Kingdom,NCT02942576,United Kingdom,,,,,,,,,,,,,,
country,NCT02942576::country::Poland,NCT02942576,Poland,,,,,,,,,,,,,,
country,NCT02942576::country::South Korea,NCT02942576,South Korea,,,,,,,,,,,,,,
country,NCT02942576::country::Spain,NCT02942576,Spain,,,,,,,,,,,,,,
country,NCT02942576::country::Taiwan,NCT02942576,Taiwan,,,,,,,,,,,,,,
country,NCT02942576::country::Belgium,NCT02942576,Belgium,,,,,,,,,,,,,,
country,NCT02942576::country::Canada,NCT02942576,Canada,,,,,,,,,,,,,,
trial,NCT02943785,NCT02943785,Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF),PHASE3,cardiovascular disease,Atrial Fibrillation,INDUSTRY,1426.0,2017-03-21,2021-02-28,14.0,230.0,,,,,
arm,NCT02943785::arm::FG000,NCT02943785,Edoxaban,,,,,,,,,,FG000,"Participants randomized to receive the Edoxaban-based regimen which included 60 mg and 30 mg film coated tablets for once-daily oral use, and 15 mg film coated tablet in case of transitioning at the e",,,
arm,NCT02943785::arm::FG001,NCT02943785,Vitamin K Antagonist (VKA),,,,,,,,,,FG001,Participants randomized to receive the VKA-based regimen which included oral VKA tablets as selected and provided by the site and used in accordance with the local label. The Investigator monitored th,,,
period,NCT02943785::period::1,NCT02943785,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02943785::outcome::primary::1,NCT02943785,Number of Participants Who Experienced Net Adverse Clinical Events (Adjudicated Data) Based on ISTH Criteria in Participants Taking Edoxaban vs VKA,,,,,,,,,,,,,PRIMARY,"Baseline through study completion, up to 36 months post-dose"
outcome,NCT02943785::outcome::primary::2,NCT02943785,Number of Participants Who Experienced Major Bleeding (Adjudicated Data) Based on ISTH Criteria in Participants Taking Edoxaban vs VKA,,,,,,,,,,,,,PRIMARY,"Baseline through study completion, up to 36 months post-dose"
country,NCT02943785::country::United States,NCT02943785,United States,,,,,,,,,,,,,,
country,NCT02943785::country::Italy,NCT02943785,Italy,,,,,,,,,,,,,,
country,NCT02943785::country::Germany,NCT02943785,Germany,,,,,,,,,,,,,,
country,NCT02943785::country::Spain,NCT02943785,Spain,,,,,,,,,,,,,,
country,NCT02943785::country::Japan,NCT02943785,Japan,,,,,,,,,,,,,,
country,NCT02943785::country::France,NCT02943785,France,,,,,,,,,,,,,,
country,NCT02943785::country::Canada,NCT02943785,Canada,,,,,,,,,,,,,,
country,NCT02943785::country::United Kingdom,NCT02943785,United Kingdom,,,,,,,,,,,,,,
country,NCT02943785::country::Belgium,NCT02943785,Belgium,,,,,,,,,,,,,,
country,NCT02943785::country::Austria,NCT02943785,Austria,,,,,,,,,,,,,,
country,NCT02943785::country::Netherlands,NCT02943785,Netherlands,,,,,,,,,,,,,,
country,NCT02943785::country::South Korea,NCT02943785,South Korea,,,,,,,,,,,,,,
country,NCT02943785::country::Switzerland,NCT02943785,Switzerland,,,,,,,,,,,,,,
country,NCT02943785::country::Poland,NCT02943785,Poland,,,,,,,,,,,,,,
trial,NCT00571649,NCT00571649,Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients,PHASE3,cardiovascular disease,Venous Thromboembolism,INDUSTRY,8101.0,2007-12,2010-11,53.0,676.0,,,,,
arm,NCT00571649::arm::FG000,NCT00571649,"Rivaroxaban (Xarelto, BAY59-7939)",,,,,,,,,,FG000,"Participants received 10 mg oral rivaroxaban tablet once daily (OD) for 35 +/- 4 days, plus subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days during treatment period",,,
arm,NCT00571649::arm::FG001,NCT00571649,Enoxaparin,,,,,,,,,,FG001,"Participants received oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days, plus 40 mg subcutaneous enoxaparin solution OD for 10 +/- 4 days during treatment period",,,
period,NCT00571649::period::1,NCT00571649,Treatment Period,,,,,,,,,,,,1.0,,
period,NCT00571649::period::2,NCT00571649,Follow-up Period,,,,,,,,,,,,2.0,,
outcome,NCT00571649::outcome::primary::1,NCT00571649,"Percentage of Participants With Composite Endpoint of Venous Thromboembolism [VTE] (Any Deep Vein Thrombosis [DVT], Non Fatal Pulmonary Embolism [PE]) and VTE-related Death up to Day 35 + 6 Days",,,,,,,,,,,,,PRIMARY,Up to Day 35 + 6 days
outcome,NCT00571649::outcome::primary::2,NCT00571649,"Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days",,,,,,,,,,,,,PRIMARY,Up to Day 10 + 5 days
country,NCT00571649::country::United States,NCT00571649,United States,,,,,,,,,,,,,,
country,NCT00571649::country::Japan,NCT00571649,Japan,,,,,,,,,,,,,,
country,NCT00571649::country::China,NCT00571649,China,,,,,,,,,,,,,,
country,NCT00571649::country::Germany,NCT00571649,Germany,,,,,,,,,,,,,,
country,NCT00571649::country::France,NCT00571649,France,,,,,,,,,,,,,,
country,NCT00571649::country::Italy,NCT00571649,Italy,,,,,,,,,,,,,,
country,NCT00571649::country::Canada,NCT00571649,Canada,,,,,,,,,,,,,,
country,NCT00571649::country::Mexico,NCT00571649,Mexico,,,,,,,,,,,,,,
country,NCT00571649::country::Australia,NCT00571649,Australia,,,,,,,,,,,,,,
country,NCT00571649::country::Austria,NCT00571649,Austria,,,,,,,,,,,,,,
country,NCT00571649::country::Belgium,NCT00571649,Belgium,,,,,,,,,,,,,,
country,NCT00571649::country::India,NCT00571649,India,,,,,,,,,,,,,,
country,NCT00571649::country::Poland,NCT00571649,Poland,,,,,,,,,,,,,,
country,NCT00571649::country::Ukraine,NCT00571649,Ukraine,,,,,,,,,,,,,,
country,NCT00571649::country::South Africa,NCT00571649,South Africa,,,,,,,,,,,,,,
country,NCT00571649::country::Portugal,NCT00571649,Portugal,,,,,,,,,,,,,,
country,NCT00571649::country::Spain,NCT00571649,Spain,,,,,,,,,,,,,,
country,NCT00571649::country::Hungary,NCT00571649,Hungary,,,,,,,,,,,,,,
country,NCT00571649::country::Russia,NCT00571649,Russia,,,,,,,,,,,,,,
country,NCT00571649::country::Sweden,NCT00571649,Sweden,,,,,,,,,,,,,,
country,NCT00571649::country::United Kingdom,NCT00571649,United Kingdom,,,,,,,,,,,,,,
country,NCT00571649::country::Czechia,NCT00571649,Czechia,,,,,,,,,,,,,,
country,NCT00571649::country::Lithuania,NCT00571649,Lithuania,,,,,,,,,,,,,,
country,NCT00571649::country::Greece,NCT00571649,Greece,,,,,,,,,,,,,,
country,NCT00571649::country::Israel,NCT00571649,Israel,,,,,,,,,,,,,,
country,NCT00571649::country::Netherlands,NCT00571649,Netherlands,,,,,,,,,,,,,,
country,NCT00571649::country::Switzerland,NCT00571649,Switzerland,,,,,,,,,,,,,,
country,NCT00571649::country::Argentina,NCT00571649,Argentina,,,,,,,,,,,,,,
country,NCT00571649::country::Brazil,NCT00571649,Brazil,,,,,,,,,,,,,,
country,NCT00571649::country::Finland,NCT00571649,Finland,,,,,,,,,,,,,,
country,NCT00571649::country::Latvia,NCT00571649,Latvia,,,,,,,,,,,,,,
country,NCT00571649::country::Bulgaria,NCT00571649,Bulgaria,,,,,,,,,,,,,,
country,NCT00571649::country::South Korea,NCT00571649,South Korea,,,,,,,,,,,,,,
country,NCT00571649::country::Colombia,NCT00571649,Colombia,,,,,,,,,,,,,,
country,NCT00571649::country::Denmark,NCT00571649,Denmark,,,,,,,,,,,,,,
country,NCT00571649::country::Peru,NCT00571649,Peru,,,,,,,,,,,,,,
country,NCT00571649::country::Croatia,NCT00571649,Croatia,,,,,,,,,,,,,,
country,NCT00571649::country::Norway,NCT00571649,Norway,,,,,,,,,,,,,,
country,NCT00571649::country::Romania,NCT00571649,Romania,,,,,,,,,,,,,,
country,NCT00571649::country::Singapore,NCT00571649,Singapore,,,,,,,,,,,,,,
country,NCT00571649::country::Slovakia,NCT00571649,Slovakia,,,,,,,,,,,,,,
country,NCT00571649::country::Taiwan,NCT00571649,Taiwan,,,,,,,,,,,,,,
country,NCT00571649::country::Estonia,NCT00571649,Estonia,,,,,,,,,,,,,,
country,NCT00571649::country::New Zealand,NCT00571649,New Zealand,,,,,,,,,,,,,,
country,NCT00571649::country::Turkey (Türkiye),NCT00571649,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00571649::country::Chile,NCT00571649,Chile,,,,,,,,,,,,,,
country,NCT00571649::country::Indonesia,NCT00571649,Indonesia,,,,,,,,,,,,,,
country,NCT00571649::country::Luxembourg,NCT00571649,Luxembourg,,,,,,,,,,,,,,
country,NCT00571649::country::Malaysia,NCT00571649,Malaysia,,,,,,,,,,,,,,
country,NCT00571649::country::Pakistan,NCT00571649,Pakistan,,,,,,,,,,,,,,
country,NCT00571649::country::Slovenia,NCT00571649,Slovenia,,,,,,,,,,,,,,
country,NCT00571649::country::Thailand,NCT00571649,Thailand,,,,,,,,,,,,,,
country,NCT00571649::country::Hong Kong,NCT00571649,Hong Kong,,,,,,,,,,,,,,
trial,NCT04929249,NCT04929249,"A Randomized Study to Evaluate the Effect of an ""Inclisiran First"" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)",PHASE3,cardiovascular disease,Atherosclerotic Cardiovascular Disease,INDUSTRY,450.0,2021-06-25,2023-09-15,1.0,43.0,,,,,
arm,NCT04929249::arm::FG000,NCT04929249,Inclisiran First,,,,,,,,,,FG000,Inclisiran sodium 300 mg 1.5 ml (equivalent to 284 mg of inclisiran) + usual care,,,
arm,NCT04929249::arm::FG001,NCT04929249,Usual Care,,,,,,,,,,FG001,Treating physicians were recommended to treat patients in accordance with the 2018 ACC/AHA guidelines,,,
period,NCT04929249::period::1,NCT04929249,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04929249::outcome::primary::1,NCT04929249,Percent Change From Baseline in LDL-C,,,,,,,,,,,,,PRIMARY,"Baseline, Day 330"
outcome,NCT04929249::outcome::primary::2,NCT04929249,Percentage of Participants Who Discontinued Statin Therapy,,,,,,,,,,,,,PRIMARY,Day 330
country,NCT04929249::country::United States,NCT04929249,United States,,,,,,,,,,,,,,
trial,NCT01191450,NCT01191450,Safety and Efficacy of Chlorthalidone + Amiloride to Elderly Patients Treatment With Arterial Hypertension,PHASE3,cardiovascular disease,Arterial Hypertension,INDUSTRY,246.0,2011-08,2013-08,1.0,10.0,,,,,
arm,NCT01191450::arm::FG000,NCT01191450,Higroton®,,,,,,,,,,FG000,"Chlorthalidone 25mg - one oral tablet a day in the morning

Higroton® Laboratório Novartis: Chlortalidone 25mg - oral tablet a day in the morning during approximately 12 weeks",,,
arm,NCT01191450::arm::FG001,NCT01191450,Diupress®,,,,,,,,,,FG001,"Chlorthalidone 25 mg + amiloride hydrochloride 5 mg - one oral tablet a day in the morning

Chlorthalidone 25 mg + amiloride hydrochloride 5 mg: Chlorthalidone 25 mg + amiloride hydrochloride 5 mg - o",,,
period,NCT01191450::period::1,NCT01191450,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01191450::outcome::primary::1,NCT01191450,Number of Subjects With Serum Potassium Levels Below 4.0 mEq/l at Visit 4,,,,,,,,,,,,,PRIMARY,Visit 4 (75 ± 3 days of V1)
country,NCT01191450::country::Brazil,NCT01191450,Brazil,,,,,,,,,,,,,,
trial,NCT00984308,NCT00984308,Diagnosis and Treatment of Sleep Apnea in Cerebrovascular Disease,PHASE3,cardiovascular disease,Obstructive Sleep Apnea; Stroke; Transient Ischemic Attack; Hypertension,FED,225.0,2008-12-23,2011-09-30,1.0,2.0,,,,,
arm,NCT00984308::arm::FG000,NCT00984308,Intervention,,,,,,,,,,FG000,The intervention group received unattended polysomnography and auto-titrating CPAP if sleep apnea was diagnosed,,,
arm,NCT00984308::arm::FG001,NCT00984308,Control,,,,,,,,,,FG001,The control group received usual clinical care which may include receipt of sleep diagnostic and therapeutic services,,,
period,NCT00984308::period::1,NCT00984308,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00984308::outcome::primary::1,NCT00984308,Sleep Apnea Diagnosis Rate,,,,,,,,,,,,,PRIMARY,The entire study period (baseline and up to one-year)
outcome,NCT00984308::outcome::primary::2,NCT00984308,Hypertension Control,,,,,,,,,,,,,PRIMARY,One year
country,NCT00984308::country::United States,NCT00984308,United States,,,,,,,,,,,,,,
trial,NCT00395135,NCT00395135,BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management,PHASE3,cardiovascular disease,Obesity,INDUSTRY,3182.0,2006-11,2009-02,1.0,1.0,,,,,
arm,NCT00395135::arm::FG000,NCT00395135,Year 1 - Lorcaserin 10 mg BID,,,,,,,,,,FG000,lorcaserin 10 mg BID tablets,,,
arm,NCT00395135::arm::FG001,NCT00395135,Year 1 - Matching Placebo BID,,,,,,,,,,FG001,matching placebo tablets,,,
arm,NCT00395135::arm::FG002,NCT00395135,Year 2 - Lorc 10 mg BID (Yr 1) / Lorc 10 mg BID (Yr 2),,,,,,,,,,FG002,"Patients were randomized to lorcaserin in Year 1, completed year 1 study and randomized to lorcaserin in Year 2.",,,
arm,NCT00395135::arm::FG003,NCT00395135,Year 2 - Lorc 10 mg BID (Yr 1) / Placebo (Yr 2),,,,,,,,,,FG003,"Patients were randomized to lorcaserin in Year 1, completed year 1 study and randomized to placebo in Year 2.",,,
arm,NCT00395135::arm::FG004,NCT00395135,Year 2 - Placebo (Yr 1) / Placebo (Yr 2),,,,,,,,,,FG004,"Patients randomized to placebo in Year 1, completed year 1 and randomized to receive placebo in Year 2.",,,
period,NCT00395135::period::1,NCT00395135,Year 1,,,,,,,,,,,,1.0,,
period,NCT00395135::period::2,NCT00395135,Year 2,,,,,,,,,,,,2.0,,
outcome,NCT00395135::outcome::primary::1,NCT00395135,Year 1: Co-Primary Endpoint- Proportion (%) of Patients Achieving > or = 5% Weight Loss From Baseline to Week 52,,,,,,,,,,,,,PRIMARY,52 weeks
outcome,NCT00395135::outcome::primary::2,NCT00395135,Year 2: Proportion (%) of Patients Maintaining > or = 5% Weight Loss at Week 104,,,,,,,,,,,,,PRIMARY,104 weeks
country,NCT00395135::country::United States,NCT00395135,United States,,,,,,,,,,,,,,
trial,NCT00177047,NCT00177047,Autologous Transplant for Multiple Myeloma,PHASE3,cardiovascular disease,Multiple Myeloma,OTHER,363.0,2004-04-20,2020-08-01,1.0,1.0,,,,,
arm,NCT00177047::arm::FG000,NCT00177047,Chemotherapy and Transplant Treatment,,,,,,,,,,FG000,"Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell tran",,,
period,NCT00177047::period::1,NCT00177047,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00177047::outcome::primary::1,NCT00177047,Number of Participants Achieving a Complete Response,,,,,,,,,,,,,PRIMARY,100 Days post transplant
outcome,NCT00177047::outcome::primary::2,NCT00177047,Number of Participants Achieving a Complete Response,,,,,,,,,,,,,PRIMARY,6 months post transplant
outcome,NCT00177047::outcome::primary::3,NCT00177047,Number of Participants Achieving a Complete Response,,,,,,,,,,,,,PRIMARY,12 months post transplant
country,NCT00177047::country::United States,NCT00177047,United States,,,,,,,,,,,,,,
trial,NCT00329238,NCT00329238,Secondary Prevention of Venous Thrombo Embolism (VTE).,PHASE3,cardiovascular disease,Thromboembolism,INDUSTRY,2867.0,2006-05,,33.0,275.0,,,,,
arm,NCT00329238::arm::FG000,NCT00329238,Dabigatran,,,,,,,,,,FG000,"150 mg twice daily, total daily dose 300 mg",,,
arm,NCT00329238::arm::FG001,NCT00329238,Warfarin,,,,,,,,,,FG001,Target International Normalized Ratio (INR) of 2.0 to 3.0,,,
period,NCT00329238::period::1,NCT00329238,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00329238::outcome::primary::1,NCT00329238,Composite of Recurrent VTE or VTE Death at 36 Months,,,,,,,,,,,,,PRIMARY,36 months
outcome,NCT00329238::outcome::primary::2,NCT00329238,Composite of Recurrent VTE or VTE Death at 18 Months,,,,,,,,,,,,,PRIMARY,18 months
country,NCT00329238::country::Russia,NCT00329238,Russia,,,,,,,,,,,,,,
country,NCT00329238::country::United States,NCT00329238,United States,,,,,,,,,,,,,,
country,NCT00329238::country::Canada,NCT00329238,Canada,,,,,,,,,,,,,,
country,NCT00329238::country::China,NCT00329238,China,,,,,,,,,,,,,,
country,NCT00329238::country::India,NCT00329238,India,,,,,,,,,,,,,,
country,NCT00329238::country::Argentina,NCT00329238,Argentina,,,,,,,,,,,,,,
country,NCT00329238::country::France,NCT00329238,France,,,,,,,,,,,,,,
country,NCT00329238::country::Czechia,NCT00329238,Czechia,,,,,,,,,,,,,,
country,NCT00329238::country::Israel,NCT00329238,Israel,,,,,,,,,,,,,,
country,NCT00329238::country::Hungary,NCT00329238,Hungary,,,,,,,,,,,,,,
country,NCT00329238::country::Spain,NCT00329238,Spain,,,,,,,,,,,,,,
country,NCT00329238::country::Brazil,NCT00329238,Brazil,,,,,,,,,,,,,,
country,NCT00329238::country::Bulgaria,NCT00329238,Bulgaria,,,,,,,,,,,,,,
country,NCT00329238::country::Germany,NCT00329238,Germany,,,,,,,,,,,,,,
country,NCT00329238::country::Netherlands,NCT00329238,Netherlands,,,,,,,,,,,,,,
country,NCT00329238::country::Italy,NCT00329238,Italy,,,,,,,,,,,,,,
country,NCT00329238::country::Sweden,NCT00329238,Sweden,,,,,,,,,,,,,,
country,NCT00329238::country::Turkey (Türkiye),NCT00329238,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00329238::country::Australia,NCT00329238,Australia,,,,,,,,,,,,,,
country,NCT00329238::country::Denmark,NCT00329238,Denmark,,,,,,,,,,,,,,
country,NCT00329238::country::Portugal,NCT00329238,Portugal,,,,,,,,,,,,,,
country,NCT00329238::country::South Africa,NCT00329238,South Africa,,,,,,,,,,,,,,
country,NCT00329238::country::Finland,NCT00329238,Finland,,,,,,,,,,,,,,
country,NCT00329238::country::Mexico,NCT00329238,Mexico,,,,,,,,,,,,,,
country,NCT00329238::country::Poland,NCT00329238,Poland,,,,,,,,,,,,,,
country,NCT00329238::country::Slovakia,NCT00329238,Slovakia,,,,,,,,,,,,,,
country,NCT00329238::country::United Kingdom,NCT00329238,United Kingdom,,,,,,,,,,,,,,
country,NCT00329238::country::Austria,NCT00329238,Austria,,,,,,,,,,,,,,
country,NCT00329238::country::Belgium,NCT00329238,Belgium,,,,,,,,,,,,,,
country,NCT00329238::country::Greece,NCT00329238,Greece,,,,,,,,,,,,,,
country,NCT00329238::country::New Zealand,NCT00329238,New Zealand,,,,,,,,,,,,,,
country,NCT00329238::country::Norway,NCT00329238,Norway,,,,,,,,,,,,,,
country,NCT00329238::country::Ukraine,NCT00329238,Ukraine,,,,,,,,,,,,,,
trial,NCT01674647,NCT01674647,Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion,PHASE3,cardiovascular disease,Atrial Fibrillation,INDUSTRY,1504.0,2012-10,2014-01,17.0,178.0,,,,,
arm,NCT01674647::arm::FG000,NCT01674647,"Rivaroxaban (Xarelto, BAY59-7939)",,,,,,,,,,FG000,"Subjects randomized to treatment with rivaroxaban received rivaroxaban 20 milligram (mg) orally once daily. Subjects with moderate renal impairment \[i.e., Creatinine clearance (CrCl) of 30 to 49 mill",,,
arm,NCT01674647::arm::FG001,NCT01674647,Vitamin K Antagonist (VKA),,,,,,,,,,FG001,"Subjects assigned to treatment with VKA received VKA orally once daily titrated to a target INR of 2.5 (range 2.0-3.0, inclusive). The specific VKA was given by the investigator based on local standar",,,
period,NCT01674647::period::1,NCT01674647,Treatment Period,,,,,,,,,,,,1.0,,
period,NCT01674647::period::2,NCT01674647,30-day Safety Follow-up Period,,,,,,,,,,,,2.0,,
outcome,NCT01674647::outcome::primary::1,NCT01674647,"Number of Participants With Composite of the Following Events, Adjudicated Centrally: Stroke, Transient Ischemic Attack, Non-central Nervous System Systemic Embolism, Myocardial Infarction and Cardiovascular Death",,,,,,,,,,,,,PRIMARY,"From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment"
outcome,NCT01674647::outcome::primary::2,NCT01674647,Number of Participants With Major Bleedings as Per Central Adjudication,,,,,,,,,,,,,PRIMARY,From randomization up to the date of the last dose of study drug + 2 days
country,NCT01674647::country::United States,NCT01674647,United States,,,,,,,,,,,,,,
country,NCT01674647::country::Germany,NCT01674647,Germany,,,,,,,,,,,,,,
country,NCT01674647::country::China,NCT01674647,China,,,,,,,,,,,,,,
country,NCT01674647::country::Canada,NCT01674647,Canada,,,,,,,,,,,,,,
country,NCT01674647::country::Finland,NCT01674647,Finland,,,,,,,,,,,,,,
country,NCT01674647::country::France,NCT01674647,France,,,,,,,,,,,,,,
country,NCT01674647::country::Italy,NCT01674647,Italy,,,,,,,,,,,,,,
country,NCT01674647::country::South Africa,NCT01674647,South Africa,,,,,,,,,,,,,,
country,NCT01674647::country::United Kingdom,NCT01674647,United Kingdom,,,,,,,,,,,,,,
country,NCT01674647::country::Belgium,NCT01674647,Belgium,,,,,,,,,,,,,,
country,NCT01674647::country::Portugal,NCT01674647,Portugal,,,,,,,,,,,,,,
country,NCT01674647::country::Spain,NCT01674647,Spain,,,,,,,,,,,,,,
country,NCT01674647::country::Brazil,NCT01674647,Brazil,,,,,,,,,,,,,,
country,NCT01674647::country::Netherlands,NCT01674647,Netherlands,,,,,,,,,,,,,,
country,NCT01674647::country::Denmark,NCT01674647,Denmark,,,,,,,,,,,,,,
country,NCT01674647::country::Greece,NCT01674647,Greece,,,,,,,,,,,,,,
country,NCT01674647::country::Singapore,NCT01674647,Singapore,,,,,,,,,,,,,,
trial,NCT00059332,NCT00059332,Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial,PHASE3,cardiovascular disease,Cerebrovascular Accident,OTHER,1700.0,2005-01,2013-03,1.0,1.0,,,,,
arm,NCT00059332::arm::FG000,NCT00059332,Normal Saline,,,,,,,,,,FG000,"Normal Saline: Paramedics initiate a loading dose of placebo normal saline IV over 15 minutes, followed after hospital arrival by a maintenance infusion of placebo normal saline IV over 24 hours.",,,
arm,NCT00059332::arm::FG001,NCT00059332,Magnesium Sulfate,,,,,,,,,,FG001,"Magnesium Sulfate: Paramedics initiate a loading dose of 4 grams magnesium sulfate IV over 15 minutes, followed after hospital arrival by a maintenance infusion of 16 grams magnesium sulfate IV over 2",,,
period,NCT00059332::period::1,NCT00059332,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00059332::outcome::primary::1,NCT00059332,Modified Rankin Scale,,,,,,,,,,,,,PRIMARY,3 months after stroke onset
country,NCT00059332::country::United States,NCT00059332,United States,,,,,,,,,,,,,,
trial,NCT02203916,NCT02203916,Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,328.0,2014-07,2016-02,1.0,15.0,,,,,
arm,NCT02203916::arm::FG000,NCT02203916,Placebo,,,,,,,,,,FG000,"Azilsartan medoxomil placebo-matching tablets, orally, once daily for 6 weeks.",,,
arm,NCT02203916::arm::FG001,NCT02203916,Azilsartan Medoxomil 40 mg,,,,,,,,,,FG001,"Azilsartan medoxomil 40 mg, tablets, orally, once daily for 6 weeks.",,,
arm,NCT02203916::arm::FG002,NCT02203916,Azilsartan Medoxomil 80 mg,,,,,,,,,,FG002,"Azilsartan medoxomil 80 mg, tablets, orally, once daily for 6 weeks.",,,
period,NCT02203916::period::1,NCT02203916,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02203916::outcome::primary::1,NCT02203916,Change From Baseline to Week 6 in Trough Clinic Sitting Systolic Blood Pressure (SBP),,,,,,,,,,,,,PRIMARY,Baseline and Week 6
country,NCT02203916::country::South Korea,NCT02203916,South Korea,,,,,,,,,,,,,,
trial,NCT00056160,NCT00056160,CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma,PHASE3,cardiovascular disease,Multiple Myeloma,INDUSTRY,353.0,2003-01-01,2008-10-01,2.0,49.0,,,,,
arm,NCT00056160::arm::FG000,NCT00056160,CC-5013/Dex,,,,,,,,,,FG000,CC-5013 (lenalidomide) plus oral high-dose dexamethasone,,,
arm,NCT00056160::arm::FG001,NCT00056160,Placebo/Dex,,,,,,,,,,FG001,"Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone",,,
period,NCT00056160::period::1,NCT00056160,Up to Unblinding (07 Jun 2005),,,,,,,,,,,,1.0,,
period,NCT00056160::period::2,NCT00056160,Extended Follow-up Cutoff (23 Jul 2008),,,,,,,,,,,,2.0,,
period,NCT00056160::period::3,NCT00056160,Final Follow-up,,,,,,,,,,,,3.0,,
outcome,NCT00056160::outcome::primary::1,NCT00056160,Time to Tumor Progression (TTP),,,,,,,,,,,,,PRIMARY,60 weeks (median Time To Progression of CC-5013/Dex treatment group)
country,NCT00056160::country::United States,NCT00056160,United States,,,,,,,,,,,,,,
country,NCT00056160::country::Canada,NCT00056160,Canada,,,,,,,,,,,,,,
trial,NCT02271217,NCT02271217,A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.,PHASE3,cardiovascular disease,Post-Ischemic Stroke,INDUSTRY,377.0,2014-12,2016-10,2.0,74.0,,,,,
arm,NCT02271217::arm::FG000,NCT02271217,Placebo,,,,,,,,,,FG000,"Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.

Placebo",,,
arm,NCT02271217::arm::FG001,NCT02271217,Dalfampridine-ER 7.5 mg,,,,,,,,,,FG001,"Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.

dalfampridine-ER 7.5mg",,,
arm,NCT02271217::arm::FG002,NCT02271217,Dalfampridine-ER 10mg,,,,,,,,,,FG002,"Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.

dalfampridine-ER 10mg",,,
period,NCT02271217::period::1,NCT02271217,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02271217::outcome::primary::1,NCT02271217,Proportion of Subjects Who Show at Least a 20% Improvement on the Two Minute Walk Test (2MinWT) at Week 12,,,,,,,,,,,,,PRIMARY,Week 12
country,NCT02271217::country::United States,NCT02271217,United States,,,,,,,,,,,,,,
country,NCT02271217::country::Canada,NCT02271217,Canada,,,,,,,,,,,,,,
trial,NCT01109004,NCT01109004,Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702),PHASE3,cardiovascular disease,Multiple Myeloma,NIH,758.0,2010-05,2018-03-03,1.0,54.0,,,,,
arm,NCT01109004::arm::FG000,NCT01109004,Tandem Auto Transplant,,,,,,,,,,FG000,"Initial autologous transplant followed by a second autologous transplant and lenalidomide maintenance

Lenalidomide: All patients will undergo a first autologous peripheral blood stem cell (PBSC) tran",,,
arm,NCT01109004::arm::FG001,NCT01109004,RVD Consolidation,,,,,,,,,,FG001,"Initial autologous transplant followed by lenalidomide, bortezomib and dexamethasone (RVD) consolidation and lenalidomide maintenance

lenalidomide, bortezomib and dexamethasone: All patients will und",,,
arm,NCT01109004::arm::FG002,NCT01109004,Lenalidomide Maintenance,,,,,,,,,,FG002,"Initial autologous transplant followed by lenalidomide maintenance

Lenalidomide: All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (20",,,
period,NCT01109004::period::1,NCT01109004,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01109004::outcome::primary::1,NCT01109004,Percentage of Participants With Progression-free Survival (PFS),,,,,,,,,,,,,PRIMARY,38 months post-randomization
country,NCT01109004::country::United States,NCT01109004,United States,,,,,,,,,,,,,,
trial,NCT00380068,NCT00380068,Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension,PHASE3,cardiovascular disease,Pulmonary Hypertension,INDUSTRY,224.0,2006-08,2009-05,3.0,39.0,,,,,
arm,NCT00380068::arm::FG000,NCT00380068,Ambrisentan,,,,,,,,,,FG000,Eligible participants received 5 mg ambrisentan once daily for the first 24 weeks. One dose reduction to 2.5 mg was permitted during the 24-week fixed-dose treatment period if the participant did not ,,,
period,NCT00380068::period::1,NCT00380068,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00380068::outcome::primary::1,NCT00380068,Change From Baseline to Week 24 in 6 Minute Walk Distance (6MWD),,,,,,,,,,,,,PRIMARY,Baseline to Week 24
country,NCT00380068::country::United States,NCT00380068,United States,,,,,,,,,,,,,,
country,NCT00380068::country::Canada,NCT00380068,Canada,,,,,,,,,,,,,,
country,NCT00380068::country::Australia,NCT00380068,Australia,,,,,,,,,,,,,,
trial,NCT00402103,NCT00402103,An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure,PHASE3,cardiovascular disease,Hypertension,INDUSTRY,556.0,2006-11,2008-04,8.0,8.0,,,,,
arm,NCT00402103::arm::FG000,NCT00402103,Aliskiren/Amlodipine,,,,,,,,,,FG000,Aliskiren and Amlodipine tablets once a day in the morning,,,
arm,NCT00402103::arm::FG001,NCT00402103,Aliskiren/Amlodipine/HCTZ,,,,,,,,,,FG001,Aliskiren and Amlodipine tablets and HCTZ capsules once a day in the morning,,,
period,NCT00402103::period::1,NCT00402103,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00402103::outcome::primary::1,NCT00402103,Overall Percentage of Patients With Adverse Events,,,,,,,,,,,,,PRIMARY,52 weeks
country,NCT00402103::country::United States,NCT00402103,United States,,,,,,,,,,,,,,
country,NCT00402103::country::Belgium,NCT00402103,Belgium,,,,,,,,,,,,,,
country,NCT00402103::country::Denmark,NCT00402103,Denmark,,,,,,,,,,,,,,
country,NCT00402103::country::Finland,NCT00402103,Finland,,,,,,,,,,,,,,
country,NCT00402103::country::Germany,NCT00402103,Germany,,,,,,,,,,,,,,
country,NCT00402103::country::Iceland,NCT00402103,Iceland,,,,,,,,,,,,,,
country,NCT00402103::country::India,NCT00402103,India,,,,,,,,,,,,,,
country,NCT00402103::country::Switzerland,NCT00402103,Switzerland,,,,,,,,,,,,,,
trial,NCT01764386,NCT01764386,Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects,PHASE3,cardiovascular disease,Obesity; Overweight,INDUSTRY,242.0,2013-02,2014-09,1.0,15.0,,,,,
arm,NCT01764386::arm::FG000,NCT01764386,NB + CLI,,,,,,,,,,FG000,"Naltrexone SR 32 mg/Bupropion SR 360 mg/day (NB) with Comprehensive Lifestyle Intervention (CLI)

NB: Naltrexone SR 32 mg/Bupropion SR 360 mg (NB) in combination tablets (daily dosage)

CLI: The Compr",,,
arm,NCT01764386::arm::FG001,NCT01764386,Usual Care,,,,,,,,,,FG001,"Usual Care (self-directed lifestyle intervention)

Usual Care: Usual Care was a self-directed lifestyle intervention in which subjects were given calorie targets, instructions to increase exercise, an",,,
period,NCT01764386::period::1,NCT01764386,Controlled Treatment Period (CTP),,,,,,,,,,,,1.0,,
period,NCT01764386::period::2,NCT01764386,Uncontrolled Treatment Period (UTP),,,,,,,,,,,,2.0,,
outcome,NCT01764386::outcome::primary::1,NCT01764386,Percent Change in Body Weight From Baseline (Day 1) to Week 26,,,,,,,,,,,,,PRIMARY,Baseline to Week 26
country,NCT01764386::country::United States,NCT01764386,United States,,,,,,,,,,,,,,
trial,NCT00489827,NCT00489827,Glutamate for Metabolic Intervention in Coronary Surgery,PHASE3,cardiovascular disease,Coronary Artery Bypass; Myocardial Ischemia; Myocardial Infarction; Coronary Artery Disease,OTHER,865.0,2005-10,2022-08,1.0,3.0,,,,,
arm,NCT00489827::arm::FG000,NCT00489827,Intravenous Glutamate,,,,,,,,,,FG000,Intravenous infusion of 0.125 M glutamic acid solution at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients ,,,
arm,NCT00489827::arm::FG001,NCT00489827,Saline Infusion,,,,,,,,,,FG001,Intravenous infusion of saline at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable co,,,
period,NCT00489827::period::1,NCT00489827,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00489827::outcome::primary::1,NCT00489827,"Number of Participants With Perioperative Myocardial Infarction, Postoperative Heart Failure or Postoperative Mortality",,,,,,,,,,,,,PRIMARY,30 days
country,NCT00489827::country::Sweden,NCT00489827,Sweden,,,,,,,,,,,,,,
trial,NCT02801669,NCT02801669,Study of DU-176b Aged 80 Years or Older,PHASE3,cardiovascular disease,Atrial Fibrillation,INDUSTRY,984.0,2016-08-05,2019-12-27,1.0,164.0,,,,,
arm,NCT02801669::arm::FG000,NCT02801669,DU-176b 15 mg,,,,,,,,,,FG000,Participants who were randomized to oral DU-176b administered at a dose of 15 mg once daily.,,,
arm,NCT02801669::arm::FG001,NCT02801669,Placebo,,,,,,,,,,FG001,Participants who were randomized to oral placebo administered once daily.,,,
period,NCT02801669::period::1,NCT02801669,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02801669::outcome::primary::1,NCT02801669,Number of Participants With a Composite Endpoint of Stroke and Systemic Embolic Events (SEE) in Participants Who Were Administered DU-176b Compared With Placebo,,,,,,,,,,,,,PRIMARY,"Randomization up to the time of onset of the initial composite event of stroke or systemic embolic event, or study discontinuation, or end of study (whichever comes first), up to 3 years 2 months postdose (maximum follow-up time)"
outcome,NCT02801669::outcome::primary::2,NCT02801669,"Number of Participants With Stroke and Systemic Embolic Events (SEE), Including Subcomponents of Stroke and Composite Event of Ischemic Stroke and SEE in Participants Who Were Administered DU-176b Compared With Placebo",,,,,,,,,,,,,PRIMARY,"Randomization up to the time of onset of the initial composite event of stroke or systemic embolic event, or study discontinuation, or end of study (whichever comes first), up to 3 years 2 months postdose (maximum follow-up time)"
country,NCT02801669::country::Japan,NCT02801669,Japan,,,,,,,,,,,,,,
trial,NCT00325442,NCT00325442,FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH),PHASE3,cardiovascular disease,Pulmonary Hypertension,INDUSTRY,354.0,2006-10,2010-12,14.0,72.0,,,,,
arm,NCT00325442::arm::FG000,NCT00325442,Placebo Arm,,,,,,,,,,FG000,Subjects were randomly allocated to receive oral placebo twice daily.,,,
arm,NCT00325442::arm::FG001,NCT00325442,Active,,,,,,,,,,FG001,Subjects in this arm were randomly allocated to receive oral treprostinil twice daily.,,,
period,NCT00325442::period::1,NCT00325442,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00325442::outcome::primary::1,NCT00325442,Six Minute Walk Distance (6MWD),,,,,,,,,,,,,PRIMARY,Baseline and 16 Weeks
country,NCT00325442::country::United States,NCT00325442,United States,,,,,,,,,,,,,,
country,NCT00325442::country::Canada,NCT00325442,Canada,,,,,,,,,,,,,,
country,NCT00325442::country::Australia,NCT00325442,Australia,,,,,,,,,,,,,,
country,NCT00325442::country::France,NCT00325442,France,,,,,,,,,,,,,,
country,NCT00325442::country::United Kingdom,NCT00325442,United Kingdom,,,,,,,,,,,,,,
country,NCT00325442::country::Israel,NCT00325442,Israel,,,,,,,,,,,,,,
country,NCT00325442::country::Spain,NCT00325442,Spain,,,,,,,,,,,,,,
country,NCT00325442::country::Austria,NCT00325442,Austria,,,,,,,,,,,,,,
country,NCT00325442::country::Belgium,NCT00325442,Belgium,,,,,,,,,,,,,,
country,NCT00325442::country::Italy,NCT00325442,Italy,,,,,,,,,,,,,,
country,NCT00325442::country::Germany,NCT00325442,Germany,,,,,,,,,,,,,,
country,NCT00325442::country::Ireland,NCT00325442,Ireland,,,,,,,,,,,,,,
country,NCT00325442::country::Netherlands,NCT00325442,Netherlands,,,,,,,,,,,,,,
country,NCT00325442::country::Poland,NCT00325442,Poland,,,,,,,,,,,,,,
trial,NCT00863681,NCT00863681,BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension,PHASE3,cardiovascular disease,"Hypertension, Pulmonary",INDUSTRY,396.0,2009-03-12,2019-08-19,27.0,99.0,,,,,
arm,NCT00863681::arm::FG000,NCT00863681,Riociguat-Former Riociguat 1.0-2.5 mg,,,,,,,,,,FG000,Participants from the former riociguat (BAY 63-2521) 1.0 - 2.5 mg treatment group in PATENT-1 on the same dose as they received on the last day of PATENT-1.,,,
arm,NCT00863681::arm::FG001,NCT00863681,Riociguat-Former Placebo,,,,,,,,,,FG001,Participants were from the former placebo group of PATENT-1. The starting dose in PATENT-2 was 1.0 mg riociguat three times one day.,,,
arm,NCT00863681::arm::FG002,NCT00863681,Riociguat-Former Riociguat 1.0-1.5 mg,,,,,,,,,,FG002,Participants from the former riociguat (BAY 63-2521) 1.0 - 1.5 mg treatment group in PATENT-1 on the same dose as they received on the last day of PATENT-1.,,,
period,NCT00863681::period::1,NCT00863681,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00863681::outcome::primary::1,NCT00863681,Number of Participants With Treatment-emergent Adverse Events (TEAE),,,,,,,,,,,,,PRIMARY,"From administration of first dose of study medication in PATENT-2 up to 2 days after end of treatment with study medication, up to 10 years and 5 months."
outcome,NCT00863681::outcome::primary::2,NCT00863681,Number of Participant With Death,,,,,,,,,,,,,PRIMARY,"From baseline to end of safety follow-up visit, up to 10 years and 6 months (1 month more than End of study visit)"
country,NCT00863681::country::Japan,NCT00863681,Japan,,,,,,,,,,,,,,
country,NCT00863681::country::United States,NCT00863681,United States,,,,,,,,,,,,,,
country,NCT00863681::country::Germany,NCT00863681,Germany,,,,,,,,,,,,,,
country,NCT00863681::country::France,NCT00863681,France,,,,,,,,,,,,,,
country,NCT00863681::country::Mexico,NCT00863681,Mexico,,,,,,,,,,,,,,
country,NCT00863681::country::Australia,NCT00863681,Australia,,,,,,,,,,,,,,
country,NCT00863681::country::China,NCT00863681,China,,,,,,,,,,,,,,
country,NCT00863681::country::Brazil,NCT00863681,Brazil,,,,,,,,,,,,,,
country,NCT00863681::country::Italy,NCT00863681,Italy,,,,,,,,,,,,,,
country,NCT00863681::country::Austria,NCT00863681,Austria,,,,,,,,,,,,,,
country,NCT00863681::country::Portugal,NCT00863681,Portugal,,,,,,,,,,,,,,
country,NCT00863681::country::South Korea,NCT00863681,South Korea,,,,,,,,,,,,,,
country,NCT00863681::country::Taiwan,NCT00863681,Taiwan,,,,,,,,,,,,,,
country,NCT00863681::country::Turkey (Türkiye),NCT00863681,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00863681::country::United Kingdom,NCT00863681,United Kingdom,,,,,,,,,,,,,,
country,NCT00863681::country::Belgium,NCT00863681,Belgium,,,,,,,,,,,,,,
country,NCT00863681::country::Canada,NCT00863681,Canada,,,,,,,,,,,,,,
country,NCT00863681::country::Russia,NCT00863681,Russia,,,,,,,,,,,,,,
country,NCT00863681::country::Singapore,NCT00863681,Singapore,,,,,,,,,,,,,,
country,NCT00863681::country::Thailand,NCT00863681,Thailand,,,,,,,,,,,,,,
country,NCT00863681::country::Argentina,NCT00863681,Argentina,,,,,,,,,,,,,,
country,NCT00863681::country::Czechia,NCT00863681,Czechia,,,,,,,,,,,,,,
country,NCT00863681::country::Denmark,NCT00863681,Denmark,,,,,,,,,,,,,,
country,NCT00863681::country::Greece,NCT00863681,Greece,,,,,,,,,,,,,,
country,NCT00863681::country::Poland,NCT00863681,Poland,,,,,,,,,,,,,,
country,NCT00863681::country::Sweden,NCT00863681,Sweden,,,,,,,,,,,,,,
country,NCT00863681::country::Switzerland,NCT00863681,Switzerland,,,,,,,,,,,,,,
trial,NCT02132767,NCT02132767,Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation,PHASE3,cardiovascular disease,Postoperative Atrial Fibrillation,OTHER,523.0,2014-05,2015-09,2.0,23.0,,,,,
arm,NCT02132767::arm::FG000,NCT02132767,Rate Control,,,,,,,,,,FG000,Patients randomized to this arm will be treated with an initial strategy of rate control. The target heart rate is \< 100 beats per minute at rest. The treating clinician will choose agents from the l,,,
arm,NCT02132767::arm::FG001,NCT02132767,Rhythm Control,,,,,,,,,,FG001,Patients assigned to an initial strategy of rhythm control will be treated with amiodarone alone or amiodarone plus direct current (DC) cardioversion if amiodarone alone does not eliminate AF within 4,,,
period,NCT02132767::period::1,NCT02132767,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02132767::outcome::primary::1,NCT02132767,Total Number of Days in Hospital,,,,,,,,,,,,,PRIMARY,Within 60 days of randomization
country,NCT02132767::country::United States,NCT02132767,United States,,,,,,,,,,,,,,
country,NCT02132767::country::Canada,NCT02132767,Canada,,,,,,,,,,,,,,
trial,NCT02441218,NCT02441218,Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study,PHASE3,heart failure,Chronic Heart Failure,OTHER,6505.0,2006-09,2010-04,2.0,2.0,,,,,
arm,NCT02441218::arm::FG000,NCT02441218,Ivabradine,,,,,,,,,,FG000,"Ivabradine: 2.5mg, 5mg or 7.5mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.",,,
arm,NCT02441218::arm::FG001,NCT02441218,Placebo,,,,,,,,,,FG001,"Placebo: Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.",,,
period,NCT02441218::period::1,NCT02441218,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02441218::outcome::primary::1,NCT02441218,Primary Composite Endpoint: First Event Among Cardiovascular Death (Including Death of Unknown Cause) or Hospitalization for Worsening Heart Failure.,,,,,,,,,,,,,PRIMARY,All over the study (up to 42 months).
country,NCT02441218::country::France,NCT02441218,France,,,,,,,,,,,,,,
country,NCT02441218::country::Sweden,NCT02441218,Sweden,,,,,,,,,,,,,,
trial,NCT01870778,NCT01870778,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",PHASE3,heart failure,Acute Heart Failure,INDUSTRY,6600.0,2013-10-02,2017-02-01,35.0,540.0,,,,,
arm,NCT01870778::arm::FG000,NCT01870778,Serelaxin (RLX030),,,,,,,,,,FG000,Participants received continuous intravenous infusion of serelaxin 30 ug/kg/day for 48 hours.,,,
arm,NCT01870778::arm::FG001,NCT01870778,Placebo,,,,,,,,,,FG001,Participants received continuous intravenous infusion of matching placebo to serelaxin for 48 hours.,,,
period,NCT01870778::period::1,NCT01870778,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01870778::outcome::primary::1,NCT01870778,Percentage of Participants With Confirmed Cardiovascular (CV) Death Through Day 180,,,,,,,,,,,,,PRIMARY,180 days
outcome,NCT01870778::outcome::primary::2,NCT01870778,Percentage of Participants With Worsening of Heart Failure (WHF) Through Day 5,,,,,,,,,,,,,PRIMARY,Day 5
country,NCT01870778::country::United States,NCT01870778,United States,,,,,,,,,,,,,,
country,NCT01870778::country::Germany,NCT01870778,Germany,,,,,,,,,,,,,,
country,NCT01870778::country::Argentina,NCT01870778,Argentina,,,,,,,,,,,,,,
country,NCT01870778::country::Russia,NCT01870778,Russia,,,,,,,,,,,,,,
country,NCT01870778::country::Italy,NCT01870778,Italy,,,,,,,,,,,,,,
country,NCT01870778::country::Spain,NCT01870778,Spain,,,,,,,,,,,,,,
country,NCT01870778::country::France,NCT01870778,France,,,,,,,,,,,,,,
country,NCT01870778::country::Romania,NCT01870778,Romania,,,,,,,,,,,,,,
country,NCT01870778::country::Czechia,NCT01870778,Czechia,,,,,,,,,,,,,,
country,NCT01870778::country::United Kingdom,NCT01870778,United Kingdom,,,,,,,,,,,,,,
country,NCT01870778::country::Hungary,NCT01870778,Hungary,,,,,,,,,,,,,,
country,NCT01870778::country::Poland,NCT01870778,Poland,,,,,,,,,,,,,,
country,NCT01870778::country::Netherlands,NCT01870778,Netherlands,,,,,,,,,,,,,,
country,NCT01870778::country::Slovakia,NCT01870778,Slovakia,,,,,,,,,,,,,,
country,NCT01870778::country::Israel,NCT01870778,Israel,,,,,,,,,,,,,,
country,NCT01870778::country::Portugal,NCT01870778,Portugal,,,,,,,,,,,,,,
country,NCT01870778::country::Australia,NCT01870778,Australia,,,,,,,,,,,,,,
country,NCT01870778::country::Bulgaria,NCT01870778,Bulgaria,,,,,,,,,,,,,,
country,NCT01870778::country::Austria,NCT01870778,Austria,,,,,,,,,,,,,,
country,NCT01870778::country::Brazil,NCT01870778,Brazil,,,,,,,,,,,,,,
country,NCT01870778::country::Belgium,NCT01870778,Belgium,,,,,,,,,,,,,,
country,NCT01870778::country::Turkey (Türkiye),NCT01870778,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01870778::country::Greece,NCT01870778,Greece,,,,,,,,,,,,,,
country,NCT01870778::country::South Africa,NCT01870778,South Africa,,,,,,,,,,,,,,
country,NCT01870778::country::Canada,NCT01870778,Canada,,,,,,,,,,,,,,
country,NCT01870778::country::Mexico,NCT01870778,Mexico,,,,,,,,,,,,,,
country,NCT01870778::country::Sweden,NCT01870778,Sweden,,,,,,,,,,,,,,
country,NCT01870778::country::Denmark,NCT01870778,Denmark,,,,,,,,,,,,,,
country,NCT01870778::country::Switzerland,NCT01870778,Switzerland,,,,,,,,,,,,,,
country,NCT01870778::country::Colombia,NCT01870778,Colombia,,,,,,,,,,,,,,
country,NCT01870778::country::Ireland,NCT01870778,Ireland,,,,,,,,,,,,,,
country,NCT01870778::country::Chile,NCT01870778,Chile,,,,,,,,,,,,,,
country,NCT01870778::country::Norway,NCT01870778,Norway,,,,,,,,,,,,,,
country,NCT01870778::country::Peru,NCT01870778,Peru,,,,,,,,,,,,,,
country,NCT01870778::country::Puerto Rico,NCT01870778,Puerto Rico,,,,,,,,,,,,,,
trial,NCT03877237,NCT03877237,DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction,PHASE3,heart failure,Heart Failure With Reduced Ejection Fraction (HFrEF),INDUSTRY,313.0,2019-04-09,2020-03-07,9.0,76.0,,,,,
arm,NCT03877237::arm::FG000,NCT03877237,Dapa 10mg,,,,,,,,,,FG000,"Dapagliflozin 10 mg, given once daily per oral use.",,,
arm,NCT03877237::arm::FG001,NCT03877237,Placebo,,,,,,,,,,FG001,"Placebo tablet to match dapagliflozin 10 mg, given once daily per oral use.",,,
period,NCT03877237::period::1,NCT03877237,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03877237::outcome::primary::1,NCT03877237,Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 16 (Higher Scores Represent Less HF Symptom Frequency and Burden).,,,,,,,,,,,,,PRIMARY,At baseline and at week 16 or death before week 16
outcome,NCT03877237::outcome::primary::2,NCT03877237,Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Physical Limitation Score (KCCQ-PLS) at Week 16 (Higher Scores Represent Less Physical Limitation Due to HF),,,,,,,,,,,,,PRIMARY,At baseline and at week 16 or death before week 16
outcome,NCT03877237::outcome::primary::3,NCT03877237,Change From Baseline in 6-minute Walk Distance (6MWD) at Week 16 (Larger Distances Represent Better Functional Capacity).,,,,,,,,,,,,,PRIMARY,At baseline and at week 16 or death prior to week 16
country,NCT03877237::country::United States,NCT03877237,United States,,,,,,,,,,,,,,
country,NCT03877237::country::Canada,NCT03877237,Canada,,,,,,,,,,,,,,
country,NCT03877237::country::Denmark,NCT03877237,Denmark,,,,,,,,,,,,,,
country,NCT03877237::country::Japan,NCT03877237,Japan,,,,,,,,,,,,,,
country,NCT03877237::country::Sweden,NCT03877237,Sweden,,,,,,,,,,,,,,
country,NCT03877237::country::Brazil,NCT03877237,Brazil,,,,,,,,,,,,,,
country,NCT03877237::country::Slovakia,NCT03877237,Slovakia,,,,,,,,,,,,,,
country,NCT03877237::country::South Africa,NCT03877237,South Africa,,,,,,,,,,,,,,
country,NCT03877237::country::South Korea,NCT03877237,South Korea,,,,,,,,,,,,,,
trial,NCT04847557,NCT04847557,A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial,PHASE3,heart failure,Obesity; Heart Failure With Preserved Ejection Fraction (HFpEF),INDUSTRY,731.0,2021-04-20,2024-07-02,10.0,146.0,,,,,
arm,NCT04847557::arm::FG000,NCT04847557,Tirzepatide - MTD,,,,,,,,,,FG000,Participants received a starting dose of 2.5 milligrams (mg) tirzepatide administered subcutaneously (SC) once weekly (QW) and escalated by 2.5 mg every 4 weeks to a maximum of 15 mg QW or maximum tol,,,
arm,NCT04847557::arm::FG001,NCT04847557,Placebo,,,,,,,,,,FG001,Participants received placebo administered SC QW.,,,
period,NCT04847557::period::1,NCT04847557,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04847557::outcome::primary::1,NCT04847557,Change From Baseline in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS),,,,,,,,,,,,,PRIMARY,"Baseline, Week 52"
outcome,NCT04847557::outcome::primary::2,NCT04847557,First Occurrence of the Composite Endpoint of Heart Failure (HF) Outcomes,,,,,,,,,,,,,PRIMARY,Baseline Up To 160 weeks
country,NCT04847557::country::United States,NCT04847557,United States,,,,,,,,,,,,,,
country,NCT04847557::country::China,NCT04847557,China,,,,,,,,,,,,,,
country,NCT04847557::country::Argentina,NCT04847557,Argentina,,,,,,,,,,,,,,
country,NCT04847557::country::Brazil,NCT04847557,Brazil,,,,,,,,,,,,,,
country,NCT04847557::country::Israel,NCT04847557,Israel,,,,,,,,,,,,,,
country,NCT04847557::country::India,NCT04847557,India,,,,,,,,,,,,,,
country,NCT04847557::country::Mexico,NCT04847557,Mexico,,,,,,,,,,,,,,
country,NCT04847557::country::Taiwan,NCT04847557,Taiwan,,,,,,,,,,,,,,
country,NCT04847557::country::Russia,NCT04847557,Russia,,,,,,,,,,,,,,
country,NCT04847557::country::Puerto Rico,NCT04847557,Puerto Rico,,,,,,,,,,,,,,
trial,NCT05093933,NCT05093933,A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035),PHASE3,heart failure,Chronic Heart Failure With Reduced Ejection Fraction,INDUSTRY,6106.0,2021-11-02,2025-02-05,36.0,519.0,,,,,
arm,NCT05093933::arm::FG000,NCT05093933,Vericiguat,,,,,,,,,,FG000,Participants received a starting dose of 2.5 mg of vericiguat taken orally once daily for 2 weeks. The vericiguat dose was titrated to 5 mg for 2 weeks and then to the target dose of 10 mg for the rem,,,
arm,NCT05093933::arm::FG001,NCT05093933,Placebo,,,,,,,,,,FG001,Participants received a placebo matched to the vericiguat dose of 2.5 mg taken orally once daily for 2 weeks. The placebo dose was sham titrated to 5 mg for 2 weeks and then to 10 mg for the remainder,,,
period,NCT05093933::period::1,NCT05093933,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT05093933::outcome::primary::1,NCT05093933,Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization: Participants With an Event Per 100 Patient-Years,,,,,,,,,,,,,PRIMARY,Up to approximately 36 months (from randomization to the primary completion data cutoff)
country,NCT05093933::country::United States,NCT05093933,United States,,,,,,,,,,,,,,
country,NCT05093933::country::China,NCT05093933,China,,,,,,,,,,,,,,
country,NCT05093933::country::Ukraine,NCT05093933,Ukraine,,,,,,,,,,,,,,
country,NCT05093933::country::Mexico,NCT05093933,Mexico,,,,,,,,,,,,,,
country,NCT05093933::country::Canada,NCT05093933,Canada,,,,,,,,,,,,,,
country,NCT05093933::country::Germany,NCT05093933,Germany,,,,,,,,,,,,,,
country,NCT05093933::country::United Kingdom,NCT05093933,United Kingdom,,,,,,,,,,,,,,
country,NCT05093933::country::Russia,NCT05093933,Russia,,,,,,,,,,,,,,
country,NCT05093933::country::Hungary,NCT05093933,Hungary,,,,,,,,,,,,,,
country,NCT05093933::country::Poland,NCT05093933,Poland,,,,,,,,,,,,,,
country,NCT05093933::country::Italy,NCT05093933,Italy,,,,,,,,,,,,,,
country,NCT05093933::country::South Africa,NCT05093933,South Africa,,,,,,,,,,,,,,
country,NCT05093933::country::Denmark,NCT05093933,Denmark,,,,,,,,,,,,,,
country,NCT05093933::country::Turkey (Türkiye),NCT05093933,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT05093933::country::Chile,NCT05093933,Chile,,,,,,,,,,,,,,
country,NCT05093933::country::Colombia,NCT05093933,Colombia,,,,,,,,,,,,,,
country,NCT05093933::country::Spain,NCT05093933,Spain,,,,,,,,,,,,,,
country,NCT05093933::country::Czechia,NCT05093933,Czechia,,,,,,,,,,,,,,
country,NCT05093933::country::France,NCT05093933,France,,,,,,,,,,,,,,
country,NCT05093933::country::Greece,NCT05093933,Greece,,,,,,,,,,,,,,
country,NCT05093933::country::Brazil,NCT05093933,Brazil,,,,,,,,,,,,,,
country,NCT05093933::country::Israel,NCT05093933,Israel,,,,,,,,,,,,,,
country,NCT05093933::country::Peru,NCT05093933,Peru,,,,,,,,,,,,,,
country,NCT05093933::country::South Korea,NCT05093933,South Korea,,,,,,,,,,,,,,
country,NCT05093933::country::Sweden,NCT05093933,Sweden,,,,,,,,,,,,,,
country,NCT05093933::country::Malaysia,NCT05093933,Malaysia,,,,,,,,,,,,,,
country,NCT05093933::country::Argentina,NCT05093933,Argentina,,,,,,,,,,,,,,
country,NCT05093933::country::New Zealand,NCT05093933,New Zealand,,,,,,,,,,,,,,
country,NCT05093933::country::Australia,NCT05093933,Australia,,,,,,,,,,,,,,
country,NCT05093933::country::Taiwan,NCT05093933,Taiwan,,,,,,,,,,,,,,
country,NCT05093933::country::Austria,NCT05093933,Austria,,,,,,,,,,,,,,
country,NCT05093933::country::Puerto Rico,NCT05093933,Puerto Rico,,,,,,,,,,,,,,
country,NCT05093933::country::Hong Kong,NCT05093933,Hong Kong,,,,,,,,,,,,,,
country,NCT05093933::country::Singapore,NCT05093933,Singapore,,,,,,,,,,,,,,
country,NCT05093933::country::Guatemala,NCT05093933,Guatemala,,,,,,,,,,,,,,
country,NCT05093933::country::Ireland,NCT05093933,Ireland,,,,,,,,,,,,,,
trial,NCT03988634,NCT03988634,"Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)",PHASE3,heart failure,Heart Failure With Preserved Ejection Fraction (HFpEF),INDUSTRY,467.0,2019-06-29,2022-12-14,2.0,97.0,,,,,
arm,NCT03988634::arm::FG000,NCT03988634,Double-blind Phase Sacubitril+ Valsartan (LCZ696),,,,,,,,,,FG000,Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg twice daily (Dose Level 3).,,,
arm,NCT03988634::arm::FG001,NCT03988634,Double-blind Phase Valsartan,,,,,,,,,,FG001,Study treatment was titrated to the target dose of valsartan 160 mg twice daily (Dose Level 3).,,,
arm,NCT03988634::arm::FG002,NCT03988634,Open-label Phase Sacubitril+ Valsartan,,,,,,,,,,FG002,Participants recruited under Protocol Version 00 (Original Protocol) and who had completed the double-blind phase before protocol amendment 01 was released. Participants were in the open-label phase f,,,
period,NCT03988634::period::1,NCT03988634,Double-Blind,,,,,,,,,,,,1.0,,
period,NCT03988634::period::2,NCT03988634,Open-Label,,,,,,,,,,,,2.0,,
outcome,NCT03988634::outcome::primary::1,NCT03988634,Time-averaged Proportional Change in NT proBNP From Baseline to Weeks 4 and 8,,,,,,,,,,,,,PRIMARY,"Baseline, Average of Week 4 and Week 8"
country,NCT03988634::country::United States,NCT03988634,United States,,,,,,,,,,,,,,
country,NCT03988634::country::Canada,NCT03988634,Canada,,,,,,,,,,,,,,
trial,NCT04788511,NCT04788511,Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity,PHASE3,heart failure,Obesity,INDUSTRY,529.0,2021-03-16,2023-04-18,13.0,146.0,,,,,
arm,NCT04788511::arm::FG000,NCT04788511,Semaglutide 2.4 mg,,,,,,,,,,FG000,Participants with obesity (body mass index \[BMI\] greater than or equal to (≥) 30.0 kilogram per square meter (kg/m\^2) related heart failure with preserved ejection fraction received semaglutide 2.4,,,
arm,NCT04788511::arm::FG001,NCT04788511,Placebo,,,,,,,,,,FG001,"Participants with obesity (BMI ≥30.0 kg/m\^2) related heart failure with preserved ejection fraction received placebo once weekly by subcutaneous injection (in the abdomen, thigh or upper arm) for 52 ",,,
period,NCT04788511::period::1,NCT04788511,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04788511::outcome::primary::1,NCT04788511,Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS),,,,,,,,,,,,,PRIMARY,From baseline (week 0) to end of treatment (week 52)
outcome,NCT04788511::outcome::primary::2,NCT04788511,Change in Body Weight,,,,,,,,,,,,,PRIMARY,From baseline (week 0) to end of treatment (week 52)
country,NCT04788511::country::United States,NCT04788511,United States,,,,,,,,,,,,,,
country,NCT04788511::country::United Kingdom,NCT04788511,United Kingdom,,,,,,,,,,,,,,
country,NCT04788511::country::Canada,NCT04788511,Canada,,,,,,,,,,,,,,
country,NCT04788511::country::Argentina,NCT04788511,Argentina,,,,,,,,,,,,,,
country,NCT04788511::country::Czechia,NCT04788511,Czechia,,,,,,,,,,,,,,
country,NCT04788511::country::Germany,NCT04788511,Germany,,,,,,,,,,,,,,
country,NCT04788511::country::Hungary,NCT04788511,Hungary,,,,,,,,,,,,,,
country,NCT04788511::country::Australia,NCT04788511,Australia,,,,,,,,,,,,,,
country,NCT04788511::country::Netherlands,NCT04788511,Netherlands,,,,,,,,,,,,,,
country,NCT04788511::country::Poland,NCT04788511,Poland,,,,,,,,,,,,,,
country,NCT04788511::country::Israel,NCT04788511,Israel,,,,,,,,,,,,,,
country,NCT04788511::country::Denmark,NCT04788511,Denmark,,,,,,,,,,,,,,
country,NCT04788511::country::Spain,NCT04788511,Spain,,,,,,,,,,,,,,
trial,NCT02678312,NCT02678312,"Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure",PHASE3,heart failure,Pediatric Heart Failure,INDUSTRY,393.0,2016-11-03,2022-01-03,29.0,98.0,,,,,
arm,NCT02678312::arm::FG000,NCT02678312,Part 1: Dose Cohort 1,,,,,,,,,,FG000,"Participants received LCZ696 0.4 mg/kg (age group 3 {1 month to \< 1 year}) or 0.8 mg/kg (age group 1 {6 to \<18 years} and age group 2 {1 to \< 6 years}), based on age, given as a single oral dose on",,,
arm,NCT02678312::arm::FG001,NCT02678312,Part 1: Dose Cohort 2,,,,,,,,,,FG001,"Participants received LCZ696 1.6 mg/kg (age group 3 {1 month to \< 1 year}) or 3.1 mg/kg (age group 1 {6 to \<18 years} and age group 2 {1 to \< 6 years}), based on age, given as a single oral dose on",,,
arm,NCT02678312::arm::FG002,NCT02678312,Part 1: Dose Cohort S,,,,,,,,,,FG002,"Participants in the dose cohort 2 who received LCZ696 3.1 mg/kg on Day 1 of period 2 and later received LCZ696 0.8 mg/kg, within period 2.",,,
arm,NCT02678312::arm::FG003,NCT02678312,Part 2: LCZ696,,,,,,,,,,FG003,"Participants received LCZ696 3.1 mg/kg (age group 1 {6 to \<18 years} and age group 2 {1 to \< 6 years}) or 2.3 mg/kg (age group 3 {1 month to \< 1 year}), based on age, orally, twice a day (BID) for ",,,
arm,NCT02678312::arm::FG004,NCT02678312,Part 2: Enalapril,,,,,,,,,,FG004,"Participants received enalapril 0.2 mg/kg (age group 1 {6 to \<18 years} and age group 2 {1 to \< 6 years}) or 0.15 mg/kg (age group 3 {1 month to \< 1 year}), based on age, orally, BID, for 52 weeks.",,,
period,NCT02678312::period::1,NCT02678312,Part 1 Open Label Epoch- Period 1,,,,,,,,,,,,1.0,,
period,NCT02678312::period::2,NCT02678312,Part 1 Open Label Epoch- Period 2,,,,,,,,,,,,2.0,,
period,NCT02678312::period::3,NCT02678312,Part 2 Double Blind Epoch,,,,,,,,,,,,3.0,,
outcome,NCT02678312::outcome::primary::1,NCT02678312,"Part 1: Pharmacokinetics of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Maximum Drug Concentration in Plasma (Cmax)",,,,,,,,,,,,,PRIMARY,"Age group 1: Pre-dose and 0.5, 1, 2, 4, 8, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2"
outcome,NCT02678312::outcome::primary::2,NCT02678312,"Part 1: Pharmacokinetics of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Time to Maximum Plasma Concentration (Tmax)",,,,,,,,,,,,,PRIMARY,"Age groups 2 and 3: Pre-dose and 1, 2, 4, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2"
outcome,NCT02678312::outcome::primary::3,NCT02678312,"Part 1: Pharmacokinetics of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf)",,,,,,,,,,,,,PRIMARY,"Age group 1: Pre-dose and 0.5, 1, 2, 4, 8, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2"
outcome,NCT02678312::outcome::primary::4,NCT02678312,"Part 1: Pharmacokinetics of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Number of Participants With Area Under the Plasma Concentration-time Curve From Time Zero to Last (AUClast)",,,,,,,,,,,,,PRIMARY,"Age groups 2 and 3: Pre-dose and 1, 2, 4, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2"
outcome,NCT02678312::outcome::primary::5,NCT02678312,"Part 1: Pharmacokinetics of LCZ696 Analytes (Sacubitril, and Valsartan): Clearance From Plasma (CL/F)",,,,,,,,,,,,,PRIMARY,"Age group 1: Pre-dose and 0.5, 1, 2, 4, 8, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2"
outcome,NCT02678312::outcome::primary::6,NCT02678312,Part 1: Pharmacokinetics of LCZ696 Analytes (Sacubitril): Time Required to Drug Concentration to Decrease by Half (T 1/2),,,,,,,,,,,,,PRIMARY,"Age groups 2 and 3: Pre-dose and 1, 2, 4, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2"
outcome,NCT02678312::outcome::primary::7,NCT02678312,"Part 1: Pharmacodynamics (PD) of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Change From Baseline in Plasma B-type Natriuretic Peptide (BNP)",,,,,,,,,,,,,PRIMARY,"Age group 1: Pre-dose and 0.5, 1, 2, 4, 8, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2"
outcome,NCT02678312::outcome::primary::8,NCT02678312,"Part 1: Pharmacodynamics of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Change From Baseline in Plasma N-terminal Pro-brain Natriuretic Peptide (NTproBNP)",,,,,,,,,,,,,PRIMARY,"Age groups 2 and 3: Pre-dose and 1, 2, 4, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2"
outcome,NCT02678312::outcome::primary::9,NCT02678312,"Part 1: Pharmacodynamics of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Change From Baseline in Plasma Cyclic Guanosine Monophosphate (cGMP)",,,,,,,,,,,,,PRIMARY,"Age group 1: Pre-dose and 0.5, 1, 2, 4, 8, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2"
outcome,NCT02678312::outcome::primary::10,NCT02678312,"Part 1: Pharmacodynamics of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Change From Baseline in Urine cGMP",,,,,,,,,,,,,PRIMARY,"Age groups 2 and 3: Pre-dose and 1, 2, 4, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2"
outcome,NCT02678312::outcome::primary::11,NCT02678312,Part 2: Percentage of Participants With Worst Event in Each Category Based on Global Ranking,,,,,,,,,,,,,PRIMARY,"Age group 1: Pre-dose and 0.5, 1, 2, 4, 8, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2"
country,NCT02678312::country::United States,NCT02678312,United States,,,,,,,,,,,,,,
country,NCT02678312::country::Italy,NCT02678312,Italy,,,,,,,,,,,,,,
country,NCT02678312::country::Japan,NCT02678312,Japan,,,,,,,,,,,,,,
country,NCT02678312::country::Germany,NCT02678312,Germany,,,,,,,,,,,,,,
country,NCT02678312::country::Spain,NCT02678312,Spain,,,,,,,,,,,,,,
country,NCT02678312::country::China,NCT02678312,China,,,,,,,,,,,,,,
country,NCT02678312::country::India,NCT02678312,India,,,,,,,,,,,,,,
country,NCT02678312::country::South Korea,NCT02678312,South Korea,,,,,,,,,,,,,,
country,NCT02678312::country::France,NCT02678312,France,,,,,,,,,,,,,,
country,NCT02678312::country::Portugal,NCT02678312,Portugal,,,,,,,,,,,,,,
country,NCT02678312::country::Turkey (Türkiye),NCT02678312,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02678312::country::Argentina,NCT02678312,Argentina,,,,,,,,,,,,,,
country,NCT02678312::country::Canada,NCT02678312,Canada,,,,,,,,,,,,,,
country,NCT02678312::country::Lebanon,NCT02678312,Lebanon,,,,,,,,,,,,,,
country,NCT02678312::country::Poland,NCT02678312,Poland,,,,,,,,,,,,,,
country,NCT02678312::country::Russia,NCT02678312,Russia,,,,,,,,,,,,,,
country,NCT02678312::country::Taiwan,NCT02678312,Taiwan,,,,,,,,,,,,,,
country,NCT02678312::country::Thailand,NCT02678312,Thailand,,,,,,,,,,,,,,
country,NCT02678312::country::Austria,NCT02678312,Austria,,,,,,,,,,,,,,
country,NCT02678312::country::Bulgaria,NCT02678312,Bulgaria,,,,,,,,,,,,,,
country,NCT02678312::country::Croatia,NCT02678312,Croatia,,,,,,,,,,,,,,
country,NCT02678312::country::Czechia,NCT02678312,Czechia,,,,,,,,,,,,,,
country,NCT02678312::country::Finland,NCT02678312,Finland,,,,,,,,,,,,,,
country,NCT02678312::country::Hungary,NCT02678312,Hungary,,,,,,,,,,,,,,
country,NCT02678312::country::Israel,NCT02678312,Israel,,,,,,,,,,,,,,
country,NCT02678312::country::Jordan,NCT02678312,Jordan,,,,,,,,,,,,,,
country,NCT02678312::country::Saudi Arabia,NCT02678312,Saudi Arabia,,,,,,,,,,,,,,
country,NCT02678312::country::Singapore,NCT02678312,Singapore,,,,,,,,,,,,,,
country,NCT02678312::country::Switzerland,NCT02678312,Switzerland,,,,,,,,,,,,,,
trial,NCT02468232,NCT02468232,Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction,PHASE3,heart failure,Heart Failure With Reduced Ejection Fraction (HF-rEF),INDUSTRY,225.0,2015-06-15,2021-02-18,1.0,49.0,,,,,
arm,NCT02468232::arm::FG000,NCT02468232,LCZ696,,,,,,,,,,FG000,"Before randomization, all patients received 2 week LCZ696 50 mg twice daily (b.i.d) as single blind run-in active treatment epoch. In double blind epoch, randomized patients in this arm started with 1",,,
arm,NCT02468232::arm::FG001,NCT02468232,Enalapril,,,,,,,,,,FG001,"Before randomization, all patients received 2 week LCZ696 50 mg twice daily (b.i.d) as single blind run-in active treatment epoch. In double blind period, all randomized patients in this arm received ",,,
arm,NCT02468232::arm::FG002,NCT02468232,LCZ696 (Core) OLE Epoch,,,,,,,,,,FG002,The patients who received LCZ696 in the core part of the study and continued to receive LCZ696 in the open-label extension (OLE) are referred to as LCZ (core) group. These patients received open-label,,,
arm,NCT02468232::arm::FG003,NCT02468232,Enalapril (Core) OLE Epoch,,,,,,,,,,FG003,The subjects who received enalapril in the core part and then switched to LCZ696 in the OLE are referred to as ENA (core) group. These patients switched from enalapril and received open-label LCZ696 i,,,
period,NCT02468232::period::1,NCT02468232,Core Part of Study,,,,,,,,,,,,1.0,,
period,NCT02468232::period::2,NCT02468232,OLE Part of Study,,,,,,,,,,,,2.0,,
outcome,NCT02468232::outcome::primary::1,NCT02468232,Number of Participants Who Had CEC (Clinical Endpoint Committee) Confirmed Composite Endpoints,,,,,,,,,,,,,PRIMARY,up to 40 months
outcome,NCT02468232::outcome::primary::2,NCT02468232,Exposure-adjusted Incident Rate (EAIR) of CEC Confirmed Composite Endpoints,,,,,,,,,,,,,PRIMARY,up to 40 months
country,NCT02468232::country::Japan,NCT02468232,Japan,,,,,,,,,,,,,,
trial,NCT03877224,NCT03877224,DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction,PHASE3,heart failure,Heart Failure With Preserved Ejection Fraction (HFpEF),INDUSTRY,504.0,2019-04-04,2020-07-09,12.0,101.0,,,,,
arm,NCT03877224::arm::FG000,NCT03877224,Dapa 10 mg,,,,,,,,,,FG000,"Dapagliflozin 10 mg, given once daily per oral use.",,,
arm,NCT03877224::arm::FG001,NCT03877224,Placebo,,,,,,,,,,FG001,"Placebo tablet to match dapagliflozin 10 mg, given once daily per oral use.",,,
period,NCT03877224::period::1,NCT03877224,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03877224::outcome::primary::1,NCT03877224,Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 16 (Higher Scores Represent Less HF Symptom Frequency and Burden),,,,,,,,,,,,,PRIMARY,At baseline and at week 16 or death before week 16
outcome,NCT03877224::outcome::primary::2,NCT03877224,Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Physical Limitation Score (KCCQ-PLS) at Week 16 (Higher Scores Represent Less Physical Limitation Due to HF),,,,,,,,,,,,,PRIMARY,At baseline and at week 16 or death before week 16
outcome,NCT03877224::outcome::primary::3,NCT03877224,Change From Baseline in 6-minute Walk Distance (6MWD) at Week 16 (Larger Distances Represent Better Functional Capacity),,,,,,,,,,,,,PRIMARY,At baseline and at week 16 or death before week 16
country,NCT03877224::country::United States,NCT03877224,United States,,,,,,,,,,,,,,
country,NCT03877224::country::Canada,NCT03877224,Canada,,,,,,,,,,,,,,
country,NCT03877224::country::Denmark,NCT03877224,Denmark,,,,,,,,,,,,,,
country,NCT03877224::country::Japan,NCT03877224,Japan,,,,,,,,,,,,,,
country,NCT03877224::country::Sweden,NCT03877224,Sweden,,,,,,,,,,,,,,
country,NCT03877224::country::Italy,NCT03877224,Italy,,,,,,,,,,,,,,
country,NCT03877224::country::Brazil,NCT03877224,Brazil,,,,,,,,,,,,,,
country,NCT03877224::country::Slovakia,NCT03877224,Slovakia,,,,,,,,,,,,,,
country,NCT03877224::country::South Korea,NCT03877224,South Korea,,,,,,,,,,,,,,
country,NCT03877224::country::Bulgaria,NCT03877224,Bulgaria,,,,,,,,,,,,,,
country,NCT03877224::country::Argentina,NCT03877224,Argentina,,,,,,,,,,,,,,
country,NCT03877224::country::South Africa,NCT03877224,South Africa,,,,,,,,,,,,,,
trial,NCT03759392,NCT03759392,Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure,PHASE3,heart failure,Heart Failure With Reduced Ejection Fraction,INDUSTRY,276.0,2019-04-09,2022-01-06,9.0,81.0,,,,,
arm,NCT03759392::arm::FG000,NCT03759392,Omecamtiv Mecarbil,,,,,,,,,,FG000,Omecamtiv mecarbil was administered as an oral modified release tablet twice daily for up to 20 weeks. Participants randomized to this arm started at an omecamtiv mecarbil dose of 25 mg twice daily. T,,,
arm,NCT03759392::arm::FG001,NCT03759392,Placebo,,,,,,,,,,FG001,Participants randomized to this arm received placebo tablets (matching the appearance of the omecamtiv mecarbil tablets) twice daily for up to 20 weeks.,,,
period,NCT03759392::period::1,NCT03759392,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03759392::outcome::primary::1,NCT03759392,Change in Peak Oxygen Uptake on Cardiopulmonary Exercise Testing From Baseline to Week 20,,,,,,,,,,,,,PRIMARY,Baseline and Week 20
country,NCT03759392::country::United States,NCT03759392,United States,,,,,,,,,,,,,,
country,NCT03759392::country::Netherlands,NCT03759392,Netherlands,,,,,,,,,,,,,,
country,NCT03759392::country::France,NCT03759392,France,,,,,,,,,,,,,,
country,NCT03759392::country::Italy,NCT03759392,Italy,,,,,,,,,,,,,,
country,NCT03759392::country::Poland,NCT03759392,Poland,,,,,,,,,,,,,,
country,NCT03759392::country::Germany,NCT03759392,Germany,,,,,,,,,,,,,,
country,NCT03759392::country::Canada,NCT03759392,Canada,,,,,,,,,,,,,,
country,NCT03759392::country::Hungary,NCT03759392,Hungary,,,,,,,,,,,,,,
country,NCT03759392::country::Sweden,NCT03759392,Sweden,,,,,,,,,,,,,,
trial,NCT03619213,NCT03619213,Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.,PHASE3,heart failure,Heart Failure With Preserved Ejection Fraction,INDUSTRY,6263.0,2018-08-27,2022-03-27,20.0,348.0,,,,,
arm,NCT03619213::arm::FG000,NCT03619213,Dapa 10 mg,,,,,,,,,,FG000,Dapagliflozin 10 mg tablets administered once daily per oral use,,,
arm,NCT03619213::arm::FG001,NCT03619213,Placebo,,,,,,,,,,FG001,"Placebo tablet to match dapagliflozin 10 mg, given once daily per oral use",,,
period,NCT03619213::period::1,NCT03619213,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03619213::outcome::primary::1,NCT03619213,"Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.",,,,,,,,,,,,,PRIMARY,Up to 42.1 months
outcome,NCT03619213::outcome::primary::2,NCT03619213,"Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure for LVEF <60% Subpopulation",,,,,,,,,,,,,PRIMARY,Up to 42.1 months
country,NCT03619213::country::United States,NCT03619213,United States,,,,,,,,,,,,,,
country,NCT03619213::country::Japan,NCT03619213,Japan,,,,,,,,,,,,,,
country,NCT03619213::country::China,NCT03619213,China,,,,,,,,,,,,,,
country,NCT03619213::country::Canada,NCT03619213,Canada,,,,,,,,,,,,,,
country,NCT03619213::country::Argentina,NCT03619213,Argentina,,,,,,,,,,,,,,
country,NCT03619213::country::Poland,NCT03619213,Poland,,,,,,,,,,,,,,
country,NCT03619213::country::Russia,NCT03619213,Russia,,,,,,,,,,,,,,
country,NCT03619213::country::Brazil,NCT03619213,Brazil,,,,,,,,,,,,,,
country,NCT03619213::country::Bulgaria,NCT03619213,Bulgaria,,,,,,,,,,,,,,
country,NCT03619213::country::Mexico,NCT03619213,Mexico,,,,,,,,,,,,,,
country,NCT03619213::country::Peru,NCT03619213,Peru,,,,,,,,,,,,,,
country,NCT03619213::country::Taiwan,NCT03619213,Taiwan,,,,,,,,,,,,,,
country,NCT03619213::country::Hungary,NCT03619213,Hungary,,,,,,,,,,,,,,
country,NCT03619213::country::Czechia,NCT03619213,Czechia,,,,,,,,,,,,,,
country,NCT03619213::country::Netherlands,NCT03619213,Netherlands,,,,,,,,,,,,,,
country,NCT03619213::country::Spain,NCT03619213,Spain,,,,,,,,,,,,,,
country,NCT03619213::country::Belgium,NCT03619213,Belgium,,,,,,,,,,,,,,
country,NCT03619213::country::Romania,NCT03619213,Romania,,,,,,,,,,,,,,
country,NCT03619213::country::Saudi Arabia,NCT03619213,Saudi Arabia,,,,,,,,,,,,,,
country,NCT03619213::country::Vietnam,NCT03619213,Vietnam,,,,,,,,,,,,,,
trial,NCT02188784,NCT02188784,Oral Iron Repletion Effects On Oxygen Uptake in Heart Failure,PHASE3,heart failure,Chronic Heart Failure,OTHER,225.0,2014-09-03,2016-04-06,1.0,17.0,,,,,
arm,NCT02188784::arm::FG000,NCT02188784,Polysaccharide Iron Complex 150 mg,,,,,,,,,,FG000,"oral Fe polysaccharide 150mg twice daily for 16 weeks

Polysaccharide Iron Complex 150 mg: Oral Iron",,,
arm,NCT02188784::arm::FG001,NCT02188784,Placebo (for Polysaccharide Iron Complex 150 mg),,,,,,,,,,FG001,"Oral placebo twice a day for 16 weeks

Placebo (for Polysaccharide Iron Complex): Sugar capsule designed to mimic Polysaccharide Iron Complex.",,,
period,NCT02188784::period::1,NCT02188784,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02188784::outcome::primary::1,NCT02188784,Change in Peak VO2 (ml/Min) (VO2 =Oxygen Consumption),,,,,,,,,,,,,PRIMARY,Baseline (BL) and Week 16
country,NCT02188784::country::United States,NCT02188784,United States,,,,,,,,,,,,,,
trial,NCT00853658,NCT00853658,Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure,PHASE3,heart failure,Chronic Heart Failure,INDUSTRY,7064.0,2009-03,2015-10,44.0,806.0,,,,,
arm,NCT00853658::arm::FG000,NCT00853658,Combination Aliskiren / Enalapril,,,,,,,,,,FG000,Aliskiren / Enalapril combination therapy-150 mg/10 mg titrated to 300 mg/ 10 mg film-coated tablets and administered orally.,,,
arm,NCT00853658::arm::FG001,NCT00853658,Aliskiren,,,,,,,,,,FG001,Aliskiren monotherapy - 150 mg titrated to 300 mg film-coated tablets and administered orally.,,,
arm,NCT00853658::arm::FG002,NCT00853658,Enalapril,,,,,,,,,,FG002,Enalapril monotherapy -10 mg film-coated tablet and administered orally.,,,
period,NCT00853658::period::1,NCT00853658,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00853658::outcome::primary::1,NCT00853658,"Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization",,,,,,,,,,,,,PRIMARY,up to End of Study (78 months)
country,NCT00853658::country::Germany,NCT00853658,Germany,,,,,,,,,,,,,,
country,NCT00853658::country::United States,NCT00853658,United States,,,,,,,,,,,,,,
country,NCT00853658::country::Italy,NCT00853658,Italy,,,,,,,,,,,,,,
country,NCT00853658::country::Japan,NCT00853658,Japan,,,,,,,,,,,,,,
country,NCT00853658::country::Russia,NCT00853658,Russia,,,,,,,,,,,,,,
country,NCT00853658::country::India,NCT00853658,India,,,,,,,,,,,,,,
country,NCT00853658::country::Argentina,NCT00853658,Argentina,,,,,,,,,,,,,,
country,NCT00853658::country::China,NCT00853658,China,,,,,,,,,,,,,,
country,NCT00853658::country::Poland,NCT00853658,Poland,,,,,,,,,,,,,,
country,NCT00853658::country::Denmark,NCT00853658,Denmark,,,,,,,,,,,,,,
country,NCT00853658::country::Slovakia,NCT00853658,Slovakia,,,,,,,,,,,,,,
country,NCT00853658::country::Spain,NCT00853658,Spain,,,,,,,,,,,,,,
country,NCT00853658::country::Brazil,NCT00853658,Brazil,,,,,,,,,,,,,,
country,NCT00853658::country::Netherlands,NCT00853658,Netherlands,,,,,,,,,,,,,,
country,NCT00853658::country::Sweden,NCT00853658,Sweden,,,,,,,,,,,,,,
country,NCT00853658::country::Romania,NCT00853658,Romania,,,,,,,,,,,,,,
country,NCT00853658::country::Czechia,NCT00853658,Czechia,,,,,,,,,,,,,,
country,NCT00853658::country::United Kingdom,NCT00853658,United Kingdom,,,,,,,,,,,,,,
country,NCT00853658::country::France,NCT00853658,France,,,,,,,,,,,,,,
country,NCT00853658::country::Belgium,NCT00853658,Belgium,,,,,,,,,,,,,,
country,NCT00853658::country::South Korea,NCT00853658,South Korea,,,,,,,,,,,,,,
country,NCT00853658::country::Australia,NCT00853658,Australia,,,,,,,,,,,,,,
country,NCT00853658::country::Colombia,NCT00853658,Colombia,,,,,,,,,,,,,,
country,NCT00853658::country::Canada,NCT00853658,Canada,,,,,,,,,,,,,,
country,NCT00853658::country::Peru,NCT00853658,Peru,,,,,,,,,,,,,,
country,NCT00853658::country::Portugal,NCT00853658,Portugal,,,,,,,,,,,,,,
country,NCT00853658::country::Turkey (Türkiye),NCT00853658,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00853658::country::Austria,NCT00853658,Austria,,,,,,,,,,,,,,
country,NCT00853658::country::Switzerland,NCT00853658,Switzerland,,,,,,,,,,,,,,
country,NCT00853658::country::Venezuela,NCT00853658,Venezuela,,,,,,,,,,,,,,
country,NCT00853658::country::Greece,NCT00853658,Greece,,,,,,,,,,,,,,
country,NCT00853658::country::Mexico,NCT00853658,Mexico,,,,,,,,,,,,,,
country,NCT00853658::country::Taiwan,NCT00853658,Taiwan,,,,,,,,,,,,,,
country,NCT00853658::country::South Africa,NCT00853658,South Africa,,,,,,,,,,,,,,
country,NCT00853658::country::Finland,NCT00853658,Finland,,,,,,,,,,,,,,
country,NCT00853658::country::Costa Rica,NCT00853658,Costa Rica,,,,,,,,,,,,,,
country,NCT00853658::country::Estonia,NCT00853658,Estonia,,,,,,,,,,,,,,
country,NCT00853658::country::Ireland,NCT00853658,Ireland,,,,,,,,,,,,,,
country,NCT00853658::country::Latvia,NCT00853658,Latvia,,,,,,,,,,,,,,
country,NCT00853658::country::Lithuania,NCT00853658,Lithuania,,,,,,,,,,,,,,
country,NCT00853658::country::Thailand,NCT00853658,Thailand,,,,,,,,,,,,,,
country,NCT00853658::country::Norway,NCT00853658,Norway,,,,,,,,,,,,,,
country,NCT00853658::country::Puerto Rico,NCT00853658,Puerto Rico,,,,,,,,,,,,,,
country,NCT00853658::country::Dominican Republic,NCT00853658,Dominican Republic,,,,,,,,,,,,,,
trial,NCT00330876,NCT00330876,Study of Pitavastatin in Elderly Patients With Primary Hypercholesterolemia or Combined Dyslipidemia,PHASE3,dyslipidemia,Hypercholesterolemia; Dyslipidemias,INDUSTRY,545.0,2006-06,2007-12,5.0,59.0,,,,,
arm,NCT00330876::arm::FG000,NCT00330876,Pitavastatin 2 mg QD,,,,,,,,,,FG000,Pitavastatin 2 mg once daily,,,
arm,NCT00330876::arm::FG001,NCT00330876,Pitavastatin 4 mg QD,,,,,,,,,,FG001,Pitavastatin 4 mg once daily,,,
period,NCT00330876::period::1,NCT00330876,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00330876::outcome::primary::1,NCT00330876,Change From Baseline in LDL-C,,,,,,,,,,,,,PRIMARY,Baseline to 60 weeks
country,NCT00330876::country::United Kingdom,NCT00330876,United Kingdom,,,,,,,,,,,,,,
country,NCT00330876::country::Germany,NCT00330876,Germany,,,,,,,,,,,,,,
country,NCT00330876::country::Netherlands,NCT00330876,Netherlands,,,,,,,,,,,,,,
country,NCT00330876::country::Israel,NCT00330876,Israel,,,,,,,,,,,,,,
country,NCT00330876::country::Denmark,NCT00330876,Denmark,,,,,,,,,,,,,,
trial,NCT01370590,NCT01370590,A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1),PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,406.0,2011-09,2012-04,0.0,0.0,,,,,
arm,NCT01370590::arm::FG000,NCT01370590,Coadministered/Combination Sequence,,,,,,,,,,FG000,Co-administration Ezetimibe 10 mg and Atorvastatin 20 mg then Ezetimibe/Atorvastatin 10 mg/20 mg fixed-dose combination,,,
arm,NCT01370590::arm::FG001,NCT01370590,Combination/Coadministered Sequence,,,,,,,,,,FG001,Ezetimibe/Atorvastatin 10 mg/20 mg fixed-dose combination then Co-administration Ezetimibe 10 mg and Atorvastatin 20 mg,,,
period,NCT01370590::period::1,NCT01370590,Period 1,,,,,,,,,,,,1.0,,
period,NCT01370590::period::2,NCT01370590,Crossover Washout Period,,,,,,,,,,,,2.0,,
period,NCT01370590::period::3,NCT01370590,Period 2,,,,,,,,,,,,3.0,,
outcome,NCT01370590::outcome::primary::1,NCT01370590,Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks of Treatment,,,,,,,,,,,,,PRIMARY,Baseline and Week 6
trial,NCT01926782,NCT01926782,Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1),PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,803.0,2013-09,2015-04,8.0,83.0,,,,,
arm,NCT01926782::arm::FG000,NCT01926782,Placebo Q2W With Concomitant Statin,,,,,,,,,,FG000,Two Subcutaneous (SC) injections of placebo (for alirocumab) every two weeks (Q2W) with stable statin therapy for 48 weeks.,,,
arm,NCT01926782::arm::FG001,NCT01926782,Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin,,,,,,,,,,FG001,One SC injection of each Alirocumab 75 mg and placebo Q2W with stable statin therapy for 48 weeks. Alirocumab dose up-titrated to 150 mg every two weeks (Q2W) from Week 12 when LDL-C levels ≥ 70 mg/dL,,,
arm,NCT01926782::arm::FG002,NCT01926782,Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin,,,,,,,,,,FG002,Two SC injections of Alirocumab 150 mg every 4 weeks (Q4W) alternating with two SC injections of placebo Q4W with stable statin therapy for 48 weeks. Alirocumab dose up-titrated to 150 mg every two we,,,
arm,NCT01926782::arm::FG003,NCT01926782,Placebo Q2W Without Concomitant Statin,,,,,,,,,,FG003,Two Subcutaneous (SC) injections of placebo (for alirocumab) every two weeks (Q2W) without stable statin therapy for 48 weeks.,,,
arm,NCT01926782::arm::FG004,NCT01926782,Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin,,,,,,,,,,FG004,One SC injection of each Alirocumab 75 mg and placebo Q2W without stable statin therapy for 48 weeks. Alirocumab dose up-titrated to 150 mg every two weeks (Q2W) from Week 12 when LDL-C levels ≥ 70 mg,,,
arm,NCT01926782::arm::FG005,NCT01926782,Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin,,,,,,,,,,FG005,Two SC injections of Alirocumab 150 mg every 4 weeks (Q4W) alternating with two SC injections of placebo Q4W without stable statin therapy for 48 weeks. Alirocumab dose up-titrated to 150 mg every two,,,
period,NCT01926782::period::1,NCT01926782,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01926782::outcome::primary::1,NCT01926782,Percent Change From Baseline in Calculated LDL-C in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis,,,,,,,,,,,,,PRIMARY,From Baseline to Week 24
outcome,NCT01926782::outcome::primary::2,NCT01926782,Percent Change From Baseline in Calculated LDL-C in Participants Receiving Concomitant Statin Therapy - Intent-to-Treat (ITT Analysis),,,,,,,,,,,,,PRIMARY,From Baseline to Week 24
country,NCT01926782::country::United States,NCT01926782,United States,,,,,,,,,,,,,,
country,NCT01926782::country::Canada,NCT01926782,Canada,,,,,,,,,,,,,,
country,NCT01926782::country::United Kingdom,NCT01926782,United Kingdom,,,,,,,,,,,,,,
country,NCT01926782::country::Hungary,NCT01926782,Hungary,,,,,,,,,,,,,,
country,NCT01926782::country::Israel,NCT01926782,Israel,,,,,,,,,,,,,,
country,NCT01926782::country::Slovakia,NCT01926782,Slovakia,,,,,,,,,,,,,,
country,NCT01926782::country::Bulgaria,NCT01926782,Bulgaria,,,,,,,,,,,,,,
country,NCT01926782::country::Norway,NCT01926782,Norway,,,,,,,,,,,,,,
trial,NCT00309738,NCT00309738,Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin,PHASE3,dyslipidemia,Hypercholesterolemia; Dyslipidemia,INDUSTRY,355.0,2005-09,2006-10,4.0,35.0,,,,,
arm,NCT00309738::arm::FG000,NCT00309738,Pitavastatin 4 mg QD,,,,,,,,,,FG000,Pitavastatin 4 mg once daily,,,
arm,NCT00309738::arm::FG001,NCT00309738,Simvastatin 40 mg QD,,,,,,,,,,FG001,Simvastatin 40 mg once daily,,,
period,NCT00309738::period::1,NCT00309738,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00309738::outcome::primary::1,NCT00309738,Percent Change From Baseline in LDL-C,,,,,,,,,,,,,PRIMARY,12 weeks
country,NCT00309738::country::Sweden,NCT00309738,Sweden,,,,,,,,,,,,,,
country,NCT00309738::country::Spain,NCT00309738,Spain,,,,,,,,,,,,,,
country,NCT00309738::country::Netherlands,NCT00309738,Netherlands,,,,,,,,,,,,,,
country,NCT00309738::country::Denmark,NCT00309738,Denmark,,,,,,,,,,,,,,
trial,NCT01078675,NCT01078675,An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia,PHASE3,dyslipidemia,Familial Hypercholesterolaemia,INDUSTRY,315.0,2010-02,2013-02,5.0,15.0,,,,,
arm,NCT01078675::arm::FG000,NCT01078675,Rosuvastatin,,,,,,,,,,FG000,"Rosuvastatin 5 mg, 10 mg or 20 mg",,,
arm,NCT01078675::arm::FG001,NCT01078675,Healthy Siblings,,,,,,,,,,FG001,Controls to HeFH patients in the cIMT evaluations,,,
period,NCT01078675::period::1,NCT01078675,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01078675::outcome::primary::1,NCT01078675,Percent Change From Baseline in LDL-C,,,,,,,,,,,,,PRIMARY,"At Month 3, Month 12 and Month 24"
outcome,NCT01078675::outcome::primary::2,NCT01078675,Sexual Maturation by Tanner Staging at Baseline,,,,,,,,,,,,,PRIMARY,At Baseline
outcome,NCT01078675::outcome::primary::3,NCT01078675,Single Dose PK - Cmax,,,,,,,,,,,,,PRIMARY,Serial blood samples over 24 hours.
outcome,NCT01078675::outcome::primary::4,NCT01078675,Percent Change From Baseline in Height,,,,,,,,,,,,,PRIMARY,At Month 12 and Month 24
outcome,NCT01078675::outcome::primary::5,NCT01078675,Sexual Maturation by Tanner Staging at Month 12,,,,,,,,,,,,,PRIMARY,At Baseline
outcome,NCT01078675::outcome::primary::6,NCT01078675,Sexual Maturation by Tanner Staging at Month 24,,,,,,,,,,,,,PRIMARY,At Baseline
outcome,NCT01078675::outcome::primary::7,NCT01078675,Single Dose PK - Tmax,,,,,,,,,,,,,PRIMARY,Serial blood samples over 24 hours
outcome,NCT01078675::outcome::primary::8,NCT01078675,Single Dose PK - AUC(0-24),,,,,,,,,,,,,PRIMARY,Serial blood samples over 24 hours
country,NCT01078675::country::Netherlands,NCT01078675,Netherlands,,,,,,,,,,,,,,
country,NCT01078675::country::Canada,NCT01078675,Canada,,,,,,,,,,,,,,
country,NCT01078675::country::Belgium,NCT01078675,Belgium,,,,,,,,,,,,,,
country,NCT01078675::country::United States,NCT01078675,United States,,,,,,,,,,,,,,
country,NCT01078675::country::Norway,NCT01078675,Norway,,,,,,,,,,,,,,
trial,NCT05763875,NCT05763875,Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.,PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,350.0,2023-03-15,2024-06-20,5.0,42.0,,,,,
arm,NCT05763875::arm::FG000,NCT05763875,Inclisiran,,,,,,,,,,FG000,Inclisiran s.c and Placebo p.o,,,
arm,NCT05763875::arm::FG001,NCT05763875,Ezetimibe,,,,,,,,,,FG001,Placebo s.c. and Ezetimibe p.o.,,,
arm,NCT05763875::arm::FG002,NCT05763875,Placebo,,,,,,,,,,FG002,Placebo s.c. and Placebo p.o.,,,
period,NCT05763875::period::1,NCT05763875,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT05763875::outcome::primary::1,NCT05763875,Percentage Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 150,,,,,,,,,,,,,PRIMARY,"Baseline, Day 150"
country,NCT05763875::country::United States,NCT05763875,United States,,,,,,,,,,,,,,
country,NCT05763875::country::Germany,NCT05763875,Germany,,,,,,,,,,,,,,
country,NCT05763875::country::Mexico,NCT05763875,Mexico,,,,,,,,,,,,,,
country,NCT05763875::country::Colombia,NCT05763875,Colombia,,,,,,,,,,,,,,
country,NCT05763875::country::Hungary,NCT05763875,Hungary,,,,,,,,,,,,,,
trial,NCT01047501,NCT01047501,Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL),PHASE3,dyslipidemia,Hypertriglyceridemia,INDUSTRY,702.0,2009-12,2011-02,1.0,80.0,,,,,
arm,NCT01047501::arm::FG000,NCT01047501,Placebo,,,,,,,,,,FG000,Placebo: Placebo 4 capsules/day for 12 weeks,,,
arm,NCT01047501::arm::FG001,NCT01047501,AMR101 (Ethyl Icosapentate) - 2 g/Day,,,,,,,,,,FG001,AMR101 (ethyl icosapentate) - 2 g/day: AMR101 (ethyl icosapentate) 2 capsules/day with placebo 2 capsules/day for 12 weeks,,,
arm,NCT01047501::arm::FG002,NCT01047501,AMR101 (Ethyl Icosapentate) - 4 g/Day,,,,,,,,,,FG002,AMR101 (ethyl icosapentate) - 4 g/day: AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks,,,
period,NCT01047501::period::1,NCT01047501,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01047501::outcome::primary::1,NCT01047501,Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Triglyceride Lowering Effect,,,,,,,,,,,,,PRIMARY,baseline and 12 weeks
country,NCT01047501::country::United States,NCT01047501,United States,,,,,,,,,,,,,,
trial,NCT00129402,NCT00129402,Effects of Ezetimibe With Simvastatin in the Therapy of Adolescents With HeFH (Study P02579),PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,248.0,2005-08,2007-06,0.0,0.0,,,,,
arm,NCT00129402::arm::FG000,NCT00129402,Ezetimibe/Simvastatin 10/10,,,,,,,,,,FG000,Subjects who received ezetimibe 10 mg plus simvastatin 10 mg once daily,,,
arm,NCT00129402::arm::FG001,NCT00129402,Ezetimibe/Simvastatin 10/20,,,,,,,,,,FG001,Subjects who received ezetimibe 10 mg with simvastatin 10 mg once daily,,,
arm,NCT00129402::arm::FG002,NCT00129402,Ezetimibe/Simvastatin 10/40,,,,,,,,,,FG002,Subjects who received ezetimibe 10 mg plus simvastatin 40 mg once daily,,,
arm,NCT00129402::arm::FG003,NCT00129402,Ezetimibe Matching Placebo/ Simvastatin 10,,,,,,,,,,FG003,Subjects who received simvastatin monotherapy 10 mg once daily,,,
arm,NCT00129402::arm::FG004,NCT00129402,Ezetimibe Matching Placebo/ Simvastatin 20,,,,,,,,,,FG004,Subjects who received simvastatin monotherapy 20 mg once daily,,,
arm,NCT00129402::arm::FG005,NCT00129402,Ezetimibe Matching Placebo/ Simvastatin 40,,,,,,,,,,FG005,Subjects who received simvastatin monotherapy 40 mg once daily,,,
arm,NCT00129402::arm::FG006,NCT00129402,Long-term Experience Ezetimbe/Simvastatin,,,,,,,,,,FG006,Subjects who received long-term coadministration of ezetimibe with simvastatin once daily,,,
period,NCT00129402::period::1,NCT00129402,Start Period1 to End Period1 (Week 1-6),,,,,,,,,,,,1.0,,
period,NCT00129402::period::2,NCT00129402,Start Period2 to End Period2 (Week 7-33),,,,,,,,,,,,2.0,,
period,NCT00129402::period::3,NCT00129402,Start Period3 to End Period3(Week 34-53),,,,,,,,,,,,3.0,,
outcome,NCT00129402::outcome::primary::1,NCT00129402,Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C),,,,,,,,,,,,,PRIMARY,baseline to 6 weeks
trial,NCT01763905,NCT01763905,Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2,PHASE3,dyslipidemia,Hyperlipidemia,INDUSTRY,307.0,2013-01-24,2013-11-19,14.0,58.0,,,,,
arm,NCT01763905::arm::FG000,NCT01763905,Ezetimibe (Q2W),,,,,,,,,,FG000,Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.,,,
arm,NCT01763905::arm::FG001,NCT01763905,Ezetimibe (QM),,,,,,,,,,FG001,Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.,,,
arm,NCT01763905::arm::FG002,NCT01763905,Evolocumab Q2W,,,,,,,,,,FG002,Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.,,,
arm,NCT01763905::arm::FG003,NCT01763905,Evolocumab QM,,,,,,,,,,FG003,Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.,,,
period,NCT01763905::period::1,NCT01763905,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01763905::outcome::primary::1,NCT01763905,Percent Change From Baseline in LDL-C at Week 12,,,,,,,,,,,,,PRIMARY,Baseline and Week 12
outcome,NCT01763905::outcome::primary::2,NCT01763905,Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12,,,,,,,,,,,,,PRIMARY,Baseline and Weeks 10 and 12
country,NCT01763905::country::United States,NCT01763905,United States,,,,,,,,,,,,,,
country,NCT01763905::country::Australia,NCT01763905,Australia,,,,,,,,,,,,,,
country,NCT01763905::country::United Kingdom,NCT01763905,United Kingdom,,,,,,,,,,,,,,
country,NCT01763905::country::Belgium,NCT01763905,Belgium,,,,,,,,,,,,,,
country,NCT01763905::country::Canada,NCT01763905,Canada,,,,,,,,,,,,,,
country,NCT01763905::country::Denmark,NCT01763905,Denmark,,,,,,,,,,,,,,
country,NCT01763905::country::France,NCT01763905,France,,,,,,,,,,,,,,
country,NCT01763905::country::Germany,NCT01763905,Germany,,,,,,,,,,,,,,
country,NCT01763905::country::Netherlands,NCT01763905,Netherlands,,,,,,,,,,,,,,
country,NCT01763905::country::South Africa,NCT01763905,South Africa,,,,,,,,,,,,,,
country,NCT01763905::country::Spain,NCT01763905,Spain,,,,,,,,,,,,,,
country,NCT01763905::country::Hong Kong,NCT01763905,Hong Kong,,,,,,,,,,,,,,
country,NCT01763905::country::Poland,NCT01763905,Poland,,,,,,,,,,,,,,
country,NCT01763905::country::Switzerland,NCT01763905,Switzerland,,,,,,,,,,,,,,
trial,NCT00418834,NCT00418834,Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112),PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,1053.0,2007-01,2008-10,0.0,0.0,,,,,
arm,NCT00418834::arm::FG000,NCT00418834,Atorva 10 mg + EZ,,,,,,,,,,FG000,\[Atorva 10 mg + Ezetimibe 10 mg\] orally once daily for 12 weeks,,,
arm,NCT00418834::arm::FG001,NCT00418834,Atorva 20 mg / Atorva 40 mg,,,,,,,,,,FG001,"Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks",,,
period,NCT00418834::period::1,NCT00418834,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00418834::outcome::primary::1,NCT00418834,Percent Change From Baseline in LDL-C at Week 6,,,,,,,,,,,,,PRIMARY,Baseline and Week 6
trial,NCT03768427,NCT03768427,Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439),PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,454.0,2019-05-27,2021-04-01,1.0,30.0,,,,,
arm,NCT03768427::arm::FG000,NCT03768427,Atorvastatin 10 mg - Ezetimibe 10 mg/Ator 10 mg,,,,,,,,,,FG000,"Participants had a 5-week run-in of atorvastatin 10 mg once daily (QD). They then received a single oral dose of ezetimibe (EZ) 10 mg/Ator 10 mg fixed dose combination (FDC) tablet QD, and 1 placebo t",,,
arm,NCT03768427::arm::FG001,NCT03768427,Atorvastatin 10mg - Atorvastatin 20 mg,,,,,,,,,,FG001,"Participants had a 5-week run-in of atorvastatin 10 mg QD. They then received 2 atorvastatin 20 mg tablets QD, and 1 placebo tablet matched to active atorvastatin tablet QD for 84 days.",,,
arm,NCT03768427::arm::FG002,NCT03768427,Atorvastatin 20 mg - EZ 10 mg/Ator 20 mg,,,,,,,,,,FG002,"Participants had a 5-week run-in of atorvastatin 20 mg QD. They then received a single oral dose of EZ 10 mg/Ator 20 mg FDC tablet QD, and 1 placebo tablet matched to active atorvastatin tablet QD for",,,
arm,NCT03768427::arm::FG003,NCT03768427,Atorvastatin 20 mg - Atorvastatin 40 mg,,,,,,,,,,FG003,"Participants had a 5-week run-in of atorvastatin 20 mg QD. They then received 2 atorvastatin 20 mg tablets administered orally, QD, and 1 placebo tablet matched to active atorvastatin tablet QD for 84",,,
period,NCT03768427::period::1,NCT03768427,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03768427::outcome::primary::1,NCT03768427,Percent Change From Baseline in LDL-C at Week 12,,,,,,,,,,,,,PRIMARY,Baseline (Day 1) and Week 12
country,NCT03768427::country::China,NCT03768427,China,,,,,,,,,,,,,,
trial,NCT02009865,NCT02009865,Epanova® for Lowering Very High Triglycerides II (EVOLVE II),PHASE3,dyslipidemia,Hypertriglyceridemia,INDUSTRY,379.0,2013-12-16,2014-12-23,7.0,40.0,,,,,
arm,NCT02009865::arm::FG000,NCT02009865,Epanova,,,,,,,,,,FG000,2g once daily (QD),,,
arm,NCT02009865::arm::FG001,NCT02009865,Olive Oil,,,,,,,,,,FG001,2g once daily (QD),,,
period,NCT02009865::period::1,NCT02009865,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02009865::outcome::primary::1,NCT02009865,Percent Change in Triglyceride for All Subjects,,,,,,,,,,,,,PRIMARY,From Baseline to Week 12 Endpoint
country,NCT02009865::country::United States,NCT02009865,United States,,,,,,,,,,,,,,
country,NCT02009865::country::Hungary,NCT02009865,Hungary,,,,,,,,,,,,,,
country,NCT02009865::country::Russia,NCT02009865,Russia,,,,,,,,,,,,,,
country,NCT02009865::country::Denmark,NCT02009865,Denmark,,,,,,,,,,,,,,
country,NCT02009865::country::Czechia,NCT02009865,Czechia,,,,,,,,,,,,,,
country,NCT02009865::country::Netherlands,NCT02009865,Netherlands,,,,,,,,,,,,,,
country,NCT02009865::country::Canada,NCT02009865,Canada,,,,,,,,,,,,,,
trial,NCT04964544,NCT04964544,Technology-Assisted Cholesterol Trial in Consumers (TACTiC),PHASE3,dyslipidemia,High Cholesterol,INDUSTRY,1196.0,2021-07-08,2023-03-01,1.0,1.0,,,,,
arm,NCT04964544::arm::FG000,NCT04964544,Nonprescription Rosuvastatin,,,,,,,,,,FG000,Combination Product: 5 mg rosuvastatin calcium with a Web App (combination product),,,
period,NCT04964544::period::1,NCT04964544,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04964544::outcome::primary::1,NCT04964544,"Overall Correct Initial TASS Outcome, Worst Case Imputation, First Co-Primary Endpoint (Self-Selection Population)",,,,,,,,,,,,,PRIMARY,"Study day -30 to -1, at initial TASS assessment"
outcome,NCT04964544::outcome::primary::2,NCT04964544,"Overall Correct Final Use Outcome With Mitigation, Second Co-primary Endpoint (Per Protocol Population)",,,,,,,,,,,,,PRIMARY,"From enrollment to end of the home use period at 180 days, at final TASS Assessment"
outcome,NCT04964544::outcome::primary::3,NCT04964544,Percent Change From Baseline in Verified LDL-C Regardless of Final Use Outcome (AUS ITT Population),,,,,,,,,,,,,PRIMARY,"From enrollment to end of the home use period at 180 days, at final assessment"
country,NCT04964544::country::United States,NCT04964544,United States,,,,,,,,,,,,,,
trial,NCT05425745,NCT05425745,Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.,PHASE3,dyslipidemia,"Dyslipidemias; High Cholesterol; Hypercholesterolemia; Familial Hypercholesterolemia; Lipid Metabolism Disorder; Metabolic Disease; Lipid Metabolism, Inborn Errors; Genetic Disease, Inborn; Hyperlipoproteinemias",INDUSTRY,354.0,2022-07-25,2024-05-28,10.0,96.0,,,,,
arm,NCT05425745::arm::FG000,NCT05425745,Placebo,,,,,,,,,,FG000,"one placebo tablet once daily

Placebo: placebo tablet made to resemble active",,,
arm,NCT05425745::arm::FG001,NCT05425745,Obicetrapib 10 mg,,,,,,,,,,FG001,"one 10 mg Obicetrapib tablet once daily

Obicetrapib: 10 mg Obicetrapib tablet",,,
period,NCT05425745::period::1,NCT05425745,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT05425745::outcome::primary::1,NCT05425745,Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC],,,,,,,,,,,,,PRIMARY,84 Days
country,NCT05425745::country::United States,NCT05425745,United States,,,,,,,,,,,,,,
country,NCT05425745::country::Spain,NCT05425745,Spain,,,,,,,,,,,,,,
country,NCT05425745::country::United Kingdom,NCT05425745,United Kingdom,,,,,,,,,,,,,,
country,NCT05425745::country::Georgia,NCT05425745,Georgia,,,,,,,,,,,,,,
country,NCT05425745::country::Canada,NCT05425745,Canada,,,,,,,,,,,,,,
country,NCT05425745::country::South Africa,NCT05425745,South Africa,,,,,,,,,,,,,,
country,NCT05425745::country::Czechia,NCT05425745,Czechia,,,,,,,,,,,,,,
country,NCT05425745::country::Netherlands,NCT05425745,Netherlands,,,,,,,,,,,,,,
country,NCT05425745::country::Poland,NCT05425745,Poland,,,,,,,,,,,,,,
country,NCT05425745::country::Norway,NCT05425745,Norway,,,,,,,,,,,,,,
trial,NCT01763866,NCT01763866,LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2,PHASE3,dyslipidemia,Hyperlipidemia,INDUSTRY,2067.0,2013-01-15,2013-12-04,21.0,244.0,,,,,
arm,NCT01763866::arm::FG000,NCT01763866,A10 PBO Q2W,,,,,,,,,,FG000,Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo ,,,
arm,NCT01763866::arm::FG001,NCT01763866,A10 PBO QM,,,,,,,,,,FG001,Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily,,,
arm,NCT01763866::arm::FG002,NCT01763866,A10 EZE (Q2W),,,,,,,,,,FG002,Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) ora,,,
arm,NCT01763866::arm::FG003,NCT01763866,A10 EZE (QM),,,,,,,,,,FG003,Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once dai,,,
arm,NCT01763866::arm::FG004,NCT01763866,A10 EvoMab Q2W,,,,,,,,,,FG004,Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and pla,,,
arm,NCT01763866::arm::FG005,NCT01763866,A10 EvoMab QM,,,,,,,,,,FG005,Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets on,,,
arm,NCT01763866::arm::FG006,NCT01763866,A80 PBO Q2W,,,,,,,,,,FG006,Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once dail,,,
arm,NCT01763866::arm::FG007,NCT01763866,A80 PBO QM,,,,,,,,,,FG007,Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for ,,,
arm,NCT01763866::arm::FG008,NCT01763866,A80 EZE (Q2W),,,,,,,,,,FG008,Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally on,,,
arm,NCT01763866::arm::FG009,NCT01763866,A80 EZE (QM),,,,,,,,,,FG009,Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once dai,,,
arm,NCT01763866::arm::FG010,NCT01763866,A80 EvoMab Q2W,,,,,,,,,,FG010,Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tabl,,,
arm,NCT01763866::arm::FG011,NCT01763866,A80 EvoMab QM,,,,,,,,,,FG011,Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets on,,,
arm,NCT01763866::arm::FG012,NCT01763866,R5 PBO Q2W,,,,,,,,,,FG012,Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.,,,
arm,NCT01763866::arm::FG013,NCT01763866,R5 PBO QM,,,,,,,,,,FG013,Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.,,,
arm,NCT01763866::arm::FG014,NCT01763866,R5 EvoMab Q2W,,,,,,,,,,FG014,Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 week,,,
arm,NCT01763866::arm::FG015,NCT01763866,R5 EvoMab QM,,,,,,,,,,FG015,Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.,,,
arm,NCT01763866::arm::FG016,NCT01763866,R40 PBO Q2W,,,,,,,,,,FG016,Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.,,,
arm,NCT01763866::arm::FG017,NCT01763866,R40 PBO QM,,,,,,,,,,FG017,Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.,,,
arm,NCT01763866::arm::FG018,NCT01763866,R40 EvoMab Q2W,,,,,,,,,,FG018,Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 wee,,,
arm,NCT01763866::arm::FG019,NCT01763866,R40 EvoMab QM,,,,,,,,,,FG019,Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.,,,
arm,NCT01763866::arm::FG020,NCT01763866,S40 PBO Q2W,,,,,,,,,,FG020,Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.,,,
arm,NCT01763866::arm::FG021,NCT01763866,S40 PBO QM,,,,,,,,,,FG021,Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.,,,
arm,NCT01763866::arm::FG022,NCT01763866,S40 EvoMab Q2W,,,,,,,,,,FG022,Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 week,,,
arm,NCT01763866::arm::FG023,NCT01763866,S40 EvoMab QM,,,,,,,,,,FG023,Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.,,,
period,NCT01763866::period::1,NCT01763866,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01763866::outcome::primary::1,NCT01763866,Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12,,,,,,,,,,,,,PRIMARY,Baseline and Week 12
outcome,NCT01763866::outcome::primary::2,NCT01763866,Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12,,,,,,,,,,,,,PRIMARY,Baseline and Weeks 10 and 12
country,NCT01763866::country::United States,NCT01763866,United States,,,,,,,,,,,,,,
country,NCT01763866::country::Canada,NCT01763866,Canada,,,,,,,,,,,,,,
country,NCT01763866::country::United Kingdom,NCT01763866,United Kingdom,,,,,,,,,,,,,,
country,NCT01763866::country::Czechia,NCT01763866,Czechia,,,,,,,,,,,,,,
country,NCT01763866::country::Germany,NCT01763866,Germany,,,,,,,,,,,,,,
country,NCT01763866::country::Hungary,NCT01763866,Hungary,,,,,,,,,,,,,,
country,NCT01763866::country::Russia,NCT01763866,Russia,,,,,,,,,,,,,,
country,NCT01763866::country::France,NCT01763866,France,,,,,,,,,,,,,,
country,NCT01763866::country::Italy,NCT01763866,Italy,,,,,,,,,,,,,,
country,NCT01763866::country::Netherlands,NCT01763866,Netherlands,,,,,,,,,,,,,,
country,NCT01763866::country::Spain,NCT01763866,Spain,,,,,,,,,,,,,,
country,NCT01763866::country::Mexico,NCT01763866,Mexico,,,,,,,,,,,,,,
country,NCT01763866::country::South Africa,NCT01763866,South Africa,,,,,,,,,,,,,,
country,NCT01763866::country::Australia,NCT01763866,Australia,,,,,,,,,,,,,,
country,NCT01763866::country::Belgium,NCT01763866,Belgium,,,,,,,,,,,,,,
country,NCT01763866::country::Sweden,NCT01763866,Sweden,,,,,,,,,,,,,,
country,NCT01763866::country::Switzerland,NCT01763866,Switzerland,,,,,,,,,,,,,,
country,NCT01763866::country::South Korea,NCT01763866,South Korea,,,,,,,,,,,,,,
country,NCT01763866::country::Denmark,NCT01763866,Denmark,,,,,,,,,,,,,,
country,NCT01763866::country::Taiwan,NCT01763866,Taiwan,,,,,,,,,,,,,,
country,NCT01763866::country::Hong Kong,NCT01763866,Hong Kong,,,,,,,,,,,,,,
trial,NCT01475825,NCT01475825,A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol,PHASE3,dyslipidemia,Hypercholesterolemia; Heterozygous Familial,INDUSTRY,309.0,2011-12,2015-12-29,30.0,113.0,,,,,
arm,NCT01475825::arm::FG000,NCT01475825,"Regimen A: Mipomersen, 200 mg, Once Weekly",,,,,,,,,,FG000,"Participants received once weekly subcutaneous (SC) injections of mipomersen sodium 200 milligrams (mg) during the 60-week Blinded Treatment Period, continued the dosing regimen during the 26-week Ope",,,
arm,NCT01475825::arm::FG001,NCT01475825,"Regimen A: Placebo, Once Weekly",,,,,,,,,,FG001,"Participants received once weekly SC injections of Placebo during the 60-week Blinded Treatment Period, continued the dosing regimen during the 26-week Open-Label Continuation Period, and then entered",,,
arm,NCT01475825::arm::FG002,NCT01475825,"Regimen B: Mipomersen, 70 mg, Thrice Weekly",,,,,,,,,,FG002,"Participants received thrice weekly SC injections of mipomersen sodium 70 mg during the 60-week Blinded Treatment Period, continued the dosing regimen during the 26-week Open-Label Continuation Period",,,
arm,NCT01475825::arm::FG003,NCT01475825,"Regimen B: Placebo, Thrice Weekly",,,,,,,,,,FG003,"Participants received thrice weekly SC injections of placebo during the 60-week Blinded Treatment Period, continued the dosing regimen during the 26-week Open-Label Continuation Period, and then enter",,,
period,NCT01475825::period::1,NCT01475825,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01475825::outcome::primary::1,NCT01475825,Percent Change From Baseline To Primary Endpoint Visit (PET) In LDL-C In Cohort 1,,,,,,,,,,,,,PRIMARY,Baseline and Week 61
country,NCT01475825::country::United States,NCT01475825,United States,,,,,,,,,,,,,,
country,NCT01475825::country::Poland,NCT01475825,Poland,,,,,,,,,,,,,,
country,NCT01475825::country::Russia,NCT01475825,Russia,,,,,,,,,,,,,,
country,NCT01475825::country::Germany,NCT01475825,Germany,,,,,,,,,,,,,,
country,NCT01475825::country::Italy,NCT01475825,Italy,,,,,,,,,,,,,,
country,NCT01475825::country::Netherlands,NCT01475825,Netherlands,,,,,,,,,,,,,,
country,NCT01475825::country::United Kingdom,NCT01475825,United Kingdom,,,,,,,,,,,,,,
country,NCT01475825::country::Turkey (Türkiye),NCT01475825,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01475825::country::Ukraine,NCT01475825,Ukraine,,,,,,,,,,,,,,
country,NCT01475825::country::Belgium,NCT01475825,Belgium,,,,,,,,,,,,,,
country,NCT01475825::country::Canada,NCT01475825,Canada,,,,,,,,,,,,,,
country,NCT01475825::country::Hungary,NCT01475825,Hungary,,,,,,,,,,,,,,
country,NCT01475825::country::Israel,NCT01475825,Israel,,,,,,,,,,,,,,
country,NCT01475825::country::Norway,NCT01475825,Norway,,,,,,,,,,,,,,
country,NCT01475825::country::Argentina,NCT01475825,Argentina,,,,,,,,,,,,,,
country,NCT01475825::country::Australia,NCT01475825,Australia,,,,,,,,,,,,,,
country,NCT01475825::country::Brazil,NCT01475825,Brazil,,,,,,,,,,,,,,
country,NCT01475825::country::Croatia,NCT01475825,Croatia,,,,,,,,,,,,,,
country,NCT01475825::country::Czechia,NCT01475825,Czechia,,,,,,,,,,,,,,
country,NCT01475825::country::Denmark,NCT01475825,Denmark,,,,,,,,,,,,,,
country,NCT01475825::country::Greece,NCT01475825,Greece,,,,,,,,,,,,,,
country,NCT01475825::country::Malaysia,NCT01475825,Malaysia,,,,,,,,,,,,,,
country,NCT01475825::country::South Africa,NCT01475825,South Africa,,,,,,,,,,,,,,
country,NCT01475825::country::Taiwan,NCT01475825,Taiwan,,,,,,,,,,,,,,
country,NCT01475825::country::Hong Kong,NCT01475825,Hong Kong,,,,,,,,,,,,,,
country,NCT01475825::country::India,NCT01475825,India,,,,,,,,,,,,,,
country,NCT01475825::country::New Zealand,NCT01475825,New Zealand,,,,,,,,,,,,,,
country,NCT01475825::country::South Korea,NCT01475825,South Korea,,,,,,,,,,,,,,
country,NCT01475825::country::Spain,NCT01475825,Spain,,,,,,,,,,,,,,
country,NCT01475825::country::Sweden,NCT01475825,Sweden,,,,,,,,,,,,,,
trial,NCT00409773,NCT00409773,Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED),PHASE3,dyslipidemia,Hypercholesterolemia; Metabolic Syndrome,INDUSTRY,1143.0,2007-01,2008-07,0.0,0.0,,,,,
arm,NCT00409773::arm::FG000,NCT00409773,Atorva 10 mg,,,,,,,,,,FG000,Atorvastatin 10 mg once daily for 6 weeks,,,
arm,NCT00409773::arm::FG001,NCT00409773,EZ/Simva 10 mg/20 mg,,,,,,,,,,FG001,Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg,,,
arm,NCT00409773::arm::FG002,NCT00409773,Atorva 20mg,,,,,,,,,,FG002,Atorvastatin 20 mg once daily for 6 weeks,,,
arm,NCT00409773::arm::FG003,NCT00409773,EZ/Simva 10 mg/40 mg,,,,,,,,,,FG003,Ezetimibe (+) simvastatin combination tablet at doses of 10/40 mg,,,
arm,NCT00409773::arm::FG004,NCT00409773,Atorva 40 mg,,,,,,,,,,FG004,Atorvastatin 40 mg once daily for 6 weeks,,,
period,NCT00409773::period::1,NCT00409773,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00409773::outcome::primary::1,NCT00409773,Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 6,,,,,,,,,,,,,PRIMARY,Baseline and 6 Weeks
trial,NCT02550288,NCT02550288,A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383),PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,309.0,2015-09-29,2016-05-30,0.0,0.0,,,,,
arm,NCT02550288::arm::FG000,NCT02550288,Ezetimibe 10 mg,,,,,,,,,,FG000,"1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.",,,
arm,NCT02550288::arm::FG001,NCT02550288,Atorvastatin 10 mg,,,,,,,,,,FG001,"1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.",,,
arm,NCT02550288::arm::FG002,NCT02550288,Atorvastatin 20 mg,,,,,,,,,,FG002,"2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.",,,
arm,NCT02550288::arm::FG003,NCT02550288,Ezetimibe 10 mg + Atorvastatin 10 mg,,,,,,,,,,FG003,"1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks",,,
arm,NCT02550288::arm::FG004,NCT02550288,Ezetimibe 10 mg + Atorvastatin 20 mg,,,,,,,,,,FG004,"1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks",,,
period,NCT02550288::period::1,NCT02550288,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02550288::outcome::primary::1,NCT02550288,Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12,,,,,,,,,,,,,PRIMARY,Baseline and Week 12
outcome,NCT02550288::outcome::primary::2,NCT02550288,Percentage of Participants Who Experience 1 or More Gastrointestinal-related Adverse Events (AEs),,,,,,,,,,,,,PRIMARY,up to 14 weeks
outcome,NCT02550288::outcome::primary::3,NCT02550288,Percentage of Participants Who Experience 1 or More Gallbladder-related AEs,,,,,,,,,,,,,PRIMARY,up to 14 weeks
outcome,NCT02550288::outcome::primary::4,NCT02550288,Percentage of Participants Who Experience 1 or More Allergic Reaction or Rash AEs,,,,,,,,,,,,,PRIMARY,up to 14 weeks
outcome,NCT02550288::outcome::primary::5,NCT02550288,Percentage of Participants Who Experience 1 or More Hepatitis-related AEs,,,,,,,,,,,,,PRIMARY,up to 14 weeks
outcome,NCT02550288::outcome::primary::6,NCT02550288,Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) ≥3 Times Upper Limit of Normal (ULN),,,,,,,,,,,,,PRIMARY,up to 12 weeks
outcome,NCT02550288::outcome::primary::7,NCT02550288,Percentage of Participants Who Experience Consecutive Elevations in Aspartate Aminotransferase (AST) ≥3 Times ULN,,,,,,,,,,,,,PRIMARY,up to 12 weeks
outcome,NCT02550288::outcome::primary::8,NCT02550288,Percentage of Participants Who Experience Consecutive Elevations in ALT and/or AST ≥3 Times ULN,,,,,,,,,,,,,PRIMARY,up to 12 weeks
outcome,NCT02550288::outcome::primary::9,NCT02550288,Percentage of Participants Who Experience Consecutive Elevations in ALT ≥5 Times ULN,,,,,,,,,,,,,PRIMARY,up to 12 weeks
outcome,NCT02550288::outcome::primary::10,NCT02550288,Percentage of Participants Who Experience Consecutive Elevations in AST ≥5 Times ULN,,,,,,,,,,,,,PRIMARY,up to 12 weeks
outcome,NCT02550288::outcome::primary::11,NCT02550288,Percentage of Participants Who Have Consecutive Elevations in ALT and/or AST ≥5 Times ULN,,,,,,,,,,,,,PRIMARY,up to 12 weeks
outcome,NCT02550288::outcome::primary::12,NCT02550288,Percentage of Participants Who Experience Consecutive Elevations in ALT ≥10 Times ULN,,,,,,,,,,,,,PRIMARY,up to 12 weeks
outcome,NCT02550288::outcome::primary::13,NCT02550288,Percentage of Participants Who Experience Consecutive Elevations in AST ≥10 Times ULN,,,,,,,,,,,,,PRIMARY,up to 12 weeks
outcome,NCT02550288::outcome::primary::14,NCT02550288,Percentage of Participants Who Have Consecutive Elevations in ALT and/or AST ≥10 Times ULN,,,,,,,,,,,,,PRIMARY,up to 12 weeks
outcome,NCT02550288::outcome::primary::15,NCT02550288,Percentage of Participants With Potential Hy's Law Condition,,,,,,,,,,,,,PRIMARY,up to 12 weeks
outcome,NCT02550288::outcome::primary::16,NCT02550288,Percentage of Participants Who Have Elevations in Creatine Kinase (CK) ≥10xULN,,,,,,,,,,,,,PRIMARY,up to 12 weeks
outcome,NCT02550288::outcome::primary::17,NCT02550288,Percentage of Participants Who Have Elevations in CK ≥10xULN With Muscle Symptoms,,,,,,,,,,,,,PRIMARY,up to 12 weeks
outcome,NCT02550288::outcome::primary::18,NCT02550288,Percentage of Participants Who Have Elevations in CK ≥10xULN and Drug-Related Muscle Symptoms,,,,,,,,,,,,,PRIMARY,up to 12 weeks
trial,NCT01370603,NCT01370603,A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1),PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,328.0,2011-09,2012-05,0.0,0.0,,,,,
arm,NCT01370603::arm::FG000,NCT01370603,Co-administration/Combination Sequence,,,,,,,,,,FG000,Co-administration Ezetimibe 10 mg and Atorvastatin 40 mg then Ezetimibe/Atorvastatin 10 mg/40 mg fixed-dose combination,,,
arm,NCT01370603::arm::FG001,NCT01370603,Combination/Co-administration Sequence,,,,,,,,,,FG001,Ezetimibe/Atorvastatin 10 mg/40 mg fixed-dose combination then Co-administration Ezetimibe 10 mg and Atorvastatin 40 mg,,,
period,NCT01370603::period::1,NCT01370603,Period 1,,,,,,,,,,,,1.0,,
period,NCT01370603::period::2,NCT01370603,Crossover Washout,,,,,,,,,,,,2.0,,
period,NCT01370603::period::3,NCT01370603,Period 2,,,,,,,,,,,,3.0,,
outcome,NCT01370603::outcome::primary::1,NCT01370603,Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks of Treatment,,,,,,,,,,,,,PRIMARY,Baseline and Week 6
trial,NCT00491530,NCT00491530,"A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia",PHASE3,dyslipidemia,Mixed Dyslipidemia,INDUSTRY,310.0,2007-06,2008-11,1.0,1.0,,,,,
arm,NCT00491530::arm::FG000,NCT00491530,ABT-335 + 20 mg Rosuvastatin,,,,,,,,,,FG000,"Oral coadministration of ABT-335 (135 mg) + rosuvastatin (20 mg), once daily, for up to 116 weeks (if beginning in the 12-week double-blind study) or up to 104 weeks (if beginning in the previous 52-w",,,
arm,NCT00491530::arm::FG001,NCT00491530,ABT-335 + 40 mg Simvastatin,,,,,,,,,,FG001,"Oral coadministration of ABT-335 (135 mg) + simvastatin (40 mg), once daily, for up to 116 weeks (if beginning in the 12-week double-blind study) or up to 104 weeks (if beginning in the previous 52-we",,,
arm,NCT00491530::arm::FG002,NCT00491530,ABT-335 + 40 mg Atorvastatin,,,,,,,,,,FG002,"Oral coadministration of ABT-335 (135 mg) + atorvastatin (40 mg), once daily, for up to 116 weeks (if beginning in the 12-week double-blind study) or up to 104 weeks (if beginning in the previous 52-w",,,
period,NCT00491530::period::1,NCT00491530,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00491530::outcome::primary::1,NCT00491530,Percentage of Subjects Reporting Adverse Events During Combination Therapy in the Preceding Double-Blind Studies or in the Preceding Open-Label Year 1 Study or in This Open-Label Year 2 Study,,,,,,,,,,,,,PRIMARY,"Anytime after initiation of combination therapy (in the preceding 12-week double-blind studies or in the preceding open-label year 1 study) up to 116 weeks, to within 30 days after the last dose of combination therapy."
country,NCT00491530::country::United States,NCT00491530,United States,,,,,,,,,,,,,,
trial,NCT00683618,NCT00683618,Compare the Efficacy of Rosuvastatin to Atorvastatin in High Risk Patients With Hypercholesterolemia,PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,934.0,2008-05,2009-07,1.0,6.0,,,,,
arm,NCT00683618::arm::FG000,NCT00683618,Rosuvastatin 5mg,,,,,,,,,,FG000,Taken orally once daily,,,
arm,NCT00683618::arm::FG001,NCT00683618,Rosuvastatin 10mg,,,,,,,,,,FG001,Taken orally once daily,,,
arm,NCT00683618::arm::FG002,NCT00683618,Atorvastatin 10mg,,,,,,,,,,FG002,Taken orally once daily,,,
period,NCT00683618::period::1,NCT00683618,Randomised Treatment Period,,,,,,,,,,,,1.0,,
period,NCT00683618::period::2,NCT00683618,Extension Treatment Period,,,,,,,,,,,,2.0,,
outcome,NCT00683618::outcome::primary::1,NCT00683618,Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 5mg With Atorvastatin 10mg,,,,,,,,,,,,,PRIMARY,"baseline, 6 weeks"
outcome,NCT00683618::outcome::primary::2,NCT00683618,Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 10mg With Atorvastatin 10mg,,,,,,,,,,,,,PRIMARY,"baseline, 6 weeks"
country,NCT00683618::country::China,NCT00683618,China,,,,,,,,,,,,,,
trial,NCT00630877,NCT00630877,Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin,PHASE3,dyslipidemia,Dyslipidemia,INDUSTRY,276.0,2008-02,2008-06,1.0,40.0,,,,,
arm,NCT00630877::arm::FG000,NCT00630877,NER/ASA,,,,,,,,,,FG000,Niacin extended-release (NER) titrated to 2000 mg plus aspirin (ASA) 325 mg once daily,,,
arm,NCT00630877::arm::FG001,NCT00630877,NER/ASA Placebo,,,,,,,,,,FG001,Niacin extended-release (NER) titrated to 2000 mg plus aspirin (ASA) placebo once daily,,,
arm,NCT00630877::arm::FG002,NCT00630877,NER Placebo/ASA Placebo,,,,,,,,,,FG002,Niacin extended-release (NER) placebo plus aspirin (ASA) placebo once daily,,,
period,NCT00630877::period::1,NCT00630877,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00630877::outcome::primary::1,NCT00630877,Flushing ASsessment Tool (FAST) Test-retest Reliability--mean Flushing Severity Score,,,,,,,,,,,,,PRIMARY,Week 1 to Week 2
outcome,NCT00630877::outcome::primary::2,NCT00630877,FAST Test-retest Reliability--maximum Flushing Severity Score,,,,,,,,,,,,,PRIMARY,Week 1 to Week 2
outcome,NCT00630877::outcome::primary::3,NCT00630877,FAST Cross-sectional Construct Validity--mean Flushing Severity Score,,,,,,,,,,,,,PRIMARY,Week 1
outcome,NCT00630877::outcome::primary::4,NCT00630877,FAST Cross-sectional Construct Validity--maximum Flushing Severity Score,,,,,,,,,,,,,PRIMARY,Week 1
outcome,NCT00630877::outcome::primary::5,NCT00630877,FAST Longitudinal Construct Validity--mean Flushing Severity Score,,,,,,,,,,,,,PRIMARY,Week 1 to Week 2
outcome,NCT00630877::outcome::primary::6,NCT00630877,FAST Longitudinal Construct Validity--maximum Flushing Severity Score,,,,,,,,,,,,,PRIMARY,Week 1 to Week 2
outcome,NCT00630877::outcome::primary::7,NCT00630877,FAST Responsiveness--mean Flushing Severity Score,,,,,,,,,,,,,PRIMARY,Study start to Day 43
outcome,NCT00630877::outcome::primary::8,NCT00630877,FAST Responsiveness--maximum Flushing Severity Score,,,,,,,,,,,,,PRIMARY,Study start to Day 43
country,NCT00630877::country::United States,NCT00630877,United States,,,,,,,,,,,,,,
trial,NCT00413972,NCT00413972,Effects of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia (Study P04420),PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,392.0,2006-04,2006-11,0.0,0.0,,,,,
arm,NCT00413972::arm::FG000,NCT00413972,Vytorin 10/10,,,,,,,,,,FG000,Ezetimibe 10 mg with Simvastatin 10 mg,,,
arm,NCT00413972::arm::FG001,NCT00413972,Vytorin 10/20,,,,,,,,,,FG001,Ezetimibe 10 mg with Simvastatin 20 mg,,,
arm,NCT00413972::arm::FG002,NCT00413972,Vytorin 10/40,,,,,,,,,,FG002,Ezetimibe 10 mg with Simvastatin 40 mg,,,
arm,NCT00413972::arm::FG003,NCT00413972,Placebo,,,,,,,,,,FG003,,,,
period,NCT00413972::period::1,NCT00413972,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00413972::outcome::primary::1,NCT00413972,Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint After 8 Weeks of Treatment,,,,,,,,,,,,,PRIMARY,"Baseline, 8 weeks"
trial,NCT00249249,NCT00249249,Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels,PHASE3,dyslipidemia,Primary Hypercholesterolemia; Dyslipidemia,INDUSTRY,830.0,2005-10,2006-11,13.0,192.0,,,,,
arm,NCT00249249::arm::FG000,NCT00249249,Pitavastatin 2 mg QD,,,,,,,,,,FG000,Pitavastatin 2 mg daily,,,
arm,NCT00249249::arm::FG001,NCT00249249,Atorvastatin 10 mg QD,,,,,,,,,,FG001,Atorvastatin 10 mg daily,,,
arm,NCT00249249::arm::FG002,NCT00249249,Pitavastatin 4 mg QD,,,,,,,,,,FG002,Pitavastatin 4 mg daily,,,
arm,NCT00249249::arm::FG003,NCT00249249,Atorvastatin 20 mg QD,,,,,,,,,,FG003,Atorvastatin 20 mg daily,,,
period,NCT00249249::period::1,NCT00249249,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00249249::outcome::primary::1,NCT00249249,Percent Change From Baseline Low Density Lipoprotein-cholesterol (LDL-C) at Week 12,,,,,,,,,,,,,PRIMARY,Baseline to 12 weeks
country,NCT00249249::country::United Kingdom,NCT00249249,United Kingdom,,,,,,,,,,,,,,
country,NCT00249249::country::Russia,NCT00249249,Russia,,,,,,,,,,,,,,
country,NCT00249249::country::India,NCT00249249,India,,,,,,,,,,,,,,
country,NCT00249249::country::Germany,NCT00249249,Germany,,,,,,,,,,,,,,
country,NCT00249249::country::Netherlands,NCT00249249,Netherlands,,,,,,,,,,,,,,
country,NCT00249249::country::Spain,NCT00249249,Spain,,,,,,,,,,,,,,
country,NCT00249249::country::Italy,NCT00249249,Italy,,,,,,,,,,,,,,
country,NCT00249249::country::Poland,NCT00249249,Poland,,,,,,,,,,,,,,
country,NCT00249249::country::Sweden,NCT00249249,Sweden,,,,,,,,,,,,,,
country,NCT00249249::country::Israel,NCT00249249,Israel,,,,,,,,,,,,,,
country,NCT00249249::country::Denmark,NCT00249249,Denmark,,,,,,,,,,,,,,
country,NCT00249249::country::Finland,NCT00249249,Finland,,,,,,,,,,,,,,
country,NCT00249249::country::Norway,NCT00249249,Norway,,,,,,,,,,,,,,
trial,NCT01854918,NCT01854918,Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia,PHASE3,dyslipidemia,Hyperlipidemia and Mixed Dyslipidemia,INDUSTRY,3681.0,2013-04-23,2018-05-31,25.0,363.0,,,,,
arm,NCT01854918::arm::FG000,NCT01854918,Standard of Care,,,,,,,,,,FG000,"Participants received standard of care (SOC) treatment for the first year of the study (SOC-controlled period). At week 48, participants began treatment with evolocumab at a dose of either 140 mg ever",,,
arm,NCT01854918::arm::FG001,NCT01854918,Evolocumab + Standard of Care,,,,,,,,,,FG001,Participants received subcutaneous evolocumab plus standard of care during the first year of the study (SOC-controlled period) and for approximately 2 years during the all-IP period. Evolocumab was ad,,,
period,NCT01854918::period::1,NCT01854918,SOC-controlled Period (Year 1),,,,,,,,,,,,1.0,,
period,NCT01854918::period::2,NCT01854918,All-IP Period (Years 2 and 3),,,,,,,,,,,,2.0,,
outcome,NCT01854918::outcome::primary::1,NCT01854918,Number of Participants With Adverse Events,,,,,,,,,,,,,PRIMARY,48 weeks in the SOC-controlled period and up to 2 years in the All-IP period
country,NCT01854918::country::United States,NCT01854918,United States,,,,,,,,,,,,,,
country,NCT01854918::country::Japan,NCT01854918,Japan,,,,,,,,,,,,,,
country,NCT01854918::country::Canada,NCT01854918,Canada,,,,,,,,,,,,,,
country,NCT01854918::country::United Kingdom,NCT01854918,United Kingdom,,,,,,,,,,,,,,
country,NCT01854918::country::Belgium,NCT01854918,Belgium,,,,,,,,,,,,,,
country,NCT01854918::country::Czechia,NCT01854918,Czechia,,,,,,,,,,,,,,
country,NCT01854918::country::Australia,NCT01854918,Australia,,,,,,,,,,,,,,
country,NCT01854918::country::Germany,NCT01854918,Germany,,,,,,,,,,,,,,
country,NCT01854918::country::Italy,NCT01854918,Italy,,,,,,,,,,,,,,
country,NCT01854918::country::Netherlands,NCT01854918,Netherlands,,,,,,,,,,,,,,
country,NCT01854918::country::Hungary,NCT01854918,Hungary,,,,,,,,,,,,,,
country,NCT01854918::country::South Africa,NCT01854918,South Africa,,,,,,,,,,,,,,
country,NCT01854918::country::France,NCT01854918,France,,,,,,,,,,,,,,
country,NCT01854918::country::Switzerland,NCT01854918,Switzerland,,,,,,,,,,,,,,
country,NCT01854918::country::Spain,NCT01854918,Spain,,,,,,,,,,,,,,
country,NCT01854918::country::Sweden,NCT01854918,Sweden,,,,,,,,,,,,,,
country,NCT01854918::country::Russia,NCT01854918,Russia,,,,,,,,,,,,,,
country,NCT01854918::country::Denmark,NCT01854918,Denmark,,,,,,,,,,,,,,
country,NCT01854918::country::Hong Kong,NCT01854918,Hong Kong,,,,,,,,,,,,,,
country,NCT01854918::country::Norway,NCT01854918,Norway,,,,,,,,,,,,,,
country,NCT01854918::country::South Korea,NCT01854918,South Korea,,,,,,,,,,,,,,
country,NCT01854918::country::Taiwan,NCT01854918,Taiwan,,,,,,,,,,,,,,
country,NCT01854918::country::Austria,NCT01854918,Austria,,,,,,,,,,,,,,
country,NCT01854918::country::New Zealand,NCT01854918,New Zealand,,,,,,,,,,,,,,
country,NCT01854918::country::Poland,NCT01854918,Poland,,,,,,,,,,,,,,
trial,NCT01623115,NCT01623115,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy,PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,486.0,2012-07,2014-12,14.0,91.0,,,,,
arm,NCT01623115::arm::FG000,NCT01623115,Placebo,,,,,,,,,,FG000,Placebo for alirocumab subcutaneous (SC) injection every 2 weeks (Q2W) on top of stable lipid-modifying therapy (LMT) for 78 weeks.,,,
arm,NCT01623115::arm::FG001,NCT01623115,Alirocumab 75 mg/Up to 150 mg Q2W,,,,,,,,,,FG001,Alirocumab 75 mg SC injection Q2W on top of stable LMT for 78 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when low-density lipoprotein cholesterol (LDL-C) levels ≥ 70 mg/dL (1.81 mmol/L),,,
period,NCT01623115::period::1,NCT01623115,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01623115::outcome::primary::1,NCT01623115,Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis,,,,,,,,,,,,,PRIMARY,From Baseline to Week 52
country,NCT01623115::country::United States,NCT01623115,United States,,,,,,,,,,,,,,
country,NCT01623115::country::Russia,NCT01623115,Russia,,,,,,,,,,,,,,
country,NCT01623115::country::South Africa,NCT01623115,South Africa,,,,,,,,,,,,,,
country,NCT01623115::country::Spain,NCT01623115,Spain,,,,,,,,,,,,,,
country,NCT01623115::country::Netherlands,NCT01623115,Netherlands,,,,,,,,,,,,,,
country,NCT01623115::country::Canada,NCT01623115,Canada,,,,,,,,,,,,,,
country,NCT01623115::country::United Kingdom,NCT01623115,United Kingdom,,,,,,,,,,,,,,
country,NCT01623115::country::Czechia,NCT01623115,Czechia,,,,,,,,,,,,,,
country,NCT01623115::country::Israel,NCT01623115,Israel,,,,,,,,,,,,,,
country,NCT01623115::country::Austria,NCT01623115,Austria,,,,,,,,,,,,,,
country,NCT01623115::country::France,NCT01623115,France,,,,,,,,,,,,,,
country,NCT01623115::country::Denmark,NCT01623115,Denmark,,,,,,,,,,,,,,
country,NCT01623115::country::Sweden,NCT01623115,Sweden,,,,,,,,,,,,,,
country,NCT01623115::country::Norway,NCT01623115,Norway,,,,,,,,,,,,,,
trial,NCT01964326,NCT01964326,Actual Use Trial of Atorvastatin Calcium 10 mg,PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,1311.0,2013-10,2014-12,1.0,37.0,,,,,
arm,NCT01964326::arm::FG000,NCT01964326,Atorvastatin,,,,,,,,,,FG000,"Participants after reading the drugs fact label (DFL), made a purchase decision, purchased (on Day 1) and used atorvastatin 10 milligram (mg) OTC for 26 weeks.",,,
period,NCT01964326::period::1,NCT01964326,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01964326::outcome::primary::1,NCT01964326,Percentage of Participants Who Complied With the Direction to Check Their Low-density Lipoprotein Cholesterol (LDL-C) Level,,,,,,,,,,,,,PRIMARY,Day 1 up to Week 26
outcome,NCT01964326::outcome::primary::2,NCT01964326,Percentage of Participants Who Took Appropriate Action Based on Their LDL-C Results,,,,,,,,,,,,,PRIMARY,Day 1 up to Week 26
country,NCT01964326::country::United States,NCT01964326,United States,,,,,,,,,,,,,,
trial,NCT01730040,NCT01730040,Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I),PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,355.0,2012-10,2014-05,9.0,97.0,,,,,
arm,NCT01730040::arm::FG000,NCT01730040,Atorvastatin 40 mg,,,,,,,,,,FG000,"Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received atorvastatin 40 mg over-encapsulated tablets orally once daily (QD), placebo for alirocumab S",,,
arm,NCT01730040::arm::FG001,NCT01730040,Ezetimibe 10 mg + Atorvastatin 20 mg,,,,,,,,,,FG001,"Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received ezetimibe 10 mg over-encapsulated tablets orally QD, atorvastatin 20 mg over-encapsulated tab",,,
arm,NCT01730040::arm::FG002,NCT01730040,Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg,,,,,,,,,,FG002,"Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received Alirocumab 75 mg SC injection Q2W, atorvastatin 20 mg over-encapsulated tablets orally QD, an",,,
arm,NCT01730040::arm::FG003,NCT01730040,Atorvastatin 80 mg,,,,,,,,,,FG003,"Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received Atorvastatin 80 mg over-encapsulated tablets orally QD, placebo for alirocumab SC injection Q",,,
arm,NCT01730040::arm::FG004,NCT01730040,Rosuvastatin 40 mg,,,,,,,,,,FG004,"Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received rosuvastatin 40 mg over-encapsulated tablets orally QD, placebo for alirocumab SC injection Q",,,
arm,NCT01730040::arm::FG005,NCT01730040,Ezetimibe 10 mg + Atorvastatin 40 mg,,,,,,,,,,FG005,"Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received ezetimibe 10 mg over-encapsulated tablets orally QD, atorvastatin 40 mg over-encapsulated tab",,,
arm,NCT01730040::arm::FG006,NCT01730040,Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg,,,,,,,,,,FG006,"Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received alirocumab 75 mg SC injection Q2W, atorvastatin 40 mg over-encapsulated tablets orally QD, an",,,
period,NCT01730040::period::1,NCT01730040,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01730040::outcome::primary::1,NCT01730040,Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis,,,,,,,,,,,,,PRIMARY,From Baseline to Week 24
country,NCT01730040::country::United States,NCT01730040,United States,,,,,,,,,,,,,,
country,NCT01730040::country::Canada,NCT01730040,Canada,,,,,,,,,,,,,,
country,NCT01730040::country::Germany,NCT01730040,Germany,,,,,,,,,,,,,,
country,NCT01730040::country::Mexico,NCT01730040,Mexico,,,,,,,,,,,,,,
country,NCT01730040::country::United Kingdom,NCT01730040,United Kingdom,,,,,,,,,,,,,,
country,NCT01730040::country::Australia,NCT01730040,Australia,,,,,,,,,,,,,,
country,NCT01730040::country::Italy,NCT01730040,Italy,,,,,,,,,,,,,,
country,NCT01730040::country::France,NCT01730040,France,,,,,,,,,,,,,,
country,NCT01730040::country::Spain,NCT01730040,Spain,,,,,,,,,,,,,,
trial,NCT00542386,NCT00542386,A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia,PHASE3,dyslipidemia,Chronic Kidney Disease; Dialysis; Hyperphosphatemia; Dyslipidemia,INDUSTRY,642.0,2007-12,2009-11,8.0,73.0,,,,,
arm,NCT00542386::arm::FG000,NCT00542386,MCI-196: 3 g,,,,,,,,,,FG000,MCI-196: 3 g/ day,,,
arm,NCT00542386::arm::FG001,NCT00542386,MCI-196: 6 g,,,,,,,,,,FG001,MCI-196: 6 g/ day,,,
arm,NCT00542386::arm::FG002,NCT00542386,MCI-196: 9 g,,,,,,,,,,FG002,MCI-196: 9 g/ day,,,
arm,NCT00542386::arm::FG003,NCT00542386,MCI-196: 12 g,,,,,,,,,,FG003,MCI-196: 12 g/ day,,,
arm,NCT00542386::arm::FG004,NCT00542386,MCI-196: 15 g,,,,,,,,,,FG004,MCI-196: 15 g/ day,,,
arm,NCT00542386::arm::FG005,NCT00542386,Pooled Placebo,,,,,,,,,,FG005,"Placebo 9 tablets, 12 tablets and 15 tablets/ day",,,
period,NCT00542386::period::1,NCT00542386,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00542386::outcome::primary::1,NCT00542386,The Change in Serum Phosphorus,,,,,,,,,,,,,PRIMARY,12 weeks
outcome,NCT00542386::outcome::primary::2,NCT00542386,The Change in LDL-cholesterol,,,,,,,,,,,,,PRIMARY,12 weeks
country,NCT00542386::country::Russia,NCT00542386,Russia,,,,,,,,,,,,,,
country,NCT00542386::country::Malaysia,NCT00542386,Malaysia,,,,,,,,,,,,,,
country,NCT00542386::country::Ukraine,NCT00542386,Ukraine,,,,,,,,,,,,,,
country,NCT00542386::country::Hungary,NCT00542386,Hungary,,,,,,,,,,,,,,
country,NCT00542386::country::Poland,NCT00542386,Poland,,,,,,,,,,,,,,
country,NCT00542386::country::Italy,NCT00542386,Italy,,,,,,,,,,,,,,
country,NCT00542386::country::Serbia,NCT00542386,Serbia,,,,,,,,,,,,,,
country,NCT00542386::country::North Macedonia,NCT00542386,North Macedonia,,,,,,,,,,,,,,
trial,NCT01763918,NCT01763918,Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2,PHASE3,dyslipidemia,Hyperlipidemia,INDUSTRY,331.0,2013-02-07,2013-12-19,14.0,39.0,,,,,
arm,NCT01763918::arm::FG000,NCT01763918,Placebo Q2W,,,,,,,,,,FG000,Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for up to 12 weeks.,,,
arm,NCT01763918::arm::FG001,NCT01763918,Placebo QM,,,,,,,,,,FG001,Participants received placebo subcutaneous injection once every month (QM) for up to 12 weeks.,,,
arm,NCT01763918::arm::FG002,NCT01763918,Evolocumab Q2W,,,,,,,,,,FG002,Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.,,,
arm,NCT01763918::arm::FG003,NCT01763918,Evolocumab QM,,,,,,,,,,FG003,Participants received 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.,,,
period,NCT01763918::period::1,NCT01763918,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01763918::outcome::primary::1,NCT01763918,Percent Change From Baseline in LDL-C at Week 12,,,,,,,,,,,,,PRIMARY,Baseline and Week 12
outcome,NCT01763918::outcome::primary::2,NCT01763918,Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12,,,,,,,,,,,,,PRIMARY,Baseline and Weeks 10 and 12
country,NCT01763918::country::Netherlands,NCT01763918,Netherlands,,,,,,,,,,,,,,
country,NCT01763918::country::Canada,NCT01763918,Canada,,,,,,,,,,,,,,
country,NCT01763918::country::South Africa,NCT01763918,South Africa,,,,,,,,,,,,,,
country,NCT01763918::country::Spain,NCT01763918,Spain,,,,,,,,,,,,,,
country,NCT01763918::country::United Kingdom,NCT01763918,United Kingdom,,,,,,,,,,,,,,
country,NCT01763918::country::France,NCT01763918,France,,,,,,,,,,,,,,
country,NCT01763918::country::United States,NCT01763918,United States,,,,,,,,,,,,,,
country,NCT01763918::country::Australia,NCT01763918,Australia,,,,,,,,,,,,,,
country,NCT01763918::country::Sweden,NCT01763918,Sweden,,,,,,,,,,,,,,
country,NCT01763918::country::Germany,NCT01763918,Germany,,,,,,,,,,,,,,
country,NCT01763918::country::Hong Kong,NCT01763918,Hong Kong,,,,,,,,,,,,,,
country,NCT01763918::country::New Zealand,NCT01763918,New Zealand,,,,,,,,,,,,,,
country,NCT01763918::country::Norway,NCT01763918,Norway,,,,,,,,,,,,,,
country,NCT01763918::country::Switzerland,NCT01763918,Switzerland,,,,,,,,,,,,,,
trial,NCT00812955,NCT00812955,"Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol (""Bad Cholesterol"") and Triglycerides",PHASE3,dyslipidemia,"Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia",INDUSTRY,474.0,2008-11,2009-06,1.0,129.0,,,,,
arm,NCT00812955::arm::FG000,NCT00812955,Simvastatin Capsules 40 mg,,,,,,,,,,FG000,Simvastatin capsules 40 mg once daily for 8 weeks,,,
arm,NCT00812955::arm::FG001,NCT00812955,ABT-143 Capsules 5/135 mg,,,,,,,,,,FG001,ABT-143 capsules 5/135 mg once daily for 8 weeks,,,
arm,NCT00812955::arm::FG002,NCT00812955,ABT-143 Capsules 10/135 mg,,,,,,,,,,FG002,ABT-143 capsules 10/135 mg once daily for 8 weeks,,,
arm,NCT00812955::arm::FG003,NCT00812955,ABT-143 Capsules 20/135 mg,,,,,,,,,,FG003,ABT-143 capsules 20/135 mg once daily for 8 weeks,,,
period,NCT00812955::period::1,NCT00812955,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00812955::outcome::primary::1,NCT00812955,Mean Percent Change From Baseline to the Final Visit in Low-density Lipoprotein Cholesterol (LDL-C) (Full Analysis Set),,,,,,,,,,,,,PRIMARY,Baseline to 8 weeks
country,NCT00812955::country::United States,NCT00812955,United States,,,,,,,,,,,,,,
trial,NCT00309777,NCT00309777,Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin,PHASE3,dyslipidemia,Hypercholesterolemia; Dyslipidemia,INDUSTRY,857.0,2005-09,2006-10,5.0,42.0,,,,,
arm,NCT00309777::arm::FG000,NCT00309777,Pitavastatin 2 mg,,,,,,,,,,FG000,Pitavastatin 2 mg once daily,,,
arm,NCT00309777::arm::FG001,NCT00309777,Simvastatin 20 mg,,,,,,,,,,FG001,Simvastatin 20 mg once daily,,,
arm,NCT00309777::arm::FG002,NCT00309777,Pitavastatin 4 mg,,,,,,,,,,FG002,Pitavastatin 4 mg once daily,,,
arm,NCT00309777::arm::FG003,NCT00309777,Simvastatin 40 mg,,,,,,,,,,FG003,Simvastatn 40 mg once daily,,,
period,NCT00309777::period::1,NCT00309777,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00309777::outcome::primary::1,NCT00309777,Percent Change From Baseline in Low Density Lipoprotein-cholesterol (LDL-C) at 12 Weeks,,,,,,,,,,,,,PRIMARY,Baseline to 12 weeks
country,NCT00309777::country::Russia,NCT00309777,Russia,,,,,,,,,,,,,,
country,NCT00309777::country::Italy,NCT00309777,Italy,,,,,,,,,,,,,,
country,NCT00309777::country::United Kingdom,NCT00309777,United Kingdom,,,,,,,,,,,,,,
country,NCT00309777::country::Finland,NCT00309777,Finland,,,,,,,,,,,,,,
country,NCT00309777::country::Norway,NCT00309777,Norway,,,,,,,,,,,,,,
trial,NCT02304484,NCT02304484,Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab,PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,770.0,2014-11-24,2018-03-09,29.0,126.0,,,,,
arm,NCT02304484::arm::FG000,NCT02304484,Evolocumab,,,,,,,,,,FG000,Participants received 420 mg evolocumab once a month for up to 2 years.,,,
period,NCT02304484::period::1,NCT02304484,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02304484::outcome::primary::1,NCT02304484,Number of Participants With Adverse Events,,,,,,,,,,,,,PRIMARY,"From first dose of evolocumab up to 30 days after the last dose, or end of study, whichever was earlier, up to 108 weeks."
country,NCT02304484::country::United States,NCT02304484,United States,,,,,,,,,,,,,,
country,NCT02304484::country::Canada,NCT02304484,Canada,,,,,,,,,,,,,,
country,NCT02304484::country::Australia,NCT02304484,Australia,,,,,,,,,,,,,,
country,NCT02304484::country::Netherlands,NCT02304484,Netherlands,,,,,,,,,,,,,,
country,NCT02304484::country::Poland,NCT02304484,Poland,,,,,,,,,,,,,,
country,NCT02304484::country::Spain,NCT02304484,Spain,,,,,,,,,,,,,,
country,NCT02304484::country::Belgium,NCT02304484,Belgium,,,,,,,,,,,,,,
country,NCT02304484::country::France,NCT02304484,France,,,,,,,,,,,,,,
country,NCT02304484::country::Hungary,NCT02304484,Hungary,,,,,,,,,,,,,,
country,NCT02304484::country::Argentina,NCT02304484,Argentina,,,,,,,,,,,,,,
country,NCT02304484::country::Czechia,NCT02304484,Czechia,,,,,,,,,,,,,,
country,NCT02304484::country::Italy,NCT02304484,Italy,,,,,,,,,,,,,,
country,NCT02304484::country::Mexico,NCT02304484,Mexico,,,,,,,,,,,,,,
country,NCT02304484::country::Russia,NCT02304484,Russia,,,,,,,,,,,,,,
country,NCT02304484::country::South Korea,NCT02304484,South Korea,,,,,,,,,,,,,,
country,NCT02304484::country::Greece,NCT02304484,Greece,,,,,,,,,,,,,,
country,NCT02304484::country::South Africa,NCT02304484,South Africa,,,,,,,,,,,,,,
country,NCT02304484::country::Brazil,NCT02304484,Brazil,,,,,,,,,,,,,,
country,NCT02304484::country::Israel,NCT02304484,Israel,,,,,,,,,,,,,,
country,NCT02304484::country::Malaysia,NCT02304484,Malaysia,,,,,,,,,,,,,,
country,NCT02304484::country::Sweden,NCT02304484,Sweden,,,,,,,,,,,,,,
country,NCT02304484::country::Chile,NCT02304484,Chile,,,,,,,,,,,,,,
country,NCT02304484::country::Germany,NCT02304484,Germany,,,,,,,,,,,,,,
country,NCT02304484::country::Iceland,NCT02304484,Iceland,,,,,,,,,,,,,,
country,NCT02304484::country::Ireland,NCT02304484,Ireland,,,,,,,,,,,,,,
country,NCT02304484::country::Norway,NCT02304484,Norway,,,,,,,,,,,,,,
country,NCT02304484::country::Switzerland,NCT02304484,Switzerland,,,,,,,,,,,,,,
country,NCT02304484::country::Taiwan,NCT02304484,Taiwan,,,,,,,,,,,,,,
country,NCT02304484::country::United Kingdom,NCT02304484,United Kingdom,,,,,,,,,,,,,,
trial,NCT00462748,NCT00462748,A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121),PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,786.0,2007-03,2008-06,0.0,0.0,,,,,
arm,NCT00462748::arm::FG000,NCT00462748,Ezetimibe/Simvastatin,,,,,,,,,,FG000,"ezetimibe (+) simvastatin 10/40mg. once daily tablet formulation, all tablet form, taken orally",,,
arm,NCT00462748::arm::FG001,NCT00462748,Atorvostatin,,,,,,,,,,FG001,"atorvastatin 40mg. once daily tablet formulation, all tablet form, taken orally",,,
arm,NCT00462748::arm::FG002,NCT00462748,Rosuvastatin,,,,,,,,,,FG002,"rosuvastatin 10 mg. once daily tablet formulation, all tablet form, taken orally",,,
period,NCT00462748::period::1,NCT00462748,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00462748::outcome::primary::1,NCT00462748,Percentage of Patients Achieving a Target of Fasting LDL-C of <2mmol/l at Study End,,,,,,,,,,,,,PRIMARY,6 Weeks
trial,NCT00680017,NCT00680017,30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease,PHASE3,dyslipidemia,Dyslipidemia; Kidney Disease,INDUSTRY,280.0,2008-06,2011-04,2.0,114.0,,,,,
arm,NCT00680017::arm::FG000,NCT00680017,ABT-335 Plus Rosuvastatin,,,,,,,,,,FG000,"ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks",,,
arm,NCT00680017::arm::FG001,NCT00680017,Rosuvastatin,,,,,,,,,,FG001,Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks,,,
period,NCT00680017::period::1,NCT00680017,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00680017::outcome::primary::1,NCT00680017,Median Percent Change in Triglycerides From Baseline to Week 8.,,,,,,,,,,,,,PRIMARY,Baseline to 8 weeks
country,NCT00680017::country::United States,NCT00680017,United States,,,,,,,,,,,,,,
country,NCT00680017::country::Puerto Rico,NCT00680017,Puerto Rico,,,,,,,,,,,,,,
trial,NCT02023879,NCT02023879,Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II),PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,233.0,2013-12-16,2017-06-30,8.0,43.0,,,,,
arm,NCT02023879::arm::FG000,NCT02023879,Placebo Q2W,,,,,,,,,,FG000,"Period 1: Placebo (for Alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable non-statin lipid modifying therapy (LMT) or diet alone for 24 weeks.

Period 2: Alirocumab 150 mg SC ",,,
arm,NCT02023879::arm::FG001,NCT02023879,Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator),,,,,,,,,,FG001,Period 1: Alirocumab 75 mg SC injection Q2W added to stable non-statin LMT or diet alone for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when targeted LDL-C levels at Week 8 were ,,,
arm,NCT02023879::arm::FG002,NCT02023879,Alirocumab 150 mg Q4W/Up to 150 mg Q2W,,,,,,,,,,FG002,Period 1: Alirocumab 150 mg SC injection Q4W added to stable non-statin LMT or diet alone for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels at Week 8 were not achi,,,
period,NCT02023879::period::1,NCT02023879,Period 1: 24-Week Double-blind Treatment,,,,,,,,,,,,1.0,,
period,NCT02023879::period::2,NCT02023879,Extension Open Label Treatment,,,,,,,,,,,,2.0,,
outcome,NCT02023879::outcome::primary::1,NCT02023879,Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis),,,,,,,,,,,,,PRIMARY,From Baseline to Week 24
country,NCT02023879::country::United States,NCT02023879,United States,,,,,,,,,,,,,,
country,NCT02023879::country::Netherlands,NCT02023879,Netherlands,,,,,,,,,,,,,,
country,NCT02023879::country::Spain,NCT02023879,Spain,,,,,,,,,,,,,,
country,NCT02023879::country::Canada,NCT02023879,Canada,,,,,,,,,,,,,,
country,NCT02023879::country::Denmark,NCT02023879,Denmark,,,,,,,,,,,,,,
country,NCT02023879::country::Australia,NCT02023879,Australia,,,,,,,,,,,,,,
country,NCT02023879::country::Belgium,NCT02023879,Belgium,,,,,,,,,,,,,,
country,NCT02023879::country::New Zealand,NCT02023879,New Zealand,,,,,,,,,,,,,,
trial,NCT02741245,NCT02741245,A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832),PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,321.0,2016-06-09,2017-01-18,0.0,0.0,,,,,
arm,NCT02741245::arm::FG000,NCT02741245,Ezetimibe 10 mg,,,,,,,,,,FG000,1 Ezetimibe 10 mg tablet and 2 Rosuvastatin placebo capsules once daily for 12 weeks,,,
arm,NCT02741245::arm::FG001,NCT02741245,Rosuvastatin 2.5 mg,,,,,,,,,,FG001,"1 Rosuvastatin 2.5 mg capsule, 1 Rosuvastatin placebo capsule and 1 Ezetimibe placebo tablet once daily for 12 weeks.",,,
arm,NCT02741245::arm::FG002,NCT02741245,Rosuvastatin 5.0 mg,,,,,,,,,,FG002,2 Rosuvastatin 2.5 mg capsules and Ezetimibe placebo tablet once daily for 12 weeks.,,,
arm,NCT02741245::arm::FG003,NCT02741245,Ezetimibe 10 mg+ Rosuvastatin 2.5 mg,,,,,,,,,,FG003,"1 Ezetimbie 10 mg tablet, 1 Rosuvastatin 2.5 mg capsule and 1 Rosuvastatin placebo capsule once daily for 12 weeks.",,,
arm,NCT02741245::arm::FG004,NCT02741245,Ezetimibe 10 mg+ Rosuvastatin 5.0 mg,,,,,,,,,,FG004,1 Ezetimbie 10 mg tablet and 2 Rosuvastatin 2.5 mg capsules once daily for 12 weeks.,,,
period,NCT02741245::period::1,NCT02741245,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02741245::outcome::primary::1,NCT02741245,Percentage Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C),,,,,,,,,,,,,PRIMARY,Baseline and Week 12
outcome,NCT02741245::outcome::primary::2,NCT02741245,Percentage of Participants Who Experience at Least 1 Adverse Event (AE),,,,,,,,,,,,,PRIMARY,up to 14 weeks
outcome,NCT02741245::outcome::primary::3,NCT02741245,Percentage of Participants Who Had Study Drug Discontinued Due to Adverse Event,,,,,,,,,,,,,PRIMARY,up to 12 weeks
outcome,NCT02741245::outcome::primary::4,NCT02741245,Percentage of Participants Who Experience 1 or More Gastrointestinal-related AEs,,,,,,,,,,,,,PRIMARY,up to 14 weeks
outcome,NCT02741245::outcome::primary::5,NCT02741245,Percentage of Participants Who Experience 1 or More Gallbladder-related AEs,,,,,,,,,,,,,PRIMARY,up to 14 weeks
outcome,NCT02741245::outcome::primary::6,NCT02741245,Percentage of Participants Who Experience 1 or More Allergic Reaction or Rash AEs,,,,,,,,,,,,,PRIMARY,up to 14 weeks
outcome,NCT02741245::outcome::primary::7,NCT02741245,Percentage of Participants Who Experience 1 or More Hepatitis-related AEs,,,,,,,,,,,,,PRIMARY,up to 14 weeks
outcome,NCT02741245::outcome::primary::8,NCT02741245,Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) ≥3 Times Upper Normal Limit (ULN),,,,,,,,,,,,,PRIMARY,up to 12 weeks
outcome,NCT02741245::outcome::primary::9,NCT02741245,Percentage of Participants Who Experience Consecutive Elevations in Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN),,,,,,,,,,,,,PRIMARY,up to 12 weeks
outcome,NCT02741245::outcome::primary::10,NCT02741245,Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN),,,,,,,,,,,,,PRIMARY,up to 12 weeks
outcome,NCT02741245::outcome::primary::11,NCT02741245,Percentage of Participants Who Experience Elevation in Alanine Aminotransferase (ALT) ≥5 Times Upper Normal Limit (ULN),,,,,,,,,,,,,PRIMARY,up to 12 weeks
outcome,NCT02741245::outcome::primary::12,NCT02741245,Percentage of Participants Who Experience Elevation in Aspartate Aminotransferase (AST) ≥5 Times Upper Normal Limit (ULN),,,,,,,,,,,,,PRIMARY,up to 12 weeks
outcome,NCT02741245::outcome::primary::13,NCT02741245,Percentage of Participants Who Experience Elevation in Alanine Aminotransferase (ALT) ≥10 Times Upper Normal Limit (ULN),,,,,,,,,,,,,PRIMARY,up to 12 weeks
outcome,NCT02741245::outcome::primary::14,NCT02741245,Percentage of Participants Who Experience Elevation in Aspartate Aminotransferase (AST) ≥10 Times Upper Normal Limit (ULN),,,,,,,,,,,,,PRIMARY,up to 12 weeks
outcome,NCT02741245::outcome::primary::15,NCT02741245,Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥10 Times Upper Normal Limit (ULN),,,,,,,,,,,,,PRIMARY,up to 12 weeks
outcome,NCT02741245::outcome::primary::16,NCT02741245,Percentage of Participants With Potential Hy's Law Condition,,,,,,,,,,,,,PRIMARY,up to 12 weeks
outcome,NCT02741245::outcome::primary::17,NCT02741245,Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN,,,,,,,,,,,,,PRIMARY,up to 12 weeks
outcome,NCT02741245::outcome::primary::18,NCT02741245,Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN With Muscle Symptoms,,,,,,,,,,,,,PRIMARY,up to 12 weeks
outcome,NCT02741245::outcome::primary::19,NCT02741245,Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN and Drug-Related Muscle Symptoms,,,,,,,,,,,,,PRIMARY,up to 12 weeks
trial,NCT02458287,NCT02458287,"Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia",PHASE3,dyslipidemia,Hyperlipidemia,INDUSTRY,299.0,2015-06,2016-02,1.0,30.0,,,,,
arm,NCT02458287::arm::FG000,NCT02458287,Placebo Matched to Bococizumab 150 mg,,,,,,,,,,FG000,Participants received single dose of placebo matched to bococizumab 150 milligram (mg) subcutaneous injection once in every 2 weeks over a period of 12 weeks. Participants were followed up to 18 weeks,,,
arm,NCT02458287::arm::FG001,NCT02458287,Bococizumab 150 mg,,,,,,,,,,FG001,"Participants received single dose of bococizumab 150 mg subcutaneous injection once in every 2 weeks, over a period of 12 weeks. Participants were followed up to 18 weeks.",,,
arm,NCT02458287::arm::FG002,NCT02458287,Placebo Matched to Bococizumab 75 mg,,,,,,,,,,FG002,"Participants received single dose of placebo matched to bococizumab 75 mg subcutaneous injection once in every 2 weeks, over a period of 12 weeks. Participants were followed up to 18 weeks.",,,
arm,NCT02458287::arm::FG003,NCT02458287,Bococizumab 75 mg,,,,,,,,,,FG003,"Participants received single dose of bococizumab 75 mg subcutaneous injection once in every 2 weeks, over a period of 12 weeks. Participants were followed up to 18 weeks.",,,
period,NCT02458287::period::1,NCT02458287,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02458287::outcome::primary::1,NCT02458287,Percent Change From Baseline at Week 12 in Fasting Low Density Lipoprotein Cholesterol (LDL-C) Level for Bococizumab 150 mg Dose Group and Matched Placebo,,,,,,,,,,,,,PRIMARY,"Baseline, Week 12"
outcome,NCT02458287::outcome::primary::2,NCT02458287,Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 150 mg Dose Group at Week 0 (Day 1),,,,,,,,,,,,,PRIMARY,Week 0 (Day 1)
outcome,NCT02458287::outcome::primary::3,NCT02458287,Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 150 mg Dose Group at Week 2,,,,,,,,,,,,,PRIMARY,Week 2
outcome,NCT02458287::outcome::primary::4,NCT02458287,Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 150 mg Dose Group at Week 4,,,,,,,,,,,,,PRIMARY,Week 4
outcome,NCT02458287::outcome::primary::5,NCT02458287,Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 150 mg Dose Group at Week 6,,,,,,,,,,,,,PRIMARY,Week 6
outcome,NCT02458287::outcome::primary::6,NCT02458287,Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 150 mg Dose Group at Week 8,,,,,,,,,,,,,PRIMARY,Week 8
outcome,NCT02458287::outcome::primary::7,NCT02458287,Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 150 mg Dose Group at Week 10,,,,,,,,,,,,,PRIMARY,Week 10
country,NCT02458287::country::United States,NCT02458287,United States,,,,,,,,,,,,,,
trial,NCT00961636,NCT00961636,A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102),PHASE3,dyslipidemia,Dyslipidemia,INDUSTRY,1152.0,2009-10,2011-01,0.0,0.0,,,,,
arm,NCT00961636::arm::FG000,NCT00961636,ERN/LRPT,,,,,,,,,,FG000,"One 1g/20 mg tablet Extended -release niacin (+) laropiprant (ERN/LRPT) once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 28 weeks",,,
arm,NCT00961636::arm::FG001,NCT00961636,ERN/LRPT Then ERN,,,,,,,,,,FG001,"One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks then Two 1g tablets ERN (2g total) once daily for 12 weeks.",,,
arm,NCT00961636::arm::FG002,NCT00961636,Placebo,,,,,,,,,,FG002,"One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks.",,,
period,NCT00961636::period::1,NCT00961636,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00961636::outcome::primary::1,NCT00961636,Number Participants With Days Per Week With Global Flushing Severity Score (GFSS) ≥4 Partitioned Into 6 Categories During the Postwithdrawal Period,,,,,,,,,,,,,PRIMARY,Week 21 to Week 32
trial,NCT00535405,NCT00535405,A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128),PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,1289.0,2007-11,2009-03,0.0,0.0,,,,,
arm,NCT00535405::arm::FG000,NCT00535405,Atorvastatin 10 mg,,,,,,,,,,FG000,Atorvastatin (Atorva) 10 mg once daily for 12 weeks,,,
arm,NCT00535405::arm::FG001,NCT00535405,Ezetimibe 10 mg/Simvastatin 20 mg,,,,,,,,,,FG001,Ezetimibe (EZ) 10 mg/simvastatin (Simva) 20 mg once daily for 12 weeks,,,
arm,NCT00535405::arm::FG002,NCT00535405,Atorvastatin 20 mg,,,,,,,,,,FG002,Atorvastatin 20 mg once daily for 12 weeks,,,
arm,NCT00535405::arm::FG003,NCT00535405,Ezetimibe 10 mg/Simvastatin 40 mg,,,,,,,,,,FG003,Ezetimibe 10 mg/simvastatin 40 mg once daily for 12 weeks,,,
arm,NCT00535405::arm::FG004,NCT00535405,Atorva 40 mg,,,,,,,,,,FG004,Atorvastatin 40 mg once daily for 12 weeks,,,
period,NCT00535405::period::1,NCT00535405,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00535405::outcome::primary::1,NCT00535405,Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 12,,,,,,,,,,,,,PRIMARY,Baseline and 12 weeks
trial,NCT00257686,NCT00257686,Study to Compare the Efficacy and Safety of Pitavastatin and Pravastatin in Elderly Patients,PHASE3,dyslipidemia,Hypercholesterolemia or Combined Dyslipidemia,INDUSTRY,962.0,2005-09,2006-05,5.0,62.0,,,,,
arm,NCT00257686::arm::FG000,NCT00257686,Pitavastatin 1 mg,,,,,,,,,,FG000,Pitavastatin 1 mg once daily,,,
arm,NCT00257686::arm::FG001,NCT00257686,Pravastatin 10 mg,,,,,,,,,,FG001,Pravastatin 10 mg once daily,,,
arm,NCT00257686::arm::FG002,NCT00257686,Pitavastatin 2 mg,,,,,,,,,,FG002,Pitavastatin 2 mg once daily,,,
arm,NCT00257686::arm::FG003,NCT00257686,Pravastatin 20 mg,,,,,,,,,,FG003,Pravastatin 20 mg once daily,,,
arm,NCT00257686::arm::FG004,NCT00257686,Pitavastatin 4 mg,,,,,,,,,,FG004,Pitavastatin 4 mg once daily,,,
arm,NCT00257686::arm::FG005,NCT00257686,Pravastatin 40 mg,,,,,,,,,,FG005,Pravastatin 40 mg once daily,,,
period,NCT00257686::period::1,NCT00257686,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00257686::outcome::primary::1,NCT00257686,Percent Change From Baseline in LDL-C,,,,,,,,,,,,,PRIMARY,Baseline to 12 weeks
country,NCT00257686::country::United Kingdom,NCT00257686,United Kingdom,,,,,,,,,,,,,,
country,NCT00257686::country::Germany,NCT00257686,Germany,,,,,,,,,,,,,,
country,NCT00257686::country::Netherlands,NCT00257686,Netherlands,,,,,,,,,,,,,,
country,NCT00257686::country::Israel,NCT00257686,Israel,,,,,,,,,,,,,,
country,NCT00257686::country::Denmark,NCT00257686,Denmark,,,,,,,,,,,,,,
trial,NCT01242527,NCT01242527,Epanova® for Lowering Very High Triglycerides,PHASE3,dyslipidemia,Severe Hypertriglyceridemia,INDUSTRY,399.0,2011-01,2012-04,7.0,68.0,,,,,
arm,NCT01242527::arm::FG000,NCT01242527,Olive Oil (Placebo Control),,,,,,,,,,FG000,placebo : 4 capsules (1g) daily for 12 weeks,,,
arm,NCT01242527::arm::FG001,NCT01242527,Epanova 2 g,,,,,,,,,,FG001,omefas : 2 capsules (1g) + 2 placebo daily for 12 weeks,,,
arm,NCT01242527::arm::FG002,NCT01242527,Epanova 3 g,,,,,,,,,,FG002,omefas : 3 capsules (1g) + 1 placebo daily for 12 weeks,,,
arm,NCT01242527::arm::FG003,NCT01242527,Epanova 4 g,,,,,,,,,,FG003,omefas : 4 capsules (1g)daily for 12 weeks,,,
period,NCT01242527::period::1,NCT01242527,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01242527::outcome::primary::1,NCT01242527,Fasting Serum Triglycerides,,,,,,,,,,,,,PRIMARY,12 weeks
country,NCT01242527::country::United States,NCT01242527,United States,,,,,,,,,,,,,,
country,NCT01242527::country::India,NCT01242527,India,,,,,,,,,,,,,,
country,NCT01242527::country::Hungary,NCT01242527,Hungary,,,,,,,,,,,,,,
country,NCT01242527::country::Ukraine,NCT01242527,Ukraine,,,,,,,,,,,,,,
country,NCT01242527::country::Netherlands,NCT01242527,Netherlands,,,,,,,,,,,,,,
country,NCT01242527::country::Denmark,NCT01242527,Denmark,,,,,,,,,,,,,,
country,NCT01242527::country::Russia,NCT01242527,Russia,,,,,,,,,,,,,,
trial,NCT00783263,NCT00783263,A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139),PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,440.0,2008-11,2010-05,0.0,0.0,,,,,
arm,NCT00783263::arm::FG000,NCT00783263,Rosuvastatin 5 mg + Ezetimibe 10 mg,,,,,,,,,,FG000,Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.,,,
arm,NCT00783263::arm::FG001,NCT00783263,Rosuvastatin 10 mg,,,,,,,,,,FG001,Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.,,,
arm,NCT00783263::arm::FG002,NCT00783263,Rosuvastatin 10 mg + Ezetimibe 10 mg,,,,,,,,,,FG002,Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.,,,
arm,NCT00783263::arm::FG003,NCT00783263,Rosuvastatin 20 mg,,,,,,,,,,FG003,Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.,,,
period,NCT00783263::period::1,NCT00783263,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00783263::outcome::primary::1,NCT00783263,Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment,,,,,,,,,,,,,PRIMARY,Baseline to 6 weeks
trial,NCT01516879,NCT01516879,Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study,PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,905.0,2012-01-05,2013-10-14,9.0,96.0,,,,,
arm,NCT01516879::arm::FG000,NCT01516879,Placebo,,,,,,,,,,FG000,Participants received placebo subcutaneously once a month for 52 weeks in addition to background lipid-lowering therapy.,,,
arm,NCT01516879::arm::FG001,NCT01516879,Evolocumab,,,,,,,,,,FG001,Participants received evolocumab 420 mg subcutaneously once a month for 52 weeks in addition to background lipid-lowering therapy.,,,
period,NCT01516879::period::1,NCT01516879,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01516879::outcome::primary::1,NCT01516879,Percent Change From Baseline in LDL-C at Week 52,,,,,,,,,,,,,PRIMARY,Baseline and Week 52
country,NCT01516879::country::United States,NCT01516879,United States,,,,,,,,,,,,,,
country,NCT01516879::country::Canada,NCT01516879,Canada,,,,,,,,,,,,,,
country,NCT01516879::country::Czechia,NCT01516879,Czechia,,,,,,,,,,,,,,
country,NCT01516879::country::Hungary,NCT01516879,Hungary,,,,,,,,,,,,,,
country,NCT01516879::country::South Africa,NCT01516879,South Africa,,,,,,,,,,,,,,
country,NCT01516879::country::Australia,NCT01516879,Australia,,,,,,,,,,,,,,
country,NCT01516879::country::Belgium,NCT01516879,Belgium,,,,,,,,,,,,,,
country,NCT01516879::country::Austria,NCT01516879,Austria,,,,,,,,,,,,,,
country,NCT01516879::country::Denmark,NCT01516879,Denmark,,,,,,,,,,,,,,
trial,NCT00479388,NCT00479388,Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067),PHASE3,dyslipidemia,Primary Hypercholesterolemia; Mixed Dyslipidemia,INDUSTRY,1216.0,2007-07,2008-10,0.0,0.0,,,,,
arm,NCT00479388::arm::FG000,NCT00479388,ER Niacin/Laropiprant + Run-in Statin,,,,,,,,,,FG000,"One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in stat",,,
arm,NCT00479388::arm::FG001,NCT00479388,Run-in Statin Dose Doubled,,,,,,,,,,FG001,Stable dose of simvastatin or atorvastatin (20mg to 40mg) for 12 weeks.,,,
period,NCT00479388::period::1,NCT00479388,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00479388::outcome::primary::1,NCT00479388,Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12,,,,,,,,,,,,,PRIMARY,Baseline and 12 Weeks
trial,NCT00536510,NCT00536510,Effect of MK0524A on Cholesterol Levels (0524A-048),PHASE3,dyslipidemia,Hypercholesterolemia; Hyperlipidemia,INDUSTRY,646.0,2007-04,2008-03,0.0,0.0,,,,,
arm,NCT00536510::arm::FG000,NCT00536510,MK0524A 2 g,,,,,,,,,,FG000,"All patients received placebo for a 4 week run-in period before randomization.

Drug: laropiprant/niacin (MK0524A)

Treatment Period 1: one 20 mg /1 g tablet of laropiprant/niacin once daily for 4 wee",,,
arm,NCT00536510::arm::FG001,NCT00536510,Placebo,,,,,,,,,,FG001,"All patients received placebo for a 4 week run-in period before randomization.

Drug: Comparator: placebo

Treatment Period 1: one 20 mg /1 g tablet placebo to laropiprant/niacin once daily for 4 week",,,
period,NCT00536510::period::1,NCT00536510,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00536510::outcome::primary::1,NCT00536510,Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) After 12 Weeks,,,,,,,,,,,,,PRIMARY,12 weeks
trial,NCT01984424,NCT01984424,Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3,PHASE3,dyslipidemia,Hyperlipidemia,INDUSTRY,511.0,2013-12-10,2017-11-21,13.0,58.0,,,,,
arm,NCT01984424::arm::FG000,NCT01984424,Ezetimibe,,,,,,,,,,FG000,Participants received 10 mg ezetimibe orally once a day and placebo to evolocumab by subcutaneous injection once a month for 24 weeks.,,,
arm,NCT01984424::arm::FG001,NCT01984424,Evolocumab,,,,,,,,,,FG001,Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo to ezetimibe orally once a day for 24 weeks.,,,
period,NCT01984424::period::1,NCT01984424,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01984424::outcome::primary::1,NCT01984424,Percent Change From Baseline in LDL-C at the Mean of Weeks 22 and 24,,,,,,,,,,,,,PRIMARY,Baseline and weeks 22 and 24
outcome,NCT01984424::outcome::primary::2,NCT01984424,Percent Change From Baseline in LDL-C at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and week 24
country,NCT01984424::country::United States,NCT01984424,United States,,,,,,,,,,,,,,
country,NCT01984424::country::Canada,NCT01984424,Canada,,,,,,,,,,,,,,
country,NCT01984424::country::Italy,NCT01984424,Italy,,,,,,,,,,,,,,
country,NCT01984424::country::South Africa,NCT01984424,South Africa,,,,,,,,,,,,,,
country,NCT01984424::country::Australia,NCT01984424,Australia,,,,,,,,,,,,,,
country,NCT01984424::country::Czechia,NCT01984424,Czechia,,,,,,,,,,,,,,
country,NCT01984424::country::France,NCT01984424,France,,,,,,,,,,,,,,
country,NCT01984424::country::Germany,NCT01984424,Germany,,,,,,,,,,,,,,
country,NCT01984424::country::Netherlands,NCT01984424,Netherlands,,,,,,,,,,,,,,
country,NCT01984424::country::United Kingdom,NCT01984424,United Kingdom,,,,,,,,,,,,,,
country,NCT01984424::country::Denmark,NCT01984424,Denmark,,,,,,,,,,,,,,
country,NCT01984424::country::Norway,NCT01984424,Norway,,,,,,,,,,,,,,
country,NCT01984424::country::New Zealand,NCT01984424,New Zealand,,,,,,,,,,,,,,
trial,NCT02833844,NCT02833844,"Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia",PHASE3,dyslipidemia,"Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection",INDUSTRY,467.0,2017-05-22,2020-01-27,15.0,78.0,,,,,
arm,NCT02833844::arm::FG000,NCT02833844,Double-Blind Placebo/Open-Label Evolocumab,,,,,,,,,,FG000,"Double-blind placebo subcutaneous (SC) injection every 4 weeks (QM) for 24 weeks in the double-blind period, followed by open-label evolocumab 420 mg SC QM for 24 weeks in the open-label period.",,,
arm,NCT02833844::arm::FG001,NCT02833844,Double-Blind Evolocumab/Open-Label Evolocumab,,,,,,,,,,FG001,"Double-blind evolocumab SC injection QM for 24 weeks in the double-blind period, followed by open-label evolocumab 420 mg SC QM for 24 weeks in the open-label period.",,,
period,NCT02833844::period::1,NCT02833844,Double-Blind Period,,,,,,,,,,,,1.0,,
period,NCT02833844::period::2,NCT02833844,Open-Label Period,,,,,,,,,,,,2.0,,
outcome,NCT02833844::outcome::primary::1,NCT02833844,Percent Change From Baseline in LDL-C at Week 24,,,,,,,,,,,,,PRIMARY,"Baseline, Week 24"
country,NCT02833844::country::United States,NCT02833844,United States,,,,,,,,,,,,,,
country,NCT02833844::country::France,NCT02833844,France,,,,,,,,,,,,,,
country,NCT02833844::country::Australia,NCT02833844,Australia,,,,,,,,,,,,,,
country,NCT02833844::country::Italy,NCT02833844,Italy,,,,,,,,,,,,,,
country,NCT02833844::country::Canada,NCT02833844,Canada,,,,,,,,,,,,,,
country,NCT02833844::country::Greece,NCT02833844,Greece,,,,,,,,,,,,,,
country,NCT02833844::country::Portugal,NCT02833844,Portugal,,,,,,,,,,,,,,
country,NCT02833844::country::Romania,NCT02833844,Romania,,,,,,,,,,,,,,
country,NCT02833844::country::Spain,NCT02833844,Spain,,,,,,,,,,,,,,
country,NCT02833844::country::Switzerland,NCT02833844,Switzerland,,,,,,,,,,,,,,
country,NCT02833844::country::Belgium,NCT02833844,Belgium,,,,,,,,,,,,,,
country,NCT02833844::country::Brazil,NCT02833844,Brazil,,,,,,,,,,,,,,
country,NCT02833844::country::South Africa,NCT02833844,South Africa,,,,,,,,,,,,,,
country,NCT02833844::country::United Kingdom,NCT02833844,United Kingdom,,,,,,,,,,,,,,
country,NCT02833844::country::Poland,NCT02833844,Poland,,,,,,,,,,,,,,
trial,NCT02463071,NCT02463071,AZD0585 Phase III Long-term Study in Japan,PHASE3,dyslipidemia,Hypertriglyceridemia,INDUSTRY,383.0,2015-06-10,2017-03-11,1.0,26.0,,,,,
arm,NCT02463071::arm::FG000,NCT02463071,AZD0585 2g Group,,,,,,,,,,FG000,AZD0585 1g × 2 capsules and AZD0585 placebo 1g × 2 capsules once daily,,,
arm,NCT02463071::arm::FG001,NCT02463071,AZD0585 4g Group,,,,,,,,,,FG001,AZD0585 1g × 4 capsules once daily,,,
arm,NCT02463071::arm::FG002,NCT02463071,Placebo Control Group,,,,,,,,,,FG002,AZD0585 placebo 1g × 4 capsules once daily,,,
period,NCT02463071::period::1,NCT02463071,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02463071::outcome::primary::1,NCT02463071,Efficacy of AZD0585 by Assessment of Percent Change in Serum Triglycerides,,,,,,,,,,,,,PRIMARY,From baseline to Week12
outcome,NCT02463071::outcome::primary::2,NCT02463071,Safety of AZD0585 by Assessment of Adverse Events in Patients,,,,,,,,,,,,,PRIMARY,From baseline to Week52
country,NCT02463071::country::Japan,NCT02463071,Japan,,,,,,,,,,,,,,
trial,NCT00289900,NCT00289900,Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024),PHASE3,dyslipidemia,Mixed Hyperlipidemia,INDUSTRY,2340.0,2006-01-24,2010-08-06,0.0,0.0,,,,,
arm,NCT00289900::arm::FG000,NCT00289900,MK-0524B 2g/20 mg,,,,,,,,,,FG000,"Co-administration of one tablet of MK-0524A (Extended Release \[ER\] niacin/laropiprant \[LRPT\] 1g + one tablet of simvastatin 10 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g ",,,
arm,NCT00289900::arm::FG001,NCT00289900,MK-0524B 2g/40mg,,,,,,,,,,FG001,"Co-administration of one tablet of MK-0524A 1g + one tablet of simvastatin 20 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 40 mg for 8 weeks",,,
arm,NCT00289900::arm::FG002,NCT00289900,Atorvastatin 10 mg,,,,,,,,,,FG002,"Atorvastatin 10 mg, orally, once daily for 12 weeks",,,
arm,NCT00289900::arm::FG003,NCT00289900,Atorvastatin 20 mg,,,,,,,,,,FG003,"Atorvastatin 20 mg, orally, once daily for 12 weeks",,,
arm,NCT00289900::arm::FG004,NCT00289900,Atorvastatin 40 mg,,,,,,,,,,FG004,"Atorvastatin 40 mg, orally, once daily for 12 weeks",,,
arm,NCT00289900::arm::FG005,NCT00289900,Atorvastatin 80 mg,,,,,,,,,,FG005,"Atorvastatin 80 mg, orally, once daily for 12 weeks",,,
period,NCT00289900::period::1,NCT00289900,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00289900::outcome::primary::1,NCT00289900,Percentage Change From Baseline in the LDL-C/HDL-C Ratio,,,,,,,,,,,,,PRIMARY,Baseline and Week 12
trial,NCT00325780,NCT00325780,Long-Term Extension Study of Pitavastatin in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia,PHASE3,dyslipidemia,Hypercholesterolemia; Dyslipidemia,INDUSTRY,1355.0,2006-07,2007-11,13.0,186.0,,,,,
arm,NCT00325780::arm::FG000,NCT00325780,Pitavastatin 4 mg QD,,,,,,,,,,FG000,Pitavastatin 4 mg once daily,,,
period,NCT00325780::period::1,NCT00325780,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00325780::outcome::primary::1,NCT00325780,Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C),,,,,,,,,,,,,PRIMARY,Baseline to 52 Weeks
country,NCT00325780::country::United Kingdom,NCT00325780,United Kingdom,,,,,,,,,,,,,,
country,NCT00325780::country::Russia,NCT00325780,Russia,,,,,,,,,,,,,,
country,NCT00325780::country::Germany,NCT00325780,Germany,,,,,,,,,,,,,,
country,NCT00325780::country::Netherlands,NCT00325780,Netherlands,,,,,,,,,,,,,,
country,NCT00325780::country::Spain,NCT00325780,Spain,,,,,,,,,,,,,,
country,NCT00325780::country::India,NCT00325780,India,,,,,,,,,,,,,,
country,NCT00325780::country::Italy,NCT00325780,Italy,,,,,,,,,,,,,,
country,NCT00325780::country::Poland,NCT00325780,Poland,,,,,,,,,,,,,,
country,NCT00325780::country::Sweden,NCT00325780,Sweden,,,,,,,,,,,,,,
country,NCT00325780::country::Israel,NCT00325780,Israel,,,,,,,,,,,,,,
country,NCT00325780::country::Denmark,NCT00325780,Denmark,,,,,,,,,,,,,,
country,NCT00325780::country::Finland,NCT00325780,Finland,,,,,,,,,,,,,,
country,NCT00325780::country::Norway,NCT00325780,Norway,,,,,,,,,,,,,,
trial,NCT02662569,NCT02662569,Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia,PHASE3,dyslipidemia,"Diabetes, Hyperlipidemia, Mixed Dyslipidemia",INDUSTRY,986.0,2016-04-14,2017-12-06,10.0,110.0,,,,,
arm,NCT02662569::arm::FG000,NCT02662569,Placebo Q2W,,,,,,,,,,FG000,Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.,,,
arm,NCT02662569::arm::FG001,NCT02662569,Placebo QM,,,,,,,,,,FG001,Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.,,,
arm,NCT02662569::arm::FG002,NCT02662569,Evolocumab Q2W,,,,,,,,,,FG002,Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.,,,
arm,NCT02662569::arm::FG003,NCT02662569,Evolocumab QM,,,,,,,,,,FG003,Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.,,,
period,NCT02662569::period::1,NCT02662569,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02662569::outcome::primary::1,NCT02662569,Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12,,,,,,,,,,,,,PRIMARY,Baseline and weeks 10 and 12
outcome,NCT02662569::outcome::primary::2,NCT02662569,Percent Change From Baseline in LDL-C at Week 12,,,,,,,,,,,,,PRIMARY,Baseline and week 12
country,NCT02662569::country::China,NCT02662569,China,,,,,,,,,,,,,,
country,NCT02662569::country::South Korea,NCT02662569,South Korea,,,,,,,,,,,,,,
country,NCT02662569::country::United States,NCT02662569,United States,,,,,,,,,,,,,,
country,NCT02662569::country::Russia,NCT02662569,Russia,,,,,,,,,,,,,,
country,NCT02662569::country::Canada,NCT02662569,Canada,,,,,,,,,,,,,,
country,NCT02662569::country::Argentina,NCT02662569,Argentina,,,,,,,,,,,,,,
country,NCT02662569::country::Colombia,NCT02662569,Colombia,,,,,,,,,,,,,,
country,NCT02662569::country::Turkey (Türkiye),NCT02662569,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02662569::country::Brazil,NCT02662569,Brazil,,,,,,,,,,,,,,
country,NCT02662569::country::France,NCT02662569,France,,,,,,,,,,,,,,
trial,NCT00276484,NCT00276484,To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090),PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,579.0,2006-02,2008-03,0.0,0.0,,,,,
arm,NCT00276484::arm::FG000,NCT00276484,Atorvastatin + Ezetemibe,,,,,,,,,,FG000,Atorvastatin 40 mg + Ezetemibe 10 mg every day for 6 weeks,,,
arm,NCT00276484::arm::FG001,NCT00276484,Atorvastatin,,,,,,,,,,FG001,Atorvastatin 80 mg every day for 6 weeks,,,
period,NCT00276484::period::1,NCT00276484,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00276484::outcome::primary::1,NCT00276484,Percent Change From Baseline to Week 6 in Low-Density Lipoprotein (LDL)-C,,,,,,,,,,,,,PRIMARY,Baseline and 6 weeks
trial,NCT01350999,NCT01350999,Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia,PHASE3,dyslipidemia,Hypertriglyceridemia,INDUSTRY,503.0,2009-11,2011-01,0.0,0.0,,,,,
arm,NCT01350999::arm::FG000,NCT01350999,TAK-085 2 g,,,,,,,,,,FG000,"TAK-085 2 g capsule, orally, once daily for up to 52 weeks.",,,
arm,NCT01350999::arm::FG001,NCT01350999,TAK-085 4 g,,,,,,,,,,FG001,"TAK-085 2 g capsules, orally, twice daily for up to 52 weeks.",,,
arm,NCT01350999::arm::FG002,NCT01350999,EPA-E 1.8 g,,,,,,,,,,FG002,"Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 52 weeks.",,,
period,NCT01350999::period::1,NCT01350999,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01350999::outcome::primary::1,NCT01350999,Number of Participants With Treatment Emergent Adverse Events (TEAEs),,,,,,,,,,,,,PRIMARY,52 Weeks
outcome,NCT01350999::outcome::primary::2,NCT01350999,Number of Participants With TEAEs Associated With Abnormal Changes in Vital Signs,,,,,,,,,,,,,PRIMARY,52 Weeks
outcome,NCT01350999::outcome::primary::3,NCT01350999,Number of Participants With TEAEs Associated With Abnormal Changes in Body Weight,,,,,,,,,,,,,PRIMARY,52 Weeks
outcome,NCT01350999::outcome::primary::4,NCT01350999,Number of Participants With Clinically Significant Findings in Electrocardiogram After Study Drug Administration,,,,,,,,,,,,,PRIMARY,52 Weeks
outcome,NCT01350999::outcome::primary::5,NCT01350999,"Number of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Chemistry, Hematology or Urinalysis",,,,,,,,,,,,,PRIMARY,52 Weeks
trial,NCT00435045,NCT00435045,"Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia",PHASE3,dyslipidemia,Hypertriglyceridemia,INDUSTRY,245.0,2007-02,2007-10,0.0,0.0,,,,,
arm,NCT00435045::arm::FG000,NCT00435045,Lovaza(Omacor) + Atorvastatin,,,,,,,,,,FG000,"Subjects who met all study requirements after screening visit and who were randomized to receive 4 gms Lovaza (Omega-3-acid ethyl esters) + Atorvastatin 10 mgs for 8 weeks, then 4 gms Lovaza + Atorvas",,,
arm,NCT00435045::arm::FG001,NCT00435045,Placebo + Atorvastatin,,,,,,,,,,FG001,"Subjects who met all study requirements after screening visit and who were randomized to receive Placebo + Atorvastatin 10 mgs for 8 weeks, then Placebo + Atorvastatin 20 mgs for 4 weeks, then Placebo",,,
period,NCT00435045::period::1,NCT00435045,Weeks 1-8 / 10 mg Dose Level,,,,,,,,,,,,1.0,,
period,NCT00435045::period::2,NCT00435045,Weeks 9-12 / 20mg Dose Level,,,,,,,,,,,,2.0,,
period,NCT00435045::period::3,NCT00435045,Weeks 13-16 / 40mg Dose Level,,,,,,,,,,,,3.0,,
outcome,NCT00435045::outcome::primary::1,NCT00435045,Percent Change in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period,,,,,,,,,,,,,PRIMARY,Baseline and Week 8
trial,NCT03001817,NCT03001817,Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function,PHASE3,dyslipidemia,Severe Hypertriglyceridemia,INDUSTRY,551.0,2016-11-28,2019-06-24,9.0,220.0,,,,,
arm,NCT03001817::arm::FG000,NCT03001817,K-877,,,,,,,,,,FG000,Participants randomized to receive K-877 0.2 mg tablets twice daily in the 12-week Efficacy Period continued to receive K-877 0.2 mg tablets twice daily (BID) as well as placebo matching fenofibrate t,,,
arm,NCT03001817::arm::FG001,NCT03001817,Placebo/Fenofibrate,,,,,,,,,,FG001,Participants randomized to receive placebo matching K-877 0.2 mg tablets BID in the 12-week Efficacy Period received fenofibrate 145 mg tablet once daily and placebo matching K-877 0.2 mg tablet BID i,,,
period,NCT03001817::period::1,NCT03001817,12 Week Efficacy,,,,,,,,,,,,1.0,,
period,NCT03001817::period::2,NCT03001817,40 Week Extension,,,,,,,,,,,,2.0,,
outcome,NCT03001817::outcome::primary::1,NCT03001817,Percent Change of Fasting Triglyceride(TG) Levels From Baseline to Week 12,,,,,,,,,,,,,PRIMARY,12 Weeks
country,NCT03001817::country::United States,NCT03001817,United States,,,,,,,,,,,,,,
country,NCT03001817::country::Russia,NCT03001817,Russia,,,,,,,,,,,,,,
country,NCT03001817::country::Ukraine,NCT03001817,Ukraine,,,,,,,,,,,,,,
country,NCT03001817::country::Poland,NCT03001817,Poland,,,,,,,,,,,,,,
country,NCT03001817::country::Belarus,NCT03001817,Belarus,,,,,,,,,,,,,,
country,NCT03001817::country::Bulgaria,NCT03001817,Bulgaria,,,,,,,,,,,,,,
country,NCT03001817::country::Hungary,NCT03001817,Hungary,,,,,,,,,,,,,,
country,NCT03001817::country::Czechia,NCT03001817,Czechia,,,,,,,,,,,,,,
country,NCT03001817::country::Georgia,NCT03001817,Georgia,,,,,,,,,,,,,,
trial,NCT01954394,NCT01954394,Open Label Study of Long Term Safety Evaluation of Alirocumab,PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,986.0,2013-12-17,2017-06-30,24.0,177.0,,,,,
arm,NCT01954394::arm::FG000,NCT01954394,Placebo to Alirocumab 75 or 150 mg Q2W,,,,,,,,,,FG000,Alirocumab 75 mg or 150 mg subcutaneous (SC) injection every 2 weeks (Q2W) added to stable lipid-modifying therapy (LMT) for up to 168 weeks in participants who received placebo in the parent studies.,,,
arm,NCT01954394::arm::FG001,NCT01954394,Alirocumab to Alirocumab 75 or 150 mg Q2W,,,,,,,,,,FG001,Alirocumab 75 mg or 150 mg SC injection Q2W added to stable LMT for up to 168 additional weeks in participants who received Alirocumab in the parent studies. Participants from parent study EFC12732 (N,,,
period,NCT01954394::period::1,NCT01954394,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01954394::outcome::primary::1,NCT01954394,Percentage of Participants Who Experienced Adverse Events (AEs),,,,,,,,,,,,,PRIMARY,Up to 10 weeks after last study drug administration (maximum of 176 weeks)
country,NCT01954394::country::United States,NCT01954394,United States,,,,,,,,,,,,,,
country,NCT01954394::country::Netherlands,NCT01954394,Netherlands,,,,,,,,,,,,,,
country,NCT01954394::country::Spain,NCT01954394,Spain,,,,,,,,,,,,,,
country,NCT01954394::country::United Kingdom,NCT01954394,United Kingdom,,,,,,,,,,,,,,
country,NCT01954394::country::South Africa,NCT01954394,South Africa,,,,,,,,,,,,,,
country,NCT01954394::country::Russia,NCT01954394,Russia,,,,,,,,,,,,,,
country,NCT01954394::country::Czechia,NCT01954394,Czechia,,,,,,,,,,,,,,
country,NCT01954394::country::Canada,NCT01954394,Canada,,,,,,,,,,,,,,
country,NCT01954394::country::France,NCT01954394,France,,,,,,,,,,,,,,
country,NCT01954394::country::Denmark,NCT01954394,Denmark,,,,,,,,,,,,,,
country,NCT01954394::country::Germany,NCT01954394,Germany,,,,,,,,,,,,,,
country,NCT01954394::country::Israel,NCT01954394,Israel,,,,,,,,,,,,,,
country,NCT01954394::country::Italy,NCT01954394,Italy,,,,,,,,,,,,,,
country,NCT01954394::country::Austria,NCT01954394,Austria,,,,,,,,,,,,,,
country,NCT01954394::country::Finland,NCT01954394,Finland,,,,,,,,,,,,,,
country,NCT01954394::country::Norway,NCT01954394,Norway,,,,,,,,,,,,,,
country,NCT01954394::country::Sweden,NCT01954394,Sweden,,,,,,,,,,,,,,
country,NCT01954394::country::Argentina,NCT01954394,Argentina,,,,,,,,,,,,,,
country,NCT01954394::country::Bulgaria,NCT01954394,Bulgaria,,,,,,,,,,,,,,
country,NCT01954394::country::Portugal,NCT01954394,Portugal,,,,,,,,,,,,,,
country,NCT01954394::country::Belgium,NCT01954394,Belgium,,,,,,,,,,,,,,
country,NCT01954394::country::Hungary,NCT01954394,Hungary,,,,,,,,,,,,,,
country,NCT01954394::country::Mexico,NCT01954394,Mexico,,,,,,,,,,,,,,
country,NCT01954394::country::Romania,NCT01954394,Romania,,,,,,,,,,,,,,
trial,NCT01763827,NCT01763827,Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2,PHASE3,dyslipidemia,Hyperlipidemia,INDUSTRY,615.0,2013-01-21,2013-10-29,10.0,83.0,,,,,
arm,NCT01763827::arm::FG000,NCT01763827,Placebo Q2W,,,,,,,,,,FG000,Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.,,,
arm,NCT01763827::arm::FG001,NCT01763827,Placebo QM,,,,,,,,,,FG001,Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.,,,
arm,NCT01763827::arm::FG002,NCT01763827,Ezetimibe (Q2W),,,,,,,,,,FG002,Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.,,,
arm,NCT01763827::arm::FG003,NCT01763827,Ezetimibe (QM),,,,,,,,,,FG003,Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.,,,
arm,NCT01763827::arm::FG004,NCT01763827,Evolocumab Q2W,,,,,,,,,,FG004,Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.,,,
arm,NCT01763827::arm::FG005,NCT01763827,Evolocumab QM,,,,,,,,,,FG005,Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.,,,
period,NCT01763827::period::1,NCT01763827,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01763827::outcome::primary::1,NCT01763827,Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12,,,,,,,,,,,,,PRIMARY,Baseline and Week 12
outcome,NCT01763827::outcome::primary::2,NCT01763827,Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12,,,,,,,,,,,,,PRIMARY,Baseline and Weeks 10 and 12
country,NCT01763827::country::United States,NCT01763827,United States,,,,,,,,,,,,,,
country,NCT01763827::country::Belgium,NCT01763827,Belgium,,,,,,,,,,,,,,
country,NCT01763827::country::South Africa,NCT01763827,South Africa,,,,,,,,,,,,,,
country,NCT01763827::country::Australia,NCT01763827,Australia,,,,,,,,,,,,,,
country,NCT01763827::country::Canada,NCT01763827,Canada,,,,,,,,,,,,,,
country,NCT01763827::country::Denmark,NCT01763827,Denmark,,,,,,,,,,,,,,
country,NCT01763827::country::South Korea,NCT01763827,South Korea,,,,,,,,,,,,,,
country,NCT01763827::country::Taiwan,NCT01763827,Taiwan,,,,,,,,,,,,,,
country,NCT01763827::country::France,NCT01763827,France,,,,,,,,,,,,,,
country,NCT01763827::country::Turkey (Türkiye),NCT01763827,Turkey (Türkiye),,,,,,,,,,,,,,
trial,NCT01624142,NCT01624142,Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders,PHASE3,dyslipidemia,Severe Familial Hypercholesterolemia,INDUSTRY,300.0,2012-06-01,2018-05-11,18.0,44.0,,,,,
arm,NCT01624142::arm::FG000,NCT01624142,HoFH,,,,,,,,,,FG000,Participants with homozygous familial hypercholesterolemia (HoFH) received 420 mg evolocumab every month (participants not on lipid apheresis) or every 2 weeks (participants on lipid apheresis) for up,,,
arm,NCT01624142::arm::FG001,NCT01624142,Severe FH,,,,,,,,,,FG001,Participants with severe (non-HoFH) familial hypercholesterolemia (FH) received 420 mg evolocumab every month (participants not on lipid apheresis) or every 2 weeks (participants on lipid apheresis) f,,,
period,NCT01624142::period::1,NCT01624142,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01624142::outcome::primary::1,NCT01624142,Number of Participants With Adverse Events,,,,,,,,,,,,,PRIMARY,"From first dose of study drug in Study 20110271 up to 30 days after the last dose or until the end of study date, whichever was earlier"
country,NCT01624142::country::United States,NCT01624142,United States,,,,,,,,,,,,,,
country,NCT01624142::country::Canada,NCT01624142,Canada,,,,,,,,,,,,,,
country,NCT01624142::country::Czechia,NCT01624142,Czechia,,,,,,,,,,,,,,
country,NCT01624142::country::Spain,NCT01624142,Spain,,,,,,,,,,,,,,
country,NCT01624142::country::Italy,NCT01624142,Italy,,,,,,,,,,,,,,
country,NCT01624142::country::Australia,NCT01624142,Australia,,,,,,,,,,,,,,
country,NCT01624142::country::Belgium,NCT01624142,Belgium,,,,,,,,,,,,,,
country,NCT01624142::country::Brazil,NCT01624142,Brazil,,,,,,,,,,,,,,
country,NCT01624142::country::France,NCT01624142,France,,,,,,,,,,,,,,
country,NCT01624142::country::Japan,NCT01624142,Japan,,,,,,,,,,,,,,
country,NCT01624142::country::Netherlands,NCT01624142,Netherlands,,,,,,,,,,,,,,
country,NCT01624142::country::South Africa,NCT01624142,South Africa,,,,,,,,,,,,,,
country,NCT01624142::country::Greece,NCT01624142,Greece,,,,,,,,,,,,,,
country,NCT01624142::country::Hong Kong,NCT01624142,Hong Kong,,,,,,,,,,,,,,
country,NCT01624142::country::Israel,NCT01624142,Israel,,,,,,,,,,,,,,
country,NCT01624142::country::Lebanon,NCT01624142,Lebanon,,,,,,,,,,,,,,
country,NCT01624142::country::New Zealand,NCT01624142,New Zealand,,,,,,,,,,,,,,
country,NCT01624142::country::United Kingdom,NCT01624142,United Kingdom,,,,,,,,,,,,,,
trial,NCT01047683,NCT01047683,Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL,PHASE3,dyslipidemia,Hypertriglyceridemia,INDUSTRY,229.0,2009-12,2011-07,11.0,60.0,,,,,
arm,NCT01047683::arm::FG000,NCT01047683,Placebo,,,,,,,,,,FG000,Placebo: Placebo 4 capsules/day for 12 weeks (Weeks 1-12),,,
arm,NCT01047683::arm::FG001,NCT01047683,AMR101 (Ethyl Icosapentate) - 2 g/Day,,,,,,,,,,FG001,AMR101 (ethyl icosapentate) - 2 g/day: AMR101 (ethyl icosapentate) 2 capsules/day with placebo 2 capsules/day for 12 weeks (Weeks 1-12),,,
arm,NCT01047683::arm::FG002,NCT01047683,AMR101 (Ethyl Icosapentate) - 4 g/Day,,,,,,,,,,FG002,AMR101 (ethyl icosapentate) - 4 g/day: AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks (Weeks 1-12),,,
period,NCT01047683::period::1,NCT01047683,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01047683::outcome::primary::1,NCT01047683,Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Triglyceride Lowering Effect,,,,,,,,,,,,,PRIMARY,baseline and 12 weeks
country,NCT01047683::country::United States,NCT01047683,United States,,,,,,,,,,,,,,
country,NCT01047683::country::India,NCT01047683,India,,,,,,,,,,,,,,
country,NCT01047683::country::Germany,NCT01047683,Germany,,,,,,,,,,,,,,
country,NCT01047683::country::South Africa,NCT01047683,South Africa,,,,,,,,,,,,,,
country,NCT01047683::country::Netherlands,NCT01047683,Netherlands,,,,,,,,,,,,,,
country,NCT01047683::country::Russia,NCT01047683,Russia,,,,,,,,,,,,,,
country,NCT01047683::country::Mexico,NCT01047683,Mexico,,,,,,,,,,,,,,
country,NCT01047683::country::Ukraine,NCT01047683,Ukraine,,,,,,,,,,,,,,
country,NCT01047683::country::Denmark,NCT01047683,Denmark,,,,,,,,,,,,,,
country,NCT01047683::country::Italy,NCT01047683,Italy,,,,,,,,,,,,,,
country,NCT01047683::country::Finland,NCT01047683,Finland,,,,,,,,,,,,,,
trial,NCT00479882,NCT00479882,MK-0524B Lipid Study (MK-0524B-063),PHASE3,dyslipidemia,Primary Hypercholesterolemia; Mixed Dyslipidemia,INDUSTRY,2414.0,2007-06-15,2008-06-16,0.0,0.0,,,,,
arm,NCT00479882::arm::FG000,NCT00479882,Sequence 1: MK-0524B 1.8g/20mg→MK-0524A 2g+Simvastatin 20mg,,,,,,,,,,FG000,"After a 2-week placebo run-in, participants will receive MK-0524B (0.9 g/simvastatin 10 mg) for 4 weeks, then MK-0524B 1.8g /20 mg combination tablet for 8 weeks. Participant is then co-administered M",,,
arm,NCT00479882::arm::FG001,NCT00479882,Sequence 2: MK-0524A 2g+Simvastatin 20mg →MK-0524B 1.8g/20mg,,,,,,,,,,FG001,"After a 2-week placebo run-in, participants will be co-administered MK-0524A 1g + simvastatin 10 mg for 4 weeks, then co-administered MK-0524A 2g +simvastatin 20 mg for 8 weeks. Participant then recei",,,
arm,NCT00479882::arm::FG002,NCT00479882,Sequence 3: MK-0524B 1.8g/40mg→MK-0524A 2g+Simvastatin 40mg,,,,,,,,,,FG002,"After a 2-week placebo run-in, participants will receive MK-0524B 0.9g/40 mg combination tablet for 4 weeks, then MK-0524B 1.8g /40 mg combination tablet for 8 weeks. Participant is then co-administer",,,
arm,NCT00479882::arm::FG003,NCT00479882,Sequence 4: MK-0524A 2g+Simvastatin 40mg →MK-0524B 1.8g/40mg,,,,,,,,,,FG003,"After a 2-week placebo run-in, participants will be co-administered MK-0524A 1g + simvastatin 40 mg for 4 weeks, then co-administration MK-0524A 2g +simvastatin 40 mg for 8 weeks. Participant then rec",,,
period,NCT00479882::period::1,NCT00479882,Precrossover: Periods I/II (Weeks 1-12),,,,,,,,,,,,1.0,,
period,NCT00479882::period::2,NCT00479882,Crossover: Period III (Weeks 13-20),,,,,,,,,,,,2.0,,
outcome,NCT00479882::outcome::primary::1,NCT00479882,Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C),,,,,,,,,,,,,PRIMARY,Baseline (Week 4 for Period II
trial,NCT03397121,NCT03397121,Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH),PHASE3,dyslipidemia,Heterozygous Familial Hypercholesterolemia; Elevated Cholesterol,INDUSTRY,482.0,2017-11-28,2019-09-17,8.0,45.0,,,,,
arm,NCT03397121::arm::FG000,NCT03397121,Inclisiran,,,,,,,,,,FG000,"Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection on Day 1, Day 90 then every 6 months.

Inclisiran: Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits P",,,
arm,NCT03397121::arm::FG001,NCT03397121,Placebo,,,,,,,,,,FG001,"Placebo will be administered as SC injections of saline solution on Day 1, Day 90 then every 6 months.

Placebo: Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for in",,,
period,NCT03397121::period::1,NCT03397121,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03397121::outcome::primary::1,NCT03397121,Percent Change in LDL-C From Baseline To Day 510,,,,,,,,,,,,,PRIMARY,"Baseline, Day 510"
outcome,NCT03397121::outcome::primary::2,NCT03397121,Time-adjusted Percent Change in LDL-C From Baseline After Day 90 and up to Day 540,,,,,,,,,,,,,PRIMARY,"Baseline, Day 90"
country,NCT03397121::country::United States,NCT03397121,United States,,,,,,,,,,,,,,
country,NCT03397121::country::South Africa,NCT03397121,South Africa,,,,,,,,,,,,,,
country,NCT03397121::country::Denmark,NCT03397121,Denmark,,,,,,,,,,,,,,
country,NCT03397121::country::Spain,NCT03397121,Spain,,,,,,,,,,,,,,
country,NCT03397121::country::Netherlands,NCT03397121,Netherlands,,,,,,,,,,,,,,
country,NCT03397121::country::Canada,NCT03397121,Canada,,,,,,,,,,,,,,
country,NCT03397121::country::Czechia,NCT03397121,Czechia,,,,,,,,,,,,,,
country,NCT03397121::country::Sweden,NCT03397121,Sweden,,,,,,,,,,,,,,
trial,NCT00626392,NCT00626392,Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia,PHASE3,dyslipidemia,Dyslipidemia,INDUSTRY,277.0,2008-02,2008-04,1.0,26.0,,,,,
arm,NCT00626392::arm::FG000,NCT00626392,"NER 500; ASA run-in, ASA Coadmin",,,,,,,,,,FG000,"Aspirin (ASA) 325 mg daily during run-in (1 week); ASA 325 mg 30 min prior to niacin extended-release (\[NER\], 500 mg starting dose), daily during coadministration (4 weeks)",,,
arm,NCT00626392::arm::FG001,NCT00626392,"NER 500; ASA Pbo run-in, ASA Coadmin",,,,,,,,,,FG001,"Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA 325 mg 30 min prior to niacin extended-release (\[NER\], 500 mg starting dose), daily during coadministration (4 weeks)",,,
arm,NCT00626392::arm::FG002,NCT00626392,"NER 500; ASA Pbo run-in, ASA Pbo Coadmin",,,,,,,,,,FG002,"Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA Pbo 30 min prior to niacin extended-release (\[NER\], 500 mg starting dose), daily during coadministration (4 weeks)",,,
arm,NCT00626392::arm::FG003,NCT00626392,NER 1000; ASA run-in; ASA Coadmin,,,,,,,,,,FG003,"Aspirin (ASA) 325 mg daily during run-in (1 week); ASA 325 mg 30 min prior to niacin extended-release (\[NER\], 1000 mg starting dose), daily during coadministration (4 weeks)",,,
arm,NCT00626392::arm::FG004,NCT00626392,"NER 1000; ASA Pbo run-in, ASA Coadmin",,,,,,,,,,FG004,"Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA 325 mg 30 min prior to niacin extended-release (\[NER\], 1000 mg starting dose), daily during coadministration (4 weeks)",,,
arm,NCT00626392::arm::FG005,NCT00626392,"NER 1000; ASA Pbo run-in, ASA Pbo Coadmin",,,,,,,,,,FG005,"Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA Pbo 30 min prior to niacin extended-release (\[NER\], 1000 mg starting dose), daily during coadministration (4 weeks)",,,
period,NCT00626392::period::1,NCT00626392,Run-in Period,,,,,,,,,,,,1.0,,
period,NCT00626392::period::2,NCT00626392,Coadministration Period,,,,,,,,,,,,2.0,,
outcome,NCT00626392::outcome::primary::1,NCT00626392,Maximum Severity of Flushing Events During Week 1 of Niacin Extended-release (NER) Treatment,,,,,,,,,,,,,PRIMARY,From Baseline to end of Week 1
country,NCT00626392::country::United States,NCT00626392,United States,,,,,,,,,,,,,,
trial,NCT01350973,NCT01350973,Efficacy of TAK-085 in Participants With Hypertriglyceridemia,PHASE3,dyslipidemia,Hypertriglyceridemia,INDUSTRY,611.0,2009-11,2010-12,0.0,0.0,,,,,
arm,NCT01350973::arm::FG000,NCT01350973,TAK-085 2 g,,,,,,,,,,FG000,"TAK-085 2 g, orally, once daily for up to 12 weeks.",,,
arm,NCT01350973::arm::FG001,NCT01350973,TAK-085 4 g,,,,,,,,,,FG001,"TAK-085 2 g, orally, twice daily for up to 12 weeks.",,,
arm,NCT01350973::arm::FG002,NCT01350973,EPA-E 1.8 g,,,,,,,,,,FG002,"Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 12 weeks.",,,
period,NCT01350973::period::1,NCT01350973,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01350973::outcome::primary::1,NCT01350973,Percent Change From Baseline in Triglyceride Level at the Final Visit,,,,,,,,,,,,,PRIMARY,Baseline and 12 weeks
trial,NCT00858637,NCT00858637,Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis,PHASE3,dyslipidemia,Chronic Kidney Disease,INDUSTRY,260.0,2009-03,2010-03,13.0,39.0,,,,,
arm,NCT00858637::arm::FG000,NCT00858637,MCI-196 (Active) + Simvastatin (Placebo)/ Comparison Phase,,,,,,,,,,FG000,"Active Comparison Phase: 3, 6, 9, 12g of MCI-196 / day as titrated

* There was a gap of 1 subject between ""STARTED"" and ""Overall Number of Baseline Participants"".
* One subject (A) was randomised to ",,,
arm,NCT00858637::arm::FG001,NCT00858637,MCI-196 (Active) + Simvastin (Placebo)/ Withdrawal Phase,,,,,,,,,,FG001,Placebo-controlled Withdrawal Phase: dose level at the end of dose titration in the flexible dose period,,,
arm,NCT00858637::arm::FG002,NCT00858637,MCI-196 (Placebo) + Simvastin (Placebo)/ Withdrawal Phase,,,,,,,,,,FG002,Placebo-controlled Withdrawal Phase: dose level at the end of dose titration in the flexible dose period,,,
arm,NCT00858637::arm::FG003,NCT00858637,Simvastatin (Active) + MCI-196 (Placebo)/ Comparion Phase,,,,,,,,,,FG003,"Active Comparison Phase: 10 mg to 40 mg of Simvastatin / day as titrated

* There was a gap of 2 subject between ""STARTED"" and ""Overall Number of Baseline Participants"".
* One subject did not take any",,,
arm,NCT00858637::arm::FG004,NCT00858637,Simvastin (Active) + MCI-196 (Placebo)/ Withdrawal Phase,,,,,,,,,,FG004,Placebo-controlled Withdrawal Phase: dose level at the end of dose titration in the flexible dose period,,,
arm,NCT00858637::arm::FG005,NCT00858637,Simvastin (Placebo) + MCI-196 (Placebo)/ Withdrawal Phase,,,,,,,,,,FG005,Placebo-controlled Withdrawal Phase: dose level at the end of dose titration in the flexible dose period,,,
period,NCT00858637::period::1,NCT00858637,Active Comparison Phase,,,,,,,,,,,,1.0,,
period,NCT00858637::period::2,NCT00858637,Placebo-controlled Withdrawal Phase,,,,,,,,,,,,2.0,,
outcome,NCT00858637::outcome::primary::1,NCT00858637,Percent Change in Serum LDL-cholesterol Levels From Week 16 to Week 20 (LOCF) (ITT2),,,,,,,,,,,,,PRIMARY,week20 minus week16
country,NCT00858637::country::Italy,NCT00858637,Italy,,,,,,,,,,,,,,
country,NCT00858637::country::Belarus,NCT00858637,Belarus,,,,,,,,,,,,,,
country,NCT00858637::country::Indonesia,NCT00858637,Indonesia,,,,,,,,,,,,,,
country,NCT00858637::country::Malaysia,NCT00858637,Malaysia,,,,,,,,,,,,,,
country,NCT00858637::country::Bulgaria,NCT00858637,Bulgaria,,,,,,,,,,,,,,
country,NCT00858637::country::Lithuania,NCT00858637,Lithuania,,,,,,,,,,,,,,
country,NCT00858637::country::Croatia,NCT00858637,Croatia,,,,,,,,,,,,,,
country,NCT00858637::country::Denmark,NCT00858637,Denmark,,,,,,,,,,,,,,
country,NCT00858637::country::Israel,NCT00858637,Israel,,,,,,,,,,,,,,
country,NCT00858637::country::Latvia,NCT00858637,Latvia,,,,,,,,,,,,,,
country,NCT00858637::country::Romania,NCT00858637,Romania,,,,,,,,,,,,,,
country,NCT00858637::country::Thailand,NCT00858637,Thailand,,,,,,,,,,,,,,
country,NCT00858637::country::Singapore,NCT00858637,Singapore,,,,,,,,,,,,,,
trial,NCT01710007,NCT01710007,Efficacy and Safety Study of Pitavastatin for Hypercholesterolemia,PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,202.0,2011-11,2012-11,1.0,8.0,,,,,
arm,NCT01710007::arm::FG000,NCT01710007,1PC002,,,,,,,,,,FG000,"2 mg 1PC002 once daily for 12 weeks.

1PC002: Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedt",,,
arm,NCT01710007::arm::FG001,NCT01710007,Lipitor,,,,,,,,,,FG001,"10 mg atorvastatin once daily for 12 weeks.

Lipitor: Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration bef",,,
period,NCT01710007::period::1,NCT01710007,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01710007::outcome::primary::1,NCT01710007,The Percentage Change From Baseline in LDL-C Level at Week 12.,,,,,,,,,,,,,PRIMARY,12 weeks
country,NCT01710007::country::Taiwan,NCT01710007,Taiwan,,,,,,,,,,,,,,
trial,NCT00463606,NCT00463606,A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia,PHASE3,dyslipidemia,Hypercholesterolemia; Dyslipidemia,INDUSTRY,760.0,2007-04,2008-02,1.0,168.0,,,,,
arm,NCT00463606::arm::FG000,NCT00463606,ABT-335 and Rosuvastatin Calcium,,,,,,,,,,FG000,"ABT-335 135 mg in combination with rosuvastatin calcium 5 mg administered orally, once daily for 12 weeks",,,
arm,NCT00463606::arm::FG001,NCT00463606,ABT-335,,,,,,,,,,FG001,"ABT-335 135 mg monotherapy administered orally, once daily for 12 weeks",,,
arm,NCT00463606::arm::FG002,NCT00463606,Rosuvastatin Calcium,,,,,,,,,,FG002,"Rosuvastatin calcium 5 mg monotherapy administered orally, once daily for 12 weeks",,,
period,NCT00463606::period::1,NCT00463606,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00463606::outcome::primary::1,NCT00463606,Mean Percent Change From Baseline to the Final Visit in High-density Lipoprotein Cholesterol (HDL-C) (Full Analysis Set),,,,,,,,,,,,,PRIMARY,Baseline to 12 Weeks
outcome,NCT00463606::outcome::primary::2,NCT00463606,Mean Percent Change From Baseline to the Final Visit in Triglycerides (Full Analysis Set),,,,,,,,,,,,,PRIMARY,Baseline to 12 Weeks
outcome,NCT00463606::outcome::primary::3,NCT00463606,Mean Percent Change From Baseline to the Final Visit in Low-density Lipoprotein Cholesterol (LDL-C) (Full Analysis Set),,,,,,,,,,,,,PRIMARY,Baseline to 12 Weeks
country,NCT00463606::country::United States,NCT00463606,United States,,,,,,,,,,,,,,
trial,NCT00827606,NCT00827606,Atorvastatin Three Year Pediatric Study,PHASE3,dyslipidemia,Familial Hypercholesterolemia,INDUSTRY,272.0,2009-03,2013-10,15.0,40.0,,,,,
arm,NCT00827606::arm::FG000,NCT00827606,Atorvastatin (5-80 mg): Tanner_Stage 1,,,,,,,,,,FG000,"Participants aged 6 to less than (\<)10 years, at Tanner\_Stage 1 received an initial dose of atorvastatin tablets, 5 milligrams per day (mg/day), orally (PO), through Week 4; after Week 4, dose may h",,,
arm,NCT00827606::arm::FG001,NCT00827606,Atorvastatin (10-80 mg): Tanner_Stage 2+,,,,,,,,,,FG001,"Participants aged greater than or equal to (≥) 10 to 15 years, at Tanner\_Stage 2+ received an initial dose of atorvastatin tablets, 10 mg/day, PO, through Week 4; after Week 4, dose may have been dou",,,
period,NCT00827606::period::1,NCT00827606,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00827606::outcome::primary::1,NCT00827606,Low Density Lipoprotein Cholesterol (LDL-C,,,,,,,,,,,,,PRIMARY,"Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36 (or early termination [ET])"
outcome,NCT00827606::outcome::primary::2,NCT00827606,Millimoles Per Liter [mMol/L]) During the Study,,,,,,,,,,,,,PRIMARY,"Months 1, 2, 3, 6, 12, 18, 24, 30 and 36 (or ET)"
outcome,NCT00827606::outcome::primary::3,NCT00827606,Percent Change From Baseline in LDL-C,,,,,,,,,,,,,PRIMARY,"Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::4,NCT00827606,High-Density Lipoprotein Cholesterol (HDL-C,,,,,,,,,,,,,PRIMARY,"Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::5,NCT00827606,mMol/L) During the Study,,,,,,,,,,,,,PRIMARY,"Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::6,NCT00827606,Percent Change From Baseline in HDL-C,,,,,,,,,,,,,PRIMARY,"Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::7,NCT00827606,Total Cholesterol (mMol/L) During the Study,,,,,,,,,,,,,PRIMARY,"Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::8,NCT00827606,Percent Change From Baseline in Total Cholesterol,,,,,,,,,,,,,PRIMARY,"Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::9,NCT00827606,Trigylcerides (mMol/L) During the Study,,,,,,,,,,,,,PRIMARY,"Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::10,NCT00827606,Percent Change From Baseline in Trigylcerides,,,,,,,,,,,,,PRIMARY,"Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::11,NCT00827606,Very Low-Density Lipoprotein (VLDL,,,,,,,,,,,,,PRIMARY,"Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::12,NCT00827606,mMol/L) During the Study,,,,,,,,,,,,,PRIMARY,"Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::13,NCT00827606,Percent Change From Baseline in VLDL,,,,,,,,,,,,,PRIMARY,"Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::14,NCT00827606,Apoliprotein A-1 (Apo A-1,,,,,,,,,,,,,PRIMARY,"Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::15,NCT00827606,Grams Per Liter [g/L]) During the Study,,,,,,,,,,,,,PRIMARY,"Baseline, Months 6, 12, 18, 24, 30, and 36/ET"
outcome,NCT00827606::outcome::primary::16,NCT00827606,Percent Change From Baseline in Apo A-1,,,,,,,,,,,,,PRIMARY,"Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::17,NCT00827606,Apoliprotein B (Apo B,,,,,,,,,,,,,PRIMARY,"Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::18,NCT00827606,g/L) During the Study,,,,,,,,,,,,,PRIMARY,"Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::19,NCT00827606,Percent Change From Baseline in Apo B,,,,,,,,,,,,,PRIMARY,"Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::20,NCT00827606,Number of Participants With Shift From Baseline in Tanner_Stage by Timepoint and Baseline Tanner_Stage,,,,,,,,,,,,,PRIMARY,"Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::21,NCT00827606,Height (Centimeters [cm]) During the Study: Males,,,,,,,,,,,,,PRIMARY,"Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::22,NCT00827606,Percent Change From Baseline in Height: Males,,,,,,,,,,,,,PRIMARY,"Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::23,NCT00827606,Height (cm) During the Study: Females,,,,,,,,,,,,,PRIMARY,"Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::24,NCT00827606,Percent Change From Baseline in Height: Females,,,,,,,,,,,,,PRIMARY,"Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::25,NCT00827606,Weight (Kilograms [kg]) During the Study: Males,,,,,,,,,,,,,PRIMARY,"Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::26,NCT00827606,Percent Change From Baseline in Weight: Males,,,,,,,,,,,,,PRIMARY,"Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::27,NCT00827606,Weight (kg) During the Study: Females,,,,,,,,,,,,,PRIMARY,"Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::28,NCT00827606,Percent Change From Baseline in Weight: Females,,,,,,,,,,,,,PRIMARY,"Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::29,NCT00827606,Body Mass Index (BMI in kg Per Square Meter [kg/m^2]) During the Study: Males,,,,,,,,,,,,,PRIMARY,"Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::30,NCT00827606,Percent Change From Baseline in BMI: Males,,,,,,,,,,,,,PRIMARY,"Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::31,NCT00827606,BMI (kg/m^2) During the Study: Females,,,,,,,,,,,,,PRIMARY,"Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::32,NCT00827606,Percent Change From Baseline in BMI: Females,,,,,,,,,,,,,PRIMARY,"Baseline, Months 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::33,NCT00827606,Age (Years) During the Study: Males,,,,,,,,,,,,,PRIMARY,"Months 6, 12, 18, 24, 30 and 36/ET"
outcome,NCT00827606::outcome::primary::34,NCT00827606,Percent Change From Baseline in Age: Males,,,,,,,,,,,,,PRIMARY,
outcome,NCT00827606::outcome::primary::35,NCT00827606,Age (Years) During the Study: Females,,,,,,,,,,,,,PRIMARY,
outcome,NCT00827606::outcome::primary::36,NCT00827606,Percent Change From Baseline in Age: Females,,,,,,,,,,,,,PRIMARY,
outcome,NCT00827606::outcome::primary::37,NCT00827606,Flow-Mediated Dilatation (FMD) During the Study,,,,,,,,,,,,,PRIMARY,
outcome,NCT00827606::outcome::primary::38,NCT00827606,Percent Change From Baseline in FMD,,,,,,,,,,,,,PRIMARY,
country,NCT00827606::country::United States,NCT00827606,United States,,,,,,,,,,,,,,
country,NCT00827606::country::Slovakia,NCT00827606,Slovakia,,,,,,,,,,,,,,
country,NCT00827606::country::Spain,NCT00827606,Spain,,,,,,,,,,,,,,
country,NCT00827606::country::Russia,NCT00827606,Russia,,,,,,,,,,,,,,
country,NCT00827606::country::Turkey (Türkiye),NCT00827606,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00827606::country::Belgium,NCT00827606,Belgium,,,,,,,,,,,,,,
country,NCT00827606::country::Canada,NCT00827606,Canada,,,,,,,,,,,,,,
country,NCT00827606::country::Germany,NCT00827606,Germany,,,,,,,,,,,,,,
country,NCT00827606::country::Hungary,NCT00827606,Hungary,,,,,,,,,,,,,,
country,NCT00827606::country::Italy,NCT00827606,Italy,,,,,,,,,,,,,,
country,NCT00827606::country::Poland,NCT00827606,Poland,,,,,,,,,,,,,,
country,NCT00827606::country::Greece,NCT00827606,Greece,,,,,,,,,,,,,,
country,NCT00827606::country::Norway,NCT00827606,Norway,,,,,,,,,,,,,,
country,NCT00827606::country::Puerto Rico,NCT00827606,Puerto Rico,,,,,,,,,,,,,,
country,NCT00827606::country::Switzerland,NCT00827606,Switzerland,,,,,,,,,,,,,,
trial,NCT01730053,NCT01730053,Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II),PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,305.0,2012-11-30,2014-05-31,9.0,93.0,,,,,
arm,NCT01730053::arm::FG000,NCT01730053,Rosuvastatin 20 mg,,,,,,,,,,FG000,"Participants who were receiving rosuvastatin 10 mg at baseline, received rosuvastatin 20 mg once daily (QD), placebo for alirocumab every 2 weeks (Q2W), and placebo for ezetimibe QD added to stable li",,,
arm,NCT01730053::arm::FG001,NCT01730053,Ezetimibe 10 mg + Rosuvastatin 10 mg,,,,,,,,,,FG001,"Participants who were receiving rosuvastatin 10 mg at baseline, received ezetimibe 10 mg QD, rosuvastatin 10 mg QD, and placebo for alirocumab Q2W added to stable LMT for 24 weeks.",,,
arm,NCT01730053::arm::FG002,NCT01730053,Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg,,,,,,,,,,FG002,"Participants who were receiving rosuvastatin 10 mg at baseline, received alirocumab 75 mg Q2W, rosuvastatin 10 mg QD, and placebo for ezetimibe QD added to stable LMT for 24 weeks. Alirocumab dose up-",,,
arm,NCT01730053::arm::FG003,NCT01730053,Rosuvastatin 40 mg,,,,,,,,,,FG003,"Participants who were receiving rosuvastatin 20 mg at baseline, received rosuvastatin 40 mg QD, placebo for alirocumab Q2W, and placebo for ezetimibe QD added to stable LMT for 24 weeks.",,,
arm,NCT01730053::arm::FG004,NCT01730053,Ezetimibe 10 mg + Rosuvastatin 20 mg,,,,,,,,,,FG004,"Participants who were receiving rosuvastatin 20 mg at baseline, received ezetimibe 10 mg QD, rosuvastatin 20 mg QD, and placebo for alirocumab Q2W added to stable LMT for 24 weeks.",,,
arm,NCT01730053::arm::FG005,NCT01730053,Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg,,,,,,,,,,FG005,"Participants who were receiving rosuvastatin 20 mg at baseline, received alirocumab 75 mg Q2W, rosuvastatin 20 mg QD, and placebo for ezetimibe QD added to stable LMT for 24 weeks. Alirocumab dose up-",,,
period,NCT01730053::period::1,NCT01730053,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01730053::outcome::primary::1,NCT01730053,Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis,,,,,,,,,,,,,PRIMARY,From Baseline to Week 24
country,NCT01730053::country::United States,NCT01730053,United States,,,,,,,,,,,,,,
country,NCT01730053::country::Canada,NCT01730053,Canada,,,,,,,,,,,,,,
country,NCT01730053::country::Australia,NCT01730053,Australia,,,,,,,,,,,,,,
country,NCT01730053::country::Germany,NCT01730053,Germany,,,,,,,,,,,,,,
country,NCT01730053::country::Italy,NCT01730053,Italy,,,,,,,,,,,,,,
country,NCT01730053::country::Mexico,NCT01730053,Mexico,,,,,,,,,,,,,,
country,NCT01730053::country::United Kingdom,NCT01730053,United Kingdom,,,,,,,,,,,,,,
country,NCT01730053::country::Spain,NCT01730053,Spain,,,,,,,,,,,,,,
country,NCT01730053::country::France,NCT01730053,France,,,,,,,,,,,,,,
trial,NCT01813422,NCT01813422,GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound,PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,970.0,2013-04-18,2016-07-29,32.0,226.0,,,,,
arm,NCT01813422::arm::FG000,NCT01813422,Placebo,,,,,,,,,,FG000,Participants received placebo to evolocumab administered by subcutaneous injection once a month for 76 weeks.,,,
arm,NCT01813422::arm::FG001,NCT01813422,Evolocumab,,,,,,,,,,FG001,Participants received 420 mg evolocumab administered by subcutaneous injection once a month for 76 weeks.,,,
period,NCT01813422::period::1,NCT01813422,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01813422::outcome::primary::1,NCT01813422,Change From Baseline in Percent Atheroma Volume at Week 78,,,,,,,,,,,,,PRIMARY,Baseline and week 78
country,NCT01813422::country::United States,NCT01813422,United States,,,,,,,,,,,,,,
country,NCT01813422::country::Canada,NCT01813422,Canada,,,,,,,,,,,,,,
country,NCT01813422::country::Australia,NCT01813422,Australia,,,,,,,,,,,,,,
country,NCT01813422::country::Netherlands,NCT01813422,Netherlands,,,,,,,,,,,,,,
country,NCT01813422::country::Argentina,NCT01813422,Argentina,,,,,,,,,,,,,,
country,NCT01813422::country::Belgium,NCT01813422,Belgium,,,,,,,,,,,,,,
country,NCT01813422::country::Brazil,NCT01813422,Brazil,,,,,,,,,,,,,,
country,NCT01813422::country::Hungary,NCT01813422,Hungary,,,,,,,,,,,,,,
country,NCT01813422::country::Spain,NCT01813422,Spain,,,,,,,,,,,,,,
country,NCT01813422::country::Czechia,NCT01813422,Czechia,,,,,,,,,,,,,,
country,NCT01813422::country::France,NCT01813422,France,,,,,,,,,,,,,,
country,NCT01813422::country::Germany,NCT01813422,Germany,,,,,,,,,,,,,,
country,NCT01813422::country::Mexico,NCT01813422,Mexico,,,,,,,,,,,,,,
country,NCT01813422::country::Poland,NCT01813422,Poland,,,,,,,,,,,,,,
country,NCT01813422::country::South Africa,NCT01813422,South Africa,,,,,,,,,,,,,,
country,NCT01813422::country::Sweden,NCT01813422,Sweden,,,,,,,,,,,,,,
country,NCT01813422::country::Greece,NCT01813422,Greece,,,,,,,,,,,,,,
country,NCT01813422::country::Italy,NCT01813422,Italy,,,,,,,,,,,,,,
country,NCT01813422::country::Chile,NCT01813422,Chile,,,,,,,,,,,,,,
country,NCT01813422::country::Russia,NCT01813422,Russia,,,,,,,,,,,,,,
country,NCT01813422::country::South Korea,NCT01813422,South Korea,,,,,,,,,,,,,,
country,NCT01813422::country::Taiwan,NCT01813422,Taiwan,,,,,,,,,,,,,,
country,NCT01813422::country::Israel,NCT01813422,Israel,,,,,,,,,,,,,,
country,NCT01813422::country::Philippines,NCT01813422,Philippines,,,,,,,,,,,,,,
country,NCT01813422::country::Denmark,NCT01813422,Denmark,,,,,,,,,,,,,,
country,NCT01813422::country::Ireland,NCT01813422,Ireland,,,,,,,,,,,,,,
country,NCT01813422::country::Malaysia,NCT01813422,Malaysia,,,,,,,,,,,,,,
country,NCT01813422::country::Norway,NCT01813422,Norway,,,,,,,,,,,,,,
country,NCT01813422::country::Switzerland,NCT01813422,Switzerland,,,,,,,,,,,,,,
country,NCT01813422::country::Iceland,NCT01813422,Iceland,,,,,,,,,,,,,,
country,NCT01813422::country::Singapore,NCT01813422,Singapore,,,,,,,,,,,,,,
country,NCT01813422::country::United Kingdom,NCT01813422,United Kingdom,,,,,,,,,,,,,,
trial,NCT00496730,NCT00496730,"A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)",PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,256.0,2007-07,2008-08,0.0,0.0,,,,,
arm,NCT00496730::arm::FG000,NCT00496730,Vytorin,,,,,,,,,,FG000,"simvastatin (+) ezetimibe 10/20 mg (Vytorin®) ; tablet, once daily, 8 Weeks",,,
arm,NCT00496730::arm::FG001,NCT00496730,Atorvastatin,,,,,,,,,,FG001,"atorvastatin 10 mg; tablet, once daily, 8 Weeks",,,
period,NCT00496730::period::1,NCT00496730,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00496730::outcome::primary::1,NCT00496730,Mean Percent Change of Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline After 8 Weeks.,,,,,,,,,,,,,PRIMARY,Baseline and 8 Weeks
trial,NCT03011450,NCT03011450,Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment,PHASE3,dyslipidemia,Severe Hypertriglyceridemia,INDUSTRY,471.0,2016-11-26,2019-07-05,9.0,241.0,,,,,
arm,NCT03011450::arm::FG000,NCT03011450,K-877,,,,,,,,,,FG000,Participants randomized to receive K-877 0.2 mg tablets twice daily in the 12-week Efficacy Period continued to receive K-877 0.2 mg tablets BID in the 40-week Extension Period,,,
arm,NCT03011450::arm::FG001,NCT03011450,Placebo/Fenofibrate,,,,,,,,,,FG001,"Patients randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period initiated fenofibrate dosing at 48 mg once daily at Visit 7 (Week 12). Starting from Visit 8 (Week 16), ",,,
period,NCT03011450::period::1,NCT03011450,12-week Efficacy,,,,,,,,,,,,1.0,,
period,NCT03011450::period::2,NCT03011450,40-week Extension,,,,,,,,,,,,2.0,,
outcome,NCT03011450::outcome::primary::1,NCT03011450,Percent Change in Fasting TG From Baseline to Week 12,,,,,,,,,,,,,PRIMARY,12 Weeks
country,NCT03011450::country::United States,NCT03011450,United States,,,,,,,,,,,,,,
country,NCT03011450::country::Russia,NCT03011450,Russia,,,,,,,,,,,,,,
country,NCT03011450::country::Ukraine,NCT03011450,Ukraine,,,,,,,,,,,,,,
country,NCT03011450::country::Poland,NCT03011450,Poland,,,,,,,,,,,,,,
country,NCT03011450::country::Belarus,NCT03011450,Belarus,,,,,,,,,,,,,,
country,NCT03011450::country::Bulgaria,NCT03011450,Bulgaria,,,,,,,,,,,,,,
country,NCT03011450::country::Hungary,NCT03011450,Hungary,,,,,,,,,,,,,,
country,NCT03011450::country::Czechia,NCT03011450,Czechia,,,,,,,,,,,,,,
country,NCT03011450::country::Georgia,NCT03011450,Georgia,,,,,,,,,,,,,,
trial,NCT00271817,NCT00271817,To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED),PHASE3,dyslipidemia,Hypercholesterolemia,INDUSTRY,1220.0,2005-12,2008-02,0.0,0.0,,,,,
arm,NCT00271817::arm::FG000,NCT00271817,Niacin,,,,,,,,,,FG000,"(Part 1): Niacin titrated to 2000 mg taken orally once daily for 24 weeks. During the first 12 weeks of the study, patients randomized to the niacin containing arms started taking niacin 500 mg and ha",,,
arm,NCT00271817::arm::FG001,NCT00271817,Ezetimibe/Simvastatin,,,,,,,,,,FG001,"(Part 1): Ezetimibe/Simvastatin 10/20 mg taken orally once daily for 24 weeks.

(Part 2): Ezetimibe/Simvastatin 10/20 mg taken orally once daily for 40 additional weeks for a total of 64 weeks.",,,
arm,NCT00271817::arm::FG002,NCT00271817,Ezetimibe/Simvastatin + Niacin,,,,,,,,,,FG002,"(Part 1): Ezetimibe/Simvastatin 10/20 mg + Niacin (titrated to 2000 mg as noted above) taken orally once daily for 24 weeks.

(Part 2): Ezetimibe/Simvastatin 10/20 mg + Niacin 2000 mg taken orally onc",,,
period,NCT00271817::period::1,NCT00271817,Part 1,,,,,,,,,,,,1.0,,
period,NCT00271817::period::2,NCT00271817,Part 2,,,,,,,,,,,,2.0,,
outcome,NCT00271817::outcome::primary::1,NCT00271817,Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C),,,,,,,,,,,,,PRIMARY,Baseline and 24 Weeks
outcome,NCT00271817::outcome::primary::2,NCT00271817,Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C),,,,,,,,,,,,,PRIMARY,Baseline and 24 weeks
trial,NCT01524289,NCT01524289,Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020),PHASE3,dyslipidemia,"Hyperlipoproteinemia Type II; Hypercholesterolemia, Familial",INDUSTRY,306.0,2012-02-03,2018-11-13,0.0,0.0,,,,,
arm,NCT01524289::arm::FG000,NCT01524289,Anacetrapib 100 mg,,,,,,,,,,FG000,Participants were administered one tablet of 100 mg anacetrapib orally once daily with a meal for 52 weeks during the treatment phase.,,,
arm,NCT01524289::arm::FG001,NCT01524289,Placebo,,,,,,,,,,FG001,Participants were administered one matching placebo tablet orally once daily with a meal for 52 weeks during the treatment phase.,,,
period,NCT01524289::period::1,NCT01524289,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01524289::outcome::primary::1,NCT01524289,Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) - Treatment Phase,,,,,,,,,,,,,PRIMARY,Baseline and Week 52
outcome,NCT01524289::outcome::primary::2,NCT01524289,Percentage of Participants With Any Adverse Event - Treatment Phase,,,,,,,,,,,,,PRIMARY,Up to 52 weeks
outcome,NCT01524289::outcome::primary::3,NCT01524289,Percentage of Participants With Any Treatment-Related Adverse Event - Treatment Phase,,,,,,,,,,,,,PRIMARY,Up to 52 weeks
outcome,NCT01524289::outcome::primary::4,NCT01524289,Percentage of Participants With Any Serious Adverse Event - Treatment Phase,,,,,,,,,,,,,PRIMARY,Up to 52 weeks
outcome,NCT01524289::outcome::primary::5,NCT01524289,Percentage of Participants Discontinuing Study Treatment Due to an Adverse Event - Treatment Phase,,,,,,,,,,,,,PRIMARY,Up to 52 weeks
outcome,NCT01524289::outcome::primary::6,NCT01524289,Percentage of Participants With Changes in Systolic Blood Pressure (SBP) >= 10 mm Hg,,,,,,,,,,,,,PRIMARY,Up to 52 weeks
outcome,NCT01524289::outcome::primary::7,NCT01524289,Percentage of Participants With Changes in SBP >= 15 mm Hg,,,,,,,,,,,,,PRIMARY,Up to 52 weeks
outcome,NCT01524289::outcome::primary::8,NCT01524289,Percentage of Participants With Changes in Diastolic Blood Pressure (DBP) >= 10 mm Hg,,,,,,,,,,,,,PRIMARY,Up to 52 weeks
outcome,NCT01524289::outcome::primary::9,NCT01524289,Percentage of Participants With Sodium Levels > Upper Limit of Normal (ULN),,,,,,,,,,,,,PRIMARY,Up to 52 weeks
outcome,NCT01524289::outcome::primary::10,NCT01524289,Percentage of Participants With Chloride Levels > ULN,,,,,,,,,,,,,PRIMARY,Up to 52 weeks
outcome,NCT01524289::outcome::primary::11,NCT01524289,Percentage of Participants With Potassium Levels < Lower Limit of Normal (LLN),,,,,,,,,,,,,PRIMARY,Up to 52 weeks
outcome,NCT01524289::outcome::primary::12,NCT01524289,Percentage of Participants With Bicarbonate Levels > ULN,,,,,,,,,,,,,PRIMARY,Up to 52 weeks
outcome,NCT01524289::outcome::primary::13,NCT01524289,Percentage of Participants With Consecutive Changes in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) of >=3 x ULN,,,,,,,,,,,,,PRIMARY,Up to 52 weeks
outcome,NCT01524289::outcome::primary::14,NCT01524289,Percentage of Participants With Creatine Kinase (CK) Level >=10 x ULN,,,,,,,,,,,,,PRIMARY,Up to 52 weeks
outcome,NCT01524289::outcome::primary::15,NCT01524289,Percentage of Participants With CK Level >=10 x ULN With Muscle Spasms,,,,,,,,,,,,,PRIMARY,Up to 52 weeks
outcome,NCT01524289::outcome::primary::16,NCT01524289,Percentage of Participants Adjudicated Cardiovascular (CV) SAE,,,,,,,,,,,,,PRIMARY,Up to 52 weeks
outcome,NCT01524289::outcome::primary::17,NCT01524289,Percentage of Participants Who Died From Any Cause - Treatment Phase,,,,,,,,,,,,,PRIMARY,Up to 52 weeks
trial,NCT04620135,NCT04620135,Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension,PHASE3,hypertension,Primary Open Angle Glaucoma; Ocular Hypertension,INDUSTRY,245.0,2020-11-30,2021-07-30,1.0,1.0,,,,,
arm,NCT04620135::arm::FG000,NCT04620135,Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle,,,,,,,,,,FG000,"1 drop netarsudil 0.02% in the evening and 1 drop netarsudil vehicle in the morning in each eye.

Netarsudil ophthalmic solution 0.02%: Topical sterile ophthalmic solution Other Name: Rhopressa®",,,
arm,NCT04620135::arm::FG001,NCT04620135,Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%,,,,,,,,,,FG001,"1 drop ripasudil twice daily in the morning and evening in each eye.

Ripasudil hydrochloride hydrate ophthalmic solution 0.4%: Other Name: Glanatec®",,,
period,NCT04620135::period::1,NCT04620135,Intent-to-Treat (ITT) Population,,,,,,,,,,,,1.0,,
period,NCT04620135::period::2,NCT04620135,Per-Protocol (PP) Population,,,,,,,,,,,,2.0,,
period,NCT04620135::period::3,NCT04620135,Safety Population,,,,,,,,,,,,3.0,,
period,NCT04620135::period::4,NCT04620135,Study Completion,,,,,,,,,,,,4.0,,
outcome,NCT04620135::outcome::primary::1,NCT04620135,Intraocular Pressure (IOP),,,,,,,,,,,,,PRIMARY,29 Days
country,NCT04620135::country::Japan,NCT04620135,Japan,,,,,,,,,,,,,,
trial,NCT02674854,NCT02674854,Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension,PHASE3,hypertension,Open-angle Glaucoma; Ocular Hypertension,INDUSTRY,750.0,2016-02,2017-03,1.0,1.0,,,,,
arm,NCT02674854::arm::FG000,NCT02674854,PG324 Ophthalmic Solution 0.02%/0.005%,,,,,,,,,,FG000,1 drop daily in the evening (PM) in both eyes (OU),,,
arm,NCT02674854::arm::FG001,NCT02674854,Netarsudil (AR-13324) Ophthalmic Solution 0.02%,,,,,,,,,,FG001,1 drop daily in the evening (PM) in both eyes (OU),,,
arm,NCT02674854::arm::FG002,NCT02674854,Latanoprost Ophthalmic Solution 0.005%,,,,,,,,,,FG002,1 drop daily in the evening (PM) in both eyes (OU),,,
period,NCT02674854::period::1,NCT02674854,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02674854::outcome::primary::1,NCT02674854,Intraocular Pressure (IOP),,,,,,,,,,,,,PRIMARY,3 months
country,NCT02674854::country::United States,NCT02674854,United States,,,,,,,,,,,,,,
trial,NCT01560637,NCT01560637,"An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension",PHASE3,hypertension,Pulmonary Arterial Hypertension,INDUSTRY,471.0,2013-09-11,2021-08-12,23.0,153.0,,,,,
arm,NCT01560637::arm::FG000,NCT01560637,UT-15C,,,,,,,,,,FG000,"Open label access

UT-15C (treprostinil diethanolamine): UT-15C sustained release oral tablet for three times daily administration",,,
period,NCT01560637::period::1,NCT01560637,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01560637::outcome::primary::1,NCT01560637,Number of Adverse Events,,,,,,,,,,,,,PRIMARY,"Participants will be followed every 12 weeks, at minimum, until they discontinue the study or the study is discontinued by the sponsor or for a period up to 2.5 years"
country,NCT01560637::country::United States,NCT01560637,United States,,,,,,,,,,,,,,
country,NCT01560637::country::China,NCT01560637,China,,,,,,,,,,,,,,
country,NCT01560637::country::Germany,NCT01560637,Germany,,,,,,,,,,,,,,
country,NCT01560637::country::India,NCT01560637,India,,,,,,,,,,,,,,
country,NCT01560637::country::Australia,NCT01560637,Australia,,,,,,,,,,,,,,
country,NCT01560637::country::Brazil,NCT01560637,Brazil,,,,,,,,,,,,,,
country,NCT01560637::country::France,NCT01560637,France,,,,,,,,,,,,,,
country,NCT01560637::country::Argentina,NCT01560637,Argentina,,,,,,,,,,,,,,
country,NCT01560637::country::Israel,NCT01560637,Israel,,,,,,,,,,,,,,
country,NCT01560637::country::South Korea,NCT01560637,South Korea,,,,,,,,,,,,,,
country,NCT01560637::country::Canada,NCT01560637,Canada,,,,,,,,,,,,,,
country,NCT01560637::country::Italy,NCT01560637,Italy,,,,,,,,,,,,,,
country,NCT01560637::country::Poland,NCT01560637,Poland,,,,,,,,,,,,,,
country,NCT01560637::country::Taiwan,NCT01560637,Taiwan,,,,,,,,,,,,,,
country,NCT01560637::country::United Kingdom,NCT01560637,United Kingdom,,,,,,,,,,,,,,
country,NCT01560637::country::Austria,NCT01560637,Austria,,,,,,,,,,,,,,
country,NCT01560637::country::Chile,NCT01560637,Chile,,,,,,,,,,,,,,
country,NCT01560637::country::Denmark,NCT01560637,Denmark,,,,,,,,,,,,,,
country,NCT01560637::country::Greece,NCT01560637,Greece,,,,,,,,,,,,,,
country,NCT01560637::country::Mexico,NCT01560637,Mexico,,,,,,,,,,,,,,
country,NCT01560637::country::Netherlands,NCT01560637,Netherlands,,,,,,,,,,,,,,
country,NCT01560637::country::Singapore,NCT01560637,Singapore,,,,,,,,,,,,,,
country,NCT01560637::country::Sweden,NCT01560637,Sweden,,,,,,,,,,,,,,
trial,NCT01156012,NCT01156012,Efficacy and Safety Assessment of T2345 in Ocular Hypertensive or Glaucomatous Patients,PHASE3,hypertension,Glaucoma,INDUSTRY,404.0,2009-09,2010-12,1.0,1.0,,,,,
arm,NCT01156012::arm::FG000,NCT01156012,T2345,,,,,,,,,,FG000,"One drop of T2345

T2345: One drop of T2345 at 9.00pm",,,
arm,NCT01156012::arm::FG001,NCT01156012,Prostaglandin,,,,,,,,,,FG001,"One drop of prostaglandin

Prostaglandin: One drop of prostaglandin at 9.00pm",,,
period,NCT01156012::period::1,NCT01156012,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01156012::outcome::primary::1,NCT01156012,Change From Baseline in Intraocular Pressure (IOP),,,,,,,,,,,,,PRIMARY,Day 0 and Day 84
country,NCT01156012::country::France,NCT01156012,France,,,,,,,,,,,,,,
trial,NCT01722604,NCT01722604,Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt,PHASE3,hypertension,Glaucoma; Open Angle or Ocular Hypertension,INDUSTRY,258.0,2012-01,2012-09,1.0,1.0,,,,,
arm,NCT01722604::arm::FG000,NCT01722604,Brinzolamide 1% Ophthalmic Suspension,,,,,,,,,,FG000,"ophthalmic suspension

brinzolamide 1% ophthalmic suspension: brinzolamide 1% ophthalmic suspension",,,
arm,NCT01722604::arm::FG001,NCT01722604,Azopt 1% Ophthalmic Suspension,,,,,,,,,,FG001,"Ophthalmic suspension

Azopt 1%: Azopt 1%, RLD",,,
period,NCT01722604::period::1,NCT01722604,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01722604::outcome::primary::1,NCT01722604,Intraocular Pressure (IOP) at Week 12,,,,,,,,,,,,,PRIMARY,Week 12
country,NCT01722604::country::United States,NCT01722604,United States,,,,,,,,,,,,,,
trial,NCT03691649,NCT03691649,A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study,PHASE3,hypertension,Glaucoma and Ocular Hypertension,INDUSTRY,426.0,2018-09-14,2020-09-03,1.0,47.0,,,,,
arm,NCT03691649::arm::FG000,NCT03691649,DE-117 Ophthalmic Solution,,,,,,,,,,FG000,"Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 months for adult subjects only.

",,,
arm,NCT03691649::arm::FG001,NCT03691649,Timolol Maleate Ophthalmic Solution 0.5%,,,,,,,,,,FG001,"Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 months for adult subjects only.

Timolol ",,,
period,NCT03691649::period::1,NCT03691649,Double Masked Treatment Period (DMTP),,,,,,,,,,,,1.0,,
period,NCT03691649::period::2,NCT03691649,Open Label Treatment Period (OLTP),,,,,,,,,,,,2.0,,
outcome,NCT03691649::outcome::primary::1,NCT03691649,Intraocular Pressure at Week 1,,,,,,,,,,,,,PRIMARY,"08:00, 10:00 and 16:00 at Week 1"
outcome,NCT03691649::outcome::primary::2,NCT03691649,Intraocular Pressure at Week 6,,,,,,,,,,,,,PRIMARY,"08:00, 10:00 and 16:00 at Week 6"
outcome,NCT03691649::outcome::primary::3,NCT03691649,Intraocular Pressure at Month 3,,,,,,,,,,,,,PRIMARY,"08:00, 10:00 and 16:00 at Month 3"
country,NCT03691649::country::United States,NCT03691649,United States,,,,,,,,,,,,,,
trial,NCT04944290,NCT04944290,To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes,PHASE3,hypertension,"Glaucoma, Open-Angle; Ocular Hypertension",INDUSTRY,447.0,2021-05-28,2022-06-21,1.0,1.0,,,,,
arm,NCT04944290::arm::FG000,NCT04944290,Perrigo Active,,,,,,,,,,FG000,Brinzolamide/brimonidine ophthalmic suspension: Test product,,,
arm,NCT04944290::arm::FG001,NCT04944290,Reference Active,,,,,,,,,,FG001,Simbrinza 0.2%/1% Ophthalmic Suspension: Reference product,,,
period,NCT04944290::period::1,NCT04944290,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04944290::outcome::primary::1,NCT04944290,Mean Change in Intra-ocular Pressure,,,,,,,,,,,,,PRIMARY,6 weeks
country,NCT04944290::country::United States,NCT04944290,United States,,,,,,,,,,,,,,
trial,NCT00690794,NCT00690794,Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular Hypertension,PHASE3,hypertension,Open-angle Glaucoma; Ocular Hypertension,INDUSTRY,726.0,2008-07,2009-05,0.0,0.0,,,,,
arm,NCT00690794::arm::FG000,NCT00690794,Travoprost,,,,,,,,,,FG000,One drop self-administered in the study eye(s) once daily for 90 days,,,
arm,NCT00690794::arm::FG001,NCT00690794,Latanoprost,,,,,,,,,,FG001,One drop self-administered in the study eye(s) once daily for 90 days,,,
period,NCT00690794::period::1,NCT00690794,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00690794::outcome::primary::1,NCT00690794,Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score,,,,,,,,,,,,,PRIMARY,"Baseline, Day 90"
trial,NCT01106014,NCT01106014,Selexipag (ACT-293987) in Pulmonary Arterial Hypertension,PHASE3,hypertension,Pulmonary Arterial Hypertension,INDUSTRY,1156.0,2009-12-01,2014-10-01,39.0,182.0,,,,,
arm,NCT01106014::arm::FG000,NCT01106014,SELEXIPAG,,,,,,,,,,FG000,"During the 12-week titration phase, treatment was initiated at 200 μg twice daily (b.i.d.) and up-titrated weekly in 200 μg b.i.d. increments to the maximum tolerated dose (MTD) for each individual pa",,,
arm,NCT01106014::arm::FG001,NCT01106014,PLACEBO,,,,,,,,,,FG001,Matching placebo was administered orally following the same administration schedule as described for selexipag,,,
period,NCT01106014::period::1,NCT01106014,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01106014::outcome::primary::1,NCT01106014,Time From Randomization to the First Morbidity Event or Death (All Causes) up to 7 Days After the Last Study Drug Intake,,,,,,,,,,,,,PRIMARY,Up to 7 days after end of double-blind treatment (maximum: 4.3 years)
country,NCT01106014::country::United States,NCT01106014,United States,,,,,,,,,,,,,,
country,NCT01106014::country::Germany,NCT01106014,Germany,,,,,,,,,,,,,,
country,NCT01106014::country::Russia,NCT01106014,Russia,,,,,,,,,,,,,,
country,NCT01106014::country::Australia,NCT01106014,Australia,,,,,,,,,,,,,,
country,NCT01106014::country::Canada,NCT01106014,Canada,,,,,,,,,,,,,,
country,NCT01106014::country::China,NCT01106014,China,,,,,,,,,,,,,,
country,NCT01106014::country::Argentina,NCT01106014,Argentina,,,,,,,,,,,,,,
country,NCT01106014::country::France,NCT01106014,France,,,,,,,,,,,,,,
country,NCT01106014::country::Hungary,NCT01106014,Hungary,,,,,,,,,,,,,,
country,NCT01106014::country::India,NCT01106014,India,,,,,,,,,,,,,,
country,NCT01106014::country::Israel,NCT01106014,Israel,,,,,,,,,,,,,,
country,NCT01106014::country::South Korea,NCT01106014,South Korea,,,,,,,,,,,,,,
country,NCT01106014::country::Netherlands,NCT01106014,Netherlands,,,,,,,,,,,,,,
country,NCT01106014::country::Poland,NCT01106014,Poland,,,,,,,,,,,,,,
country,NCT01106014::country::Sweden,NCT01106014,Sweden,,,,,,,,,,,,,,
country,NCT01106014::country::Switzerland,NCT01106014,Switzerland,,,,,,,,,,,,,,
country,NCT01106014::country::Turkey (Türkiye),NCT01106014,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01106014::country::Ukraine,NCT01106014,Ukraine,,,,,,,,,,,,,,
country,NCT01106014::country::Belarus,NCT01106014,Belarus,,,,,,,,,,,,,,
country,NCT01106014::country::Chile,NCT01106014,Chile,,,,,,,,,,,,,,
country,NCT01106014::country::Italy,NCT01106014,Italy,,,,,,,,,,,,,,
country,NCT01106014::country::Spain,NCT01106014,Spain,,,,,,,,,,,,,,
country,NCT01106014::country::United Kingdom,NCT01106014,United Kingdom,,,,,,,,,,,,,,
country,NCT01106014::country::Austria,NCT01106014,Austria,,,,,,,,,,,,,,
country,NCT01106014::country::Belgium,NCT01106014,Belgium,,,,,,,,,,,,,,
country,NCT01106014::country::Colombia,NCT01106014,Colombia,,,,,,,,,,,,,,
country,NCT01106014::country::Denmark,NCT01106014,Denmark,,,,,,,,,,,,,,
country,NCT01106014::country::Mexico,NCT01106014,Mexico,,,,,,,,,,,,,,
country,NCT01106014::country::Peru,NCT01106014,Peru,,,,,,,,,,,,,,
country,NCT01106014::country::Romania,NCT01106014,Romania,,,,,,,,,,,,,,
country,NCT01106014::country::Serbia,NCT01106014,Serbia,,,,,,,,,,,,,,
country,NCT01106014::country::Taiwan,NCT01106014,Taiwan,,,,,,,,,,,,,,
country,NCT01106014::country::Czechia,NCT01106014,Czechia,,,,,,,,,,,,,,
country,NCT01106014::country::Greece,NCT01106014,Greece,,,,,,,,,,,,,,
country,NCT01106014::country::Ireland,NCT01106014,Ireland,,,,,,,,,,,,,,
country,NCT01106014::country::Malaysia,NCT01106014,Malaysia,,,,,,,,,,,,,,
country,NCT01106014::country::Singapore,NCT01106014,Singapore,,,,,,,,,,,,,,
country,NCT01106014::country::Slovakia,NCT01106014,Slovakia,,,,,,,,,,,,,,
country,NCT01106014::country::Thailand,NCT01106014,Thailand,,,,,,,,,,,,,,
trial,NCT02250651,NCT02250651,Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension,PHASE3,hypertension,"Glaucoma, Open-Angle; Ocular Hypertension",INDUSTRY,528.0,2014-12-15,2020-07-22,15.0,113.0,,,,,
arm,NCT02250651::arm::FG000,NCT02250651,Bimatoprost SR 15 μg,,,,,,,,,,FG000,"Study Eye: bimatoprost sustained-release (SR) 15 micrograms (μg) administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once",,,
arm,NCT02250651::arm::FG001,NCT02250651,Bimatoprost SR 10 μg,,,,,,,,,,FG001,"Study Eye: bimatoprost SR 10 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 mont",,,
arm,NCT02250651::arm::FG002,NCT02250651,Timolol 0.5%: Comparator,,,,,,,,,,FG002,"Study Eye and Non-Study Eye: sham administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 month",,,
period,NCT02250651::period::1,NCT02250651,Treatment Period 1 (Day 1 to Week 15),,,,,,,,,,,,1.0,,
period,NCT02250651::period::2,NCT02250651,Treatment Period 2 (Week 16 to Week 31),,,,,,,,,,,,2.0,,
period,NCT02250651::period::3,NCT02250651,Treatment Period 3 (Week 32 to Week 52),,,,,,,,,,,,3.0,,
outcome,NCT02250651::outcome::primary::1,NCT02250651,Change From Baseline in Intraocular Pressure (IOP) in the Study Eye to Week 12 (Hours 0 and 2),,,,,,,,,,,,,PRIMARY,Baseline (Up to 3 days prior to Day 1 at Hours 0 and 2) to Week 12 (Hours 0 and 2)
outcome,NCT02250651::outcome::primary::2,NCT02250651,IOP in the Study Eye at Week 2 (Hour 0),,,,,,,,,,,,,PRIMARY,Week 2 (Hour 0)
outcome,NCT02250651::outcome::primary::3,NCT02250651,IOP in the Study Eye at Week 2 (Hour 2),,,,,,,,,,,,,PRIMARY,Week 2 (Hour 2)
outcome,NCT02250651::outcome::primary::4,NCT02250651,IOP in the Study Eye at Week 6 (Hour 0),,,,,,,,,,,,,PRIMARY,Week 6 (Hour 0)
outcome,NCT02250651::outcome::primary::5,NCT02250651,IOP in the Study Eye at Week 6 (Hour 2),,,,,,,,,,,,,PRIMARY,Week 6 (Hour 2)
outcome,NCT02250651::outcome::primary::6,NCT02250651,IOP in the Study Eye at Week 12 (Hour 0),,,,,,,,,,,,,PRIMARY,Week 12 (Hour 0)
outcome,NCT02250651::outcome::primary::7,NCT02250651,IOP in the Study Eye at Week 12 (Hour 2),,,,,,,,,,,,,PRIMARY,Week 12 (Hour 2)
country,NCT02250651::country::United States,NCT02250651,United States,,,,,,,,,,,,,,
country,NCT02250651::country::Canada,NCT02250651,Canada,,,,,,,,,,,,,,
country,NCT02250651::country::United Kingdom,NCT02250651,United Kingdom,,,,,,,,,,,,,,
country,NCT02250651::country::Argentina,NCT02250651,Argentina,,,,,,,,,,,,,,
country,NCT02250651::country::Italy,NCT02250651,Italy,,,,,,,,,,,,,,
country,NCT02250651::country::Germany,NCT02250651,Germany,,,,,,,,,,,,,,
country,NCT02250651::country::Colombia,NCT02250651,Colombia,,,,,,,,,,,,,,
country,NCT02250651::country::Czechia,NCT02250651,Czechia,,,,,,,,,,,,,,
country,NCT02250651::country::Egypt,NCT02250651,Egypt,,,,,,,,,,,,,,
country,NCT02250651::country::Singapore,NCT02250651,Singapore,,,,,,,,,,,,,,
country,NCT02250651::country::South Korea,NCT02250651,South Korea,,,,,,,,,,,,,,
country,NCT02250651::country::Turkey (Türkiye),NCT02250651,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT02250651::country::South Africa,NCT02250651,South Africa,,,,,,,,,,,,,,
country,NCT02250651::country::Malaysia,NCT02250651,Malaysia,,,,,,,,,,,,,,
country,NCT02250651::country::New Zealand,NCT02250651,New Zealand,,,,,,,,,,,,,,
trial,NCT01342081,NCT01342081,DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%,PHASE3,hypertension,Open Angle Glaucoma; Ocular Hypertension,INDUSTRY,489.0,2011-05,,1.0,1.0,,,,,
arm,NCT01342081::arm::FG000,NCT01342081,DE-111,,,,,,,,,,FG000,"DE-111 ophthalmic solution (one drop at a time, once daily) and Placebo ophthalmic solution (one drop at a time, BID) in both eyes.",,,
arm,NCT01342081::arm::FG001,NCT01342081,Tafluprost,,,,,,,,,,FG001,"Tafluprost ophthalmic solution 0.0015% (one drop at a time, once daily) and Placebo ophthalmic solution (one drop at a time, BID) in both eyes.",,,
arm,NCT01342081::arm::FG002,NCT01342081,Tafluprost Plus Timolol,,,,,,,,,,FG002,"Tafluprost ophthalmic solution 0.0015% (one drop at a time, once daily) and Timolol ophthalmic solution 0.5% (one drop at a time, BID) in both eyes.",,,
period,NCT01342081::period::1,NCT01342081,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01342081::outcome::primary::1,NCT01342081,Change From Baseline in Mean Diurnal IOP(Intraocular Pressure) at End of Study,,,,,,,,,,,,,PRIMARY,Week 0(Baseline) and Week 4(End of Study)
country,NCT01342081::country::Japan,NCT01342081,Japan,,,,,,,,,,,,,,
trial,NCT00660179,NCT00660179,Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension,PHASE3,hypertension,Pulmonary Arterial Hypertension,INDUSTRY,742.0,2008-05,2012-04,38.0,153.0,,,,,
arm,NCT00660179::arm::FG000,NCT00660179,Placebo,,,,,,,,,,FG000,"Matching ACT-064992 placebo tablet, once daily",,,
arm,NCT00660179::arm::FG001,NCT00660179,ACT-064992 3 mg,,,,,,,,,,FG001,"ACT-064992 tablet, 3 mg, once daily",,,
arm,NCT00660179::arm::FG002,NCT00660179,ACT-064992 10 mg,,,,,,,,,,FG002,"ACT-064992 tablet, 10 mg, once daily",,,
period,NCT00660179::period::1,NCT00660179,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00660179::outcome::primary::1,NCT00660179,Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event),,,,,,,,,,,,,PRIMARY,Up to end of treatment (data presented up to month 36)
country,NCT00660179::country::United States,NCT00660179,United States,,,,,,,,,,,,,,
country,NCT00660179::country::Germany,NCT00660179,Germany,,,,,,,,,,,,,,
country,NCT00660179::country::Russia,NCT00660179,Russia,,,,,,,,,,,,,,
country,NCT00660179::country::China,NCT00660179,China,,,,,,,,,,,,,,
country,NCT00660179::country::Argentina,NCT00660179,Argentina,,,,,,,,,,,,,,
country,NCT00660179::country::India,NCT00660179,India,,,,,,,,,,,,,,
country,NCT00660179::country::Spain,NCT00660179,Spain,,,,,,,,,,,,,,
country,NCT00660179::country::Canada,NCT00660179,Canada,,,,,,,,,,,,,,
country,NCT00660179::country::Israel,NCT00660179,Israel,,,,,,,,,,,,,,
country,NCT00660179::country::South Africa,NCT00660179,South Africa,,,,,,,,,,,,,,
country,NCT00660179::country::Thailand,NCT00660179,Thailand,,,,,,,,,,,,,,
country,NCT00660179::country::Australia,NCT00660179,Australia,,,,,,,,,,,,,,
country,NCT00660179::country::Belarus,NCT00660179,Belarus,,,,,,,,,,,,,,
country,NCT00660179::country::Chile,NCT00660179,Chile,,,,,,,,,,,,,,
country,NCT00660179::country::France,NCT00660179,France,,,,,,,,,,,,,,
country,NCT00660179::country::Hungary,NCT00660179,Hungary,,,,,,,,,,,,,,
country,NCT00660179::country::Poland,NCT00660179,Poland,,,,,,,,,,,,,,
country,NCT00660179::country::Serbia,NCT00660179,Serbia,,,,,,,,,,,,,,
country,NCT00660179::country::Colombia,NCT00660179,Colombia,,,,,,,,,,,,,,
country,NCT00660179::country::Hong Kong,NCT00660179,Hong Kong,,,,,,,,,,,,,,
country,NCT00660179::country::Mexico,NCT00660179,Mexico,,,,,,,,,,,,,,
country,NCT00660179::country::Peru,NCT00660179,Peru,,,,,,,,,,,,,,
country,NCT00660179::country::Romania,NCT00660179,Romania,,,,,,,,,,,,,,
country,NCT00660179::country::Singapore,NCT00660179,Singapore,,,,,,,,,,,,,,
country,NCT00660179::country::Slovakia,NCT00660179,Slovakia,,,,,,,,,,,,,,
country,NCT00660179::country::Sweden,NCT00660179,Sweden,,,,,,,,,,,,,,
country,NCT00660179::country::Taiwan,NCT00660179,Taiwan,,,,,,,,,,,,,,
country,NCT00660179::country::Ukraine,NCT00660179,Ukraine,,,,,,,,,,,,,,
country,NCT00660179::country::Austria,NCT00660179,Austria,,,,,,,,,,,,,,
country,NCT00660179::country::Belgium,NCT00660179,Belgium,,,,,,,,,,,,,,
country,NCT00660179::country::Bulgaria,NCT00660179,Bulgaria,,,,,,,,,,,,,,
country,NCT00660179::country::Croatia,NCT00660179,Croatia,,,,,,,,,,,,,,
country,NCT00660179::country::Italy,NCT00660179,Italy,,,,,,,,,,,,,,
country,NCT00660179::country::Malaysia,NCT00660179,Malaysia,,,,,,,,,,,,,,
country,NCT00660179::country::Netherlands,NCT00660179,Netherlands,,,,,,,,,,,,,,
country,NCT00660179::country::Norway,NCT00660179,Norway,,,,,,,,,,,,,,
country,NCT00660179::country::Turkey (Türkiye),NCT00660179,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT00660179::country::United Kingdom,NCT00660179,United Kingdom,,,,,,,,,,,,,,
trial,NCT04024072,NCT04024072,To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes,PHASE3,hypertension,"Glaucoma, Open-Angle; Ocular Hypertension",INDUSTRY,495.0,2019-06-24,2020-04-30,1.0,1.0,,,,,
arm,NCT04024072::arm::FG000,NCT04024072,Perrigo Active,,,,,,,,,,FG000,"Test product

Brinzolamide 1% ophthalmic suspension: Test product",,,
arm,NCT04024072::arm::FG001,NCT04024072,Reference Active,,,,,,,,,,FG001,"Azopt ophthalmic suspension

Azopt 1% Ophthalmic Suspension: Reference product",,,
period,NCT04024072::period::1,NCT04024072,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04024072::outcome::primary::1,NCT04024072,Mean Change in Intra-ocular Pressure,,,,,,,,,,,,,PRIMARY,6 weeks
country,NCT04024072::country::United States,NCT04024072,United States,,,,,,,,,,,,,,
trial,NCT01908699,NCT01908699,Beraprost-314d Added-on to Tyvaso® (BEAT),PHASE3,hypertension,Pulmonary Arterial Hypertension,INDUSTRY,273.0,2013-05-31,2019-02-19,2.0,75.0,,,,,
arm,NCT01908699::arm::FG000,NCT01908699,Esuberaprost,,,,,,,,,,FG000,Participants received 1 tablet of esuberaprost (BPS-314d-MR) 14.2 micrograms (mcg) orally 4 times daily (QID) (total daily dose: 56.8 mcg) in conjunction with inhaled treprostinil for 2 weeks. After 2,,,
arm,NCT01908699::arm::FG001,NCT01908699,Placebo,,,,,,,,,,FG001,Participants received 1 or 2 tablets of placebo matched to esuberaprost orally QID in conjunction with inhaled treprostinil.,,,
period,NCT01908699::period::1,NCT01908699,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01908699::outcome::primary::1,NCT01908699,Number of Participants That Experienced Clinical Worsening,,,,,,,,,,,,,PRIMARY,up to 144 weeks
country,NCT01908699::country::United States,NCT01908699,United States,,,,,,,,,,,,,,
country,NCT01908699::country::Israel,NCT01908699,Israel,,,,,,,,,,,,,,
trial,NCT03284853,NCT03284853,Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension,PHASE3,hypertension,Open Angle Glaucoma; Ocular Hypertension,INDUSTRY,436.0,2017-09-05,2020-11-06,11.0,68.0,,,,,
arm,NCT03284853::arm::FG000,NCT03284853,Netarsudil/Latanoprost 0.02%/0.005%,,,,,,,,,,FG000,"PG324 Ophthalmic Solution (netarsudil 0.02% / latanoprost 0.005%) one drop daily to each eye for 180 days.

Netarsudil/Latanoprost 0.02%/0.005%: Topical sterile ophthalmic solution",,,
arm,NCT03284853::arm::FG001,NCT03284853,GANFORT®,,,,,,,,,,FG001,"GANFORT® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic solution one drop daily to each eye for 180 days.

GANFORT®: Topical sterile ophthalmic solution",,,
period,NCT03284853::period::1,NCT03284853,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03284853::outcome::primary::1,NCT03284853,Mean Diurnal Intraocular Pressure by Goldmann Applanation Tonometry,,,,,,,,,,,,,PRIMARY,Day 90
country,NCT03284853::country::Spain,NCT03284853,Spain,,,,,,,,,,,,,,
country,NCT03284853::country::Italy,NCT03284853,Italy,,,,,,,,,,,,,,
country,NCT03284853::country::United Kingdom,NCT03284853,United Kingdom,,,,,,,,,,,,,,
country,NCT03284853::country::Hungary,NCT03284853,Hungary,,,,,,,,,,,,,,
country,NCT03284853::country::France,NCT03284853,France,,,,,,,,,,,,,,
country,NCT03284853::country::Germany,NCT03284853,Germany,,,,,,,,,,,,,,
country,NCT03284853::country::Latvia,NCT03284853,Latvia,,,,,,,,,,,,,,
country,NCT03284853::country::Poland,NCT03284853,Poland,,,,,,,,,,,,,,
country,NCT03284853::country::Austria,NCT03284853,Austria,,,,,,,,,,,,,,
country,NCT03284853::country::Czechia,NCT03284853,Czechia,,,,,,,,,,,,,,
country,NCT03284853::country::Belgium,NCT03284853,Belgium,,,,,,,,,,,,,,
trial,NCT02507687,NCT02507687,Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension,PHASE3,hypertension,"Glaucoma, Open-Angle; Ocular Hypertension",INDUSTRY,240.0,2015-08-27,2023-05-31,12.0,95.0,,,,,
arm,NCT02507687::arm::FG000,NCT02507687,Stage 1: SLT (Primary Eye) / Bimatoprost SR 15 µg (Contralateral Eye),,,,,,,,,,FG000,"Participants enrolled prior to implementation of Protocol Amendment 3 (August 2018) received the following treatment in each eye:

Assigned Primary Eye: Selective laser trabeculoplasty (SLT) administe",,,
arm,NCT02507687::arm::FG001,NCT02507687,Stage 1: Bimatoprost SR 15 µg (Primary Eye) / SLT (Contralateral Eye),,,,,,,,,,FG001,"Participants enrolled prior to implementation of Protocol Amendment 3 received the following treatment in each eye:

Assigned Primary Eye: Sham SLT administered on Day 1 followed by up to three bimato",,,
arm,NCT02507687::arm::FG002,NCT02507687,Stage 2: SLT (Primary Eye) / Bimatoprost SR 10 µg (Contralateral Eye),,,,,,,,,,FG002,"Participants enrolled after implementation of Protocol Amendment 3 received the following treatment in each eye:

Assigned Primary Eye: SLT administered on Day 1 followed by up to two sham bimatoprost",,,
arm,NCT02507687::arm::FG003,NCT02507687,Stage 2: Bimatoprost SR 10 µg (Primary Eye) / SLT (Contralateral Eye),,,,,,,,,,FG003,"Participants enrolled after implementation of Protocol Amendment 3 received the following treatment in each eye:

Assigned Primary Eye: Sham SLT administered on Day 1 followed by up to two bimatoprost",,,
period,NCT02507687::period::1,NCT02507687,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02507687::outcome::primary::1,NCT02507687,Change From Baseline in Intraocular Pressure at Week 4,,,,,,,,,,,,,PRIMARY,Baseline and Week 4
outcome,NCT02507687::outcome::primary::2,NCT02507687,Change From Baseline in Intraocular Pressure at Week 12,,,,,,,,,,,,,PRIMARY,Baseline and Week 12
outcome,NCT02507687::outcome::primary::3,NCT02507687,Change From Baseline in Intraocular Pressure at Week 24,,,,,,,,,,,,,PRIMARY,Baseline and Week 24
country,NCT02507687::country::United States,NCT02507687,United States,,,,,,,,,,,,,,
country,NCT02507687::country::United Kingdom,NCT02507687,United Kingdom,,,,,,,,,,,,,,
country,NCT02507687::country::Australia,NCT02507687,Australia,,,,,,,,,,,,,,
country,NCT02507687::country::France,NCT02507687,France,,,,,,,,,,,,,,
country,NCT02507687::country::Israel,NCT02507687,Israel,,,,,,,,,,,,,,
country,NCT02507687::country::Philippines,NCT02507687,Philippines,,,,,,,,,,,,,,
country,NCT02507687::country::Germany,NCT02507687,Germany,,,,,,,,,,,,,,
country,NCT02507687::country::New Zealand,NCT02507687,New Zealand,,,,,,,,,,,,,,
country,NCT02507687::country::Russia,NCT02507687,Russia,,,,,,,,,,,,,,
country,NCT02507687::country::Canada,NCT02507687,Canada,,,,,,,,,,,,,,
country,NCT02507687::country::Denmark,NCT02507687,Denmark,,,,,,,,,,,,,,
country,NCT02507687::country::Poland,NCT02507687,Poland,,,,,,,,,,,,,,
trial,NCT00323284,NCT00323284,A Study of the Trabecular Micro-bypass Stent in Combination With Cataract Surgery in Subjects With Open Angle Glaucoma,PHASE3,hypertension,Open-Angle Glaucoma,INDUSTRY,240.0,2005-06,2010-03,1.0,31.0,,,,,
arm,NCT00323284::arm::FG000,NCT00323284,A--iStent Plus Cataract Surgery,,,,,,,,,,FG000,iStent plus Cataract Surgery,,,
arm,NCT00323284::arm::FG001,NCT00323284,B--Cataract Surgery Only,,,,,,,,,,FG001,Cataract Surgery only,,,
period,NCT00323284::period::1,NCT00323284,12 Months Follow-up,,,,,,,,,,,,1.0,,
period,NCT00323284::period::2,NCT00323284,24 Months Follow-up,,,,,,,,,,,,2.0,,
outcome,NCT00323284::outcome::primary::1,NCT00323284,Intraocular Pressure (Measured in mm Hg) Less or Equal to 21 mm Hg on no Topical Hypotensive Meds,,,,,,,,,,,,,PRIMARY,12 months
country,NCT00323284::country::United States,NCT00323284,United States,,,,,,,,,,,,,,
trial,NCT01749904,NCT01749904,Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension,PHASE3,hypertension,Open-Angle Glaucoma; Ocular Hypertension,INDUSTRY,420.0,2013-01-31,2015-09-30,1.0,1.0,,,,,
arm,NCT01749904::arm::FG000,NCT01749904,BOL-303259-X,,,,,,,,,,FG000,"BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) administered for 3 months (Visit 6) into the study eye(s).

BOL-303259-X: Topical ocular BOL-303259-X will be administered QD in the evenin",,,
arm,NCT01749904::arm::FG001,NCT01749904,Timolol,,,,,,,,,,FG001,"Timolol maleate ophthalmic solution, 0.5%, administered BID for 3 months (Visit 6) into study eye(s).

Timolol: Timolol will be administered BID once in the morning and once in the evening for 3 month",,,
period,NCT01749904::period::1,NCT01749904,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01749904::outcome::primary::1,NCT01749904,Mean IOP,,,,,,,,,,,,,PRIMARY,"8 AM, 12 PM, and 4 PM at Visit 4(Week 2), Visit 5 (Week 6), and Visit 6 (Month 3)"
country,NCT01749904::country::United States,NCT01749904,United States,,,,,,,,,,,,,,
trial,NCT02207491,NCT02207491,Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,PHASE3,hypertension,Ocular Hypertension; Open-angle Glaucoma,INDUSTRY,411.0,2014-07,2015-03,1.0,1.0,,,,,
arm,NCT02207491::arm::FG000,NCT02207491,AR-13324 Ophthalmic Solution 0.02% & Placebo,,,,,,,,,,FG000,1 drop AR-13324 in the evening (PM) \& 1 drop placebo in the morning (AM) in both eyes (OU),,,
arm,NCT02207491::arm::FG001,NCT02207491,Timolol Maleate Ophthalmic Solution 0.5% BID,,,,,,,,,,FG001,1 drop Timolol maleate twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU),,,
period,NCT02207491::period::1,NCT02207491,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02207491::outcome::primary::1,NCT02207491,Intraocular Pressure (IOP),,,,,,,,,,,,,PRIMARY,3 months
country,NCT02207491::country::United States,NCT02207491,United States,,,,,,,,,,,,,,
trial,NCT00449956,NCT00449956,MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED),PHASE3,hypertension,Glaucoma,INDUSTRY,474.0,2007-03-12,2008-02-16,0.0,0.0,,,,,
arm,NCT00449956::arm::FG000,NCT00449956,MK0507A (Dorzolamide 1.0% / Timolol 0.5% Combination),,,,,,,,,,FG000,"MK0507A (Dorzolamide 1.0% / Timolol 0.5% combination), one drop per dose twice daily to the study eye.",,,
arm,NCT00449956::arm::FG001,NCT00449956,Timolol 0.5%,,,,,,,,,,FG001,"Timolol 0.5%, one drop per dose twice daily to the study eye.",,,
arm,NCT00449956::arm::FG002,NCT00449956,Concomitant (Dorzolamide 1.0% / Timolol 0.5%),,,,,,,,,,FG002,"Concomitant (Dorzolamide 1.0%, one drop per dose three times daily to the study eye / Timolol 0.5%, one drop per dose twice daily to the study eye).",,,
period,NCT00449956::period::1,NCT00449956,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00449956::outcome::primary::1,NCT00449956,Change in Intraocular Pressure (IOP) From Baseline at 8 Weeks,,,,,,,,,,,,,PRIMARY,8 weeks
trial,NCT00848536,NCT00848536,Efficacy Study of Travoprost APS Versus TRAVATAN,PHASE3,hypertension,Open Angle Glaucoma; Ocular Hypertension,INDUSTRY,371.0,2009-03,2010-01,0.0,0.0,,,,,
arm,NCT00848536::arm::FG000,NCT00848536,TRAVATAN APS,,,,,,,,,,FG000,One drop once daily in the evening for 3 months,,,
arm,NCT00848536::arm::FG001,NCT00848536,TRAVATAN,,,,,,,,,,FG001,One drop once daily in the evening for 3 months,,,
period,NCT00848536::period::1,NCT00848536,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00848536::outcome::primary::1,NCT00848536,Mean Intraocular Pressure at 9:00 am,,,,,,,,,,,,,PRIMARY,3 months (measured at 9:00 am)
outcome,NCT00848536::outcome::primary::2,NCT00848536,Mean Intraocular Pressure at 11:00 am,,,,,,,,,,,,,PRIMARY,3 months (measured at 11:00 am)
outcome,NCT00848536::outcome::primary::3,NCT00848536,Mean Intraocular Pressure at 4:00 pm,,,,,,,,,,,,,PRIMARY,3 months (measured at 4:00 pm)
trial,NCT03868124,NCT03868124,Clinical Study Comparing Two Models of a Travoprost Intraocular Implant,PHASE3,hypertension,"Glaucoma, Open-Angle; Ocular Hypertension",INDUSTRY,560.0,2018-09-17,2024-06-19,1.0,1.0,,,,,
arm,NCT03868124::arm::FG000,NCT03868124,Implant Group 1,,,,,,,,,,FG000,"G2-TR intraocular implant containing Travoprost 75 mcg with high elution rate, plus postoperative placebo eye drops.

G2-TR intraocular implant containing travoprost: Provided in Arm/Group description",,,
arm,NCT03868124::arm::FG001,NCT03868124,Implant Group 2,,,,,,,,,,FG001,"G2-TR intraocular implant containing Travoprost 75 mcg with low elution rate, plus postoperative placebo eye drops.

G2-TR intraocular implant containing travoprost: Provided in Arm/Group descriptions",,,
arm,NCT03868124::arm::FG002,NCT03868124,Control Group,,,,,,,,,,FG002,"Sham surgery + active-comparator eye drops

Sham surgery + active-comparator eye drops: Sham surgery plus postoperative active-comparator eye drops (Timolol Maleate ophthalmic solution, 0.5%)",,,
period,NCT03868124::period::1,NCT03868124,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03868124::outcome::primary::1,NCT03868124,Change From Baseline in Diurnal IOP (as Measured at 8AM and 10AM) Through 3 Months Postoperative,,,,,,,,,,,,,PRIMARY,3 Months
country,NCT03868124::country::United States,NCT03868124,United States,,,,,,,,,,,,,,
trial,NCT02558374,NCT02558374,Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension,PHASE3,hypertension,Open-angle Glaucoma; Ocular Hypertension,INDUSTRY,708.0,2015-09,2016-12,1.0,1.0,,,,,
arm,NCT02558374::arm::FG000,NCT02558374,AR-13324 Ophthalmic Solution 0.02% & Placebo,,,,,,,,,,FG000,1 drop AR-13324 in the evening (PM) \& 1 drop placebo in the morning (AM) in both eyes (OU),,,
arm,NCT02558374::arm::FG001,NCT02558374,Timolol Maleate Ophthalmic Solution 0.5% BID,,,,,,,,,,FG001,1 drop twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU),,,
period,NCT02558374::period::1,NCT02558374,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02558374::outcome::primary::1,NCT02558374,IOP (Intraocular Pressure),,,,,,,,,,,,,PRIMARY,3 months
country,NCT02558374::country::United States,NCT02558374,United States,,,,,,,,,,,,,,
trial,NCT00947661,NCT00947661,Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension,PHASE3,hypertension,Open Angle Glaucoma; Ocular Hypertension,INDUSTRY,578.0,2010-07,2012-05,1.0,1.0,,,,,
arm,NCT00947661::arm::FG000,NCT00947661,SPARC0912,,,,,,,,,,FG000,SPARC0912 administered once daily for 12 weeks,,,
arm,NCT00947661::arm::FG001,NCT00947661,Reference0912,,,,,,,,,,FG001,Reference0912 administered once daily for 12 weeks,,,
period,NCT00947661::period::1,NCT00947661,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00947661::outcome::primary::1,NCT00947661,Change in Intraocular Pressure From Baseline to Week 12,,,,,,,,,,,,,PRIMARY,12 weeks
country,NCT00947661::country::United States,NCT00947661,United States,,,,,,,,,,,,,,
trial,NCT01830140,NCT01830140,A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension,PHASE3,hypertension,Glaucoma; Ocular Hypertension,INDUSTRY,466.0,2013-07,2014-05,1.0,2.0,,,,,
arm,NCT01830140::arm::FG000,NCT01830140,Bimatoprost 0.01%,,,,,,,,,,FG000,Bimatoprost 0.01% (LUMIGAN® 0.01%) administered each evening in both eyes for 6 weeks.,,,
arm,NCT01830140::arm::FG001,NCT01830140,Bimatoprost 0.03%,,,,,,,,,,FG001,Bimatoprost 0.03% (LUMIGAN® 0.03%) administered each evening in both eyes for 6 weeks.,,,
period,NCT01830140::period::1,NCT01830140,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01830140::outcome::primary::1,NCT01830140,Percentage of Patients With an Increase in Macroscopic Conjunctival Hyperemia in Either Eye,,,,,,,,,,,,,PRIMARY,"Baseline, 6 Weeks"
country,NCT01830140::country::United States,NCT01830140,United States,,,,,,,,,,,,,,
trial,NCT02059278,NCT02059278,Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension,PHASE3,hypertension,Primary Open Angle Glaucoma; Ocular Hypertension,INDUSTRY,335.0,2014-01,2015-01,1.0,1.0,,,,,
arm,NCT02059278::arm::FG000,NCT02059278,T-2345,,,,,,,,,,FG000,T-2345 Ophthalmic Solution,,,
arm,NCT02059278::arm::FG001,NCT02059278,Xalatan,,,,,,,,,,FG001,Xalatan (Latanoprost 0.005% Ophthalmic Solution),,,
period,NCT02059278::period::1,NCT02059278,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02059278::outcome::primary::1,NCT02059278,Intraocular Pressure,,,,,,,,,,,,,PRIMARY,"Measured at 8am 10 am and 4 pm at Baseline and on Days 15, 42 and 84"
country,NCT02059278::country::United States,NCT02059278,United States,,,,,,,,,,,,,,
trial,NCT00051168,NCT00051168,A Long-term Safety Study of Once-daily Travatan,PHASE3,hypertension,"Glaucoma, Open-angle; Ocular Hypertension",INDUSTRY,502.0,2006-01,,1.0,1.0,,,,,
arm,NCT00051168::arm::FG000,NCT00051168,Travatan,,,,,,,,,,FG000,Travoprost (0.004%),,,
period,NCT00051168::period::1,NCT00051168,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00051168::outcome::primary::1,NCT00051168,Mean Intraocular Pressure,,,,,,,,,,,,,PRIMARY,At 5 years.
country,NCT00051168::country::United States,NCT00051168,United States,,,,,,,,,,,,,,
trial,NCT01841762,NCT01841762,Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument,PHASE3,hypertension,Pulmonary Arterial Hypertension,INDUSTRY,284.0,2013-04-01,2015-11-01,1.0,81.0,,,,,
arm,NCT01841762::arm::FG000,NCT01841762,Macitentan,,,,,,,,,,FG000,"Macitentan tablet, dose of 10 mg, once daily",,,
period,NCT01841762::period::1,NCT01841762,Screening Period,,,,,,,,,,,,1.0,,
period,NCT01841762::period::2,NCT01841762,Treatment Period,,,,,,,,,,,,2.0,,
period,NCT01841762::period::3,NCT01841762,Post-Treatment Safety Follow-Up Period,,,,,,,,,,,,3.0,,
outcome,NCT01841762::outcome::primary::1,NCT01841762,Development and Refinement of the Patient-reported Outcome Measure of Symptoms and Their Impact in PAH (the PAH-SYMPACT),,,,,,,,,,,,,PRIMARY,"From Screening Visit (Day -14) to End of Treatment (EOT) Visit (Visit 4, Week 16)"
outcome,NCT01841762::outcome::primary::2,NCT01841762,"Validation of the Patient-reported Outcome Measure of Symptoms and Their Impact in PAH (the PAH-SYMPACT), With Reliability Assessed Via Test-retest Reliability.",,,,,,,,,,,,,PRIMARY,From ePRO period 1 (Days -14 to -8) to ePRO period 2 (Days -7 to -1) in screening period.
outcome,NCT01841762::outcome::primary::3,NCT01841762,"Validation of the Patient-reported Outcome Measure of Symptoms and Their Impact in PAH (the PAH-SYMPACT), Assessing Internal Consistency Reliability.",,,,,,,,,,,,,PRIMARY,From ePRO period 1 (Days -14 to -8) to ePRO period 2 (Days -7 to -1) in screening period.
country,NCT01841762::country::United States,NCT01841762,United States,,,,,,,,,,,,,,
trial,NCT01355159,NCT01355159,High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention,PHASE3,hypertension,Pregnancy Complications; Preeclampsia,OTHER,2464.0,2011-04,2016-09,5.0,72.0,,,,,
arm,NCT01355159::arm::FG000,NCT01355159,Folic Acid 4 mg,,,,,,,,,,FG000,"Folic Acid 1.0 mg x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by t",,,
arm,NCT01355159::arm::FG001,NCT01355159,Placebo,,,,,,,,,,FG001,"Women will be randomised in a 1:1 ratio to folic acid 4.0 mg or placebo

Placebo: Placebo x 4 tablets will be taken daily by oral administration.",,,
period,NCT01355159::period::1,NCT01355159,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01355159::outcome::primary::1,NCT01355159,Preeclampsia,,,,,,,,,,,,,PRIMARY,Participants will be followed from 20+0 weeks of gestational age until 42 days postpartum (after delivery)
country,NCT01355159::country::United Kingdom,NCT01355159,United Kingdom,,,,,,,,,,,,,,
country,NCT01355159::country::Canada,NCT01355159,Canada,,,,,,,,,,,,,,
country,NCT01355159::country::Argentina,NCT01355159,Argentina,,,,,,,,,,,,,,
country,NCT01355159::country::Australia,NCT01355159,Australia,,,,,,,,,,,,,,
country,NCT01355159::country::Jamaica,NCT01355159,Jamaica,,,,,,,,,,,,,,
trial,NCT03541174,NCT03541174,A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety,PHASE3,hypertension,Resistant Hypertension,INDUSTRY,730.0,2018-06-18,2022-04-25,20.0,159.0,,,,,
arm,NCT03541174::arm::FG000,NCT03541174,Aprocitentan 12.5 mg in Part 1 (Double-blind),,,,,,,,,,FG000,"Participants were randomized and received aprocitentan 12.5 mg, orally, once daily in the morning for 4 weeks.",,,
arm,NCT03541174::arm::FG001,NCT03541174,Aprocitentan 25 mg in Part 1 (Double-blind),,,,,,,,,,FG001,"Participants were randomized and received aprocitentan 25 mg, orally, once daily in the morning for 4 weeks.",,,
arm,NCT03541174::arm::FG002,NCT03541174,Placebo in Part 1 (Double-blind),,,,,,,,,,FG002,"Participants were randomized and received placebo (matching aprocitentan), orally, once daily in the morning for 4 weeks.",,,
arm,NCT03541174::arm::FG003,NCT03541174,Aprocitentan 25 mg in Part 2 (Single-blind),,,,,,,,,,FG003,"Participants that completed the double-blind part received aprocitentan 25 mg, orally, once daily in the morning for 32 weeks.",,,
arm,NCT03541174::arm::FG004,NCT03541174,Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal),,,,,,,,,,FG004,"After the 32-week single-blind, single-arm aprocitentan 25 mg (Part 2), participants were re-randomized and received aprocitentan 25 mg, orally, once daily in the morning for 12 weeks.",,,
arm,NCT03541174::arm::FG005,NCT03541174,Placebo in Part 3 (Double-blind Withdrawal),,,,,,,,,,FG005,"After the 32-week single-blind, single-arm aprocitentan 25 mg (Part 2), participants were re-randomized and received placebo (matching aprocitentan), orally, once daily in the morning for 12 weeks.",,,
period,NCT03541174::period::1,NCT03541174,Part 1 Double-Blind,,,,,,,,,,,,1.0,,
period,NCT03541174::period::2,NCT03541174,Part 2 Single-Blind,,,,,,,,,,,,2.0,,
period,NCT03541174::period::3,NCT03541174,Part 3 Double-Blind Withdrawal,,,,,,,,,,,,3.0,,
outcome,NCT03541174::outcome::primary::1,NCT03541174,Change From Baseline to Week 4 of Double-blind Treatment in Mean Trough Sitting Systolic Blood Pressure (SiSBP) Measured by Automated Office Blood Pressure Measurement,,,,,,,,,,,,,PRIMARY,Pre-dose Day 1 (Part 1 double-blind randomized baseline) up to Week 4 (End of double-blind randomized part 1)
country,NCT03541174::country::United States,NCT03541174,United States,,,,,,,,,,,,,,
country,NCT03541174::country::Poland,NCT03541174,Poland,,,,,,,,,,,,,,
country,NCT03541174::country::Russia,NCT03541174,Russia,,,,,,,,,,,,,,
country,NCT03541174::country::Ukraine,NCT03541174,Ukraine,,,,,,,,,,,,,,
country,NCT03541174::country::Spain,NCT03541174,Spain,,,,,,,,,,,,,,
country,NCT03541174::country::China,NCT03541174,China,,,,,,,,,,,,,,
country,NCT03541174::country::Australia,NCT03541174,Australia,,,,,,,,,,,,,,
country,NCT03541174::country::Germany,NCT03541174,Germany,,,,,,,,,,,,,,
country,NCT03541174::country::Canada,NCT03541174,Canada,,,,,,,,,,,,,,
country,NCT03541174::country::Czechia,NCT03541174,Czechia,,,,,,,,,,,,,,
country,NCT03541174::country::Israel,NCT03541174,Israel,,,,,,,,,,,,,,
country,NCT03541174::country::Italy,NCT03541174,Italy,,,,,,,,,,,,,,
country,NCT03541174::country::Belgium,NCT03541174,Belgium,,,,,,,,,,,,,,
country,NCT03541174::country::France,NCT03541174,France,,,,,,,,,,,,,,
country,NCT03541174::country::Greece,NCT03541174,Greece,,,,,,,,,,,,,,
country,NCT03541174::country::Hungary,NCT03541174,Hungary,,,,,,,,,,,,,,
country,NCT03541174::country::Netherlands,NCT03541174,Netherlands,,,,,,,,,,,,,,
country,NCT03541174::country::Finland,NCT03541174,Finland,,,,,,,,,,,,,,
country,NCT03541174::country::United Kingdom,NCT03541174,United Kingdom,,,,,,,,,,,,,,
country,NCT03541174::country::Lithuania,NCT03541174,Lithuania,,,,,,,,,,,,,,
trial,NCT01357616,NCT01357616,Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension,PHASE3,hypertension,Open-Angle Glaucoma; Ocular Hypertension,INDUSTRY,328.0,2010-11,2013-01,0.0,0.0,,,,,
arm,NCT01357616::arm::FG000,NCT01357616,AZARGA,,,,,,,,,,FG000,"Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension, 1 drop in the affected eye(s) dosed twice daily (9AM and 9PM) for 8 weeks. Both eyes were dosed unless there was a potential saf",,,
arm,NCT01357616::arm::FG001,NCT01357616,AZOPT + TIMOLOL,,,,,,,,,,FG001,"Brinzolamide 1% ophthalmic suspension and Timolol 0.5% ophthalmic solution, 1 drop of each component instilled in the affected eye(s), waiting approximately 10 minutes between instillation of the 2 dr",,,
period,NCT01357616::period::1,NCT01357616,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01357616::outcome::primary::1,NCT01357616,Mean Diurnal IOP Change From Baseline at Week 8,,,,,,,,,,,,,PRIMARY,"Baseline, Week 8"
trial,NCT01297920,NCT01297920,Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%,PHASE3,hypertension,Open-Angle Glaucoma; Ocular Hypertension,INDUSTRY,1062.0,2011-03,2012-06,0.0,0.0,,,,,
arm,NCT01297920::arm::FG000,NCT01297920,Brinz/Brim,,,,,,,,,,FG000,"Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled in each eye 3 times a day for 3 months",,,
arm,NCT01297920::arm::FG001,NCT01297920,Brinzolamide,,,,,,,,,,FG001,"Brinzolamide ophthalmic suspension, 1%, 1 drop instilled in each eye 3 times a day for 3 months",,,
arm,NCT01297920::arm::FG002,NCT01297920,Brimonidine,,,,,,,,,,FG002,"Brimonidine tartrate ophthalmic solution, 0.2%, 1 drop instilled in each eye 3 times a day for 3 months",,,
period,NCT01297920::period::1,NCT01297920,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01297920::outcome::primary::1,NCT01297920,"Mean Intraocular Pressure (IOP) at Each Assessment Timepoint (8 AM, +2 h, +7 h, and +9 h) at Month 3",,,,,,,,,,,,,PRIMARY,Month 3
trial,NCT04445519,NCT04445519,Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension,PHASE3,hypertension,Open Angle Glaucoma; Ocular Hypertension,INDUSTRY,691.0,2020-06-01,2022-09-16,1.0,1.0,,,,,
arm,NCT04445519::arm::FG000,NCT04445519,NCX 470 0.065%,,,,,,,,,,FG000,"NCX 470 Ophthalmic Solution, 0.065% dosed once daily to both eyes",,,
arm,NCT04445519::arm::FG001,NCT04445519,NCX 470 0.1%,,,,,,,,,,FG001,"NCX 470 Ophthalmic Solution, 0.1% dosed once daily to both eyes",,,
arm,NCT04445519::arm::FG002,NCT04445519,Latanoprost 0.005%,,,,,,,,,,FG002,"Latanoprost Ophthalmic Solution, 0.005% dosed once daily to both eyes",,,
period,NCT04445519::period::1,NCT04445519,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04445519::outcome::primary::1,NCT04445519,"Mean IOP Reduction From Time-Matched Baseline at the 8AM and 4PM Time-Points at Week 2, Week 6, and Month 3",,,,,,,,,,,,,PRIMARY,"Baseline, Week 2, Week 6, and Month 3"
country,NCT04445519::country::United States,NCT04445519,United States,,,,,,,,,,,,,,
trial,NCT02914509,NCT02914509,Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT,PHASE3,hypertension,Open Angle Glaucoma; Ocular Hypertension,INDUSTRY,565.0,2016-11-07,2019-03-30,1.0,10.0,,,,,
arm,NCT02914509::arm::FG000,NCT02914509,OTX-TP,,,,,,,,,,FG000,Three forty eight (348) subjects were randomized to OTX-TP,,,
arm,NCT02914509::arm::FG001,NCT02914509,Placebo Vehicle (PV),,,,,,,,,,FG001,Two hundred seventeen (217) subjects were randomized to the PV.,,,
period,NCT02914509::period::1,NCT02914509,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02914509::outcome::primary::1,NCT02914509,Mean IOP,,,,,,,,,,,,,PRIMARY,"Mean IOP at 8AM, 10AM, and 4PM at the 2 Week Visit"
outcome,NCT02914509::outcome::primary::2,NCT02914509,Mean IOP,,,,,,,,,,,,,PRIMARY,"Mean IOP at 8AM, 10AM, and 4PM at the 6 Week Visit"
outcome,NCT02914509::outcome::primary::3,NCT02914509,Mean IOP,,,,,,,,,,,,,PRIMARY,"Mean IOP at 8AM, 10AM, and 4PM at the 12 Week Visit"
country,NCT02914509::country::United States,NCT02914509,United States,,,,,,,,,,,,,,
trial,NCT01027949,NCT01027949,An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension,PHASE3,hypertension,Pulmonary Arterial Hypertension,INDUSTRY,894.0,2007-01-16,2020-02-12,20.0,135.0,,,,,
arm,NCT01027949::arm::FG000,NCT01027949,Oral Treprostinil,,,,,,,,,,FG000,"Subjects eligible for TDE-PH-304 previously participated in Studies TDE-PH-202 (NCT01104870), TDE-PH-203 (NCT01477333), and TDE-PH-205 (NCT01588405), TDE-PH-301 (NCT00325442), TDE-PH-302 (NCT00325403)",,,
period,NCT01027949::period::1,NCT01027949,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01027949::outcome::primary::1,NCT01027949,Change in Exercise Capacity at Month 12,,,,,,,,,,,,,PRIMARY,From First Visit (Visit 1) to Month 12
country,NCT01027949::country::United States,NCT01027949,United States,,,,,,,,,,,,,,
country,NCT01027949::country::India,NCT01027949,India,,,,,,,,,,,,,,
country,NCT01027949::country::France,NCT01027949,France,,,,,,,,,,,,,,
country,NCT01027949::country::Germany,NCT01027949,Germany,,,,,,,,,,,,,,
country,NCT01027949::country::Canada,NCT01027949,Canada,,,,,,,,,,,,,,
country,NCT01027949::country::Israel,NCT01027949,Israel,,,,,,,,,,,,,,
country,NCT01027949::country::United Kingdom,NCT01027949,United Kingdom,,,,,,,,,,,,,,
country,NCT01027949::country::Australia,NCT01027949,Australia,,,,,,,,,,,,,,
country,NCT01027949::country::Italy,NCT01027949,Italy,,,,,,,,,,,,,,
country,NCT01027949::country::Austria,NCT01027949,Austria,,,,,,,,,,,,,,
country,NCT01027949::country::China,NCT01027949,China,,,,,,,,,,,,,,
country,NCT01027949::country::Mexico,NCT01027949,Mexico,,,,,,,,,,,,,,
country,NCT01027949::country::Poland,NCT01027949,Poland,,,,,,,,,,,,,,
country,NCT01027949::country::Spain,NCT01027949,Spain,,,,,,,,,,,,,,
country,NCT01027949::country::Belgium,NCT01027949,Belgium,,,,,,,,,,,,,,
country,NCT01027949::country::Netherlands,NCT01027949,Netherlands,,,,,,,,,,,,,,
country,NCT01027949::country::Ireland,NCT01027949,Ireland,,,,,,,,,,,,,,
country,NCT01027949::country::Portugal,NCT01027949,Portugal,,,,,,,,,,,,,,
country,NCT01027949::country::Puerto Rico,NCT01027949,Puerto Rico,,,,,,,,,,,,,,
country,NCT01027949::country::Sweden,NCT01027949,Sweden,,,,,,,,,,,,,,
trial,NCT01453855,NCT01453855,Travoprost 3-Month Safety and Efficacy Study,PHASE3,hypertension,Open-Angle Glaucoma; Ocular Hypertension,INDUSTRY,1099.0,2011-11,2012-08,0.0,0.0,,,,,
arm,NCT01453855::arm::FG000,NCT01453855,Travoprost 0.003%,,,,,,,,,,FG000,"Travoprost ophthalmic solution, 0.003%, one drop instilled in each eye, once daily, for three months",,,
arm,NCT01453855::arm::FG001,NCT01453855,TRAVATAN,,,,,,,,,,FG001,"Travoprost ophthalmic solution, 0.004%, one drop instilled in each eye, once daily, for three months",,,
period,NCT01453855::period::1,NCT01453855,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01453855::outcome::primary::1,NCT01453855,"Mean Intraocular Pressure (IOP) at Week 2, Week 6, and Month 3 for Each Assessment Time Point (8 AM, 10 AM, and 4 PM)",,,,,,,,,,,,,PRIMARY,"Week 2, Week 6, Month 3 (8 AM, 10 AM, 4 PM)"
trial,NCT02558231,NCT02558231,The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension,PHASE3,hypertension,Pulmonary Arterial Hypertension,INDUSTRY,247.0,2016-05-01,2020-04-20,15.0,58.0,,,,,
arm,NCT02558231::arm::FG000,NCT02558231,"Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag)",,,,,,,,,,FG000,"Participants received macitentan oral tablet, 10 milligrams (mg) once daily and tadalafil oral tablet, 20 mg, once daily from Day 1 up to End of treatment (10 months after last participant was enrolle",,,
arm,NCT02558231::arm::FG001,NCT02558231,"Double Oral Therapy (Macitentan, Tadalafil, and Placebo)",,,,,,,,,,FG001,"Participants received macitentan oral tablet, 10 mg once daily and tadalafil oral tablet, 20 once daily from Day 1 up to End of treatment (10 months after last participant was enrolled). Tadalafil was",,,
period,NCT02558231::period::1,NCT02558231,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02558231::outcome::primary::1,NCT02558231,Change From Baseline to Week 26 in Pulmonary Vascular Resistance (PVR),,,,,,,,,,,,,PRIMARY,"Baseline, Week 26"
country,NCT02558231::country::United States,NCT02558231,United States,,,,,,,,,,,,,,
country,NCT02558231::country::Canada,NCT02558231,Canada,,,,,,,,,,,,,,
country,NCT02558231::country::Germany,NCT02558231,Germany,,,,,,,,,,,,,,
country,NCT02558231::country::United Kingdom,NCT02558231,United Kingdom,,,,,,,,,,,,,,
country,NCT02558231::country::Austria,NCT02558231,Austria,,,,,,,,,,,,,,
country,NCT02558231::country::Sweden,NCT02558231,Sweden,,,,,,,,,,,,,,
country,NCT02558231::country::Australia,NCT02558231,Australia,,,,,,,,,,,,,,
country,NCT02558231::country::Belgium,NCT02558231,Belgium,,,,,,,,,,,,,,
country,NCT02558231::country::Denmark,NCT02558231,Denmark,,,,,,,,,,,,,,
country,NCT02558231::country::Netherlands,NCT02558231,Netherlands,,,,,,,,,,,,,,
country,NCT02558231::country::Spain,NCT02558231,Spain,,,,,,,,,,,,,,
country,NCT02558231::country::France,NCT02558231,France,,,,,,,,,,,,,,
country,NCT02558231::country::Ireland,NCT02558231,Ireland,,,,,,,,,,,,,,
country,NCT02558231::country::Italy,NCT02558231,Italy,,,,,,,,,,,,,,
country,NCT02558231::country::Switzerland,NCT02558231,Switzerland,,,,,,,,,,,,,,
trial,NCT01310777,NCT01310777,Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension,PHASE3,hypertension,Open-Angle Glaucoma; Ocular Hypertension,INDUSTRY,771.0,2011-05,2013-01,0.0,0.0,,,,,
arm,NCT01310777::arm::FG000,NCT01310777,Brinz/Brim,,,,,,,,,,FG000,"Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled in each eye 2 times a day for 6 months",,,
arm,NCT01310777::arm::FG001,NCT01310777,Brinz,,,,,,,,,,FG001,"Brinzolamide 1% ophthalmic suspension, 1 drop instilled in each eye 2 times a day for 6 months",,,
arm,NCT01310777::arm::FG002,NCT01310777,Brim,,,,,,,,,,FG002,"Brimonidine tartrate 0.2% ophthalmic solution, 1 drop instilled in each eye 2 times a day for 6 months",,,
period,NCT01310777::period::1,NCT01310777,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01310777::outcome::primary::1,NCT01310777,Mean Diurnal IOP Change From Baseline at Month 3,,,,,,,,,,,,,PRIMARY,"Baseline (Day 1), Month 3"
trial,NCT02105272,NCT02105272,Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension,PHASE3,hypertension,Glaucoma; Ocular Hypertension,INDUSTRY,237.0,2014-04,2015-03,1.0,1.0,,,,,
arm,NCT02105272::arm::FG000,NCT02105272,OPC-1085EL Ophthalmic Solution,,,,,,,,,,FG000,"Once daily

OPC-1085EL ophthalmic solution",,,
arm,NCT02105272::arm::FG001,NCT02105272,Latanoprost Ophthalmic Solution,,,,,,,,,,FG001,"Once daily

Latanoprost ophthalmic solution",,,
period,NCT02105272::period::1,NCT02105272,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02105272::outcome::primary::1,NCT02105272,Decrease From Baseline in Intraocular Pressure,,,,,,,,,,,,,PRIMARY,"Baseline, week 8 predose"
country,NCT02105272::country::Japan,NCT02105272,Japan,,,,,,,,,,,,,,
trial,NCT00383019,NCT00383019,A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).,PHASE3,hypertension,Glaucoma; Ocular Hypertension,INDUSTRY,300.0,2006-11-14,2007-10-01,1.0,54.0,,,,,
arm,NCT00383019::arm::FG000,NCT00383019,KP2035 Group,,,,,,,,,,FG000,"Subjects were treated with KP2035 (0.005% latanoprost + 0.5% timolol combination eye drop) one drop, once daily in the evening (20:00-23:00).",,,
arm,NCT00383019::arm::FG001,NCT00383019,Xalatan Group,,,,,,,,,,FG001,"Subjects were treated with Xalatan (0.005% latanoprost), one drop, once daily in the evening (20:00-23:00).",,,
period,NCT00383019::period::1,NCT00383019,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00383019::outcome::primary::1,NCT00383019,Change of Intraocular Pressure (IOP) From Baseline to Week 8,,,,,,,,,,,,,PRIMARY,Baseline to Week 8
country,NCT00383019::country::Japan,NCT00383019,Japan,,,,,,,,,,,,,,
trial,NCT02512042,NCT02512042,Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes,PHASE3,hypertension,Glaucoma,INDUSTRY,973.0,2015-04,2016-05,1.0,10.0,,,,,
arm,NCT02512042::arm::FG000,NCT02512042,Generic Brinzolamide Ophthalmic Suspension USP 1%,,,,,,,,,,FG000,Study subjects used one drop in both eyes three times daily for 42 days.,,,
arm,NCT02512042::arm::FG001,NCT02512042,Azopt® (Brinzolomide Ophthalmic Suspension USP 1%),,,,,,,,,,FG001,Study subjects used one drop in both eyes three times daily for 42 days.,,,
period,NCT02512042::period::1,NCT02512042,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02512042::outcome::primary::1,NCT02512042,Mean Difference in Intraocular Pressure (IOP) of Both Eyes Between the Two Treatment Groups at Four Time Points,,,,,,,,,,,,,PRIMARY,Day 14 and 42 at 8AM and 10AM
country,NCT02512042::country::United States,NCT02512042,United States,,,,,,,,,,,,,,
trial,NCT00568178,NCT00568178,"An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))",PHASE3,hypertension,Proteinuria,INDUSTRY,306.0,2007-06-01,2011-03-01,0.0,0.0,,,,,
arm,NCT00568178::arm::FG000,NCT00568178,Losartan Double Blind Normortensive,,,,,,,,,,FG000,"Normotensive participants who were randomized to losartan.

Losartan dispensed as tablets or suspension depending on participant weight and ability to swallow tablets.

Losartan suspension dosing: 0.7",,,
arm,NCT00568178::arm::FG001,NCT00568178,Placebo Double Blind Normotensive,,,,,,,,,,FG001,"Normotensive participants who were randomized to losartan placebo.

Losartan placebo dispensed as tablets or suspension depending on participant weight and ability to swallow tablets.

Losartan placeb",,,
arm,NCT00568178::arm::FG002,NCT00568178,Losartan Double Blind Hypertensive,,,,,,,,,,FG002,"Hypertensive patients who were randomized to receive losartan and amlodipine placebo for 12 weeks.

Losartan dispensed as tablets or suspension depending on participant weight and ability to swallow t",,,
arm,NCT00568178::arm::FG003,NCT00568178,Amlodipine Double Blind Hypertensive,,,,,,,,,,FG003,"Hypertensive patients who were randomized to receive amlodipine and losartan placebo for 12 weeks.

Losartan placebo dispensed as tablets or suspension depending on participant weight and ability to s",,,
arm,NCT00568178::arm::FG004,NCT00568178,Losartan Open Label Extension,,,,,,,,,,FG004,"Participants were stratified based on assigned treatment in the double-blind treatment phase and were randomized in a 1:1 ratio to either losartan or enalapril.

Dosing of study medication during the ",,,
arm,NCT00568178::arm::FG005,NCT00568178,Enalapril Open Label Extension,,,,,,,,,,FG005,"Participants were stratified based on assigned treatment in the double-blind treatment phase and were randomized in a 1:1 ratio to either losartan or enalapril.

Dosing of study medication during the ",,,
period,NCT00568178::period::1,NCT00568178,Double Blind Base Study,,,,,,,,,,,,1.0,,
period,NCT00568178::period::2,NCT00568178,Open Label Extension,,,,,,,,,,,,2.0,,
outcome,NCT00568178::outcome::primary::1,NCT00568178,Double-Blind Treatment Phase: Percent Change From Baseline in Urinary Protein/Creatinine (Pr/Cr) Ratio (gm/gm) at Week 12,,,,,,,,,,,,,PRIMARY,Baseline and Week 12
outcome,NCT00568178::outcome::primary::2,NCT00568178,Open Label Extension: Percent Change From Baseline of Urinary Pr/Cr Ratio (gm/gm) at Month 36,,,,,,,,,,,,,PRIMARY,Baseline and Month 36
outcome,NCT00568178::outcome::primary::3,NCT00568178,Open Label Extension: Change From Baseline in Glomerular Filtration Rate (GFR) at Month 36,,,,,,,,,,,,,PRIMARY,Baseline and Month 36
trial,NCT00000125,NCT00000125,Ocular Hypertension Treatment Study (OHTS),PHASE3,hypertension,Ocular Hypertension; Glaucoma,OTHER,1636.0,1994-02,2019-06-30,0.0,0.0,,,,,
arm,NCT00000125::arm::FG000,NCT00000125,Observation,,,,,,,,,,FG000,Close Observation,,,
arm,NCT00000125::arm::FG001,NCT00000125,Treatment,,,,,,,,,,FG001,Topical ocular hypotensive eye drops.,,,
period,NCT00000125::period::1,NCT00000125,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00000125::outcome::primary::1,NCT00000125,Incidence of Primary Open-Angle Glaucoma in Hypotensive Patients,,,,,,,,,,,,,PRIMARY,"5 yrs (OHTS I, June 2002) and 13.0 yrs (completion of both phases of OHTS, March 2009)"
trial,NCT05022004,NCT05022004,A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension,PHASE3,hypertension,Primary Open Angle Glaucoma; Ocular Hypertension,INDUSTRY,599.0,2021-12-20,2023-01-06,2.0,40.0,,,,,
arm,NCT05022004::arm::FG000,NCT05022004,BRIN-20-01,,,,,,,,,,FG000,Brinzolamide ophthalmic suspension: dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks,,,
arm,NCT05022004::arm::FG001,NCT05022004,Azopt®,,,,,,,,,,FG001,Azopt®: dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks,,,
period,NCT05022004::period::1,NCT05022004,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT05022004::outcome::primary::1,NCT05022004,Mean Difference in Intraocular Pressure of Both Eyes Between the Two Treatment Groups,,,,,,,,,,,,,PRIMARY,"Baseline, Week 2 & Week 6"
country,NCT05022004::country::Russia,NCT05022004,Russia,,,,,,,,,,,,,,
country,NCT05022004::country::India,NCT05022004,India,,,,,,,,,,,,,,
trial,NCT03758638,NCT03758638,Healthy Eating and Active Living Taught at Home (HEALTH) Dissemination & Implementation (D&I),PHASE3,obesity,Obesity,OTHER,620.0,2019-01-25,2025-06-30,1.0,1.0,,,,,
arm,NCT03758638::arm::FG000,NCT03758638,Healthy Eating & Active Living Taught at Home,,,,,,,,,,FG000,"PAT National Center will train educators affiliated with PAT sites in HEALTH; among these, using the HEALTH training curriculum (implementation strategy).

Participants at HEALTH sites receive usual c",,,
arm,NCT03758638::arm::FG001,NCT03758638,Usual Care,,,,,,,,,,FG001,"Participants at usual care PAT sites will receive PAT as usual

Usual Care: The Foundational (usual care) curriculum uses a strength-based, solution-focused model to provide parents with child develop",,,
period,NCT03758638::period::1,NCT03758638,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03758638::outcome::primary::1,NCT03758638,Change in Weight,,,,,,,,,,,,,PRIMARY,24-months
country,NCT03758638::country::United States,NCT03758638,United States,,,,,,,,,,,,,,
trial,NCT01570829,NCT01570829,Clinical Trial of Safety and Efficacy of New Dosage Schedule for Dietressa Drug in Treatment of Obese Patients,PHASE3,obesity,Obesity,INDUSTRY,331.0,2011-12,2013-06,1.0,17.0,,,,,
arm,NCT01570829::arm::FG000,NCT01570829,Dietressa,,,,,,,,,,FG000,"Tablet for oral use. 1 tablet 6 times a day. The duration of Dietressa therapy is 24 weeks.

Dietressa: Oral administration.",,,
arm,NCT01570829::arm::FG001,NCT01570829,Placebo,,,,,,,,,,FG001,"Tablet for oral use. 1 tablet 6 times a day. The duration of Placebo therapy is 24 weeks.

Placebo: Oral administration.",,,
period,NCT01570829::period::1,NCT01570829,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01570829::outcome::primary::1,NCT01570829,Percentage of Patients With at Least 5% Weight Loss.,,,,,,,,,,,,,PRIMARY,24 weeks
outcome,NCT01570829::outcome::primary::2,NCT01570829,Average Absolute Weight Change,,,,,,,,,,,,,PRIMARY,On baseline and after 24 weeks
outcome,NCT01570829::outcome::primary::3,NCT01570829,Average Relative Weight Change,,,,,,,,,,,,,PRIMARY,On baseline and after 24 weeks
country,NCT01570829::country::Russia,NCT01570829,Russia,,,,,,,,,,,,,,
trial,NCT02398188,NCT02398188,Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2),PHASE3,obesity,Central Abdominal Bulging,INDUSTRY,793.0,2015-04-09,2015-10-29,1.0,35.0,,,,,
arm,NCT02398188::arm::FG000,NCT02398188,LIPO-202,,,,,,,,,,FG000,"Experimental arm

LIPO-202",,,
arm,NCT02398188::arm::FG001,NCT02398188,Placebo,,,,,,,,,,FG001,"Placebo comparator

Placebo",,,
period,NCT02398188::period::1,NCT02398188,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02398188::outcome::primary::1,NCT02398188,Percentage of Subjects Who Achieved a Composite P-GAPS1/CPnS2 Response,,,,,,,,,,,,,PRIMARY,"Baseline and End of Study (1 week post last treatment, 9 weeks after first treatment)"
outcome,NCT02398188::outcome::primary::2,NCT02398188,Percent Change in the Patient Reported Global Abdominal Perception Score,,,,,,,,,,,,,PRIMARY,8 weeks post the start of treatment
country,NCT02398188::country::United States,NCT02398188,United States,,,,,,,,,,,,,,
trial,NCT04844918,NCT04844918,A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease,PHASE3,obesity,Obesity,INDUSTRY,267.0,2021-05-10,2023-06-24,1.0,18.0,,,,,
arm,NCT04844918::arm::FG000,NCT04844918,10 Milligrams (mg) Tirzepatide,,,,,,,,,,FG000,"Participants received maintenance dose 10 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg and then 10 mg tirzepatide administered subcutaneously (SC) once weekly (QW).",,,
arm,NCT04844918::arm::FG001,NCT04844918,15 mg Tirzepatide,,,,,,,,,,FG001,"Participants received maintenance dose 15 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and then 15 mg tirzepatide administered SC QW.",,,
arm,NCT04844918::arm::FG002,NCT04844918,Placebo,,,,,,,,,,FG002,Participants received matching placebo administered SC QW.,,,
period,NCT04844918::period::1,NCT04844918,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04844918::outcome::primary::1,NCT04844918,Mean Percent Change in Body Weight,,,,,,,,,,,,,PRIMARY,"Baseline, 72 Weeks"
outcome,NCT04844918::outcome::primary::2,NCT04844918,Percentage of Participants Who Achieve ≥5% Body Weight Reduction,,,,,,,,,,,,,PRIMARY,Week 72
country,NCT04844918::country::Japan,NCT04844918,Japan,,,,,,,,,,,,,,
trial,NCT02963935,NCT02963935,Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting,PHASE3,obesity,Metabolism and Nutrition Disorder; Obesity,INDUSTRY,282.0,2017-02-06,2018-06-19,1.0,10.0,,,,,
arm,NCT02963935::arm::FG000,NCT02963935,Liraglutide 3.0 mg,,,,,,,,,,FG000,"Subjects received liraglutide 3.0 mg once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Subjects received 0.6 mg liraglutide during the firs",,,
arm,NCT02963935::arm::FG001,NCT02963935,Placebo,,,,,,,,,,FG001,"Subjects received matching placebo once daily by subcutaneous injection (in the abdomen, thigh or upper arm) irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutid",,,
period,NCT02963935::period::1,NCT02963935,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02963935::outcome::primary::1,NCT02963935,Change in Body Weight (%),,,,,,,,,,,,,PRIMARY,"Week 0, week 56"
outcome,NCT02963935::outcome::primary::2,NCT02963935,Proportion of Subjects Losing at Least 5% of Baseline Body Weight at Week 56,,,,,,,,,,,,,PRIMARY,Week 56
country,NCT02963935::country::United States,NCT02963935,United States,,,,,,,,,,,,,,
trial,NCT04074161,NCT04074161,Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity,PHASE3,obesity,Overweight; Obesity,INDUSTRY,338.0,2019-09-11,2021-05-11,1.0,19.0,,,,,
arm,NCT04074161::arm::FG000,NCT04074161,Semaglutide 2.4 mg,,,,,,,,,,FG000,"The trial included an initial dose-escalation period during which the dose was gradually increased (0.24, 0.5, 1.0, 1.7 milligram (mg)) to the maintenance dose of semaglutide 2.4 mg once weekly (16-we",,,
arm,NCT04074161::arm::FG001,NCT04074161,Liraglutide 3.0 mg,,,,,,,,,,FG001,"The trial included an initial dose-escalation period during which the dose was gradually increased (0.6, 1.2, 1.8, 2.4 mg) to the maintenance dose of liraglutide 3.0 mg once daily (4-week dose-escalat",,,
arm,NCT04074161::arm::FG002,NCT04074161,Pooled Placebo,,,,,,,,,,FG002,"Participants received placebo matched to either once weekly semaglutide or once daily liraglutide up to week 68 (end of treatment). In week 44, all participants randomized to semaglutide placebo switc",,,
period,NCT04074161::period::1,NCT04074161,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04074161::outcome::primary::1,NCT04074161,Change From Baseline (Week 0) to Week 68 in Body Weight (%) (Semaglutide 2.4 mg Versus Liraglutide 3.0 mg),,,,,,,,,,,,,PRIMARY,"Baseline (week 0), week 68"
country,NCT04074161::country::United States,NCT04074161,United States,,,,,,,,,,,,,,
trial,NCT00594399,NCT00594399,Enhancing Fitness in Older Pre-diabetic Veterans,PHASE3,obesity,Impaired Glucose Tolerance; Obesity; Diabetes,FED,302.0,2008-10,2011-06,1.0,1.0,,,,,
arm,NCT00594399::arm::FG000,NCT00594399,Arm 1 Physical Activity Counseling,,,,,,,,,,FG000,"Physical activity (PA) counseling program with the following components: baseline in-person counseling session; telephone calls, one physician endorsement of PA in a primary care clinic visit, monthly",,,
arm,NCT00594399::arm::FG001,NCT00594399,"Arm 2, Usual Care",,,,,,,,,,FG001,"Usual care from primary, womens or geriatric clinics",,,
arm,NCT00594399::arm::FG002,NCT00594399,"Arm 3, Physical Activity Counseling, Reduced Dose",,,,,,,,,,FG002,"Upon rerandomization, individuals in this group continued to receive monthly physical activity counseling through 6 months which was then reduced to every other month during months 6-12.",,,
period,NCT00594399::period::1,NCT00594399,Initial 3 Month Counseling,,,,,,,,,,,,1.0,,
period,NCT00594399::period::2,NCT00594399,Rerandomization Arm 1 Only,,,,,,,,,,,,2.0,,
outcome,NCT00594399::outcome::primary::1,NCT00594399,Fasting Insulin,,,,,,,,,,,,,PRIMARY,Baseline
outcome,NCT00594399::outcome::primary::2,NCT00594399,3 Month Fasting Insulin,,,,,,,,,,,,,PRIMARY,3 month
outcome,NCT00594399::outcome::primary::3,NCT00594399,12 Month Fasting Insulin,,,,,,,,,,,,,PRIMARY,12 months
outcome,NCT00594399::outcome::primary::4,NCT00594399,Fasting Glucose,,,,,,,,,,,,,PRIMARY,Baseline
outcome,NCT00594399::outcome::primary::5,NCT00594399,3 Month Fasting Glucose,,,,,,,,,,,,,PRIMARY,3 months
outcome,NCT00594399::outcome::primary::6,NCT00594399,12 Month Fasting Glucose,,,,,,,,,,,,,PRIMARY,12 Months
country,NCT00594399::country::United States,NCT00594399,United States,,,,,,,,,,,,,,
trial,NCT03693430,NCT03693430,Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity,PHASE3,obesity,Overweight; Obesity,INDUSTRY,304.0,2018-10-05,2021-03-23,5.0,41.0,,,,,
arm,NCT03693430::arm::FG000,NCT03693430,Semaglutide 2.4 mg,,,,,,,,,,FG000,"Participants received once-weekly subcutaneous (s.c) injection of semaglutide in 16 week dose escalation period with dose escalation (0.25 mg, 0.5 mg, 1.0 mg and 1.7 mg) every fourth week until mainte",,,
arm,NCT03693430::arm::FG001,NCT03693430,Placebo,,,,,,,,,,FG001,Participants received once-weekly s.c. injection of placebo matched to semaglutide for 104 weeks.,,,
period,NCT03693430::period::1,NCT03693430,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03693430::outcome::primary::1,NCT03693430,Percentage Change From Baseline (Week 0) to Week 104 in Body Weight,,,,,,,,,,,,,PRIMARY,From Baseline (Week 0) to Week 104
outcome,NCT03693430::outcome::primary::2,NCT03693430,Number of Participants Who Achieved (Yes/no): Body Weight Reduction More Than or Equal to 5%,,,,,,,,,,,,,PRIMARY,At Week 104
country,NCT03693430::country::United States,NCT03693430,United States,,,,,,,,,,,,,,
country,NCT03693430::country::Canada,NCT03693430,Canada,,,,,,,,,,,,,,
country,NCT03693430::country::Hungary,NCT03693430,Hungary,,,,,,,,,,,,,,
country,NCT03693430::country::Spain,NCT03693430,Spain,,,,,,,,,,,,,,
country,NCT03693430::country::Italy,NCT03693430,Italy,,,,,,,,,,,,,,
trial,NCT03548935,NCT03548935,STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity,PHASE3,obesity,Metabolism and Nutrition Disorder; Overweight or Obesity,INDUSTRY,1961.0,2018-06-04,2021-03-05,17.0,128.0,,,,,
arm,NCT03548935::arm::FG000,NCT03548935,Semaglutide 2.4 mg,,,,,,,,,,FG000,Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg Semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing Semaglutide 1.0 mg/mL ,,,
arm,NCT03548935::arm::FG001,NCT03548935,Placebo,,,,,,,,,,FG001,Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg Semaglutide placebo administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing Semaglutide pl,,,
period,NCT03548935::period::1,NCT03548935,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03548935::outcome::primary::1,NCT03548935,Change in Body Weight (%),,,,,,,,,,,,,PRIMARY,Baseline (week 0) to week 68
outcome,NCT03548935::outcome::primary::2,NCT03548935,Participants Who Achieve 5 or More Percent Body Weight Reduction (Yes/no),,,,,,,,,,,,,PRIMARY,After week 68
country,NCT03548935::country::United States,NCT03548935,United States,,,,,,,,,,,,,,
country,NCT03548935::country::Germany,NCT03548935,Germany,,,,,,,,,,,,,,
country,NCT03548935::country::India,NCT03548935,India,,,,,,,,,,,,,,
country,NCT03548935::country::United Kingdom,NCT03548935,United Kingdom,,,,,,,,,,,,,,
country,NCT03548935::country::Russia,NCT03548935,Russia,,,,,,,,,,,,,,
country,NCT03548935::country::Canada,NCT03548935,Canada,,,,,,,,,,,,,,
country,NCT03548935::country::France,NCT03548935,France,,,,,,,,,,,,,,
country,NCT03548935::country::Argentina,NCT03548935,Argentina,,,,,,,,,,,,,,
country,NCT03548935::country::Belgium,NCT03548935,Belgium,,,,,,,,,,,,,,
country,NCT03548935::country::Japan,NCT03548935,Japan,,,,,,,,,,,,,,
country,NCT03548935::country::Bulgaria,NCT03548935,Bulgaria,,,,,,,,,,,,,,
country,NCT03548935::country::Poland,NCT03548935,Poland,,,,,,,,,,,,,,
country,NCT03548935::country::Mexico,NCT03548935,Mexico,,,,,,,,,,,,,,
country,NCT03548935::country::Finland,NCT03548935,Finland,,,,,,,,,,,,,,
country,NCT03548935::country::Denmark,NCT03548935,Denmark,,,,,,,,,,,,,,
country,NCT03548935::country::Puerto Rico,NCT03548935,Puerto Rico,,,,,,,,,,,,,,
country,NCT03548935::country::Taiwan,NCT03548935,Taiwan,,,,,,,,,,,,,,
trial,NCT00554216,NCT00554216,Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults,PHASE3,obesity,Obesity,INDUSTRY,1267.0,2007-11,2009-05,1.0,5.0,,,,,
arm,NCT00554216::arm::FG000,NCT00554216,Placebo,,,,,,,,,,FG000,,,,
arm,NCT00554216::arm::FG001,NCT00554216,VI-0521 Low,,,,,,,,,,FG001,PHEN/TPM 3.75 mg/23 mg,,,
arm,NCT00554216::arm::FG002,NCT00554216,VI-0521 Top,,,,,,,,,,FG002,PHEN/TPM 15 mg/92 mg,,,
period,NCT00554216::period::1,NCT00554216,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00554216::outcome::primary::1,NCT00554216,Percent Weight Loss From Baseline to Week 56,,,,,,,,,,,,,PRIMARY,baseline to 56 weeks
outcome,NCT00554216::outcome::primary::2,NCT00554216,Percentage of Subjects With at Least 5% Weight Loss at Week 56,,,,,,,,,,,,,PRIMARY,baseline to 56 weeks
country,NCT00554216::country::United States,NCT00554216,United States,,,,,,,,,,,,,,
trial,NCT03229057,NCT03229057,Comparing the Effects of Oral Contraceptive Pills Versus Metformin,PHASE3,obesity,PCOS,OTHER,240.0,2018-01-15,2024-07-15,1.0,2.0,,,,,
arm,NCT03229057::arm::FG000,NCT03229057,OCP + Placebo,,,,,,,,,,FG000,The OCP will be started on the first Sunday after spontaneous or induced menses. All subjects with no menses the 4 weeks before randomization will be given medroxyprogesterone acetate after a negative,,,
arm,NCT03229057::arm::FG001,NCT03229057,Metformin + Placebo,,,,,,,,,,FG001,Metformin will be initiated in a step-up fashion on cycle day 1-3 of spontaneously or induced menses. Extended release pills will be utilized as they are associated with fewer gastrointestinal side ef,,,
arm,NCT03229057::arm::FG002,NCT03229057,OCP + Metformin,,,,,,,,,,FG002,The OCP will be started on the first Sunday after spontaneous or induced menses. All subjects with no menses the 4 weeks before randomization will be given medroxyprogesterone acetate after a negative,,,
period,NCT03229057::period::1,NCT03229057,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03229057::outcome::primary::1,NCT03229057,Number of Participants With Metabolic Syndrome After 6 Months of Treatment Metformin or OCP+Metformin for 6 Months.,,,,,,,,,,,,,PRIMARY,Baseline and 6 months
country,NCT03229057::country::United States,NCT03229057,United States,,,,,,,,,,,,,,
trial,NCT01320722,NCT01320722,Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function,PHASE3,obesity,Renal Function; Endothelial Function; Blood Pressure; Overweight; Obesity,OTHER,242.0,2011-03,2015-06,1.0,1.0,,,,,
arm,NCT01320722::arm::FG000,NCT01320722,Vitamin D,,,,,,,,,,FG000,"Vitamin D ergocalciferol 50,000 unit soft gel capsule once per week for 8 weeks.",,,
arm,NCT01320722::arm::FG001,NCT01320722,Placebo- Vitamin D,,,,,,,,,,FG001,Placebo soft gel once per week for 8 weeks.,,,
arm,NCT01320722::arm::FG002,NCT01320722,Probenecid,,,,,,,,,,FG002,"Probenecid 500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total).",,,
arm,NCT01320722::arm::FG003,NCT01320722,Allopurinol,,,,,,,,,,FG003,Allopurinol 300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total).,,,
arm,NCT01320722::arm::FG004,NCT01320722,Placebo- Uric Acid,,,,,,,,,,FG004,Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total).,,,
period,NCT01320722::period::1,NCT01320722,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01320722::outcome::primary::1,NCT01320722,Change in Renal Plasma Flow (RPF) in Response to Captopril in High Sodium Balance [Vitamin D],,,,,,,,,,,,,PRIMARY,Week 8 (pre and post captopril)
outcome,NCT01320722::outcome::primary::2,NCT01320722,Plasma Renin Activity (PRA) [Vitamin D],,,,,,,,,,,,,PRIMARY,Week 8
outcome,NCT01320722::outcome::primary::3,NCT01320722,Angiotensin II (ATII) Concentration [Vitamin D],,,,,,,,,,,,,PRIMARY,Week 8
outcome,NCT01320722::outcome::primary::4,NCT01320722,Change in Renal Plasma Flow (RPF) Response to Captopril in High Sodium Balance [Uric Acid],,,,,,,,,,,,,PRIMARY,Week 8 (pre and post captopril)
outcome,NCT01320722::outcome::primary::5,NCT01320722,Plasma Renin Activity (PRA) [Uric Acid],,,,,,,,,,,,,PRIMARY,Week 8
outcome,NCT01320722::outcome::primary::6,NCT01320722,Angiotensin II (ATII) Concentration [Uric Acid],,,,,,,,,,,,,PRIMARY,Week 8
country,NCT01320722::country::United States,NCT01320722,United States,,,,,,,,,,,,,,
trial,NCT00600483,NCT00600483,Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection,PHASE3,obesity,Cardiac Surgery; Sternal Wound Infection,INDUSTRY,1502.0,2007-12,2010-09,1.0,43.0,,,,,
arm,NCT00600483::arm::FG000,NCT00600483,Gentamicin Group,,,,,,,,,,FG000,"Insertion of 2 gentamicin-collagen sponges between the sternal halves before closure of the sternotomy

gentamicin-collagen sponge dipped in saline: 100-cm2 sponge",,,
arm,NCT00600483::arm::FG001,NCT00600483,Control Group,,,,,,,,,,FG001,"Standard of care, ie, insertion of no gentamicin-collagen sponge.",,,
period,NCT00600483::period::1,NCT00600483,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00600483::outcome::primary::1,NCT00600483,Number of Participants With Surgical Wound Infections From Surgery Through Post-operative Day 90,,,,,,,,,,,,,PRIMARY,90 days post cardiac surgery
country,NCT00600483::country::United States,NCT00600483,United States,,,,,,,,,,,,,,
trial,NCT01814072,NCT01814072,Opt-IN: Optimization of Remotely Delivered Intensive Lifestyle Treatment for Obesity,PHASE3,obesity,Weight Loss,OTHER,562.0,2013-09,2017-09-20,1.0,1.0,,,,,
arm,NCT01814072::arm::FG000,NCT01814072,"1. 12 Calls, PCP",,,,,,,,,,FG000,"Participant's received biweekly (12) coaching calls, and PCP Reports",,,
arm,NCT01814072::arm::FG001,NCT01814072,"2. 12 Calls, PCP, MR, Buddy",,,,,,,,,,FG001,"Participant's received biweekly (12) coaching calls, PCP Reports, Meal Replacement Recommendations, and Buddy Training.",,,
arm,NCT01814072::arm::FG002,NCT01814072,"3. 12 Calls, PCP, Texts, Buddy",,,,,,,,,,FG002,"Participant received 12 calls, PCP Reports, Texts, and Buddy Training",,,
arm,NCT01814072::arm::FG003,NCT01814072,"4. 12 Calls, PCP, Texts, MR",,,,,,,,,,FG003,"Participant received 12 calls, PCP Reports, Texts, and Meal Replacement Recommendations",,,
arm,NCT01814072::arm::FG004,NCT01814072,"5. 12 Calls, Buddy",,,,,,,,,,FG004,"Participant received 12 calls, and Buddy Training",,,
arm,NCT01814072::arm::FG005,NCT01814072,"6. 12 Calls, MR",,,,,,,,,,FG005,"Participant received 12 calls, and Meal Replacement Recommendations",,,
arm,NCT01814072::arm::FG006,NCT01814072,"7. 12 Calls, Texts",,,,,,,,,,FG006,"Participant received 12 calls, and Texts",,,
arm,NCT01814072::arm::FG007,NCT01814072,"8. 12 Calls, Texts, MR, Buddy",,,,,,,,,,FG007,"Participant received 12 calls, Texts, Meal Replacement Recommendations, and Buddy Training",,,
arm,NCT01814072::arm::FG008,NCT01814072,"9. 24 Calls, PCP",,,,,,,,,,FG008,"Participants received 24 calls, and PCP Reports",,,
arm,NCT01814072::arm::FG009,NCT01814072,"10. 24 Calls, PCP, MR, Buddy",,,,,,,,,,FG009,"Participants received 24 calls, PCP Reports, Meal Replacement Recommendations, and Buddy Training",,,
arm,NCT01814072::arm::FG010,NCT01814072,"11. 24 Calls, PCP, Texts, Buddy",,,,,,,,,,FG010,"Participants received 24 calls, PCP Reports, Texts, and Buddy Training",,,
arm,NCT01814072::arm::FG011,NCT01814072,"12. 24 Calls, PCP, Texts, MR",,,,,,,,,,FG011,"Participants received 24 calls, PCP Reports, Texts, and Meal Replacement Recommendations",,,
arm,NCT01814072::arm::FG012,NCT01814072,"13. 24 Calls, Buddy",,,,,,,,,,FG012,"Participants received 24 calls, and Buddy Training",,,
arm,NCT01814072::arm::FG013,NCT01814072,"14. 24 Calls, MR",,,,,,,,,,FG013,"Participants received 24 calls, and Meal Replacement Recommendations",,,
arm,NCT01814072::arm::FG014,NCT01814072,"15. 24 Calls, Texts",,,,,,,,,,FG014,"Participants received 24 calls, and Texts",,,
arm,NCT01814072::arm::FG015,NCT01814072,"16. 24 Calls, Texts, MR, Buddy",,,,,,,,,,FG015,"Participants received 24 calls, Texts, Meal Replacement Recommendations, and Buddy Training",,,
arm,NCT01814072::arm::FG016,NCT01814072,17. 12 Calls,,,,,,,,,,FG016,Participants received 12 calls,,,
arm,NCT01814072::arm::FG017,NCT01814072,"18. 12 Calls, MR, Buddy",,,,,,,,,,FG017,"Participants received 12 calls, Meal Replacement Recommendations, and Buddy Training",,,
arm,NCT01814072::arm::FG018,NCT01814072,"19. 12 Calls, Texts, Buddy",,,,,,,,,,FG018,"Participants received 12 calls, Texts, and Buddy Training",,,
arm,NCT01814072::arm::FG019,NCT01814072,"20. 12 Calls, Texts, MR",,,,,,,,,,FG019,"Participants received 12 calls, Texts, Meal Replacement Recommendations",,,
arm,NCT01814072::arm::FG020,NCT01814072,"21. 12 Calls, PCP, Buddy",,,,,,,,,,FG020,"Participants received 12 calls, PCP Reports, and Buddy Training",,,
arm,NCT01814072::arm::FG021,NCT01814072,"22. 12 Calls, PCP, MR",,,,,,,,,,FG021,"Participants received 12 calls, PCP Reports, and Meal Replacement Recommendations",,,
arm,NCT01814072::arm::FG022,NCT01814072,"23. 12 Calls PCP, Texts",,,,,,,,,,FG022,"Participants received 12 calls, PCP Reports, and Texts",,,
arm,NCT01814072::arm::FG023,NCT01814072,"24. 12 Calls, PCP, Texts, MR, Buddy",,,,,,,,,,FG023,"Participants received 12 calls, PCP Reports, Texts, Meal Replacement Recommendations, and Buddy Training",,,
arm,NCT01814072::arm::FG024,NCT01814072,25. 24 Calls,,,,,,,,,,FG024,Participants received 24 calls,,,
arm,NCT01814072::arm::FG025,NCT01814072,"26. 24 Calls, MR, Buddy",,,,,,,,,,FG025,"Participants received 24 calls, Meal Replacement Recommendations, and Buddy Training",,,
arm,NCT01814072::arm::FG026,NCT01814072,"27. 24 Calls, Texts, Buddy",,,,,,,,,,FG026,"Participants received 24 calls, Texts, and Buddy Training",,,
arm,NCT01814072::arm::FG027,NCT01814072,"28. 24 Calls, Texts, MR",,,,,,,,,,FG027,"Participants received 24 calls, Texts, and Meal Replacement Recommendations",,,
arm,NCT01814072::arm::FG028,NCT01814072,"29. 24 Calls, PCP, Buddy",,,,,,,,,,FG028,"Participants received 24 calls, PCP Reports, and Buddy Training",,,
arm,NCT01814072::arm::FG029,NCT01814072,"30. 24 Calls, PCP, MR",,,,,,,,,,FG029,"Participants received 24 calls, PCP Reports, and Meal Replacement Recommendations",,,
arm,NCT01814072::arm::FG030,NCT01814072,"31. 24 Calls, PCP, Texts",,,,,,,,,,FG030,"Participants received 24 calls, PCP Reports, and Texts",,,
arm,NCT01814072::arm::FG031,NCT01814072,"32. 24 Calls, PCP, Texts, MR, Buddy",,,,,,,,,,FG031,"Participants received 24 calls, PCP Reports, Texts, Meal Replacement Recommendations, and Buddy Training",,,
period,NCT01814072::period::1,NCT01814072,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01814072::outcome::primary::1,NCT01814072,"Weight Change (kg) From Baseline to Month 6, Main Effect of Time",,,,,,,,,,,,,PRIMARY,From Baseline to Month 6
outcome,NCT01814072::outcome::primary::2,NCT01814072,"Weight Change (kg) From Baseline to Month 6, Time by Factor Interaction",,,,,,,,,,,,,PRIMARY,From Baseline to Month 6
country,NCT01814072::country::United States,NCT01814072,United States,,,,,,,,,,,,,,
trial,NCT00781937,NCT00781937,Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance,PHASE3,obesity,Metabolism and Nutrition Disorder; Obesity,INDUSTRY,422.0,2008-10-30,2010-09-01,2.0,37.0,,,,,
arm,NCT00781937::arm::FG000,NCT00781937,Lira 3.0 mg,,,,,,,,,,FG000,A 12-week run-in period where screened subjects were treated with a low calorie diet. Randomised subjects (those who lost more than or equal to 5% of screening body weight) were treated with liragluti,,,
arm,NCT00781937::arm::FG001,NCT00781937,Placebo,,,,,,,,,,FG001,A 12-week run-in period where screened subjects were treated with a low calorie diet. Randomised subjects (those who lost more than or equal to 5% of screening body weight) were treated with liragluti,,,
period,NCT00781937::period::1,NCT00781937,Main Trial Period Through Week 56,,,,,,,,,,,,1.0,,
period,NCT00781937::period::2,NCT00781937,Follow up Period (Week 56-68),,,,,,,,,,,,2.0,,
outcome,NCT00781937::outcome::primary::1,NCT00781937,Mean Percentage Change in Fasting Body Weight From Baseline,,,,,,,,,,,,,PRIMARY,"Week 0, week 56"
outcome,NCT00781937::outcome::primary::2,NCT00781937,Percentage of Subjects Who Maintained Their run-in Fasting Weight Loss From Week 0,,,,,,,,,,,,,PRIMARY,"Week 0, week 56"
outcome,NCT00781937::outcome::primary::3,NCT00781937,Percentage of Subjects Who Lost More Than or Equal to 5% of Fasting Body Weight From Week 0,,,,,,,,,,,,,PRIMARY,"Week 0, week 56"
country,NCT00781937::country::United States,NCT00781937,United States,,,,,,,,,,,,,,
country,NCT00781937::country::Canada,NCT00781937,Canada,,,,,,,,,,,,,,
trial,NCT00567255,NCT00567255,A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects,PHASE3,obesity,Obesity; Overweight,INDUSTRY,1496.0,2007-12,2009-06,1.0,36.0,,,,,
arm,NCT00567255::arm::FG000,NCT00567255,NB32,,,,,,,,,,FG000,Naltrexone SR 32 mg/bupropion SR 360 mg/day,,,
arm,NCT00567255::arm::FG001,NCT00567255,Placebo,,,,,,,,,,FG001,Placebo,,,
period,NCT00567255::period::1,NCT00567255,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00567255::outcome::primary::1,NCT00567255,Co-primary: Body Weight- Mean Percent Change From Baseline to Week 28,,,,,,,,,,,,,PRIMARY,"Baseline, 28 weeks"
outcome,NCT00567255::outcome::primary::2,NCT00567255,Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease From Baseline to Week 28,,,,,,,,,,,,,PRIMARY,"Baseline, 28 weeks"
country,NCT00567255::country::United States,NCT00567255,United States,,,,,,,,,,,,,,
trial,NCT03651765,NCT03651765,Long Term Extension Trial of Setmelanotide,PHASE3,obesity,Obesity Associated With Defects in Leptin-melanocortin Pathway,INDUSTRY,205.0,2018-07-15,2025-01-09,8.0,27.0,,,,,
arm,NCT03651765::arm::FG000,NCT03651765,Setmelanotide,,,,,,,,,,FG000,Participants received setmelanotide at the same starting dose as received in the index trials as a subcutaneous (SC) injection once daily for up to 5.6 years in this extension trial.,,,
period,NCT03651765::period::1,NCT03651765,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03651765::outcome::primary::1,NCT03651765,Number of Participants With Treatment-Emergent Adverse Events (TEAEs),,,,,,,,,,,,,PRIMARY,From first dose up to 5.6 years
country,NCT03651765::country::United States,NCT03651765,United States,,,,,,,,,,,,,,
country,NCT03651765::country::Germany,NCT03651765,Germany,,,,,,,,,,,,,,
country,NCT03651765::country::United Kingdom,NCT03651765,United Kingdom,,,,,,,,,,,,,,
country,NCT03651765::country::France,NCT03651765,France,,,,,,,,,,,,,,
country,NCT03651765::country::Canada,NCT03651765,Canada,,,,,,,,,,,,,,
country,NCT03651765::country::Greece,NCT03651765,Greece,,,,,,,,,,,,,,
country,NCT03651765::country::Netherlands,NCT03651765,Netherlands,,,,,,,,,,,,,,
country,NCT03651765::country::Spain,NCT03651765,Spain,,,,,,,,,,,,,,
trial,NCT04520256,NCT04520256,Rapid Evaluation of Innovative Intervention Components to Maximize the Health Benefits of Behavioral Obesity Treatment Delivered Online: An Application of Multiphase Optimization Strategy,PHASE3,obesity,Overweight and Obesity,OTHER,384.0,2020-09-22,2023-05-18,1.0,1.0,,,,,
arm,NCT04520256::arm::FG000,NCT04520256,Core Program Only,,,,,,,,,,FG000,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.",,,
arm,NCT04520256::arm::FG001,NCT04520256,Social Support,,,,,,,,,,FG001,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Platform for Social Support \& Friendly Com",,,
arm,NCT04520256::arm::FG002,NCT04520256,Dysregulated Eating,,,,,,,,,,FG002,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Skills Training for Dysregulated Eating: Pe",,,
arm,NCT04520256::arm::FG003,NCT04520256,"Social Support, Dysregulated Eating",,,,,,,,,,FG003,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Skills Training for Dysregulated Eating: Pe",,,
arm,NCT04520256::arm::FG004,NCT04520256,Exercise,,,,,,,,,,FG004,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Tailored Intervention for Structured Physic",,,
arm,NCT04520256::arm::FG005,NCT04520256,"Social Support, Exercise",,,,,,,,,,FG005,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Tailored Intervention for Structured Physic",,,
arm,NCT04520256::arm::FG006,NCT04520256,"Dysregulated Eating, Exercise",,,,,,,,,,FG006,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Tailored Intervention for Structured Physic",,,
arm,NCT04520256::arm::FG007,NCT04520256,"Social Support, Dysregulated Eating, Exercise",,,,,,,,,,FG007,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Tailored Intervention for Structured Physic",,,
arm,NCT04520256::arm::FG008,NCT04520256,Feedback,,,,,,,,,,FG008,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Tailored Interactive Video Feedback: Video-",,,
arm,NCT04520256::arm::FG009,NCT04520256,"Social Support, Feedback",,,,,,,,,,FG009,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Tailored Interactive Video Feedback: Video-",,,
arm,NCT04520256::arm::FG010,NCT04520256,"Dysregulated Eating, Feedback",,,,,,,,,,FG010,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Tailored Interactive Video Feedback: Video-",,,
arm,NCT04520256::arm::FG011,NCT04520256,"Social Support, Dysregulated Eating, Feedback",,,,,,,,,,FG011,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Tailored Interactive Video Feedback: Video-",,,
arm,NCT04520256::arm::FG012,NCT04520256,"Exercise, Feedback",,,,,,,,,,FG012,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Tailored Interactive Video Feedback: Video-",,,
arm,NCT04520256::arm::FG013,NCT04520256,"Social Support, Exercise, Feedback",,,,,,,,,,FG013,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Tailored Interactive Video Feedback: Video-",,,
arm,NCT04520256::arm::FG014,NCT04520256,"Dysregulated Eating, Exercise, Feedback",,,,,,,,,,FG014,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Tailored Interactive Video Feedback: Video-",,,
arm,NCT04520256::arm::FG015,NCT04520256,"Social Support, Dysregulated Eating, Exercise, Feedback",,,,,,,,,,FG015,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Tailored Interactive Video Feedback: Video-",,,
arm,NCT04520256::arm::FG016,NCT04520256,Virtual Reality,,,,,,,,,,FG016,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Virtual Reality for Behavioral Weight Loss ",,,
arm,NCT04520256::arm::FG017,NCT04520256,"Social Support, VR",,,,,,,,,,FG017,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Virtual Reality for Behavioral Weight Loss ",,,
arm,NCT04520256::arm::FG018,NCT04520256,"Dysregulated Eating, VR",,,,,,,,,,FG018,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Virtual Reality for Behavioral Weight Loss ",,,
arm,NCT04520256::arm::FG019,NCT04520256,"Social Support, Dysregulated Eating, VR",,,,,,,,,,FG019,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Virtual Reality for Behavioral Weight Loss ",,,
arm,NCT04520256::arm::FG020,NCT04520256,"Exercise, VR",,,,,,,,,,FG020,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Virtual Reality for Behavioral Weight Loss ",,,
arm,NCT04520256::arm::FG021,NCT04520256,"Social Support, Exercise, VR",,,,,,,,,,FG021,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Virtual Reality for Behavioral Weight Loss ",,,
arm,NCT04520256::arm::FG022,NCT04520256,"Dysregulated Eating, Exercise, VR",,,,,,,,,,FG022,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Virtual Reality for Behavioral Weight Loss ",,,
arm,NCT04520256::arm::FG023,NCT04520256,"Social Support, Dysregulated Eating, Exercise, VR",,,,,,,,,,FG023,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Virtual Reality for Behavioral Weight Loss ",,,
arm,NCT04520256::arm::FG024,NCT04520256,"Feedback, VR",,,,,,,,,,FG024,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Virtual Reality for Behavioral Weight Loss ",,,
arm,NCT04520256::arm::FG025,NCT04520256,"Social Support, Feedback, VR",,,,,,,,,,FG025,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Virtual Reality for Behavioral Weight Loss ",,,
arm,NCT04520256::arm::FG026,NCT04520256,"Dysregulated Eating, Feedback, VR",,,,,,,,,,FG026,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Virtual Reality for Behavioral Weight Loss ",,,
arm,NCT04520256::arm::FG027,NCT04520256,"Social Support, Dysregulated Eating, Feedback, VR",,,,,,,,,,FG027,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Virtual Reality for Behavioral Weight Loss ",,,
arm,NCT04520256::arm::FG028,NCT04520256,"Exercise, Feedback, VR",,,,,,,,,,FG028,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Virtual Reality for Behavioral Weight Loss ",,,
arm,NCT04520256::arm::FG029,NCT04520256,"Social Support, Exercise, Feedback, VR",,,,,,,,,,FG029,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Virtual Reality for Behavioral Weight Loss ",,,
arm,NCT04520256::arm::FG030,NCT04520256,"Dysregulated Eating, Exercise, Feedback, VR",,,,,,,,,,FG030,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Virtual Reality for Behavioral Weight Loss ",,,
arm,NCT04520256::arm::FG031,NCT04520256,"Social Support, Dysregulated Eating, Exercise, Feedback, VR",,,,,,,,,,FG031,"Online Behavioral Weight Loss Program: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Virtual Reality for Behavioral Weight Loss ",,,
period,NCT04520256::period::1,NCT04520256,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04520256::outcome::primary::1,NCT04520256,"Weight Change (Percent of Initial Body Weight) From Baseline to Month 12, Main Effect of Time",,,,,,,,,,,,,PRIMARY,From Baseline to Month 12
outcome,NCT04520256::outcome::primary::2,NCT04520256,"Weight Change (Percent of Initial Body Weight) From Baseline to Month 12, Time by Intervention Component Interaction",,,,,,,,,,,,,PRIMARY,From Baseline to Month 12
outcome,NCT04520256::outcome::primary::3,NCT04520256,"Proportion of Participants With Weight Loss ≥ 5% at Month 12, Main Effect of Time",,,,,,,,,,,,,PRIMARY,Month 12
outcome,NCT04520256::outcome::primary::4,NCT04520256,"Proportion of Participants With Weight Loss ≥ 5% at Month 12, Time by Intervention Component Interaction",,,,,,,,,,,,,PRIMARY,Month 12
country,NCT04520256::country::United States,NCT04520256,United States,,,,,,,,,,,,,,
trial,NCT05040971,NCT05040971,Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes,PHASE3,obesity,Obesity,INDUSTRY,207.0,2021-09-06,2023-07-14,5.0,43.0,,,,,
arm,NCT05040971::arm::FG000,NCT05040971,Semaglutide 2.4 mg,,,,,,,,,,FG000,"Participants received once-weekly subcutaneous (s.c) injection of 0.25 milligram (mg) Semaglutide administered using a DV3396 pen-injector followed by a fixed-dose escalation regimen, with dose increa",,,
arm,NCT05040971::arm::FG001,NCT05040971,Placebo,,,,,,,,,,FG001,Participants received once-weekly subcutaneous (s.c) injection of 0.25 milligram (mg) placebo matched to 2.4 mg Semaglutide administered using a DV3396 pen-injector followed by a fixed-dose escalation,,,
period,NCT05040971::period::1,NCT05040971,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT05040971::outcome::primary::1,NCT05040971,Change in Body Weight (Percentage [%]),,,,,,,,,,,,,PRIMARY,From randomisation (week 0) to end of treatment (week 52)
outcome,NCT05040971::outcome::primary::2,NCT05040971,Participants With Change to Normoglycemia,,,,,,,,,,,,,PRIMARY,At week 52
country,NCT05040971::country::Canada,NCT05040971,Canada,,,,,,,,,,,,,,
country,NCT05040971::country::United Kingdom,NCT05040971,United Kingdom,,,,,,,,,,,,,,
country,NCT05040971::country::Spain,NCT05040971,Spain,,,,,,,,,,,,,,
country,NCT05040971::country::Denmark,NCT05040971,Denmark,,,,,,,,,,,,,,
country,NCT05040971::country::Finland,NCT05040971,Finland,,,,,,,,,,,,,,
trial,NCT05412004,NCT05412004,Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea,PHASE3,obesity,Obstructive Sleep Apnea; Obesity,INDUSTRY,469.0,2022-06-21,2024-03-29,10.0,58.0,,,,,
arm,NCT05412004::arm::FG000,NCT05412004,Tirzepatide MTD_GPI1,,,,,,,,,,FG000,Participants not on positive airway pressure (PAP) therapy received a maximum tolerated dose (MTD) of 10 milligrams (mg) or 15 mg of Tirzepatide once weekly (QW) as a subcutaneous (SC) injection for 5,,,
arm,NCT05412004::arm::FG001,NCT05412004,Placebo_GPI1,,,,,,,,,,FG001,Participants not on PAP therapy received placebo QW as an SC injection for 52 weeks.,,,
arm,NCT05412004::arm::FG002,NCT05412004,Tirzepatide MTD_GPI2,,,,,,,,,,FG002,"Participants who are on PAP therapy received an MTD of 10 mg or 15 mg of Tirzepatide QW as an SC injection for 52 weeks, including the initial dose escalation by 2.5 mg every 4 weeks.",,,
arm,NCT05412004::arm::FG003,NCT05412004,Placebo_GPI2,,,,,,,,,,FG003,Participants who are on PAP therapy received placebo QW as an SC injection for 52 weeks.,,,
period,NCT05412004::period::1,NCT05412004,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT05412004::outcome::primary::1,NCT05412004,Change From Baseline in Apnea-Hypopnea Index (AHI),,,,,,,,,,,,,PRIMARY,"Baseline, Week 52"
country,NCT05412004::country::United States,NCT05412004,United States,,,,,,,,,,,,,,
country,NCT05412004::country::Mexico,NCT05412004,Mexico,,,,,,,,,,,,,,
country,NCT05412004::country::Germany,NCT05412004,Germany,,,,,,,,,,,,,,
country,NCT05412004::country::Brazil,NCT05412004,Brazil,,,,,,,,,,,,,,
country,NCT05412004::country::China,NCT05412004,China,,,,,,,,,,,,,,
country,NCT05412004::country::Japan,NCT05412004,Japan,,,,,,,,,,,,,,
country,NCT05412004::country::Australia,NCT05412004,Australia,,,,,,,,,,,,,,
country,NCT05412004::country::Czechia,NCT05412004,Czechia,,,,,,,,,,,,,,
country,NCT05412004::country::Taiwan,NCT05412004,Taiwan,,,,,,,,,,,,,,
country,NCT05412004::country::Puerto Rico,NCT05412004,Puerto Rico,,,,,,,,,,,,,,
trial,NCT02918279,NCT02918279,Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity,PHASE3,obesity,Metabolism and Nutrition Disorder; Obesity,INDUSTRY,251.0,2016-09-29,2019-08-08,5.0,33.0,,,,,
arm,NCT02918279::arm::FG000,NCT02918279,Liraglutide 3.0 mg,,,,,,,,,,FG000,"Participants received liraglutide in a dose escalation manner for 56 weeks: 0.6 mg during week 1, 1.2 mg during week 2, 1.8 mg during week 3, 2.4 mg during week 4 and 3.0 mg from week 5 to week 56. Th",,,
arm,NCT02918279::arm::FG001,NCT02918279,Placebo,,,,,,,,,,FG001,Subjects received liraglutide matching placebo for 56 weeks. There was a 26-week off-study-drug follow-up period (week 57-82). Placebo for liraglutide was administered once daily by s.c. injection in ,,,
period,NCT02918279::period::1,NCT02918279,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02918279::outcome::primary::1,NCT02918279,"Change in BMI SDS (Week 0, Week 56)",,,,,,,,,,,,,PRIMARY,"Week 0, week 56"
country,NCT02918279::country::United States,NCT02918279,United States,,,,,,,,,,,,,,
country,NCT02918279::country::Russia,NCT02918279,Russia,,,,,,,,,,,,,,
country,NCT02918279::country::Belgium,NCT02918279,Belgium,,,,,,,,,,,,,,
country,NCT02918279::country::Sweden,NCT02918279,Sweden,,,,,,,,,,,,,,
country,NCT02918279::country::Mexico,NCT02918279,Mexico,,,,,,,,,,,,,,
trial,NCT03611582,NCT03611582,Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program,PHASE3,obesity,Overweight; Obesity,INDUSTRY,611.0,2018-08-01,2020-04-28,1.0,41.0,,,,,
arm,NCT03611582::arm::FG000,NCT03611582,Semaglutide 2.4 mg,,,,,,,,,,FG000,Participants were to receive once-weekly subcutaneous (s.c) injection of semaglutide using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL or 3.2 m,,,
arm,NCT03611582::arm::FG001,NCT03611582,Placebo,,,,,,,,,,FG001,Participants were to receive once-weekly s.c injection of matching semaglutide placebo using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide placebo 1.0 mg/mL or 3.0 mg/m,,,
period,NCT03611582::period::1,NCT03611582,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03611582::outcome::primary::1,NCT03611582,Change in Body Weight (%),,,,,,,,,,,,,PRIMARY,Baseline (week 0) to week 68
outcome,NCT03611582::outcome::primary::2,NCT03611582,Participants Who Achieve (Yes/no): Body Weight Reduction More Than or Equal to 5%,,,,,,,,,,,,,PRIMARY,After 68 weeks
country,NCT03611582::country::United States,NCT03611582,United States,,,,,,,,,,,,,,
trial,NCT00456521,NCT00456521,A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program,PHASE3,obesity,Obesity; Overweight,INDUSTRY,793.0,2007-03,2008-12,1.0,9.0,,,,,
arm,NCT00456521::arm::FG000,NCT00456521,NB32,,,,,,,,,,FG000,Naltrexone SR 32 mg/ bupropion SR 360 mg/ day,,,
arm,NCT00456521::arm::FG001,NCT00456521,Placebo,,,,,,,,,,FG001,Placebo,,,
period,NCT00456521::period::1,NCT00456521,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00456521::outcome::primary::1,NCT00456521,Co-primary: Body Weight- Mean Percent Change,,,,,,,,,,,,,PRIMARY,"Baseline, 56 weeks"
outcome,NCT00456521::outcome::primary::2,NCT00456521,Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease,,,,,,,,,,,,,PRIMARY,"Baseline, 56 weeks"
country,NCT00456521::country::United States,NCT00456521,United States,,,,,,,,,,,,,,
trial,NCT01535014,NCT01535014,Clinical Trial of Safety and Efficacy of Various Dosage Schedules for Dietressa Drug in Treatment of Obese Patients,PHASE3,obesity,Obesity,INDUSTRY,493.0,2011-12-12,2013-06,1.0,17.0,,,,,
arm,NCT01535014::arm::FG000,NCT01535014,Dietressa 1,,,,,,,,,,FG000,Dietressa: 1 tablet 6 times daily,,,
arm,NCT01535014::arm::FG001,NCT01535014,Dietressa 2,,,,,,,,,,FG001,Dietressa: 2 tablets 3 times daily,,,
arm,NCT01535014::arm::FG002,NCT01535014,Placebo 3,,,,,,,,,,FG002,Placebo: 1 tablet 6 times daily,,,
arm,NCT01535014::arm::FG003,NCT01535014,Placebo 4,,,,,,,,,,FG003,Placebo: 2 tablets 3 times daily,,,
period,NCT01535014::period::1,NCT01535014,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01535014::outcome::primary::1,NCT01535014,Percentage of Subjects Who Lose at Least 5 Percent of Baseline Body Weight After 24 Weeks of Treatment Weeks of Treatment,,,,,,,,,,,,,PRIMARY,assessed after 24 weeks of treatment
outcome,NCT01535014::outcome::primary::2,NCT01535014,Average Body Weight Change After 24 Weeks of Treatment,,,,,,,,,,,,,PRIMARY,assessed after 24 weeks of treatment
outcome,NCT01535014::outcome::primary::3,NCT01535014,Average Relative Change in Body Weight After 24 Weeks of Treatment,,,,,,,,,,,,,PRIMARY,assessed after 24 weeks of treatment
country,NCT01535014::country::Russia,NCT01535014,Russia,,,,,,,,,,,,,,
trial,NCT02432209,NCT02432209,Improving Reproductive Fitness Through Pretreatment With Lifestyle Modification in Obese Women With Unexplained Infertility,PHASE3,obesity,"Infertility, Female",OTHER,379.0,2015-08,2020-05,1.0,10.0,,,,,
arm,NCT02432209::arm::FG000,NCT02432209,Intensive Lifestyle Mod. Intervention,,,,,,,,,,FG000,"The intensive lifestyle modification intervention will consist of caloric restriction (consumption of approximately 1200-1500 kcal/d), use of an over-the-counter weight loss medication (Alli, which is",,,
arm,NCT02432209::arm::FG001,NCT02432209,Standard Lifestyle Intervention,,,,,,,,,,FG001,"Women in the standard lifestyle intervention (standard) will receive publicly available written materials that promote engagement in moderate physical activity with target of 10,000 steps a day. Detai",,,
period,NCT02432209::period::1,NCT02432209,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT02432209::outcome::primary::1,NCT02432209,Rate of Good Birth Outcomes,,,,,,,,,,,,,PRIMARY,"At time of birth, approximately 17 months into the study"
country,NCT02432209::country::United States,NCT02432209,United States,,,,,,,,,,,,,,
trial,NCT01557166,NCT01557166,Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea,PHASE3,obesity,Metabolism and Nutrition Disorder; Obesity; Obstructive Sleep Apnoea,INDUSTRY,359.0,2012-06-07,2013-06-17,2.0,42.0,,,,,
arm,NCT01557166::arm::FG000,NCT01557166,Liraglutide 3.0 mg,,,,,,,,,,FG000,"Subjects were administered 3.0 mg of liraglutide subcutaneously (s.c., under the skin) once daily for 32 weeks. Subjects were also prescribed a 500 kcal/day-deficit diet and exercise for a minimum of ",,,
arm,NCT01557166::arm::FG001,NCT01557166,Placebo,,,,,,,,,,FG001,"Subjects were administered placebo subcutaneously (s.c., under the skin) once daily for 32 weeks. Subjects were also prescribed a 500 kcal/day-deficit diet and exercise for a minimum of 150 min/week.",,,
period,NCT01557166::period::1,NCT01557166,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01557166::outcome::primary::1,NCT01557166,Change From Baseline in Apnoea-hypopnoea Index (AHI),,,,,,,,,,,,,PRIMARY,"Week 0, Week 32"
country,NCT01557166::country::United States,NCT01557166,United States,,,,,,,,,,,,,,
country,NCT01557166::country::Canada,NCT01557166,Canada,,,,,,,,,,,,,,
trial,NCT01272219,NCT01272219,Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes,PHASE3,obesity,Metabolism and Nutrition Disorder; Obesity,INDUSTRY,3731.0,2011-06-01,2015-03-02,29.0,226.0,,,,,
arm,NCT01272219::arm::FG000,NCT01272219,"Liraglutide 3.0 mg, no Pre-diabetes",,,,,,,,,,FG000,"Arm 1 (Arm 1A + Arm 1B): Subjects with no pre-diabetes at screening received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks followed by a re-randomisa",,,
arm,NCT01272219::arm::FG001,NCT01272219,Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68),,,,,,,,,,FG001,"Arm 1A: Subjects of Arm 1 (with no pre-diabetes at screening) receiving liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks were re-randomised (1:1 into li",,,
arm,NCT01272219::arm::FG002,NCT01272219,Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68),,,,,,,,,,FG002,"Arm 1B: Subjects of Arm 1 (with no pre-diabetes at screening) receiving liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks were re-randomised (1:1 into li",,,
arm,NCT01272219::arm::FG003,NCT01272219,"Liraglutide Placebo, no Pre-diabetes",,,,,,,,,,FG003,"Arm 2: Subjects with no pre-diabetes at screening received liraglutide placebo once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks and then continued with liraglutide placebo ",,,
arm,NCT01272219::arm::FG004,NCT01272219,"Liraglutide 3.0 mg, Pre-diabetes",,,,,,,,,,FG004,"Arm 3: Subjects with pre-diabetes at screening received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for initial 56 weeks then continued treatment till 160 weeks",,,
arm,NCT01272219::arm::FG005,NCT01272219,"Liraglutide Placebo, Pre-diabetes",,,,,,,,,,FG005,"Arm 4: Subjects with pre-diabetes at screening received liraglutide placebo once daily (OD) subcutaneously (s.c. injection, under the skin) for initial 56 weeks then continued treatment till 160 weeks",,,
period,NCT01272219::period::1,NCT01272219,Main Period: Week 0 to Week 56,,,,,,,,,,,,1.0,,
period,NCT01272219::period::2,NCT01272219,Re-randomised Period: Week 56 to Week 68,,,,,,,,,,,,2.0,,
period,NCT01272219::period::3,NCT01272219,Main + Extension Period: Week 0-172,,,,,,,,,,,,3.0,,
outcome,NCT01272219::outcome::primary::1,NCT01272219,Change From Baseline in Fasting Body Weight,,,,,,,,,,,,,PRIMARY,"Week 0, Week 56"
outcome,NCT01272219::outcome::primary::2,NCT01272219,Proportion of Subjects Losing at Least 5% of Baseline Fasting Body Weight.,,,,,,,,,,,,,PRIMARY,At Week 56
outcome,NCT01272219::outcome::primary::3,NCT01272219,Proportion of Subjects Losing More Than 10% of Baseline Fasting Body Weight,,,,,,,,,,,,,PRIMARY,At 56 weeks
outcome,NCT01272219::outcome::primary::4,NCT01272219,Proportion of Subjects With Onset of Type 2 Diabetes,,,,,,,,,,,,,PRIMARY,At 160 weeks
country,NCT01272219::country::United States,NCT01272219,United States,,,,,,,,,,,,,,
country,NCT01272219::country::Canada,NCT01272219,Canada,,,,,,,,,,,,,,
country,NCT01272219::country::Germany,NCT01272219,Germany,,,,,,,,,,,,,,
country,NCT01272219::country::India,NCT01272219,India,,,,,,,,,,,,,,
country,NCT01272219::country::Russia,NCT01272219,Russia,,,,,,,,,,,,,,
country,NCT01272219::country::United Kingdom,NCT01272219,United Kingdom,,,,,,,,,,,,,,
country,NCT01272219::country::Israel,NCT01272219,Israel,,,,,,,,,,,,,,
country,NCT01272219::country::Italy,NCT01272219,Italy,,,,,,,,,,,,,,
country,NCT01272219::country::Mexico,NCT01272219,Mexico,,,,,,,,,,,,,,
country,NCT01272219::country::Netherlands,NCT01272219,Netherlands,,,,,,,,,,,,,,
country,NCT01272219::country::Poland,NCT01272219,Poland,,,,,,,,,,,,,,
country,NCT01272219::country::France,NCT01272219,France,,,,,,,,,,,,,,
country,NCT01272219::country::Spain,NCT01272219,Spain,,,,,,,,,,,,,,
country,NCT01272219::country::Turkey (Türkiye),NCT01272219,Turkey (Türkiye),,,,,,,,,,,,,,
country,NCT01272219::country::Brazil,NCT01272219,Brazil,,,,,,,,,,,,,,
country,NCT01272219::country::Switzerland,NCT01272219,Switzerland,,,,,,,,,,,,,,
country,NCT01272219::country::Argentina,NCT01272219,Argentina,,,,,,,,,,,,,,
country,NCT01272219::country::Australia,NCT01272219,Australia,,,,,,,,,,,,,,
country,NCT01272219::country::Austria,NCT01272219,Austria,,,,,,,,,,,,,,
country,NCT01272219::country::Ireland,NCT01272219,Ireland,,,,,,,,,,,,,,
country,NCT01272219::country::Norway,NCT01272219,Norway,,,,,,,,,,,,,,
country,NCT01272219::country::Belgium,NCT01272219,Belgium,,,,,,,,,,,,,,
country,NCT01272219::country::Denmark,NCT01272219,Denmark,,,,,,,,,,,,,,
country,NCT01272219::country::Finland,NCT01272219,Finland,,,,,,,,,,,,,,
country,NCT01272219::country::Hungary,NCT01272219,Hungary,,,,,,,,,,,,,,
country,NCT01272219::country::South Africa,NCT01272219,South Africa,,,,,,,,,,,,,,
country,NCT01272219::country::Hong Kong,NCT01272219,Hong Kong,,,,,,,,,,,,,,
country,NCT01272219::country::Serbia and Montenegro,NCT01272219,Serbia and Montenegro,,,,,,,,,,,,,,
country,NCT01272219::country::Serbia,NCT01272219,Serbia,,,,,,,,,,,,,,
trial,NCT00796367,NCT00796367,A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787),PHASE3,obesity,Obesity,INDUSTRY,676.0,2008-12,2010-07,0.0,0.0,,,,,
arm,NCT00796367::arm::FG000,NCT00796367,Placebo,,,,,,,,,,FG000,Placebo,,,
arm,NCT00796367::arm::FG001,NCT00796367,VI-0521 Mid,,,,,,,,,,FG001,VI-0521 7.5 mg PHEN/46 mg TPM,,,
arm,NCT00796367::arm::FG002,NCT00796367,VI-0521 Top,,,,,,,,,,FG002,VI-0521 15 mg PHEN/92 mg TPM,,,
period,NCT00796367::period::1,NCT00796367,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00796367::outcome::primary::1,NCT00796367,"Percent Weight Change at End of Treatment, Week 108.",,,,,,,,,,,,,PRIMARY,From baseline to end of treatment
outcome,NCT00796367::outcome::primary::2,NCT00796367,"Percentage of Subjects With at Least 5% Weight Loss at End of Treatment, Week 108.",,,,,,,,,,,,,PRIMARY,Baseline to End of Treatment
trial,NCT03811574,NCT03811574,STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity,PHASE3,obesity,Overweight; Obesity,INDUSTRY,401.0,2019-01-21,2020-11-20,2.0,28.0,,,,,
arm,NCT03811574::arm::FG000,NCT03811574,Semaglutide 1.7 mg,,,,,,,,,,FG000,Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 milliliter (mL) cartridge containing semaglutide 1.0 milligr,,,
arm,NCT03811574::arm::FG001,NCT03811574,Semaglutide 2.4 mg,,,,,,,,,,FG001,Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL a,,,
arm,NCT03811574::arm::FG002,NCT03811574,Placebo,,,,,,,,,,FG002,Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks.,,,
period,NCT03811574::period::1,NCT03811574,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03811574::outcome::primary::1,NCT03811574,Change in Body Weight (%),,,,,,,,,,,,,PRIMARY,"Baseline (week 0), week 68"
outcome,NCT03811574::outcome::primary::2,NCT03811574,Number of Participants Who Achieve (Yes/no): Body Weight Reduction More Than or Equal to 5%,,,,,,,,,,,,,PRIMARY,At week 68
country,NCT03811574::country::Japan,NCT03811574,Japan,,,,,,,,,,,,,,
country,NCT03811574::country::South Korea,NCT03811574,South Korea,,,,,,,,,,,,,,
trial,NCT00532779,NCT00532779,A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects,PHASE3,obesity,Obesity; Overweight,INDUSTRY,1742.0,2007-10,2009-05,1.0,34.0,,,,,
arm,NCT00532779::arm::FG000,NCT00532779,NB16,,,,,,,,,,FG000,Naltrexone SR 16 mg/Bupropion SR 360 mg /day,,,
arm,NCT00532779::arm::FG001,NCT00532779,NB32,,,,,,,,,,FG001,Naltrexone SR 32 mg/Bupropion SR 360 mg /day,,,
arm,NCT00532779::arm::FG002,NCT00532779,Placebo,,,,,,,,,,FG002,Placebo,,,
period,NCT00532779::period::1,NCT00532779,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00532779::outcome::primary::1,NCT00532779,Co-primary: Body Weight- Mean Percent Change,,,,,,,,,,,,,PRIMARY,"Baseline, 56 weeks"
outcome,NCT00532779::outcome::primary::2,NCT00532779,Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease,,,,,,,,,,,,,PRIMARY,"Baseline, 56 weeks"
country,NCT00532779::country::United States,NCT00532779,United States,,,,,,,,,,,,,,
trial,NCT05064735,NCT05064735,Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis,PHASE3,obesity,Obesity,INDUSTRY,407.0,2021-10-01,2023-09-08,11.0,122.0,,,,,
arm,NCT05064735::arm::FG000,NCT05064735,Semaglutide 2.4 mg,,,,,,,,,,FG000,Participants initiated at a once-weekly dose of 0.24 milligrams (mg) semaglutide subcutaneously (s.c.) as a adjunct to a reduced calorie diet and increased physical activity and followed a fixed-dose ,,,
arm,NCT05064735::arm::FG001,NCT05064735,Placebo,,,,,,,,,,FG001,Participants received semaglutide matching placebo subcutaneously once weekly as a adjunct to a reduced calorie diet and increased physical activity from week 0 to week 68. Participants were followed ,,,
period,NCT05064735::period::1,NCT05064735,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT05064735::outcome::primary::1,NCT05064735,Percentage Change in Body Weight,,,,,,,,,,,,,PRIMARY,"Baseline (week 0), end of treatment (week 68)"
outcome,NCT05064735::outcome::primary::2,NCT05064735,Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score,,,,,,,,,,,,,PRIMARY,"Baseline (week 0), end of treatment (week 68)"
country,NCT05064735::country::United States,NCT05064735,United States,,,,,,,,,,,,,,
country,NCT05064735::country::Canada,NCT05064735,Canada,,,,,,,,,,,,,,
country,NCT05064735::country::Russia,NCT05064735,Russia,,,,,,,,,,,,,,
country,NCT05064735::country::France,NCT05064735,France,,,,,,,,,,,,,,
country,NCT05064735::country::South Africa,NCT05064735,South Africa,,,,,,,,,,,,,,
country,NCT05064735::country::Colombia,NCT05064735,Colombia,,,,,,,,,,,,,,
country,NCT05064735::country::Saudi Arabia,NCT05064735,Saudi Arabia,,,,,,,,,,,,,,
country,NCT05064735::country::Sweden,NCT05064735,Sweden,,,,,,,,,,,,,,
country,NCT05064735::country::Norway,NCT05064735,Norway,,,,,,,,,,,,,,
country,NCT05064735::country::Spain,NCT05064735,Spain,,,,,,,,,,,,,,
country,NCT05064735::country::Denmark,NCT05064735,Denmark,,,,,,,,,,,,,,
trial,NCT03345771,NCT03345771,Antimicrobial Barrier Dressing Versus Closed-incision Negative Pressure Therapy in the Obese Primary Total Joint Arthroplasty,PHASE3,obesity,Osteoarthritis,OTHER,230.0,2017-11-13,2021-06-01,1.0,1.0,,,,,
arm,NCT03345771::arm::FG000,NCT03345771,Antimicrobial Barrier Dressing,,,,,,,,,,FG000,"postoperative wound dressing with either anti-microbial dressing placed in the operating room from surgery to postoperative day 7

Antimicrobial Barrier Dressing: Ionic Silver is a soft, nonwoven pad ",,,
arm,NCT03345771::arm::FG001,NCT03345771,Closed-incision Negative Pressure Therapy,,,,,,,,,,FG001,"portable NPWT device placed in the operating room from surgery to postoperative day 7

Negative Pressure Wound Therapy (NPWT): PICO provides suction known as negative Pressure wound Therapy (NPWT) whi",,,
period,NCT03345771::period::1,NCT03345771,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03345771::outcome::primary::1,NCT03345771,Visual Analog Scale (VAS) Pain Score,,,,,,,,,,,,,PRIMARY,Day 8
outcome,NCT03345771::outcome::primary::2,NCT03345771,Wound Evaluation Scale (WES),,,,,,,,,,,,,PRIMARY,Day 8
country,NCT03345771::country::United States,NCT03345771,United States,,,,,,,,,,,,,,
trial,NCT04102189,NCT04102189,A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity,PHASE3,obesity,Overweight; Obesity,INDUSTRY,201.0,2019-10-07,2022-03-28,8.0,51.0,,,,,
arm,NCT04102189::arm::FG000,NCT04102189,Semaglutide 2.4 mg,,,,,,,,,,FG000,Participants received once weekly s.c. injection of semaglutide for 68 weeks. Participants initially received 0.25 milligrams (mg) of semaglutide and the dose was then escalated once in 4 weeks for 16,,,
arm,NCT04102189::arm::FG001,NCT04102189,Placebo,,,,,,,,,,FG001,Participants received once weekly s.c. injection of placebo matched to semaglutide for 68 weeks. The treatment was an adjunct to a reduced-calorie diet and increased physical activity.,,,
period,NCT04102189::period::1,NCT04102189,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT04102189::outcome::primary::1,NCT04102189,Change in Body Mass Index (BMI) (Percentage [%]),,,,,,,,,,,,,PRIMARY,"Baseline (week 0), week 68"
country,NCT04102189::country::United States,NCT04102189,United States,,,,,,,,,,,,,,
country,NCT04102189::country::Russia,NCT04102189,Russia,,,,,,,,,,,,,,
country,NCT04102189::country::United Kingdom,NCT04102189,United Kingdom,,,,,,,,,,,,,,
country,NCT04102189::country::Belgium,NCT04102189,Belgium,,,,,,,,,,,,,,
country,NCT04102189::country::Ireland,NCT04102189,Ireland,,,,,,,,,,,,,,
country,NCT04102189::country::Austria,NCT04102189,Austria,,,,,,,,,,,,,,
country,NCT04102189::country::Croatia,NCT04102189,Croatia,,,,,,,,,,,,,,
country,NCT04102189::country::Mexico,NCT04102189,Mexico,,,,,,,,,,,,,,
trial,NCT05822830,NCT05822830,A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities,PHASE3,obesity,Obesity; Overweight,INDUSTRY,751.0,2023-04-21,2024-11-13,2.0,32.0,,,,,
arm,NCT05822830::arm::FG000,NCT05822830,15 mg or MTD - Tirzepatide,,,,,,,,,,FG000,"Participants received a starting dose of 2.5 milligrams (mg) tirzepatide administered subcutaneously (SC) once weekly (QW) for 4 weeks, then the dose was increased by 2.5 mg every 4 weeks (2.5 to 5 to",,,
arm,NCT05822830::arm::FG001,NCT05822830,2.4 mg or MTD - Semaglutide,,,,,,,,,,FG001,"Participants received a starting dose of 0.25 mg semaglutide administered SC QW for 4 weeks, then the dose was increased every 4 weeks (0.25 to 0.5 to 1.0 to 1.7 to 2.4 mg) up to 2.4 mg QW or MTD (1.7",,,
period,NCT05822830::period::1,NCT05822830,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT05822830::outcome::primary::1,NCT05822830,Percent Change From Baseline in Body Weight,,,,,,,,,,,,,PRIMARY,"Baseline, Week 72"
country,NCT05822830::country::United States,NCT05822830,United States,,,,,,,,,,,,,,
country,NCT05822830::country::Puerto Rico,NCT05822830,Puerto Rico,,,,,,,,,,,,,,
trial,NCT03548987,NCT03548987,Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity,PHASE3,obesity,Metabolism and Nutrition Disorder; Obesity,INDUSTRY,902.0,2018-06-04,2020-03-20,10.0,72.0,,,,,
arm,NCT03548987::arm::FG000,NCT03548987,Semaglutide 2.4 mg,,,,,,,,,,FG000,Participants were to receive once-weekly subcutaneous (s.c) injection of semaglutide using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL in 20 we,,,
arm,NCT03548987::arm::FG001,NCT03548987,Placebo,,,,,,,,,,FG001,Participants were to receive once-weekly s.c injection of semaglutide using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL in 20 week run-in perio,,,
period,NCT03548987::period::1,NCT03548987,Run-in Period (Week 0 to Week 20),,,,,,,,,,,,1.0,,
period,NCT03548987::period::2,NCT03548987,Maintenance Period (Week 20 to Week 68),,,,,,,,,,,,2.0,,
outcome,NCT03548987::outcome::primary::1,NCT03548987,Change From Randomisation to Week 68 in Body Weight (%),,,,,,,,,,,,,PRIMARY,Randomisation (week 20) to week 68
country,NCT03548987::country::United States,NCT03548987,United States,,,,,,,,,,,,,,
country,NCT03548987::country::Spain,NCT03548987,Spain,,,,,,,,,,,,,,
country,NCT03548987::country::Israel,NCT03548987,Israel,,,,,,,,,,,,,,
country,NCT03548987::country::Portugal,NCT03548987,Portugal,,,,,,,,,,,,,,
country,NCT03548987::country::South Africa,NCT03548987,South Africa,,,,,,,,,,,,,,
country,NCT03548987::country::Switzerland,NCT03548987,Switzerland,,,,,,,,,,,,,,
country,NCT03548987::country::Ukraine,NCT03548987,Ukraine,,,,,,,,,,,,,,
country,NCT03548987::country::Netherlands,NCT03548987,Netherlands,,,,,,,,,,,,,,
country,NCT03548987::country::Sweden,NCT03548987,Sweden,,,,,,,,,,,,,,
country,NCT03548987::country::Denmark,NCT03548987,Denmark,,,,,,,,,,,,,,
trial,NCT00563368,NCT00563368,A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults,PHASE3,obesity,Obesity,INDUSTRY,756.0,2007-12,2008-09,1.0,2.0,,,,,
arm,NCT00563368::arm::FG000,NCT00563368,Placebo,,,,,,,,,,FG000,Placebo,,,
arm,NCT00563368::arm::FG001,NCT00563368,PHEN 7.5 mg,,,,,,,,,,FG001,7.5 mg phentermine,,,
arm,NCT00563368::arm::FG002,NCT00563368,TPM 46 mg,,,,,,,,,,FG002,46 mg topiramate,,,
arm,NCT00563368::arm::FG003,NCT00563368,VI-0521 Mid,,,,,,,,,,FG003,7.5 mg/46 mg phentermine/topiramate,,,
arm,NCT00563368::arm::FG004,NCT00563368,PHEN 15 mg,,,,,,,,,,FG004,15 mg phentermine,,,
arm,NCT00563368::arm::FG005,NCT00563368,TPM 92 mg,,,,,,,,,,FG005,92 mg topiramate,,,
arm,NCT00563368::arm::FG006,NCT00563368,VI-0521 Top,,,,,,,,,,FG006,15 mg/92 mg phentermine/topiramate,,,
period,NCT00563368::period::1,NCT00563368,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00563368::outcome::primary::1,NCT00563368,Percent Weight Loss From Baseline to Week 28,,,,,,,,,,,,,PRIMARY,baseline to 28 weeks
outcome,NCT00563368::outcome::primary::2,NCT00563368,Percentage of Subjects With at Least 5% Weight Loss at Week 28 With LOCF,,,,,,,,,,,,,PRIMARY,baseline to 28 weeks
country,NCT00563368::country::United States,NCT00563368,United States,,,,,,,,,,,,,,
trial,NCT00166205,NCT00166205,Safety and Effectiveness Study of The Swedish Adjustable Gastric Band (SAGB) in the Treatment of Morbid Obesity,PHASE3,obesity,"Obesity, Morbid",INDUSTRY,276.0,2003-06,2006-12,1.0,12.0,,,,,
arm,NCT00166205::arm::FG000,NCT00166205,Swedish Adjustable Gastric Band (SAGB),,,,,,,,,,FG000,,,,
period,NCT00166205::period::1,NCT00166205,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00166205::outcome::primary::1,NCT00166205,Percent of Subjects Who Had Adverse Events With the Swedish Adjustable Gastric Band (SAGB),,,,,,,,,,,,,PRIMARY,3 years
outcome,NCT00166205::outcome::primary::2,NCT00166205,Percent Excess Weight Loss,,,,,,,,,,,,,PRIMARY,3 Years Post Operative
country,NCT00166205::country::United States,NCT00166205,United States,,,,,,,,,,,,,,
trial,NCT01375647,NCT01375647,Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh,PHASE3,metabolic syndrome,Rotavirus Diarrhea; Vaccine Virus Shedding; Tropical Enteropathy,OTHER,700.0,2011-05,2014-11,1.0,1.0,,,,,
arm,NCT01375647::arm::FG000,NCT01375647,Rotarix + IPV (Inactivated Polio Vaccine),,,,,,,,,,FG000,Rotarix vaccine at 10 and 17 weeks of age plus IPV (inactivated polio vaccine) boost at 39 weeks in place of routine oral polio vaccine dose,,,
arm,NCT01375647::arm::FG001,NCT01375647,Rotarix + No IPV (Inactivated Polio Vaccine),,,,,,,,,,FG001,Rotarix vaccine at 10 and 17 weeks of age and routine oral polio vaccine series,,,
arm,NCT01375647::arm::FG002,NCT01375647,No Rotarix + IPV (Inactivated Polio Vaccine),,,,,,,,,,FG002,IPV (inactivated polio vaccine) boost at 39 weeks in place of routine oral polio vaccine dose,,,
arm,NCT01375647::arm::FG003,NCT01375647,No Rotarix + No IPV (Inactivated Polio Vaccine),,,,,,,,,,FG003,No Rotarix vaccine and routine oral polio vaccine series,,,
period,NCT01375647::period::1,NCT01375647,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT01375647::outcome::primary::1,NCT01375647,Presence of Fecal Shedding of Polio Vaccine Virus Determined by Culture (Polio Trial),,,,,,,,,,,,,PRIMARY,25 days following week 52 visit
outcome,NCT01375647::outcome::primary::2,NCT01375647,Number of Participants With One or More Episodes of Rotavirus-associated Diarrhea (Rotavirus Trial),,,,,,,,,,,,,PRIMARY,Birth to one year
country,NCT01375647::country::Bangladesh,NCT01375647,Bangladesh,,,,,,,,,,,,,,
trial,NCT03389555,NCT03389555,"Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial",PHASE3,metabolic syndrome,Sepsis; Septic Shock; Metabolic Disturbance,OTHER,205.0,2018-02-09,2020-02-28,1.0,13.0,,,,,
arm,NCT03389555::arm::FG000,NCT03389555,"Vitamin C, Vitamin B1, Corticosteroids",,,,,,,,,,FG000,"The combination of vitamin C, vitamin B1, hydrocortisone :

* Vitamin C (ascorbic acid) 1.5g every 6 hours x 4-days
* Vitamin B1 (thiamine) 100mg every 6 hours x 4-days
* Hydrocortisone 50mg every 6 h",,,
arm,NCT03389555::arm::FG001,NCT03389555,Placebo,,,,,,,,,,FG001,"Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components

Normal saline: Normal saline (0.9% NaCl solution) volume to match all components",,,
period,NCT03389555::period::1,NCT03389555,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT03389555::outcome::primary::1,NCT03389555,Sequential Organ Failure Assessment (SOFA) Score at Baseline and 72 Hours,,,,,,,,,,,,,PRIMARY,Enrollment to 72-hours
country,NCT03389555::country::United States,NCT03389555,United States,,,,,,,,,,,,,,
trial,NCT00082628,NCT00082628,Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients,PHASE3,metabolic syndrome,HIV Infections; Lipodystrophy,INDUSTRY,326.0,2004-05-28,2005-09-28,2.0,31.0,,,,,
arm,NCT00082628::arm::FG000,NCT00082628,Period I: Placebo,,,,,,,,,,FG000,Subjects received placebo matched to serostim® as subcutaneous injection daily for a period of 12 weeks.,,,
arm,NCT00082628::arm::FG001,NCT00082628,Period I: Serostim® 4 mg,,,,,,,,,,FG001,Subjects received Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight for a period of 12 weeks.,,,
arm,NCT00082628::arm::FG002,NCT00082628,Period II: Serostim® 4 mg to Placebo,,,,,,,,,,FG002,All subjects who were initially randomized to Serostim® 4 mg arm in Period I and received placebo matched to Serostim® on alternate days for 24 weeks in Period II.,,,
arm,NCT00082628::arm::FG003,NCT00082628,Period II: Serostim® 4 mg to Serostim® 2 mg,,,,,,,,,,FG003,All subjects who were initially randomized to Serostim® 4 mg arm in Period I and received Serostim® 2 mg on alternate days for 24 weeks in Period II.,,,
arm,NCT00082628::arm::FG004,NCT00082628,Period II: Placebo to Placebo/Serostim® 4 mg,,,,,,,,,,FG004,All subjects who were initially randomized to Placebo arm in Period I continued receiving placebo matched to Serostim® on alternate days for 12 weeks followed by Serostim® 4 mg daily 12 weeks.,,,
period,NCT00082628::period::1,NCT00082628,Treatment Period I (Week 1 to Week 12),,,,,,,,,,,,1.0,,
period,NCT00082628::period::2,NCT00082628,Treatment Period II: Week 12 to Week 36,,,,,,,,,,,,2.0,,
outcome,NCT00082628::outcome::primary::1,NCT00082628,Treatment Period I: Change From Baseline in Absolute Area of Visceral Adipose Tissue (VAT) at Week 12,,,,,,,,,,,,,PRIMARY,"Baseline, Week 12"
country,NCT00082628::country::United States,NCT00082628,United States,,,,,,,,,,,,,,
country,NCT00082628::country::Canada,NCT00082628,Canada,,,,,,,,,,,,,,
trial,NCT00608023,NCT00608023,TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy,PHASE3,metabolic syndrome,Lipodystrophy; HIV Infections,INDUSTRY,263.0,2007-08,2008-10,6.0,47.0,,,,,
arm,NCT00608023::arm::FG000,NCT00608023,Tesamorelin (52 Weeks),,,,,,,,,,FG000,Tesamorelin 2 mg/day for 52 Weeks,,,
arm,NCT00608023::arm::FG001,NCT00608023,Tesamorelin (26 Weeks) - Placebo (26 Weeks),,,,,,,,,,FG001,Tesamorelin 2 mg/day for 26 weeks followed by Placebo for 26 weeks,,,
arm,NCT00608023::arm::FG002,NCT00608023,Placebo-Tesamorelin (P-T),,,,,,,,,,FG002,Placebo for 26 weeks followed by Tesamorelin 2 mg/day for 26 weeks,,,
period,NCT00608023::period::1,NCT00608023,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00608023::outcome::primary::1,NCT00608023,Changes From Baseline in Fasting Blood Glucose at Week 52,,,,,,,,,,,,,PRIMARY,Baseline and Week 52
outcome,NCT00608023::outcome::primary::2,NCT00608023,Changes From Baseline in 2 h Oral Glucose Tolerance Test (OGTT) at Week 52,,,,,,,,,,,,,PRIMARY,Baseline and Week 52
country,NCT00608023::country::United States,NCT00608023,United States,,,,,,,,,,,,,,
country,NCT00608023::country::Canada,NCT00608023,Canada,,,,,,,,,,,,,,
country,NCT00608023::country::United Kingdom,NCT00608023,United Kingdom,,,,,,,,,,,,,,
country,NCT00608023::country::France,NCT00608023,France,,,,,,,,,,,,,,
country,NCT00608023::country::Spain,NCT00608023,Spain,,,,,,,,,,,,,,
country,NCT00608023::country::Belgium,NCT00608023,Belgium,,,,,,,,,,,,,,
trial,NCT00980174,NCT00980174,Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis,PHASE3,metabolic syndrome,Low Bone Mass; Low Bone Mineral Density; Males With Osteoporosis; Osteopenia; Osteoporosis,INDUSTRY,242.0,2009-10-01,2012-05-23,0.0,0.0,,,,,
arm,NCT00980174::arm::FG000,NCT00980174,Placebo,,,,,,,,,,FG000,,,,
arm,NCT00980174::arm::FG001,NCT00980174,Denosumab 60 mg Q6M,,,,,,,,,,FG001,,,,
period,NCT00980174::period::1,NCT00980174,Overall Study,,,,,,,,,,,,1.0,,
outcome,NCT00980174::outcome::primary::1,NCT00980174,Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12,,,,,,,,,,,,,PRIMARY,From Baseline to 12 Months
trial,NCT03096314,NCT03096314,Vitamin D to Improve Outcomes by Leveraging Early Treatment,PHASE3,metabolic syndrome,Acute Respiratory Distress Syndrome; Vitamin D Deficiency; Critical Illness,OTHER,1358.0,2017-04-27,2018-12-11,1.0,47.0,,,,,
arm,NCT03096314::arm::FG000,NCT03096314,High Dose Vitamin D Formulation,,,,,,,,,,FG000,"Patients at high risk for ARDS and mortality with initial screening 25OHD levels \< 20 ng/mL randomized to receive 540,00 IU vitamin D3 (cholecalciferol) as a single, liquid enteral dose, administered",,,
arm,NCT03096314::arm::FG001,NCT03096314,Placebo,,,,,,,,,,FG001,"Patients at high risk for ARDS and mortality with initial screening 25OHD levels \< 20 ng/mL randomized to receive placebo (similar in appearance to the vitamin D3 treatment) as a single, liquid enter",,,
period,NCT03096314::period::1,NCT03096314,Screened Vitamin D Deficient,,,,,,,,,,,,1.0,,
period,NCT03096314::period::2,NCT03096314,Confirmed Vitamin D Deficient,,,,,,,,,,,,2.0,,
outcome,NCT03096314::outcome::primary::1,NCT03096314,"All-cause, All-location Mortality to Day 90",,,,,,,,,,,,,PRIMARY,90 days after randomization
country,NCT03096314::country::United States,NCT03096314,United States,,,,,,,,,,,,,,
